<SEC-DOCUMENT>0001193125-20-206488.txt : 20200731
<SEC-HEADER>0001193125-20-206488.hdr.sgml : 20200731
<ACCEPTANCE-DATETIME>20200731163033
ACCESSION NUMBER:		0001193125-20-206488
CONFORMED SUBMISSION TYPE:	F-1
PUBLIC DOCUMENT COUNT:		40
FILED AS OF DATE:		20200731
DATE AS OF CHANGE:		20200731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immatics N.V.
		CENTRAL INDEX KEY:			0001809196
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-240260
		FILM NUMBER:		201066322

	BUSINESS ADDRESS:	
		STREET 1:		PAUL EHRLICH-STRASSE 15
		CITY:			TUBINGEN
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 5397 700

	MAIL ADDRESS:	
		STREET 1:		PAUL EHRLICH-STRASSE 15
		CITY:			TUBINGEN
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Immatics B.V.
		DATE OF NAME CHANGE:	20200413
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1
<SEQUENCE>1
<FILENAME>d96389df1.htm
<DESCRIPTION>F-1
<TEXT>
<HTML><HEAD>
<TITLE>F-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with the Securities and Exchange Commission on July&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">F-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:19pt; font-family:Times New Roman" ALIGN="center"><B>Immatics N.V. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name
of Registrant as specified in its charter) </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>The Netherlands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of<BR>incorporation or organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Primary Standard Industrial<BR>Classification Code Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification Number</B><I>)</I><B></B></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Paul-Ehrlich-Stra&szlig;e 15 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>72076 T&uuml;bingen, Federal Republic of Germany </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Tel: +49 <FONT STYLE="white-space:nowrap">(7071)&nbsp;5397-0</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of Registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Edward A. Sturchio </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Immatics US, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>2130 W.
Holcombe Blvd., Suite 900 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Houston, Texas 77030 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(281) <FONT STYLE="white-space:nowrap">810-7545</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Mitchell S. Bloom, Esq.<BR>Edwin M. O&#146;Connor, Esq.<BR>Goodwin Procter LLP<BR>100 Northern Avenue<BR>Boston, Massachusetts 02210<BR><FONT STYLE="white-space:nowrap">(617)&nbsp;570-1000</FONT></B></TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933,
check the following box.&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective
amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If an emerging growth
company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#134;
provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">&#134; The term &#147;new or revised financial accounting
standard&#148; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April&nbsp;5, 2012. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF
REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities to be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to be</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registered<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering
Price</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Per Security<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering Price<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registration Fee</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Ordinary shares, nominal value of &#128;0.01 per
share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">39,332,281</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$10.29</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$404,532,510.09</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$52,508.32</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents ordinary shares offered by the selling securityholders identified in this prospectus. Includes an
indeterminable number of additional ordinary shares that, pursuant to Rule 416 under the Securities Act of 1933, as amended, may be issued to prevent dilution from stock splits, stock dividends or similar transactions that could affect the ordinary
shares to be offered by the selling securityholders. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule 457(c) under the Securities Act of 1933, as amended, and solely for the purpose of calculating
the registration fee, the proposed maximum offering price is $10.29, which is the average of the high and low prices of the registrant&#146;s ordinary shares on July 27, 2020 on The Nasdaq Stock Market LLC. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall
file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become
effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#eb0029"><B>The information in this prospectus is not complete and may be changed. Neither we nor
the selling securityholders may sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy
these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#eb0029"><B>Subject to completion, dated July&nbsp;31, 2020 </B></FONT></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRELIMINARY PROSPECTUS </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Immatics N.V.
</B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g04i20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>39,332,281 ordinary shares </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the offer and sale from time to time by the selling securityholders or their permitted transferees (collectively, the &#147;selling
securityholders&#148;) of up to 39,332,281 of our ordinary shares, &#128;0.01 nominal value per share. This prospectus also covers any additional securities that may become issuable by reason of share splits, share dividends or other similar
transactions. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares covered by this prospectus include (i) 28,917,281 ordinary shares issued to certain selling securityholders in connection with
the closing of the business combination (the &#147;Business Combination&#148;) between us, ARYA Sciences Acquisition Corp., a Cayman Islands exempted company, Immatics Biotechnologies GmbH, a German limited liability company, Immatics Merger Sub 1,
a Cayman Islands exempted company, and Immatics Merger Sub 2, a Cayman Islands exempted company, and (ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10,415,000 ordinary shares issued to certain
securityholders in connection with the closing of a private placement offering at a price per share of $10.00, for gross proceeds of approximately $104.2&nbsp;million, both of which closed on July&nbsp;1, 2020. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering the offer and sale of the securities described above to satisfy certain registration rights we have granted. We are registering these
securities for resale by the selling securityholders named in this prospectus, or their transferees, pledgees, donees or assignees or other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> that
receive any of the shares as a gift, distribution, or other <FONT STYLE="white-space:nowrap">non-sale</FONT> related transfer. The selling securityholders may offer all or part of the securities for resale from time to time through public or private
transactions, at either prevailing market prices or at privately negotiated prices. These securities are being registered to permit the selling securityholders to sell securities from time to time, in amounts, at prices and on terms determined at
the time of offering. The selling securityholders may sell these securities through ordinary brokerage transactions, directly to market makers of our shares or through any other means described in the section titled &#147;<I>Plan of
Distribution</I>&#148;. In connection with any sales of ordinary shares offered hereunder, the selling securityholders, any underwriters, agents, brokers or dealers participating in such sales may be deemed to be &#147;underwriters&#148; within the
meaning of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the ordinary shares offered by the selling securityholders
pursuant to this prospectus will be sold by the selling securityholders for their respective accounts. We will not receive any of the proceeds from such sales. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay certain expenses associated with the registration of the securities covered by this prospectus, as described in the section titled &#147;<I>Plan of
Distribution</I>&#148;. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ordinary shares are listed on The Nasdaq Stock Market LLC (&#147;Nasdaq&#148;) under the symbol &#147;IMTX&#148;. On
July&nbsp;30, 2020, the last reported sale price of our ordinary shares as reported on Nasdaq was $11.10 per share. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may amend or supplement this
prospectus from time to time by filing amendments or supplements as required. You should read this entire prospectus and any amendments or supplements carefully before you make your investment decision. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as that term is defined in the Jumpstart Our Business Startups Act of 2012 and, as such, are subject to reduced
public company reporting requirements. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at Paul-Ehrlich-Stra&szlig;e 15, 72076 T&uuml;bingen, Federal Republic
of Germany. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of material risks of
investing in our securities in &#147;<A HREF="#rom96389_5">Risk Factors</A>&#148; beginning on page 14 of this prospectus. </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed on the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_2">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_3">SELECTED CONSOLIDATED HISTORICAL AND OTHER FINANCIAL
INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_4">SELECTED UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_5">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_6">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_8">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_9">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_10">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_11">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_12">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
 OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_13">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_14">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_15">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_16">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_17">PRINCIPAL SECURITYHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_18">SELLING SECURITYHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_19">TAXATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_20">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_21">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_22">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_23">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_24">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom96389_25">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained in this prospectus, any amendment or supplement to this prospectus or any
free writing prospectus prepared by us or on our behalf. Neither we, nor the selling securityholders, have authorized any other person to provide you with different or additional information. Neither we, nor the selling securityholders, take
responsibility for, nor can we provide assurance as to the reliability of, any other information that others may provide. The selling securityholders are not making an offer to sell these securities in any jurisdiction where the offer or sale is not
permitted. The information contained in this prospectus is accurate only as of the date of this prospectus or such other date stated in this prospectus, and our business, financial condition, results of operations and/or prospects may have changed
since those dates. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise set forth in this prospectus, neither we nor the selling securityholders have taken any action to permit a
public offering of these securities outside the United States or to permit the possession or distribution of this prospectus outside the United States. Persons outside the United States who come into possession of this prospectus must inform
themselves about and observe any restrictions relating to the offering of these securities and the distribution of this prospectus outside the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMPORTANT INFORMATION ABOUT IFRS AND <FONT STYLE="white-space:nowrap">NON-IFRS</FONT>
FINANCIAL MEASURES </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The audited financial statements of Immatics Biotechnologies GmbH are prepared in accordance with International Financial
Reporting Standards as issued by the International Accounting Standards Board (&#147;IFRS&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONVENTIONS THAT APPLY TO THIS
PROSPECTUS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this prospectus, unless otherwise specified or the context otherwise requires: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;$&#148;, &#147;USD&#148; and &#147;U.S. dollar&#148; each refer to the United States dollar; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;&#128;&#148;, &#147;EUR&#148; and &#147;Euro&#148; each refer to the Euro. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exchange rate used for conversion between U.S. dollars and Euros is based on the ECB euro reference exchange rate published by the European Central Bank.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRADEMARKS, SERVICE MARKS AND TRADE NAMES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Immatics logo


<IMG SRC="g96389g07b07.jpg" ALT="LOGO">
, Immatics<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, XPRESIDENT<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, ACTengine<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, ACTallo<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, ACTolog<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, XCEPTOR<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>,
TCER<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, AbsQuant<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>, IMADetect<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> and other trademarks or service marks of
Immatics appearing in this prospectus are the property of the company. Solely for convenience, some of the trademarks, service marks, logos and trade names referred to in this prospectus are presented without the <SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under
applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This prospectus contains additional trademarks, service marks and trade names of others. All trademarks, service marks and trade
names appearing in this prospectus are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies&#146; trademarks, service marks, copyrights or trade names to imply a relationship with, or
endorsement or sponsorship of us by, any other companies. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us, this offering and selected information contained elsewhere in this prospectus. This summary is not
complete and does not contain all of the information that you should consider before deciding whether to invest in the securities covered by this prospectus. For a more complete understanding of the our company and this offering, we encourage you to
read and consider carefully the more detailed information in this prospectus, any related prospectus supplement and any related free writing prospectus, including the information set forth in the section titled &#147;Risk Factors&#148; in this
prospectus, any related prospectus supplement and any related free writing prospectus in their entirety before making an investment decision. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unless otherwise stated or the context otherwise indicates, (i)&nbsp;references to the &#147;company&#148;, &#147;we&#148;, &#147;our&#148; or
&#147;us&#148; refer to Immatics N.V., together with its subsidiaries, including Immatics Biotechnologies GmbH; (ii)&nbsp;references to &#147;Immatics&#148; refer solely to Immatics N.V.; and (iii)&nbsp;references to &#147;Immatics OpCo&#148; refer
solely to Immatics Biotechnologies GmbH. Immatics N.V. is a Dutch public limited liability company (naamloze vennootschap) incorporated on March&nbsp;10, 2020 and the holding company of Immatics Biotechnologies GmbH, a German biopharmaceutical
company incorporated in 2000 focused on the development of T cell receptor-based immunotherapies for the treatment of cancer. Immatics Biotechnologies GmbH holds all material assets and conducts all business activities and operations of Immatics
N.V. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We combine the discovery of
true targets for cancer immunotherapies with the development of the right T cell receptors (&#147;TCRs&#148;) with the goal of enabling a robust and specific T cell response against these targets. This deep
<FONT STYLE="white-space:nowrap">know-how</FONT> is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics, as well as for our collaborations with global leaders in the pharmaceutical industry. We are committed to delivering
the power of T cells and to unlocking new avenues for patients in our fight against cancer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pioneering Therapies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our pipeline consists of two lead product classes, engineered Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics (TCER). Each therapeutic
modality has distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors focusing on particularly
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">hard-to-treat</FONT></FONT> solid cancers. With this approach, we believe that we are well positioned to expand the potential therapeutic value for patients across a broad range of
tumor types and stages. In addition, we are developing strategies designed to advance commercial viability, safety and clinical efficacy via process optimization for Adoptive Cell Therapy (ACT) programs and implementing next-generation ACT
approaches including allogeneic cell therapies (ACTallo) and a novel ultra-personalized approach to immunotherapy. We are developing the following product candidates: ACTengine IMA201, IMA202, IMA203 programs are in Phase 1 clinical trials and
IMA204 is in preclinical development. In addition, we are developing one preclinical stage ACTallo product candidate (IMA301). ACTolog, currently in a Phase 1 clinical trial, is our clinical pilot trial (IMA101) for multi-target ACT. ACTolog
(IMA101) is a clinical pilot trial (not intended to be developed as a product candidate) delivering a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-principle</FONT></FONT> for our next-generation <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">multi-TCR-T</FONT></FONT> approach. Within its TCER modality, we are advancing two preclinical TCR Bispecifics candidates towards the IND stage of development and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trials, IMA401 and IMA402. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Competitive Advantage
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We aim to cover all required areas key to developing effective <FONT STYLE="white-space:nowrap">TCR-based</FONT> cancer immunotherapies in one
company. Our two proprietary technology discovery platforms enabling identification of true targets and </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development of right TCRs are a unique strength to this end. We believe that our systematic application of the XPRESIDENT platform over more than a decade has created the largest <FONT
STYLE="white-space:nowrap">peptide-HLA</FONT> (pHLA) target database known in the industry and enables identification of otherwise inaccessible and intracellular drug targets with very high sensitivity. From this large pool of targets, we have
recently focused on a prioritized short-list of over 200 cancer targets and have developed an extensive intellectual property portfolio to protect our discoveries. The proprietary XCEPTOR technology platform is designed to facilitate the fast and
efficient discovery, engineering and validation of TCRs with high affinity and high specificity and benefits from a unique interplay with the XPRESIDENT target database. We believe that our technology platforms, therapeutic modalities and scientific
knowledge provide us with a significant competitive advantage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual Property Portfolio </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to continue building on our extensive intellectual property portfolio in the field of cancer targets, TCRs and technologies. Our portfolio currently
includes over 3,000 worldwide active patent applications and more than 1,550 secured patents, of which over 230 are granted in the United States. We own patent applications directed to its IMA202 (MAGEA1) product candidate and patents and
applications directed to its IMA201 (MAGE4/8), IMA203 (PRAME), IMA204 (COL6A3 exon 6), IMA301 (cancer testis antigen), and IMA401 (cancer testis antigen) product candidates. The protection of our assets is a key element of our ability to not only
strengthen our product pipeline, but also to successfully defend and expand our position as a leader in the field of TCR therapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaborations
with Global Leaders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The differentiated nature of our discovery programs has been validated by our recent collaborations, including with Amgen,
Genmab, Bristol Myers Squibb and GlaxoSmithKline, which involve a total of 10 Immatics targets. We will seek to capitalize on the respective collaborator&#146;s drug development and regulatory expertise and commercial capabilities to bring our
collaboration product candidates to market. We do not rely or depend on any of the above-mentioned collaborations, however, and we do not consider them material for our proprietary pipeline. We established material collaborations and/or licenses
with MD Anderson Cancer Center, UTHealth and Sanquin and consider them important for further development of our clinical pipeline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Highly
Experienced Global Leadership Team </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a highly experienced global leadership team that operates seamlessly between our locations in Germany
and the United States. Our management consists of an interdisciplinary team that includes medical and scientific experts, as well as accomplished business leaders, and collectively has multiple decades of experience in the pharmaceutical and
biotechnology industries. In addition, our management team includes the creators and developers of our core technologies, and benefits from their continued contributions. From its research and development origins in T&uuml;bingen, Germany, to its
cell therapy research and development and manufacturing center in Houston, Texas, our global team is committed to developing and advancing the our therapeutic pipeline and supporting our collaboration programs to address significant unmet medical
needs in oncology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Developments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Closing of the Business Combination </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
July&nbsp;1, 2020 (the &#147;Closing Date&#148;), we closed the previously announced business combination (the &#147;Business Combination&#148;) pursuant to the Business Combination Agreement, dated as of March&nbsp;17, 2020, as amended by Amendment
No.&nbsp;1, dated June&nbsp;7, 2020 (as amended, the &#147;Business Combination Agreement&#148;), by and among Immatics, Immatics OpCo, ARYA Sciences Acquisition Corp., a Cayman Islands exempted company (&#147;ARYA&#148;), Immatics Merger Sub 1, a
Cayman Islands exempted company (&#147;ARYA Merger Sub&#148;), and Immatics Merger Sub 2, a Cayman Islands exempted company (&#147;IB Merger Sub&#148;). </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Closing Date, Immatics issued (i) 52,493,617 ordinary shares to securityholders of Immatics OpCo and
ARYA in exchange for their securities in Immatics OpCo and ARYA, and (ii) 7,187,500 public warrants to certain warrant holders of ARYA in exchange for outstanding public warrants of ARYA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, Immatics did not conduct any material activities other than those incident to its formation and the matters contemplated by
the Business Combination Agreement, such as the making of certain required securities law filings, and the establishment of ARYA Merger Sub and IB Merger Sub. Upon the closing of the Business Combination, Immatics OpCo became the direct, wholly
owned subsidiary of Immatics, and holds all material assets and conducts all business activities and operations of Immatics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ordinary shares and
public warrants began trading on Nasdaq under the symbols &#147;IMTX&#148; and &#147;IMTXW&#148;, respectively, on July&nbsp;2, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>PIPE
Financing </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;17, 2020, concurrently with the execution of the Business Combination Agreement, Immatics and ARYA entered into
Subscription Agreements (the &#147;Subscription Agreements&#148;) with certain investors (the &#147;PIPE Investors&#148;), pursuant to which the PIPE Investors agreed to subscribe for and purchase, and the Company agreed to issue and sell to such
PIPE Investors, an aggregate of 10,415,000 ordinary shares (the &#147;PIPE Shares&#148;) at a price of $10.00 per share, for gross proceeds of approximately $104.2&nbsp;million (the &#147;PIPE Financing&#148;) on the Closing Date, $25.0&nbsp;million
of which was funded by an affiliate of ARYA Sciences Holdings, a Cayman Islands exempted company and an affiliate of ARYA (the &#147;ARYA Sponsor&#148;). The PIPE Financing closed concurrently with the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The PIPE Shares were not registered under the Securities Act, in reliance upon the exemption provided in Section&nbsp;4(a)(2) of the Securities Act of 1933,
as amended (the &#147;Securities Act&#148;) and/or Regulation D or Regulation S promulgated thereunder without any form of general solicitation or general advertising. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coronavirus <FONT STYLE="white-space:nowrap">(COVID-19)</FONT> Pandemic </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;30, 2020, the World Health Organization declared the outbreak of coronavirus <FONT STYLE="white-space:nowrap">(&#147;COVID-19&#148;)</FONT> to
be a public health emergency of international concern. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak has severely restricted the level of economic activity around the world. In response to this coronavirus outbreak, the governments
of many countries, states, cities and other geographic regions have taken preventative or protective actions, such as imposing restrictions on travel and business operations and advising or requiring individuals to limit or forego their time outside
of their homes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are monitoring developments surrounding the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and have taken steps to identify
and mitigate the adverse effects and risks to the company as a result of the pandemic. As a result, we have modified our business practices, including implementing work from home arrangements for employees able to perform their duties remotely,
restricting nonessential travel, and practicing safe social distancing in our laboratory operations. We expect to continue to take actions as may be required or recommended by government authorities or in the best interests of our employees and
business partners. To date, the pandemic has resulted in a slowdown in activities related to our laboratory operations and at some of our suppliers. The ongoing spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> may also negatively impact
our clinical trials in the future, including potential delays and restrictions on our ability to recruit and retain patients, principal investigators and healthcare employees. <FONT STYLE="white-space:nowrap">COVID-19</FONT> could also affect the
operations of contract research organizations (&#147;CROs&#148;), or other contracted suppliers which may result in delays or disruptions in the supply of product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we have also experienced delays in research activities performed under our
collaboration agreements. Consequently, we recognized less revenue under these agreements during the first </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
quarter of 2020 than previously planned. We believe that declines in revenue associated with the delay in research activities are largely temporary, as revenue is primarily associated with <FONT
STYLE="white-space:nowrap">non-refundable</FONT> upfront payments recognized as this project plan is implemented and costs are incurred. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may continue to impact the timing and amount of
revenue recognized under these agreements in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic remains a rapidly evolving
situation and we do not yet know the full extent of its potential impact on our business operations. We will continue to closely monitor the effects of the pandemic. For additional information on risks posed by the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, refer to the section titled &#147;<I>Risk Factors</I>&#148; included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Foreign Private Issuer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#147;JOBS Act&#148;). As an emerging
growth company, we will take advantage of certain exemptions from specified disclosure and other requirements that are otherwise generally applicable to public companies. These exemptions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with the auditor attestation requirements for the assessment of our internal control
over financial reporting provided by Section&nbsp;404 of the Sarbanes-Oxley Act of 2002; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to hold a nonbinding advisory vote on executive compensation or seek shareholder approval of
any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will take advantage of these provisions for up to five years or such earlier
time that we are no longer an emerging growth company. We would cease to be an emerging growth company upon the earliest to occur of (i)&nbsp;the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue;
(ii)&nbsp;the date we qualify as a &#147;large accelerated filer&#148;, with at least $700&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> (iii)&nbsp;the issuance, in any three-year period, by our
Company of more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities; or (iv)&nbsp;the last day of the fiscal year ending after the fifth anniversary of the date of the first sale of common equity
securities pursuant to an effective registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also considered a &#147;foreign private issuer&#148; subject to reporting requirements
under the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company with foreign private issuer status. This means that, even after we no longer qualify as an emerging
growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of
a security registered under the Exchange Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading
activities and liability for insiders who profit from trades made in a short period of time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rules under the Exchange Act requiring the filing with the Securities and Exchange Commission (the
&#147;SEC&#148;) of quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> containing unaudited financial and other specified information, or current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> upon the occurrence of
specified significant events; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the SEC rules on disclosure of compensation on an individual basis unless individual disclosure is required in
our home country (the Netherlands) and is not otherwise publicly disclosed by us. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until such
time as we are no longer a foreign private issuer. We would cease to be a foreign private issuer at such time as more than 50% of our outstanding voting securities are </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
held by U.S. residents and any of the following three circumstances applies: (i)&nbsp;the majority of our executive officers or directors are U.S. citizens or residents, (ii)&nbsp;more than 50%
of our assets are located in the United States or (iii)&nbsp;our business is administered principally in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may choose to take
advantage of some but not all of these reduced reporting requirements of which we have taken advantage of in this prospectus. Accordingly, the information contained herein may be different from the information you receive from our competitors that
are U.S. domestic filers, or other U.S. domestic public companies in which you have made an investment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investing in our securities entails a high degree of risk as more fully described in the &#147;<I>Risk Factors</I>&#148; section beginning on page 14. These
risks include, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a history of operating losses, expect to continue to incur losses and may never be profitable.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need additional financing to fund our operations and complete the development and commercialization of
our various product candidates, and if we are unable to obtain such financing, we may be unable to complete the development and commercialization of our product candidates. Raising additional capital may cause dilution to our existing shareholders,
restrict our operations or require us to relinquish rights to our technologies or product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have limited experience in operating our current business, which makes it difficult to evaluate our business
plan and our prospects. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are substantially dependent on the success of our product candidates and cannot guarantee that these product
candidates will successfully complete development, receive regulatory approval, or be successfully commercialized. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are subject to extensive regulation, and the regulatory approval processes in the U.S., Europe and other
countries or regions are costly, lengthy and time-consuming. We may also experience significant delays in the regulatory approval of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical trials are expensive, time-consuming and difficult to design and implement, and our clinical trial costs
may be higher than for more conventional therapeutic technologies or drug products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The results of preclinical studies and early clinical trials of our product candidates with small patient
populations may not be predictive of the results of later-stage clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Because our current products represent, and our other potential product candidates will represent novel
approaches to the treatment of diseases, there are many uncertainties regarding the development, the market acceptance, third-party reimbursement coverage and the commercial potential of our product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have limited experience in large-scale or commercial manufacturing, and there can be no assurance that we will
be able to effectively manufacture clinical or commercial quantities of our products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our existing therapeutic collaborations are important to our business, and future collaborations may also be
important to our company. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If third parties claim that our activities or products infringe upon their intellectual property, our operations
could be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We may not be able to protect our intellectual property rights throughout the world. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly
qualified personnel, we may not be able to successfully implement our business strategy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are organized and existing under the laws of the Netherlands, and, as such, the rights of our shareholders and
the civil liability of our directors and executive officers will be governed in certain respects by the laws of the Netherlands. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We do not anticipate paying dividends on our ordinary shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are an &#147;emerging growth company&#148;, and it cannot be certain if the reduced SEC reporting requirements
applicable to emerging growth companies will make our ordinary shares less attractive to investors, which could have a material and adverse effect on us, including on our growth prospects. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">COVID-19</FONT> may materially and adversely affect our business and financial
results. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
were incorporated as a Dutch private limited liability company (<I>besloten vennootschap met beperkte aansprakelijkheid</I>) under the name Immatics B.V. on March&nbsp;10, 2020 solely for the purpose of effectuating the Business Combination. Upon
the closing of the Business Combination on July&nbsp;1, 2020, we converted into a Dutch public limited liability company (<I>naamloze vennootschap</I>) and changed our name to Immatics N.V. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, we did not conduct any material activities other than those incident to our formation and certain matters related to the
Business Combination, such as the making of certain required securities law filings and the establishment of subsidiaries to effect the Business Combination. Upon the closing of the Business Combination, Immatics OpCo became the direct, wholly owned
subsidiary of Immatics, and holds all material assets and conducts all business activities and operations of Immatics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registered in the
Commercial Register of the Chamber of Commerce (<I>Kamer</I><I>&nbsp;van</I><I>&nbsp;Koophandel</I>) in the Netherlands under number 77595726. We have our corporate seat is in Amsterdam, the Netherlands and our registered office is at
Paul-Ehrlich-Stra&szlig;e 15, 72076 T&uuml;bingen, Federal Republic of Germany and our telephone number is +49 (7071) <FONT STYLE="white-space:nowrap">5397-0.</FONT> Our executive office in the United States is located at Immatics US, Inc., 2130 W.
Holcombe Boulevard, Houston, Texas 77030 and our telephone number is +1 (346) <FONT STYLE="white-space:nowrap">204-5400.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a website at
www.immatics.com, where we regularly post copies of our press releases as well as additional information about us. Our filings with the SEC are available free of charge through the website as soon as reasonably practicable after being electronically
filed with or furnished to the SEC. Information contained in our website is not a part of, nor incorporated by reference into, this prospectus or our other filings with the SEC, and should not be relied upon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All trademarks, service marks and trade names appearing in this prospectus are the property of their respective holders. Use or display by us of other
parties&#146; trademarks, trade dress, or products in this prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary shares that may be offered and sold from time to time by the selling securityholders</I></B>
</P></TD>
<TD>39,332,281 ordinary shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary shares outstanding</I></B> </P></TD>
<TD>62,908,617 ordinary shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><I>Offering price</I></B> </P></TD>
<TD>The ordinary shares offered by this prospectus may be offered and sold at prevailing market prices, privately negotiated prices or such other prices as the selling securityholders may determine. See the section titled &#147;<I>Plan of
Distribution</I>&#148;. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><I>Use of proceeds</I></B> </P></TD>
<TD>All of the ordinary shares offered by the selling securityholders pursuant to this prospectus will be sold by the selling securityholders for their respective accounts. We will not receive any of the proceeds from such sales. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><I>Transfer restrictions</I></B> </P></TD>
<TD>Pursuant to the Business Combination Agreement and related agreements, the selling securityholders who received ordinary shares in connection with the Business Combination agreed not to sell, transfer, pledge or otherwise dispose of such shares
for 180 days from the closing of the Business Combination, subject to certain limited exceptions.&nbsp;See the section titled &#147;<I>Description of Securities &#151; Transfer Restrictions</I>&#148;. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><I>Dividend policy</I></B> </P></TD>
<TD>We have never declared or paid any cash dividends and have no plan to declare or pay any dividends on our ordinary shares in the foreseeable future. We currently intend to retain any earnings for future operations and expansion.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We will have the power to make distributions to shareholders only to the extent that our equity exceeds the aggregate amount of the issued share capital and the reserves that must be maintained pursuant to Dutch law or
by our articles of association. Any future distributions will be at the discretion of our Management Board and Supervisory Board, as applicable. See the section titled &#147;<I>Dividend Policy</I>&#148;. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><I>Market for our ordinary shares</I></B> </P></TD>
<TD>Our ordinary shares are listed on Nasdaq under the symbol &#147;IMTX&#148;. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B><I>Risk factors</I></B> </P></TD>
<TD>Investing in our securities involves substantial risks. See &#147;<I>Risk Factors</I>&#148; beginning on page&nbsp;14 of this prospectus for a description of certain of the risks you should consider before investing in our ordinary shares or
warrants. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_3"></A>SELECTED CONSOLIDATED HISTORICAL AND OTHER FINANCIAL INFORMATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Selected Historical Financial Data of Immatics OpCo </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables set forth selected historical financial information and operating data for Immatics OpCo as of and for the three months ended
March&nbsp;31, 2020 and 2019 as well as of and for the years ended December&nbsp;31, 2019 and 2018. You should read the following selected historical financial information and operating data in conjunction with the section titled
&#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>&#148;, Immatics OpCo&#146;s unaudited interim condensed consolidated financial statements and related notes thereto and Immatics OpCo&#146;s
consolidated financial statements and related notes, all included elsewhere in this prospectus. The consolidated statement of operations data and consolidated cash flow data for the years ended December&nbsp;31, 2019 and 2018 and the consolidated
balance sheet data as of December&nbsp;31, 2019 and 2018 have been derived from Immatics OpCo&#146;s audited consolidated financial statements appearing elsewhere in this prospectus. The consolidated statement of operations data and cash flow data
for the three months ended March&nbsp;31, 2020 and 2019 and the consolidated balance sheet data as of March&nbsp;31, 2020 have been derived from Immatics OpCo&#146;s unaudited consolidated financial statements appearing elsewhere in this prospectus
and have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, the unaudited data reflects all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of
the financial information in those statements. Immatics OpCo&#146;s historical results may not be indicative of the results that may be achieved in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Statement of Operations Data: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Euros in thousands, except share and per share data</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">18,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,971</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating result</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(11,281</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,636</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(33,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(34,409</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(264</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial result</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,701</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>755</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>526</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,054</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,881</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,487</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,355</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes on income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,881</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,487</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,355</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attributable to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equityholders of the parent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net Loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,881</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,487</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,355</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share &#151; basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7.14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4.89</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(27.13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(27.02</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For more information on the calculation of basic and diluted net loss per share attributable to equityholders
of the parent for the years ended December&nbsp;31, 2019 and 2018, see Note&nbsp;25 to Immatics OpCo&#146;s consolidated financial statements included elsewhere in this prospectus. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Balance Sheet Data: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Euros in thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">72,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">103,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">39,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">69,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,651</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,031</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,835</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidated Cash Flow Data: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Euros in thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2020&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;2019&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">68,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(611</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,862</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Selected Historical Financial Data of ARYA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables contain summary historical financial data for ARYA. Such data as of December&nbsp;31, 2019 and 2018, for the year ended December&nbsp;31,
2019 and for the period from June&nbsp;29, 2018 (inception) through December&nbsp;31, 2018 has been derived from the audited financial statements of ARYA included elsewhere in this prospectus. The summary historical financial data for ARYA as of
March&nbsp;31, 2020 and for the three months ended March&nbsp;31, 2020 and 2019 are derived from ARYA&#146;s unaudited interim financial statements included in this statement prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information below is only a summary and should be read in conjunction with ARYA&#146;s financial statements, and the notes and schedules related thereto,
which are included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year<BR>Ended<BR>December&nbsp;31,<BR>2019<BR>(audited)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period<BR>from June&nbsp;29,<BR>2018<BR>(inception) to<BR>December&nbsp;31,<BR>2018<BR>(audited)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020<BR>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019<BR>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,127,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">153,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">774,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,127,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(774,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment income on Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">857,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">872,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,353,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">738,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,269,852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">718,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,578,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">626,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding of Class&nbsp;A ordinary shares<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net income per share, Class&nbsp;A ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding of Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,593,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,593,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,593,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,593,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share, Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Including 13,545,245, 13,686,244, 13,872,230 and 13,614,368 ARYA Class&nbsp;A ordinary shares subject to
possible redemption as of March&nbsp;31, 2020 and 2019 and December&nbsp;31, 2019 and 2018, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31, 2020<BR>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December&nbsp;31,<BR>2019<BR>(audited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2018<BR>(audited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Condensed Balance Sheet Data (At Period End):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,574,634</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">552,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,327,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">149,483,579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">148,776,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">145,820,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,031,128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,054,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,676,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares subject to possible redemption<SUP
STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135,452,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">138,722,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">136,143,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Working capital calculated as current assets less current liabilities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">13,545,245, 13,872,230 and 13,614,368 ARYA Class&nbsp;A ordinary shares subject to possible redemption at
redemption value at March&nbsp;31, 2020, December&nbsp;31, 2019 and 2018, respectively. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year<BR>Ended<BR>December&nbsp;31,&nbsp;2019<BR>(audited)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period<BR>from June&nbsp;29,<BR>2018&nbsp;(inception)&nbsp;to<BR>December&nbsp;31,&nbsp;2018<BR>(audited)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020<BR>(audited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019<BR>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flow Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(172,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(122,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(323,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(238,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143,750,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,186,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_4"></A>SELECTED UNAUDITED PRO FORMA CONDENSED FINANCIAL INFORMATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following selected pro forma statement of financial positions as of March&nbsp;31, 2020 and the combined statements of loss for the three months
ended March&nbsp;31, 2020 and the year ended December&nbsp;31, 2019 are based on Immatics&#146; historical consolidated financial statements prepared in accordance with International Financial Reporting Standards as issued by the International
Accounting Standards Board (&#147;IFRS&#148;) and ARYA&#146;s historical financial statements and gives effect to all of the transactions contemplated by the Business Combination Agreement and the PIPE Financing (together, the
&#147;Transaction&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The historical financial information has been adjusted to give effect to the events that are related and/or directly
attributable to the Transaction, are factually supportable and are expected to have a continuing impact on the combined results. The adjustments presented in the selected unaudited pro forma condensed combined financial statements have been
identified and presented to provide relevant information necessary for an understanding of the combined company upon consummation of the Transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This selected unaudited pro forma condensed combined financial information should be read together with Immatics&#146;s and ARYA&#146;s financial statements
and related notes, &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and other financial information included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selected unaudited pro forma condensed combined financial information is presented for illustrative purposes only. Such information is only a summary and
should be read in conjunction with the section titled &#147;Unaudited Pro Forma Condensed Combined Financial Statements.&#148; The assumptions and estimates underlying the unaudited pro forma adjustments are described in the notes to the
accompanying unaudited pro forma condensed combined financial information. The financial results may have been different if the companies always had been combined. As the unaudited pro forma condensed combined financial information has been prepared
based on these preliminary estimates, the final amounts recorded may differ materially from the information presented. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Selected Unaudited Pro Forma Condensed Financial Information </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousand)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Immatics</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ARYA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro<BR>Forma*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Financial Position Data as of March&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents and term deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">72,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">303,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121,769</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">352,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50,031</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,564</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Income Data Three Months Ended March&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,018</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,580</TD>
<TD NOWRAP VALIGN="bottom">))&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,540</TD>
<TD NOWRAP VALIGN="bottom">))&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(7.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Income Data Year Ended December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">18,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&#128;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">18,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating result</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,013</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,380</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,487</TD>
<TD NOWRAP VALIGN="bottom">))&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(27.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The pro forma column gives effect to the actual amount of redemptions by stockholders of ARYA at the closing of
the Transaction. For details regarding all of the pro forma adjustments made, please see the section entitled &#147;Unaudited Pro Forma Combined Financial Information.&#148; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our ordinary shares involves a high degree of risk. In addition to the other information set forth in this prospectus, you should carefully
consider the risk factors discussed below when considering an investment in our ordinary shares and any risk factors that may be set forth in the applicable prospectus supplement, any related free writing prospectus, as well as the other information
contained in this prospectus, any applicable prospectus supplement and any related free writing prospectus. If any of the following risks occur, our business, financial condition, results of operations and prospects could be materially and adversely
affected. In that case, the market price of our ordinary shares could decline and you could lose some or all of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our
business operations. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a history of operating losses, expect to continue to incur losses and may never be profitable. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company active in the development and discovery of potential T&nbsp;cell redirecting immunotherapies for the
treatment of cancer. We do not have products approved for commercial sale and have not generated revenue from operations. We have incurred net losses in each year since 2000, including consolidated net losses of &#128;32.5&nbsp;million and
&#128;32.4&nbsp;million for the years ended December&nbsp;31, 2019 and 2018, respectively. As of December&nbsp;31, 2019, we had accumulated consolidated losses of &#128;233.2&nbsp;million. We do not expect to generate any meaningful product sales or
royalty revenues for the foreseeable future. We expect to incur significant additional operating losses in the future as we expand our development and clinical trial activities in support of demonstrating the effectiveness of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to achieve long-term profitability is dependent upon obtaining regulatory approvals for our products and successfully commercializing our products
alone or with third parties. However, our operations may not be profitable even if any of our products under development are successfully developed and produced and thereafter commercialized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need additional financing to fund our operations and complete the development and commercialization of our various product candidates, and if we
are unable to obtain such financing, we may be unable to complete the development and commercialization of our product candidates. Raising additional capital may cause dilution to our existing shareholders, restrict our operations or require us to
relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations have consumed substantial amounts of cash since inception. Our
research and development and our operating costs have also been substantial and are expected to increase. While we have been successful in the past in obtaining financing, we expect to continue to spend substantial amounts to continue the clinical
development of our product candidates. As of December&nbsp;31, 2019, we had $133&nbsp;million in cash and cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, we believe that
our existing cash and cash equivalents will be sufficient to fund our operations until the third quarter of 2021. With this level of funding we plan to continue development of our clinical stage programs IMA201, IMA202, IMA203, and IMA101, the
development of our preclinical stage programs IMA204, IMA401 and IMA402, and to perform further technology advancement and research activities that may lead to new product candidates. See the section titled &#147;<I>Business</I>&#148;. It is
difficult to estimate how far into the development of the current product candidates we will reach with the current level of funding. However, in order to complete the development of our current product candidates, and in order to effectuate our
business plan, we anticipate that we will have to spend more than the funds currently available to us. Additional funding will be required for all programs, including clinical and preclinical programs, prior to market approval and commercialization.
Furthermore, changing circumstances may cause us to increase our spending significantly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
faster than we currently anticipate, and we may require additional capital for the further development and commercialization of our product candidates and may need to raise additional funds
sooner if we choose to expand more rapidly than we presently anticipate. Moreover, our fixed expenses such as rent, minimum payments to our contract manufacturers, and other contractual commitments, including those for our research collaborations,
are substantial and are expected to increase in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will need to obtain additional financing to fund our future operations, including
completing the development and commercialization of our product candidates. Our future funding requirements will depend on many factors, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">progress, timing, scope and costs of our clinical trials, including the ability to timely initiate clinical
sites, enroll subjects and manufacture Adoptive Cell Therapy (&#147;ACT&#148;) and bispecific T cell engaging receptor (&#147;TCR Bispecific&#148;) product candidates for our ongoing, planned and potential future clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">time and cost to conduct investigational new drug application (&#147;IND&#148;) or clinical trial application
(&#147;CTA&#148;) enabling studies for our preclinical programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">time and costs required to perform research and development to identify and characterize new product candidates
from our research programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">time and cost necessary to obtain regulatory authorizations and approvals that may be required by regulatory
authorities to execute clinical trials or commercialize our products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to have clinical and commercial products successfully manufactured consistent with U.S. Food and Drug
Administration (&#147;FDA&#148;), European Medicines Agency (&#147;EMA&#148;), and other authorities&#146; regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amount of sales and other revenues from product candidates that we may commercialize, if any, including the
selling prices for such potential products and the availability of adequate third-party coverage and reimbursement for patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales and marketing costs associated with commercializing our products, if approved, including the cost and
timing of building our marketing and sales capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost of building, staffing and validating our manufacturing processes, which may include capital expenditure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">terms and timing of our current and any potential future collaborations, licensing or other arrangements that we
have established or may establish; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cash requirements of any future acquisitions or the development of other product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">time and cost necessary to respond to technological, regulatory, political and market developments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with any potential business or product acquisitions, strategic collaborations, licensing
agreements or other arrangements that we may establish. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless and until we can generate a sufficient amount of revenue, we may finance
future cash needs through public or private equity offerings, license agreements, debt financings, collaborations, strategic alliances and marketing or distribution arrangements. Additional funds may not be available when we need them on terms that
are acceptable to us, or at all. We have no committed source of additional capital and if we are unable to raise </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional capital in sufficient amounts or on acceptable terms to us, we may be required to delay or reduce the scope of or eliminate one or more of our research or development programs or our
commercialization efforts. Our current license and collaboration agreements may also be terminated if we are unable to meet our obligations to perform contractually agreed research and development work under those agreements. As a result, we may
seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the
terms may include liquidation or other preferences that adversely affect your rights as a shareholder. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as
limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise
additional funds through strategic collaborations and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited experience in operating our current business, which makes it difficult to evaluate our business plan and our prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have only a limited operating history in our current line of business on which a decision to invest in us can be based. Our future currently is dependent
upon our ability to implement our business plan, as that business plan may be modified from time to time by our Management and Supervisory Boards. While we believe that we have a reasonable business plan and research and development strategy, we
have only a limited operating history against which we can test our plans and assumptions, and investors therefore cannot evaluate the likelihood of our success based on previous experience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face the problems, expenses, difficulties, complications and delays normally associated with
<FONT STYLE="white-space:nowrap">a&nbsp;pre-commercial&nbsp;biopharmaceutical</FONT> company, many of which are beyond our control. Accordingly, our prospects should be considered in light of the risks, expenses and difficulties frequently
encountered in the establishment of a new business developing technologies in an industry that is characterized by a number of market entrants and intense competition. Because of our size and limited resources, we may not possess the ability to
successfully overcome many of the risks and uncertainties frequently encountered by <FONT STYLE="white-space:nowrap">pre-commercial</FONT> companies involved in the rapidly evolving field of immunotherapy. If our research and development efforts are
successful, we may also face the risks associated with the shift from development to commercialization of new products based on innovative technologies. There can be no assurance that we will be successful in developing and commercialization of our
product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are substantially dependent on the success of our product candidates and cannot guarantee that these product candidates will
successfully complete development, receive regulatory approval, or be successfully commercialized. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently have no products approved for
commercial sale. We have invested a significant portion of our efforts and financial resources in the development of our current product candidates and expect that we will continue to invest heavily in our current product candidates, as well as in
any future product candidates we may develop. Our business depends entirely on the successful development and commercialization of our product candidates, which may never occur. Our ability to generate revenues in the future is substantially
dependent on our ability to develop, obtain regulatory approval for, and then successfully commercialize our product candidates. We currently generate no revenue from the sale of any products, and we may never be able to develop or commercialize a
marketable product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates will require additional clinical
<FONT STYLE="white-space:nowrap">and&nbsp;non-clinical&nbsp;development,</FONT> regulatory approval, commercial manufacturing arrangements, establishment of a commercial organization, significant marketing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
efforts, and further investment before we generate any revenue from product sales. We cannot assure you that we will meet our timelines for our current or future clinical trials, which may be
delayed or not completed for a number of reasons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not permitted to market or promote any of our product candidates before we receive regulatory
approval from the FDA or comparable regulatory authorities in other countries, and we may never receive such regulatory approval for any of our product candidates or regulatory approval that will allow us to successfully commercialize our product
candidates. If we do not receive regulatory approval with the necessary conditions to allow successful commercialization, and then successfully commercialize our product candidates, we will not be able to generate revenue from those product
candidates in the United States or other countries in the foreseeable future, or at all. Any significant delays in obtaining approval for and commercializing our product candidates will have a material adverse impact on our business and financial
condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not previously submitted a biologics license application (&#147;<I>BLA</I>&#148;) to the FDA, or similar marketing application to
comparable foreign authorities, for any product candidate, and we cannot be certain that our current or any future product candidates will be successful in clinical trials or receive regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates are susceptible to the risks of failure inherent at any stage of product development, including the appearance of unexpected adverse
events or failure to achieve primary endpoints in clinical trials. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will be unable to commercialize our products if our trials are not successful. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development programs are at an early stage. We must demonstrate our products&#146; safety and effectiveness in humans through extensive
clinical testing. We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent commercialization of our products, including but not limited to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after reviewing trial results, we or our collaborators may abandon projects that we might previously have
believed to be promising; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, our collaborators or regulators may suspend or terminate clinical trials if the participating subjects or
patients are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects our potential products have may not be the desired effects or may include undesirable side effects or
other characteristics that preclude regulatory approval or limit their commercial use if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturers may not meet the necessary standards for the production of the product candidates or may not be
able to supply the product candidates in a sufficient quantity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may find that our clinical trial design or conduct does not meet the applicable approval
requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safety and efficacy results in various human clinical trials reported in scientific and medical literature may
not be indicative of results we obtain in our clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical testing is very expensive, can take many years, and the outcome
is uncertain. It could take several years before we learn the results from any clinical trial using ACT or TCR Bispecifics. The data collected from our clinical trials may not be sufficient to support approval by the FDA, EMA, or regulatory
authorities in other countries of <FONT STYLE="white-space:nowrap">our&nbsp;ACT-&nbsp;or</FONT> TCR Bispecifics-based product candidates for the treatment of tumors. The clinical trials for our products under development may not be completed on
schedule and the FDA, EMA or regulatory authorities in other countries may not ultimately approve any of our product candidates for commercial sale. If we fail to adequately demonstrate the safety and effectiveness of any product candidate under
development, we may not receive regulatory approval for those products, which would prevent us from generating revenues or achieving profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Business and the Development, Regulatory Review and Approval of our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA regulatory pathways can be difficult to predict, and whether, for example, the FDA&#146;s Accelerated Approval pathway is available or further
unanticipated clinical trials are required will depend on the data obtained in our ongoing clinical trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regulatory approval pathway and
the amount of time it takes us to obtain regulatory approvals for our product candidates will depend on the data that are obtained in our ongoing clinical trials and any future clinical trials, including future registrational or pivotal clinical
trials. We may attempt to seek approval on a per indication basis for our product candidates on the basis of a single pivotal trial or on the basis of data from one or more uncontrolled trials. While the FDA requires in most cases two adequate and
well-controlled pivotal clinical trials to demonstrate the efficacy of a product candidate, a single trial with strong confirmatory evidence may be sufficient in instances where the trial is a large multicenter trial demonstrating internal
consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and if confirmation of the result in a second trial would be
practically or ethically impossible. In rare cancer indications with very limited treatment options, a large and/or controlled trial is often not feasible and thus data from smaller and even uncontrolled trials may be sufficient for regulatory
approval. Depending on the data we obtain, the FDA or other regulatory authorities may require additional clinical trials to be carried out or further patients to be treated prior to the granting of any regulatory approval for marketing of our
product candidates. It is difficult for us to predict with such a novel technology exactly what will be required by the regulatory authorities in order to take our product candidates to market or the timeframes under which the relevant regulatory
approvals can be obtained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has various programs that are intended to facilitate and expedite development and review of new drugs to address unmet
medical need in the treatment of serious or life-threatening conditions. These expedited programs help ensure that therapies for serious conditions are available as soon as it can be concluded that the therapies&#146; benefits justify their risks,
taking into account the seriousness of the condition and the availability of alternative treatment. These programs include Breakthrough Therapy designation, Fast Track designation, Accelerated Approval, and Priority Review designation. Depending on
the data that is we obtain in our current and future clinical trials for our wholly owned product candidates, we may seek Breakthrough Therapy or Fast Track designation, Priority Review, or Accelerated Approval from the FDA for our product
candidates and equivalent accelerated approval procedures in other countries. However, given the novel nature of our product candidates, it is difficult for us to predict or guarantee whether the FDA or other regulatory authorities will approve such
requests or what further clinical or other data may be required to support an application for such accelerated approval procedures. Even if we obtain Breakthrough Therapy designation, the FDA may decide to rescind the designation if, for example,
the designation is no longer supported by clinical data obtained after designation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process of obtaining marketing approvals, both in the United
States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product
candidates involved. For example, clinical trials may be required in pediatric populations before any marketing approval can be obtained, which can be time-consuming and costly. Changes in marketing approval policies during the development period,
changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and foreign regulatory authorities
also have substantial discretion in the drug and biologics approval processes. The number and types of preclinical programs and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or
condition that the product candidate is designed to address, and the regulations applicable to any particular product candidate. Approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the
course of a product candidate&#146;s clinical development and may vary among jurisdictions, and there may be varying interpretations of data obtained from preclinical programs or clinical trials, either of which may cause delays or limitations in
the approval or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
decision not to approve an application. In addition, approval of our product candidates could be delayed or refused for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our or our
collaborators&#146; clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or our collaborators may be unable to demonstrate to the satisfaction of the FDA or comparable foreign
regulatory authorities that our product candidates are safe, pure, potent and have a favorable risk/benefit profile for any of their proposed indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or
comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from
preclinical programs or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of product candidates may not be sufficient to the satisfaction of the
FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our manufacturing processes or facilities or those of the third-party manufacturers we use may not be adequate to
support approval of our product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly
change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that no product candidates will ever obtain
the appropriate regulatory approvals necessary to commercialize one of our ACT and TCR Bispecific therapies. Any delay in obtaining, or failure to obtain, required approvals would materially adversely affect our ability to generate revenue from the
particular product candidate, which would result in significant harm to our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to extensive regulation, and the regulatory
approval processes in the U.S., Europe and other countries or regions are costly, lengthy and time-consuming. We may also experience significant delays in the regulatory approval of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our potential products, cell processing and manufacturing activities, are subject to comprehensive regulation by the FDA in the United States and by comparable
authorities in other countries. The process of obtaining FDA and other required regulatory approvals, including foreign approvals, is expensive and often takes many years and can vary substantially based upon the type, complexity and novelty of the
products involved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not previously submitted a BLA to the FDA, or similar approval submissions to comparable foreign authorities. A BLA must
include extensive preclinical and clinical data and supporting information to establish that the product candidate meets the prescribed requirements of safety, purity and potency for each desired indication. The BLA must also include detailed
information regarding the chemistry, manufacturing and controls for the product. International marketing authorization applications equivalent to a BLA must contain similar types of data and information. We expect the novel nature of our product
candidates to create additional challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of T cell directed therapies for cancer. Accordingly, the regulatory approval pathway for our
product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained. Requirements and requests for additional information can occur for any clinical trial of any of our product candidates. Such request can result in
delays of the start of our clinical trials or in clinical holds being imposed on ongoing trials, and there is no guarantee that the FDA will not continue to require further or additional information ahead of permitting any trial to proceed, whether
from our collaborators or from us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we violate regulatory requirements at any stage, whether before or after marketing approval is obtained, we may
face a number of regulatory consequences, including refusal to approve pending applications, license </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
suspension or revocation, withdrawal of an approval, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, modification of promotional materials or
labeling, provision of corrective information, imposition of post-marketing requirements and commitments including the need for additional testing, imposition of distribution or other restrictions under a Risk Evaluation and Mitigation Strategy
(&#147;<I>REMS</I>&#148;), product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, FDA debarment, injunctions, fines, consent decrees, corporate integrity
agreements, debarment from receiving government contracts, and new orders under existing contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement, or civil or criminal penalties, including fines and
imprisonment, and adverse publicity, among other adverse consequences. Additionally, we may not be able to obtain the labeling claims necessary or desirable for the promotion of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We or our collaborators could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of
our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us or a collaborator, Institutional Review Boards (&#147;IRBs&#148;)
for the institutions in which such trials are being conducted or by responsible Ethics Committees (&#147;ECs&#148;), the Data Monitoring Committee for such trial, or by the FDA or other regulatory authorities due to a number of factors, including
failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a
clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical
trial. If we or our collaborators experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product
revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow our product development and approval process and jeopardize our ability to commence product sales and generate revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we have limited experience in conducting clinical trials with adoptive cellular therapies and T cell engaging biologics and in conducting
clinical trials through to regulatory approval. Because of this lack of experience, we cannot be certain that planned clinical trials will begin or be completed on time, if at all. Large-scale trials would require significant additional financial
and management resources, and reliance on third-party clinical investigators, contract research organizations (&#147;CROs&#148;), or consultants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of
the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to manufacturing risks that could substantially increase our costs and limit supply of our products. The manufacture of our product
candidates is complex, and we may encounter difficulties in production, particularly with respect to process development, quality control, upscaling <FONT STYLE="white-space:nowrap">or&nbsp;scaling-out&nbsp;of</FONT> our manufacturing capabilities.
If we, or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or stopped, or we may be unable to
maintain a commercially viable cost structure. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our product candidates are cellular products or biologics and the process of manufacturing our
products is complex, highly regulated and subject to multiple risks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacture of our cellular product candidates involves complex processes,
including, for example, for ACTengine genetically modified autologous T cell products (IMA201, IMA202, IMA203, and IMA204), harvesting and transporting blood cells from every patient for T cell isolation, engineering of the T cells to express a
specific T cell receptor for a tumor target,<I>&nbsp;ex vivo</I>&nbsp;multiplying the T cells to obtain the desired cell numbers for the dose, and finally transporting of the T cell product back to the patient for infusing the modified
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
T&nbsp;cells back into the same patient. As a result of the complexities, the cost to manufacture cellular products per dose is generally higher than traditional small molecule chemical compounds
or biologics, and the manufacturing process is less reliable, more variable and is more difficult to reproduce. Our manufacturing process may be susceptible to product loss or failure due to logistical issues associated with the collection of
patients&#146; blood cells, shipping such material to the manufacturing site, shipping the final product back to the patient, and infusing the patient with the product. Product loss or failure may also be caused by manufacturing issues associated
with the variability in patient starting material especially from heavily treated cancer patients, interruptions in the manufacturing process, contamination, equipment failure, assay failures, improper installation or operation of equipment, vendor
or operator error, inconsistency in cell growth, and variability in product characteristics. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If for
any reason we lose a patient&#146;s starting material, or any intermediate product at any point in the process, or if any product does not meet the preset specifications, the manufacturing process for that patient will need to be restarted,
sometimes <FONT STYLE="white-space:nowrap">including&nbsp;re-collection&nbsp;of</FONT> blood cells from the patient, and the resulting delay may adversely affect that patient&#146;s outcome. It may even happen, that failed product manufacture may
prevent a patient from getting a T cell product. If microbial, environmental or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities
may need to be closed for an extended period of time to investigate and remedy the contamination. If such contaminations or other product quality issues are not discovered and if as a result thereof patients are exposed to a health risk, we may be
held liable. Our insurance may not cover those cases, or the financial coverage may not be sufficient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because our ACTengine cellular product candidates
are manufactured specifically for each individual patient, we will be required to maintain a chain of identity with respect to the patient&#146;s cellular material as it moves from the patient to the manufacturing facility, through the manufacturing
process, and back to the patient. Maintaining such a chain of identity is difficult and complex, and failure to do so could result in adverse patient outcomes, loss of product, or regulatory action including withdrawal of our products from the
market. Further, as product candidates are developed through preclinical to late stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered
along the way to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of planned
clinical trials or other future clinical trials or otherwise necessitate the conduct of additional studies, including bridging clinical trials, which can be costly and time-consuming. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, our cellular product candidates are manufactured using processes developed or modified by us but based on current industry standards and are
designed to deliver a clinical proof of concept (&#147;PoC&#148;). We have selected an open process as the manufacturing process for early stage clinical trials through PoC. However, we are currently developing a second-generation process that is
closed, partially automated and viable for advanced clinical trials through product registration, and all ongoing and future company-sponsored clinical trials. Although we believe that the
2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>&nbsp;generation process is commercially viable, there are risks associated with scaling to the level required for advanced clinical trials or commercialization, including, among others, cost
overruns, potential problems with process <FONT STYLE="white-space:nowrap">upscaling,&nbsp;scale-out,&nbsp;process</FONT> reproducibility, technology transfer, stability issues, lot consistency, and timely availability of raw materials. This
includes potential risks associated with FDA not agreeing with all of the details of our validation data or our potency assay for our Phase 1 or future Phase 2 clinical trials. Furthermore, some of our contract manufacturing organizations
(&#147;CMOs&#148;) may not be able to establish comparability of their products with the ACT products used in our Phase 1 or future Phase 2 clinical trials or may not be fully validated prior to starting our pivotal or registration clinical trial.
As a result of these challenges, we may experience delays in our clinical development and/or commercialization plans. We may ultimately be unable to reduce the cost of goods for our product candidates to levels that will allow for an attractive
return on investment if and when those product candidates are commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our manufacturing capabilities for our allogenic cellular therapy product
candidate IMA301 are still in the process of being developed. We may not successfully establish a robust production process that fulfills the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements of the FDA and other regulatory authorities. If we fail to establish such a manufacturing process, we may not be able to commence clinical trials in IMA301 or clinical trials may be
delayed. We also cannot guarantee that the production process we are currently developing for IMA301 is viable and can be effectively scaled up or transferred to an CMO for later phase clinical testing and commercialization. For example, there is
insufficient experience in the field regarding vectors for transduction of the&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> T cells used to manufacture IMA301. If it turns out that we cannot
generate a suitable <FONT STYLE="white-space:nowrap">and&nbsp;GMP-compliant&nbsp;vector,</FONT> the IMA301 manufacturing process may be endangered. If we fail to develop a process that can be used throughout the life cycle of the product candidate,
commercialization of IMA301 may be delayed or may not occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing of TCR Bispecifics (TCER), such as IMA401, IMA402 and potential future product
candidates, is susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, inconsistency in yields, issues with purity, variability in product characteristics and
difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, inacceptable purity, product defects, loss of production batches and other supply disruptions. In
such cases, our development program may experience major delays and we may have to produce a new batch of a given TCER. This will be costly and will delay our TCER development program. In particular, production of a new GMP batch may be
time-consuming, as it relies on the availability of facilities with GMP capabilities at our CMO, and such facilities must be booked far in advance. We may also experience failure of production of the master cell bank that is used to produce our TCER
molecules. For example, missing clonality of the cell line <FONT STYLE="white-space:nowrap">or&nbsp;non-sterility&nbsp;of</FONT> the cell bank may require production of a new master cell bank which would be associated with additional costs and
delays. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any failure to follow current Good Manufacturing Practice (&#147;cGMP&#148;) or other regulatory requirements or any delay, interruption or other
issues that arise in the manufacture, fill and finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any
regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of drug product for our clinical trials or the termination of or
hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our TCR Bispecific
product candidates that have been produced and are stored for later use may degrade, become contaminated or suffer other quality defects, which may cause the affected product candidates to no longer be suitable for their intended use in clinical
trials or other development activities. If the defective product candidates cannot be replaced in a timely fashion, we may incur significant delays in our development programs that could adversely affect the value of such product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2015, we entered into a lease agreement with the University of Texas Health (&#147;UTH&#148;) facility in Houston, Texas for clinical production
of ACT products, including our product candidates IMA101, IMA201, IMA202, and IMA203 for clinical trials, and we also intend to manufacture IMA204, IMA301 and potentially also future cellular therapy product candidates in this facility once INDs or
CTAs have been approved for these product candidates, especially for early stage clinical trials, by the respective regulatory bodies. We would expect that development and construction of our own manufacturing facility would provide us with enhanced
control of material supply for both clinical trials and the commercial market, enable a more efficient implementation of process changes, and allow for better long-term margins. However, we have no experience as a company in developing a large
manufacturing facility, and we may not be successful in finalizing the development of our own manufacturing facility or capability. We may establish multiple manufacturing facilities as we expands our commercial footprint to multiple geographies,
which may lead to regulatory delays or prove costly. Even if we are successful, our manufacturing capabilities could be affected by cost-overruns due to idle capacity, unexpected delays, equipment failures, labor shortages, natural disasters,
epidemics, power failures, and numerous other factors that could prevent us from realizing the intended benefits of our manufacturing strategy and have a material adverse effect on our business. The manufacture of cell therapy products requires
significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling up initial production. These problems include difficulties with production costs and
yields, quality control, including stability, patient to patient variability of the product candidate and quality assurance testing, shortages of qualified personnel, and compliance with strictly enforced federal, state, local and foreign
regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any problems or delays we or our CMOs experience in preparing for commercial scale manufacturing of a cell therapy or biologic product
candidate or component may result in a delay in the FDA approval of the product candidate or may impair our ability to manufacture commercial quantities or such quantities at an acceptable cost, which could result in the delay, prevention, or
impairment of clinical development and commercialization of our product candidates and could adversely affect our business. Furthermore, if we or our commercial manufacturers fail to deliver the required commercial quantities or supply of our
product candidates on a timely basis and at reasonable costs, we would likely be unable to meet demand for our products, and we would lose potential revenues. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the manufacturing process and facilities for any products that we may develop is subject to FDA and/or foreign regulatory authority approval
processes, and we our our CMOs will need to meet all applicable regulatory authority requirements, including cGMP and current Good Tissue Practices (&#147;cGTP&#148;) requirements, on an ongoing basis, including requirements pertaining to quality
control, quality assurance, and the maintenance of records and documentation. The FDA and other regulatory authorities enforce these requirements through facility inspections. Manufacturing facilities must be approved by the FDA pursuant to
inspections that will be conducted after we submit our marketing applications. Manufacturers are also subject to continuing FDA and other regulatory authority inspections following marketing approval. Further, we, in cooperation with our CMOs, must
supply all necessary chemistry, manufacturing, and control documentation in support of a BLA on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, or our CMOs&#146; manufacturing
facilities, may be unable to comply with our specifications, cGMP and cGTP requirements, and with other FDA, state, and foreign regulatory requirements. Poor control of production processes can lead to the introduction of adventitious agents or
other contaminants, or to inadvertent changes in the properties or stability of product candidates that may not be detectable in final product testing. If we or our CMOs are unable to reliably produce products to specifications acceptable to the FDA
or other regulatory authorities, or in accordance with the strict regulatory requirements, we may not obtain or maintain the approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates,
there is no assurance that either we or our CMOs will be able to manufacture the approved product to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the
potential launch of the product, or to meet potential future demand. Deviations from manufacturing requirements may further require remedial measures that may be costly and/or time-consuming for us or a third party to implement and may include the
temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even to the extent we use and continue to use CMOs, we are ultimately responsible for the manufacture of our products and product candidates. A failure to
comply with these requirements may result in regulatory enforcement actions against our manufacturers or us, including fines and civil and criminal penalties, which could result in imprisonment, suspension or restrictions of production, suspension,
injunctions, delay or denial of product approval or supplements to approved products, clinical holds or termination of clinical trials, warning or untitled letters, regulatory authority communications warning the public about safety issues with the
biologic, refusal to permit the import or export of the products, product seizure, detention, or recall, operating restrictions, suits under the civil False Claims Act (&#147;FCA&#148;), corporate integrity agreements, consent decrees, or withdrawal
of product approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Challenges we may face could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more
clinical trials, increase clinical trial costs, delay approval of our product candidates, impair </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialization efforts, increase our cost of goods, cause a lack of patient participation in clinical trials and have an adverse effect on our business, financial condition, results of
operations and growth prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are engaged in preclinical development to identify, generate and characterize new product candidates for
potential clinical development. Drug development is expensive, time-consuming and we are uncertain that such development programs will lead to new drug candidates that may continue to be tested in clinical trials and receive regulatory approval.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A significant portion of our research activities focus on the identification, generation and characterization of new product candidates. These
activities are expensive, time-consuming and costly, and may never lead to a product candidate that shows appropriate safety and efficacy data in preclinical studies to enter clinical development. This means that success from research and
development is uncertain, early programs may not reach clinical development and we may never produce revenues from our preclinical development activities. If the target criteria for a product candidate are not met, we may also decide to prolong
preclinical development to improve the profile of a product candidate. In addition, if new treatment options are approved for the same indications as our preclinical product candidates, we may discontinue such early development programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The targets addressed by IMA201, IMA202, IMA203, IMA301, IMA401, IMA402 belong to the class of cancer testis antigens that are well-established immunotherapy
targets. Future targets for product development may not belong to well-known target proteins and generation of such product candidates may be challenging. For example, IMA204 is directed against a tumor stroma target. We are not aware of a
comparable product candidate currently in preclinical or clinical development. We may find out during preclinical development that targets like the one addressed by IMA204 cannot be safely addressed by immunotherapy. We cannot guarantee that we will
be able to show safety and efficacy for product candidates addressing new target classes like the one addressed by IMA204, and we may not be able to enter clinical testing with or to successfully market IMA204 or similar future product candidates.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Development of a product candidate intended for use in combination with an already approved product may present more or different challenges than
development of a product candidate for use as a single agent. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently developing IMA201, IMA202, IMA203, IMA204, IMA101, IMA301, IMA401,
and IMA402. We and our collaborators are also studying or intending to study ACT product candidates and TCR Bispecifics product candidates along with other products, such as checkpoint inhibitor immunotherapies. The development of product candidates
for use in combination with another product may present challenges. For example, the FDA may require us to use more complex clinical trial designs, in order to evaluate the contribution of each product and product candidate to any observed effects.
It is possible that the results of these trials could show that most or any positive results are attributable to the already approved product. Moreover, following product approval, the FDA may require that products used in conjunction with each
other be cross-labeled. To the extent that we do not have rights to already approved products, this may require us to work with another company to satisfy such a requirement. Moreover, developments related to the already approved products may impact
our clinical trials for the combination as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the approved product&#146;s safety or efficacy profile, changes to the availability of the
approved product, and changes to the standard of care. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we encounter difficulties enrolling patients in our clinical trials, our clinical
development activities could be delayed or otherwise adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The timely completion of clinical trials in accordance with their
protocols depends, among other things, on our ability to enroll a sufficient number of patients. Despite diligent planning of our clinical trials and analysis of their feasibility regarding patient recruitment, we may experience difficulties, delays
or inability in patient enrollment in our clinical trials for a variety of reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and nature of the patient population; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity and incidence of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the general health condition of the patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient eligibility criteria and study procedures defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size of the study population required for analysis of the trial&#146;s primary endpoints;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the trial and the complexity for patients and clinical sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the screening procedures and the rate of patients failing screening procedures; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the duration required for screening and manufacturing of the patients&#146; investigational products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients&#146; general health conditions do not allow the conduct of study/screening procedures
(for example, tumor biopsy, or leukapheresis) or application of lymphodepletion regimen; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to manufacture patient products appropriately (for example, at a sufficient high dose, or with
sufficiently active T cells); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insufficient manufacturing capacities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to establish appropriate drug substance or drug product logistics/transportation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to obtain approval (regulatory and ethical approval and approval according to local law) for the
conduct of the clinical trial in a sufficient number of countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to recruit appropriate clinical sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to provide appropriate screening assays; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the efforts to facilitate timely enrollment in clinical trials and the effectiveness of recruiting publicity;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patient referral practices of physicians within the same hospital as well as within other hospitals or
private practices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competing clinical trials for similar therapies, other new therapeutics, new combination treatments, new
medicinal products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval of new indications for existing therapies or approval of new therapies in general or changes in standard
of care; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of surgical measures leading to a higher cure rate of patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of preventive measures leading to early detection of the disease under investigation and a
higher cure rate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of measures (for example, prophylactic vaccines) leading to a dramatic reduction in incidence
of the disease under investigation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages and side effects of the product
candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved or become standard of care for the indications we are investigating; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical investigators enrolling patients who do not meet the enrollment criteria, requiring the inclusion of
additional patients in clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to obtain and maintain patient consents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients having received a single anti-tumor infusion in clinical trials start additional
anti-tumor treatments despite of not having experienced progression of tumor disease; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability of clinical sites to enroll patients as health care capacities are required to cope with natural
disasters, epidemics or other health system emergencies, such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some eligible
patients may instead opt to enroll in a competitor&#146;s trial. Because the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use,
which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Enrolling patients at the same sites as our competitors may compromise the quality and conclusiveness of our clinical data by
introducing bias. Moreover, because our product candidates represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and
approved immunotherapies, rather than enroll patients in any clinical trial. In addition, potential enrollees in our ACT trials with IMA101, IMA201, IMA202, IMA203 or IMA204 may opt to participate in other clinical trials because of the length of
time between the time that their tumor is excised and the ACT is infused back into the patient. Amendments to our clinical protocols may affect enrollment in, or results of our trials, including amendments we have made to further define the patient
populations to be studied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not all patients suffering from a specific cancer that is in principle addressable by our product candidates are eligible for
our trials and therapies. First, patients have to express a specific genetic marker <FONT STYLE="white-space:nowrap">called&nbsp;HLA-A*02.&nbsp;While</FONT> this marker is found on
<FONT STYLE="white-space:nowrap">approximately&nbsp;40-50%&nbsp;of</FONT> individuals in North America and Europe, it is less frequent in other populations, such as China or Japan. If human leukocyte antigen (&#147;HLA&#148;) screening for a patient
shows <FONT STYLE="white-space:nowrap">that&nbsp;HLA-A*02&nbsp;is</FONT> not expressed, he or she cannot be treated with our current product candidates. Second, the prevalence of the targets addressed by IMA201, IMA202, IMA203 and IMA204 differs
between different tumor entities. For a given patient, a biomarker assay must be performed in order to find out whether he or she expresses one of the targets and can be treated with one of our product candidates. We cannot be certain that the
anticipated and assumed target prevalence are confirmed in the patient populations of our Phase 1 trials, and lower target prevalences may be experienced. Third, further eligibility criteria are in place to ensure that the patients can tolerate and
potentially benefit from the treatment. Thus, only a fraction of patients screened for our clinical trials will finally receive cellular products. Patients may therefore be hesitant to consent to our trials, and overall many more patients will have
to be screened to treat the targeted number of patients. This may hinder recruitment for our trials and may delay our development timelines. It is uncertain how many more patients we will be required to screen. If the required number of patient
screenings is much higher than anticipated, our clinical trial costs may increase. We may combine two or more product candidates into multi-target trials to mitigate this risk. However, we cannot be certain whether this measure will be effective in
enhancing recruitment. Multi-target trials may also be more difficult to implement and to be permitted to proceed by FDA or other competent authority outside the U.S. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we are able to enroll a sufficient number of patients in our clinical trials, delays in patient enrollment or small population size may result in
increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The FDA may disagree with our regulatory plan, and we may fail to obtain regulatory approval of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If and when our ongoing Phase 1 clinical trials for IMA201, IMA202, IMA203, and IMA101 are completed and, assuming positive data, we expect to advance to
potential registrational trials. The general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two well-controlled, Phase 3 clinical studies of the relevant biologic or drug in the relevant
patient population. Phase&nbsp;3 clinical studies typically involve hundreds of patients, have significant costs and take years to complete. We anticipate pursuing registrational trials, for example for IMA201, IMA202, and IMA203, as single agents
or in combination that are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
designed to evaluate the efficacy of the respective product candidate in a single open-label, <FONT STYLE="white-space:nowrap">non-comparative,</FONT>
<FONT STYLE="white-space:nowrap">two-stage,</FONT> pivotal, <FONT STYLE="white-space:nowrap">multicenter,&nbsp;single-arm&nbsp;clinical</FONT> trials in patients who have exhausted available treatment options. We plan to discuss our proposed trial
designs with the FDA and other authorities prior to submission of INDs and CTAs. If the trial results are sufficiently compelling, we intend to discuss with the FDA submission of a BLA for the relevant product candidate. Further, we plan to have
discussions with other authorities, such as the EMA in Europe or Health Canada in Canada regarding any planned marketing authorization submissions. It cannot be guaranteed that FDA and other regulatory authorities will agree to move to a
registrational trial on the basis of data generated from a single completed Phase 1 trial. Authorities may ask for additional early stage or Phase 2 clinical data first. Even if the FDA agrees with the design and implementation of the clinical
trials set forth in an IND, we cannot guarantee that the FDA will not change their requirements in the future. For example, the FDA may require that we conduct a comparative trial against an approved therapy including potentially an approved
autologous T cell therapy, which would significantly delay our development timelines and require substantially more resources. In addition, the FDA may only allow us to evaluate patients that have already failed autologous therapy or very late stage
patients, which are extremely difficult patients to treat and patients with advanced and aggressive cancer, and our product candidates may fail to improve outcomes for such patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may pursue an approval under FDA&#146;s Accelerated Approval pathway, and we believe our Accelerated Approval strategy is warranted given the limited
alternatives for patients with relapsed and/or refractory cancers. However, the FDA may ultimately require a Phase 3 clinical trial prior to approval, particularly since our product candidates represent a novel treatment. In addition, the standard
of care may change with the approval of new products, which may result in the FDA requiring a demonstration of meaningful therapeutic benefit to patients over such existing treatments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a condition of approval, the FDA may require that we implement various post-marketing requirements and conduct post-marketing studies, any of which
would require a substantial investment of time, effort, and money, and which may limit our commercial prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a condition of biologic
licensing, the FDA is authorized to require that sponsors of approved BLAs implement various post-market requirements, including a REMS, and/or one or more Phase 4 studies. For example, when the FDA approved Novartis&#146; Kymriah in August 2017, <FONT
STYLE="white-space:nowrap">a&nbsp;CAR-T&nbsp;cell</FONT> therapy for the treatment of patients up to 25 years of age <FONT STYLE="white-space:nowrap">with&nbsp;B-cell&nbsp;precursor</FONT> acute lymphoblastic leukemia (&#147;<I>ALL</I>&#148;) that
is refractory or in second or later relapse, the FDA required significant post-marketing commitments, including a Phase 4 trial, revalidation of a test method, and a substantial REMS program that included, among other requirements, the certification
of hospitals and their associated clinics that dispense Kymriah, which certification includes a number of requirements, the implementation of a Kymriah training program, and limited distribution only to certified hospitals and their associated
clinics. If we receive approval of our product candidates, the FDA may determine that similar or additional post-approval requirements are necessary. To the extent that we are required to establish and implement any post-approval requirements, we
will likely need to invest a significant amount of time, effort, and money. Such post-approval requirements may also limit the commercial prospects of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to market and sell our products outside the United States, we or
our third-party collaborators are required to obtain separate marketing approvals and comply with numerous and varying regulatory requirements. Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not
guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in
others. Approval policies and requirements may vary among jurisdictions. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing,
marketing and promotion of the product candidate in those countries. Approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical
studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement
before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. We or our collaborators may not be able to file for regulatory approval of our product
candidates in international jurisdictions or obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us
and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our
ability to realize the full market potential of our product candidates will be harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to file applications to commence
additional clinical trials on the timelines we expect, and even if we are able to, the FDA or applicable competent authorities may not permit us to proceed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to submit INDs for additional product candidates to the FDA in the future. We also plan to submit applications to start clinical trials of additional
product candidates outside the U.S. to the national competent authorities (for example, CTA to Paul-Ehrlich Institute (&#147;PEI&#148;) in Germany). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
filing of INDs to the FDA and the filing of applications outside the U.S. is dependent on additional data that have to be generated to support such regulatory filings. Hence, these filings may be delayed if the tests to generate those data show
unexpected results or if technical issues arise in generating those data in the first place. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot be sure that submission of an IND, IND amendment
or CTA will result in the FDA or any other competent authority outside the U.S. allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trials. The manufacturing and
preclinical safety and efficacy testing requirements of both ACT and TCR Bispecifics remain emerging and evolving fields. Accordingly, we expect chemistry, manufacturing and control related topics, including product specification, as well as
preclinical safety testing, will be a focus of IND reviews, which may delay the allowance of INDs by the FDA or CTA approval by other competent authorities outside the U.S. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our current clinical trials are being conducted outside the United States, and the FDA may not accept data from trials conducted in foreign
locations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain current clinical trials of our drug candidates are being conducted or planned to be conducted partially outside the United
States. We may also conduct future clinical trials for our drug candidates partially or fully outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to
certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles and good clinical practice (&#147;GCP&#148;) requirements.
Further, the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In general, the patient population for any clinical trials conducted outside of the United States must be
representative of the population for whom we intend to label the product in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination
that the trials also complied with all applicable U.S. laws and regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conducting clinical trials outside the United States also exposes us to
additional risks, including risks associated with: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additional foreign regulatory requirements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign exchange fluctuations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with foreign manufacturing, customs, shipment and storage requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an inability to negotiate the terms of clinical trial agreements at arms&#146; length in countries where a
template agreement for such trials is required by law; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cultural differences in medical practice and clinical research; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diminished protection of intellectual property in some countries. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot assure you that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from such clinical
trials, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of our drug candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>It may take longer and cost more to complete our clinical trials than we project, or we may not be able to complete them at all. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For budgeting and planning purposes, we have projected the date for the commencement of future trials, and continuation and completion of our ongoing clinical
trials. However, a number of factors, including scheduling conflicts with participating clinicians and clinical institutions, difficulties in identifying and enrolling patients who meet trial eligibility criteria, and unanticipated adverse events
may cause significant delays. We may even not be able to complete clinical trials involving any of our products at all or as projected. Delays in clinical trials are associated with significant costs to maintain the necessary services,
infrastructure and to pay running obligations to internal staff, clinical sites and service providers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The timely completion of clinical trials in
accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. In addition, our clinical trials will compete with other clinical trials for product
candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to
enroll in a competitor&#146;s trial. Accordingly, we cannot guarantee that our trials will progress as planned or as scheduled. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing and planned
clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
expect to rely on outside vendors (for example, independent contractors and contract research organizations) to conduct, supervise or monitor some or all aspects of clinical trials involving our products. We will have less control over the timing
and other aspects of these clinical trials than if we conducted them entirely on our own. If we fail to commence or complete, or experience delays in, any of our planned clinical trials, our stock price and our ability to conduct our business as
currently planned could be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently anticipate that we will have to rely on CMOs to manufacture our adoptive cell therapy products for
clinical trials. If they fail to commence or complete, or experiences delays in, manufacturing our adoptive cell therapy products, our planned clinical trials will be delayed, which will adversely affect our stock price and our ability to conduct
our business as currently planned. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Clinical trials are expensive, time-consuming and difficult to design and implement, and our clinical trial
costs may be higher than for more conventional therapeutic technologies or drug products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials are expensive and difficult to design,
implement and conduct, in part because they are subject to rigorous regulatory requirements. Because our ACT product candidates are based on new cell therapy technologies and manufactured on <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">a&nbsp;patient-by-patient&nbsp;basis,</FONT></FONT> we expect that such candidates will require </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extensive research and development and have substantial manufacturing costs per dose. Our TCR Bispecific product candidates also require extensive research and development, as the applicable
technology is new and experience with developing such biologics is rare in the field. Moreover, the development of a companion diagnostic will also require extensive research and development, and such companion diagnostic must be suitable to support
both enrollment into larger clinical trials and routine hospital procedures after marketing approval. Any failure or delay in developing a suitable companion diagnostic will delay or make it impossible to conduct larger clinical trials for ACT
product candidates and/or TCR Bispecific product candidates. In addition, costs to treat patients with recurrent and/or refractory cancer and to treat potential side effects that may result from our product
<FONT STYLE="white-space:nowrap">candidates,&nbsp;non-investigational&nbsp;medicinal</FONT> products, rescue or prophylactic medication applied in our clinical trials can be significant. Some clinical trial sites do not bill or obtain coverage from
Medicare, Medicaid, health insurance or other third-party payors for some or all of these costs for patients enrolled in our clinical trials, and we can be required by those trial sites to pay such costs. In countries outside the U.S., it is
expected that all costs related to the clinical trial and to the management of study patients (for example, management of adverse reactions or hospitalization) are paid by the sponsor of the clinical trial. As trial designs for development of our
product candidates are complex, our clinical trial costs are likely to be significantly higher per patient than those of more conventional therapeutic technologies or drug products. We aim to combine two or more of our ACT product candidates within
one clinical trial or within <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;multi-TCR-T&nbsp;concept</FONT></FONT> in order to achieve durable clinical efficacy results and to increase the patient population. The set up and
conduct of such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">multi-TCR-T</FONT></FONT> clinical trials is expensive and may bear unknown risks, such as regulatory, preclinical, safety and manufacturing risks. In addition, our
proposed personalized product candidates involve several complex and costly manufacturing and processing steps, the costs of which will be borne by us. We are also responsible for the manufacturing costs of products for patients that do not receive
the product due to any reason (for example, rapid degradation of general health status, not meeting inclusion/exclusion criteria for infusion). Depending on the number of patients that we ultimately screen and enroll in our trials, the number of
trials that we may need to conduct, and the companion diagnostic we need to develop, our overall clinical trial costs may be higher than for more conventional treatments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates, which would prevent or delay regulatory
approval and commercialization. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The clinical trials of our product candidates are, and the manufacturing and marketing of our products will be,
subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market our product candidates. Before obtaining regulatory approvals for the
commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe and efficacious for use in each target indication or use in a
biomarker driven population. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. The risk/benefit profile required for product licensure will vary depending on
these factors and may include not only the ability to show tumor shrinkage, but also adequate duration of response, a delay in the progression of the disease, and/or an improvement in survival. For example, response rates from the use of our product
candidates may not be sufficient to obtain regulatory approval unless we can also show an adequate improvement of survival. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we are able to show
anti-tumor efficacy for one or several of our product candidates, the risk/benefit profile may be negatively impacted by an unfavorable safety profile, which could force us to discontinue a development program. This may happen if the risk for
patients is deemed unacceptable based on the number or severity of adverse events, or the number of patient deaths related to the clinical trial treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory authorities may ultimately disagree with our chosen endpoints or may find that our studies or study results do not support product approval. We
cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not
satisfactory to the FDA or foreign regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential
approval of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The results of preclinical studies and early clinical trials of our product candidates with small patient
populations may not be predictive of the results of later-stage clinical trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have opened enrollment into four Phase 1 clinical trials
investigating cellular product candidates. The primary objectives of these clinical trials are to establish safety and tolerability and, for our ACTengine clinical trials, to determine the recommended Phase 2 dose. Preliminary, single cohort, <FONT
STYLE="white-space:nowrap">or&nbsp;top-line&nbsp;results</FONT> from those and future early stage studies may not be representative of the final study results. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have reported preliminary results for clinical trials of our product candidates, including ACT for the treatment of recurrent and/or refractory solid
tumors. We may also report preliminary results from future clinical trials. These preliminary results are subject to substantial risk of change due to small sample sizes and may change as patients are evaluated or as additional patients are enrolled
in these or newly set up clinical trials. These outcomes may be unfavorable, deviate from our earlier reports, and/or delay or prevent regulatory approval or commercialization of our product candidates, including candidates for which we have
reported preliminary favorable safety and efficacy results. In clinical studies where a staged expansion is expected, such as studies using a Simon&#146;s two stage design, these outcomes may result in the failure to meet an initial efficacy
threshold for the first stage. Furthermore, other measures of efficacy for these clinical trials and product candidates may not be as favorable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, initial trial (for example, Phase 1 or Phase 2a) results may not be representative of later-stage trial results (for example, Phase 2b or Phase 3),
even if conducted in a very similar trial population. The results of studies in one set of patients or line of treatment may not be predictive of those obtained in another and the results in various human clinical trials reported in scientific and
medical literature may not be indicative of results we obtain in our clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies
and initial clinical trials. Additional <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies may also reveal unfavorable product candidate characteristics, including safety concerns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For example, our studies of cellular therapies in patients without any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">indicated&nbsp;standard-of-care&nbsp;treatment</FONT></FONT> utilize an &#147;open-label, single arm, <FONT STYLE="white-space:nowrap">dose-escalation/de-escalation&#148;</FONT> trial
design. An open-label, single arm, <FONT STYLE="white-space:nowrap">dose-escalation/de-escalation</FONT> trial is one where both the patient and investigator know what investigational treatment (monotherapy or combination) at which dose the patient
is receiving. This trial design has the potential to create selection bias by encouraging the investigators to enroll a more favorable patient population (for example, indications better suitable for immunotherapies, fitter patients, less prior
therapies) compared to a more broader patient population. In our current Phase 1 clinical trials investigators have significant discretion over the selection of patient participants. Although preliminary data from these trials was generally
positive, that data may not necessarily be representative of interim or final results, as new patients are cycled through the applicable treatment regimens. As the trials continue, the investigators may prioritize patients with more progressed forms
of cancer and/or worse general health condition than the initial patient population, based on the safety/success or perceived safety/success of that initial population. Patients with more progressed forms of cancer or worse general health conditions
may experience more and/or worse adverse events or be less responsive to treatment, and accordingly, interim or final safety and efficacy data may show an increase in frequency or severity of adverse events and/or a decline in patient response rate
or change in other assessment metrics. As the trials continue or in subsequent trials, investigators may shift their approach to the patient population, which may ultimately experience more and/or worse adverse events and/or result in a decline in
both interim and final efficacy data from the preliminary data, or conversely, a decrease in frequency and/or severity of adverse events or an increase in final efficacy data following a decline in the interim efficacy data, as patients with more
progressed forms of cancer or worse general health condition are cycled out of the trials and replaced by patients with less advanced forms of cancer or with better general health conditions. This opportunity for investigator
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
selection bias in our trials as a result of open-label design, which is standard <FONT STYLE="white-space:nowrap">in&nbsp;dose-escalation/de-escalation</FONT> trials, may not be adequately
handled and may cause a decline in or distortion of clinical trial data from our preliminary results. Any future trial which utilizes an open-label design is similarly susceptible to such bias. Depending on the outcome of our open-label studies, we
may need to conduct one or <FONT STYLE="white-space:nowrap">more&nbsp;follow-up&nbsp;or</FONT> supporting studies in order to successfully develop our products for FDA approval. Many companies in the biotechnology, pharmaceutical and medical device
industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we cannot be certain that we will not face such setbacks. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect there may be greater variability in results for products processed and administered on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">patient-by-patient</FONT></FONT> basis, as anticipated for our cellular therapy product candidates, than for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;off-the-shelf&#148;</FONT></FONT>
products, like many other drugs. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired
safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or
unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to
numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial
participants. Our current and future clinical trial results may not be successful. Moreover, should there be a flaw in a clinical trial, it may not become apparent until the clinical trial is well advanced. In the case that we decide to develop our
product candidates for use with other oncology products, or combine more than one ACT product candidate, the design, implementation, and interpretation of the clinical trials necessary for marketing approval will be more complex than if we would
have developed our product candidates alone. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The deviations in our proposed new products from existing products may require us to perform
additional testing, which will increase the cost, and extend the time for obtaining approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ACT based therapy is based on first-generation
adoptive cell therapy technology suitable for delivering for small early phase clinical trials. These current methods of treatment are very labor intensive and expensive, which has limited their widespread application. We have developed new
processes that we anticipate will enable more efficient manufacturing of ACT. We may have difficulty demonstrating that the products produced from our new processes are comparable to the existing products. The FDA and regulatory authorities in other
countries may require additional clinical testing before permitting a larger clinical trial with the new processes, and the product may not demonstrate the desired activity in new clinical trials. Cellular products are not considered as well
characterized products because there are hundreds of markers present on these cells, and even small changes in manufacturing processes could alter the cell types. It is unclear at this time which of those markers are critical for success of these
cells to combat cancer, so our ability to predict the outcomes with newer manufacturing processes is limited. The changes that we have made to the historical manufacturing process may require additional testing, which may increase costs and
timelines associated with these developments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our TCR Bispecific product candidates contain features that have not been previously tested in this
composition in clinical trials or marketed products. Regulatory authorities (for example, the FDA or EMA) may require <FONT STYLE="white-space:nowrap">additional&nbsp;non-clinical&nbsp;studies</FONT> before permitting us to enter clinical trials
with our product candidates. Regulatory authorities may also ask for additional early-stage trials or production of additional batches of TCR Bispecific products before permitting larger clinical trials or registration trials. To comply with those
requests would increase costs and timelines for the development of our TCR Bispecifics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are, and if we receive regulatory approval of our product candidates, will continue to be subject
to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our
product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and
efficacy of such product candidate(s). The FDA may also require a REMS to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as
restricted distribution methods, patient registries and other risk minimization tools. The FDA may also require post-approval Phase 4 studies. Moreover, the FDA and comparable foreign regulatory authorities will continue to closely monitor the
safety profile of any product even after approval. If the FDA or comparable foreign regulatory authorities become aware of new safety information after approval of any of our product candidates, they may withdraw approval, require labeling changes
or establishment of a REMS or similar strategy, impose significant restrictions on a product&#146;s indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. Any such
restrictions could limit sales of the product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we, our contractors, and our collaborators are and will remain responsible for FDA
compliance, including requirements related to product design, testing, clinical and preclinical trials approval, manufacturing processes and quality, labeling, packaging, distribution, adverse event and deviation reporting, storage, advertising,
marketing, promotion, sale, import, export, submissions of safety and other post-marketing information and reports such as deviation reports, registration, product listing, annual user fees, and recordkeeping for our product candidates. We and any
of our collaborators, including our contract manufacturers, could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with regulatory requirements. Application holders must further notify the FDA, and depending
on the nature of the change, obtain <FONT STYLE="white-space:nowrap">FDA&nbsp;pre-approval&nbsp;for</FONT> product and manufacturing changes. The cost of compliance with post-approval regulations may have a negative effect on our operating results
and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity
or frequency, that the product is less effective than previously thought, problems with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing, distribution, or manufacturing of our product candidates, withdrawal of the
product from the market, or voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the labeling of our product candidates, including required additional warnings, such as black box
warnings, contraindications, precautions, and restrictions on the approved indication or use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modifications to promotional pieces; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes to product labeling or the way the product is administered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liability for harm caused to patients or subjects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, restitution, disgorgement, warning letters, untitled letters, or holds on or termination of clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or
suspension or revocation of license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties, including imprisonment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA debarment, debarment from government contracts, and refusal of future orders under existing contracts,
exclusion from federal healthcare programs, consent decrees, or corporate integrity agreements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authority issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other
communications containing warnings or other safety information about the product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reputational harm; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the product becoming less competitive. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these events could further have other material and adverse effects on our operations and business and could adversely impact our stock price and could
significantly harm our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA&#146;s and other regulatory authorities&#146;
policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise
from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain
regulatory compliance, we may lose any marketing approval that we may have obtained, be subject to other regulatory enforcement action, and may not achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The regulatory landscape that will govern our product candidates is still evolving; regulations relating to more established gene therapy and cell
therapy products and TCR Bispecific products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we are developing novel cell immunotherapy product candidates that are unique biological entities, the regulatory requirements to which we
will be subject are not entirely clear. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing
gene therapy products and cell therapy products have become more stringent and comprehensive frequently and may continue to extend in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for
regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies (&#147;OTAT&#148;), formerly known as the Office of Cellular, Tissue and
Gene Therapies (&#147;OCTGT&#148;), within its Center for Biologics Evaluation and Research (&#147;CBER&#148;) to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise
CBER on its review. Gene therapy clinical trials in the U.S. are also subject to review and oversight by an institutional biosafety committee (&#147;IBC&#148;), a local institutional committee that reviews and oversees basic and clinical research
conducted at the institution participating in the clinical trial. Similar regulatory bodies exist in Europe and other jurisdictions. Although the FDA or specific regulatory authorities in other countries (for example, EMA or PEI) decides whether
individual gene therapy protocols may proceed, review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical study, even if for example, the FDA has reviewed the study and approved its initiation.
Conversely, the FDA can place an IND application on clinical hold even if such other entities have provided a favorable review. Furthermore, each clinical trial must be reviewed and approved by an independent IRB at or servicing each institution at
which a clinical trial will be conducted; equivalent processes are in place in other regions of the world. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory bodies
to change the requirements for approval of any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While there is already a T cell engaging bispecific molecule approved and
regulatory guidelines have been issued for this class of drugs, bispecific therapeutics are still new in the field and regulators have even less experience with TCR Bispecifics. Thus, guidance for development and regulatory approval of such drugs
may change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Complex regulatory environments exist in the different jurisdictions in which we might consider seeking regulatory approvals for our product
candidates, further complicating the regulatory landscape. For example, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the EU a special committee called the Committee for Advanced Therapies was established within the EMA in accordance with Regulation (EC) No.&nbsp;1394/2007 on advanced therapy medicinal products
(&#147;ATMPs&#148;) to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include gene therapy products as well as somatic cell therapy products and tissue engineered products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the
regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to
significant post-approval limitations or restrictions. Because the regulatory landscape for our cell immunotherapy product candidates is new, it may face even more cumbersome and complex regulations than those emerging for other gene therapy
products and cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be revoked, suspended or otherwise withdrawn as a result of changes in regulations or the interpretation
of regulations by applicable regulatory agencies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to
bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because our current
products represent, and our other potential product candidates will represent novel approaches to the treatment of diseases, there are many uncertainties regarding the development, the market acceptance, third-party reimbursement coverage and the
commercial potential of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human immunotherapy products are a new category of therapeutics. Because this is a relatively new
and expanding area of novel therapeutic interventions, there are many uncertainties related to development, marketing, reimbursement, and the commercial potential for our product candidates. There can be no assurance as to the number of required
clinical trials, the length of the trial period, the number of patients the FDA and regulatory authorities in other jurisdictions will require to be enrolled in the trials in order to establish the safety and efficacy of immunotherapy products, or
that the data generated in these trials will be acceptable to the FDA to support marketing approval. The FDA and comparable foreign regulatory may take longer than usual to come to a decision on any BLA or similar marketing application that we
submit and may ultimately determine that there is not enough data, information, or experience with our product candidates to support an approval decision. Regulatory authorities may also require that we conduct additional post-marketing studies or
implement risk management programs. For example, the FDA may require a REMS until more experience with our product candidates is obtained. Finally, after increased usage, we may find that our product candidates do not have the intended effect or
have unanticipated side effects, potentially jeopardizing initial or continuing regulatory approval and commercial prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also find that the
manufacture of our product candidates is more difficult or more expensive than anticipated, resulting in an inability to produce a sufficient amount of our product candidates for our clinical trials or, if approved, commercial supply. Moreover,
because of the complexity and novelty of our manufacturing process, there are only a limited number of manufacturers who have the capability of producing our product candidates. Should any of our contract manufacturers no longer produce our product
candidates, it may take us significant time to find a replacement, if we are able to find a replacement at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also find that the development of
a companion diagnostic for our product candidates is more difficult or more expensive than anticipated, resulting in an inability to provide the required diagnostic testing for our clinical trials, or if approved, for the market. Moreover, because
of the complexity and novelty of our companion diagnostic biomarker, there are only a limited number of providers who have the capability of supporting the development of a companion diagnostic. Should any of our CRO partners fail to meet our
development goals, it may take us significant time to find a replacement, if we are able to find a replacement at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no assurance that the
approaches offered by our products will gain broad acceptance among doctors or patients or that governmental agencies or third-party medical insurers will be willing to provide reimbursement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
coverage for proposed product candidates. Moreover, we do not have verifiable internal marketing data regarding the potential size of the commercial market for our product candidates, nor have we
obtained current independent marketing surveys to verify the potential size of the commercial markets for our current product candidates or any future product candidates. Since our current product candidates and any future product candidates will
represent novel approaches to treating various conditions, it may be difficult, in any event, to accurately estimate the potential revenues from these product candidates. Accordingly, we may spend significant capital trying to obtain approval for
product candidates that have an uncertain commercial market. The market for any products that we successfully develop will also depend on the cost of the product. We do not yet have sufficient information to reliably estimate what it will cost to
commercially manufacture our current product candidates, and the actual cost to manufacture these products could materially and adversely affect the commercial viability of these products. Our goal is to reduce the cost of manufacturing and
providing our therapies. However, unless we can reduce those costs to an acceptable amount, we may never be able to develop a commercially viable product. If we do not successfully develop and commercialize products based upon our approach or find
suitable and economical sources for materials used in the production of our products, we will not become profitable, which would materially and adversely affect the value of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ACT product candidate may be provided to patients in combination with other agents provided by third parties. The cost of such combination therapy may
increase the overall cost of ACT therapy and may result in issues regarding the allocation of reimbursements between our therapy and the other agents, all of which may affect our ability to obtain reimbursement coverage for the combination therapy
from third party medical insurers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">COVID-19&nbsp;may</FONT> materially and adversely affect our business and
financial results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business could be adversely affected by health epidemics in regions where we have clinical trial sites or other business
operations; epidemics could also cause significant disruptions in the operations of third-party manufacturers and CROs upon whom we rely. In December 2019, a novel strain of coronavirus, which causes the disease known
<FONT STYLE="white-space:nowrap">as&nbsp;COVID-19,&nbsp;was</FONT> reported to have surfaced in Wuhan, China. Since <FONT STYLE="white-space:nowrap">then,&nbsp;COVID-19&nbsp;has</FONT> spread globally. In March 2020, the World Health Organization
declared <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;outbreak</FONT> a pandemic and governments imposed restrictions on travel between the United States, Europe and certain other countries. Further, the President of the United States
declared <FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic</FONT> a national emergency, invoking powers under the Stafford Act, the legislation that directs federal emergency disaster response. In Germany and many other European
countries, governmental orders became effective in March 2020 to reduce virus transmission by social distancing. Those measures impact social and working life and travel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The effects of these and other governmental orders, as well
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as&nbsp;shelter-in-place&nbsp;or</FONT></FONT> work-from-home policies may negatively impact productivity, disrupt our and our partners&#146; business and delay our clinical programs
and timelines (including our ACTengine genetically modified autologous T cell products), the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the
ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, financial condition and results of operations, including our ability to obtain financing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Quarantines,&nbsp;shelter-in-place&nbsp;and</FONT></FONT> similar government orders, or the
perception that further orders, shutdowns or other restrictions on the conduct of business operations could occur related <FONT STYLE="white-space:nowrap">to&nbsp;COVID-19&nbsp;and</FONT> could impact personnel at our company, at suppliers, our
collaborators or at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. Our operations, including research and manufacturing, could also be
disrupted due to staff absences as a result of self-isolation procedures or extended illness at our company or at suppliers or collaborators. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our clinical trials may be affected by
<FONT STYLE="white-space:nowrap">the&nbsp;COVID-19&nbsp;pandemic,</FONT> including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in enrolling patients in clinical trials, including that patients may not be able to
comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site
investigators and clinical site staff; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion or prioritization of healthcare resources away from the conduct of clinical trials and towards the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials, who, as healthcare providers, may have heightened
exposure to <FONT STYLE="white-space:nowrap">COVID-19;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on
travel imposed or recommended by federal, state or provincial governments, employers and others; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials,
including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the risks listed above, we may also experience the following adverse impacts for our clinical trials: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption in global shipping that may affect the transport of clinical trial materials, such as
investigational drug product and patient specimens used in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in local regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
coronavirus outbreak, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government employees; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the refusal of the FDA or other regulatory agencies to accept data from clinical trials from strongly affected
geographies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global outbreak <FONT STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;continues</FONT> to rapidly evolve. The extent
to <FONT STYLE="white-space:nowrap">which&nbsp;COVID-19&nbsp;may</FONT> impact our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic
spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States, Germany and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States,
Germany and other countries to contain and treat the disease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Reliance on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Independent clinical investigators and CROs that we engage to conduct our clinical trials may not devote sufficient time or attention to our clinical
trials or be able to repeat their past success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to continue to depend on independent clinical investigators and CROs to conduct our
clinical trials. CROs may also assist us in the collection and analysis of data. Identifying, qualifying and managing performance of third-party service providers can be difficult, time-consuming and cause delays in our development programs. These
investigators and CROs will not be our employees and we will not be able to control, other than by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the
development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service
providers may require us to disclose some of our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further, regulatory agencies require that we comply with GCP requirements for
conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. Failure of clinical investigators or CROs to
meet their obligations to us or comply with GCP requirements could adversely affect, for example, the costs and timelines of the clinical development of our product candidates and harm our business. Not fulfilling GCP requirements by investigators
or CROs could even lead to denial of a BLA or similar marketing application to comparable foreign authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure of third-party contractors
to successfully develop and commercialize companion diagnostics for use with our product candidates could harm our ability to commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to develop companion diagnostics for our product candidates where appropriate. Such developments are expensive and time-consuming. The FDA and similar
regulatory authorities outside the United States may request or require the development and regulatory approval of a companion diagnostic as a condition to approving one or more of our product candidates, including, for example, IMA201, IMA202,
IMA203, IMA204, and IMA401. We do not have experience or capabilities in developing, seeking regulatory approval for or commercializing diagnostics and plan to rely in large part on third parties to perform these functions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will likely outsource the development, production and commercialization of companion diagnostics to third parties. By outsourcing these companion
diagnostics to third parties, we become dependent on the efforts of our third-party contractors to successfully develop and commercialize these companion diagnostics. Our contractors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may not perform their obligations as expected; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may encounter production difficulties that could constrain the supply of the companion diagnostic;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may encounter difficulties in obtaining regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may not commit sufficient resources to the marketing and distribution of such product; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may terminate their relationship with us. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to obtain reagents and raw materials. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacture of our product candidates by us or any of our CMOs requires access to a number of reagents and other critical raw materials from third-party
suppliers. Such third parties may refuse to supply such reagents or other raw materials or alternatively refuse to supply on commercially reasonable terms. There may also be capacity issues at such third-party suppliers that impact our ability to
increase production of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of the materials used in the manufacture and processing of our product candidates may only be
supplied by one or a few vendors, which means that, should those vendors be unable to supply, for whatever reason, our ability to manufacture product candidates and progress product candidates through clinical trials could be severely impacted and
result in additional delays. Such failure to supply could also impact other supply relationships with other third parties and potentially result in additional payments being made or required in relation to such delays. In addition, where any raw
material or precursor material (including, for example, lentiviral vector, cell culture medium, chromatographic column material or other essential raw material) is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
currently supplied by one or a few vendors, replacing such raw material or precursor or finding alternative vendors may not be possible or may significantly impact on the timescales for
manufacture and supply of our product candidates. Even where alternative materials or precursors or alternative vendors are identified, such alternative materials, precursors or vendors and their materials will need to be properly assessed and
qualified and additional regulatory approvals may also need to be obtained all of which could result in significant delays to the supply of our product candidates or an inability to supply product candidates within anticipated timescales, if at all.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have contracted and expect to contract additional third parties for the manufacture of some of our product candidates for clinical testing in
the future, and we expect to do so for commercialization. Third-party contractors are also important to supply us or our CMOs with important materials required for our product candidates or to develop and perform services essential for the
manufacturing process. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost and when needed, which could delay, prevent or impair
our development or commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, our ACT product candidates are manufactured by our personnel at the UTH facility. We
expect to continue to manufacture product candidates for early phase trials using our personnel at the UTH facility; but we are currently negotiating contracts with larger CMOs with experience in cell therapy development and manufacturing to
manufacture our products for late stage clinical trials, including any pivotal trials. The process will involve the development of a given manufacturing process in house using our personnel followed by technology transfer of each manufacturing
process to the CMO. Our manufacturing strategy for bispecific T cell engagers includes CMOs for cell line development, process development, formulation development, cGMP manufacturing, analytics, release testing, fill and finish, packaging and
storage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not succeed in maintaining our relationships with current CMOs or establishing relationships with additional or alternative CMOs. Our
product candidates may compete with other products and product candidates for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP and, for cellular products, also under cGTP regulations and that
are both capable of manufacturing for us and willing to do so. In addition, there are limited CMOs specialized in the manufacturing of cellular therapy products. If our current and/or future CMOs for any of our product candidates or products that
obtain approval should cease manufacturing for us, we would experience delays in obtaining sufficient quantities of our product candidates for clinical trials and, if approved, commercial supply. Further, our CMOs may breach, terminate, or not renew
these agreements. If we were to need to find alternative manufacturing facilities, it would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. The commercial terms of any new
arrangement could be less favorable than our existing arrangements and the expenses relating to the transfer of necessary technology and processes and obtaining applicable regulatory approvals could be significant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reliance on third-party manufacturers entails exposure to risks to which we would not be subject if we manufactured the product candidate ourselves,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> control over
the manufacturing process for our product candidates as a result of using third-party manufacturers for all aspects of manufacturing activities, which can result in significant delays of drug supply to any clinical trial or commercial product;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any new manufacturer would have to be educated in processes for the production of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">contract manufacturers may not be able to execute manufacturing of our product candidates and other logistical
support requirements appropriately; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the development of processes or the supply with materials important for the manufacturing of our product
candidates may be delayed. This may lead to a situation that manufacturing of our product candidates may not be possible at a preplanned and booked manufacturing slot at one of our CMOs. In this case, we may be held liable for significant
cancelation fees, and reservation of a new manufacturing slot may delay manufacturing by several months and may thereby impact our development timelines; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturers are subject to ongoing periodic unannounced inspection by the FDA, by authorities from other
jurisdictions and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards, and FDA or regulatory authorities from other countries further inspect any manufacturers for
current cGMP and, if applicable, cGTP compliance as part of any marketing application we submit. We do not have control over third-party manufacturers&#146; compliance with these regulations and standards; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced control over the protection of our trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT>
from misappropriation or inadvertent disclosure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that may be
costly or damaging to us or result in delays in the development or commercialization of our product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our
business or operations, including the bankruptcy of the manufacturer or supplier. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any of these factors could cause the delay of
approval or commercialization of our product candidates, cause us to incur higher costs or prevent us from commercializing our product candidates successfully. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required commercial quantities of finished product
on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis,
we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for our product candidates and to have any such new source approved by the FDA or any
other relevant regulatory authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>At some point in the future, we may decide to operate our own manufacturing facility for our ACT product
candidates in late-stage clinical testing and for our marketed products, which would require significant resources and we may fail to successfully operate our facility, which could adversely affect our clinical trials and the commercial viability of
our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, we have no immediate plans to operate our own manufacturing facility for our product candidates in late-stage
clinical testing or for our marketed products. However, we may not be able to achieve clinical or commercial manufacturing and cell processing at a scale to satisfy demands for late stage clinical trials or commercialization on our own or with a CMO
and thus may decide to operate a manufacturing facility for our product candidates. While we believe the manufacturing and processing approaches are appropriate to support our clinical product development, we have limited experience in managing a
large-scale manufacturing facility. We cannot be sure that the manufacturing processes we employ or the technologies that we incorporate for manufacturing will result <FONT STYLE="white-space:nowrap">in&nbsp;TCR-T&nbsp;cell</FONT> product candidates
suitable for clinical trials or commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have exclusive access to the early stage facility at UTH designed for the manufacturing of cellular
products comprised of three fully functional GMP suites and support areas where our hired and trained personnel perform all manufacturing related activities. The current lease extends through the end of 2021 with negotiations in place to extend the
lease through the end of 2024. In case, the lease is not prolonged, we may decide to run our own manufacturing facility. There can be no assurance that we will complete <FONT STYLE="white-space:nowrap">the&nbsp;build-out&nbsp;of</FONT> our
manufacturing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
facility in a timely manner or at all. We also do not yet have sufficient information to reliably estimate the cost of the clinical and commercial manufacturing and processing of our product
candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. In addition, the ultimate clinical and any commercial dose will affect our
ability to scale our costs per dose. As a result, we may never be able to develop a commercially viable product. The commercial manufacturing facility we may build will also require regulatory approval, including from FDA, which we may never obtain.
Even if approved, we would be subject to ongoing periodic unannounced inspection by the FDA or authorities from other jurisdictions, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP and cGTP
requirements, and other government regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we were to decide in the future to own and operate a manufacturing facility, the designing and
building process would be time-consuming, expensive, and we may not realize the benefit of this investment. As a manufacturer of pharmaceutical products, we are required to demonstrate and maintain compliance with cGMP and cGTP requirements, which
include requirements related to production processes, quality control and assurance and recordkeeping. Furthermore, establishing and maintaining manufacturing operations requires a reallocation of other resources, particularly the time and attention
of certain of our senior management. Any failure or delay in our manufacturing capabilities could adversely impact the clinical development or commercialization of our or our collaborators&#146; product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacture of biopharmaceutical products, especially of those cellular in nature like our ACT product candidates, is complex and requires significant
expertise, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and
ensuring the absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as
compliance with strictly enforced federal, state and foreign regulations. The application of new regulatory guidelines or parameters, such as those related to release testing, may also adversely affect our ability to manufacture our product
candidates. Furthermore, if contaminants are discovered in our supply of product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the
contamination. We cannot assure that any stability or other issues relating to the manufacture of our product candidates will not occur in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
or any of our CMOs may fail to manage the logistics of storing and shipping our raw materials and product candidates. Storage failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather,
could result in the inability to manufacture product, the loss of usable product or prevent or delay the delivery of product candidates to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
may also experience manufacturing difficulties due to resource constraints or as a result of labor disputes. If we were to encounter any of these difficulties, our ability to provide our product candidates to patients would be jeopardized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have limited experience in large-scale or commercial manufacturing, and there can be no assurance that we will be able to effectively manufacture
clinical or commercial quantities of our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2015, we entered into a collaboration agreement with UTH to gain exclusive access
to a cGMP facility specialized in the manufacturing of cellular products. This facility is used exclusively for the manufacturing of our product candidates by our hired and trained personnel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although some of our employees have experience in the manufacturing of pharmaceutical products from prior employment at other companies, we as a company do
not have experience in large-scale or commercial manufacturing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not succeed in scaling up our production processes for ACT and/or biologics for pivotal trials and/or
commercial supply. We may need a larger scale manufacturing process for any TCR Bispecifics molecule than what we have planned, depending on the dose and regimen that is to be determined in our Phase 1 and future Phase 2 studies. Any changes in our
manufacturing processes, including those utilized by our CMOs, as a result of scaling up may result in the need to obtain additional regulatory approvals. Difficulties in achieving commercial-scale production or the need for additional regulatory
approvals could delay the development and regulatory approval of our product candidates and ultimately affect our success. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or our third-party
suppliers use <FONT STYLE="white-space:nowrap">hazardous,&nbsp;non-hazardous,&nbsp;biological</FONT> or other materials in a manner that causes injury or violates applicable law, we may be liable for damages. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials,
potentially infectious material and genetically modified cells. We and our suppliers are subject to federal, state and local laws and regulations in the United States and Germany governing the use, manufacture, storage, handling and disposal of such
hazardous materials. Although we believe that we and our suppliers&#146; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, and that we and our suppliers have all necessary permits, we
and our suppliers cannot completely eliminate the risk of contamination or injury resulting from hazardous chemical or biological materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal
authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We have insurance in
place for liabilities arising from handling biological and hazardous substances, but it may not or may not fully cover all costs from such accidents. Compliance with applicable environmental laws and regulations is expensive, and current or future
environmental regulations may impair our research, development and production efforts, which could impact our business, prospects, financial condition or results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal, state, local and foreign
healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these
laws, we could face substantial penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These laws may impact, among other things, our clinical research program, as well as our proposed and
future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive
practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. We may also be subject to federal, state and foreign
laws governing the privacy and security of identifiable patient information. The U.S. healthcare laws and regulations that may affect our ability to operate include, but are not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, any person or entity from knowingly and
willfully, offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, the purchasing, leasing, ordering or arranging for the purchase, lease, or order of
any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. Although there are a number of statutory exceptions and
regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Practices that may be alleged to be intended to induce
prescribing, purchases or recommendations, include any payments of more than fair market value, and may be subject to scrutiny if they do not qualify for an </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
exception or safe harbor. In addition, a person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In
addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act and the Civil Monetary
Penalties Statute; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal civil and criminal false claims laws and civil monetary penalty laws, including the federal civil False
Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other federal government programs that are false or fraudulent
or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government, including federal healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal
criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or
property owned by, or under the custody or control of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by any trick, scheme or device, a material fact or making
any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual
knowledge of the statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and their
respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use,
or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologicals
and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the United States Department of Health and Human Services&#146; (HHS)
Centers for Medicare&nbsp;&amp; Medicaid Services (CMS) information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate
family members; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we may be subject to state, local and foreign equivalents of each of the
healthcare laws described above, among others, some of which may be broader in scope. For example, we may be subject to the following: state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving
healthcare items or services reimbursed <FONT STYLE="white-space:nowrap">by&nbsp;non-governmental&nbsp;third</FONT> party payors, including private insurers, or that apply regardless of payor; state laws that require pharmaceutical companies to
comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state and local laws that require drug manufacturers to report information related to payments
and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require the reporting of information related to drug pricing; state and local laws requiring the registration of pharmaceutical
sales and medical representatives; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus
complicating compliance efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe
harbors available, it is possible that some of our business activities, or our arrangements with physicians, some of whom receive stock options as compensation, could be subject to challenge under one or more of such laws. If we or our employees,
independent contractors, consultants, commercial partners and vendors violate these laws, we may be subject to investigations, enforcement actions and/or significant penalties. We have adopted a code of business conduct and ethics, but it is not
always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us
from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve
substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other
healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of
civil, criminal and administrative penalties, damages, disgorgement, monetary fines, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished
profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve
<FONT STYLE="white-space:nowrap">allegations&nbsp;of&nbsp;non-compliance&nbsp;with</FONT> these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In
addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to
maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have limited
capabilities for drug development and does not yet have any capability for sales, marketing or distribution. We have entered into collaborations with other companies that we believe can provide such capabilities, including our collaboration and
license agreements with, for example, MD Anderson, Amgen, Genmab, Celgene Corporation, a Bristol-Myers Squibb Company (&#147;BMS&#148;), and GlaxoSmithKline (&#147;GSK&#148;). These collaborations have also provided us with important funding for our
development programs and technology platforms, and we expect to receive additional funding under these collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks,
including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not perform their obligations as expected; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory
approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that
divert resources or create competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a
clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or
indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; this may
also happen if the collaborators&#146; development of competing products is substantially faster than our development timelines; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not further develop product candidates developed by us or
<FONT STYLE="white-space:nowrap">co-developed</FONT> with us under the collaboration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with
their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve
regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the
preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in
litigation or arbitration, any of which would be time-consuming and expensive; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators have certain defined rights to change or expand the scope of development programs during the course
of the collaboration. This may lead to additional research work for us that may be time-consuming and expensive. Such work may compete with our own development programs and may delay timelines to market or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> for our product candidates. If development programs under the collaboration turn out to be more costly and time-consuming, such unanticipated costs and work could likewise compete with our
internal development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary
information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation
and potential liability; we may also be held liable by the collaborator for potential infringement of third party intellectual property during the research and development work for the collaboration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be
required to raise additional capital to pursue further development or commercialization of the applicable product candidates. For example, certain of our collaboration and license agreements may be terminated for convenience upon the completion of a
specified notice period; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may discontinue the development of product candidates within the collaboration, for example if they
consider the results achieved so far or the product candidates not promising enough or if their development strategies change. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our
therapeutic collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments
under the <FONT STYLE="white-space:nowrap">collaboration.&nbsp;Hoffmann-La&nbsp;Roche</FONT> Ltd <FONT STYLE="white-space:nowrap">and&nbsp;Hoffmann-La&nbsp;Roche</FONT> Inc. (&#147;Roche&#148;) recently informed us that it did not intend to continue
development as contemplated under the collaboration agreement of April&nbsp;26, 2016 and terminated the agreement as of September&nbsp;30, 2020; as a result, we will not receive any milestone or royalty payments under the collaboration. All of the
risks relating to product development, regulatory approval and commercialization described in this prospectus also apply to the activities of our program collaborators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might
deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, it may find it more difficult to attract new collaborators. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For some of our product candidates, we may in the future determine to collaborate with additional
pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration
will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. These factors may
include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing
and delivering such product candidate to patients, the potential of competing products, and the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the
merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration
could be more attractive than the one with us for our product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Collaborations are complex and time-consuming to negotiate and document. In
addition, there have been a significant number of recent business combinations among large pharmaceutical companies that reduced the number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a
timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay one or more of our other development programs, delay our potential commercialization or reduce the scope of any sales or
marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain
additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and
commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our technology platforms and our business may be materially and adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Subject
to certain specified exceptions, each of our existing therapeutic collaborations contains an exclusivity restriction on our engaging in activities that are the subject of the collaboration with third parties for specified periods of time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such
alliances or licensing arrangements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional
licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these
relationships may require us to <FONT STYLE="white-space:nowrap">incur&nbsp;non-recurring&nbsp;and</FONT> other charges, increase our near and long-term expenditures, issue securities that dilute our existing shareholders or disrupt our management
and business. In addition, we face significant competition in seeking appropriate strategic collaborations and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish strategic
collaborations or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the
requisite potential to demonstrate safety and efficacy. Any delays in entering into new strategic collaboration agreements related to our product candidates could delay the development and commercialization of our product candidates in certain
geographies for certain indications, which would harm our business prospects, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on intellectual property licensed from third parties and termination of any of these
licenses could result in the loss of significant rights, which would harm our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are dependent or may depend in the future on <FONT
STYLE="white-space:nowrap">patents,&nbsp;know-how&nbsp;and</FONT> proprietary technology, both our own and licensed from others. We may also enter into additional license agreements that are material to the development of our product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disputes may also arise between us and our licensors and licensees regarding intellectual property subject to a license agreement, including those
related to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor
that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our product candidates, and what activities satisfy those diligence obligations; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by us, our licensors, and our collaborators. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we
have licensed, or will license in the future, prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as it is for intellectual property
that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If
third parties claim that our activities or products infringe upon their intellectual property, our operations could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There
is a substantial amount of litigation, both within and outside the United States, involving patents and other intellectual property rights in the pharmaceutical industry. We may, from time to time, be notified of claims that we or our third party
suppliers are infringing upon patents, trademarks, copyrights, or other intellectual property rights owned by third parties, and we cannot provide assurances that other companies will not, in the future, pursue such infringement claims against us or
any third-party proprietary technologies we have licensed. If we or our third party suppliers were found to infringe upon a patent or other intellectual property right, or if we failed to obtain or renew a license under a patent or other
intellectual property right from a third party, or if a third party that we were licensing technologies from was found to infringe upon a patent or other intellectual property rights of another third party, we may be required to pay damages,
including triple damages if the infringement is found to be willful, suspend the manufacture of certain product candidates or reengineer or rebrand our product candidates, if feasible, or we may be unable to enter certain new product markets. Any
such claims could also be expensive and time-consuming to defend and divert management&#146;s attention and resources. Our competitive position could suffer as a result. In addition, if we have declined to enter into a
<FONT STYLE="white-space:nowrap">valid&nbsp;non-disclosure&nbsp;or</FONT> assignment agreement for any reason, we may not own an invention or intellectual property rights and may not be adequately protected. Although we have reviewed certain
third-party patents and patent filings that we believe may be relevant to our product candidates, we have not conducted a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">full&nbsp;freedom-to-operate&nbsp;search</FONT></FONT> or
analysis for such product candidates, and we may not be aware of patents or pending or future patent applications that, if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issued, would block us from commercializing our product candidates. Thus, we cannot guarantee that we can successfully commercialize product candidates in a way that will not infringe any third
party&#146;s intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Where we license certain technology from a third party, the prosecution, maintenance and defense of the patent
rights licensed from such third party may be controlled by the third party which may impact the scope of patent protection which will be obtained or enforced. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where we license patent rights or technology from a third-party, control of such third-party patent rights may vest in the licensor, particularly where the
license <FONT STYLE="white-space:nowrap">is&nbsp;non-exclusive&nbsp;or</FONT> field restricted. This may mean that we are not able to control or affect the scope of the claims of any relevant third-party patent or have control over any enforcement
of such a patent. Where a licensor brings an enforcement action, this could negatively impact our business or result in additional restrictions being imposed on the license we have and the scope of such license, or result in invalidation or
limitation of the scope of the licensed patent. In addition, should we wish to enforce the relevant patent rights against a third person, we may be reliant on consent from the relevant licensor or the cooperation of the licensor. The licensor may
refuse to bring such action and leave us unable to restrict competitor entry into the market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in lawsuits to protect or enforce
our patents or the patents of our licensors, or lawsuits accusing our products of patent infringement, which could be expensive, time-consuming and unsuccessful. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may infringe the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can
be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds
that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our
patents applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful
claim of infringement against us, we may be enjoined from manufacturing, use, and marketing our products, or may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses
from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated <FONT STYLE="white-space:nowrap">for&nbsp;non-compliance&nbsp;with</FONT> these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees on any issued patent are due to be paid to the United States Patent and Trademark Office (&#147;USPTO&#148;) and foreign patent
agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application
process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent
application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to
official actions within prescribed time <FONT STYLE="white-space:nowrap">limits,&nbsp;non-payment&nbsp;of</FONT> fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market,
which would have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may incur substantial costs as a result of litigation or other proceedings relating to patent and
other intellectual property rights. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cost to us of any litigation or other proceeding relating to intellectual property rights, even if
resolved in our favor, could be substantial. Some of our competitors may be better able to sustain the costs of complex patent litigation because they have substantially greater resources. If there is litigation against us, we may not be able to
continue to operate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Should third parties file patent applications or be issued patents claiming technology we also use or claim, we may be required to
participate in interference proceedings in the USPTO to determine priority of invention. We may be required to participate in interference proceedings involving our issued patents and pending applications. We may be required to cease using the
technology or to license rights from prevailing third parties as a result of an unfavorable outcome in an interference proceeding. A prevailing party in that case may not offer us a license on commercially acceptable terms or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or one of our licensing collaborators initiates legal proceedings against a third party to enforce a patent covering one of our product candidates, the
defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are
commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the
context of litigation. Such mechanisms <FONT STYLE="white-space:nowrap">include&nbsp;re-examination,</FONT><I>&nbsp;inter partes</I>&nbsp;and post grant review, and equivalent proceedings in foreign jurisdictions (for example, opposition
proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With
respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion
of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our agreements with employees and our personnel policies also generally provide that any inventions conceived by such individuals in the course of rendering
services to us shall be our exclusive property or that we may obtain full rights to such inventions, at our election. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply
with their terms. We may be subject to claims that former employees, collaborators, or other third parties have an ownership interest in our patents or other intellectual property (&#147;IP&#148;). Ownership disputes may arise, for example, from
conflicting obligations of consultants or others who are involved in developing our development candidates. We also face the risk that present or former employees could continue to hold rights to intellectual property we use, may demand the
registration of intellectual property rights in their name and demand damages pursuant to the German Employee Invention Act. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in
defending any such claims, in addition to paying monetary damages, we may lose valuable IP rights, such as exclusive ownership of, or right to use, valuable IP. Such an outcome could have a material adverse impact on our business. Even if we are
successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of
trade secrets and other proprietary information. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we seek to rely on trade secret protection and
confidentiality agreements to protect <FONT STYLE="white-space:nowrap">proprietary&nbsp;know-how&nbsp;that</FONT> is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development
processes that involve <FONT STYLE="white-space:nowrap">proprietary&nbsp;know-how,&nbsp;information</FONT> or technology that is not covered by patents. Trade secrets, however, may be difficult to protect. Although we require all of our employees to
assign their inventions to us, and require all of our employees and key consultants who have access to our <FONT STYLE="white-space:nowrap">proprietary&nbsp;know-how,&nbsp;information,</FONT> or technology to enter into confidentiality agreements,
we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information
and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and
defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive
advantage in our market, which could materially adversely affect our business, operating results and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to
claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors
or potential competitors. In addition, our employees involved in our strategic collaborations have access to certain joint confidential information or such information from the collaborator. Although we try to ensure that our employees, consultants,
and independent contractors do not use the proprietary information <FONT STYLE="white-space:nowrap">or&nbsp;know-how&nbsp;of</FONT> others in their work for us, from time to time we may be subject to claims that we, or our employees, consultants, or
independent contractors, have inadvertently or otherwise used or disclosed IP, including trade secrets or other proprietary information, of any of our employees&#146; former employers or other third parties. Litigation may be necessary to defend
against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable IP rights or personnel, which could adversely impact our business. Even if we are successful in defending against such
claims, litigation could result in substantial costs and be a distraction to management and other employees. Such liability can also occur if we publish or disclose confidential information from our collaboration without permission of the respective
collaborator. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. or foreign countries&#146; patent law could diminish the value of patents in general, thereby impairing our ability
to protect our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the case with other biopharmaceutical companies, our success is dependent on intellectual property, particularly
patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. In addition, the United&nbsp;States has recently enacted
and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations.
In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress,
the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.
While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents, nor can
we predict changes in international patent law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The legal protection afforded to inventors and owners of intellectual property in countries outside of the United States may not be as protective or effective
as that in the United States and we may, therefore, be unable to acquire and enforce intellectual property rights outside the United States to the same extent as in the United States. Whether filed in the United States or abroad, our patent
applications may be challenged or may fail to result in issued patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our existing patents and any future patents we obtain may not be
sufficiently broad to prevent others from utilizing our technologies or from developing or commercializing competing products. Furthermore, others may independently develop or commercialize similar or alternative technologies or therapies, or design
around our patents. Our patents may be challenged, invalidated, circumvented or narrowed, or fail to provide us with any competitive advantages. In many foreign countries, patent applications and/or issued patents, or parts thereof, must be
translated into the native language. If our patent applications or issued patents are translated incorrectly, they may not adequately cover our technologies; in some countries, it may not be possible to rectify an incorrect translation, which may
result in patent protection that does not adequately cover our technologies in those countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing, prosecuting, enforcing, and defending patents on
product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States are less extensive than those in the United States. In addition, the laws of
some foreign countries do not protect intellectual property rights to the same extent as federal and certain state laws in the United States. Consequently, we may not be able to prevent third parties from utilizing our inventions in all countries
outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies, or technology that we license, in jurisdictions where we have not
obtained patent protection to develop our own products and, further, may export otherwise infringing products to territories where we has patent protection, but enforcement is not as strong as that in the United States. These products may compete
with our lead product candidate or any other current or future product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of
certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology. In addition, certain countries have compulsory licensing
laws under which a patent owner may be compelled to grant licenses to third parties. Thus, it may be difficult for us to stop the infringement of our patents or the marketing of competing products in violation of our proprietary rights, generally.
Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly,
could place our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially
meaningful. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position on our product candidate or any future product candidates for an adequate amount of
time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is
generally 20 years from our earliest <FONT STYLE="white-space:nowrap">U.S.&nbsp;non-provisional&nbsp;filing</FONT> date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents
covering our product candidates or any future product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing, and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory review of new product candidates, patents protecting our current product candidates or any future product candidates might expire before or shortly after we or our collaborators
commercialize those candidates. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business and Industry </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are
highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified
managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including our Chief Executive Officer and other executive officers in our senior management. The loss of the services of any
of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conduct substantially all of our operations at our facilities in T&uuml;bingen, Germany, Houston, Texas and Munich, Germany where many other
biopharmaceutical companies, academic and research institutions have facilities and/or headquarters which substantially increases our competition for skilled personnel in our market and may limit our ability to hire and retain highly qualified
personnel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To induce current valuable employees to remain with us through salary and cash incentives, we have provided stock appreciation rights which
have been converted into a new employee incentive scheme. Despite our efforts to retain valuable employees, members of our management, scientific and development teams could always terminate their employment with us on short notice. Even though we
have employment agreements in place with all our employees including key personnel, these employment agreements provide <FONT STYLE="white-space:nowrap">for&nbsp;at-will&nbsp;employment,</FONT> which means that any of our employees could leave us at
any time, subject to notice periods and <FONT STYLE="white-space:nowrap">non-competition</FONT> clauses. If key employees leave us, this may result in delays in the development of our product candidates or may endanger the proper and regulation
compliant conduct of our clinical trials. Our success highly depends on our ability to continue to attract, retain and motivate highly skilled junior-, <FONT STYLE="white-space:nowrap">mid-</FONT> and senior-level personnel as well as scientific and
medical personnel. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of fraud or other illegal activity by
our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties may include intentional, reckless and/or negligent conduct that fails to: comply with the laws of the FDA and other similar foreign
regulatory bodies, provide true, complete and accurate information to the FDA and other similar foreign regulatory bodies, comply with manufacturing standards we have established, comply with healthcare fraud and abuse laws in the United States and
similar foreign fraudulent misconduct laws, or report financial information or data accurately or to disclose unauthorized activities to us. If we obtain FDA approval for any of our product candidates and begin commercializing those products in the
United States, our potential exposure under such laws will increase significantly, and the costs associated with compliance with such laws are also likely to increase. Failure to comply with these laws may impact, among other things, our current
activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business
arrangements in the healthcare industry, are subject to extensive laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing,
discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a Code of Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect
and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or
regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that we, or our employees&#146;,
consultants&#146;, collaborators&#146;, contractors&#146;, or vendors&#146; business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations.
If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including civil, criminal and administrative penalties, damages,
disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, compliance agreements, withdrawal of
product approvals, and curtailment of our operations, among other things, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product
candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations are dependent upon the services of our executives and our employees who are engaged in research and development. The loss of the services of our
executive officers or senior research personnel could delay our product development programs and our research and development efforts. In order to develop our business in accordance with our business plan, we will have to hire additional qualified
personnel, including in the areas of research, manufacturing, clinical trials management, regulatory affairs, and sales and marketing. We are continuing our efforts to recruit and hire the necessary employees to support our planned operations in the
near term. However, competition for qualified employees among companies in the biotechnology and biopharmaceutical industry is intense, and no assurance can be given that we will be able to attract, hire, retain and motivate the highly skilled
employees that we need. Future growth will impose significant added responsibilities on members of management, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identifying, recruiting, integrating, maintaining, and motivating additional employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">managing our internal development efforts effectively, including the clinical and FDA review process for our
product candidates, while complying with our contractual obligations to contractors and other third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">improving our operational, financial and management controls, reporting systems, and procedures.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to
effectively manage any future growth, and our management may also have to divert a disproportionate amount of our attention away <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">from&nbsp;day-to-day&nbsp;activities</FONT></FONT> in
order to devote a substantial amount of time to managing these growth activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently rely, and for the foreseeable future will continue to
rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be
available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality, compliance or accuracy of the services provided by
consultants is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other
competent outside contractors and consultants on economically reasonable terms, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are not able to effectively expand our organization by
hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our
research, development, and commercialization goals on a timely basis, or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If product liability lawsuits are brought against us, we may incur
substantial liabilities and may be required to limit commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We face an inherent risk of product liability as
a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise
unsuitable during clinical testing, manufacturing, marketing or sale. We may also still face risks from previous research and development activities. For example, IMA950, a multi-peptide vaccine we previously developed, is still in clinical use
under the responsibility of clinical investigators outside of our clinical trials (investigator-initiated trials). While any sponsor responsibility is with the investigator, we cannot fully be sure that we will not be held liable in the future for
any potential product defects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of
dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. Large judgements have also been awarded in class action lawsuits based on therapeutics that
had unanticipated side effects. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would
require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decreased demand for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">withdrawal of clinical trial participants or sites and potential termination of clinical trial sites or entire
clinical programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiation of investigations by regulators, refusal to approve marketing applications or supplements, and
withdrawal or limitation of product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a diversion of management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">significant negative media attention; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">decrease in the price of our stock and our overall value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exhaustion of our available insurance coverage and our capital resources; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inability to commercialize our product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or
inhibit the commercialization of products we develop, alone or with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. While we have obtained clinical
trial insurance for our Phase 1 clinical trials and will also seek to obtain such insurance for future trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered
by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be
available or adequate should any claim arise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with federal and state healthcare and promotional laws, including fraud and
abuse and information privacy and security laws, we could face substantial penalties and our business, financial condition, results of operations, and prospects could be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a biopharmaceutical company, we are subject to many federal and state healthcare laws, including the federal Anti-Kickback Statute, the federal civil and
criminal False Claims Act (&#147;FCA&#148;), the civil monetary penalties statute, the Medicaid Drug Rebate statute and other price reporting requirements, the Veterans Health Care Act of 1992, the federal Health Insurance Portability and
Accountability Act of 1996 (as amended by the Health Information Technology for Economics and Clinical Health Act), the Foreign Corrupt Practices Act of 1977, the Patient Protection and Affordable Care Act of 2010, and similar state laws. Even
though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid, or other third-party payors, certain healthcare laws (for example, federal, state and European laws) and regulations pertaining to fraud
and abuse and patients&#146; rights are and will be applicable to our business. If we do not comply with all applicable fraud and abuse laws, we may be subject to healthcare fraud and abuse enforcement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Laws and regulations require calculation and reporting of complex pricing information for prescription drugs, and compliance will require us to invest in
significant resources and develop a price reporting infrastructure or depend on third parties to compute and report our drug pricing. Pricing reported to CMS must be
<FONT STYLE="white-space:nowrap">certified.&nbsp;Non-compliant&nbsp;activities</FONT> expose us to FCA risk if they result in overcharging agencies, underpaying rebates to agencies, or causing agencies to overpay providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or our operations are found to be in violation of any federal or state healthcare law, or any other governmental regulations that apply to it, we may be
subject to penalties, including civil, criminal, and administrative penalties, damages, fines, disgorgement, debarment from government contracts, refusal of orders under existing contracts, exclusion from participation in U.S. federal or state
health care programs, corporate integrity agreements, and the curtailment or restructuring of our operations, any of which could materially adversely affect our ability to operate our business and our financial results. If any of the physicians or
other healthcare providers or entities with whom we expect to do business, including our collaborators, is found not to be in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including but not
limited to, exclusions from participation in government healthcare programs, which could also materially affect our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States,
engaging in the impermissible promotion of our products, following approval, for <FONT STYLE="white-space:nowrap">off-label</FONT> uses can also subject us to false claims and other litigation under federal and state statutes, including fraud and
abuse and consumer protection laws, which can lead to civil and criminal penalties and fines, agreements with governmental authorities that materially restrict the manner in which we promote or distribute therapeutic products and do business
through, for example, corporate integrity agreements, suspension or exclusion from participation in federal and state healthcare programs, and debarment from government contracts and refusal of future orders under existing contracts. These false
claims statutes include the federal civil False Claims Act, which allows any individual to bring a lawsuit against a biopharmaceutical company on behalf of the federal government alleging submission of false or fraudulent claims or causing others to
present such false or fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the government decides to intervene and prevails in the lawsuit, the individual will share in the proceeds from any fines or settlement funds.
If the government declines to intervene, the individual may pursue the case alone. These False Claims Act lawsuits </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
against manufacturers of drugs and biologics have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements, up to $3.0&nbsp;billion, pertaining
to certain sales practices and <FONT STYLE="white-space:nowrap">promoting&nbsp;off-label&nbsp;uses.</FONT> In addition, False Claims Act lawsuits may expose manufacturers <FONT STYLE="white-space:nowrap">to&nbsp;follow-on&nbsp;claims</FONT> by
private payors based on fraudulent marketing practices. This growth in litigation has increased the risk that a biopharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, as well as criminal and civil
penalties, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid, or other federal and state healthcare programs. If we or our future collaborators do not lawfully promote our approved
products, if any, we may become subject to such litigation and, if we do not successfully defend against such actions, those actions may have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although an effective compliance program can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely
eliminated. Moreover, achieving and sustaining compliance with applicable federal and state fraud laws may prove costly. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur
significant legal expenses and divert our management&#146;s attention from the operation of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not comply with laws regulating
the protection of the environment and health and human safety, our business could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development involves,
and may in the future involve, the use of potentially hazardous materials, including chemicals, potentially infectious biological substances and genetically modified organisms. Our operations produce hazardous waste products. Although we believe
that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the risk of accidental contamination or injury from these materials cannot be fully
eliminated. If an accident occurs, we could be held liable for resulting damages. We are also subject to numerous environmental, health and workplace safety laws and regulations and fire and building codes, including those governing laboratory
procedures, exposure to blood-borne, potentially infectious pathogens, use and storage of flammable agents and the handling of biohazardous materials and genetically modified organisms. Although we maintain workers&#146; compensation insurance as
prescribed by Texas and German laws to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against all potential liabilities. We do
not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs
to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Negative public opinion and increased
regulatory scrutiny of genetic research and therapies involving gene editing and research done on animals may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals
for our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The gene-editing technologies that we use are novel. Public perception may be influenced by claims that gene editing
is unsafe, and products incorporating gene editing may not gain the acceptance of the public or the medical community. The development of some of our product candidates included research on animals or may in future require animal experiments. We try
to limit the use of animal studies in the development of our products to the extent possible. However, FDA and regulatory authorities in other countries asked and may also ask in the future for some aspects of our products to be studied using animal
experiments, and certain aspects of product development require animal studies by applicable regulations and laws. Public perception of our business may also be influenced by claims that studies on animals are unethical. In particular, our success
will depend upon physicians specializing in our targeted diseases prescribing our product candidates as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater clinical data may be available. Any increase in
negative perceptions of gene editing and animal studies may result in fewer physicians prescribing our treatments or may reduce the willingness of patients to utilize our treatments or participate in clinical trials for our product
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates. In addition, given the novel nature of gene-editing and cell therapy technologies, governments may place import or export restrictions in order to retain control of the technologies.
Increased negative public opinion or more restrictive government regulations in the United States, Europe or internationally would have a negative effect on our business or financial condition and may delay or impair the development and
commercialization of our product candidates or demand for such product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those used by our contract
research organizations or other contractors or consultants, may fail or suffer security breaches. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures,
our internal computer systems and those of our contract research organizations and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized and authorized access, natural disasters, terrorism, war and
telecommunication and electrical failures. If such an event was to occur and cause interruptions in our operations, it could result in a disruption of our drug development programs. For example, the loss of clinical trial data from completed or
ongoing clinical trials for a product candidate could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a
loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of any product candidates could be delayed. Loss of XPRESIDENT raw data, the
XPRESIDENT database or target information could result in disruption of drug discovery and product candidate development activities. Unauthorized access to the aforementioned could limit development options and value potential for future target
candidates or proprietary programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are dependent on information technology systems, infrastructure and data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are dependent upon information technology systems, infrastructure and data. The multitude and complexity of our computer systems make them inherently
vulnerable to service interruption or destruction, malicious intrusion and random attack. Likewise, data privacy or security breaches by third parties, employees, contractors or others may pose a risk that sensitive data, including our intellectual
property, trade secrets or personal information of our employees, patients, or other business partners may be exposed to unauthorized persons or to the public. Cyberattacks are increasing in their frequency, sophistication and intensity.
Cyberattacks could include the deployment of harmful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">malware,&nbsp;denial-of-service,&nbsp;social</FONT></FONT> engineering and other means to affect service reliability and threaten
data confidentiality, integrity and availability. Our business and technology partners face similar risks and any security breach of their systems could adversely affect our security posture. While we have invested, and continue to invest, in the
protection of our data and information technology infrastructure, there can be no assurance that our efforts, or the efforts of our partners and vendors, will prevent service interruptions, or identify breaches in our systems, that could adversely
affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm to us. In addition, our liability insurance may not be sufficient in type or
amount to cover us against claims related to security breaches, cyberattacks and other related breaches. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business disruptions could seriously harm
our future revenue and financial condition and increase costs and expenses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations and those of our third-party suppliers and
collaborators could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes or other extreme weather conditions, medical epidemics, labor disputes or other business interruptions. Although we have
limited business interruption insurance policies in place, any interruption could come with high costs for us, as salaries and loan payments would usually continue. Moreover, any interruption could seriously harm our ability to timely proceed with
any clinical programs or to supply product candidates for use in our clinical programs or during commercialization. For example, the <FONT STYLE="white-space:nowrap">current&nbsp;COVID-19&nbsp;pandemic</FONT> is causing an interruption in our
clinical trial activities. Specifically, we had to reduce our business activities including those in the laboratory according to governmental orders in the U.S. as well as in Germany. Additionally, supply chains disruptions impact and may continue
to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
impact our research activities. Clinical sites involved may not be able to enroll patients into our trials as they have to keep free or use capacities for the treatment <FONT
STYLE="white-space:nowrap">of&nbsp;COVID-19&nbsp;patients.</FONT> Any of the sites where we conduct clinical trials may announce that they will not enroll further patients into clinical trials until further notice. We currently do not know, how
substantial the delay for the development of our product candidates will be. Even if the situation improves in the U.S. and/or Europe, the impact on supply chains and patient recruitment may last longer. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur
debt or assume contingent liabilities, and subject us to other risks. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may evaluate various acquisitions and strategic partnerships, including
licensing or acquiring complementary products, intellectual property rights, technologies, or businesses. Any potential acquisition or strategic partnership may entail numerous risks, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the assumption of additional indebtedness or contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assimilation of operations, intellectual property and products of an acquired company or product, including
difficulties associated with integrating new personnel; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the diversion of our management&#146;s attention from our existing product programs and initiatives in pursuing
such a strategic merger or acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that
party and their existing products or product candidates and regulatory approvals; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in
undertaking the acquisition or even to offset the associated acquisition and maintenance costs. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending on the size and nature of
future strategic acquisitions, we may acquire assets or businesses that require us to raise additional capital or to operate or manage businesses in which we have limited experience. Making larger acquisitions that require us to raise additional
capital to fund the acquisition will expose us to the risks associated with capital raising activities. Acquiring and thereafter operating larger new businesses will also increase our management, operating and reporting costs and burdens. In
addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur <FONT STYLE="white-space:nowrap">large&nbsp;one-time&nbsp;expenses</FONT> and acquire intangible assets that could result in
significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the
development of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and
stock price. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global credit and financial markets have experienced extreme volatility and disruptions in the past, including severely
diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and
financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions.
If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Our portfolio of corporate and government bonds would also be adversely impacted. Failure to
secure any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
necessary financing in a timely manner and on favorable terms could have a material adverse effect on our operations, growth strategy, financial performance and stock price and could require us
to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain
our operating goals on schedule and on budget. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are exposed to risks related to currency exchange rates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conduct a significant portion of our operations within Germany in both U.S. dollars and Euros and our arrangements with, for example, MD Anderson, Amgen,
Genmab, BMS, and GSK are denominated in U.S. dollars or Euros. Changes in currency exchange rates have had and could have a significant effect on our operating results. Exchange rate fluctuations between U.S. dollars and local currencies create risk
in several ways, including the following: weakening of the Euro may increase the cost of overseas research and development expenses and other costs outside of Germany; strengthening of the U.S. dollar may decrease the value of any future revenues
denominated in other currencies. Effects of exchange rates on transactions and cash deposits held in a currency other than the functional currency of a subsidiary can distort our financial results; and commercial pricing and profit margins are
affected by currency fluctuations. For example, international crises, conflicts or disasters such as the <FONT STYLE="white-space:nowrap">current&nbsp;COVID-19&nbsp;pandemic</FONT> may result in substantial instability in international financial
markets, including with respect to exchange rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A variety of risks associated with conducting research and clinical trials in multiple countries
and marketing our product candidates internationally could materially adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials are currently being conducted
in the United States and in Germany, and we plan to globally develop our current and future product candidates. Accordingly, we expect that we will be subject to additional risks related to operating in foreign countries, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing regulatory requirements in foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing standards for the conduct of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased difficulties in managing the logistics and transportation of storing and shipping product candidates
produced in the United States or elsewhere and shipping the product candidate to patients in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">import and export requirements and restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">economic weakness, including inflation, or political instability in foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign taxes, including withholding of payroll taxes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulties staffing and managing foreign operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States or Germany;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">differing payor reimbursement regimes, governmental payors or patient
<FONT STYLE="white-space:nowrap">self-pay</FONT> systems, and price controls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that
do not respect and protect intellectual property rights to the same extent as the United States or Germany; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities
abroad; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including
war and terrorism. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These and other risks associated with our international operations may materially adversely affect our ability to
attain or maintain profitable operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our projections regarding the market opportunities for our product candidates may not be accurate, and
the actual market for our products may be smaller than we estimate. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our projections of both the number of people who have the cancers we are
targeting, as well as the subset of people with these cancers who are in a position to receive second- or third-line therapy, and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates.
These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research by third parties, and may prove to be incorrect. Further, new studies or approvals of new
therapeutics may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or
may not be amenable to treatment with our product candidates and may also be limited by the cost of our treatments and the reimbursement of those treatment costs by third-party payors. Even if we obtain significant market share for our product
candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such
designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or
condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or
biologic in the United States will be recovered from sales in the United States for that drug or biologic. In order to obtain orphan drug designation, the request must be made before submitting a BLA. In the European Union, EMA&#146;s Committee for
Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than 5 in
10,000 persons in the European Union. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages,
<FONT STYLE="white-space:nowrap">and&nbsp;user-fee&nbsp;waivers.</FONT> After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not
convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a product that has orphan drug designation
subsequently receives the first FDA approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications,
including a BLA, to market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product
with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other biologics that do not have the same
principal molecular structural features for use in treating the same indication or disease or the same biologic for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable
to manufacture sufficient supply of our product or if a subsequent applicant demonstrates clinical superiority over our product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may seek orphan drug
designations for some or all of our product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products. Even if we obtain orphan drug designations, exclusive marketing rights in the United
States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient
quantities of the product to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if approved. In addition, although we may seek orphan drug designation for
other product candidates, we may never receive such designations. Even with respect to the indications for which we received orphan designation, we may not be the first to obtain marketing approval for any particular orphan indication due to the
uncertainties associated with developing pharmaceutical products, and thus approval of our product candidates could be blocked for seven years if another company previously obtained approval and orphan drug exclusivity for the same drug and same
condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek Breakthrough Therapy or Fast Track designations and may pursue Accelerated Approval for some or all of our current product
candidates, but we may be unable to obtain such designations or, where obtained, we may be unable to maintain Breakthrough Therapy designation or obtain or maintain the benefits associated with such designations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2012, the FDA established a Breakthrough Therapy designation which is intended to expedite the development and review of products that treat serious or
life-threatening diseases when &#147;preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects
observed early in clinical development.&#148; The designation of a product candidate as a Breakthrough Therapy provides potential benefits that include intensive guidance on an efficient drug development program, beginning as early as Phase 1,
organizational commitment involving senior managers; and eligibility for rolling review and priority review. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Breakthrough Therapy designation does not
change the standards for product approval. There can be no assurance that we will receive Breakthrough Therapy designation for any product candidate or any particular indication. Additionally, other treatments from competing companies may obtain the
designations and impact our ability to develop and commercialize our product candidates, which may adversely impact our business, financial condition or results of operation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also seek Fast Track designation. If a drug or biologic candidate is intended for the treatment of a serious or life-threatening condition or disease
and the drug demonstrates the potential to address unmet medical needs for the condition, the sponsor may apply for Fast Track designation. Under the Fast Track program, the sponsor of a new drug or biologic candidate may request that the FDA
designate the candidate for a specific indication as a Fast Track drug or biologic concurrent with, or after, the submission of the IND for the candidate. The FDA must determine if the drug or biologic candidate qualifies for Fast Track designation
within 60 calendar days of receipt of the sponsor&#146;s request. Even if we do apply for and receive Fast Track designation, we may not experience a faster development, review or approval process compared to conventional FDA procedures. The FDA may
rescind Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also seek
Accelerated Approval under the FDA&#146;s Accelerated Approval programs. The FDA may approve a drug or biologic for a serious or life-threatening disease or condition that generally provides </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meaningful advantages over available treatments and demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be
measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and
the availability or lack of alternative treatments. For drugs granted Accelerated Approval, post-marketing confirmatory trials have been required to describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit.
These confirmatory trials must be completed with due diligence. Moreover, the FDA may withdraw approval of our product candidate or indication approved under the Accelerated Approval pathway if, for example: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trial or trials required to verify the predicted clinical benefit of our product candidate fails to verify
such benefit or does not demonstrate sufficient clinical benefit to justify the risks associated with the drug; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other evidence demonstrates that our product candidate is not shown to be safe or effective under the conditions
of use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we fail to conduct any required post approval trial of our product candidate with due diligence; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we disseminate false or misleading promotional materials relating to the relevant product candidate.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Europe, the EMA has implemented <FONT STYLE="white-space:nowrap">the&nbsp;so-called&nbsp;&#147;PRIME&#148;</FONT> (PRIority
MEdicines) status in order support the development and accelerate the approval of complex innovative medicinal products addressing an unmet medical need. The PRIME status enables early dialogue with the relevant EMA scientific committees and,
possibly, some payers; and thus reinforces the EMA&#146;s scientific and regulatory support. It also opens accelerated assessment of the marketing authorization application (150 days instead of 210 days). The PRIME status, which is decided by the
EMA, is reserved to medicines that may benefit from accelerated assessment, i.e. medicines of major interest from a public health perspective, in particular from a therapeutic innovation perspective and that target unmet medical need. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel,
prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our
business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and
funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding
of the FDA and other government agencies on which our operations may rely are subject to the political process, which is inherently fluid and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies,
which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA and other government
employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly
capitalize and continue our operations due to insufficient funding of the SEC and other government agencies or due to a government shutdown that affects the SEC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Immatics OpCo and Immatics US, Inc. are subject to taxes and may have increased tax reporting and
liabilities as a result of tax authority assessments. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics OpCo and Immatics US, Inc. (&#147;Immatics US&#148;) have not been subject to
detailed income tax audits in the past. Both companies&#146; tax returns since 2015 may therefore be subject to change based on subsequent tax audits. This could lead to potential court procedures and increased tax liabilities in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have identified material weaknesses in our internal control over financial reporting which could, if not remediated, result in material misstatements
in our financial statements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, we were a private company and had limited accounting and financial reporting
personnel and other resources with which to address our internal controls and procedures. In connection with the audit of our consolidated financial statements for the year ended December&nbsp;31, 2019, our management identified material weaknesses
in our internal controls related to (i)&nbsp;the sufficiency of resources with an appropriate level of technical accounting and SEC reporting experience, (ii)&nbsp;clearly defined control processes, roles and segregation of duties within our finance
and accounting functions and (iii)&nbsp;the design and operating effectiveness of information technology general controls for information systems that are significant to the preparation of our consolidated financial statements. A material weakness
is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented
or detected on a timely basis. If our remedial measures are insufficient to address the material weaknesses, or if additional material weakness or significant deficiencies in our internal control are discovered or occur in the future, our financial
statements may contain material misstatements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Actual or anticipated changes to the laws and regulations governing the health care system may have
a negative impact on cost and access to health insurance coverage and reimbursement of healthcare items and services. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The United States and
several foreign jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our future approved products profitably.
Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to
healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives, including the Patient Protection and Affordable Care Act
(&#147;ACA&#148;), which became law in 2010. While it is difficult to assess the impact of the ACA in isolation, either in general or on our business specifically, it is widely thought that the ACA increases downward pressure on pharmaceutical
reimbursement, which could negatively affect market acceptance of, and the price we may charge for, any products we develop that receive regulatory approval. Further, the United States, European and foreign governments regularly consider reform
measures that affect healthcare coverage and costs. Such reforms may include changes to the coverage and reimbursement of healthcare services and products. For example, there have been recent judicial and Congressional challenges to the ACA, which
could have an impact on coverage and reimbursement for healthcare services covered by plans authorized by the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. In September 2017, members of the United
States Congress unsuccessfully introduced legislation with the announced intention to repeal major provisions of the ACA. Executive or legislative branch attempts to repeal, reform or to repeal and replace the ACA will likely continue. In addition,
various other healthcare reform proposals have also emerged at the federal and state level. In addition, recent changes to United States tax laws could negatively impact the ACA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot predict what healthcare initiatives, if any, will be implemented in the U.S. at the federal or
state level or in European or other jurisdictions, however, government and other regulatory oversight and future regulatory and government interference with the healthcare systems could adversely impact our business and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the
increasing influence of health maintenance organizations and additional legislative proposals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to comply with international data
protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">European Union (&#147;EU&#148;) member states and other foreign jurisdictions, including Switzerland, have adopted data protection laws and regulations which
impose significant compliance obligations on us. Moreover, the collection and use of personal health data in the EU, which was formerly governed by the provisions of the EU Data Protection Directive, was replaced with the EU General Data Protection
Regulation (&#147;GDPR&#148;) in May 2018. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security
and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EU to the
U.S., provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#128;20&nbsp;million or 4% of the annual global revenues of the noncompliant company, whichever is greater. The GDPR
requirements apply not only to third-party transactions, but also to transfers of information between us and our subsidiaries, including employee information. The recent implementation of the GDPR has increased our responsibility and liability in
relation to personal data that we process, including in clinical trials, and we may, in the future, be required to put in place additional mechanisms to ensure compliance with the GDPR, which could divert management&#146;s attention and increase our
cost of doing business. In addition, new regulation or legislative actions regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue
to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the EU and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our failure to comply with state and/or national data protection laws and regulations could lead to government enforcement actions and
significant penalties against us, and adversely impact our operating results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the European Union, regulations regarding data protection were
revised in 2016 by Regulation (EU) 2016/679 to implement more strict regulations. There are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns. In the U.S., some
state privacy laws apply more broadly than the Health Insurance Portability and Accountability Act (&#147;HIPAA&#148;) and associated regulations. For example, California recently enacted legislation &#150; the California Consumer Privacy Act
(&#147;CCPA&#148;) &#150; which went into effect January&nbsp;1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out
of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Although the law includes limited
exceptions, including for certain information collected as part of clinical trials as specified in the law, it may regulate or impact our processing of personal information depending on the context. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our insurance policies are expensive and protect only from some business risks, which leaves us
exposed to significant uninsured liabilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not carry insurance for all categories of risks that our business may encounter, and insurance
coverage is becoming increasingly expensive. We do not know if we will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for
any expenses or losses we may suffer. If we obtain marketing approval for any product candidates that we or our collaborators may develop, we intend to acquire insurance coverage to include the sale of commercial products, but we may be unable to
obtain such insurance on commercially reasonable terms or in adequate amounts. Required coverage limits for such insurances are difficult to predict and may not be sufficient. If potential losses exceed our insurance coverage, our financial
condition would be adversely affected. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources. Clinical trials or regulatory approvals for any of our product
candidates could be suspended, which could adversely affect our results of operations and business, including by preventing or limiting the development and commercialization of any product candidates that we or our collaborators may develop.
Additionally, operating as a public company will make it more expensive for us to obtain director and officer liability insurance. As a result, it may be more difficult to attract and retain qualified individuals to serve on our supervisory board
(the &#147;Supervisory Board&#148;), the board committees or our management board (the &#147;Management Board&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to new
legislation, regulatory proposals, and healthcare payor initiatives that may increase our costs of compliance, and adversely affect our ability to market our products, obtain collaborators, and raise capital. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States and other foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the
healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability, or the ability of our collaborators, to profitably sell any products for which we
obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or our
collaborators, may receive for any approved products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since 2010, when the United States enacted the Affordable Care Act (&#147;ACA&#148;), there have
been a number of legislative and regulatory changes to the health care system in U.S. and also certain foreign jurisdictions that could impact our ability to sell our products profitably. In August 2011, the Budget Control Act of 2011, among other
things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach
required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect on April&nbsp;1, 2013
and were to remain in effect until 2024. The Bipartisan Budget Act of 2015 extended the 2% sequestration to 2025. In January 2013, the American Taxpayer Relief Act of 2012 (&#147;ATRA&#148;) was approved which, among other things, reduced Medicare
payments to several providers, with primary focus on the hospital outpatient setting and ancillary services, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to
recover overpayments to providers from three to five years. On January&nbsp;20, 2017, the new administration signed an Executive Order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions
from, or delay the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices, and, for that
reason, some final regulations have yet to take effect. In December 2017, Congress repealed the individual mandate for health insurance required by the ACA and could consider further legislation to repeal other elements of the ACA. At the end of
2017, CMS promulgated regulations that reduce the amount paid to hospitals for outpatient drugs purchased under the 340B program, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
some states have enacted transparency laws requiring manufacturers to report information on drug prices and price increases. On December&nbsp;14, 2018, the United States District Court for the
Northern District of Texas struck down the ACA, deeming it unconstitutional given that Congress repealed the individual mandate in 2017. In December 2019, the U.S. Court of Appeals for the Fifth Circuit affirmed the district court&#146;s decision
that the individual mandate is unconstitutional, but remanded the case to the district court to reconsider the severability question. It is unclear how the ultimate decision in this case, which is now pending before the U.S. Supreme Court, and other
efforts to repeal and replace the ACA will impact the ACA and our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional federal and state healthcare reform measures in the U.S. or
foreign countries may be adopted in the future that may result in more rigorous coverage criteria, increased regulatory burdens and operating costs, decreased net revenue from our pharmaceutical products, decreased potential returns from our
development efforts, and additional downward pressure on the price that we receive for any approved drug. Any reduction in reimbursement from Medicare or other foreign government healthcare programs may result in a similar reduction in payments from
private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals may also be made to expand post-approval requirements and restrict sales and promotional activities for drugs. We cannot
be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In
addition, increased scrutiny by Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, there have been a number of other policy, legislative and regulatory proposals aimed at changing the pharmaceutical industry. For instance, on
May&nbsp;11, 2018, the current administration presented its &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs, as well as additional proposals to increase drug manufacturer competition, increase the negotiating power
of certain federal healthcare programs, and incentivize manufacturers to lower the list price of their products. Although some proposals related to the administration&#146;s Blueprint may require additional authorization to become effective, may
ultimately be withdrawn, or may face challenges in the courts, the U.S. Congress and the administration have indicated that they will continue to seek new legislative and administrative measures to control drug costs, including by addressing the
role of pharmacy benefit managers in the supply chain. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are unable to predict the future course of federal or state healthcare legislation in the United States or other major drug markets directed at broadening
the availability of healthcare and containing or lowering the cost of healthcare. The ACA and any further changes in the law or regulatory framework that reduce our revenue or increase our costs could also have a material and adverse effect on our
business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The use of Immatics Opco and Immatics US&#146;s net operating loss carryforwards and
research tax credits may be limited as a result of the Business Combination. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both Immatics OpCo and Immatics US incurred significant losses in the
past and therefore are entitled to use net operating loss carryforwards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, we had German federal net operating loss
carryforwards of at least &#128;155&nbsp;million. These net operating loss carryforwards will not expire. However, the Business Combination resulted in an ownership change in accordance with &#167; 8c (1)&nbsp;KStG (German corporation tax code).
Therefore, these net </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operating loss carryforwards can be preserved only to the extent that our fair value exceeds the equity in the tax books plus the net operating loss carryforwards. Therefore, our net operating
loss carryforwards could be reduced or eliminated as part of the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, Immatics US had U.S. federal net operating
loss carryforwards of at least $65&nbsp;million. Immatics US&#146;s net operating loss carryforwards arising in taxable years ending on or prior to December&nbsp;31, 2017 will begin expiring in 2027 if Immatics US has not used them prior to that
time. Net operating loss carryforwards arising in taxable years ending after December&nbsp;31, 2017 are no longer subject to expiration under the U.S. Tax Code. Under the Coronavirus Aid, Relief, and Economic Security Act (the &#147;CARES
Act&#148;), net operating losses arising in tax years beginning after December&nbsp;31, 2017<I></I>&nbsp;and before January&nbsp;1, 2021 may be carried back to each of the five tax years<I></I>&nbsp;preceding the tax year of such loss. Due to the
cumulative losses of Immatics US<I></I>&nbsp;through December&nbsp;31, 2019, Immatics US does not anticipate that such provision<I></I>&nbsp;of the CARES Act will be relevant to it. Additionally, Immatics US&#146;s ability to use any net operating
loss and credit carryforwards to offset taxable income or tax, respectively, in the future will be limited under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986, as amended (the &#147;U.S. Tax Code&#148;) respectively, if Immatics US
has a cumulative change in ownership of more than 50% within a three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have performed an analysis under Section&nbsp;382 of the U.S. Tax
Code as of the expected closing of the Business Combination. Per the analysis, the Business Combination may have triggered such an ownership change. As a result, the federal carryforwards associated with the net operating losses and research tax
credits may be limited and more likely to expire unutilized. Based on our analysis, the annual limitation under Section&nbsp;382 of the U.S. Tax Code is expected to be approximately $2.1&nbsp;million. In addition to this limitation, Section&nbsp;382
of the U.S. Tax Code provides that a corporation with a net unrealized <FONT STYLE="white-space:nowrap">built-in</FONT> gain immediately before an ownership change may increase its limitation by the amount of recognized <FONT
STYLE="white-space:nowrap">built-in</FONT> gain recognized during a recognition period, which is generally the five-year period immediately following an ownership change. Based on our analysis, we believe that Immatics US has a net unrealized <FONT
STYLE="white-space:nowrap">built-in</FONT> gain at the time of the Business Combination; as a result, the limitation under Section&nbsp;382 of the U.S. Tax Code may be increased during the recognition period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, since we will need to raise substantial additional funding to finance our operations, we may undergo further ownership changes in the future. Any
such annual limitation may significantly reduce the utilization of the net operating loss carryforwards and research tax credits before they expire. Depending on our future tax position, limitation of our ability to use net operating loss
carryforwards in which we are subject to income tax could have an adverse impact on our results of operations and financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related
to Ownership of Our Ordinary Shares and the Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are organized and existing under the laws of the Netherlands, and, as such, the rights
of our shareholders and the civil liability of our directors and executive officers are governed in certain respects by the laws of the Netherlands. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are organized and existing under the laws of the Netherlands, and, as such, the rights of our shareholders and the civil liability of our directors and
executive officers are governed in certain respects by the laws of the Netherlands. The ability of our shareholders in certain countries other than the Netherlands to bring an action against us, our directors and executive officers may be limited
under applicable law. In addition, substantially all of our assets are located outside the United States. As a result, it may not be possible for shareholders to effect service of process within the United States upon us or our directors and
executive officers or to enforce judgments against us or them in U.S. courts, including judgments predicated upon the civil liability provisions of the federal securities laws of the United States. In addition, it is not clear whether a Dutch court
would impose civil liability on us or any of our directors and executive officers in an original action based solely upon the federal securities laws of the United States brought in a court of competent jurisdiction in the Netherlands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, the United States and the Netherlands do not have a treaty providing for
the reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters. Accordingly, a judgment rendered by a court in the United States, whether or not predicated solely upon U.S. securities laws,
would not automatically be recognized and enforced by the competent Dutch courts. However, if a person has obtained a final and conclusive judgment for the payment of money rendered by a court in the United States that is enforceable in the United
States and files a claim with the competent Dutch court, the Dutch court will generally give binding effect to such foreign judgment insofar as it finds that (i)&nbsp;the jurisdiction of the U.S. court has been based on a ground of jurisdiction that
is generally acceptable according to international standards, (ii)&nbsp;the judgment by the U.S. court was rendered in legal proceedings that comply with the Dutch standards of proper administration of justice including sufficient safeguards
(<I>behoorlijke rechtspleging</I>) and (iii)&nbsp;the judgment by the U.S. court is not incompatible with a decision rendered between the same parties by a Dutch court, or with a previous decision rendered between the same parties by a foreign court
in a dispute that concerns the same subject and is based on the same cause, provided that the previous decision qualifies for acknowledgment in the Netherlands and except to the extent that the foreign judgment contravenes Dutch public policy
(<I>openbare orde</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the lack of a treaty as described above, U.S. investors may not be able to enforce against the company or our directors,
representatives or certain experts named herein who are residents of the Netherlands or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal
securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our articles of association, and certain other contractual arrangements between us and our directors, we will indemnify and hold
our directors harmless against all claims and suits brought against them, subject to limited exceptions. There is doubt, however, as to whether U.S. courts would enforce such indemnity provisions in an action brought against one of our directors in
the United States under U.S. securities laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not anticipate paying dividends on our ordinary shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our articles of association prescribe that any profits in any financial year will be distributed first to holders of financing preferred shares, if
outstanding. Any remaining profits may be reserved by the Management Board subject to the approval of the Supervisory Board or, after July&nbsp;1, 2021, the Board. Any profits remaining thereafter and our reserves may be distributed as dividends to
the holders of our ordinary shares, subject to the appropriate record date. The general meeting will be authorized to declare distributions on the proposal of the Management Board, which proposal will require the prior approval of the Supervisory
Board or, after July&nbsp;1, 2021, the Board. We will have power to make distributions to shareholders only to the extent that our equity exceeds the aggregate amount of the issued share capital and the reserves which must be maintained pursuant to
Dutch law or by our articles of association. We may not make any distribution of profits on shares held by the company as treasury shares and such treasury shares will not be taken into account when determining the profit entitlement of our
shareholders. The Management Board or, after July&nbsp;1, 2021, the Board, determines whether and how much of the profit shown in the adopted annual accounts it will reserve and the manner and date of any dividend. All calculations to determine the
amounts available for dividends will be based on company-only annual accounts, which may be different from our consolidated financial statements, such as those included in this prospectus. In addition, the Management Board is permitted, subject to
Supervisory Board approval and subject to certain requirements, to declare interim dividends without the approval of the shareholders. We may reclaim any distributions, whether interim or not interim, made in contravention of certain restrictions of
Dutch law from shareholders that knew or should have known that such distribution was not permissible. In addition, on the basis of Dutch case law, if after a distribution we are not able to pay our due and collectable debts, then our shareholders
or directors who at the time of the distribution knew or reasonably should have foreseen that result may be liable to our creditors. We have never declared or paid any cash dividends and have no plan to declare or pay any dividends in the
foreseeable future on our ordinary shares. We currently intend to retain any earnings for future operations and expansion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since we are a holding company, our ability to pay dividends will be dependent upon the financial condition,
liquidity and results of operations of, and our receipt of dividends, loans or other funds from, our subsidiaries. Our subsidiaries are separate and distinct legal entities and have no obligation to make funds available to us. In addition, there are
various statutory, regulatory and contractual limitations and business considerations on the extent, if any, to which our subsidiaries may pay dividends, make loans or otherwise provide funds to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Each of ARYA Sponsor and certain of Immatics OpCo&#146;s former equityholders own a significant portion of our ordinary shares and will have
representation on the Supervisory Board, and after July&nbsp;1, 2021, the Board. The ARYA Sponsor and such former Immatics OpCo&#146;s current equityholders may have interests that differ from those of other shareholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, approximately 9.7% of our ordinary shares are owned by the <FONT STYLE="white-space:nowrap">pre-Business</FONT> Combination
independent directors of ARYA (but not including a certain affiliate (the &#147;Sponsor PIPE Entity&#148;) of ARYA Sponsor), approximately 55.2% of our ordinary shares are owned by certain former Immatics OpCo equityholders and approximately 16.4%
of our ordinary shares are owned by the investors in the PIPE Financing (including certain Immatics OpCo equityholders and the Sponsor PIPE Entity). In addition, two of our director nominees were designated by the ARYA Sponsor. As a result, the ARYA
Sponsor and certain former Immatics OpCo equityholders may be able to significantly influence the outcome of matters submitted for director action, subject to obligation of the Management Board and Supervisory Board or, after July&nbsp;1, 2021, the
Board to act in the interest of all of our stakeholders, and for shareholder action, including the designation and appointment of the Management Board and Supervisory Board and, after July&nbsp;1, 2021, the Board (and committees thereof) and
approval of significant corporate transactions, including business combinations, consolidations and mergers. The influence of ARYA Sponsor and certain former Immatics OpCo equityholders over our management could have the effect of delaying or
preventing a change in control or otherwise discouraging a potential acquirer from attempting to obtain control of our company, which could cause the market price of our ordinary shares to decline or prevent our shareholders from realizing a premium
over the market price for our ordinary shares. Additionally, ARYA Sponsor is controlled by Perceptive Advisors LLC and its affiliates (&#147;Perceptive&#148;), which is in the business of making investments in companies and which may from time to
time acquire and hold interests in businesses that compete directly or indirectly with us or that supply us with goods and services. Perceptive may also pursue acquisition opportunities that may be complementary to (or competitive with) our
business, and as a result those acquisition opportunities may not be available to us. Prospective investors in our ordinary shares should consider that the interests of ARYA Sponsor and certain former Immatics OpCo equityholders may differ from
their interests in material respects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions of our articles of association or Dutch corporate law might deter acquisition bids for us that our
shareholders might consider to be favorable and prevent or frustrate any attempt to replace or remove the Supervisory Board or Management Board at the time of such acquisition bid. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain provisions of our articles of association may make it more difficult for a third party to acquire control of the Supervisory Board, Management Board
or, after July&nbsp;1, 2021, the Board or effect a change in the composition of such boards. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a provision that our directors can only be removed (or a binding nomination by the Supervisory Board or, after
July&nbsp;1, 2021, the Board or shareholders representing, individually or jointly, 10% of our issued share capital to appoint directors can only be set aside) by the shareholders by a majority of at least two thirds of the votes cast during a
general meeting, provided such votes represent more than half of the issued share capital (unless the removal was proposed by the Supervisory Board or, after July&nbsp;1, 2021, the Board, in which case a majority of votes cast representing more than
half of the issued share capital is required); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuant to our articles of association, the Management Board and, after July&nbsp;1, 2021, the Board, is
irrevocably authorized for a period of five years from the date of the Business Combination, to issue ordinary shares which could enable us to dilute the holding of an acquirer by issuing ordinary shares to other parties. Issuances of ordinary
shares may make it more difficult for a shareholder or potential acquirer to obtain control over us; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a requirement that certain matters, including an amendment of our articles of association, may only be brought to
the shareholders for a vote upon a proposal by the Management Board, which proposal requires the prior approval of the Supervisory Board or, after July&nbsp;1, 2021, upon a proposal by the Board; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a provision implementing a staggered board, pursuant to which only one class of Supervisory Directors, or after
July&nbsp;1, 2021, our Directors, will be elected at each general meeting, with the other classes continuing for the remainder of their respective terms. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such provisions could discourage a takeover attempt and impair the ability of shareholders to benefit from a change in control and realize any potential
change of control premium. This may adversely affect the market price of our ordinary shares. See the section titled &#147;<I>Description of Securities</I>&#148;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results
or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which is likely to negatively affect our business and the market price of our ordinary shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and prevent fraud. Any failure to implement
required new or improved controls, or difficulties encountered in our implementation could cause us to fail to meet our reporting obligations. In addition, any testing conducted by us, or any testing conducted by our independent registered public
accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for
further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which is likely to negatively affect our business and the market price of our ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required to disclose changes made in our internal controls and procedures on a quarterly basis and our management is required to assess the
effectiveness of these controls annually. However, for as long as we are an &#147;emerging growth company&#148; under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal
control over financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002 (the &#147;Sarbanes-Oxley Act&#148;). We could be an &#147;emerging growth company&#148; for up to five years. An independent assessment of the
effectiveness of our internal controls could detect problems that our management&#146;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense
of remediation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price and trading volume of our ordinary shares may be volatile and could decline significantly following the Business
Combination. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock markets, including Nasdaq, on which our ordinary shares and public warrants are listed, have from time to time experienced
significant price and volume fluctuations. Even if an active, liquid and orderly trading market develops and is sustained for our ordinary shares, the market price of our ordinary shares may be volatile and could decline significantly. In addition,
the trading volume in our ordinary shares and public warrants may fluctuate and cause significant price variations to occur. Generally, securities of biotechnology companies tend to be volatile and experience significant price and volume
fluctuations. If the market price of our ordinary shares declines significantly, you may be unable to resell your securities at or above the price you purchased them for. We cannot assure you that the market price of our ordinary shares will not
fluctuate widely or decline significantly in the future in response to a number of factors, including, among others, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the realization of any of the risk factors presented in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated differences in our estimates, or in the estimates of analysts, for our revenues, results of
operations, liquidity or financial condition; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions and departures of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to comply with the requirements of Nasdaq; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to comply with the Sarbanes-Oxley Act or other laws or regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future issuances, sales or resales, or anticipated issuances, sales or resales, of our ordinary shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports about us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the performance and market valuations of other similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">broad disruptions in the financial markets, including sudden disruptions in the credit markets;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material and adverse impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the markets and
the broader global economy; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">speculation in the press or investment community; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual, potential or perceived control, accounting or reporting problems; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting principles, policies and guidelines. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past, securities class-action litigation has often been instituted against companies following periods of volatility in the market price of their
shares. This type of litigation could result in substantial costs and divert our management&#146;s attention and resources, which could have a material adverse effect on us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts publish inaccurate or unfavorable research or cease publishing research about us, our share price and trading volume
could decline significantly. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The market for our ordinary shares depends in part on the research and reports that securities or industry analysts
publish about us or our business. If one or more of the analysts who covers us downgrades its opinions about our ordinary shares, publishes inaccurate or unfavorable research about us, or ceases publishing about us regularly, demand for our ordinary
shares could decrease, which might cause our share price and trading volume to decline significantly. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future issuances of financing preferred
shares or other equity securities may adversely affect us, including the market price of our ordinary shares, and may be dilutive to existing shareholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the future, we may issue financing preferred shares or other equity ranking senior to our ordinary shares. Financing preferred shares have, and those other
securities will generally have, priority upon liquidation. Such securities also may be governed by an instrument containing covenants restricting our operating flexibility. Additionally, any convertible or exchangeable securities that we issue in
the future may have rights, preferences and privileges more favorable than those of our ordinary shares. Because our decision to issue equity in the future will depend on market conditions and other factors beyond our control, we cannot predict or
estimate the amount, timing, nature or success of our future capital raising efforts. As a result, future capital raising efforts may reduce the market price of our ordinary shares and be dilutive to existing shareholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our shareholders may not have any preemptive rights in respect of future issuances of our ordinary shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of an increase in our share capital by way of an issue of our ordinary shares, holders of our ordinary shares are generally entitled under Dutch
law to full preemptive rights, unless these rights are limited or excluded either by a resolution of the general meeting or by a resolution of the Management Board, subject to the prior approval of the Supervisory Board or, after July&nbsp;1, 2021,
the Board (if authorized by the general meeting for this purpose), or where shares are issued to our employees or a group company (i.e., certain affiliates, subsidiaries or related companies) or paid up by means of
<FONT STYLE="white-space:nowrap">a&nbsp;non-cash&nbsp;contribution,</FONT> or in case of an exercise of a previously acquired right to subscribe for shares. The same preemptive rights apply when rights to subscribe for shares are granted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our articles of association, the preemptive rights in respect of newly issued ordinary shares may be
restricted or excluded by a resolution of the general meeting, which resolution requires <FONT STYLE="white-space:nowrap">a&nbsp;two-thirds&nbsp;majority</FONT> of the votes cast if less than half of the issued share capital is present or
represented at the meeting. The general meeting may authorize the Management Board, subject to the prior approval of the Supervisory Board or, after July&nbsp;1, 2021, the Board to limit or exclude the preemptive rights in respect of newly issued
ordinary shares. Such authorization for the Management Board, subject to the prior approval of the Supervisory Board or, after July&nbsp;1, 2021, the Board can be granted and extended, in each case for a period not exceeding five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our resolution of the general meeting dated June&nbsp;30, 2020, the Management Board is irrevocably authorized for a period of five years from the
date of the Business Combination to limit or exclude preemptive rights on our ordinary shares up to 100% of the number of our ordinary shares in our authorized share capital (from time to time). On July&nbsp;1, 2021, the powers of the Management
Board will vest in the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, holders of our ordinary shares may not have any preemptive rights in connection with, and may be diluted by,
an issue of new ordinary shares and it may be more difficult for a shareholder to obtain control over the general meeting. See the sections titled &#147;<I>Description of</I><I></I><I>&nbsp;Securities &#151; Share Capital</I>&#148;, &#147;<I> &#151;
Issuance of</I><I></I><I>&nbsp;Ordinary Shares</I>&#148; and &#147;<I> &#151; Preemptive Rights</I>&#148;. Certain of our ordinary shareholders outside the Netherlands, in particular, U.S. ordinary shareholders, may not be allowed to exercise
preemptive rights to which they are entitled, if any, unless a registration statement under the Securities Act is declared effective with respect to ordinary shares issuable upon exercise of such rights or an exemption from the registration
requirements is available. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preemptive rights do not exist with respect to the issue of financing preferred shares and holder of financing preferred
shares have no preemptive right to acquire newly issued ordinary shares. We are not obligated to and do not comply with all the best practice provisions of the DCGC. This could adversely affect your rights as a shareholder. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we have our registered office in the Netherlands and our ordinary shares are listed on a
<FONT STYLE="white-space:nowrap">third&nbsp;(non-EU)&nbsp;country</FONT> market equivalent to a regulated market (Nasdaq), we are subject to the Dutch Corporate Governance Code, as of December&nbsp;8, 2016 and as amended from time to time (the
&#147;DCGC&#148;). The DCGC contains both principles and best practice provisions for the Management Board, the Supervisory Board or, after July&nbsp;1, 2021, the Board, shareholders and the general meeting, financial reporting, auditors, disclosure
compliance and enforcement standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DCGC is based on a &#147;comply or explain&#148; principle. Accordingly, we are required to disclose in our
management report publicly filed in the Netherlands, whether or not we are complying with the various provisions of the DCGC. If we do not comply with one or more of those provisions (e.g., because of a conflicting Nasdaq requirement or U.S. market
practice), we are required to explain the reasons for <FONT STYLE="white-space:nowrap">such&nbsp;non-compliance.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We acknowledge the importance of
good corporate governance. However, we do not comply with all the provisions of the DCGC, to a large extent because such provisions conflict with or are inconsistent with the corporate governance rules of Nasdaq and U.S. securities laws applicable
to us, or because we believe such provisions do not reflect customary practices of global companies listed on Nasdaq. This could adversely affect your rights as a shareholder and you may not have the same level of protection as a shareholder in a
Dutch company that fully complies with the DCGC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148;, and we cannot be certain if the reduced SEC
reporting requirements applicable to emerging growth companies will make our ordinary shares less attractive to investors, which could have a material and adverse effect on us, including on our growth prospects. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the JOBS Act. We will remain an &#147;emerging growth company&#148; until the earliest to occur of
(i)&nbsp;the last day of the fiscal year (a)&nbsp;following October&nbsp;10, 2023, the fifth anniversary of ARYA&#146;s initial public offering, (b)&nbsp;in which we have total annual gross revenue of at least
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
$1.07&nbsp;billion or (c)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our ordinary shares that are held
<FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;exceeds</FONT> $700.0&nbsp;million as of the last business day of our prior second fiscal quarter, and (ii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion <FONT
STYLE="white-space:nowrap">in&nbsp;non-convertible&nbsp;debt</FONT> during the prior three-year period. We intend to take advantage of exemptions from various reporting requirements that are applicable to most other public companies, whether or not
they are classified as &#147;emerging growth companies&#148;, including, but not limited to, an exemption from the provisions of Section&nbsp;404(b) of the Sarbanes-Oxley Act requiring that our independent registered public accounting firm provide
an attestation report on the effectiveness of our internal control over financial reporting and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of
holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. The JOBS Act also provides that an &#147;emerging growth company&#148; can take advantage of the extended
transition period provided in the Securities Act for complying with new or revised accounting standards. However, we have chosen to &#147;opt out&#148; of this extended transition period and, as a result, we will comply with new or revised
accounting standards on the relevant dates on which adoption of such standards is required for all public companies that are not emerging growth companies. our decision to opt out of the extended transition period for complying with new or revised
accounting standards is irrevocable. We cannot predict if investors will find our ordinary shares less attractive because we intend to rely on certain of these exemptions and benefits under the JOBS Act. If some investors find our ordinary shares
less attractive as a result, there may be a less active, liquid and/or orderly trading market for our ordinary shares and the market price and trading volume of our ordinary shares may be more volatile and decline significantly. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>As a foreign private issuer, we will be exempt from a number of rules under the U.S. securities laws and will be permitted to file less information with
the SEC than a U.S. company. This may limit the information available to holders of our ordinary shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a foreign private issuer, as such
term is defined in Rule&nbsp;405 under the Securities Act. As a foreign private issuer, we will not be subject to all of the disclosure requirements applicable to public companies organized within the United States. For example, we will be exempt
from certain rules under the Exchange Act that regulate disclosure obligations and procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security registered under the Exchange Act, including the
U.S. proxy rules under Section&nbsp;14 of the Exchange Act. As long as we are eligible for the foreign private issuer exemption, we will not be required to obtain shareholder approval for certain dilutive events, such as the establishment or
material amendment of certain equity-based compensation plans, we will not be required to provide detailed executive compensation disclosure in our periodic reports, and we will be exempt from the requirements of holding a nonbinding advisory vote
on executive compensation and shareholder approval of any golden parachute payments not previously approved. In addition, our officers and directors will be exempt from the reporting and &#147;short-swing&#148; profit recovery provisions of
Section&nbsp;16 of the Exchange Act and related rules with respect to their purchases and sales of our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While we will submit quarterly interim
consolidated financial data to the SEC under cover of the SEC&#146;s <FONT STYLE="white-space:nowrap">Form&nbsp;6-K,&nbsp;we</FONT> will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as
U.S. public companies and will not be required to file quarterly reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;or</FONT> current reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;under</FONT> the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, as a foreign private issuer, we will be permitted to follow home country practice in lieu of certain corporate governance rules of the Nasdaq, including
those that require listed companies to have a majority of independent directors and independent director oversight of executive compensation, nomination of directors and corporate governance matters. As long as we rely on the foreign private issuer
exemption, a majority of our board of directors will not be required to be independent directors and our compensation committee will not be required to be composed entirely of independent directors. Accordingly, holders of our ordinary shares may
not have the same protections afforded to shareholders of listed companies that are subject to all of the applicable corporate governance requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our tax residency might change if Germany ratifies the MLI and changes its provisional election on the
corporate <FONT STYLE="white-space:nowrap">residence&nbsp;tie-breaker.</FONT> </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our sole tax residency in Germany for purposes of the convention
between Germany and the Netherlands for the avoidance of double taxation and the prevention of fiscal evasion with respect to taxes on income (the &#147;German-Dutch tax treaty&#148;) is subject to the application of the provisions on tax residency
as stipulated in the German-Dutch tax treaty as effective as of the date of this prospectus. However, among others, Germany and the Netherlands entered into a Multilateral Convention to Implement Tax Treaty Related Measures to Prevent Base Erosion
and Profit Shifting (&#147;MLI&#148;). The MLI operates to amend bilateral tax treaties between participating states, provided there is a match between certain options made by the relevant states. The MLI provides, amongst others, for an amendment
of relevant treaty rules regarding tax residency for purposes of relevant tax treaties. According to its elections, the Netherlands applies such deviating rules on tax residency,<I>&nbsp;i.e.</I>, it did not opt out. With regard to Germany,
provisional statements made at the time of signing the MLI indicate that it is intended <FONT STYLE="white-space:nowrap">to&nbsp;opt-out&nbsp;of</FONT> the application of such provisions. However, given that the MLI has to date not been ratified in
Germany and the options provided for in the MLI remain subject to discussion, it cannot be ruled out that Germany ultimately opts to amend the current rules regarding tax residency in line with the option exercised by the Netherlands. If Germany
changes its provisional view on the election, the MLI rules on tax residency would become applicable to the German-Dutch tax treaty. In this case, the competent authorities of the Netherlands and Germany shall endeavor to determine by mutual
agreement our sole tax residency. During the period in which a mutual agreement between both states is absent, we may not be entitled to any relief or exemption from tax provided by the German-Dutch tax treaty. During such period, there would also
be a risk that both Germany and the Netherlands would levy dividend withholding tax on distributions by us, in addition to the risk of double taxation on our profits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be or may become a PFIC, which could result in adverse U.S. federal income tax consequences to U.S. Holders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or any of our subsidiaries is a passive foreign investment company (a &#147;PFIC&#148;) for any taxable year, or portion thereof, that is included in the
holding period of a beneficial owner of our ordinary shares that is a U.S. Holder, such U.S. Holder (as defined in the section entitled &#147;<I>Material U.S. Federal Income Tax Considerations for U.S. Holders</I>&#148;), may be subject to certain
adverse U.S. federal income tax consequences and may be subject to additional reporting requirements. It is uncertain whether we or any of our subsidiaries, including Immatics OpCo, will be treated as a PFIC for U.S. federal income tax purposes for
the current or any subsequent tax year. If we determine that we and/or any of our subsidiaries is a PFIC for any taxable year, we intend to provide a U.S. Holder with such information necessary for the U.S.&nbsp;Holder to make and maintain a QEF
Election (as defined in the section entitled &#147;<I>Material U.S. Federal Income Tax Considerations for U.S. Holders</I>&#148;) with respect to us and/or such subsidiaries, but there can be no assurance that we will have timely knowledge of our
status as a PFIC in the future or of the required information to be provided. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See the section entitled &#147;<I>Material U.S. Federal Income Tax
Considerations for U.S. Holders</I>&#148; for a more detailed discussion with respect to our PFIC status. Prospective U.S. Holders of our ordinary shares or public warrants are urged to consult their tax advisors regarding the possible application
of the PFIC rules to them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_6"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements regarding our current expectations or forecasts of future events. Forward-looking statements include
statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as &#147;anticipate&#148;, &#147;believe&#148;, &#147;continue&#148;, &#147;could&#148;,
&#147;estimate&#148;, &#147;expect&#148;, &#147;intend&#148;, &#147;may&#148;, &#147;might&#148;, &#147;objective&#148;, &#147;ongoing&#148;, &#147;plan&#148;, &#147;potential&#148;, &#147;predict&#148;, &#147;project&#148;, &#147;should&#148;,
&#147;will&#148; and &#147;would&#148;, or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not
forward-looking. Examples of forward-looking statements in this prospectus include, but are not limited to, statements regarding our operations, cash flows, financial position and dividend policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements are subject to risks and uncertainties, including with regards to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future operating or financial results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future payments of dividends and the availability of cash for payment of dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations relating to dividend payments and forecasts of our ability to make such payments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">future acquisitions, business strategy and expected capital spending; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assumptions regarding interest rates and inflation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business disruptions arising from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial condition and liquidity, including our ability to obtain additional financing in the future to fund
capital expenditures, acquisitions and other general corporate activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">estimated future capital expenditures needed to preserve our capital base; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to effect future acquisitions and to meet target returns; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the initiation, timing, progress, costs and results of our clinical trials, including our ACT and TCER Bispecific
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of meetings with and feedback from regulatory authorities as well as any submission of filings for
regulatory approval of our ACT and TCER Bispecific programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential advantages and differentiated profile of ACT and TCER Bispecific product candidates compared to
existing therapies for the applicable indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully manufacture or have manufactured drug product for clinical trials and
commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize drug products, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance of our product candidates IMA201, IMA202, IMA203, IMA204, IMA301, IMA401
and IMA402, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the size of the patient populations for and opportunity for and clinical utility of
ACT and TCER Bispecific product candidates, if approved for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, ongoing losses, future revenue, capital requirements and needs for or ability
to obtain additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain intellectual property protection for our drug products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> and develop new product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify, recruit and retain key personnel; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments and projections relating to our competitors or industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other factors discussed in the section titled &#147;<I>Risk Factors</I>&#148;. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause
actual results to differ materially from those expected or implied by the forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in
the section titled &#147;<I>Risk Factors</I>&#148; in this prospectus. Accordingly, you should not rely on these forward-looking statements, which speak only as of the date of this prospectus. We undertake no obligation to publicly revise any
forward-looking statement to reflect circumstances or events after the date of this prospectus or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks we describe in the reports it will file from time
to time with the SEC after the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, statements reflecting our beliefs and opinions on certain subjects are based on
information available to us as of the date of this prospectus. And while we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Such statements should not be read to indicate that
we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely on these statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we believe the expectations reflected in the forward-looking statements were reasonable at the time made, we cannot guarantee future results, level
of activity, performance or achievements. We do not assume responsibility for the accuracy or completeness of any of these forward-looking statements. You should carefully consider the cautionary statements contained or referred to in this section
in connection with the forward looking statements contained in this prospectus and any subsequent written or oral forward-looking statements that may be issued by us or persons acting on our behalf. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the ordinary shares offered by the selling securityholders pursuant to this prospectus will be sold by the selling securityholders for their respective
accounts. We will not receive any of the proceeds from such sales. We will pay certain expenses associated with the registration of the securities covered by this prospectus, as described in the section titled &#147;<I>Plan of
Distribution</I>&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends and have no plan to declare or pay any dividends on our ordinary shares in the foreseeable future. We
currently intend to retain any earnings for future operations and expansion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will be able to make distributions to our shareholders only to the extent
that our equity exceeds the aggregate amount of issued share capital and reserves that must be maintained pursuant to Dutch law or under our articles of association. We may not make any distribution of profits on shares held as treasury shares and
such treasury shares will not be taken into account when determining the profit entitlement of our shareholders. Our articles of association prescribe that profits in any financial year will be distributed first to holders of our financing preferred
shares, if any are outstanding. Any remaining profits may be reserved by our Management Board, subject to the approval of our Supervisory Board or, after July&nbsp;1, 2021, our Board. Any profits remaining thereafter and reserves may be distributed
as dividends to the holders of our ordinary shares, subject to the appropriate record date. The general meeting is authorized to declare distributions upon the proposal of our Management Board, which proposal requires the prior approval of our
Supervisory Board or, after July&nbsp;1, 2021, our Board. Our Management Board or, after July&nbsp;1, 2021, our Board determines whether and how much of the profits shown in the adopted annual accounts will be reserved and the manner and date of any
dividend. All calculations to determine the amounts available for dividends will be based on our company-only annual accounts, which may be different from our consolidated financial statements, such as those included in this prospectus. In addition,
our Management Board is permitted, subject to Supervisory Board approval and certain requirements, to declare interim dividends without the approval of our shareholders. We may reclaim any distributions, whether interim or not interim, made in
contravention of certain restrictions of Dutch law from shareholders that knew or should have known that such distribution was not permissible. In addition, on the basis of Dutch case law, if after a distribution we are not able to pay our due and
collectable debts, then our shareholders or directors who at the time of the distribution knew or reasonably should have foreseen that result may be liable to our creditors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since we are a holding company, our ability to pay dividends will be dependent upon the financial condition, liquidity and results of operations of, and the
receipt of dividends, loans or other funds from, our subsidiaries. Our subsidiaries are separate and distinct legal entities and have no obligation to make funds available to us. In addition, there are various statutory, regulatory and contractual
limitations and business considerations on the extent, if any, to which our subsidiaries may pay dividends, make loans or otherwise provide funds to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_9"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and capitalization as of March&nbsp;31, 2020 on: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a historical basis for Immatics OpCo; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma basis, after giving effect to the Business Combination and PIPE Financing. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this table should be read in conjunction with the financial statements and notes thereto and other financial information included in this
prospectus and any prospectus supplement and the information under &#147;<I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I>&#148;. Our historical results do not necessarily indicate our expected results
for any future periods. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of March&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro forma</B><br><B>for</B><br><B>Business<BR>Combination</B><br><B>and&nbsp;PIPE&nbsp;Financing</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(</B><I>&#128;</I><B></B><I> in millions</I><B>)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">72.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">303.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total indebtedness</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">191.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">575.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(241.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(427.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Non-controlling interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(50.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total capitalization</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(50.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">146.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_10"></A>UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Introduction </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma
condensed combined financial information is based on the historical consolidated financial statements of Immatics OpCo prepared in accordance with IFRS and the historical financial statements of ARYA, and gives effect to all of the transactions
contemplated by the Business Combination and the PIPE Financing (together, the &#147;Transaction&#148;). ARYA historically prepared its financial statements in accordance with U.S. GAAP with the U.S. dollar as its reporting currency. The unaudited
pro forma condensed combined financial information gives effect to adjustments required to convert the historical financial information of ARYA to IFRS and its reporting currency to Euros. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following unaudited pro forma condensed combined statement of financial position as of March&nbsp;31, 2020 gives effect to the Transaction as if had
occurred on March&nbsp;31, 2020. The following unaudited pro forma condensed combined statements of loss for the three months ended March&nbsp;31, 2020 and the year ended December&nbsp;31, 2019 give effect to the Transaction as if it had occurred on
January&nbsp;1, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This unaudited pro forma information has been presented for informational purposes only and is not necessarily indicative of what
the actual financial position or results of operations of Immatics would have been had the Transaction been completed as of the dates indicated. In addition, the unaudited pro forma information does not purport to project the future financial
position or operating results of Immatics. The unaudited pro forma adjustments are based on information currently available. The assumptions and estimates underlying the unaudited pro forma adjustments are described in the notes to the accompanying
unaudited pro forma condensed combined financial information. Actual results may differ materially from the assumptions used to present the accompanying unaudited pro forma condensed combined financial information. Management of Immatics OpCo and
ARYA have made significant estimates and assumptions in the determination of the pro forma adjustments. As the unaudited pro forma condensed combined financial information has been prepared based on these preliminary estimates, the final amounts
recorded may differ materially from the information presented. This information should be read together with Immatics OpCo&#146;s and ARYA&#146;s audited financial statements and related notes for the years ended December&nbsp;31, 2019 and 2018, the
unaudited financial statements and notes for the three months ended March&nbsp;31, 2020 and 2019, the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;, and the other financial
information included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Description of the Transaction </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Business Combination Agreement, upon consummation of the Transaction each participating shareholder exchanged his, her or its equity interest
in Immatics OpCo for ordinary shares in accordance with an allocation schedule (a total of 33,093,838 ordinary shares were issued in connection with such exchange). Immediately after giving effect to the exchange, ARYA Merger Sub merged with and
into ARYA (the &#147;First Merger&#148;). The separate existence of ARYA Merger Sub ceased and ARYA continued as the surviving entity of the First Merger. In connection with the First Merger, each ARYA Ordinary Share was exchanged for an ordinary
share. Pursuant to the Business Combination Agreement, each ARYA public warrant, by its terms, converted into a public warrant, on the same contractual terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Transaction, Immatics and a <FONT STYLE="white-space:nowrap">co-founder</FONT> of
Immatics US affiliated with University of Texas MD Anderson Cancer (the &#147;Immatics US <FONT STYLE="white-space:nowrap">Co-Founder&#148;)</FONT> agreed that the Immatics US <FONT STYLE="white-space:nowrap">Co-Founder</FONT> would exchange all
shares in the share capital of Immatics US held by it for 697,431 ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Business Combination Agreement,
Immatics OpCo and ARYA entered into Subscription Agreements with PIPE Investors pursuant to which, among other things, the PIPE Investors agreed to subscribe for and purchase, and Immatics agreed to issue and sell to the PIPE Investors, an aggregate
of 10,415,000 ordinary shares for gross proceeds of approximately $104.2&nbsp;million on the Closing Date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting for the Transaction </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Transaction is comprised of a series of transactions pursuant to the Business Combination Agreement. For accounting purposes, the Transaction was
effectuated in three main steps: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The exchange of shares held by Immatics OpCo participating shareholders for ordinary shares, which is accounted
for as a recapitalization in accordance with IFRS. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The merger of ARYA with ARYA Merger Sub, which is not within the scope of IFRS 3 (&#147;Business
Combinations&#148;) since ARYA does not meet the definition of a business in accordance with IFRS 3, is accounted for within the scope of IFRS 2 (&#147;Share-based payment&#148;). Any difference between the fair value of the ordinary shares issued
and the fair value of ARYA&#146;s identifiable net assets represents a service to be expensed as incurred. The closing quoted market price of ARYA&#146;s ordinary shares and public warrants on Nasdaq as of July&nbsp;1, 2020 are the basis for
determining the fair value of the share-based consideration paid to ARYA&#146;s stockholders. These amounts represent the market prices at which any existing or new investor could trade during the period after the expiration of the redemption
deadline for ARYA shareholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Subscription Agreements related to the PIPE Financing, which were executed concurrently with the Business
Combination Agreement, resulted in the issuance of ordinary shares, leading to an increase in share capital and share premium. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRO FORMA CONDENSED COMBINED STATEMENT OF FINANCIAL POSITION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS OF MARCH&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousand)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Immatics<BR>GmbH<BR>Historical<BR>IFRS<BR>EUR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ARYA<BR>Sciences<BR>Acquisitions<BR>Corp.<BR>Historical<BR>U.S. GAAP<BR>USD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ARYA<BR>Sciences<BR>Acquisitions<BR>Corp.<BR>Historical<BR>U.S. GAAP<BR>EUR<SUP STYLE="font-size:85%; vertical-align:top">1</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Adjustments<BR>EUR<SUP STYLE="font-size:85%; vertical-align:top">1</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro</B><br><B>Forma<BR>Combined<BR>EUR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,786</TD>
<TD NOWRAP VALIGN="bottom">(b)(c)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(511</TD>
<TD NOWRAP VALIGN="bottom">)(d)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>109,737</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>785</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>716</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>230,275</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>340,728</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(135,724</TD>
<TD NOWRAP VALIGN="bottom">)(b)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,032</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>148,699</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>135,724</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(135,724</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,032</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>121,769</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>149,484</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>136,440</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>94,551</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>352,760</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,648</TD>
<TD NOWRAP VALIGN="bottom">(e)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,165</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,219</TD>
<TD NOWRAP VALIGN="bottom">(e)(f)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>77,263</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,359</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,979</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32,867</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>114,109</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,772</TD>
<TD NOWRAP VALIGN="bottom">)(f)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,264</TD>
<TD NOWRAP VALIGN="bottom">)(e)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>94,537</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,674</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,264</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,036</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>91,765</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares, $0.0001 par value; 13,545,245 shares subject to possible redemption
at redemption value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,452</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,633</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(123,633</TD>
<TD NOWRAP VALIGN="bottom">)(b)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">4</SUP>&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(535</TD>
<TD NOWRAP VALIGN="bottom">)(a)(b)(c)(f)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,064</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">5</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,349</TD>
<TD NOWRAP VALIGN="bottom">(a)(b)(c)(d)(e)(f)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">574,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(241,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65</TD>
<TD NOWRAP VALIGN="bottom">)<SUP STYLE="font-size:85%; vertical-align:top">6</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(185,677</TD>
<TD NOWRAP VALIGN="bottom">)(b)(e)(f)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(427,235</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other reserves</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total equity attributable to shareholders of the parent</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(50,814</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,999</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,564</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>193,136</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>146,887</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(783</TD>
<TD NOWRAP VALIGN="bottom">)(a)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; deficit/equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(50,031</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,999</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,564</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>192,353</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>146,887</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and shareholders&#146; deficit/equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>121,769</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>149,484</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>136,440</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>94,551</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>352,760</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Refer to note 4 (foreign currency adjustments). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2</SUP><SUP STYLE="font-size:85%; vertical-align:top">)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount classified as prepaid expenses in ARYA&#146;s historical financial statements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount classified as accrued expenses in ARYA&#146;s historical financial statements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount includes ARYA&#146;s Class A ordinary shares and Class B ordinary shares historically classified within
equity in ARYA&#146;s historical financial statements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount classified as additional paid-in capital in ARYA&#146;s historical financial statements.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount classified as retained earnings in ARYA&#146;s historical financial statements. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRO FORMA CONDENSED COMBINED STATEMENT OF LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THREE MONTHS ENDED MARCH&nbsp;31, 2020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands, except share and per share<BR>data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Immatics<BR>GmbH<BR>Historical<BR>IFRS EUR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ARYA<BR>Sciences<BR>Acquisitions<BR>Corp.<BR>Historical<BR>U.S. GAAP<BR>USD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ARYA<BR>Sciences<BR>Acquisitions<BR>Corp.<BR>Historical<BR>U.S. GAAP<BR>EUR<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Adjustments<BR>EUR<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Combined<BR>EUR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(956</TD>
<TD NOWRAP VALIGN="bottom">)(f)(g)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,127</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,962d</TD>
<TD NOWRAP VALIGN="bottom">)(f)(g)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,969</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating result</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(11,281</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,127</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,743</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,006</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(14,018</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">857</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial result</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,701</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>857</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>777</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,478</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,270</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,966</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,006</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,540</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes on income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,270</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,966</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,006</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,540</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attributable to:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equityholders of the parent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">732</TD>
<TD NOWRAP VALIGN="bottom">(a)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,540</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274</TD>
<TD NOWRAP VALIGN="bottom">(a)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,270</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,966</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,006</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,540</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,744,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,908,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(7.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount classified as investment income on ARYA&#146;s trust account (the &#147;Trust Account&#148;) in
ARYA&#146;s historical financial statements. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Refer to note 4 (foreign currency adjustments). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PRO FORMA CONDENSED COMBINED STATEMENT OF LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE YEAR ENDED DECEMBER&nbsp;31, 2019 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(UNAUDITED) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands, except share and per share<BR>data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Immatics<BR>GmbH<BR>Historical<BR>IFRS<BR>EUR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ARYA<BR>Sciences<BR>Acquisitions<BR>Corp.<BR>Historical<BR>U.S. GAAP<BR>USD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ARYA<BR>Sciences<BR>Acquisitions<BR>Corp.<BR>Historical<BR>U.S. GAAP<BR>EUR2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Adjustments<BR>EUR2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Combined<BR>EUR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,824</TD>
<TD NOWRAP VALIGN="bottom">)(f)(g)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,915</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,851</TD>
<TD NOWRAP VALIGN="bottom">)(d)(f)(g)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating result</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(33,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(775</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(692</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,675</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(40,380</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,353</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,785</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(264</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(264</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial result</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>526</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,353</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,995</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,521</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,487</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,578</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,303</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,675</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(36,859</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes on income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,487</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,578</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,303</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,675</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(36,859</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attributable to:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equityholders of the parent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,591</TD>
<TD NOWRAP VALIGN="bottom">)(a)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B></B>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(<B>36,859</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B>)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">916</TD>
<TD NOWRAP VALIGN="bottom">(a)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,487</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,578</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,303</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,675</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(36,859</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,744,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,908,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(27.13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount classified as investment income on Trust Account in ARYA&#146;s historical financial statements.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Refer to note 4 (foreign currency adjustments). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Basis of preparation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the Transaction and has been prepared for
informational purposes only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The historical consolidated financial statements of Immatics OpCo and the historical financial statements of ARYA have been
adjusted in the pro forma condensed combined financial information to give effect to pro forma events that are (1)&nbsp;directly attributable to the Transaction, (2)&nbsp;factually supportable and (3)&nbsp;with respect to the pro forma condensed
combined statement of loss, expected to have a continuing impact on the combined results following the Transaction. The adjustments presented in the unaudited pro forma condensed combined financial information are based on currently available
information and certain information that management of Immatics OpCo and ARYA believe are reasonable under the circumstances. The unaudited condensed pro forma adjustments may be revised as additional information becomes available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics OpCo and ARYA did not have any historical relationship prior to the Transaction. Accordingly, no pro forma adjustments were required to eliminate
activities between the companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No holders of ARYA Class&nbsp;A shares exercised their redemption rights upon consummation of the Transaction. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Accounting policy conformity changes </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The historical financial information of ARYA was prepared in accordance with U.S. GAAP. No adjustments were required to convert ARYA&#146;s historical
financial information from U.S. GAAP to IFRS or to align ARYA&#146;s accounting policies to those applied by Immatics OpCo. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As ARYA&#146;s historical
financial information is presented in accordance with the presentation of Immatics OpCo&#146;s historical financial information, certain reclassifications of ARYA&#146;s historical financial information are required, which are disclosed on the
unaudited condensed combined statement of financial position and statement of loss. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Foreign currency adjustments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The historical financial statements of ARYA are presented in U.S. dollars. The historical financial information was translated from U.S. dollars to Euros using
the following historical exchange rates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Euros<BR>per<BR>U.S.<BR>Dollar</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average exchange rate for three months ended March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Period end exchange rate as of March&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Average exchange rate for year ended December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Adjustments to unaudited pro forma condensed combined financial information </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pro forma adjustments are based on preliminary estimates and assumptions that are subject to change. The following adjustments have been reflected in the
unaudited pro forma condensed combined financial information: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transaction </I></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the adjustments to share capital and share premium after the contribution of Immatics OpCo&#146;s
shares outstanding to Immatics in exchange for 33,093,838 ordinary shares, and the exchange of all shares </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
in the share capital of Immatics US held by the Immatics US <FONT STYLE="white-space:nowrap">Co-Founder</FONT> for 697,431 ordinary shares resulting in an increase to share capital and share
premium of &#128;338&nbsp;thousand and &#128;1.6&nbsp;million, respectively. Immatics OpCo&#146;s historical share capital of &#128;1.2&nbsp;million and the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest of &#128;783 are
eliminated. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the contribution of all outstanding ARYA ordinary shares and ARYA public warrants to Immatics and the
issuance of 17,968,750 ordinary shares and 7,187,500 public warrants in exchange. The Transaction is accounted for under IFRS 2 with an expense reflected for the difference between the fair value of ordinary shares and public warrants issued to ARYA
shareholders and warrantholders and the fair value of ARYA&#146;s net assets contributed. As the holders of redeemable ARYA Class&nbsp;A shares did not exercise their redemption rights, Immatics issued 17,968,750 ordinary shares and 7,187,500 public
warrants and recognized share capital of &#128;180&nbsp;thousand and share premium of &#128;123.4&nbsp;million in exchange for all outstanding ARYA Class&nbsp;A shares, ARYA Class&nbsp;B shares and ARYA warrants. ARYA&#146;s historical equity,
including additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital of &#128;4.6&nbsp;million, an accumulated deficit of &#128;58&nbsp;thousand, and ARYA Class&nbsp;A shares and ARYA Class&nbsp;B shares of &#128;123.6&nbsp;million are
eliminated. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In accordance with IFRS 2, the difference between the fair value of ordinary shares issued and the fair
value of ARYA&#146;s identifiable net assets is reflected as an expense, resulting in a &#128;155.8&nbsp;million increase to accumulated deficit in accordance with the calculation described below. This IFRS 2 expense, which is <FONT
STYLE="white-space:nowrap">non-recurring</FONT> and therefore excluded from the unaudited pro forma condensed combined statement of loss, reflects increases in the prices for ARYA ordinary shares and ARYA public warrants during the time from the
signing of the Business Combination Agreement on March&nbsp;17, 2020 and the closing price on July&nbsp;1, 2020. The book value of ARYA&#146;s net assets are assumed to approximate fair value. ARYA&#146;s net assets consist primarily of marketable
securities, which are recorded at fair value, and current liabilities. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>(Euros in thousands, except share and per share data)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>shares/<BR>warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(a) ARYA Ordinary Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,968,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(b) Closing price of ARYA Ordinary Shares on Nasdaq as of July&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">13.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(c) Fair value of ordinary shares issued to ARYA shareholders (a * b)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">248,473</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(d) Outstanding ARYA Public Warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,187,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(e) Closing price of ARYA Public Warrants on Nasdaq as of July&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(f) Fair value of outstanding ARYA Public Warrants (d * e)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">35,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total fair value of ARYA Ordinary Shares and ARYA Public Warrants(c + f)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>283,964</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARYA&#146;s identifiable net assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">128,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IFRS 2 Expense on the closing date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>155,767</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The entire amount of cash and cash equivalents held in the ARYA Trust Account of &#128;135.7&nbsp;million
(as of March&nbsp;31, 2020) becomes available to Immatics following the transaction, and is reclassified to cash and cash equivalents. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects proceeds from the PIPE Financing, increasing cash and cash equivalents by &#128;95.1&nbsp;million
($104.2 million), with corresponding increases to share capital and share premium of &#128;104&nbsp;thousand and &#128;95.0&nbsp;million, respectively. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the elimination of transaction-related costs of &#128;2.7&nbsp;million and &#128;152&nbsp;thousand for
the three months ended March&nbsp;31, 2020 and the year ended December&nbsp;31, 2019, respectively, which are reflected in Immatics OpCo&#146;s historical consolidated statement of loss and the elimination of &#128;511&nbsp;thousand of costs
directly attributable to raising new capital, which had been capitalized within other current assets as of March&nbsp;31, 2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects &#128;18.6&nbsp;million of additional incremental costs incurred in the Transaction after
March&nbsp;31, 2020, which are classified in accounts payable in the unaudited pro forma condensed combined statement of financial position. The amount of transaction costs deemed directly attributable to raising new capital is
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
determined based on the percentage of share capital held by ARYA shareholders and PIPE Investors immediately following the transaction. As a result, &#128;5.7&nbsp;million of the transaction
costs were determined to be directly attributable to raising new capital in the Transaction, which is reflected as a decrease in share premium. The remaining &#128;12.9&nbsp;million, which is not directly related to raising new capital, is reflected
as an increase to accumulated deficit. Deferred underwriting commissions of &#128;4.3&nbsp;million, which are reflected in ARYA&#146;s historical statement of financial position and payable after the Transaction, are reclassified to other current
liabilities. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Holders of vested Immatics OpCo stock appreciation rights (&#147;SARs&#148;) received for each vested Immatics
OpCo SAR outstanding immediately prior to the Closing a right to receive a cash payment equal to the value, if any, of such vested Immatics OpCo SAR less the applicable exercise price of such vested Immatics OpCo SAR (&#147;SAR Cash Proceeds&#148;).
Under the Business Combination Agreement, active employees and management members are required to <FONT STYLE="white-space:nowrap">re-invest</FONT> a minimum of <FONT STYLE="white-space:nowrap">25%-50%</FONT> of the SAR Cash Proceeds, net of taxes,
up to a maximum of 50%. The <FONT STYLE="white-space:nowrap">re-investment</FONT> minimum is dependent on seniority, with management members required to <FONT STYLE="white-space:nowrap">re-invest</FONT> a minimum of 50%. Recipients of SAR Cash
Proceeds elected to <FONT STYLE="white-space:nowrap">re-invest</FONT> approximately 48% of their SAR Cash Proceeds in exchange for ordinary shares. Therefore, the cash payment net of employee <FONT STYLE="white-space:nowrap">re-investment</FONT>
results in an increase to other current liabilities of &#128;10.0&nbsp;million, a decrease in other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities related to the previously outstanding awards of &#128;2.8&nbsp;million, an increase
to share capital of &#128;7&nbsp;thousand and share premium of &#128;9.8&nbsp;million, and an increase to accumulated deficit of &#128;17.0&nbsp;million. The increase to accumulated deficit represents the added expense from the accelerated vesting
of the Immatics OpCo SARs. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">For each ordinary share purchased by active employees and management members <FONT
STYLE="white-space:nowrap">re-investing</FONT> a portion of his or her SAR Cash Proceeds, Immatics granted two options to purchase one ordinary share under the 2020 Stock Option and Incentive Plan (the &#147;2020 Equity Plan&#148;), with an exercise
price equal to $10.00 (or higher, as necessary to comply with Section&nbsp;409A of the U.S. Tax Code). These options vest over a period of 12 months following the close of the Transaction. The award recipient must remain employed by Immatics or one
of its affiliates through the vesting date to receive the option. As the options vest over 12 months and do not have a continuing impact on the combined results following the Transaction, no adjustment with respect to the options was reflected in
the unaudited pro forma condensed combined statement of financial position or the unaudited pro forma condensed combined statement of loss. Based on the SAR <FONT STYLE="white-space:nowrap">re-investment,</FONT> management expects Immatics to incur
an additional &#128;14.1&nbsp;million in share-based compensation expense related to these options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">In addition, ARYA and Immatics OpCo
granted performance-based options and service-based options out of the 2020 Equity Plan to Immatics OpCo&#146;s executive officers and key personnel in connection with the Business Combination. The performance-based options vest based both on
achievement of market capitalization milestones and satisfaction of a four-year time-based vesting schedule. As the market capitalization milestones represent market vesting conditions, the grant date fair value of these awards is reduced by the
probability of not achieving each respective milestone. The service-based options will vest solely on a four-year time-based vesting schedule. The pro forma condensed combined statement of loss reflects additional research and development expenses
and general and administrative expenses of &#128;1.7&nbsp;million and &#128;2.3&nbsp;million, respectively, in connection with these awards for the 12 months ended December&nbsp;31, 2019. Additional research and development expenses and general and
administrative expenses of &#128;446&nbsp;thousand and &#128;592&nbsp;thousand, respectively, are reflected in connection with these awards for the three months ended March&nbsp;31, 2020. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the terms and conditions of the Business Combination Agreement and effective as of the Closing,
solely with respect to Immatics OpCo SARs held by certain active employees and members of management, any Immatics OpCo SARs that would vest on or after January 1, 2021 each such Immatics OpCo SAR that was outstanding immediately prior to the
Closing was cancelled in exchange for an option to purchase a certain number of ordinary shares under the 2020 Equity Plan. Shares under the 2020 Equity Plan have comparable terms as Immatics OpCo SAR, with revised exercise prices reflecting the
reorganized capital structure of Immatics. The options granted under the 2020 Equity Plan are accounted for as a modification under IFRS 2, with the incremental fair value </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
expensed over the remaining vesting period. The incremental fair value is the difference between the fair value of the options to purchase ordinary shares under the 2020 Equity Plan and the net
fair value of the exchanged unvested Immatics OpCo SAR (both measured at the date on which the replacement award is issued). The planned issuance of options to purchase ordinary shares under the 2020 Equity Plan results in an increase to research
and development expenses of &#128;512&nbsp;thousand and &#128;2.0&nbsp;million and additional general and administrative expenses of &#128;159&nbsp;thousand and &#128;638&nbsp;thousand in the unaudited pro forma condensed combined statement of loss
for the three months ended March&nbsp;31, 2020 and the year ended December&nbsp;31, 2019, respectively. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Net loss per share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pro forma basic and diluted net loss per share amounts presented in the unaudited pro forma condensed combined statement of loss are based upon the number
of the ordinary shares outstanding as of March&nbsp;31, 2020 and December&nbsp;31, 2019, respectively, assuming the Transaction occurred on January&nbsp;1, 2019. As the unaudited pro forma condensed combined statement of loss is in a loss position,
anti-dilutive instruments are excluded in the calculation of diluted weighted average number of ordinary shares outstanding, including 7,187,500 public warrants, which are held by former holders of ARYA public warrants, and share-based awards issued
under the 2020 Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the Transaction and related proposed equity transactions are being reflected as if they had occurred at the beginning of
the period presented, the calculation of weighted average ordinary shares outstanding for basic and diluted net loss per share assumes that the shares issuable relating to the Transaction have been outstanding for the entire period presented. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro Forma<BR>Adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro forma weighted average number of ordinary shares outstanding</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Immatics founder shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares issued to Immatics OpCo participating shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,093,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares issued to the Immatics US
<FONT STYLE="white-space:nowrap">Co-Founder</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">697,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares issued to ARYA Class&nbsp;A and Class&nbsp;B shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,968,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares issued to PIPE Investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,415,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares issued in relation to the Immatics OpCo Equity Plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">733,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro forma weighted average number of ordinary shares outstanding &#151; basic and
diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,908,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Three months ended March&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro forma net loss attributable to equityholders of the parent</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,540</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro forma net loss per share &#151; basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year ended December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro forma net loss attributable to equityholders of the parent</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Pro forma net loss per share &#151; basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.59</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OVERVIEW </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are dedicated to the development of T cell
receptor (&#147;TCR&#148;)-based immunotherapies for the treatment of cancer. We use our proprietary suite of technologies to identify intracellular drug targets, so called <FONT STYLE="white-space:nowrap">peptide-HLA</FONT> or pHLA targets, as a
basis for a broad range of potential immunotherapies designed to overcome the current limitations in immuno-oncology. <FONT STYLE="white-space:nowrap">Unlike&nbsp;CAR-T&nbsp;therapy</FONT> and current antibody-based approaches, which can only target
cell surface proteins, our technology enables the identification of otherwise inaccessible intercellular protein targets and thus significantly increases the diversity and novelty of the targets we can pursue. Such intracellular targets are
generally recognized as one of the most important keys to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">unlock&nbsp;hard-to-treat&nbsp;cancer,</FONT></FONT> particularly solid cancers. We believe that the elucidation of these
targets gives us an advantage that we are leveraging to develop a pipeline of <FONT STYLE="white-space:nowrap">novel&nbsp;TCR-based&nbsp;products</FONT> designed to deliver a robust and specific T cell response against cancer cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing our targeted immunotherapy candidates with an emphasis on treating solid tumors through two distinct treatment modalities: Adoptive Cell
Therapies (&#147;ACT&#148;) and antibody-like TCR Bispecifics (&#147;TCER&#148;). As of today, our wholly owned pipeline comprises eight therapeutic programs, of which four are in clinical trials and four are in preclinical stage. In addition to
this proprietary pipeline, we are also developing some of our targets and TCRs through programs in alliances with global leaders, such as Amgen, Genmab, BMS and GlaxoSmithKline. In these collaborations, we seek to evaluate and enable the development
of ten collaborative programs based on novel company-derived targets in a variety of immunotherapeutic approaches. From our research and development origins in T&uuml;bingen, Germany, to our cell therapy research and development
(&#147;R&amp;D&#148;) and manufacturing center in Houston, Texas, our global team is committed to developing and advancing our therapeutic pipeline and collaboration programs to address significant unmet medical needs in oncology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T cells are critical actors in staging an effective immune response against diseased and abnormal cells, such as cancer cells. The human leukocyte antigen
(&#147;HLA&#148;) system, also known as the major histocompatibility complex (&#147;MHC&#148;) in humans, is an important part of the immune system because it presents antigenic or foreign peptides on the surface of the cell to be recognized by the
T cell receptor. Due to their biologic purpose to bind to peptides presented on HLA receptors (&#147;pHLA targets&#148;), we believe that TCRs represent a new therapeutic opportunity for leveraging the power of T cells. Our investigational
immunotherapies are designed to use the potency and specificity of natural and engineered TCRs to attack and kill cancer cells and, in the case of solid tumors, invade the tumor, potentially overcoming significant hurdles for current immuno-oncology
approaches. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our target discovery platform, called XPRESIDENT, is a high throughput quantitative and ultrasensitive mass
<FONT STYLE="white-space:nowrap">spectrometry&nbsp;(LC-MS/MS)&nbsp;based</FONT> approach, which we have utilized to conduct a comparative and <FONT STYLE="white-space:nowrap">HLA-focused</FONT> proteomic analysis combined with a transcriptomic
analysis on thousands of cancer and healthy tissues. Using XPRESIDENT we have identified cancer targets that are presented on tumors but not, or to a far lower extent, on healthy tissues. We believe that XPRESIDENT allows us to confirm that these
targets are naturally presented &#151; in contrast to typical discovery methodologies relying on artificially cultured cell lines or&nbsp;in silico&nbsp;prediction algorithms. We delineate these mass spectrometry validated cancer targets into three
classes: (1)&nbsp;peptides of well-known and characterized cancer target proteins; (2)&nbsp;unknown or poorly characterized proteins; and (3)&nbsp;crypto targets/neoantigens. Following analysis of over 400,000,000 MS/MS spectra and an initial
long-list of 8,000 tumor-associated pHLA targets, we have focused on a prioritized short-list of over 200 tumor-associated and tumor-selected targets from these three categories and developed an extensive intellectual property portfolio to protect
our discoveries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once a suitable target is identified, we leverage our XCEPTOR TCR discovery platform to develop, engineer and validate cognate TCRs for
these targets. A rigorous process of assessing and optimizing the specificity and affinity of TCRs is critical for selecting the right TCR which, as part of an immunotherapeutic approach, is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
designed to focus an immune system attack on the tumor and confer a potent and well-tolerated therapeutic effect. Our XCEPTOR platform is differentiated from other TCR discovery platforms through
leveraging the XPRESIDENT target database to generate highly specific TCRs, as a result of our capabilities to screen for <FONT STYLE="white-space:nowrap">off-target</FONT> toxicity and cross-reactivity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 1. Proprietary pipeline and milestones. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g90g91.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our fully-owned pipeline consists of two distinct modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR
Bispecifics (TCER) directed against various targets relevant in a broad range of cancers. We expect several clinical and preclinical milestones in the near term and expects to further advance part of our preclinical programs towards clinical stage
within the next two years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each therapeutic modality is designed with distinct attributes to produce the desired therapeutic effect for patients at
different disease stages and with different types of tumors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Adoptive Cell Therapy (ACT)</B>: Our clinical ACTengine program is a personalized approach for which the
patient&#146;s own T cells are genetically modified to express a novel proprietary TCR created by us and then reinfused, this approach is also known as <FONT STYLE="white-space:nowrap">TCR-T.</FONT> The ACTallo program is advancing the ACT concept
beyond individualized manufacturing and is being developed to generate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;off-the-shelf&#148;</FONT></FONT> cellular therapy product candidates. The ACTolog program is a pilot
approach for ultra-personalized, multi-target immunotherapy product candidates utilizing endogenous <FONT STYLE="white-space:nowrap">(non-genetically</FONT> engineered) T&nbsp;cells with the goal of paving the way for a next step of enabling a fully
engineered <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">multi-TCR-T.</FONT></FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>TCR Bispecifics (TCER)</B>: TCER are engineered <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#145;off-the-shelf&#146;</FONT></FONT> biologics consisting of a portion of the TCR which directly recognizes cancer cells and a T cell recruiter domain which recruits and activates T&nbsp;cells. TCER are designed to
attract any patient&#146;s circulating T cells to bind and come into direct proximity with the cancer to destroy it. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 2. Lead product classes: Personalized engineered Adoptive Cell Therapy (ACTengine)
and antibody-like TCR Bispecifics (TCER). </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g91j27.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are advancing two distinct therapeutic modalities of Adoptive Cell Therapies and TCR Bispecifics, ACTengine and TCER.
While the ACTengine approach is based on engineering a patient&#146;s own T cells to specifically attack the patient&#146;s tumor, our TCER molecules
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">are&nbsp;off-the-shelf&nbsp;biologics</FONT></FONT> designed <FONT STYLE="white-space:nowrap">to&nbsp;re-direct&nbsp;any</FONT> T cell in a patient&#146;s body against the tumor and
for immediate treatment of the patient. ACTengine and TCER provide two distinct mechanisms of actions suitable for patients at different cancer stages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are pursuing a clinical development strategy that accelerates product candidates toward pivotal trials preceding submission of a Biologics License
Application (&#147;BLA&#148;) with regulatory authorities. Each program enters clinical development initially in a &#147;basket trial&#148; to broadly investigate safety, tolerability and initial signs of efficacy in patients with various types of
solid tumors confirmed to be expressing the specific cancer target tested in a tumor biopsy taken from the patient. Assuming favorable results from these trials, we plan to expand our Phase 1 clinical trials to enable fast entry into pivotal
clinical trials and potentially achieve an accelerated approval pathway. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Initial biological data from the first patients treated in the ACTengine trials
demonstrated very high frequencies of persisting target-specific T cell in the bloodstream as well as their infiltration in tumor lesions even at the lowest treatment dose. We expect a combined initial
<FONT STYLE="white-space:nowrap">data&nbsp;read-out&nbsp;for</FONT> the ACTengine trials by early 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have developed a proprietary manufacturing
process, optimized to generate T cell products within a short manufacturing period of only&nbsp;6&nbsp;days, utilizing a proprietary cytokine cocktail. The process is designed to rapidly produce younger, better-persisting T cells, capable of
&#147;serial&#148; killing of tumor cells<I>&nbsp;in vitro</I>. Processing time compares favorably to published reports by other companies operating in the CAR and TCR sectors. T cell products are manufactured by our personnel at the UTHealth Evelyn
H. Griffin Stem Cell Therapeutics Research Laboratory in a 1,850 square <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">foot&nbsp;state-of-the-art</FONT></FONT></FONT> cGMP facility exclusively used
by us in Houston, Texas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics OpCo was founded in 2000 in T&uuml;bingen, Germany by Harpreet Singh, Toni Weinschenk and others based on the
revolutionary research of Professor Hans-Georg Rammensee at the University of T&uuml;bingen. In 2015, Immatics&nbsp;OpCo <FONT STYLE="white-space:nowrap">co-launched</FONT> Immatics US as part of a strategic collaboration with the University of
Texas MD Anderson Cancer Center and entered an agreement with UTHealth. These collaborations have allowed us to gain access to critical cell therapy expertise and cGMP manufacturing infrastructure. Since Immatics OpCo&#146;s inception, we have
raised more than $200.0&nbsp;million through equity financing and have also added more than $250.0&nbsp;million in nondilutive capital through our collaborations and public grants. We have applied this capital toward our strategy to identify,
deliver and pioneer new treatments for cancer patients through identifying tumor-associated pHLA targets recognized by T cells. We believe that identifying true cancer targets that are presented on tumor tissue but not on healthy cells and the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subsequent discovery, selection, and engineering of the right TCRs are central to our mission: delivering the power of T cells to cancer patients and advancing the next wave in cancer
immunotherapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a highly experienced global leadership team that operates seamlessly between our locations in Germany and the United States, and
currently employ more than 200 people. Our management consists of an interdisciplinary team that includes medical and scientific experts, as well as accomplished business leaders, and collectively has multiple decades of experience in the
pharmaceutical and biotechnology industries. In addition, our management team includes the creators and developers of our core technologies, and benefits from their continued contributions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Current Cancer Immunotherapies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cancer
incidence continues to increase globally and despite advances in treatment options, cancer remains a major health problem and ranks second to cardiovascular disease as an overall cause of mortality. It is characterized by the uncontrolled growth of
abnormal cells whose ability to evade the immune system&#146;s surveillance is a key factor in their proliferation and persistence. In particular, patients with advanced, recurrent or refractory solid tumors have a generally poor prognosis and there
remains for these patients a very high unmet medical need. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In recent years, the field of immunotherapy, a form of cancer treatment utilizing the
patients&#146; own immune system to specifically seek and destroy cancer cells, has significantly changed the standard of care in many segments of oncology and emerged as a major pillar in the treatment of cancer. Terminally ill cancer patients have
experienced tumor reductions, long term benefits, and even cure in some cases through immunotherapy. Although treatment with immunotherapy including checkpoint <FONT STYLE="white-space:nowrap">inhibitors,&nbsp;CAR-T&nbsp;cells</FONT> and monoclonal
antibodies has resulted in durable responses in some tumor types, a majority of cancers do not respond to current immunotherapeutic approaches. Explanations for the lack of effective therapies in many cancers are summarized below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Limited to specific patient populations</I>: Checkpoint inhibitors have proven to be highly effective against
particular cancers while being ineffective against the majority of solid cancers. Checkpoint inhibitors are thought to be effective predominantly in tumors with high mutational burden, which account for less than 10% of all cancer types. However,
the market and medical need for tumors without high mutational burden is significantly larger. We believe such tumors with low mutational burden will be best addressed with targeted therapies to <FONT STYLE="white-space:nowrap">non-mutated</FONT>
antigens covering various target classes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Limited target space</I>: The limited target space is a major constraint to
<FONT STYLE="white-space:nowrap">CAR-T</FONT> cell therapies and classical monoclonal antibody-based targeted therapies. Both of these approaches target surface proteins on cancer cells, which constitute only ~25% of the human proteome, leaving ~75%
of intracellular proteins not accessible for these types of treatments. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Limited success in solid cancers</I>: <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell therapies have
demonstrated antitumor activity in hematological cancers, including <FONT STYLE="white-space:nowrap">B-cell</FONT> acute lymphoblastic leukemia (&#147;ALL&#148;) and subtypes of <FONT STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> lymphoma
(&#147;NHL&#148;), such as diffuse large B cell lymphoma (&#147;DLBCL&#148;). However, clinical success in the majority of solid cancers, which represent a larger patient population and market, has not been achieved to date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Inhibitory tumor microenvironment (&#147;TME&#148;)</I>: The tumor microenvironment is a dynamic network
composed of immune cells, blood vessels, stromal cells, signaling molecules and the extracellular matrix imposing a significant barrier to effective therapeutic approaches. Immunosuppressive cells and immunomodulatory factors build an
immunosuppressive environment and together with the rigid extracellular matrix are thought to inhibit drugs and T cells from accessing the tumor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Tumor Heterogeneity</I>: The tumor of each cancer patient evolves during the course of the disease. As a
result, the tumor becomes more heterogenous with <FONT STYLE="white-space:nowrap">co-existing</FONT> <FONT STYLE="white-space:nowrap">sub-populations</FONT> of tumor cell clones. The associated intra-tumoral heterogeneity of target expression might
contribute to tumor evasion and consequently to treatment failures and recurrence of the tumor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our approach might be able to overcome the current challenges of immunotherapy and develop
truly novel opportunities for patients. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our mission is to become a leading oncology-focused biopharmaceutical company by developing differentiated <FONT STYLE="white-space:nowrap">TCR-based</FONT>
immunotherapies, particularly for solid tumors that are inadequately addressed with existing treatment modalities. Specifically, we seek to execute on the following strategy to maximize the value of our technology platforms and broad portfolio of
product candidates: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 3. Differentiated approach to deliver
<FONT STYLE="white-space:nowrap">novel&nbsp;TCR-based&nbsp;immunotherapies</FONT> to cancer patients. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g93b23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We combine the discovery of true targets (via XPRESIDENT) with the development of the right TCRs (via XCEPTOR) to generate
Adoptive Cell Therapies (ACT) (<I>e.g.</I>, ACTengine) and TCR Bispecifics (TCER). Our product candidates pass through a comprehensive preclinical characterization and validation process before entering the manufacturing phase and clinical trials.
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance the proprietary pipeline of product candidates focusing on ACTengine and TCR Bispecifics through
clinical development.</B> Our ACTengine IMA200 Series includes three product candidates in Phase 1 clinical trials (IMA201, IMA202, IMA203) and one preclinical stage product candidate (IMA204). The Phase 1 trials are investigating safety,
tolerability and initial signs of efficacy in patients suffering from solid cancers such as head and neck cancer, <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, liver cancer, uterine and ovarian carcinoma and several other tumor
types. After FDA approval and start of patient recruitment at the University of Texas MD Anderson Cancer Center, we received regulatory approval to initiate the first ACTengine trial in Germany. To facilitate clinical development, four additional
clinical centers have been opened in the United States and Europe and initiation of a further three sites is planned in 2020. Should the trials demonstrate safety and evidence of significant tumor control and tumor reduction, we may request FDA Fast
Track designation and start pivotal trials with any of our ACTengine programs. We are also advancing two preclinical TCR Bispecifics candidates towards the IND stage of development and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trials. IND filing for the lead program IMA401 is planned for <FONT STYLE="white-space:nowrap">year-end</FONT> 2021 and preclinical proof of
concept for the second program IMA402 for <FONT STYLE="white-space:nowrap">year-end</FONT> 2020. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Develop cell therapies and biologics providing two distinct mechanisms of actions suitable for different
cancer stages. </B>We intend to leverage our technology and <FONT STYLE="white-space:nowrap">know-how</FONT> to expand the potential therapeutic value for patients across a broad range of tumor types and stages. Both ACT and TCR Bispecifics programs
are designed to overcome the limitation of <FONT STYLE="white-space:nowrap">CAR-T</FONT> programs and improve the outcome for patients in solid cancers. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our proprietary class of engineered T cell therapy has the potential to provide cancer patients with a potent
therapy that infiltrates the tumor. Our clinical ACT programs aim to improve patient benefit even in advanced stage disease, which is often accompanied with high tumor burden that is difficult to treat with other approaches. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our novel class of TCR Bispecifics are designed to <FONT STYLE="white-space:nowrap">re-direct</FONT> any T cell
in a patient&#146;s body against the tumor. TCER have the potential to be cost-effective biologic drug candidates, due to their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> availability and simple
treatment regimen. They are designed to treat advanced cancers with reduced (&#147;debulked&#148;) tumor burden as well as earlier stages of cancer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Enhance potency, usability and commercial viability.</B> Our latest proprietary ACTengine manufacturing
processes are designed to generate cell product candidates within a short <FONT STYLE="white-space:nowrap">six-day</FONT> manufacturing window and deliver high proliferative capacity T cells, with the capability to infiltrate the patient&#146;s
tumor and function in a challenging solid tumor microenvironment. We are actively investigating multiple next-generation enhancement strategies to render T cells even more potent to combat solid tumors. For advanced-stage clinical trials and
commercial supply, manufacturing processes are planned to be further optimized to ensure a robust manufacturing capability incorporating functionally closed and automated manufacturing systems as well as the use of serum free, chemically defined
media. In addition, we are advancing our first allogeneic, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> product candidate IMA301 towards the IND stage of development and a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial. IMA301 utilizes <FONT STYLE="white-space:nowrap">TCR-transduced</FONT> <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT
STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> (gamma-delta) T cells derived from healthy donors as allogeneic <FONT STYLE="white-space:nowrap">TCR-T</FONT> products. This
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> product candidate would not require cell harvesting from the immune-compromised patient, thus could be infused directly and is expected to have
significantly decreased cost of goods compared to autologous cell products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Enhance the competitive edge of our technology platforms.</B> XPRESIDENT offers the potential exploitation of
the whole tumor-associated antigen repertoire exhibiting an approximately 300% increased cancer target space and greater application potential compared to <FONT STYLE="white-space:nowrap">CAR-T</FONT> and classical antibody approaches which can
target surface antigens only. Beyond the identification of true targets from well-known tumor antigens (such as the MAGE antigen family used in IMA201 and IMA202), XPRESIDENT also identifies novel cancer targets (such as the tumor stroma target
COL6A3 exon 6 used in IMA204 designed to disrupt the tumor microenvironment). In addition, we are utilizing XPRESIDENT to unlock new target spaces through novel target classes such as crypto-targets and shared neoantigens. Based on the unique
interplay between our target and TCR discovery platforms XPRESIDENT and XCEPTOR, we have the capability to identify and engineer the right T cell receptors with the desired affinity and specificity. These technology platforms are the foundation for
strengthening the product pipeline and our leading position in the field of <FONT STYLE="white-space:nowrap">TCR-based</FONT> therapies. Over time, we have published our discoveries in multiple peer-reviewed, high-impact publications in Nature,
Nature Medicine, Nature Biotechnology, Nature Communications and Lancet Oncology. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand our leading intellectual property portfolio.</B> We intend to continue building on our extensive
intellectual property portfolio in the field of cancer targets, TCRs and technologies. Our portfolio currently includes over 3,000 worldwide active patent applications and more than 1,550 secured patents, of which over 230 are granted in the United
States. The protection of our intellectual property assets is a foundational element of our ability to not only strengthen our product pipeline, but also to successfully defend and expand our position as a leader in the field of TCR therapies.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Leverage the full potential of strategic collaborations. </B>The differentiated nature of our discovery
programs has been validated by recent collaborations including Amgen, Genmab, BMS and GlaxoSmithKline and which involve a total of ten company targets. We will seek to capitalize on the respective collaborator&#146;s drug development and regulatory
expertise and commercial capabilities to bring our collaboration product candidates to market. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Extend the impact of immunotherapy through a novel ultra-personalized
<FONT STYLE="white-space:nowrap">multi-TCR</FONT> warehouse approach.</B> We will take the first step towards <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">multi-TCR-T</FONT></FONT> immunotherapy through combinatorial
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
treatment of patients using anti-tumor and anti-stroma ACTengine products. This will enable attacking different compartments of the tumor and its microenvironment through different target
classes, thereby aiming to avoid the tumor adjusting to and escaping from a single cancer target attack. With the portfolio of more than 200 prioritized cancer targets and the high-throughput capabilities in TCR discovery and characterization, we
are well-positioned to build a broad library of TCR product candidates (TCR warehouse) aimed at delivering a pioneering, ultra-personalized cancer treatment. A treatment algorithm to select and deliver multiple
<FONT STYLE="white-space:nowrap">TCR-based</FONT> cell therapy products for any cancer patient will not only expand the treatable patient population, but is designed to ultimately reduce the likelihood for tumors to evade immunotherapy and prolong
durability of clinical responses, possibly even resulting in cure. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Further developing the qualities and capabilities of our organization and realizing the potential of our
exceptional people.</B> We are defined by people passionately dedicated to delivering the power of T cells to cancer patients. We have a long-term management and employee base that is the backbone of our past and future achievements. We will
continue to rely on this foundation and to support and develop our outstanding team to elevate the organization to the next level. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IMMATICS&#146; THERAPEUTIC&nbsp;PIPELINE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ACT<SMALL>ENGINE</SMALL> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:1%; font-size:10pt; font-family:Times New Roman"><B>ACTengine at a glance </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expanded target space compared to <FONT STYLE="white-space:nowrap">CAR-T.</FONT></B>&nbsp;ACTengine <FONT
STYLE="white-space:nowrap">TCR-T</FONT> targets tumor-associated peptides presented by <FONT STYLE="white-space:nowrap">HLA-molecules</FONT> on the tumor cell surface. Most relevant solid cancer targets are of intracellular nature and thus only
accessible by <FONT STYLE="white-space:nowrap">TCR-based</FONT> approaches. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>TCRs with desirable affinity and specificity.</B>&nbsp;ACTengine TCRs identified via XCEPTOR TCR discovery and
characterized via XPRESIDENT guided <FONT STYLE="white-space:nowrap">on-</FONT> and <FONT STYLE="white-space:nowrap">off-target</FONT> toxicity screening show desirable affinity and high specificity. Our competitive advantage to other <FONT
STYLE="white-space:nowrap">TCR-T</FONT> approaches is the combination of the suitable target (via XPRESIDENT) with the right TCR (via XCEPTOR). </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Active at physiological levels of target expression.</B>&nbsp;We believe that ACTengine <FONT
STYLE="white-space:nowrap">TCR-T</FONT> products are highly potent and capable of inducing the killing of tumor cells presenting physiological target copy numbers identified by quantitative mass spectrometry and TCR validation. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Optimized manufacturing.</B>&nbsp;Our proprietary short manufacturing process including a significantly
shorter manufacturing period (6 days for IMA203) and a proprietary cytokine cocktail used to promote T cell expansion in culture is designed to produce younger, less differentiated T cell phenotypes which are associated with better engraftment
and<I>&nbsp;in vivo</I>&nbsp;persistence. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Patient recruitment.</B>&nbsp;Patient recruitment is underway in three Phase 1 clinical trials. First combined
initial data <FONT STYLE="white-space:nowrap">read-out</FONT> is expected by early 2021 and further results are expected throughout 2021. The clinical trials are investigating safety, tolerability and initial signs of efficacy in patients and are
designed to include potential expansion cohorts in the case of initial signs of clinical efficacy. This may enable a fast way forward towards pivotal clinical trials in specific indications. In case the data allow, we may seek fast track
designation(s) as accelerated approval pathway(s) to bring the product candidate(s) to the market. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Early biological data from first patients treated.</B>&nbsp;Initial biological data from the first patients
treated in the ACTengine trials (N=4) suggest a high persistence of target-specific T cells after infusion, already at the first <FONT STYLE="white-space:nowrap">low-dose</FONT> level, which constitutes approximately
<FONT STYLE="white-space:nowrap">5-10%</FONT> of our anticipated target dose. These target-specific T cells can also be detected in post-treatment tumor biopsies. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are developing Adoptive Cell Therapies, which are designed to leverage the power of T cells to actively
infiltrate tumor tissue and kill tumor cells in a specific and serial fashion. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 4. Mechanism of action of our ACTengine product
candidate: from infusion to tumor killing. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g96b02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon infusion of an ACTengine product, T cells &#147;equipped&#148; with the cancer target-specific TCR, are supposed to
bind to the pHLA target on the tumor. Subsequent activation of the T cell induces release of cytotoxic granules which might ultimately lead to tumor killing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are several reasons why a patient&#146;s own T cells are often not able to protect the body against cancer, such as unavailability of activated tumor
antigen specific T cells or insufficient affinity of endogenous target-specific TCRs to properly activate the T cell and fight the tumor. We believe that these problems can be overcome by engineering of autologous T cells with a well characterized
and potent TCR, an approach used in our ACTengine program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACTengine is based on genetically engineering a patient&#146;s own T cells with a novel TCR
designed to recognize the cancer target identified by our XPRESIDENT platform. If the target of interest is confirmed on a patient&#146;s tumor by the IMADetect companion diagnostic device candidate, lentiviral transduction of the patient&#146;s
autologous T cells with a target-specific exogenous TCR aims to essentially &#147;reprogram&#148; the T cells to attack the tumor. The engineered T cells are then multiplied<I>&nbsp;in vitro</I>&nbsp;and reinfused back into the patient for the
treatment of the tumor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our current ACTengine clinical trials, infusion of the engineered T cells is preceded by a preconditioning lymphodepleting
chemotherapy to activate proliferation, facilitate T cell engrafting and persistence. Post-infusion of the T cell <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product,&nbsp;low-dose&nbsp;IL-2&nbsp;is</FONT></FONT> administered
for 14 days to further enhance persistence of the transferred cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 5. Schematic representation of our ACTengine process. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g10y56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Process overview on how we generate a personalized ACTengine T cell product from leukapheresis to patient treatment. If the
target of interest is present on the patient&#146;s tumor as demonstrated by biomarker profiling, the patient undergoes leukapheresis followed by genetic engineering of the patient&#146;s own (autologous) T cells with a proprietary TCR. T cells
engineered with the TCR are supposed to recognize the biomarker tested target on the tumor and are expanded to larger numbers prior <FONT STYLE="white-space:nowrap">to&nbsp;re-infusion&nbsp;into</FONT> the patient. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Development of ACTengine Product Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
preclinical activities for ACTengine programs aim to reduce the risk <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">of&nbsp;on-&nbsp;and&nbsp;off-target&nbsp;toxicity</FONT></FONT> by careful selection and validation of targets
and powerful TCRs. All ACTengine targets demonstrate high prevalence in major solid cancer indications as well as in niche indications with high medical need and limited available treatment options. We selected the highly tumor-associated ACTengine
targets based on XPRESIDENT&#146;s comprehensive dataset on mass spectrometry-based peptide presentation, as well as on mRNA expression levels for the respective source genes at the exon level. T cell activation assays with target expressing tumor
cell lines further confirm that the targets are endogenously processed, naturally presented peptides. Thus, we believe the targets are promising for T cell-based immunotherapies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 6. Target characteristics of ACTengine targets. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g10t87.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ACTengine targets are expressed in a broad range of tumor indications. Comparison of our ACTengine targets to
clinically <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">validated&nbsp;NY-ESO-1&nbsp;demonstrates</FONT></FONT> that IMA201, IMA202 and IMA203 targets show specificity profiles similar <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">to&nbsp;NY-ESO-1&nbsp;while</FONT></FONT> having significantly higher peptide copy numbers.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Natural presentation of this peptide has been validated by clinical data,</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Validated by XPRESIDENT mass spectrometry. Target peptide copy numbers per cell were determined by AbsQuant
technology,</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">3</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Internal specificity categorization used by us. Specificity class 1: peptide not routinely found on any normal
tissue; no relevant RNA expression detected on critical organs, Specificity class 2: peptide showing a large therapeutic window with rare detections on normal tissue and low RNA expression on critical organs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The target-specific TCRs identified via our XCEPTOR technology are designed to recognize their targets with high specificity. XPRESIDENT-guided specificity
testing confirmed that there have been no peptides identified in the natural HLA peptidome that cross-react with these TCRs. In addition, all TCRs are tested against a human primary cell panel of various healthy donors to reaffirm specificity and
the absence of cross-reactivity. The panel covers critical organs (such as brain, heart, lung, liver, kidney) and multiple different cell types (such as endothelial cells, epithelial cells, smooth muscle cell) as well as organ-specific cell types
(such as cardiomyocytes, hepatocytes, astrocytes, neurons, osteoblasts, keratinocytes). Finally, all TCRs used in current ACTengine programs were able to mediate the robust functional activation of T cells as evidenced by recognition of calibrated
target cell lines presenting the target peptides at physiological levels. In contrast to IMA201 and IMA202, which use naturally occurring TCRs isolated from healthy donors, the TCR used in IMA203 is a pairing-optimized variant of a naturally
occurring TCR which shows higher expression levels in T cells and increased affinity for its target. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Delivery of ACTengine Product Candidates to
Patients </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients eligible for clinical trials with ACTengine product candidates have a portion of their white blood cells collected using a
well-established process called leukapheresis, a procedure in which a fraction of the white blood cells of a patient are extracted from their peripheral blood. These white blood cells are transferred to a manufacturing facility where peripheral
blood mononuclear cells (&#147;PBMCs&#148;), which are a subset of white blood cells, are isolated from the leukapheresis product. PBMCs or a selected subset of T cells (e.g. CD8+ T cells) form the starting point of the ACTengine manufacturing
process, which is currently being conducted at a central manufacturing site in the United States by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T cells contained within PBMCs are activated and subsequently mixed with a lentiviral vector to transduce
the T&nbsp;cells with the genes encoding the target-specific TCR. The transduced cells are expanded in the presence of a cytokine mixture, concentrated and frozen before undergoing quality control release testing. The resulting cell product can be
stored frozen long-term until the patient is ready to receive the infusion. The manufacturing time is <FONT STYLE="white-space:nowrap">7-10</FONT> days for IMA201/202 and 6 days for IMA203. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the introduction of the engineered TCR into the cells, our manufacturing process utilizes a third generation, self-inactivating lentiviral vector that is
designed to improve the safety and eliminate the risk of replication-competent viral particles, as well as produce stable integration of the TCR sequences in the modified cells. The lentiviral vector includes the transgene required for production of
engineered TCRs along with other additional elements necessary for producing the lentiviral particles needed for the delivery of the TCR genes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enhancing Commercial Application of Autologous Cell Therapies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are using a semi-closed, partially automated manufacturing process for IMA203 and is currently moving towards a commercially compatible manufacturing
process for all ACTengine programs that is automated and utilizes closed manufacturing systems available on the market. Additional manufacturing improvements being developed include the use of selected T cell subsets, as well as manufacturing
processes that use chemically defined media free from human or animal derived serum. Proof of concept studies for multiple manufacturing systems, including automated devices, have already been carried out to prepare for implementation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will continue manufacturing for Phase 1 clinical trials at the current cGMP manufacturing facility through clinical proof of concept for a <FONT
STYLE="white-space:nowrap">given&nbsp;TCR-T&nbsp;cell</FONT> product. For pivotal trials and commercial scale manufacturing, we are evaluating the use of commercial scale Contract Manufacturing Organizations (&#147;CMOs&#148;) in addition to
evaluating building a dedicated commercial facility for launching our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current time from leukapheresis collection until infusion ready for
our T cell products varies between 20 and 24 days, depending on the manufacturing length and <FONT STYLE="white-space:nowrap">including&nbsp;14-day&nbsp;full</FONT> sterility testing according to United States Pharmacopeial Convention standards.
However, we are already working with regulatory authorities in the United States and Europe to release the T cell products for infusion on <FONT STYLE="white-space:nowrap">interim&nbsp;(7-day)&nbsp;sterility</FONT> results while continuing the
testing for <FONT STYLE="white-space:nowrap">14-days.</FONT> By further reducing the sterility testing for infusion to five days, the commercial manufacturing duration is expected to be reduced to eleven days. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 7. Schematic overview of our manufacturing process. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g12u96.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon leukapheresis, our manufacturing duration to generate a personalized IMA203 ACTengine product is 6&nbsp;days followed
by <FONT STYLE="white-space:nowrap">14-day</FONT> sterility testing. For commercial ACTengine products, we plan to implement an accelerated <FONT STYLE="white-space:nowrap">5-day&nbsp;sterility</FONT> testing, reducing the overall manufacturing time
to&nbsp;11&nbsp;days. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ongoing ACTengine Clinical Trials </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The three Phase 1 clinical <FONT STYLE="white-space:nowrap">trials&nbsp;IMA201-101,</FONT> <FONT STYLE="white-space:nowrap">IMA202-101&nbsp;and</FONT>
IMA203-101 are open for patient recruitment and are currently in the dose escalation phase. We plan to enroll <FONT STYLE="white-space:nowrap">12-15</FONT> patients for each trial and will evaluate up
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to four dose levels of each ACTengine product (50x10<SUP STYLE="font-size:85%; vertical-align:top">6</SUP>&nbsp;to
1,000x10<SUP STYLE="font-size:85%; vertical-align:top">6</SUP>&nbsp;target-specific T cells/m&sup2;). Upon signs of clinical activity we may extend clinical trials in a certain or several cancer subtypes, and recruit additional patients of the
respective indications to access anti-tumor activity of product candidates in more detail. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">IMA201-101</FONT> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">The&nbsp;IMA201-101&nbsp;trial</FONT> (NCT03247309) is a Phase 1 dose-escalating trial evaluating safety, tolerability and
initial signs of clinical efficacy of our IMA201 ACTengine product, which targets melanoma-associated antigen 4 or 8 (&#147;MAGEA4/A8&#148;) in patients with solid tumors. Among the range of solid cancer indications being studied, this trial is
focused on, but not limited to, <FONT STYLE="white-space:nowrap">squamous&nbsp;non-small&nbsp;cell</FONT> lung carcinoma (&#147;squamous NSCLC&#148;), head and neck squamous cell carcinoma (&#147;HNSCC&#148;), and subtypes of sarcoma due to the high
frequency of MAGEA4/8 expression in these tumors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lung cancer is the second most common cancer in the United States and the leading cause of
cancer-related deaths. It is estimated that there were 228,000 new cases and 143,000 deaths of lung cancer in 2019. NSCLC accounts for about 85% of all lung cancers, while squamous cell NSCLC accounts for approximately 35% (estimated 66,000
patients) of NSCLC. <FONT STYLE="white-space:nowrap">The&nbsp;5-year&nbsp;survival</FONT> rate for NSCLC is 23%, but varies materially by the stage of the disease. For localized NSCLC, the
<FONT STYLE="white-space:nowrap">overall&nbsp;5-year&nbsp;survival</FONT> rate is about 60%, whereas patients with metastatic lung cancer have <FONT STYLE="white-space:nowrap">a&nbsp;5-year&nbsp;survival</FONT> rate of only 6%. Treatment options for
NSCLC also depend on the stage of the disease. Compared <FONT STYLE="white-space:nowrap">to&nbsp;non-squamous&nbsp;NSCLC,</FONT> recurrent or refractory squamous NSCLC has fewer treatment options and typically leads to unfavorable outcomes despite
recent advances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HNSCC comprises a heterogeneous group of cancers at different anatomic locations, which can be found in the oral cavity, the pharyngeal
area, and the larynx. Approximately 65,000 Americans are diagnosed with HNSCC each year and around 15,000 die from this disease annually. <FONT STYLE="white-space:nowrap">The&nbsp;5-year&nbsp;survival</FONT> for laryngeal cancer, one of the most
common types of HNSCC, has not significantly changed over the past 30 years. Despite several treatment options, overall long-term survival rates for recurrent/metastatic HNSCC remain low. Thus, recurrent or metastatic HNSCC is a severely underserved
patient population with limited treatment options. Despite all the advances made recently, these cancer patients have a very poor prognosis with a short median survival of <FONT STYLE="white-space:nowrap">4-6&nbsp;months</FONT> and no available and
approved standard treatment. Thus, the target population for <FONT STYLE="white-space:nowrap">IMA201-101</FONT> consists of patients with an urgent unmet need for new treatment options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">ACTengine&nbsp;IMA201-101&nbsp;study</FONT> is actively recruiting in its dose-escalation phase. To be eligible for <FONT
STYLE="white-space:nowrap">IMA201-101,</FONT> adult patients with pathologically confirmed advanced/metastatic cancer must be <FONT STYLE="white-space:nowrap">HLA-A*02:01</FONT> positive and MAGEA4/A8 needs to be present in a biopsy of the
patient&#146;s tumor. Upon successful manufacturing and release testing of the IMA201, the patient can be treated, given that all treatment eligibility criteria are fulfilled. IMA201 is administered when disease recurs/progresses, or becomes
refractory, no indicated standard of care treatment is available, or if this treatment is no longer warranted. The primary study purpose is to establish the safety and tolerability of the treatment with IMA201 T cell products. Thus, the primary
outcome is to determine the incidence of adverse events (&#147;AE&#148;) upon treatment including dose limiting toxicity (&#147;DLT&#148;) and determination of recommended Phase 2 dose. Secondary outcomes are the evaluation of T cell persistence of
the TCR engineered T cells within the patient&#146;s blood after T cell infusion, as well as the evaluation of anti-tumor activity (tumor response and duration of response). T cell persistence is considered as a
<FONT STYLE="white-space:nowrap">major&nbsp;pre-requisite&nbsp;to</FONT> obtain anti-tumor response. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">IMA202-101</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">The&nbsp;IMA202-101&nbsp;trial</FONT> (NCT03441100) is a Phase 1 dose-escalating trial evaluating safety, tolerability and initial signs of clinical efficacy of our IMA202 ACTengine product, which targets
melanoma-associated antigen 1 (&#147;MAGEA1&#148;) in patients with various solid tumors, including NSCLC and hepatocellular carcinoma (&#147;HCC&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HCC is the most common type of primary liver cancer. According to the World Health Organization liver cancer is one of the top five causes of cancer-related
death worldwide and it is estimated that there were 42,000 new </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
cases of liver cancer in the Unites States in 2019. Death rates from liver cancer have been steadily increasing over the last decades and the <FONT STYLE="white-space:nowrap">5-year</FONT>
survival rate for liver cancer remains low at approximately 18%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The standard care therapies for unresectable HCC patients are very limited and comprise
various local therapies for early and intermediate patients and systemic therapies for advanced HCC patients. Thus, the target patient population <FONT STYLE="white-space:nowrap">for&nbsp;IMA202-101&nbsp;is</FONT> comprised of patients with very
poor prognosis and high unmet medical need for new treatment options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">ACTengine&nbsp;IMA202-101&nbsp;study</FONT> is
actively recruiting in its dose-escalation phase. The study is targeting patients with recurrent or refractory solid tumors including, but not limited to unresectable advanced HCC. To be eligible for&nbsp;IMA202-101,&nbsp;adult patients with
pathologically confirmed advanced/metastatic cancer including HCC not amenable to resection are considered for enrollment into the trial if they are tested to be <FONT STYLE="white-space:nowrap">HLA-A*02:01</FONT> positive and MAGEA1 was found to be
present in a biopsy of the patient&#146;s tumor. The patients have relapsed and/or have refractory solid cancers with no established treatment available. Upon successful manufacturing and release testing of the IMA202 product the patient can be
treated, given that all treatment eligibility criteria are fulfilled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The study purpose is to evaluate the safety and tolerability of the treatment with
IMA202 T cell products. Thus, the primary outcome is to determine the incidence of AE upon treatment including DLT and determination of recommended Phase 2 dose. Secondary outcomes are the evaluation of T cell persistence of the TCR engineered T
cells within the patient&#146;s blood after T cell infusion, as well as the evaluation of anti-tumor activity (tumor response and duration of response). T cell persistence is considered as a
<FONT STYLE="white-space:nowrap">major&nbsp;pre-requisite&nbsp;to</FONT> obtain anti-tumor response. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">IMA203-101</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">The&nbsp;IMA203-101&nbsp;trial</FONT> (NCT03686124) is a Phase 1 dose-escalating trial evaluating safety, tolerability and initial signs of clinical efficacy of our IMA203 ACTengine product, which targets preferentially
expressed antigen in melanoma (&#147;PRAME&#148;) in adult patients with relapsed and/or refractory solid tumors. Among a broad range of solid cancer indications, uterine cancer (endometrial cancer and uterine carcinoma), ovarian cancer, melanoma,
several subtypes of sarcoma and squamous NSCLC are of special interest because PRAME is expressed in these tumors at a very high frequency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to
estimates for 2019, ovarian cancer accounted for 23,000 new cases per year in the United States. Approximately 14,000 patients died from this disease in 2019, being the fifth most common cause of cancer-related deaths in women. Beside ovarian
cancer, uterine cancer is another common cancer in women with unfavorable prognosis and where advances in available treatments are urgently needed. Melanoma is the fifth most common cancer type in the United States and has an incidence of
approximately 96,000 new cases and 7,000 estimated deaths per year. While localized melanoma has a very favorable prognosis with <FONT STYLE="white-space:nowrap">a&nbsp;5-year&nbsp;survival</FONT> rate of 99%, metastasized melanoma has <FONT
STYLE="white-space:nowrap">a&nbsp;5-year&nbsp;survival</FONT> rate of only 25%. Despite recent advances in treatment approaches the prognosis for advanced melanoma remains poor. Thus, the target population
<FONT STYLE="white-space:nowrap">for&nbsp;IMA203-101&nbsp;is</FONT> cancer patients with no or limited treatments available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT
STYLE="white-space:nowrap">ACTengine&nbsp;IMA203-101&nbsp;study</FONT> is actively recruiting in its dose-escalation phase. Before start of study treatment, patients must have recurrent and/or refractory solid tumors and must have received or not be
eligible for all available <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">indicated&nbsp;standard-of-care&nbsp;treatments</FONT></FONT> known to confer clinical benefit (e.g., surgery, radiation therapy, chemotherapy,
immunotherapy or targeted therapy). Thus, IMA203 is administered if the last available <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">indicated&nbsp;standard-of-care&nbsp;treatment</FONT></FONT> is no longer warranted. For a
patient to be eligible for this study, there is no limitation on either the type or the number of prior anti-tumor treatments they may have received. These cancer patients have a very poor prognosis and an urgent unmet medical need for new treatment
options. Moreover, patients are eligible for inclusion into the trial if they are tested to <FONT STYLE="white-space:nowrap">be&nbsp;HLA-A*02:01&nbsp;positive</FONT> and PRAME was found to be present in a biopsy of the patient&#146;s tumor. Upon
successful manufacturing and release testing of the IMA203 product, the patient can be treated, given that all treatment eligibility criteria are fulfilled. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The study purpose is to evaluate the safety and tolerability of the treatment with IMA203 T cell products.
Thus, the primary outcome is the determination of the incidence of AE upon treatment including DLT and determination of recommended Phase 2 dose. Secondary outcomes are the evaluation of T cell persistence of the TCR engineered T cells within the
patient&#146;s blood after T cell infusion, as well as the evaluation of anti-tumor activity (tumor response and duration of response). T cell persistence is considered as a <FONT STYLE="white-space:nowrap">major&nbsp;pre-requisite&nbsp;to</FONT>
obtain anti-tumor response. After establishing the initial safety profile, we plan to add atezolizumab to a cohort of patients to test the safety of <FONT STYLE="white-space:nowrap">the&nbsp;IMA203-atezolizumab&nbsp;combination.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Initial Results from Ongoing Clinical Trials </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
recruitment status as of January 2020 is the following: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">22&nbsp;HLA-A*02:01-positive&nbsp;patients</FONT></FONT> were found to express one of the three targets (for IMA201, IMA202 or
IMA203) in their tumor biopsy. 13 of those patients have been enrolled into the manufacturing phase of the trials. Manufacturing was successful for all 10 patients for which manufacturing has already been completed. Four patients <FONT
STYLE="white-space:nowrap">(IMA201-101:&nbsp;n=1;</FONT> <FONT STYLE="white-space:nowrap">IMA202-101:&nbsp;n=2;</FONT> <FONT STYLE="white-space:nowrap">IMA203-101:&nbsp;n=1)</FONT> have been infused at the lowest dose (50&nbsp;million specific T
cells/m&sup2;) of the dose escalation scheme in their respective trial. So far, ACTengine treatment has been tolerated well. The most frequent adverse events observed to date included cytopenias associated with the lymphodepleting regimen and <FONT
STYLE="white-space:nowrap">Grade&nbsp;1-2&nbsp;cytokine</FONT> release syndrome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary biological data indicate very high frequencies of
target-specific T cells (up to 45% of CD8+ T cells) in the patient&#146;s blood after T cell infusion even at the lowest dose level. Target-specific T cells persisted until the end of the observation period (up to 12 weeks, immunomonitoring is still
ongoing). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 8. Initial biological activity data in first ACTengine patients. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cellular immunomonitoring in Blood</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B></B>IMA203 Patient #1<B></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g96389g13f64.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Molecular&nbsp;immunomonitoring&nbsp;in&nbsp;blood</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g96389g14p53.jpg" ALT="LOGO">
</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Initial data for biological activity in ACTengine patient (status January 2020). Left panel: Representative plot for cellular
immunomonitoring of target-specific T&nbsp;cells in the blood of IMA203 patient #1 one week after infusion. Right panel: Molecular immunomonitoring in the blood of n=4 ACTengine patients. Target-specific T&nbsp;cells were determined in the
patient&#146;s blood for up to 12&nbsp;weeks after infusion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, target-specific T cells were detected in tumor biopsies that were taken after
T cell infusion, indicating their infiltration into the tumor. Biological activity is the prerequisite for clinical efficacy, which will likely be assessed in the forthcoming months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 9. Detection of target-specific T cells in the tumor. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Molecular immunomonitoring in Tumor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">IMA202 Patient #2, IMA203 Patient #1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g21t54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Initial data for detection of target-specific T cells within post-treatment biopsies six weeks after infusion for n=2
ACTengine patients (status January 2020). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After completion of the dose-escalation phase, assuming favorable safety profiles of the IMA201, IMA202 and
IMA203 product candidates and signs of clinical activity in a certain or several cancer subtypes, we may extend the described clinical trials and recruit patients of a respective indication in an extension cohort to assess potential anti-tumor
activity in more detail, both as a single agent and in combination therapy with atezolizumab. We may target Fast Track designation(s) and Accelerated Approval(s) to bring the product candidate(s) to the market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NEXT-GENERATION&nbsp;ACT </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; margin-left:1%; font-size:10pt; font-family:Times New Roman"><B>Next-Generation ACT at a glance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:1%; margin-right:1%; font-size:10pt; font-family:Times New Roman">We are committed to developing our ACTengine programs, with the goal to deliver the potential benefits of our innovative
science to cancer patients as soon as possible. At the same time, in order to achieve the best outcomes for cancer patients in the longer term, we strive to enhance the tolerability, potency and ease of use of our product candidates. To accomplish
these goals, we have taken the following steps: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Addressing the tumor stroma and microenvironment.</B>&nbsp;The complex tumor microenvironment is currently
regarded as one of the biggest challenges to the success of immunotherapies in solid tumors. We believe that the combination of stroma targets with tumor targets, as well as our second-generation enhancements to generate more potent T cells, may
address this unmet need. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Combating target heterogeneity and tumor evasion.</B>&nbsp;Our next-generation multi-target approach is
designed to combat target heterogeneity and tumor escape for deeper and longer clinical responses. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Enhancing commercial viability.</B>&nbsp;Aside from improving commercially compatible manufacturing of
autologous ACT, we aim to decrease the cost of goods and to reach patients more quickly with our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> cell therapy, ACTallo. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Pioneering personalized multi-target precision cancer medicines.</B>&nbsp;The ACTolog pilot trial served as
the first proof of concept for the feasibility of a personalized multi-target approach. The ACTolog pilot trial indicated a favorable tolerability profile, persistence and biological activity of transfused T&nbsp;cells as well as clinical benefit by
the long-term stabilization of tumor growth in some last-line patients. The ACTolog approach is limited by the properties of the patient&#146;s own T cell repertoire (i.e.&nbsp;TCRs with limited affinities). We believe that this limitation can be
overcome by a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">multi-TCR-based</FONT></FONT> ACTengine approach, which utilizes highly potent and optimized TCRs that may enable significant clinical responses. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE></div>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Exploit the full target potential and offer treatment options for potentially any patient.</B>&nbsp;We believe
that our pool of more than 200 prioritized targets combined with the capability to develop the right TCRs offers a possibly unique foundation to develop treatments for almost any patient. We believe that our fast manufacturing process, combined with
our broad target portfolio, may put us in a unique position to develop personalized medication efficiently and cost-effectively for any patient. </P></TD>
<TD WIDTH="1%">&nbsp;</TD></TR></TABLE></div> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Targeting Tumor Stroma &#151; ACTengine IMA204 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most current anti-tumor therapies directly target the malignant tumor cells. For Adoptive Cell Therapy, this approach has been successful as demonstrated by
others in several indications. Challenges remain, however, for solid tumors, where access and activity of the T cells to the tumor is limited by a rigid tumor stroma and the immunosuppressive tumor microenvironment. Tumor stroma, which are
cancer-associated fibroblasts, may promote tumor growth, inhibit drugs and T cells from entering the tumor and thus prohibit them from reaching and killing the tumor cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With the XPRESIDENT target discovery platform, we are not only able to identify tumor cell-associated targets, but also innovative targets that are
predominantly expressed in tumor stroma. One such stroma-associated target is COL6A3 exon 6, which was selected for the IMA204 ACTengine program. The IMA204 ACTengine program is in preclinical development with a planned IND submission in 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COL6A3 exon 6 is a novel cancer stroma target identified and validated by our XPRESIDENT technology platform. COL6A3 is an extracellular matrix component
found in most connective tissues, however COL6A3 exon 6 is expressed predominantly by tumor stromal cells and not in normal tissues. COL6A3 exon 6 is highly prevalent in a broad range of tumor tissues including lung, pancreas, esophagus, breast,
ovary, colon and stomach cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that targeting the tumor stroma via IMA204 ACTengine is a promising approach for many solid tumors. This
could result in tumor cell death due to tumor cells&#146; dependency on the stroma, could allow endogenous tumor specific T cells to reach the tumor and exert their anti-tumor activity, or could trigger additional local inflammation in the tumor
microenvironment. We are considering combining IMA204 with other ACTengine products directly targeting tumor cells, offering a potentially orthogonal and synergistic mechanism of action. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Off-the-Shelf&nbsp;Adoptive</FONT></FONT> Cell Therapy &#151; ACTallo </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACT based on genetically engineered, patient-derived T cells has demonstrated remarkable clinical successes. However, the high costs and logistics associated
with use of autologous cells as starting material are a challenge to the widespread use of autologous ACT. In addition, autologous patient material is of heterogenous quality, and the efficacy of cell therapy products in patients may be impacted by
the patient&#146;s age, the quality of the patient&#146;s T cell, the cancer itself or <FONT STYLE="white-space:nowrap">immunosuppressive&nbsp;pre-treatments.&nbsp;The</FONT> development of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">simpler,&nbsp;off-the-shelf&nbsp;ACT</FONT></FONT> approaches with large batches of therapeutic doses derived <FONT STYLE="white-space:nowrap">from&nbsp;pre-tested&nbsp;healthy</FONT> donors may make the benefits of these
therapies more easily accessible and affordable to cancer patients with challenging, unmet medical needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACTallo is a process we developed for the
manufacture of allogeneic, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf,</FONT></FONT> <FONT STYLE="white-space:nowrap">TCR-engineered</FONT> cellular therapies derived from healthy donors&#146;&nbsp;<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> T cells. We believe that <FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> T cells are ideally suited for allogenic ACT
approaches:&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> T cells naturally infiltrate tumors, which has been shown to be the most favorable prognostic factor for patient outcome.&nbsp;<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> T cells possess intrinsic antitumor activity and recognize target cells in an HLA/peptide independent fashion, not causing Graft-versus-Host Disease. In clinical
trials, the transfer of autologous&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> T cells has been repeatedly shown to be well tolerated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The life span of ACTallo T cells in patients is expected to be limited by their allogeneic nature, and the
transferred cells will ultimately be rejected by the host immune system. Therefore, any potential autoimmune reactions driven by the ACTallo product are expected to be limited in duration and severity. Thus, in order to sustain clinical activity,
repeated ACTallo cell infusion may be required. The picture emerging from commercial <FONT STYLE="white-space:nowrap">CAR-T&nbsp;products</FONT> indicates that while peak product concentration correlates with response rate, it is the long-term
persistence that correlates with the duration of response. As a result, if an allogeneic product is not applied multiple times, premature rejection of the product may limit patients&#146; long-term prognosis. Therefore, we are investigating
preclinically second-generation approaches that could be suited towards making ACTallo less immunogenic. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have developed a process that
allows<I>&nbsp;ex vivo</I>&nbsp;expansion of&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> T cells isolated from a single healthy donor to manufacture multiple ACTallo doses, which we believe
represents an ideal modality for an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> approach. Using healthy donor T cells circumvents the need to use T cells from heavily treated or aging cancer
patients, thus allogeneic cells are not encumbered by suppressive environments of the patients&#146; immune system. In addition, products are available immediately for patient treatment without any delays for cellular manufacturing upon enrollment.
At the laboratory scale, we have observed that our proprietary manufacturing process could generate hundreds of doses from a single donor. We are currently translating these lessons into larger scale solutions. A schematic summary of the ACTallo T
cell manufacturing process is shown below in Figure 10. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 10. Schematic representation of our ACTallo process. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g22k64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Within the ACTallo process
allogeneic&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;T cells from healthy donors are genetically engineered to express TCRs specific for one of our cancer <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">targets.&nbsp;Off-the-shelf&nbsp;ACTallo</FONT></FONT> product candidates are then ready for treatment directly after patient enrollment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For manufacturing of ACTallo products,&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;T cells are
isolated from healthy donor leukapheresis, activated and transduced with target-specific TCR and the <FONT STYLE="white-space:nowrap">CD8&nbsp;co-receptor,&nbsp;and</FONT> further expanded before cryopreservation as <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">an&nbsp;off-the-shelf&nbsp;product.</FONT></FONT> After infusion,
<FONT STYLE="white-space:nowrap">these&nbsp;TCR-engineered&nbsp;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;T cells can recognize and eliminate cancer cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently developing the manufacturing process for ACTallo products. Process development efforts are aimed at optimizing cell selection, enrichment,
activation and expansion, as well as transduction of&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;T cells. Our plans to use a proprietary lentiviral vector system capable of transducing&nbsp;<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;T cells with a single vector incorporating the proprietary TCR and a <FONT STYLE="white-space:nowrap">CD8&nbsp;co-receptor&nbsp;&#151;</FONT> which we
believe significantly reduces costs and complexity. For our first ACTallo product, <FONT STYLE="white-space:nowrap">IMA301,&nbsp;non-cGMP&nbsp;production</FONT> runs from selected healthy donors will be performed at clinical batch scale, before the
transfer of the manufacturing process to a cGMP facility. Finally, cGMP&nbsp;technology transfer run(s) will be performed in preparation of clinical batch manufacturing for patient infusion in a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-human</FONT></FONT> IMA301 clinical trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;T
cells transduced with the TCR developed for use in IMA301 showed high<I>&nbsp;in vitro</I>&nbsp;anti-tumor activity. In addition, IMA301 TCR+&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;T
cells were able to effectively kill a tumor cell line<I>&nbsp;in vitro</I>&nbsp;that expressed the targeted antigen at copy numbers that are usually seen on target-positive solid tumors (Figure 11). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 11. Specific&nbsp;in vitro tumor cell killing by ACTallo T cells. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g23b98.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACTallo T cells transduced with IMA301 TCR were observed to kill tumor cells endogenously expressing the IMA301 target at
relevant copy numbers (U20S cell line, approximately 250 target copies per cell). The figure further demonstrates the intrinsic anti-tumor activity
of&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>&nbsp;T cells without TCR transduction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to
enter <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trials with the first ACTallo product IMA301 after completion of process development
<FONT STYLE="white-space:nowrap">and&nbsp;IND-enabling&nbsp;studies,</FONT> with a planned IND submission in 2022. Development of IMA301 in solid tumors as well as in hematological indications is an option. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Multi-target Cell Therapy Pilot Trial &#151; ACTolog </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
ACTolog approach was designed as the first known multi-target precision immunotherapy. The <FONT STYLE="white-space:nowrap">IMA101-101</FONT> Phase 1 clinical trial is currently being conducted as a pilot trial to demonstrate safety and feasibility
of a multi-target ACT approach (NCT02876510). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACTolog is based on the principle of endogenous T cell therapy pioneered by Cassian Yee. ACTolog T cells
are not genetically modified: IMA101 T cell products are generated from peripheral blood cells and are the patient&#146;s own T cells, which are applied after<I>&nbsp;ex vivo</I>&nbsp;expansion. This approach is based on the observation that tumor
antigen-specific T cells are naturally occurring and can be identified in the peripheral blood of melanoma patients. Despite their natural ability to recognize tumor associated antigens that are presented by tumor cells, these T cells may not be
activated and capable to act against cancer, as peptides presented without <FONT STYLE="white-space:nowrap">co-stimulatory</FONT> signals are only poorly immunogenic. Moreover, the frequency of endogenous target-specific T cells is usually very low.
Expanding and activating those naturally occurring T cells allows great flexibility in targeting tumors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 12. Schematic representation of our ACTolog process. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g31s12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ACTolog concept is based on selecting and expanding a patient&#146;s own autologous T cells dependent on the detection
of ACTolog targets in the patient&#146;s tumor tissue. Thus, the manufacturing of a patient&#146;s personalized multi-targeted ACTolog product is tailored to the individual target expression profile of each patient. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In ACTolog, this autologous T cell expansion approach is amended to use a warehouse including multiple novel cancer targets discovered by the target discovery
platform XPRESIDENT.&nbsp;From this target pool (COL6A3 exon&nbsp;6, PRAME, MAGEA1, MAGEA4, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">MAGEA4/8,&nbsp;NY-ESO-1,&nbsp;MXRA5),</FONT></FONT> the suitable targets for each
patient&#146;s tumor are identified by analyzing their relative presence within a tumor biopsy. Up to four personalized IMA101 T cell products, each with a defined target specificity, are then manufactured for each patient by isolation, propagation
and activation of the patient&#146;s endogenous T cells<I>&nbsp;in vitro</I>. Billions of such activated and specific T&nbsp;cells are <FONT STYLE="white-space:nowrap">then&nbsp;re-infused&nbsp;into</FONT> the cancer patient for the purpose of
attacking the tumor.&nbsp;The patient-tailored IMA101 T cell product(s) are infused as single dose after <FONT STYLE="white-space:nowrap">a&nbsp;pre-conditioning&nbsp;lymphodepletion</FONT> to facilitate engraftment of transferred T cells.
Thereafter, patients <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">receive&nbsp;low-dose&nbsp;IL-2&nbsp;to</FONT></FONT> further improve T cell engraftment and activation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Initial results </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
<FONT STYLE="white-space:nowrap">ongoing&nbsp;IMA101-101&nbsp;study</FONT> is a Phase 1 trial investigating the safety and tolerability of IMA101 alone (cohort 1) or in combination with
<FONT STYLE="white-space:nowrap">the&nbsp;PD-L1&nbsp;inhibitor</FONT> atezolizumab (cohort 2) <FONT STYLE="white-space:nowrap">in&nbsp;HLA-A*02:01&nbsp;positive</FONT> patients with advanced solid cancers. As of December 2019, initial data from the
ongoing trial has revealed no treatment related deaths. The most common adverse events observed so far were expected cytopenias associated with the lymphodepleting regimen and <FONT STYLE="white-space:nowrap">Grade&nbsp;1-2&nbsp;cytokine</FONT>
release syndrome. Many patients have received high ACTolog cell doses and multiple T cell products. These initial results indicate that ACTolog is well-tolerated with no changes to treatment regime required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 1. Initial tolerability profile for ACTolog product candidates. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Adverse Events (N = 12)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT><B></B><B>&nbsp;Grade&nbsp;3<BR>(N)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SAE<BR>(N)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AESI<BR>(N)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anemia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leukopenia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lymphopenia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neutropenia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thrombocytopenia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bacteremia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cellulitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Abdominal pain</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Device-related infection</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sinus bradycardia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hypotension/ Orthostatic hypotension</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Appendicitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytopenia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cytokine release syndrome</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Infusion-related reaction</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Haematochezia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fatigue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Overview of Adverse Events in ACTolog trial provides preliminary data for n=12 initial patients (Status as of December 2019).
AE: adverse event; SAE, serious adverse event; AESI, adverse event of special interest. Only AEs from treated patients are listed. If a patient experienced &gt; 1 event, the patient is counted only once for the most severe AE. If an SAE or AESI
was&nbsp;<FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>&nbsp;Grade 3, the same AE is counted in both columns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very high frequencies of target-specific T
cells could be detected within the patients&#146; blood up to one year after infusion which is seen as an <FONT STYLE="white-space:nowrap">important&nbsp;pre-requisite&nbsp;for</FONT> clinical activity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 13. Initial biological activity results in ACTolog patients. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T cell Persistence in Blood</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T cell infiltration into Tumor</B></P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g96389g34b67.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">


<IMG SRC="g96389g37z45.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Initial data for biological activity in ACTolog patients (status January 2020). Left panel: T cell persistence in the
periphery of n=12 patients was determined up to one year after infusion, right panel: Detection of target-specific T cells within post-treatment biopsies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As presented by the study&#146;s principal investigator at public conferences, two interesting case studies were observed in the <FONT
STYLE="white-space:nowrap">ACTolog&nbsp;IMA101-101&nbsp;trial</FONT> to date. One patient with nasopharyngeal cancer was treated with a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
T&nbsp;cell product against the novel tumor stromal target COL6A3 exon 6 and showed stable disease for one year without the requirement of subsequent anti-tumor treatment and with an indication
of necrosis in tumor biopsies. Another patient with squamous cell carcinoma of the anus received T cell products directed to COL6A3&nbsp;exon&nbsp;6 and PRAME and showed a 26% decrease in tumor measurements (RECIST1.1, irRECIST) at week six. A
significant drop of T cells at week eight and a presumably unfavorable shift in T cell phenotype towards terminal differentiation was associated with progression of the patient at week twelve. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Overall, preliminary results of this multi-target pilot study demonstrate that large T cell doses of multiple products can be applied simultaneously and are
generally well tolerated. <FONT STYLE="white-space:nowrap">The&nbsp;IMA101-101&nbsp;pilot</FONT> trial demonstrated the feasibility of multi-target ACT and generated Phase 1 tolerability data for the investigated targets. Clinical topline data are
expected to be available at the end of 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of the targets tested in the <FONT STYLE="white-space:nowrap">ACTolog&nbsp;IMA101-101&nbsp;trial</FONT>
either are, or may soon be, entering clinical development in our ACTengine trials. For the next wave of ACT, we envision utilizing the highly potent TCRs from ACTengine within such actively tailored, multi-target, precision immunotherapy approach.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Personalized Multi-target ACTengine and TCR Warehouse </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currently, the few publicly available targets in ACT trials are usually tackled separately by individual products and trials. As intra-tumor heterogeneity has
been observed as a source for <FONT STYLE="white-space:nowrap">clonal&nbsp;re-growth&nbsp;of</FONT> the tumor, tumor escape can occur if only one target is addressed. Targeting multiple antigens relevant for individual patients is therefore an
important strategic objective for us that may enable us to see durable clinical responses by lowering the risk of relapse due to tumor antigen escape. We believe that an <FONT STYLE="white-space:nowrap">ACTengine&nbsp;TCR-T&nbsp;therapy</FONT> with
multiple TCRs against multiple targets may have the potential to realize durable and deep clinical responses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proprietary target discovery platform
XPRESIDENT positions us to simultaneously address multiple targets. As a first step, we have already created a library, which we call our &#147;warehouse&#148;, of seven promising tumor antigens for use in the ACTolog pilot trial. In this study,
endogenous,<I>&nbsp;ex vivo</I>&nbsp;amplified T cells (in contrast to ACTengine they are not genetically engineered but selected from the patient&#146;s own T cell repertoire) are applied to solid cancer patients in a multi-target precision
approach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phase 1 clinical trials <FONT STYLE="white-space:nowrap">with&nbsp;TCR-engineered&nbsp;ACTengine</FONT> product candidates are either <FONT
STYLE="white-space:nowrap">ongoing&nbsp;(IMA201-203)&nbsp;or</FONT> planned (IMA204). While development of these product candidates is pursued with full commitment, we envision combining all four products into a &#147;TCR warehouse&#148; to allow
treatment of individual patients with more than one TCR specificity. With an initial TCR warehouse <FONT STYLE="white-space:nowrap">including&nbsp;IMA201-204,&nbsp;patients</FONT> could then potentially be treated with up to four different products
depending on their individual target expression pattern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enabled by the XPRESIDENT target pool and the TCR identification platform XCEPTOR, we aim to
develop further TCRs with supplementary target specificities and to include them into this TCR warehouse. We envision the combination of a <FONT STYLE="white-space:nowrap">warehouse-based&nbsp;TCR-T&nbsp;approach</FONT> with next-generation
technologies and other immuno-oncology drugs (such as checkpoint inhibitors) on a data-driven, patient-individual basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have broad experience with
the regulatory and clinical realization of such warehouse-based concepts as demonstrated with ACTolog in the United States, as well as a previous personalized vaccine trial (GAPVAC) in the European regulatory environment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offering a treatment option to potentially any cancer patient with a possibility of multiple targets per patient would require a substantially larger TCR
warehouse. We envision expanding the warehouse, gradually, with additional TCRs targeting additional tumor and tumor stroma antigens available through XPRESIDENT. Moreover, we plan to include targets presented by HLA alleles other <FONT
STYLE="white-space:nowrap">than&nbsp;HLA-A*02:01,&nbsp;such</FONT> as <FONT STYLE="white-space:nowrap">HLA-A*01,</FONT> <FONT STYLE="white-space:nowrap">HLA-A*03,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">HLA-A*24,&nbsp;HLA-B*07,&nbsp;HLA-B*08,&nbsp;HLA-B*44.&nbsp;This</FONT></FONT></FONT></FONT> has the potential to broaden the patient population that might benefit from the TCR warehouse
approach from approximately 40% of the population in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
North America and approximately 45% of Europe <FONT STYLE="white-space:nowrap">expressing&nbsp;HLA-A*02:01&nbsp;to</FONT> more than 90% of individuals expressing at least one suitable HLA allele,
and to similar values for populations in other major markets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 14. Our
<FONT STYLE="white-space:nowrap">multi-target&nbsp;TCR-T&nbsp;strategy.</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g41w69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We combine the expertise from the ACTolog multi-target pilot study with the capability to develop novel engineered TCRs as
used in the ACTengine approach. While developing ACTengine targets individually, we plan to <FONT STYLE="white-space:nowrap">combine&nbsp;IMA201-204&nbsp;TCRs</FONT> into an initial TCR warehouse, enabling patient treatment with multiple ACTengine
products including anti-tumor and anti-stroma targets. We plan to extend that warehouse with the goal to treat ultimately any cancer patient and achieve durable responses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TCR B<SMALL>ISPECIFICS</SMALL> &#151; TCER </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TCER at a glance</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B>TCR
Bispecifics</B><B></B><B>&nbsp;redirect any T cell.</B><B></B>&nbsp;Our TCR Bispecifics, called TCER (T Cell Engaging Receptors), are <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> biologics that
leverage the body&#146;s immune system by redirecting and activating T cells towards cancer cells expressing specific tumor targets. The design of these novel biologics allows any T cell in the body to become activated and attack the tumor,
regardless of the T&nbsp;cells&#146; intrinsic specificity.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B>Expanded target space compared to classical</B><B></B><B>&nbsp;T</B><B></B><B>&nbsp;cell
engagers.</B>&nbsp;TCER compounds target tumor-associated peptides presented by <FONT STYLE="white-space:nowrap">HLA-molecules</FONT> on the tumor cell surface exploiting the whole proteome.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B>Active at low levels of
target expression.</B>&nbsp;TCER are designed to induce the killing of tumor cells even when presenting physiological low copy numbers of the target.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B>High affinity and preclinical activity.</B>&nbsp;Very low concentration (low pM range) required
for<I>&nbsp;in vitro</I>&nbsp;killing of tumor cells expressing physiological levels of target pHLA and significant tumor growth inhibition<I>&nbsp;in vivo</I>&nbsp;in a therapeutic model.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B>Extended
half-life.</B>&nbsp;The TCER-scaffold is designed to exhibit a long functional half-life in the patient&#146;s bloodstream in order to achieve clinical activity without the requirement for daily and/or continuous intravenous application.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="98%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B>Modularity.</B>&nbsp;The TCER-scaffold is designed to offer modularity. This allows for the
efficient exchange of tumor-targeting and T cell engaging binders.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Off-the-shelf</FONT></FONT>
therapeutics.</B>&nbsp;TCER are biologics designed for cost-effective manufacturing and immediate application availability.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B>Manufacturing activities for IMA401 have started.</B>&nbsp;The TCER-scaffold is designed to be
produced in <FONT STYLE="white-space:nowrap">CHO-cells</FONT> relying on well-established processes used in the production of antibody-based therapeutics. Manufacturing development for our lead TCER candidate IMA401 is ongoing and submission of an
IND is planned for the end of 2021.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;<B>The planned
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial with IMA401</B>&nbsp;is designed to assess safety and tolerability, establish a suitable dose and potentially observe initial signs of
clinical activity.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our TCER are designed to leverage the well-established and validated mode of action <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">and&nbsp;off-the-shelf&nbsp;usage</FONT></FONT> of bispecific T cell engagers (prototyped by Blinatumomab) and to combine this mechanism with the expanded target space available to T cell therapies against pHLA targets.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once administered, TCER compounds are supposed to bind to the tumor cells presenting the target peptide in context of HLA and simultaneously recruit,
activate and stimulate the patient&#146;s own T cells to attack the tumor cells. This is expected to result in T cell expansion and subsequent tumor regression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A TCER consists of three distinct elements: (i)&nbsp;an affinity and stability improved T cell receptor recognizing the target presented <FONT
STYLE="white-space:nowrap">by&nbsp;HLA-molecules&nbsp;on</FONT> tumor cells, (ii)&nbsp;a T cell stimulating and recruiting domain derived from an antibody, and (iii)&nbsp;an effector function
<FONT STYLE="white-space:nowrap">silenced&nbsp;Fc-part&nbsp;based</FONT> on human IgG conferring preferential stability, serum half-life and manufacturability. Our TCER molecules can be produced and purified utilizing established processes to
manufacture antibodies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 15. Proposed mechanism of action of our TCER: from administration to tumor killing. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g44v90.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Administration of the biologic compound, which
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">is&nbsp;off-the-shelf&nbsp;available,</FONT></FONT> to a biomarker positive cancer patient. TCER molecules are supposed to specifically bind to the pHLA targets on cancer cells,
direct and activate any patient&#146;s circulating T cell into proximity of the cancer cell with the goal of destroying the malignant cell. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our TCER
scaffold is the result of a campaign to engineer and evaluate various molecular scaffolds incorporating binding domains derived from affinity and stability enhanced TCRs and from T cell recruiting </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
antibodies, respectively. The TCER architecture, in our<I>&nbsp;in vitro</I><I></I>&nbsp;testing, proved to be superior to other tested scaffolds with respect to preclinical activity, stability
and physico-chemical properties, so called &#147;developability&#148;. TCER molecules can readily be expressed <FONT STYLE="white-space:nowrap">in&nbsp;CHO-cells&nbsp;with</FONT> titers comparable to antibody-based biologics. The TCER protein can be
purified using common chromatographic techniques <FONT STYLE="white-space:nowrap">and&nbsp;size-exclusion-chromatography,&nbsp;facilitating</FONT> the cGMP-compliant manufacturing in established plants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For all TCER programs, extensive<I>&nbsp;in vitro</I>&nbsp;and<I>&nbsp;in vivo</I><I></I>&nbsp;experiments are compiled. The activity of all TCER molecules is
evaluated in various<I></I><I>&nbsp;in vitro</I>&nbsp;assays utilizing tumor cell lines presenting the target at physiological low levels. Figure 16 representatively illustrates such a tumor cell killing assay by a target-specific TCER. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 16. Specific tumor cell killing by a TCER. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g45c23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PBMC-mediated cytotoxicity of a TCER against target positive tumor cells was assessed by live-cell analysis. Shown are
representative images after 60 hours. Unstained (grey/black): PBMCs (lymphocytes, including T&nbsp;cells); Red: Living tumor cells, Green: Dead cells, Yellow: cell death in clusters of activated T cells and tumor cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, TCER molecules exhibiting high<I>&nbsp;in vitro</I>&nbsp;potency and the ability to target low abundant peptides are selected. In parallel,
tolerability of TCER candidates is extensively tested in various<I>&nbsp;in vitro</I>&nbsp;assay systems. TCER molecules exhibiting low reactivity towards healthy tissue as well as high therapeutic windows are then selected for further development.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In vivo</I><I></I>&nbsp;half-life of TCER molecules is assessed in mice by quantification of functional TCER molecules in blood. For a representative
TCER molecule, a long terminal half-life of several days was determined, confirming the functionality of <FONT STYLE="white-space:nowrap">the&nbsp;Fc-part&nbsp;utilized</FONT> in the TCER-scaffold. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The targets used in our current TCER programs
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">are&nbsp;HLA-A*02:01-restricted,&nbsp;naturally</FONT></FONT> presented peptide cancer targets identified by our comprehensive target discovery and validation process. The identified
peptides demonstrate high target copy numbers and are highly tumor-associated targets with high target prevalence in several solid cancer types, which we believe makes them excellent targets for TCER programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 2. Prevalence of IMA401 and IMA402 targets in selected cancer indications. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>IMA401</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>IMA402</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tumor types with</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">significant target</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">prevalence</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sq NSCLC (50%)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HNSCC (35%)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Bladder carcinoma
(30%)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Uterine carcinosarcoma (25%)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Esophageal carcinoma (25%)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ovarian
carcinoma (20%)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Melanoma (20%)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sarcoma Subtypes</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(up to 80%)</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">...</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Uterine carcinoma (100%)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Melanoma (95%)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Ovarian carcinoma
(80%)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sq NSCLC (65%)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Uveal
melanoma (50%)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cholangiocarcinoma (35%)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Diffuse large B-cell lymphoma (30%)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Breast carcinoma (25%)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">HNSCC
(25%)</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Sarcoma Subtypes</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(up to
100%)</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">...</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table provides an overview of selected tumor indications with high target prevalence for our preclinical IMA401 and IMA402
TCER product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IMA401 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on
preclinical data, we believe that the IMA401 TCER represents a promising clinical product candidate. IND submission is targeted for the end of 2021, followed by a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial to assess safety and tolerability, escalate the dose and potentially observe initial signs of clinical activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMA401 can readily be expressed <FONT STYLE="white-space:nowrap">in&nbsp;CHO-cells&nbsp;with</FONT> titers exceeding 2 g/L. Once purified, IMA401 exhibits low
aggregation and fragmentation even prior to formulation development and under heat stress suggesting favorable stability characteristics. The activity of the IMA401 TCER was evaluated in various<I>&nbsp;in vitro</I><I></I>&nbsp;assays utilizing
tumor cell lines presenting the target at physiological low levels. Thereby the TCER-concentration needed<I>&nbsp;in vitro</I><I></I>&nbsp;to achieve half-maximal tumor cell killing was determined to be as low as 10 pM to 300 pM depending on the
individual donor of effector cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In parallel, tolerability of the IMA401 TCER was extensively tested in various&nbsp;in vitro&nbsp;assay systems. To
screen for reactivity towards healthy tissue and prevent toxicity, the therapeutic window for IMA401 TCER was determined in <FONT STYLE="white-space:nowrap">a&nbsp;co-culture&nbsp;assay</FONT> with PBMC (effector cells) and a multitude of primary
normal cell types derived <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">from&nbsp;HLA-A*02-positive&nbsp;donors.</FONT></FONT> The primary cell panel covers critical organs and different cell types thereof as well as
organ-specific cell types. Reactivity against the different normal cell types and a tumor cell line for comparison was assessed for increasing concentrations of IMA401 by <FONT STYLE="white-space:nowrap">an&nbsp;LDH-release&nbsp;cytotoxicity</FONT>
assay. In the same experiment, cytotoxicity against a human tumor cell line (&#147;Hs695T&#148;) was recorded. While robust tumor cell killing was observed at low pM concentrations, reactivity towards primary tissue was observed only at high TCER
concentrations in the nM range, if at all. Therapeutic windows are calculated based on lowest effective concentrations (&#147;LOEL&#148;) observed for normal cells and the tumor cell line and were at least 1000-fold for the IMA401 TCER on all tested
normal tissue cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 3. Therapeutic window of IMA401 TCER. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="23%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Normal Tissue Type</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Therapeutic&nbsp;Window&nbsp;(x-fold)</FONT></B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">iPSC-derived Astrocytes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&gt;10,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">iPSC-derived GABA neurons</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&gt;10,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">iPSC-derived cardiomyocytes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&gt;10,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Osteoblasts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pulmonary Fibroblasts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&gt;10,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dermal Microvascular Endothelial Cells</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mesenchymal Stem Cells from Bone Marrow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tracheal Smooth Muscle Cells</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&gt;10,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Epidermal keratinocytes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&gt;10,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Renal Cortical Epithelial Cells</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&gt;10,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adrenal Cortical Cells</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cardiac Microvascular Endothelial Cells</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&gt;10,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chondrocytes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&gt;10,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Coronary Artery Endothelial Cells</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&gt;10,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasal Epithelial Cells</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&gt;10,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pulmonary Artery Smooth Muscle Cells</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&gt;10,000</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exemplary specificity assessment for IMA401 TCER, which demonstrated a broad therapeutic window (<FONT
STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT>&nbsp;1,000 &#150; 10,000 fold) as defined by reactivity against tumor cells and normal tissue cells. iPSC: induced pluripotent stem cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>In vivo</I>&nbsp;experiments using human tumor cell lines to establish solid tumors in immune-deficient mice, demonstrated that the IMA401 TCER was, upon
transfer of human PBMC, able to induce complete remissions. In these experiments the TCER was administered at very low doses, confirming the biological activity as well as high stability and long serum half-life of the TCER scaffold. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 17. Potency of our lead TCER candidate IMA401&nbsp;</B><B><I>in vivo</I></B><B>. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g58q47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NOG mice were injected subcutaneously with human Hs695T tumor cells expressing the target peptide. After 20 days of
engraftment visible tumors have developed. At day 1 PBMCs derived from two healthy donors were intravenously injected. IMA401 TCER or vehicle was administered at low doses and tumor volume was assessed by caliper measurements. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generation of <FONT STYLE="white-space:nowrap">the&nbsp;IND-enabling&nbsp;data</FONT> package for IMA401 is
currently underway in parallel to the manufacturing phase. Data will include additional tests for preclinical evaluation of safety and tolerability, such as whole blood cytokine release assays and additional alloreactivity screenings. We are also
planning to generate data from patient-derived xenograft (&#147;<I></I>PDX<I></I>&#148;) models and/or patient-derived spheroid models. A minimum anticipated biological effect level (&#147;<I></I>MABEL<I></I>&#148;) approach is planned to define the
starting dose for the clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacturing development phase of IMA401 TCER is ongoing and includes cell line development, upstream and
downstream process development, GMP production, fill and finish, release testing, storage and stability testing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IMA402 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the selected target, IMA402 could address a broad patient population in a variety of solid and hematological malignancies. This may include ovarian
cancer, uterine cancer, melanoma, several subtypes of sarcoma, subtypes of lung cancer, breast cancer, subtypes of B cell lymphoma and several other indications. Lead candidates for the IMA402 program are currently being generated. Early data
indicate high-affinity binding and specific target recognition. IMA402 TCER lead candidate selection is targeted towards the end of 2020, after which we intend to start the manufacturing phase followed by IND submission and a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>ECHNOLOGY</SMALL>&nbsp;P<SMALL>LATFORMS</SMALL> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our proprietary target and TCR technology platforms at a
glance:</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One of the largest target discovery databases. The XPRESIDENT primary
tissue database is comprised of thousands of cancer and normal tissue samples covering most relevant organs. From these tissues a multitude of data is gathered (including genome, proteome, immunopeptidome, in depth transcriptome) and compiled in our
database, building the foundation for its target discovery.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Identification of true target peptides for <FONT STYLE="white-space:nowrap">TCR-based</FONT>
immunotherapies. XPRESIDENT is built to identify the peptides actually presented on real tumors, and provides quantitative information on copy numbers, which allows differentiation between peptides originating from the same parent protein. Thus, we
believe XPRESIDENT enables the identification of the most relevant tumor-associated pHLA targets.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Large pool of prioritized targets. We have prioritized more than 200 pHLA targets encompassing all
known target classes.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Favorable target characteristics. Targets discovered and validated by XPRESIDENT are
(i)&nbsp;naturally presented on real tumors; (ii)&nbsp;presented in sufficient copy numbers; (iii)&nbsp;highly prevalent in several cancer patient populations; and (iv)&nbsp;expressed in tumor tissue with no or quantitatively lower expression in
normal tissue to avoid potential toxicities that might occur if healthy tissue were attacked by product candidates.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;High-throughput TCR identification. Our proprietary XCEPTOR platform enables fast, efficient and
highly sensitive discovery of natural TCRs with high affinity and high specificity.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Right TCRs for ACT and TCR Bispecifics. We have significant protein engineering expertise to
design TCRs with increased preclinical activity for Adoptive Cell Therapy and TCR Bispecifics product candidates.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman">&#149;&#8195;&#8202;Optimized TCRs. Unique interplay between our target and TCR discovery platforms enables early <FONT
STYLE="white-space:nowrap">de-selection</FONT> of cross-reactive TCRs. We believe that XPRESIDENT-guided <FONT STYLE="white-space:nowrap">on-</FONT> and <FONT STYLE="white-space:nowrap">off-target</FONT> toxicity screening, enabled by the large
normal tissue immunopeptidome database, minimizes safety risks in clinical development.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TARGET&nbsp;DISCOVERY&nbsp;&amp; CHARACTERIZATION&nbsp;PLATFORM&nbsp;XPRESIDENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discovering True Targets for Cancer Immunotherapy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">XPRESIDENT is a high-throughput technology platform based on ultra-sensitive mass
<FONT STYLE="white-space:nowrap">spectrometry&nbsp;(LC-MS/MS),&nbsp;coupled</FONT> with a proprietary sample preparation workflow and a proprietary immunoinformatics platform. XPRESIDENT is centered on the identification <FONT
STYLE="white-space:nowrap">of&nbsp;HLA-bound&nbsp;peptides</FONT> (pHLA targets) presented on tumor cells and not, or to a far lower extent, on the cell surface of normal tissue. XPRESIDENT is capable of detecting pHLA targets down to attomolar
amounts. Key features of XPRESIDENT&nbsp;include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All XPRESIDENT peptides are sourced from native tumors (in 20 major cancer indications), including primary
tissues and metastatic biopsies as well as tissues derived from healthy organs (40 most relevant organs all over the human body). The vast collection of over 2,000 tissue samples combined with XPRESIDENT&#146;s high-throughput approach has led to
the generation of one of the largest target databases in the industry. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Peptides are analyzed and identified through a combination of quantitative HLA peptidomics (mass spectrometry)
complemented by quantitative transcriptomics (mRNA sequencing), enabling the analysis of the differential expression and presentation of these potential drug targets between tumor and normal tissue. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All <FONT STYLE="white-space:nowrap">HLA-bound</FONT> targets discovered by XPRESIDENT on any allele are proven
to be present on a patient&#146;s cancer tissues, in contrast to those predicted by in silico techniques. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our proprietary AbsQuant technology allows absolute quantification of target peptide copy numbers per cell, a
crucial parameter to determine which peptide target of a given source antigen is the most promising, which is a key strength of XPRESIDENT. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 18. Discovery of true cancer targets by our proprietary XPRESIDENT platform. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g59u30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">XPRESIDENT&#146;s large-scale database is based on the analysis of thousands of primary healthy and tumor tissue samples by
quantitative HLA peptidomics (mass spectrometry) and quantitative transcriptomics (RNA sequencing) enabling target discovery, validation, specificity assessment, treatment personalization and artificial intelligence approaches for highly
personalized immunotherapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">XPRESIDENT has identified and characterized all cancer targets in clinical and preclinical development of proprietary and
collaborative pipelines, all of which are currently <FONT STYLE="white-space:nowrap">targeting&nbsp;HLA-A*02,&nbsp;which</FONT> is found on <FONT STYLE="white-space:nowrap">approximately&nbsp;40-50%&nbsp;of</FONT> individuals in North America,
Europe, China and Japan and is one of the most common HLA types worldwide. Additionally, XPRESIDENT is used to discover cancer targets for other HLA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
types, and comprises a pipeline of more than 200 prioritized cancer targets across several HLA types, and with high prevalence across multiple cancer indications. These targets encompass three
target classes: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class</B><B></B><B>&nbsp;1:</B> Well-known and characterized parent protein, for which we believe we can uniquely understand which
peptide derived from the protein sequence is truly presented on the cancer cell. Examples include ACTengine programs IMA201, IMA202, IMA203. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class</B><B></B><B>&nbsp;2:</B> Unknown or poorly characterized parent protein (e.g., COL6A3). Examples include our ACTengine program IMA204 and the
ACTolog pilot study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Class</B><B></B><B>&nbsp;3</B>: Crypto-targets including neoantigens. These are pHLA targets from novel target classes such as <FONT
STYLE="white-space:nowrap">RNA-edited</FONT> peptides, alternative or proteasomal splicing variants, short or alternative open reading frames, gene fusions, ribosomal frameshifting events and <FONT STYLE="white-space:nowrap">non-classical</FONT>
neoantigens. In addition, XPRESIDENT is also able to identify and validate classical neoantigens derived from mutational events. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure
19. Prioritization of more than 200 pHLA targets covering all known target classes. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g61i18.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">XPRESIDENT&#146;s extensive pHLA database is based on more than 2,000 primary tissue samples from 40 healthy organs and 20
major cancer indications. Following analysis of over 400,000,000 MS/MS spectra and an initial long-list of 8,000 tumor-associated pHLA targets, we have prioritized over 200 mass spectrometry validated pHLA targets covering all target classes: 1)
peptides of well-known and characterized cancer target proteins; 2) unknown or poorly characterized proteins and 3) crypto targets/neoantigens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All our
targets undergo an extensive target characterization and validation process before entering the product pipeline. RNA in situ hybridization analysis is used to demonstrate homogeneous target expression in the tumor (in case of a cancer target) or
tumor stroma (in cases of a tumor stroma target), used in ACTengine IMA204 and the ACTolog pilot trial. Cell type-specific target expression for a stroma and tumor target is shown in Figure 20. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tumor stroma cells are a key component of the tumor microenvironment, playing a crucial role in tumorigenesis, tumor progression, and metastasis as well as
therapy resistance. We believe our innovative anti-cancer approach to target tumor stroma cells opens new avenues for developing <FONT STYLE="white-space:nowrap">powerful&nbsp;TCR-based&nbsp;immunotherapies.</FONT> The combination of TCRs directed
against tumor targets with TCRs directed against stroma targets could result in a breakthrough in immunotherapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 20. Pioneering novel targets such as stroma target COL6A3 exon 6. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g63h82.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Demonstration of target-cell specific expression of a representative stroma target and tumor target in the same ovarian
cancer tissue sample using RNA in situ hybridization. Both pictures show the same image section. Red dots indicate target mRNA expression, which is highly tumor cell specific in case of a tumor target and restricted predominantly to tumor stroma
cells in case of a stroma target, COL6A3 exon 6 as example. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pipeline Targets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">The&nbsp;HLA-A*02:01&nbsp;restricted</FONT> targets for our ACTengine clinical-stage product candidates IMA201 (derived from
MAGEA4/8), IMA202 (derived from MAGEA1) and IMA203 (derived from PRAME) show specificity profiles similar to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;NY-ESO-1&nbsp;derived</FONT></FONT> peptide, which is a target that
has been used in several <FONT STYLE="white-space:nowrap">clinical&nbsp;TCR-T&nbsp;trials</FONT> showing promising results (e.g. NCT00670748, NCT01352286, NCT01343043). This means that our targets have been detected with high frequency on several
cancer types, but have been detected to a much lower extent, or not at all, on normal tissue. However, the targets selected for our drug development programs have significantly higher peptide copy numbers <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">than&nbsp;NY-ESO-1,&nbsp;making</FONT></FONT> them potentially even more promising targets for immunotherapy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table 4. Comparison of our frontrunner targets to clinically
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">validated&nbsp;NY-ESO-1.</FONT></FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>NY-ESO-l</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>MAGEA4/A8</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>MAGEA1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>PRAME</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>COL6A3&nbsp;exon&nbsp;6</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Cancer/<BR>testis<BR>antigen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Cancer/<BR>testis<BR>antigen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Cancer/<BR>testis<BR>antigen</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">IMA201</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">IMA202</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">IMA203</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">IMA204</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">IMA301</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">IMA401</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">IMA402</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Naturally presented</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes<SUP STYLE="font-size:85%; vertical-align:top">1</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Yes<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Specificity Class<SUP STYLE="font-size:85%; vertical-align:top">3</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Copy number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">10-50</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">100-1,000</FONT><SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">50-900</FONT><SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">100-1,000</FONT><SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">100-700</FONT><SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">100-1,000</FONT><SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">100&middot;1.000<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">100-1,000</FONT><SUP STYLE="font-size:85%; vertical-align:top">2</SUP></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table compares specificity and copy number of our pipeline targets with clinically <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">validated&nbsp;NY-ESO-1.&nbsp;Our</FONT></FONT> ACTengine clinical stage product candidates IMA20, IMA202, and IMA203 show specificity profiles similar to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;NY-ESO-1&nbsp;derived</FONT></FONT> peptide while having significantly higher copy numbers
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">than&nbsp;NY-ESO-1.</FONT></FONT><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;1</SUP>Natural </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
presentation of this peptide has been validated by clinical data,<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;2</SUP>Validated by XPRESIDENT mass spectrometry. Target peptide copy numbers
per cell were determined by AbsQuant technology,<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;3</SUP>Internal specificity categorization used by us. Specificity class 1: peptide not routinely found on any normal tissue; no relevant RNA
expression detected on critical organs, Specificity class 2: peptide showing a large therapeutic window with rare detections on normal tissue and low RNA expression on critical organs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 21. Our mass spectrometry validated ACTengine targets. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g68a44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Peptide presentation profile<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;for our ACTengine clinical
frontrunner targets MAGEA4/8 (IMA201), MAGEA1 (IMA202), PRAME (IMA203) (as submitted with the IND application) and the preclinical program COL6A3 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(IMA204, status March&nbsp;25, 2020) based on XPRESIDENT mass <FONT STYLE="white-space:nowrap">spectrometry&nbsp;(LC-MS/MS)&nbsp;data.</FONT> AML: acute myeloid leukemia; CCC: cholangiocellular
carcinoma; CLL: chronic lymphocytic leukemia; GEJC: gastro-esophageal junction cancer; HCC: hepatocellular carcinoma; HNSCC: head and neck squamous cell carcinoma; <FONT STYLE="white-space:nowrap">NHL:&nbsp;non-Hodgkin&nbsp;lymphoma;</FONT> <FONT
STYLE="white-space:nowrap">NSCLCadeno:&nbsp;non-small&nbsp;cell</FONT> lung cancer adenocarcinoma; NSCLCother: NSCLC samples that could not unambiguously be assigned to NSCLCadeno or NSCLCsquam; NSCLCsquam: squamous
<FONT STYLE="white-space:nowrap">cell&nbsp;non-small&nbsp;cell</FONT> lung cancer; SCLC: small cell lung cancer; UBC: urinary bladder carcinoma; UEC: uterine and endometrial cancer.<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;1</SUP>Please
note that such profiles are indicative of tumor selectivity but are not sufficient to establish safety. To establish safety of a novel pHLA target, additional data is gathered from further<I>&nbsp;in vitro</I>&nbsp;experiments and clinical trials.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Proprietary Immunoinformatics Platform for Target Discovery and Validation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to leverage the wealth of XPRESIDENT data, we have developed a comprehensive, proprietary immunoinformatics platform that integrates three interacting
engines for all bioinformatics needs &#150; computing, database and analytics &#151; to pioneer next-generation immunotherapies (Figure 22). The Computing engine is optimized for standardized and automated data processing of mass spectrometry and
next-generation sequencing data. We overcome the inherent challenges of immunopeptidomics by tailored pipeline and algorithm development, and ensure software validation by thorough benchmarks and testing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The XPRESIDENT Database engine combines a data <FONT STYLE="white-space:nowrap">warehouse&nbsp;back-end&nbsp;with</FONT>
<FONT STYLE="white-space:nowrap">a&nbsp;web-based&nbsp;user</FONT> interface <FONT STYLE="white-space:nowrap">front-end.</FONT> The data warehouse integrates all XPRESIDENT associated data, whether small or big data. The user interface provides
unified and central access for knowledge discovery, providing interactive visualization, crosslinks between information and data provenance down to the raw data level. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The data warehouse also serves as base for the proprietary Analytics engine, which is a collection of predictive models based on statistical modelling and
machine learning. We achieve effective artificial intelligence (&#147;<I></I>AI<I></I>&#148;) machine learning by the power of XPRESIDENT&#146;s data in comprehensiveness, breadth, depth and standardization, as well as from the incorporation of
domain knowledge in immunopeptidomics. With the models currently used, we are capable of automating quality control and target prioritization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Figure
22. Our immunoinformatics platform combines all required key features to serve target discovery and validation. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g71d99.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our proprietary immunoinformatics platform combines three engines &#151; computing, database and analytics
to serve every bioinformatics need in an optimized and integrated fashion. The platform is powered by XPRESIDENT data from biobanking, sample preparation, mass spectrometry and peptide synthesis to enable target discovery, validation and toxicity
assessment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Extensive Database for Pioneering Novel Target Classes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">XPRESIDENT is one of the largest pHLA target databases in the industry, comprising more than 400&nbsp;million MS/MS fragment spectra, millions of peptide
sequences and quantitative information on tissue presentation. This database also enables the discovery of crypto targets not derived from the canonical human proteome <FONT STYLE="white-space:nowrap">(e.g.&nbsp;RNA-edited&nbsp;peptides,</FONT>
alternative or proteasomal splicing variants, short or alternative open reading frames, gene fusions, ribosomal frameshifting events <FONT STYLE="white-space:nowrap">and&nbsp;non-classical&nbsp;neoantigens</FONT> &#151; described as class 3 targets
in the previous chapter). This novel type of target is only visible directly at the pHLA level and not on mRNA level, based on exclusive detection on tumor but not, or to a far lower amount, on normal tissues. We believe that the wealth of data
contained in XPRESIDENT database provides an ideal basis for the detection of crypto targets and also facilitates deeper characterization, such as for quantitative information and other characteristics, revealing the full potential of all types of
pHLA targets for immunotherapy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Artificial Intelligence Guided Epitope Prediction for Personalized Immunotherapies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We prefer direct elution from native tumor and normal tissues and sequencing of pHLA targets by mass spectrometry over<I>&nbsp;in silico</I>&nbsp;prediction of
such pHLA targets which is common in the industry. Such current algorithms frequently predict targets that are often false positives and do not truly exist on patients&#146; cancer cells. Thus, based on our assessment, current<I>&nbsp;in
silico</I>&nbsp;approaches &#151; unless combined with extended target validation confirming the natural presentation of the investigated targets &#151; are insufficient to move into clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, we believe that XPRESIDENT may be the best basis to develop a suitable<I>&nbsp;in silico</I>&nbsp;prediction algorithm with a minimal false-positive
rate. &#147;Big data&#148; is necessary for development of such reliable predictive models by machine learning (<I>e.g.</I>, deep learning). We have created one of the largest (if not the largest) HLA peptidome dataset, which allows us to develop
artificial intelligence algorithms designed for evidence based, personalized immunotherapies and precision medicine. Several other immunopeptidomics datasets have also triggered attempts to predict HLA targets. However, due to the complexity of the
HLA repertoire, confounding factors and variation between patients and organs, only large databases enable accurate predictions. Our database is based on native tissues, where other approaches rely on artificial cell lines. With our extensive and
continuously growing tissue bank of thousands of real cancer and normal tissues and the resulting XPRESIDENT pHLA target database, covering more than 130 HLA allotypes, we have a competitive advantage compared to other artificial intelligence
approaches (Figure 23). Moreover, we have acquired and will continue to acquire additional complementary data on mRNA expression, genomics and proteomics from the same tissue specimens. XPRESIDENT&#146;s dataset, in combination with our Analytics
engine, allows generation of statistical and AI models that elucidate the antigen processing machinery. Current statistical models underlying IMADetect already enable personalized target selection. These current capabilities combined with the future
models using XPRESIDENT data ideally position us to develop and continuously improve statistical <FONT STYLE="white-space:nowrap">and&nbsp;AI-based&nbsp;models</FONT> and advance pHLA target prediction. We believe this provides the basis for full
antigenic profiling and target selection of an individual tumor of an individual patient for ultra-personalized immunotherapies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 23. Our competitive advantage based on the wealth of our immunopeptidome database.
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g74f39.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With our extensive dataset of more than 2,000 real primary tissues covering more than 130 HLA allotypes, we have a
competitive advantage compared to other artificial intelligence approaches that are primarily based on artificial cell lines. Our extensive immunopeptidome database provides a competitive advantage for artificial intelligence and the development of
improved AI algorithms for highly personalized immunotherapies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Translation to Clinical Use &#151; Companion Diagnostic IMADetect </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">XPRESIDENT&nbsp;know-how&nbsp;can</FONT> also be translated to clinical application for&nbsp;decision-making&nbsp;and
personalized target selection for cancer patients. XPRESIDENT-based analysis of correlation between peptide presentation and expression of the peptide-encoding exon(s) allows for the definition of mRNA-based thresholds that are designed to be
predictive of presence of the target peptide on the tumor. Based on this expertise, we are developing the companion diagnostic IMADetect to define target peptide positive patient populations and their inclusion into our clinical trials. IMADetect is
a reverse transcription quantitative PCR <FONT STYLE="white-space:nowrap">(&#147;RT-qPCR&#148;)</FONT> based biomarker assay that enables treatment decisions based on presence of the drug target in the tumor, implementing precision medicine for
cancer immunotherapies. The assay is currently performed for the clinical trials in <FONT STYLE="white-space:nowrap">our&nbsp;in-house&nbsp;CLIA-certified</FONT> <FONT STYLE="white-space:nowrap">and&nbsp;CAP-accredited&nbsp;laboratory</FONT> at our
R&amp;D facilities in Houston, Texas, and will be further developed as companion diagnostics for our drug products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interaction between XPRESIDENT and
XCEPTOR Technology Platforms for the Development of TCRs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Apart from identifying cancer targets, XPRESIDENT also significantly contributes to our TCR
discovery and engineering platform XCEPTOR. The extensive information available on the HLA peptidome in normal tissues is specifically useful for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">guiding&nbsp;on-and&nbsp;off-target&nbsp;toxicity</FONT></FONT> screenings by determining which peptides potentially cross-recognized by a TCR are actually presented on normal tissues
which is of relevance and importance to safety. The information of <FONT STYLE="white-space:nowrap">relevant&nbsp;off-target&nbsp;peptides</FONT> can also be utilized to guide TCR engineering and affinity maturation for TCR Bispecifics. Absolute
target copy numbers determined on tumor cell lines or tissue samples from animal models in relation to copy numbers on primary tumor tissues are an essential piece of information for designing relevant models for TCR efficacy testing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>D<SMALL>ISCOVERY</SMALL>, E<SMALL>NGINEERING</SMALL>&nbsp;&amp;
V<SMALL>ALIDATION</SMALL>&nbsp;<SMALL>OF</SMALL>&nbsp;R<SMALL>IGHT</SMALL>&nbsp;TCRS&nbsp;&#151; XCEPTOR </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TCRs naturally recognize <FONT
STYLE="white-space:nowrap">human&nbsp;HLA-bound&nbsp;peptides</FONT> (&#147;pHLA targets&#148;) derived from foreign and endogenous proteins, regardless of their extracellular or intracellular localization. We have established XCEPTOR, a
next-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generation technology platform designed to discover, engineer and validate TCRs. The process comprises the discovery and selection of highly specific parental, membrane-bound TCRs with optional
engineering (e.g. chain pairing enhancement, engineering towards CD8 independency) to serve ACT modalities, and further engineering via affinity-maturation for TCR Bispecifics. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Many unique TCRs are identified for each target in a high throughput approach and for several targets in
parallel. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Multiple TCR sources are used for each target, such as blood cells from many different <FONT
STYLE="white-space:nowrap">HLA-matched</FONT> and <FONT STYLE="white-space:nowrap">HLA-mismatched</FONT> donors or patients. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">TCRs are <FONT STYLE="white-space:nowrap">re-expressed</FONT> in human donor cells, extensively screened in vitro
(e.g. testing of killing of tumor cell lines vs normal cells to establish a therapeutic window) and qualified as candidates for Adoptive Cell Therapies or TCR Bispecifics. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Information exchange with the XPRESIDENT platform throughout TCR identification and candidate screening ensures
selection of specific and potent TCRs, e.g. by providing information on <FONT STYLE="white-space:nowrap">TCR-motif</FONT> and target similar peptide expression on healthy tissue, or calibrated tumor cell lines with physiological target levels as
screening tool. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Qualified TCRs are subject to further engineering, including affinity maturation, engineering towards CD8
independency or chain pairing enhancement, if needed. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 24. Key principles of our proprietary XCEPTOR platform
for development of the right TCR. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g77s47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our proprietary XCEPTOR technology platform is designed to allow the fast and efficient discovery of a multitude of TCRs
with high affinity and high specificity, which optionally can be engineered and enhanced. TCR identification and engineering is guided by XPRESIDENT to serve development of product candidates for Adoptive Cell Therapy (ACTengine, ACTallo) and TCR
Bispecifics (TCER). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We <FONT STYLE="white-space:nowrap">use&nbsp;HLA-matched&nbsp;and</FONT> mismatched human donors as starting material for TCR
discovery, both from healthy donors and patients. A large number of unique, fully human TCR sequences per target are identified at single cell level, characterized in a transient
<FONT STYLE="white-space:nowrap">human&nbsp;re-expression&nbsp;system</FONT> and selected based on functional avidity measurements, specificity screening with target similar peptides expressed on normal tissue (XPRESIDENT database) and TCR binding
motif determination by guided positional scanning. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suitable candidates for Adoptive Cell Therapies are selected based on<I>&nbsp;in
vitro</I><I></I>&nbsp;specificity and efficacy screenings, including human tumor cell lines expressing the respective target at physiological levels (AbsQuant), target-negative cell lines and primary healthy cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Optionally, those fully human membrane-bound TCRs can be optimized by engineering, either<I>&nbsp;in silico</I>&nbsp;or using yeast display. For the majority
of targets, lead TCRs with low to single digit micromolar affinity are identified from the natural human repertoire, and we may choose to moderately enhance the TCR affinity for Adoptive Cell Therapies. Additionally, engineering to address
alpha/beta chain pairing and CD8 independency is pursued as an additional approach. For preclinical validation, TCR candidates for ACT are subsequently expressed as lentiviral constructs and further tested for potency and tolerability, again making
use of calibrated target cell lines (AbsQuant) to validate that the chosen TCR can recognize physiological target levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For bispecific immunotherapies,
TCRs are converted into stable high affinity scTvs (single-chain TCR variable fragments) using yeast display, serving as building blocks for the generation of bispecific T cell engaging receptor molecules (TCER). Affinity maturation includes
counterselection with target similar peptides <FONT STYLE="white-space:nowrap">(potential&nbsp;&#147;off-targets&#148;),&nbsp;resulting</FONT> in TCR binding domains with strongly augmented binding towards the
<FONT STYLE="white-space:nowrap">target&nbsp;peptide-HLA&nbsp;while</FONT> retaining high specificity. Together with a T cell recruiting domain, scTVs are incorporated in our proprietary TCER format that comprises extended half-life and
antibody-like stability and manufacturability characteristics (see &#147;<I> &#151;TCR Bispecifics &#151; TCER</I>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The entire TCR selection
process is accompanied by input from the XPRESIDENT database, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">guiding&nbsp;on-and&nbsp;off-target&nbsp;toxicity</FONT></FONT> screenings as well as potency evaluation, including by
providing absolute target-copy numbers on primary human tumor tissue in relation to pHLA copy numbers found on human tumor cell lines or healthy tissue. <FONT STYLE="white-space:nowrap">Testing&nbsp;TCR-mediated&nbsp;killing</FONT> of tumor cell
lines with defined target pHLA copies versus normal cells allows for the determination of therapeutic windows. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 25. Preclinical
anti-tumor activity of our TCRs. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>U20S tumor line &#151; 240 target copies</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>A375 tumor line &#151; 50 target copies</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g96389g81b24.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g96389g84h47.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exemplary data for XPRESIDENT-guided determination of potency for a naturally occurring (WT TCR) and an engineered, enhanced
TCR (Enhanced TCR). Physiological target copy numbers for the respective target range <FONT STYLE="white-space:nowrap">from&nbsp;100-1,000&nbsp;copies</FONT> per cell. TCRs mediate reduction in tumor growth and tumor cell killing of A375 (50 copies/
cell) and U2OS tumor cells (240 copies/ cell). The engineered and enhanced TCR is active<I>&nbsp;in vitro</I>&nbsp;down <FONT STYLE="white-space:nowrap">to&nbsp;sub-physiological&nbsp;copy</FONT> numbers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In summary, our XCEPTOR platform enables fast and efficient discovery, engineering and validation of a large number of high-affinity and highly specific
natural TCRs that can be used for Adoptive Cell Therapies, such as ACTengine, ACTallo and TCR Bispecifics. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>M<SMALL>ANUFACTURING</SMALL>&nbsp;<SMALL>AND</SMALL>&nbsp;S<SMALL>UPPLY</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ACT drug products are manufactured by our own employees who are cGMP-trained within The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory at
UTHealth (&#147;UTH&#148;) McGovern Medical School (the &#147;Griffin Facility&#148;) in Houston, Texas through a multi-year collaboration between us and UTHealth. The Griffin Facility is part of the Cellular Therapy Core (&#147;CTC&#148;) at
UTHealth and is an 1,850 square <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">foot&nbsp;state-of-the-art&nbsp;multiple</FONT></FONT></FONT> ISO 7 class 10,000 Human Cell Processing cGMP Facility.
UTHealth procures the necessary supplies and reagents for cGMP manufacturing ACT products based on our requests. These supplies and reagents are purchased from qualified vendors specialized in supplying cGMP grade reagents for the cell and gene
therapy industry and approved by UTHealth management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The UTHealth facility is FDA registered to produce cells and tissues for clinical applications in
compliance with cGMP and has received accreditation by the Foundation for Accreditation of Cellular Therapy (&#147;FACT&#148;) in January 2016 which was renewed in 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have exclusive access to three cGMP suites and support areas for the manufacturing of various ACT products. Facility operation/maintenance, supply
procurement/release <FONT STYLE="white-space:nowrap">and&nbsp;co-release&nbsp;of</FONT> final drug product is performed by UTHealth, while our trained personnel carry out the manufacturing
<FONT STYLE="white-space:nowrap">and&nbsp;in-process&nbsp;controls.</FONT> In addition, we have contractual agreements in place with two suppliers of lentiviral vectors which is the most critical raw material for the manufacturing of genetically
modified T cells products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For pivotal trials, we plan to sign agreements with one or multiple CMOs for cellular manufacturing with dedicated access to
multiple cGMP suites and trained personnel. We are in the process of obtaining proposals from multiple CMOs for manufacturing of ACT products beyond Phase 1 or once clinical proof of concept has been established. Similarly, we are in the process of
pursuing commercial supply agreements with raw material vendors ahead of pivotal trials and commercial manufacturing, especially for the lentiviral vector supply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our TCR Bispecifics are expressed in mammalian cells. We have established a laboratory scale production process to generate R&amp;D material suitable for
compound characterization and early preclinical assessments. In the course of preclinical development, the process is transferred to and further developed by CMOs. Our CMOs are experienced in cGMP manufacturing of biologics and regulatory compliance
for these processes. The IND enabling studies (e.g.,<I>&nbsp;in vitro</I><I></I>&nbsp;toxicology studies) are performed with material which we receive from CMOs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The manufacturing phase at CMOs includes cell line development, establishment of master- and working cell banks, upstream and downstream process development,
formulation development, development of suitable analytical methods for testing and release, cGMP manufacturing for clinical supplies, fill and finish, drug substance and drug product release testing, storage and stability testing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">An&nbsp;in-house&nbsp;chemistry,</FONT> manufacturing and control (&#147;CMC&#148;) team guides and manages the processes at
our CMOs through the different stages. Before and during the cooperation with a contract manufacturer we conduct audits to control compliance with the mutually agreed process descriptions and to cGMP regulations. Our manufacturers themselves are
controlled by <FONT STYLE="white-space:nowrap">their&nbsp;in-house&nbsp;quality</FONT> assurance functions and inspected by regulatory agencies, including European national agencies and the FDA. During the development of TCER candidates, our
contract manufacturers may need to modify or scale the manufacturing process to suitable size. Potentially, the drug formulation or other parameters may be changed. Such modifications may require a renewed qualification of the manufacturing process
with the relevant authorities. In addition to the currently contracted CMOs, we expect to engage with additional third-party manufacturers to support potential pivotal trials and potential commercial supplies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MARKETING&nbsp;AND&nbsp;SALES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently do not have
our own marketing, sales or distribution capabilities. In order to commercialize any future product candidate, if approved for commercial sale, it is our current plan to develop a sales and marketing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
infrastructure. We may opportunistically seek strategic collaborations to maximize the commercial opportunities for our future product candidates inside and outside the United States. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COMPETITION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immunotherapy and the companies and academic
groups <FONT STYLE="white-space:nowrap">using&nbsp;TCR-based&nbsp;approaches</FONT> against cancer are rapidly evolving. While we believe that our technology platforms, therapeutic modalities and scientific knowledge provide us with a competitive
advantage, we also face significant competition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other pharmaceutical and biotechnology companies are active in the field of TCR therapies, with the goal
to target solid tumors following the success <FONT STYLE="white-space:nowrap">of&nbsp;CAR-T&nbsp;therapies</FONT> in hematology. Companies developing other immunotherapies such <FONT STYLE="white-space:nowrap">as&nbsp;CAR-T,&nbsp;bispecific</FONT>
antibodies or immune checkpoint inhibitors, may show that their products applied alone or in combination may demonstrate significant improvement in efficacy and compete with our approach and candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become
available in the future. Our competitors fall primarily into the following groups, depending on their treatment approach: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Academic institutions as well as industry competitors (including Adaptimmune, Gritstone, Immunocore, Adaptive
Biotechnologies, pureMHC, BioNTech, and Genentech) are also seeking to identify HLA targets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adaptimmune, Immunocore, <FONT STYLE="white-space:nowrap">T-Knife,</FONT> Adaptive Biotechnologies, 3T
Biosciences, Medigene, Regeneron, Gilead, Bluebird Bio, Agentus and possibly others are also working on <FONT STYLE="white-space:nowrap">TCR-based</FONT> approaches. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Takara Bio Inc., Kite Gilead, Tmunity, Cell Medica, BMS, GSK, Adaptimmune, Bluebird Bio, Medigene and Bellicum,
in addition to various academic institutions and possibly industry competitors, are investigating novel autologous <FONT STYLE="white-space:nowrap">TCR-T</FONT> therapeutics. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Several companies, including Takeda Bio Inc., Adaptimmune, Bluebird Bio and Medigene, are developing <FONT
STYLE="white-space:nowrap">TCR-T</FONT> programs to the same proteins, although possibly not the same peptide targets, as utilized in our ACTengine pipeline. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Allogene, Celyad, CRISPR Therapeutics, Fate Therapeutics, Intellia Therapeutics, Precision Biosciences, Sangamo
Therapeutics, Cellectis, TC Biopharm and Adicet Bio, and possible others, are developing allogeneic cell therapies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Companies such as Immunocore, Amgen, Genmab and MorphoSys are developing TCR Bispecific compounds or TCR mimetic
antibodies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Marker Therapeutics, Achilles and Neximmune, and possibly others, are developing multi-target immunotherapies to
pHLA targets. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The availability of reimbursement from government and other third-party payors will also significantly affect the pricing
and competitiveness of our products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than us, which might result in competitors establishing a strong market position before we are able to enter the
market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development,
manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than us. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These competitors also compete in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well
as in acquiring technologies complementary to, or necessary for, our programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>INTELLECTUAL&nbsp;PROPERTY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a robust intellectual property portfolio which includes a large number of patents in many commercially significant jurisdictions worldwide. Our patent
portfolio is a strategically important asset. As of January&nbsp;27, 2020, the portfolio contains over 3,000 active worldwide patent applications and more than 100 active patent families. Our patent application portfolio is diverse and covers a
large number of cancer antigen targets, T cell receptors, <FONT STYLE="white-space:nowrap">antibodies,&nbsp;bi-specific&nbsp;molecules,</FONT> and antigen discovery platforms. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As of January&nbsp;27, 2020, we had secured over 1,550 world-wide patents, including 239 U.S. patents. Of the
239 granted U.S. patents, a total of 198 U.S. patents have been issued since 2017. We plan to continue to expand our U.S. patent portfolio by filing new patent applications as well as filing continuation and divisional applications of pending U.S.
applications. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We recognize the need for a global intellectual property strategy in order to protect future products and
assets around the world. As a result, we file patent applications with an aim of protecting our technology throughout many commercially relevant jurisdictions, such as Europe, the United States, Canada, Brazil, China, Japan, South Korea, Argentina,
Russia, Australia, New Zealand, Singapore, Vietnam, Thailand, Indonesia, Mexico, Taiwan and the Gulf states. For applications deemed to be of highest commercial importance to us, filing may take place in more than 50 countries.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Patent coverage for our product candidates, encompassing proprietary cancer antigens, TCRs, TCER and
antibodies, includes the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One issued patent in the U.S. and 34 pending applications in Argentina, Australia, Brazil, Canada, Chile, China,
Columbia, Costa Rica, Algeria, Eurasia, Egypt, Europe, Hong Kong, Indonesia, Israel, India, Japan, South Korea, Morocco, Mexico, Malaysia, New Zealand, Peru, Philippines, Singapore, Thailand, Taiwan, the Ukraine, the U.S., Vietnam and South Africa
relate to IMA201 (MAGEA4/8). These patents and applications are expected to expire on March&nbsp;16, 2037. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No issued patent in and 34 pending applications in Argentina, Australia, Brazil, Canada, Chile, China, Columbia,
Costa Rica, Germany, Algeria, Eurasia, Egypt, Europe, Gulf Cooperation Council, Hong Kong, Indonesia, Israel, India, Japan, South Korea, Morocco, Mexico, Malaysia, New Zealand, Peru, Philippines, Singapore, Thailand, Taiwan, the Ukraine, the U.S.,
Vietnam and South Africa relate to IMA202 (MAGEA1). These patents and applications are expected to expire on December&nbsp;7, 2037. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One issued patent in the U.S. and 33 pending applications in Argentina, Australia, Brazil, Canada, Chile, China,
Columbia, Costa Rica, Germany, Algeria, Eurasia, Egypt, Europe, Gulf Cooperation Council, Hong Kong, Indonesia, Israel, India, Japan, South Korea, Morocco, Mexico, Malaysia, New Zealand, Peru, Philippines, Singapore, Thailand, Taiwan, the Ukraine,
the U.S., Vietnam and South Africa relate to IMA203 (PRAME). These patents and applications are expected to expire on March&nbsp;28, 2038. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Two issued patents in the U.S. and 35 pending applications in Argentina, Australia, Brazil, Canada, Chile, China,
Columbia, Costa Rica, Germany, Algeria, Eurasia, Egypt, Europe, Hong Kong, Indonesia, Israel, India, Japan, South Korea, Morocco, Mexico, Malaysia, New Zealand, Peru, Philippines, Singapore, Thailand, Taiwan, the Ukraine, the U.S., Vietnam and South
Africa relate to IMA204 (COL6A3 exon 6). These patents and applications are expected to expire July&nbsp;4, 2037. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One issued patent in the U.S. and 36 pending applications in Argentina, Australia, Brazil, Canada, Chile, China,
Columbia, Costa Rica, Germany, Algeria, Eurasia, Egypt, Europe, Gulf Cooperation Council, Hong Kong, Indonesia, Israel, India, Japan, South Korea, Morocco, Mexico, Malaysia, New Zealand, Peru, Philippines, Singapore, Thailand, Taiwan, the Ukraine,
the U.S., Vietnam, South Africa and PCT IMA301 (Cancer testis antigen). These patents and applications are expected to expire between March&nbsp;16, 2037 and March&nbsp;17, 2040. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One issued patent in the U.S. and 36 pending applications in Argentina, Australia, Brazil, Canada, Chile, China,
Columbia, Costa Rica, Algeria, Eurasia, Egypt, Europe, Hong Kong, Indonesia, Israel, India, Japan, South Korea, Morocco, Mexico, Malaysia, New Zealand, Peru, Philippines, Singapore, Thailand, Taiwan, the Ukraine, the U.S., Vietnam and South Africa
relate to IMA401 (Cancer testis antigen). These patents and applications are expected to expire between March&nbsp;16, 2037 and September&nbsp;25, 2040. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are currently devising an application covering the clinical candidates for IMA402. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In addition to patent coverage for our proprietary cancer antigens, TCRs, TCER and antibodies, we seek
protection for aspects of our ACT protocols via patent filings. To this end, our subsidiary, Immatics US, has filed eleven patent families. These patent applications are predominantly focused on securing claims to ACT methods, cell populations, and
other immunotherapy methodologies, and are expected to expire between November&nbsp;26, 2038 and March&nbsp;11, 2041. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">e.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We also place an emphasis on protecting our expanding brand recognition by filing and registering Trademark
applications throughout the world. We are the owner of 23 different Trademarks most of which are registered or have been allowed, in multiple countries and classes. Prominent Trademarks are, for example, XPRESIDENT, TCER, ACTallo, ACTengine, ACTolog
and Immatics. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>COLLABORATIONS&nbsp;AND&nbsp;OTHER&nbsp;AGREEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g85r44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have forged strategic collaborations with biotech and pharmaceutical companies as well as academic research
institutions. Key collaborations include: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>MD Anderson Cancer Center </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2015, we and&nbsp;MD Anderson Cancer Center&nbsp;(&#147;MD Anderson&#148;) announced the launch of Immatics US to develop multiple T cell <FONT
STYLE="white-space:nowrap">and&nbsp;TCR-based&nbsp;adoptive</FONT> cellular therapies. Immatics US secured over $60&nbsp;million in total funding &#150; more than $40.0&nbsp;million from the parent company Immatics OpCo and a $19.7&nbsp;million
grant from the Cancer Prevention and Research Institute of Texas (&#147;CPRIT&#148;) and entered into several agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Collaboration and
License Agreement, MD Anderson and Immatics US will conduct work pursuant to agreed research plans to develop (i)&nbsp;ACTolog IMA101 and (ii)&nbsp;ACTengine IMA201, 202, 203 and 204 products </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in certain cancer indications. Immatics US will fund all activities by MD Anderson under the research plans. Immatics US owns all intellectual property resulting from or directly related to the
work conducted under the research plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, pursuant to several license agreements MD Anderson granted Immatics US access and rights to certain of
its IL21, CD25 and K562 technologies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>GlaxoSmithKline </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, we entered into a strategic collaboration agreement with&nbsp;GlaxoSmithKline&nbsp;(&#147;GSK&#148;) to develop novel adoptive cell therapies
targeting multiple cancer indications with a focus on solid tumors. Under the agreement, we and GSK are collaborating on the identification, research and development of next-generation TCR Therapeutics and will initially develop autologous T cell
therapies with GSK having an option to add allogeneic cell therapies using our ACTallo approach. We will utilize proprietary TCRs identified by our XCEPTOR and directed against two proprietary targets, discovered and validated by our XPRESIDENT with
the primary responsibility for the development and validation of the TCR Therapeutics up to designation of a clinical candidate. GSK will then assume sole responsibility for further worldwide development, manufacturing and commercialization of the
TCR Therapeutics with the possibility for us <FONT STYLE="white-space:nowrap">to&nbsp;co-develop&nbsp;one</FONT> or more TCR Therapeutics including the conduct of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial upon GSK&#146;s request. GSK also obtained an option to select additional target programs to include in the collaboration. For each
additional program, we are entitled to predetermined option, milestone and royalty payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, we received an upfront
payment of &#128;45&nbsp;million for two initial programs and are eligible to receive additional development, regulatory and sales milestones up to $575&nbsp;million, respectively, as well as additional royalties on net sales for each licensed
product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Bristol-Myers Squibb </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and Celgene
Corporation, a Bristol-Myers Squibb Company (&#147;BMS&#148;), entered into a strategic collaboration and license agreement in August 2019 to develop novel adoptive cell therapies targeting multiple cancers. Under the agreement, we may <FONT
STYLE="white-space:nowrap">develop&nbsp;TCR-T&nbsp;programs</FONT> against solid tumor targets discovered with our XPRESIDENT technology. We will utilize proprietary TCRs identified by our XCEPTOR TCR discovery and engineering platform. We will be
responsible for the development and validation of these programs through the lead candidate stage, at which time BMS may exercise <FONT STYLE="white-space:nowrap">its&nbsp;opt-in&nbsp;right</FONT> to exclusively license one or more programs, thereby
assuming sole responsibility for further worldwide development, manufacturing and commercialization of <FONT STYLE="white-space:nowrap">the&nbsp;TCR-T&nbsp;cell</FONT> therapies. We retain certain early <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">stage&nbsp;co-development&nbsp;and&nbsp;co-funding&nbsp;rights</FONT></FONT> for <FONT STYLE="white-space:nowrap">selected&nbsp;TCR-T&nbsp;cell</FONT> therapies arising from the collaboration. BMS has the option to
exclusively license up to two additional targets to expand the collaboration at predetermined economics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, we received an
upfront payment of $75&nbsp;million for three programs and are eligible to receive additional regulatory and sales milestones in aggregate amounts of up to $190&nbsp;million, and $300&nbsp;million, respectively, as well as tiered royalties based on
net sales for each licensed product at percentages ranging from high single digits to teens, subject to customary reductions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Genmab </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2018, we and Genmab entered into a research collaboration and license agreement to develop next-generation, T cell engaging bispecific immunotherapies
targeting multiple cancer indications. Under the agreement, we are conducting joint research, funded by Genmab, and combining XPRESIDENT, XCEPTOR and TCER technology platforms with Genmab&#146;s proprietary antibody technologies to develop multiple
bispecific immunotherapies in oncology. Both we and Genmab are exclusively discovering and developing immunotherapies directed against three proprietary targets, discovered and developed by our XPRESIDENT
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
platform. Genmab is responsible for development, manufacturing and worldwide commercialization. We retain an option to contribute certain promotion efforts at predetermined levels in selected
countries in the EU. Genmab has the option to exclusively license up to two additional targets to expand the collaboration at predetermined economics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, we received an upfront fee of $54&nbsp;million and is eligible to receive additional development, regulatory and commercial
milestone payments, totaling $550&nbsp;million, for each licensed product resulting from the collaboration In addition, we are eligible to receive tiered royalties on net sales for each licensed product at up to double-digit percentages. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amgen </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since December 2016, Amgen and us have been
developing next-generation, T cell engaging bispecific immunotherapies targeting multiple cancers under the research collaboration and exclusive license agreement. The collaboration combines our XPRESIDENT and XCEPTOR technology platforms with
Amgen&#146;s validated<I>&nbsp;BiTE</I>( Bispecific T cell Engager) technology. Amgen is responsible for the clinical development, manufacturing and commercialization worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, we received
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;non-refundable,&nbsp;non-creditable&nbsp;upfront</FONT></FONT> fee of $30&nbsp;million and are eligible to receive additional development, regulatory and commercial milestone
payments in aggregate amounts of up to $525&nbsp;million, respectively, as well as tiered royalties on net sales for each licensed product at percentages ranging from high-single digits to low teens subject to customary reductions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>MorphoSys </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2015, we announced a strategic
alliance with MorphoSys, a German company in the field of immuno-oncology. The alliance was formed to develop novel antibody-based therapies against a variety of cancer antigens that are recognized by T cells. The alliance agreement gives MorphoSys
access to several of our proprietary tumor-associated peptides and, in return, we receive the right to develop MorphoSys&#146;s Ylanthia antibodies against several tumor-associated peptides. The companies will pay each other milestone payments and
royalties on commercialized products based on the companies&#146; development progress. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Roche </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2013, we entered into a research and clinical development collaboration with Roche focused on identification of novel and relevant XPRESIDENT
targets for cancer vaccine candidates and other immunotherapies in oncology, primarily in gastric, prostate <FONT STYLE="white-space:nowrap">and&nbsp;non-small&nbsp;cell</FONT> lung cancer indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2017, Roche exercised its option under the existing discovery, development and commercialization agreement with us to exclusively license from us
a proprietary immunotherapy target for further development and commercialization in oncology. In December 2019, Roche discontinued development of the immunotherapy product directed against the target it has exclusively licensed from us in 2017 and
delivered notice to us in February 2020 that it was terminating the collaboration, effective as of September&nbsp;30, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into a number of collaborations that are important for our ability to manufacture, supply and offer our adoptive cell therapies and TCR Bispecifics.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>UTHealth </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into a multi-year collaboration
agreement to secure exclusive access to three UTHealth cGMP suites to manufacture various ACT products within the Griffin Research Laboratory. Under the agreement, general </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
facility operations, maintenance, supply and reagents for cGMP manufacture, <FONT STYLE="white-space:nowrap">and&nbsp;co-release&nbsp;of</FONT> product is provided by UTHealth. Under the
agreement, we perform all manufacturing <FONT STYLE="white-space:nowrap">and&nbsp;in-process&nbsp;controls.</FONT> The UTHealth facility is FDA registered to produce cells and tissues for clinical applications in compliance with cGMP and has
received accreditation by the FACT in January 2016, which was renewed in 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We use several third-party contract manufacturers acting in accordance
with FDA&#146;s good laboratory practice (&#147;GLP&#148;) or cGMP, as applicable, practices for the manufacture of viral vectors and cell bank development. We generally apply second-supplier strategies to mitigate supply risks and to secure access
to manufacturing innovation and competitive supply costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For pivotal trial supply of ACT products, we plan on entering into one or more relationships
with large CMOs with dedicated access to multiple cGMP suites and trained personnel, as well as into commercial supply agreements with raw material vendors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For manufacturing and supply of TCR Bispecifics, we have contracted third party manufacturers and may enter into additional CMO relationships in the future.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>REGULATIONS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Government authorities in the United
States, at the federal, state, and local level, and in other countries and jurisdictions, including the EU, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage,
recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, as well as import and export of biological products. Some jurisdictions also regulate the pricing of medicinal products. The processes
for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Licensure and Regulation of Biologics in the United States </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, biological products, including gene therapy products, are regulated under the Public Health Service Act (&#147;PHSA&#148;) and the
Federal Food, Drug, and Cosmetic Act (&#147;FDCA&#148;), and their implementing regulations, as well as other federal, state and local statutes and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The failure of an applicant to comply with the applicable regulatory requirements at any time during the product development process, including during
testing, the approval process or post-approval process, may result in delays to the conduct of a study, regulatory review and approval, and/or administrative or judicial sanctions. Failure to comply with regulatory requirements may result in the
FDA&#146;s refusal to allow an applicant to proceed with clinical trials, refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, warning letters, product recalls, product seizures, total or partial
suspension of production or distribution, injunctions, fines, and civil or criminal investigations and penalties brought by the FDA or Department of Justice (&#147;DOJ&#148;), or other government entities, including state agencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An applicant seeking to market and distribute a new biologic in the United States generally must satisfactorily complete each of the following steps before
the product candidate will be licensed by the FDA: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preclinical testing including laboratory tests, animal studies, and formulation studies, which must be performed
in accordance with the FDA&#146;s GLP regulations, as applicable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND for human clinical testing, which must become effective before human clinical
trials may begin; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an institutional review board (&#147;IRB&#148;) representing each clinical site before each clinical
trial may be initiated; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials to establish the safety, and efficacy of the
product candidate for each proposed indication, in accordance with current good clinical practices (&#147;GCP&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation and submission to the FDA of a Biologics License Application (&#147;BLA&#148;) for a biological
product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA acceptance and substantive review of the BLA; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">review of the product candidate by an FDA advisory committee, where appropriate or if applicable;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities, including those of
third parties, at which the product candidate or components thereof are manufactured to assess compliance with cGMP requirements and to assure that the facilities, methods, and controls are adequate to preserve the product&#146;s identity, strength,
quality, and purity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of any FDA audits of clinical trial sites to assure compliance with GCP and the integrity
of clinical data in support of the BLA; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">securing FDA approval of the BLA to allow marketing of the new biological product. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preclinical Studies and Investigational New Drug Application </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before an applicant begins testing a product candidate with potential therapeutic value in humans, the product candidate enters preclinical testing.
Preclinical studies include studies to evaluate, among other things, the toxicity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements, as applicable, including GLP regulations. Some
long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and long-term toxicity studies, may continue after the IND is submitted. Additional nonclinical tests are conducted and include laboratory
evaluations of product chemistry, formulation, and stability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The IND and IRB Processes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical
trial and a request for FDA authorization to administer such investigational product to humans. Such authorization must be secured prior to interstate shipment and administration of any product candidate that is not the subject of an approved BLA.
In support of a request for an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the results of the preclinical tests, together with
manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, must be submitted to the FDA as part of an IND. The FDA requires
<FONT STYLE="white-space:nowrap">a&nbsp;30-day&nbsp;waiting</FONT> period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects
will be exposed to unreasonable health risks. At any time during <FONT STYLE="white-space:nowrap">this&nbsp;30-day&nbsp;period</FONT> the FDA may raise concerns or questions about the conduct of the trials as outlined in the IND and impose a
clinical hold or partial clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following commencement of a clinical trial, the FDA may also place a clinical hold or partial clinical hold on that trial. A clinical hold is an order issued
by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. No more than 30 days after
imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA
has notified the sponsor that the investigation may proceed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A sponsor may choose, but is not required, to conduct a foreign clinical trial under an IND. When a foreign
clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the
FDA in order to use the study as support for an IND or application for marketing approval or licensing. In particular, such studies must be conducted in accordance with GCP, including review and approval by an independent ethics committee
(&#147;IEC&#148;) and informed consent from subjects. The FDA must be able to validate the data through an onsite inspection, if deemed necessary by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that
institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must
operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements
or if the product candidate has been associated with unexpected serious harm to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some trials are overseen by an independent group of qualified
experts organized by the trial sponsor, known as a data safety monitoring board or committee (&#147;DSMB&#148;). This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the
group maintains to available data from the study. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United
States, certain human clinical trials involving recombinant or synthetic nucleic acid molecules had historically been subject to review by the Recombinant DNA Advisory Committee (&#147;RAC&#148;) of the National Institutes of Health
(&#147;NIH&#148;), Office of Biotechnology Activities (&#147;OBA&#148;), pursuant to the NIH Guidelines for Research Involving Recombinant DNA Molecules (&#147;NIH Guidelines&#148;). On August&nbsp;17, 2018, the NIH issued a notice in the Federal
Register and issued a public statement proposing changes to the oversight framework for gene therapy trials, including changes to the applicable NIH Guidelines to modify the roles and responsibilities of the RAC with respect to human clinical trials
of gene therapy products, and requesting public comment on its proposed modifications. During the public comment period, which closed October&nbsp;16, 2018, the NIH announced that it will no longer accept new human gene transfer protocols for review
as a part of the protocol registration process or convene the RAC to review individual clinical protocols. In April 2019, NIH announced the updated guidelines, which reflect these proposed changes, and clarified that these trials will remain subject
to the FDA&#146;s oversight and other clinical trial regulations, and oversight at the local level will continue as set forth in the NIH Guidelines. Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes
evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any
potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question being conducted at or sponsored by
institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Trials in Support of a BLA </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials
involve the administration of the investigational product candidate to human subjects under the supervision of a qualified investigator in accordance with GCP requirements which include, among other things, the requirement that all research subjects
provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written clinical trial protocols detailing, among other things, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness and safety criteria to be evaluated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Human clinical trials are typically conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may also be required
after licensing. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1 clinical trials are initially conducted in a limited population to test the product candidate for safety,
including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion, and pharmacodynamics in healthy humans or in patients. During Phase 1 clinical trials, information about the investigational biological product&#146;s
pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2 clinical trials are generally conducted in a limited patient population to identify possible adverse
effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications, and determine dose tolerance and optimal dosage. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide
substantial evidence of clinical efficacy, and further test for safety. A well-controlled, statistically robust Phase 3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to license, and, if
licensed, how to appropriately label a biologic. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While the FDA requires in most cases two adequate and well-controlled pivotal clinical
trials to demonstrate the efficacy of a product candidate, a single trial with strong confirmatory evidence may be sufficient in instances where the trial is a large multicenter trial demonstrating internal consistency and a statistically very
persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible. In
rare cancer indications with very limited treatment options a large and/or controlled trial are often not feasible and thus data from smaller and even uncontrolled trials may be sufficient for regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may approve a BLA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product
candidate&#146;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of a larger number of patients in the
intended treatment group and to further document a clinical benefit in the case of biologics licensed under Accelerated Approval regulations. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in
withdrawal of approval for products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA. In
addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or<I>&nbsp;in vitro</I>&nbsp;testing that suggest a significant risk in
humans exposed to the product; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed
successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials including the use of an investigational device sometimes require submission of an application for an Investigational Device Exemption
(&#147;IDE&#148;), to the FDA. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the investigational protocol is scientifically
sound. The IDE application must be approved in advance by the FDA, unless the product is deemed <FONT STYLE="white-space:nowrap">a&nbsp;non-significant&nbsp;risk</FONT> device and eligible for more abbreviated IDE requirements. Clinical trials for a
significant risk device may begin once the IDE application is approved by the FDA as well as the appropriate IRBs at the clinical trial sites, and the informed consent of the patients participating in the clinical trial is obtained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Review and Approval of a BLA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to obtain approval to market a biological product in the United States, a biologics license application must be submitted to the FDA that provides
sufficient data establishing the safety, purity and potency of the proposed biological product for its intended indication. The BLA includes all relevant data available from pertinent preclinical studies and clinical trials, including negative or
ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls and proposed labeling, among other things. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under federal law, the submission of most BLAs is subject to an application user fee, which for federal fiscal year 2020 is $2,942,965 for an application
requiring clinical data. The sponsor of an approved BLA is also subject to an annual program fee, which for fiscal year 2020 is $325,424. Certain exceptions and waivers are available for some of these fees, such as an exception from the application
fee for products with orphan designation and a waiver for certain small businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following submission of a BLA, the FDA conducts a preliminary review
of the application generally within 60 calendar days of its receipt and strives to inform the sponsor by the 74th day after the FDA&#146;s receipt of the submission whether the application is sufficiently complete to permit substantive review. The
FDA may request additional information rather than accept the application for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it
for filing. Once the submission is accepted for filing, the FDA begins <FONT STYLE="white-space:nowrap">an&nbsp;in-depth&nbsp;substantive</FONT> review. The FDA has agreed to specified performance goals in the review process of the BLAs. Under that
agreement, 90% of original BLA submissions are meant to be reviewed within ten months of <FONT STYLE="white-space:nowrap">the&nbsp;60-day&nbsp;filing</FONT> date, and 90% of original BLAs that have been designated for &#147;priority review&#148; are
meant to be reviewed within six months of <FONT STYLE="white-space:nowrap">the&nbsp;60-day&nbsp;filing</FONT> date. The review process may be extended once per review cycle by the FDA for three additional months to consider new information or
clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before approving an
application, the FDA will typically audit the preclinical study and clinical trial sites that generated the data in support of the BLA. Additionally, the FDA typically will inspect the facility or facilities where the product is or will be
manufactured. <FONT STYLE="white-space:nowrap">These&nbsp;pre-approval&nbsp;inspections</FONT> may cover all facilities associated with a BLA submission, including component manufacturing, finished product manufacturing and control testing
laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a condition of approval, the FDA may require an applicant to develop a Risk Evaluation Mitigation Strategy (REMS). REMS use risk
minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product,
seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events and whether the product is a new molecular entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA will refer an application for a novel product to an advisory committee or explain why such referral was not made. Typically, an advisory committee is
a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the
recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fast Track, Breakthrough Therapy,
Priority Review and Regenerative Advanced Therapy Designations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA is authorized to designate certain products for expedited review if they are
intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
referred to as Fast Track designation, Breakthrough Therapy designation, Priority Review designation and Regenerative Advanced Therapy designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Specifically, the FDA may designate a product for Fast Track designation if it is intended, whether alone or in combination with one or more other products,
for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA
and the FDA may initiate review of sections of a Fast Track product&#146;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the
sponsor, that a Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA&#146;s time
period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer
supported by data emerging in the clinical trial process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Second, a product may be designated as a Breakthrough Therapy if it is intended, either alone
or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or
more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor throughout the
development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to
design the clinical trials in an efficient manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third, the FDA may designate a product for Priority Review if it is a product that treats a serious
condition and, if licensed, would provide a significant improvement in safety or effectiveness. The FDA determines, on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;case-by-case&nbsp;basis,</FONT></FONT> whether the
proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial
reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to
direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#146;s goal for taking action on a marketing application from ten months to six months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA can accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a
regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product has the potential to address unmet medical needs for
such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for Priority Review
and Accelerated Approval based on surrogate or intermediate endpoints. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accelerated Approval Pathway </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may grant Accelerated Approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over
existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant Accelerated Approval for such a condition when the product has an
effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (&#147;IMM&#148;) and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account
the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Products granted Accelerated Approval must meet the same statutory standards for safety and effectiveness as those granted traditional
approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of Accelerated Approval, a surrogate endpoint is a marker, such as a laboratory
measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical
endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with Accelerated Approvals
based on intermediate clinical endpoints, but has indicated that such endpoints generally may support Accelerated Approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if
there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Accelerated
Approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical
endpoint occurs rapidly. Thus, Accelerated Approval has been used extensively in the development and approval of products for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and
the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit. Thus, the benefit of Accelerated Approval derives from the potential to receive approval based on surrogate
endpoints sooner than possible for trials with clinical or survival endpoints, rather than deriving from any explicit shortening of the FDA approval timeline, as is the case with Priority Review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Accelerated Approval pathway is usually contingent on a sponsor&#146;s agreement to conduct, in a diligent manner, additional post-approval confirmatory
studies to verify and describe the product&#146;s clinical benefit. As a result, a product candidate licensed on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical
trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to initiate expedited proceedings to withdraw approval of the
product. All promotional materials for product candidates licensed under accelerated regulations are subject to prior review by the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The
FDA&#146;s Decision on a BLA </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of the FDA&#146;s evaluation of the application and accompanying information, including the results of the
inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A
complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If those deficiencies have been addressed to the
FDA&#146;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this
additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for licensing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the FDA licenses a
new product, it may limit the licensed indications for use of the product. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions
or other risk management mechanisms, including REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS can include medication guides, communication plans for health care professionals, and elements to assure safe use
(&#147;ETASU&#148;). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. The FDA may prevent
or limit further marketing of a product based on the results of post-market studies or surveillance programs. After licensing, many types of changes to the licensed product, such as adding new indications, manufacturing changes and additional
labeling claims, are subject to further testing requirements and FDA review and approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Post-Licensing Regulation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If regulatory licensing for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all
regular post-licensing regulatory requirements as well as any post-licensing requirements that the FDA may have imposed as part of the licensing process. The sponsor will be required to report, among other things, certain adverse reactions and
manufacturing problems to the FDA, provide updated safety and potency or efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required
to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations,
which impose certain procedural and documentation requirements upon manufacturers. Changes to the manufacturing processes are strictly regulated and often require prior FDA approval before being implemented. Accordingly, the sponsor and its
third-party manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution.
After a BLA is approved for a biological product, the product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the
product is subject to official release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed
on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. In addition, the FDA conducts laboratory research related to the regulatory standards on the
safety, purity, potency, and effectiveness of biological products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once a license is granted, the FDA may suspend or revoke the license if compliance
with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with
manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the labeling to add new safety information; imposition of post-market studies or clinical trials to assess safety risks; or imposition of
distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the
market, or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters, or holds on post-licensing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to licensed applications, or suspension or
revocation of product licenses; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes,
among other things, standards and regulations for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer&nbsp;advertising,</FONT></FONT> communications regarding unapproved uses, industry-sponsored scientific and
educational activities, and promotional activities involving the Internet and social media. After licensing, a drug product generally may not be promoted for uses that are not licensed by the FDA, as reflected in the product&#146;s prescribing
information. In the United States, health care professionals are generally permitted to prescribe drugs for such uses not described in the drug&#146;s labeling, known <FONT STYLE="white-space:nowrap">as&nbsp;off-label&nbsp;uses,</FONT> because the
FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#146; communications, prohibiting the promotion <FONT STYLE="white-space:nowrap">of&nbsp;off-label&nbsp;uses.</FONT> It may be
permissible, under very specific, narrow </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
conditions, for a manufacturer to engage in <FONT STYLE="white-space:nowrap">nonpromotional,&nbsp;non-misleading&nbsp;communication</FONT> regarding
<FONT STYLE="white-space:nowrap">off-label</FONT> information, such as distributing scientific or medical journal information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a company is found to
have <FONT STYLE="white-space:nowrap">promoted&nbsp;off-label&nbsp;uses,</FONT> it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector
General of the Department of Health and Human Services (&#147;HHS&#148;), as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and
agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has also requested that
companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the
distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#147;PDMA&#148;) and its implementing regulations, as well as the Drug Supply Chain Security Act (&#147;DSCA&#148;), which regulate the
distribution and tracing of prescription drug samples at the federal level, and set minimum standards for the regulation of distributors by the states. The PDMA, its implementing regulations and state laws limit the distribution of prescription
pharmaceutical product samples, and the DSCA imposes requirements to ensure accountability in distribution and to identify and remove counterfeit and other illegitimate products from the market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pediatric Studies and Exclusivity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Pediatric
Research Equity Act, a BLA or supplement thereto for a biological product with a new active ingredient, indication, dosage form, dosing regimen or route of administration must contain data that are adequate to assess the safety and effectiveness of
the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Sponsors must also submit pediatric study plans
prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests and other information required by
regulation. The applicant, the FDA, and the FDA&#146;s internal review committee must then review the information submitted, consult with each other and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For products intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of an applicant, meet to discuss
preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments. In addition, FDA will meet early in the development process to discuss pediatric study plans with sponsors and FDA must meet with sponsors by
no later than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;end-of-Phase&nbsp;1</FONT></FONT> meeting for serious or life-threatening diseases and by no later than ninety (90)&nbsp;days after FDA&#146;s receipt of the
study plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until
after licensing of the product for use in adults, or full or partial waivers from the pediatric data requirements. Generally, the pediatric data requirements do not apply to products with orphan designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA Reauthorization Act of 2017 established new requirements to govern certain molecularly targeted cancer indications. Any company that submits a BLA
three years after the date of enactment of that statute must submit pediatric assessments with the BLA if the biologic is intended for the treatment of an adult cancer and is directed at a molecular target that FDA determines to be substantially
relevant to the growth or progression of a pediatric cancer. The investigation must be designed to yield clinically meaningful pediatric study data regarding the dosing, safety and preliminary potency to inform pediatric labeling for the product.
Deferrals and waivers as described above are also available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pediatric exclusivity is another type
<FONT STYLE="white-space:nowrap">of&nbsp;non-patent&nbsp;marketing</FONT> exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory exclusivity, including <FONT STYLE="white-space:nowrap">the&nbsp;non-patent&nbsp;and</FONT> orphan exclusivity.
<FONT STYLE="white-space:nowrap">This&nbsp;six-month&nbsp;exclusivity</FONT> may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be
effective in the pediatric population studied. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover
the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot license another application. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Orphan Drug Designations and Exclusivity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the
Orphan Drug Act, the FDA may designate a biological product as an &#147;orphan drug&#148; if it is intended to treat a rare disease or condition, generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases
in which there is no reasonable expectation that the cost of developing and making a product available in the United States for treatment of disease or condition will be recovered from sales of the product. A company must seek orphan drug
designation before submitting a BLA for the candidate product. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan drug designation does not shorten the PDUFA goal dates for the
regulatory review and licensing process, although it does convey certain advantages such as tax benefits and exemption from the PDUFA application fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product
generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not license another sponsor&#146;s marketing application for the same drug for the same condition for seven years, except in certain limited
circumstances. Orphan exclusivity does not block the licensing of a different product for the same rare disease or condition, nor does it block the licensing of the same product for different conditions. If a biologic designated as an orphan drug
ultimately receives marketing licensing for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orphan drug exclusivity will not bar licensing of another product under certain circumstances, including if a subsequent product with the same biologic for
the same condition is shown to be clinically superior to the licensed product on the basis of greater effectiveness, safety in a substantial portion of the target populations, or providing a major contribution to patient care, or if the company with
orphan drug exclusivity is not able to meet market demand. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Biosimilars and Exclusivity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2010 Patient Protection and Affordable Care Act, which was signed into law on March&nbsp;23, 2010, included a subtitle called the Biologics Price
Competition and Innovation Act of 2009 (&#147;BPCIA&#148;). The BPCIA established a regulatory scheme authorizing the FDA to license biosimilars and interchangeable biosimilars. The FDA has licensed several biosimilar products for use in the United
States. The FDA has issued several guidance documents outlining an approach to review and licensing of biosimilars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BPCIA, a manufacturer may
submit an application for licensure of a biological product that is &#147;biosimilar to&#148; or &#147;interchangeable with&#148; a previously licensed biological product or &#147;reference product.&#148; In order for the FDA to license a biosimilar
product, it must find, among other things, that the product is &#147;highly similar&#148; to the reference product notwithstanding minor differences in clinically inactive components and that there are no clinically meaningful differences between
the reference product and proposed biosimilar product in terms of safety, purity, and potency. For the FDA to license a biosimilar product as interchangeable with a reference product, the agency must find that the biosimilar product can be expected
to produce the same clinical results as the reference product, and, for products administered multiple times, that the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or
risks of diminished potency relative to exclusive use of the reference biologic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the BPCIA, an application for a biosimilar or interchangeable biological product may not be submitted
to the FDA until four years following the date of licensing of the reference product. The FDA may not license a biosimilar or interchangeable biological product until 12 years from the date on which the reference product was licensed. Even if a
product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA licenses a full BLA for such product containing the sponsor&#146;s own preclinical data and data
from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product. The BPCIA also created certain exclusivity periods for biosimilars licensed as interchangeable products. At this juncture, it is
unclear whether products deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patent Term Restoration and Extension </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A patent claiming
a new biological product may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent restoration of up to five years for patent term lost during product development and FDA regulatory review. The
restoration period granted on a patent covering a product is <FONT STYLE="white-space:nowrap">typically&nbsp;one-half&nbsp;the</FONT> time between the effective date of an IND and the submission date of a marketing application (such as a BLA), plus
the time between the submission date of a marketing application and the ultimate licensing date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#146;s licensing date. Only
one patent applicable to a licensed product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question and within 60 days after approval of the relevant marketing
application. A patent that covers multiple products for which licensing is sought can only be extended in connection with one of the licenses. The USPTO reviews and licenses the application for any patent term extension or restoration in
consultation with the FDA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulation of Companion Diagnostics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The success of certain of our product candidates may depend, in part, on the development and commercialization of a companion diagnostic. Companion diagnostics
identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to
treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics are regulated as medical devices by the FDA. In the United States, the FDCA and its
implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing,
manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption or FDA exercise of enforcement discretion applies, diagnostic tests generally require marketing
clearance or approval from the FDA prior to commercialization. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and approval of a premarket approval
(&#147;PMA&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To obtain 510(k) clearance for a medical device, or for certain modifications to devices that have received 510(k) clearance, a
manufacturer must submit a premarket notification demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or to a preamendment device that was in commercial distribution before May&nbsp;28, 1976, or a
predicate device, for which the FDA has not yet called for the submission of a PMA. In making a determination that the device is substantially equivalent to a predicate device, the FDA compares the proposed device to the predicate device or
predicate devices and assesses whether the subject device is comparable to the predicate device or predicate devices with respect to intended use, technology, design and other features which could affect safety and effectiveness. If the FDA
determines that the subject device is substantially equivalent to the predicate device or predicate devices, the subject device may be cleared for marketing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PMA applications must be supported by valid scientific evidence, which typically requires extensive data, including technical, preclinical, clinical and
manufacturing data, to demonstrate to the FDA&#146;s satisfaction the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
safety and effectiveness of the device. For diagnostic tests, a PMA application typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the
FDA will conduct <FONT STYLE="white-space:nowrap">a&nbsp;pre-approval&nbsp;inspection</FONT> of the manufacturing facility or facilities to ensure compliance with the Quality System Regulation (&#147;QSR&#148;), which requires manufacturers to
follow design, testing, control, documentation and other quality assurance procedures. If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable
letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#146;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny the approval of the PMA
or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. Once granted, PMA approval may be withdrawn by the FDA if
compliance with post-approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;31, 2014, the FDA issued a final guidance document addressing the development and approval process for &#147;<I>In Vitro</I>&nbsp;Companion
Diagnostic Devices.&#148; According to the guidance document, for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device could be essential for the safe and effective use of the corresponding
therapeutic product, the premarket application for the companion diagnostic device should be developed and approved or cleared contemporaneously with the therapeutic, although the FDA recognizes that there may be cases when contemporaneous
development may not be possible. However, in cases where a drug cannot be used safely or effectively without the companion diagnostic, the FDA&#146;s guidance indicates it will generally not approve the drug without the approval or clearance of the
diagnostic device. The FDA also issued a draft guidance in July 2016 setting forth the principles <FONT STYLE="white-space:nowrap">for&nbsp;co-development&nbsp;of</FONT> an<I>&nbsp;in vitro</I>&nbsp;companion diagnostic device with a therapeutic
product. The draft guidance describes principles to guide the development and contemporaneous marketing authorization for the therapeutic product and its corresponding<I>&nbsp;in vitro</I>&nbsp;companion diagnostic. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once cleared or approved, the companion diagnostic device must adhere to post-marketing requirements including the requirements of FDA&#146;s quality system
regulation, adverse event reporting, recalls and corrections along with product marketing requirements and limitations. Like drug and biologic makers, companion diagnostic makers are subject to unannounced FDA inspections at any time during which
the FDA will conduct an audit of the product(s) and the company&#146;s facilities for compliance with its authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Healthcare Law and Regulation
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Health care providers and third-party payors play a primary role in the recommendation and prescription of biological products that are granted
marketing licensing. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, patient privacy laws and regulations and other health care laws and
regulations that may constrain business and/or financial arrangements. Restrictions under applicable federal and state health care laws and regulations, include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and
willfully soliciting, offering, paying, receiving or providing remuneration, directly or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase,
order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal health care program such as Medicare and Medicaid; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary
penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious or fraudulent or knowingly making, using or
causing to made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;), which created
additional federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program or making false statements relating to health care matters;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective
implementing regulations, which impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering
up a material fact or making any materially false statement in connection with the delivery of or payment for health care benefits, items or services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal transparency requirements known as the federal Physician Payments Sunshine Act, under the 2010
Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act (the ACA), which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for
Medicare&nbsp;&amp; Medicaid Services (&#147;CMS&#148;) within HHS, information related to payments and other transfers of value made by that entity to physicians (as defined by the statute) and teaching hospitals, as well as ownership and
investment interests held by physicians and their immediate family members; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may
apply to health care items or services that are reimbursed by <FONT STYLE="white-space:nowrap">non-government</FONT> third-party payors, including private insurers. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance
guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. State and foreign laws also govern the privacy
and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pharmaceutical Insurance Coverage and Health Care Reform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed
services generally rely on third-party payors to reimburse all or part of the associated health care costs. Significant uncertainty exists as to the coverage and reimbursement status of products licensed by the FDA and other government authorities.
Thus, even if a product candidate is licensed, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers
and managed care organizations, provide coverage and establish adequate reimbursement levels for, the product. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or
reimbursement rate that the payor will pay for the product once coverage is licensed. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost-effectiveness of medical products and
services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on a licensed list, also known as a formulary, which might not include all of the licensed products for a particular indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to secure coverage and reimbursement for any product that might be licensed for sale, a company may need to conduct expensive pharmacoeconomic
studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing licenses. Nonetheless, product candidates may not be considered medically
necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
licensed and have a material adverse effect on sales, results of operations and financial condition. Additionally, a payor&#146;s decision to provide coverage for a product does not imply that an
adequate reimbursement rate will be licensed. Further, one payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and
reimbursement can differ significantly from payor to payor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The containment of health care costs also has become a priority of federal, state and foreign
governments and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution
of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#146;s revenue generated from the sale of
any licensed products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing
licenses, less favorable coverage policies and reimbursement rates may be implemented in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2010, Congress passed the ACA, a sweeping
law intended to broaden access to health insurance, reduce or constrain the growth of health spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes
and fees on the health industry, and impose additional policy reforms. The ACA, for example, contains provisions that subject products to potential competition by lower-cost products and may reduce the profitability of products through increased
rebates for drugs reimbursed by Medicaid programs; address a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increase
the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations; establish annual fees and taxes on manufacturers of certain
branded prescription drugs; and create a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% (increased pursuant to the Bipartisan Budget Act of 2018 (&#147;BBA&#148;), effective as of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2019)&nbsp;point-of-sale&nbsp;discounts</FONT></FONT> off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer&#146;s outpatient drugs to be covered under Medicare Part D. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial, administrative, executive and
Congressional legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, various portions of the ACA are currently undergoing constitutional
challenges in the United States Supreme Court, the current Administration has issued various Executive Orders eliminating cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or
regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices, and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. It is
unclear whether the ACA will be overturned, repealed, replaced, or further amended, and we cannot predict what affect further changes to the ACA would have on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include the Budget Control Act of 2011, which, among other
things, led to aggregate reductions to Medicare payments to providers of up to 2% per fiscal year that started in 2013 and will stay in effect through 2029 unless additional Congressional action is taken, and the American Taxpayer Relief Act of
2012, which, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in
additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory licensing or the frequency with which any such product candidate is
prescribed or used. Further, there have been several recent U.S. congressional inquiries and proposed state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and
manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may
result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price for any licensed product and/or the level of reimbursement physicians
receive for administering any licensed product. Reductions in reimbursement levels may negatively impact the prices or the frequency with which products are prescribed or administered. Any reduction in reimbursement from Medicare or other government
programs may result in a similar reduction in payments from private payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, there have been several recent U.S. congressional inquiries and
proposed federal and proposed and enacted state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare
and reform government program reimbursement methodologies for drug products. At the federal level, Congress and the current Administration have each indicated that it will continue to seek new legislative and/or administrative measures to control
drug costs. At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care
authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the
ultimate demand for our product candidates, once licensed, or put pressure on our product pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, on May&nbsp;11, 2018, the current U.S.
presidential administration (the &#147;<I>Administration</I>&#148;) issued a plan to lower drug prices. Under this blueprint for action, the Administration indicated that HHS will: take steps to end the gaming of regulatory and patent processes by
drug makers to unfairly protect monopolies; advance biosimilars and generics to boost price competition; evaluate the inclusion of prices in drug makers&#146; ads to enhance price competition; speed access to and lower the cost of new drugs by
clarifying policies for sharing information between insurers and drug makers; avoid excessive pricing by relying more on value-based pricing by expanding outcome-based payments in Medicare and Medicaid; work to give Part D plan sponsors more
negotiation power with drug makers; examine which Medicare Part B drugs could be negotiated for a lower price by Part D plans, and improving the design of the Part B Competitive Acquisition Program; update Medicare&#146;s drug-pricing dashboard to
increase transparency; prohibit Part D contracts that include &#147;gag rules&#148; that prevent pharmacists from informing patients when they could pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">less&nbsp;out-of-pocket&nbsp;by</FONT></FONT> not using insurance; and require that Part D plan members be provided with an annual statement of plan <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">payments,&nbsp;out-of-pocket&nbsp;spending,</FONT></FONT> and drug price increases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the state level, individual states are
increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using
bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our product candidates, once licensed,
or put pressure on our product pricing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Review and Approval of Medicinal Products in the EU </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries
and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA licensing for a product, an applicant
will need to obtain the necessary approvals by the <FONT STYLE="white-space:nowrap">comparable&nbsp;non-U.S.&nbsp;regulatory</FONT> authorities before it can commence clinical trials or marketing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the EU generally follows the same lines as in the United States. It
entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent
authorities of a marketing authorization application (&#147;MAA&#148;), and granting of a marketing authorization by these authorities before the product can be marketed and sold in the EU. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clinical Trial Approval in the EU </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Clinical Trials
Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national implementing provisions of the individual EU Member States govern the system for the approval of clinical trials in the EU. Under this system, an applicant must obtain
prior approval from the competent national authority of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the competent ethics committee has
issued a favorable opinion. The clinical trial application must be accompanied by, among other documents, an investigational medicinal product dossier (the Common Technical Document) with supporting information prescribed by Directive 2001/20/EC,
Directive 2005/28/EC, where relevant the implementing national provisions of the individual EU Member States and further detailed in applicable guidance documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2014, the EU adopted a new Clinical Trials Regulation (EU) No 536/2014, which is set to replace the current Clinical Trials Directive 2001/20/EC. It
is expected that the new Clinical Trials Regulation (EU) No 536/2014 will apply following confirmation of full functionality of the Clinical Trials Information System (&#147;CTIS&#148;), the centralized EU portal and database for clinical trials
foreseen by the regulation, through an independent audit. The regulation becomes applicable six months after the European Commission publishes notice of this confirmation. It will overhaul the current system of approvals for clinical studies in the
EU. Specifically, the new regulation, which will be directly applicable in all member states, aims at simplifying and streamlining the approval of clinical studies in the EU. For instance, the new Clinical Trials Regulation provides for a
streamlined application procedure via a single point and strictly defined deadlines for the assessment of clinical study applications. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRIME
Designation in the EU </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the European Medicines Agency (&#147;EMA&#148;), launched an initiative to facilitate development of product
candidates in indications, often rare, for which few or no therapies currently exist. The PRIority Medicines (&#147;PRIME&#148;) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of
products representing substantial innovation reviewed under the centralized procedure. Products from small- and <FONT STYLE="white-space:nowrap">medium-sized&nbsp;enterprises</FONT> may qualify for earlier entry into the PRIME scheme than products
from larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other
development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated Agency contact and rapporteur from the Committee for Human Medicinal Products (&#147;CHMP&#148;)
or Committee for Advanced Therapies are appointed early in PRIME scheme facilitating increased understanding of the product at EMA&#146;s Committee level. <FONT STYLE="white-space:nowrap">A&nbsp;kick-off&nbsp;meeting</FONT> initiates these
relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Marketing Authorization in the EU </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To obtain a marketing
authorization for a product under EU regulatory systems, an applicant must submit an MAA, either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in EU Member States (decentralized
procedure, national procedure, or mutual recognition procedure). A marketing authorization may be granted only to an applicant established in the EU. Regulation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(EC) No.&nbsp;1901/2006 provides that prior to obtaining a marketing authorization in the EU, applicants must demonstrate compliance with all measures included in
<FONT STYLE="white-space:nowrap">an&nbsp;EMA-approved&nbsp;Pediatric</FONT> Investigation Plan (&#147;PIP&#148;) covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver, or a deferral for
one or more of the measures included in the PIP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The centralized procedure provides for the grant of a single marketing authorization by the European
Commission that is valid across the European Economic Area. Pursuant to Regulation (EC) No.&nbsp;726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes,
products designated as orphan medicinal products, ATMPs and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for
the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. The centralized procedure may at the request of the applicant also
be used in certain other cases. We anticipate that the centralized procedure will be mandatory for the product candidates we are developing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the
centralized procedure, the CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the EU,
the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation may be
granted by the CHMP in exceptional cases and under PRIME designation, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a
request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated
assessment. At the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 15 calendar days of receipt of a final opinion from the CHMP, the
European Commission must prepare a draft decision concerning an application for marketing authorization. This draft decision must take the opinion and any relevant provisions of EU law into account. Before arriving at a final decision on an
application for centralized authorization of a medicinal product the European Commission must consult the Standing Committee on Medicinal Products for Human Use. The Standing Committee is composed of representatives of the EU Member States and
chaired by <FONT STYLE="white-space:nowrap">a&nbsp;non-voting&nbsp;European</FONT> Commission representative. The European Parliament also has a related &#147;droit de regard.&#148; The European Parliament&#146;s role is to ensure that the European
Commission has not exceeded its powers in deciding to grant or refuse to grant a marketing authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The European Commission may grant <FONT
STYLE="white-space:nowrap">a&nbsp;so-called&nbsp;&#147;marketing</FONT> authorization under exceptional circumstances.&#148; Such authorization is intended for products for which the applicant can demonstrate that it is unable to provide
comprehensive data on the efficacy and safety under normal conditions of use, because the indications for which the product in question is intended are encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive
evidence, or in the present state of scientific knowledge, comprehensive information cannot be provided, or it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, marketing authorization
under exceptional circumstances may be granted subject to certain specific obligations, which may include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicant must complete an identified program of studies within a time period specified by the competent
authority, the results of which form the basis of a reassessment of the benefit/risk profile; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the medicinal product in question may be supplied on medical prescription only and may in certain cases be
administered only under strict medical supervision, possibly in a hospital and in the case of a radiopharmaceutical, by an authorized person; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the package leaflet and any medical information must draw the attention of the medical practitioner to the fact
that the particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A marketing authorization under exceptional circumstances is subject to annual review to reassess the
risk-benefit balance in an annual reassessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being suspended or revoked. The
renewal of a marketing authorization of a medicinal product under exceptional circumstances, however, follows the same rules as a &#147;normal&#148; marketing authorization. Thus, a marketing authorization under exceptional circumstances is granted
for an initial five years, after which the authorization will become valid indefinitely, unless the EMA decides that safety grounds merit one additional five-year renewal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The European Commission may also grant <FONT STYLE="white-space:nowrap">a&nbsp;so-called&nbsp;&#147;conditional</FONT> marketing authorization&#148; prior to
obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products),
if (i)&nbsp;the risk-benefit balance of the product candidate is positive, (ii)&nbsp;it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (iii)&nbsp;the product fulfills an unmet medical
need and (iv)&nbsp;the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may
contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing
authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the
centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The EU
medicines rules expressly permit the EU Member States to adopt national legislation prohibiting or restricting the sale, supply or use of any medicinal product containing, consisting of or derived from a specific type of human or animal cell, such
as embryonic stem cells. While the product candidates we have in development do not make use of embryonic stem cells, it is possible that the national laws in certain EU Member States may prohibit or restrict us from commercializing our product
candidates, even if they have been granted an EU marketing authorization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unlike the centralized authorization procedure, the decentralized marketing
authorization procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be
submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment
report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related
materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European Commission, whose decision is binding on all EU Member States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The mutual recognition procedure similarly is based on the acceptance by the competent authorities of the EU Member States of the marketing authorization of a
medicinal product by the competent authorities of other EU Member States. The holder of a national marketing authorization may submit an application to the competent authority of an EU Member State requesting that this authority recognize the
marketing authorization delivered by the competent authority of another EU Member State. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulatory Data Protection in the EU </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the EU, innovative medicinal products approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon
marketing authorization and an additional two years of market exclusivity pursuant to Directive 2001/83/EC. Regulation (EC) No.&nbsp;726/2004 repeats the entitlement for medicinal products </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
authorized in accordance with the centralized authorization procedure. Data exclusivity prevents applicants for authorization of generics of these innovative products from referencing the
innovator&#146;s data to assess a generic (abridged) application for a period of eight years. During the <FONT STYLE="white-space:nowrap">additional&nbsp;two-year&nbsp;period</FONT> of market exclusivity, a generic marketing authorization
application can be submitted and authorized, and the innovator&#146;s data may be referenced, but no generic medicinal product can be placed on the EU market until the expiration of the market exclusivity. The
<FONT STYLE="white-space:nowrap">overall&nbsp;ten-year&nbsp;period</FONT> will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new
therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so
that the innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical
<FONT STYLE="white-space:nowrap">tests,&nbsp;non-clinical&nbsp;tests</FONT> and clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Periods of Authorization and Renewals </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A marketing authorization has an initial validity for five years in principle. The marketing authorization may be renewed after five years on the basis of <FONT
STYLE="white-space:nowrap">a&nbsp;re-evaluation&nbsp;of</FONT> the risk-benefit balance by the EMA or by the competent authority of the EU Member State. To this end, the marketing authorization holder must provide the EMA or the competent authority
with a consolidated version of the file in respect of quality, safety, and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The European Commission or the competent authorities of the EU Member States may decide, on justified grounds relating to pharmacovigilance, to proceed with
one further five-year period of marketing authorization. Once subsequently definitively renewed, the marketing authorization shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal
product on the EU market (in case of centralized procedure) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid <FONT STYLE="white-space:nowrap">(the&nbsp;so-called&nbsp;sunset</FONT>
clause). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Orphan Drug Designation and Exclusivity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulation (EC) No.&nbsp;141/2000, as implemented by Regulation (EC) No.&nbsp;847/2000 provides that a drug can be designated as an orphan drug by the European
Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1)&nbsp;a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when
the application is made, or (2)&nbsp;a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to
justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if
such method exists, the drug will be of significant benefit to those affected by that condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once authorized, orphan medicinal products are entitled
to 10 years of market exclusivity in all EU Member States and in addition a range of other benefits during the development and regulatory review process including scientific assistance for study protocols, authorization through the centralized
marketing authorization procedure covering all member countries and a reduction or elimination of registration and marketing authorization fees. However, marketing authorization may be granted to a similar medicinal product with the same orphan
indication during <FONT STYLE="white-space:nowrap">the&nbsp;10-year&nbsp;period</FONT> with the consent of the marketing authorization holder for the original orphan medicinal product or if the manufacturer of the original orphan medicinal product
is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this product is safer, more effective or otherwise clinically superior to the original orphan
medicinal product. The period of market exclusivity may, in addition, be reduced to six years if it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify
maintenance of market exclusivity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulatory Requirements after a Marketing Authorization has been Obtained </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In case an authorization for a medicinal product in the EU is obtained, the holder of the marketing authorization is required to comply with a range of
requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compliance with the European Union&#146;s stringent pharmacovigilance or safety reporting rules must be ensured.
These rules can impose post-authorization studies and additional monitoring obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manufacturing of authorized medicinal products, for which a separate manufacturer&#146;s license is
mandatory, must also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good
Manufacturing Practice. These requirements include compliance with EU cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with
the intention to import the active pharmaceutical ingredients into the EU; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and
advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the EU notably under Directive 2001/83EC, as amended, and EU Member State laws.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription medicines is prohibited across the EU. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Brexit and the Regulatory Framework in the United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;23, 2016, the electorate in the United Kingdom voted in favor of leaving the EU (commonly referred to as &#147;Brexit&#148;). Thereafter, on
March&nbsp;29, 2017, the country formally notified the EU of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The United Kingdom formally left the EU on January&nbsp;31, 2020. A transition period began on February&nbsp;1, 2020,
during which EU pharmaceutical law remains applicable to the United Kingdom. This transition period is due to end on December&nbsp;31, 2020. Since the regulatory framework for pharmaceutical products in the United Kingdom covering quality, safety
and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from EU directives and regulations, Brexit could materially impact the future regulatory
regime which applies to products and the approval of product candidates in the United Kingdom. It remains to be seen how, if at all, Brexit will impact regulatory requirements for product candidates and products in the United Kingdom. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pricing Decisions for Approved Products in the EU </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that
compare the cost-effectiveness of a Member States to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Member States may approve a
specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other Member States allow companies to fix their own prices for products, but monitor
and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to
manage health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a
result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been
obtained. Reference pricing used by various Member States, and parallel trade, or arbitrage, <FONT STYLE="white-space:nowrap">between&nbsp;low-priced&nbsp;and</FONT> high-priced Member States, can further reduce prices. There can be no assurance
that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FACILITIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of January&nbsp;27, 2020, Immatics OpCo has three locations in Germany. The corporate headquarters are located at Paul-Ehrlich-Stra&szlig;e 15 in 72076
T&uuml;bingen. It comprises approximately 1,600 square meters of office space as well as research and laboratory space. It houses Operations, Immunology, TCR Discovery and Validation, TCR Engineering&nbsp;&amp; Bispecifics, Immunomonitoring,
Discovery, Companion Diagnostics and CMC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our operations facility is approximately 700 square meters and is located at Aischbachstra&szlig;e 1 in 72070
T&uuml;bingen. It houses Operations, HR, IT, Finance, Translational Development, Regulatory Affairs and Clinical Development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our third facility is
approximately 380 square meters and is located in Machtlfinger Stra&szlig;e 11 in 81379 Munich. It houses Intellectual Property, IT, Communications and Business Development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics US has two locations, the corporate headquarters, which is a direct lease, and the research and laboratory facility, which is subleased from
University of Texas MD Anderson Cancer Center. The corporate headquarters is a 6,690 square foot facility located at 2201 West Holcombe, Houston, TX 77030, and houses Operations, Human Resources, Finance, Clinical Operations, Regulatory,
Bioinformatics and Program Management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The research and laboratory facility is is a 15,694 square foot facility located in the Life Science Plaza
building at 2130 West Holcombe, Suite 1100, Houston, Texas 77030. The research and laboratory facility is comprised primarily of laboratory space, with limited office seating that houses CMC, Immunology, Biomarkers, Quality Assurance and Quality
Control. Our sublease on the space will expire in August 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T cell products are manufactured by our at the UTHealth Evelyn H. Griffin Stem Cell
Therapeutics Research Laboratory in a 1,850 square foot <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> cGMP facility exclusively used by us in Houston, Texas.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our office, research and laboratory facilities in Germany and the United States are sufficient to meet our current needs. However, in
anticipation of future demand, we are negotiating for a new lease for a larger office facility and also pursuing options for a laboratory facility at both locations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EMPLOYEES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of July&nbsp;31, 2020, Immatics US employed
71 full-time employees of which 22 hold doctorate degrees and 2 have the credentials of M.D. Of these employees, 46 are employed in positions relating to research and development (including CMC, Target-based Biomarkers, Immunology and Quality
Assurance and Control, and Bioinformatics), 14 are employed in positions relating to Clinical Operations/Development, Regulatory and Program Management, 8 are employed in administrative functions (including Finance, IT, Operations and Human
Resources), and 3 were employed in senior management positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of July&nbsp;31, 2020, Immatics OpCo has a headcount of 156 employees and 134
full-time equivalent employees. 59 of these employees hold a doctorate degree. 109 are full-time employed. Of these 156 employees, 107 are employed in positions relating to research and development positions (including Immunology, Discovery,
Companion Diagnostics, CMC, Translational Development), 6 are employed in Clinical Development, 2 are employed in Regulatory Affairs, 2 are employed in Business Development, 4 are employed in Intellectual Property and 30 are employed in
Administrative Functions (including Finance, IT, Operations, Quality Management, human resources, Communications and Facility) and 5 in senior management positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never had a work stoppage and is not covered under any collective bargaining agreements nor are any of our employees represented by a labor union. We
believe we have good employee relations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LEGAL&nbsp;PROCEEDINGS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of July 2020, there are no ongoing material legal proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_12"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>You
should read the following discussion and analysis of our financial condition and results of operations together with Immatics OpCo&#146;s consolidated financial statements and the related notes thereto and the unaudited pro forma condensed combined
financial information included elsewhere in this prospectus. The following discussion is based on the financial information of Immatics OpCo prepared in accordance with IFRS, which may differ in material respects from generally accepted accounting
principles in other jurisdictions, including U.S. GAAP. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business,
includes forward-looking statements that involve risks and uncertainties. You should review the section titled &#147;Risk Factors&#148; for a discussion of important factors that could cause actual results to differ materially from the results
described in or implied by the forward-looking statements contained in the following discussion and analysis. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Business Impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> Pandemic </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management is monitoring the global outbreak and spread of the novel strain of coronavirus <FONT
STYLE="white-space:nowrap">(&#147;COVID-19&#148;)</FONT> and has taken steps to identify and mitigate the adverse effects and risks to our company as a result of the pandemic. As a result, we have modified our business practices, including
implementing work from home arrangements for employees able to perform their duties remotely, restricting nonessential travel, and practicing safe social distancing in our laboratory operations. Management expects to continue to take actions as may
be required or recommended by government authorities or in the best interests of our employees and business partners. To date, the pandemic has resulted in a slowdown in activities related to our laboratory operations and at some of our suppliers.
The ongoing spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> may also negatively impact our clinical trials in the future, including potential delays and restrictions on our ability to recruit and retain patients, principal investigators
and healthcare employees. <FONT STYLE="white-space:nowrap">COVID-19</FONT> could also affect the operations of CROs, which may result in delays or disruptions in the supply of product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> we have also experienced delays in research activities performed under our collaboration agreements.
Consequently, we recognized less revenue under these agreements during the first quarter of 2020 than previously planned. Management believes declines in revenue associated with the delay in research activities is largely temporary, as the revenue
is primarily associated with <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payments recognized on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> basis.
<FONT STYLE="white-space:nowrap">COVID-19</FONT> may continue to impact the timing and amount of revenue recognized under these agreements in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic remains a rapidly evolving situation and management does not yet know the full extent of our
potential impact on our business operations. We will continue to closely monitor the effects of the pandemic. For additional information on risks posed by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, refer to the section titled
&#147;<I>Risk Factors</I>&#148; included elsewhere in this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a biotechnology company that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. We
use our proprietary suite of technologies to identify intracellular drug targets, so&nbsp;called&nbsp;pHLA targets, as a basis for a broad range of potential immunotherapies designed to overcome the current limitations in <FONT
STYLE="white-space:nowrap">immuno-oncology.&nbsp;Unlike&nbsp;CAR-T&nbsp;therapy&nbsp;and</FONT> current antibody-based approaches, which can only target cell surface proteins, our technology enables the identification of otherwise inaccessible
intercellular protein targets and thus significantly increases the diversity and novelty of the targets it can pursue. Such intracellular targets are generally recognized as one of the most important keys <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">to&nbsp;unlock&nbsp;hard-to-treat&nbsp;cancer,&nbsp;particularly</FONT></FONT> solid cancers. We believe that the elucidation of these targets gives us an advantage that we are leveraging to develop a pipeline <FONT
STYLE="white-space:nowrap">of&nbsp;novel&nbsp;TCR-based&nbsp;products&nbsp;designed</FONT> to deliver a robust and specific T cell response against cancer cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since 2000, when Immatics OpCo was incorporated, we have focused on raising capital and performing research
and development activities to advance our research, development and technology. We are a development phase company and have not yet marketed any products commercially. Our success depends on the successful development and regulatory approval of our
products and our ability to finance operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have assembled a team of approximately 200 employees and have established relationships with four
pharmaceutical collaborators, including Amgen Inc. (&#147;Amgen&#148;), Genmab A/S, (&#147;Genmab&#148;), Celgene Switzerland LLC (&#147;BMS&#148;) and GlaxoSmithKline plc (&#147;GSK&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics OpCo has raised approximately &#128;378.5&nbsp;million through private placements of securities and from our collaborators. These funds are used to
fund operations and investing activities across research for technology creation, drug discovery and clinical development programs, infrastructure (including digital infrastructure), creation of portfolio of intellectual property, and administrative
support. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics OpCo has incurred significant operating losses since its incorporation. Net losses were &#128;8.6&nbsp;million and
&#128;5.9&nbsp;million for the three months ended March&nbsp;31, 2020 and 2019, respectively, and &#128;32.5&nbsp;million and &#128;32.4&nbsp;million for the years ended December&nbsp;31, 2019 and 2018, respectively. As of March&nbsp;31, 2020,
Immatics OpCo&#146; accumulated deficit was &#128;241.5&nbsp;million. We expect to continue to incur significant expenses and operating losses for the near future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not expect to generate revenue from our product candidates unless and until we successfully complete clinical development and obtain regulatory approval
for such product candidates. If we seek to obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, we will need substantial additional funding to support our continued operations and pursue our growth strategy. Until we can generate significant
revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings, government funding arrangements, collaborations and marketing, distribution and licensing
arrangements. We may be unable to raise additional funds or enter into such other arrangements on favorable terms, or at all. If we fail to raise capital or enter into such arrangements as, and when, needed, we may have to significantly delay, scale
back or discontinue the development and commercialization of one or more of our programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with
pharmaceutical development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. If we fail to become profitable or is unable to sustain profitability on a continuing
basis, then we may be unable to continue our operations at planned levels and may be forced to reduce our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more details concerning our
business and key areas of focus for research, see the section titled &#147;<I>Business</I>&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of Operating Results </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue from Collaboration Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we
have not generated any revenue from the sale of pharmaceutical products. Our revenue has been solely derived from our collaboration agreements with Amgen, Genmab, BMS and GSK. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our revenue from collaboration agreements consists of upfront payments as well as reimbursement of research and development expenses. Upfront payments are
initially recorded on our statement of financial position as deferred revenue and are subsequently recognized as revenue
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">on&nbsp;a&nbsp;cost-to-cost&nbsp;measurement&nbsp;basis</FONT></FONT> in accordance with our accounting policy as described further in &#147;Significant accounting judgements,
estimates and assumptions&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the collaboration arrangements, we grant exclusive licensing rights for the development and
commercialization of future product candidates developed for specified targets defined in the respective collaboration agreement, in addition to research activities, including screening of highly specific molecules for reactivity with the specified <FONT
STYLE="white-space:nowrap">targets&nbsp;and&nbsp;off-targets&nbsp;using&nbsp;our</FONT> proprietary technology <FONT STYLE="white-space:nowrap">and&nbsp;know-how,&nbsp;participation</FONT> on a joint steering committee, and preparation of data
packages. In each of our collaboration agreements, these promises represent one combined performance obligation, because the research activities are mutually dependent and the collaborator is unable to derive significant benefits from its access to
these targets without our research activities, which are highly specialized and cannot be performed by other organizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collaboration agreements
resulted in <FONT STYLE="white-space:nowrap">&#128;186.6&nbsp;million&nbsp;of&nbsp;up-front&nbsp;cash&nbsp;payments,</FONT> intended to fund the research and development activities under each contract. As part of the agreements, we contribute our
XPRESIDENT technology, as well as other technology and commit to participate in joint research activities. In addition, we agree to license certain target rights and the possible product candidates developed under the collaboration. The agreements
provide for future payments if development, regulatory or sales milestones are achieved. In addition, we are entitled to future royalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under each of
our collaboration agreements, we are entitled to receive payments for certain development and commercial milestone events, in addition to royalty payments upon successful commercialization of a product. The uncertainty of achieving these certain
milestones significantly impacts our ability to generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ability to generate revenue from sales of pharmaceutical products and to become
profitable depends on our ability to successfully commercialize our product candidates. For the foreseeable future, we do not expect revenue from product sales. To the extent that existing or potential future collaborations generate revenue, our
revenue may vary due to many uncertainties in the development of our product candidates and other factors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of personnel-related costs (including share-based compensation) for the various research and
development departments, IP expenses, facility-related costs and amortization as well as direct expenses for programs such as direct cost for clinical trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our core business is focused on the following initiatives with the goal of enabling us to achieve the next advance in immunotherapy: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance the proprietary pipeline of product candidates focusing on ACTengine<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and TCR Bispecifics; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Develop Adoptive Cell Therapies and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> biologics with distinct mode of actions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advance <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> cell
therapies into the clinic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enhance commercial viability of autologous cell therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Disrupt the tumor microenvironment through combination therapies, next-generation technologies and novel target
classes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand leadership in ultra-personalized multi-target immunotherapy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maintain and enhance the competitive edge of our target and TCR technology platforms; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leverage existing collaboration agreements with Amgen, Genmab, BMS and GSK; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Expand our intellectual property portfolio. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research expenses are defined as costs incurred for current or planned investigations undertaken with the prospect of gaining new scientific or technical
knowledge and understanding. All research and development costs are expensed as incurred due to scientific uncertainty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our research and development expenses to increase substantially in the future as we advance
existing and future proprietary product candidates into and through clinical studies and pursue regulatory approval. The process of conducting the necessary clinical studies to obtain regulatory approval is costly and time-consuming. We are
increasing our headcount to support our continued research activities and development of our product candidates. Clinical studies generally become larger and more costly to conduct as they advance into later stages and, in the future, we will be
required to make estimates for expense accruals related to clinical study expenses. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of any
product candidates that we develop from our programs. Our research and development programs are at an early stage. We must demonstrate our products&#146; safety and efficacy in humans through extensive clinical testing. We may experience numerous
unforeseen events during, or as a result of, the testing process that could delay or prevent commercialization of our products, including but not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after reviewing trial results, we or our collaborators may abandon projects that might previously have believed
to be promising; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we, our collaborators or regulators, may suspend or terminate clinical trials if the participating subjects or
patients are being exposed to unacceptable health risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects our potential products have may not be the desired effects or may include undesirable side effects or
other characteristics that preclude regulatory approval or limit their commercial use if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturers may not meet the necessary standards for the production of the product candidates or may not be
able to supply the product candidates in a sufficient quantity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may find that our clinical trial design or conduct does not meet the applicable approval
requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safety and efficacy results in various human clinical trials reported in scientific and medical literature may
not be indicative of results we obtain in our clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical testing is very expensive, can take many years, and the outcome
is uncertain. It could take several years before we learn the results from any clinical trial using ACT or TCR Bispecifics. The data collected from our clinical trials may not be sufficient to support approval by the FDA, EMA, or regulatory
authorities in other countries of our <FONT STYLE="white-space:nowrap">ACT-&nbsp;or</FONT> TCR Bispecifics-based product candidates for the treatment of solid tumors. The clinical trials for our products under development may not be completed on
schedule and the FDA, EMA or regulatory authorities in other countries may not ultimately approve any of our product candidates for commercial sale. If we fail to adequately demonstrate the safety and effectiveness of any product candidate under
development, we may not receive regulatory approval for those product candidates, which would prevent us from generating revenues or achieving profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative expenses consist primarily of personnel-related costs (including share-based compensation) for finance, legal, human resources, business development and other administrative and operational functions, professional fees, accounting and
legal services, information technology and facility-related costs. These costs relate to the operation of the business, unrelated to the research and development function or any individual program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to our substantial increase in planned research and development expenses, as explained above, we also expect that our general and administrative expenses
will increase proportionally. We expect to incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance costs, as well as investor and public relations expenses associated with being a public company. We
anticipate that the additional costs for these services will substantially increase our general and administrative expenses. Additionally, if and when a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and expenses as a result of our preparation for commercial operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We receive income through government
grants for specific research and development projects. We recognize grant income as we perform research and development activities specified by the grant agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other components of other income have historically been immaterial. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Result </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial result consists of
both financial income and financial expense. Financial income results primarily from interest income on cash and foreign exchange gains. Our financial expense consists of interest expense related to lease liabilities and foreign exchange losses.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table
summarizes our consolidated statements of operations for each period presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">18,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,971</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating result</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(11,281</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,636</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(33,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(34,409</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(264</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial result</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,701</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>755</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>526</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,054</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,881</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,487</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,355</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes on income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,881</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,487</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,355</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share &#151; basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7.14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4.89</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(27.13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(27.02</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue from Collaboration Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from collaboration agreements increased by &#128;3.4&nbsp;million, from &#128;3.6&nbsp;million for the three months ended March&nbsp;31, 2019 to
&#128;7.0&nbsp;million for the three months ended March&nbsp;31, 2020. Approximately &#128;2.9&nbsp;million of the increase resulted from the collaboration agreements with GSK and BMS, which we entered into during December 2019 and August 2019,
respectively. Due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we experienced delays in research activities performed under the Amgen and Genmab collaboration agreements. As we recognize revenue under these contracts on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> model based on research activities, we recognized less revenue under the Amgen and Genmab agreements during the first quarter of 2020 than previously planned.
Consequently, revenue recognized under the Genmab agreement decreased by &#128;440&nbsp;thousand. While revenue earned under the Amgen </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agreement was less than initially planned, revenue recognized during the three months ended March&nbsp;31, 2020 exceed the prior year comparative period by &#128;979&nbsp;thousand. We believe
that any declines in revenue associated with delayed research activities are largely temporary, because the revenue is primarily associated with <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from collaboration agreements increased by &#128;14.6&nbsp;million, from &#128;3.8&nbsp;million for the year ended December&nbsp;31, 2018 to
&#128;18.4&nbsp;million for the year ended December&nbsp;31, 2019. This increase primarily resulted from the new collaboration agreement with BMS and <FONT STYLE="white-space:nowrap">a&nbsp;ramp-up&nbsp;in</FONT> research activities performed under
the Genmab and Amgen agreements. Our collaboration with GSK did not result in any revenue in 2019 as no work was performed under the collaboration agreement in 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We did not achieve any milestones or receive any royalty payments in connection with our collaboration agreements during the presented periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our collaboration revenue for the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months<BR>Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue from collaboration agreements:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amgen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;2,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;1,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;6,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;1,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genmab</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BMS</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GSK</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total revenue from collaboration agreements</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;7,040</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;3,626</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;18,449</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;3,770</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Direct research and development expenses by program:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ACTengine</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;1,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Next Generation ACT</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TCR Bispecifics</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,585</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Technology Platforms</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Sub-total&nbsp;direct</FONT> expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,273</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,078</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,381</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,971</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Internal research and development expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">4,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">3,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">15,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">12,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IP Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other internal costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Sub-total&nbsp;internal</FONT> expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,973</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,912</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28,710</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total research and development expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,246</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,990</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40,091</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>33,971</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three months ended March&nbsp;31, 2020, our research and development expenses were
&#128;12.2&nbsp;million compared to &#128;8.0&nbsp;million for the three months ended March&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three months ended March&nbsp;31,
2020, direct research and development expenses associated with our programs increased due to increased preclinical and clinical work performed under the programs compared to three months ended March&nbsp;31, 2019. The increase in ACTengine expenses
is mainly due to the start of clinical trials in the United States, which began in February 2019. The decrease in Next Generation ACT expenses in the three months ended March&nbsp;31, 2020 is due to a planned slow-down in the ACTolog clinical trial,
as no additional patients are being enrolled into this trial. The increase in TCR Bispecifics expenses is related to the start of GMP manufacturing of a cell line in 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direct research expenses related to collaboration agreements increased due to an overall increase in research activities performed under our four
collaboration agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Personnel related research and development expenses for the three months ended March&nbsp;31, 2020 and 2019 were
&#128;4.8&nbsp;million and &#128;3.3&nbsp;million, respectively. These increases were primarily a result of our increased research and development headcount and increased share-based compensation expenses. The increase in IP expenses for the three
months ended March&nbsp;31, 2020 compared to the three months ended March&nbsp;31, 2019 is due to timing of legal cost related to filing and defending of the Group&#146;s patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2019, our research and development expenses were &#128;40.1&nbsp;million compared to &#128;34.0&nbsp;million for the year
ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2019, our direct research and development expenses associated with our programs
increased due to increased preclinical and clinical work performed under the programs compared to the year ended December&nbsp;31, 2018. The increase in ACTengine expenses is mainly due to the start of clinical trials in the United States. The
increase in Next Generation ACT expenses is mainly due to additional expenses related to the ACTolog clinical trial. The decrease in expenses in Technology Platforms is mainly due to a time shift of expenses. It is expected that expenses for
Technology Platforms will go up again in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direct research expenses related to collaboration agreements increased due to further increase in
the work performed under the collaboration agreements with Amgen and Genmab as well as the additional collaboration with BMS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Personnel related research
and development expenses for the years ended December&nbsp;31, 2019 and 2018 were &#128;15.2&nbsp;million and &#128;12.6&nbsp;million, respectively. This increase of &#128;2.6&nbsp;million was primarily a result of our increased research and
development headcount and increased share-based compensation expenses. Facility related research and development expenses decreased, whereas depreciation expenses increased due to the first-time application of IFRS 16. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative expenses for the three months ended March&nbsp;31, 2020 and 2019 were &#128;6.2&nbsp;million and &#128;2.3&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
&#128;3.9&nbsp;million increase in general and administrative expenses for the three months ended March&nbsp;31, 2020 compared to the three months ended March&nbsp;31, 2019 was primarily due to an increase in personnel related expenses of
&#128;0.7&nbsp;million and an increase in professional and consulting fees of &#128;2.7&nbsp;million. Personnel related expenses increased mainly due to the growth in headcount in our finance function as well as the communications functions. The
increase in professional and consulting fees resulted from an increase in accounting, audit and legal fees as well as costs associated with ongoing business activities and our preparations to operate as a public company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expenses for the years ended December&nbsp;31, 2019 and 2018 were
&#128;11.8&nbsp;million and &#128;7.7&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increase in general and administrative expenses in the year ended 2019 compared to
the year ended December&nbsp;31, 2018 was primarily due to an increase in personnel related expenses of &#128;1.8&nbsp;million and an increase in professional and consulting fees of &#128;1.7&nbsp;million. Personnel related expenses increased mainly
due to the growth in headcount in our finance function as well as IP and communications function. The increase in professional and consulting fees resulted from an increase in accounting, audit and legal fees, as well as costs associated with
ongoing business activities and our preparations to operate as a public company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income during the three months ended March&nbsp;31, 2020 and 2019 was &#128;113&nbsp;thousand and &#128;3&nbsp;thousand, respectively. This increase of
&#128;110&nbsp;thousand resulted primarily from a &#128;82&nbsp;thousand increase in grant income in the three months ended March&nbsp;31, 2020 compared to three months ended March&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income during the years ended December&nbsp;31, 2019 and 2018 was &#128;385&nbsp;thousand and &#128;3.5&nbsp;million, respectively. The decrease of
&#128;3.1&nbsp;million in 2019 resulted primarily from lower grant income, which decreased from &#128;2.9&nbsp;million in 2018 to &#128;26&nbsp;thousand in 2019. The decrease in grant income resulted from the closing of the CPRIT grant of Immatics
US in 2018. There are no unfulfilled conditions or contingencies related to these grants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Result </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial result consists of both financial income and financial expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial income increased to &#128;2.7&nbsp;million for the three months ended March&nbsp;31, 2020 compared to &#128;825&nbsp;thousand for the three months
ended March&nbsp;31, 2019. This increase of &#128;1.9&nbsp;million resulted primarily from an increase in foreign exchange gains of &#128;1.7&nbsp;million for the three months ended March&nbsp;31, 2020 compared to the three months ended
March&nbsp;31, 2019. Interest income increased by &#128;175&nbsp;thousand to &#128;319&nbsp;thousand for the three months ended March&nbsp;31, 2020, compared to &#128;144&nbsp;thousand for the three months ended March&nbsp;31, 2019. This increase is
due to higher cash balances as well as short-term deposits, resulting from the upfront payments received as part of the collaboration agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During
the three months ended March&nbsp;31, 2020, financial expenses amounted to &#128;29&nbsp;thousand, compared to &#128;70&nbsp;thousand during the three months ended March&nbsp;31, 2019. Our interest expenses for both periods are substantially related
to lease liabilities. Financial expenses for the three months ended March&nbsp;31, 2020 consisted primarily of &#128;28&nbsp;thousand in interest expense from lease liabilities, with the remainder resulting from foreign exchange losses. Financial
expenses for the three months ended March&nbsp;31, 2019 consisted primarily of &#128;51&nbsp;thousand in interest from lease liabilities with the remainder resulting from foreign exchange losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial income decreased to &#128;790&nbsp;thousand for the 12 months ended December&nbsp;31, 2019, compared to &#128;2.2&nbsp;million during the 12 months
ended December&nbsp;31, 2018. During 2019, financial income consisted almost entirely of interest income from short-term deposits. During 2018, financial income consisted of foreign exchange gains of &#128;1.7&nbsp;million and interest income of
&#128;507&nbsp;thousand. Changes in foreign currency gains resulted from changes in the exchange rates between the U.S.&nbsp;Dollar and Euro. Interest income increased due to higher cash balances as well as short-term deposits, resulting from the
upfront payments received as part of the collaboration agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2019, financial expenses amounted to &#128;264&nbsp;thousand, compared to
&#128;161&nbsp;thousand during 2018. Financial expenses in 2019 consisted primarily of &#128;170&nbsp;thousand in interest expense from lease liabilities, with the remainder resulting from foreign exchange losses. Financial expenses in 2018
consisted primarily of &#128;145&nbsp;thousand in foreign exchange losses. The increase in interest expense from lease liabilities resulted from the adoption of IFRS 16 in 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sources of Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have historically funded
our operations primarily from private placements of our ordinary shares and proceeds from collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2020 and as of
December&nbsp;31, 2019, we had cash and cash equivalents of &#128;72.2&nbsp;million and &#128;103.4&nbsp;million, respectively. Cash and cash equivalents are invested in accordance with our investment policy, primarily with a view to liquidity and
capital preservation, and consist primarily of cash in banks and short-term deposits with an original maturity of between three and nine months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following table summarizes the primary sources and uses of cash for each period presented: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash (used in) provided by:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,286</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">(248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">68,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">7,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(611</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,862</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash flow</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(31,284</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,027</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>64,046</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,818</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We primarily derive cash from our collaboration agreements. Our cash flows from operating activities are significantly influenced by our use of cash for
operating expenses and working capital to support the business, in addition to the placement of cash and cash equivalents into short-term deposits, which do not meet the classification criteria of cash and cash equivalents in accordance with IAS 7
(&#147;Statement of Cash Flows&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We experienced net cash outflows from operating activities during both the three months ended March&nbsp;31, 2020
and 2019, resulting primarily from the net loss of the periods and working capital changes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the first quarter 2020, net cash used in operating
activities of &#128;28.3&nbsp;million primarily resulted from an increase in working capital of &#128;21.2&nbsp;million combined with a net loss of &#128;8.6&nbsp;million during the quarter, partially offset
<FONT STYLE="white-space:nowrap">by&nbsp;non-cash&nbsp;charges</FONT> of &#128;1.5&nbsp;million. The increase in working capital mainly resulted from an increase in short-term deposits of &#128;16.8&nbsp;million, which have an original maturity of
four to six months and do not meet the requirements of cash and cash equivalents under IAS 7, and a decrease in accounts payable and other current liabilities of &#128;4.8&nbsp;million, primarily related to the recognition of deferred revenue from
upfront payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended March&nbsp;31, 2019, net cash used in operating activities of &#128;0.2&nbsp;million resulted from a net
loss of &#128;5.9&nbsp;million during the quarter, offset by a decrease in working capital of &#128;4.5&nbsp;million <FONT STYLE="white-space:nowrap">and&nbsp;non-cash&nbsp;charges</FONT> of &#128;1.2&nbsp;million. The decrease in working capital
mainly resulted from a decrease in other assets of &#128;9.0&nbsp;million, resulting from the disbursement of cash held in short-term deposits that previously did not meet the definition of cash and cash equivalents according to IAS 7, partially
offset by a decrease in accounts payable and other current liabilities of &#128;4.4&nbsp;million primarily related to the recognition of deferred revenue from upfront payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2019 and 2018, we experienced positive cash flows from operating activities primarily from upfront payments of
collaboration agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net loss amounted to &#128;32.5&nbsp;million and &#128;32.4&nbsp;million for the years ended December&nbsp;31, 2019 and 2018,
respectively, and drove the operating cashflow in 2019 and 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2019, net cash flow from operating activities of &#128;68.0&nbsp;million primarily resulted from a
&#128;94.6&nbsp;million change in working capital <FONT STYLE="white-space:nowrap">and&nbsp;non-cash&nbsp;charges</FONT> of &#128;5.9&nbsp;million, partially offset by &#128;32.5&nbsp;million net loss for the year. This increase in working capital
mainly resulted from an increase in accounts payable and other current liabilities of &#128;98.9&nbsp;million primarily related to deferred revenue from upfront payments received from our collaborators BMS and GSK, partially offset by an increase in
other assets of &#128;4.4&nbsp;million that primarily resulted from a &#128;3.0&nbsp;million increase in short-term deposits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2018, net cash flow
from operating activities of &#128;7.6&nbsp;million consisted primarily of a change in working capital amounting to &#128;36.6&nbsp;million <FONT STYLE="white-space:nowrap">and&nbsp;non-cash&nbsp;charges</FONT> of &#128;3.3&nbsp;million, partially
offset by &#128;32.4&nbsp;million of net loss for the year. This increase in working capital mainly resulted from an increase in accounts payable and other current liabilities of &#128;43.7&nbsp;million primarily related to deferred revenue from
upfront payments received from our collaborator Genmab, partially offset by an increase in other assets of &#128;7.5&nbsp;million that primarily resulted from a &#128;6.9&nbsp;million decrease in grant receivables and a &#128;13.1&nbsp;million
increase in short-term deposits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the three months ended March&nbsp;31, 2020 was &#128;2.4&nbsp;million, mainly due to payments related to new
laboratory space and office equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the three months ended March&nbsp;31, 2019 was &#128;333&nbsp;thousand,
which is primarily attributable to the acquisition of new property, plant and equipment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the year ended
December&nbsp;31, 2019 was &#128;2.1&nbsp;million, of which &#128;91&nbsp;thousand was attributable to the purchase of intangible assets, and &#128;2.1&nbsp;million to the purchase of property, plant and equipment, partially offset by proceeds from
the sale of property, plant and equipment amounting to &#128;97&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the year ended December&nbsp;31,
2018 was &#128;413&nbsp;thousand, of which &#128;78&nbsp;thousand was attributable to the purchase of intangible assets, and &#128;429&nbsp;thousand was attributable to the purchase of property, plant and equipment, partially offset by proceeds from
the sale of property, plant and equipment amounting to &#128;94&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The increase in investing activities reflects the increase in our research
and development activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended March&nbsp;31, 2020 and 2019 net cash used in financing activities was of &#128;611&nbsp;thousand and &#128;446&nbsp;thousand,
resulting entirely from the payment of the principal portion of lease liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2019 net cash used in
financing activities consisted of &#128;1.9&nbsp;million from the payment of the principal portion of lease liabilities. During the year ended December&nbsp;31, 2018, cash inflow from financing activities of &#128;23.6&nbsp;million was generated
from the share premium proceeds received relating to the issuance of shares in 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operation and Funding Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Historically, we have incurred significant losses due to our substantial research and development expenses. We had an accumulated deficit of
&#128;241.5&nbsp;million as of March&nbsp;31, 2020 and of &#128;233.2&nbsp;million as of December&nbsp;31, 2019. We expect to continue to incur significant losses in the foreseeable future and expect our expenses to increase in connection with our
ongoing activities, particularly as we continue research and development and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical activities for our product candidates. In addition, we expect to incur additional costs associated with operating as a public company. Our expenses will also increase if, and as, we:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue or expand our research or development programs in preclinical development; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue or expand the scope of our clinical trials for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate additional preclinical studies or clinical or other trials for our product candidates, including under
our collaboration agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to invest in our immunotherapy platforms to conduct research to identify novel technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change or add to internal manufacturing capacity or capability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change or add additional suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">add additional infrastructure to our quality control, quality assurance, legal, compliance and other groups to
support our operations as we progress product candidates toward commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">attract and retain skilled personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">create additional infrastructure to support our operations as a public company and our product development and
planned future commercialization efforts, including expansion of sites in Germany and in the United States; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek marketing approvals and reimbursement for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize any products for which we may
obtain marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seek to identify and validate additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-licenses</FONT> other product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make milestone or other payments under any <FONT STYLE="white-space:nowrap">in-license</FONT> agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain, protect, defend, enforce and expand our intellectual property portfolio; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">experience any delays, interruptions or encounter issues with any of the above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to all of the risks related to the development and commercialization of pharmaceutical products, and we may encounter unforeseen expenses,
difficulties, complications, delays and other unknown factors that may adversely affect our business. Our forecast of sufficient financial runway to support our operations is a forward-looking statement and involves risks and uncertainties, and
actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and could utilize our available capital resources sooner than we currently expect. We believe that our cash and cash
equivalents, will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through at least the next 12 months. We will need to obtain additional financing to fund our future operations, including completing the
development and commercialization of our product candidates. Our future funding requirements will depend on many factors, including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">progress, timing, scope and costs of our clinical trials, including the ability to timely initiate clinical
sites, enroll subjects and manufacture Adoptive Cell Therapy (&#147;ACT&#148;), and bispecific T cell engaging receptor, or TCR Bispecific, product candidates for our ongoing, planned and potential future clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">time and cost to conduct investigational new drug application (&#147;IND&#148;) or clinical trial application
(&#147;CTA&#148;) enabling studies for our preclinical programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">time and costs required to perform research and development to identify and characterize new product candidates
from our research programs; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">time and cost necessary to obtain regulatory authorizations and approvals that may be required by regulatory
authorities to execute clinical trials or commercialize our product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully commercialize our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to have clinical and commercial products successfully manufactured consistent with U.S. Food and Drug
Administration (&#147;FDA&#148;), European Medicines Agency (&#147;EMA&#148;), and other authorities&#146; regulations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">amount of sales and other revenues from product candidates that we may commercialize, if any, including the
selling prices for such potential products and the availability of adequate third-party coverage and reimbursement for patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales and marketing costs associated with commercializing our products, if approved, including the cost and
timing of building our marketing and sales capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost of building, staffing and validating our manufacturing processes, which may include capital expenditure;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">terms and timing of our current and any potential future collaborations, licensing or other arrangements that we
have established or may establish; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cash requirements of any future acquisitions or the development of other product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of operating as a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">time and cost necessary to respond to technological, regulatory, political and market developments;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs associated with any potential acquisitions, strategic collaborations, licensing agreements or other
arrangements that we may establish; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">inability of clinical sites to enroll patients as health care capacities are required to cope with natural
disasters, epidemics or other health system emergencies, such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
change in the outcome of any of these or other variables with respect to the development of any of our current and future product candidates could significantly change the costs and timing associated with the development of that product candidate.
Furthermore, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until we can generate sufficient product and royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future cash
needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements as well as grant funding. We will use the proceeds from
the PIPE Financing, together with the proceeds received from our trust account, to fund our future research and development activities. These estimates are based on assumptions that may prove to be wrong. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with
third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we raise additional capital through
public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our shareholders&#146; rights. Further, to the extent that we raise additional capital through the sale of ordinary
shares or securities convertible or exchangeable into ordinary shares, our shareholders&#146; ownership interest will be diluted. If we raise additional capital through debt financing, we would be subject to fixed payment obligations and may be
subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital expenditures or declaring dividends. If we are unable to obtain additional funding on favorable terms when needed, we may have to delay, reduce the scope of or terminate one or more of
our research and development programs or clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance&nbsp;Sheet</FONT> Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the periods presented, we did not <FONT STYLE="white-space:nowrap">have&nbsp;any&nbsp;off-balance&nbsp;sheet&nbsp;arrangements</FONT> that have or are
reasonably likely to have a current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Commitments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
table summarizes our contractual obligations as of December&nbsp;31, 2019 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments due by period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than&nbsp;1<BR>year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;-&nbsp;3<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3&nbsp;-&nbsp;5<BR>years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than</B><br><B>5 years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;1,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;3,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other lease obligations<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-license&nbsp;agreements</FONT><SUP
STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract research organization
agreements<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total contractual obligations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,813</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>347</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>300</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&#128;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,700</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents our future minimum commitments under <FONT STYLE="white-space:nowrap">non-cancellable</FONT> lease
liabilities reflected on the balance sheet in our audited consolidated financial statements included elsewhere in this prospectus. In addition, in 2020, we signed further lease agreements leading to additional payments of approximately &#128;3.2
million. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents our future minimum commitments under <FONT STYLE="white-space:nowrap">non-cancellable</FONT> leasing
arrangements, which are not capitalized under IFRS 16. These arrangements include short-term as well as low value leases, which are not reflected on our balance sheet. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents obligations of <FONT STYLE="white-space:nowrap">non-cancellable</FONT> terms of license agreements.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents obligations from contract research organization agreements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have lease agreements for land and buildings in our locations T&uuml;bingen, Munich and Houston, Texas, which will expire between 2020 and 2026. In
addition, we have various leases for equipment and cars, which will expire in 2022. The amounts in the table above represent our fixed contractual lease obligations and do not include the optional extensions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the above obligations, we enter into a variety of agreements and financial commitments in the normal course of business. The terms generally
provide us with the option to cancel, reschedule and adjust our requirements based on our business needs, prior to the delivery of goods or performance of services. However, it is not possible to predict the maximum potential amount of future
payments under these agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements for the years ended December&nbsp;31, 2019 and 2018, respectively, have been prepared in accordance with IFRS. The
preparation of the consolidated financial statements in accordance with IFRS requires the use of estimates and assumptions that affect the value of assets and liabilities &#151; as well as contingent assets and liabilities &#151; as reported on the
balance sheet date, and revenues and expenses arising during the fiscal year. The main areas in which assumptions, estimates and the exercising of a degree of discretion are appropriate relate to revenue recognition, research and development
expenses, share-based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
compensation and income taxes. We based our assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions
about future developments, however, may change due to market changes or circumstances arising that are beyond our control. Hence, our estimates may vary from the actual values. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our
consolidated financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition for Collaboration Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize revenue through collaboration and license agreements and reimbursement for research and development costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our collaboration and license agreements, we <FONT STYLE="white-space:nowrap">may&nbsp;receive&nbsp;up-front&nbsp;licensing&nbsp;payments,</FONT>
milestone payments and reimbursement of research and development expenses. Such collaboration agreements also include licenses of certain of our intellectual property to the respective collaborators. As these agreements comprise several promises, it
must be assessed whether these promises are capable of being distinct within the context of the contract. For each of our four collaboration agreements, we determined that the promises included in each agreement represented single combined
performance obligation with a single measure of progress. The performance obligation is accounted for as a performance obligation satisfied over time on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT>
basis, as our customer simultaneously receives and consumes the benefits from our performance. <FONT STYLE="white-space:nowrap">Up-front</FONT> licensing payments and reimbursement for development expenses are initially deferred on our statement of
financial position and subsequently recognized as revenue over time as costs are incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Milestone payments are generally included in the transaction
price at the amount stipulated in the respective agreement and recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. To date, no milestone has been included in
the transaction price and recognized into revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For further information regarding our revenue recognition policy, please refer to Note
4.9&nbsp;Revenue from collaboration agreements&nbsp;of the Notes to the Consolidated Financial Statements as of December&nbsp;31, 2019 of our consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and
development expenses are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities
costs, laboratory supplies, depreciation, manufacturing expenses and external costs of vendors engaged to conduct preclinical development activities and clinical trials as well as the cost of licensing technology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All patent-related costs incurred in connection with filing and prosecuting patent applications are classified as research and development expenses and
expensed as incurred due to the uncertainty about the recovery of the expenditure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the equity plan of Immatics OpCo, management applied a Black Scholes pricing model to estimate the fair value of Immatics Stock Appreciation Rights
(&#147;SARs&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We determined the value of the SARs with the assistance of a third party valuation specialist using certain assumptions, such as
share price volatility, the determination of an appropriate risk-free interest rate, expected </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dividends and the probability of reaching certain exercisability criteria. Expected volatility of the equity plan of Immatics OpCo was determined by calculating the historic volatility in share
prices of peer companies within the biotechnology industry and the expected life in the model has been adjusted, based on our management&#146;s best estimate, for the effects
<FONT STYLE="white-space:nowrap">of&nbsp;non-transferability&nbsp;and</FONT> exercise restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercisability is dependent on our estimated
combined probability of exit events. We discounted the fair values of the SARs based on these assumed probabilities of the awards becoming exercisable. The present value of the probability-weighted fair value under all scenarios represents the value
of the SARs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Uncertainties
exist with respect to the interpretation of complex tax regulations, changes in tax laws, and the amount and timing of future taxable income. Given the wide range and complexity of existing contractual agreements, differences arising between the
actual results and the assumptions made, or future changes to such assumptions, could necessitate future adjustments to tax income and expense already recorded. Deferred tax assets are recognized for unused tax losses to the extent that it is
probable that taxable profit will be available against which the losses can be utilized. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level
of future taxable profits together with future tax planning strategies. Currently, all tax loss carryforwards are fully reserved due to management judgement regarding the future profitability of the company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued and Adopted Accounting Pronouncement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
information on the standards applied for the first time as of January&nbsp;1, 2020 and 2019, please refer to our consolidated financial statements as of December&nbsp;31, 2019 provided elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to various risks in relation to financial instruments, including liquidity risk and currency risk. Our risk management is coordinated by our
Executive Committee. We do not engage in the trading of financial assets for speculative purposes. The most significant financial risks to which we are exposed include the risks discussed below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our principal financial instruments comprise cash, cash equivalents and fixed-term deposits. The main purpose of these financial instruments is to invest the
proceeds of capital contributions and upfront payments from collaboration agreements. We have various other financial instruments such as other receivables and trade accounts payable, which arise directly from our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with our internal guidelines, we do not trade in derivatives. The main risks arising from our financial instruments are interest rate risk,
liquidity risk and currency exchange risk. The Management Board reviews and agrees to policies for managing these risks as summarized below. We also monitor the market price risk arising from all financial instruments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interest rate risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our exposure to changes in
interest rates relates to investments in deposits and to changes in the interest for overnight deposits. Changes in the general level of interest rates may lead to an increase or decrease in the fair value of these investments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regarding the liabilities shown in the statement of financial position, we are currently not subject to interest rate risks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Credit risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject us to concentrations of credit and liquidity risk consist primarily of cash, cash equivalents, deposits and
accounts receivable. Our cash, cash equivalents and deposits are denominated in Euros and U.S. Dollars. Cash, cash equivalents and deposits securities are maintained with two high-quality financial institutions in Germany and one in the United
States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We continually monitor our positions with, and the credit quality of, the financial institutions and corporations that are counterparts to our
financial instruments and we are not currently anticipating <FONT STYLE="white-space:nowrap">non-performance.</FONT> The maximum default risk corresponds to the carrying amount of the financial assets shown in the statement of financial position. We
monitor the risk of a liquidity shortage. The main factors considered here are the maturities of financial assets, as well as expected cash flows from equity measures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Currency risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currency risk shows the risk that
the value of a financial instrument will fluctuate due to changes in foreign exchange rates. In particular, it poses a threat if the value of the currency in which liabilities are priced appreciates relative to the currency of the assets. Our
business transactions are generally conducted in Euros and U.S. Dollars. In the finance committee meetings, we analyze the currency risks. We aim to match U.S.&nbsp;Dollar cash inflows with U.S.&nbsp;Dollar cash outflows where possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our cash and cash equivalents were &#128;72.2&nbsp;million and &#128;103.4&nbsp;million as of March&nbsp;31, 2020 and December&nbsp;31, 2019, respectively. As
of March&nbsp;31, 2020 approximately 92% of our cash and cash equivalents were held in Germany, of which approximately 27% were denominated in Euros and 73% were denominated in U.S. Dollars. The remainder of our cash and cash equivalents are held in
the United States and denominated in U.S. Dollars. Additionally, we have short-term deposits classified as other current assets denominated in U.S Dollars in the amount of &#128;32.9&nbsp;million as of March&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We continuously monitor our risk
to a shortage of funds. Our objective is to maintain a balance between continuity of funding and flexibility through the use of capital increases. We concluded that our liquidity risk is moderate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal Control over Financial Reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A material
weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a
timely basis. In connection with the audit of our consolidated financial statements for the year ended December&nbsp;31, 2019, we identified material weaknesses in our internal controls related to (i)&nbsp;the sufficiency of resources with an
appropriate level of technical accounting and SEC reporting experience, (ii)&nbsp;clearly defined control processes, roles and segregation of duties within our finance and accounting functions, and (iii)&nbsp;the design and operating effectiveness
of IT general controls for information systems that are significant to the preparation of our consolidated financial statements. We are developing a remediation plan designed to address these material weaknesses and other existing deficiencies. In
addition, we have, and are in the process of, recruiting, hiring, and retaining additional financial reporting personnel to develop and implement appropriate internal controls and reporting procedures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Structure </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a Dutch public limited
liability company (<I>naamloze vennootschap</I>) with <FONT STYLE="white-space:nowrap">a&nbsp;two-tier&nbsp;board</FONT> structure that consists of a management board (<I>bestuur</I>) (the &#147;Management Board&#148;) and a supervisory board
(<I>raad van commissarissen</I>) (the &#147;Supervisory Board&#148;). The Management Board and the Supervisory Board are separate boards and no individual may simultaneously be a member of both boards. We also have an executive committee (the
&#147;Executive Committee&#148;) consisting of a sole managing director and executive officers appointed by the Management Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Dutch law, the
Management Board is responsible for our management, strategy, policy and operations. The Supervisory Board is responsible for supervising the conduct of and providing advice to our Management Board and for supervising the business generally.
Furthermore, each member of the Management Board and Supervisory Board has a duty to act in the corporate interest of the company and the business connected with it. Under Dutch law, the corporate interest extends to the interests of all corporate
stakeholders, such as shareholders, creditors, employees, customers and suppliers. The duty to act in the corporate interest of the company also applies in the event of a proposed sale <FONT STYLE="white-space:nowrap">or&nbsp;break-up&nbsp;of</FONT>
the company, whereby the circumstances generally dictate how such duty is to be applied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2021, and pursuant to our articles of
association, <FONT STYLE="white-space:nowrap">our&nbsp;two-tier&nbsp;board</FONT> structure will automatically convert into <FONT STYLE="white-space:nowrap">a&nbsp;one-tier&nbsp;board</FONT> structure. There will be one board of directors that will
consist of executive directors and <FONT STYLE="white-space:nowrap">non-executive&nbsp;directors.</FONT> In <FONT STYLE="white-space:nowrap">the&nbsp;one-tier&nbsp;board</FONT> structure, the Executive Committee will consist of all executive
directors and all executive officers. As used herein, the term &#147;Board&#148; refers to the Management Board and the Supervisory Board collectively through July&nbsp;1, 2021, and to the <FONT STYLE="white-space:nowrap">one-tier</FONT> board of
directors after such date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management Board </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Harpreet Singh, Ph.D., our Chief Executive Officer, serves as the sole managing director. The Management Board consists of such number of managing directors as
the Supervisory Board may determine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to our articles of association, the Management Board is charged with the management of the company. In
fulfilling their duties, managing directors serve the interest of the company and the business connected therewith. Resolutions of our Management Board that result in an important change in the identity or character of the company or the business
connected with it (for example, transfer of the entire business to a third party) require approval of the general meeting. Additionally, resolutions of our Management Board that relate to significant corporate action (for example, listing on Nasdaq,
capital expenditures or debt incurrence of over $500,000 and related party transactions) require prior approval by the Supervisory Board. A resolution taken by our Management Board in violation of our articles of association will be void or
voidable. The Management Board has the power to represent the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our articles of association, managing directors are elected by the
general meeting upon a binding nomination. The Supervisory Board is authorized to nominate a director candidate for appointment at the general meeting. Shareholders who individually or jointly represent at
<FONT STYLE="white-space:nowrap">least&nbsp;one-tenth&nbsp;of</FONT> the issued share capital have the same right to nominate a director candidate for appointment at the general meeting. The general meeting may at any time suspend and dismiss a
managing director. The general meeting may only adopt a resolution to suspend or dismiss a managing director by a majority of at least two thirds of the votes cast, representing more than half of the issued share capital, unless the resolution is
adopted on the basis of a proposal of the Supervisory Board; in that case, the resolution may be adopted by an absolute majority of the votes cast, representing more than half of the issued share capital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Management Board is required to provide the Supervisory Board with the information it needs to carry out
its duties. In addition, at least once a year, the Management Board must inform the Supervisory Board in writing of the strategic policy, the general and financial risks and the management and control system of the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our articles of association provide that if one or more managing directors have a direct or indirect personal interest that conflicts with the interest of the
company and the business connected with it, they will not be authorized to participate in the discussion and the decision-making process. In the event that all managing directors have, or the only managing director has, a direct or indirect personal
interest that conflicts with the interest of the company and the business connected with it, the resolution will be adopted by the Supervisory Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Supervisory Board </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Supervisory Board consists
of seven supervisory directors, although only six supervisory directors have been appointed at this time. The Supervisory Board may consist of such number of supervisory directors as the Supervisory Board may determine, but not less than three. The
Supervisory Board is divided into three classes, with each class as nearly equal in number as possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The role of the Supervisory Board is the
supervision of the policies of the Management Board and of the general course of affairs of the company and the business connected with it. In doing so, the Supervisory Board also focuses on the effectiveness of our internal risk management and
control systems and the integrity and quality of our financial reporting. In fulfilling their duties, the supervisory directors must serve the interests of the company and the business connected with it. This supervision includes the power to
intervene whenever necessary and to take corrective actions as may be required in the interest of the company, subject to Dutch law and our articles of association. Our articles of association provide the Supervisory Board with the authority to
approve or reject Management Board resolutions that relate to significant corporate action (for example, listing on Nasdaq, capital expenditures or debt incurrence of over $500,000 and related party transactions). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our articles of association, the supervisory directors are appointed by the general meeting upon a binding nomination. The Supervisory Board is
authorized to nominate a director candidate for appointment at the general meeting. Shareholders who individually or jointly represent at <FONT STYLE="white-space:nowrap">least&nbsp;one-tenth&nbsp;of</FONT> the issued share capital have the same
right to nominate a director candidate for appointment at the general meeting. The general meeting may at all times overrule the binding nature of each nomination by a resolution adopted by a majority of at least two thirds of the votes cast,
representing more than half of the issued share capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general meeting may at any time suspend and dismiss a supervisory director. The general
meeting may only adopt a resolution to suspend or dismiss a supervisory director by a majority of at least two thirds of the votes cast, representing more than half of the issued share capital, unless the resolution is adopted on the basis of a
proposal of the Supervisory Board; in that case, the resolution may be adopted by an absolute majority of the votes cast representing more than half of the issued share capital. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board of Directors </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2021, and
pursuant to our articles of association, <FONT STYLE="white-space:nowrap">our&nbsp;two-tier&nbsp;board</FONT> structure will automatically convert into <FONT STYLE="white-space:nowrap">a&nbsp;one-tier&nbsp;board</FONT> structure. There will be one
Board that will consist of executive directors and <FONT STYLE="white-space:nowrap">non-executive&nbsp;directors.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to our articles of
association, the Board will be charged with the management of the company. In fulfilling their duties, our directors will serve the interest of the company and the business connected with it. The executive directors and the Executive Committee are
charged with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">the&nbsp;day-to-day&nbsp;management</FONT></FONT> of the company. Supervision of the fulfilment of duties by the executive directors and of the general course of the
company&#146;s affairs and the business connected with it will primarily be carried out by the <FONT STYLE="white-space:nowrap">non-executive</FONT> directors. The executive directors must in due time provide the
<FONT STYLE="white-space:nowrap">non-executive</FONT> directors with the information they need to carry out their duties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board consists of one or more executive directors and three or more
<FONT STYLE="white-space:nowrap">non-executive</FONT> directors. The majority of the Board, however, consists <FONT STYLE="white-space:nowrap">of&nbsp;non-executive&nbsp;directors.</FONT> The number of executive directors and <FONT
STYLE="white-space:nowrap">non-executive</FONT> directors is determined by the Board. The Board will be divided into three classes with each class as nearly equal in number as possible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After July&nbsp;1, 2021, our directors will be elected by the general meeting upon a binding nomination. The Board will be authorized to nominate a director
candidate for appointment at the general meeting. Shareholders who individually or jointly represent at <FONT STYLE="white-space:nowrap">least&nbsp;one-tenth&nbsp;of</FONT> the issued share capital will have the same right to nominate a director
candidate for appointment at the general meeting. The general meeting may at all times overrule the binding nature of each nomination by a resolution adopted by a majority of at least two thirds of the votes cast, representing more than half of the
issued share capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general meeting may at any time suspend and dismiss a <FONT STYLE="white-space:nowrap">non-executive</FONT> director or
executive director. The general meeting may only adopt a resolution to suspend or dismiss a <FONT STYLE="white-space:nowrap">non-executive</FONT> director or executive director by a majority of at least two thirds of the votes cast, representing
more than half of the issued share capital, unless the resolution is adopted on the basis of a proposal of the Board; in that case, the resolution may be adopted by an absolute majority of the votes cast, representing more than half of the issued
share capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Committee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to
the Management Board and the Supervisory Board, or the Board after July&nbsp;1, 2021, we have an Executive Committee. Pursuant to our articles of association, the Executive Committee consists of all managing directors and executive officers.
Executive officers who are not managing directors are appointed by the Management Board. The Management Board may at any time suspend or dismiss an executive officer who is not a managing director. A resolution of the Management Board to appoint,
suspend or dismiss an executive officer requires the prior approval of the Supervisory Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Executive Committee is charged with the matters
concerning the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of the company determined by the Management Board. Two executive officers acting jointly have the power to represent the company.
The Management Board may, whether or not by rule, determine the duties with which each executive officer will be particularly charged, such resolution requires the prior approval of the Supervisory Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Directors and Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Management Board consists of one managing director, the Executive Committee consists of seven executive officers, and the Supervisory Board consists of
seven supervisory directors, although only six supervisory directors have been appointed at this time. The following table lists the names, ages as of July&nbsp;31, 2020 and positions of the individuals who are serving as managing director,
executive officers and supervisory directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Executive Committee</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harpreet Singh, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Ulmer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cedrik Britten, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carsten Reinhardt, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Development Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Toni Weinschenk, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Innovation Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rainer Kramer, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Business Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steffen Walter, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Technology Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Management Board</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harpreet Singh, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Supervisory Board</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Chambr&eacute;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairman of the Supervisory Board</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael G. Atieh</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Supervisory Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul R. Carter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Supervisory Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christof Hettich, L.L.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Supervisory Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heather L. Mason</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Supervisory Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adam Stone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Supervisory Director</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Harpreet Singh, Ph.D.</I><I></I><FONT STYLE="white-space:nowrap">&nbsp;Dr.&nbsp;Singh&nbsp;co-founded&nbsp;Immatics</FONT> OpCo in 2000, and since its
foundation, Dr.&nbsp;Singh has served in a number of roles, including as managing director and Chief Scientific Officer. In addition, in 2014, Dr.&nbsp;Singh became President&nbsp;&amp; CEO of Immatics U.S., overseeing all operations in Houston,
Texas and a strategic collaboration with MD Anderson Cancer Center to develop next-generation adoptive cell therapies. In 2019, Dr.&nbsp;Singh became CEO of Immatics OpCo. Dr.&nbsp;Singh has played a leadership role in raising more than
$200&nbsp;million of venture capital funding over several financing rounds as well $30&nbsp;million of public grants. Dr.&nbsp;Singh is the inventor of numerous granted patents and patent applications
<FONT STYLE="white-space:nowrap">and&nbsp;co-author&nbsp;of</FONT> numerous scientific papers published by peer-reviewed journals including Nature, Nature Medicine, Nature Biotechnology, Journal of Experimental Medicine, Brain, Lancet Oncology and
more. A scholar of Prof. Hans-Georg Rammensee, Dr.&nbsp;Singh completed his academic studies by gaining a Ph.D. in immunology at the University of T&uuml;bingen, Germany.<B><I>&nbsp;</I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Singh&#146;s qualifications to serve on our Management Board include his corporate leadership experience, perspective and experience as
one of Immatics OpCo&#146;s founders and as a long-term executive of Immatics in the United States and Germany, and his scientific background. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Thomas
Ulmer.</I><I></I>&nbsp;Mr.&nbsp;Ulmer joined Immatics OpCo as its Chief Financial Officer in April 2018 from the Merck Group (&#147;Merck&#148;), where he was Chief Financial Officer of the Allergopharma Business Unit. Mr.&nbsp;Ulmer began his
professional career with Merck in 2004 where he held several roles, including Head of Business Planning&nbsp;&amp; Analysis and previously Head of Planning, Forecasting&nbsp;&amp; Resource Allocation. Mr.&nbsp;Ulmer has also been Chief Financial
Officer for Australia and New Zealand and Financial Controller for Merck&#146;s global generics business which was sold to Mylan Laboratories Inc. Mr.&nbsp;Ulmer also played a leading role of the integration of the business and built up an OTC
business unit in Australia for which he received the company&#146;s innovation award. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Mr.&nbsp;Ulmer is a Certified Practicing Accountant of Australia and holds an MBA from Justus-Liebig-University of Giessen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Mr.&nbsp;Ulmer&#146;s qualifications to serve on the Executive Committee include his financial background and corporate leadership experience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cedrik M. Britten, M.D.</I>&nbsp;Dr.&nbsp;Britten joined Immatics OpCo as its Chief Medical Officer in June 2020, assuming leadership for the management
and global clinical development of our adoptive cell therapy and TCR Bispecifics pipeline from first testing in humans to registration trials, including managing regulatory affairs. Prior to that, Dr.&nbsp;Britten served as the Vice President and
Head of the Oncology Cell Therapy Research Unit at GlaxoSmithKline plc (NYSE: GSK) from February 2015 to May 2020. While at GlaxoSmithKline, Dr.&nbsp;Britten was responsible for building the Oncology Cell Therapy Unit and driving the strategy and
establishing the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-to-end</FONT></FONT> capabilities required to research and develop innovative cell therapies in oncology. His main focus was on the early cell therapy portfolio
covering target validation, the preclinical space and clinical trials up to proof of concept in patients. He also led several technical due diligences and deal preparations for new partnerships with various life science companies in the cell therapy
space. He coordinated the <FONT STYLE="white-space:nowrap">opt-in</FONT> and transfer of the late-stage <FONT STYLE="white-space:nowrap">NY-ESO</FONT> <FONT STYLE="white-space:nowrap">TCR-T</FONT> cell asset with multiple active clinical protocols
into GSK, and oversaw four early cell therapy programs. Prior to his role at GlaxoSmithKline, Dr.&nbsp;Britten was Vice President of Research and Development at BioNTech RNA Pharmaceuticals GmbH. While at BioNTech, Dr.&nbsp;Britten was a key player
establishing its clinical research group and led the clinical trial applications for BioNTech&#146;s initial clinical assets until January 2015. Dr.&nbsp;Britten holds an M.D. from the University Medical Center of the Johannes-Gutenberg University.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Britten&#146;s qualifications to serve on the Executive Committee include his long-term experience in drug development, his specific
experience in immune-oncology including cell therapy, his medical background, his leadership experience, and his track record of developing corporate partnerships. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Carsten Reinhardt, M.D., Ph.D.</I><I></I>&nbsp;Dr.&nbsp;Reinhardt joined Immatics OpCo as its managing director and Chief Medical Officer in October 2009
from Micromet, Inc., where he was Chief Medical Officer and a member of the management board. In June 2020, Dr.&nbsp;Reinhardt began serving as Immatics OpCo&#146;s Chief Development Officer leading its Product Development Strategy. Furthermore, he
leads our TCR Bispecifics platform and pipeline as well as the Immunology and Translational Development functions. Previously, as International Medical Leader <FONT STYLE="white-space:nowrap">at&nbsp;Hoffmann-La&nbsp;Roche</FONT>
(&#147;Roche&#148;), Dr.&nbsp;Reinhardt had global responsibility for the development of Herceptin. Prior to his tenure at Roche, Dr.&nbsp;Reinhardt was Head of Clinical Development at Fresenius Biotech GmbH. Prior to joining the pharma and biotech
industry, Dr.&nbsp;Reinhardt held various academic medical positions and worked at the University of T&uuml;bingen and Max Planck Institute, Munich to complete his curriculum in Neurology. Dr.&nbsp;Reinhardt
<FONT STYLE="white-space:nowrap">has&nbsp;co-authored&nbsp;more</FONT> than 40 publications in peer-reviewed journals including Nature, Science, Nature Medicine, Lancet, Journal of Clinical Oncology, Cancer Research, and Journal of Experimental
Medicine. Dr.&nbsp;Reinhardt is a Visiting Professor for Pharmaceutical Medicine at the University of Basel. Dr.&nbsp;Reinhardt received a Medical Degree in 1994 from the University of Munich, Germany and, in addition, completed a Ph.D. thesis in
cellular immunology at the Institute of Immunology in Munich, Germany. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Reinhardt&#146;s qualifications to serve on the Executive
Committee include his corporate leadership experience, his long-term experience in the areas of early- and late-stage drug development, and his medical and scientific background, as well as his track record of developing corporate partnerships and
serving as an executive at public companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Toni Weinschenk,
Ph.D.</I><I></I><FONT STYLE="white-space:nowrap">&nbsp;Dr.&nbsp;Weinschenk&nbsp;co-founded&nbsp;Immatics</FONT> OpCo in 2000. From 2002 to 2014, Dr.&nbsp;Weinschenk served as Immatics&#146; Head of Discovery. In 2015, Dr.&nbsp;Weinschenk became
Immatics Opco&#146;s Vice President Discovery, later transitioning to Chief Technology Officer for Immatics U.S. in 2015. In 2017, Dr.&nbsp;Weinschenk assumed the role of Immatics OpCo&#146;s Chief Technology Officer. As of June 2020,
Dr.&nbsp;Weinschenk serves as our Chief Innovation Officer. Dr.&nbsp;Weinschenk is the inventor of our proprietary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
XPRESIDENT technology platform and leads the discovery and validation of novel and innovative I/O targets. Furthermore, he is responsible for advancing our vision for ultrapersonalized
multi-target immunotherapies and the <FONT STYLE="white-space:nowrap">X-AI</FONT> data computing platform. pHLA targets discovered by his XPRESIDENT platform have been utilized for all of our drug candidates and for the collaboration with leading
players in the field including Amgen, Genmab, BMS and GSK. Dr.&nbsp;Weinschenk is an inventor who holds many patents and <FONT STYLE="white-space:nowrap">has&nbsp;co-authored&nbsp;numerous</FONT> publications in the cancer immunology field in
peer-reviewed journals including Nature, Nature Medicine, Nature Immunology, Immunological Reviews and Cell Report. Dr.&nbsp;Weinschenk holds a Doctor of Science degree and a diploma in biochemistry from the University of T&uuml;bingen, Germany.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Weinschenk&#146;s qualifications to serve on the Executive Committee include his corporate leadership experience, his globally
leading expertise in the field of pHLA target discovery, his perspective and experience as one of Immatics OpCo&#146;s founders and his scientific background. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Rainer Kramer, Ph.D.</I><I></I>&nbsp;Dr.&nbsp;Kramer joined Immatics OpCo as its Chief Business Officer in April 2012 from Signature Diagnostics AG, where
he was a member of the Management Board and Chief Business Officer. Dr.&nbsp;Kramer still serves as Chief Business Officer, and he is responsible for our corporate business development activities, intellectual property and strategic alliance
management. Dr.&nbsp;Kramer also currently serves as a director on the board of Immatics U.S. Dr.&nbsp;Kramer has worked in research and business development functions with increasing responsibilities at Amgen Inc., MorphoSys AG, Jerini AG, Shire
PLC and Signature Diagnostics AG. During his career, Dr.&nbsp;Kramer negotiated and contributed to the completion of more than 50 partnering, M&amp;A and financing transactions with an aggregate value of more than $6&nbsp;billion. Dr.&nbsp;Kramer
holds a diploma in molecular biology from the University of Regensburg and a Ph.D. in neurobiology from <FONT STYLE="white-space:nowrap">the&nbsp;Max-Planck-Institute,&nbsp;Martinsried,</FONT> Germany. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Kramer&#146;s qualifications to serve on the Executive Committee include his corporate leadership experience and educational background,
as well as his broad business experience and track record within the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dr.</I><I></I><I>&nbsp;Steffen Walter</I>. After serving
as a scientific consultant in 2004, Dr.&nbsp;Walter joined Immatics OpCo `in 2005 where he initially served as Director and Head of Immunology from January 2005 until December 2013, then as Vice President Immunology from January 2014 until April
2015, and then served as Chief Scientific Officer of Immatics U.S. As of June 2020, Dr.&nbsp;Walter serves as our Chief Technology Officer. Dr.&nbsp;Walter also established operations of Immatics US in Houston, Texas and contributed significantly to
raising the necessary funding including a $20&nbsp;million Cancer Prevention and Research grant by the State of Texas. Dr.&nbsp;Walter leads our Cell Therapy platform and pipeline including manufacturing and process development. Furthermore, he
leads our Quality Management. For over 15 years, Dr.&nbsp;Walter has been active in the field of cancer immunotherapy and a leader in human T cell biology. In addition to supporting the development of the XPRESIDENT technology platform, under his
initial leadership, we developed our powerful XCEPTOR platforms to support the generation of safe and effective <FONT STYLE="white-space:nowrap">TCR-based</FONT> therapeutic modalities. Dr.&nbsp;Walter is an inventor on numerous patents and patent
applications and <FONT STYLE="white-space:nowrap">has&nbsp;co-authored&nbsp;more</FONT> than 30 publications in prestigious peer-reviewed journals including Nature Medicine, Cell Reports, Lancet Oncology, Brain and Blood. Dr.&nbsp;Walter gained his
diploma in biochemistry and a Ph.D. in immunology from the University of T&uuml;bingen, Germany. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Walter&#146;s qualifications to
serve on the Executive Committee include his corporate leadership experience, his long-term experience in the field of T cell biology, his perspective and experience as one of the founders of Immatics US and his scientific background. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Managing Director </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Harpreet Singh, Ph.D., our
Chief Executive Officer, serves as the sole managing director. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Supervisory Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Peter Chambr&eacute;</I>. Mr.&nbsp;Chambr&eacute; joined Immatics OpCo as Chairman of the Board in October 2012, and still maintains the position of
Chairman. Mr.&nbsp;Chambr&eacute; also acted as Executive Chairman between August 2015 and June 2019. Mr.&nbsp;Chambr&eacute; was the Chief Executive Officer of Cambridge Antibody Technology Group plc (&#147;CAT&#148;) from 2002 until its
acquisition by AstraZeneca plc in 2006. Before joining CAT, Mr.&nbsp;Chambr&eacute; was Chief Operating Officer of Celera Genomics Group and, previously, CEO of Bespak plc (later Consort Medical plc), a drug delivery company. From 2008 to 2010,
Mr.&nbsp;Chambr&eacute; was Chairman of ApaTech Ltd., a specialist in orthobiologic bone graft technologies, which was acquired by Baxter International Inc. in March 2010. From 2008 to 2013, Mr.&nbsp;Chambr&eacute; was Chairman of Xellia
Pharmaceuticals AS, a company focused on the development, manufacturing and global commercialization of anti-infective therapies and between 2011 and 2019 he was Chairman of OneMed AB a leading distributor of medical products in Northern Europe.
From 2006 to 2012, Mr.&nbsp;Chambr&eacute; served <FONT STYLE="white-space:nowrap">as&nbsp;Non-executive&nbsp;Director</FONT> of BTG plc and between 2006 and 2016, he served as
<FONT STYLE="white-space:nowrap">a&nbsp;Non-Executive&nbsp;Director</FONT> of Spectris plc. Mr.&nbsp;Chambr&eacute; also currently holds chairman <FONT STYLE="white-space:nowrap">and&nbsp;non-executive&nbsp;board</FONT> positions with other
companies, including UDG Healthcare plc, Cancer Research UK (trustee), and 7TM Holding ApS. Mr.&nbsp;Chambr&eacute; holds a Bachelor of Science in food science from the University of Reading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Mr.&nbsp;Chambr&eacute;&#146;s qualifications to serve on the Supervisory Board include his extensive business and leadership experience within the
life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Michael G. Atieh</I><B>.</B>&nbsp;Mr.&nbsp;Atieh was Executive Vice President, Chief Financial and Business Officer at
Ophthotech Inc. (Nasdaq: OPHT) from September 2014 until his retirement in March 2016. Previously, he was Executive Chairman of Eyetech Inc., a private biotech company from 2009 until the company was acquired in 2012. Prior to Eyetech, he was with
OSI Pharmaceuticals (Nasdaq: OSIP) where he served as Executive Vice President and Chief Financial Officer from 2005 until 2009. Mr.&nbsp;Atieh spent the majority of his career with Merck and Co., Inc. (NYSE: MRK) where he held various executive
level positions over a 19 year period, including Vice President- U.S. Human Health, Senior Vice President- Merck Medco Managed Care, Vice President- Public Affairs, Vice President- Government Relations, and Treasurer. Mr.&nbsp;Atieh began his career
at Arthur Young (now Ernst&nbsp;&amp; Young), where he became an Audit Manager. Mr.&nbsp;Atieh currently serves on the Board of Directors of Chubb Limited (NYSE: CB), where he is a member of the Risk&nbsp;&amp; Finance Committee, and previously
chaired the Audit Committee from 2012 to 2018. His previous Board experience was with Theravance Biopharma (Nasdaq: TBPH) from 2014 to 2015, where he was a member of the Audit Committee, OSI Pharmaceuticals, where he served as a member of the Board
and Chairman of the Audit Committee from 2003 to 2005 and Clintrak Clinical Labeling Services LLC, a private company where he served on the Board from 2004 to 2006. Mr.&nbsp;Atieh earned a B.A. from Upsala College. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Mr.&nbsp;Atieh&#146;s qualifications to serve on the Supervisory Board include his business leadership experience, financial background and track
record within the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Paul R. Carter, FCMA.</I>&nbsp;Mr.&nbsp;Carter&#146;s background includes 10 years of experience at Gilead
Sciences, Inc., in their Foster City, CA and London, UK offices, where he was employed as Executive Vice President, Commercial Operations from 2014 to 2016 and Senior Vice President and Head, International Commercial Operations from 2006-2014. Prior
to that role, Mr.&nbsp;Carter spent 10 years at GlaxoSmithKline plc, where he served as Regional Vice President, China&nbsp;&amp; Hong Kong from 2002 to 2005, Vice President and General Manager, Pharmaceutical&nbsp;&amp; Consumer Health, Hong
Kong&nbsp;&amp; South China from 1999-2002, and General Manager, SmithKline Beecham Consumer Health, Russia&nbsp;&amp; CIS from 1995 to 1999. Mr.&nbsp;Carter currently serves on the board of Hutchison China MediTech Ltd. (Nasdaq: HCM), a role he has
held since 2017, where he is the Chairman of the Remuneration Committee and member of the Audit Committee, Nomination Committee and Technical Committee. Mr.&nbsp;Carter has also served as a board member of Mallinckrodt PLC (NYSE: MNK) since 2018,
where he serves as a member of the Audit Committee. Mr.&nbsp;Carter is also the Chairman of Evox Therapeutics Ltd, a private biotechnology company based in Oxford, UK. Mr.&nbsp;Carter is also a board observer of Echosens SA, a private medical
technology company. From 2015-2019, Mr.&nbsp;Carter was a board member, member of the Remuneration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Committee, and Chair of the Audit Committee of Alder BioPharmaceuticals, Inc. In addition to his board memberships, Mr.&nbsp;Carter also serves as a healthcare advisor to numerous entities,
including Astorg Partners SAS (2017 to present), ZambonGroup (2017 to present), Indegene Inc. (2017 to present) and GLG Institute (2017 to present). Mr.&nbsp;Carter holds a Bachelor&#146;s degree in business studies from the University of West
London. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Mr.&nbsp;Carter&#146;s qualifications to serve on the Supervisory Board include his extensive business and leadership experience
within the life sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Christof Hettich, L.L.D.</I>&nbsp;Dr.&nbsp;Hettich has served on the Board of Directors of Immatics OpCo since
2006. Dr.&nbsp;Hettich has served as the Chief Executive Officer of SRH Holding (SdbR) since February 2015. Dr.&nbsp;Hettich also serves as chairman and a member on the board of several companies and foundations. Dr.&nbsp;Hettich is an attorney and
partner of RITTERSHAUS Rechtsanwaelte in Mannheim/Frankfurt, Germany. Dr.&nbsp;Hettich is also a founding partner and managing director of dievini Hopp BioTech holding GmbH&nbsp;&amp; Co. KG (&#147;dievini&#148;). Dr.&nbsp;Hettich was nominated
Honorary Professor at the University of Applied Sciences (FH) in Heidelberg, Germany in 2004. Dr.&nbsp;Hettich has a law degree from the University of Freiburg (Germany) and a Doctorate in Law from the University of W&uuml;rzburg, Germany. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Dr.&nbsp;Hettich&#146;s qualifications to serve on the Supervisory Board include his extensive business and leadership experience within the life
sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Heather L. Mason.</I><I></I>&nbsp;Ms.&nbsp;Mason served in numerous roles in 27 years at Abbott Laboratories, Inc. from 1990-2017,
including as Executive Vice President, Corporate Officer of Abbott Nutrition from 2014 to 2017, and as Senior Vice President, Corporate Officer of Abbott Diabetes Care from 2008 to 2014. Since 2019, Ms.&nbsp;Mason has served as a board member of
Assertio Therapeutics, Inc. (Nasdaq: ASRT) (formerly Depomed), where she is a member of the Audit and Compensation Committees. Since April 2020, Ms.&nbsp;Mason has also served on the board of Pendulum Therapeutics, Inc., a private, venture
capital-backed microbiome company. Ms.&nbsp;Mason holds a B.S.E. from the University of Michigan, Ann Arbor and an M.B.A. from the University of Chicago. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Ms.&nbsp;Mason&#146;s qualifications to serve on the Supervisory Board include her extensive business and leadership experience within the life
sciences industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Adam Stone</I>. Mr.&nbsp;Stone was the Chief Executive Officer of ARYA and a member of the board of directors of ARYA.
Mr.&nbsp;Stone joined Perceptive Advisors in 2006 and has acted as Chief Investment Officer since 2012 and is a member of the internal investment committees of Perceptive Advisors&#146; credit opportunities and venture funds. Mr.&nbsp;Stone
currently also serves on the boards of directors of Solid Biosciences (Nasdaq: SLDB), Renovia, and Xontogeny, which are portfolio companies of Perceptive Advisors. Prior to joining Perceptive Advisors, Mr.&nbsp;Stone was a Senior Analyst at Ursus
Capital from 2001 to 2006 where he focused on biotechnology and specialty pharmaceuticals. During Mr.&nbsp;Stone&#146;s tenure at Ursus Capital, Mr.&nbsp;Stone focused on biotech and specialty pharmaceuticals. Mr.&nbsp;Stone graduated with honors
from Princeton University with a BA in molecular biology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe Mr.&nbsp;Stone&#146;s qualifications to serve on the Supervisory Board include his
broad investment and transactional experience. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Director and Officer Qualifications </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not established any specific, minimum qualifications that must be met by each of our officers. However, we generally evaluate the following qualities:
educational background, diversity of professional experience, including whether the person is a current or was a former chief executive officer or chief financial officer of a public company or the head of a division of a prominent international
organization, knowledge of our business, integrity, professional reputation, independence, wisdom, and ability to represent the best interests of our shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating Committee of the Supervisory Board has prepared policies regarding director qualification
requirements and the process for identifying and evaluating director candidates for adoption by the Supervisory Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Management Board consists of one managing director and the Supervisory Board consists of six supervisory directors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the managing director is Harpreet Singh; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;I supervisory directors are Michael G. Atieh, a designee of the ARYA Sponsor and the <FONT
STYLE="white-space:nowrap">pre-Business</FONT> Combination independent directors of ARYA (collectively, the &#147;ARYA Initial shareholders&#148;) and Paul R. Carter, a designee of dievini, and their terms will expire at the first annual meeting of
shareholders following the Closing Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;II supervisory directors are Peter Chambr&eacute; and Heather L. Mason, and their terms will expire at
the second annual meeting of shareholders following the date of the Closing Date; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Class&nbsp;III supervisory directors are Adam Stone, a designee of the ARYA Initial shareholders, and Christof
Hettich, a designee of dievini, and their terms will expire at the third annual meeting of shareholders following the Closing Date. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
July&nbsp;1, 2021, and pursuant to our articles of association, <FONT STYLE="white-space:nowrap">our&nbsp;two-tier&nbsp;board</FONT> structure will automatically convert into <FONT STYLE="white-space:nowrap">a&nbsp;one-tier&nbsp;board</FONT>
structure which will consist of a nine member staggered board divided into three classes. The supervisory directors will retain their designated class upon the transition to the <FONT STYLE="white-space:nowrap">one-tier</FONT> board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of the staggered board, only one class of directors will be elected at each annual meeting of shareholders, with the other classes continuing for
the remainder of their respective terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our executive officers or directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Supervisory Board </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Supervisory
Board has established three standing committees: Audit Committee, Compensation Committee and Nominating&nbsp;&amp; Corporate Governance Committee. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Audit Committee members include
Michael G. Atieh, Paul R. Carter and Heather L. Mason. Mr.&nbsp;Atieh serves as chairman of the Audit Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each member of the Audit Committee is
expected to be financially literate and is expected to qualify as an &#147;Audit Committee financial expert&#148; as defined in applicable SEC rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Supervisory Board has adopted Audit Committee rules, which detail the principal functions of the Audit Committee, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">monitoring the independence of our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assuring the rotation of the audit partners (including the lead and concurring partners) as required by law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> all audit services and permitted <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent registered public accounting firm; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">making recommendations regarding the appointment or replacement of our independent registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">determining the compensation and oversight of the work of our independent registered public accounting firm
(including resolution of disagreements between the Executive Committee and the independent auditors regarding financial reporting) for the purpose of preparing or issuing an audit report or related work; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with the independent auditors and the Executive Officers our annual financial statements
and related disclosures as well as critical accounting policies and practices used by us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing all related person transactions for potential conflict of interest situations and voting with respect
to all such transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">supervising the integrity of our financial reporting and the effectiveness of our internal risk management and
control systems; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing procedures for the receipt, retention and treatment of complaints received by the company regarding
accounting, internal accounting controls or auditing matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compensation Committee members include Paul R. Carter, Adam Stone and Heather L. Mason. Mr.&nbsp;Carter serves as chairman of the Compensation Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Supervisory Board has adopted Compensation Committee rules, which detail the principal functions of the Compensation Committee, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the corporate goals and objectives relevant to the compensation of our Chief Executive
Officer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">evaluating the performance of our Chief Executive Officer in light of such goals and objectives and determining
and approving the compensation of the Chief Executive Officer based on such evaluation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and approving the compensation of all other executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and making recommendations to the Supervisory Board regarding policies and procedures for the grant of
equity-based awards; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">administering our incentive-based and equity-based compensation plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">retaining or obtaining the advice of outside compensation consultants, legal counsel or other advisers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management which executive compensation information should be included in our
annual proxy statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and, where appropriate, making recommendations with regard to the compensation of directors.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The rules will also provide that the Compensation Committee may, in its sole discretion, retain or obtain the advice of a compensation
consultant, legal counsel or other adviser and is directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal
counsel or any other adviser, the Compensation Committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nominating and Corporate Governance Committee members include Peter Chambr&eacute;, Christof Hettich and Adam Stone. Mr.&nbsp;Chambr&eacute; serves as chairman
of the nominating and corporate governance committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Supervisory Board has adopted Nominating and Corporate Governance Committee rules, which detail the
principal functions of the Nominating and Corporate Governance Committee, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recommending criteria for Management Board, Supervisory Board and committee membership; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">assessing the performance of individual managing directors, supervisory directors and Supervisory Board committee
members and reporting findings to the Supervisory Board; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing a plan for the succession of managing directors and supervisory directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">supervising selection criteria and appointment procedures for executive officers other than the Chief Executive
Officer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developing and recommending to the Supervisory Board a set of corporate governance guidelines and periodically
reviewing and reassessing the adequacy of such guidelines; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reviewing and discussing with management disclosure of the company&#146;s corporate governance practices.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a code of business conduct and ethics that applies to all of our employees, officers and directors, including those officers responsible for
financial reporting. Our code of business conduct and ethics is available on our website. We intend to disclose any amendment to the code, or any waivers of its requirements, on our website. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividend Policy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently expect to retain all future
earnings for use in the operation and expansion of our business and does not plan to pay any dividends on our shares in the near future. The general meeting is authorized to declare distributions. The general meeting may only resolve to declare
distributions on the proposal of our Management Board, which requires the prior approval of the Supervisory Board or, after July&nbsp;1, 2021, the Board. Declaration and payment of any dividends in the future will depend on a number of factors,
including our earnings, capital requirements, overall financial condition, applicable law and contractual restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_14"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Immatics OpCo became our wholly owned subsidiary upon the closing of the Business Combination on July&nbsp;1, 2020, and its senior management became our
senior management. The following summarizes the compensation earned by the executive officers of Immatics OpCo for the fiscal year ended December&nbsp;31, 2019. This section also discusses the material elements of the executive compensation policies
and decisions of Immatics OpCo and important factors relevant to an analysis of such policies and decisions. It provides qualitative information regarding the manner and context in which compensation is awarded to and earned by our executive
officers and is intended to place in perspective the information presented in the following tables and the corresponding narrative. The following section is historical and has not been adjusted to give effect to the Business Acquisition. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of Executive Officers </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of
compensation, including benefits in kind, accrued or paid to the executive officers of Immatics OpCo with respect to the year ended December&nbsp;31, 2019 is described in the table below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="21%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(Euros in thousands)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Harpreet&nbsp;Singh,&nbsp;Ph.D.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All&nbsp;other&nbsp;executives</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Periodically-paid remuneration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">1,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bonuses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">598</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional benefit payments<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">2,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts paid in U.S. dollars have been converted to Euros using an annual exchange rate for 2019 of 1.1195 to
one U.S. dollar. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Harpreet Singh was appointed Chief Executive Officer of Immatics OpCo on July&nbsp;1, 2019. His annual base
salary was adjusted to &#128;350,000 and the maximum annual bonus was adjusted to 70% of his base salary at such time. The numbers here display the aggregate for 2019 including remuneration prior to and following his appointment.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In 2019, the compensation committee of Immatics OpCo approved, with supervisory board approval, an additional <FONT
STYLE="white-space:nowrap">all-cash</FONT> performance bonus to two executive officers, which amounts are included in the bonus line in the table above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Additional benefit payments include monthly stipends, housing allowance, medical, retirement, and life
insurances, as well as car leasing and associated costs. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of compensation, including benefits in kind, accrued or paid to the Immatics OpCo directors who provided services to Immatics OpCo with respect to
the year ended December&nbsp;31, 2019 is described in the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Peter<BR>Chambr&eacute;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Harald&nbsp;F.&nbsp;Stock,<BR>Ph.D</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Periodically-paid remuneration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total cash compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#128;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Peter Chambr&eacute; was executive chairman of Immatics OpCo until June&nbsp;30, 2019. The fee he received in
this role was &#128;400&nbsp;thousand annually. On July&nbsp;1, 2019, his role reverted to <FONT STYLE="white-space:nowrap">non-executive</FONT> chairman of the Supervisory Board, for which he received a fee of &#128;200&nbsp;thousand annually.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The directors and executive officers of Immatics OpCo held the following SARs and option awards (both vested
and unvested) as of March&nbsp;31, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Beneficiary</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Grant date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vesting
date<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>SARs/options<BR>outstanding<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Strike<BR>price<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Expiration<BR>date</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Harpreet Singh, Ph.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1,&nbsp;2007</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of December&nbsp;31, 2008</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2007</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of December&nbsp;31, 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,175</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of December&nbsp;31, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Subject-to-exit</FONT></FONT> SAR</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;21, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3,636 vested as of March&nbsp;31, 2020, and an additional 189 will vest daily thereafter until the award is fully vested</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3,825</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$16.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">July&nbsp;1,&nbsp;2025</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;21, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3,622 vested as of March&nbsp;31, 2020, and an additional 2,956 will vest daily thereafter until the award is fully vested</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6,578</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$16.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">July&nbsp;1, 2027</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">July, 1, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2,645 SARs will vest as of June&nbsp;30, 2020, and an additional 10,580 will vest daily thereafter until the award is fully vested</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">13,225</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$18.30</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">July&nbsp;1, 2029</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Thomas Ulmer</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;21, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2,000 SARs vested as of March&nbsp;31, 2020, and an additional 3,000 will vest daily thereafter until the award is fully vested</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$16.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">April&nbsp;1,&nbsp;2028</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cedrik Britten, M.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">February&nbsp;14,&nbsp;2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1,200 SARs will vest as of May&nbsp;31, 2021, and an additional 4,800 will vest daily thereafter until the award is fully vested</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$157.22</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">June&nbsp;1, 2030</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Carsten Reinhardt, M.D., Ph.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">October&nbsp;1,&nbsp;2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of September&nbsp;30, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,750</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of December&nbsp;31, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,300</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Subject-to-exit</FONT></FONT> SARs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3,010</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;21, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2,109 vested as of March&nbsp;31, 2020, and an additional 111 will vest daily thereafter</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,220</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$16.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">July&nbsp;1, 2025</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;21, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2,196 vested as of March&nbsp;31, 2020, and an additional 1,791 will vest daily thereafter until the award is fully vested</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3,987</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$16.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">July&nbsp;1, 2027</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Beneficiary</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Grant date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vesting
date<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>SARs/options<BR>outstanding<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Strike<BR>price<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Expiration<BR>date</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Rainer Kramer, Ph.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">April&nbsp;1, 2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of March&nbsp;31, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Subject-to-exit</FONT></FONT> SARs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;21, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of July&nbsp;1, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$16.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">July&nbsp;1, 2025</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;21, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2,852 SARs vested as of March&nbsp;31, 2020, and an additional 148 will vest daily thereafter until the award is fully vested</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$16.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">July&nbsp;1, 2025</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;21, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2,677 SARs vested as of March&nbsp;31, 2020, and an additional 2,185 will vest daily thereafter until the award is fully vested</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4,862</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$16.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">July&nbsp;1, 2027</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Toni Weinschenk, Ph.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2007</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of December&nbsp;31, 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2008</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of December&nbsp;31, 2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of December&nbsp;31, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of December&nbsp;31, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Subject-to-exit</FONT></FONT> SARs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;21, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1,939 SARs vested as of March&nbsp;31, 2020, and an additional 101 will vest daily thereafter until the award is fully vested</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,040</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$16.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">July&nbsp;1, 2025</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;21, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">919 SARs vested as of March&nbsp;31, 2020, and an additional 750 will vest daily thereafter until the award is fully vested</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,669</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$16.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">July&nbsp;1, 2027</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Beneficiary</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Grant date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Vesting
date<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>SARs/options<BR>outstanding<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Strike<BR>price<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Expiration<BR>date</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Steffen Walter, Ph.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2006</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of December&nbsp;31, 2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2007</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of December&nbsp;31, 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2008</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of December&nbsp;31, 2012</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2009</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of December&nbsp;31, 2013</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">January&nbsp;1, 2011</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Fully vested as of December&nbsp;31, 2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">250</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;21, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2,424 SARs vested as of March&nbsp;31, 2020, and an initial 126 will vest daily thereafter until the award is fully vested</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,550</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$16.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">July&nbsp;1, 2025</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;21, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">340 SARs vested as of March&nbsp;31, 2020, and an initial 60 will vest daily thereafter until the award is fully vested</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$16.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">January&nbsp;1,&nbsp;2026</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">March&nbsp;21, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1,049 SARs vested as of March&nbsp;31, 2020, and an initial 855 will vest daily thereafter until the award is fully vested</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,904</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$16.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">July&nbsp;1, 2027</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stephen L. Eck, M.D.,
Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">June&nbsp;21, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1,728 SARs vested as of March&nbsp;31, 2020, and an initial 2,772 will vest daily thereafter until the award is fully vested</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">$16.65</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">May&nbsp;1, 2028</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Supervisory Board of Immatics OpCo determined that all <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">subject-to-exit</FONT></FONT> SARs will be fully vested on the Closing Date. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">SARs and options granted before the Closing Date were (i)&nbsp;in the case of SARs and options that vested or
are scheduled to vest prior to December&nbsp;31, 2020, cancelled in exchange for cash payments or (ii)&nbsp;in the case of SARs and options that are not scheduled to vest until after December&nbsp;31, 2020, converted into options to purchase
ordinary shares by using the following conversion method (simplified): numbers of SARs and options will be multiplied by, and the related exercise price will be divided by, the multiplier ratio of 15.722 used for purposes of the Business
Combination. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The strike price is based on 1.163&nbsp;million shares of Immatics OpCo outstanding as of March&nbsp;31, 2020,
it does not relate to the share price of the ordinary shares outstanding upon consummation of the Business Combination and is presented only for completeness. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Eck stepped down from the role of Chief Medical Officer, US effective June&nbsp;30, 2020.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immatics OpCo 2010 Stock Appreciation Rights (SAR) Program </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the Business Combination, from January&nbsp;1, 2005, in addition to performance-related compensation, certain Immatics OpCo employees were given the
opportunity to participate in a Stock Appreciation Rights (&#147;SAR&#148;) program, also referred to as phantom stock, as part of a long-term equity incentive scheme. The SAR </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
program was adopted by the Supervisory Board of Immatics OpCo in January 2005 and amended according to provisions set forth in the shareholder agreements dated February&nbsp;6, 2007 and
September&nbsp;7, 2010. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the SAR program, the beneficiaries received SARs without having to make any cash investment into Immatics OpCo. All SARs
granted under this program carry no dividend or voting rights, and all SARs have an exercise price of zero. The holder of the SARs has the right to exercise vested SARs in a defined &#147;Exit Event&#148;. The &#147;Exit Event&#148; was defined in
the SAR Program as a transaction in which more than 50% of the shareholdings (calculated according to nominal values) in Immatics OpCo are acquired by a third person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SARs vest over time. The granted SARs have fixed vesting periods between two and five years. Vesting is contingent on the beneficiary&#146;s continued service
to Immatics OpCo. The vesting period begins on the grant date or a defined starting date and ends after the defined period, and may include a cliff between zero and two years, during such cliff period, if any, no vesting occurs. Employees leaving
Immatics OpCo may retain any SARs vested as of their termination date, unless they are terminated for cause. Effective March&nbsp;22, 2018, the &#147;2010 Stock Appreciation Rights (SAR) Program&#148; was amended to adjust vesting to the extent
impacted by regulations relating to unpaid leaves or working time reductions due to family or health reasons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any SARs that are unvested at the time of
an Exit Event will be forfeited without consideration. At Immatics OpCo&#146; discretion, however, selected employees can receive accelerated vesting in an Exit Event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the 2010 Stock Appreciation Rights Program, Immatics OpCo was also entitled to grant stock appreciation rights that only vest if the employee is
regularly employed by Immatics OpCo at the time of the Exit Event <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(&#147;subject-to-exit</FONT></FONT> SARs&#148;). SARs that were granted as <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">subject-to-exit</FONT></FONT> SARs are forfeited in the event of termination of an employee&#146;s employment prior to an Exit Event and generally expire if no Exit Event takes place in the first five years after the grant
date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In total, 52,478 SARs were granted under the 2010 Stock Appreciation Rights Program, of which 43,521 were outstanding as of March&nbsp;31, 2020.
These share numbers are based on the current Immatics OpCo capitalization and have not been adjusted to reflect the impact of the Business Combination. No further grants were made under the 2010 Stock Appreciation Rights Program after June 2017,
when the 2016 Equity Incentive Plan (as described below) became effective. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Immatics OpCo 2016 Equity Incentive Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;8, 2017, the shareholders of Immatics OpCo approved the &#147;2016 Equity Incentive Plan&#148; in order to give employees and other designated
service providers of Immatics OpCo and its affiliates (as well as employees and consultants of such service providers) the ability to share in Immatics OpCo&#146;s future success. All rights under the 2010 Stock Appreciation Rights Program remained
unaffected. The aggregate number of shares available for grant under all current Immatics OpCo employee incentive programs (2010 Stock Appreciation Rights Program and 2016 Equity Incentive Plan) shall not exceed 158,690. If an award or any portion
thereof expires or otherwise terminates without all of the shares covered by such award having been issued, such respective number will again be available for issuance of awards under the 2016 Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the 2016 Equity Incentive Plan, Immatics OpCo is entitled to issue <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;Tandem Awards&#148;, each
consisting of an option to buy a number of shares, at the exercise price mentioned below (the &#147;Option Rights&#148;), and the right to alternatively receive any appreciation in the value of such shares above the aggregate exercise price (the
&#147;SAR Right&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tandem Awards may vest based on the satisfaction of service requirements (time-based vesting) or upon the achievement of
individual or company or affiliate performance goals (performance-based vesting), or any other criteria established by Immatics OpCo. Generally, the granted Tandem Awards have a five-year vesting period with a
<FONT STYLE="white-space:nowrap">one-year</FONT> cliff. Most Tandem Awards provide that in the event of a &#147;change in control&#148;, the unvested </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
portion of the Tandem Award immediately vests. Vesting is contingent on the recipient&#146;s continued service to Immatics OpCo. Employees leaving Immatics OpCo may generally retain any Tandem
Awards that are vested as of their termination date, unless they are terminated for cause. Any portion of the Tandem Award that is unvested cannot be exercised. An Option Right (to the extent vested) may only be exercised after the completion of a
&#147;Share Swap&#148; (as defined in the 2016 Equity Incentive Plan, i.e., the contribution of all shares in Immatics OpCo to a holding company of Immatics OpCo in exchange for shares in such holding company for purposes of an IPO). A SAR Right (to
the extent vested) may only be exercised upon the occurrence of a &#147;Liquidity Event&#148; (as defined in the 2016 Equity Incentive Plan, i.e., a change in control or expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT>
period following completion of an IPO). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to these restrictions on exercise, the grantee may elect to exercise either the Option Right or the SAR
Right with respect to each share subject to a Tandem Award. The exercise of the Option Right will automatically result in the cancellation of the related SAR Right on a share by share basis. Vice versa, the exercise of the SAR Right will
automatically result in the cancellation of the related Option Right on a share by share basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics OpCo may impose limitations or a prohibition on
the transfer of shares acquired by a participant pursuant to the exercise of a Tandem Award including a prohibition against the transfer of shares for a certain <FONT STYLE="white-space:nowrap">lock-up</FONT> period (up to 365 days) following an
IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount payable upon exercise of a SAR Right will be made, in the discretion of Immatics OpCo: (i)&nbsp;in cash, (ii)&nbsp;in whole Immatics OpCo
common shares (rounded down to the nearest whole share) based on the fair market value of such shares at the time of settlement, or (iii)&nbsp;a combination of (i)&nbsp;or (ii). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The granted Tandem Awards have different exercise prices depending on when they were granted; these exercise prices are $16.65, $18.30, or $23.82,
respectively, which were intended to reflect the fair market value of the shares upon the date of grant. The expiration date of the Tandem Awards is 10 years after the applicable vesting commencement date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2020, Tandem Awards with respect to 113,779 shares were granted, of which 106,410 were outstanding. These share numbers are based on the
current Immatics OpCo capitalization and have not been adjusted to reflect the impact of the Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2020 Stock Option and Incentive
Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outstanding SARs and Tandem Awards described above were converted into options to purchase ordinary shares under our 2020 Stock Option and
Incentive Plan (the &#147;2020 Equity Plan&#148;). The 2020 Equity Plan was approved by the Management Board and the general meeting prior to the consummation of the Business Combination. The 2020 Equity Plan will allow our Compensation Committee to
make equity-based incentive awards to its officers, employees, directors and other key persons, including consultants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares.</I> A total
of 10,006,230 ordinary shares were initially authorized and reserved for the issuance of awards under the 2020 Equity Plan. This number will be subject to adjustment in the event of a share split, share dividend or other change in our
capitalization. The shares issued under the 2020 Equity Plan will be authorized but unissued shares or shares that we reacquire. The ordinary shares underlying any awards that are forfeited, cancelled, held back upon exercise or settlement of an
award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without the issuance of shares, expire or are otherwise terminated, other than by exercise, under the 2020 Equity Plan will be added back to the
ordinary shares available for issuance under the 2020 Equity Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration</I>. The 2020 Equity Plan is administered by our Compensation
Committee. Our Compensation Committee has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, to make any combination of awards to participants, and to determine the specific terms
and conditions of each award, subject to the provisions of the 2020 Equity Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. Persons eligible to participate in the 2020 Equity Plan will be those employees, <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors and consultants, as selected from time to time by our Compensation Committee in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Options</I>. The 2020 Equity Plan permits the granting of both options to purchase ordinary shares intended to qualify as incentive stock options under
Section&nbsp;422 of the U.S. Tax Code and options that do not so qualify. The option exercise price of each option will be determined by our Compensation Committee but may not be less than 100% of the fair market value of our ordinary shares on the
date of grant unless the option is granted (i)&nbsp;pursuant to a transaction described in, and in a manner consistent with, Section&nbsp;424(a) of the U.S. Tax Code or (ii)&nbsp;to individuals who are not subject to U.S. income tax. The term of
each option will be fixed by our Compensation Committee and may not exceed 10 years from the date of grant. Our Compensation Committee will determine at what time or times each option may be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights</I>. Our Compensation Committee may award stock appreciation rights subject to such conditions and restrictions as it may
determine. Stock appreciation rights entitle the recipient to ordinary shares, or cash, equal to the value of the appreciation in our share price over the exercise price. The exercise price may not be less than 100% of the fair market value of our
ordinary shares on the date of grant. The term of each stock appreciation right will be fixed by our Compensation Committee and may not exceed 10 years from the date of grant. Our Compensation Committee will determine at what time or times each
stock appreciation right may be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Restricted Shares and Restricted Stock Units</I>. Our Compensation Committee may award restricted shares
and restricted stock units to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with us through a
specified vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Unrestricted Stock Awards</I>. Our Compensation Committee may grant ordinary shares that are free from any restrictions
under the 2020 Equity Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividend Equivalent Rights</I>. Our Compensation Committee may grant dividend equivalent rights to participants that entitle the recipient to receive
credits for dividends that would be paid if the recipient had held a specified number of ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash-Based Awards</I>. Our Compensation
Committee may grant cash bonuses under the 2020 Equity Plan to participants, subject to the achievement of certain performance goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sale Event</I>.
The 2020 Equity Plan provides that upon the effectiveness of a &#147;sale event&#148;, as defined in the 2020 Equity Plan, an acquirer or successor entity may assume, continue or substitute for the outstanding awards under the 2020 Equity Plan. To
the extent that awards granted under the 2020 Equity Plan are not assumed or continued or substituted by the successor entity, all unvested awards granted under the 2020 Equity Plan shall terminate. In such case, except as may be otherwise provided
in the relevant award agreement, all options and stock appreciation rights with time-based vesting, conditions or restrictions that are not exercisable immediately prior to the sale event will become fully exercisable as of the sale event, all other
awards with time-based vesting, conditions or restrictions will become fully vested and nonforfeitable as of the sale event, and all awards with conditions and restrictions relating to the attainment of performance goals may become vested and
nonforfeitable in connection with the sale event in the plan administrator&#146;s discretion or to the extent specified in the relevant award agreement. In the event of such termination, individuals holding options and stock appreciation rights will
be permitted to exercise such options and stock appreciation rights (to the extent exercisable) prior to the sale event. In addition, in connection with the termination of the 2020 Equity Plan upon a sale event, we may make or provide for a cash
payment to participants holding vested and exercisable options and stock appreciation rights equal to the difference between the per share cash consideration payable to shareholders in the sale event and the exercise price of the options or stock
appreciation rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment</I>. Our board of directors may amend or discontinue the 2020 Equity Plan and our Compensation
Committee can amend or cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may adversely affect rights under an award without the holder&#146;s consent. Our Compensation Committee is
specifically authorized to exercise its discretion to reduce the exercise price of outstanding options or effect the repricing of such options through cancellation and <FONT STYLE="white-space:nowrap">re-grants</FONT> without additional shareholder
approval. Certain amendments to the 2020 Equity Plan will require the approval of our shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No awards may be granted under the 2020 Equity Plan
after the date that is 10 years from the date of shareholder approval of the 2020 Equity Plan. No awards under the 2020 Equity Plan have been made prior to the date hereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Grants to Management and Directors in Connection with the Closing of the Business Combination</B><B><I> </I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics OpCo granted certain performance-based and service-based options out of the 2020 Incentive Plan to its management and directors at the closing of the
Business Combination. The performance-based options will vest based both on achievement of market capitalization milestones and satisfaction of a four-year time-based vesting schedule, which provides for 25% vesting on the first anniversary of the
vesting commencement date and quarterly vesting thereafter. The service-based options will vest based upon satisfaction of a four-year time-based vesting schedule, which provides for 25% vesting on the first anniversary of the vesting commencement
date and quarterly vesting thereafter. An aggregate of 3,278,000 performance-based options and 2,250,000 service options to purchase ordinary shares were granted to Immatics OpCo&#146;s management and directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing options are in addition to 417,415 converted options and 962,050 matching options that were granted to Immatics OpCo&#146; management and
directors under the 2020 Incentive Plan in connection with the closing of the Business Combination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_15"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This section of the prospectus includes a description of the material terms of our articles of association and of applicable Dutch law. The following
description is intended as a summary only and does not constitute legal advice regarding those matters and should not be regarded as such. The description is qualified in its entirety by reference to the complete text of our articles of association,
which are filed as an exhibit hereto and incorporated herein by reference. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated on March&nbsp;10, 2020 as a private limited liability company (<I>besloten</I> <I>vennootschap</I> <I>met</I> <I>beperkte</I>
<I>aansprakelijkheid</I>) under Dutch law, and upon the consummation of the Business Combination, we converted into a Dutch public limited liability company (<I>naamloze</I> <I>vennootschap</I>). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registered in the Commercial Register of the Chamber of Commerce (<I>Kamer</I><I>&nbsp;van</I><I>&nbsp;Koophandel</I>) in the Netherlands under number
77595726. We have our corporate seat is in Amsterdam, the Netherlands and our registered office is at Paul-Ehrlich-Stra&szlig;e 15, 72076 T&uuml;bingen, Federal Republic of Germany. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ordinary shares sold in this offering are subject to, and have been created under, Dutch law. Set forth below is a summary of relevant information
concerning the material provisions of our articles of association and applicable Dutch law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2021, and pursuant to our articles of
association, our current <FONT STYLE="white-space:nowrap">two-tier&nbsp;board</FONT> structure will automatically convert into <FONT STYLE="white-space:nowrap">a&nbsp;one-tier&nbsp;board</FONT> structure, which will consist of a nine member
staggered board divided into three classes. In <FONT STYLE="white-space:nowrap">the&nbsp;one-tier&nbsp;board</FONT> structure, we will also have an Executive Committee consisting of all our executive directors and other executive officers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Authorized Share Capital
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized share capital consists of 285,000,000 ordinary shares, nominal value of &#128;0.01 per share, and 15,000,000 financing preferred
shares. The financing preferred shares are divided into five series, each consisting of 3,000,000 financing preferred shares. As of July&nbsp;31, 2020, there were 62,908,617 ordinary shares outstanding and no financing preferred shares outstanding.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financing preferred shares may, at the request of the holder, be converted into ordinary shares pursuant to a resolution of our Management Board or,
after July&nbsp;1, 2021, our Board. The conditions for conversion and the further terms and conditions related to the financing preferred shares will be determined by our Management Board subject to the prior approval of our Supervisory Board or,
after July&nbsp;1, 2021, our Board, our general meeting and the meeting of holders of the series of financing preferred shares concerned, if such series of financing preferred shares has been issued and are held by persons other than us. The
preceding sentence applies by analogy to any adjustment to the conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuance of Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Dutch law, shares are issued and rights to subscribe for shares are granted pursuant to a resolution of our general meeting. Our articles of association
provide that the general meeting may only resolve to issue shares upon the proposal of our Management Board, which proposal requires the prior approval of our Supervisory Board. The general meeting may authorize the Management Board to issue new
ordinary shares or grant rights to subscribe for ordinary shares, subject to the approval of our Supervisory Board. The authorization can be granted and extended, in each case for a period not exceeding five years. For as long as, and to the extent,
that such authorization is effective, our general meeting will not have the power to issue ordinary shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a resolution of the general meeting dated June&nbsp;30, 2020, our Management Board is
irrevocably authorized to for a period of five years from the date of the Business Combination, to issue ordinary shares or financing preferred shares up to the amount of the authorized share capital (from time to time). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2021, the powers of our Management Board will vest in our Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preemptive Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to restrictions in our
articles of association, holders of ordinary shares have preemptive rights in relation to newly issued ordinary shares under Dutch law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our
articles of association, the preemptive rights in respect of newly issued ordinary shares may be restricted or excluded by a resolution of our general meeting, which resolution requires
<FONT STYLE="white-space:nowrap">a&nbsp;two-thirds&nbsp;majority</FONT> of the votes cast if less than half of the issued share capital is present or represented at the meeting. The general meeting may authorize our Management Board, subject to the
prior approval of our Supervisory Board or, after July&nbsp;1, 2021, our Board to limit or exclude the preemptive rights in respect of newly issued ordinary shares. Such authorization for our Management Board, subject to the prior approval of our
Supervisory Board or, after July&nbsp;1, 2021, our Board can be granted and extended, in each case for a period not exceeding five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a
resolution of the general meeting dated June&nbsp;30, 2020, our Management Board is irrevocably authorized for a period of five years from the date of the Business Combination to limit or exclude preemptive rights on ordinary shares up to 100% of
the number of ordinary shares in our authorized share capital (from time to time). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preemptive rights do not exist with respect (a)&nbsp;to the issue of
ordinary shares or grant of rights to subscribe for ordinary shares to our employees or a &#147;group&#148; company of ours, and (b)&nbsp;the issue of ordinary shares against a contribution in kind. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preemptive rights do not exist with respect to the issue of financing preferred shares and holders of financing preferred shares have no preemptive right to
acquire newly issued ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2021, the powers of our Management Board will vest in our Board. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer of Ordinary Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Dutch law,
transfers of ordinary shares (other than in book-entry form) require a written deed of transfer and, unless the company is a party to the deed of transfer, and acknowledgement by or proper service upon the company to be effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our articles of association, if one or more ordinary shares are admitted to trading on Nasdaq or any other regulated foreign stock exchange located in
the United States, we may, by resolution of our Management Board, determine that the laws of the State of New York will apply to the property law aspects of the ordinary shares included in the part of the register of shareholders kept by the
relevant transfer agent. Such resolution, as well as the revocation thereof, will be made public as required by law and will be made available for inspection at our office and the Dutch trade register. Our management has adopted such resolution
effective as of the Closing Date. On July&nbsp;1, 2021, the powers of our Management Board will vest in our Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form of Ordinary Shares
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our articles of association, the ordinary shares are registered shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purchase and Repurchase of Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Dutch law, we may not subscribe for newly issued ordinary shares. We may acquire ordinary shares, subject to applicable provisions and restrictions of
Dutch law and our articles of association, to the extent that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such ordinary shares are fully <FONT STYLE="white-space:nowrap">paid-up;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such repurchase would not cause our shareholders&#146; equity to fall below an amount equal to the sum of the <FONT
STYLE="white-space:nowrap">paid-up</FONT> and <FONT STYLE="white-space:nowrap">called-up</FONT> part of the issued share capital and the reserves we are required to maintain pursuant to Dutch law or our articles of association; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately after the acquisition of such ordinary shares, we and our subsidiaries would not hold, or would not
hold as pledgees, shares having an aggregate nominal value that exceeds 50% of our issued share capital. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than ordinary shares
acquired for no valuable consideration or under universal title of succession (<I>onder</I><I>&nbsp;algemene</I><I>&nbsp;titel</I>) (<I>e.g.</I>, through a merger or spin off) under statutory Dutch or other law, we may acquire ordinary shares only
if our general meeting has authorized our Management Board to do so, subject to prior approval of our Supervisory Board or, after July&nbsp;1, 2021, our Board. An authorization by our general meeting for the acquisition of ordinary shares can be
granted for a maximum period of 18 months. Such authorization must specify the number of ordinary shares that may be acquired, the manner in which these shares may be acquired and the price range within which the shares may be acquired. No
authorization of our general meeting is required if ordinary shares are acquired by us on Nasdaq with the intention of transferring such ordinary shares to our employees or employees of a group company pursuant to an arrangement applicable to them.
For each annual general meeting, we expect that our Management Board, or, after July&nbsp;1, 2021, our Board will place on the agenda a proposal <FONT STYLE="white-space:nowrap">to&nbsp;re-authorize&nbsp;our</FONT> Management Board, or, after
July&nbsp;1, 2021, our Board to repurchase shares for a period of 18 months from the date of the resolution. We cannot derive any right to any distribution from ordinary shares, or voting rights attached to ordinary shares acquired by it. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a resolution of the general meeting dated June&nbsp;30, 2020, the our Management Board is irrevocably authorized for a period of 18 months to
resolve for us to acquire <FONT STYLE="white-space:nowrap">fully&nbsp;paid-up&nbsp;ordinary</FONT> shares up to the maximum number of ordinary shares permitted pursuant to the law and our articles of association from time to time, through privately
negotiated repurchases, in self-tender offers, or through accelerated repurchase arrangements, at prices ranging from the nominal value of the ordinary shares up to one hundred and ten percent(110%) of the market price of ordinary shares, provided
that (i)&nbsp;for open market or privately negotiated repurchases, the market price will be the price for ordinary shares Nasdaq at the time of the transaction, (ii)&nbsp;for self-tender offers, the market price will be the volume weighted average
price for the ordinary shares on Nasdaq during a period, determined by the Management Board, of no less than one and no more than five consecutive trading days immediately prior to the expiration of the tender offer, and (iii)&nbsp;for accelerated
repurchase arrangements, the market price will be the volume weighted average price of the ordinary shares on the NYSE over the term of the arrangement. The volume weighted average price for any number of trading days will be calculated as the
arithmetic average of the daily volume weighted average price on those trading days. On July&nbsp;1, 2021, the powers of our Management Board will vest in our Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to a resolution of the general meeting dated June&nbsp;30, 2020, our Management Board is furthermore irrevocably authorized for a period of 18 months
from the date of the Business Combination to resolve for us to acquire fully paid up financing preferred shares up to the maximum number of financing preferred shares permitted pursuant to the law and our articles of association from time to time
and that financing preferred shares may be acquired through privately negotiated repurchases, in self-tender offers, or through accelerated repurchase arrangements, at prices ranging from the nominal value of the financing preferred shares up to the
amount that would be paid by us upon cancellation of such financing preferred shares in accordance with the relevant provisions of our articles of association. On July&nbsp;1, 2021, the powers of our Management Board will vest in our Board. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Reduction </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At a general meeting, our shareholders may resolve on the proposal of our Management Board, which proposal will require the prior approval of our Supervisory
Board to reduce our issued share capital by (i)&nbsp;cancelling ordinary shares or (ii)&nbsp;reducing the nominal value of the ordinary shares by amending our articles of association (provided that the nominal value of an ordinary shares cannot be
less than &#128;0.01). In either case, this reduction would be subject to applicable statutory provisions. A resolution to cancel ordinary shares may only relate to (i)&nbsp;ordinary shares held by us or in respect of which we hold the depository
receipts, or (ii)&nbsp;all financing preferred shares of a class if approved by the holders of all shares of that class. In order to be approved by our general meeting, a resolution to reduce the capital requires approval of a majority of the votes
cast at a general meeting if at least 50% of the issued share capital is represented at such meeting or at least 66 2/3% of the votes cast at a general meeting if less than 50% of the issued share capital is represented at such meeting. On
July&nbsp;1, 2021, the powers of our Management Board will vest in our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reduction of the nominal value of ordinary shares without repayment and
without release from the obligation to pay up the ordinary shares must be effectuated proportionally on shares of the same class (unless all affected shareholders agree to a disproportional reduction). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A resolution that would result in a reduction of capital requires approval by a majority of the votes cast of each group of shareholders of the same class
whose rights are prejudiced by the reduction. In addition, a reduction of capital involves <FONT STYLE="white-space:nowrap">a&nbsp;two-month&nbsp;waiting</FONT> period during which creditors have the right to object to a reduction of capital under
specified circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General Meeting of Shareholders and Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General Meeting of Shareholders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General meetings
are held in Amsterdam, Rotterdam, The Hague, Arnhem, Utrecht, or in the municipality of Haarlemmermeer (Schiphol Airport), the Netherlands. All of our shareholders and others entitled to attend our general meetings are authorized to address the
meeting and, in so far as they have such right, to vote, either in person or by proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will hold at least one general meeting each year, to be held
within six months after the end of its financial year. A general meeting will also be held within three months after our Board has determined it to be likely that our equity has decreased to an amount equal to or lower than half of its paid up and
called up capital, in order to discuss the measures to be taken if so required. If our Board fails to hold such general meeting in a timely manner, each shareholder and other person entitled to attend our general meeting may be authorized by the
Dutch court to convene our general meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Management Board or our Supervisory Board or, after July&nbsp;1, 2021, our Board may convene additional
extraordinary general meetings of shareholders at its discretion, subject to the notice requirements described below. Pursuant to Dutch law, one or more shareholders and/or others entitled to attend general meetings of shareholders, alone or jointly
representing at least 10% of our issued share capital, may on their application be authorized by the Dutch court to convene a general meeting. The Dutch court will disallow the application if (i)&nbsp;the applicants have not previously requested in
writing that our Management Board or our Supervisory Board or, after July&nbsp;1, 2021, our Board convenes a shareholders&#146; meeting or (ii)&nbsp;our Management Board or our Supervisory Board or, after July&nbsp;1, 2021, Board convenes a
shareholders&#146; meeting or (ii)&nbsp;our Board has not taken the necessary steps so that the shareholders&#146; meeting could be held within six weeks after such request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general meeting is convened by a notice, which includes an agenda stating the items to be discussed and the location and time of our general meeting. For
the annual general meeting the agenda will include, among other things, the adoption of our annual accounts, the appropriation of its profits or losses and proposals relating to the composition of and filling of any vacancies on our Management
Board, our Supervisory Board or, after July&nbsp;1, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2021, our Board. In addition, the agenda for a general meeting includes such additional items as determined by our Management Board, our Supervisory Board or, after July&nbsp;1, 2021, our Board.
Pursuant to Dutch law, one or more shareholders and/or others entitled to attend general meetings of shareholders, alone or jointly representing at least 3% of the issued share capital, have the right to request the inclusion of additional items on
the agenda of shareholders&#146; meetings. Such requests must be made in writing, and may include a proposal for a shareholder resolution, and must be received by us no later than on the 60th day before the day the relevant shareholders&#146;
meeting is held. No resolutions will be adopted on items other than those which have been included in the agenda. Under our articles of association, certain items can only be put on the agenda as a voting item by our Management Board or our
Supervisory Board, after July&nbsp;1, 2021 our Board, shareholders meeting the relevant requirements may still request the inclusion of such items on the agenda as a discussion item. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will give notice of each general meeting by publication on its website and, to the extent required by applicable law, in a Dutch daily newspaper with
national distribution, and in any other manner that we may be required to follow in order to comply with Dutch law and applicable stock exchange and SEC requirements. We will observe the statutory minimum convening notice period for a general
meeting. Holders of registered shares may further be provided notice of the meeting in writing at their addresses as stated in its shareholders&#146; register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our articles of association and Dutch law, our Management Board, or, after July&nbsp;1, 2021, our Board may determine a record date
(<I>registratiedatum</I>) of 28 calendar days prior to a general meeting to establish which shareholders and others with meeting rights are entitled to attend and, if applicable, vote at our general meeting. The record date, if any, and the manner
in which shareholders can register and exercise their rights will be set out in the notice of our general meeting. Our articles of association provide that a shareholder must notify us in writing of his or her identity and his or her intention to
attend (or be represented at) our general meeting, such notice to be received by us on the date set by our Management Board, or, after July&nbsp;1, 2021, our Board in accordance with our articles of association and as set forth in the convening
notice. If this requirement is not complied with or if upon request no proper identification is provided by any person wishing to enter our general meeting, the chairman of our general meeting may, in his or her sole discretion, refuse entry to the
shareholder or his or her proxy holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our articles of association, our general meeting is chaired by the Chairman of our Supervisory Board,
who, nevertheless, may charge another person to preside over the meeting in his place even if he himself is present at the meeting. If the chairman of our Supervisory Board is absent and he has not charged another person to preside over the meeting
in his place, our general meeting will be presided over by the vice-chairman of our Supervisory Board. If both the chairman and the vice-chairman are absent, our Supervisory Directors present at the meeting will appoint one of them to be chairman.
In the absence of all Supervisory Directors, our general meeting will be presided over by the chief executive officer. If all Supervisory Directors and the chief executive officer are absent, our Managing Directors present at the meeting will
appoint one of them as chairman. If all Supervisory Directors and all Managing Directors are absent, our general meeting will appoint its chairman. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After
July&nbsp;1, 2021, our general meeting will be presided over by the chairman of our Board, who, nevertheless, may charge another person to preside over the meeting in his place even if he himself is present at the meeting. If the chairman of our
Board is absent and he has not charged another person to preside over the meeting in his place, the directors present at the meeting will appoint one of them to be chairman. In the absence of all directors, our general meeting will appoint its
chairman. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights and Quorum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
accordance with Dutch law and our articles of association, each ordinary share, irrespective of which class it concerns, confers the right on the holder thereof to cast one vote at our general meeting. The voting rights attached to any ordinary
shares held by us or our direct or indirect subsidiaries are suspended, unless the ordinary shares were encumbered with a right of usufruct or a pledge in favor of a party other than us or a direct or indirect subsidiary before such ordinary shares
were acquired by us or such a subsidiary, in which case, the other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
party may be entitled to exercise the voting rights on the ordinary shares. We may not exercise voting rights for ordinary shares in respect of which its or a direct or indirect subsidiary has a
right of usufruct or a pledge. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voting rights may be exercised by shareholders or by a duly appointed proxy holder (the written proxy being acceptable to
the chairman of our general meeting) of a shareholder, which proxy holder need not be a shareholder. The holder of a usufruct or pledge on shares will have the voting rights attached thereto if so provided for when the usufruct or pledge was
created. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our articles of association, blank votes (votes where no choice has been made), abstentions and invalid votes will not be counted as votes
cast. However, shares in respect of which a blank vote or invalid vote has been cast and shares in respect of which the person with meeting rights who is present or represented at the meeting has abstained from voting are counted when determining
the part of the issued share capital that is present or represented at a general meeting. The chairman of our general meeting will determine the manner of voting and whether voting may take place by acclamation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Resolutions of the shareholders are adopted at a general meeting by a majority of votes cast, except where Dutch law or our articles of association provide
for a special majority in relation to specified resolutions. Our articles of association do not provide for a quorum requirement, subject to any provision of mandatory Dutch law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to certain restrictions in our articles of association, the determination during our general meeting made by the chairman of that general meeting with
regard to the results of a vote will be decisive. Our Board will keep a record of the resolutions passed at each general meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of
Articles of Association </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At a general meeting, at the proposal of our Management Board, which proposals requires the prior approval of our
Supervisory Board, our general meeting may resolve to amend the articles of association. A resolution by the shareholders to amend the articles of association requires a majority of the votes cast. On July&nbsp;1, 2021, the powers of our Management
Board will vest in our Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Merger, Demerger and Dissolution </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the proposal of our Management Board, which proposal requires the prior approval of our Supervisory Board, our general meeting may resolve with a majority
of the votes cast (subject to certain exceptions) or with at <FONT STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> the votes cast if less than half of the issued capital is present or represented at our general meeting, to legally
merge or demerge the company within the meaning of Title 7, Book 2 of the Dutch Civil Code. On July&nbsp;1, 2021, the powers of our Management Board will vest in our Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our shareholders may at a general meeting, based on a proposal by our Management Board which proposal requires the prior approval of our Supervisory Board, by
means of a resolution passed by a majority of the votes cast resolve that the company will be dissolved. In the event of dissolution of the company, the liquidation will be effected by our Managing Directors, under the supervision of our Supervisory
Board unless our general meeting decides otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After July&nbsp;1, 2021, the liquidation will be effected by our Executive Directors, under the
supervision of <FONT STYLE="white-space:nowrap">our&nbsp;Non-Executive&nbsp;Directors,</FONT> unless our general meeting decides otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Squeeze
Out </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shareholder who for its own account (or together with its group companies) holds at least 95% of our issued share capital may institute
proceedings against the other shareholders jointly for the transfer of their shares to the shareholder who holds such 95% majority. The proceedings are held before the Enterprise Chamber of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Amsterdam Court of Appeal (<I>Ondernemingskamer van het Gerechtshof Amsterdam</I>) (the &#147;<I>Enterprise</I><I>&nbsp;Chamber</I>&#148;) and can be instituted by means of a writ of summons
served upon each of the minority shareholders in accordance with the provisions of the Dutch Code of Civil Procedure (<I>Wetboek van Burgerlijke Rechtsvordering</I>). The Enterprise Chamber may grant the claim
<FONT STYLE="white-space:nowrap">for&nbsp;squeeze-out&nbsp;in</FONT> relation to all minority shareholders and will determine the price to be paid for the shares, if necessary after appointment of one or three experts who will offer an opinion to
the Enterprise Chamber on the value of the shares of the minority shareholders. Once the order to transfer by the Enterprise Chamber becomes final and irrevocable, the majority shareholder that instituted
<FONT STYLE="white-space:nowrap">the&nbsp;squeeze-out&nbsp;proceedings</FONT> will give written notice of the date and place of payment and the price to the holders of the shares to be acquired whose addresses are known to the majority shareholder.
Unless the addresses of all minority shareholders are known to the majority shareholder acquiring the shares, the majority shareholder is required to publish the same in a newspaper with a national circulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shareholder that holds a majority of our issued share capital, but less than the 95% required to institute
<FONT STYLE="white-space:nowrap">the&nbsp;squeeze-out&nbsp;proceedings</FONT> described above, may seek to propose and implement one or more restructuring transactions with the objective of obtaining at least 95% of our issued share capital so the
shareholder may <FONT STYLE="white-space:nowrap">initiate&nbsp;squeeze-out&nbsp;proceedings.</FONT> Those restructuring transactions could, among other things, include a merger or demerger involving the company, a contribution of cash and/or assets
against issuance of ordinary shares, the issue of new ordinary shares to the majority shareholder without preemptive rights for minority shareholders or an asset sale transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending on the circumstances, an asset sale of a Dutch public limited liability company (<I>naamloze</I><I>&nbsp;vennootschap</I>) is sometimes used as a
way to squeeze out minority shareholders, for example, after a successful tender offer through which a third party acquires a supermajority, but less than all, of the company&#146;s shares. In such a scenario, the business of the target company is
sold to a third party or a special purpose vehicle, followed by the liquidation of the target company. The purchase price is distributed to all shareholders in proportion to their respective shareholding as liquidation proceeds, thus separating the
business from the company in which minority shareholders had an interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any sale or transfer of all of our assets and our dissolution or liquidation is
subject to approval by a majority of the votes cast in its general meeting. Our articles of association provide that our general meeting may only adopt such resolution upon a proposal of our Management Board, which proposal requires the prior
approval of our Supervisory Board. On July&nbsp;1, 2021, the powers of our Management Board will vest in our Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certain Other Major
Transactions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our articles of association and Dutch law provide that resolutions of our Management Board, or, after July&nbsp;1, 2021, our Board
concerning a material change in our identity, character or business are subject to the approval of our general meeting. Such changes include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a transfer of all or materially all of its business to a third party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the entry into or termination of a long-lasting alliance of the company or of a subsidiary either with another
entity or company, or as a fully liable partner of a limited partnership or partnership, if this alliance or termination is of significant importance to the company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the acquisition or disposition of an interest in the capital of a company by the company or by its subsidiary
with a value of at least one third of the value of our assets, according to the balance sheet with explanatory notes or, if the company prepares a consolidated balance sheet, according to the consolidated balance sheet with explanatory notes in our
most recently adopted annual accounts. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends and Other Distributions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company may only make distributions to its shareholders if its equity exceeds the aggregate amount of the issued share capital and the reserves which must
be maintained pursuant to Dutch law or by our articles of association. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our articles of association, any profits or distributable reserves must first be applied to pay a
dividend on the financing preferred shares, if outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any amount remaining out of distributable profits is added to our reserves as our Management
Board, with the approval of our Supervisory Board determines. After reservation by our Management Board of any distributable profits, our general meeting will be authorized to declare distributions on the proposal of our Management Board which
proposal will require the prior approval of our Supervisory Board. Our Management Board is permitted, subject to approval of our Supervisory Board and certain requirements, to declare interim dividends without the approval of the shareholders.
Interim dividends may be declared as provided in our articles of association and may be distributed to the extent that the shareholders&#146; equity, based on interim financial statements, exceeds <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">the&nbsp;paid-up&nbsp;and&nbsp;called-up&nbsp;share</FONT></FONT> capital and the reserves that must be maintained under Dutch law or our articles of association. We may reclaim any distributions, whether interim or not
interim, made in contravention of certain restrictions of Dutch law from shareholders that knew or should have known that such distribution was not permissible. In addition, on the basis of Dutch case law, if after a distribution we are not able to
pay its due and collectable debts, then our shareholders or directors who at the time of the distribution knew or reasonably should have foreseen that result may be liable to its creditors. On July&nbsp;1, 2021, the powers of our Management Board
will vest in our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general meeting may determine that distributions will be made in whole or in part in a currency other than the Euro. Our
Management Board or, after July&nbsp;1, 2021, our Board, will set the record date to establish which shareholders (or usufructuaries or pledgees, as the case may be) are entitled to the distribution, such date not being earlier than the date on
which the distribution was announced. Claims for payment of dividends and other distributions not made within five years from the date that such dividends or distributions became payable will lapse, and any such amounts will be considered to have
been forfeited to the company (<I>verjaring). </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not anticipate paying any dividends on ordinary shares for the foreseeable future. See the
section titled &#147;<I>Dividend Policy</I>&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, there are 7,187,500 warrants outstanding. The warrants, which entitle the holder to purchase one ordinary share at an
exercise price of $11.50 per share, will become exercisable thirty days after the completion of the Business Combination. The warrants will expire five years after the completion of the Business Combination or earlier upon redemption or liquidation
in accordance with their terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notices </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will
give notice of each general meeting by publication on its website and, to the extent required by applicable law, in a Dutch daily newspaper with national distribution, and in any other manner that we may be required to follow in order to comply with
Dutch law and applicable stock exchange and SEC requirements. Holders of registered shares may further be provided notice of the meeting in writing at their addresses as stated in its shareholders&#146; register. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Disclosure Obligations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of consummation of the
Business Combination, we will be subject to certain disclosure obligations under Dutch and U.S. law and the rules of Nasdaq. The following is a description of the general disclosure obligations of public companies under Dutch and U.S. law and the
rules of Nasdaq as such laws and rules exist as of the date of this document, and should not be viewed as legal advice for specific circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Reporting under Dutch Law </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Dutch Financial Reporting Supervision Act (<I>Wet</I><I>&nbsp;toezicht</I><I>&nbsp;financi&euml;le</I><I>&nbsp;verslaggeving</I>, the &#147;FRSA&#148;),
applies to our financial reporting. Under the FRSA, the Netherlands Authority for the Financial Markets (&#147;AFM&#148;) supervises the application of financial reporting standards by, among others, companies whose corporate seats are in the
Netherlands and whose securities are listed on a regulated market within the EU or on an equivalent <FONT STYLE="white-space:nowrap">third&nbsp;(non-EU)&nbsp;country</FONT> market. As we have our corporate seat in the Netherlands and our ordinary
shares will be listed on Nasdaq, the FRSA will be applicable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the FRSA, the AFM has an independent right to (i)&nbsp;request an
explanation from the company regarding the application of the applicable financial reporting standards if, based on publicly known facts or circumstances, it has reason to doubt our financial reporting meets such standards and (ii)&nbsp;recommend to
the company that it make available further explanations. If the company does not comply with such a request or recommendation, the AFM may request that the Enterprise Chamber orders the company to (i)&nbsp;provide an explanation on the way it has
applied the applicable financial reporting standards to its financial reports or (ii)&nbsp;prepare its financial reports in accordance with the Enterprise Chamber&#146;s instructions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Periodic Reporting under U.S. Securities Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
are a &#147;foreign private issuer&#148; under the securities laws of the United States and the rules of the Nasdaq. Under the securities laws of the United States, &#147;foreign private issuers&#148; are subject to different disclosure requirements
than U.S. registrants. We intend to take all actions necessary to maintain compliance as a foreign private issuer under the applicable corporate governance requirements of the Sarbanes-Oxley Act of 2002, the rules adopted by the SEC and Nasdaq
listing standards. Under the Nasdaq rules, a &#147;foreign private issuer&#148; is subject to less stringent corporate governance requirements. Subject to certain exceptions, the Nasdaq rules permit a &#147;foreign private issuer&#148; to comply
with its home country rules in lieu of the listing requirements of Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have one or
<FONT STYLE="white-space:nowrap">more&nbsp;non-independent&nbsp;directors</FONT> serving as committee members on its corporate governance and nominating committee. As a
<FONT STYLE="white-space:nowrap">result,&nbsp;non-independent&nbsp;directors</FONT> may, among other things, participate in resolving governance issues regarding the company. Accordingly, in the future you may not have the same protections afforded
to shareholders of companies that are subject to all of the Nasdaq corporate governance requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nasdaq Rules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For so long as its shares will be listed on Nasdaq, we will be required to meet certain requirements relating to ongoing communication and disclosure to our
shareholders, including a requirement to make any annual report filed with the SEC available on or through our website and to comply with the &#147;prompt disclosure&#148; requirement of Nasdaq with respect to earnings and dividend announcements,
combination transactions, stock splits, major management changes and any substantive items of an unusual <FONT STYLE="white-space:nowrap">or&nbsp;non-recurrent</FONT> nature. Issuers listing shares on Nasdaq must also meet certain corporate
governance standards, such as those relating to annual meetings, board independence, the formation and composition of nominating/corporate governance, compensation and audit committees and approval of our shareholders of certain transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Insider Trading and Market Manipulation Laws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dutch and U.S. law each contain rules intended to prevent insider trading and market manipulation. The following is a general description of those laws as such
laws exist as of the date of this document, and should not be viewed as legal advice for specific circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our listing on
Nasdaq, we adopted an insider trading policy. This policy will provide for, among other things, rules on transactions by members of our Board and our employees in ordinary shares or in financial instruments the value of which is determined by the
value of the shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Netherlands </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;3, 2016, the Regulation (EU) No 596/2014 of the European Parliament and of the Council of April&nbsp;16, 2014 (the &#147;MAR&#148;) replaced all
of the Dutch market abuse rules. The MAR does not apply to the company or to ordinary shares as the ordinary shares are solely listed on Nasdaq, a stock exchange outside the European Economic Area. As a result, there are no EU rules applicable to
the company relating to market abuse, such as insider trading, tipping, market manipulation and notification rules for director dealings applicable to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United States </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. securities laws generally
prohibit any person from trading in a security while in possession of <FONT STYLE="white-space:nowrap">material,&nbsp;non-public&nbsp;information</FONT> or assisting someone who is engaged in doing the same. The insider trading laws cover not only
those who trade based on <FONT STYLE="white-space:nowrap">material,&nbsp;non-public&nbsp;information,</FONT> but also those who disclose material <FONT STYLE="white-space:nowrap">non-public</FONT> information to others who might trade on the basis
of that information (known as &#147;tipping&#148;). A &#147;security&#148; includes not just equity securities, but any security (e.g., derivatives). Thus, members of our Board, officers and other employees of ours may not purchase or sell shares or
other securities of ours when he or she is in possession of <FONT STYLE="white-space:nowrap">material,&nbsp;non-public&nbsp;information</FONT> about the company (including our business, prospects or financial condition), nor may they tip any other
person by disclosing <FONT STYLE="white-space:nowrap">material,&nbsp;non-public&nbsp;information</FONT> about the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have identified those
persons working for it who could have access to inside information on a regular or incidental basis and have informed such persons of the prohibitions on insider trading and market manipulation imposed by U.S. laws, including the sanctions which can
be imposed in the event of a violation of those rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Disclosure and Reporting Obligations of Our Directors, Officers and Shareholders
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our directors, officers and shareholders are subject to certain disclosure and reporting obligations under Dutch and U.S. law. The following is a
description of the general disclosure obligations of directors, officers, and shareholders under Dutch law as such laws exist as of the date of this prospectus, and should not be viewed as legal advice for specific circumstances. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>DCGC </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have our registered office in the
Netherlands and our ordinary shares are listed on an equivalent <FONT STYLE="white-space:nowrap">third&nbsp;(non-EU)&nbsp;country</FONT> market to a regulated market (Nasdaq), we are subject to the DCGC. The DCGC contains both principles and best
practice provisions for our Management Board, our Supervisory Board (and after July&nbsp;1, 2021, our Board), shareholders and our general meeting, financial reporting, auditors, disclosure compliance and enforcement standards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DCGC is based on a &#147;comply or explain&#148; principle. Accordingly, we are required to disclose in its management report publicly filed in the
Netherlands, whether or not it is complying with the various provisions of the DCGC. If we do not comply with one or more of those provisions (<I>e.g.</I>, because of a conflicting Nasdaq requirement or U.S. market practice), we are required to
explain the reasons for <FONT STYLE="white-space:nowrap">such&nbsp;non-compliance.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dutch Civil Code </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Dutch Civil Code provides for certain disclosure obligations in our annual accounts. Information on the remuneration and rights to acquire ordinary shares
of our Managing Directors and our Supervisory Directors need to be disclosed in our annual accounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Warrant Agent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our articles of association, our Management Board may resolve, with due observation of the statutory requirements, that the laws of the State of New York
will apply to the property law aspects of the ordinary shares </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
included in the part of the register of shareholders kept by the relevant transfer agent. Our Board has adopted such resolution effective as of the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ordinary shares are listed in registered form and, through our transfer agent, are not certificated. We appointed Continental Stock Transfer&nbsp;&amp;
Trust Company as our agent in New York to maintain our shareholders&#146; register on behalf of our Management Board and to act as transfer agent and registrar for the ordinary shares. The ordinary shares will be traded on Nasdaq in book-entry form.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrant agent for warrants is Continental Stock Transfer&nbsp;&amp; Trust Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing of Our Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ordinary shares and
warrants are listed on Nasdaq under the symbols IMTX and IMTXW, respectively. Holders of our ordinary shares and warrants should obtain current market quotations for their securities. There can be no assurance that our ordinary shares and/or
warrants will remain listed on Nasdaq. If we fail to comply with the Nasdaq listing requirements, our ordinary shares and/or warrants could be delisted from Nasdaq. A delisting of our ordinary shares will likely affect the liquidity of our ordinary
shares and could inhibit or restrict our ability to raise additional financing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our transfer agent is Continental Stock Transfer&nbsp;&amp; Trust Company, 1 State Street, 30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, New
York, New York 10004-1561. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_16"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2020 (the &#147;Closing Date&#148;), we closed the Business Combination, pursuant to which the following transactions occurred: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shareholders of Immatics OpCo exchanged their equity interests in Immatics OpCo for an aggregate of 33,791,269
ordinary shares (including (A)&nbsp;holders of vested Immatics OpCo stock appreciation rights that received cash proceeds in exchange for the cancellation of such stock appreciation rights and subsequently invested portions of such cash proceeds in
our company in exchange for ordinary shares, and (B)&nbsp;holders of unvested Immatics OpCo stock appreciation rights that received options to purchase ordinary shares in exchange for the cancellation of such rights). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ARYA Merger Sub 1, a Cayman Islands exempted company, merged with and into Arya Sciences Acquisition Corp.
(&#147;ARYA&#148;) (the &#147;First Merger&#148;), with ARYA as the surviving company (the &#147;First Surviving Company&#148;), and, after giving effect to the First Merger, becoming our wholly-owned subsidiary. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In connection with the First Merger, each issued and outstanding ordinary share of ARYA was converted into one
ordinary share of the First Surviving Company and, immediately thereafter, each of the resulting ordinary shares of the First Surviving Company was automatically exchanged for one ordinary share, for an aggregate of 17,968,750 ordinary shares.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Each outstanding warrant to purchase a Class&nbsp;A ordinary share of ARYA was, by its terms, converted into a
warrant to purchase one ordinary share, for an aggregate of 7,187,500 public warrants, other than the warrants held by ARYA Sciences Holdings, a Cayman Islands exempted company and an affiliate of ARYA (the &#147;ARYA Sponsor&#148;), which were
forfeited. The public warrants entitle the holder to purchase one ordinary share at an exercise price of $11.50 per share and become exercisable 30 days after the Closing Date. The public warrants expire five years after the Closing Date or earlier
upon redemption or liquidation in accordance with their terms. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The First Surviving Company merged with and into Immatics Merger Sub 2, a Cayman Islands exempted company
(&#147;IB Merger Sub&#148;), with IB Merger Sub as the surviving company in the merger, and each issued and outstanding First Surviving Company share was automatically converted into one ordinary share of IB Merger Sub. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Business Combination Agreement contained customary representations and warranties and <FONT STYLE="white-space:nowrap">pre-</FONT> and post-closing
covenants of each party and customary closing conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PIPE Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;17, 2020, concurrently with the execution of the Business Combination Agreement, Immatics OpCo and ARYA entered into Subscription Agreements with
certain investors (the &#147;PIPE Investors&#148;), pursuant to which the PIPE Investors agreed to subscribe for and purchase, and the Company agreed to issue and sell to such PIPE Investors, an aggregate of 10,415,000 ordinary shares at a price of
$10.00 per share, for gross proceeds of approximately $104.2&nbsp;million on the Closing Date, $25.0&nbsp;million of which was funded by an affiliate of the ARYA Sponsor. The PIPE Financing closed concurrently with the Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Business
Combination and the PIPE Financing, we granted certain registration rights to certain securityholders under the Investor Rights Agreement entered into as of the closing of the Business Combination. Pursuant to the Investor Rights Agreement, we
agreed to promptly, but no later than 45 calendar days from the Closing Date, file, subject to customary exceptions, a Registration Statement covering all ordinary shares issued in connection with the First Merger, the Exchange and the PIPE
Financing. The Investor Rights Agreement also provides the parties with demand and &#147;piggy-back&#148; registration rights, subject to certain minimum requirements and customary conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our articles of association provide for certain indemnification rights for our directors and executive officers, and we entered into an indemnification
agreement with each of our executive officers and directors providing for procedures for indemnification and advancements by us of certain expenses and costs relating to claims, suits or proceedings arising from his or her service to us or, at our
request, service to other entities, as officers or directors to the maximum extent permitted by Dutch law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Review, Approval or Ratification of
Transactions with Related Persons </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We adopted a code of business conduct and ethics that prohibits directors and executive officers from engaging in
transactions that may result in a conflict of interest with us. The code of business conduct and ethics includes a policy requiring that our Board review any transaction a director or executive officer proposes to have with us that could give rise
to a conflict of interest or the appearance of a conflict of interest, including any transaction that would require disclosure under <FONT STYLE="white-space:nowrap">Item&nbsp;404(a)&nbsp;of&nbsp;Regulation&nbsp;S-K.&nbsp;In</FONT> conducting this
review, our Supervisory Board (and later, our Board) will be obligated to ensure that all such transactions are approved by a majority of such Board (including a majority of independent directors) not otherwise interested in the transaction and are
fair and reasonable to the company and on terms not less favorable to us than those available from unaffiliated third parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_17"></A>PRINCIPAL SECURITYHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information relating to the beneficial ownership of our ordinary shares as of July&nbsp;31, 2020 by: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of outstanding ordinary
shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC has defined &#147;beneficial ownership&#148; of a security to mean the possession, directly or indirectly, of voting power and/or investment power
over such security. A shareholder is also deemed to be, as of any date, the beneficial owner of all securities that such shareholder has the right to acquire within 60 days after that date through (i)&nbsp;the exercise of any option, warrant or
right, (ii)&nbsp;the conversion of a security, (iii)&nbsp;the power to revoke a trust, discretionary account or similar arrangement, or (iv)&nbsp;the automatic termination of a trust, discretionary account or similar arrangement. In computing the
number of shares beneficially owned by a person and the percentage ownership of that person, ordinary shares subject to options or other rights (as set forth above) held by that person that are currently exercisable, or will become exercisable
within 60 days thereafter, are deemed outstanding, while such shares are not deemed outstanding for purposes of computing percentage ownership of any other person. Each person named in the table has sole voting and investment power with respect to
all of the ordinary shares shown as beneficially owned by such person, except as otherwise indicated in the table or footnotes below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The percentage of
ordinary shares beneficially owned is computed on the basis of 62,908,617 ordinary shares outstanding on July&nbsp;31, 2020, and does not include 7,187,500 ordinary shares issuable upon the exercise of our public warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, we believe that all persons named in the table below have sole voting and
investment power with respect to all ordinary shares beneficially owned by them. To our knowledge, no ordinary shares beneficially owned by any executive officer, director or director nominee have been pledged as security. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Beneficial Owner</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of<BR>ordinary&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B><br><B>of<BR>All&nbsp;ordinary&nbsp;shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers, Directors and Director Nominees</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harpreet Singh, Ph. D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Ulmer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carsten Reinhardt, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Toni Weinschenk, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rainer Kramer, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steffen Walter, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cedrik Britten, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Chambr&eacute;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael G. Atieh</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul R. Carter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christof Hettich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heather L. Mason</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adam Stone<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All executive officers and directors as a group (13 persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Other 5% shareholders</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARYA Sciences Holdings<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,093,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">dievini Hopp BioTech holding GmbH&nbsp;&amp; Co.
KG<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,476,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AT lmpf GmbH<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,911,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wellington Partners<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,721,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates beneficial ownership of less than 1% of total outstanding ordinary shares. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Does not include any ordinary shares indirectly owned by Adam Stone as a result of his membership interest in
ARYA Sponsor. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ARYA Sciences Holdings is governed by a three member board of directors. Each director has one vote, and the
approval of a majority of the directors is required to approve an action. Under the <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;rule of three&#148;, if voting and dispositive decisions regarding an entity&#146;s securities are made by
two or more individuals, and a voting and dispositive decision requires the approval of a majority of those individuals, then none of the individuals is deemed a beneficial owner of the entity&#146;s securities. The business address of ARYA Sciences
Holdings is c/o Perceptive Advisors, 51 Astor Place, 10th Floor, New York, New York 10003. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dr.&nbsp;Friedrich von Bohlen und Halbach, Dr.&nbsp;Christof Hettich and Dr.&nbsp;Mathias Hotum are managing
directors of dievini Hopp BioTech holding GmbH&nbsp;&amp; Co. KG and have sole representation over such securities, and Dietmar Hopp, also a managing director of dievini Hopp BioTech holding GmbH&nbsp;&amp; Co. KG, has joint power of representation
over such securities. The business address of Hopp BioTech holding GmbH&nbsp;&amp; Co. KG is dievini Hopp BioTech holding GmbH&nbsp;&amp; Co. KG, Johann-Jakob-Astor-Strasse 57, 69190 Walldorf, Federal Republic of Germany. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Helmut Jeggle is a managing director of AT Impf GmbH and has sole power of representation over such securities,
Thomas Maier is a managing director of AT Impf GmbH and has joint power of representation over such securities, and Melissa Simon and Sebastian Beyer are procurists of AT Impf GmbH and have joint power of representation over such securities. The
business address of AT Impf GmbH is c/o Athos Service GmbH, Rosenheimer Platz 6, 81669 Munich, Federal Republic of Germany. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 2,740,987 ordinary shares held by Wellington Partners Ventures II GmbH&nbsp;&amp; Co. KG (A),
1,184,440 ordinary shares held by Wellington Partners Nominee Ltd. and 796,163 ordinary shares held by Wellington Partners Ventures IV Life Science Fund L.P. The business address for Wellington Partners Ventures II GmbH&nbsp;&amp; Co. KG (A)&nbsp;is
Tuerkenstrasse 5, 80333 Munich, Federal Republic of Germany. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Cornelia Huber and Rolf Christof Dienst are managing directors of Wellington Partners Verwaltungs GmbH, the liquidator of Wellington Partners Ventures II GmbH&nbsp;&amp; Co. KG (A), and have
ultimate voting authority with respect to the shares held by Wellington Partners Ventures II GmbH&nbsp;&amp; Co. KG (A). The business address for each of Wellington Partners Ventures IV Life Sciences Fund L.P. and Wellington Partners Nominee Ltd. is
<FONT STYLE="white-space:nowrap">11-15</FONT> Seaton Place St Helier Jersey JE4 0QH, Channel Island. Matthew Hague and Patrycja Bocianowska are representatives of Wellington Partners Management Limited, the general partner of Wellington Partners
Ventures IV Life Science Fund L.P., and have sole power of representation over the securities held by each of Wellington Partners Ventures IV Life Sciences Fund L.P. and Wellington Partners Nominee Ltd. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_18"></A>SELLING SECURITYHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the possible offer and sale from time to time of up to 39,332,281 ordinary shares by the selling securityholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling securityholders may from time to time offer and sell any or all of the ordinary shares set forth below pursuant to this prospectus. When we refer
to the &#147;selling securityholders&#148; in this prospectus, we mean the persons listed in the tables below, and the pledgees, donees, transferees, assignees, successors and others who later come to hold any of the selling securityholders&#146;
interest in our securities after the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below sets forth, as of the date of this prospectus, the name of the selling
securityholders for which we are registering ordinary shares for resale to the public and the aggregate principal amount that the selling securityholders may offer pursuant to this prospectus. The individuals and entities listed below have
beneficial ownership over their respective securities. The SEC has defined &#147;beneficial ownership&#148; of a security to mean the possession, directly or indirectly, of voting power and/or investment power over such security. A shareholder is
also deemed to be, as of any date, the beneficial owner of all securities that such shareholder has the right to acquire within 60 days after that date through (i)&nbsp;the exercise of any option, warrant or right, (ii)&nbsp;the conversion of a
security, (iii)&nbsp;the power to revoke a trust, discretionary account or similar arrangement, or (iv)&nbsp;the automatic termination of a trust, discretionary account or similar arrangement. In computing the number of shares beneficially owned by
a person and the percentage ownership of that person, ordinary shares subject to options or other rights (as set forth above) held by that person that are currently exercisable, or will become exercisable within 60 days thereafter, are deemed
outstanding, while such shares are not deemed outstanding for purposes of computing percentage ownership of any other person.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ordinary shares held by
certain of the selling securityholders are subject to transfer restrictions, as described in the section titled &#147;<I>Description of Securities &#151; Transfer Restrictions</I>&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot advise you as to whether the selling securityholders will in fact sell any or all of such securities. In addition, the selling securityholders may
sell, transfer or otherwise dispose of, at any time and from time to time, the ordinary shares in transactions exempt from the registration requirements of the Securities Act after the date of this prospectus, subject to applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Selling securityholder information for each additional selling securityholder, if any, will be set forth by prospectus supplement to the extent required prior
to the time of any offer or sale of such selling securityholder&#146;s securities pursuant to this prospectus. Any prospectus supplement may add, update, substitute, or change the information contained in this prospectus, including the identity of
each selling securityholder and the number of ordinary shares registered on its behalf. A selling securityholder may sell all, some or none of such securities in this offering. See the section titled &#147;<I>Plan of Distribution</I>&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares owned by the persons named below do not have voting rights different from the shares owned by
other holders. Unless otherwise indicated, the business address of each beneficial owner listed in the tables below is c/o Immatics N.V., Paul-Ehrlich-Stra&szlig;e 15, 72076 T&uuml;bingen, Federal Republic of Germany. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Owned<BR>Before the<BR>Offering</B><br><B>(#)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B><br><B>Being<BR>Offered</B><br><B>(#)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Shares&nbsp;Owned&nbsp;After<BR>the Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Selling Shareholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(#)<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(%)<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Harpreet Singh</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">267,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Chambre</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Carsten Reinhardt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Toni Weinschenk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stephen Eck</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rainer Kramer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas Ulmer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steffen Walter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">dievini Hopp BioTech holding GmbH&nbsp;&amp; Co.
KG<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,476,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,476,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AT Impf GmbH<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,911,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,911,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MIG GmbH&nbsp;&amp; Co Fonds 11
KG<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,823,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,823,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MIG GmbH&nbsp;&amp; Co Fonds 13 geschlossene <FONT STYLE="white-space:nowrap">Investment-KG</FONT><SUP
STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,674</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wellington Partners Ventures II GmbH&nbsp;&amp; Co. KG<SUB
STYLE="font-size:85%; vertical-align:bottom">(6)</SUB></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,740,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,740,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wellington Partners Nominee Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wellington Partners Ventures IV Life Science Fund L.P.<SUP
STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">796,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">796,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ARYA Sciences Holdings<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,503,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,503,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kevin Conroy<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Todd Wider<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Hung<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alyeska Master Fund, LP<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">496,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">496,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alyeska Master Fund 3, LP<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,968</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Baker Brothers Life Sciences, L.P.<SUP STYLE="font-size:85%; vertical-align:top">(11)
</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">667, L.P. <SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dellora Investments LP<SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federated Hermes Kaufmann Fund<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federated Hermes Kaufmann Fund
II<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federated Hermes Kaufmann Small Cap
Fund<SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund
Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redmile Capital Offshore II Master Fund,
Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">894,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">894,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redmile Strategic Master Fund,
LP<SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,105,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,105,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RTW Innovation Master Fund, Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RTW Master Fund, Ltd.<SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">240,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RTW Venture Fund Limited<SUP STYLE="font-size:85%; vertical-align:top">(16) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Schonfeld Strategic 460 Fund LLC<SUP STYLE="font-size:85%; vertical-align:top">(17)
</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sphera Biotech Master Fund L.P<SUP STYLE="font-size:85%; vertical-align:top">(18)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sphera Global Healthcare Master
Fund<SUP STYLE="font-size:85%; vertical-align:top">(18)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Less than 1% </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The percentage of ordinary shares beneficially owned is computed on the basis of 62,908,617 ordinary shares
outstanding on July&nbsp;31, 2020, and does not include 7,187,500 ordinary shares issuable upon the exercise of our public warrants. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes the sale of all shares offered in this prospectus. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of Hopp BioTech holding GmbH&nbsp;&amp; Co. KG is dievini Hopp BioTech holding
GmbH&nbsp;&amp; Co. KG, Johann-Jakob-Astor-Strasse 57, 69190 Walldorf, Federal Republic of Germany. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of AT Impf GmbH is c/o Athos Service GmbH, Rosenheimer Platz 6, 81669 Munich, Federal
Republic of Germany. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of each of MIG GmbH&nbsp;&amp; Co Fonds 11 KG and MIG GmbH&nbsp;&amp; Co Fonds 13
geschlossene <FONT STYLE="white-space:nowrap">Investment-KG</FONT> is Ismaniger Str. 102, 81675 Munich, Federal Republic of Germany. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of Wellington Partners Ventures II GmbH&nbsp;&amp; Co. KG (A)&nbsp;is Tuerkenstrasse 5,
80333 Munich, Federal Republic of Germany. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of each of Wellington Partners Ventures IV Life Sciences Fund L.P. and Wellington Partners
Nominee Ltd. is <FONT STYLE="white-space:nowrap">11-15</FONT> Seaton Place St Helier Jersey JE4 0QH, Channel Island. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of each of ARYA Sciences Holdings, Kevin Conroy, Todd Wider and David Hung is c/o
Perceptive Advisors, 51 Astor Place, 10th Floor, New York, New York 10003. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of Alyeska Master Fund, LP is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland
House, South Church Street, George Town, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1104</FONT> Cayman Islands, British West Indies. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of Alyeska Master Fund 3, LP is c/o Corporation Service Company, 251 Little Falls Drive,
Wilmington, DE 19808. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of each of Baker Brothers Life Sciences, L.P. and 667, L.P. is 860 Washington Street, 3rd
Floor, New York, NY 10014. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of Dellora Investments LP is 4 Murdock Road, Scarsdale, NY 10583. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of each of Federated Hermes Kaufmann Fund, Federated Hermes Kaufmann Fund II and Federated
Hermes Kaufmann Small Cap Fund is 4000 Ericsson Drive, Warrendale, PA 15086-7561. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of Perceptive Life Sciences Master Fund Ltd. is 51 Astor Place, 10th Floor, New York, NY
10003. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of each of Redmile Capital Offshore II Master Fund, Ltd. and Redmile Strategic Master
Fund, LP is One Letterman Drive, Suite <FONT STYLE="white-space:nowrap">D3-300</FONT> , San Francisco, CA 94129. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of each of RTW Innovation Master Fund, Ltd., RTW Master Fund, Ltd. and RTW Venture Fund
Limited is 412 W. 15th St., Floor 9, New York, NY 10011. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(17)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of Schonfeld Strategic 460 Fund LLC is 460 Park Ave, Fl. 19, New York, NY 10022.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(18)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The business address of each of Sphera Biotech Master Fund L.P and Sphera Global Healthcare Master Fund is c/o
Maples Corporate Services Limited P.O. Box 309 , Ugland House, South Church Street, George Town, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-1104</FONT> Cayman Islands. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Relationships with Selling Securityholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See
the section titled &#147;<I>Certain Relationships and Related Person Transactions</I>&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_19"></A>TAXATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Considerations for U.S. Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of the material U.S. federal income tax consequences to the U.S. Holders (as defined below) described below of owning and
disposing of our ordinary shares. It is not a comprehensive description of all tax considerations that may be relevant to a particular person&#146;s decision to acquire ordinary shares. This discussion applies only to a U.S. Holder that is an
initial purchaser of ordinary shares pursuant to the offering and that holds our ordinary shares as a capital asset for tax purposes (generally, property held for investment). In addition, it does not describe all of the tax consequences that may be
relevant in light of a U.S. Holder&#146;s particular circumstances, including state and local tax consequences, estate tax consequences, alternative minimum tax consequences, the potential application of the Medicare contribution tax, and tax
consequences applicable to U.S. Holders subject to special rules, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, insurance companies, and certain other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mutual funds and pension plans; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dealers or traders in securities who use a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of tax accounting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding ordinary shares as part of a hedging transaction, &#147;straddle,&#148; &#147;hedge,&#148;
&#147;conversion,&#148; &#147;synthetic security,&#148; &#147;constructive ownership transaction,&#148; &#147;constructive sale&#148; or other integrated transaction for U.S. federal income tax purposes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons whose &#147;functional currency&#148; for U.S. federal income tax purposes is not the U.S. dollar;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers or traders in securities, commodities or currencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> entities (including private foundations) or government
organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">S corporations, partnerships, or other entities or arrangements classified as partnerships for U.S. federal
income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies or real estate investment trusts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">trusts and estates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who acquired our ordinary shares pursuant to the exercise of any employee stock option or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our ordinary shares in connection with a trade or business, permanent establishment, or fixed
base outside the United States; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who own (directly or through attribution) 10% or more (by vote or value) of our outstanding ordinary
shares. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an entity that is classified as a partnership for U.S. federal income tax purposes holds ordinary shares, the U.S. federal
income tax treatment of a partner will generally depend on the status of the partner and the activities of the partnership. Partnerships holding ordinary shares and partners in such partnerships are encouraged to consult their tax advisors as to the
particular U.S. federal income tax consequences of holding and disposing of ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The discussion is based on the Internal Revenue Code of
1986, as amended (the &#147;Code&#148;), administrative pronouncements, judicial decisions, final, temporary and proposed Treasury Regulations, all as of the date hereof, changes to any of which may affect the tax consequences described herein
&#151; possibly with retroactive effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A &#147;U.S. Holder&#148; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of
ordinary shares and is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An individual who is a citizen or individual resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the
United States, any state therein or the District of Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a trust if (1)&nbsp;a U.S. court is able to exercise primary supervision over the administration of the trust
and one or more U.S. persons have authority to control all substantial decisions of the trust or (2)&nbsp;the trust has a valid election to be treated as a U.S. person under applicable U.S. Treasury Regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PERSONS CONSIDERING AN INVESTMENT IN ORDINARY SHARES SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE PARTICULAR TAX CONSEQUENCES APPLICABLE TO THEM RELATING
TO THE ACQUISITION, OWNERSHIP AND DISPOSITION OF THE ORDINARY SHARES, INCLUDING THE APPLICABILITY OF U.S. FEDERAL, STATE AND LOCAL TAX LAWS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Distributions </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the
discussion below under &#147;Passive Foreign Investment Company Rules,&#148; distributions paid on ordinary shares, other than certain pro rata distributions of ordinary shares, will generally be treated as dividends to the extent paid out of our
current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Distributions in excess of our current and accumulated earnings and profits will constitute a return of capital that will be applied against and
reduce (but not below zero) the U.S. Holder&#146;s adjusted tax basis in its ordinary shares. Any remaining excess will be treated as gain realized on the sale or other disposition of the ordinary shares and will be treated as described below under
&#147;Sale or Other Taxable Disposition of Ordinary Shares.&#148; Subject to applicable limitations, amounts treated as dividend income to certain <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders may be taxable at preferential
rates applicable to &#147;qualified dividend income&#148; if we are a &#147;qualified foreign corporation&#148; and certain other requirements are met. However, the qualified dividend income treatment will not apply if we are treated as a PFIC (as
defined below) with respect to the U.S. Holder. The amount of any such distribution will include any amounts withheld by us (or another applicable withholding agent), which, as described below under the heading &#147;<I>&#151;Material German Tax
Considerations&#151;Taxation of dividends</I>,&#148; is expected to be in respect of German, and not Dutch, income taxes. The amount of the dividend will be treated as foreign-source dividend income to U.S. Holders and will not be eligible for the
dividends-received deduction generally available to U.S. corporations under the Code. Dividends will generally be included in a U.S. Holder&#146;s income on the date of the U.S. Holder&#146;s receipt of the dividend. The amount of any dividend
income paid in foreign currency will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars. If the
dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend
is converted into U.S. dollars after the date of receipt. Such gain or loss would generally be treated as U.S.-source ordinary income or loss. The amount of any distribution of property other than cash (and other than certain pro rata distributions
of ordinary shares or rights to acquire ordinary shares) will be the fair market value of such property on the date of distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For foreign tax
credit limitation purposes, our dividends will generally be treated as passive category income. The rules governing foreign tax credits are complex and U.S. Holders should therefore consult their tax advisors regarding the effect of the receipt of
dividends for foreign tax credit limitation purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to applicable limitations, German income taxes withheld from dividends on ordinary shares
at a rate not exceeding the rate provided by the applicable treaty with the United States will be eligible for credit against the U.S. treaty beneficiary&#146;s (as defined below) U.S. federal income tax liability. Subject to certain complex
limitations, <FONT STYLE="white-space:nowrap">the&nbsp;non-refundable&nbsp;withheld</FONT> German taxes generally will be eligible for credit against a U.S. treaty beneficiary&#146;s (as defined below) federal income tax liability. For purposes of
this discussion, a &#147;<I>U.S. treaty beneficiary</I>&#148; is a resident of the United States for purposes of the Convention Between the United States of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
America and the Federal Republic of Germany for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Income and Capital and to Certain Other Taxes as of
June&nbsp;4, 2008 (the &#147;Treaty&#148;), who is fully eligible for benefits under the Treaty and is, inter alia, the beneficial owner of the ordinary shares and the dividends paid with respect thereto (and is not also a resident of Germany for
German tax purposes, and is not subject to the limitation on benefits (i.e., anti-treaty shopping) article of the Treaty that applies in limited circumstances). The rules governing foreign tax credits are complex and U.S. Holders are urged to
consult their tax advisors regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, a U.S. Holder may deduct foreign taxes, including any German income tax, in computing their taxable
income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sale or Other Taxable Disposition of Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion below under &#147;Passive Foreign Investment Company Rules,&#148; gain or loss realized on the sale or other taxable disposition of
ordinary shares will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder held the ordinary shares for more than one year at the time of sale or other taxable disposition. The amount of the gain or loss will equal
the difference between the U.S. Holder&#146;s tax basis in the ordinary shares disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. This gain or loss will generally be U.S.-source gain or loss for
foreign tax credit purposes. Subject to the PFIC rules described below, long-term capital gains recognized by certain <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders (including individuals) will generally be subject to reduced
rates of U.S. federal income tax. The deductibility of capital losses is subject to limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the consideration received by a U.S. Holder is not
paid in U.S. dollars, the amount realized will be the U.S. dollar value of the payment received determined by reference to the spot rate of exchange on the date of the sale or other disposition. However, if the ordinary shares are treated as traded
on an &#147;established securities market&#148; and you are either a cash basis taxpayer or an accrual basis taxpayer that has made a special election (which must be applied consistently from year to year and cannot be changed without the consent of
the U.S. Internal Revenue Service (the &#147;IRS&#148;)), you will determine the U.S. dollar value of the amount realized in a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> dollar currency by translating the amount received at the spot rate of
exchange on the settlement date of the sale. If you are an accrual basis taxpayer that is not eligible to or does not elect to determine the amount realized using the spot rate on the settlement date, you will recognize foreign currency gain or loss
to the extent of any difference between the U.S. dollar amount realized on the date of sale or disposition and the U.S. dollar value of the currency received at the spot rate on the settlement date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Rules </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we
are classified as a passive foreign investment company under Section&nbsp;1297 of the Code (a &#147;PFIC&#148;) in any taxable year, a U.S. Holder will be subject to special rules generally intended to reduce or eliminate any benefits from the
deferral of U.S. federal income tax that a U.S. Holder could derive from investing in a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company that does not distribute all of its earnings on a current basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation will be classified as a PFIC for any taxable year in which, after applying certain look-through
rules, either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least 75% of its gross income is passive income (such as interest income) (the &#147;Income Test&#148;); or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least 50% of its gross assets (determined on the basis of a quarterly average) is attributable to assets that
produce passive income or are held for the production of passive income (the &#147;Asset Test&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is uncertain whether we or any
of our subsidiaries, including Immatics OpCo, will be treated as a PFIC for U.S. federal income tax purposes for the current or any subsequent tax year. The determination of whether we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
are a PFIC is a fact-intensive determination made on an annual basis applying principles and methodologies that in some circumstances are unclear and subject to varying interpretation. Under the
Income Test, our status as a PFIC depends on the composition of our income which will depend on the transactions we enter into in the future and our corporate structure. The composition of our income and assets is also affected by the spending of
the cash we raise in any offering, including this offering. Because PFIC status is based on our income, assets, and activities for the entire taxable year, it is not possible to determine whether we will be characterized as a PFIC for the 2020
taxable year or any subsequent year until after the close of the relevant taxable year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are classified as a PFIC in any year with respect to which
a U.S. Holder owns the ordinary shares, we will continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding years during which the U.S. Holder owns the ordinary shares, regardless of whether we continue to meet the tests
described above unless (i)&nbsp;we cease to be a PFIC and the U.S. Holder has made a &#147;deemed sale&#148; election under the PFIC rules, or (ii)&nbsp;the U.S. Holder makes a QEF Election (as defined below) with respect to all taxable years during
such U.S. Holders holding period in which we are a PFIC. If the &#147;deemed sale&#148; election is made, a U.S. Holder will be deemed to have sold the ordinary shares the U.S. Holder holds at their fair market value and any gain from such deemed
sale would be subject to the rules described below. After the deemed sale election, so long as we do not become a PFIC in a subsequent taxable year, the U.S. Holder&#146;s ordinary shares with respect to which such election was made will not be
treated as shares in a PFIC and the U.S. Holder will not be subject to the rules described below with respect to any &#147;excess distribution&#148; the U.S. Holder receives from us or any gain from an actual sale or other disposition of the
ordinary shares. U.S. Holders should consult their tax advisors as to the possibility and consequences of making a deemed sale election if we cease to be a PFIC and such election becomes available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For each taxable year we are treated as a PFIC with respect to U.S. Holders, U.S. Holders will be subject to special tax rules with respect to any
&#147;excess distribution&#148; such U.S. Holder receives and any gain such U.S. Holder recognizes from a sale or other disposition (including, under certain circumstances, a pledge) of ordinary shares, unless (i)&nbsp;such U.S. Holder makes a QEF
Election (as defined below) or (ii)&nbsp;our ordinary shares constitute &#147;marketable&#148; securities, and such U.S. Holder makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election as
discussed below. Distributions a U.S. Holder receives in a taxable year that are greater than 125% of the average annual distributions a U.S. Holder received during the shorter of the three preceding taxable years or the U.S. Holder&#146;s holding
period for the ordinary shares will be treated as an excess distribution. Under these special tax rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the excess distribution or gain will be allocated ratably over a U.S. Holder&#146;s holding period for ordinary
shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to the taxable year of disposition, and any taxable year prior to the first taxable year in
which we became a PFIC, will be treated as ordinary income; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount allocated to each other year will be subject to the highest tax rate in effect for that year for
individuals or corporations, as appropriate, and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax liability for amounts allocated to years prior to the year of disposition or &#147;excess distribution&#148; cannot be offset by any net operating
losses for such years, and gains (but not losses) realized on the sale of the ordinary shares cannot be treated as capital, even if a U.S. Holder holds the ordinary shares as capital assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are a PFIC, a U.S. Holder will generally be subject to similar rules with respect to distributions we receive from, and our dispositions of the stock
of, any of our direct or indirect subsidiaries that also are PFICs, as if such distributions were indirectly received by, and/or dispositions were indirectly carried out by, such U.S. Holder. U.S. Holders should consult their tax advisors regarding
the application of the PFIC rules to our subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain elections exist that may alleviate some of the adverse consequences of PFIC status and
would result in an alternative treatment of the ordinary shares. A U.S. Holder may avoid the general tax treatment for PFICs described above by electing to treat us as a &#147;qualified electing fund&#148; under Section&nbsp;1295 of the Code (a
&#147;QEF,&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and such election, a &#147;QEF Election&#148;) for each of the taxable years during the U.S. Holder&#146;s holding period that we are a PFIC. If a QEF Election is not in effect for the first
taxable year in the U.S. Holder&#146;s holding period in which we are a PFIC, a QEF Election generally can only be made if the U.S. Holder elects to make an applicable deemed sale or deemed dividend election on the first day of its taxable year in
which the PFIC becomes a QEF pursuant to the QEF Election. The deemed gain or deemed dividend recognized with respect to such an election would be subject to the general tax treatment of PFICs discussed above. In order to comply with the
requirements of a QEF Election, a U.S. Holder must receive a PFIC Annual Information Statement from us. We intend to provide the information necessary for U.S.&nbsp;Holders to make or maintain a QEF Election, including information necessary to
determine the appropriate income inclusion amounts for purposes of the QEF Election. However, there is also no assurance that we will have timely knowledge of our status as a PFIC in the future or of the required information to be provided. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a U.S. Holder makes a QEF Election with respect to a PFIC, it will be taxed currently on its pro rata share of the PFIC&#146;s ordinary earnings and net
capital gain (at ordinary income and capital gain rates, respectively) for each taxable year that the entity is a PFIC, even if no distributions were received. Any distributions we make out of our earnings and profits that were previously included
in such a U.S. Holder&#146;s income under the QEF Election would not be taxable to such U.S. Holder. Such U.S. Holder&#146;s tax basis in its ordinary shares would be increased by an amount equal to any income included under the QEF Election and
decreased by any amount distributed on the ordinary shares that is not included in its income. In addition, a U.S. Holder will recognize capital gain or loss on the disposition of its ordinary shares in an amount equal to the difference between the
amount realized and its adjusted tax basis in the ordinary shares, each as determined in U.S. dollars. Once made, a QEF Election remains in effect unless invalidated or terminated by the IRS or revoked by the shareholder. A QEF Election can be
revoked only with the consent of the IRS. A U.S. Holder will not be currently taxed on the ordinary income and net capital gain of a PFIC with respect to which a QEF Election was made for any taxable year of the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation that such corporation does not satisfy the Income Test or Asset Test. Each U.S. Holder should consult its tax advisor regarding the availability of, and procedure for making, any deemed
gain, deemed dividend or QEF Election. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Alternatively, U.S. Holders can avoid the interest charge on excess distributions or gain relating to the ordinary
shares by making a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to the ordinary shares, provided that the ordinary shares constitute &#147;marketable stock.&#148;
&#147;Marketable stock&#148; is, generally, stock that is &#147;regularly traded&#148; on certain U.S. stock exchanges or on a foreign stock exchange that meets certain conditions. For these purposes, the ordinary shares will be considered regularly
traded during any calendar year during which they are traded, other than in de minimis quantities, on at least 15&nbsp;days during each calendar quarter. Any trades that have as their principal purpose meeting this requirement will be disregarded.
Our ordinary shares are listed on Nasdaq, which is a qualified exchange for these purposes. Consequently, if our ordinary shares remain listed on Nasdaq and are regularly traded, and you are a U.S. Holder of ordinary shares, we expect the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election would be available to you if we are a classified as a PFIC. Each U.S. Holder should consult its tax advisor as to the whether a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is available or advisable with respect to the ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A U.S. Holder that makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election must include in ordinary
income for each year an amount equal to the excess, if any, of the fair market value of the ordinary shares at the close of the taxable year over the U.S. Holder&#146;s adjusted tax basis in the ordinary shares. An electing holder may also claim an
ordinary loss deduction for the excess, if any, of the U.S. Holder&#146;s adjusted basis in the ordinary shares over the fair market value of the ordinary shares at the close of the taxable year, but this deduction is allowable only to the extent of
any net <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> gains for prior years. Gains from an actual sale or other disposition of the ordinary shares will be treated as ordinary income, and any losses
incurred on a sale or other disposition of the shares will be treated as an ordinary loss to the extent of any net <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> gains for prior years. Once made, the
election cannot be revoked without the consent of the IRS, unless the ordinary shares cease to be marketable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election generally cannot be made for equity interests in any lower-tier PFICs that we own, unless shares of such lower-tier PFIC are themselves
&#147;marketable.&#148; As a result, even if a U.S. Holder </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
validly makes a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to our ordinary shares, the U.S. Holder may continue to be
subject to the PFIC rules (described above) with respect to its indirect interest in any of our investments that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. U.S. Holders should consult their tax advisors to
determine whether any of these elections would be available and if so, what the consequences of the alternative treatments would be in their particular circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise provided by the IRS, each U.S. shareholder of a PFIC is required to file an annual report containing such information as the IRS may require.
A U.S. Holder&#146;s failure to file the annual report will cause the statute of limitations for such U.S. Holder&#146;s U.S. federal income tax return to remain open with regard to the items required to be included in such report until three years
after the U.S. Holder files the annual report, and, unless such failure is due to reasonable cause and not willful neglect, the statute of limitations for the U.S. Holder&#146;s entire U.S. federal income tax return will remain open during such
period. U.S. Holders should consult their tax advisors regarding the requirements of filing such information returns under these rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WE STRONGLY URGE
YOU TO CONSULT YOUR TAX ADVISOR REGARDING THE IMPACT OF OUR PFIC STATUS ON YOUR INVESTMENT IN THE ORDINARY SHARES AS WELL AS THE APPLICATION OF THE PFIC RULES TO YOUR INVESTMENT IN THE ORDINARY SHARES. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries generally are subject
to information reporting, and may be subject to backup withholding, unless (i)&nbsp;the U.S. Holder is a corporation or other exempt recipient or (ii)&nbsp;in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification
number and certifies that it is not subject to backup withholding on a duly executed IRS Form <FONT STYLE="white-space:nowrap">W-9</FONT> or otherwise establishes an exemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount of any backup withholding from a payment to a U.S. Holder may be allowed as a credit against the U.S. Holder&#146;s U.S. federal income tax
liability and may entitle the U.S. Holder to a refund, provided that the required information is timely furnished to the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Information with
Respect to Foreign Financial Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders who are individuals (and, under regulations, certain entities) may be required to report
information relating to the ordinary shares, subject to certain exceptions (including an exception for ordinary shares held in accounts maintained by certain U.S. financial institutions), by filing IRS Form 8938 (Statement of Specified Foreign
Financial Assets) with their federal income tax return. Such U.S. Holders who fail to timely furnish the required information may be subject to a penalty. Additionally, if a U.S. Holder does not file the required information, the statute of
limitations with respect to tax returns of the U.S. Holder to which the information relates may not close until three years after such information is filed. U.S. Holders should consult their tax advisors regarding their reporting obligations with
respect to their ownership and disposition of the ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Treasury Regulations meant to require the reporting of certain tax shelter
transactions could be interpreted to cover transactions generally not regarded as tax shelters, including certain foreign currency transactions. Under the applicable U.S. Treasury Regulations, certain transactions are required to be reported to the
IRS including, in certain circumstances, a sale, exchange, retirement or other taxable disposition of foreign currency, to the extent that such sale, exchange, retirement or other taxable disposition results in a tax loss in excess of a threshold
amount. U.S. Holders should consult their tax advisors to determine the tax return obligations, if any, with respect to our ordinary shares, and the receipt of Euro in respect thereof, including any requirement to file IRS Form 8886 (Reportable
Transaction Disclosure Statement). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Dutch Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Taxation in the Netherlands </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section outlines the
principal Dutch tax consequences of the acquisition, holding, settlement, redemption and disposal of ordinary shares. It does not purport to present a comprehensive or complete description of all aspects of Dutch tax law which could be of relevance
to a holder of ordinary shares in the capital of Immatics, which we refer to as a shareholder. For Dutch tax purposes, a shareholder may include an individual who, or an entity that, does not hold the legal title to the ordinary shares, but to whom,
or to which, nevertheless the ordinary shares or the income thereof, are attributed based either on such individual or entity owning a beneficial interest in the ordinary shares or based on specific statutory provisions. These include statutory
provisions pursuant to which ordinary shares are attributed to an individual who is, or who has directly or indirectly inherited from a person who was, the settlor, grantor or similar originator of a trust, foundation or similar entity that holds
the ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section is intended as general information only. A prospective shareholder should consult his own tax adviser regarding the tax
consequences of any acquisition, holding, redemption and disposal of ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided, this section is based on Dutch tax
law as applied and interpreted by Dutch tax courts and as published and in effect on the date of this proxy statement/prospectus, including, for the avoidance of doubt, the tax rates applicable on the date hereof, without prejudice to any amendments
introduced at a later date and implemented with or without retroactive effect. On this basis, the statements included in this section are the opinion of CMS Derks Star Busmann N.V., Dutch counsel to Immatics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any reference in this section made to Dutch taxes, Dutch tax or Dutch tax law must be construed as a reference to any taxes of any nature levied by or on
behalf of the Netherlands or any of its subdivisions or taxing authorities or to the law governing such taxes, respectively. The Netherlands means the part of the Kingdom of the Netherlands located in Europe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any reference hereafter made to a treaty for the avoidance of double taxation concluded by the Netherlands includes the Tax Regulation for the Kingdom of the
Netherlands (<I>Belastingregeling voor het Koninkrijk</I>), the Tax Regulations for the Netherlands and Curacao (<I>Belastingregeling Nederland Cura&ccedil;ao</I>), the Tax Regulations for the Netherlands and Sint Maarten (<I>Belastingregeling
Nederland Sint Maarten</I>), the Tax Regulation for the State of the Netherlands (<I>Belastingregeling voor het land Nederland</I>) and the Agreement between the Taipei Representative Office in the Netherlands and the Netherlands Trade and
Investment Office in Taipei for the avoidance of double taxation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section does not describe any Dutch tax considerations or consequences that may be
relevant to a shareholder: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">who is an individual and for whom the income or capital gains derived from the ordinary shares are attributable
to employment activities, the income from which is taxable in the Netherlands; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">who has, or that has, a substantial interest (<I>aanmerkelijk belang</I>) or a fictitious substantial interest
(<I>fictief aanmerkelijk belang</I>) in Immatics within the meaning of chapter 4 of the Dutch Income Tax Act 2001 (<I>Wet inkomstenbelasting 2001</I>). Generally, a shareholder has a substantial interest in Immatics if such shareholder, alone or
&#151; in case of an individual &#151; together with a partner for Dutch tax purposes, or any relative by blood or by marriage in the ascending or descending line (including foster-children) of either of them, directly or indirectly:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">owns, or holds, or is deemed to own or hold, certain rights to shares representing 5% or more of the total
issued capital of Immatics, or of the issued and outstanding capital of any class of shares of Immatics; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">holds, or is deemed to hold, rights to, directly or indirectly, acquire shares, whether or not already issued,
representing 5% or more of the total issued capital of Immatics, or of the issued capital of any class of shares of Immatics; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">owns, or holds, or is deemed to own or hold, certain rights on profit participating certificates
(<I>winstbewijzen</I>) that relate to 5% or more of the annual profit of Immatics or to 5% or more of the liquidation proceeds of Immatics. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">A shareholder who is an individual will also have a substantial interest if a partner for Dutch tax purposes or any relative by blood or by
marriage in the ascending or descending line (including foster-children) of either of them has a substantial interest in Immatics. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that is an entity which is, pursuant to the Dutch Corporate Income Tax Act 1969 (<I>Wet op de
vennootschapsbelasting 1969</I>) (the &#147;<I>CITA</I>&#148;), not subject to Dutch corporate income tax or is in full or in part exempt from Dutch corporate income tax (such as a qualifying pension fund); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that is an investment institution (<I>beleggingsinstelling</I>) as described in clause 6a or 28 CITA; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that is required to apply the participation exemption (<I>deelnemingsvrijstelling</I>) with respect to the
ordinary shares, or a combination thereof (as defined in clause 13 CITA). Generally, a holding of ordinary shares is considered to qualify as a participation for the participation exemption if it represents a holding of, or right to acquire, an
interest of 5% or more of the nominal <FONT STYLE="white-space:nowrap">paid-up</FONT> share capital in Immatics. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Withholding Tax
on Dividend Payments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>shareholders </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
shareholder is generally subject to Dutch dividend withholding tax at a rate of 15% on dividends distributed by Immatics. Generally, Immatics is responsible for the withholding of such dividend withholding tax at source. However, a shareholder will
not be subject to Dutch dividend withholding tax on dividends distributed by Immatics if, and for as long as, Immatics is resident solely in Germany for purposes of the convention between Germany and the Netherlands for the avoidance of double
taxation and the prevention of fiscal evasion with respect to taxes on income (the &#147;<I>German-Dutch tax treaty</I>&#148;), unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the shareholder is a Dutch Individual (as defined below) or a Dutch Corporate Entity (as defined below); or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the shareholder is a <FONT STYLE="white-space:nowrap">Non-Dutch</FONT> Individual (as defined below) or a <FONT
STYLE="white-space:nowrap">Non-Dutch</FONT> Corporate Entity (as defined below) and derives profits from an enterprise, which enterprise is, in whole or in part, carried on through a permanent establishment (<I>vaste inrichting</I>) or a permanent
representative (<I>vaste vertegenwoordiger</I>) in the Netherlands, to which the ordinary shares are attributable. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current
German-Dutch tax treaty stipulates that if a company is treated as tax resident of both the Netherlands and Germany it shall be treated as resident of the country in which it has its place of effective management for purposes of the treaty. It is
currently envisaged that Immatics shall have its place of effective management in Germany. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is currently uncertain what evidence, information and
documentation will be required by the Dutch tax authorities for purposes of accepting application of the German-Dutch tax treaty as described above, either at source or through a refund request by a shareholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends distributed by Immatics include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">distributions of profits in cash or in kind, whatever they be named or in whatever form; </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">proceeds from the liquidation of Immatics or proceeds from the repurchase of ordinary shares by Immatics, other
than as a temporary portfolio investment (<I>tijdelijke belegging</I>), in excess of the average <FONT STYLE="white-space:nowrap">paid-in</FONT> capital recognized for Dutch dividend withholding tax purposes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the nominal value of ordinary shares issued to a shareholder or an increase in the nominal value of ordinary
shares, to the extent that no related contribution, recognized for Dutch dividend withholding tax purposes, has been made or will be made; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">partial repayment of <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, that is not recognized for Dutch
dividend withholding tax purposes, or if recognized for Dutch dividend withholding tax purposes, to the extent that Immatics has &#147;net profits&#148;(<I>zuivere winst</I>), unless </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the general meeting has resolved in advance to make such repayment and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the nominal value of the ordinary shares concerned has been reduced with an equal amount by way of an amendment
to the articles of association of Immatics. The term &#147;net profits&#148; includes anticipated profits that have yet to be realized. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a shareholder is resident or deemed to be resident in the Netherlands, such shareholder is generally entitled to an exemption or a credit for any Dutch
dividend withholding tax against his Dutch (corporate) income tax liability and to a refund of any residual Dutch dividend withholding tax. Depending on his specific circumstances, a shareholder resident in a country other than the Netherlands, may
be entitled to exemptions from, reduction of, or full or partial refund of, Dutch dividend withholding tax pursuant to Dutch law, EU law, the agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the EU and the
European Atomic Community (but only for Dutch tax events arising up to and including 31&nbsp;December 2020 (which date may be extended) (&#147;<I>Final Transition Date</I>&#148;)), or treaties for avoidance of double taxation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shareholder that is resident (i)&nbsp;in an EU member state, or (ii)&nbsp;the United Kingdom (for Dutch tax events arising up to and including the Final
Transition Date), or (iii)&nbsp;in a state that is a party to the Agreement on the European Economic Area (&#147;<I>EEA</I>&#148;; Iceland, Liechtenstein or Norway), or (iv)&nbsp;in a designated third state with which the Netherlands has agreed to
an arrangement for the exchange of information on tax matters, is entitled to a full or partial refund of Dutch dividend withholding tax incurred in respect of ordinary shares if the final tax burden in respect of the dividends distributed by
Immatics of a comparable Dutch resident shareholder is lower than the withholding tax incurred by the <FONT STYLE="white-space:nowrap">non-Dutch</FONT> resident shareholder. The refund is granted upon request, and is subject to conditions and
limitations. No entitlement to a refund exists if the disadvantage for the <FONT STYLE="white-space:nowrap">non-Dutch</FONT> resident shareholder is entirely compensated in his state of residence under the provisions of a treaty for the avoidance of
double taxation concluded between this state of residence and the Netherlands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to Dutch domestic anti-dividend stripping rules, no credit
against Dutch (corporate) income tax, exemption from, reduction in or refund of, Dutch dividend withholding tax will be granted if the recipient of the dividends paid by Immatics is not considered to be the beneficial owner (<I>uiteindelijk
gerechtigde</I>) of such dividends. The DWTA provides for a <FONT STYLE="white-space:nowrap">non-exhaustive</FONT> negative description of a beneficial owner. According to the DWTA, a shareholder will not be considered the beneficial owner of the
dividends if as a consequence of a combination of transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a person other than the shareholder wholly or partly, directly or indirectly, benefits from the dividends;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">whereby this other person retains or acquires, directly or indirectly, an interest similar to that in the
ordinary shares on which the dividends were paid; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that other person is entitled to a credit, reduction or refund of Dutch dividend withholding tax that is less
than that of the shareholder. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please refer to the paragraph &#147;<I>Risk Factors</I>&#148; for a risk regarding Immatics&#146; tax
residency and the consequences thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxes on Income and Capital Gains </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Residents of the Netherlands </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The description of certain
Dutch tax consequences in this paragraph is only intended for the following shareholders: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">individuals who are resident or deemed to be resident in the Netherlands for Dutch income tax purposes
(&#147;<I>Dutch Individuals</I>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">entities or enterprises that are subject to the CITA and are resident or deemed to be resident in the
Netherlands for corporate income tax purposes (&#147;<I>Dutch Corporate Entities</I>&#148;) </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dutch individuals engaged or deemed
to be engaged in an enterprise or in miscellaneous activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dutch Individuals engaged or deemed to be engaged in an enterprise or who derive
income frommiscellaneous activities (<I>resultaat uit overige werkzaamheden</I>) are generally subject to income tax at statutory progressive rates with a maximum of 49.5% on any benefits derived or deemed to be derived from the ordinary shares,
that are either attributable to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an enterprise from which a Dutch Individual derives profits, whether as an entrepreneur (<I>ondernemer</I>) or
pursuant to a <FONT STYLE="white-space:nowrap">co-entitlement</FONT> (<I>medegerechtigde</I>) to the net worth of such enterprise other than as an entrepreneur or a shareholder; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the benefits of which are attributable to miscellaneous activities, including, without limitation, activities
which are beyond the scope of active portfolio investment activities (<I>meer dan normal vermogensbeheer</I>). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dutch individuals
not engaged or deemed to be engaged in an enterprise or in miscellaneous activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, the ordinary shares held by a Dutch Individual who
is not engaged or deemed to be engaged in an enterprise or miscellaneous activities, or who is so engaged or deemed to be engaged but the ordinary shares are not attributable to that enterprise or miscellaneous activities, will be subject to annual
income tax imposed on a fictitious yield on the ordinary shares under the regime for savings and investments (<I>inkomen uit sparen en beleggen</I>). Irrespective of the actual income and capital gains realized the annual taxable benefit of all the
assets and liabilities of a Dutch Individual that are taxed under this regime, including the ordinary shares, is set at a percentage of the positive balance of the fair market value of these assets, including the ordinary shares and the fair market
value of these liabilities. The percentage, which is annually indexed, increases: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">from 1.79% over the first &#128;72,797; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to 4.19% over &#128;72,798 up to and including &#128;1,005,572; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to a maximum of 5.28% over &#128;1,005,573 or higher. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No taxation occurs if this positive balance does not exceed a certain threshold (<I>heffingvrij vermogen</I>), which is &#128;30,846 in 2020. The fair market
value of assets, including the ordinary shares and liabilities that are taxed under this regime is measured once in each calendar year on January 1. The tax rate under the regime for savings and investments is a flat rate of 30%. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dutch Corporate Entities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dutch Corporate Entities
are generally subject to corporate income tax at statutory rates up to 25% on any benefits derived or deemed to be derived from the ordinary shares. A reduced rate of 16.5% applies to the first &#128;&nbsp;200,000 of taxable profits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-residents</FONT> of the Netherlands </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The description of certain Dutch tax consequences in this paragraph is only intended for the following shareholders: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">individuals not resident and not deemed to be resident in the Netherlands for Dutch income tax purposes
(&#147;<I><FONT STYLE="white-space:nowrap">Non-Dutch</FONT> Individuals</I>&#148;); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">entities not resident and not deemed to be resident in the Netherlands for Dutch corporate income tax purposes
(&#147;<I><FONT STYLE="white-space:nowrap">Non-Dutch</FONT> Corporate Entities</I>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
<FONT STYLE="white-space:nowrap">Non-Dutch</FONT> Individual or a <FONT STYLE="white-space:nowrap">Non-Dutch</FONT> Corporate Entity will not be subject to any Dutch taxes on income or capital gains in respect of the acquisition, holding, redemption
and disposal of ordinary shares, other than withholding tax as described above, except if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the <FONT STYLE="white-space:nowrap">Non-Dutch</FONT> Individual or the
<FONT STYLE="white-space:nowrap">Non-Dutch</FONT> Corporate Entity derives profits from an enterprise, whether as entrepreneur or pursuant to a <FONT STYLE="white-space:nowrap">co-entitlement</FONT> to the net worth of such enterprise other than as
an entrepreneur or a shareholder, which enterprise is, in whole or in part, carried on through a permanent establishment (<I>vaste inrichting</I>) or a permanent representative (<I>vaste vertegenwoordiger</I>) in the Netherlands, to which the
ordinary shares are attributable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the <FONT STYLE="white-space:nowrap">Non-Dutch</FONT> Individual derives benefits from miscellaneous activities
carried out in the Netherlands in respect of the ordinary shares, including (without limitation) activities which are beyond the scope of active portfolio investment activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the <FONT STYLE="white-space:nowrap">Non-Dutch</FONT> Corporate Entity is entitled to a share in the profits of
an enterprise or a <FONT STYLE="white-space:nowrap">co-entitlement</FONT> to the net worth of an enterprise, other than by way of securities, which enterprise is effectively managed in the Netherlands and to which enterprise the ordinary shares are
attributable; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the <FONT STYLE="white-space:nowrap">Non-Dutch</FONT> Individual is entitled to a share in the profits of an
enterprise, other than by way of securities, which enterprise is effectively managed in the Netherlands and to which enterprise the ordinary shares are attributable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under certain specific circumstances, Dutch taxation rights may be restricted for <FONT STYLE="white-space:nowrap">Non-Dutch</FONT> Individuals and <FONT
STYLE="white-space:nowrap">Non-Dutch</FONT> Corporate Entities pursuant to treaties for the avoidance of double taxation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dutch Gift Tax or
Inheritance Tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Dutch gift tax or inheritance tax is due in respect of any gift of the ordinary shares by, or inheritance of the ordinary
shares on the death of, a shareholder, except if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at the time of the gift or death of the shareholder, the shareholder is resident, or is deemed to be resident, in
the Netherlands; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the shareholder passes away within 180 days after the date of the gift of the ordinary shares and is not, or not
deemed to be, at the time of the gift, but is, or deemed to be resident in the Netherlands at the time of his death; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gift of the ordinary shares is made under a condition precedent and the shareholder is resident, or is deemed
to be resident, in the Netherlands at the time the condition is fulfilled. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Dutch gift tax or inheritance tax, an
individual who is of Dutch nationality will be deemed to be resident in the Netherlands if such individual has been resident in the Netherlands at any time during the 10 years preceding the date of the gift or his death. For purposes of Dutch gift
tax, any individual, irrespective of his nationality, be deemed to be resident in the Netherlands if such individual has been resident in the Netherlands at any time during the 12 months preceding the date of the gift. Applicable tax treaties may
override deemed residency </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Value added tax (VAT) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Dutch VAT will be payable by a shareholder in respect of any purchase, ownership and disposal of the ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Taxes and Duties </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No other Dutch taxes,
including taxes of a documentary nature, such as capital tax, stamp or registration tax or duty, are payable by or on behalf of the shareholder by reason only of the purchase, ownership and disposal of the ordinary shares </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Residency </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shareholder will not become resident,
or deemed resident, in the Netherlands for tax purposes by reason only of holding the ordinary shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material German Tax Considerations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following section is a description of the material German tax considerations that become relevant when acquiring, owning and transferring Immatics&#146;
ordinary shares. It is based on the German tax law applicable as of the date of this prospectus without prejudice to any amendments introduced at a later date and implemented with or without retroactive effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This section is intended as general information only and does not purport to be a comprehensive or complete description of all potential German tax effects of
the acquisition, ownership or transfer of ordinary shares and does not set forth all German tax considerations that may be relevant to a particular person&#146;s decision to acquire ordinary shares. It does not constitute particular German tax
advice and potential purchasers of Immatics&#146; ordinary shares are urged to consult their own tax advisors regarding the tax consequences of the acquisition, ownership and transfer of ordinary shares in light of their particular circumstances
with regard to the application of German tax law to their particular situations, in particular with respect to the procedure to be complied with to obtain a relief of withholding tax on dividends and on capital gains (<I>Kapitalertragsteuer</I>) and
with respect to the influence of double tax treaty provisions, as well as any tax consequences arising under the laws of any state, local or other <FONT STYLE="white-space:nowrap">non-German</FONT> jurisdiction. For German tax purposes, a
shareholder may include an individual who or an entity that does not have the legal title to the ordinary shares, but to whom nevertheless the ordinary shares are attributed, based either on such individual or entity owning a beneficial interest in
the ordinary shares or based on specific statutory provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the following is subject to change. Such changes could apply retroactively and
could affect the consequences set forth below. This section does not refer to any foreign account tax compliance act (FATCA) aspects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Immatics&#146; tax residency status </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics has
its statutory seat in the Netherlands and its sole place of management in Germany and is therefore tax resident in Germany (for purposes of the German-Dutch tax treaty). Thus, Immatics qualifies as a corporation subject to German unlimited liability
for corporate income tax purposes. However, because Immatics&#146; tax residency depends on future facts regarding its place of management the German unlimited liability for corporate income tax purposes may change in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of dividends </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Withholding tax on dividend payments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividends
distributed from Immatics to its shareholders are generally subject to German withholding tax, conditionally upon certain exemptions (for example, repayments of capital from the tax contribution account (<I>steuerliches Einlagekonto</I>)), as
further described. The withholding tax rate is 25% plus a 5.5% solidarity surcharge (<I>Solidarit&auml;tszuschlag</I>) thereon totaling 26.375% of the gross dividend amount. Withholding tax is to be withheld and passed on for the account of the
shareholders by a domestic branch of a domestic or foreign credit or financial services institution (<I>Kredit</I>- <I>und</I> <I>Finanzdienstleistungsinstitut</I>), by the domestic securities trading company (<I>inl&auml;ndisches</I>
<I>Wertpapierhandelsunternehmen</I>) or a domestic securities trading bank (<I>inl&auml;ndische Wertpapierhandelsbank</I>) which keeps and administers the ordinary shares and disburses or credits the dividends or disburses the dividends to a foreign
agent, or by the securities custodian bank (<I>Wertpapiersammelbank</I>) to which the ordinary shares were entrusted for collective custody if the dividends are distributed to a foreign agent by such securities custodian bank (which is referred to
as the &#147;<B>Dividend Paying Agent</B>&#148;). In case the ordinary shares are not held in collective deposit with a Dividend Paying Agent, Immatics is responsible for withholding and remitting the tax to the competent tax office. Such
withholding tax is levied and withheld irrespective of whether and to what extent the dividend distribution is taxable at the level of the shareholder and whether the shareholder is a person residing in Germany or in a foreign country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of dividends distributed to a company within the meaning of Art. 2 of the amended EU Directive 2011/96/EU of the Council of November&nbsp;30, 2011
(the &#147;<B>EU Parent Subsidiary Directive</B>&#148;) domiciled in another Member State of the European Union, withholding tax is effectively reduced to zero. This also applies to dividends distributed to a permanent establishment located in
another Member State of the European Union of such a parent company or of a parent company tax resident in Germany if the participation in Immatics is effectively connected with this permanent establishment. The key prerequisite for the application
of the EU Parent Subsidiary Directive is that the shareholder has held a direct participation in the share capital of Immatics of at least 10% for at an uninterrupted period of least one year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The withholding tax on dividends distributed to other foreign resident shareholders is reduced in accordance with an applicable double tax treaty (to 15%, 5%
or 0% depending on certain prerequisites) if Germany has concluded such double tax treaty with the country of residence of the shareholder and if the shareholder does not hold his ordinary shares either as part of the assets of a permanent
establishment or a fixed place of business in Germany or as business assets for which a permanent representative has been appointed in Germany. Further, the foreign resident shareholder must be eligible for treaty purposes and no limitation of
benefits provision in a double tax treaty and &#150; both in relation to a reduction pursuant to the EU Parent Subsidiary Directive and an applicable tax treaty &#150; no German anti-directive/treaty shopping provision of Section&nbsp;50d paragraph
3 of the German Income Tax Act (<I>Einkommensteuergesetz</I>) must be applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, the deduction of withholding taxes will generally apply
irrespective of a possible reduction pursuant to the EU Parent Subsidiary Directive or applicable double tax treaty except for the case that the recipient of the dividends has been granted an exemption from the German Federal Central Tax Office
(<I>Bundeszentralamt f&uuml;r Steuern</I>) upon formal application by the recipient of the dividends (<I>Freistellung im Steuerabzugsverfahren</I>). In case of deducted withholding taxes, the reduction of the withholding tax pursuant to both the EU
Parent Subsidiary Directive and an applicable double tax treaty is procedurally granted in such a manner that the difference between the total amount withheld, including the solidarity surcharge, and the tax liability determined on the basis of the
EU Parent Subsidiary Directive (0%) or on the basis of the tax rate set forth in the applicable double tax treaty (15% unless further qualifications are met) is upon request refunded by the German Federal Central Tax Office (<I>Bundeszentralamt
f&uuml;r Steuern</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of dividends received by corporations who are not tax resident in Germany,
<FONT STYLE="white-space:nowrap">two-fifths</FONT> of the withholding tax deducted and remitted are refunded without the need to fulfill all prerequisites required for such refund under the EU Parent Subsidiary Directive or under a double tax treaty
or if no double tax treaty has been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
concluded between the state of residence of the shareholder, however, likewise subject to the conditions of the German anti-directive/treaty shopping provision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to receive a refund pursuant to a double tax treaty or the aforementioned option for foreign corporations, the shareholder has to submit a completed
form for refund (available at the website of the Federal Central Tax Office (http://www.bzst.de) as well as at the German embassies and consulates) together with a withholding tax certificate (<I>Kapitalertragsteuerbescheinigung</I>) issued by the
institution that deducted the respective withholding tax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aforementioned reductions of (or exemptions from) withholding tax are further restricted if
(i)&nbsp;the applicable double tax treaty provides for a tax reduction resulting in an applicable tax rate of less than 15% and (ii)&nbsp;the shareholder is not a corporation that directly holds at least 10% in the equity capital of Immatics and is
subject to tax on its income and profits in its state of residence without being exempt. In this case, the reduction of (or exemption from) withholding tax is subject to the following three cumulative prerequisites: (i)&nbsp;the shareholder must
qualify as beneficial owner of the shares in a company for a minimum holding period of 45 consecutive days occurring within a period of 45 days prior and 45 days after the due date of the dividends, (ii)&nbsp;the shareholder has to bear at least
70&nbsp;% of the change in value risk related to the shares in a company during the minimum holding period without being directly or indirectly hedged, and (iii)&nbsp;the shareholder must not be required to fully or largely compensate directly or
indirectly the dividends to third parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the absence of the fulfillment of all of the three prerequisites, three fifths of the withholding tax
imposed on the dividends must not be credited against the shareholder&#146;s (corporate) income tax liability, but may, upon application, be deducted from the shareholder&#146;s tax base for the relevant assessment period. Furthermore, a shareholder
that has received gross dividends without any deduction of withholding tax due to a tax exemption without qualifying for such a full tax credit has (i)&nbsp;to notify the competent local tax office accordingly, (ii)&nbsp;to declare according to the
officially prescribed form and (iii)&nbsp;has to make a payment in the amount of the omitted withholding tax deduction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, these special rules on
the restriction of withholding tax credit do not apply to a shareholder whose overall dividend earnings within an assessment period do not exceed &#128;20,000 or that has been the beneficial owner of the shares in a company for at least one
uninterrupted year upon receipt of the dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For individual or corporate shareholders tax resident outside Germany not holding the ordinary shares
through a permanent establishment (<I>Betriebsst&auml;tte</I>) in Germany or as business assets (<I>Betriebsverm&ouml;gen</I>) for which a permanent representative (<I>st&auml;ndiger</I> <I>Vertreter</I>) has been appointed in Germany, the remaining
and paid withholding tax (if any) is then final (i.e., not refundable) and settles the shareholder&#146;s limited tax liability in Germany. For individual or corporate shareholders tax resident in Germany (for example, those shareholders whose
residence, domicile, registered office or place of management is located in Germany) holding their ordinary shares as business assets, as well as for shareholders tax resident outside of Germany holding their ordinary shares through a permanent
establishment in Germany or as business assets for which a permanent representative has been appointed in Germany, the withholding tax withheld (including solidarity surcharge) can be credited against the shareholder&#146;s personal income tax or
corporate income tax liability in Germany. Any withholding tax (including solidarity surcharge) in excess of such tax liability is refunded. For individual shareholders tax resident in Germany holding Immatics&#146; ordinary shares as private
assets, the withholding tax is a final tax (<I>Abgeltungsteuer</I>), subject to the exceptions described in the following section. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Taxation of
dividend income of shareholders tax resident in Germany holding Immatics&#146; ordinary shares as private assets (private individuals) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For individual
shareholders (individuals) resident in Germany holding Immatics&#146; ordinary shares as private assets, dividends are subject to a flat rate tax which is satisfied by the withholding tax actually withheld (<I>Abgeltungsteuer</I>). Accordingly,
dividend income will be taxed at a flat tax rate of 25% plus 5.5% solidarity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
surcharge thereon totaling 26.375% and church tax (<I>Kirchensteuer</I>) in case the shareholder is subject to church tax because of his personal circumstances. An automatic procedure for
deduction of church tax by way of withholding will apply to shareholders being subject to church tax unless the shareholder has filed a blocking notice (<I>Sperrvermerk</I>) with the German Federal Tax Office (details related to the computation of
the specific tax rate including church tax are to be discussed with the individual tax advisor of the relevant shareholder). Except for an annual lump sum savings allowance (<I>Sparer-Pauschbetrag</I>) of up to &#128;801 (for individual filers) or
up to &#128;1,602 (for married couples and for partners in accordance with the registered partnership law (<I>Gesetz &uuml;ber die Eingetragene Lebenspartnerschaft</I>) filing jointly), private individual shareholders will not be entitled to deduct
expenses incurred in connection with the capital investment from their dividend income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax owed for the dividend income is satisfied by the
withholding tax withheld by the Dividend Paying Agent. However, if the flat tax results in a higher tax burden as opposed to the private individual shareholder&#146;s personal income tax rate, the private individual shareholder can opt for taxation
at his personal income tax rate. In that case, the final withholding tax will be credited against the income tax. The option can be exercised only for all capital income from capital investments received in the relevant assessment period uniformly
and married couples as well as partners in accordance with the registered partnership law filing jointly may only jointly exercise the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exceptions
from the flat rate tax (satisfied by withholding the tax at source, <I>Abgeltungswirkung</I>) may apply &#150; that is, only upon application &#150; for shareholders who have a shareholding of at least 25% in Immatics and for shareholders who have a
shareholding of at least 1% in Immatics and work for a company in a professional capacity. In such a case, the same rules apply as for sole proprietors holding the ordinary shares as business assets (see below &#147;Taxation of dividend income of
shareholders tax resident in Germany holding the company&#146;s ordinary shares as business assets &#150; Sole proprietors&#148;). Further, the flat rate tax does not apply if and to the extent dividends reduced Immatics taxable income. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Taxation of dividend income of shareholders tax resident in Germany holding Immatics&#146; ordinary shares as business assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a shareholder holds the Immatics&#146; ordinary shares as business assets, the taxation of the dividend income depends on whether the respective shareholder
is a corporation, a sole proprietor or a partnership. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividend income of corporate shareholders is exempt from corporate income tax, provided that the corporation holds a direct participation of at least 10% in
the share capital of a company at the beginning of the calendar year in which the dividends are paid (participation exemption). The acquisition of a participation of at least 10% in the course of a calendar year is deemed to have occurred at the
beginning of such calendar year. Participations in the share capital of the company which a corporate shareholder holds through a partnership, including <FONT STYLE="white-space:nowrap">co-entrepreneurships</FONT> (<I>Mitunternehmerschaften</I>),
are attributable to such corporate shareholder only on a pro rata basis at the ratio of the interest share of the corporate shareholder in the assets of the relevant partnership. However, 5% of the <FONT STYLE="white-space:nowrap">tax-exempt</FONT>
dividends are deemed to be <FONT STYLE="white-space:nowrap">non-deductible</FONT> business expenses for tax purposes and therefore are effectively subject to corporate income tax (plus solidarity surcharge) and trade tax; i.e. tax exemption of 95%.
Business expenses incurred in connection with the dividends received are entirely tax deductible. The participation exemption does not apply if and to the extent dividends reduced Immatics taxable income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For trade tax purposes the entire dividend income is subject to trade tax (i.e. the <FONT STYLE="white-space:nowrap">tax-exempt</FONT> dividends must be added
back when determining the trade taxable income), unless the corporation shareholder holds at least 15% of the company&#146;s registered share capital at the beginning of the relevant tax assessment period (<I>Erhebungszeitraum</I>). In case of an
indirect participation via a partnership please refer to the section &#147;Partnerships&#148; below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the shareholding is below 10% in the share capital, dividends are taxable at the applicable corporate
income tax rate of 15% plus 5.5% solidarity surcharge thereon and trade tax (the rate of which depends on the applicably municipality levy rate determined by the municipality the corporate shareholder has its place of management and permanent
establishments respectively). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Special regulations apply which abolish the 95% tax exemption, if the company&#146;s ordinary shares are held as trading
portfolio assets in the meaning of Section&nbsp;340e of the German Commercial Code (<I>Handelsgesetzbuch</I>) by (i)&nbsp;a credit institution (<I>Kreditinstitut</I>), (ii) a financial service institution (<I>Finanzdienstleistungsinstitut</I>) or
(iii)&nbsp;a financial enterprise within the meaning of the German Banking Act (<I>Kreditwesengesetz</I>), in case more than 50% of the shares of such financial enterprise are held directly or indirectly by a credit institution or a financial
service institution, as well as by a life insurance company, a health insurance company or a pension fund in case the shares are attributable to the capital investments, resulting in fully taxable income. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sole proprietors </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For sole proprietors (individuals)
resident in Germany holding ordinary shares as business assets dividends are subject to the partial income rule (<I>Teileink&uuml;nfteverfahren</I>). Accordingly, only (i) 60% of the dividend income will be taxed at his/her personal income tax rate
plus 5.5% solidarity surcharge thereon and church tax (if applicable) and (ii) 60% of the business expenses related to the dividend income are deductible for tax purposes. In addition, the dividend income is entirely subject to trade tax if the
ordinary shares are held as business assets of a permanent establishment in Germany within the meaning of the German Trade Tax Act (<I>Gewerbesteuergesetz</I>), unless the shareholder holds at least 15% of the company&#146;s registered share capital
at the beginning of the relevant assessment period. The trade tax levied will be eligible for credit against the shareholder&#146;s personal income tax liability based on the applicable municipal trade tax rate and the individual tax situation of
the shareholder limited to currently 4.0 times the trade tax measurement amount (<I>Gewerbesteuer-Messbetrag</I>). As from 2021 onwards the solidarity surcharge likely will be abolished in case a certain income threshold is not exceeded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Partnerships </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In case ordinary shares are held by a
partnership, the partnership itself is not subject to corporate income tax or personal income tax. In this regard, corporate income tax or personal income tax (and church tax, if applicable) as well as solidarity surcharge are levied only at the
level of the partner with respect to their relevant part of the partnership&#146;s taxable income and depending on their individual circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the partner is a corporation, the dividend income will be subject to corporate income tax plus solidarity
surcharge (see above &#147;Corporations&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the partner is a sole proprietor, the dividend income will be subject to the partial income rule (see above
&#147;Sole proprietors&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the partner is a private individual, the dividend income will be subject to the flat tax rate (see above
&#147;private individuals&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In case the partnership is a (operative or deemed) commercial partnership with its place of
management in Germany the dividend income is subject to German trade tax at the level of the partnership, unless the partnership holds at least 15% of a company&#146;s registered share capital at the beginning of the relevant assessment period, in
which case the dividend income is exempt from trade tax. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Taxation of dividend income of shareholders tax resident outside of Germany </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For foreign individual or corporate shareholders tax resident outside of Germany not holding the ordinary shares through a permanent establishment in Germany
or as business assets for which a permanent representative has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been appointed in Germany, the deducted withholding tax (possibly reduced by way of a tax relief under a double tax treaty or domestic tax law, such as in connection with the EU Parent Subsidiary
Directive) is final (that is, not refundable) and settles the shareholder&#146;s limited tax liability in Germany, unless the shareholder is entitled to apply for a withholding tax refund or exemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In contrast, individual or corporate shareholders tax resident outside of Germany holding the company&#146;s ordinary shares through a permanent establishment
in Germany or as business assets for which a permanent representative has been appointed in Germany are subject to the same rules as applicable (and described above) to shareholders resident in Germany holding the ordinary shares as business assets.
The withholding tax withheld (including solidarity surcharge) is credited against the shareholder&#146;s personal income tax or corporate income tax liability in Germany. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of capital gains </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Withholding tax on
capital gains </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capital gains realized on the disposal of ordinary shares are only subject to withholding tax if (i)&nbsp;a permanent establishment in
Germany of a German or foreign credit or financial institution, (ii)&nbsp;a German securities trading company or (iii)&nbsp;a German securities trading bank stores or administrates or carries out the disposal of the ordinary shares and pays or
credits the capital gains. In those cases, the institution (and not the company) is required to deduct the withholding tax at the time of payment for the account of the shareholder and has to pay the withholding tax to the competent tax authority.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In case the ordinary shares in the company are held (i)&nbsp;as business assets by a sole proprietor, a partnership or a corporation and such shares are
attributable to a German business or (ii)&nbsp;in case of a corporation being subject to unlimited corporate income tax liability in Germany, the capital gains are not subject to withholding tax. In case of the aforementioned exemption under
(i)&nbsp;the withholding tax exemption is subject to the condition that the paying agent has been notified by the beneficiary (<I>Gl&auml;ubiger</I>) that the capital gains are exempt from withholding tax. The respective notification has to be filed
by using the officially prescribed form. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Taxation of capital gains realized by shareholders tax resident in Germany holding Immatics&#146; ordinary
shares as private assets (private individuals) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For individual shareholders (individuals) resident in Germany holding ordinary shares as private
assets, capital gains realized on the disposal of ordinary shares are subject to final withholding tax (<I>Abgeltungsteuer</I>). Accordingly, capital gains will be taxed at a flat tax rate of 25% plus 5.5% solidarity surcharge thereon totaling
26.375% and church tax, in case the shareholder is subject to church tax because of his personal circumstances. An automatic procedure for deduction of church tax by way of withholding will apply to shareholders being subject to church tax unless
the shareholder has filed a blocking notice (<I>Sperrvermerk</I>) with the German Federal Central Tax Office (details related to the computation of the specific tax rate including church tax are to be discussed with the personal tax advisor of the
relevant shareholder). The taxable capital gain is calculated by deducting the acquisition costs of the ordinary shares and the expenses directly and materially related to the disposal from the proceeds of the disposal. Apart from that, except for
an annual lump sum savings allowance (<I>Sparer- Pauschbetrag</I>) of up to &#128;801 (for individual filers) or up to &#128;1,602 (for married couples and for partners in accordance with the registered partnership law (<I>Gesetz &uuml;ber die
Eingetragene Lebenspartnerschaft</I>) filing jointly), private individual shareholders will not be entitled to deduct expenses incurred in connection with the capital investment from their capital gain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In case the flat tax results in a higher tax burden as opposed to the private individual shareholder&#146;s personal income tax rate the private individual
shareholder can opt for taxation at his personal income tax rate. In that case, the withholding tax (including solidarity surcharge) withheld will be credited against the income tax. The option can be exercised only for all capital income from
capital investments received in the relevant assessment period uniformly and married couples as well as for partners in accordance with the registered partnership law filing jointly may only jointly exercise the option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capital losses arising from the disposal of the ordinary shares can only be offset against other capital
gains resulting from the disposition of the ordinary shares or shares in other stock corporations during the same calendar year. Offsetting of overall losses with other income (such as business or rental income) and other capital income is not
possible. Such losses are to be carried forward and to be offset against positive capital gains deriving from the disposal of ordinary shares in stock corporations in future years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The final withholding tax (<I>Abgeltungsteuer</I>) will not apply if the seller of the ordinary shares or in case of gratuitous transfer, its legal
predecessor has held, directly or indirectly, at least 1% of the company&#146;s registered share capital at any time during the five years prior to the disposal. In that case capital gains are subject to the partial income rule
(<I>Teileink&uuml;nfteverfahren</I>). Accordingly, only (i) 60% of the capital gains will be taxed at his / her personal income tax rate plus 5.5% solidarity surcharge thereon and church tax (if applicable) and (ii) 60% of the business expenses
related to the capital gains are deductible for tax purposes. The withholding tax withheld (including solidarity surcharge) will be credited against the shareholder&#146;s personal income tax liability in Germany. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Taxation of capital gains realized by shareholders tax resident in Germany holding Immatics&#146; ordinary shares as business assets </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a shareholder holds ordinary shares as business assets, the taxation of capital gains realized on the disposal of such shares depends on whether the
respective shareholder is a corporation, a sole proprietor or a partnership: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Corporations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capital gains realized on the disposal of ordinary shares by a corporate shareholder are generally exempt from corporate income tax and trade tax. However, 5%
of the <FONT STYLE="white-space:nowrap">tax-exempt</FONT> capital gains are deemed to be <FONT STYLE="white-space:nowrap">non-deductible</FONT> business expenses for tax purposes and therefore are effectively subject to corporate income tax (plus
solidarity surcharge) and trade tax; i.e. tax exemption of 95%. Business expenses incurred in connection with the capital gains are entirely tax deductible. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capital losses incurred upon the disposal of ordinary shares or other impairments of the share value are not tax deductible. A reduction of profit is also
defined as any losses incurred in connection with a loan or security in the event the loan or the security is granted by a shareholder or by a related party thereto or by a third person with the right of recourse against the before mentioned persons
and the shareholder holds directly or indirectly more than 25% of the company&#146;s registered share capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Special regulations apply, if the ordinary
shares are held as trading portfolio assets by a credit institution, a financial service institution or a financial enterprise within the meaning of the German Banking Act (<I>Kreditwesengesetz</I>) as well as by a life insurance company, a health
insurance company or a pension fund (see &#147;Corporations&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sole proprietors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the ordinary shares are held by a sole proprietor, capital gains realized on the disposal of the ordinary shares are subject to the partial income rule
(<I>Teileink&uuml;nfteverfahren</I>). Accordingly, only (i) 60% of the capital gains will be taxed at his /her personal income tax rate plus 5.5% solidarity surcharge thereon and church tax (if applicable) and (ii) 60% of the business expenses
related to the dividend income are deductible for tax purposes. In addition, 60% of the capital gains are subject to trade tax if the ordinary shares are held as business assets of a permanent establishment in Germany within the meaning of the
German Trade Tax Act (<I>Gewerbesteuergesetz</I>). The trade tax levied, depending on the applicable municipal trade tax rate and the individual tax situation, is partly or entirely be credited against the shareholder&#146;s personal income tax
liability. As from 2021 onwards the solidarity surcharge likely will be abolished in case a certain income threshold is not exceeded. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Partnerships </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In case the ordinary shares are held by a partnership, the partnership itself is not subject to corporate income tax or personal income tax as well as
solidarity surcharge (and church tax) since partnerships qualify as transparent for German income tax purposes. In this regard, corporate income tax or personal income tax as well as solidarity surcharge (and church tax, if applicable) are levied
only at the level of the partner with respect to their relevant part of the partnership&#146;s taxable income and depending on their individual circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the partner is a corporation, the capital gains will be subject to corporate income tax plus solidarity
surcharge (see above &#147;Corporations&#148;). Trade tax will be levied additionally at the level of the partner insofar as the relevant profit of the partnership is not subject to trade tax at the level of the partnership. However, with respect to
both corporate income and trade tax, the 95%-exemption rule as described above applies. With regard to corporate partners, special regulations apply if they are held as trading portfolio assets by credit institutions, financial service institutions
or financial enterprises within the meaning of the German Banking Act or life insurance companies, health insurance companies or pension funds, as described above. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the partner is a sole proprietor (individual), the capital gains are subject to the partial income rule (see
above &#147;Sole proprietors&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, if the partnership is liable to German trade tax, 60% of the capital gains are
subject to trade tax at the level of the partnership, to the extent the partners are individuals, and 5% of the capital gains are subject to trade tax, to the extent the partners are corporations. However, if a partner is a private individual the
trade tax paid at the level of the is credited against the partner&#146;s personal income tax liability at up to 4.0 times of the trade tax measurement amount (<I>Gewerbesteuer-Messbetrag</I>) depending on the applicable municipal trade tax levy
rate and the personal tax situation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Taxation of capital gains realized by shareholders tax resident outside of Germany </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capital gains realized on the disposal of the ordinary shares by a shareholder tax resident outside of Germany are subject to German taxation provided that
(i)&nbsp;the company&#146;s ordinary shares are held as business assets of a permanent establishment or as business assets for which a permanent representative has been appointed in Germany, or (ii)&nbsp;the shareholder or, in case of a gratuitous
transfer, its legal predecessor has held, directly or indirectly at least 1% of the company&#146;s shares capital at any time during a five years period prior to the disposal. In these cases, capital gains are generally subject to the same rules as
described above for shareholders resident in Germany. However, except for the cases referred to in (i)&nbsp;above, most double tax treaties concluded by Germany provide for a full exemption from German taxation except that that the company is
considered a real estate holding entity for treaty purposes. Further, in case of <FONT STYLE="white-space:nowrap">non-German</FONT> corporation, the participation exemption applies in full resulting in a tax exemption of 100% (i.e. no deemed <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-tax-deductible</FONT></FONT> business expenses). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Inheritance and gift tax
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer of Immatics&#146; ordinary shares to another person by way of succession or donation is subject to German inheritance and gift tax
(<I>Erbschaft- und Schenkungsteuer</I>) if </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the decedent, the donor, the heir, the donee or any other beneficiary has his /her /its residence, domicile,
registered office or place of management in Germany at the time of the transfer, or is a German citizen who has not stayed abroad for more than five consecutive years without having a residence in Germany; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(irrespective of the personal circumstances) the ordinary shares are held by the decedent or donor as business
assets for which a permanent establishment in Germany is maintained or a permanent representative is appointed in Germany; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(irrespective of the personal circumstances) at least 10% of the ordinary shares are held directly or
indirectly by the decedent or person making the gift, himself or together with a related party in terms of Section&nbsp;6 Foreign Tax Act. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Special regulations apply to qualified German citizens who maintain neither a residence nor their domicile in Germany but in a low tax jurisdiction and to
former German citizens, also resulting in inheritance and gift tax. The few double tax treaties on inheritance and gift tax which Germany has entered into provide that German inheritance and gift tax is levied only in case of (i)&nbsp;and, with
certain restrictions, in case of (ii). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Value added tax (VAT) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No German value added tax (<I>Umsatzsteuer</I>) will be payable by a shareholder in respect of any purchase, ownership and disposal of the ordinary shares
except for a valid option to waive VAT exemption requiring a sale between entrepreneurs for VAT purposes. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Transfer taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No German capital transfer tax (<I>Kapitalverkehrsteuer</I>) or stamp duty (<I>Stempelgeb&uuml;hr</I>) or similar taxes are levied when acquiring, owning or
transferring the company&#146;s ordinary shares. Net wealth tax (<I>Verm&ouml;gensteuer</I>) is currently not levied in Germany. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;22,
2013, the Council of the European Union approved the resolution of the ministers of finance from eleven EU member states (including Germany) to introduce a financial transaction tax (&#147;<B>FTT</B>&#148;) within the framework of enhanced
cooperation. On February&nbsp;14, 2013, the European Commission accepted the proposal for a Council Directive implementing enhanced cooperation in the area of FTT. The plan focuses on levying a financial tax of 0.1% (0.01% for derivates) on the
purchase and sale of financial instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A joint statement issued by ten of the eleven participating EU Member States in October 2016 reaffirmed the
intention to introduce a FTT. However, at the moment not many details are available. Thus, it is not known to what extent the elements of the European Commission&#146;s proposal outlined in the preceding paragraph will be followed in relation to the
taxation of shares. The FTT proposal remains subject to negotiation between the participating EU Member States and is subject to political discussion. It may therefore be altered prior to the implementation, the timing of which remains unclear. With
the EU Council&#146;s conclusion of <FONT STYLE="white-space:nowrap">COVID-19</FONT> fincial support and the German Resideny starting in July 2020 the agreement on a FTT becomes more realistic as one of the measures to fund the EU&#146;s response to
the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Additional EU Member States may decide to participate. If an <FONT STYLE="white-space:nowrap">EU-wide</FONT> FTT (see above) fails, representatives of the IfW (Institute for the World
Economy) intend to advocate the introduction of a comprehensive version of the tax in Germany after the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Prospective holders of the ordinary shares are advised to seek their own professional
advice in relation to FTT. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_20"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are registering the possible offer and sale from time to time of up to 39,332,281 ordinary shares by the selling securityholders. All of the ordinary
shares offered by the selling securityholders pursuant to this prospectus will be sold by the selling securityholders for their respective accounts. We will not receive any of the proceeds from such sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling securityholders will pay any underwriting discounts and commissions and expenses incurred by the selling securityholders for brokerage,
accounting, tax or legal services or any other expenses incurred by the selling securityholders in disposing of the securities. We will bear all other costs, fees and expenses incurred in effecting the registration of the securities covered by this
prospectus, including, without limitation, all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent registered public accountants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities beneficially owned by the selling securityholders covered by this prospectus may be offered and sold from time to time by the selling
securityholders. The term &#147;selling securityholders&#148; includes donees, pledgees, transferees or other successors in interest selling securities received after the date of this prospectus from a selling securityholder as a gift, pledge,
partnership distribution or other transfer. The selling securityholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise, at prices and under terms then prevailing or at prices related to the then current market price or in negotiated transactions. Each
selling securityholder reserves the right to accept and, together with its respective agents, to reject, any proposed purchase of securities to be made directly or through agents. The selling securityholders and any of their permitted transferees
may sell their securities offered by this prospectus on any stock exchange, market or trading facility on which the securities are traded or in private transactions. If underwriters are used in the sale, such underwriters will acquire the shares for
their own account. These sales may be at a fixed price or varying prices, which may be changed, or at market prices prevailing at the time of sale, at prices relating to prevailing market prices or at negotiated prices. The securities may be offered
to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. The obligations of the underwriters to purchase the securities will be subject to certain conditions. The underwriters will be
obligated to purchase all the securities offered if any of the securities are purchased. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the limitations set forth in any applicable
registration rights agreement, the selling securityholders may use any one or more of the following methods when selling the securities offered by this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this
prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker solicits purchasers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which the broker-dealer so engaged will attempt to sell the securities as agent but may position
and resell a portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> distribution
in accordance with the rules of Nasdaq; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through trading plans entered into by a selling securityholder pursuant to Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the
basis of parameters described in such trading plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to or through underwriters or broker-dealers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in &#147;at the market&#148; offerings, as defined in Rule 415 under the Securities Act, at negotiated prices,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales
made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">directly to purchasers, including through a specific bidding, auction or other process or in privately negotiated
transactions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in options transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any of the above methods of sale; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other method permitted pursuant to applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, a selling securityholder that is an entity may elect to make a pro rata <FONT STYLE="white-space:nowrap">in-kind</FONT> distribution of
securities to its members, partners or shareholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus with a plan of distribution. Such members, partners or shareholders would thereby receive freely
tradeable securities pursuant to the distribution through a registration statement. To the extent a distributee is an affiliate of ours (or to the extent otherwise required by law), we may file a prospectus supplement in order to permit the
distributees to use the prospectus to resell the securities acquired in the distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There can be no assurance that the selling securityholders will
sell all or any of the securities offered by this prospectus. In addition, the selling securityholders may also sell securities under Rule 144 under the Securities Act, if available, or in other transactions exempt from registration, rather than
under this prospectus. The selling securityholders have the sole and absolute discretion not to accept any purchase offer or make any sale of securities if they deem the purchase price to be unsatisfactory at any particular time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling securityholders also may transfer the securities in other circumstances, in which case the transferees, pledgees or other <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> will be the selling beneficial owners for purposes of this prospectus. Upon being notified by a selling securityholder that a donee, pledgee,
transferee, other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successor-in-interest</FONT></FONT> intends to sell our securities, we will, to the extent required, promptly file a supplement to this prospectus to name
specifically such person as a selling securityholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to a particular offering of the securities held by the selling securityholders, to the
extent required, an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement of which this prospectus is part, will be prepared and will set forth the following information: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the specific securities to be offered and sold; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of the selling securityholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the respective purchase prices and public offering prices, the proceeds to be received from the sale, if any, and
other material terms of the offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">settlement of short sales entered into after the date of this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the names of any participating agents, broker-dealers or underwriters; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any applicable commissions, discounts, concessions and other items constituting compensation from the selling
securityholders. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with distributions of the securities or otherwise, the selling securityholders may enter into hedging
transactions with broker-dealers or other financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short sales of the securities in the course of hedging the positions they assume
with selling securityholders. The selling securityholders may also sell the securities short and redeliver the securities to close out such short positions. The selling securityholders may also enter into option or other transactions with
broker-dealers or other financial institutions which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell
pursuant to this prospectus (as supplemented or amended to reflect such transaction). The selling securityholders may also pledge securities to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other
financial institution, may effect sales of the pledged securities pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the securities, any underwriters or agents, as the case may be,
involved in the offering of such securities may engage in transactions that stabilize, maintain or otherwise affect the price of our securities. Specifically, the underwriters or agents, as the case may be, may overallot in connection with the
offering, creating a short position in our securities for their own account. In addition, to cover overallotments or to stabilize the price of our securities, the underwriters or agents, as the case may be, may bid for, and purchase, such securities
in the open market. Finally, in any offering of securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allotted to an underwriter or a broker-dealer for distributing such securities in the offering
if the syndicate repurchases previously distributed securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the securities above
independent market levels. The underwriters or agents, as the case may be, are not required to engage in these activities, and may end any of these activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling securityholders may solicit offers to purchase the securities directly from, and they may sell such securities directly to, institutional
investors or others. In this case, no underwriters or agents would be involved. The terms of any of those sales, including the terms of any bidding or auction process, if utilized, will be described in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is possible that one or more underwriters may make a market in our securities, but such underwriters will not be obligated to do so and may discontinue any
market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for our securities. Our ordinary shares are listed on Nasdaq under the symbol &#147;IMTX&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selling securityholders may authorize underwriters, broker-dealers or agents to solicit offers by certain purchasers to purchase the securities at the
public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. The contracts will be subject only to those conditions set forth in the
prospectus supplement, and the prospectus supplement will set forth any commissions we or the selling securityholders pay for solicitation of these contracts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A selling securityholder may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in
privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short
sale transactions. If so, the third party may use securities pledged by any selling securityholder or borrowed from any selling securityholder or others to settle those sales or to close out any related open borrowings of stock, and may use
securities received from any selling securityholder in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and will be identified in the applicable
prospectus supplement (or a post-effective amendment). In addition, any selling securityholder may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus.
Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In effecting sales, broker-dealers or agents engaged by the selling securityholders may arrange for other broker-dealers to participate. Broker-dealers or
agents may receive commissions, discounts or concessions from the selling securityholders in amounts to be negotiated immediately prior to the sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
compliance with the guidelines of the Financial Industry Regulatory Authority (&#147;FINRA&#148;), the aggregate maximum discount, commission, fees or other items constituting underwriting compensation to be received by any FINRA member or
independent broker-dealer will not exceed 8% of the gross proceeds of any offering pursuant to this prospectus and any applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Notice to prospective investors in the European Economic Area </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each, a &#147;Relevant State&#148;), no shares have been offered or will be offered pursuant to
the offering to the public in that Relevant State, except that offers of shares may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation (Regulation (EU) 2017/1129): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined in the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus
Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall require Immatics or the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation
or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each person in a Relevant State who initially acquires any shares or to
whom any offer is made will be deemed to have represented, acknowledged and agreed that it is a &#147;qualified investor&#148; within the meaning of Article 2(e) of the Prospectus Regulation. In the case of any shares being offered to a financial
intermediary as that term is used in Article 5(1) of the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <FONT
STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer
or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, the representatives and each of our and the representatives&#146; affiliates will rely upon the truth and accuracy of the foregoing representations,
acknowledgements and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus has been prepared on the basis that any offer of shares in any Relevant State will be made pursuant to
an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of shares. Accordingly, any person making or intending to make an offer in that Relevant State of shares which are the subject of the offering
contemplated in this prospectus may only do so in circumstances in which no obligation arises for the company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Regulation in relation to such offer. Neither we
nor the underwriters have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the company or the underwriters to publish a prospectus for such offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of the above provisions, the expression &#147;an offer to the public&#148; in relation to any shares in any Relevant State means the
communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>MiFID II Product Governance </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any person offering, selling
or recommending the shares (a &#147;distributor&#148;) should take into consideration the manufacturers&#146; target market assessment; however, a distributor subject to MiFID II (Directive 2014/65/EU) is responsible for undertaking its own target
market assessment in respect of the shares (by either adopting or refining the manufacturers&#146; target market assessment) and determining appropriate distribution channels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Specific Dutch selling restriction for exempt offers</I>: Each distributor will be required to represent and agree that it will not make an offer of
securities which are the subject of the offering contemplated by this prospectus to the public in the Netherlands in reliance on Article 1(4) of the Prospectus Regulation, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such offer is made exclusively to legal entities which are qualified investors in the Netherlands; or
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">standard exemption logo and wording are disclosed as required by article 5:4(2) of the Dutch Financial Markets
Supervision Act (<I>Wet op het financieel toezicht</I> ); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such offer is otherwise made in circumstances in which article 5:4(2) of the Dutch Financial Markets
Supervision Act is not applicable, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of securities shall require Immatics or any distributor to publish a
prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_21"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have 285,000,000 ordinary shares authorized and 62,908,617 ordinary shares issued and outstanding as of July&nbsp;31, 2020. Additionally, we have 7,187,500
public warrants issued and outstanding, which entitle the holder to purchase one ordinary share per warrant at an exercise price of $11.50 per share and that became exercisable on July&nbsp;31, 2020. The public warrants expire five years after
July&nbsp;1, 2020 (the Closing Date of the Business Combination) or earlier upon redemption or liquidation in accordance with their terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the
ordinary shares that were issued in connection with the Business Combination are freely transferable without restriction or further registration under the Securities Act, other than 28,917,281 ordinary shares issued to our &#147;affiliates&#148;.
The PIPE Shares were not registered under the Securities Act, in reliance upon the exemption provided in Section&nbsp;4(a)(2) of the Securities Act and/or Regulation D or Regulation S promulgated thereunder, and are not freely transferable. The
shares issued to our &#147;affiliates&#148; and the PIPE Shares are &#147;restricted securities&#148; as that term is defined in Rule 144 under the Securities Act and may be sold publicly in the United States only if they are subject to an effective
registration statement under the Securities Act or pursuant to an exemption from the registration requirement, such as those provided by Rule 144 and Rule 701 promulgated under the Securities Act (see description below). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registration statement of which this prospectus forms a part has been filed to satisfy our obligations to register the offer and sale of ordinary shares
by our affiliates and PIPE Investors pursuant to the Investor Rights Agreement. We cannot make any prediction as to the effect, if any, that sales of our shares or the availability of our shares for sale will have on the market price of our ordinary
shares. Sales of substantial amounts of our ordinary shares in the public market could adversely affect prevailing market price of our ordinary shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Rule 144 of the Securities Act
(&#147;Rule 144&#148;), a person who has beneficially owned restricted ordinary shares for at least six months would be entitled to sell their securities, provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the
time of, or at any time during the three months preceding, a sale and (ii)&nbsp;we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports under Section&nbsp;13 or
15(d) of the Exchange Act during the 12 months (or such shorter period as we were required to file reports) preceding the sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Persons who have
beneficially owned restricted ordinary shares or warrants for at least six months but who are our affiliates at the time of, or at any time during the three months preceding, a sale, would be subject to additional restrictions, by which such person
would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the total number of ordinary shares then issued and outstanding; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly reported trading volume of the ordinary shares during the four calendar weeks preceding the
filing of a notice on Form 144 with respect to the sale. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales by our affiliates under Rule 144 are also limited by manner of sale
provisions and notice requirements and to the availability of current public information about us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restrictions on the Use of Rule 144 by Shell
Companies or Former Shell Companies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rule 144 is not available for the resale of securities initially issued by shell companies (other than business
combination related shell companies) or issuers that have been at any time previously a shell company. However, Rule 144 also includes an important exception to this prohibition if the following conditions are met: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuer of the securities that was formerly a shell company has ceased to be a shell company;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">232 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuer of the securities is subject to the reporting requirements of Section&nbsp;13 or 15(d) of the Exchange
Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable,
during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials), other than Current Reports on Form <FONT STYLE="white-space:nowrap">8-K;</FONT> and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC
reflecting its status as an entity that is not a shell company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were formed as a shell company in March 2020. Upon the consummation
of the Business Combination, in July 2020, we ceased to be a shell company and so, once the conditions set forth in the exceptions listed above are satisfied, Rule 144 will become available for the resale of restricted securities and securities held
by affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulation S </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulation S under the
Securities Act provides an exemption from registration requirements in the United States for offers and sales of securities that occur outside the United States. Rule 903 of Regulation S provides the conditions to the exemption for a sale by an
issuer, a distributor, their respective affiliates or anyone acting on their behalf, while Rule 904 of Regulation S provides the conditions to the exemption for a resale by persons other than those covered by Rule 903. In each case, any sale must be
completed in an offshore transaction, as that term is defined in Regulation S, and no directed selling efforts, as that term is defined in Regulation S, may be made in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a foreign issuer as defined in Regulation S. As a foreign issuer, securities that we sell outside the United States pursuant to Regulation S are not
considered to be restricted securities under the Securities Act, and, subject to the offering restrictions imposed by Rule 903, are freely tradable without registration or restrictions under the Securities Act, unless the securities are held by our
affiliates. Generally, subject to certain limitations, holders of our restricted shares who are not affiliates of our company or who are affiliates of our company by virtue of their status as an officer or director may, under Regulation S, resell
their restricted shares in an &#147;offshore transaction&#148; if none of the seller, its affiliate nor any person acting on their behalf engages in directed selling efforts in the United States and, in the case of a sale of our restricted shares by
an officer or director who is an affiliate of ours solely by virtue of holding such position, no selling commission, fee or other remuneration is paid in connection with the offer or sale other than the usual and customary broker&#146;s commission
that would be received by a person executing such transaction as agent. Additional restrictions are applicable to a holder of our restricted shares who will be an affiliate of our company other than by virtue of his or her status as an officer or
director of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In general, under
Rule 701 of the Securities Act as currently in effect, each of our employees, consultants or advisors who purchases equity shares from us in connection with a compensatory stock plan or other written agreement that was executed prior to the
completion of the Business Combination is eligible to resell those equity shares in reliance on Rule 144, but without compliance with some of the restrictions, including the holding period, contained in Rule 144. However, the Rule 701 shares would
remain subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> arrangements and would only become eligible for sale when the <FONT STYLE="white-space:nowrap">lock-up</FONT> period expires. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Investor Rights Agreement, each holder party agreed not to sell, transfer, pledge or otherwise dispose of any ordinary shares received in
connection with the Business Combination for 180 days from the Closing Date, subject to certain limited exceptions. The <FONT STYLE="white-space:nowrap">lock-up</FONT> restriction does not apply to ordinary shares purchased in the PIPE Financing and
ordinary shares acquired in the open market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">233 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Business Combination and the PIPE Financing, we granted certain registration rights to certain securityholders under the Investor Rights
Agreement. Pursuant to the Investor Rights Agreement, we agreed to promptly, but no later than 180 calendar days from the Closing Date, file, subject to customary exceptions, a Registration Statement covering all ordinary shares issued in connection
with the First Merger, the Exchange and the PIPE Financing. The Investor Rights Agreement also provides the parties with demand and &#147;piggy-back&#148; registration rights, subject to certain minimum requirements and customary conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">234 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXPENSES RELATED TO THE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below is an itemization of the total expenses which are expected to be incurred by us in connection with the offer and sale of our ordinary shares
by our selling securityholders. With the exception of the SEC registration fee, all amounts are estimates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52,508.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">302,508.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">235 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_22"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CMS Derks Star Busmann N.V. has advised us on certain legal matters as to Dutch law including the issuance of the ordinary shares offered by this prospectus.
We have been advised on U.S. securities matters by Goodwin Procter LLP. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_23"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of Immatics Biotechnologies GmbH as of December&nbsp;31, 2019 and 2018, and for each of the two years in the period ended
December&nbsp;31, 2019, included in this prospectus have been so included in reliance on the report of PricewaterhouseCoopers GmbH Wirtschaftspr&uuml;fungsgesellschaft, an independent registered public accounting firm, given on the authority of said
firm as experts in auditing and accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of ARYA as of December&nbsp;31, 2019 and 2018, for the year ended December&nbsp;31,
2019 and for the period from June&nbsp;29, 2018 (inception) to December&nbsp;31, 2018, have been included in this prospectus in reliance upon the report of WithumSmith+Brown, PC (which report contains an explanatory paragraph regarding the ability
of ARYA to continue as a going concern), appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">236 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_24"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement (including amendments and exhibits to the registration statement) on Form
<FONT STYLE="white-space:nowrap">F-1</FONT> under the Securities Act. For purposes of this section, the term registration statement means the original registration statement and any and all amendments including the schedules and exhibits to the
original registration statement or any amendment. This prospectus, which is part of the registration statement, does not contain all of the information set forth in the registration statement and the exhibits and schedules to the registration
statement. For further information, we refer you to the registration statement and the exhibits and schedules filed as part of the registration statement. If a document has been filed as an exhibit to the registration statement, we refer you to the
copy of the document that has been filed. Each statement in this prospectus relating to a document filed as an exhibit is qualified in all respects by the filed exhibit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the informational requirements of the Exchange Act that are applicable to foreign private issuers. Accordingly, we are required to file or
furnish reports and other information with the SEC, including annual reports on Form <FONT STYLE="white-space:nowrap">20-F</FONT> and reports on Form <FONT STYLE="white-space:nowrap">6-K.</FONT> The SEC maintains an Internet website that contains
reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are available to the public through the SEC&#146;s website at <I>http://www.sec.gov.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, we are exempt under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy
statements, and our executive officers, directors and principal and selling shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we will not be required
under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a corporate website at <I>www.immatics.com.</I> Information contained on, or that can be accessed through, our website does not constitute a part
of this prospectus. We have included our website address in this prospectus solely for informational purposes. </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">237 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom96389_25"></A><A NAME="rom96389_25"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page<BR>No.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited Financial Statements of ARYA Sciences Acquisition Corp.:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_2">Balance Sheets as of December&nbsp;31, 2019 and 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_3">Statements of Operations for the year ended December&nbsp;
31, 2019 and for the period from June&nbsp;29, 2018 (inception) through December&nbsp;31, 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_4">Statements of Changes in Shareholders&#146; Equity for the year ended December&nbsp;31,
 2019 and for the period from June&nbsp;29, 2018 (inception) through December&nbsp;31, 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_5">Statements of Cash Flows for the year ended December&nbsp;
31, 2019 and for the period from June&nbsp;29, 2018 (inception) through December&nbsp;31, 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited Condensed Interim Financial Statements of ARYA Sciences Acquisition
Corp.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_6a">Unaudited Condensed Balance Sheets as of March 31, 2020 and December 31, 2019
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_6b">Unaudited Condensed Statements of Operations for the three months ended March
 31, 2020 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_6c">Unaudited Condensed Statements of Changes in Shareholders&#146; Equity for
 the three months ended March&nbsp;31, 2020 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_6d">Unaudited Condensed Statements of Cash Flows for the three months ended March
 31, 2020 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_6e">Notes to Unaudited Condensed Interim Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited Consolidated Financial Statements of Immatics Biotechnologies GmbH:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_7">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_8">Consolidated Statement of Financial Position as of December&nbsp;
31, 2019 and December&nbsp;31, 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_9">Consolidated Statement of Loss for the years ended December&nbsp;
31, 2019 and December&nbsp;31, 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_10">Consolidated Statement of Comprehensive Loss for the years ended December&nbsp;31,
 2019 and December&nbsp;31, 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_11">Consolidated Statement of Cash Flows for the years ended December&nbsp;
31, 2019 and December&nbsp;31, 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_12">Consolidated Statement of Changes in Shareholders&#146; Deficit for the years
 ended December&nbsp;31, 2019 and December&nbsp;31, 2018</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_13">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Condensed Consolidated Financial Statements of Immatics Biotechnologies
GmbH</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_20">Unaudited Condensed Consolidated Statement of Financial Position as of March
 31, 2020 and December&nbsp;31, 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_21">Unaudited Condensed Consolidated Statement of Loss for the three months ended
 March 31, 2020 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_22">Unaudited Condensed Consolidated Statement of Comprehensive Loss for the three
months ended March&nbsp;31, 2020 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_23">Unaudited Condensed Consolidated Statement of Cash Flows for the three months
 ended March 31, 2020 and 2019</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_24">Unaudited Condensed Consolidated Statement of Changes in Shareholders&#146;
 Deficit </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin96389_25">Notes to the Unaudited Condensed Consolidated Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin96389_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Shareholders and the Board of Directors of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARYA Sciences
Acquisition Corp. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheets of ARYA Sciences Acquisition Corp. (the &#147;Company&#148;), as of December 31, 2019 and 2018, and the related
statements of operations, changes in shareholders&#146; equity and cash flows for the year ended December 31, 2019 and for the period June 29, 2018 (inception) through December 31, 2018 and the related notes (collectively referred to as the
&#147;financial statements&#148;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for
the year ended December 31, 2019 and for the period from June 29, 2018 (inception) through December 31, 2018, in conformity with accounting principles generally accepted in the United States of America. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Going Concern </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have
been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, if the Company does not complete a business combination by October 10, 2020, then the Company will cease all operations
except for the purpose of winding down and liquidating. This mandatory liquidation and subsequent dissolution raises substantial doubt about the Company&#146;s ability to continue as a going concern. The financial statements do not include any
adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (the &#147;PCAOB&#148;) and are required to be independent with respect to the Company in accordance with
the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our
audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.
The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for
the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ WithumSmith+Brown, PC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s
auditor since 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whippany, New Jersey </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 6, 2020
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin96389_2"></A>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BALANCE SHEETS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 874,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,198,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">934,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,332,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,841,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,488,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>148,776,423</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>145,820,556</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Shareholders&#146; Equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>382,245</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,671,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,671,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,054,120</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,676,875</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares, $0.0001 par value; 13,872,230 and 13,614,368 shares subject to
possible redemption at redemption value at December&nbsp;31, 2019 and 2018, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,722,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,143,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares, $0.0001 par value; 479,000,000 shares authorized; 502,770 and
760,632 shares issued and outstanding (excluding 13,872,230 and 13,614,368 shares subject to possible redemption) at December&nbsp;31, 2019, and 2018, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 3,593,750 shares
issued and outstanding at December&nbsp;31, 2019, and 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,794,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,372,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Retained earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,205,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities and Shareholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>148,776,423</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>145,820,556</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin96389_3"></A>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENTS OF OPERATIONS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended<BR>December&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Period&nbsp;From&nbsp;June&nbsp;29,</B><br><B>2018&nbsp;(inception)&nbsp;Through</B><br><B>December&nbsp;31,&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 774,607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 111,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(774,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment income on Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,353,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">738,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,578,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 626,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding of Class&nbsp;A ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net income per share, Class&nbsp;A</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding of Class&nbsp;B ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,593,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,593,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net loss per share, Class&nbsp;B</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.22</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin96389_4"></A>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENTS OF CHANGES IN SHAREHOLDERS&#146; EQUITY </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Shareholders&#146;</B><br><B>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Additional&nbsp;Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Retained</B><br><B>Earnings</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance - June 29, 2018 (inception)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of Class&nbsp;B ordinary shares to Sponsor</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,593,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale of units in initial public offering, gross</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,748,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,211,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,211,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale of private placement warrants to Sponsor in private placement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,953,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,953,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,614,368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(136,142,319</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(136,143,680</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance - December 31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>760,632</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 76</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,593,750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>359</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 4,372,966</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 626,600</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 5,000,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(257,862</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,578,594</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,578,620</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,578,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,578,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance - December 31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>502,770</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 50</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,593,750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>359</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 1,794,372</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,205,222</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 5,000,003</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin96389_5"></A>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STATEMENTS OF CASH FLOWS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;ended</B><br><B>December&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Period&nbsp;From&nbsp;June&nbsp;29,&nbsp;2018</B><br><B>(inception)&nbsp;Through&nbsp;December&nbsp;31,</B><br><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,578,622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 626,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income earned on investment held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,353,229</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(738,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Formation and operating costs paid by Sponsor in exchange for issuance of Class&nbsp;B ordinary
shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,382</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(133,966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(323,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(238,298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Investing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal deposited in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143,750,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(143,750,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Financing Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Repayment of note payable and advances to related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(149,960</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from repayment of advances to related parties</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds received from initial public offering, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds received from private placement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,953,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payment of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,368,085</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,186,604</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net change in cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(323,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,198,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash - beginning of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,198,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash - end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 874,326</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 1,198,306</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value of Class&nbsp;A ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,578,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 136,143,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs paid by Sponsor in exchange for issuance of Class&nbsp;B ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 22,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions in connection with the initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 4,671,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs paid by Sponsor under note payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 148,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 23,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin96389_6"></A>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1
&#151; Description of Organization and Business Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Organization and General </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARYA Sciences Acquisition Corp. (the &#147;Company&#148;) is a blank check company incorporated on June&nbsp;29, 2018 (inception) as a Cayman Islands exempted
company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (the &#147;Business Combination&#148;). While the Company may pursue an
acquisition opportunity in any business, industry, sector or geographical location, it focuses on industries that complement its management team&#146;s background, and in its search for targets for its Business Combination capitalizes on the ability
of its management team to identify and acquire a business, focusing on the healthcare or healthcare related industries. In particular, the Company is targeting North American or European companies in the biotech, pharmaceutical, medical device and
therapeutics subsectors where its management has extensive investment experience. The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the Company had not commenced any operations. All activity for the period from June&nbsp;29, 2018 (inception) through
December&nbsp;31, 2019 relates to the Company&#146;s formation, the preparation for its initial public offering (the &#147;Initial Public Offering&#148;) described below, and since the Initial Public Offering, the search for a target for a Business
Combination. The Company will not generate any operating revenues until after the completion of its Business Combination, at the earliest. The Company generates <FONT STYLE="white-space:nowrap">non-operating</FONT> income in the form of interest
income on cash and investments from the proceeds derived from the Initial Public Offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sponsor and Initial Public Offering </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s sponsor is ARYA Sciences Holdings, a Cayman Islands exempted limited company (the &#147;Sponsor&#148;). The registration statement for the
Company&#146;s Initial Public Offering was declared effective on October&nbsp;4, 2018. On October&nbsp;10, 2018, the Company consummated the Initial Public Offering, and offered and sold 14,375,000 units (each, a &#147;Unit&#148; and collectively,
the &#147;Units&#148;) for $10.00 per Unit, which is discussed in Note 3, generating gross proceeds of $143.75&nbsp;million, and incurring offering costs of approximately $9.2&nbsp;million, inclusive of approximately $4.672&nbsp;million in deferred
underwriting commissions (Note 5). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (the
&#147;Private Placement&#148;) of 5,953,125 warrants (each, a &#147;Private Placement Warrant&#148; and collectively, the &#147;Private Placement Warrants&#148;) at a price of $1.00 per Private Placement Warrant, to the Sponsor, generating gross
proceeds of approximately $5.95&nbsp;million (Note 4).</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trust Account </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon the closing of the Initial Public Offering and the Private Placement, $143.75&nbsp;million ($10.00 per Unit) of the net proceeds of the Initial Public
Offering and certain of the proceeds of the Private Placement were placed in a trust account (the &#147;Trust Account&#148;), located in the United States at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer&nbsp;&amp; Trust Company
acting as trustee, and was invested in U.S. government securities, within the meaning set forth in Section&nbsp;2(a)(16) of the Investment Company Act of 1940, as amended (the &#147;Investment Company Act&#148;), with a maturity of 180 days or less
or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of paragraphs (d)(2), (d)(3) and (d)(4) of Rule <FONT STYLE="white-space:nowrap">2a-7</FONT> of the Investment
Company Act, as determined by the Company, until the earlier of: (i)&nbsp;the completion of a Business Combination and (ii)&nbsp;the distribution of the assets held in the Trust Account as described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Initial Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the Private
Placement, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The
Company must complete one or more Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on income earned on the Trust
Account) at the time of the agreement to enter into the Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the
target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company will provide the holders of its outstanding Class&nbsp;A ordinary shares, par value $0.0001 (the &#147;Class&nbsp;A ordinary shares&#148;), sold
in the Initial Public Offering (the &#147;Public Shareholders&#148;) with the opportunity to redeem all or a portion of their Public Shares (as defined in Note 3) upon the completion of a Business Combination either (i)&nbsp;in connection with a
shareholder meeting called to approve the Business Combination or (ii)&nbsp;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the
Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per Public Share). The <FONT
STYLE="white-space:nowrap">per-share</FONT> amount to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note
5). These Public Shares were recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering. In such case, the Company will proceed with a Business Combination if the Company has net tangible
assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not decide to hold a
shareholder vote for business or other legal reasons, the Company will, pursuant to its amended and restated memorandum and articles of association, conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange
Commission (the &#147;SEC&#148;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transactions is required by law, or the Company decides to obtain shareholder approval
for business or legal reasons, the Company will offer to redeem Public Shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder may elect to redeem
their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks shareholder approval in connection with a Business Combination, the initial shareholders (as defined below) agreed to vote their
Founder Shares (as defined in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. In addition, the initial shareholders agreed to waive their redemption rights with respect to their
Founder Shares and any Public Shares acquired by them in connection with the completion of a Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the
Company&#146;s amended and restated memorandum and articles of association provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a
&#147;group&#148; (as defined under Section&nbsp;13 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;)), is restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public
Shares, without the prior consent of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Sponsor, officers and directors (the &#147;initial shareholders&#148;) agreed not to
propose an amendment to the amended and restated memorandum and articles of association that would affect the substance or timing of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company&#146;s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below), unless the Company
provides the Public Shareholders with the opportunity to redeem their Class&nbsp;A ordinary shares in conjunction with any such amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company
is unable to complete a Business Combination within 24 months from the closing of the Initial Public Offering, or October&nbsp;10, 2020 (the &#147;Combination Period&#148;), the Company will (i)&nbsp;cease all operations except for the purpose of
winding up, (ii)&nbsp;as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a <FONT STYLE="white-space:nowrap">per-share</FONT> price, payable in cash, equal to the aggregate amount then on
deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its income taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of
then outstanding Public Shares, which redemption will completely extinguish Public Shareholders&#146; rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii)&nbsp;as
promptly as reasonably possible following such redemption, subject to the approval of the Company&#146;s remaining shareholders and the Company&#146;s board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution
of the Company, subject in each case to the Company&#146;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial shareholders agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination
within the Combination Period. However, if the initial shareholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the
Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not
complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds held in the Trust Account that will be available to fund the redemption of the Company&#146;s Public Shares. In the event
of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only the $10.00 per share initially held in the Trust Account (or less than that in
certain circumstances). In order to protect the amounts held in the Trust Account, the Sponsor agreed to be liable to the Company if and to the extent any claims by third parties, including any vendor for services rendered or products sold to the
Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who
executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company&#146;s indemnity of the underwriters of the Initial Public Offering against certain liabilities,
including liabilities under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the
extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all third parties, including vendors,
service providers (except for the Company&#146;s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title,
interest or claim of any kind in or to monies held in the Trust Account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;22, 2020, the Company received a letter (the &#147;Notification
Letter&#148;) from the staff of the Listing Qualifications Department of The Nasdaq Stock Market (&#147;NASDAQ&#148;) notifying the Company that it no longer complies with NASDAQ Listing Rule 5620(a) for continued listing due to its failure to hold
an annual meeting of shareholders within twelve months of the end of the Company&#146;s fiscal year ended December&nbsp;31, 2018. NASDAQ has granted an exception of up to 180 calendar days from the fiscal year end, or until June&nbsp;29, 2020, to
regain compliance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notification Letter does not impact the Company&#146;s listing on NASDAQ at this time, and the Company
Class&nbsp;A ordinary shares, units and warrants have continued to trade on NASDAQ under the symbols &#147;ARYA,&#148; &#147;ARYAU&#148; and &#147;ARYAW,&#148; respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company does not expect that the Notification Letter will affect its ability to consummate an initial Business Combination. The Company intends to file
and mail to its shareholders a definitive proxy statement and to hold an annual meeting prior to June&nbsp;29, 2020 to regain compliance with the NASDAQ listing rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern Consideration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At December&nbsp;31,
2019, the Company has approximately $874,000 in its operating bank account, and working capital of approximately $552,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our liquidity needs were
satisfied through receipt of a $25,000 capital contribution from our Sponsor in exchange for the issuance of the Founder Shares to our Sponsor, approximately $148,000 in note payable to related parties, and the net proceeds of the Private Placement
not held in the Trust Account for working capital needs. We repaid the note to the Sponsor in October 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s
assessment of going concern considerations in accordance with Financial Accounting Standard Board&#146;s Accounting Standards Updated (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2014-15,</FONT> &#147;Disclosure of Uncertainties about an
Entity&#146;s Ability to Continue as a Going Concern&#148;, management has determined that the mandatory liquidation and subsequent dissolution raises substantial doubt about the Company&#146;s ability to continue as a going concern. No adjustments
have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after October&nbsp;10, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2 &#151;
Summary of Significant Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis of Presentation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America
(&#147;U.S. GAAP&#148;) and pursuant to the rules and regulations of the SEC. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Use of Estimates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the financial statements in conformity with U.S. GAAP requires the Company&#146;s management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition,
situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual
results could differ from those estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Emerging Growth Company </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our Business
Startups Act of 2012 (the &#147;JOBS Act&#148;), and it may take advantage of certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply
with the independent registered public accounting firm attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and
exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting
standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised
financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to <FONT STYLE="white-space:nowrap">non-emerging</FONT> growth
companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private
companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This may make comparison of the Company&#146;s financial statements with another public company that is neither an emerging growth company nor an emerging
growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Concentration of Credit Risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that
potentially subject the Company to credit risk consist principally of cash and investments held in Trust Account. Cash is maintained in accounts with financial institutions, which, at times may exceed the Federal depository insurance coverage of
$250,000. The Company has not experienced losses on its cash accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant. The Company&#146;s
investments held in Trust Account consists entirely of U.S government securities with an original maturity of 180 days or less. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketable Securities
Held in Trust Account </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s portfolio of marketable securities is comprised solely of U.S. government securities, within the meaning set
forth in Section&nbsp;2(a)(16) of the Investment Company Act, with a maturity of 180 days or less, classified as trading securities. Trading securities are presented on the balance sheets at fair value at the end of each reporting period. Gains and
losses resulting from the change in fair value of these securities is included in gain on marketable securities (net), dividends and interest, held in Trust Account in the accompanying statements of operations. The estimated fair values of
marketable securities held in Trust Account are determined using available market information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fair Value Measurements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market
participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical
assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active
markets; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an
entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the
fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, and 2018, the carrying values of cash, accounts payable and accrued expenses approximate their fair values due to the short-term
nature of the instruments. The Company&#146;s investments held in Trust Account is comprised of investments in U.S. Treasury securities with an original maturity of 180 days or less and are recognized at fair value. The fair value of investments
held in Trust Account is determined using quoted prices in active markets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;A Ordinary Shares subject to possible redemption </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally
redeemable Class&nbsp;A ordinary shares (including Class&nbsp;A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the
Company&#146;s control) are classified as temporary equity. At all other times, Class&nbsp;A ordinary shares are classified as shareholders&#146; equity. The Company&#146;s Class&nbsp;A ordinary shares feature certain redemption rights that are
considered to be outside of the Company&#146;s control and subject to the occurrence of uncertain future events. Accordingly, at December&nbsp;31, 2019, and 2018, 13,872,230 and 13,614,368 Class&nbsp;A ordinary shares subject to possible redemption
at the redemption amount are presented as temporary equity, outside of the shareholders&#146; equity section of the Company&#146;s balance sheets.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net
Income (Loss) Per Ordinary Share </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of ordinary
shares outstanding during the period. The Company has not considered the effect of warrants sold in the Initial Public Offering and Private Placement to purchase 13,140,625 Class&nbsp;A ordinary shares of the Company in the calculation of diluted
income per share, since their inclusion would be anti-dilutive under the treasury stock method. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s statements of operation include a
presentation of income per share for Class&nbsp;A ordinary shares subject to redemption in a manner similar to the <FONT STYLE="white-space:nowrap">two-class</FONT> method of income per share. Net income per share, basic and diluted for Class&nbsp;A
ordinary shares is calculated by dividing the interest income earned on the Trust Account, by the weighted average number of Class&nbsp;A ordinary shares outstanding for the period. Net loss per share, basic and diluted for Class&nbsp;B ordinary
shares is calculated by dividing the net income, less income attributable to Public Shares, by the weighted average number of Class&nbsp;B ordinary shares outstanding for the periods. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income Taxes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company follows the asset and liability
method of accounting for income taxes under FASB ASC Topic&nbsp;740, &#147;<I>Income Taxes</I>.&#148; Deferred tax assets and liabilities are recognized for the estimated future tax </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities
are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is
recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FASB ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions
taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December&nbsp;31,
2019. The Company&#146;s management determined that the Cayman Islands is the Company&#146;s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no
unrecognized tax benefits and no amounts were accrued for interest and penalties for the year ended December&nbsp;31, 2019 and 2018. The Company is currently not aware of any issues under review that could result in significant payments, accruals or
material deviation from its position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may be subject to potential examination by U.S. federal, U.S. state or foreign taxing authorities in
the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with U.S. federal, U.S. state and foreign tax laws. There is
currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the Company. Consequently, deferred tax assets and income taxes are not
reflected in the Company&#146;s financial statements. The Company&#146;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recent Accounting Pronouncements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company&#146;s financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3 &#151; Initial Public Offering </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
October&nbsp;10, 2018, the Company sold 14,375,000 Units at a price of $10.00 per Unit in the Initial Public Offering. Each Unit consists of one Class&nbsp;A ordinary share (such Class&nbsp;A ordinary shares included in the Units being offered, the
&#147;Public Shares&#148;), and <FONT STYLE="white-space:nowrap">one-half</FONT> of one redeemable warrant (each, a &#147;Public Warrant&#148;). Each whole Public Warrant entitles the holder to purchase one Class&nbsp;A ordinary share at a price of
$11.50 per share, subject to adjustment (see Note 6).</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4 &#151; Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Founder Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;5, 2018, the Sponsor paid
$25,000 to cover certain expenses and offering costs on behalf of the Company in consideration of 3,593,750 shares (the &#147;Founder Shares&#148;) of the Company&#146;s Class&nbsp;B ordinary shares, par value $0.0001 per share (the
&#147;Class&nbsp;B ordinary shares&#148;). Prior to the consummation of the Initial Public Offering, the Sponsor transferred 30,000 Founder Shares to each of Kevin Conroy, Dr.&nbsp;Todd Wider and Dr.&nbsp;David Hung, the Company&#146;s independent
directors. The Founder Shares will automatically convert into Class&nbsp;A ordinary shares at the time of the Company&#146;s initial Business Combination and are subject to certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transfer restrictions, as described in Note 6. The Sponsor had agreed to forfeit up to 468,750 Founder Shares to the extent that the over-allotment option was not exercised in full by the
underwriters. On October&nbsp;10, 2018, the underwriters exercised the over-allotment option in full; thus, these Founder Shares were no longer subject to forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The initial shareholders agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of:
(A)&nbsp;one year after the completion of the initial Business Combination or (B)&nbsp;subsequent to the initial Business Combination, (x)&nbsp;if the last sale price of the Class&nbsp;A ordinary shares equals or exceeds $12.00 per share (as
adjusted for share splits, share dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any <FONT STYLE="white-space:nowrap">30-trading</FONT> day period commencing at least 150 days after the initial Business
Combination, or (y)&nbsp;the date on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Company&#146;s shareholders having the right to exchange their ordinary shares for cash,
securities or other property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Private Placement Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrently with the closing of the Initial Public Offering, the Sponsor purchased&nbsp;5,953,125 Private Placement Warrants at a price of $1.00 per Private
Placement Warrant, generating proceeds of approximately $5.953&nbsp;million in the Private Placement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Private Placement Warrant is exercisable for
one Class&nbsp;A ordinary share at a price of $11.50 per share. A portion of the proceeds from the sale of the Private Placement Warrants was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not
complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be <FONT STYLE="white-space:nowrap">non-redeemable</FONT> and exercisable on a cashless basis so
long as they are held by the Sponsor or its permitted transferees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor and the Company&#146;s officers and directors agreed, subject to limited
exceptions, not to transfer, assign or sell any of their Private Placement Warrants until 30 days after the completion of the initial Business Combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Related Party Loans </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;5, 2018, the Sponsor
agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the &#147;Note&#148;). This loan was <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing and
payable upon the completion of the Initial Public Offering. The Sponsor paid an aggregate of approximately $148,000 to cover for expenses on the Company&#146;s behalf under the Note. On October&nbsp;10, 2018, the Company repaid the Note in full and
advanced an additional $1,524 to the Sponsor. The Sponsor repaid this advance back to the Company on October&nbsp;12, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in order to
finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#146;s officers and directors may, but are not obligated to, loan the Company funds as may be required
(&#147;Working Capital Loans&#148;). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be
repaid only out of funds held outside the Trust Account. In the event that a Business Combination is not completed, the Company may use a portion of the proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held
in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender&#146;s discretion, up to $1.5&nbsp;million of such Working
Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. As of December&nbsp;31, 2019, there were no outstanding
Working Capital Loans under this arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administrative Support Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commencing on the effective date of the Initial Public Offering in October 2018 through the earlier of the Company&#146;s consummation of a Business
Combination and its liquidation, the Company agreed to pay the Sponsor a total of $10,000 per month for office space, utilities and secretarial and administrative support. The Company recognized $120,000 and $29,000 and in expenses in connection
with the aforementioned arrangements with the related parties on the Statements of Operations for the year ended December&nbsp;31, 2019 and for the period from June&nbsp;29, 2018 (inception) through December&nbsp;31, 2018, respectively. As of
December&nbsp;31, 2019 and 2018, there were no amounts owed to the Sponsor in connection with such services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Private Placement of Ordinary Shares
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sponsor has indicated an interest to purchase up to $25&nbsp;million of the Company&#146;s ordinary shares in a private placement that would occur
concurrently with the consummation of the initial Business Combination. The funds from such private placement would be used as part of the consideration to the sellers in the initial Business Combination, and any excess funds from such private
placement would be used for working capital in the post-transaction company. However, because indications of interest are not binding agreements or commitments to purchase, the Sponsor may determine not to purchase any such shares, or to purchase
fewer shares than it indicated an interest in purchasing. Furthermore, the Company is not under any obligation to sell any such shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5 &#151;
Commitments&nbsp;&amp; Contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration and Shareholder Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans, if any, will be entitled to
registration rights (in the case of the Founder Shares, only after conversion of such shares into Class&nbsp;A ordinary shares) pursuant to a registration and shareholder rights agreement entered into in connection with the consummation of the
Initial Public Offering. These holders are entitled to certain demand and &#147;piggyback&#148; registration and shareholder rights. However, the registration and shareholder rights agreement provides that the Company will not permit any
registration statement filed under the Securities Act to become effective until the termination of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> period for the securities to be registered. The Company will bear the expenses incurred
in connection with the filing of any such registration statements.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Underwriting Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company granted the underwriters a <FONT STYLE="white-space:nowrap">45-day</FONT> option from the date of the final prospectus relating to the Initial
Public Offering to purchase up to 1,875,000 additional Units to cover over-allotments, if any, at $10.00 per Unit, less underwriting discounts and commissions. The underwriters exercised this option in full on October&nbsp;10, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters were entitled to underwriting discounts of $0.275 per Unit, or approximately $3.953&nbsp;million in the aggregate, paid upon the closing of
the Initial Public Offering. An additional fee of $0.325 per Unit, or approximately $4.672&nbsp;million in the aggregate, will be payable to the underwriters for deferred underwriting commissions. The deferred underwriting commissions will become
payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6 &#151; Shareholders&#146; Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class</I></B><B><I></I></B><B><I>&nbsp;A Ordinary Shares</I></B> &#151; The Company is authorized to issue 479,000,000 Class&nbsp;A ordinary shares with
a par value of $0.0001 per share. Holders of the Company&#146;s Class&nbsp;A ordinary shares are entitled to one vote for each share on each matter on which they are entitled to vote. As of December&nbsp;31, 2019, and 2018, there were 14,375,000
Class&nbsp;A ordinary shares issued or outstanding, including 13,872,230 and 13,614,368 Class&nbsp;A ordinary shares subject to possible redemption, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Class</I></B><B><I></I></B><B><I>&nbsp;B Ordinary Shares</I></B> &#151; The Company is authorized to issue 20,000,000 Class&nbsp;B ordinary shares with
a par value of $0.0001 per share. Holders of Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares will vote together as a single class on all matters submitted to vote, except as required by law. Holders of Class&nbsp;B ordinary shares are
entitled to one vote for each share. As of December&nbsp;31, 2019, and 2018, there were 3,593,750 Class&nbsp;B ordinary shares outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Class&nbsp;B ordinary shares will automatically convert into Class&nbsp;A ordinary shares at the time of the Business Combination at a ratio such that the number of Class&nbsp;A ordinary shares issuable upon conversion of all Class&nbsp;B ordinary
shares will equal, in the aggregate, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, 20.0% of the sum of (i)&nbsp;the total number of Class&nbsp;A ordinary shares issued and outstanding upon completion of the Initial Public
Offering, plus (ii)&nbsp;the sum of (a)&nbsp;the total number of Class&nbsp;A ordinary shares or equity-linked securities exercisable for or convertible into Class&nbsp;A ordinary shares issued or deemed issued in connection with the Business
Combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the Business Combination or any warrants issued to the Sponsor upon conversion of Working Capital Loans), minus (b)&nbsp;the number of Public
Shares redeemed by Public Shareholders in connection with the Business Combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Preference Shares</I></B>&nbsp;&#151; The Company is authorized
to issue 1,000,000 preference shares with a par value of $0.0001 per share, and with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#146;s board of directors. As of December&nbsp;31,
2019 and 2018, there were no preference shares issued or outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Warrants</I></B><B><I></I></B>&nbsp;&#151; Public Warrants may only be
exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion
of a Business Combination or (b)&nbsp;twelve months from the closing of the Initial Public Offering; provided in each case that the Company has an effective registration statement under the Securities Act covering the Class&nbsp;A ordinary shares
issuable upon exercise of the Public Warrants and a current prospectus relating to them is available (or the Company permits holders to exercise their Public Warrants on a cashless basis and such cashless exercise is exempt from registration under
the Securities Act). The Company agreed that as soon as practicable, but in no event later than 20 business days, after the closing of a Business Combination, the Company will use its best efforts to file with the SEC a registration statement for
the registration, under the Securities Act, of the Class&nbsp;A ordinary shares issuable upon exercise of the Public Warrants. The Company will use its best efforts to cause the same to become effective and to maintain the effectiveness of such
registration statement, and a current prospectus relating thereto, until the expiration of the Public Warrants in accordance with the provisions of the warrant agreement. If a registration statement covering the Class&nbsp;A ordinary shares issuable
upon exercise of the Public Warrants is not effective by the sixtieth (60th) day after the closing of the initial Business Combination, warrantholders may, until such time as there is an effective registration statement and during any period when
the Company will have failed to maintain an effective registration statement, exercise warrants on a &#147;cashless basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act or another exemption. The Public Warrants will expire five
years after the completion of a Business Combination or earlier upon redemption or liquidation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants are identical to the Public Warrants included in the Units sold in the Initial
Public Offering, except that the Private Placement Warrants and the Class&nbsp;A ordinary shares issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a
Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants will be <FONT STYLE="white-space:nowrap">non-redeemable</FONT> so long as they are held by the Sponsor or its permitted transferees. If the
Private Placement Warrants are held by someone other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company may call the Public Warrants for redemption: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon a minimum of 30 days&#146; prior written notice of redemption; and </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">if, and only if, the last reported closing price of the ordinary shares equals or exceeds $18.00 per share for any 20 trading days within a <FONT
STYLE="white-space:nowrap">30-trading</FONT> day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrantholders.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to
do so on a &#147;cashless basis,&#148; as described in the warrant agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price and number of Class&nbsp;A ordinary shares issuable upon
exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuance of Class&nbsp;A
ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrant shares. If the Company is unable to complete a Business Combination within the Combination Period and the
Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#146;s assets held outside of the Trust Account
with the respect to such warrants. Accordingly, the warrants may expire worthless. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7 &#151; Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company&#146;s assets that are measured at fair value on a recurring basis as of December&nbsp;31, 2019, and
2018 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2019
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted</B><br><B>Prices</B><br><B>in&nbsp;Active</B><br><B>Markets</B><br><B>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Other</B><br><B>Observable</B><br><B>Inputs</B><br><B>(Level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Other</B><br><B>Unobservable</B><br><B>Inputs</B><br><B>(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">147,841,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2018 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted</B><br><B>Prices</B><br><B>in&nbsp;Active</B><br><B>Markets</B><br><B>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Other</B><br><B>Observable</B><br><B>Inputs</B><br><B>(Level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Other</B><br><B>Unobservable</B><br><B>Inputs</B><br><B>(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,488,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transfers to/from Levels 1, 2, and 3 are recognized at the end of the reporting period.&nbsp;There were no
transfers between levels of the hierarchy for the year ended December&nbsp;31, 2019 and for the period from June&nbsp;29, 2018 (inception) through December&nbsp;31, 2018. Level&nbsp;1 instruments include investments U.S. Treasury securities with an
original maturity of 180 days or less. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8 &#151; Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated subsequent events and transactions that occurred up to the date financial statements were available to be issued. Based upon this review,
the Company determined that there have been no events that have occurred that would require adjustments to the disclosures in the financial statements, except as disclosed in Note 1. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART I. FINANCIAL INFORMATION </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements (Unaudited) </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin96389_6a"></A>CONDENSED BALANCE SHEETS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">701,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">874,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">784,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">934,910</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Marketable securities held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,698,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,841,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>149,483,579</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>148,776,423</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and Shareholders&#146; Equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">194,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">107,245</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,164,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,359,253</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>382,245</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred underwriting commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,671,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,671,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,031,128</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,054,120</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Commitments</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares, $0.0001 par value; 13,545,245 and 13,872,230 shares subject to
possible redemption at redemption value at March&nbsp;31, 2020 and December&nbsp;31, 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,452,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,722,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and
outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares, $0.0001 par value; 479,000,000 shares authorized; 829,755 and
502,770 shares issued and outstanding (excluding 13,545,245 and 13,872,230 shares subject to possible redemption) at March&nbsp;31, 2020 and December&nbsp;31, 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Class&nbsp;B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; 3,593,750 shares
issued and outstanding at March&nbsp;31, 2020 and December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,064,189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,794,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Accumulated deficit) Retained earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64,630</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,205,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liabilities and Shareholders&#146; Equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;149,483,579</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>148,776,423</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin96389_6b"></A>UNAUDITED CONDENSED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,127,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">153,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,127,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(153,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment income on Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">857,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">872,335</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net (loss) income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,269,852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">718,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding of Class&nbsp;A ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net income per share, Class&nbsp;A</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Weighted average shares outstanding of Class&nbsp;B ordinary shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,593,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,593,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic and diluted net loss per share, Class&nbsp;B</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.04</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin96389_6c"></A>UNAUDITED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS&#146; EQUITY </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three Months Ended March&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Retained&nbsp;Earnings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Additional&nbsp;Paid-In</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Accumulated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shareholders&#146;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Deficit)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; December 31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>502,770</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,593,750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>359</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,794,372</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,205,222</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,000,003</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,269,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,269,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,269,852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,269,852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; March 31, 2020 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>829,755</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>83</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,593,750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>359</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,064,189</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(64,630</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,000,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="28"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="26" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the three months ended March&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class&nbsp;B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Additional&nbsp;Paid-In</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Retained</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Shareholders&#146;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Earnings</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; December 31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>760,632</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,593,750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>359</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,372,966</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 626,600</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,000,001</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(71,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(718,753</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(718,760</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">718,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">718,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance &#151; March 31, 2019 (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>688,756</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>69</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,593,750</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>359</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,654,213</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 1,345,365</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,000,006</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin96389_6d"></A>UNAUDITED CONDENSED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash Flows from Operating Activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (loss) income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,269,852</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">718,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net (loss) income to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income earned on investment held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(872,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,385</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,877</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,889,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net change in cash</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172,676</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(122,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash - beginning of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">874,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,198,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash - end of the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>701,650</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,075,870</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of noncash activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in value of Class&nbsp;A ordinary shares subject to possible redemption</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,269,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">718,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin96389_6e"></A>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 1 &#151; Description of Organization and Business Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Organization and General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ARYA
Sciences Acquisition Corp. (the &#147;Company&#148;) is a blank check company incorporated on June&nbsp;29, 2018 (inception) as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share
purchase, reorganization or similar business combination with one or more businesses (the &#147;Business Combination&#148;). While the Company may pursue an acquisition opportunity in any business, industry, sector or geographical location, it
focuses on industries that complement its management team&#146;s background, and in its search for targets for its Business Combination capitalizes on the ability of its management team to identify and acquire a business, focusing on the healthcare
or healthcare related industries. In particular, the Company is targeting North American or European companies in the biotech, pharmaceutical, medical device and therapeutics subsectors where its management has extensive investment experience. The
Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2020, the Company had not commenced any operations. All activity for the period from June&nbsp;29, 2018 (inception)
through March&nbsp;31, 2020 relates to the Company&#146;s formation, the preparation for its initial public offering (the &#147;Initial Public Offering&#148;) described below, and since the Initial Public Offering, the search for a target for a
Business Combination. The Company will not generate any operating revenues until after the completion of its Business Combination, at the earliest. The Company <FONT STYLE="white-space:nowrap">generates&nbsp;non-operating&nbsp;income</FONT> in the
form of interest income on cash and investments from the proceeds derived from the Initial Public Offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sponsor and Initial Public Offering
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s sponsor is ARYA Sciences Holdings, a Cayman Islands exempted limited company (the &#147;Sponsor&#148;). The
registration statement for the Company&#146;s Initial Public Offering was declared effective on October&nbsp;4, 2018. On October&nbsp;10, 2018, the Company consummated the Initial Public Offering, and offered and sold 14,375,000 units (each, a
&#147;Unit&#148; and collectively, the &#147;Units&#148;) for $10.00 per Unit, which is discussed in Note 3, generating gross proceeds of $143.75&nbsp;million, and incurring offering costs of approximately $9.2&nbsp;million, inclusive of
approximately $4.672&nbsp;million in deferred underwriting commissions (Note 5). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Simultaneously with the closing of the Initial Public
Offering, the Company consummated the private placement (the &#147;Private Placement&#148;) of 5,953,125 warrants (each, a &#147;Private Placement Warrant&#148; and collectively, the &#147;Private Placement Warrants&#148;) at a price of $1.00 per
Private Placement Warrant, to the Sponsor, generating gross proceeds of approximately $5.95&nbsp;million (Note 4). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Trust Account </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of the Initial Public Offering and the Private Placement, $143.75&nbsp;million ($10.00 per Unit) of the net proceeds of the
Initial Public Offering and certain of the proceeds of the Private Placement were placed in a trust account (the &#147;Trust Account&#148;), located in the United States at J.P. Morgan Chase Bank, N.A., with Continental Stock Transfer&nbsp;&amp;
Trust Company acting as trustee, and was invested in U.S. government securities, within the meaning set forth in Section&nbsp;2(a)(16) of the Investment Company Act of 1940, as amended (the &#147;Investment Company Act&#148;), with a maturity of 180
days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of paragraphs (d)(2), (d)(3) and (d)(4) of
<FONT STYLE="white-space:nowrap">Rule&nbsp;2a-7&nbsp;of</FONT> the Investment Company Act, as determined by the Company, until the earlier of: (i)&nbsp;the completion of a Business Combination and (ii)&nbsp;the distribution of the assets held in the
Trust Account as described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Initial Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering
and the Private Placement, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination
successfully. The Company must complete one or more Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on income
earned on the Trust Account) at the time of the agreement to enter into the Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting
securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will provide the holders of its outstanding Class&nbsp;A ordinary shares, par value $0.0001 (the &#147;Class&nbsp;A ordinary
shares&#148;), sold in the Initial Public Offering (the &#147;Public Shareholders&#148;) with the opportunity to redeem all or a portion of their Public Shares (as defined in Note 3) upon the completion of a Business Combination either (i)&nbsp;in
connection with a shareholder meeting called to approve the Business Combination or (ii)&nbsp;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will
be made by the Company, solely in its discretion. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.00 per Public Share). <FONT
STYLE="white-space:nowrap">The&nbsp;per-share&nbsp;amount</FONT> to be distributed to Public Shareholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as
discussed in Note 5). These Public Shares were recorded at a redemption value and classified as temporary equity upon the completion of the Initial Public Offering. In such case, the Company will proceed with a Business Combination if the Company
has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and a majority of the shares voted are voted in favor of the Business Combination. If a shareholder vote is not required by law and the Company does not
decide to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its amended and restated memorandum and articles of association, conduct the redemptions pursuant to the tender offer rules of the U.S. Securities
and Exchange Commission (the &#147;SEC&#148;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transactions is required by law, or the Company decides to obtain
shareholder approval for business or legal reasons, the Company will offer to redeem Public Shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Shareholder
may elect to redeem their Public Shares irrespective of whether they vote for or against the proposed transaction. If the Company seeks shareholder approval in connection with a Business Combination, the initial shareholders (as defined below)
agreed to vote their Founder Shares (as defined in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business Combination. In addition, the initial shareholders agreed to waive their redemption rights
with respect to their Founder Shares and any Public Shares acquired by them in connection with the completion of a Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the Company&#146;s amended and restated memorandum and articles of association provide that a Public
Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#147;group&#148; (as defined under Section&nbsp;13 of the Securities Exchange Act of 1934, as amended (the
&#147;Exchange Act&#148;)), is restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Sponsor, officers and directors (the &#147;initial shareholders&#148;) agreed not to propose an amendment to the amended
and restated memorandum and articles of association that would affect the substance or timing of the Company&#146;s obligation to redeem 100% of its Public Shares if the Company does not complete a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Business Combination within the Combination Period (as defined below), unless the Company provides the Public Shareholders with the opportunity to redeem their Class&nbsp;A ordinary shares in
conjunction with any such amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company is unable to complete a Business Combination within 24 months from the closing of the
Initial Public Offering, or October&nbsp;10, 2020 (the &#147;Combination Period&#148;), the Company will (i)&nbsp;cease all operations except for the purpose of winding up, (ii)&nbsp;as promptly as reasonably possible but not more than ten business
days thereafter, redeem the Public Shares, at <FONT STYLE="white-space:nowrap">a&nbsp;per-share&nbsp;price,</FONT> payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the
Trust Account and not previously released to the Company to pay its income taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish
Public Shareholders&#146; rights as shareholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii)&nbsp;as promptly as reasonably possible following such redemption, subject to the
approval of the Company&#146;s remaining shareholders and the Company&#146;s board of directors, proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company, subject in each case to the Company&#146;s obligations
under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial shareholders agreed
to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the initial shareholders acquire Public Shares in or after the Initial Public
Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their
rights to their deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the funds
held in the Trust Account that will be available to fund the redemption of the Company&#146;s Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution
(including Trust Account assets) will be only the $10.00 per share initially held in the Trust Account (or less than that in certain circumstances). In order to protect the amounts held in the Trust Account, the Sponsor agreed to be liable to the
Company if and to the extent any claims by third parties, including any vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce
the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any
claims under the Company&#146;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). Moreover, in the event
that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have
to indemnify the Trust Account due to claims of creditors by endeavoring to have all third parties, including vendors, service providers (except for the Company&#146;s independent registered public accounting firm), prospective target businesses or
other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NASDAQ Notification Letter </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
January&nbsp;2, 2020, the Company received a letter (the &#147;Notification Letter&#148;) from the staff of the Listing Qualifications Department of The Nasdaq Stock Market (&#147;NASDAQ&#148;) notifying the Company that it no longer complies with
NASDAQ Listing Rule 5620(a) for continued listing due to its failure to hold an annual meeting of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shareholders within twelve months of the end of the Company&#146;s fiscal year ended December&nbsp;31, 2019. NASDAQ has granted an exception of up to 180 calendar days from the fiscal year end,
or until June&nbsp;29, 2020, to regain compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Notification Letter does not impact the Company&#146;s listing on NASDAQ at this
time, and the Company Class&nbsp;A ordinary shares, units and warrants have continued to trade on NASDAQ under the symbols &#147;ARYA,&#148; &#147;ARYAU&#148; and &#147;ARYAW,&#148; respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not expect that the Notification Letter will affect its ability to consummate an initial Business Combination. The Company
intends to file and mail to its shareholders a definitive proxy statement and to hold an annual meeting prior to June&nbsp;29, 2020 to regain compliance with the NASDAQ listing rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Immatics Business Combination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;17, 2020, the Company entered into a business combination agreement (as it may be amended, supplemented or otherwise modified
from time to time, the &#147;Business Combination Agreement&#148;), by and among the Company, Immatics B.V., a Netherlands private limited liability company (&#147;TopCo&#148;), Immatics Biotechnologies GmbH, a German limited liability company
(&#147;Immatics&#148;), Immatics Merger Sub 1, a Cayman Islands exempted company (&#147;ARYA Merger Sub&#148;), and Immatics Merger Sub 2, a Cayman Islands exempted company (&#147;IB Merger Sub&#148;). The Business Combination Agreement and the
transactions contemplated thereby were approved by the boards of directors of each of the Company and Immatics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Business Combination
Agreement provides for, among other things, the following transactions on the closing date (collectively, the &#147;Immatics Business Combination&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The shareholders of Immatics that have agreed to participate in the transaction will exchange (the
&#147;Exchange&#148;) their interests in Immatics for ordinary shares in the share capital of TopCo (the &#147;TopCo Ordinary Shares&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Immediately after the Exchange, the legal form of TopCo shall be changed from a private company with limited
liability (<I>besloten vennootschap met beperkte aansprakelijkheid</I>) to a public limited liability company (<I>naamloze vennootschap</I>); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ARYA Merger Sub will merge with and into the Company (the &#147;First Merger&#148;), with the Company as the
surviving company (the &#147;First Surviving Company&#148;) in the merger and, after giving effect to such merger, becoming a wholly owned subsidiary of TopCo; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In connection with the First Merger, each issued and outstanding ordinary share of the Company will be converted
into one ordinary share of the First Surviving Company, and immediately thereafter, each resulting ordinary shares of the First Surviving Company will be automatically exchanged for one TopCo Ordinary Share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Each outstanding warrant to purchase a Class&nbsp;A ordinary share of the Company will, by its terms, convert
into a warrant to purchase one Topco Ordinary Share, on the same contractual terms, other than the warrants held by the Sponsor which shall be forfeited pursuant to the Sponsor Letter Agreement (as defined below); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On the first business day following the closing date of the Immatics Business Combination, the First Surviving
Company will merge with and into IB Merger Sub, with IB Merger Sub as the surviving company in the merger, and each issued and outstanding First Surviving Company share will be automatically converted into one ordinary share of IB Merger Sub.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Business Combination Consideration </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms and subject to the conditions of the Business Combination Agreement, the consideration to be received by the
shareholders of Immatics in connection with the transaction contemplated under the Business Combination Agreement shall be an aggregate number of TopCo Ordinary Shares equal to (a) $350,000,000 (subject to downward adjustments for certain changes in
control costs as set forth in the Business Combination Agreement and assuming that all shareholders of Immatics have agreed to participate in the transaction), divided by (b) $10.00. In addition, the holders of Immatics stock appreciation rights may
also be entitled to receive a portion of the transaction consideration otherwise payable to Immatics shareholders pursuant to the preceding sentence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each shareholder of the Company will receive one TopCo Ordinary Share per ordinary share of the Company, as set forth above. Cash held in the
Trust Account net of redemptions and the proceeds of the PIPE Investment (as defined below), less the transaction costs of the Immatics Business Combination, will be received by TopCo and used for general corporate purposes after the Immatics
Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sponsor Letter Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrent with the execution of the Business Combination Agreement, the Sponsor, the Company, TopCo and the independent directors of the
Company entered into a Sponsor Letter Agreement (the &#147;Sponsor Letter Agreement&#148;), pursuant to which (a)&nbsp;each of the Sponsor and the independent directors of the Company agreed to vote in favor of the Business Combination Agreement and
the transactions contemplated hereby, (b)&nbsp;the Sponsor agreed to forfeit the Private Placement Warrants and (c)&nbsp;the Sponsor and the independent directors of the Company have agreed to waive any adjustment to the conversion ratio set forth
in the Company&#146;s amended and restated memorandum and articles of association or any other anti-dilution or similar protection with respect to the Class&nbsp;B ordinary shares held by them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PIPE Investment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the
execution of the Business Combination Agreement, the Company and TopCo entered into Subscription Agreements with certain investors (collectively, the &#147;Private Placement Investors&#148;) pursuant to which, among other things, such investors
agreed to subscribe for and purchase and TopCo agreed to issue and sell to such investors, 10,415,000 TopCo Ordinary Shares (the &#147;Private Placement Shares&#148;), for an aggregate of $104,150,000 (the &#147;PIPE Investment&#148;) in proceeds.
The closing of the PIPE Investment is contingent upon, among other things, the substantially concurrent consummation of the Immatics Business Combination and related transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the PIPE Investment, TopCo will grant the Private Placement Investors certain customary registration rights. The Private
Placement Shares have not been registered under the Securities Act, in reliance upon the exemption provided in Section&nbsp;4(a)(2) of the Securities Act and/or Regulation D or Regulation S promulgated thereunder without any form of general
solicitation or general advertising. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consummation of the transactions contemplated by the Business Combination Agreement is subject
to customary conditions of the respective parties, and conditions customary to special purpose acquisition companies, including the approval of the Company&#146;s shareholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern Consideration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At
March&nbsp;31, 2020, the Company has approximately $702,000 in its operating bank account, and working capital deficit of approximately $3.6&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our liquidity needs were satisfied through receipt of a $25,000 capital contribution from our
Sponsor in exchange for the issuance of the Founder Shares to our Sponsor, approximately $148,000 in note payable to related parties, and the net proceeds of the Private Placement not held in the Trust Account for working capital needs. We repaid
the note to the Sponsor in October 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management is currently evaluating the impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the industry and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company&#146;s financial position, results of its operations and/or
search for a target company, the specific impact is not readily determinable as of the date of these unaudited condensed financial statements. The unaudited condensed financial statements do not include any adjustments that might result from the
outcome of this uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Company&#146;s assessment of going concern considerations in accordance with
Financial Accounting Standard Board&#146;s Accounting Standards Updated <FONT STYLE="white-space:nowrap">(&#147;ASU&#148;)&nbsp;2014-15,&nbsp;&#147;Disclosure</FONT> of Uncertainties about an Entity&#146;s Ability to Continue as a Going
Concern&#148;, management has determined that the working capital deficit, the mandatory liquidation and subsequent dissolution if the Company is unable to consummate a business combination raises substantial doubt about the Company&#146;s ability
to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after October&nbsp;10, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 2 &#151; Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis of Presentation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying
unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) for financial information and pursuant to the rules and regulations
of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments
necessary for the fair statement of the balances and results for the periods presented. Operating results for the three months ended March&nbsp;31, 2020 are not necessarily indicative of the results that may be expected through December&nbsp;31,
2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and
notes thereto included in the annual report on Form <FONT STYLE="white-space:nowrap">10-K/A</FONT> and Form <FONT STYLE="white-space:nowrap">10-K</FONT> and filed by the Company with the SEC on April&nbsp;17, 2020 and March&nbsp;6, 2020,
respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Use of Estimates </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
preparation of the unaudited condensed financial statements in conformity with U.S. GAAP requires the Company&#146;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a
condition, situation or set of circumstances that existed at the date of the unaudited condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming
events. Accordingly, the actual results could differ from those estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Emerging Growth Company </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the Jumpstart Our
Business Startups Act of 2012 (the &#147;JOBS Act&#148;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not
limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic
reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, Section&nbsp;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial
accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or
revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply
<FONT STYLE="white-space:nowrap">to&nbsp;non-emerging&nbsp;growth</FONT> companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued
or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This may make comparison of the Company&#146;s financial statements with another public company that is neither an emerging growth company nor
an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Concentration of Credit Risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial
instruments that potentially subject the Company to credit risk consist principally of cash and investments held in Trust Account. Cash is maintained in accounts with financial institutions, which, at times may exceed the Federal depository
insurance coverage of $250,000. The Company has not experienced losses on its cash accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant. The
Company&#146;s investments held in Trust Account consists entirely of U.S government securities with an original maturity of 180 days or less. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Marketable Securities Held in Trust Account </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s portfolio of marketable securities is comprised solely of U.S. government securities, within the meaning set forth in
Section&nbsp;2(a)(16) of the Investment Company Act, with a maturity of 180 days or less, classified as trading securities. Trading securities are presented on the condensed balance sheets at fair value at the end of each reporting period. Gains and
losses resulting from the change in fair value of these securities is included in gain on marketable securities (net), dividends and interest, held in Trust Account in the accompanying unaudited condensed statements of operations. The estimated fair
values of marketable securities held in Trust Account are determined using available market information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fair Value Measurements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction
between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers
include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active
markets; </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly
observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an
entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In
those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2020 and December&nbsp;31, 2019, the carrying values of cash, accounts payable and accrued expenses approximate their
fair values due to the short-term nature of the instruments. The Company&#146;s investments held in Trust Account is comprised of investments in U.S. Treasury securities with an original maturity of 180 days or less and are recognized at fair value.
The fair value of investments held in Trust Account is determined using quoted prices in active markets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Class&nbsp;A Ordinary Shares subject to
possible redemption </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&nbsp;A ordinary shares subject to mandatory redemption (if any) are classified as liability instruments and
are measured at fair value. Conditionally redeemable Class&nbsp;A ordinary shares (including Class&nbsp;A ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of
uncertain events not solely within the Company&#146;s control) are classified as temporary equity. At all other times, Class&nbsp;A ordinary shares are classified as shareholders&#146; equity. The Company&#146;s Class&nbsp;A ordinary shares feature
certain redemption rights that are considered to be outside of the Company&#146;s control and subject to the occurrence of uncertain future events. Accordingly, at March&nbsp;31, 2020 and December&nbsp;31, 2019, 13,545,245 and 13,872,230
Class&nbsp;A ordinary shares subject to possible redemption at the redemption amount are presented as temporary equity, outside of the shareholders&#146; equity section of the Company&#146;s condensed balance sheets, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Net Income (Loss) Per Ordinary Share </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net
income (loss) per share is computed by dividing net income (loss) by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of warrants sold in the Initial Public Offering and Private
Placement to purchase 13,140,625 Class&nbsp;A ordinary shares of the Company in the calculation of diluted income per share, since their inclusion would be anti-dilutive under the treasury stock method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s unaudited condensed statements of operation include a presentation of income per share for Class&nbsp;A ordinary shares
subject to redemption in a manner similar to <FONT STYLE="white-space:nowrap">the&nbsp;two-class&nbsp;method</FONT> of income per share. Net income per share, basic and diluted for Class&nbsp;A ordinary shares is calculated by dividing the interest
income earned on the Trust Account, of approximately $857,000 by the weighted average number of Class&nbsp;A ordinary shares outstanding for the period. Net loss per share, basic and diluted for Class&nbsp;B ordinary shares is calculated by dividing
the net loss, less income attributable to Public Shares, by the weighted average number of Class&nbsp;B ordinary shares outstanding for the periods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income Taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, &#147;<I>Income Taxes</I>.&#148;
Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred
tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a
change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FASB ASC Topic 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of
tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of
March&nbsp;31, 2020 and December&nbsp;31, 2019. The Company&#146;s management determined that the Cayman Islands is the Company&#146;s only major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax
benefits as income tax expense. There were no unrecognized tax benefits and no amounts were accrued for interest and penalties for the three months ended March&nbsp;31, 2020 and 2019. The Company is currently not aware of any issues under review
that could result in significant payments, accruals or material deviation from its position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may be subject to potential
examination by U.S. federal, U.S. state or foreign taxing authorities in the area of income taxes. These potential examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and
compliance with U.S. federal, U.S. state and foreign tax laws. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman federal income tax regulations, income taxes are not levied on the
Company. Consequently, deferred tax assets and income taxes are not reflected in the Company&#146;s unaudited condensed financial statements. The Company&#146;s management does not expect that the total amount of unrecognized tax benefits will
materially change over the next twelve months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Recent Accounting Pronouncements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently
adopted, would have a material effect on the Company&#146;s unaudited condensed financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 3 &#151; Initial Public Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;10, 2018, the Company sold 14,375,000 Units at a price of $10.00 per Unit in the Initial Public Offering. Each Unit consists of
one Class&nbsp;A ordinary share (such Class&nbsp;A ordinary shares included in the Units being offered, the &#147;Public Shares&#148;), <FONT STYLE="white-space:nowrap">and&nbsp;one-half&nbsp;of</FONT> one redeemable warrant (each, a &#147;Public
Warrant&#148;). Each whole Public Warrant entitles the holder to purchase one Class&nbsp;A ordinary share at a price of $11.50 per share, subject to adjustment (see Note 6). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 4 &#151; Related Party Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Founder
Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;5, 2018, the Sponsor paid $25,000 to cover certain expenses and offering costs on behalf of the Company in
consideration of 3,593,750 shares (the &#147;Founder Shares&#148;) of the Company&#146;s Class&nbsp;B ordinary shares, par value $0.0001 per share (the &#147;Class&nbsp;B ordinary shares&#148;). Prior to the consummation of the Initial
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Public Offering, the Sponsor transferred 30,000 Founder Shares to each of Kevin Conroy, Dr.&nbsp;Todd Wider and Dr.&nbsp;David Hung, the Company&#146;s independent directors. The Founder Shares
will automatically convert into Class&nbsp;A ordinary shares at the time of the Company&#146;s initial Business Combination and are subject to certain transfer restrictions, as described in Note 6. The Sponsor had agreed to forfeit up to 468,750
Founder Shares to the extent that the over-allotment option was not exercised in full by the underwriters. On October&nbsp;10, 2018, the underwriters exercised the over-allotment option in full; thus, these Founder Shares were no longer subject to
forfeiture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial shareholders agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares
until the earlier to occur of: (A)&nbsp;one year after the completion of the initial Business Combination or (B)&nbsp;subsequent to the initial Business Combination, (x)&nbsp;if the last sale price of the Class&nbsp;A ordinary shares equals or
exceeds $12.00 per share (as adjusted for share splits, share dividends, reorganizations, recapitalizations and the like) for any 20 trading days within <FONT STYLE="white-space:nowrap">any&nbsp;30-trading&nbsp;day</FONT> period commencing at least
150 days after the initial Business Combination, or (y)&nbsp;the date on which the Company completes a liquidation, merger, share exchange or other similar transaction that results in all of the Company&#146;s shareholders having the right to
exchange their ordinary shares for cash, securities or other property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Private Placement Warrants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the closing of the Initial Public Offering, the Sponsor purchased&nbsp;5,953,125 Private Placement Warrants at a price of
$1.00 per Private Placement Warrant, generating proceeds of approximately $5.953&nbsp;million in the Private Placement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Private
Placement Warrant is exercisable for one Class&nbsp;A ordinary share at a price of $11.50 per share. A portion of the proceeds from the sale of the Private Placement Warrants was added to the proceeds from the Initial Public Offering held in the
Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will
<FONT STYLE="white-space:nowrap">be&nbsp;non-redeemable&nbsp;and</FONT> exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Sponsor and the Company&#146;s officers and directors agreed, subject to limited exceptions, not to transfer, assign or sell any of their
Private Placement Warrants until 30 days after the completion of the initial Business Combination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Related Party Loans </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;5, 2018, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public
Offering pursuant to a promissory note (the &#147;Note&#148;). This loan <FONT STYLE="white-space:nowrap">was&nbsp;non-interest&nbsp;bearing</FONT> and payable upon the completion of the Initial Public Offering. The Sponsor paid an aggregate of
approximately $148,000 to cover for expenses on the Company&#146;s behalf under the Note. On October&nbsp;10, 2018, the Company repaid the Note in full and advanced an additional $1,524 to the Sponsor. The Sponsor repaid this advance back to the
Company on October&nbsp;12, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in order to finance transaction costs in connection with a Business Combination, the
Sponsor or an affiliate of the Sponsor, or certain of the Company&#146;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#147;Working Capital Loans&#148;). If the Company completes a Business
Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that
a Business Combination is not completed, the Company may use a portion of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the
foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without
interest, or, at the lender&#146;s discretion, up to $1.5&nbsp;million of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the
Private Placement Warrants. To date, there were no outstanding Working Capital Loans under this arrangement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administrative Support Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing on the effective date of the Initial Public Offering in October 2018 through the earlier of the Company&#146;s consummation of a
Business Combination and its liquidation, the Company agreed to pay the Sponsor a total of $10,000 per month for office space, utilities and secretarial and administrative support. The Company recognized $30,000 in expenses in connection with the
aforementioned arrangements with the related parties on the unaudited condensed statements of operations for each of the three months ended March&nbsp;31, 2020 and 2019. As of March&nbsp;31, 2020 and December&nbsp;31, 2019, the Company owed $30,000
and $0 to the Sponsor in connection with such services, respectively, as recorded in accounts payable in the accompanying unaudited condensed Balance Sheets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Private Placement of Ordinary Shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Sponsor has indicated an interest to purchase up to $25&nbsp;million of the Company&#146;s ordinary shares in a private placement that would occur concurrently with the consummation of the initial Business Combination. The funds from such private
placement would be used as part of the consideration to the sellers in the initial Business Combination, and any excess funds from such private placement would be used for working capital in the post-transaction company. However, because indications
of interest are not binding agreements or commitments to purchase, the Sponsor may determine not to purchase any such shares, or to purchase fewer shares than it indicated an interest in purchasing. Furthermore, the Company is not under any
obligation to sell any such shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 5 &#151; Commitments&nbsp;&amp; Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration and Shareholder Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans, if any, will be entitled to registration rights (in the case of the Founder Shares, only after conversion of such shares
into Class&nbsp;A ordinary shares) pursuant to a registration and shareholder rights agreement entered into in connection with the consummation of the Initial Public Offering. These holders are entitled to certain demand and &#147;piggyback&#148;
registration and shareholder rights. However, the registration and shareholder rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until the termination of the <FONT
STYLE="white-space:nowrap">applicable&nbsp;lock-up&nbsp;period</FONT> for the securities to be registered. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Underwriting Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
granted the underwriters <FONT STYLE="white-space:nowrap">a&nbsp;45-day&nbsp;option</FONT> from the date of the final prospectus relating to the Initial Public Offering to purchase up to 1,875,000 additional Units to cover over-allotments, if any,
at $10.00 per Unit, less underwriting discounts and commissions. The underwriters exercised this option in full on October&nbsp;10, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters were entitled to underwriting discounts of $0.275 per Unit, or approximately
$3.953&nbsp;million in the aggregate, paid upon the closing of the Initial Public Offering. An additional fee of $0.325 per Unit, or approximately $4.672&nbsp;million in the aggregate, will be payable to the underwriters for deferred underwriting
commissions. The deferred underwriting commissions will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting
agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 6 &#151; Shareholders&#146; Equity </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Class</I></B><B><I></I></B><B><I>&nbsp;A Ordinary Shares</I></B>&nbsp;&#151; The Company is authorized to issue 479,000,000 Class&nbsp;A
ordinary shares with a par value of $0.0001 per share. Holders of the Company&#146;s Class&nbsp;A ordinary shares are entitled to one vote for each share on each matter on which they are entitled to vote. As of March&nbsp;31, 2020 and
December&nbsp;31, 2019, there were 14,375,000 Class&nbsp;A ordinary shares issued or outstanding, including 13,545,245 and 13,872,230 Class&nbsp;A ordinary shares subject to possible redemption, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Class</I></B><B><I></I></B><B><I>&nbsp;B Ordinary Shares</I></B>&nbsp;&#151; The Company is authorized to issue 20,000,000 Class&nbsp;B
ordinary shares with a par value of $0.0001 per share. Holders of Class&nbsp;A ordinary shares and Class&nbsp;B ordinary shares will vote together as a single class on all matters submitted to vote, except as required by law. Holders of Class&nbsp;B
ordinary shares are entitled to one vote for each share. As of March&nbsp;31, 2020 and December&nbsp;31, 2019, there were 3,593,750 Class&nbsp;B ordinary shares outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Class&nbsp;B ordinary shares will automatically convert into Class&nbsp;A ordinary shares at the time of the Business Combination at a
ratio such that the number of Class&nbsp;A ordinary shares issuable upon conversion of all Class&nbsp;B ordinary shares will equal, in the aggregate, on <FONT STYLE="white-space:nowrap">an&nbsp;as-converted&nbsp;basis,</FONT> 20.0% of the sum of
(i)&nbsp;the total number of Class&nbsp;A ordinary shares issued and outstanding upon completion of the Initial Public Offering, plus (ii)&nbsp;the sum of (a)&nbsp;the total number of Class&nbsp;A ordinary shares or equity-linked securities
exercisable for or convertible into Class&nbsp;A ordinary shares issued or deemed issued in connection with the Business Combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the Business Combination
or any warrants issued to the Sponsor upon conversion of Working Capital Loans), minus (b)&nbsp;the number of Public Shares redeemed by Public Shareholders in connection with the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Preference Shares</I></B>&nbsp;&#151; The Company is authorized to issue 1,000,000 preference shares with a par value of $0.0001 per
share, and with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#146;s board of directors. As of March&nbsp;31, 2020 and December&nbsp;31, 2019, there were no preference shares issued
or outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Warrants</I></B>&nbsp;&#151; Public Warrants may only be exercised for a whole number of shares. No fractional
Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination or (b)&nbsp;twelve months
from the closing of the Initial Public Offering; provided in each case that the Company has an effective registration statement under the Securities Act covering the Class&nbsp;A ordinary shares issuable upon exercise of the Public Warrants and a
current prospectus relating to them is available (or the Company permits holders to exercise their Public Warrants on a cashless basis and such cashless exercise is exempt from registration under the Securities Act). The Company agreed that as soon
as practicable, but in no event later than 20 business days, after the closing of a Business Combination, the Company will use its best efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the
Class&nbsp;A ordinary shares issuable upon exercise of the Public Warrants. The Company will use its best efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus
relating thereto, until the expiration of the Public Warrants in accordance with the provisions of the warrant agreement. If </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a registration statement covering the Class&nbsp;A ordinary shares issuable upon exercise of the Public Warrants is not effective by the sixtieth (60th) day after the closing of the initial
Business Combination, warrantholders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#147;cashless
basis&#148; in accordance with Section&nbsp;3(a)(9) of the Securities Act or another exemption. The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Private Placement Warrants are identical to the Public Warrants included in the Units sold in the Initial Public Offering, except that the
Private Placement Warrants and the Class&nbsp;A ordinary shares issuable upon exercise of the Private Placement Warrants will not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain
limited exceptions. Additionally, the Private Placement Warrants will <FONT STYLE="white-space:nowrap">be&nbsp;non-redeemable&nbsp;so</FONT> long as they are held by the Sponsor or its permitted transferees. If the Private Placement Warrants are
held by someone other than the Sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company may call the Public Warrants for redemption: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in whole and not in part; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a price of $0.01 per warrant; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon a minimum of 30 days&#146; prior written notice of redemption; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if, and only if, the last reported closing price of the ordinary shares equals or exceeds $18.00 per share for
any 20 trading days within <FONT STYLE="white-space:nowrap">a&nbsp;30-trading&nbsp;day</FONT> period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrantholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the
Public Warrants to do so on a &#147;cashless basis,&#148; as described in the warrant agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exercise price and number of
Class&nbsp;A ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, or recapitalization, reorganization, merger or consolidation. However, the warrants will not be
adjusted for issuance of Class&nbsp;A ordinary shares at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrant shares. If the Company is unable to complete a Business Combination
within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#146;s
assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 7 &#151; Fair Value
Measurements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company&#146;s assets that are measured at fair value on a recurring
basis as of March&nbsp;31, 2020 and December&nbsp;31, 2019 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARYA SCIENCES ACQUISITION CORP. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>March&nbsp;31, 2020 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted<BR>Prices<BR>in&nbsp;Active<BR>Markets<BR>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs<BR>(Level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Unobservable<BR>Inputs<BR>(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">148,698,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2019 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted<BR>Prices<BR>in&nbsp;Active<BR>Markets<BR>(Level&nbsp;1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Observable<BR>Inputs<BR>(Level&nbsp;2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Other<BR>Unobservable<BR>Inputs<BR>(Level&nbsp;3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investments held in Trust Account</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">147,841,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Transfers to/from Levels 1, 2, and 3 are recognized at the end of the reporting period.&nbsp;There were no
transfers between levels of the hierarchy for the three months ended March&nbsp;31, 2020 and 2019. Level&nbsp;1 instruments include investments U.S. Treasury securities with an original maturity of 180 days or less. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note 8 &#151; Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company evaluated subsequent events and transactions that occurred up to the date unaudited condensed financial statements were available to be issued. Based upon this review, the Company determined that there have been no events that have occurred
that would require adjustments to the disclosures in the unaudited condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin96389_7"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To<B> </B>the Shareholders and Management Board of Immatics Biotechnologies GmbH </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opinion on the Financial Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
audited the accompanying consolidated statement of financial position of Immatics Biotechnologies GmbH and its subsidiary (the &#147;Company&#148;) as of December&nbsp;31, 2019 and 2018, and the related consolidated statements of loss, comprehensive
loss, changes in shareholders&#146; deficit and cash flows for the years then ended, including the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial statements
present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2019 and 2018, and the results of its operations and its cash flows for the years then ended in conformity with International Financial Reporting
Standards as issued by the International Accounting Standards Board. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Change in Accounting Principle </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 3 to the consolidated financial statements, the Company changed the manner in which it accounts for leases in 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis for Opinion </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial
statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or
fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Munich, Germany </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 15, 2020 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PricewaterhouseCoopers GmbH </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wirtschaftspr&uuml;fungsgesellschaft </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="57%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Dietmar&nbsp;Eglauer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">/s/ ppa. Andreas Schuster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Wirtschaftspr&uuml;fer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Wirtschaftspr&uuml;fer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(German&nbsp;Public&nbsp;Auditor)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(German Public Auditor)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin96389_8"></A>Consolidated Statement of Financial Position </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,528</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>124,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>55,288</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,277</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,030</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>134,277</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61,318</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>69,296</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26,838</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>105,816</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>43,651</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(233,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(201,623</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(741</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total (deficit) equity attributable to shareholders of the parent</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(41,855</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,407</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(40,835</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,171</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>134,277</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>61,318</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin96389_9"></A>Consolidated Statement of Loss </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros&nbsp;in&nbsp;thousands,&nbsp;except<BR>share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,971</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating result</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(33,013</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(34,409</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(264</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(161</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial result</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>526</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,054</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,487</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,355</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes on income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,487</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,355</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attributable to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equityholders of the parent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,487</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,355</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share &#151; basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(27.13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(27.02</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding &#151; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin96389_10"></A>Consolidated Statement of Comprehensive Loss </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net Loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,487</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,355</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive (loss) income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Items that may be reclassified subsequently to profit or loss, net of tax Currency translation
differences from foreign operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,516</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,042</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Attributable to:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equityholders of the parent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,600</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,516</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,042</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin96389_11"></A>Consolidated Statement of Cash Flows </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before taxation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,487</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,355</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjustments for:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(790</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(507</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,858</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity settled share-based payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MD Anderson compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities resulting from
share appreciation rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Changes in working capital</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(563</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,419</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in accounts payable and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>68,045</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,583</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from disposal of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,137</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(413</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of shares to equityholders of the parent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,862</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash (used in) provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,862</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,648</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>64,046</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,818</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents at beginning of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>39,367</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,415</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effects of exchange rate changes on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents at end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>103,353</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>39,367</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin96389_12"></A>Consolidated Statement of Changes in Shareholders Deficit </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share<BR>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other<BR>reserves</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;(deficit)<BR>equity<BR>attributable<BR>to<BR>shareholders<BR>of the parent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-controlling</FONT><BR>interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;share-<BR>holders&#146;<BR>(deficit)<BR>equity</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,164</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>167,027</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(168,547</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,054</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,410</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>787</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(623</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustment on adoption of IFRS&nbsp;15</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,632</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;1, 2018, adjusted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,164</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>167,027</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(170,179</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,054</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(3,042</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>787</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,255</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,444</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Comprehensive loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(31,444</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>313</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(31,131</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(911</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,042</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity-settled tandem awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MD Anderson compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,164</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>190,793</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(201,623</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(741</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,407</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,236</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,171</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,487</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Comprehensive loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(31,571</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(29</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(31,600</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(916</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,516</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity-settled tandem awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MD Anderson compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,164</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>190,945</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(233,194</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(770</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(41,855</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,020</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(40,835</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin96389_13"></A>Notes to the Consolidated Financial Statements </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Group information </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics Biotechnologies GmbH (&#147;the Company&#148;), together with its U.S. subsidiary, Immatics US Inc., (together, &#147;Immatics&#148; or &#147;the
Group&#148;) is a biotechnology Group that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. Immatics Biotechnologies GmbH is located at Paul-Ehrlich Str. 15 in 72076
T&uuml;bingen, Germany and was founded in September 2000 as a German limited liability company. It is registered with the commercial register at Stuttgart local court under HRB no. 382151. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These consolidated financial statements of the Group for the year ended December&nbsp;31, 2019 were authorized for issue by the Management Board on
April&nbsp;15, 2020. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Basis of presentation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (&#147;IFRS&#148;) as
issued by the International Accounting Standards Board (&#147;IASB&#148;), taking into account the recommendations of the International Financial Reporting Interpretations Committee (&#147;IFRIC&#148;). The consolidated financial statements are
presented in Euro. Amounts are stated in thousands of Euros, unless otherwise indicated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company controls an entity when it is exposed to, or has the
right to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. A subsidiary is consolidated from the date on which control commences until the date on which control
ceases. The consolidated financial statements include the accounts and results of Immatics Biotechnologies GmbH and its subsidiary Immatics US Inc. Immatics US Inc., located in Houston, Texas, is controlled by the Company, which holds a 96.04%
interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest, representing approximately 3.96% of the Group&#146;s Immatics
US, Inc. subsidiary as of December&nbsp;31, 2019 (2018: 3.96%). See note 18 for further details. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Going concern </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since inception, the Group&#146;s activities have consisted primarily of raising capital and performing research and development activities to advance its
technologies. The Group is still in the development phase and has not yet marketed any products commercially. Immatics&#146; ongoing success depends on the successful development and regulatory approval of its products and its ability to finance
operations. The Group will seek additional funding in order to reach its development and commercialization objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group plans to seek funds
either through an initial public offering or further private equity financings, debt financings, collaboration agreements and marketing, distribution or licensing arrangements. The Group may not be able to obtain financing or enter into
collaboration or other arrangements on acceptable terms. If the Group is unable to obtain funding, it could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or
commercialization efforts, which could adversely affect its business prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, Immatics&#146; cash and cash equivalents will be sufficient to
fund operating expenses and capital expenditure requirements for at least twelve months from the issuance date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying consolidated financial
statements have been prepared on a going concern basis. This contemplates that Immatics will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of operations.
The consolidated financial statements do not reflect any adjustments relating to the recoverability and classification of assets or the amounts and classification of liabilities that would be necessary, was the Group unable to continue as a going
concern. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Application of new and revised international financial reporting standards </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Application of new standards </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accounting policies adopted in the preparation of the consolidated financial statements are consistent with those followed in the preparation of the
Group&#146;s annual consolidated financial statements for the year ended December&nbsp;31, 2018, except for the adoption of new standards and interpretations effective as of January&nbsp;1, 2019. The Group has not early adopted any standard,
interpretation or amendment that has been issued but is not yet effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New standards and interpretations applied for the first time: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Standard/interpretation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Effective&nbsp;date</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IFRS 16 Leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">January&nbsp;1,&nbsp;2019</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendments to IFRS 9: Prepayment Features with Negative Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">January&nbsp;1, 2019</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">January&nbsp;1, 2019</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Annual Improvements to IFRS Standards 2015-2017 Cycle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">January&nbsp;1, 2019</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendments to IAS 19: Plan Amendment, Curtailment or Settlement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">January&nbsp;1, 2019</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IFRIC 23: Uncertainty over Income Tax Treatments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">January&nbsp;1, 2019</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for IFRS 16 as outlined below, the other amendments had no effect on the consolidated financial statements of the
Group. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IFRS 16 Leases </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group adopted IFRS 16
(&#147;Leases&#148;) effective January&nbsp;1, 2019. In this context, the exception granted by IFRS 16 C5 b) in conjunction with IFRS 16 C7 &#150; C13 is applied for the transition, meaning the Group has applied IFRS 16 using the modified
retrospective approach, under which the cumulative effect of initial application is recognized in accumulated deficit as of January&nbsp;1, 2019. Accordingly, any comparative information presented for 2018 has not been restated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The new standard specifies how to recognize, measure, present and disclose lease agreements. The standard provides a single lessee accounting model, requiring
lessees to recognize <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets, representing the lessee&#146;s rights to use the underlying assets, and lease liabilities representing the lessee&#146;s
obligations to make lease payments. Lessor accounting under IFRS 16 is similar with the previous guidance under IAS 17. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the previous standard (IAS
17), Immatics determined at contract inception whether an arrangement was or contained a lease under IFRIC 4 (&#147;Determining Whether an Arrangement contains a Lease&#148;). Under IFRS 16, Immatics now assesses whether a contract is or contains a
lease based on the new definition of a lease. This definition states that a contract is or contains a lease if the contract conveys a right to control the use of an identified asset for a period of time in exchange for consideration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon transition to IFRS 16, Immatics elected
to apply the practical expedient to grandfather the assessment of which transactions are leases. It applied IFRS 16 only to contracts that were previously identified as leases. Contracts that were previously not identified as leases were not
reassessed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a lessee, Immatics previously classified leases as operating or finance leases based on its assessment of
whether the lease transferred substantially all of the risks and rewards of ownership. Under IFRS 16, Immatics recognizes <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities for
all leases with lease terms greater than 12 months and with a value of the leased asset of more than &#128;5&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At transition, for leases
classified as operating leases under IAS 17, lease liabilities were measured at the present value of the remaining lease payments, discounted by the Group&#146;s incremental borrowing rates for similar assets as of January&nbsp;1, 2019. The weighted
average incremental borrowing rates applied to the lease liabilities on January&nbsp;1, 2019 were 2.68% for Immatics GmbH and 5.74% for Immatics US Inc. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets are measured at an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In applying IFRS 16 for
the first time, the Group applied the following practical expedients permitted by the standard: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">applying a single discount rate to a portfolio of leases with reasonably similar characteristics;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">accounting for operating leases with a remaining lease term of less than 12 months as of January&nbsp;1, 2019
as short-term leases; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">excluding initial direct costs for the measurement of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset at the date of initial application. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics presents <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets in a separate line item on the consolidated statement of financial position under <FONT STYLE="white-space:nowrap">non-current</FONT> assets. Lease
liabilities are shown as separate line items on the consolidated statement of financial position and classified as either current or <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities, depending on the maturity date of the underlying
lease payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below reconciles the Group&#146;s operating lease commitments as of December&nbsp;31, 2018 to the lease liability recognized as
of the transition date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Measurements of lease liabilities </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Euros in<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease commitments as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Discounted using the lessee&#146;s incremental borrowing rate of at the date of initial
application</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(298</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add: finance lease liabilities recognized as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">302</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Lease liability recognized as of January&nbsp;1, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Of which are</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Adjustments recognized in the balance sheet on January&nbsp;1, 2019 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The adoption of IFRS 16 resulted in the following impact to the statement of financial position as of January&nbsp;1, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Euros in<BR>thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,927</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assessment of potential impact of future standards, amendments to existing standards and interpretations
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following standards and interpretations have been issued by the IASB but were not yet mandatory for the year ended
December&nbsp;31, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Standard/interpretation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Effective&nbsp;date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Material&nbsp;effect&nbsp;expected<BR>on Immatics financial<BR>statements</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IFRS 17 Insurance contracts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">January&nbsp;1,&nbsp;2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">No</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendments to IAS 1, IAS 8: Definition of Material</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">January&nbsp;1, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">No</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendments to IFRS 3: Definition of a Business</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">January&nbsp;1, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">No</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendments to IFRS 9, IAS 39, IFRS 7: Interest Rate Benchmark Reform</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">January&nbsp;1, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">No</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendments to IAS 1: Classification of Liabilities as Current or Noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">January&nbsp;1, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">No</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendments to IFRS 10, IAS 28: Sale or contribution of assets between an investor and its
associate or joint venture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">n/a</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">n/a</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amendments to References to the Conceptual Framework in IFRS Standards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">January&nbsp;1, 2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">No</TD></TR>
</TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Summary of accounting policies applied by the Group for the annual reporting period ending December&nbsp;31,
2019 </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following are the significant accounting policies applied by the Group in preparing its consolidated financial statements:
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Segment information </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Group&#146;s focus is on the
research and development of T cell redirecting immunotherapies for the treatment of cancer. The Chief Executive Officer is the chief operating decision maker who regularly reviews the consolidated operating results and makes decisions about the
allocation of the Group&#146;s resources. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cash and cash equivalents </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents in the statement of financial position comprise of cash held at banks (including money market funds) and short-term deposits with an
original maturity of three months or less. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial assets </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Initial recognition and measurement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial assets
within the scope of IFRS 9 include cash and cash equivalents, loans, short-term deposits and receivables. Immatics determines the classification of its financial assets at initial recognition. All financial assets are recognized initially at fair
value plus transaction costs. Purchases and sales of financial assets are recognized on their trade date on which the Group commits to purchase or sell the asset. The subsequent measurement of financial assets depends on their classification as
described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Short-term deposits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics has short-term deposits with original maturities between three and nine months which are classified as other current assets. Short-term deposits with
an original maturity of three months or less are classified as cash and cash equivalents. Under IFRS 9 short-term deposits are classified within financial assets at fair value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Receivables </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has receivables from collaboration
agreements. A receivable must be capitalized at the point in time at which the Group has become a contractual partner and a claim to cash and cash equivalents has arisen. In subsequent reporting periods, a receivable is measured at amortized cost
using the effective interest method. Since the receivables are short-term receivables without a fixed interest rate, these receivables are capitalized at the original invoice or contract amount. Receivable balances are classified as current assets,
because all of the Group&#146;s receivables have an expected maturity of less than 12 months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest and other finance income </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments include money market funds and short-term deposits measured at fair value. Interest income is recorded using the effective interest rate
(EIR). EIR is the rate that discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the net carrying amount of the financial asset or liability. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Property, plant and equipment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property, plant and equipment is stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. All repair and maintenance costs
are recognized as expense when incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. The estimated useful lives are generally within the following ranges: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;useful&nbsp;life</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3&nbsp;&#150; 5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1&nbsp;&#150;&nbsp;14&nbsp;years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2 &#150; 6 years</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Intangible assets </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acquired intangible assets are initially recognized at cost. Following initial recognition, intangible assets are carried at cost less accumulated amortization
and accumulated impairment losses, if any. Intangible assets with finite lives are amortized over their useful economic lives and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization
period and the amortization method for an intangible asset with a finite useful life is reviewed at least at the end of each reporting period. Immatics does not have any internally developed intangible assets or intangible assets with indefinite
useful lives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization is calculated on a straight-line basis over the estimated useful lives of the assets as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;useful&nbsp;life</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Licenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5&nbsp;&#150;&nbsp;20&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 &#150; 5 years</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Research and development </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research expenses are defined as costs incurred for current or planned investigations undertaken with the prospect of gaining new scientific or technical
knowledge and understanding. All Research costs are expensed as incurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An intangible asset arising from development expenditure on an individual project is recognized only when
the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, its intention to complete and its ability to use or sell the asset, how the asset will generate future economic
benefits, the availability of resources to complete and the ability to measure reliably the expenditure during the development. The Group did not recognize any intangible assets from development expenditures in 2019 or 2018 due to the existing
uncertainties in connection with its development activities. Research and development expenses include the following types of costs: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in
research and development functions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">expenses incurred in connection with the preclinical development of our programs and clinical trials of our
product candidates, including under agreements with third parties, such as consultants, contractors, academic institutions and contract research organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the cost of manufacturing product candidates for use in clinical trials, including under agreements with third
parties, such as, consultants and contractors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">laboratory costs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">leased facility costs, equipment depreciation and other expenses, which include direct and allocated expenses;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">intellectual property costs incurred in connection with filing and prosecuting patent applications as well as
third-party license fees. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial liabilities Initial recognition and measurement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial liabilities within the scope of IFRS 9 are classified as financial liabilities at fair value through profit or loss or at amortized cost, as
appropriate. The Group determines the classification of its financial liabilities at initial recognition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All financial liabilities are recognized
initially at fair value and, in the case of loans and borrowings, carried at amortized cost. This includes directly attributable transaction costs. Immatics only recognized accounts payable as other financial liabilities at amortized costs. The
Group has not designated any financial liabilities upon initial recognition as fair value through profit or loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group does not engage in hedging
transactions. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Leases </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Application of IAS 17 (&#147;Leases&#148;) until December&nbsp;31, 2018 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to 2019, the Group applied IAS 17 when accounting for leases. As a lessee under IAS 17, leases for which substantially all the risks and rewards of
ownership transferred to the Group were classified as finance leases. Finance leases were capitalized at the lease&#146;s inception at the fair value of the leased property or, if lower, the present value of the minimum lease payments. The
corresponding rental obligations, net of finance charges, were included in other current liabilities and other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities. Each lease payment was allocated between the liability and finance cost.
The finance cost was charged as an expense over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The assets associated with the finance leases are depreciated over the
shorter of the asset&#146;s useful life or the lease term if there is no reasonable certainty that the Group will obtain ownership at the end of the lease term. Leases in which a significant portion of the risks and rewards of ownership were not
transferred to the Group as lessee were classified as operating leases. Payments made under operating leases (net of any incentives received from the lessor) were charged as an expense on a straight-line basis over the period of the lease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Application of IFRS 16 (&#147;Leases&#148;) effective January&nbsp;1, 2019 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group adopted IFRS 16 (&#147;Leases&#148;) effective January&nbsp;1, 2019. The Group leases various offices, equipment and vehicles. Rental contracts are
typically made for fixed periods of two to seven years but may have extension options as described in below. Contracts may contain both lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components. The Group has elected not to separate
lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components and instead accounts for these as a single lease component. Lease terms are negotiated on an individual basis. The lease agreements do not impose any covenants other than the
security interests in the leased assets that are held by the lessor. Leased assets may not be used as security for borrowing purposes. Prior to adopting IFRS 16, leases were classified as either finance leases or operating leases. Under IFRS 16,
leases are now recognized as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset with a corresponding liability on the date at which the leased asset is available for use by the Group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following
lease payments: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fixed payments (including <FONT STYLE="white-space:nowrap">in-substance</FONT> fixed payments), less any lease
incentives received; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">amounts expected to be payable by the Group under residual value guarantees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the exercise price of a purchase option if the Group is reasonably certain to exercise that option; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payments of penalties for terminating the lease, if the lease term reflects the Group exercising that option.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability. The lease
payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for the Group&#146;s leases, the lessee&#146;s incremental borrowing rate is used. The incremental
borrowing rate is the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset in a
similar economic environment with similar terms, security and conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine the incremental borrowing rate, the Group: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">uses a <FONT STYLE="white-space:nowrap">build-up</FONT> approach that starts with a risk-free interest rate
adjusted for credit risk for leases held by Immatics, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">makes adjustments specific to the lease, including lease term, country, currency and security.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets are measured at cost comprising the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the amount of the initial measurement of lease liability, </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any lease payments made at or before the commencement date less any lease incentives received,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any initial direct costs, and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">restoration costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets are generally depreciated over the shorter of the
asset&#146;s useful life or the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset is
depreciated over the underlying asset&#146;s useful life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments associated with short-term leases of equipment and vehicles and all leases of <FONT
STYLE="white-space:nowrap">low-value</FONT> assets are recognized on a straight-line basis as an expense. Short-term leases are leases with a lease term of 12 months or less. <FONT STYLE="white-space:nowrap">Low-value</FONT> assets have a value of
less than &#128;5&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Extension and termination options are included in a number of property and equipment leases across the Group. These are
used to maximize operational flexibility in terms of managing the assets used in the Group&#146;s operations. The extension and termination options held are exercisable only by the Group and not by the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respective lessor. For relevant leases which include an extension option, Immatics performed an assessment as of January&nbsp;1, 2019 to determine whether option extensions are reasonably
certain. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Revenue from collaboration agreements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group earns revenue through collaboration agreements with third-party pharmaceutical and biotechnology companies. As of December&nbsp;31, 2019, the Group
had four collaboration agreements in place with Amgen Inc., Thousand Oaks/CA/USA (&#147;Amgen&#148;), Genmab A/S, Copenhagen/Denmark (&#147;Genmab&#148;), Celgene Switzerland LLC (&#147;BMS&#148;) and GlaxoSmithKline Intellectual Property
Development Limited (&#147;GSK&#148;). Each of the Group&#146;s four collaboration agreements are in the preclinical stage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To determine the recognition
of revenue from arrangements that fall within the scope of IFRS 15, the Group performs the following five steps: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">identify the contract(s) with a customer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">identify the performance obligations in the contract; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">determine the transaction price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">allocate the transaction price to the performance obligations in the contract; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">recognize revenue when (or as) the Group satisfies a performance obligation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of these agreements, Immatics agrees to collaborate in the development, manufacture, and commercialization of cancer immunotherapy treatments
for specified targets identified through the use of Immatics XPRESIDENT technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the collaboration arrangements, Immatics grants exclusive
licensing rights for the development and commercialization of future product candidates developed for targets defined in the collaboration agreements. Additionally, Immatics agrees to perform certain research activities under the collaboration
agreements, including screening of highly specific molecules for reactivity with the specified targets and <FONT STYLE="white-space:nowrap">off-targets</FONT> using Immatics&#146; proprietary technology and
<FONT STYLE="white-space:nowrap">know-how,</FONT> participation on steering committees, and preparation of data packages. The research activities are the predominant item in each of the Group&#146;s collaboration agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group performs an analysis to identify the performance obligations under the contract, including licenses and rights to future intellectual property
developed under the contract and research activities. As these agreements comprise several promises, it must be assessed whether these promises are capable of being distinct and distinct within the context of the contract. <FONT
STYLE="white-space:nowrap">Up-front</FONT> licensing payments and reimbursement for research and development expenses are initially deferred on our statement of financial position and subsequently recognized as costs are incurred using a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> method. Milestone payments are generally included in the transaction price at the amount stipulated in the respective agreement and recognized to the extent that
it is highly probable that a&nbsp;significant reversal&nbsp;in the amount of cumulative revenue recognized will not occur. To date, no milestone has been included in the transaction price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As stated above, the licenses contributed under the collaboration agreements currently in place do not represent distinct performance obligations, because the
Group&#146;s collaboration partners would likely be unable to derive significant benefits from their access to these targets without Immatics&#146; research activities. Identification of a viable product candidate that will bind to the targets
specified in the agreements requires use of the Group&#146;s XPRESIDENT technology and database of target and <FONT STYLE="white-space:nowrap">off-target</FONT> data. These agreements include a <FONT STYLE="white-space:nowrap">non-refundable</FONT>
upfront payment, payments for research and development activities in certain circumstances, and payments based upon the achievement of defined milestones. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under IFRS 15, the Group applies significant judgement when evaluating whether the obligations under these agreements represent one or more combined
performance obligations, the allocation of the transaction price to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
identified performance obligations, and the determination of whether milestone payments should be included in the transaction price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Upfront payment </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the Group&#146;s collaboration
agreements included a <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment, meant to subsidize research activities. The Group recorded these payments as deferred revenue, which it allocated to the combined performance obligations
for each agreement. Such amounts are recognized as revenue over the performance period of the research activities on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> basis using direct costs and directly attributable personal
costs was considered the best measure of progress in which control of the combined performance obligations transfers to the Group&#146;s collaboration partners, due to the nature of the work being performed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Reimbursement for services </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the collaboration
agreement with Genmab, the Group receives reimbursement for employee research and development costs. These employee costs are presented as research and development expenses, while reimbursements of those costs, which is based on an FTE rate defined
in the contract, are presented as revenue and not deducted from expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Development and Commercial Milestones </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collaboration agreements include contingent payments related to development and commercial milestone events. These milestone payments represent variable
consideration that are not initially recognized within the transaction price, due to the scientific uncertainties and the required commitment from the collaboration partners to develop and commercialize a product candidate. The Group assesses the
probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sales-based milestones and royalty payments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
collaboration agreements also include sales-based royalty payments upon successful commercialization of a licensed product. In accordance with IFRS 15.B63, the Group recognizes revenue from sales-based milestone and royalty payments at the later of
(i)&nbsp;the occurrence of the subsequent sale; or (ii)&nbsp;the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied. The Group anticipates recognizing these milestones
and royalty payments if and when subsequent sales are generated from a licensed product by the collaboration partner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cost to fulfill contracts
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group incurs costs for personnel, supplies and other costs related to its laboratory operations as well as fees from third parties and license
expenses in connection with its research and development obligations under the collaboration and licensing agreement. These costs are recognized as research and development expenses over the period in which services are performed. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other income </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group primarily earns other income from government research grants. Government grants are recognized as income when there is reasonable assurance that the
grant will be received and all required conditions have been complied with. Grants from governmental agencies for the support of specific research and development projects are recorded as other income to the extent the related expenses have been
incurred. Grant agreements include a budget that specifies the amount and nature of expenses allowed during the entire grant term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expenses incurred under the grants are calculated according to agreed-upon terms on a quarterly basis, filed
with the governmental agencies, and recorded as income. The governmental agencies make payments to the Group based on these calculations of expenses incurred under the grants. If these estimated calculations change, the Group will then adjust grant
revenue in the subsequent period. The Group believes that its calculations are based on the agreed-upon terms as stated in the grant agreements. The governmental agencies generally have the right to audit the Group&#146;s calculations. If the
governmental agencies disagree with the Group&#146;s calculations the amount of grant revenue recognized could change. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Foreign currency </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transactions and balances in Germany and in the USA </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements are presented in Euro, which is the Group&#146;s functional and presentation currency. Assets and liabilities of foreign operations are translated into Euros at the rate of exchange prevailing at the reporting date.
The statements of loss is translated at average exchange rates. The currency translation differences are recognized in other comprehensive income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transactions in foreign currencies are initially recorded by the Group&#146;s entities at their respective functional currency spot rates at the date the
transaction first qualifies for recognition. The Group used the following exchange rates to convert the financial statements of its U.S. subsidiary: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2018</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="white-space:nowrap">Year-end&nbsp;rate</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Average&nbsp;rate</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="white-space:nowrap">Year-end&nbsp;rate</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Average&nbsp;rate</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Euros per U.S.&nbsp;Dollar</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Fair value of financial instruments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the
measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the principal market for the asset or liability or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the absence of a principal market, in the most advantageous market for the asset or liability that is
accessible by the Group. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of an asset or a liability is measured using the assumptions that market participants would use
when pricing the asset or liability, assuming that market participants act in their economic best interest. The Group uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair
value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorized within the fair
value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1 &#151; Quoted (unadjusted) market prices in active markets for identical assets or liabilities
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2 &#151; Valuation techniques for which the lowest level input that is significant to the fair value
measurement is directly or indirectly observable </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3 &#151; Valuation techniques for which the lowest level input that is significant to the fair value
measurement is unobservable </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For assets and liabilities that are recognized in the consolidated financial statements at fair value on a
recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by <FONT STYLE="white-space:nowrap">re-assessing</FONT> categorization (based on the lowest level input that is significant to the fair value
measurement as a whole) at the end of each reporting period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Provisions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of
resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Where the Group expects some or all of a provision to be reimbursed, for example under an insurance
contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the effect of the time value of
money is material, provisions are discounted using a current <FONT STYLE="white-space:nowrap">pre-tax</FONT> rate that reflects, when appropriate, the risks specific to the liability. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.14</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Income Tax </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income tax results from temporary differences between the carrying amount of an asset or a liability and its tax base. Deferred income tax is provided
in full using the liability method on temporary differences. In accordance with IAS 12 (&#147;Income Taxes&#148;), the deferred tax assets and liabilities reflect all temporary valuation and accounting differences between financial statements
prepared for tax purposes and IFRS financial statements. Tax losses carried forward are taken into account in deferred tax assets calculation. The Group offsets tax assets and liabilities if and only if it has a legally enforceable right to set off
current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Significant accounting judgements, estimates and assumptions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of the Group&#146;s consolidated financial statements requires management to make judgements, estimates and assumptions that affect the
reported amounts of revenue, expenses, assets and liabilities, income taxes and the accompanying disclosures. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the
asset or liability affected in future periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Estimates &#151; Taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Uncertainties exist with respect to the interpretation of complex tax regulations, changes in tax laws, and the amount and timing of future taxable income.
Given the wide range and complexity of existing contractual agreements, differences arising between the actual results and the assumptions made, or future changes to such assumptions, could necessitate future adjustments to tax income and expense
already recorded. Deferred tax assets are recognized for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Significant management judgement is required to determine
the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits together with future tax planning strategies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue recognition from collaboration agreements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the
collaboration agreements comprise several promises, it must be assessed whether these promises are capable of being distinct within the context of the contract. For the four collaboration agreements the Group assessed that these promises are not
capable of being distinct within the context of the contract which results in accounting for all goods and services promised as a single performance obligation with a single measure of progress. The performance obligation is accounted for as a
performance obligation satisfied over time using a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> method as the customer simultaneously receives and consumes the benefits from Immatics&#146; performance.
<FONT STYLE="white-space:nowrap">Up-front</FONT> licensing payments are initially deferred on our statement of financial position and subsequently recognized as revenue over time as costs are incurred. Milestone payments are generally included in
the transaction price at the amount stipulated in the respective agreement and recognized as revenue to the extent that it is highly probable that a&nbsp;significant reversal&nbsp;in the amount of cumulative revenue recognized will not occur. To
date, no milestone has been included in the transaction price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics provides development and manufacturing services to customers and recognizes revenue over time using
an input-based method to measure progress toward complete satisfaction of the service because the customer simultaneously receives and consumes the benefits provided. Forecast values are used for the calculation of expected future revenue for the
remaining term of the contract. These costs estimated as part of the budgeting process must be reviewed and approved before the Group can use them for recognition purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share-based payments </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Determining the fair value of
share-based payment transactions requires the most appropriate valuation for the specific program, which depends on the underlying terms and conditions. This estimate also requires the determination of the most appropriate inputs to the valuation
model, including the fair value of the share option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the lack of quoted market prices, the management determined the value of share-based awards
with the assistance of a third party valuation specialist using certain assumptions, such as share price volatility, the determination of an appropriate risk-free interest rate, expected dividends and the probability of reaching certain
exercisability criteria. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The vested SARs under the 2010 Plan can only be exercised in an event that more than 50% of the shareholdings in the Company
will be acquired by a third person (&#147;Change of control&#148;) and the vested SARs of the 2016 Plan may only be exercised upon the occurrence of a change in control or expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT>
period following completion of an initial public offering (&#147;IPO&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair values of these awards were discounted based on the probability of
the awards becoming exercisable. It is necessary to look at different scenarios under which the award would be expected to be realized. Therefore, it was necessary to estimate the probability of each such scenario. The present value of the
probability-weighted fair value under all scenarios represents the value of the awards. The difficulty in applying this method is the estimation of the different possible outcomes and the probabilities associated with such outcomes.
Management&#146;s assessment is updated at each valuation date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Accounts receivable </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivables from collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accounts receivable</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>957</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>393</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, and 2018, no receivables were considered impaired. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other current and <FONT STYLE="white-space:nowrap">non-current</FONT> assets </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other current assets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value added tax receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,690</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,528</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group recognizes receivables for government grants when it is reasonably assured that the grant will be
received, and all contractual conditions have been complied with. As of December&nbsp;31, 2019, and 2018, no receivables were considered impaired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses include &#128;622&nbsp;thousand fees paid for the successful arrangement of the BMS and Genmab collaboration agreements as of
December&nbsp;31, 2019 (December 31, 2018: &#128;181 thousand). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Short-term deposits have original maturity dates between three and nine months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,262</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>984</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses entirely consist of &#128;937&nbsp;thousand fees paid for the successful arrangement of the BMS and Genmab
collaboration agreements as of December&nbsp;31, 2019 (December 31, 2018: &#128;665 thousand). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Property, plant and equipment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes to property, plant and equipment during 2019 and 2018 consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ROWSPAN="3"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Laboratory<BR>equipment</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Computer<BR>equipment</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Office<BR>equipment</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="3">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; "></TR>
<TR STYLE="font-size:1px; "></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cost as of January&nbsp;1, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,849</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,299</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,417</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,565</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cost as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,222</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,439</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,455</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,116</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accumulated depreciation as of January&nbsp;1, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,665</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>842</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,087</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,058</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accumulated depreciation as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,279</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,793</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,037</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,109</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net book value as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,943</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>646</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>418</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,007</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cost as of January&nbsp;1, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,222</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,439</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,455</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,116</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of IFRS 16 adoption</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cost as of January&nbsp;1, 2019, adjusted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,781</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,439</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,455</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,675</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">515</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(314</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(316</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cost as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,723</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,956</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,753</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>17,432</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accumulated depreciation as of January&nbsp;1, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,279</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,793</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,037</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11,109</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,797</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disposals</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(218</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(219</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accumulated depreciation as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,303</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,050</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,359</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,712</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net book value at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,420</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>906</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>394</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,720</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense is included in the following line items of the consolidated statement of loss: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,797</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,058</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Intangible assets </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Changes to intangible assets during 2019 and 2018 consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Patents&nbsp;and<BR>licenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Software<BR>licenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cost as of January&nbsp;1, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,156</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>473</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,629</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cost as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,201</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>551</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,752</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accumulated amortization as of January&nbsp;1, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>249</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>340</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>589</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accumulated amortization as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>314</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>399</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>713</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net book value at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>887</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>152</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,039</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cost as of January&nbsp;1, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,201</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>551</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,752</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cost as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,220</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>643</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,863</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accumulated amortization as of January&nbsp;1, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>314</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>399</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>713</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accumulated amortization as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>369</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>486</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>855</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net book value at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>851</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>157</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,008</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amortization expense is classified as follows within the consolidated statement of profit or loss: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>111</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>118</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Leases </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Right-of</FONT> use assets consist of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buildings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IT and telecommunication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vehicles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Others</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,287</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,927</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lease liabilities consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;1,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability &#151; current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liability &#151; <FONT STYLE="white-space:nowrap">non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,234</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,787</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additions to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets were
&#128;261&nbsp;thousand in 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currency translation differences included in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets were &#128;49&nbsp;thousand in 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expenses related
to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Depreciation charges of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Buildings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IT and telecommunication</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vehicles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,950</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expenses from leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expenses related to short-term leases and <FONT STYLE="white-space:nowrap">low-value</FONT> assets
(included in administrative expenses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total cash payments for leases was &#128;2,059&nbsp;thousand in 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the Group has committed lease payments of &#128;3,352&nbsp;thousand, of which &#128;1,482&nbsp;thousand will occur in the next
12 months. The remaining lease payments will occur between January&nbsp;1, 2021 and December&nbsp;31, 2024. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Accounts Payable </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Accounts Payable</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,082</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,201</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other accrued liabilities classified within accounts payable mainly relate to outstanding invoices amounting
&#128;1,962&nbsp;thousand as of December&nbsp;31, 2019 (December 31, 2018: &#128;1,270 thousand). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Revenue from collaboration agreements and Deferred revenue </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group earns revenue through collaboration agreements with third party pharmaceutical and biotechnology companies. As of December&nbsp;31, 2019, the Group
had four collaboration agreements in place, each of which is in the preclinical stage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of these collaboration arrangements, Immatics grants
exclusive licensing rights or options thereto for the development and commercialization of future product candidates developed for several targets defined in the respective collaboration agreements, in addition to research activities, including
screening of highly specific molecules for reactivity with the specified targets and <FONT STYLE="white-space:nowrap">off-targets</FONT> using Immatics&#146; proprietary technology and <FONT STYLE="white-space:nowrap">know-how,</FONT> participation
on a joint steering committee, and preparation of data packages. For each collaboration agreement, these promises represent one combined performance obligation, because the research activities are mutually dependent and the respective collaboration
partner is unable to derive significant benefits from its access to these targets without Immatics&#146; research activities, which are highly specialized and cannot be performed by other organizations. Under each agreement, research activities were
determined to be the predominant item under the contract. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amgen Collaboration Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2016, Immatics Biotechnologies GmbH entered into a research collaboration and license agreement with Amgen Inc. (&#147;Amgen&#148;) to develop
next-generation, T cell engaging bispecific immunotherapies targeting multiple cancers. Under the terms of the agreement, Immatics contributed its XPRESIDENT target discovery and T cell receptor (TCR) capabilities to the preclinical development of
product candidates. Amgen Inc. contributed its validated BiTE (Bispecific T&nbsp;cell Engager) technology and will be responsible for the clinical development, manufacturing and commercialization worldwide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the collaboration agreement with Amgen, Immatics is eligible to receive development, regulatory and commercial milestone payments amounting up to
$525&nbsp;million for each program and tiered royalties on net sales for each licensed product at percentages ranging from high-single digits to low teens subject to customary reductions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group received a <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment of $30&nbsp;million upon signing of the Amgen agreement. The Group
classified the initial receipt of the upfront payment as deferred revenue, which it recognizes into revenue as on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> basis using forecasted costs. A <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> basis was determined most representative of the transfer of benefits to Amgen. During the years ended December 31, 2019 and 2018, the Group recognized &#128;6,197
thousand and &#128;1,501 thousand of revenue associated with research activities performed under the Amgen collaboration agreement. Total deferred revenue under the agreement was &#128;15,093&nbsp;thousand and &#128;20,809&nbsp;thousand as of
December&nbsp;31, 2019 and 2018, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Genmab Collaboration Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2018, Immatics Biotechnologies GmbH entered into a research collaboration and license agreement with Genmab A/S (&#147;Genmab&#148;) to develop
next-generation, T cell engaging bispecific immunotherapies targeting multiple cancer indications. Under the agreement, Immatics and Genmab conduct joint research to combine Immatics&#146; XPRESIDENT and Bispecific TCR technology platforms with
Genmab&#146;s proprietary antibody technologies to develop multiple bispecific immunotherapies in oncology. The two companies plan to develop immunotherapies directed against three proprietary targets. Genmab will be responsible for development,
manufacturing and worldwide commercialization. Immatics will have an option to contribute certain promotion efforts at predetermined levels in selected countries in the EU. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Genmab collaboration agreement contains a maximum of $550&nbsp;million of milestone payments for each
licensed product resulting from the collaboration. In addition, Immatics is entitled to receive royalty payments. Royalty rates are based on aggregate net sales of a licensed product. The agreement provides for higher royalty rates as annual net
sales of a licensed product increases. Under the agreement, Immatics is eligible to receive tiered royalties on net sales for each licensed product up to double-digit percentages. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group received a <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment of $54&nbsp;million upon signing of the agreement. The Group
classified the initial receipt of the upfront payment as deferred revenue. The Group recognized &#128;11,191 thousand and &#128;2,269 of revenue for research activities performed under the Genmab collaboration agreement during the years ended
December 31, 2019 and 2018, respectively. Revenue for the Genmab collaboration agreement is recognized on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> basis using forecasted costs. A <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> basis was determined most representative of the transfer of benefits to Genmab. Total deferred revenue under the agreement was &#128;34,767&nbsp;thousand and
&#128;44,212&nbsp;thousand as of December&nbsp;31, 2019 and 2018, respectively. Under the agreement, the Group also receives reimbursement for research and development costs performed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>BMS Collaboration Agreement </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2019, Immatics
Biotechnologies GmbH and BMS entered into a collaboration and option agreement to develop novel adoptive cell therapies targeting multiple cancers. Under the agreement, Immatics may develop T Cell Receptor Engineered T cell Therapy <FONT
STYLE="white-space:nowrap">(TCR-T)</FONT> programs against solid tumor targets discovered with Immatics&#146; XPRESIDENT technology. Programs would utilize proprietary T Cell Receptors (TCRs) identified by Immatics&#146; XCEPTOR TCR discovery and
engineering platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Immatics develops programs against the <FONT STYLE="white-space:nowrap">TCR-T</FONT> targets, Immatics will be responsible for
the development and validation of these programs through lead candidate stage, at which time BMS may exercise <FONT STYLE="white-space:nowrap">opt-in</FONT> rights and assume sole responsibility for further worldwide development, manufacturing and
commercialization of the <FONT STYLE="white-space:nowrap">TCR-T</FONT> cell therapies. Immatics would have certain early stage <FONT STYLE="white-space:nowrap">co-development</FONT> rights or <FONT STYLE="white-space:nowrap">co-funding</FONT> rights
for selected <FONT STYLE="white-space:nowrap">TCR-T</FONT> cell therapies arising from the collaboration. With respect to this collaboration agreement with BMS, Immatics may be eligible to receive regulatory and sales milestones in aggregate amounts
of up to $190 million, and $300 million, respectively. In addition, Immatics is entitled to royalty payments. Royalty rates are based on aggregate net sales of a licensed product resulting from the collaboration. The agreement provides for higher
royalty rates as annual net sales of a licensed product increases. Under each contract, the royalty rates begin in the high single-digits, increasing to the teen-digits as a percentage of aggregate annual net sales of a licensed product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group received a <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payment of $75&nbsp;million upon signing of the agreement. The Group
classified the initial receipt of the upfront payment as deferred revenue. The Group recognized &#128;1,061&nbsp;thousand of revenue associated with the upfront payment during 2019. Revenue for the BMS collaboration agreement is recognized on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> basis using forecasted costs. A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> basis was determined most
representative of the transfer of benefits to BMS. Total deferred revenue under the agreement was &#128;66,514&nbsp;thousand as of December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>GSK </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, Immatics entered into a
collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications. Immatics and GSK plan to collaborate on the identification, research and development of next-generation TCR Therapeutics focusing on
solid tumors. The collaboration will initially focus on the development of autologous T cell therapies and GSK has an option to develop allogeneic T cell therapies using Immatics ACTallo approach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics and GSK intend to utilize proprietary TCRs identified by Immatics TCR discovery platform XCEPTOR which are planned to be directed against two
proprietary targets. Those proprietary targets were </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discovered and validated by the respective XPRESIDENT technology. Immatics will be mainly responsible for the development and validation of the <FONT STYLE="white-space:nowrap">TCR-T</FONT> up to
designation of a clinical candidate. GSK will then assume sole responsibility for further development, manufacturing and commercialization of the <FONT STYLE="white-space:nowrap">TCR-T</FONT> with the option for Immatics to <FONT
STYLE="white-space:nowrap">co-develop</FONT> one or more <FONT STYLE="white-space:nowrap">TCR-Ts</FONT> upon GSK&acute;s request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group received a <FONT
STYLE="white-space:nowrap">non-refundable</FONT> upfront payment of &#128;45&nbsp;million for two initial programs upon signing of the GSK agreement and is eligible to receive up to $575&nbsp;million of development, regulatory and sales milestone
payments per program. In addition, Immatics is entitled to royalty payments. Royalty rates are based on aggregate net sales of a licensed product resulting from the collaboration. The agreement provides for higher royalty rates as annual net sales
of a licensed product increases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group classified the initial receipt of the upfront payment as deferred revenue. The Group recognized no revenue
associated with the upfront payment during 2019. Total deferred revenue under the agreement was &#128;45,000&nbsp;thousand as of December&nbsp;31, 2019. The Group has not recognized any royalty or milestone revenue under the collaboration
agreements, due to the scientific uncertainty of achieving the milestones or the successful commercialization of a product. As of December&nbsp;31, 2019, Immatics had not received any milestone or royalty payments in connection with the
collaboration agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group plans to recognize the remaining deferred revenue balance into revenue as it performs the related performance
obligations under each contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred revenue related to the collaboration agreements consists of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>161,374</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>65,021</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contract Costs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group
incurs costs from a third party, who assists in identifying collaboration partners. The Group recognizes a contract asset to the extent these costs are directly related to a specific contract. The Group then amortizes the contract cost consistently
with the pattern of revenue recognition for the related contracts. Total contract assets recognized were &#128;1,559&nbsp;thousand and &#128;846&nbsp;thousand as of December&nbsp;31, 2019 and 2018, respectively, which are classified in other current
assets and other <FONT STYLE="white-space:nowrap">non-current</FONT> assets. Immatics recognized expenses related to the amortization of capitalized contract costs of &#128;195&nbsp;thousand and &#128;36&nbsp;thousand during 2019 and 2018,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the Group is potentially liable to pay $2&nbsp;million to a third-party upon successful completing the
milestone of the first clinical lead selection in connection with Immatics&#146; collaboration agreements. The Group does not recognize a liability for these contingent payments due to the scientific uncertainty of achieving the related milestones.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other income </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other income includes grant income, in addition to other immaterial sources. The Group receives income through government grants for specific research and
development projects. The Group recognizes grant income as it performs research and development activities specified by the grant agreements. Total grant income was &#128;26&nbsp;thousand and &#128;2,933&nbsp;thousand during 2019 and 2018,
respectively. There are no unfulfilled conditions or contingencies attached to these grants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group had the following deferred income and receivable balances under these agreements: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group classifies receivables under these agreements within other current assets, while it presents deferred income within
other current liabilities. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other current liabilities </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of other current liabilities are: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued vacation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred grant income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued bonuses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,288</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,047</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other current liabilities are <FONT STYLE="white-space:nowrap">non-interest-bearing</FONT> and are due within one year. The
carrying amounts of other current liabilities represent fair value due to their short-term nature. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial result </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial income and financial expenses consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income from short-term deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency gains</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>790</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,215</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expenses on current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expenses from leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(170</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(94</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(264</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(161</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial result</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>526</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,054</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Share incentive program </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, and 2018, the Group had the following share-based payment plans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share appreciation rights (&#147;the 2010 Plan&#148;) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective January&nbsp;1, 2005, in addition to performance-related compensation, certain Immatics employees became eligible to participate in a Stock
Appreciation Rights (SAR) Program as part of a long-term equity incentive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
scheme. The aim of this program was to give employees a long-term stake in the success of the Company. The SAR program was adopted by resolutions by the supervisory board in January 2005 and
subsequently amended on February&nbsp;6, 2007 and September&nbsp;7, 2010. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the 2010 Plan, the beneficiaries received SAR awards, which do not
require any cash investment into the company. SARs granted under this program carry no dividend or voting rights. The award holders have the right to execute the vested SARs only in a defined exit event. An exit event is defined as the acquisition
of more than 50.00% of the outstanding shares by a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SARs granted under the 2010 Plan vest based on the satisfaction of service requirements
(time-based vesting). These awards generally have a five-year graded vesting period. Employees leaving the Group are able to retain any vested awards as of their termination date, unless they are terminated for cause. Per the terms of the SAR
agreements, employees are not entitled to subscribe to shares in the Group. Therefore, SARs granted under the 2010 Plan may be settled in cash only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
awards issued under the 2010 Plan are cash settled, the Group applies liability accounting and revalues the outstanding awards at each reporting date. The Group applied a Black Scholes pricing model to estimate the fair value of the SARs as of
December&nbsp;31, 2019 and 2018 based on a company value of $350,000&nbsp;thousand and $160,000&nbsp;thousand, respectively. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Amounts in USD</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underlying share price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64.28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time period (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.59</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.77</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Combined probability of exit events</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expected volatility was determined by calculating the historic volatility in share prices of peer companies within the
biotechnology industry. The expected life in the model has been adjusted, based on management&#146;s best estimate, for the effects of <FONT STYLE="white-space:nowrap">non-transferability</FONT> and exercise restrictions. Furthermore, the fair value
of SARs issued under the 2010 Plan were discounted based on the probability of the awards becoming exercisable due to either a change in control or an IPO as management expects to settle these awards also in case of an IPO. The Black Scholes model
considered for an IPO event a time period of one year and for a trade sale event a time period of five years. Awards issued under the 2010 Plan do not expire. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set out below are summaries of SARs issued during 2019 and 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average<BR>exercise<BR>price&nbsp;in<BR>USD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average<BR>exercise<BR>price&nbsp;in<BR>USD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SARs outstanding at January&nbsp;1,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SARs granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SARs forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SARs outstanding at December&nbsp;31,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SARs vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SARs exercisable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no awards issued under the 2010 Plan in 2019 or 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, and 2018 Immatics had other
<FONT STYLE="white-space:nowrap">non-current</FONT> liabilities of &#128;2,084&nbsp;thousand and &#128;220&nbsp;thousand, respectively, resulting from these awards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2016 Equity Incentive Plan (&#147;the 2016 Plan&#148;) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;8, 2017, the Company established the &#147;2016 Equity Incentive Plan&#148; to provide employees and consultants of the Group the ability to
share in the Company&#146;s future success. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Awards issued under the 2016 Plan are tandem awards, which consist of an option to acquire a stated the
number of shares at a stated exercise price, or alternatively, the right to receive any appreciation in the value of the stated number of shares (&#147;SAR portion&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, the tandem awards issued under the 2016 Plan have a five-year vesting period. The first annual tranche vests on the first anniversary of the grant
date. Following the first anniversary, the awards continue to vest on a monthly basis. Vesting is contingent on the recipient&#146;s continued service to the Group. Employees leaving the Group are able to retain any awards vested as of their
termination date, unless they are terminated for cause. Former employees forfeit their awards if they remain unexercised more than three months after an IPO or change in control. In the event of a change in control, the unvested portion of the
Tandem Award shall immediately vest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Tandem Award (to the extent vested) may only be exercised after the contribution of all Immatics shares to a
holding company for purposes of an indirect IPO, a change in control, or the expiration of a certain <FONT STYLE="white-space:nowrap">lock-up</FONT> period following the completion of a direct IPO. A change in control is defined as the acquisition
of more than 50% of the outstanding shares by a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the 2016 Plan, options must be settled in equity shares of the Group,
while SAR portions may be settled in either equity shares or cash, at the Group&#146;s discretion. While the Group does not have a policy or prior history of settling these awards, it intends to settle outstanding awards in equity shares. As a
result, the Group is treating awards issued under the 2016 plan as equity-settled. Subsequent settlements of SARs in cash, to the extent they occur, would be recorded via an adjustment to equity. Each option or SAR issued under the plan may be
settled for one common share of the Group in the event it is exercisable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2016 Plan may be converted into a regular employee stock option plan if
Immatics changes its legal form to a German stock corporation (Aktiengesellschaft). All awards issued under the 2016 Plan have a <FONT STYLE="white-space:nowrap">ten-year</FONT> contractual life. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set out below are summaries of tandem awards issued during 2019 and 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average<BR>exercise<BR>price in<BR>USD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average<BR>exercise<BR>price in<BR>USD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tandem Awards outstanding at January&nbsp;1,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tandem awards granted in June to September</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tandem awards granted in December</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tandem awards forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tandem awards outstanding at December&nbsp;31,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tandem awards vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tandem awards exercisable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining contract life (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average fair value of options granted in USD till September</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average fair value of options granted in USD for December</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group used a Black Scholes pricing model to estimate the fair value of equity settled tandem awards issued during 2019
until September 2019 based on a company valuation of $160,000&nbsp;thousand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of tandem awards issued in December 2019 is based on a
company valuation of $350,000&nbsp;thousand. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Amounts in USD</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><FONT STYLE="white-space:nowrap">June&nbsp;2019&nbsp;-&nbsp;September&nbsp;2019</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>December&nbsp;2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price in USD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underlying share price in USD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64.28</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time period (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.59</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.04</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.77</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Combined probability of exit events</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expected volatility was determined by calculating the historic volatility in share prices of peer companies within the
biotechnology industry. The expected life in the model has been adjusted, based on management&#146;s best estimate, for the effects of <FONT STYLE="white-space:nowrap">non-transferability</FONT> and exercise restrictions. Furthermore, the fair value
of awards issued under the 2016 Plan were discounted based on the probability of the awards becoming exercisable due to either a change in control or an IPO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2019, the Group recognized total share-based compensation as set out below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total share-based compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,016</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>338</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Shareholders&#146; deficit </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total number of ordinary shares issued and outstanding is 1,163,625 as of December&nbsp;31, 2019 (December 31, 2018: 1,163,625 shares) with a par value of
&#128;1.00. All ordinary shares are fully paid and outstanding. Each ordinary share is entitled to one vote. In 2019, there was no capital increase and, hence, no change in share capital or share premium. In 2018, &#128;23,648&nbsp;thousand were
paid into share premium by the shareholders based on the Series E financing round, which closed in 2017. The related Series E share capital was previously paid in full in 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other reserves is related to accumulated foreign currency translation amounts associated with the Group&#146;s US operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation preferences for ordinary shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
case of an exit event, such as a sale or dissolution of the Group, the sales proceeds, after deducting for selling costs, and remaining assets of the Group, shall be used for satisfying the liquidation preferences from the shareholders. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>a.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><FONT STYLE="white-space:nowrap">E-Round</FONT> </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shareholders shall receive with the same rank an amount equal to 1.5x of their invested capital in the Series E Financing which was in 2017. The Investors
which participated in the Series E Financing, have two options for full-/partial liquidation preferences. The first option is 1.0x of the Series E purchase price plus 5.00% p.a. IRR (Internal Rate of Return) and an additional participation in the
pro rata payout. The second option is 1.5x of the Series E purchase price without a participation in the pro rata payout. In the Series <FONT STYLE="white-space:nowrap">E-Financing</FONT> round 548,539 shares were issued, which were all outstanding
as of December&nbsp;31, 2019 and 2018. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>b.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><FONT STYLE="white-space:nowrap">D-Round</FONT> </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As far as there are remaining proceeds after deduction of the claims pursuant to the Series <FONT STYLE="white-space:nowrap">E-Financing</FONT> round, the
shareholders shall receive with the same rank their invested capital in the Series D Financing (2013/2014) plus an annual interest of 5.00% for the time beginning with the receipt of the respective payment by Immatics until the date of the
distribution of the remaining assets. If the remaining assets are not sufficient for the complete payment of the claims of the shareholder, then they shall be entitled with the same rank to a corresponding proportional amount pro rata to all claims
of the investors inter se. In <FONT STYLE="white-space:nowrap">D-Round</FONT> 123,018 shares were issued, which were all outstanding as of December&nbsp;31, 2019 and 2018. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>c.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><FONT STYLE="white-space:nowrap">C-Round</FONT> </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">C-Round</FONT> Investors, which contributed in 2010, shall be satisfied with the remaining proceeds after satisfying the
shareholders from the <FONT STYLE="white-space:nowrap">D-Round.</FONT> The conditions are the identical to <FONT STYLE="white-space:nowrap">D-Round.</FONT> In <FONT STYLE="white-space:nowrap">C-Round</FONT> 196,568 shares were issued, which were all
outstanding as of December&nbsp;31, 2019 and 2018. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>d.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><FONT STYLE="white-space:nowrap">B-Round</FONT> </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As far as there are still remaining proceeds after deduction of the claims mentioned above, these shall be distributed as follows: all shareholders excluding
Amgen Investments Ltd., GBG 1 Corporation, Paul Gerard Kimball, Jens Peter Stein, Kornelius Klobucar, KOR Holding S.&agrave; r.l., Peter Murray, Palmetto Partners 2017, LP, Kuwaiti Life Sciences Company (KSCC), OrbiMed Private Investments VI, LP,
Leerink Holdings LLC, Leerink Swann <FONT STYLE="white-space:nowrap">Co-Investment</FONT> Fund, LLC, MIG GmbH&nbsp;&amp; Co. Fonds 11 KG, AT Impf GmbH, MIG GmbH&nbsp;&amp; Co. Fonds 13 geschlossene
<FONT STYLE="white-space:nowrap">Investment-KG,</FONT> Wellington Partners Advisory AG, Wellington Partners Ventures IV Life Science Fund L.P., Paul Higham, Dr.&nbsp;Carsten Reinhardt, Mona Lisa Capital AG, PB Invest (Schweiz) AG,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Grazia Beteiligungen GmbH&nbsp;&amp; Co. KG and SB Verm&ouml;gensverwaltung KG shall each receive with the same rank their invested capital invested outside the Series C Financing Round
(2010)&nbsp;and the Series D Financing Round (2013/2014) and the Series E Financing Round plus an annual interest of 5.00% p.a. IRR (Internal Rate of Return). The number of total shares after <FONT STYLE="white-space:nowrap">B-Round</FONT> amounts
to 295,500, which represents an increase in shares of 175,150. All <FONT STYLE="white-space:nowrap">B-Round</FONT> shares remained outstanding as of December&nbsp;31, 2019 and 2018. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>e.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><FONT STYLE="white-space:nowrap">Pro-Rata</FONT> Participation </I></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If there are remaining proceeds after the deduction related to <FONT STYLE="white-space:nowrap">E-Round,</FONT>
<FONT STYLE="white-space:nowrap">D-Round,</FONT> <FONT STYLE="white-space:nowrap">C-Round</FONT> and <FONT STYLE="white-space:nowrap">B-Round,</FONT> the amount shall be allocated to the shareholders proportion in the share capital irrespective of
the amount of their invested capital, whereby the <FONT STYLE="white-space:nowrap">E-Shares</FONT> shall be disregarded in this distribution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Capital
management </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capital includes equity attributable to the equity holders of the parent. The aim of capital management is to ensure that the Group has
sufficient financial flexibility to achieve its growth targets and to meet legal requirements. The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions. To maintain or adjust the capital
structure, the Group may issue new shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group is not subject to any external minimum capital requirements. No changes were made in the objectives,
policies or processes for managing capital for the years ended December&nbsp;31, 2019 and 2018. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interests </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interests represent The University of Texas M.D. Anderson Cancer Center, Houston/Texas/USA&#146;s,
(&#147;MD Anderson&#148;) minority interest in Immatics US, Inc. which have been acquired pursuant to the restricted stock acquisition agreement described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Loss allocated to the <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest amounted to &#128;916&nbsp;thousand in 2019 and &#128;911&nbsp;thousand
in 2018. During 2019 and 2018, income and expenses related to Immatics US, Inc. consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,912</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,199</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,285</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating result</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(22,936</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(16,999</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial (expense)/income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(257</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(23,193</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(16,996</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes on income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(23,193</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(16,996</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attributable to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(911</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividends paid to <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest
holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B></B>3.96%<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B></B>3.96%<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interests on equity amounted to
&#128;1,020&nbsp;thousand and &#128;1,236&nbsp;thousand as of December&nbsp;31, 2019 and 2018, respectively. During 2019 and 2018, the statement of financial position for Immatics US, Inc. consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,717</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,483</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attributable to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equityholders of the parent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,503</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and shareholders&#146; (deficit) equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,566</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,717</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Net operating cash outflow of Immatics US, Inc. amounted to &#128;(18,990) thousand in 2019 (2018: &#128;(6,882) thousand).
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MD Anderson initial and subsequent milestones (&#147;RSAA&#148;) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restricted Stock Acquisition Agreement with The University of Texas M.D. Anderson Cancer Center </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics US Inc. and MD Anderson entered into a Restricted Stock Acquisition Agreement (&#147;RSAA&#148;) on August&nbsp;14, 2015. Under this agreement, MD
Anderson performs research services on behalf of Immatics US Inc. for an initial term of three years. In return, MD Anderson is entitled to receive restricted shares in Immatics US Inc, based on the achievement of specified milestones included in
the RSAA. Performance of the milestones specified in the RSAA is monitored by a joint steering committee (&#147;JSC&#148;) consisting of representatives from both Immatics US Inc. and MD Anderson. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per the terms of the agreement, MD Anderson is entitled to receive, restricted shares in Immatics US Inc., as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Initial shares: Upon signing of the agreement, MD Anderson became entitled to an upfront share payment of $2,900&nbsp;thousand in exchange for services over
the first three years of the agreement. As a result, MD Anderson received 282,620 shares in Immatics US Inc. with a par value of $0.0001. The total expense recognized for the upfront payment in 2019 and 2018 was $0 (&#128;0) and $604&nbsp;thousand
(&#128;512 thousand), respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">A-1</FONT> milestones: Under the terms of the agreement, MD Anderson was entitled to
a certain amount of restricted stock awards based on the completion of certain performance-based milestones <FONT STYLE="white-space:nowrap">(A-1</FONT> milestones) specified in the RSAA. The <FONT STYLE="white-space:nowrap">A-1</FONT> milestones
had an initial aggregate fair value of $2,000&nbsp;thousand as of the RSAA signing date, representing 201,610 shares with a par value of $0.0001. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon
signing of the agreement in August 2015, Immatics US Inc. issued one stock certificate for all shares covered by both the upfront payment and the <FONT STYLE="white-space:nowrap">A-1</FONT> milestones. Shares contingent on achievement of the <FONT
STYLE="white-space:nowrap">A-1</FONT> milestones had a claw-back right, whereby the Group was entitled to receive the shares allocated to any <FONT STYLE="white-space:nowrap">non-achieved</FONT> milestones as of the initial determination date. As of
the initial determination date, the JSC determined that milestones in the amount of $66&nbsp;thousand, representing 6,388 shares, had been satisfactorily completed. As a result, the Group exercised its claw-back right over all shares allocated to
the uncompleted milestones, representing 195,222 shares. Following the claw-back, MD Anderson holds a 3.96% voting interest in Immatics US Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">A-2</FONT> work orders: Under the agreement, MD Anderson is entitled to
additional restricted shares in Immatics US Inc, based on performance of certain work orders between August&nbsp;14, 2018 and August&nbsp;14, 2020. MD Anderson is entitled to receive a variable number of shares with a fair value of up to
&#128;3,700&nbsp;thousand on August&nbsp;14, 2020 (&#147;subsequent determination date&#148;), contingent on its performance of the <FONT STYLE="white-space:nowrap">A-2</FONT> work orders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JSC resolutions have been adopted for each of the <FONT STYLE="white-space:nowrap">A-2</FONT> work orders, which report value ascribed to each work order, to
be paid to MD Anderson in a variable number of shares in August 2020. The Group recognizes expense for the <FONT STYLE="white-space:nowrap">A-2</FONT> work orders as they are performed. The Group monitors completion of these work orders as of each
reporting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019 and 2018, the Group assessed MD Anderson&#146;s performance in relation to the <FONT
STYLE="white-space:nowrap">A-2</FONT> work orders, resulting in expense of &#128;700&nbsp;thousand and &#128;848&nbsp;thousand, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In total,
the Group recognized expenses in relation to MD Anderson&#146;s performance under the RSAA of &#128;700&nbsp;thousand (2018: &#128;1,360 thousand) related to the <FONT STYLE="white-space:nowrap">up-front</FONT> payment, <FONT
STYLE="white-space:nowrap">A-1</FONT> milestones, and <FONT STYLE="white-space:nowrap">A-2</FONT> work orders. Thereof, a corresponding increase in equity was recognized with an amount of &#128;700&nbsp;thousand and &#128;1,360&nbsp;thousand during
2019 and 2018, respectively, for the vested equity-shares under the <FONT STYLE="white-space:nowrap">A-2</FONT> milestone. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Personnel expenses </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group recognized the following personnel expenses: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Wages and salaries</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total wages and salaries</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,231</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,718</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other employee benefits</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">728</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">607</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total other employee benefits</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,763</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,527</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Share-based compensation expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total share-based compensation expense</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,016</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>338</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20,010</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,583</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other employee benefit expenses include employee retirement fund contributions, health insurance, and statutory social
expenses. Immatics US Inc. sponsors a defined contribution retirement plan for employees in the United States. During 2019, total Group contributions to the defined contribution plan amounted to &#128;128&nbsp;thousand (2018: &#128;116 thousand).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2019, other employee benefits also include employee health insurance costs amounting to &#128;307&nbsp;thousand for
Immatics US Inc., statutory social expenses amounting to &#128;1,273&nbsp;thousand for our German operations and other miscellaneous expenses amounting to &#128;74&nbsp;thousand (2018: &#128;365&nbsp;thousand, &#128;1,020&nbsp;thousand and
&#128;235&nbsp;thousand, respectively). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Taxes on income </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group generates losses in both Germany and the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2019, the Group&#146;s German operations were subject to a statutory tax rate of 29.10% (2018: 29.10%).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, the Group incurred a corporate income tax rate of 21.00% in 2019 (2018: 21.00%). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation between taxes on income reflected on the consolidated statement of loss and the expected income tax benefit, based on the Group&#146;s German
statutory tax rate, for the years ended December&nbsp;31, 2019 and 2018 is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,487</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,355</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Effects</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Difference in tax rates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,373</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Non-deductible&nbsp;
tax-expenses</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government grants exempted from taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-recognition&nbsp;of</FONT> deferred taxes on tax losses and
temporary differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,526</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Taxes on income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Intangible<BR>assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT><BR>asset</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Deferred<BR>revenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Other<BR>liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Lease<BR>liabilities</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Deferred<BR>expenses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Valuation<BR>adjustment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2018, adjusted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,183</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>475</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,658</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recognized to profit&nbsp;&amp; loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,156</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>443</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>64</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,663</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,156</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>443</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>64</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,663</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Recognized to profit&nbsp;&amp; loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(85</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">543</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,064</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>854</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>358</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>607</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>886</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4,783</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the Group has accumulated tax losses of &#128;223,528&nbsp;thousand (December 31, 2018:
&#128;204,100 thousand) that may be offset against future taxable profits of the Group. As of December&nbsp;31, 2019 &#128;25,839&nbsp;thousand of total tax losses is subject to a twenty-year carryforward period (December&nbsp;31, 2018: &#128;25,839
thousand). All other tax losses have an indefinite carryforward period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has limited taxable temporary differences and no tax planning
opportunities available that could partly support the recognition of these losses as deferred tax assets. On this basis, the Group has determined that it cannot recognize deferred tax assets on the tax losses carried forward as well as on temporary
differences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Limitation on tax loss carryforwards in the US Inc. is 80.00% starting with losses generated after January&nbsp;1, 2018. These have an
indefinite carryforward period, but no carryback option. Any losses generated prior to January&nbsp;1, 2018 still can be utilized at 100.00% and are subject to a twenty-year carry forward expiration period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets have not been recognized in respect of these losses due to the uncertainty of the Group&#146;s ability to generate taxable profits in the
foreseeable future. The current assessment regarding the usability of deferred tax assets may change depending on the income situation of future years and may result in higher or lower valuation allowances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Risk Management Objectives and Policies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group&#146;s principal financial instruments comprise cash, cash equivalents and fixed-term deposits. The main purpose of these financial instruments is to
invest the proceeds of capital contributions and upfront payments from collaboration agreements. The Group has various other financial instruments such as other receivables and trade accounts payable, which arise directly from its operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the internal guidelines, the Group does not trade in derivatives. The main risks arising from the Group&#146;s financial instruments are
interest rate risk, liquidity risk and currency exchange risk. The Board of Management reviews and agrees policies for managing these risks as summarized below. The Group also monitors the market price risk arising from all financial instruments.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interest rate risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exposure of the Group to
changes in interest rates relates to investments in deposits and to changes in the interest for overnight deposits. Changes in the general level of interest rates may lead to an increase or decrease in the fair value of these investments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regarding the liabilities shown in the statement of financial position, the Group is currently not subject to interest rate risks. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Credit risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially
subject the Group to concentrations of credit and liquidity risk consist primarily of cash and cash equivalents including short-term deposits and accounts receivable. The Group&#146;s cash and cash equivalents are denominated in Euros and US Dollars
and maintained with two high-quality financial institutions in Germany and one in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group continually monitors its positions with,
and the credit quality of, the financial institutions and corporation, which are counterparts to its financial instruments and does not anticipate <FONT STYLE="white-space:nowrap">non-performance.</FONT> The maximum default risk corresponds to the
carrying amount of the financial assets shown in the statement of financial position. The Group monitors the risk of a liquidity shortage. The main factors considered here are the maturities of financial assets as well as expected cash flows from
equity measures<B>.</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Currency risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Currency risk
shows the risk that the value of a financial instrument will fluctuate due to changes in foreign exchange rates. In particular, it poses a threat if the value of the currency in which liabilities are priced appreciates relative to the currency of
the assets. The business transactions of the Group are generally conducted in Euros and US Dollars. In the finance committee meetings, the Group analyses the currency risks. The Group aims to match U.S. dollar cash inflows with U.S.&nbsp;Dollar cash
outflows where possible. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity risk </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group
continuously monitors its risk to a shortage of funds. The Group&#146;s objective is to maintain a balance between continuity of funding and flexibility through the use of capital increases. The Group concluded that its liquidity risk is moderate.
The current investors have undertaken to provide continuing financial support so that the Group can pay its debts as and when they fall due. All financial liabilities are due within six months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Instruments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set out below are the carrying amounts and fair values of the Group&#146;s financial instruments that are carried in the consolidated financial statements.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Carrying amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Fair value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>IFRS 9</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>12/31/2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>12/31/2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>12/31/2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">At fair value through profit or loss (FVTPL)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">At fair value through profit or loss (FVTPL)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">other financial assets at amortized cost</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">current/non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">other financial assets at amortized cost</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>122,042</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,962</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>122,042</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>53,962</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">other financial liabilities at amortized cost</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,201</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">other financial liabilities at amortized cost</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,370</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,248</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,370</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,248</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying value of financial instruments such as cash and cash equivalents, deposits, accounts receivable and accounts
payable approximate their fair value based on the short-term maturities of these instruments. The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction
between willing parties, other than in a forced or liquidation sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following methods and assumptions were used to estimate the fair values: All
financial assets are categorized in Level&nbsp;1 and therefore are valued using quoted (unadjusted) market prices. Except for the Stock Appreciation Rights, which are categorized at Level&nbsp;2, all other financial liabilities are also categorized
at Level&nbsp;1. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Commitments and contingencies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes contractual obligations as of December&nbsp;31, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments due by period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;-&nbsp;3&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3&nbsp;-&nbsp;5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-license</FONT> agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract research organization agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,466</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total contractual obligations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,813</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>347</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,700</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes contractual obligations as of December&nbsp;31, 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments due by period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1&nbsp;-&nbsp;3&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3&nbsp;-&nbsp;5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-license</FONT> agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract research organization agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total contractual obligations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,681</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,741</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>861</B></TD>
<TD NOWRAP VALIGN="bottom"><B></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,283</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>24.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Related party disclosures </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group did not enter into transactions with related entities in 2019 or 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key management personnel have been defined as the members of the Management Board and of the Supervisory Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compensation of key management personnel: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">433</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total key management compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,420</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,640</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2019, the company held a receivable of &#128;65&nbsp;thousand related to key management personnel
(December 31, 2018: &#128;0). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Harald F. Stock and Peter Chambr&eacute; were members of the Supervisory Board of Immatics in 2019 and in 2018. They
received a fixed fee as Supervisory Board members and reimbursement for travel expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total compensation for the Supervisory Board amounted to
&#128;416&nbsp;thousand in 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Peter<BR>Chambr&eacute;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Harald<BR>F.&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supervisory board fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>309</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travel expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>107</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total board expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>387</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>416</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total compensation for the Supervisory Board amounted to &#128;478&nbsp;thousand in 2018: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Peter<BR>Chambr&eacute;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Harald<BR>F.&nbsp;Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supervisory board fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>410</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Travel expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>68</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total board expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>452</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>478</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>25.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Net loss per share </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is computed by dividing net loss attributable to the equityholders of parent by the weighted average number of common shares
outstanding during the period, excluding common stock equivalents. The diluted net loss per share reflects the basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period
presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Options granted to employees under the 2016 Plan are considered to be potential ordinary shares. They would have been included in the
determination of diluted earnings per share if the awards would have been exercisable due to either a change in control or an IPO. The 103,469 options outstanding under the 2016 plan are not included in the calculation of diluted earnings per share
because they are antidilutive. These options could potentially dilute basic earnings per share in the future. Details relating to the options are set out in note 16. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>26.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Events after the reporting period </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluated subsequent events for recognition or disclosure through April&nbsp;15, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;17, 2020, Immatics entered into a definitive merger agreement with Arya Sciences Acquisition Corp. (&#147;ARYA&#148;), a special purpose
acquisition company sponsored by Perceptive Advisors. Under the terms of the agreement, the transaction will be structured through Immatics B.V., a Dutch private limited liability company. The merger will be effectuated in three principal steps:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The shareholders of Immatics will exchange their interests in Immatics for ordinary shares in the share capital
of Immatics B.V., which will be accounted for as a recapitalization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ARYA will merge into a subsidiary of Immatics B.V., with Arya shareholders receiving one ordinary share in
Immatics B.V. for each issued and outstanding ordinary share of ARYA. The merger of ARYA constitutes an acquisition by Immatics B.V., which will be accounted for within the scope of IFRS 2 (&#147;Share-based Payment&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In connection with the agreement, Immatics B.V. expects to raise an additional $104&nbsp;million in equity
proceeds through a private placement of ordinary shares with existing shareholders of Immatics and ARYA. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the agreement,
awards issued under Immatics&#146; existing employee equity incentive plans will be converted into an equity incentive plan sponsored by Immatics B.V. This conversion includes an expected cash payout of up to &#128;12&nbsp;million for SAR and tandem
awards currently outstanding and scheduled to vest prior to December&nbsp;31, 2020, to occur immediately after the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total expected proceeds from
the transaction, including marketable securities held in a trust account by ARYA and the private placement, are $252&nbsp;million. The transaction is expected to close in the second quarter of 2020. Following the transaction, Immatics shareholders
will own a controlling interest in Immatics B.V. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of the transaction, Immatics B.V. will become a publicly traded corporation. The
transaction is subject to the approval of the shareholders of Immatics and ARYA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2019, a novel strain of coronavirus <FONT
STYLE="white-space:nowrap">(COVID-19)</FONT> emerged in Wuhan, China. While initially concentrated in China, the outbreak has spread to over 150 countries and every state in the United States. On January&nbsp;30, 2020, the World Health Organization
declared the outbreak a pandemic and a global emergency. In response, many countries and businesses have instituted travel restrictions, quarantines, and office closures. While the pandemic has not yet caused any significant disruptions to the
Group&#146;s operations, management continues to monitor the potential impact. Specifically, the extent of the pandemic and governmental responses may impact our ability to obtain raw materials and equipment used for research and development, obtain
sufficient additional funds to finance our operations, and conduct clinical trials, any of which could materially and adversely affect our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin96389_20"></A>Unaudited Condensed Consolidated Statement of Financial Position </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>109,737</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>124,000</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT>
assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,914</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,032</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,277</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>121,769</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>134,277</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>77,263</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>69,296</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,823</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>94,537</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>105,816</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(241,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(233,194</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other reserves</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(770</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total deficit attributable to shareholders of the parent</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(50,814</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(41,855</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(50,031</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(40,835</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and shareholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>121,769</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>134,277</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin96389_21"></A>Unaudited Condensed Consolidated Statement of Loss </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros&nbsp;in&nbsp;thousands,&nbsp;except<BR>share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaboration agreements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,990</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,275</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating result</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(11,281</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,636</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial result</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,701</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>755</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before taxes</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,881</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taxes on income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,881</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Attributable to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equityholders of the parent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,881</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss per share - basic and diluted</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7.14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4.89</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding - basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,163,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin96389_22"></A>Unaudited Condensed Consolidated Statement of Comprehensive Loss </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net Loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,881</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Items that may be reclassified subsequently to profit or loss, net of tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Currency translation differences from foreign operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,272</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,038</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Attributable to:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equityholders of the parent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,998</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,841</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-controlling</FONT> interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive loss for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,272</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,038</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin96389_23"></A>Unaudited Condensed Consolidated Statement of Cash Flows </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss before taxation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,580</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,881</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjustments for:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(319</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(144</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity settled share-based payment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MD Anderson compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities resulting from
share appreciation rights</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Changes in working capital</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease (increase) in accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Increase) decrease in other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease in accounts payable and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest received</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(28,286</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(248</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(294</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(2,387</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(333</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(611</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(446</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash used in by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(611</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(446</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net decrease in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(31,284</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,027</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents at beginning of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>103,353</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>39,367</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effects of exchange rate changes on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash and cash equivalents at end of period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>72,202</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>38,331</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin96389_24"></A>Unaudited Condensed Consolidated Statement of Changes in Shareholders&#146;
Deficit </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share<BR>capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Other<BR>reserves</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total deficit<BR>attributable<BR>to<BR>shareholders<BR>of the parent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-</FONT></B><br><B>controlling<BR>interest</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;share-<BR>holders&#146;<BR>deficit</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;1, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,164</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>190,793</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(201,623</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(741</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10,407</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,236</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,171</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(157</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,684</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,881</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Comprehensive loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,684</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(157</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(5,841</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(197</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(6,038</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity-settled tandem awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MD Anderson compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of March&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,164</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>190,831</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(207,307</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(898</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(16,210</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,128</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(15,082</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of January&nbsp;1, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,164</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>190,945</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(233,194</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(770</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(41,855</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,020</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(40,835</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,306</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(274</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,580</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Comprehensive loss for the year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,306</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(692</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,998</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(274</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(9,272</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity-settled tandem awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MD Anderson compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance as of March&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,164</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>190,984</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(241,500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(1,462</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(50,814</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>783</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(50,031</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin96389_25"></A>Notes to the Unaudited Condensed Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Group information </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics Biotechnologies GmbH, together with its U.S. subsidiary, Immatics US Inc., (&#147;Immatics&#148; or &#147;the Group&#148;) is a biotechnology group
that is primarily engaged in the research and development of <FONT STYLE="white-space:nowrap">T-cell</FONT> redirecting immunotherapies for the treatment of cancer. Immatics Biotechnologies GmbH is located at Paul-Ehrlich Str. 15 in 72076
T&uuml;bingen, Germany and was founded in September 2000 as a German limited liability company. It is registered with the commercial register at Stuttgart local court under HRB no. 382151. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These interim condensed consolidated financial statements of the Group for the three months ended March&nbsp;31, 2020 were authorized for issue by the
Management Board on May&nbsp;22, 2020. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Significant events and changes in the current reporting period </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group was affected by following events or transactions during the three months ended March&nbsp;31, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ARYA Merger </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;17, 2020, Immatics entered
into a definitive merger agreement with Arya Sciences Acquisition Corp. (&#147;ARYA&#148;), a special purpose acquisition company sponsored by Perceptive Advisors. Under the terms of the agreement, the transaction will be structured through Immatics
B.V., a Dutch private limited liability company. The merger (&#147;ARYA Merger&#148;) will be effectuated in three principal steps: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The shareholders of Immatics will exchange their interests in Immatics for ordinary shares in the share capital
of Immatics B.V., which will be accounted for as a recapitalization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ARYA will merge into a subsidiary of Immatics B.V., with Arya shareholders receiving one ordinary share in
Immatics B.V. for each issued and outstanding ordinary share of ARYA. The merger of ARYA constitutes an acquisition by Immatics B.V., which will be accounted for within the scope of IFRS 2 (&#147;Share-based Payment&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In connection with the agreement, Immatics B.V. expects to raise an additional $104&nbsp;million in equity
proceeds through a private placement of ordinary shares with existing shareholders of Immatics and ARYA. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the agreement,
awards issued under Immatics&#146; existing employee equity incentive plans will be converted into an equity incentive plan sponsored by Immatics B.V. This conversion includes a maximum cash payout of up to &#128;12&nbsp;million for SAR and tandem
awards currently outstanding and scheduled to vest prior to December&nbsp;31, 2020, to occur immediately after the merger. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total expected proceeds from
the transaction, including marketable securities held in a trust account by ARYA and the private placement, are up to $252&nbsp;million (&#128;230 million). The transaction is expected to close in the second quarter of 2020. Following the
transaction, Immatics shareholders will own a controlling interest in Immatics B.V. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon consummation of the transaction, Immatics B.V. will become a
publicly traded corporation. The transaction is subject to the approval of the shareholders of Immatics and ARYA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The&nbsp;closing&nbsp;of&nbsp;the&nbsp;Merger&nbsp;is&nbsp;subject&nbsp;to&nbsp;certain&nbsp;closing&nbsp;conditions.&nbsp;As&nbsp;of&nbsp;May 22,
2020,&nbsp;the date&nbsp;these&nbsp;interim&nbsp;consolidated&nbsp;financial&nbsp;statements&nbsp;were&nbsp;issued,&nbsp;the&nbsp;Merger&nbsp;has&nbsp;not&nbsp;closed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
December 2019, a novel strain of coronavirus <FONT STYLE="white-space:nowrap">(COVID-19)</FONT> emerged in Wuhan, China. While initially concentrated in China, the outbreak has spread to several other countries. On January&nbsp;30, 2020, the World
Health </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Organization declared the outbreak a pandemic and a global emergency. In response, many countries and businesses have instituted travel restrictions, quarantines, and office closures. The extent
of the pandemic and governmental responses may impact our ability to obtain raw materials and equipment used for research and development, obtain sufficient additional funds to finance our operations, and conduct clinical trials, any of which could
materially and adversely affect our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As the pandemic is still evolving, management continues to monitor the situation and has put significant
measures in place to protect the Group&#146;s employees, supply chain and the execution of clinical trials. To date, the pandemic has resulted in a slowdown in activities related to the Group&#146;s laboratory operations and at some of its
suppliers. The ongoing spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> may also negatively impact the Group&#146;s clinical trials, including potential delays and restrictions on the Group&#146;s ability to recruit and retain patients,
principal investigators and healthcare employees. <FONT STYLE="white-space:nowrap">COVID-19</FONT> could also affect the operations of contract research organizations (&#147;CROs&#148;), which may also result in delays or disruptions in the supply
of product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to <FONT STYLE="white-space:nowrap">COVID-19,</FONT> the Group has also experienced delays in research activities performed
under its collaboration agreements. Consequently, the Group recognized less revenue under these agreements during the first quarter of 2020 than previously planned. Management believes the declines in revenue associated with the delay in research
activities is largely temporary, as the revenue is primarily associated with <FONT STYLE="white-space:nowrap">non-refundable</FONT> upfront payments recognized on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cost-to-cost</FONT></FONT> basis. <FONT STYLE="white-space:nowrap">COVID-19</FONT> may continue to impact the timing and amount of revenue recognized under these agreements in the
future. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Significant accounting policies </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of presentation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interim condensed consolidated
financial statements of the Group as of March&nbsp;31, 2020 and 2019 and for the three months ended March&nbsp;31, 2020 and 2019 have been prepared in accordance with International Accounting Standard 34 Interim financial reporting, as issued by the
International Accounting Standards Board (&#147;IASB&#148;). The interim condensed consolidated financial statements should be read in conjunction with the annual financial statements for the year ended December&nbsp;31 2019, which have been
prepared in accordance with International Financial Reporting Standards (&#147;IFRS&#148;) as issued by the IASB, taking into account the recommendations of the International Financial Reporting Standards Interpretations Committee
(&#147;IFRIC&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interim condensed consolidated financial statements are presented in Euro. Amounts are stated in thousands of Euros, unless
otherwise indicated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with
those followed in the preparation of the Group&#146;s annual consolidated financial statements for the year ended December&nbsp;31, 2019. The new and amended standards and interpretations applied for the first time as of January&nbsp;1, 2020, as
disclosed in the notes to the consolidated financial statements for the year ended December&nbsp;31, 2019, had no impact on the interim condensed consolidated financial statements of the Group for the three months ended as of March&nbsp;31, 2020.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group has a <FONT STYLE="white-space:nowrap">non-controlling</FONT> interest, representing approximately 3.96% of the Group&#146;s Immatics US, Inc.
subsidiary as of March&nbsp;31, 2020 (2019: 3.96%). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capitalized equity financing costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as other assets until
such financings are consummated. After consummation of the equity financing, these costs are recorded in shareholders&#146; deficit as a reduction of share premium generated as a result of the financing. Should the equity financing no longer be
considered probable of being consummated, the deferred costs would be expensed immediately as a charge to operating expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Segment information </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Group&#146;s focus is on the
research and development of <FONT STYLE="white-space:nowrap">T-cell</FONT> redirecting immunotherapies for the treatment of cancer. The Chief Executive Officer is the chief operating decision maker who regularly reviews the consolidated operating
results and makes decisions about the allocation of the Group&#146;s resources. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other current assets </B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">998</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Value added tax receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>37,203</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,690</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group recognizes receivables for government grants when it is reasonably assured that the grant will be received, and all
contractual conditions have been complied with. As of March&nbsp;31, 2020, and December&nbsp;31, 2019, no receivables were considered impaired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid
expenses include &#128;676&nbsp;thousand fees paid for the successful arrangement of the BMS and Genmab collaboration agreements as of March&nbsp;31, 2020 (December 31, 2019: &#128;622 thousand). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2020, the Group capitalized &#128;511&nbsp;thousand in costs associated with the ARYA Merger, which the Group plans to deduct from the
total proceeds of merger as a reduction in Shareholder Premium. These costs are directly attributed to the ARYA Merger and primarily related to legal and accounting fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Short-term deposits have original maturity dates between three and nine months. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Revenue from collaboration agreements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group earns revenue through strategic collaboration agreements with third party pharmaceutical and biotechnology companies. As of March&nbsp;31, 2020, the
Group had four collaboration agreements in place. All collaboration agreements are still in the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> stage. During the three months ended March&nbsp;31, 2020, the Group did not enter into any new
collaboration agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group earned revenue from collaboration agreements from the following collaborators during the three months ended
March&nbsp;31, 2020 and 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amgen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Genmab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,455</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BMS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GSK</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>7,040</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,626</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2020, the Group has not recognized any royalty or milestone revenue under the collaboration agreements,
due to the scientific uncertainty of achieving the milestones or the successful commercialization of a product. As of March&nbsp;31, 2020, Immatics had not received any milestone or royalty payments in connection with the collaboration agreements.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred revenue related to the collaboration agreements consists of the following as of March&nbsp;31, 2020
and December&nbsp;31, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-current</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>154,649</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>161,374</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Income Tax </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended March&nbsp;31, 2020 the Group generated losses in both Germany and the United States. During the three months ended
March&nbsp;31, 2020, the Group&#146;s German operations were subject to a statutory tax rate of 29.1% (2019: 29.1%). In the United States, the Group incurred a corporate income tax rate of 21% during the three months ended March&nbsp;31, 2020 (2019:
21%). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2020 and 2019, no deferred tax assets have been recognized in respect of these losses due to the uncertainty of the
Group&#146;s ability to generate taxable profits in the foreseeable future. The current assessment regarding the usability of deferred tax assets may change depending on the income situation of future years and may result in higher or lower
valuation allowances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, due to the planned transaction described in Note 2, limitations on tax loss carryforwards for net operating losses
incurred by the Group&#146;s subsidiary Immatics US Inc. might occur after the closing of the transaction in accordance with Section 382 of the United States Tax Code. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Property, plant and equipment and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Right-of-use</FONT></FONT> assets </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended
March&nbsp;31, 2020, the Group acquired property, plant and equipment in the amount of &#128;1,682&nbsp;thousand (March 31, 2019: &#128;219 thousand). The acquisitions during the three months ended March&nbsp;31, 2020 were mainly related to
laboratory equipment in the amount of &#128;922&nbsp;thousand and office equipment in the amount of &#128;594&nbsp;thousand (March 31, 2019: &#128;108&nbsp;thousand and &#128;15&nbsp;thousand, respectively). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended March&nbsp;31, 2020, new leases and extensions to existing lease agreements resulted in an increase in <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets in the amount of &#128;1,197&nbsp;thousand, mainly due to the commencement of a lease agreement of a new office building in T&uuml;bingen. The Group used
its incremental borrowing rate (&#147;IBR&#148;) to calculate the initial lease liability. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Provisions </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions consisted of the following as of March&nbsp;31, 2020 and December&nbsp;31, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Provision for bonuses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other provisions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>715</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These amounts include provisions for the Group&#146;s annual employee bonuses, which are due to be paid each December. These
amounts are classified as a provision as of March&nbsp;31, 2020, because the amount to be paid is uncertain. As of December&nbsp;31, 2019, the Group had a liability for annual employee bonuses of &#128;52&nbsp;thousand (classified as other current
liabilities) related to amounts paid in January 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Share-based payments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group issues share-based awards to its employees under two different plans. Under the 2010 Plan, the Group issues stock appreciation rights
(&#147;SARs&#148;), which are treated as cash-settled. The Group applies liability accounting to SAR awards under the 2010 Plan and revalues the outstanding awards at each reporting date. The Group applied a Black Scholes pricing model to estimate
the fair value of the 2010 Plan awards as of March&nbsp;31, 2020 and December&nbsp;31, 2019 based on a company valuation of $350,000&nbsp;thousand. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercise price in USD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underlying share price in USD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Time period (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.59</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Combined probability of exit events</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80.00</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There were no awards issued under the 2010 Plan in 2020 or 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2020, and December&nbsp;31, 2019 Immatics had other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities of
&#128;2,772&nbsp;thousand and &#128;2,084&nbsp;thousand, respectively, resulting from these awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended March&nbsp;31, 2020,
the Group granted 6,000 tandem awards in accordance with the 2016 Plan. These tandem awards have not yet commenced vesting, as the service commencement date has not yet been reached. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group recognized total share-based compensation expense during the three months ended March&nbsp;31, 2020 and 2019 as set out below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Euros in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total share-based compensation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>728</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>206</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Related party disclosures </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended March&nbsp;31, 2020 the Group did not enter into related-party transactions with its key management personnel and with related
entities. There were no significant changes in the compensation arrangements for key management personnel or members of the Management Board and of the Supervisory Board during the three months ended March&nbsp;31, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Instruments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set out below are the carrying amounts and fair values of the Group&#146;s financial instruments that are carried in the interim condensed consolidated
financial statements. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>Euros in thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>IFRS 9</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3/31/2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>12/31/2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3/31/2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>12/31/2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">At fair value through profit or loss (FVTPL)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">At fair value through profit or loss (FVTPL)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">other financial assets at amortized cost</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">current/non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">other financial assets at amortized cost</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>107,186</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>122,042</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>107,186</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>122,042</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">other financial liabilities at amortized cost</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">other financial liabilities at amortized cost</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,818</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,370</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,818</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,370</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying value of financial instruments such as cash and cash equivalents, deposits, accounts receivable and accounts
payable approximate their fair value based on the short-term maturities of these instruments. The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction
between willing parties, other than in a forced or liquidation sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following methods and assumptions were used to estimate the fair values: All
financial assets are categorized in Level&nbsp;1 and therefore are valued using quoted (unadjusted) market prices. Except for the Stock Appreciation Rights, which are categorized at Level&nbsp;2, all other financial liabilities are also categorized
at Level&nbsp;1. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Events occurring after the reporting period </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Group evaluated subsequent events for recognition or disclosure through May&nbsp;22, 2020. Based on its review, the Group determined that there have been
no events that have occurred subsequent to the reporting period that would require adjustments to the disclosures in the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Immatics N.V. </B></P>
<P STYLE="font-size:100pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g96389g04i20.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:100pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:250pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Information Not Required in Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Directors and Officers. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under Dutch law, directors of a Dutch public company may be held jointly and severally liable to the company for damages in the event of improper performance
of their duties. In addition, directors may be held liable to third parties for any actions that may give rise to a tort. This applies equally to our managing directors, supervisory directors, <FONT STYLE="white-space:nowrap">non-executive</FONT>
directors and executive directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our articles of association and unless Dutch law provides otherwise, the following will be reimbursed to
actual and former managing directors, supervisory directors, <FONT STYLE="white-space:nowrap">non-executive</FONT> directors and executive directors and other members of the Executive Committee: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the costs of conducting a defense against claims, also including claims by the company and its group companies,
as a consequence of any acts or omissions in the fulfillment of their duties or any other duties currently or previously performed by them at our request; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any damages or financial penalties payable by them as a result of any such acts or omissions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any amounts payable by them under settlement agreements entered into by them in connection with any such acts
or omissions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the costs of appearing in other legal proceedings in which they are involved in such capacity, with the
exception of proceedings primarily aimed at pursuing a claim on their own behalf; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any taxes payable by them as a result of any reimbursements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No indemnification shall be given to an indemnified officer or director under our articles of association unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has been adjudicated by a Dutch court or, in the case of arbitration, an arbitrator, in a final and
conclusive decision that the act or omission may be characterized as intentional, deliberately reckless or grossly negligent conduct, unless Dutch law provides otherwise or this would, in view of the circumstances of the case, be unacceptable
according to standards of reasonableness and fairness; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the costs or financial loss are covered by an insurance and the insurer has paid out the costs or financial
loss. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into indemnification agreement with each of our directors and executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the
foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is theretofore unenforceable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recent Sales of Unregistered Securities. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding all securities sold or granted by us within the past three years that were not registered under the Securities Act and
the consideration, if any, received by us for such securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In connection with the closing of the Business Combination, on July&nbsp;1, 2020, we issued (i) 52,493,617
ordinary shares to former securityholders of Immatics OpCo and ARYA in exchange for their securities in Immatics OpCo and ARYA, as applicable, and (ii) 7,187,500 public warrants to former warrant holders of ARYA in exchange for outstanding public
warrants of ARYA (other than public warrants held by the ARYA Sponsor, which were forfeited). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In connection with the closing of the PIPE Financing, on July&nbsp;1, 2020, we issued 10,415,000 ordinary shares
to the PIPE investors for gross proceeds of approximately $104.2&nbsp;million, $25.0&nbsp;million of which was funded by an affiliate of the ARYA Sponsor. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing securities issuances were made in reliance upon the exemption provided in Section&nbsp;4(a)(2) of the Securities Act and/or Regulation D or
Regulation S promulgated thereunder. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits and Financial Statement Schedules. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The following exhibits are included or incorporated by reference in this registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;F-1:</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842df4.htm#anxa">Business Combination Agreement, dated as of March&nbsp;
17, 2020, by and among ARYA Sciences Acquisition Corp., Immatics Biotechnologies GmbH, Immatics B.V., Immatics Merger Sub 1 and Immatics Merger Sub 2 (incorporated by reference to Exhibit 2.1 to the Registration Statement on <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;F-4&nbsp;(Reg.&nbsp;No.&nbsp;333-237702),&nbsp;filed</FONT></FONT> with the SEC on April&nbsp;16, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520163109/d865842dex22.htm">Amendment No.&nbsp;
1 to Business Combination Agreement, dated as of June 7, 2020, by and among ARYA Sciences Acquisition Corp., Immatics Biotechnologies GmbH, Immatics B.V., Immatics Merger Sub 1 and Immatics Merger Sub 2 (incorporated by reference to Exhibit 2.2 to Amendment
 No.&nbsp;3 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">F-4</FONT> (Reg. <FONT STYLE="white-space:nowrap">No.&nbsp;333-237702),</FONT> filed with the SEC on June&nbsp;8, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520163109/d865842dex23.htm">Plan of First Merger (incorporated by reference to Exhibit 2.3 to Amendment No.&nbsp;3 to the Registration Statement on Form <FONT
STYLE="white-space:nowrap">F-4</FONT> (Reg. <FONT STYLE="white-space:nowrap">No.&nbsp;333-237702),</FONT> filed with the SEC on June&nbsp;8, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;2.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520163109/d865842dex24.htm">Plan of Second Merger (incorporated by reference to Exhibit 2.4 to Amendment No.&nbsp;3 to the Registration Statement on Form <FONT
STYLE="white-space:nowrap">F-4</FONT> (Reg. <FONT STYLE="white-space:nowrap">No.&nbsp;333-237702),</FONT> filed with the SEC on June&nbsp;8, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d96389dex31.htm">Deed of Conversion of Immatics B.V. and Articles of Association of Immatics N.V. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001809196/000119312520162185/d865842dex41.htm">Amended and Restated Warrant Agreement, between Continental Stock Transfer &amp; Trust Company, Immatics B.V. and ARYA Sciences Acquisition
 Corp. (incorporated by reference to Exhibit 4.1 to Amendment No.&nbsp;2 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">F-4</FONT> (Reg. <FONT STYLE="white-space:nowrap">No.&nbsp;333-237702),</FONT> filed with the SEC on
June&nbsp;5, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d96389dex51.htm">Opinion of CMS Derks Star Busmann N.V. regarding the validity of ordinary shares </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d96389dex101.htm">Investor Rights and <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex102.htm">Form of Subscription Agreement (incorporated by reference to Exhibit 10.2 to the Registration Statement on Form <FONT
STYLE="white-space:nowrap">F-4</FONT> (Reg. <FONT STYLE="white-space:nowrap">No.&nbsp;333-237702),</FONT> filed with the SEC on April&nbsp;16, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520150257/d865842df4a.htm#anxf">Form of Sponsor Letter Agreement (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form <FONT
STYLE="white-space:nowrap">F-4</FONT> (Reg. <FONT STYLE="white-space:nowrap">No.&nbsp;333-237702),</FONT> filed with the SEC on April&nbsp;16, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001809196/000119312520162185/d865842dex104.htm">Form of Indemnification Agreement (Executive Officers and Directors) (incorporated by reference to Exhibit 10.4 to Amendment No.&nbsp;
2 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">F-4</FONT> (Reg. <FONT STYLE="white-space:nowrap">No.&nbsp;333-237702),</FONT> filed with the SEC on June&nbsp;5, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex105.htm">Collaboration&nbsp;&amp; License Agreement, dated as of August&nbsp;14, 2015, by and between Immatics US,&nbsp;
Inc. and The University of Texas M.D. Anderson Center (incorporated by reference to Exhibit 10.5 to the Registration Statement on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;F-4&nbsp;(Reg.&nbsp;No.&nbsp;
333-237702),&nbsp;filed</FONT></FONT> with the SEC on April&nbsp;16, 2020) </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">10.6&#134;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex106.htm">License Royalty Adjustment Agreement, dated as of January&nbsp;5,
 2016, by and between Immatics US, Inc. and The Board of Regents of The University of Texas System on behalf of the University of Texas M.D. Anderson Cancer Center (incorporated by reference to Exhibit 10.6 to the Registration Statement on <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;F-4&nbsp;(Reg.&nbsp;No.&nbsp;333-237702),&nbsp;filed</FONT></FONT> with the SEC on April&nbsp;16, 2020) </A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex107.htm">Master Clinical Trial Agreement, dated as of December&nbsp;
1, 2016, by and between Immatics US, Inc. and The University of Texas MD Anderson Center (incorporated by reference to Exhibit 10.7 to the Registration Statement on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;F-4&nbsp;
(Reg.&nbsp;No.&nbsp;333-237702),&nbsp;filed</FONT></FONT> with the SEC on April&nbsp;16, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex108.htm">Restricted Stock Acquisition Agreement, dated as of August&nbsp;
14, 2015, by and between Immatics US, Inc. and The University of Texas M.D. Anderson Cancer Center (incorporated by reference to Exhibit&nbsp;
10.8 to the Registration Statement on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;F-4&nbsp;(Reg.&nbsp;No.&nbsp;333-237702),&nbsp;filed</FONT></FONT> with the SEC on April&nbsp;16, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex109.htm"><FONT STYLE="white-space:nowrap">Non-Exclusive&nbsp;License</FONT> Agreement, dated as of August&nbsp;
3, 2015, by and between Immatics Biotechnologies GmbH and Stichting Sanquin Bloedvoorziening (incorporated by reference to Exhibit 10.9 to the Registration Statement on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;
F-4&nbsp;(Reg.&nbsp;No.&nbsp;333-237702),&nbsp;filed</FONT></FONT> with the SEC on April&nbsp;16, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex1010.htm">Facilities/Equipment Use and Services Agreement, dated as of September&nbsp;
1, 2015, by and between Immatics US, Inc. and The University of Texas Health Science Center at Houston (incorporated by reference to Exhibit 10.10 to the Registration Statement on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;F-4&nbsp;(Reg.&nbsp;No.&nbsp;333-237702),&nbsp;filed
</FONT></FONT> with the SEC on April&nbsp;16, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex1011.htm">Amendment Number 1 &#151; Facilities/Equipment Use and Services Agreement, dated as of February&nbsp;
1, 2016, by and between Immatics US, Inc. and The University of Texas Health Science Center at Houston (incorporated by reference to Exhibit 10.11 to the Registration Statement on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;F-4&nbsp;(Reg.&nbsp;No.&nbsp;333-237702),&nbsp;filed
</FONT></FONT> with the SEC on April&nbsp;16, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex1012.htm">Amendment Number 2 &#151; Facilities/Equipment Use and Services Agreement, dated as of August&nbsp;
10, 2016, by and between Immatics US, Inc. and The University of Texas Health Science Center at Houston (incorporated by reference to Exhibit 10.12 to the Registration Statement on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;F-4&nbsp;(Reg.&nbsp;No.&nbsp;333-237702),&nbsp;filed
</FONT></FONT> with the SEC on April&nbsp;16, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex1013.htm">Amendment Number 3 &#151; Facilities/Equipment Use and Services Agreement, dated as of October&nbsp;
1, 2016, by and between Immatics US, Inc. and The University of Texas Health Science Center at Houston (incorporated by reference to Exhibit 10.13 to the Registration Statement on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;F-4&nbsp;(Reg.&nbsp;No.&nbsp;333-237702),&nbsp;filed
</FONT></FONT> with the SEC on April&nbsp;16, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex1014.htm">Amendment Number 4 &#151; Facilities/Equipment Use and Services Agreement, dated as of April&nbsp;
1, 2017, by and between Immatics US, Inc. and The University of Texas Health Science Center at Houston (incorporated by reference to Exhibit 10.14 to the Registration Statement on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;F-4&nbsp;(Reg.&nbsp;No.&nbsp;333-237702),&nbsp;filed
</FONT></FONT> with the SEC on April&nbsp;16, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520108419/d865842dex1015.htm">Amendment Number 5 &#151; Facilities/Equipment Use and Services Agreement, dated as of July&nbsp;
1, 2018, by and between Immatics US, Inc. and The University of Texas Health Science Center at Houston (incorporated by reference to Exhibit 10.15 to the Registration Statement on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Form&nbsp;F-4&nbsp;(Reg.&nbsp;No.&nbsp;333-237702),&nbsp;filed
</FONT></FONT> with the SEC on April&nbsp;16, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16**</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1809196/000119312520163109/d865842dex1016.htm">2020 Stock Option Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.16 to Amendment No.&nbsp;3
 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">F-4</FONT> (Reg. <FONT STYLE="white-space:nowrap">No.&nbsp;333-237702),</FONT> filed with the SEC on June&nbsp;8, 2020) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/0001809196/000119312520162185/d865842dex211.htm">List of subsidiaries of Immatics N.V. (incorporated by reference to Exhibit 21.1 to Amendment No.&nbsp;
2 to the Registration Statement on Form <FONT STYLE="white-space:nowrap">F-4</FONT> (Reg. <FONT STYLE="white-space:nowrap">No.&nbsp;333-237702),</FONT> filed with the SEC on June&nbsp;5, 2020)
</A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="91%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">23.1*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d96389dex51.htm">Consent of CMS Derks Star Busmann N.V. (included in Exhibit 5.1 to this Registration Statement)</A></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d96389dex232.htm">Consent of PricewaterhouseCoopers GmbH Wirtschaftspr&uuml;fungsgesellschaft, independent registered accounting firm for Immatics Biotechnologies GmbH </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d96389dex233.htm">Consent of WithumSmith+Brown, PC, independent registered accounting firm of ARYA Sciences Acquisition Corp. </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of attorney (included on the signature page to this Registration Statement) </A></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Filed herewith. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indicates a management contract or any compensatory plan, contract or arrangement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Certain information has been excluded from the exhibit because such information (i)&nbsp;is not material and
(ii)&nbsp;would likely cause competitive harm to the registrant if publicly disclosed. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Financial Statement Schedules. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All schedules have been omitted because they are not required, are not applicable or the information is otherwise set forth in the financial statements or
notes thereto. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Undertakings. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned registrant hereby undertakes: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to file, during any period in which offers or sales are being made, a post-effective amendment to this
registration statement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to reflect in the prospectus any facts or events arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in
volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20&nbsp;percent change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration Fee&#148; table
in the effective registration statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to include any material information with respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the registration statement provided, however, that: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Paragraphs (i), (ii) and (iii)&nbsp;do not apply if the information required to be included in a post-effective amendment by those paragraphs
is contained in reports filed with or furnished to the SEC by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Securities and Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), that are incorporated by reference
in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That for the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To file a post-effective amendment to the registration statement to include any financial statements required
by &#147;Item 8.A. of Form <FONT STYLE="white-space:nowrap">20-F&#148;</FONT> at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section&nbsp;10(a)(3) of the
Securities Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all
other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, a post-effective amendment need not be filed to include financial statements and information required by
Section&nbsp;10(a)(3) of the Securities Act or Item 8.A. of Form <FONT STYLE="white-space:nowrap">20-F</FONT> if such financial statements and information are contained in periodic reports filed with or furnished to the SEC by the registrant
pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act that are incorporated by reference in this registration statement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability under the Securities Act to any purchaser:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the registrant is relying on Rule 430B: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration
statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information required by section 10(a) of the Securities Act shall be deemed to be part of and included
in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for
liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus
relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or
made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date,
supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a
registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the
date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the
registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or
prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act
and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the
securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against
public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned registrant hereby undertakes: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That for purposes of determining any liability under the Securities Act, the information omitted from the form
of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part
of this registration statement as of the time it was declared effective. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of determining any liability under the Securities Act, each post-effective amendment that
contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form <FONT STYLE="white-space:nowrap">F-1</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of T&uuml;bingen, Germany, on the 31st day of July,
2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Immatics N.V.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Harpreet Singh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Harpreet Singh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Managing Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>Power of Attorney </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Harpreet Singh, Thomas Ulmer and Edward
A. Sturchio, and each of them singly, as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, each with full power of substitution and
<FONT STYLE="white-space:nowrap">re-substitution,</FONT> for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and any
subsequent registration statement filed by the registrant pursuant to Rule 462(b) of the Securities Act, and to file or cause to be filed the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto
said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in
connection therewith and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, or any of them, or their or his or her substitutes or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates
indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Signature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Capacity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Date</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Harpreet Singh</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Harpreet Singh</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Executive Officer and Managing Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Principal Executive Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;31, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas Ulmer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Thomas Ulmer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Principal Financial and Accounting Officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;31, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael G. Atieh</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Michael G. Atieh</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Supervisory Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;31, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Paul R. Carter</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Paul R. Carter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Supervisory Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;31, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Chambr&eacute;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Peter Chambr&eacute;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Supervisory Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;31, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christof Hettich</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Christof Hettich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Supervisory Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;31, 2020</TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Signature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Capacity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Date</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Heather L. Mason</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Heather L. Mason</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Supervisory Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">July&nbsp;31, 2020</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Adam Stone</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Adam Stone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Supervisory Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;31, 2020</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AUTHORIZED REPRESENTATIVE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirement of the Securities Act, the undersigned, the duly undersigned representative in the United States of Immatics N.V., has signed this
registration statement in the city of Houston, United States, on the 31st day of July, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Immatics N.V.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Edward A. Sturchio</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Edward A. Sturchio</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Representative in the United States</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d96389dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is an unofficial English translation of a document prepared in Dutch. In preparing this document, an attempt has been made to translate as
literally as possible without jeopardising the overall continuity of the text, except that, for convenience, the definitions set out in article 1.1 of the articles of association contained in this document have been placed in the English
alphabetical order. Inevitably, however, differences may occur in translation and if they do, the Dutch text will govern by law. In this translation, Dutch legal concepts are expressed in English terms and not in their original Dutch terms. The
concepts concerned may not be identical to concepts described by the English terms as such terms may be understood under the laws of other jurisdictions. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEED OF CONVERSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMATICS B.V. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(new name:
Immatics N.V.) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the first day of July two thousand and twenty appears before me, Martijn Michiel, civil law notary in Amsterdam, the Netherlands: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Elainne Maria Lassooij, candidate civil law notary, born in Nieuwerkerk aan den Ijssel, the Netherlands, on the fourth day of January nineteen hundred and
ninety-four, having her office address at Parnassusweg 737, 1077 DG Amsterdam, the Netherlands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The person appearing declares: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On the thirtieth day of June two thousand and twenty the general meeting of <B>Immatics B.V.</B>, a private
company with limited liability under Dutch law, having its seat in Amsterdam, the Netherlands, and its address at Paul-Ehrlich-Strasse 15, 72076 T&uuml;bingen, Germany, registered with the Dutch trade register under number 77595726 (the
&#147;<B>Company</B>&#148;), resolved to convert the Company into a public company, to amend the articles of association of the Company and to authorise the person appearing to execute the deed of conversion. The resolutions to convert the Company,
amend the articles of association and authorise the person appearing are evidenced by a document, which is attached to this deed (<U>annex</U>). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company was incorporated by deed, executed on the tenth day of March two thousand and twenty before M.M.
van der Bie, civil law notary in Amsterdam, the Netherlands. The articles of association of the Company have never been amended. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
order to implement the aforementioned resolutions to convert the Company and to amend the articles of association, the person appearing declares that the Company is hereby converted into a public company and that the articles of association of the
Company are hereby amended such that these shall read in full as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLES OF ASSOCIATION </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Definitions and interpretation </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In these Articles of Association the following terms shall have the following meanings: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Annual Accounts</B>&#148; means the annual accounts referred to in section 2:361 of the Dutch Civil Code; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Articles of Association</B>&#148; means these articles of association; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Associate</B>&#148; means, with respect to any person: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any trust or other estate in which such person has a substantial beneficial interest or as to which such person
serves as trustee or in a similar fiduciary capacity, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any relative or spouse of such person, or any relative of such spouse, who has the same home as such person or
who is an Executive Officer or a Supervisory Director; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Auditor</B>&#148; means an auditor as referred to in
section 2:393 subsection 1 of the Dutch Civil Code, or an organisation within which such auditors cooperate; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Chief Executive
Officer</B>&#148; means the Managing Director having, or having been granted, the title of Chief Executive Officer pursuant to these Articles of Association; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company</B>&#148; means the public company under Dutch law which is governed by these Articles of Association; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Convertible Reserve</B>&#148; means a reserve referred to in sections 2:389 or 2:390 of the Dutch Civil Code; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Distributable Reserve</B>&#148; means a distributable reserve other than a share premium reserve maintained by the Company for the
benefit of the holders of a series of Financing Preferred Shares pursuant to these Articles of Association; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Executive
Committee</B>&#148; means the executive committee of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Executive Officer</B>&#148; means a member of the Executive
Committee, including each Managing Director and each other member of the Executive Committee, unless the context otherwise requires; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Financing Preferred Share</B>&#148; means a financing preferred share in the share capital of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>General Meeting</B>&#148; means the body of the Company consisting of the Persons with Meeting Rights, or a meeting of Persons with
Meeting Rights, in each case, as the context may require; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Group</B>&#148; means a group as referred to in section 2:24b of the
Dutch Civil Code; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Group Company</B>&#148; means a legal person or company affiliated with the Company in a group as referred to
in section 2:24b of the Dutch Civil Code; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnitee</B>&#148; means any current or former Executive Officer or Supervisory
Director; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Management Board</B>&#148; means the management board of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Management Report</B>&#148; means the management report referred to in section 2:391 of the Dutch Civil Code; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Managing Director</B>&#148; means a managing director of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Ordinary Share</B>&#148; means an ordinary share in the share capital of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Participating Interest</B>&#148; means a participating interest as referred to in section 2:24c of the Dutch Civil Code; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person with Meeting Rights</B>&#148; means a Shareholder and a Usufructuary and Pledgee who are entitled to the voting rights; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Pledgee</B>&#148; means a holder of a right of pledge on one or more Shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Share</B>&#148; means a share in the share capital of the Company, including each Ordinary Share and each Financing Preferred Share,
unless the context otherwise requires; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Shareholder</B>&#148; means a holder of one or more Shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Shareholder Affiliate</B>&#148; means, with respect to any Shareholder: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any person controlling, directly or indirectly, or acting in concert with, such Shareholder;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any beneficial owner of Shares owned of record or beneficially by such Shareholder, or </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">any person directly or indirectly controlling, controlled by or under common control with such Shareholder; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subsidiary</B>&#148; means a subsidiary as referred to in section 2:24a of the Dutch Civil Code; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Supervisory Board</B>&#148; means the supervisory board of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Supervisory Director</B>&#148; means a supervisory director of the Company, including each Supervisory Director&nbsp;I, each
Supervisory Director&nbsp;II and each Supervisory Director&nbsp;III, unless the context otherwise requires; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Supervisory
Director</B><B></B><B>&nbsp;I</B>&#148; means a Supervisory Director designated by the Supervisory Board as supervisory director&nbsp;I pursuant to these Articles of Association; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Supervisory Director</B><B></B><B>&nbsp;II</B>&#148; means a Supervisory Director designated by the Supervisory Board as supervisory
director&nbsp;II pursuant to these Articles of Association; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Supervisory Director</B><B></B><B>&nbsp;III</B>&#148; means a
Supervisory Director designated by the Supervisory Board as supervisory director&nbsp;II pursuant to these Articles of Association; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transition Date</B>&#148; means first day of July two thousand and <FONT STYLE="white-space:nowrap">twenty-one;</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Usufructuary</B>&#148; means a holder of a right of usufruct on one or more Shares. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In these Articles of Association references to Articles are to articles of these Articles of Association,
unless otherwise specified. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Name and seat</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The name of the Company is: Immatics N.V. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has its seat in Amsterdam, the Netherlands. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Objects </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The objects of the Company are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to research, develop, manufacture and commercialise products for the detection, prevention and treatment of
human diseases and conditions and to render advice and services in connection therewith; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to participate in, to take an interest in any other way in, to conduct the management of and to finance other
businesses, of whatever nature; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to provide security, to give guarantees and to bind itself in any other way for its own debts and obligations
and for those of other persons; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to borrow, to lend and to raise funds, including the issue of bonds, debt instruments and other securities, as
well as to enter into agreements in connection therewith; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to acquire, manage, exploit and dispose of immovable property and other registered property;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to trade in currencies and securities, as well as in items of property in general; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to develop, exploit and trade in patents, trademarks, licenses,
<FONT STYLE="white-space:nowrap">know-how,</FONT> copyrights, database rights and other intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to perform all activities of an industrial, financial or commercial nature, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">as well as all activities which are incidental to or which may be conducive to any of the foregoing in the broadest sense. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Share capital and Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The authorised share capital of the Company amounts to three million euros (EUR 3,000,000) and is divided into:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">two hundred and eighty-five million (285,000,000) Ordinary Shares with a nominal value of one eurocent (EUR
0.01) each; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fifteen million (15,000,000) Financing Preferred Shares with a nominal value of one eurocent (EUR 0.01) each,
which are convertible into Ordinary Shares on the terms and subject to the conditions determined in accordance with Article 5.2, divided into: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a series A consisting of three million (3,000,000) Financing Preferred Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a series B consisting of three million (3,000,000) Financing Preferred Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a series C consisting of three million (3,000,000) Financing Preferred Shares; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a series D consisting of three million (3,000,000) Financing Preferred Shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a series E consisting of three million (3,000,000) Financing Preferred Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each series of Financing Preferred Shares shall constitute a separate class. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Shares shall be in registered form and shall be numbered in such a manner that they can be distinguished
from each other at any time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Shares shall be uncertificated and shall be registered in the register of shareholders, provided that the
Board may determine that certain or all of the Shares shall be represented by share certificates. Share certificates shall be issued in such form, and shall be signed by a Managing Director or such other persons, as the Board may determine, and
shall be numbered in such manner as the Board may determine to be necessary to distinguish the share certificates from each other. The Board may, in its sole discretion, establish further rules with respect to the issue of share certificates.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Conversion of Financing Preferred Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Financing Preferred Shares may, at the request of the holder, be converted into Ordinary Shares pursuant to a
resolution of the Management Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The conditions for conversion and the further terms and conditions related to the Financing Preferred Shares
shall be determined by the Management Board, subject to the prior approval of the Supervisory Board, the General Meeting and the meeting of holders of the series of Financing Preferred Shares concerned, if Financing Preferred Shares of such series
have been issued and are held by persons other than the Company and provided that in no event may any Financing Preferred Share be converted into more than ten Ordinary Shares. The preceding sentence shall apply by analogy to any amendments of or
supplementations to the terms and conditions related to the Financing Preferred Shares determined in accordance with that sentence. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board shall implement the conversion of any Financing Preferred Shares in accordance with the
applicable conditions for such conversion, as determined in accordance with Article 5.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any obligation to pay up Ordinary Shares arising from a conversion of Financing Preferred Shares into Ordinary
Shares shall be charged to the share premium reserve maintained by the Company for the benefit of the holders of the series of Financing Preferred Shares that are converted; if this reserve is insufficient, the difference shall be charged to the
Distributable Reserves or the Convertible Reserves determined by the Management Board; if these reserves are insufficient, the difference shall be satisfied by the holder of the Ordinary Shares by payment in cash. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Financing Preferred Shares of a particular series are converted into Ordinary Shares, the <FONT
STYLE="white-space:nowrap">pro-rata</FONT> entitlement to the balance of the share premium reserve maintained by the Company for the benefit of the holders of such Financing Preferred Shares, minus the amount charged to such share premium reserve by
way of application of Article 5.4 shall be added to the Distributable Reserves determined by the Management Board. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Issue of Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares may be issued pursuant to a resolution of the General Meeting or of the Management Board, if the
Management Board has been authorised by a resolution of the General Meeting to issue Shares for a specified period not exceeding five years. The resolution of the General Meeting granting the authorisation shall specify the number of Shares that may
be issued by the Management Board. The authorisation may from time to time be extended, in each case, for a period not exceeding five years. Unless otherwise specified in the resolution of the General Meeting granting the authorisation, the
authorisation may not be revoked. For as long as and to the extent that the Management Board is authorised to issue Shares, the General Meeting shall not have the authority to issue Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the General Meeting is authorised to issue Shares, it may only do so on the proposal of the Management
Board, which proposal shall require the prior approval of the Supervisory Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution of the Management Board to issue Shares shall require the prior approval of the Supervisory Board.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The validity of a resolution of the General Meeting to issue Shares or to authorise the Management Board to
issue Shares shall require a prior or simultaneous approving resolution of each group of holders of Shares of a same class whose rights are prejudiced by such issue. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Articles 6.1 up to and including 6.4 shall apply by analogy to a grant of rights to subscribe for Shares, but
shall not apply to the issue of Shares to a person who exercises a previously acquired right to subscribe for Shares. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Pre-emption</FONT> rights upon issue of Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the issue of Ordinary Shares, each holder of Ordinary Shares shall have a
<FONT STYLE="white-space:nowrap">pre-emption</FONT> right in proportion to the aggregate amount of the Ordinary Shares held by such holder, subject to Article 7.2. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A holder of Ordinary Shares shall have no <FONT STYLE="white-space:nowrap">pre-emption</FONT> right in respect
of: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ordinary Shares which are issued against payment in a form of consideration other than cash;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ordinary Shares which are issued to employees of the Company or of a Group Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Financing Preferred Shares to be issued. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Holders of Financing Preferred Shares shall have no <FONT STYLE="white-space:nowrap">pre-emption</FONT> right
in respect of Shares to be issued. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-emption</FONT> rights may be limited or excluded by a resolution of the
General Meeting or of the Management Board, if the Management Board has been authorised by a resolution of the General Meeting to limit or exclude <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights for a specified period not exceeding five
years. The authorisation may from time to time be extended, in each case for a period not exceeding five years. Unless otherwise specified in the resolution of the General Meeting granting the authorisation, the authorisation may not be revoked. For
as long as and to the extent that the Management Board is authorised to limit or exclude <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights, the General Meeting shall not have the authority to limit or exclude
<FONT STYLE="white-space:nowrap">pre-emption</FONT> rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution of the General Meeting to limit or exclude <FONT STYLE="white-space:nowrap">pre-emption</FONT>
rights or to authorise the Management Board to limit or exclude <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights shall require a majority of at least two thirds of the votes cast, if less than half the issued share capital is represented
at the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the General Meeting is authorised to limit or exclude <FONT STYLE="white-space:nowrap">pre-emption</FONT>
rights, it may only do so on the proposal of the Management Board, which proposal shall require the prior approval of the Supervisory Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution of the Management Board to limit or exclude <FONT STYLE="white-space:nowrap">pre-emption</FONT>
rights shall require the prior approval of the Supervisory Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall announce an issue of Shares where <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights
apply in accordance with applicable law. Such announcement shall include the period within which such <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights may be exercised. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Articles 7.1 up to and including 7.8 shall apply by analogy to a grant of rights to subscribe for Shares, but
shall not apply to an issue of Shares to a person who exercises a previously acquired right to subscribe for Shares. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payment for Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without prejudice to section 2:80 subsection 2 of the Dutch Civil Code, upon any subscription for Shares, the
full nominal value must be paid up on such Shares and, in the event that the subscription price of such Shares is greater than the nominal value of such Shares, the difference between the nominal value and such higher amount. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution of the Management Board to call any further payments on Shares shall require the prior approval of
the Supervisory Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment must be made in cash, unless an alternative contribution has been agreed. Payment in a form of
consideration other than cash shall be made with due observance of sections 2:80b and 2:94b of the Dutch Civil Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment in a currency other than the euro may only be made with the consent of the Company and with due
observance of section 2:80a subsection 3 of the Dutch Civil Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ordinary Shares which are issued to current or former Executive Officers, Supervisory Directors, employees or
other service providers of the Company or any of its Group Companies under any equity incentive plan or other program may be paid up at the expense of the Distributable Reserves or the Convertible Reserves determined by the Management Board.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board shall be authorised to perform the legal acts referred to in section 2:94 subsection 1 of
the Dutch Civil Code without the prior approval of the General Meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acquisition of Shares by the Company </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without prejudice to Article 9.2, the Company may only acquire fully paid up Shares for consideration if and to
the extent the General Meeting has authorised the Management Board to acquire Shares. Such authorisation shall be valid for a period not exceeding eighteen months. The resolution of the General Meeting granting the authorisation shall specify the
number of Shares that may be acquired, the manner in which such Shares may be acquired and the limits within which the price must be set. The authorisation may from time to time be extended, in each case for a period not exceeding eighteen months.
Unless otherwise specified in the resolution of the General Meeting granting the authorisation, the authorisation may not be revoked. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The authorisation of the General Meeting shall not be required if the Company acquires Shares for the purpose
of transferring such Shares to employees of the Company or of a Group Company by virtue of any equity incentive plan or other program applicable to such employees, provided that such Shares are listed on any stock exchange. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution of the Management Board to acquire Shares shall require the prior approval of the Supervisory
Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any acquisition of Shares by the Company shall be effected with due observance of section 2:98 of the Dutch
Civil Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If depositary receipts for Shares have been issued, such depositary receipts for Shares shall be put on par
with Shares for the purpose of Articles 9.1 up to and including 9.4. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial assistance </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In respect of the subscription for or acquisition of Shares or depositary receipts thereof by other persons,
the Company may not provide security, give a guarantee as to the price of the Shares, give guarantees in any other manner and may not bind itself either jointly or severally in addition to or for other persons. This prohibition shall also apply to
its Subsidiaries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In respect of the subscription for or acquisition of Shares or depositary receipts thereof by other persons,
the Company and its Subsidiaries may only grant loans with due observance of section 2:98c subsections 2 up to and including 7 of the Dutch Civil Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Articles 10.1 and 10.2 shall not apply if Shares are subscribed for or acquired by or for the account of
employees of the Company or of a Group Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reduction of share capital </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may resolve to reduce the issued share capital by cancelling Shares or by reducing the
nominal value of Shares by an amendment of the Articles of Association. The resolution shall specify the Shares to which the resolution applies and shall describe how such a resolution shall be implemented. The amount of the issued share capital may
not fall below the minimum share capital as required by law in effect at the time of the resolution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may only resolve to reduce the issued share capital on the proposal of the Management
Board, which proposal shall require the prior approval of the Supervisory Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution to cancel Shares may only apply to Shares which are held by the Company itself or to Shares for
which the Company holds depositary receipts or to all Financing Preferred Shares of a particular series. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cancellation of Financing Preferred Shares which are held by another person than the Company shall be effected
against: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">repayment of the amount paid up on such Financing Preferred Shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">simultaneous distribution of an amount equal to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the balance of the share premium reserve maintained by the Company for the benefit of the holders of the series
of Financing Preferred Shares that is cancelled; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any deficit, referred to in Article 44.2; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the amount, referred to in Article 44.2 under (a), calculated up to the date on which such Financing Preferred
Shares are cancelled, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">all with due observance of Articles 45.5 and 45.6. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Repayment in implementation of a resolution to reduce the nominal value of the Shares shall be made pro rata on
all Shares or exclusively on all Shares of a same class. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The validity of a resolution of the General Meeting to reduce the issued share capital shall require a prior or
simultaneous approving resolution of each group of holders of Shares of a same class whose rights are prejudiced by such share capital reduction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution of the General Meeting to reduce the issued share capital shall require a majority of at least two
thirds of the votes cast, if less than half the issued share capital is represented at the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reduction of the issued share capital shall be effected with due observance of sections 2:99 and 2:100 of the
Dutch Civil Code. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Right of usufruct and right of pledge on Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A right of usufruct may be created on Shares. The voting rights on the Shares encumbered with a right of
usufruct shall accrue to the Shareholder. In derogation of the preceding sentence, the voting rights shall accrue to the Usufructuary if so provided at the time of the creation of the right of usufruct. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A right of pledge may be created on Shares. The voting rights on the Shares encumbered with a right of pledge
shall accrue to the Shareholder. In derogation of the preceding sentence, the voting rights shall accrue to the Pledgee if so provided at the time of the creation of the right of pledge. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Shareholder who pursuant to a right of usufruct or a right of pledge is not entitled to voting rights and
any Usufructuary or Pledgee who is entitled to voting rights shall have the rights conferred by law on holders of depositary receipts for shares issued with a company&#146;s cooperation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Usufructuary or Pledgee who is not entitled to voting rights shall not have the rights conferred by law on
holders of depositary receipts for shares issued with a company&#146;s cooperation. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Depositary receipts for Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company is not authorised to cooperate in the issue of depositary receipts for Shares. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Shareholders register </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A register shall be kept by or on behalf of the Company in which the names and addresses of all Shareholders,
Usufructuaries and Pledgees shall be recorded, stating the information that must be recorded pursuant to section 2:85 of the Dutch Civil Code and such further information as the Management Board may consider appropriate. Part of the register may be
kept outside the Netherlands to comply with applicable law or stock exchange rules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The register shall be updated regularly. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Joint holding </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If one or more Shares, or a right of usufruct or a right of pledge on one or more Shares, are jointly held by
two or more persons, the joint holders may only be represented <FONT STYLE="white-space:nowrap">vis-&agrave;</FONT> <FONT STYLE="white-space:nowrap">-vis</FONT> the Company by a person who has been designated by such joint holders in writing for
that purpose. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board may, whether or not subject to certain conditions, grant an exemption from Article 15.1.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Transfer of Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise provided in these Articles of Association or permitted by applicable law, the transfer of
Shares or of a right of usufruct on Shares, or the creation or release of a right of usufruct or a right of pledge on Shares, shall require an instrument intended for such purpose and, unless the Company is a party to the legal act, the written
acknowledgement by the Company of such transfer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The acknowledgement shall be made in the instrument or by a dated statement of acknowledgement on the
instrument or on a copy or extract thereof signed as a true copy by the transferor. Service of such instrument, true copy or extract upon the Company shall be deemed to have the same effect as an acknowledgement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A right of pledge may also be created without acknowledgement by or service upon the Company. In such case
section 3:239 of the Dutch Civil Code shall apply by analogy, whereby acknowledgement by or service upon the Company shall substitute the notice referred to in section 3:239 subsection 3 of the Dutch Civil Code. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For so long as one or more Shares are listed on the NASDAQ Stock Market or any other regulated foreign stock
exchange, the Company may, by a resolution of the Management Board for that purpose, determine that the laws of the State of New York, United States of America, shall apply to the property law aspects of the Shares included in the part of the
register of shareholders kept by the relevant transfer agent. Articles 16.1 up to and including 16.3 shall not apply to such Shares. Such resolution, as well as a resolution to revoke such designation, shall be made public in accordance with
applicable law and shall be deposited at the offices of the Company and the Dutch trade register for inspection. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution of the Management Board to designate applicable law as referred to in Article 16.4 shall require
the prior approval of the Supervisory Board. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Management Board </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board shall consist of such number of Managing Directors as the Supervisory Board may determine.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Managing Directors must be natural persons. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Appointment, suspension and dismissal of Managing Directors </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Managing Directors shall be appointed by the General Meeting on the basis of one or more binding nominations in
accordance with Article 18.2. The nomination shall specify the vacancy for which the nomination is made. Each nomination shall comprise one candidate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Binding nominations may be made by the Supervisory Board or by one or more Shareholders who individually or
jointly represent at least <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the issued share capital of the Company at the time of giving the notice referred to in Article 18.3. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A nomination made by Shareholders in accordance Article 18.2 shall only be binding if such Shareholders have
given notice thereof to the Company in writing no later than on the sixtieth day prior to the date of the General Meeting at which the appointment is to be discussed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may at all times overrule the binding nature of each nomination by a resolution adopted by
a majority of at least two thirds of the votes cast, representing more than half of the issued share capital. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is only one nomination, a resolution on the nomination will result in the candidate having been
appointed, unless the binding nature of the nomination is overruled in accordance with Article 18.4. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is more than one nomination, the candidate who obtained the highest number of votes shall be
appointed, unless the binding nature of all nominations is overruled in accordance with Article 18.4. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If none of the candidates are appointed, the Supervisory Board, or one or more Shareholders who individually or
jointly represent at least <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the issued share capital, may, in accordance with Article 18.2, make a new nomination for the next General Meeting, unless the Supervisory Board resolves to reduce the
number of Managing Directors in accordance with Article 17.1. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may at any time suspend or dismiss a Managing Director. The General Meeting may only adopt
a resolution to suspend or dismiss a Managing Director by a majority of at least two thirds of the votes cast, representing more than half of the issued share capital, or, in the case that such resolution is adopted on the proposal of the
Supervisory Board, by an absolute majority of the votes cast, representing more than half of the issued share capital. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Supervisory Board shall be authorised to suspend a Managing Director at any time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the General Meeting or the Supervisory Board has suspended a Managing Director, the General Meeting shall
within three months after the suspension has taken effect resolve either to dismiss such Managing Director or to terminate the suspension, failing which the suspension will lapse. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Remuneration of Managing Directors </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall have a policy regarding remuneration of the Management Board. The policy shall be adopted by
the General Meeting on the proposal of the Supervisory Board. The remuneration policy shall include the matters described in sections 2:383c up to and including 2:383e of the Dutch Civil Code, to the extent they apply to the Management Board.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The remuneration of Managing Directors shall be determined by the Supervisory Board with due observance of the
policy referred to in Article 19.1. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Supervisory Board shall submit proposals concerning arrangements for issuing Shares or granting rights to
subscribe for Shares in accordance with the policy referred to in Article 19.1 to the General Meeting for approval. The proposal shall include the information required pursuant to section 2:135 subsection 5 of the Dutch Civil Code.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Duties, division of duties and decision-making of the Management Board </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the limitations provided in these Articles of Association, the Management Board shall be charged
with the management of the Company. In fulfilling their duties the Managing Directors shall serve the interest of the Company and the business connected with it. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board may adopt rules with respect to the matters concerning the Management Board. A resolution
of the Management Board to adopt, amend, supplement or terminate such rules shall require the prior approval of the Supervisory Board. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board may, whether or not by rule, determine the duties with which each Managing Director will
be particularly charged. A resolution of the Management Board to determine the duties with which each Managing Director will be particularly charged shall require the prior approval of the Supervisory Board. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is more than one Managing Director, the Supervisory Board shall appoint from among the Managing
Directors a chairman. The Supervisory Board shall grant to a Managing Director the title of Chief Executive Officer. The offices of chairman and Chief Executive Officer are compatible. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board shall meet whenever a Managing Director considers appropriate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Managing Director may only be represented at a meeting by another Managing Director authorised in writing.
The requirement of written form for the authorisation shall be met if the authorisation has been recorded electronically. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Managing Director may participate in a meeting by electronic means of communication, provided that all
Managing Directors participating in the meeting can hear each other simultaneously. A Managing Director so participating shall be deemed to be present at the meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Managing Director shall have one vote. All resolutions shall be adopted by an absolute majority of the
votes cast. In the event of a tie vote, the Supervisory Board shall decide. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that one or more Managing Directors have a direct or indirect personal interest that conflicts
with the interest of the Company and the business connected with it, they shall not be authorised to participate in the discussion and the decision-making process. In the event that all Managing Directors have or the only Managing Director has a
direct or indirect personal interest that conflicts with the interest of the Company and the business connected with it, the resolution shall be adopted by the Supervisory Board. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A written statement of the chairman of the meeting of the Management Board that the Management Board has
adopted a resolution shall constitute proof of such resolution <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> third parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board may adopt resolutions without holding a meeting, provided that all Managing Directors have
consented to this manner of adopting resolutions and the votes are cast in writing or by electronic means. Articles 20.8 and 20.9 shall apply by analogy to the adoption of resolutions by the Management Board without holding a meeting.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Approval of resolutions of the Management Board </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Resolutions of the Management Board with regard to an important change in the identity or character of the
Company or the business connected with it are subject to the prior approval of the General Meeting, including in any case: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfer of the business or almost the entire business to a third party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">entry into or termination of a long-term cooperation by the Company or a Subsidiary thereof with another legal
person or partnership or as a fully liable partner in a limited or general partnership, if such cooperation or termination thereof is of <FONT STYLE="white-space:nowrap">far-reaching</FONT> significance to the Company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">acquisition or disposal by the Company or a Subsidiary thereof of a Participating Interest in the capital of a
company with a value of at least <FONT STYLE="white-space:nowrap">one-third</FONT> of the amount of the assets as shown in the balance sheet with explanatory notes or, if the Company prepares a consolidated balance sheet, as shown in the
consolidated balance sheet with explanatory notes, according to the most recently adopted Annual Accounts of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without prejudice to Article 21.1, resolutions of the Management Board on the following matters are subject to
the prior approval of the Supervisory Board: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">application for admission of securities issued by the Company to trading on the NASDAQ Stock Market or any
other regulated foreign stock exchange located in the United States of America or elsewhere, or application for withdrawal of such admission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">entry into or termination of a long-term cooperation by the Company or a Subsidiary of the Company with another
legal person or company or as a fully liable partner in a limited partnership or general partnership, if such cooperation or termination thereof is of <FONT STYLE="white-space:nowrap">far-reaching</FONT> significance to the Company or the Subsidiary
of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">acquisition of a Participating Interest by the Company or a Subsidiary of the Company in the capital of another
company with a value of at least five hundred thousand United States dollars (USD 500,000), or such higher amount as determined by the Supervisory Board and recorded in writing, as well as any <FONT STYLE="white-space:nowrap">far-reaching</FONT>
increase or decrease in the size of any such Participating Interest; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">incurring debt by the Company or a Subsidiary of the Company in an amount of at least five hundred thousand
United States dollars (USD 500,000), or such higher amount as determined by the Supervisory Board and recorded in writing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">capital investments by the Company or a Subsidiary of the Company requiring an amount equal to at least five
hundred thousand United States dollars (USD 500,000), or such higher amount as determined by the Supervisory Board and recorded in writing; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">acquisition, disposal or encumbrance of intellectual property rights and acquisition or granting of licences
and sublicenses by the Company or a Subsidiary of the Company, if the interest or value of such intellectual property rights, licences or sublicenses to the Company or the Subsidiary amounts to at least five hundred thousand United States dollars
(USD 500,000), or such higher amount as determined by the Supervisory Board and recorded in writing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">entry into of any agreement, including any amendment or modification to any existing agreement, with or
consummate, directly or indirectly, any transaction or series of related transactions with: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any affiliate of the Company other than, in the case of the Company, any of its Subsidiaries or, in the case of
any Subsidiary of the Company, the Company or another Subsidiary of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Shareholder that, along with any Shareholder Affiliates and Associates of such Shareholder, to the
Company&#146;s actual knowledge, beneficially owns at least five per cent (5.00%) of Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any person who is or was, since the beginning of the last financial year for which the General Meeting has
adopted Annual Accounts, even if such person does not presently serve in that role, an Executive Officer or Supervisory Director, or, to the Company&#146;s actual knowledge, any other person described under (i)&nbsp;or (ii) above or any nominee for
Executive Officer or Supervisory Director; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Associate, to the Company&#146;s actual knowledge, of any person described under (i)&nbsp;or (ii) above, in
each case other than any transaction involving one hundred and twenty thousand United States dollars (USD 120,000) or less in a financial year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">adoption of an equity incentive plan or other program for the benefit of Executive Officers, Supervisory
Directors, employees or other service providers of the Company or any of its Group Companies, as well as any material amendment or termination thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">termination of the employment of a considerable number of employees of the Company and any of its Subsidiaries,
determined on a consolidated basis, at the same time or within a short time span; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a <FONT STYLE="white-space:nowrap">far-reaching</FONT> change in the working conditions of a considerable
number of employees of the Company and any of its Subsidiaries, determined on a consolidated basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">entry into any sale or disposition of all or substantially all of the Company&#146;s assets determined on a
consolidated basis, whether in one or more series of transactions and irrespective of how such sale or disposition is structured, including by sale, exchange or transfer of the Company&#146;s consolidated assets or otherwise; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">entry into any acquisition, whether in one or more series of transactions and irrespective of how such
acquisition is structured, including by merger, exchange or transfer, by the Company or any of its Subsidiaries, if such transaction has a value of at least one million United States dollars (USD 1,000,000), or such higher or lower amount as
determined by the Supervisory Board and recorded in writing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">entry into any agreement other than as referred to above by the Company or a Subsidiary of the Company the
interest or value of which to the Company or the Subsidiary of the Company amounts to at least one million United States dollars (USD 1,000,000), or such higher or lower amount as determined by the Board and recorded in writing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the dissolution or liquidation or a similar transaction involving the Company or a material Subsidiary of the
Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue, sale, exchange, redemption, cancellation or purchase of Shares or shares in the share capital of any
Subsidiary of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">declaration of any distributions with respect to the Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">increasing or decreasing the monetary thresholds set out in this Article 21.2; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such other resolutions as specified in writing from time to time by the Supervisory Board.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The absence of the approval of the General Meeting of a resolution as referred to in Article 21.1 or of the
approval of the Supervisory Board of a resolution as referred to in Article 21.2 shall not affect the power of the Management Board or Managing Directors to represent the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Executive Committee </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall have an Executive Committee. The Executive Committee shall consist of all Managing Directors
and such number of other Executive Officers as the Management Board may determine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive Officers who are not Managing Directors shall be appointed by the Management Board. The Management
Board may at any time suspend or dismiss an Executive Officer who is not a Managing Director. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution of the Management Board to appoint, suspend or dismiss an Executive Officer shall require the
prior approval of the Supervisory Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dismissal of an Executive Officer who is not a Managing Director shall not cause the termination of an
employment agreement or similar agreement between the Company or a Group Company and the Executive Officer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Executive Committee shall be charged with the matters concerning the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of the Company determined by the Management Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board may adopt rules with respect to the matters concerning the Executive Committee. A
resolution of the Management Board to adopt, amend, supplement or terminate such rules shall require the prior approval of the Supervisory Board. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board may, whether or not by rule, determine the duties with which each Executive Officer will
be particularly charged. A resolution of the Management Board to determine the duties with which each Executive Officer will be particularly charged shall require the prior approval of the Supervisory Board. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board may grant a title to each Executive Officer who is not a Managing Director.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representation </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board shall have the power to represent the Company. The power to represent the Company shall,
in addition to the power of the Management Board, only be vested in two Executive Officers acting jointly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board may appoint one or more officers with general or restricted power to represent the Company
on a continuing basis. Each officer shall represent the Company with due observance of the restrictions imposed on him or her. The Management Board may grant a title to such officers. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>24.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Failing or prevention from acting of Managing Directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In the event that one or more Managing Directors are failing or are prevented from acting, the remaining Managing Directors or the only
remaining Managing Director shall temporarily be in charge of the management; in such case the Supervisory Board shall be authorised to designate one or more temporary Managing Directors. In the event that all Managing Directors or the only Managing
Director is failing or is prevented from acting, the Supervisory Board shall temporarily be in charge of the management, unless the Supervisory Board designates one or more temporary Managing Directors. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>25.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Supervisory Board </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall have a Supervisory Board. The Supervisory Board shall consist of such number of Supervisory
Directors as the Supervisory Board may determine, but not less than three. If the number of Supervisory Directors is less than three, the Supervisory Board shall fully retain its powers. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Supervisory Directors shall be divided by the Supervisory Board into Supervisory Directors I, Supervisory
Directors II and Supervisory Directors III, with each class as nearly equal in number as possible. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Supervisory Directors must be natural persons. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>26.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Appointment, retirement, suspension and dismissal of Supervisory Directors </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Supervisory Directors shall be appointed by the General Meeting on the basis of one or more binding nominations
in accordance with Article 26.2. The nomination shall specify the vacancy for which the nomination is made. Each nomination shall comprise one candidate. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Binding nominations may be made by the Supervisory Board or by one or more Shareholders who individually or
jointly represent at least <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the issued share capital of the Company at the time of giving the notice referred to in Article 26.3. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A nomination made by Shareholders in accordance Article 26.2 shall only be binding if such Shareholders have
given notice thereof to the Company in writing no later than on the sixtieth day prior to the date of the General Meeting at which the appointment is to be discussed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A nomination for the appointment of a Supervisory Director shall state which class of Supervisory Directors the
candidate is proposed to be appointed to, his or her age and profession, the number of Shares held by him or her and the positions he or she holds or held insofar as relevant to the fulfilment of the duties as a Supervisory Director. Furthermore,
mention shall be made of the legal persons for which he or she serves as a supervisory director whereby, provided that if legal persons are included which belong to the same Group, it shall be sufficient to mention such Group. The nomination for
appointment or reappointment shall include the reasons. In case of reappointment, account shall be taken of the manner in which the candidate has fulfilled his or her duties as a Supervisory Director. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may at all times overrule the binding nature of each nomination by a resolution adopted by
a majority of at least two thirds of the votes cast, representing more than half of the issued share capital. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is only one nomination, a resolution on the nomination will result in the candidate having been
appointed, unless the binding nature of the nomination is overruled in accordance with Article 26.5. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is more than one nomination, the candidate who obtained the highest number of votes shall be
appointed, unless the binding nature of all nominations is overruled in accordance with Article 26.5. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If none of the candidates are appointed, the Supervisory Board, or one or more Shareholders who individually or
jointly represent at least <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the issued share capital, may, in accordance with Article 26.2, make a new nomination for the next General Meeting, unless the Supervisory Board resolves to reduce the
number of Supervisory Directors in accordance with Article 25.1. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All Supervisory Directors of a same class shall retire simultaneously at the close of the first annual General
Meeting held after three years have elapsed since their appointment, provided, however, that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Supervisory Directors I shall for the first time retire at the close of the annual General Meeting to be held
in two thousand and <FONT STYLE="white-space:nowrap">twenty-one</FONT> and subsequently at the close of each third succeeding annual General Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Supervisory Directors II shall for the first time retire at the close of the annual General Meeting to be held
in two thousand and <FONT STYLE="white-space:nowrap">twenty-two</FONT> and subsequently at the close of each third succeeding annual General Meeting; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Supervisory Directors III shall for the first time retire at the close of the annual General Meeting to be held
in two thousand and twenty-three and subsequently at the close of each third succeeding annual General Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Supervisory Director appointed to fill a vacancy resulting from the early resignation or dismissal of a
Supervisory Director shall retire at the time at which his or her predecessor would retire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a decrease of the number of Supervisory Directors of a particular class may not require that a Supervisory
Director of such class shall retire early against his or her will; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a retiring Supervisory Director shall be eligible for reappointment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may at any time suspend and dismiss a Supervisory Director. The General Meeting may only
adopt a resolution to suspend or dismiss a Supervisory Director by a majority of at least two thirds of the votes cast, representing more than half of the issued share capital, unless the resolution is adopted on the basis of a proposal of the
Supervisory Board; in that case, the resolution may be adopted by an absolute majority of the votes cast, representing more than half of the issued share capital. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the General Meeting has suspended a Supervisory Director, the General Meeting shall within three months
after the suspension has taken effect resolve either to dismiss such Supervisory Director or to terminate the suspension, failing which the suspension shall lapse. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>27.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Remuneration of Supervisory directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The General Meeting may grant the Supervisory Directors a remuneration. The Supervisory Directors shall be reimbursed for their expenses. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>28.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Duties, division of duties and working procedures of the Supervisory Board </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">28.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Supervision of the policies of the Management Board and of the general course of affairs of the Company and the
business connected with it shall be carried out by the Supervisory Board. It shall support the Management Board with advice. In fulfilling their duties the Supervisory Directors shall serve the interests of the Company and the business connected
with it. The Management Board shall in due time provide the Supervisory Board with the information it needs to carry out its duties. At least once a year the Management Board shall inform the Supervisory Board in writing in respect of the principles
of the strategic policy, the general and financial risks and the management and control system of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">28.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Supervisory Board may adopt rules with respect to the matters concerning the Supervisory Board.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">28.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Supervisory Board may, whether or not by rule, determine the duties with which each Supervisory Director
will be particularly charged. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">28.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Supervisory Board shall appoint from among its members a chairman, as well as a vice-chairman, who shall
substitute the chairman in his absence. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">28.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Supervisory Board may appoint from among its members one or more delegated Supervisory Directors. A
delegated Supervisory Director is a Supervisory Director who is charged with a special task. The delegated authority may not exceed the responsibilities of the Supervisory Board itself and shall not include managing the Company. It entails more
intensive supervision and advice and more regular consultation with the Management Board. The delegation shall not affect the duties and powers of the Supervisory Board. The delegated Supervisory Directors shall report on their findings to the
Supervisory Board. A Supervisory Director may only be temporarily appointed as delegated Supervisory Director. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">28.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Supervisory Board may decide that one or more Supervisory Directors shall have access to all premises of
the Company and shall be authorised to examine all of the Company&#146;s books, correspondence and other records and to be fully informed of all actions which have taken place, or the Supervisory Board may decide that one or more Supervisory
Directors shall be authorised to exercise a portion of such powers. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>29.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Meetings and decision-making of the Supervisory Board </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Supervisory Board shall meet whenever a Supervisory Director or the Management Board considers appropriate.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Supervisory Director may only be represented at a meeting by another Supervisory Director authorised in
writing. The requirement of written form for the authorisation shall be met if the authorisation has been recorded electronically. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Supervisory Director may participate in a meeting by electronic means of communication, provided that all
Supervisory Directors participating in the meeting can hear each other simultaneously. A Supervisory Director so participating shall be deemed to be present at the meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Managing Directors shall attend the meetings of the Supervisory Board, if invited to do so, and they shall
provide in such meetings all information required by the Supervisory Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Supervisory Director shall have one vote. All resolutions shall be adopted by an absolute majority of
votes cast at a meeting at which more than half of the Supervisory Directors are present or represented. In the event of a tie vote, the proposal shall have been rejected. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that one or more Supervisory Directors have a direct or indirect personal interest that conflicts
with the interest of the Company and the business connected with it, they shall not be authorised to participate in the discussion and the decision-making process. In the event that all Supervisory Directors have or the only Supervisory Director has
a direct or indirect personal interest that conflicts with the interest of the Company and the business connected with it, the resolution shall nevertheless be adopted by the Supervisory Board and the Supervisory Directors shall, in derogation of
the preceding sentence, continue to be authorised to participate in the discussion and decision-making process. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When determining to what extent the Supervisory Directors cast votes, are present or represented, no account
shall be taken of Supervisory Directors who are not authorised to participate in the discussion and the decision-making process pursuant to Article 29.6. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A written statement of the chairman of the meeting of the Supervisory Board that the Management Board has
adopted a resolution shall constitute proof of such resolution <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> third parties. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Supervisory Board may adopt resolutions without holding a meeting, provided that all Supervisory Directors
have consented to this manner of adopting resolutions and the votes are cast in writing or by electronic means. Articles 29.5 up to and including 29.7 shall apply by analogy to the adoption of resolutions by the Supervisory Board without holding a
meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>30.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Failing or prevention from acting of Supervisory Directors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In the event that one or more Supervisory Directors are failing or are prevented from acting, the remaining Supervisory Directors or the only
remaining Supervisory Director shall temporarily exercise the duties and powers conferred upon the Supervisory Board and the Supervisory Directors by law or these Articles of Association; in such case the Supervisory Board shall be authorised to
designate one or more temporary Supervisory Directors. In the event that all Supervisory Directors are failing or are prevented from acting, these duties and powers shall temporarily be exercised by one or more persons to be designated for that
purpose by the General Meeting. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>31.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Executive Officers and Supervisory Directors </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the fullest extent permitted by Dutch law, the following shall be reimbursed to the Indemnitees:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the costs of conducting a defence against claims, also including claims by the Company and its Group Companies,
as a consequence of any acts or omissions in the fulfilment of their duties or any other duties currently or previously performed by them at the Company&#146;s request; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any damages or financial penalties payable by them as a result of any such acts or omissions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any amounts payable by them under settlement agreements entered into by them in connection with any such acts
or omissions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the costs of appearing in other legal proceedings in which they are involved as Executive Officers, Supervisory
Directors, former Executive Officers or former Supervisory Directors, with the exception of proceedings primarily aimed at pursuing a claim on their own behalf; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any taxes payable by them as a result of any reimbursements in accordance with this Article 31.1.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An Indemnitee shall not be entitled to reimbursement as referred to in Article 31.1 if and to the extent that:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has been adjudicated by a Dutch court or, in the case of arbitration, an arbitrator, in a final and
conclusive decision that the act or omission of the Indemnitee may be characterised as intentional, deliberately reckless or grossly negligent conduct, unless Dutch law provides otherwise or this would, in view of the circumstances of the case, be
unacceptable according to standards of reasonableness and fairness; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the costs or financial loss of the Indemnitee are covered by an insurance and the insurer has paid out the
costs or financial loss. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If and to the extent that it has been adjudicated by a Dutch court or, in the case of arbitration, an
arbitrator, in a final and conclusive decision that the act or omission of the Indemnitee may be characterised as intentional, deliberately reckless or grossly negligent conduct or that the Indemnitee is otherwise not entitled to reimbursement as
referred to in Article 31.1, he or she shall immediately repay the amount reimbursed by the Company. The Company may request that the Indemnitee provides appropriate security for his repayment obligation. The Company may take out liability insurance
for the benefit of Executive Officers, Supervisory Directors, former Executive Officers and former Supervisory Directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may, by agreement or otherwise, give further implementation to Articles 31.1 up to and including
31.3. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where this Article 31 would limit any contractual entitlement of any Indemnitees to indemnification or
reimbursement, such contractual entitlement shall prevail. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amendment of this Article 31&nbsp;may not prejudice the entitlement of any Indemnitees to reimbursement as
referred to in Article 31.1 as a result of acts or omissions in the period during which that Article was in force. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>32.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General Meetings </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Annually, within six months of the end of the financial year, a General Meeting shall be held. The notice for
this meeting shall in any case mention the following matters: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the consideration of the Annual Accounts, the Management Report and the information, referred to in section
2:392 subsection 1 of the Dutch Civil Code, insofar as that provision applies to the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the adoption of the Annual Accounts; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the allocation of the profits or the determination how a loss will be accounted for. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">These items need not be mentioned in the notice of meeting if the period for preparing the
Annual Accounts and for presenting the Management Report has been extended by the General Meeting or if the notice of meeting mentions a proposal to that effect. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board and the Supervisory Board shall be authorised to convene a General Meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A General Meeting shall be convened whenever the Management Board or the Supervisory Board considers
appropriate, without prejudice to sections 2:110 up to including 2:112 of the Dutch Civil Code. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>33.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Venue, notice and agenda of the General Meetings </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General Meetings shall be held in the Netherlands, in Amsterdam, Rotterdam, The Hague, Arnhem, Utrecht or
Haarlemmermeer (Schiphol Airport). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of a General Meeting shall be given by the Management Board, the Supervisory Board, a Managing Director
or a Supervisory Director. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of a General Meeting shall be given by means of an announcement made by electronic means of
communication which is directly and permanently accessible until the General Meeting and with due observance of the applicable law and stock exchange rules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The notice of a General Meeting shall mention: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the matters to be discussed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the place and time of the meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the procedure for attending the meeting by a proxy authorised in writing; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the procedure for attending the meeting and the exercise of the voting rights by any means of electronic
communication in the event such right can be exercised in accordance with Article 36.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notifications which pursuant to the law or these Articles of Association are to be addressed to the General
Meeting may be included in the notice of meeting and, where applicable, in the document that has been made available at the offices of the Company for inspection, provided that this is mentioned in the notice. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A matter of which discussion has been requested in writing by one or more Persons with Meeting Rights who are
so entitled pursuant to section 2:114a subsection 2 of the Dutch Civil Code shall be mentioned in the notice of meeting or announced in the same manner if the Company has received the request, including the reasons, or a proposal for a resolution no
later than on the date specified in section 2:114a subsection 2 of the Dutch Civil Code. The requirement of written form for the request shall be met if the request has been recorded electronically. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice shall be given with due observance of the notice period prescribed by applicable law.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>34.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Chairman and secretary of the General Meeting </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The General Meeting shall be presided over by the chairman of the Supervisory Board, who, nevertheless, may charge another person to preside
over the meeting in his or her place even if he or she is present at the meeting. If the chairman of the Supervisory Board is absent and he or she has not charged another person to preside over the meeting in his or her place, the General Meeting
shall be presided over by the vice-chairman of the Supervisory Board. If both the chairman and the vice-chairman of the Supervisory Board are absent, the Supervisory Directors present at the meeting shall appoint one of them to be chairman. In the
absence of all Supervisory Directors, the General Meeting shall be presided over by the Chief Executive Officer. If all Supervisory Directors and the Chief Executive Officer are absent, the Managing Directors present at the meeting shall appoint one
of them as chairman. If all Supervisory Directors and all Managing Directors are absent, the General Meeting shall appoint its chairman. The chairman shall designate the secretary of the General Meeting. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>35.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Minutes and recording of resolutions of the General Meeting </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">35.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The secretary of the General Meeting shall keep minutes of the proceedings at the meeting, unless a notarial
record is prepared in accordance with Article 35.2. Minutes shall be adopted and in evidence of such adoption be signed by the chairman and the secretary of the General Meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">35.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman of the General Meeting and each Managing Director may at any time give instructions that a
notarial record of the proceedings at the meeting be prepared at the expense of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">35.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Management Board or the Supervisory Board was not represented at the meeting, the chairman of the
General Meeting shall as soon as possible notify the Management Board or the chairman of the Supervisory Board of the adopted resolutions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">35.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board shall keep a record of the adopted resolutions. The records shall be available at the
offices of the Company for inspection by the Persons with Meeting Rights. Upon request, each of them shall be provided with a copy or extract of such records at no more than cost. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>36.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rights at the General Meeting </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Person with Meeting Rights shall be authorised to attend the General Meeting, to address the General
Meeting and to exercise the voting rights he or she is entitled to in person or by a proxy authorised in writing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Person with Meeting Rights shall be authorised to attend the General Meeting in person or by a proxy
authorised in writing, to address the General Meeting and to exercise the voting rights he or she is entitled to by electronic means of communication, if this is mentioned in the notice of the meeting. To do so, the Person with Meeting Rights must
be identifiable through the electronic means of communication and be able to directly observe the proceedings at the meeting and to exercise the voting rights. A Person with Meeting Rights so attending shall be deemed to be present or represented at
the meeting. The persons giving notice of the meeting may set conditions for the use of the electronic means of communication. These conditions shall be mentioned in the notice of the meeting. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of Articles 36.1 and 36.2 the requirement of written form for the authorisation shall be met if
the authorisation has been recorded electronically. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of Articles 36.1 and 36.2 the persons who on a record date to be set by the Management Board
with due observance of section 2:119 subsection 2 of the Dutch Civil Code have the right to vote or attend the General Meeting and are registered as such in a register designated by the Management Board shall be deemed to have such rights and
therefore be deemed to be Persons with Meeting Rights, irrespective of whom are entitled to the Shares at the time of the meeting. The notice of meeting shall mention the record date as well as the manner in which the persons entitled to vote and
attend the General Meeting can register and the manner in which they can exercise their rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Person with Meeting Rights who on the record date referred to in Article 36.4 has the right to vote or attend
the General Meeting, or a proxy authorised in writing, will only be admitted to the meeting if the Person with Meeting Rights has informed the Management Board of his or her intention to attend the meeting and, if applicable, of the authorisation
prior to the date to be set by the Management Board. Such date may not be set earlier than on the eighth day prior to the date of the meeting. The notice of meeting shall mention the date referred to in the preceding sentence. The Company shall
offer the Person with Meeting Rights the possibility to inform the Company by electronic means of the authorisation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each person present at the General Meeting who is entitled to vote must sign the attendance list, stating his
or her name and the number of votes he or she may cast. The chairman of the meeting may determine that the attendance list must also be signed by other persons present at the meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Managing Directors and the Supervisory Directors shall as such have an advisory vote at the General Meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman of the General Meeting shall decide on the admittance of other persons to the meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>37.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Order of the General Meeting </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">37.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman of the General Meeting shall determine the order of the meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">37.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman of the General Meeting may limit the time any person present at the meeting may address the
meeting and may take any other measures as to ensure orderly proceedings at the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>38.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Adoption of resolutions at the General Meeting </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Share confers the right to cast one vote. Blank votes and invalid votes shall be regarded as not having
been cast. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon convening a General Meeting, the Management Board may determine that votes which are cast prior to the
meeting by electronic means of communication or by letter shall be put on par with votes which are cast at the time of the meeting. These votes shall not be cast earlier than on the record date set by the Management Board with due observance of
section 2:117b subsection 3 of the Dutch Civil Code. For the purposes of the two preceding sentences, the persons who have the right to vote or attend the meeting and are registered as such in a register designated by the Management Board as of the
record date set by the Management Board shall be deemed to have such rights for purposes of the General Meeting and therefore be deemed to be Persons with Meeting Rights, irrespective of whoever is entitled to the Shares at the time of the General
Meeting. The notice of meeting shall mention the record date as well as the manner in which the persons entitled to vote and attend the General Meeting can register and the manner in which they can exercise their rights. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless the law or these Articles of Association require a larger majority, all resolutions shall be adopted by
an absolute majority of the votes cast. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman of the General Meeting shall determine the manner of voting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman&#146;s decision at the General Meeting on the result of a vote shall be conclusive. The same shall
apply to the contents of an adopted resolution, to the extent that the vote related to a proposal not made in writing. If immediately after the chairman&#146;s decision its correctness is contested, there shall be a new free vote if the majority of
the meeting or, if the original vote was not taken on a poll or by a ballot, any person present who is entitled to vote so requires. Such new vote shall overrule the legal consequences of the original vote. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A written statement of the chairman of the General Meeting that the General Meeting has adopted a resolution
shall constitute proof of such resolution <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> third parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the General Meeting no votes may be cast in respect of a Share held by the Company or a Subsidiary thereof;
no votes may be cast in respect of a Share the depositary receipt for which is held by the Company or a Subsidiary thereof. However, the holders of a right of usufruct and holders of a right of pledge on Shares held by the Company and its
Subsidiaries are not excluded from their right to vote, if the right of usufruct or the right of pledge was created prior to the time such Share was held by the Company or a Subsidiary thereof. Neither the Company nor a Subsidiary thereof may cast
votes in respect of a Share on which it holds a right of usufruct or a right of pledge. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When determining to what extent the Shareholders cast votes, are present or represented or to what extent the
share capital is provided or represented, no account shall be taken of Shares which are not entitled to voting rights pursuant to Article 38.7. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>39.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Meetings of holders of Shares of a particular class </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board and the Supervisory Board shall be authorised to convene a meeting of holders of Shares of
a particular class. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A meeting of holders of Shares of a particular class shall be convened whenever pursuant to the law or these
Articles of Association a resolution of the meeting of holders of Shares of such class is required and furthermore whenever the Management Board or the Supervisory Board considers appropriate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Articles 33 up to and including 38 shall apply by analogy to meetings of holders of Shares of a particular
class, provided, however, that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notice shall be given no later than on the sixth day prior to the date of the meeting; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the proposal of the Management Board, which proposal shall require the prior approval of the Supervisory
Board, holders of Shares of a particular class may adopt resolutions without holding a meeting, provided that they are adopted by unanimous vote of the holders of Shares of the particular class entitled to vote and that the votes are cast in writing
or by electronic means; the holders of Shares of the particular class involved shall as soon as possible notify the Management Board and the chairman of the Supervisory Board of the adopted resolutions; Article 35.4 shall apply by analogy to these
resolutions. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>40.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial year </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial year shall coincide with the calendar year. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>41.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Annual Accounts and Management Report </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Annually, within five months of the end of the financial year, subject to an extension of such period not
exceeding five months by the General Meeting on the basis of special circumstances, the Management Board shall prepare Annual Accounts and shall make these available at the offices of the Company for inspection by the Persons with Meeting Rights.
The Management Board shall also make the Management Report available at the offices of the Company for inspection by the Persons with Meeting Rights within said period. The Management Board shall add to the Annual Accounts and the Management Report
the information, referred to in section 2:392 subsection 1 of the Dutch Civil Code, insofar as that subsection applies to the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Annual Accounts shall be signed by all Managing Directors and all Supervisory Directors. If the signature
of one or more of them is lacking, this shall be disclosed, stating the reasons thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall ensure that the Annual Accounts as prepared, the Management Report and the additional
information to be added pursuant to section 2:392 subsection 1 of the Dutch Civil Code shall be available at the offices of the Company as of the date of the notice of the General Meeting at which they are to be discussed. The Persons with Meeting
Rights may inspect the documents at the offices of the Company and obtain a copy thereof at no cost. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Annual Accounts shall be adopted by the General Meeting. Adoption of the Annual Accounts shall not be
deemed to grant a Managing Director or a Supervisory Director a discharge. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>42.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Auditor </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">42.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall give an assignment to an Auditor to audit the Annual Accounts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">42.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting shall be authorised to give the assignment. If the General Meeting fails to do so, then the
Supervisory Board shall be authorised to give the assignment. The assignment may be revoked at any time by the General Meeting or, if the Supervisory Board has given the assignment, by the Supervisory Board. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">42.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Auditor shall report on his or her audit to the Supervisory Board and to the Management Board and shall
issue a certificate containing its results. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>43.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Share premium reserves </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">43.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall maintain separate share premium reserves for the benefit of the holders of each series of
Financing Preferred Shares. Payments on Financing Preferred Shares of a particular series in excess of the nominal value shall be added to the share premium reserve maintained by the Company for the benefit of the holders of the series of Financing
Preferred Shares on which the payment is made. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">43.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Article 43.1 shall apply by analogy to any disposal by the Company of Financing Preferred Shares, or of
depositary receipts thereof, provided that in such case the nominal value of the Financing Preferred Shares of the series concerned, or of the Financing Preferred Shares of the series concerned for which the depositary receipts have been issued,
also shall be added to the relevant share premium reserve. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>44.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Profit and loss </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">44.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting shall be authorised to allocate the profits, subject to Articles 44.2 up to and including
44.4. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">44.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From the profits made in any financial year, first of all, to the extent possible, the following distributions
shall be made: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the holders of Financing Preferred Shares, an amount equal to the average during the financial year
concerned of the twelve month Euro Interbank Offered Rate (Euribor), as set by the European Central Bank, weighted by the number of days on which such interest rate was applicable, increased by a margin not exceeding five hundred basis points, to be
set by the Management Board upon issue of the relevant Financing Preferred Shares, calculated on the weighted average during that financial year of the aggregate amount paid up and called up on their Financing Preferred Shares; therefore, any
increases and reductions of the amounts paid up and called up on their Financing Preferred Shares during that financial year shall be taken into account for the purpose of calculating each distribution; the days during which the Financing Preferred
Shares were held by the Company shall be disregarded; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if Financing Preferred Shares were cancelled during the preceding financial year, to the last former holders of
those Financing Preferred Shares, an amount equal to the amount of the distribution referred to in Article 11.4 under (b), reduced by the amount of the distribution already received by them pursuant to that provision. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If in any financial year the profits are insufficient to make such distributions, the deficit shall, to the extent possible, be distributed
from any of the Distributable Reserves determined by the Management Board. If the profits made in any financial year or the Distributable Reserves are insufficient to make such distributions, the deficit shall be distributed from the profits made
and the Distributable Reserves maintained in the following financial years and the preceding sentence of this Article 44.2 and Article 44.3 shall first apply after the deficit has been fully made up. Other than as set out in this Article 44.2, the
Financing Preferred Shares shall not participate in the profits and the reserves of the Company, except that the holders of a series of Financing Preferred Shares shall participate in the share premium reserve maintained by the Company for the
benefit of the holders of such series of Financing Preferred Shares. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">44.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board shall be authorised to determine that the profits remaining after application of Article
44.2 shall in whole or in part be reserved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">44.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution of the Management Board to reserve any profits shall require the prior approval of the Supervisory
Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">44.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board shall be authorised to determine how a loss will be accounted for. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">44.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A deficit may only be applied against reserves maintained pursuant to the law to the extent permitted by law.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>45.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Distributions </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">45.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting shall be authorised to declare distributions, subject to Articles 45.2 up to and including
45.4. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">45.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may only resolve to declare distributions on the proposal of the Management Board, which
proposal shall require the prior approval of the Supervisory Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">45.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may only make distributions to the Shareholders and other persons entitled to distributable profits
to the extent that its equity exceeds the aggregate amount of the issued share capital and the reserves which must be maintained pursuant to applicable law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">45.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any distribution of profits shall be made only following the adoption of the Annual Accounts by the General
Meeting that show such distribution is permitted in accordance with Article 45.3. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">45.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Management Board may resolve to may make interim distributions, provided that the requirement of Article
45.3 has been met as evidenced by an interim financial statement as referred to in section 2:105 subsection 4 of the Dutch Civil Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">45.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution of the Management Board to make an interim distribution shall require the prior approval of the
Supervisory Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">45.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares held by the Company shall not be taken into account for the purpose of calculating each distribution,
unless such Shares are encumbered with a right of usufruct or a right of pledge. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">45.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Distributions on Shares of a particular class shall be made pro rata on all Shares of such particular class.
Distributions to the last former holders of Financing Preferred Shares that have been cancelled shall be made pro rata on the aggregate amount of the Financing Preferred Shares held by such holders immediately before the cancellation.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">45.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Distributions shall be due and payable four weeks after they have been declared, unless the General Meeting
determines another date on the proposal of the Management Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">45.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Distributions which have not been collected within five years of the start of the day after the day on which
they became due and payable shall revert to the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">45.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may determine that distributions shall be made in whole or in part in the form of Shares or
in a currency other than the euro, provided on the proposal of the Management Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">45.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution of the General Meeting to determine that distributions shall be made in whole or in part in the
form of Shares or in a currency other than the euro shall require the prior approval of the Supervisory Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">45.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall announce any proposal for a distribution and the date when and the place where the
distribution will be payable to all Shareholders by electronic means of communication with due observance of applicable law and stock exchange rules. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>46.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendment of these Articles of Association </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">46.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting shall be authorised to amend these Articles of Association. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">46.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may only resolve to amend these Articles of Association on the proposal of the Management
Board, which proposal shall require the prior approval of the Supervisory Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">46.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a proposal to amend these Articles of Association is to be made to the General Meeting, such shall always be
mentioned in the notice of the General Meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>47.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Dissolution and liquidation </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">47.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting shall be authorised to dissolve the Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">47.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may only resolve to dissolve the Company on the proposal of the Management Board, which
proposal shall require the prior approval of the Supervisory Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">47.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Article 46.3 shall apply by analogy to a proposal to dissolve the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">47.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Company is dissolved pursuant to a resolution of the General Meeting, its assets shall be liquidated by
the Managing Directors, under the supervision of the Supervisory Board, if and to the extent that the General Meeting shall not resolve otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">47.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting shall determine the remuneration of the liquidators and of the persons charged with the
supervision of the liquidation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">47.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The liquidation shall take place with due observance of the relevant provisions of Book 2 title 1 of the Dutch
Civil Code. During the liquidation period these Articles of Association shall, to the extent possible, remain in full force. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">47.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From the balance of the assets of the Company remaining after the creditors have been paid first of all, to the
extent possible, the following distributions shall be made: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the holders of Financing Preferred Shares, in proportion to the aggregate amount of the Financing Preferred
Shares held by such holders: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the amount paid up on their Financing Preferred Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any deficit, referred to in Article 44.2; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an amount equal to the amount referred to in Article 44.2 under (a)&nbsp;calculated up to the date on which the
Company was dissolved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the holders of each series of Financing Preferred Shares, in proportion to the aggregate amount of the
Financing Preferred Shares held by such holders, the balance of the share premium reserve maintained by the Company for the benefit of the holders of the relevant series of Financing Preferred Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the last former holders of the Financing Preferred Shares that have been cancelled, in proportion to the
aggregate amount of the Financing Preferred Shares held by such holders immediately before cancellation: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any deficit, referred to in Article 44.2; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if their Financing Preferred Shares were cancelled in the financial year in which the Company was dissolved, an
amount equal to the amount of the distribution referred to in Article 11.4 under (b), reduced by the amount of the distribution already received by them pursuant to that provision. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the surplus is insufficient to make such distributions in full, the surplus shall be distributed to the holders of Financing Preferred
Shares and last former holders of Financing Preferred Shares that have been cancelled in proportion to the aggregate amount to which they would be entitled if the surplus would be sufficient. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">47.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The balance remaining after application of Article 47.7 shall be distributed to the holders of Ordinary Shares
in proportion to the aggregate amount of the Ordinary Shares held by such holders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">47.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After the Company has ceased to exist, its books, records and other data carriers shall remain in the custody
of the person designated for that purpose by the liquidators for a period of seven years. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>48.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Transitional provision I </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company&#146;s first financial year ends on the thirty-first day of December two thousand and twenty. This Article 48 shall lapse after
expiry of the first financial year. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>49.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Transitional provision II </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">49.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In derogation of Article 4.1, the authorised share capital of the Company amounts to one million and five
hundred thousand euros (EUR 1,500,000) and is divided into: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one hundred and <FONT STYLE="white-space:nowrap">forty-two</FONT> million five hundred thousand (142,500,000)
Ordinary Shares with a nominal value of one eurocent (EUR 0.01) each; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">seven million five hundred thousand (7,500,000) Financing Preferred Shares with a nominal value of one eurocent
(EUR 0.01) each, which are convertible into Ordinary Shares on the terms and subject to the conditions determined in accordance with Article5.2, divided into: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a series A consisting of one million five hundred thousand (1,500,000) Financing Preferred Shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a series B consisting of one million five hundred thousand (1,500,000) Financing Preferred Shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a series C consisting of one million five hundred thousand (1,500,000) Financing Preferred Shares;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a series D consisting of one million five hundred thousand (1,500,000) Financing Preferred Shares; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a series E consisting of one million five hundred thousand (1,500,000) Financing Preferred Shares.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Article 4.1 shall first apply as of the date on which the number of issued Ordinary Shares amounts to or exceeds sixty
million (60,000,000). As soon as Article 4.1 applies, the Company shall file a statement with the Dutch trade register evidencing that Article 4.1 applies, stating the date as of which that Article applies. This Article 49 shall lapse once Article
4.1 applies. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>50.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Transitional provision III </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">As of the Transition Date, these Articles of Association shall read in full as set out in Article 51, provided, however, that article 42 of the
articles of association as set out in Article 51 shall only be deemed to form part of such articles of association if on the Transition Date Article 49 has not yet lapsed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">50.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Until the Transition Date, Article 51 shall be deemed not to form part of these Articles of Association.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">50.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Articles 1 up to and including 49, this Article 50 and the heading of Article 51 shall lapse as of the
Transition Date. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>51.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Articles of association as they will read as of the Transition Date </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARTICLES OF ASSOCIATION </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Definitions and interpretation </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In these Articles of Association the following terms shall have the following meanings: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Annual Accounts</B>&#148; means the annual accounts referred to in section 2:361 of the Dutch Civil Code; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Articles of Association</B>&#148; means these articles of association; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Associate</B>&#148; means, with respect to any person: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any trust or other estate in which such person has a substantial beneficial interest or as to which such person
serves as trustee or in a similar fiduciary capacity, and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any relative or spouse of such person, or any relative of such spouse, who has the same home as such person or
who is an Executive Officer or <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director of the Company; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Auditor</B>&#148; means an auditor as referred to in section 2:393 subsection 1 of the Dutch Civil Code or an organisation within
which such auditors cooperate; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Board</B>&#148; means the board of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Chief Executive Officer</B>&#148; means the Executive Director with the title of Chief Executive Officer; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company</B>&#148; means the public company under Dutch law which is governed by these Articles of Association; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Convertible Reserve</B>&#148; means a reserve referred to in sections 2:389 or 2:390 of the Dutch Civil Code; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Director</B>&#148; means a director of the Company, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Executive Director and each <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Director I, each Director II and each Director III, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">in each case, unless the context otherwise requires; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Director</B><B></B><B>&nbsp;I</B>&#148; means a Director designated by the Board as director&nbsp;I pursuant to these Articles of
Association; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Director</B><B></B><B>&nbsp;II</B>&#148; means a Director designated by the Board as director&nbsp;II pursuant to
these Articles of Association; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Director</B><B></B><B>&nbsp;III</B>&#148; means a Director designated by the Board
as director&nbsp;III pursuant to these Articles of Association; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Distributable Reserve</B>&#148; means a distributable reserve
other than a share premium reserve maintained by the Company for the benefit of the holders of a series of Financing Preferred Shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Executive Committee</B>&#148; means the executive committee of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Executive Director</B>&#148; means a Director appointed by the General Meeting as executive director; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Executive Officer</B>&#148; means a member of the Executive Committee, including each Executive Director and each other member of the
Executive Committee, unless the context otherwise requires; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Financing Preferred Share</B>&#148; means a financing preferred share
in the share capital of the Company; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>General Meeting</B>&#148; means the body of the Company consisting of the Persons with
Meeting Rights or a meeting of Persons with Meeting Rights, in each case, as the context may require; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Group</B>&#148; means a
group as referred to in section 2:24b of the Dutch Civil Code; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Group Company</B>&#148; means a legal person or company affiliated
with the Company in a group as referred to in section 2:24b of the Dutch Civil Code; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnitee</B>&#148; means any current or
former Executive Officer or <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Management Report</B>&#148; means the
management report referred to in section 2:391 of the Dutch Civil Code; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Non-Executive</FONT>
Director</B>&#148; means a Director appointed by the General Meeting as <FONT STYLE="white-space:nowrap">non-executive</FONT> director; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Ordinary Share</B>&#148; means an ordinary share in the share capital of the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Participating Interest</B>&#148; means a participating interest as referred to in section 2:24c of the Dutch Civil Code; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Person with Meeting Rights</B>&#148; means a Shareholder and a Usufructuary and Pledgee who are entitled to the voting rights; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Pledgee</B>&#148; means a holder of a right of pledge on one or more Shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Share</B>&#148; means a share in the share capital of the Company, including each Ordinary Share and each Financing Preferred Share,
unless the context otherwise requires; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Shareholder</B>&#148; means a holder of one or more Shares; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Shareholder Affiliate</B>&#148; means, with respect to any Shareholder: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any person controlling, directly or indirectly, or acting in concert with, such Shareholder;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any beneficial owner of Shares owned of record or beneficially by such Shareholder, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any person directly or indirectly controlling, controlled by or under common control with such Shareholder;
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subsidiary</B>&#148; means a subsidiary as referred to in section 2:24a of the Dutch Civil Code; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">&#147;<B>Usufructuary</B>&#148; means a holder of a right of usufruct on one or more Shares. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In these Articles of Association references to Articles are to articles of these Articles of Association,
unless otherwise specified. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Name, seat and structure </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The name of the Company is: Immatics N.V. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company has its seat in Amsterdam, the Netherlands. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company applies section 2:129a of the Dutch Civil Code. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Objects </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The objects of the Company are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to research, develop, manufacture and commercialise products for the detection, prevention and treatment of
human diseases and conditions and to render advice and services in connection therewith; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to participate in, to take an interest in any other way in, to conduct the management of and to finance other
businesses, of whatever nature; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to provide security, to give guarantees and to bind itself in any other way for its own debts and obligations
and for those of other persons; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to borrow, to lend and to raise funds, including the issue of bonds, debt instruments and other securities, as
well as to enter into agreements in connection therewith; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to acquire, manage, exploit and dispose of immovable property and other registered property;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to trade in currencies and securities, as well as in items of property in general; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to develop, exploit and trade in patents, trademarks, licenses,
<FONT STYLE="white-space:nowrap">know-how,</FONT> copyrights, database rights and other intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to perform all activities of an industrial, financial or commercial nature, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">as well as all activities which are incidental to or which may be conducive to any of the foregoing in the broadest sense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Share capital and Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The authorised share capital of the Company amounts to three million euros (EUR 3,000,000) and is divided into:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">two hundred and eighty-five million (285,000,000) Ordinary Shares with a nominal value of one eurocent (EUR
0.01) each; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">fifteen million (15,000,000) Financing Preferred Shares with a nominal value of one eurocent (EUR 0.01) each,
which are convertible into Ordinary Shares on the terms and subject to the conditions determined in accordance with Article 5.2, divided into: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a series A consisting of three million (3,000,000) Financing Preferred Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a series B consisting of three million (3,000,000) Financing Preferred Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a series C consisting of three million (3,000,000) Financing Preferred Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a series D consisting of three million (3,000,000) Financing Preferred Shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a series E consisting of three million (3,000,000) Financing Preferred Shares. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each series of Financing Preferred Shares shall constitute a separate class. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Shares shall be in registered form and shall be numbered in such a manner that they can be distinguished
from each other at any time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Shares shall be uncertificated and shall be registered in the register of shareholders, provided that the
Board may determine that certain or all of the Shares shall be represented by share certificates. Share certificates shall be issued in such form, and shall be signed by an Executive Director or such other persons, as the Board may determine, and
shall be numbered in such manner as the Board may determine to be necessary to distinguish the share certificates from each other. The Board may, in its sole discretion, establish further rules with respect to the issue of share certificates.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Conversion of Financing Preferred Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Financing Preferred Shares may, at the request of the holder, be converted into Ordinary Shares pursuant to a
resolution of the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The conditions for conversion and the further terms and conditions related to the Financing Preferred Shares
shall be determined by the Board, subject to the prior approval of the General Meeting and the meeting of holders of the series of Financing Preferred Shares concerned, if Financing Preferred Shares of such series have been issued and are held by
persons other than the Company and provided that in no event may any Financing Preferred Share be converted into more than ten Ordinary Shares. The preceding sentence shall apply by analogy to any amendments of or supplementations to the terms and
conditions related to the Financing Preferred Shares determined in accordance with that sentence. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall implement the conversion of any Financing Preferred Shares in accordance with the applicable
conditions for such conversion, as determined in accordance with Article 5.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any obligation to pay up Ordinary Shares arising from a conversion of Financing Preferred Shares into Ordinary
Shares shall be charged to the share premium reserve maintained by the Company for the benefit of the holders of the series of Financing Preferred Shares that are converted; if this reserve is insufficient, the difference shall be charged to the
Distributable Reserves or the Convertible Reserves determined by the Board; if these reserves are insufficient, the difference shall be satisfied by the holder of the Ordinary Shares by payment in cash. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Financing Preferred Shares of a particular series are converted into Ordinary Shares, the <FONT
STYLE="white-space:nowrap">pro-rata</FONT> entitlement to the balance of the share premium reserve maintained by the Company for the benefit of the holders of such Financing Preferred Shares, minus the amount charged to such share premium reserve by
way of application of Article 5.4 shall be added to the Distributable Reserves determined by the Board. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Issue of Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares may be issued pursuant to a resolution of the General Meeting or of the Board, if the Board has been
authorised by a resolution of the General Meeting to issue Shares for a specified period not exceeding five years. The resolution of the General Meeting granting the authorisation shall specify the number of Shares that may be issued by the Board.
The authorisation may from time to time be extended, in each case, for a period not exceeding five years. Unless otherwise specified in the resolution of the General Meeting granting the authorisation, the authorisation may not be revoked. For as
long as and to the extent that the Board is authorised to issue Shares, the General Meeting shall not have the authority to issue Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the General Meeting is authorised to issue Shares, it may only do so on the proposal of the Board.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The validity of a resolution of the General Meeting to issue Shares or to authorise the Board to issue Shares
shall require a prior or simultaneous approving resolution of each group of holders of Shares of a same class whose rights are prejudiced by such issue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Articles 6.1 up to and including 6.3 shall apply by analogy to a grant of rights to subscribe for Shares, but
shall not apply to the issue of Shares to a person who exercises a previously acquired right to subscribe for Shares. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Pre-emption</FONT> rights upon issue of Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the issue of Ordinary Shares, each holder of Ordinary Shares shall have a
<FONT STYLE="white-space:nowrap">pre-emption</FONT> right in proportion to the aggregate amount of the Ordinary Shares held by such holder, subject to Article 7.2. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A holder of Ordinary Shares shall have no <FONT STYLE="white-space:nowrap">pre-emption</FONT> right in respect
of: </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ordinary Shares which are issued against payment in a form of consideration other than cash;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ordinary Shares which are issued to employees of the Company or of a Group Company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Financing Preferred Shares to be issued. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Holders of Financing Preferred Shares shall have no <FONT STYLE="white-space:nowrap">pre-emption</FONT> right
in respect of Shares to be issued. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-emption</FONT> rights may be limited or excluded by a resolution of the
General Meeting or of the Board, if the Board has been authorised by a resolution of the General Meeting to limit or exclude <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights for a specified period not exceeding five years. The
authorisation may from time to time be extended, in each case for a period not exceeding five years. Unless otherwise specified in the resolution of the General Meeting granting the authorisation, the authorisation may not be revoked. For as long as
and to the extent that the Board is authorised to limit or exclude <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights, the General Meeting shall not have the authority to limit or exclude <FONT STYLE="white-space:nowrap">pre-emption</FONT>
rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution of the General Meeting to limit or exclude <FONT STYLE="white-space:nowrap">pre-emption</FONT>
rights or to authorise the Board to limit or exclude <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights shall require a majority of at least two thirds of the votes cast, if less than half the issued share capital is represented at the
meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the General Meeting is authorised to resolve to limit or exclude
<FONT STYLE="white-space:nowrap">pre-emption</FONT> rights, it may only do so on the proposal of the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall announce an issue of Shares where <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights
apply in accordance with applicable law. Such announcement shall include the period within which such <FONT STYLE="white-space:nowrap">pre-emption</FONT> rights may be exercised. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Articles 7.1 up to and including 7.7 shall apply by analogy to a grant of rights to subscribe for Shares, but
shall not apply to an issue of Shares to a person who exercises a previously acquired right to subscribe for Shares. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payment for Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without prejudice to section 2:80 subsection 2 of the Dutch Civil Code, upon any subscription for Shares, the
full nominal value must be paid up on such Shares and, in the event that the subscription price of such Shares is greater than the nominal value of such Shares, the difference between the nominal value and such higher amount. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment must be made in cash, unless an alternative contribution has been agreed. Payment in a form of
consideration other than cash shall be made with due observance of sections 2:80b and 2:94b of the Dutch Civil Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Payment in a currency other than the euro may only be made with the consent of the Company and with due
observance of section 2:80a subsection 3 of the Dutch Civil Code. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Ordinary Shares which are issued to current or former Executive Officers,
<FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors, employees or other service providers of the Company or any of its Group Companies under any equity incentive plan or other program may be paid up at the expense of the Distributable
Reserves or the Convertible Reserves determined by the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall be authorised to perform the legal acts referred to in section 2:94 subsection 1 of the Dutch
Civil Code without the prior approval of the General Meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acquisition of Shares by the Company </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without prejudice to Article 9.2, the Company may only acquire fully paid up Shares for consideration if and to
the extent the General Meeting has authorised the Board to acquire Shares. Such authorisation shall be valid for a period not exceeding eighteen months. The resolution of the General Meeting granting the authorisation shall specify the number of
Shares that may be acquired, the manner in which such Shares may be acquired and the limits within which the price must be set. The authorisation may from time to time be extended, in each case for a period not exceeding eighteen months. Unless
otherwise specified in the resolution of the General Meeting granting the authorisation, the authorisation may not be revoked. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The authorisation of the General Meeting shall not be required if the Company acquires Shares for the purpose
of transferring such Shares to employees of the Company or of a Group Company by virtue of any equity incentive plan or other program or arrangement applicable to such employees, provided that such Shares are listed on any stock exchange.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any acquisition of Shares by the Company shall be effected with due observance of section 2:98 of the Dutch
Civil Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If depositary receipts for Shares have been issued, such depositary receipts for Shares shall be put on par
with Shares for the purpose of Articles 9.1 up to and including 9.3. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial assistance </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In respect of the subscription for or acquisition of Shares or depositary receipts thereof by other persons,
the Company may not provide security, give a guarantee as to the price of the Shares, give guarantees in any other manner and may not bind itself either jointly or severally in addition to or for other persons. This prohibition shall also apply to
its Subsidiaries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In respect of the subscription for or acquisition of Shares or depositary receipts thereof by other persons,
the Company and its Subsidiaries may only grant loans with due observance of section 2:98c subsections 2 up to and including 7 of the Dutch Civil Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Articles 10.1 and 10.2 shall not apply if Shares are subscribed for or acquired by or for the account of
employees of the Company or of a Group Company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Reduction of share capital </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may resolve to reduce the issued share capital by cancelling Shares or by reducing the
nominal value of Shares by an amendment of the Articles of Association. The resolution shall specify the Shares to which the resolution applies and shall describe how such a resolution shall be implemented. The amount of the issued share capital may
not fall below the minimum share capital as required by law in effect at the time of the resolution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may only resolve to reduce the issued share capital on the proposal of the Board.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution to cancel Shares may only apply to Shares which are held by the Company itself or to Shares for
which the Company holds depositary receipts or to all Financing Preferred Shares of a particular series. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cancellation of Financing Preferred Shares which are held by another person than the Company shall be effected
against: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">repayment of the amount paid up on such Financing Preferred Shares; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">simultaneous distribution of an amount equal to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the balance of the share premium reserve maintained by the Company for the benefit of the holders of the series
of Financing Preferred Shares that is cancelled; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any deficit, referred to in Article 38.2; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the amount, referred to in Article 38.2 under (a), calculated up to the date on which such Financing Preferred
Shares are cancelled, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">all with due observance of Article 39.5. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Repayment in implementation of a resolution to reduce the nominal value of the Shares shall be made pro rata on
all Shares or exclusively on all Shares of a same class. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The validity of a resolution of the General Meeting to reduce the issued share capital shall require a prior or
simultaneous approving resolution of each group of holders of Shares of a same class whose rights are prejudiced by such share capital reduction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A resolution of the General Meeting to reduce the issued share capital shall require a majority of at least two
thirds of the votes cast, if less than half the issued share capital is represented at the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reduction of the issued share capital shall be effected with due observance of sections 2:99 and 2:100 of the
Dutch Civil Code. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Right of usufruct and right of pledge on Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A right of usufruct may be created on Shares. The voting rights on the Shares encumbered with a right of
usufruct shall accrue to the Shareholder. In derogation of the preceding sentence, the voting rights shall accrue to the Usufructuary if so provided at the time of the creation of the right of usufruct. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A right of pledge may be created on Shares. The voting rights on the Shares encumbered with a right of pledge
shall accrue to the Shareholder. In derogation of the preceding sentence, the voting rights shall accrue to the Pledgee if so provided at the time of the creation of the right of pledge. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Shareholder who pursuant to a right of usufruct or a right of pledge is not entitled to voting rights and
any Usufructuary or Pledgee who is entitled to voting rights shall have the rights conferred by law on holders of depositary receipts for shares issued with a company&#146;s cooperation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Usufructuary or Pledgee who is not entitled to voting rights shall not have the rights conferred by law on
holders of depositary receipts for shares issued with a company&#146;s cooperation. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Depositary receipts for Shares </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company is not authorised to cooperate in the issue of depositary receipts for Shares. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Shareholders register </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A register shall be kept by or on behalf of the Company in which the names and addresses of all Shareholders,
Usufructuaries and Pledgees shall be recorded, stating the information that must be recorded pursuant to section 2:85 of the Dutch Civil Code and such further information as the Board may consider appropriate. Part of the register may be kept
outside the Netherlands to comply with applicable law or stock exchange rules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The register shall be updated regularly. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Joint holding </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If one or more Shares, or a right of usufruct or a right of pledge on one or more Shares, are jointly held by
two or more persons, the joint holders may only be represented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> the Company by a person who has been designated by such joint holders in writing for that
purpose. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may, whether or not subject to certain conditions, grant an exemption from Article 15.1.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Transfer of Shares </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise provided in these Articles of Association or permitted by applicable law, the transfer of
Shares or of a right of usufruct on Shares, or the creation or release of a right of usufruct or a right of pledge on Shares, shall require an instrument intended for such purpose and, unless the Company is a party to the legal act, the written
acknowledgement by the Company of such transfer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The acknowledgement shall be made in the instrument or by a dated statement of acknowledgement on the
instrument or on a copy or extract thereof signed as a true copy by the transferor. Service of such instrument, true copy or extract upon the Company shall be deemed to have the same effect as an acknowledgement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A right of pledge may also be created without acknowledgement by or service upon the Company. In such case
section 3:239 of the Dutch Civil Code shall apply by analogy, whereby acknowledgement by or service upon the Company shall substitute the notice referred to in section 3:239 subsection 3 of the Dutch Civil Code. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For so long as one or more Shares are listed on the NASDAQ Stock Market or any other regulated foreign stock
exchange, the Company may, by a resolution of the Board for that purpose, determine that the laws of the State of New York, United States of America, shall apply to the property law aspects of the Shares included in the part of the register of
shareholders kept by the relevant transfer agent. Articles 16.1 up to and including 16.3 shall not apply to such Shares. Such resolution, as well as a resolution to revoke such designation, shall be made public in accordance with applicable law and
shall be deposited at the offices of the Company and the Dutch trade register for inspection. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Board </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall consist of one or more Executive Directors and three or more
<FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors. The majority of the Directors must be <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors. If the number of <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors
is less than three, the Board shall fully retain its powers. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The number of Directors, including the number of Executive Directors and
<FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors, shall be determined by the Board with due observance of Article 17.1. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting shall determine whether a Director is appointed Executive Director or <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Director, subject to Article 17.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Directors shall be divided by the Board into Directors I, Directors II and Directors III, with each class
as nearly equal in number as possible. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Directors must be natural persons. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Appointment, retirement, suspension and dismissal of Directors </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Directors shall be appointed by the General Meeting on the basis of one or more binding nominations in
accordance with Article 18.2. The nomination shall specify the vacancy for which the nomination is made. Each nomination shall comprise one candidate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Binding nominations may be made by the Board or by one or more Shareholders who individually or jointly
represent at least <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the issued share capital of the Company at the time of giving the notice referred to in Article 18.3. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A nomination made by Shareholders in accordance Article 18.2 shall only be binding if such Shareholders have
given notice thereof to the Company in writing no later than on the sixtieth day prior to the date of the General Meeting at which the appointment is to be discussed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A nomination for the appointment of a Director shall state which class of Directors the candidate is proposed
to be appointed to, his or her age and profession, the number of Shares held by him or her and the positions he or she holds or held insofar as relevant to the fulfilment of the duties as a Director. Furthermore, mention shall be made of the legal
persons for which he or she serves as a director whereby, provided that if legal persons are included which belong to the same Group, it shall be sufficient to mention such Group. The nomination for appointment or reappointment shall include the
reasons. In case of reappointment, account shall be taken of the manner in which the candidate has fulfilled his duties as a Director. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may at all times overrule the binding nature of each nomination by a resolution adopted by
a majority of at least two thirds of the votes cast, representing more than half of the issued share capital. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is only one nomination, a resolution on the nomination will result in the candidate having been
appointed, unless the binding nature of the nomination is overruled in accordance with Article 18.5. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is more than one nomination, the candidate who obtained the highest number of votes shall be
appointed, unless the binding nature of all nominations is overruled in accordance with Article 18.5. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If none of the candidates are appointed, the Board, or one or more Shareholders who individually or jointly
represent at least <FONT STYLE="white-space:nowrap">one-tenth</FONT> of the issued share capital, may, in accordance with Article 18.2, make a new nomination for the next General Meeting, unless the Board resolves to reduce the number of Directors
in accordance with Article 17.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All Directors of a same class shall retire simultaneously at the close of the first annual General Meeting held
after three years have elapsed since their appointment, provided, however, that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Directors I shall for the first time retire at the close of the annual General Meeting to be held in two
thousand and <FONT STYLE="white-space:nowrap">twenty-one</FONT> and subsequently at the close of each third succeeding annual General Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Directors II shall for the first time retire at the close of the annual General Meeting to be held in two
thousand and <FONT STYLE="white-space:nowrap">twenty-two</FONT> and subsequently at the close of each third succeeding annual General Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Directors III shall for the first time retire at the close of the annual General Meeting to be held in two
thousand and twenty-three and subsequently at the close of each third succeeding annual General Meeting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a Director appointed to fill a vacancy resulting from the early resignation or dismissal of a Director shall
retire at the time at which his or her predecessor would retire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a decrease of the number of Directors of a particular class may not require that a Director of such class shall
retire early against his or her will; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a retiring Director shall be eligible for reappointment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may at any time suspend or dismiss a Director. The General Meeting may only adopt a
resolution to suspend or dismiss a Director by a majority of at least two thirds of the votes cast, representing more than half of the issued share capital, or, in the case that such resolution is adopted on the proposal of the Board, by an absolute
majority of the votes cast, representing more than half of the issued share capital. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall be authorised to suspend an Executive Director at any time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the General Meeting has suspended a Director or the Board has suspended an Executive Director, the General
Meeting shall within three months after the suspension has taken effect resolve either to dismiss such Director or to terminate the suspension, failing which the suspension will lapse. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Remuneration of Directors </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall have a policy regarding remuneration of the Board. The policy shall be adopted by the General
Meeting on the proposal of the Board. The remuneration policy shall include the matters described in sections 2:383c up to and including 2:383e of the Dutch Civil Code, to the extent they apply to the Board. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The remuneration of Directors shall be determined by the Board with due observance of the policy referred to in
Article 19.1. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall submit proposals concerning arrangements for issuing Shares or granting rights to subscribe for
Shares in accordance with the policy referred to in Article 19.1 to the General Meeting for approval. The proposal shall include the information required pursuant to section 2:135 subsection 5 of the Dutch Civil Code. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Duties, division of duties and decision-making of the Board </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the limitations provided in these Articles of Association, the Board shall be charged with the
management of the Company. In fulfilling their duties the Directors shall serve the interest of the Company and the business connected with it. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to the authority of the Board, the Executive Directors shall be charged with the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Supervision of the fulfilment of duties by the Executive Directors and of the general course of the
Company&#146;s affairs and the business connected with it shall be primarily carried out by the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors. The Executive Directors shall in due time provide the
<FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors with the information they need to carry out their duties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may adopt rules with respect to the matters concerning the Board. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may, whether or not by rule, determine the duties with which each Director will be particularly
charged. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall appoint from among the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors a
chairman. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall grant to an Executive Director the title of Chief Executive Officer. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall meet whenever a Director considers appropriate. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An Executive Director may only be represented at a meeting by another Director authorised in writing and a <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Director may only be represented at a meeting by another <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director authorised in writing. The requirement of written form for the authorisation
shall be met if the authorisation has been recorded electronically. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Director may participate in a meeting by electronic means of communication, provided that all Directors
participating in the meeting can hear each other simultaneously. A Director so participating shall be deemed to be present at the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Director shall have one vote. All resolutions shall be adopted by an absolute majority of the votes cast
at a meeting at which more than half of the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors are present or represented. In the event of a tie vote, the proposal shall have been rejected. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that one or more Directors have a direct or indirect personal interest that conflicts with the
interest of the Company and the business connected with it, they shall not be authorised to participate in the discussion and the decision-making process. In the event that all Directors have a direct or indirect personal interest that conflicts
with the interest of the Company and the business connected with it, the resolution shall nevertheless be adopted by the Board and the Directors shall, in derogation of the preceding sentence, continue to be authorised to participate in the
discussion and decision-making process. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive Directors shall not be authorised to participate in the discussion and the decision-making process
regarding the determination of the remuneration of Executive Directors or, if the General Meeting has failed to do so, the giving of an assignment to an Auditor to audit the Annual Accounts. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When determining to what extent the Directors cast votes, are present or represented, no account shall be taken
of Directors who are not authorised to participate in the discussion and the decision-making process pursuant to Articles 20.12 and 20.13. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A written statement of the chairman of the meeting of the Board that the Board has adopted a resolution shall
constitute proof of such resolution <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> third parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may adopt resolutions without holding a meeting, provided that all Directors have consented to this
manner of adopting resolutions and the votes are cast in writing or by electronic means. Articles 20.11 up to and including 20.14 shall apply by analogy to the adoption of resolutions by the Board without holding a meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Executive Directors may validly adopt resolutions with regard to matters falling within the scope of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of the Company. Articles 20.8 up to and including 20.16 shall apply by analogy to the adoption of resolutions by the Executive Directors. The Executive
Directors shall as soon as possible notify the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors of the adopted resolutions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">20.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors may validly adopt resolutions with regard
to matters falling within the scope of their authority pursuant to the law or these Articles of Association. Articles 20.8 up to and including 20.16 shall apply by analogy to the adoption of resolutions by the
<FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors. The <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors shall as soon as possible notify the Executive Directors of the adopted resolutions. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Approval of resolutions of the Board </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Resolutions of the Board with regard to an important change in the identity or character of the Company or the
business connected with it are subject to the prior approval of the General Meeting, including in any case: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfer of the business or almost the entire business to a third party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">entry into or termination of a long-term cooperation by the Company or a Subsidiary thereof with another legal
person or partnership or as a fully liable partner in a limited or general partnership, if such cooperation or termination thereof is of <FONT STYLE="white-space:nowrap">far-reaching</FONT> significance to the Company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">acquisition or disposal by the Company or a Subsidiary thereof of a participating interest in the capital of a
company with a value of at least <FONT STYLE="white-space:nowrap">one-third</FONT> of the amount of the assets as shown in the balance sheet with explanatory notes or, if the Company prepares a consolidated balance sheet, as shown in the
consolidated balance sheet with explanatory notes, according to the most recently adopted Annual Accounts of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Without prejudice to Article 21.1, resolutions of the Board on the following matters are subject to the
approval of the majority of the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors, which approval shall be deemed to have been granted if the majority of the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors have cast
their vote in favour of the proposal concerned: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">application for admission of securities issued by the Company to trading on the NASDAQ Stock Market or any
other regulated foreign stock exchange located in the United States of America or elsewhere, or application for withdrawal of such admission; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">entry into or termination of a long-term cooperation by the Company or a Subsidiary of the Company with another
legal person or company or as a fully liable partner in a limited partnership or general partnership, if such cooperation or termination thereof is of <FONT STYLE="white-space:nowrap">far-reaching</FONT> significance to the Company or the Subsidiary
of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">acquisition of a Participating Interest by the Company or a Subsidiary of the Company in the capital of another
company with a value of at least five hundred thousand United States dollars (USD 500,000), or such higher amount as determined by the Board and recorded in writing, as well as any <FONT STYLE="white-space:nowrap">far-reaching</FONT> increase or
decrease in the size of any such Participating Interest; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">incurring debt by the Company or a Subsidiary of the Company in an amount of at least five hundred thousand
United States dollars (USD 500,000), or such higher amount as determined by the Board and recorded in writing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">capital investments by the Company or a Subsidiary of the Company requiring an amount equal to at least five
hundred thousand United States dollars (USD 500,000), or such higher amount as determined by the Board and recorded in writing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">acquisition, disposal or encumbrance of intellectual property rights and acquisition or granting of licences
and sublicenses by the Company or a Subsidiary of the Company, if the interest or value of such intellectual property rights, licences or sublicenses to the Company or the Subsidiary amounts to at least five hundred thousand United States dollars
(USD 500,000), or such higher amount as determined by the Board and recorded in writing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">entry into of any agreement, including any amendment or modification to any existing agreement, with or
consummate, directly or indirectly, any transaction or series of related transactions with: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any affiliate of the Company other than, in the case of the Company, any of its Subsidiaries or, in the case of
any Subsidiary of the Company, the Company or another Subsidiary of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Shareholder that, along with any Shareholder Affiliates and Associates of such Shareholder, to the
Company&#146;s actual knowledge, beneficially owns at least five per cent (5.00%) of Shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any person who is or was, since the beginning of the last financial year for which the General Meeting has
adopted Annual Accounts, even if such person does not presently serve in that role, an Executive Officer or <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director, or, to the Company&#146;s actual knowledge, any other person described under
(i)&nbsp;or (ii) above or any nominee for Executive Officer or <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any Associate, to the Company&#146;s actual knowledge, of any person described under (i)&nbsp;or (ii) above, in
each case other than any transaction involving one hundred and twenty thousand United States dollars (USD 120,000) or less in a financial year; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">adoption of an equity incentive plan or other program for the benefit of Executive Officers, <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Directors, employees or other service providers of the Company or any of its Group Companies, as well as any material amendment or termination thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">termination of the employment of a considerable number of employees of the Company and any of its Subsidiaries,
determined on a consolidated basis, at the same time or within a short time span; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a <FONT STYLE="white-space:nowrap">far-reaching</FONT> change in the working conditions of a considerable
number of employees of the Company and any of its Subsidiaries, determined on a consolidated basis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">entry into any sale or disposition of all or substantially all of the Company&#146;s assets determined on a
consolidated basis, whether in one or more series of transactions and irrespective of how such sale or disposition is structured, including by sale, exchange or transfer of the Company&#146;s consolidated assets or otherwise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">entry into any acquisition, whether in one or more series of transactions and irrespective of how such
acquisition is structured, including by merger, exchange or transfer, by the Company or any of its Subsidiaries, if such transaction has a value of at least one million United States dollars (USD 1,000,000), or such higher or lower amount as
determined by the Board and recorded in writing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">entry into any agreement other than as referred to above by the Company or a Subsidiary of the Company the
interest or value of which to the Company or the Subsidiary of the Company amounts to at least one million United States dollars (USD 1,000,000), or such higher or lower amount as determined by the Board and recorded in writing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the dissolution or liquidation or a similar transaction involving the Company or a material Subsidiary of the
Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(o)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">issue, sale, exchange, redemption, cancellation or purchase of Shares or shares in the share capital of any
Subsidiary of the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(p)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">declaration of any distributions with respect to the Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(q)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">increasing or decreasing the monetary thresholds set out in this Article 21.2; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(r)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">such other resolutions as specified in writing from time to time by the majority of the <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">21.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The absence of the approval of the General Meeting of a resolution as referred to in Article 21.1 or of the
approval of the majority of the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors of a resolution as referred to in Article 21.2 shall not affect the power of the Board or Executive Directors to represent the Company.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Executive Committee </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall have an Executive Committee. The Executive Committee shall consist of all Executive Directors
and such number of other Executive Officers as the Board may determine. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Executive Officers who are not Executive Directors shall be appointed by the Board. The Board may at any time
suspend or dismiss an Executive Officer who is not an Executive Director. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Dismissal of an Executive Officer who is not an Executive Director shall not cause the termination of an
employment agreement or similar agreement between the Company or a Group Company and the Executive Officer. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Executive Committee shall be charged with the matters concerning the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of the Company determined by the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may adopt rules with respect to the matters concerning the Executive Committee.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may, whether or not by rule, determine the duties with which each Executive Officer will be
particularly charged. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">22.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may grant a title to each Executive Officer who is not an Executive Director. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representation </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall have the power to represent the Company. The power to represent the Company shall, in addition
to the power of the Board, only be vested in two Executive Officers acting jointly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">23.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may appoint one or more officers with general or restricted power to represent the Company on a
continuing basis. Each officer shall represent the Company with due observance of the restrictions imposed on him or her. The Board may grant a title to such officers. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>24.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Failing or prevention from acting of Directors </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that one or more Executive Directors are failing or are prevented from acting, the remaining
Executive Directors or the only remaining Executive Director shall temporarily be in charge of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of the Company; in such case the <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Directors shall be authorised to designate one or more temporary Executive Directors. In the event that all Executive Directors or the only Executive Director is failing or is prevented from acting,
the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors shall temporarily be in charge of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of the Company, unless the <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Directors designate one or more temporary Executive Directors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">24.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event that one or more <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors are failing or
are prevented from acting, the remaining <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors or the only remaining <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director shall temporarily exercise the duties and powers conferred
upon the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors by law or these Articles of Association; in such case the remaining <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors or the only remaining <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Director shall be authorised to designate one or more temporary <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors. In the event that all
<FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors or the only <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors is failing or is prevented from acting, these duties and powers shall temporarily be exercised by one or more
persons to be designated for that purpose by the General Meeting. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>25.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Executive Officers and <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors
</B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To the fullest extent permitted by Dutch law, the following shall be reimbursed to the Indemnitees:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the costs of conducting a defence against claims, also including claims by the Company and its Group Companies,
as a consequence of any acts or omissions in the fulfilment of their duties or any other duties currently or previously performed by them at the Company&#146;s request; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any damages or financial penalties payable by them as a result of any such acts or omissions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any amounts payable by them under settlement agreements entered into by them in connection with any such acts
or omissions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the costs of appearing in other legal proceedings in which they are involved as Executive Officers, <FONT
STYLE="white-space:nowrap">Non-Executive</FONT> Directors, former Executive Officers or former <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors, with the exception of proceedings primarily aimed at pursuing a claim on their own
behalf; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any taxes payable by them as a result of any reimbursements in accordance with this Article 25.1.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An Indemnitee shall not be entitled to reimbursement as referred to in Article 25.1 if and to the extent that:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it has been adjudicated by a Dutch court or, in the case of arbitration, an arbitrator, in a final and
conclusive decision that the act or omission of the Indemnitee may be characterised as intentional, deliberately reckless or grossly negligent conduct, unless Dutch law provides otherwise or this would, in view of the circumstances of the case, be
unacceptable according to standards of reasonableness and fairness; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the costs or financial loss of the Indemnitee are covered by an insurance and the insurer has paid out the
costs or financial loss. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If and to the extent that it has been adjudicated by a Dutch court or, in the case of arbitration, an
arbitrator, in a final and conclusive decision that the act or omission of the Indemnitee may be characterised as intentional, deliberately reckless or grossly negligent conduct or that the Indemnitee is otherwise not entitled to reimbursement as
referred to in Article 25.1, he or she shall immediately repay the amount reimbursed by the Company. The Company may request that the Indemnitee provides appropriate security for his repayment obligation. The Company may take out liability insurance
for the benefit of Executive Officers, <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors, former Executive Officers and former <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may, by agreement or otherwise, give further implementation to Articles 25.1 up to and including
25.3. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Where this Article 25 would limit any contractual entitlement of any Indemnitees to indemnification or
reimbursement, such contractual entitlement shall prevail. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">25.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amendment of this Article 25&nbsp;may not prejudice the entitlement of any Indemnitees to reimbursement as
referred to in Article 25.1 as a result of acts or omissions in the period during which that Article was in force. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>26.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>General Meetings </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Annually, within six months of the end of the financial year, a General Meeting shall be held. The notice for
this meeting shall in any case mention the following matters: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the consideration of the Annual Accounts, the Management Report and the information, referred to in section
2:392 subsection 1 of the Dutch Civil Code, insofar as that provision applies to the Company; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the adoption of the Annual Accounts; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the allocation of the profits or the determination how a loss will be accounted for. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">These items need not be mentioned in the notice of meeting if the period for preparing the Annual Accounts and for presenting the Management
Report has been extended by the General Meeting or if the notice of meeting mentions a proposal to that effect. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall be authorised to convene a General Meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">26.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A General Meeting shall be convened whenever the Board considers appropriate, without prejudice to sections
2:110 up to including 2:112 of the Dutch Civil Code. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>27.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Venue, notice and agenda of the General Meetings </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">27.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General Meetings shall be held in the Netherlands, in Amsterdam, Rotterdam, The Hague, Arnhem, Utrecht or
Haarlemmermeer (Schiphol Airport). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">27.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of a General Meeting shall be given by the Board or a Director. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">27.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice of a General Meeting shall be given by means of an announcement made by electronic means of
communication which is directly and permanently accessible until the General Meeting and with due observance of the applicable law and stock exchange rules. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">27.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The notice of a General Meeting shall mention: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the matters to be discussed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the place and time of the meeting; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the procedure for attending the meeting by a proxy authorised in writing; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the procedure for attending the meeting and the exercise of the voting rights by any means of electronic
communication in the event such right can be exercised in accordance with Article 30.2. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">27.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notifications which pursuant to the law or these Articles of Association are to be addressed to the General
Meeting may be included in the notice of meeting and, where applicable, in the document that has been made available at the offices of the Company for inspection, provided that this is mentioned in the notice. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">27.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A matter of which discussion has been requested in writing by one or more Persons with Meeting Rights who are
so entitled pursuant to section 2:114a subsection 2 of the Dutch Civil Code shall be mentioned in the notice of meeting or announced in the same manner if the Company has received the request, including the reasons, or a proposal for a resolution no
later than on the date specified in section 2:114a subsection 2 of the Dutch Civil Code. The requirement of written form for the request shall be met if the request has been recorded electronically. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">27.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notice shall be given with due observance of the notice period prescribed by applicable law.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>28.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Chairman and secretary of the General Meeting </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The General Meeting shall be presided over by the chairman of the Board, who, nevertheless, may charge another person to preside over the
meeting in his or her place even if he or she is present at the meeting. If the chairman of the Board is absent and he has not charged another person to preside over the meeting in his or her place, the Directors present at the meeting shall appoint
one of them to be chairman. In the absence of all Directors, the General Meeting shall appoint its chairman. The chairman shall designate the secretary of the General Meeting. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>29.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Minutes and recording of resolutions of the General Meeting </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The secretary of the General Meeting shall keep minutes of the proceedings at the meeting, unless a notarial
record is prepared in accordance with Article 29.2. Minutes shall be adopted and in evidence of such adoption be signed by the chairman and the secretary of the General Meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman of the General Meeting and each Director may at any time give instructions that a notarial record
of the proceedings at the meeting be prepared at the expense of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Board was not represented at the meeting, the chairman of the General Meeting shall as soon as possible
notify the chairman of the Board of the adopted resolutions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">29.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall keep a record of the adopted resolutions. The records shall be available at the offices of the
Company for inspection by the Persons with Meeting Rights. Upon request, each of them shall be provided with a copy or extract of such records at no more than cost. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>30.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Rights at the General Meeting </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">30.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Person with Meeting Rights shall be authorised to attend the General Meeting, to address the General
Meeting and to exercise the voting rights he or she is entitled to in person or by a proxy authorised in writing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">30.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Person with Meeting Rights shall be authorised to attend the General Meeting in person or by a proxy
authorised in writing, to address the General Meeting and to exercise the voting rights he or she is entitled to by electronic means of communication, if this is mentioned in the notice of the meeting. To do so, the Person with Meeting Rights must
be identifiable through the electronic means of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
communication and be able to directly observe the proceedings at the meeting and to exercise the voting rights. A Person with Meeting Rights so attending shall be deemed to be present or
represented at the meeting. The persons giving notice of the meeting may set conditions for the use of the electronic means of communication. These conditions shall be mentioned in the notice of the meeting. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">30.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of Articles 30.1 and 30.2 the requirement of written form for the authorisation shall be met if
the authorisation has been recorded electronically. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">30.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the purpose of Articles 30.1 and 30.2 the persons who on a record date to be set by the Board with due
observance of section 2:119 subsection 2 of the Dutch Civil Code have the right to vote or attend the General Meeting and are registered as such in a register designated by the Board shall be deemed to have such rights and therefore be deemed to be
Persons with Meeting Rights, irrespective of whom are entitled to the Shares at the time of the meeting. The notice of meeting shall mention the record date as well as the manner in which the persons entitled to vote and attend the General Meeting
can register and the manner in which they can exercise their rights. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">30.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Person with Meeting Rights who on the record date referred to in Article 30.4 has the right to vote or attend
the General Meeting, or a proxy authorised in writing, will only be admitted to the meeting if the Person with Meeting Rights has informed the Board of his or her intention to attend the meeting and, if applicable, of the authorisation prior to the
date to be set by the Board. Such date may not be set earlier than on the eighth day prior to the date of the meeting. The notice of meeting shall mention the date referred to in the preceding sentence. The Company shall offer the Person with
Meeting Rights the possibility to inform the Company by electronic means of the authorisation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">30.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each person present at the General Meeting who is entitled to vote must sign the attendance list, stating his
or her name and the number of votes he or she may cast. The chairman of the meeting may determine that the attendance list must also be signed by other persons present at the meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">30.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Directors shall as such have an advisory vote at the General Meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">30.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman of the General Meeting shall decide on the admittance of other persons to the meeting.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>31.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Order of the General Meeting </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman of the General Meeting shall determine the order of the meeting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">31.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman of the General Meeting may limit the time any person present at the meeting may address the
meeting and may take any other measures as to ensure orderly proceedings at the meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>32.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Adoption of resolutions at the General Meeting </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Share confers the right to cast one vote. Blank votes and invalid votes shall be regarded as not having
been cast. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon convening a General Meeting, the Board may determine that votes which are cast prior to the meeting by
electronic means of communication or by letter shall be put on par with votes which are cast at the time of the meeting. These votes shall not be cast earlier than on the record date set by the Board with due observance of section 2:117b subsection
3 of the Dutch Civil Code. For the purposes of the two preceding sentences, the persons who have the right to vote or attend the meeting and are registered as such in a register designated by the Board as of the record date set by the Board shall be
deemed to have such rights for purposes of the General Meeting and therefore be deemed to be Persons with Meeting Rights, irrespective of whoever is entitled to the Shares at the time of the General Meeting. The notice of meeting shall mention the
record date as well as the manner in which the persons entitled to vote and attend the General Meeting can register and the manner in which they can exercise their rights. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless the law or these Articles of Association require a larger majority, all resolutions shall be adopted by
an absolute majority of the votes cast. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman of the General Meeting shall determine the manner of voting. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The chairman&#146;s decision at the General Meeting on the result of a vote shall be conclusive. The same shall
apply to the contents of an adopted resolution, to the extent that the vote related to a proposal not made in writing. If immediately after the chairman&#146;s decision its correctness is contested, there shall be a new free vote if the majority of
the meeting or, if the original vote was not taken on a poll or by a ballot, any person present who is entitled to vote so requires. Such new vote shall overrule the legal consequences of the original vote. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A written statement of the chairman of the General Meeting that the General Meeting has adopted a resolution
shall constitute proof of such resolution <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">vis-&agrave;-vis</FONT></FONT> third parties. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the General Meeting no votes may be cast in respect of a Share held by the Company or a Subsidiary thereof;
no votes may be cast in respect of a Share the depositary receipt for which is held by the Company or a Subsidiary thereof. However, the holders of a right of usufruct and holders of a right of pledge on Shares held by the Company and its
Subsidiaries are not excluded from their right to vote, if the right of usufruct or the right of pledge was created prior to the time such Share was held by the Company or a Subsidiary thereof. Neither the Company nor a Subsidiary thereof may cast
votes in respect of a Share on which it holds a right of usufruct or a right of pledge. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">32.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When determining to what extent the Shareholders cast votes, are present or represented or to what extent the
share capital is provided or represented, no account shall be taken of Shares which are not entitled to voting rights pursuant to Article 32.7. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>33.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Meetings of holders of Shares of a particular class </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall be authorised to convene a meeting of holders of Shares of a particular class.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A meeting of holders of Shares of a particular class shall be convened whenever pursuant to the law or these
Articles of Association a resolution of the meeting of holders of Shares of such class is required and furthermore whenever the Board considers appropriate. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">33.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Articles 27 up to and including 32 shall apply by analogy to meetings of holders of Shares of a particular
class, provided, however, that: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notice shall be given no later than on the sixth day prior to the date of the meeting; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">on the proposal of the Board, holders of Shares of a particular class may adopt resolutions without holding a
meeting, provided that they are adopted by unanimous vote of the holders of Shares of the particular class entitled to vote and that the votes are cast in writing or by electronic means; the holders of Shares of the particular class involved shall
as soon as possible notify the chairman of the Board of the adopted resolutions; Article 29.4 shall apply by analogy to these resolutions. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>34.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial year </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The Company&#146;s financial year shall coincide with the calendar year. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>35.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Annual Accounts and Management Report </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">35.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Annually, within five months of the end of the financial year, subject to an extension of such period not
exceeding five months by the General Meeting on the basis of special circumstances, the Board shall prepare Annual Accounts and shall make these available at the offices of the Company for inspection by the Persons with Meeting Rights. The Board
shall also make the Management Report available at the offices of the Company for inspection by the Persons with Meeting Rights within said period. The Board shall add to the Annual Accounts and the Management Report the information, referred to in
section 2:392 subsection 1 of the Dutch Civil Code, insofar as that subsection applies to the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">35.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Annual Accounts shall be signed by all Directors. If the signature of one or more of them is lacking, this
shall be disclosed, stating the reasons thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">35.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall ensure that the Annual Accounts as prepared, the Management Report and the additional
information to be added pursuant to section 2:392 subsection 1 of the Dutch Civil Code shall be available at the offices of the Company as of the date of the notice of the General Meeting at which they are to be discussed. The Persons with Meeting
Rights may inspect the documents at the offices of the Company and obtain a copy thereof at no cost. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">35.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Annual Accounts shall be adopted by the General Meeting. Adoption of the Annual Accounts shall not be
deemed to grant a Director a discharge. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>36.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Auditor </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall give an assignment to an Auditor to audit the Annual Accounts. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting shall be authorised to give the assignment. If the General Meeting fails to do so, then the
Board shall be authorised to give the assignment. The assignment may be revoked at any time by the General Meeting or, if the Board has given the assignment, by the Board. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">36.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Auditor shall report on his or her audit to the Board and shall issue a certificate containing its results.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>37.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Share premium reserves </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">37.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall maintain separate share premium reserves for the benefit of the holders of each series of
Financing Preferred Shares. Payments on Financing Preferred Shares of a particular series in excess of the nominal value shall be added to the share premium reserve maintained by the Company for the benefit of the holders of the series of Financing
Preferred Shares on which the payment is made. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">37.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Article 37.1 shall apply by analogy to any disposal by the Company of Financing Preferred Shares, or of
depositary receipts thereof, provided that in such case the nominal value of the Financing Preferred Shares of the series concerned, or of the Financing Preferred Shares of the series concerned for which the depositary receipts have been issued,
also shall be added to the relevant share premium reserve. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>38.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Profit and loss </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting shall be authorised to allocate the profits, subject to Articles 38.2 and 38.3.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From the profits made in any financial year, first of all, to the extent possible, the following distributions
shall be made: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the holders of Financing Preferred Shares, an amount equal to the average during the financial year
concerned of the twelve month Euro Interbank Offered Rate (Euribor), as set by the European Central Bank, weighted by the number of days on which such interest rate was applicable, increased by a margin not exceeding five hundred basis points, to be
set by the Board upon issue of the relevant Financing Preferred Shares, calculated on the weighted average during that financial year of the aggregate amount paid up and called up on their Financing Preferred Shares; therefore, any increases and
reductions of the amounts paid up and called up on their Financing Preferred Shares during that financial year shall be taken into account for the purpose of calculating each distribution; the days during which the Financing Preferred Shares were
held by the Company shall be disregarded; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if Financing Preferred Shares were cancelled during the preceding financial year, to the last former holders of
those Financing Preferred Shares, an amount equal to the amount of the distribution referred to in Article 11.4 under (b), reduced by the amount of the distribution already received by them pursuant to that provision. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If in any financial year the profits are insufficient to make such distributions, the
deficit shall, to the extent possible, be distributed from any of the Distributable Reserves determined by the Board. If the profits made in any financial year or the Distributable Reserves are insufficient to make such distributions, the deficit
shall be distributed from the profits made and the Distributable Reserves maintained in the following financial years and the preceding sentence of this Article 38.2 and Article 38.3 shall first apply after the deficit has been fully made up. Other
than as set out in this Article 38.2, the Financing Preferred Shares shall not participate in the profits and the reserves of the Company, except that the holders of a series of Financing Preferred Shares shall participate in the share premium
reserve maintained by the Company for the benefit of the holders of such series of Financing Preferred Shares. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall be authorised to determine that the profits remaining after application of Article 38.2 shall
in whole or in part be reserved. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board shall be authorised to determine how a loss will be accounted for. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">38.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A deficit may only be applied against reserves maintained pursuant to the law to the extent permitted by law.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>39.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Distributions </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting shall be authorised to declare distributions, subject to Articles 39.2 up to and including
39.4. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may only resolve to declare distributions on the proposal of the Board.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company may only make distributions to the Shareholders and other persons entitled to distributable profits
to the extent that its equity exceeds the aggregate amount of the issued share capital and the reserves which must be maintained pursuant to applicable law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any distribution of profits shall be made only following the adoption of the Annual Accounts by the General
Meeting that show such distribution is permitted in accordance with Article 39.3. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Board may resolve to may make interim distributions, provided that the requirement of Article 39.3 has been
met as evidenced by an interim financial statement as referred to in section 2:105 subsection 4 of the Dutch Civil Code. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shares held by the Company shall not be taken into account for the purpose of calculating each distribution,
unless such Shares are encumbered with a right of usufruct or a right of pledge. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Distributions on Shares of a particular class shall be made pro rata on all Shares of such particular class.
Distributions to the last former holders of Financing Preferred Shares that have been cancelled shall be made pro rata on the aggregate amount of the Financing Preferred Shares held by such holders immediately before the cancellation.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Distributions shall be due and payable four weeks after they have been declared, unless the General Meeting
determines another date on the proposal of the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Distributions which have not been collected within five years of the start of the day after the day on which
they became due and payable shall revert to the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may determine that distributions shall be made in whole or in part in the form of Shares or
in a currency other than the euro, provided on the proposal of the Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">39.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company shall announce any proposal for a distribution and the date when and the place where the
distribution will be payable to all Shareholders by electronic means of communication with due observance of the applicable law and stock exchange rules. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>40.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendment of these Articles of Association </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">40.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting shall be authorised to amend these Articles of Association. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">40.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may only resolve to amend these Articles of Association on the proposal of the Board.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">40.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a proposal to amend these Articles of Association is to be made to the General Meeting, such shall always be
mentioned in the notice of the General Meeting. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>41.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Dissolution and liquidation </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting shall be authorised to dissolve the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting may only resolve to dissolve the Company on the proposal of the Board.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Article 40.3 shall apply by analogy to a proposal to dissolve the Company. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Company is dissolved pursuant to a resolution of the General Meeting, its assets shall be liquidated by
the Executive Directors, under the supervision of the <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Directors, if and to the extent that the General Meeting shall not resolve otherwise. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The General Meeting shall determine the remuneration of the liquidators and of the persons charged with the
supervision of the liquidation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The liquidation shall take place with due observance of the relevant provisions of Book 2 title 1 of the Dutch
Civil Code. During the liquidation period these Articles of Association shall, to the extent possible, remain in full force. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">From the balance of the assets of the Company remaining after the creditors have been paid first of all, to the
extent possible, the following distributions shall be made: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the holders of Financing Preferred Shares, in proportion to the aggregate amount of the Financing Preferred
Shares held by such holders: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the amount paid up on their Financing Preferred Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any deficit, referred to in Article 38.2; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an amount equal to the amount referred to in Article 38.2 under (a)&nbsp;calculated up to the date on which the
Company was dissolved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the holders of each series of Financing Preferred Shares, in proportion to the aggregate amount of the
Financing Preferred Shares held by such holders, the balance of the share premium reserve maintained by the Company for the benefit of the holders of the relevant series of Financing Preferred Shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to the last former holders of the Financing Preferred Shares that have been cancelled, in proportion to the
aggregate amount of the Financing Preferred Shares held by such holders immediately before cancellation: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any deficit, referred to in Article 38.2; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if their Financing Preferred Shares were cancelled in the financial year in which the Company was dissolved, an
amount equal to the amount of the distribution referred to in Article 11.4 under (b), reduced by the amount of the distribution already received by them pursuant to that provision. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If the surplus is insufficient to make such distributions in full, the surplus shall be distributed to the holders of Financing Preferred
Shares and last former holders of Financing Preferred Shares that have been cancelled in proportion to the aggregate amount to which they would be entitled if the surplus would be sufficient. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The balance remaining after application of Article 41.7 shall be distributed to the holders of Ordinary Shares
in proportion to the aggregate amount of the Ordinary Shares held by such holders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">41.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">After the Company has ceased to exist, its books, records and other data carriers shall remain in the custody
of the person designated for that purpose by the liquidators for a period of seven years. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FINAL DECLARATIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, the person appearing declares: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">pursuant to the present amendment of articles of association becoming effective each issued share in the share
capital of the Company is converted into an ordinary share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by a resolution, dated the thirtieth day of June two thousand and twenty, the general meeting of the Company
authorised the management board for a period of five years, commencing on the date on which this deed is executed and consequently ending on the thirtieth day of June two thousand and twenty-five, to issue shares and to grant rights to subscribe for
shares. The resolution of the general meeting granting the authorisation specifies that the authority to issue shares and to grant rights to subscribe for shares concerns all unissued shares of the authorised share capital as applicable on the date
on which this deed is executed or at any time in the future minus any shares that will be issued after that date pursuant to a resolution of the general meeting adopted prior to that date; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by a resolution, dated the thirtieth day of June two thousand and twenty, the general meeting of the Company
authorised the management board for a period of five years, commencing on the date on which this deed is executed and consequently ending on the thirtieth day of June two thousand and twenty-five, to limit or exclude
<FONT STYLE="white-space:nowrap">pre-emption</FONT> rights in respect of ordinary shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by a resolution, dated the thirtieth day of June two thousand and twenty, the general meeting of the Company
authorised the management board for a period of eighteen months, commencing on the date on which this deed is executed and consequently ending on the thirty-first day of December two thousand and <FONT STYLE="white-space:nowrap">twenty-one,</FONT>
to acquire ordinary shares in the share capital of the Company or depositary receipts thereof for consideration. The resolution of the general meeting granting the authorisation specifies that the maximum number of ordinary shares permitted pursuant
to applicable law and the articles of association from time to time may be acquired and that ordinary shares may be acquired through repurchases negotiated in the open market or privately, in self-tender offers, or through accelerated repurchase
arrangements, at prices ranging from the nominal value of the ordinary shares up to one hundred and ten percent (110%) of the market price of ordinary shares, provided that: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for open market or privately negotiated repurchases, the market price shall be the price for ordinary shares on
the NASDAQ Stock Market at the time of the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for self-tender offers, the market price shall be the volume weighted average price for the ordinary shares on
the NASDAQ Stock Market during a period, determined by the management board, of no less than one and no more than five consecutive trading days immediately prior to the expiration of the tender offer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">for accelerated repurchase arrangements, the market price shall be the volume weighted average price of the
ordinary shares on the NASDAQ Stock Market over the term of the arrangement. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The volume weighted average price for any
number of trading days shall be calculated as the arithmetic average of the daily volume weighted average price on those trading days; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by a resolution, dated the thirtieth day of June two thousand and twenty, the general meeting of the Company
authorised the management board for a period of eighteen months, commencing on the date on which this deed is executed and consequently ending on the thirty-first day of December two thousand and <FONT STYLE="white-space:nowrap">twenty-one,</FONT>
to acquire financing preferred shares in the share capital of the Company or depositary receipts thereof for consideration. The resolution of the general meeting granting the authorisation specifies that the maximum number of financing preferred
shares permitted pursuant to applicable law and the articles of association from time to time may be acquired and that financing preferred shares may be acquired through repurchases negotiated in the open market or privately, in self-tender offers,
or through accelerated repurchase arrangements, at prices ranging from the nominal value of the financing preferred shares up to the higher of: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the amount that would be paid by the Company upon cancellation of such financing preferred shares in accordance
with the relevant provisions of the articles of association of the Company; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">one hundred and ten percent (110%) of the market price of the ordinary shares into which the financing
preferred shares may be converted in accordance with the relevant provisions of the articles of association of the Company, whereby the market price shall be determined in the manner as set out above under (d); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">by a resolution dated the thirtieth day of June two thousand and twenty, the general meeting of the Company
resolved that the authorisations referred to above shall survive the transition of the articles of association of the Company in accordance with article 50 of the articles of association and that such authorisations shall, to the extent necessary,
from the first day of July two thousand and <FONT STYLE="white-space:nowrap">twenty-one</FONT> be deemed to have been granted to the board of the Company for the respective unexpired periods of such authorisations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the time of the present amendment of articles of association becoming effective the issued share capital of
the Company amounts to three hundred and thirty-seven thousand nine hundred and twelve euros and sixty-nine eurocents (EUR 337,912.69). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The certificate of which section 2:72 subsection 1 of the Dutch Civil Code prescribes that it shall be attached to this deed is attached to this deed
(<U>annex</U>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The person appearing is known to me, civil law notary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In witness whereof this deed is executed in Amsterdam, the Netherlands, on the date first mentioned in the head of this deed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After having conveyed the contents of this deed and having given an explanation thereto to the person appearing, she declared that she has taken note of the
contents of this deed and agrees with the same. Thereupon, immediately after limited reading of this deed, it is signed by the person appearing and by me, civil law notary, at ten hours and forty-five minutes Central European Time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d96389dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">


<IMG SRC="g96389g0731200351135.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PRIVILEGED AND STRICTLY CONFIDENTIAL</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immatics N.V.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paul-Ehrlich-Stra&szlig;e 15</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">72076 T&uuml;bingen,</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Federal Republic of Germany</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CMS Derks Star Busmann N.V.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Atrium |
Parnassusweg 737</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">NL-1077</FONT> DG Amsterdam</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">P.O. Box 94700</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">NL-1090</FONT> GS
Amsterdam</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bank&nbsp;account&nbsp;(Stichting&nbsp;Derdengelden)</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iban: NL31 RABO 0103 3545 49</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Swift/bic: RABONL2U</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>T </B>+31 20 301 63 01</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B></B><B>F </B>+31 20 301 63 35</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Subject: Immatics N.V. / Legal Opinion</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31&nbsp;July 2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sirs, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as
Dutch legal counsel to Immatics N.V., a public company with limited liability (<I>naamloze vennootschap</I>) of Amsterdam, the Netherlands (the &#147;<B>Company</B>&#148;) in respect of certain matters of Dutch law in connection with the filing of a
registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (the &#147;<B>Registration</B> <B>Statement</B>&#148;) with the United States Securities and Exchange Commission. The Registration Statement<B> </B>describes the business
combination between Immatics Biotechnologies GmbH and Arya Sciences Acquisition Corp. (&#147;<B>ARYA</B>&#148;), pursuant to which several transactions have occurred and in connection therewith, the Company has become the ultimate parent company of
Immatics Biotechnologies GmbH and ARYA (the &#147;<B>Business Combination</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the Business Combination, 10,415,000 ordinary shares in
the capital of the Company with a nominal value of &#128;&nbsp;0.01 each have been issued to the PIPE Investors (as such term has been defined in the Registration Statement) (the &#147;<B>PIPE Shares</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not express any opinion in relation to the content of the Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purpose of this legal opinion, we have examined and relied solely upon the following documents: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an electronically received copy of an extract relative to the Company, dated 31&nbsp;July 2020 (the
&#147;<B>Extract</B>&#148;) from the trade register (<I>handelsregister</I>) of the Dutch Chamber of Commerce (<I>Kamer van Koophandel</I>) (the &#147;<B>Trade Register</B>&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an official copy of the notarial deed of incorporation (<I>akte van oprichting</I>) of Immatics B.V., dated
10&nbsp;March 2020 (the &#147;<B>Deed of Incorporation</B>&#148;), containing the articles of association of the Company before the execution of the Deed of Conversion (the &#147;<B>B.V. Articles of Association</B>&#148;); </P></TD></TR></TABLE>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">All services are rendered under an agreement of instruction with CMS Derks Star Busmann N.V., with registered office in Amsterdam, the Netherlands. This
agreement is subject to the General Conditions of CMS Derks Star Busmann N.V., which have been filed with the registrar of the District Court Amsterdam, the Netherlands, under no. 2017/51 and which contain a limitation of liability. These terms have
been published on the website cms.law and will be provided upon request. CMS Derks Star Busmann N.V. is a company with limited liability under the laws of the Netherlands and is registered in the Netherlands with the trade register under no.
30201194 and in Belgium with the RPR Brussels under no. 0877.478.727. The VAT number of CMS Derks Star Busmann N.V. for the Netherlands is NL8140.16.479.B01 and for Belgium BE 0877.478.727. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">CMS Derks Star Busmann is a member of CMS, the organisation of European law firms. In certain circumstances, CMS is used as a brand or business name of, or to
refer to, some or all of the member firms or their offices. Further information can be found at www.cms.law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">CMS offices and associated offices: Aberdeen,
Algiers, Amsterdam, Antwerp, Barcelona, Beijing, Belgrade, Berlin, Bratislava, Bristol, Brussels, Bucharest, Budapest, Casablanca, Cologne, Dresden, Duesseldorf, Dubai, Edinburgh, Frankfurt, Geneva, Hamburg, Hong Kong, Istanbul, Kyiv, Leipzig,
Lisbon, Ljubljana, London, Luxembourg, Lyon, Madrid, Milan, Moscow, Munich, Muscat, Paris, Prague, Rio de Janeiro, Rome, Sarajevo, Seville, Shanghai, Sofia, Strasbourg, Stuttgart, Tehran, Tirana, Utrecht, Vienna, Warsaw, Zagreb and Zurich. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g96389g0731200351851.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an official copy of the notarial deed of conversion, dated 1&nbsp;July 2020 (the &#147;<B>Deed of</B>
<B>Conversion</B>&#148;), containing the current articles of association of the Company (the &#147;<B>N.V. Articles of Association</B>&#148;);<B> </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a copy of the deed of issue of the PIPE Shares to the investors as set out in the deed (the &#147;<B>Deed</B>
<B>of Issue</B>&#148;);<B> </B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an electronically received copy of a written resolution of the management board (<I>het bestuur</I>) of the
Company, dated 30&nbsp;June 2020 (the &#147;<B>Board Resolution</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an electronically received copy of a written resolution of the general meeting (<I>algemene</I>
<I>vergadering</I>) of the Company, dated 30&nbsp;June 2020 (the &#147;<B>Shareholder Resolution</B>&#148;, the<I> </I>Shareholder Resolution and the Board Resolution shall collectively be referred to as the &#147;<B>Resolutions</B>&#148;).
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with such examination and for the purpose of the legal opinion expressed herein we have assumed: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the time of the issuance of the PIPE Shares, the Company&#146;s authorized capital was sufficient;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the PIPE Shares issued pursuant to the Deed of Issue have been accepted by their subscribers in accordance with
all applicable laws (including for the avoidance of doubt, Dutch law); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the PIPE Shares have been validly paid up at the time of the issuance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the genuineness of all signatures on all original documents of the persons purported to have signed the same;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the conformity to their originals of all documents submitted or transmitted to us in the form of photocopies,
electronically or otherwise, and the authenticity and completeness of such originals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Resolutions and the resolutions reflected therein have been validly signed and were and are in full
force and effect at the time of the issuance of the PIPE Shares and that none of these resolutions have been or will be withdrawn or restated and that no resolutions have been or will be adopted to amend the contents of these resolutions;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Deed of Incorporation and the Deed of Conversion are valid notarial deeds (<I>notari&euml;le</I>
<I>aktes</I>), that the contents thereof are correct and complete, it being hereby confirmed that on<I> </I>the face of the Deed of Incorporation and the Deed of Conversion it does not appear that the Deed of Incorporation and the Deed of Conversion
are not valid notarial deeds; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(viii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the B.V. Articles of Association were in full force and effect before the execution of the Deed of
Conversion and that the N.V. Articles of Association are in full force and effect as at the date hereof, it being hereby confirmed that on the face of the N.V. Articles of Association and the Extract it does not appear that the N.V. Articles of
Association are not in full force and effect as at the date hereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ix)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any and all authorisations and consents of, or other filings with or notifications to, any public authority or
other relevant body or person in or of any jurisdiction which may be required (other than under Dutch law) in respect of the execution or performance of the Business Combination have been or will be duly obtained or made, as the case may be;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g96389g0731200351851.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(x)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that no petition has been presented to nor order made by a court for the bankruptcy (<I>faillissement</I>) of
the Company and that no resolution has been adopted concerning a statutory merger (<I>juridische fusie</I>) or division (<I>splitsing</I>) involving the Company as disappearing entity, or a voluntary liquidation (<I>ontbinding</I>) of the Company;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that, at the date hereof, the information contained in the Extract truly and correctly reflects the position of
the Company as mentioned therein; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that, at the date hereof, the Company is not included on the consolidated list of persons, groups and entities
subject to EU financial sanctions (the &#147;<B>Sanctions List</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xiii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that, at the date hereof, the directors of the Company are not included on the list of natural persons subject
to a director&#146;s disqualification (<I>civielrechtelijk bestuursverbod</I>) under the laws of the Netherlands (the &#147;<B>Disqualification List</B>&#148;); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(xiv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">that the Company has not been dissolved (<I>ontbonden</I>), merged (<I>gefuseerd</I>) involving the Company as
disappearing entity, demerged (<I>gesplitst</I>), converted (<I>omgezet</I>), granted a suspension of payments (<I>surs&eacute;ance verleend</I>), subjected to emergency regulations (<I>noodregeling</I>) as provided for in the Financial Supervision
Act (<I>Wet op het Financieel</I> <I>Toezicht</I>), declared bankrupt (<I>failliet verklaard</I>), subjected to any other insolvency<I> </I>proceedings listed in Annex A or winding up proceedings listed in Annex B of Council Regulation (EC) No
1346/2000 on insolvency proceedings of 29&nbsp;May 2000, listed on the list referred to in article 2 (3) of Council Regulation (EC) No 2580/2001 of 27&nbsp;December 2001, listed in Annex I to Council Regulation (EC) No 881/2002 of 27&nbsp;May 2002
or listed and marked with an asterisk in the Annex to Council Common Position 2001/931 of 27&nbsp;December 2001 relating to measures to combat terrorism, as amended from time to time, and no trustee (<I>curator</I>), administrator
(<I>bewindvoerder</I>) or similar officer has been appointed in respect of the Company or any of its respective assets. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In support of
the assumptions under (xi), (xii) and (xiv), we have carried out the following investigations. The office of the bankruptcy registrar of the District Court of Amsterdam has confirmed to us by telephone today at 10:19 CEST that the Company has not
been declared bankrupt (<I>in staat van</I> <I>faillissement</I>) and has not been granted a suspension of payment (<I>surs&eacute;ance van betaling</I>). Furthermore,<I> </I>we have obtained a confirmation through <U>http://www.rechtspraak.nl</U>,
derived from the segment for EU registrations of the Central Insolvency Register, that the Company is not registered as being subject to insolvency proceedings. The Trade Register has confirmed to us by telephone today at 10:16 CEST that the Company
has not been dissolved at the initiative of the Dutch Chamber of Commerce and that no resolution to dissolve, merge (<I>juridisch fuseren</I>) or demerge (<I>splitsen</I>) the Company was filed. In the same telephone call, the official of the Trade
Register confirmed to us that no amendments in the registration of the Company occurred in the period from the provision of the Extract to us through the date and time hereof. Moreover, in support of the assumption under (xii), we have carried out
an online search today at 10:23 CEST <U>https://webgate.ec.europa.eu/europeaid/fsd/fsf</U> showing that the Company is not included on the Sanctions List. We have not investigated any matter that is the subject of an assumption made in this legal
opinion other than as set forth herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g96389g0731200351851.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We express no opinion as to any law other than the laws of the Netherlands in force at the date hereof as
applied and interpreted according to present duly published case law of the Dutch courts. No opinion is rendered with respect to any matters of fact, anti-trust law, market abuse, equal treatment of shareholders, financial assistance, tax law or the
laws of the European Communities, to the extent not or not fully implemented in the laws of the Netherlands. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this legal opinion, Dutch legal concepts
are expressed in English terms and not in their original Dutch terms. Where indicated in italics, Dutch equivalents of these English terms have been given for the purpose of clarification. The Dutch concepts may not be identical to the concepts
described by the same English terms as they exist under the laws of other jurisdictions. Terms and expressions of law and of legal concepts as used in this legal opinion have the meaning attributed to them under the laws of the Netherlands and this
legal opinion should be read and understood accordingly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This legal opinion is strictly limited to the matters stated herein and may not be read as
extending by implication to any matter not specifically referred to. Nothing in this legal opinion should be taken as expressing an opinion in respect of the factual accuracy of any representations or warranties, or other information, contained in
any document, referred to herein or examined in connection with this legal opinion, except as expressly stated otherwise. For the purpose hereof, we have assumed such accuracy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the foregoing (including, without limitation, the documents and the assumptions set out above) and subject to the qualifications set out below and
any facts, circumstances, events or documents not disclosed to us in the course of our examination referred to above, we are, at the date hereof, of the opinion that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The PIPE Shares have been validly issued, fully paid and are <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinion expressed above is subject to the following qualifications: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The opinion expressed above may be affected or limited by any applicable bankruptcy, insolvency, fraudulent
conveyance <I>(actio pauliana</I>), reorganization, suspension of payment and other or similar laws now or hereafter in effect, relating to or affecting the enforcement or protection of creditors&#146; rights. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A power of attorney (<I>volmacht</I>) or mandate (<I>lastgeving</I>) granted or issued by the Company will
terminate by force of law and without any notice being required upon bankruptcy of the Company and will become ineffective upon a suspension of payments (<I>surs&eacute;ance van</I> <I>betaling</I>) being granted to the Company.<I> </I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A court applying the laws of the Netherlands may: (i)&nbsp;at the request of any party to an agreement change
the effect of an arrangement or dissolve it in whole or in part in the event of unforeseen circumstances (<I>onvoorziene omstandigheden</I>) of such nature that do not, according the standards of reasonableness and fairness, justify the other party
to expect the agreement to be maintained unchanged; (ii)&nbsp;limit any claim for damages or penalties on the basis that such claim is deemed excessive by the court; and (iii)&nbsp;refuse to give effect to any provisions for the payment of expenses
in respect of the costs of enforcement (actual or attempted) or unsuccessful litigation brought before such court or tribunal or where such court or tribunal has itself made an order for costs. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g96389g0731200351851.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a party is controlled by or otherwise connected with a person, organization or country that is currently the
subject of sanctions by the United Nations, the European Community or the Netherlands, implemented, effective or sanctioned in the Netherlands under the Sanctions Act 1977 (<I>Sanctiewet 1977</I>), the Economic Offences Act (<I>Wet op de economische
delicten</I>) or the Financial Supervision Act (<I>Wet op het Financieel Toezicht</I>) or is otherwise the target of any such sanctions, the obligations of the Company to that party may be unenforceable, void or otherwise affected.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The term <FONT STYLE="white-space:nowrap">&#147;non-assessable&#148;</FONT> has no equivalent legal term under
Dutch law and for the purpose of these opinions, <FONT STYLE="white-space:nowrap">&#147;non-assessable&#148;</FONT> means that a holder of a PIPE Share will not by reason of merely being such a holder, be subject to assessment or calls by the
Company or its creditors for further payment on such PIPE Share. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is rendered to you for the sole purpose of the filing of
this opinion as an exhibit to the Registration Statement to be submitted by the Company on the date hereof, to which filing we consent under the express condition that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we do not admit that we are within the category of persons whose consent is required within Section&nbsp;7 of
the Securities Act of 1933; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any issues of interpretation of liability arising under this legal opinion will be governed exclusively by the
laws of the Netherlands and be brought exclusively before a Dutch court; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this legal opinion is subject to acceptance of the limitation of liability as mentioned on the first page of
this letter; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">we do not assume any obligation to notify or to inform you of any developments subsequent to the date hereof
that might render its contents untrue or inaccurate in whole or in part at such time; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">this legal opinion is strictly limited to the matters set forth herein and no opinion may be inferred or
implied beyond our opinion expressly stated herein. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully, </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g96389img002.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CMS Derks Star Busmann N.V. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>d96389dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INVESTOR RIGHTS AND <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS INVESTOR RIGHTS AND <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT</B> (this &#147;<B>Agreement</B>&#148;) is entered into
as of July&nbsp;1, 2020, by and among Immatics N.V., a Dutch public limited liability company (the &#147;<B>Company</B>&#148;), the parties listed as Investors on Schedule I hereto (each, an &#147;<B>Investor</B>&#148; and collectively, the
&#147;<B>Investors</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, ARYA Sciences Acquisition Corp., a Cayman Islands exempted limited company
(&#147;<B>ARYA</B>&#148;), the Company, Immatics Merger Sub 1, a Cayman Islands exempted company (&#147;<B>ARYA</B> <B>Merger Sub</B>&#148;), Immatics Merger Sub 2, a Cayman Islands exempted company (&#147;<B>IB Merger Sub</B>&#148;), and Immatics
Biotechnologies GmbH, a German limited liability company (&#147;<B>GmbH</B>&#148;) have entered into that certain Business Combination Agreement, dated as of March&nbsp;17, 2020 (as amended or supplemented from time to time, the &#147;<B>Business
Combination Agreement</B>&#148;), pursuant to which, among other things: (i)&nbsp;each Participating Shareholder (as defined in the Business Combination Agreement) of GmbH exchanged his, her or its shares of GmbH for Ordinary Shares on the terms and
subject to the conditions therein (the &#147;<B>Exchange</B>&#148;) and (ii)&nbsp;ARYA Merger Sub will merge with and into ARYA (the &#147;<B>First Merger</B>&#148;), with ARYA surviving as a wholly owned subsidiary of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, ARYA, ARYA Sciences Holdings, a Cayman Islands exempted company (&#147;<B>Sponsor</B>&#148;), Dr.&nbsp;David Hung, Dr.&nbsp;Todd
Wider and Kevin Conroy (together with Sponsor, the &#147;<B>ARYA IPO Investors</B>&#148;) are parties to that certain Registration and Shareholder Rights Agreement, dated October&nbsp;10, 2018 (the &#147;<B>Prior Agreement</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the ARYA IPO Investors currently hold (i)&nbsp;Class&nbsp;B ordinary shares, par value $0.0001 per share, of ARYA issued by ARYA
prior to the consummation of ARYA&#146;s initial public offering (collectively, the &#147;<B>Founder Shares</B>&#148;) and (ii)&nbsp;warrants to purchase Class&nbsp;A ordinary shares, par value $0.0001 per share (&#147;<B>Class</B><B></B><B>&nbsp;A
Shares</B>&#148;), of ARYA issued by ARYA simultaneously with the consummation of ARYA&#146;s initial public offering (the &#147;<B>Sponsor&#146;s Warrants</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Founder Shares will automatically convert into Class&nbsp;A Shares at the time of the initial Business Combination (as defined in
the Prior Agreement) on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis, subject to adjustment, on the terms and conditions provided in ARYA&#146;s amended and restated memorandum and articles of
association, as the same may be amended from time, and will be exchanged for Ordinary Shares in connection with the First Merger; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Sponsor will forfeit all Sponsor&#146;s Warrants at the consummation of the Business Combination; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Perceptive Life Sciences Master Fund, Ltd, a Cayman Island exempted company (together with the ARYA IPO Investors, the &#147;<B>ARYA
Investors</B>&#148;) has subscribed to purchase Ordinary Shares in the PIPE Financing (defined below) in connection with the consummation of the Business Combination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, certain Investors (&#147;<B>GmbH Investors</B>&#148;) hold ownership interests in GmbH, consisting of ordinary shares (&#147;<B>GmbH
ordinary shares</B>&#148;); shares designated as Series C preferred shares (&#147;<B>GmbH Series C Preferred Shares</B>&#148;); shares designated as Series D preferred shares (&#147;<B>GmbH Series D Preferred Shares</B>&#148;), and shares designated
as Series E preferred shares (&#147;<B>GmbH Series E Preferred Shares</B>&#148; and together with GmbH ordinary shares, GmbH Series C Preferred Shares and GmbH Series D Preferred Shares, the &#147;<B>GmbH Shares</B>&#148;); </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, GmbH Shares will be exchanged for ordinary shares, nominal value &#128;0.01 per
share, of the Company (&#147;<B>Ordinary Shares</B>&#148;) on or about the date hereof, pursuant to the Business Combination Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the parties to the Prior Agreement desire to terminate the Prior Agreement to provide for the terms and conditions included herein.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>DEFINITIONS</U>. The following capitalized terms
used herein have the following meanings: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Addendum Agreement</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;8.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Agreement</B>&#148; is defined in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>ARYA Investors</B>&#148; is defined in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>ARYA IPO Investors</B>&#148; is defined in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Block Trade</B>&#148; means any <FONT STYLE="white-space:nowrap">non-marketed</FONT> underwritten offering taking the form of a block
trade to a financial institution, QIB or Institutional Accredited Investor, bought deal, over-night deal or similar transaction that does not include &#147;road show&#148; presentations to potential investors requiring substantial marketing effort
from management over multiple days, the issuance of a &#147;comfort letter&#148; by the Company&#146;s auditors, and the issuance of legal opinions by the Company&#146;s legal counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Combination Agreement</B>&#148; is defined in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Business Day</B>&#148; means a day other than a Saturday, Sunday or other day on which commercial banks in New York, New York are
authorized or required by law to close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Closing Date</B>&#148; is defined in the Business Combination Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Commission</B>&#148; means the Securities and Exchange Commission, or any other Federal agency then administering the Securities Act
or the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Company</B>&#148; is defined in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Demand Registration</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.2.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Demanding Holder</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.2.1</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Dievini</B>&#148; means dievini Hopp BioTech holding GmbH&nbsp;&amp; Co. KG. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Effectiveness Period</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;3.1.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission
promulgated thereunder, all as the same shall be in effect at the time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Form</B><B></B><B><FONT STYLE="white-space:nowrap">&nbsp;F-1</FONT></B>&#148; means a Registration Statement on Form <FONT
STYLE="white-space:nowrap">F-1.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Form <FONT STYLE="white-space:nowrap">F-3</FONT></B>&#148; means a Registration Statement
on Form <FONT STYLE="white-space:nowrap">F-3</FONT> or any similar short-form registration that may be available at such time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Founder Shares</B>&#148; is defined in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>GmbH Investors</B>&#148; is defined in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>GmbH Shares</B>&#148; is defined in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnified Party</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;4.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Indemnifying Party</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;4.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Institutional Accredited Investor</B>&#148; means an institutional &#147;accredited&#148; investor as defined in Rule 501(a) of
Regulation D under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Investor</B>&#148; is defined in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Investor Indemnified Party</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;4.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;6.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Maximum Number of Shares</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.2.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>New Registration Statement</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.1.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>New Securities</B>&#148;<B> </B>means all Ordinary Shares issued in connection with any of the First Merger, the Exchange or the PIPE
Financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Notices</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;8.3</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Ordinary Shares</B>&#148; is defined in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Perceptive</B>&#148; is defined in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Permitted Transferee</B>&#148; means (i)&nbsp;the members of an Investor&#146;s immediate family (for purposes of this Agreement,
&#147;<B>immediate family</B>&#148; shall mean with respect to any natural person, any of the following: such person&#146;s spouse, the siblings of such person and his or her spouse, and the direct descendants and ascendants (including adopted and
step children and parents) of such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
person and his or her spouses and siblings); (ii) any trust for the direct or indirect benefit of an Investor or the immediate family of an Investor; (iii)&nbsp;if an Investor is a trust, to the
trustor or beneficiary of such trust or to the estate of a beneficiary of such trust; (iv)&nbsp;any officer, director, general partner, limited partner, shareholder, member, or owner of similar equity interests in an Investor; (v)&nbsp;any affiliate
of an Investor or the immediate family of such affiliate or (vi)&nbsp;any affiliate of an immediate family of the Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Piggy-Back Registration</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.3.1</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>PIPE Financing</B>&#148; means the private placement of 10,415,000 Ordinary Shares to certain investors pursuant to
Section&nbsp;4(a)(2) of the Securities Act and/or Regulation D promulgated thereunder, for gross proceeds to the Company in an aggregate amount of approximately $104,150,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Prior Agreement</B>&#148; is defined in the preamble to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Pro Rata</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.2.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Q</B><B>IB</B>&#148; means &#147;qualified institutional buyer&#148; as defined in Rule 144A under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration</B>&#148; mean a registration effected by preparing and filing a registration statement or similar document in
compliance with the requirements of the Securities Act, and the applicable rules and regulations promulgated thereunder, and such registration statement becoming effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registrable Securities</B>&#148; means (i)&nbsp;New Securities and (ii)&nbsp;all Ordinary Shares issued to any Investor with respect
to such securities referenced in clause (i)&nbsp;by way of any share split, share dividend or other distribution, recapitalization, share exchange, share reconstruction, amalgamation, contractual control arrangement or similar event. As to any
particular Registrable Securities, such securities shall cease to be Registrable Securities when: (a)&nbsp;a Registration Statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities
shall have been sold, transferred, disposed of or exchanged in accordance with such Registration Statement; (b)&nbsp;such securities shall have been otherwise transferred, new certificates for them not bearing a legend restricting further transfer
shall have been delivered by the Company and subsequent public distribution of them shall not require registration under the Securities Act; or (c)&nbsp;such securities shall have ceased to be outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Registration Statement</B>&#148; means a registration statement filed by the Company or its successor with the Commission in
compliance with the Securities Act and the rules and regulations promulgated thereunder for a public offering and sale of equity securities, or securities or other obligations exercisable or exchangeable for, or convertible into, equity securities
(other than a registration statement on Form <FONT STYLE="white-space:nowrap">F-4,</FONT> Form <FONT STYLE="white-space:nowrap">S-4</FONT> or Form <FONT STYLE="white-space:nowrap">S-8,</FONT> or their successors, or any registration statement
covering only securities proposed to be issued in exchange for securities or assets of another entity). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Resale Shelf
Registration Statement</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.1.1</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>SEC Guidance</B>&#148; is defined in <U>Section</U><U></U><U>&nbsp;2.1.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated
thereunder, all as the same shall be in effect at the time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor&#146;s Warrants</B>&#148; is defined in the preamble to this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Transfer</B>&#148; means to (i)&nbsp;sell, offer to sell, contract or agree to sell, hypothecate, pledge, grant any
option to purchase or otherwise dispose of or agree to dispose of, directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section&nbsp;16 of the Exchange
Act, and the rules and regulations of the Commission promulgated thereunder, with respect to any Ordinary Shares, (ii)&nbsp;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of
ownership of any Ordinary Shares, whether any such transaction is to be settled by delivery of such securities, in cash or otherwise, or (iii)&nbsp;publicly announce any intention to effect any transaction, including the filing of a registration
statement specified in clause (i)&nbsp;or (ii), other than a Registration Statement filed pursuant to this Agreement. Notwithstanding the foregoing, a Transfer shall not be deemed to include any transfer for no consideration if the donee, trustee,
heir or other transferee has agreed in writing to be bound by the same terms under this Agreement to the extent and for the duration that such terms remain in effect at the time of the Transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Underwriter</B>&#148; means a securities dealer who purchases any Registrable Securities as principal in an underwritten offering and
not as part of such dealer&#146;s market-making activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Underwritten Demand Registration</B>&#148; shall mean an
underwritten public offering of Registrable Securities pursuant to a Demand Registration, as amended or supplemented, that is a fully marketed underwritten offering that requires Company management to participate in &#147;road show&#148;
presentations to potential investors requiring substantial marketing effort from management over multiple days, the issuance of a &#147;comfort letter&#148; by the Company&#146;s auditors, and the issuance of legal opinions by the Company&#146;s
legal counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Underwritten Takedown</B>&#148; shall mean an underwritten public offering of Registrable Securities pursuant to
the Resale Shelf Registration Statement, as amended or supplemented that requires the issuance of a &#147;comfort letter&#148; by the Company&#146;s auditors and the issuance of legal opinions by the Company&#146;s legal counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>REGISTRATION RIGHTS</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Resale
Shelf Registration Rights</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.1 <U>Registration Statement Covering Resale of Registrable Securities</U>. Provided compliance by the
Investors with <U>Section</U><U></U><U>&nbsp;3.4</U>, the Company shall prepare and file or cause to be prepared and filed with the Commission, no later than forty five (45)&nbsp;days following the Closing Date, a Registration Statement on Form <FONT
STYLE="white-space:nowrap">F-3</FONT> or its successor form, or, if the Company is ineligible to use Form <FONT STYLE="white-space:nowrap">F-3,</FONT> a Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1,</FONT> for an offering to
be made on a continuous basis pursuant to Rule 415 of the Securities Act registering the resale from time </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to time by Investors of all of the Registrable Securities then held by such Investors that are not covered by an effective resale registration statement (the &#147;<B>Resale Shelf Registration
Statement</B>&#148;). The Company shall use reasonable best efforts to cause the Resale Shelf Registration Statement to be declared effective as soon as possible after filing, and in no event later than the date that the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Period expires, and once effective, to keep the Resale Shelf Registration Statement continuously effective under the Securities Act at all times until the expiration of the Effectiveness Period. In the event
that the Company files a Form <FONT STYLE="white-space:nowrap">F-1</FONT> pursuant to this <U>Section</U><U></U><U>&nbsp;2.1</U>, the Company shall use its commercially reasonable efforts to convert the Form
<FONT STYLE="white-space:nowrap">F-1</FONT> to a Form <FONT STYLE="white-space:nowrap">F-3</FONT> as soon as practicable after the Company is eligible to use Form <FONT STYLE="white-space:nowrap">F-3.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.2 <U>Notification and Distribution of Materials</U>. The Company shall notify the Investors in writing of the effectiveness of the Resale
Shelf Registration Statement and shall furnish to them, without charge, such number of copies of the Resale Shelf Registration Statement (including any amendments, supplements and exhibits), the prospectus contained therein (including each
preliminary prospectus and all related amendments and supplements) and any documents incorporated by reference in the Resale Shelf Registration Statement or such other documents as the Investors may reasonably request in order to facilitate the sale
of the Registrable Securities in the manner described in the Resale Shelf Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.3 <U>Amendments and
Supplements</U>. Subject to the provisions of <U>Section</U><U></U><U>&nbsp;2.1.1</U> above, the Company shall promptly prepare and file with the Commission from time to time such amendments and supplements to the Resale Shelf Registration Statement
and prospectus used in connection therewith as may be necessary to keep the Resale Shelf Registration Statement effective and to comply with the provisions of the Securities Act with respect to the disposition of all the Registrable Securities
during the Effectiveness Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.4 Notwithstanding the registration obligations set forth in this
<U>Section</U><U></U><U>&nbsp;2.1</U>, in the event the Commission informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single
registration statement, the Company agrees to promptly (i)&nbsp;inform each of the holders thereof and use its commercially reasonable efforts to file amendments to the Resale Shelf Registration Statement as required by the Commission and/or
(ii)&nbsp;withdraw the Resale Shelf Registration Statement and file a new registration statement (a &#147;<B>New Registration Statement</B>&#148;), in either case covering the maximum number of Registrable Securities permitted to be registered by
the Commission, on Form <FONT STYLE="white-space:nowrap">F-1,</FONT> Form <FONT STYLE="white-space:nowrap">F-3</FONT> or such other form available to register for resale the Registrable Securities as a secondary offering; provided, however, that
prior to filing such amendment or New Registration Statement, the Company shall be obligated to use its commercially reasonable efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance with any
publicly-available written or oral guidance, comments, requirements or requests of the Commission staff (the &#147;<B>SEC Guidance</B>&#148;), including, without limitation, the Manual of Publicly Available Telephone Interpretations D.29.
Notwithstanding any other provision of this Agreement, if any SEC Guidance sets forth a limitation of the number of Registrable Securities permitted to be registered on a particular Registration Statement as a secondary offering (and notwithstanding
that the Company used diligent efforts to advocate with the Commission for the registration of all or a greater number of Registrable Securities), unless otherwise directed in writing by a holder as to its Registrable Securities, the number of
Registrable Securities to be registered on such Registration Statement </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be reduced on a Pro Rata basis, subject to a determination by the Commission that certain Investors must be reduced first based on the number of Registrable Securities held by such
Investors. In the event the Company amends the Resale Shelf Registration Statement or files a New Registration Statement, as the case may be, under clauses (i)&nbsp;or (ii) above, the Company will use its commercially reasonable efforts to file with
the Commission, as promptly as allowed by Commission or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form <FONT STYLE="white-space:nowrap">F-1,</FONT> Form <FONT
STYLE="white-space:nowrap">F-3</FONT> or such other form available to register for resale those Registrable Securities that were not registered for resale on the Resale Shelf Registration Statement, as amended, or the New Registration Statement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.5 <U>Notice of Certain Events</U>. The Company shall promptly notify the Investors in writing of any request by the Commission for
any amendment or supplement to, or additional information in connection with, the Resale Shelf Registration Statement required to be prepared and filed hereunder (or prospectus relating thereto). The Company shall promptly notify each Investor in
writing of the filing of the Resale Shelf Registration Statement or any prospectus, amendment or supplement related thereto or any post-effective amendment to the Resale Shelf Registration Statement and the effectiveness of any post-effective
amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.6 <U>Underwritten Takedown</U>. If the Company shall receive a request from the holders of Registrable Securities with an
estimated market value of at least $25,000,000 that the Company effect a Underwritten Takedown of all or any portion of the requesting holder&#146;s Registrable Securities, then the Company shall promptly give notice of such requested Underwritten
Takedown at least seven (7)&nbsp;Business Days prior to the anticipated filing date of the prospectus or supplement relating to such Underwritten Takedown to the other Investors and thereupon shall use its reasonable best efforts to effect, as
expeditiously as possible, the offering in such Underwritten Takedown of: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) subject to the restrictions set forth in
<U>Section</U><U></U><U>&nbsp;2.2.4</U>, all Registrable Securities for which the requesting holder has requested such offering under <U>Section</U><U></U><U>&nbsp;2.1.6</U>, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) subject to the restrictions set forth in <U>Section</U><U></U><U>&nbsp;2.2.4</U>, all other Registrable Securities that
any holders of Registrable Securities have requested the Company to offer by request received by the Company within two (2)&nbsp;Business Days after such holders receive the Company&#146;s notice of the Underwritten Takedown Notice, all to the
extent necessary to permit the disposition (in accordance with the intended methods thereof as aforesaid) of the Registrable Securities so to be offered. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) Promptly after the expiration of the <FONT STYLE="white-space:nowrap">two-Business</FONT>
<FONT STYLE="white-space:nowrap">Day-period</FONT> referred to in <U>Section</U><U></U><U>&nbsp;2.1.6(ii)</U>, the Company will notify all selling holders of the identities of the other selling holders and the number of shares of Registrable
Securities requested to be included therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) the Company shall only be required to effectuate: (i)&nbsp;one Underwritten Takedown by
each of (A)&nbsp;the ARYA Investors, collectively, and (B)&nbsp;GmbH Investors, collectively within any <FONT STYLE="white-space:nowrap">six-month</FONT> period; (ii)&nbsp;no more than three Underwritten Takedowns in respect of all Registrable
Securities held by ARYA Investors after giving effect to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;2.2.1(c)</U>; (iii) no more than three Underwritten Takedowns in respect of all Registrable Securities held by Company Investors (excluding dievini) after giving
effect to <U>Section</U><U></U><U>&nbsp;2.2.1(d)</U> and (iv)&nbsp;no more than nine Underwritten Takedowns in respect of all Registrable Securities held by dievini after giving effect to <U>Section</U><U></U><U>&nbsp;2.2.1(e)</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.7 <U>Block Trade</U>. If the Company shall receive a request from the holders of Registrable Securities with an estimated market value of
at least $10,000,000 that the Company effect the sale of all or any portion of the Registrable Securities in a Block Trade, then the Company shall, as expeditiously as possible, the offering in such Block Trade of the Registrable Securities for
which such requesting holder has requested such offering under <U>Section</U><U></U><U>&nbsp;2.1.7</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.8 <U>Selection of
Underwriters</U>. Selling holders holding a majority in interest of the Registrable Securities requested to be sold in an Underwritten Takedown shall have the right to select an Underwriter or Underwriters in connection with such Underwritten
Takedown, which Underwriter or Underwriters shall be reasonably acceptable to the Company. In connection with an Underwritten Takedown, the Company shall enter into customary agreements (including an underwriting agreement in customary form) and
take such other actions as are reasonably required in order to expedite or facilitate the disposition of the Registrable Securities in such Underwritten Takedown, including, if necessary, the engagement of a &#147;qualified independent
underwriter&#148; in connection with the qualification of the underwriting arrangements with the Financial Industry Regulatory Authority, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.9 Underwritten Takedowns effected pursuant to this <U>Section</U><U></U><U>&nbsp;2.1</U> shall be counted as Demand Registrations effected
pursuant to <U>Section</U><U></U><U>&nbsp;2.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Demand Registration</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.1 <U>Request for Registration</U>. At any time and from time to time after the expiration of any
<FONT STYLE="white-space:nowrap">lock-up</FONT> to which an Investor&#146;s shares are subject, if any, provided compliance by the Investors with <U>Section</U><U></U><U>&nbsp;3.4</U>, and provided further there is not an effective Resale Shelf
Registration Statement available for the resale of the Registerable Securities pursuant to <U>Section</U><U></U><U>&nbsp;2.</U><U>1</U> (i) ARYA Investors who hold a majority of the Registrable Securities held by all ARYA Investors,
(ii)&nbsp;Dievini or (iii)&nbsp;Company Investors (other than Dievini) who hold a majority of the Registrable Securities held by all Company Investors, as the case may be, may make a written demand for Registration under the Securities Act of all or
any portion of their Registrable Securities on Form <FONT STYLE="white-space:nowrap">F-1</FONT> or any similar long-form Registration or, if then available, on Form <FONT STYLE="white-space:nowrap">F-3.</FONT> Each registration requested pursuant to
this <U>Section</U><U></U><U>&nbsp;2.2.1</U> is referred to herein as a &#147;<B>Demand Registration</B>&#148;. Any demand for a Demand Registration shall specify the number of shares of Registrable Securities proposed to be sold and the intended
method(s) of distribution thereof. The Company will notify all Investors that are holders of Registrable Securities of the demand, and each such holder of Registrable Securities who wishes to include all or a portion of such holder&#146;s
Registrable Securities in the Demand Registration (each such holder including shares of Registrable Securities in such registration, a &#147;<B>Demanding Holder</B>&#148;) shall so notify the Company within fifteen (15)&nbsp;days after the receipt
by the holder of the notice from the Company. Upon any such request, the Demanding Holders shall be entitled to have their Registrable Securities included in the Demand Registration, subject to <U>Section</U><U></U><U>&nbsp;2.2.4</U> and the
provisos set forth in <U>Section</U><U></U><U>&nbsp;3.1.1</U>. The Company shall not be obligated to effect: (a)&nbsp;more than one (1)&nbsp;Demand </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Registration during any <FONT STYLE="white-space:nowrap">six-month</FONT> period; (b)&nbsp;any Demand Registration at any time there is an effective Resale Shelf Registration Statement on file
with the Commission pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>; (c) more than three Underwritten Demand Registrations in respect of all Registrable Securities held by ARYA Investors; (d)&nbsp;more than three Underwritten Demand Registrations
in respect of all Registrable Securities held by Company Investors (excluding dievini) or (e)&nbsp;more than nine Underwritten Demand Registrations in respect of all Registrable Securities held by dievini. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.2 <U>Effective Registration</U>. A Registration will not count as a Demand Registration until the Registration Statement filed with the
Commission with respect to such Demand Registration has been declared effective and the Company has complied with all of its obligations under this Agreement with respect thereto; provided, however, that if, after such Registration Statement has
been declared effective, the offering of Registrable Securities pursuant to a Demand Registration is interfered with by any stop order or injunction of the Commission or any other governmental agency or court, the Registration Statement with respect
to such Demand Registration will be deemed not to have been declared effective, unless and until, (i)&nbsp;such stop order or injunction is removed, rescinded or otherwise terminated, and (ii)&nbsp;a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the Demanding Holders thereafter elect to continue the offering; provided, further, that the Company shall not be obligated to file a second Registration Statement until a Registration
Statement that has been filed is counted as a Demand Registration or is terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.3 <U>Underwritten Demand Registration</U>. If the
Demanding Holders so elect and such holders so advise the Company as part of their written demand for a Demand Registration, the offering of such Registrable Securities pursuant to such Demand Registration shall be in the form of an Underwritten
Demand Registration. In such event, the right of any holder to include its Registrable Securities in such registration shall be conditioned upon such holder&#146;s participation in such underwriting and the inclusion of such holder&#146;s
Registrable Securities in the underwriting to the extent provided herein. All Demanding Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the
Underwriter or Underwriters selected for such underwriting by the holders initiating the Demand Registration, and subject to the approval of the Company. The parties agree that, in order to be effected, any Underwritten Demand Registration must
result (i)&nbsp;in aggregate proceeds to the selling shareholders of at least $50,000,000 or (ii)&nbsp;the shareholders exercising the demand no longer holding Ordinary Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.4 <U>Reduction of Offering</U>. If the managing Underwriter or Underwriters for a Underwritten Demand Registration that is to be an
underwritten offering advises the Company and the Demanding Holders in writing that, in such Underwriter&#146;s or Underwriters&#146; opinion, the dollar amount or number of shares of Registrable Securities which the Demanding Holders desire to
sell, taken together with all other Ordinary Shares or other securities which the Company desires to sell and the Ordinary Shares, if any, as to which registration has been requested pursuant to written contractual piggy-back registration rights
held by other shareholders of the Company who desire to sell, exceeds the maximum dollar amount or maximum number of shares that can be sold in such offering without adversely affecting the proposed offering price, the timing, the distribution
method, or the probability of success of such offering (such maximum dollar amount or maximum number of shares, as applicable, the &#147;<B>Maximum Number of Shares</B>&#148;), then the Company shall include in such registration: (i)&nbsp;first,
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Registrable Securities as to which Demand Registration has been requested by the Demanding Holders (pro rata in accordance with the number of shares that each such person has requested be
included in such registration, regardless of the number of shares held by each such person (such proportion is referred to herein as &#147;<B>Pro Rata</B>&#148;)) that can be sold without exceeding the Maximum Number of Shares; (ii)&nbsp;second, to
the extent that the Maximum Number of Shares has not been reached under the foregoing clause (i), the Ordinary Shares or other securities that the Company desires to sell; and (iii)&nbsp;any Ordinary Shares or other securities for the account of
other persons that the Company is obligated to register pursuant to written contractual arrangements with such persons, as to which &#147;piggy-back&#148; registration has been requested by the holders thereof that can be sold without exceeding the
Maximum Number of Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2.5 <U>Withdrawal</U>. A
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the Demanding Holders may elect to withdraw from such Demand Registration by giving written notice to the Company and the Underwriter or
Underwriters of their request to withdraw prior to the effectiveness of the Registration Statement filed with the Commission with respect to such Demand Registration. If the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the Demanding Holders withdraws from a proposed offering, then either the Demanding Holders shall reimburse the Company for the costs associated
with the withdrawn registration (in which case such registration shall not count as a Demand Registration provided for in <U>Section</U><U></U><U>&nbsp;2.2.1</U>) or the withdrawn registration shall count as a Demand Registration provided for in
<U>Section</U><U></U><U>&nbsp;2.2.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Piggy-Back Registration</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.1 <U>Piggy-Back Rights</U>. If at any time after the expiration of the any <FONT STYLE="white-space:nowrap">lock-up</FONT> to which an
Investor&#146;s shares are subject, if any, provided compliance by the Investors with <U>Section</U><U></U><U>&nbsp;3.4,</U> the Company proposes to file a Registration Statement under the Securities Act with respect to an offering of equity
securities, or securities or other obligations exercisable or exchangeable for, or convertible into, equity securities, by the Company for its own account or for shareholders of the Company for their account (or by the Company and by shareholders of
the Company including, without limitation, pursuant to <U>Section</U><U></U><U>&nbsp;2.2.1</U>), other than a Registration Statement (i)&nbsp;filed in connection with any employee stock option or other benefit plan, (ii)&nbsp;for an exchange offer
or offering of securities solely to the Company&#146;s existing shareholders, (iii)&nbsp;for an offering of debt that is convertible into equity securities of the Company or (iv)&nbsp;for a dividend reinvestment plan, then the Company shall
(x)&nbsp;give written notice of such proposed filing to the holders of Registrable Securities as soon as practicable but in no event less than ten (10)&nbsp;days before the anticipated filing date, which notice shall describe the amount and type of
securities to be included in such offering, the intended method(s) of distribution, and the name of the proposed managing Underwriter or Underwriters, if any, of the offering, and (y)&nbsp;offer to the holders of Registrable Securities in such
notice the opportunity to register the sale of such number of shares of Registrable Securities as such holders may request in writing within five (5)&nbsp;days following receipt of such notice (a &#147;<B>Piggy-Back Registration</B>&#148;). The
foregoing rights shall not be available to any Investor at such time as (i)&nbsp;there is an effective Resale Shelf Registration Statement available for the resale of the Registerable Securities pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>,
(ii) such Registration is solely to be used for the offering of securities by the Company for its own account and (iii)&nbsp;no other shareholder of the Company is entitled to participate in such Registration. The Company shall cause such
Registrable Securities to be included in such registration and shall use its best efforts to cause the managing Underwriter or Underwriters of a </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proposed underwritten offering to permit the Registrable Securities requested to be included in a Piggy-Back Registration on the same terms and conditions as any similar securities of the Company
and to permit the sale or other disposition of such Registrable Securities in accordance with the intended method(s) of distribution thereof. All holders of Registrable Securities proposing to distribute their securities through a Piggy-Back
Registration that involves an Underwriter or Underwriters shall enter into an underwriting agreement in customary form with the Underwriter or Underwriters selected for such Piggy-Back Registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.2 <U>Reduction of Offering</U>. If the managing Underwriter or Underwriters for a Piggy-Back Registration that is to be an underwritten
offering advises the Company and the holders of Registrable Securities in writing that the dollar amount or number of Ordinary Shares which the Company desires to sell, taken together with Ordinary Shares, if any, as to which registration has been
demanded pursuant to written contractual arrangements with persons other than the holders of Registrable Securities hereunder and the Registrable Securities as to which registration has been requested under this
<U>Section</U><U></U><U>&nbsp;2.3</U>, exceeds the Maximum Number of Shares, then the Company shall include in any such registration: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a) If the registration is undertaken for the Company&#146;s account: (A)&nbsp;first, the Ordinary Shares or other securities that the
Company desires to sell that can be sold without exceeding the Maximum Number of Shares; and (B)&nbsp;second, to the extent that the Maximum Number of Shares has not been reached under the foregoing clause (A), the Ordinary Shares or other
securities, if any, comprised of Registrable Securities, as to which registration has been requested pursuant to the terms hereof, that can be sold without exceeding the Maximum Number of Shares, Pro Rata; and (C)&nbsp;third, to the extent that the
Maximum Number of Shares has not been reached under the foregoing clauses (A)&nbsp;and (B), the Ordinary Shares or other securities for the account of other persons that the Company is obligated to register pursuant to written contractual piggy-back
registration rights with such persons and that can be sold without exceeding the Maximum Number of Shares; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) If the registration
is a &#147;demand&#148; registration undertaken at the demand of persons other than either the holders of Registrable Securities or the Company, (A)&nbsp;first, the Ordinary Shares or other securities for the account of the demanding persons that
can be sold without exceeding the Maximum Number of Shares; (B)&nbsp;second, to the extent that the Maximum Number of Shares has not been reached under the foregoing clause (A), the Ordinary Shares or other securities that the Company desires to
sell that can be sold without exceeding the Maximum Number of Shares; (C)&nbsp;third, to the extent that the Maximum Number of Shares has not been reached under the foregoing clauses (A)&nbsp;and (B), the Ordinary Shares or other securities, if any,
comprised of Registrable Securities, Pro Rata, as to which registration has been requested pursuant to the terms hereof, that can be sold without exceeding the Maximum Number of Shares; and (D)&nbsp;fourth, to the extent that the Maximum Number of
Shares has not been reached under the foregoing clauses (A), (B) and (C), the Ordinary Shares or other securities for the account of other persons that the Company is obligated to register pursuant to written contractual arrangements with such
persons, that can be sold without exceeding the Maximum Number of Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.3 <U>Withdrawal</U>. Any holder of Registrable Securities may elect to withdraw such
holder&#146;s request for inclusion of Registrable Securities in any Piggy-Back Registration by giving written notice to the Company of such request to withdraw prior to the effectiveness of the Registration Statement, if such offering is pursuant
to a Demand Registration, or prior to the public announcement of the offering, if such offering is pursuant to an Underwritten Takedown. The Company (whether on its own determination or as the result of a withdrawal by persons making a demand
pursuant to written contractual obligations) may withdraw a Registration Statement at any time prior to the effectiveness of such Registration Statement. Notwithstanding any such withdrawal, the Company shall pay all expenses incurred by the holders
of Registrable Securities in connection with such Piggy-Back Registration as provided in <U>Section</U><U></U><U>&nbsp;3.3</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>REGISTRATION
PROCEDURES</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Filings; Information</U>. Whenever the Company is required to effect the registration of any Registrable Securities
pursuant to <U>Section</U><U></U><U>&nbsp;2</U>, the Company shall use its commercially reasonable best efforts to effect the registration and sale of such Registrable Securities in accordance with the intended method(s) of distribution thereof as
expeditiously as practicable, and in connection with any such request: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.1 <U>Filing Registration Statement</U>. The Company shall use
its reasonable best efforts to, as expeditiously as possible after receipt of a request for a Demand Registration pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>, prepare and file with the Commission a Registration Statement on any form for which
the Company then qualifies or which counsel for the Company shall deem appropriate and which form shall be available for the sale of all Registrable Securities to be registered thereunder in accordance with the intended method(s) of distribution
thereof, and shall use its reasonable best efforts to cause such Registration Statement to become effective and use its reasonable best efforts to keep it effective for the Effectiveness Period; provided, however, that the Company shall have the
right to defer any Demand Registration for up to sixty (60)&nbsp;days, and any Piggy-Back Registration for such period as may be applicable to deferment of any Demand Registration to which such Piggy-Back Registration relates, in each case if the
Company shall furnish to the holders a certificate signed by the Chief Executive Officer or Chairman of the Company stating that, in the good faith judgment of the Board of Directors of the Company (the &#147;<B>Company Board</B>&#148;), it would be
materially detrimental to the Company and its shareholders for such Registration Statement to be effected at such time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.2
<U>Copies</U>. The Company shall, prior to filing a Registration Statement or prospectus, or any amendment or supplement thereto, furnish without charge to the holders of Registrable Securities included in such registration, and such holders&#146;
legal counsel, copies of such Registration Statement as proposed to be filed, each amendment and supplement to such Registration Statement (in each case, including all exhibits thereto and documents incorporated by reference therein), the prospectus
included in such Registration Statement (including each preliminary prospectus), and such other documents as the holders of Registrable Securities included in such registration or legal counsel for any such holders may request in order to facilitate
the disposition of the Registrable Securities owned by such holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.3 <U>Amendments and Supplements</U>. The Company shall prepare
and file with the Commission such amendments, including post-effective amendments, and supplements to such Registration Statement and the prospectus used in connection therewith as may be necessary to keep such Registration Statement effective and
in compliance with the provisions of the Securities Act until all Registrable Securities and other securities covered by such Registration Statement have been disposed of in accordance with the intended method(s) of distribution set forth in such
Registration Statement or such securities have been withdrawn (the &#147;<B>Effectiveness Period</B>&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.4 <U>Notification</U>. After the filing of a Registration Statement, the Company shall
promptly, and in no event more than three (3)&nbsp;Business Days after such filing, notify the holders of Registrable Securities included in such Registration Statement of such filing, and shall further notify such holders promptly and confirm such
advice in writing in all events within three (3)&nbsp;Business Days of the occurrence of any of the following: (i)&nbsp;when such Registration Statement becomes effective; (ii)&nbsp;when any post-effective amendment to such Registration Statement
becomes effective; (iii)&nbsp;the issuance or threatened issuance by the Commission of any stop order (and the Company shall take all actions required to prevent the entry of such stop order or to remove it if entered); and (iv)&nbsp;any request by
the Commission for any amendment or supplement to such Registration Statement or any prospectus relating thereto or for additional information or of the occurrence of an event requiring the preparation of a supplement or amendment to such prospectus
so that, as thereafter delivered to the purchasers of the securities covered by such Registration Statement, such prospectus will not contain an untrue statement of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein not misleading, and promptly make available to the holders of Registrable Securities included in such Registration Statement any such supplement or amendment; except that before filing with the Commission a
Registration Statement or prospectus or any amendment or supplement thereto, including documents incorporated by reference, the Company shall furnish to the holders of Registrable Securities included in such Registration Statement and to the legal
counsel for any such holders, copies of all such documents proposed to be filed sufficiently in advance of filing to provide such holders and legal counsel with a reasonable opportunity to review such documents and comment thereon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.5 <U>Securities Laws Compliance</U>. The Company shall use its reasonable best efforts to (i)&nbsp;register or qualify the Registrable
Securities covered by the Registration Statement under such securities or &#147;blue sky&#148; laws of such jurisdictions in the United States as the holders of Registrable Securities included in such Registration Statement (in light of their
intended plan of distribution) may reasonably request and (ii)&nbsp;take such action necessary to cause such Registrable Securities covered by the Registration Statement to be registered with or approved by such other governmental authorities as may
be necessary by virtue of the business and operations of the Company and do any and all other acts and things that may be necessary or advisable to enable the holders of Registrable Securities included in such Registration Statement to consummate
the disposition of such Registrable Securities in such jurisdictions; provided, however, that the Company shall not be required to qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this
paragraph or subject itself to taxation in any such jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.6 <U>Agreements for Disposition</U>. The Company shall enter into
customary agreements (including, if applicable, an underwriting agreement in customary form) and take such other actions as are reasonably required in order to expedite or facilitate the disposition of such Registrable Securities. The
representations, warranties and covenants of the Company in any underwriting agreement which are made to or for the benefit of any Underwriters, to the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
extent applicable, shall also be made to and for the benefit of the holders of Registrable Securities included in such registration statement, and the representations, warranties and covenants of
the holders of Registrable Securities included in such registration statement in any underwriting agreement which are made to or for the benefit of any Underwriters, to the extent applicable, shall also be made to and for the benefit of the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.7 <U>Comfort Letter</U>. In the event of an Underwritten Takedown or an Underwritten Demand Registration, the Company shall obtain a
&#147;cold comfort&#148; letter from the Company&#146;s independent registered public accountants in the event of an underwritten offering, and a customary &#147;bring-down&#148; thereof, in customary form and covering such matters of the type
customarily covered by &#147;cold comfort&#148; letters, as the managing Underwriter may reasonably request, and reasonably satisfactory to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the
participating holders. For the avoidance of doubt, this <U>Section</U><U></U><U>&nbsp;3.17</U> shall not apply to Block Trades. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.8
<U>Opinions and Negative Assurance Letters</U>. In the event of an Underwritten Takedown or an Underwritten Demand Registration, on the date the Registrable Securities are delivered for sale pursuant to any Registration, the Company shall obtain an
opinion and negative assurances letter, each dated such date, of one (1)&nbsp;counsel representing the Company for the purposes of such Registration, including an opinion of local counsel if applicable, addressed to the holders, the placement agent
or sales agent, if any, and the Underwriters, if any, covering such legal matters with respect to such Registration in respect of which such opinion is being given as the holders, placement agent, sales agent, or Underwriter may reasonably request
and as are customarily included in such opinions, and reasonably satisfactory to a majority in interest of the participating holders. For the avoidance of doubt, this <U>Section</U><U></U><U>&nbsp;3.18</U> shall not apply to Block Trades. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.9 <U>Cooperation</U>. The principal executive officer of the Company, the principal financial officer of the Company, the principal
accounting officer of the Company and all other officers and members of the management of the Company shall cooperate fully in any offering of Registrable Securities hereunder, which cooperation shall include, without limitation, the preparation of
the Registration Statement with respect to such offering and all other offering materials and related documents, and participation in meetings with Underwriters, attorneys, accountants and potential investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.10 <U>Transfer Agent</U>. The Company shall provide and maintain a transfer agent and registrar for the Registrable Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.11 <U>Records</U>. Upon execution of confidentiality agreements, the Company shall make available for inspection by the holders of
Registrable Securities included in such Registration Statement, any Underwriter participating in any disposition pursuant to such registration statement and any attorney, accountant or other professional retained by any holder of Registrable
Securities included in such Registration Statement or any Underwriter, all financial and other records, pertinent corporate documents and properties of the Company, as shall be necessary to enable them to exercise their due diligence responsibility,
and cause the Company&#146;s officers, directors and employees to supply all information requested by any of them in connection with such Registration Statement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.12 <U>Earnings Statement</U>. The Company shall comply with all applicable rules and
regulations of the Commission and the Securities Act, and make available to its shareholders, as soon as practicable, an earnings statement covering a period of twelve (12)&nbsp;months, which earnings statement shall satisfy the provisions of
Section&nbsp;11(a) of the Securities Act and Rule 158 thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.13 <U>Road Show</U>. If an offering pursuant to this Agreement is
conducted as an Underwritten Takedown or Underwritten Demand Registration and involves Registrable Securities with an aggregate offering price (before deduction of underwriting discounts) exceeds $50,000,000, the Company shall use its reasonable
best efforts to make available senior executives of the Company to participate in customary &#147;road show&#148; presentations that may be reasonably requested by the Underwriter in such offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1.14 <U>Listing</U>. The Company shall use its reasonable best efforts to cause all Registrable Securities included in any Registration
Statement to be listed on such exchanges or otherwise designated for trading in the same manner as similar securities issued by the Company are then listed or designated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Obligation to Suspend Distribution</U>. Upon receipt of any notice from the Company of the happening of any event of the kind described
in <U>Section</U><U></U><U>&nbsp;3.1.4(iv)</U>, or, upon any suspension by the Company, pursuant to a written insider trading compliance program adopted by the Company Board, of the ability of all &#147;insiders&#148; covered by such program to
transact in the Company&#146;s securities because of the existence of material <FONT STYLE="white-space:nowrap">non-public</FONT> information, each holder of Registrable Securities included in any registration shall immediately discontinue
disposition of such Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until such holder receives the supplemented or amended prospectus contemplated by <U>Section</U><U></U><U>&nbsp;3.1.4(iv)</U> or
the restriction on the ability of &#147;insiders&#148; to transact in the Company&#146;s securities is removed, as applicable, and, if so directed by the Company, each such holder will deliver to the Company all copies, other than permanent file
copies then in such holder&#146;s possession, of the most recent prospectus covering such Registrable Securities at the time of receipt of such notice. The foregoing right to delay or suspend may be exercised by the Company for no longer than 180
days in any consecutive <FONT STYLE="white-space:nowrap">12-month</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Registration Expenses</U>. The Company shall bear
all costs and expenses incurred in connection with the Resale Shelf Registration Statement pursuant to <U>Section</U><U></U><U>&nbsp;2.1</U>, any Demand Registration pursuant to <U>Section</U><U></U><U>&nbsp;2.2.1</U>, any Underwritten Takedown
pursuant to <U>Section</U><U></U><U>&nbsp;2.1.6</U>, any Block Trade pursuant to <U>Section</U><U></U><U>&nbsp;2.1.7 </U>(other than expenses set forth below in clause (ix)&nbsp;of this <U>Section</U><U></U><U>&nbsp;3.3</U>), any Piggy-Back
Registration pursuant to <U>Section</U><U></U><U>&nbsp;2.3</U>, and all expenses incurred in performing or complying with its other obligations under this Agreement, whether or not the Registration Statement becomes effective, including, without
limitation: (i)&nbsp;all registration and filing fees; (ii)&nbsp;fees and expenses of compliance with securities or &#147;blue sky&#148; laws (including fees and disbursements of counsel in connection with blue sky qualifications of the Registrable
Securities); (iii) printing expenses; (iv)&nbsp;the Company&#146;s internal expenses (including, without limitation, all salaries and expenses of its officers and employees); (v) the fees and expenses incurred in connection with the listing of the
Registrable Securities as required by <U>Section</U><U></U><U>&nbsp;3.1.12</U>; (vi) Financial Industry Regulatory Authority fees; (vii)&nbsp;fees and disbursements of counsel for the Company and fees and expenses for independent certified public
accountants retained by the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company; (viii)&nbsp;the fees and expenses of any special experts retained by the Company in connection with such registration; and (ix)&nbsp;the reasonable fees and expenses of one legal counsel
selected by the holders of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">majority-in-interest</FONT></FONT> of the Registrable Securities included in such registration not to exceed $62,500. The Company shall have no obligation
to pay any underwriting discounts or selling commissions attributable to the Registrable Securities being sold by the holders thereof, which underwriting discounts or selling commissions shall be borne by such holders, but the Company shall pay any
underwriting discounts or selling commissions attributable to the securities it sells for its own account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 <U>Information</U>. The
holders of Registrable Securities shall promptly provide such information as may reasonably be requested by the Company, or the managing Underwriter, if any, in connection with the preparation of any Registration Statement, including amendments and
supplements thereto, in order to effect the registration of any Registrable Securities under the Securities Act and in connection with the Company&#146;s obligation to comply with Federal and applicable state securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5 <U>Other Obligations</U>. At any time and from time to time after the expiration of any <FONT STYLE="white-space:nowrap">lock-up</FONT> to
which such shares are subject, if any, in connection with a sale or transfer of Registrable Securities exempt from registration under the Securities Act or through any broker-dealer transactions described in the plan of distribution set forth within
any prospectus and pursuant to the Registration Statement of which such prospectus forms a part, the Company shall, subject to the receipt of customary documentation required from the applicable holders in connection therewith, (i)&nbsp;promptly
instruct its transfer agent to remove any restrictive legends applicable to the Registrable Securities being sold or transferred and (ii)&nbsp;cause its legal counsel to deliver the necessary legal opinions, if any, to the transfer agent in
connection with the instruction under subclause (i). In addition, the Company shall cooperate reasonably with, and take such customary actions as may reasonably be requested by such holders in connection with the aforementioned sales or transfers.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>INDEMNIFICATION AND CONTRIBUTION</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Indemnification by the Company</U>. The Company agrees to indemnify and hold harmless each Investor and each other holder of Registrable
Securities, and each of their respective officers, employees, affiliates, directors, partners, members, attorneys and agents, and each person, if any, who controls an Investor and each other holder of Registrable Securities (within the meaning of
Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act) (each, an &#147;<B>Investor Indemnified Party</B>&#148;), from and against any expenses, losses, judgments, claims, damages or liabilities, whether joint or several,
arising out of or based upon any untrue statement (or allegedly untrue statement) of a material fact contained in any Registration Statement under which the sale of such Registrable Securities was registered under the Securities Act, any preliminary
prospectus, final prospectus or summary prospectus contained in the Registration Statement, or any amendment or supplement to such Registration Statement, or arising out of or based upon any omission (or alleged omission) to state a material fact
required to be stated therein or necessary to make the statements therein not misleading, or any violation by the Company of the Securities Act or any rule or regulation promulgated thereunder applicable to the Company and relating to action or
inaction required of the Company in </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with any such registration; and the Company shall promptly reimburse the Investor Indemnified Party for any legal and any other expenses reasonably incurred by such Investor
Indemnified Party in connection with investigating and defending any such expense, loss, judgment, claim, damage, liability or action; provided, however, that the Company will not be liable in any such case to the extent that any such expense, loss,
claim, damage or liability arises out of or is based upon any untrue statement or allegedly untrue statement or omission or alleged omission made in such Registration Statement, preliminary prospectus, final prospectus, or summary prospectus, or any
such amendment or supplement, in reliance upon and in conformity with information furnished to the Company, in writing, by such selling holder expressly for use therein, or is based on any selling holder&#146;s violation of the federal securities
laws (including Regulation M) or failure to sell the Registrable Securities in accordance with the plan of distribution contained in the prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Indemnification by Holders of Registrable Securities</U>. Each selling holder of Registrable Securities will, in the event that any
Registration is being effected under the Securities Act pursuant to this Agreement of any Registrable Securities held by such selling holder, indemnify and hold harmless the Company, each of its directors and officers, and each other selling holder
and each other person, if any, who controls another selling holder within the meaning of the Securities Act, against any losses, claims, judgments, damages or liabilities, whether joint or several, insofar as such losses, claims, judgments, damages
or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or allegedly untrue statement of a material fact contained in any Registration Statement under which the sale of such Registrable Securities was
registered under the Securities Act, any preliminary prospectus, final prospectus or summary prospectus contained in the Registration Statement, or any amendment or supplement to the Registration Statement, or arise out of or are based upon any
omission or the alleged omission to state a material fact required to be stated therein or necessary to make the statement therein not misleading, if the statement or omission was made in reliance upon and in conformity with information furnished in
writing to the Company by such selling holder expressly for use therein, or is based on any selling holder&#146;s violation of the federal securities laws (including Regulation M) or failure to sell the Registrable Securities in accordance with the
plan of distribution contained in the prospectus, and shall reimburse the Company, its directors and officers, and each other selling holder or controlling person for any legal or other expenses reasonably incurred by any of them in connection with
investigation or defending any such loss, claim, damage, liability or action. Each selling holder&#146;s indemnification obligations hereunder shall be several and not joint and shall be limited to the amount of any net proceeds actually received by
such selling holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Conduct of Indemnification Proceedings</U>. Promptly after receipt by any person of any notice of any loss,
claim, damage or liability or any action in respect of which indemnity may be sought pursuant to <U>Sections 4.1</U> or <U>4.2</U>, such person (the &#147;<B>Indemnified Party</B>&#148;) shall, if a claim in respect thereof is to be made against any
other person for indemnification hereunder, notify such other person (the &#147;<B>Indemnifying Party</B>&#148;) in writing of the loss, claim, judgment, damage, liability or action; provided, however, that the failure by the Indemnified Party to
notify the Indemnifying Party shall not relieve the Indemnifying Party from any liability which the Indemnifying Party may have to such Indemnified Party hereunder, except and solely to the extent the Indemnifying Party is actually prejudiced by
such failure. If the Indemnified Party is seeking indemnification with respect to any claim or action brought against the Indemnified </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Party, then the Indemnifying Party shall be entitled to participate in such claim or action, and, to the extent that it wishes, jointly with all other Indemnifying Parties, to assume control of
the defense thereof with counsel satisfactory to the Indemnified Party. After notice from the Indemnifying Party to the Indemnified Party of its election to assume control of the defense of such claim or action, the Indemnifying Party shall not be
liable to the Indemnified Party for any legal or other expenses subsequently incurred by the Indemnified Party in connection with the defense thereof other than reasonable costs of investigation; provided, however, that in any action in which both
the Indemnified Party and the Indemnifying Party are named as defendants, the Indemnified Party shall have the right to employ separate counsel (but no more than one such separate counsel, which counsel is reasonably acceptable to the Indemnifying
Party) to represent the Indemnified Party and its controlling persons who may be subject to liability arising out of any claim in respect of which indemnity may be sought by the Indemnified Party against the Indemnifying Party, with the fees and
expenses of such counsel to be paid by such Indemnifying Party if, based upon the written opinion of counsel of such Indemnified Party, representation of both parties by the same counsel would be inappropriate due to actual or potential differing
interests between them. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, consent to entry of judgment or effect any settlement of any claim or pending or threatened proceeding in respect of which the
Indemnified Party is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such judgment or settlement includes an unconditional release of such Indemnified Party from all liability arising out
of such claim or proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4.1 If the indemnification provided for in the foregoing <U>Sections 4.1</U>, <U>4.2</U> and <U>4.3</U> is unavailable to any Indemnified
Party in respect of any loss, claim, damage, liability or action referred to herein, then each such Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a
result of such loss, claim, damage, liability or action in such proportion as is appropriate to reflect the relative fault of the Indemnified Parties and the Indemnifying Parties in connection with the actions or omissions which resulted in such
loss, claim, damage, liability or action, as well as any other relevant equitable considerations. The relative fault of any Indemnified Party and any Indemnifying Party shall be determined by reference to, among other things, whether the untrue or
alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by such Indemnified Party or such Indemnifying Party and the parties&#146; relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4.2 The parties hereto agree that it would not be just
and equitable if contribution pursuant to this <U>Section</U><U></U><U>&nbsp;4.4</U> were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in
<U>Section</U><U></U><U>&nbsp;4.4.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4.3 The amount paid or payable by an Indemnified Party as a result of any loss, claim, damage,
liability or action referred to in the immediately preceding paragraph shall be deemed to include, subject to the limitations set forth above, any legal or other expenses incurred by such Indemnified Party in connection with investigating or
defending any such </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
action or claim. Notwithstanding the provisions of this <U>Section</U><U></U><U>&nbsp;4.4</U>, no holder of Registrable Securities shall be required to contribute any amount in excess of the
dollar amount of the net proceeds (after payment of any underwriting fees, discounts, commissions or taxes) actually received by such holder from the sale of Registrable Securities which gave rise to such contribution obligation. No person guilty of
fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>UNDERWRITING AND DISTRIBUTION</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1
<U>Rule 144</U>. The Company covenants that it shall file any reports required to be filed by it under the Securities Act and the Exchange Act and shall take such further action as the holders of Registrable Securities may reasonably request, all to
the extent required from time to time to enable such holders to sell Registrable Securities without registration under the Securities Act within the limitation of the exemptions provided by Rule 144 under the Securities Act, as such Rules may be
amended from time to time, or any similar rule or regulation hereafter adopted by the Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U><FONT STYLE="white-space:nowrap">LOCK-UP</FONT>
AGREEMENTS</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>Investor <FONT STYLE="white-space:nowrap">Lock-Up</FONT></U>. (a)&nbsp;Each Investor (other than the ARYA IPO
Investors) agrees that such Investor shall not Transfer any Ordinary Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Ordinary Shares (including New Securities) for
<FONT STYLE="white-space:nowrap">180-days</FONT> following the Closing Date; and (b)&nbsp;each ARYA IPO Investor agrees that such ARYA IPO Investor shall not Transfer any Ordinary Shares or any securities convertible into or exercisable or
exchangeable (directly or indirectly) for Ordinary Shares (including New Securities) for the earlier of (1)&nbsp;one year following the Closing Date or (2)&nbsp;if the closing price of the Ordinary Shares equals or exceeds $12.00 per share (as
adjusted for share splits, share capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <FONT STYLE="white-space:nowrap">30-trading</FONT> day period commencing at least 150 days after the Closing Date
(such applicable period, the &#147;<B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Period</B>&#148;). The foregoing restriction is expressly agreed to preclude each Investor during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period from
engaging in any hedging or other transaction which is designed to or which reasonably could be expected to lead to or result in a sale or disposition of such Investor&#146;s Ordinary Shares even if such Ordinary Shares would be disposed of by
someone other than the undersigned. Such prohibited hedging or other transactions during the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period would include without limitation any short sale or any purchase, sale or grant of any right
(including, without limitation, any put or call option) with respect to any of the Investor&#146;s Ordinary Shares or with respect to any security that includes, relates to, or derives any significant part of its value from such Ordinary Shares. The
foregoing notwithstanding, each executive officer and director of GmbH shall be permitted to establish a plan to acquire and sell Ordinary Shares pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act, provided that
such plan does not provide for the Transfer of Ordinary Shares during <FONT STYLE="white-space:nowrap">the&nbsp;Lock-up&nbsp;Period.</FONT> The foregoing restrictions shall not apply to Transfers made: (i)&nbsp;pursuant to a<I>&nbsp;bona
fide</I>&nbsp;gift or charitable contribution; (ii)&nbsp;by will or intestate succession upon the death of an Investor; (iii)&nbsp;to any Permitted Transferee; (iv)&nbsp;pursuant to a court order or settlement agreement related to the distribution
of assets in connection with the dissolution of marriage or civil union; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or (v)&nbsp;in the event of the Company&#146;s completion of a liquidation, merger, share exchange or other similar transaction which results in all of its shareholders having the right to
exchange their Ordinary Shares for cash, securities or other property; provided that in the case of (i)&nbsp;or (iii), the recipient of such Transfer must enter into a written agreement agreeing to be bound by the terms of this Agreement, including
the transfer restrictions set forth in this <U>Section</U><U></U><U>&nbsp;6.1</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>BOARD OF DIRECTORS AND CONSENT RIGHT</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 <U>ARYA Directors</U>. Until the fifth (5<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) anniversary of the date of this
Agreement, at each annual or special meeting of shareholders of the Company, the ARYA Investors shall have the right, but not the obligation, to designate for election as a director of the Company, and the Company Board (including any committee
thereof) shall nominate (and recommend for election and include such recommendation in a timely manner in any proxy statement, consent solicitation or other applicable announcement to the Company&#146;s shareholders) two individuals to serve on the
Company Board (one Class&nbsp;I Director and one Class&nbsp;III Director); provided, however, that if at any time during such five-year period, the ARYA Investors collectively own less than 5% of the Ordinary Shares then outstanding (as adjusted for
any share split, share dividend or other share recapitalization, share exchange or other event), the rights of the ARYA Investors and obligations of the Company Board under this <U>Section</U><U></U><U>&nbsp;7.1</U> shall terminate. The directors
designated pursuant to this <U>Section</U><U></U><U>&nbsp;7.1</U> may, but do not need to, qualify as &#147;independent&#148; pursuant to the listing standards of Nasdaq. For the avoidance of doubt, the individuals designated by the ARYA Investors
to serve on the Company Board shall serve on the &#147;supervisory board&#148; of the Company, at such time as the Company Board is structured as a <FONT STYLE="white-space:nowrap">&#147;two-tier&#148;</FONT> board; on such date as the Company Board
is reorganized to be structured as a <FONT STYLE="white-space:nowrap">&#147;one-tier&#148;</FONT> board pursuant to Section&nbsp;6.17 of the Business Combination Agreement (the &#147;<U>Board Structure Provision</U>&#148;) and the individuals
designated by the ARYA Investors to serve on the Company Board shall continue as directors of the Company without any further action by the ARYA Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <U>ARYA Director Vacancies</U>. Each Investor agrees to vote, or cause to be voted, all Ordinary Shares owned by such Investor, or over
which such Investor has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that: (a)&nbsp;no director elected pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U> may be removed from office, unless:
(i)&nbsp;such removal is directed or approved by the affirmative vote of the ARYA Investors entitled under <U>Section</U><U></U><U>&nbsp;7.1</U> to designate such director; or (ii)&nbsp;the ARYA Investors are no longer entitled to designate the
Company directors pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U>; and (b)&nbsp;any vacancies created by the resignation, removal or death of a director elected pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U> shall be filled pursuant to the
provisions of this <U>Section</U><U></U><U>&nbsp;7</U>. The Company and the Company Board shall take all actions necessary to fill such vacancy with such replacement director promptly upon written notice to the Company of the name of such
replacement director by the ARYA Investors entitled under <U>Section</U><U></U><U>&nbsp;7.1</U> to designate such director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3
<U>Dievini Directors</U>. Until the fifth (5<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) anniversary of the date of this Agreement, at each annual or special meeting of shareholders of the Company, <U>Dievini</U> shall have the right,
but not the obligation, to designate for election as a director of the Company, and the Company Board (including any committee thereof) shall nominate (and recommend for election and include such recommendation in a timely manner in any proxy
statement, consent solicitation or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other applicable announcement to the Company&#146;s shareholders) two individuals to serve on the Company Board (one Class&nbsp;I Director and one Class&nbsp;III Director); provided, however,
that if at any time during such five-year period, Dievini owns less than 5% of the Ordinary Shares then outstanding (as adjusted for any share split, share dividend or other share recapitalization, share exchange or other event), the rights of
Dievini and obligations of the Company Board under this <U>Section</U><U></U><U>&nbsp;7.3</U> shall terminate. The directors designated pursuant to this <U>Section</U><U></U><U>&nbsp;7.3</U> may, but do not need to, qualify as
&#147;independent&#148; pursuant to the listing standards of Nasdaq. For the avoidance of doubt, the individuals designated by Dievini to serve on the Company Board shall serve in accordance with the Board Structure Provision and the individuals
designated by Dievini to serve on the Company Board shall continue as directors of the Company without any further action by Dievini. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4
<U>Dievini Director Vacancies</U>. Each Investor agrees to vote, or cause to be voted, all Ordinary Shares owned by such Investor, or over which such Investor has voting control, from time to time and at all times, in whatever manner as shall be
necessary to ensure that: (a)&nbsp;no director elected pursuant to <U>Section</U><U></U><U>&nbsp;7.3</U> may be removed from office, unless: (i)&nbsp;such removal is directed or approved by the affirmative vote of Dievini entitled under
<U>Section</U><U></U><U>&nbsp;7.3</U> to designate such director; or (ii)Dievini is no longer entitled to designate the Company directors pursuant to <U>Section</U><U></U><U>&nbsp;7.3</U>; and (b)&nbsp;any vacancies created by the resignation,
removal or death of a director elected pursuant to <U>Section</U><U></U><U>&nbsp;7.3</U> shall be filled pursuant to the provisions of this <U>Section</U><U></U><U>&nbsp;7</U>. The Company and the Company Board shall take all actions necessary to
fill such vacancy with such replacement director promptly upon written notice to the Company of the name of such replacement director by Dievini entitled under <U>Section</U><U></U><U>&nbsp;7.3</U> to designate such director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5 <U>Indemnification</U>. As promptly as reasonably practicable following the request of any director designated pursuant to
<U>Section</U><U></U><U>&nbsp;7.1</U> or <U>Section</U><U></U><U>&nbsp;7.3</U>, the Company shall enter into an indemnification agreement with the director, in the form entered into with the other members of the Company Board or, if not entered into
by other members of the Company Board, a customary form. the Company shall pay the reasonable, documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">and&nbsp;out-of-pocket&nbsp;expenses</FONT></FONT> incurred by such director
related to his or her service to the Company, including attending meetings of the Company Board or any committee <FONT STYLE="white-space:nowrap">or&nbsp;sub-committee&nbsp;thereof</FONT> or events attended on behalf of the Company or any of its
subsidiaries at the Company&#146;s request. For so long as a director designated pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U> or <U>Section</U><U></U><U>&nbsp;7.3</U> serves as a director of the Company, the Company shall not amend, alter or
repeal any right to indemnification or exculpation covering or benefiting any director designated pursuant to <U>Section</U><U></U><U>&nbsp;7.1</U> or <U>Section</U><U></U><U>&nbsp;7.3</U> as and to the extent consistent with applicable law,
including but not limited to under the articles of association of the Company (except to the extent such amendment or alteration permits the Company to provide broader indemnification or exculpation rights on a retroactive basis than permitted prior
thereto). The Company shall (i)&nbsp;purchase directors&#146; and officers&#146; liability insurance in an amount determined by the Company Board to be reasonable and customary and (ii)&nbsp;for so long as any director designated pursuant to
<U>Section</U><U></U><U>&nbsp;7.1</U> or <U>Section</U><U></U><U>&nbsp;7.3</U> serves as a director of the Company Board, maintain such coverage with respect to such director;&nbsp;provided<I></I>&nbsp;that upon removal or resignation of such
director for any reason, the Company shall take all actions reasonably necessary to extend such directors&#146; and officers&#146; liability insurance coverage for a period of not less than six (6)&nbsp;years from any such event in respect of any
act or omission occurring at or prior to such event. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.6 <U>Consent Right</U>. None of the Company, the Company Board or any of the GmbH
Investors shall take any action to amend or repeal the Board Structure Provision without the express written consent of a majority in interest of the ARYA Investors. The right provided for in this <U>Section</U><U></U><U>&nbsp;7.6</U> shall be of no
further force or effect upon the adoption by the Company of a <FONT STYLE="white-space:nowrap">&#147;one-tier&#148;</FONT> board structure on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>MISCELLANEOUS</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 <U>Other
Registration Rights and Arrangements</U>. The Company represents and warrants that no person, other than a holder of the Registrable Securities has any right to require the Company to register any of the Company&#146;s share capital for sale or to
include the Company&#146;s share capital in any registration filed by the Company for the sale of shares for its own account or for the account of any other person. The parties hereby terminate the Prior Agreement, which shall be of no further force
and effect and is hereby superseded and replaced in its entirety by this Agreement. The Company shall not hereafter enter into any agreement with respect to its securities which is inconsistent with or violates the rights granted to the holders of
Registrable Securities in this Agreement and in the event of any conflict between any such agreement or agreements and this Agreement, the terms of this Agreement shall prevail. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2 <U>Assignment; No Third-Party Beneficiaries</U>. This Agreement and the rights, duties and obligations of the Company hereunder may not be
assigned or delegated by the Company in whole or in part. This Agreement and the rights, duties and obligations of the holders of Registrable Securities hereunder may be freely assigned or delegated by such holder of Registrable Securities in
conjunction with and to the extent of any permitted transfer of Registrable Securities by any such holder. This Agreement and the provisions hereof shall be binding upon and shall inure to the benefit of each of the parties hereto and their
respective successors and assigns and the holders of Registrable Securities and their respective successors and permitted assigns. This Agreement is not intended to confer any rights or benefits on any persons that are not party hereto other than as
expressly set forth in <U>Section</U><U></U><U>&nbsp;4</U> and this <U>Section</U><U></U><U>&nbsp;8.2</U>. The rights of a holder of Registrable Securities under this Agreement may be transferred by such a holder to a transferee who acquires or
holds Registrable Securities; provided, however, that such transferee has executed and delivered to the Company a properly completed agreement to be bound by the terms of this Agreement substantially in form attached hereto as Exhibit A (an
&#147;<B>Addendum Agreement</B>&#148;), and the transferor shall have delivered to the Company no later than thirty (30)&nbsp;days following the date of the transfer, written notification of such transfer setting forth the name of the transferor,
the name and address of the transferee, and the number of Registrable Securities so transferred. The execution of an Addendum Agreement shall constitute a permitted amendment of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3 <U>Amendments and Modifications</U>. Upon the written consent of the Company and the Holders of at least a majority in interest of the
Registrable Securities at the time in question, which majority shall include ARYA Investors who hold a majority in interest of the Registrable Securities held by all ARYA Investors at the time in question, compliance with any of the provisions,
covenants and conditions set forth in this Agreement may be waived, or any of such provisions, covenants or conditions may be amended or modified; provided, however, that notwithstanding the foregoing, any amendment hereto or waiver hereof that
adversely affects an </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Investor, solely in his, her or its capacity as a holder of the shares of capital stock of the Company, in a manner that is materially different from other Investors (in such capacity) shall
require the consent of such Investor so affected. No course of dealing between any Investor or the Company and any other party hereto or any failure or delay on the part of an Investor or the Company in exercising any rights or remedies under this
Agreement shall operate as a waiver of any rights or remedies of any Investor or the Company. No single or partial exercise of any rights or remedies under this Agreement by a party shall operate as a waiver or preclude the exercise of any other
rights or remedies hereunder or thereunder by such party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.4 <U>Term</U>. This Agreement shall terminate upon the earlier of
(i)&nbsp;the tenth anniversary of the date of this Agreement or (ii)&nbsp;the date as of which there shall be no Registrable Securities outstanding; provided further that with respect to any Investor, such Investor will have no rights under this
Agreement and all obligations of the Company to such Investor under this Agreement shall terminate upon the earlier of (x)&nbsp;the date at least one year after the date hereof that such Investor ceases to hold at least 1% of the Registrable
Securities outstanding on the date hereof or (y)&nbsp;if such Investor is a director or an executive officer of the Company, the date such Investor no longer serves as a director or an executive officer of the Company; provided, however, that such
termination as to an Investors shall not apply to the following provisions until such Investor no longer holds any Registrable Securities: <U>Sections 3.1.4</U>, <U>3.1.5</U>, <U>3.1.10</U>, <U>3.1.12</U>, <U>3.1.14</U>, <U>3.2</U>, <U>3.3</U>,
<U>3.4</U>, <U>3.5</U>, <U>7.5</U>, <U>8.3</U>, <U>8.5</U> and <U>Articles IV</U> and <U>V</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.5 <U>Notices</U>. All notices, demands,
requests, consents, approvals or other communications (collectively, &#147;<B>Notices</B>&#148;) required or permitted to be given hereunder or which are given with respect to this Agreement shall be in writing and shall be personally served,
delivered by reputable air courier service with charges prepaid, or transmitted by facsimile or email, addressed as set forth below, or to such other address as such party shall have specified most recently by written notice. Notice shall be deemed
given (i)&nbsp;on the date of service or transmission if personally served or transmitted by telegram, telex or facsimile; provided, that if such service or transmission is not on a Business Day or is after normal business hours, then such notice
shall be deemed given on the next Business Day or (ii)&nbsp;one Business Day after being deposited with a reputable courier service with an order for <FONT STYLE="white-space:nowrap">next-day</FONT> delivery, to the parties as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Immatics
Biotechnology, GmbH </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Paul-Ehrlich-Str.</FONT> 15 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">72076 Tuebingen </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Germany </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attn: Harpreet Singh </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Facsimile:
49 (7071) <FONT STYLE="white-space:nowrap">5397-900</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with a copy to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">100 Northern
Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Boston, MA 02210 Attn: Jocelyn Arel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Facsimile: (617) <FONT STYLE="white-space:nowrap">321-4344</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Email: [***] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to ARYA: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">51 Astor Place, 10th floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New
York, NY 10003 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attn: Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Facsimile: (646) <FONT STYLE="white-space:nowrap">205-5301</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">with a copy to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Kirkland&nbsp;&amp; Ellis LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">601 Lexington Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">New York,
New York 10022 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attn: Jonathan L. Davis </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Christian O. Nagler </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Peter S.
Seligson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Ryan Brissette </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Facsimile: (212) <FONT STYLE="white-space:nowrap">446-4934</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Email: [***] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to an Investor,
to the address set forth under such Investor&#146;s signature to this Agreement or to such Investor&#146;s address as found in the Company&#146;s books and records. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.6 <U>Severability</U>. This Agreement shall be deemed severable, and the invalidity or unenforceability of any term or provision hereof
shall not affect the validity or enforceability of this Agreement or of any other term or provision hereof. Furthermore, in lieu of any such invalid or unenforceable term or provision, the parties hereto intend that there shall be added as a part of
this Agreement a provision as similar in terms to such invalid or unenforceable provision as may be possible that is valid and enforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.7 <U>Counterparts</U>. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, and all of which
taken together shall constitute one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.8 <U>Entire Agreement</U>. This Agreement (including all agreements
entered into pursuant hereto and all certificates and instruments delivered pursuant hereto and thereto) constitute the entire agreement of the parties with respect to the subject matter hereof and supersede all prior and contemporaneous agreements,
representations, understandings, negotiations and discussions between the parties, whether oral or written, including, without limitation the Prior Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>IMMATICS N.V.:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Harpreet Singh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Harpreet Singh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Managing Director</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Harpreet Singh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Harpreet Singh</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Rainer Kramer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Rainer Kramer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Wellington Partners Partners Ventures II GmbH&nbsp;&amp; Co. KG (A)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Represented by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Wellington Partners Verwaltungs GmbH, its liquidator</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Represented by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cornelia Hulser</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Cornelia Hulser</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Managing Director</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Wellington Partners Partners Ventures IV Life Science Fund L.P.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Represented by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Wellington Partners Management Limited</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Represented by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ernst Mannheimer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Ernst Mannheimer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Director</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Wellington Partners Nominee Limited</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Represented by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Ernst Mannheimer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Ernst Mannheimer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Director</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Chambr&eacute;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Peter Chambr&eacute;</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>AT Impf GmbH</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Represented by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas Maier</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Thomas Maier</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Melissa Simon</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Melissa Simon</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Carsten Reinhardt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Carsten Reinhardt</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>dievini Hopp BioTech holding GmbH&nbsp;&amp; Co. KG</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Represented by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Dievini Verwaltungs GmbH, its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Represented by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ F.V. Bohlen</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: F.V. Bohlen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Managing Partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christof Hettich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Christof Hettich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Authorized Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MIG GmbH&nbsp;&amp; Co. Fonds 13 geschlossene <FONT STYLE="white-space:nowrap">Investment-KG</FONT></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Represented by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HMW Komplement&auml;r GmbH, its general manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Represented by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Pervin Persenkli</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Pervin Persenkli</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MIG GmbH&nbsp;&amp; Co. Fonds 11 KG</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Represented by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">HMW Verwaltungs GmbH, its general manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Represented by:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Pervin Persenkli</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Pervin Persenkli</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Steffen Walter</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Steffen Walter</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen Eck</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Stephen Eck</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Toni Weinschenk</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Toni Weinschenk</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Thomas Ulmer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Thomas Ulmer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ARYA Sciences Holdings</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Adam Stone</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Adam Stone</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title: Director</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kevin Conroy</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Kevin Conroy</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Hung</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dr.&nbsp;David Hung</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have caused this Investor Rights and Lock Up
Agreement to be executed and delivered by their duly authorized representatives as of the date first written above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>INVESTORS:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Todd Wider</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dr.&nbsp;Todd Wider</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[S<SMALL>IGNATURE</SMALL>
P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> I<SMALL>NVESTOR</SMALL> R<SMALL>IGHTS</SMALL> A<SMALL>GREEMENT</SMALL>] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Addendum Agreement </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
Addendum Agreement (&#147;<B>Addendum Agreement</B>&#148;) is executed on __________________, 20___, by the undersigned (the &#147;<B>New Holder</B>&#148;) pursuant to the terms of that certain Investor Rights and
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreement dated as of July&nbsp;1, 2020 (the &#147;<B>Agreement</B>&#148;), by and among the Company and the Investors identified therein, as such Agreement may be amended, supplemented or otherwise
modified from time to time. Capitalized terms used but not defined in this Addendum Agreement shall have the respective meanings ascribed to such terms in the Agreement. By the execution of this Addendum Agreement, the New Holder agrees as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Acknowledgment</U>. New Holder acknowledges that New Holder is acquiring certain ordinary shares of the Company (the
&#147;<B>Ordinary</B> <B>Shares</B>&#148;) as a transferee of such Ordinary Shares from a party in such party&#146;s capacity as a holder of Registrable Securities under the Agreement, and after such transfer, New Holder shall be considered an
&#147;Investor&#148; and a holder of Registrable Securities for all purposes under the Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Agreement</U>. New Holder hereby
(a)&nbsp;agrees that the Ordinary Shares shall be bound by and subject to the terms of the Agreement and (b)&nbsp;adopts the Agreement with the same force and effect as if the New Holder were originally a party thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Notice</U>. Any notice required or permitted by the Agreement shall be given to New Holder at the address or facsimile number listed
below New Holder&#146;s signature below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NEW HOLDER:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">ACCEPTED AND AGREED:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Print&nbsp;Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Immatics N.V.</B></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SCHEDULE I </U></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. Harpreet Singh </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. Peter Chambre </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Carsten Reinhardt </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. Toni Weinschenk </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. Stephen Eck </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. Rainer Kramer </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. Thomas Ulmer </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. Steffen Walter </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. dievini Hopp BioTech holding GmbH&nbsp;&amp; Co. KG </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. AT
Impf GmbH </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. MIG Fonds 11 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. MIG Fonds 13 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. Wellington Partners Ventures II </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. Wellington Partners
Nominee Ltd. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. Wellington Partners Ventures IV </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16. ARYA
Sciences Holdings </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17. Kevin Conroy </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18. Todd Wider </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19. David Hung </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>d96389dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in this Registration Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;F-1&nbsp;of</FONT> Immatics N.V. of our report dated
April&nbsp;15, 2020 relating to the financial statements of Immatics Biotechnologies GmbH, which appears in this Registration Statement. We also consent to the reference to us under the heading &#147;Experts&#148; in such Registration Statement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Munich, Germany </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;31, 2020 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PricewaterhouseCoopers GmbH </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wirtschaftspr&uuml;fungsgesellschaft </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">/s/ Dietmar Eglauer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">/s/ ppa. Andreas Schuster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Wirtschaftspr&uuml;fer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Wirtschaftspr&uuml;fer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">(German Public Auditor)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(German Public Auditor)</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>6
<FILENAME>d96389dex233.htm
<DESCRIPTION>EX-23.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the use in the Registration Statement of Immatics N.V. on Form <FONT STYLE="white-space:nowrap">F-1,</FONT> of our report dated
March&nbsp;6, 2020 (which includes an explanatory paragraph relating to ARYA Sciences Acquisition Corp.&#146;s ability to continue as a going concern), relating to the balance sheets of ARYA Sciences Acquisitions Corp. as of December&nbsp;31, 2019
and 2018, and the related statements of operations, changes in shareholders&#146; equity and cash flows for the year ended December&nbsp;31, 2019 and for the period from June&nbsp;29, 2018 (inception) through December&nbsp;31, 2018, and to the
reference to our Firm under the caption &#147;Experts&#148; in the Registration Statement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ WithumSmith+Brown, PC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">New York, New York</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">July&nbsp;31, 2020</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g96389g04i20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g04i20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1?"4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0%@            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M     #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         ".$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M    .@   *$          0                         !
M  "A    .@                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    .@    !29VAT;&]N9P   *$    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   #H     4F=H
M=&QO;F<   "A     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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MB=SJA_I\=W^$Q_\ 7V?S2UL
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                      #_X4 /:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U
M33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@]
M(F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M
M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^
M"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY
M.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871E
M1&%T93XR,#(P+3 W+3(W5# V.C$V.C4S*S U.C,P/"]X;7 Z0W)E871E1&%T
M93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y04V-R:7!T-2YD;&P@5F5R
M<VEO;B U+C(N,CPO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO
M9&EF>41A=&4^,C R,"TP-RTR-U0P-CHR,CHQ,RLP-3HS,#PO>&UP.DUO9&EF
M>41A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C M,#<M,C=4
M,#8Z,C(Z,3,K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC
M;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B870@
M1&ES=&EL;&5R(#$P+C$N,38@*%=I;F1O=W,I/"]P9&8Z4')O9'5C97(^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z=&ET;&4^
M"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI
M('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7;W)D("T@26UM871I
M8W,@+2T@4F5S86QE($8M,2 R,#(P($9)3D%,/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @
M/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" \<F1F.FQI/G)R,3<V,S8R/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z
M9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@
M(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-33I)
M;G-T86YC94E$/GAM<"YI:60Z.#E"1D8V-T$X,$-&14$Q,4$U.3!&-#)!13 V
M.45"1CD\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U
M;65N=$E$/GAM<"YD:60Z.#="1D8V-T$X,$-&14$Q,4$U.3!&-#)!13 V.45"
M1CD\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA
M;$1O8W5M96YT240^>&UP+F1I9#HX-T)&1C8W03@P0T9%03$Q034Y,$8T,D%%
M,#8Y14)&.3PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \
M>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z.#="1D8V-T$X,$-&14$Q,4$U.3!&-#)!13 V.45"1CD\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M
M,#<M,C=4,#8Z,C(Z,#(K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HX.$)&1C8W03@P0T9%
M03$Q034Y,$8T,D%%,#8Y14)&.3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,"TP-RTR-U0P-CHR,CHQ,RLP
M-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T
M179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC
M:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV
M97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S
M:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I
M;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI
M:60Z.#E"1D8V-T$X,$-&14$Q,4$U.3!&-#)!13 V.45"1CD\+W-T179T.FEN
M<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M
M,#<M,C=4,#8Z,C(Z,3,K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I
M=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z.#A"1D8V-T$X,$-&14$Q,4$U
M.3!&-#)!13 V.45"1CD\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @
M(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z.#="1D8V-T$X,$-&14$Q,4$U
M.3!&-#)!13 V.45"1CD\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @
M(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HX-T)&1C8W03@P
M0T9%03$Q034Y,$8T,D%%,#8Y14)&.3PO<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N
M861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO
M<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0]
M(G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0'_P  1"  Z *$# 1$  A$! Q$!_\0 'P   0,$ P$
M    "0 ("@(#!0<!! 8+_\0 1A    8! @0#!@(%!PP#     0(#! 4&!P@1
M  D2(1,4,0H5(D%183)Q%R-"4Y$6.E)RDM'3&!DH,SE#1WB3E*.QM]+P_\0
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M_9[.6VO)9F8SQN6:>)X9@$Z$"10O;7F8R^FY,9V6;OLK>W5O'-<XV\,LRJ9
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M%(+)N6 Z(Q!7<GO4DAA_I/0]:\[I=I+D]DQF-RQ9>7WBSM++LBA=^9G4<ZJ
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MA_X.WFB%N=5ZCM(K;/Y*T%MC[ .TG[*Q\K0R2K.S@;W<CPHK,0KH@EC(':.
M5+M^Z+_9/_A<49SGXM]&_2MF^4_[4_[#]*1G+<BQ&QW")7"A>I- RJ95CE^+
MXB)"8#F+\!^Y2B'P&[_".RIJLRB9"'5.H0J9"B<ZAC%*0A"EZS'.<1 I2@3X
MA,(@ %^(1V[\*5A8^TUF6<*-(JQP4FZ2*)U6T?+Q[UPF0O5U'41;.%%"%+TF
MW,8H '2;<>P[*5DGL@PC6RCR1>M&#-$!,LZ>N46K9(H#L)E%USII$ ![")C
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M,G(8H4IT>2/9F<FN=HQXK 9R-:\PHNEHV]M<CU1JP?2 0*S"NX0!U*CE!/\
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MAC<H33::(\N  [R"60\'I />A;A) _!40W_7@H0HJ@8QU"]A.;N&ZE'E-L(
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M"(>I@ ?7A2K8?M?=81'[B"R0 (_D'8/MVX4JC]E<W[13"!1^90*HH  4?4
M!$  /0!$ ["/"E7P*43G*)0$HB("40 0VZ$>VP]MN%*J+V$ #L&ZP[!Z;^(
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-1^8[>F_Y<*4N%*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g96389g0731200351135.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g0731200351135.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I )@# 2(  A$! Q$!_\0
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BHHH ****5P"BBBF 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g96389g0731200351851.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g0731200351851.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !< ((# 2(  A$! Q$!_\0
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g96389g07b07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g07b07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[0]^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    #V*^.3@X0DE-! 0      %,< 5H  QLE1QP"   "0  < E  "')R,3<V
M,S8R' (% #)-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3  X0DE-!"4      ! +=,'SV@4F(];JWT$YQP]M.$))
M300Z      #E    $     $       MP<FEN=$]U='!U=     4     4'-T
M4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I
M>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0%@            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M     #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         ".$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M    %P   #D          0                         !
M   Y    %P                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    %P    !29VAT;&]N9P   #D    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   !<     4F=H
M=&QO;F<    Y     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! ?_  !$( !< .0,!$0 "$0$#$0'_Q  ;   " @,!
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M:*EU*D"G! VK:656H!B '4ZDU(S8J))J"-UO7TS6B(=J-D&37S#/(<KR44G
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:V14[;V7!\OOVOU^F'#_SX_Y_U[_SY#!C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g96389g10t87.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g10t87.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2/84&AO=&]S:&]P(#,N,  X0DE-! 0
M    ([R^D4@X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!7\G\         "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         /P   )<          $                          0
M       "7    /P                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   /P     4F=H=&QO;F<   )<    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #\
M %)G:'1L;VYG   "7     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      910    $   "@    0P   >   'V@
M   9*0 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')2
M1T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M       !  #VU@ !     -,M2% @(
M                                $6-P<G0   %0    ,V1E<V,   &$
M    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H
M  (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U
M960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M)'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\
M   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R
M9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M        $G-21T(@245#-C$Y-C8M,BXQ
M                                      !865H@        \U$  0
M  $6S%A96B                      6%E:(        &^B   X]0   Y!8
M65H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P
M       6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT
M=' Z+R]W=W<N:65C+F-H
M                     &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F
M875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V
M,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                      !D97-C         "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                        =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03
M"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                   "CP    )S:6<@     $-25"!C=7)V        !
M   %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M
M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L T #5 -L
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M8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@X0FDJ'$\4=C9(*UP__$ !L! 0$!  ,! 0             ! @,$!@4'_\0
M6!$  0(# P0-" 8*  0$! <  0 1 @,A!#%!!1)18083%!9357&!D9*3T? 5
M%R)6E*&QTS)25,'2X2,S-$)#8G*RU/$'8X+")2:#LT1&<Z(D-D5D=*/#_]H
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MA$,6; 3"Q-CV;16Q93'4& 9J]-@N-W>GGJKMI=IB$I*KQZHW,54DQI)2) /
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MLCI92IW'UK%L<M=HLUKFVB7.LD^&6#D^1/@,F*W3A$\R5+@FPPQ1-+?,B&;
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MQ,60XIXB.!(>7X<K>>$'<=7E.,)3XEJ:SG/A1A*4YSG/9.,8]F,8Y\>&;-A
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MY5;00@P !],?AU_+3[)&<J=Q8I,R+.BSO2SQ$(2S-#2&OI$4=Q=6YPY0S8
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M-WV&N'4!JYCIVG+D<Y*.5BN[1DM/SE:F+'6L3:H66P"U*-0[B(>6DZX<P5*
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M=4;N8=Q""?3>Q,7:2B[0-'M- CE1S+X3"HHZ+D9(H0S7U#GG)8#F;I:]UO\
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M-^F4?4_+7M&3?\E/A4V'^KYLSZQJ/\8XWH67UFR5V-N^0F_3*/J?EKVC)O\
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M#D\$TFS!RI(65+<:4,5&M+R1ALE4W6<Z &4808XH8Q$0\ AEPS,[07@B=M1
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M(A&Y( !SH882:DB*' M/+1U(T,:)LA%&FHFWS-8+KH90*5284,4;96(DV&B
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MHE O\&-P\VTUA$$B'T"[9L1BI"(7)(=RP-68@,""7!HM&;%Z; >F!"03%$
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MO&<>2CXO&G_1S$R?.S(_TL8]$USCH6H;+9Q$&DR[Z^B+A7I\.MK?<E6\?%#
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MEI6SW5QQ3V$0S"8H',8!<P-FF\NYS8@0S,[4O7()!)A:(-'FB66/I&(Q!FP
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M69&0E840@%\A(A<MZH]9)<<?*=>-%-]ST+@F.D'"XYW$4 E0O89K">T+-(
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M\JQ65P^TM3(FP#DD,H<O ,ZN#R>')H2CP"IP/7(@$58GA6,"PXPCOAYQ7+M
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MMLHF*PU36XSS4J:3"PHU4CQ/5"\>BECFS.'L8<EBEY&5#$(F)!BF0S,X7B*
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MN/DJ8)+8PHE3##"U=\N+%PAK"&^_A2G&098-&OO:\ZN1M5RI!UW!^0-?[O\
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MYZ+*B2C3*CFF'V$GU02G33XJF&7&RY)]1+2"G'L<(MQ>$3A$X1:XW[_.<_\
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M,38$U:ZZH!)<W,7!N;H0 G$-R$ <I=O]C6%Y/A$"O".+9I\P&6Y N3\<U*&
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M..-LNV <W*81AL?T1EO,*SZ&VHX9XE!67'/,PT[X,,V.C'4>0FK=][TNJH"
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MHI#J0\X=&>=DR$NM.X4VM.&L*3G*.^:9<)Q(+,[X.2W(YJ/OJL@UN!)K4.,
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M,4+.X( ?3\?]IFD,6-X%2;R6TG7][7KH3L?7+-=<O:WPHX=F)4=G)T;ZIG<
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MQ;/KTA)DB0VV^00(XW'I:#;\'9U]VB!GK?BPTDUP-^C3I*S2E* NQ+E]6B[
M8WJ+Q?2U4@078TR37+@D !L.CR4."8T*<(3,.(.B&C7"V0$(&G9 01A]L]T'
M_!2&3/-'SYLVL=U&KRUTG21I6C$:$,_1CB<: 8-J4JH.EL4*=C"A[%(3$+$,
M694:/*D&$G OSY@JF8]ATE\OM#1L<RZ..SZ0GPO9;<2RGNO.;##FL, YO-Y\
M'1?TY<EA1F&-VO6=9TFZBO?FT3A$X1.$3A%2>V-)Q6V#H R1EGXS,(T8/A0P
M:'S,,FNCO+?C#%$LJBI1EP5K(Q^&C$M8RO&15Y5A2<10YS%V9ZXZB"]&KTJB
M)@6O.GW8CGK6ZB@CG2G4$2#$A&R3D>^V'+-9>3']WQSI&8EII,K&I&D HX<S
M!,N^V>H^-E?63#(R59'<;PYF;7H+'2UQT@.!>Y_TZ9T50[N'H , &K?=@S5<
MFBQ072;6XQF,9394IR AIQ&'8;#[<@>).$V$54@Q)3)R"HX$PEYP01OR9)K.
M5Y<FG67'F'9M<,( =L<:F\FIYW+G754QDAFK6I/1=\6UL"RF5YTE%760LYR;
M8+&ILXE89D4^J 33&7:\4X6.T-*ID Y .'DA72&2HL5X=S[=184@,O+V':8
M1]+14 5$.!-:7O47],>H.;4.QU,W.S4=]8I3"0W3C2J^F$<A[ 'DT8@9;ALG
M%0TJ[+@"T:O4++:,..,Y1(,@UU@H&70LAV/)+.90PXP0XA4$N$7&XA[C5A#S
M$L*L]XNHD41.<]S%@"6%7U@!SB#JU8I/2Y0 Q6RX^R-LEY37P6I,J/B3A338
M;WL6(EF58\QE,LPX[K6);7'NE-Y=1*&LLNLJ\ISDVJ $$%HG9S6[-H6;ZHT7
MG$A!$268_ %WNUE\*8$$T0;I6U@@%X9,PT0>:W*H'F%B0CLD.X=!P\*XJ-?R
MVI;#4:J,07'"L*\B-63Z.PE#3:.^LR%L ^+,;L"]*!\1C<AB-"2X %30/6K.
M6/+722*#/QVCHVO5ZU@Q=O9-F;9;(&W@ER*4LAYFX*75(Q;;[+)1F74%D(0.
M<H-MEI[#784$?&/*2S U"+P:7&N-2[GX,R7D&@ !!(I0UJ:Z]=<2LP]HI<G(
MQLE8+4S-% W4FX9E7JR.W9,LJE(>3#K0,WF4>]55Q2(,&(GXL() 5DA6U#&#
MLEODG/W,HQ+^EG&E;P6ONHQT@ET'H@L2"V:Q.IB;FT$/<7(T+"A=-D= R A5
M=L!8@*[)4;'*PGE9#@W)"NWB NIAX,.$O$:.02NO"PT8V@5AR,BR26GCY!*!
MVVIM=  6 8T>\$$MJ+8-T44,1(9A6%@:DW-HI>_OP*VF%_RH?_;-]O\ \^/^
M_9Q-_51_TE6'![S$.9@ 0SZ:NU7OT[;\\6O3K5O=6O[A8MG:XM<?5<W^HP=5
MO, 56?=&+"I@KO8):DFU+9#P\C)18IK-7CX"RQJWP'3+$![HO-AHTE3A#C$(
M?QX>NFB8'3A[Z/ARK5E_476N>= 60VSR;LA6T0[,BR]8*#[HSC7D/C;9-UX6
M/'-UR+A+E%J%$UB%<VG)*MG,.$VC K2\+5<>G[O'@HLO)ZKZZ'J^\6SMZS!R
M3T]&#IBHI.L9:: HBQ=AN,X$1*,5FOF7V,DCM7(M,@99FH"0"KMF57A7UG,,
MGQC6N(;D#?&J4\<ONZ#W9:>UOU=DO14VBQ767ME1V?L299:#NNOZQ0K55YNA
M;EAM<-C1+4:=*!1U>-F]7#6^/LN)8CUX!*3E?!E&@1C'[SGDI3QXUL;F'2<.
M:M?RP].M]6=64-2MRS=ELRB=M6K5T%5:;-$%55B<;(JNX>I2P0@[S03LW48R
M=&UIL'7D2)(D.S$2F:&4Y*D2J 3'7G*K1]6F[O/B[!=!M!ZS[!>Y1@"X6JD:
MU+ U\ (F1G]92UK'!%V!HB4M1J9&/BY 5BR^X8/>M=DV,1!44MXZ#/B)F6*/
M%3 AR,EQP-^G1X;6NUS5G5M,/0>7;G8H*3%.FXFU6AR8UL069%2>^M"V PK7
MV!J\<[#5@_4%6V1$!QE@&5/L&%,H/0J4Q%2F"4]VO0?>[:J8"_$1^M^NTLB#
M E]DRH"\@ZE&M5A!E-=JC'X@6"TJ%LABOQRJZ_(B7Y5HB=R3BY<T)VJD0<]'
M 18SQKH@\*4-]':M^.O4-1JO/(ZTZ[X2#BHFO[,EK,6X9294NPRTGKQV2#DH
MF2O;<_&$B8@ZV 34IB!'UZW(.AY>FAI-<D_'@R"2S,QHXM30_P#K[D%U16OY
M7$]^M97J#TIOS9EAW-'T H./<D[#IZU0YTS+3E;C[%4JK6B&H&E!V6&",<87
M4]J"6^_3<,GT?)6)NNMR#JXF7* DB:>1KSIJS_1Y1T/51Z7Z6MNS$ALC%3-L
M%('/W('M*@6"6LE2=GA[E+7C9EUV#/2A<$Q,IE-:-@R5)KVIZ_)!)N45YTU"
M69"*<^_C#QR7^,,4\<OWTKJJMF^EBGW"FQ6T K;#EP;9E[ICM> )\[#"08?I
MRT/4K(]'((E9UWT)[9%;O*_2<S4QB4+]+E\3$QZP]:&$^Y;3<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBUQOW^<Y_^JQ_PD\]
M1DO]CE_U3/[ROA6[]ICY(/[ H;SZ"ZB<(J2O.BX"_6%^S2-FN,3).1#D(PNN
M&PT.X("^X(X2T@]B"5+&-O*$3GT:5D9$)A3Q*A16,OK[XB@$1=R"+FO&ECKY
MVJUZ D.&#4+G$C&FC4US:UAX[IOHT&!&!1DS:H_,>J2:R<D^'6:>)-@#1<M'
M&N$0;K*AY 01EM:V&!S6<XRH0H=2L9PVL, \5-8K<[TQ8?<J8B7#Z :#"K>]
M<,]-%%2M;YTI:I8MQ8?B,/,A_.R/'J@\QPG@#@A!O)#9KT:.TKR//6TAW+[S
MSR\/(@EBKEWU#5JU"YE,Z@ I1_NK6\N=#LV%/3$=/-5A+"-8H^R79!$?7I6M
MQL<1*QAL-&"S(XPQQ(489"OCM%O(%:6O"\.".NJ=60(]YG; 2P"XBB<!@[%@
M6NZ.GD6G/(#6YKOBW3=BHU\%K7;0ZP4V>X#A^$EV0!8/K H9!A;$L,V>X&U6
M6QXW(C4R6@$"):C8=G^:QF.<PE25A &8Q$B&K4I?T!B='N3./*VG12E35];F
M\NNJ0Z8*DNMV"(CK79,G3L65%'RDJ9$.K7@^8&F'CEXC8>-R+(,>0ZV"_'Y"
MPAMY>'D/ISG.(9=X$1<AC5G#WTJ&?D>YE'J"P+-2MPZ>7P5UXZ4:A(N$.S5C
MLK[(]@)GZL-%O1 0U<>(''&]('\<.2\<:2,SEHQ4F0> YAQ2QPF',^/EVL$?
M2.D7$#6*:-?NHCD8NX8Z#XO>A<GGM^CZL@:!)RTC!GS.6Y<<4=Z)>=CF(0=8
MOMR8+%Q49&C(D"L^TP]U+Q1..V'',XPG&+#!FF]Z:!J>[2:\ZE=6HMZ7(27I
MHT78!69S:)PB<(G")PB<(G")PB<(HZ@BUYE<M.1<"F%])>2DQ$R<J2]$PAK+
M#J@%0J1\/K<R\EQG$BIMM"&U)>7EQ:&X\3W!M+_<WAL72C7E]#4Z7^Y2+E1.
M$3A$X1.$3A$X1.$3A%4>U]>S%_Q5VX>Q%5G,+(2YA4A'K#1(^6=7I.):9%Q(
M1$T"I*R#&_2L/!^+ N'<L.(?\&<8CA)9B007HV@C'HYT%']%WN&FHK>, <;N
MA:O!=)UVCR84I,_!R3*VHB.NL25+3,>U8HV"UT%6HHH>1"AW7 9<6;9DT86R
M"T,N'FS"'$++8%#3D01 ABU #4U:%@::_C4%;S^AW#B[TGQ.A]!?1>L[$].^
MPAHR0CI!&O#'I*GHJL!,]DC2NL,!REF*8D*TF-IP,>3)R@DX%F9.BA*JH@Z&
M$4ZV3G/IB()<3$4<AOZ6)8AA5P0#<S*9U X>\D$TBT U- SLV.MA:C]$L(E8
MHX0-&H\!F$O<3*R=1II"EUHP9+#8+4H6Z] PBE*CS\L2Q.51Q)&1(P=6%D%9
M]';T0<T#-N(H&:C5PT7WWZ0LEB36(^BP)9QR&]GO#B_IK"%Z=;4R53)DF&H4
M!/ 6*;/L>*Z:R_718"PG5IV;A*O#F41EV,<,C*Z-'"'Q1< 2.8RY+D./YDS
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M#3?"7 P-^DBC/2IO66 %:T%01INH+V!-*>Y\9)W[JDA8>5[U6.GIG$NPQ".
MT2<;!>#8DM@#/)/8$L<H4QB1!K]2+'D4?X*&196FC?)"7B0&/,YWHP84=JDD
ML6%;O28E/1)I$0 *EP30 '!N8"@!I5C,+[-;1K6S3I2J1=BMD&Y"1GI<<F&G
M,1=<%!*>>E"8M(XJ8RW2$V.XD=J/ .]T48:*.X@ V.))\BDQ9U'8M@?1 !?
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M1V$O\:><7*/V"Q=:?\Q/ALV;\1X+ZSD/V7'F\LG&5H["7^-/.+E'[!8NM/\
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:RP6:1N?:&S)DV/.V[;G?.9LW:@S7N="__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g96389g10y56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g10y56.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &BB^9I8X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!=            "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         4L   &%          $                          0
M       !A0   4L                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   4L     4F=H=&QO;F<   &%    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   %+
M %)G:'1L;VYG   !A0    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      /L0    $   "@    B    >   /\
M   /E0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M[ZCH.*(QV?#^*,DI2 [#HDNK!I>?SJP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-C="E9>QM<$8)E5DH;*SM-%$4W2#E+;"U>'_Q  < 0$!  ,! 0$!
M     0(#!00&!PC_Q !-$0 " 0(#!00&!0@( P@#     0(#$00A,04205'P
M$V%Q@0:1H;'!T105(B/A!S)5=)25T_$6)#0U5+*STC,V0A=24V-R=8.2<Y.D
M_]H # ,!  (1 Q$ /P#^_C@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@'F-
M*:$&68]KGM$%(*<QOV<]L$3Y5:U5\HCG(Q43^M> :26VCO;\^6T-MK%LLLGR
M0#AGF!"AP^?=$/! -/"Q8XD_5T[99)'JYSWN]_A":NE:]U=ZIKR:7AG?NRS(
MW97NKWTX::-ZK-ZV2-D>I=+8:&A-BM)7$ETMDM:AC_'R%#N"$,@?,K41JSQH
M2Z"1?".>V*.5R)\J>76?7J[M0G?EY>M>RQ:?!1P!P!P!P!P!P!P!P!P!P!P!
MP!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P"-ZO25^5I
MB+2Q8Z>/WL%@#C]JRG%$(Y(A8T=^7\[6R22O=^2$>.:>3Q'$]4-VS94F]#3
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MZ&GNX7-]WNK; 8IS6K^BOCBD=+&B^4\>]C>0I(^ . . . . . . . . . .
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M=$?!901RHB>YPYD"-2:!R^5C62.*5&_SXVKR%5^*MYW,[P4?[?[?Z%X X X
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M9W'7==7O76/P]5+BMY;'R.["LK[1R:G%:VAII0,\))B*&OO:1U'HZBS/+4@
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MO!*)#,)#%(+KG3/ )F@BEG">3%\!#Q97M<\=T\*K%*Z)S5DC56.56JJ< '
MV8SP[$,8\21\$CQ2X(R('R#3Q%#O=%*U['/@)AA(A<K56.:*.1BH]C50"N>[
M-AI.O>I>P]]E :2SNL1D+_7PUNAG/&J[ ;-5A-R<%*16QS%P3%!A3P"2LB?'
M&5)$Z9JQ(]. 5O/ZA'92AZP3;YDJTUFZQIV\NQ\+-6?@&5RM2RH(N+TDK8W>
M>,-$JH+^L22OJHK2_/D8:M;4$NC@@G!:7T[NO;\37BI]=-%V'K^F#,#@;".F
MWSM#5_C.V AK;H8);CH:44O.$5I5J#84EU1=KUYI;Q[!?IKNDDH[*$>UJ+ 8
M5U[[ L32>M;.976;_&D839Z&QPNAK*.QL\_!G(*.OFU-G)G<4-937FJKK.8J
M^TL$M<Z:IJC1*\9?K[!X8\3GR!E[_8[,C>+]=V??UI3:'L#%:X3>RYJ/07F/
MS %/:2CJ3BZSL2(>N=%I"82!1\S>UK2;*4N,:(B$T@QP0T$CHP,HSUO=6V1T
M=:?G+C1 /U%*,ZRH692[IL[57%SUCGLQH;,U=5*/>,-V/9E'7BD8=NB=!# 7
M;RQ#5X:&$ L_;[/P+OZ ]0F<]0N=GT>?R^OR<,=7C+Z #90T$1YF?[!R57ML
ME<0?NYH-&$R"TH+84A1"38+,*57CG@C3-<Q +\1K6IX:UJ)Y5WA$1$]SG*YS
MO"?;RKE5RK^JN557[KYX!BYZ*E**).)J:T@TR"L%++F"'E()&I##+&G'GF?&
MZ26&JL+ XVOC>YS RS"2!TCEFD>X#*\ < CFKR.;W-++G-;3AWU'.;46,U8>
MU[Q93*&W!OJB:1C'L5ZA6]:"=&QRK&Z0=C9621J]C@/;^ 47_H6I_P""H%_<
MT/\ X$C58@G^\_\ !48JM0?_ 'KVJK?9X^W .Q:6G<^*1U36+) V=D#U %5\
M+"ED<2R)RQ>Z-I+IIG3M8J),LLBR(Y7N\@=[0 631D,"$:1$DR13M&A;-&A'
MQ_4)'*C$>Q)_BB^9&N3Y?CC]_N]C? &)UT7S9;1,_7S2V;D3]/*QAS2-^_\
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M/?/A<:;&MQI+,T-#?D0=71,<V56+(\#-YKTSU&7J]74U^WUGQ6]OK-%CS/\
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MD)MP=-[/D(L5A:\MSOC:UB^V9SXVJUJ(K6(OCRO,3)=^I). . . . . . .
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MJ_\ O 9/^SB'_%I_K&'_ -6G\V:9_G/_ -5+_4IGT7Y^H'UPX X X X X X
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M2$8[R<:D-];ZBFY7_IS87Y<_1+"[%V/L[TDV3L7TDQWHSAG@]@;07I+'9:>
MCBJ^-PNSMM8?#PJO:.%P6)Q-=T)4:V"Q3PTXX.==TJ=*4+7N,5T=+U;B^L<M
MVCF\G#UNRK?A;V+44%K85)U4),$AA\1QR0V_XD,4;';QD+']6II$D<@\OQO9
MZMH>@^.QNS<-L^EL[:V%^@RI5,%B(X#$U:E"K2C*"G*,Z6[54X3G&K&36^IR
MLXNS7X_Z7^E6!],]IX_;>T_2+9=/:V.VC4VH\50Q6"C"CBJCFMVGA^U[/Z/&
ME.6'C0;LJ-HJ2E%3.?55)U]AKJWU^K[IQ6UV-M6CT49\5CGZ*JJ*$<B0Q:VK
MJX[@][7&&2(58%DF3S$21#QM2*$>-G-.Q/0;;.RZU?%XG"[3Q^-KTXT%56RL
M1AZ5'#PDY]E1HI5;;\WO5*DIN4VHK)12.#L[%['PM:KB\7Z1[+QF,JTXT%4C
MB<'0I4:$9.?9TJ2Q%1ISF]ZI.4W*;4%DH(UBL?2!T:;MB3HO4!1"=9'7$UL;
MUVRRS3B7#%FN./S8VI_&6EP4!DTL\*I]"^R' E<% <B-9.SQS_)QM&6)E)87
M:T<#.IVDL)]6XESW92WIT%B'#>5&;NOS.TC"3C&:LI'U<?3'9"I=G];;*<E%
M14_K#"Y65M[=[2UUKJE=OAD;N]B=@==2]<;&MK=KCI9'Y.X#""#T5/+(]5K9
MH1QAAX3'/>Y?R1Q11M557PUJ>>?H&Q]D;4I;4V;*6R]H4Z=/&85N4L'B(0A"
M%6#;E*5-1C&*6;;22U/F-N[<V-5V-M6%/:VS:E2I@,7&$(8W#3G.<J,[1C&-
M1N4I/))*[;+2R*>,GF$7RBIGJ5%\IX7[5HR?=%^Z+_4OZ<Y&/_MV-X_UO$Y_
M_-,[VSO[OP-\G]#PMUR^X@2'GD/8. . 5ANM=GZ>WSE9;V4-7- =#HWRGJH@
M;ZD$:VCL28CI?:-(M7[(Y;&%LBRB#E"$2L2*=CN<C:.-PM"MAJ5>M&C*%2.+
MWJK[.FZ%.-:-6<:DK0?8I)U8I[T(SA)JTDSG8S%T*-6A3JU%2:FJ[E/[,.RA
M&JJDE.5HOLK*51)WA&49/)DHL=&R'-,O@(9)7GC!+3BF#D"33F6SH8:R D:9
ML1,#I)R84G@D9&1&WWL<ULK?;SV5<4HX18FG&3=2$'0A4C*G*4ZVZJ,)PDE.
M#<I1WHM*<<TTI*QZ:E=*@JU--N<8.E&2E!RE5LJ:E&24HN\EO1:4EFK*61Z<
M_1QTHCOD?]5:FN0JXLY$12+ YZ>Z61[_  BM'C<Y8@QF(V$09L<,,;&-\<RP
MV'CAX9O?K5+3KUI6<ZM5YR;=E:*;<:<$E&$%&,4DK&5&BJ4<WOU)_:JU';>J
M3XMNR^RM(1LE"*44DD9[GI-PX X X X X X X X X X X X!K;WCY_&,_P#X
MLL$7^K^VQ%_T_P#AS&7YK\O>B/5>/P92/-)Z3/93_C5FO\=!_P#O.YMI_P#5
MW)>^WQ-517W>YW]QO%S,P' ' ' ' ' ' ' ' ' /'8. 8"9):N#961BSR6#[
M!86@L"CB<\F0QQ*H.T5D+7NG=.J1-B1SI%1B*O,HRE"49PE*$XM2C*+<91DL
MTXR3333S33NC&<(5(RA.,9PFG&4)Q4HRBU9QE%IJ2:R::::R9&X:# D.#8/2
MX^=]B$^RKVPUU+*X^NB41)3PVLA52@HUL $>7!\D#%.$1ST^IA^3U?6.T/\
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M:^="1X2)84@^=K7-C?(V*%CI$C]ZN:U7>/>C7?JWE22T1&V]6WYEL)^B<H'
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MY!F/1%D?3D/956'A/>R5())41\_E:U;C?KK\-#%.^3R?+->J^OE?Q-G.0R'
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MB/=2V5BV)KE:Z1S7-9[U:J);W25]+Y6X.UW?77GS5B:/Q]=_Y++SYYWOR%'
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M+$ LD:14E\,>Z*9T<OPI&X1^-L_7W$Y_V7@HX X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X!0?9WNV>XP/6(Z_(#$>/O\ :1M\
M^U:'/E(ZHKR&_=JQ7%XR-CHI$]LL 9"M5'1)YO\ +UWN3C:W?ZFB_.0HX X
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M:#X<K4[(O,[6C&KJHI(-I+%%7@WQ =Y9!U).296ZIP%<<52D'%320+'2V#>
M3?,^K/L8O!Y7='!==GA:+U8:3J"WLA="\K+4G7P%'I#P;"GTM;7K%<FNLJ06
MM%(G%8AEB>RI1)#7PJX\N#_F/E?/+O\ <1P+]HW^)T6STU;UE"7G<'#V;9W=
MZ[23C DT6'SW1-]4'5<#Z20^4B\=WQ2@%UIPX-C5S9Z\^4-Y+8@N!UUUZC#,
M_:(;J_H[*;)=,5A!XV)T>JBMS-Y2QT/TP-9MKFAO(*\F4'4V=#8@Y$6.U%!I
M7WN=.OE#NP*\C.Z"$,--<LNO9GX(^FN,NI])D,MH2OP_ZF\SU/;D?A)?U]7\
MUC7CER_AQJ-8A82/E=]*3[6_-#[)/">Y4X!)> . . . . . . . . 0'==<T
M.]'$<>I=;=U,CB:#35$[@KRC+7])@RXU17PO5$0@*=)!26)[9(_<C7M$:OW/
M@^O;S*\BW>XZS8@7:=4?J*6-?$'8F/II3(F0)]D749ZO;(;6D,1/?,;7C3US
MT<WV-B>OQ(]=[V[O&^B7.]NZ_!GGRX6U\UKX63[RT,WV%A]A D^:U5'<-\(K
MX1; =3('.1%2,L"1\9P<R(J>82AX94\IY8G&@NGHT_,F"*BHBHJ*B_=%1?**
MG]**GZ\%,<-<5!AIM:':5Q5C6O9'8@#&C3F 221MFC88+%*Z<5[XGLE8V9C%
M=&]KT16N15 R7 (/LM:#11QU3;2&MO;>%S*F:<,DP4>62>(6&<YT$,L(D4I$
MS!Q9"_$<LZN5L<\8Q+6<_'XVGAHJCVT:.)KJU"4J<YPC*4HPC*HXQE&"E.2C
M!U+1E+A)1FEY,3B844J?:*G5J*U-N$IQ3<E%.>[%J"E)J,7.R<M%)1E;3&WO
M++0V)7QP#QD6CF4YT6=B45FR(A+E''//CA^!M@MA))\@D$C6"^R=LWQ-<YGQ
M? XC$5<55G:$(RK.-"HL(I06T)J<HTZE51W'555RO",ON]V6^UFE'YR4Y5I5
M)RC#[S[J:HIQ6+:G)0G44=WM.T;O&+^Q:2DUGEB&5!@%2-<"N^BK;R.QIXK&
MH,*B5)!I"0;"FLHGPAD#RH\<A%#*'D!.AB=+!(5![7.T1P\Z=&&(A]W1Q,:N
M'56A4FOM0E.G5H5HRA2G%_8FE3E3=.K&#<7*%F]<*494XU(K<A756E&K1<HY
MP<J=2E-6A*+6[);CBX32NG.*SO3K/3%'6-&A6CK* *NE;0,RXSRXF6,C15(4
MY@/M<*L=I*4QS[$ESE'.AD 'G^9?;+]'L?&3JU</OXJAAH4FL*L%!SCVK5-R
M[54LXM5Y33525W"I!THROE+J8&M)U*49UJ=&--JC'#IS3G]ER[1T_P VU1R_
MXDKI33IQ>]D]J?\ ;_1S[([PX X!KQII7]N[J/!!.27 8DX2T[!-C<BPW=\.
MYI5-CH96+XDA$F;'97B,=^18A19/#W.:MRLV]7IZ\W\./'D8YMJS6ZLWWO@M
M.&KS7#@;"L8V-C6,:UC&-1C&,1$:UC4\,:U$1$1&M1$1$^R?HGVY#(Y< < <
M < < < \Q88A\*CG"C&#N<QZP%P1$0J^)Z21O6*9KV*Z-[6O8Y6^6/1'-5%1
M%X!7=#TQU7F+^]U%%A<]7WVE*--NK&,)LLAA5C=$Z2PG2,ATL SSM 85=EJ)
M% D]H1,=(CB'ND4.O7J6#^'5_AR?0A^'HC7)]-#X<UJS.:UWY/NC7$$*B+Y1
M%GF5$3Y7^X#KCJ:J%B1Q5M?%&@:5R1QAC,C2O17.^A1C8D:@?N<YWTR)\/E5
M7V>57R!Q935#%A<RJK6.&$_#QW-!%:L 'EJ_10JV)%B$\L9_:S/;#^1J^SRU
M. 0G1Z/)Y2^S]3=4<(D&NM%<+?NKP/PA--$C?HX;(A526&V+8UJ5Y<T2_*]B
M0,(25&QJ)Q2MTK=>1-6TM.DK9VU-:V>-"VQS( *DK&G.5YR,D2+WM::Y5<6C
M7(A+E]TR/7SP4[6U=8P5@+*X%@4;X9(PVB#M%CD'?'(.]@Z1_$U\#XHGPN:Q
M'1.CC=&K7,:J 8'083&ZJ@LLMH,U3V>>N(UCLJJ8*%@I;5)%,5TC86Q.21"P
M@RDF8YLK2!!ID>DD,;F@=&5Z[P^)J1*3+9:FIZP)+-!H!@HG.9^-%S'W"N(G
M24F5UH:1,4>LLSU+FD<^;WJO )?%%%!%'!!%'##"QL<4,3&QQ11L1&LCCC8C
M6,8QJ(UK&HC6HB(B(B< [. . . . . . . . . . . 5YHNI^N=5*I-WD*4D
MWRKFV,(<8=BR1?/F5AP:0$-E^_\ OGR>_P#KX)99Y+/7S(;_ "!9T55_ ]?V
M7G6^?+8ZS:V4T4?W5?$<5JEDQC4_1K&M1C43PC?'+>[OEK?0;J6E_7KE;JUN
M')%+$^FC5V/:\.A@WNWJJ:I@@^?5&Z"M-U6AD5K'_1 LKZ>OC"#'1%@E(MY+
M![_#?A%]K47B^5K+ASX)\.+_ !O<CC?/>:?-))O3)V2RR\>\W9@B6""*%999
MEBC9'\T[_?-+[&HWY)7HC4=(_P >Y[D:B*Y55$3D,BO.QJU9A*VV&H,U<&5I
ML7OFTT[!0@@)'M<1(XA\\$;6_+'"ONE0EL*_V9@93VI!)RMJ4G*%&O##X.O.
MA4BW+&24*=.FY)RDY-Q2M*,6G+?47]I4YR2B_#CJ;<(5(T</5E3FKO$2W80A
M>\FW=+515WO;M[J$_P UZ;Y MF5NZ&2Q8V;]U[44.U8.OU'L?53,%-D@:Q$6
M;X_B<4-[4:LK&PO:WP]&K\'@9K!5\,ZL=[Z%7A3KJ#W\Z$E3JN,5G+=2=2&Z
MEO+=:235OG\,U1="Z4EAITX55#[5I4FH5++5[N[>.2<K)VL[&0N0\4*(61ES
M;4R>ZTA=E%76,A;_ ,!K16D@DN*)E/-:>;=&11V8$DWP3@4\HX+Q!)6$/*V5
MJ6SH0G/!U*U26)Q<ZL:55S:PM&&_3FZDY5*O:U<14BJU*4MV=+#N--PIM3=3
M%4<)!RGAI5).IB)U53J.<G1IQ4J<E)RJ3[2=>:52&]NRIT7&#C"TG++=?Q7_
M ,MO;96MHKFQ856",BG0(V\"DJ(K0CYXP99H7P5!15R.$8=\T<D4HTL<3&O]
MI4/HV6L3_6*V!HX6O6C.E!1FZ=3$4W1C6EOJDY0<:$IXB-.=7>34H248I_;C
MOPSJN=2IAH4:M2+ITVI.,Z]-TNUEO;C::I2G6C"<[IQ<6HI.TH[SQJ]8V+(B
M-D5C5>UJJK6O5$5R-5415:CO*(JHGV\?9.?HBO97UMGXGU*O;/7C;2YSY05+
MV;HM"GX?AL'**FTTZ2>XN5Z/3*YR-4CL=24.UR/5(7O8%6,<K$*LIHV,56PS
M.CMNN?=[?41O-+B^'=SR3\KV3>5R78G&4V#SH.<I(Y/IA$?+.60])3K,\ASI
M3;.PG]K5G--(>^:>54^[G>UJ-8UK4A>GXDLX X X X X X X X X X X X!'
M=9E:3:T%AF] &TRLL85BE8OALL,B*CX219?'N@*&E:V8>9BHZ.1C5^Z>44'G
MUIX%3X?7W60NX.K>RC'3V:M<F(V<Z?&'M:Z%/L&5,OY(-57Q>UIHLCD4^-OU
M@JR>96LNNG+-<M?.WCZR*^=^;MX=_F[+N+Z147[IR%' ' ' ' ' (OL-77XR
MC)N[!'S-B5L(@4+F(38&S*J0"#^_\OO?X=))(OY8!XYIWHK(G<\>.QM+ 8:>
M)JIR46HPIQMOU:DLH4X7:5WFV](PC*;^S%FC$5X8>DZDTWFHQA&V].;TC&[2
MN[-M\(IR>29@A^R:FPI@+JF".MX33):^0>%L8<XID 7UA$#ELW!0RK"Y6CO?
M'+\:R^]&.>L;VI<'C*&.H*OAY.4&]U[T9P<9I)RC:48W<6U%M7C=-)W30H8B
MGB*:J4VW%RW'>+BU-).47O6ONWLVKJ]TFR74-HMU5"63H$&?.DS)AVRK.R$@
M8B40B..=8X5FB;/!(D4KH8721^USH8G*K&^LWF7X X X X X X X X X X!@
M-+G1-15OJC99X8G30$,E'<U)(YAW^^-WA[7L>WSY1S'M5'(O\%1%3S8O"PQ=
M%T:CE%.49*4&DXRB[IYII]Z::9IKT8UZ>Y)RBKJ2<79IQ=T^3\&:W=B];-I8
M2KI'CU]%24E-14#*[XG''%H\4$9^A85",&V"%4\2G1EME8.Y6PPJ[VQ<^5VK
MLE4%/$IQI4,-AL/AL*J6ZZM2:W:4'B^TC&GN0=KU%/>4+M*]HOB8S!.@I5HR
MC"E2HTJ%",+-RG>,(RKJ:C!*-LYJ5U%Y1NDB*TW6%E<S5[4DLB*ZXR,MZ(:)
M7I61LLGL<@U249,38PQ*KD1'D12(]/DA?"R:%TDD?AH;&K8B5+.LZ6(P+Q4*
ME.EV"59_F4*E24JT8[SS<HYYIQ33<HZJ>$K5=Q7FZ=;#2K1G"&YNU+.U.4I2
MJ13;=]Y23NU:\;M;"=:9=  H+>VS@U)?0P.J8E@:\=9*Z)L"-FF!864+"5*^
M-8Y)TDE((AABEDF7Y7-Y]1LG!JE2A6K82&'Q,8=@MV\;T8J*3E252I3C-N-G
M)2E*48Q;EG8ZV P^Y!5*E&-*LEV=XIQWH)16\X;\XQDW&S=]Z22;=F6MSLG0
M-5>RO41)E>R9^ML^'6V%LW/CO62Q*8  !?6LS'B2VUE-+' '55-6K;*Q8C9"
MB4+%'$3Y%D<S)1OGZ[9OU>PQ<K22MKDK6UXWNU;599M\.1;'6O7\66B-T5K9
MLT^UU+82]!J53W-)C5$D%K:A'*Y1*$-KD0(6-R-D3VSS>Z3V^R/C;)<BI<=>
M_G\EW+\2TN0HX X X X X X X X X X X X X!%-GC*'=T<]#H!5G&D>P@8B
M&1XYU:? ON%LJTN)6S"'"2>)(9HG(OE%:]',<YJ@5-4;C0]8V 61[:)4NE*G
M8#ENT$B2*N/\JC!*W7_$Q(:6Z]B(Q#Y5CKCU19%ECE5Z<K:;R5NO+KN)HLVO
M'3XLV!CDCEC9+$]LD<C4>R1CD>Q[')Y:YKFJJ.:J?='(JHJ?=%5.0ISX X!X
MCK*NK(V361X=?%(_XHY32816/D5%=\;'SO8US_:U7>U%5?#57QX15X!3]E:V
M78NH-RV;OUK,S1#CR:"UIR8W'691C??#7!EPN5XXS(_S$2CO:Z1R>Q\BP^Z"
M9U[N_P >M)>^FF6>M]<O=UK$-YZ?9+,:NGQ.D-I;("=\Q+;9RVXMG'(L'RQ2
MQ2HWXI70Q311R0K%(V6=DB3,CBDBGXNV-E5-J1PT88AX?L*N])J"GO1DX*>4
MLF^S4XQ5D]^49*45&49\_'X*IBU0[*OV#I5-Z3=-5%*,G#?5GDFX*25DFI24
ME))2C/$XVIVF[S8U54'LP5-E)'5\<XX8-D9;Z4.21MD?,M@,2U@TDTDKEA;'
M^1TR^YTZHC(.EA<-3P>'I8>BOL4HJ-WK)ZRG+G*<KRE?BWPR/51HQI4J=..<
M81LVVFY2><I.V5VVY.S6;T5D31V/VG75.RYHM?::1]=&\J^IKGXY [=BR.G/
MG!A9&D521(Y\I*,K818FRJ[RR2'^P+Z#=I?.^=\^"_#RRYET4-P+H*:KNPE7
MZ6T"'-A1WV>QL\:/6.1/^;)$Y71R-7[M>US51%1404RW ' ' ' ' ' ' ' '
M ' .N2**9CHIHXYHW(B/CD8V1CD\^41S'(K53RB*GE/U3SR-*2:DDT]4TFGX
MIY$:35FDT]4U=/R9@\[HJK1#%RU/RI!7'25DK98/I_$L, \[5B9Y5%@>.3 ^
M)WY51'>Q[(WL<QM225DK)9)+1+D5>%N%B0< ?[?KP"N9NH^LBKL[1F8;.'7M
MD4IIMM85T-@;.2K6-^3YC$G='X;&QK(XO9&Q&(C&-3@EE>]L^98<<;(HV11,
M;'%&QL<<;&HUC&,:C6,8U$1&M:U$:UJ(B(B(B)X3@ISX X X X X X X X X
M X X X X X X!X+.KKKH JKM@AK&N.A= 6$7"R<<B)Z>',DBD1S7)^BHOCRU
MR(YJHY$5 *(7(;WJ9SR>M9';'%J]92>N[LQ66=.SSY<N,NYG>UL"(OEM+9HL
M#?;[8"HT>U(7777B3-/+--YW>GA\<_!%BXGLO,[IY@=;(;7WU6QKKC,W8<U9
M?57O=[&N*!G:CG0N?^6,J!TPTOE%CE<U[54$T\N*U3UZ\"P>"D&W[ XZ);8Z
MSBJQ:.=+*2>0%+!95;'(/&-'$T@69)9Y)VQQI"1&LDCFQO\ =&YR<$>CZZ\.
M.A2&,QG:!-W<=@"6%/G9=$$$*, 6'+(]U8&B*&\J!\EBR,F=J))+)$^/V(_X
MH_D8B2O6SO=\OQL[Y^;"OI9)=WCX>?GIJ26S[)UE 4'FM9!2TUP:; ,)=10%
MD5-P(4D@K5"@4Z"46QB,D&5T;RIH_@^8A60-C6) ;M?)OP[[]9:&+ZT[#R.3
M%M\C;7*+)57YR16Z-<:*>P]S3%4@L)LT;3X)Y98#HU:WX)6^QZH]'M9>O/KE
M==^:1(N^N5\UKI9:7[WZ[ZZD^[3W$=)U];6><)K+:WLZYT.<$;*PYEI,9XA8
MX: <H=QK/8]ZM;$5 V5Z-B^=CGM1?'CZF)I82O4P=-5<3"FW2A*._&4EG9Q[
M2EO9)VCVM/>>2FKW-.*G6IX>K/#PC4K1@Y4X2S4FN&[OT]YVO:._#>>6\KE7
M]&;W1*^JZ^LZ@4J0$4H@XP9)JHZF6:2<Z5EG4GSSRN9]81]+$V*2(F&.09)1
M96)*7S@[(VWC<9B5A,3AZ3J;DJE6=)3H2P[6L:M"M.I)WDU%6FIK>BY0DFYG
M.P./Q-:K&A6ITW/<<JKIJ5*5!I9QG2J2F_SK15I*2O%N,E>1M3SZD[(X X X
M X X X X X X!7VDM=X)9K!GZ*O-K4@B<TLA7S323.1WS-6-EB!\+8U1K6I[
M95?Y]_O1/RH]Q'?@K]VA477]GMP@+=F<J0K2&2V;,:\H5\3HK%U76-D@C5+F
M!$C2%@\J>62*QTKF++)[?/*[9<[+3PXYZZ::\LR+PLKN^NM^%UH;)U[RY01)
M#X(Q3GCPN+'BD^6* AS$66)DG_/:Q_E$=Y7[)_.=_.6&1^G'!U@1=C8E#@U]
M>*0<<:7-&.(&&)$^<HHHB5S8H!QX(WS332.;''&QSWN1K55 *\QO<776]KY[
M;-Z!\E7"96@165Q37V7 LB+GW_A"T9>HJZ<>_@M/C=^'E4DAXQ:JQ()7_+%[
MP)E^\N<^5T*W]*DS#H:QT2VH*2-L2(UF@ 6/Y_>AL\2++"*J)/)&BO9&YJ*O
M (MG>VNM-="45FMOG;H -1V$6H%D/-3LG+M3J2 -+9')7//?;5I@*@,)<8V>
M-C7P-2>!90)D1<TXA#Q"[6M%+C$^OD%(.&A(8#\J0?6.@DE;*T3YG-A^H5J0
M_*J1^_WJC> 82SWF-J!(#3=)4_$6%^(@QB%Q6)EB!\L<"F5@%>I)MF,V61C7
MS CD1L\^7.1J*J!Y7ZU,DNFSB1$S.OZ5L(18X!DKK0%L8AY<C(A02GNG1HYA
M,LL<< LRLGEDD8QD;G/:BA\=.\_"M-G DL%*OJ>!:J6$>S9)9!MD ))@^J%&
M+B6;Y!R2AE2<8>5K9B(E;)"Q[7(J@>,#;9.Q!98#Z"KC'=4QWLC3BHZTH2HD
M\(VQ/!L%&-KQ45R-?*<..V-ZHQZM=]N+I:L&?#-#L18#J\L8X(EB2C%ASQ%"
MD1KY1)("('OBE8JHJ(^-[FKX7PO /3P!P!P!P!Y_\/\ V\ XM>UZ>6.:Y/*I
MY:Y')Y1?"IY3RGE/XIY\HO .7 /Q51/NOV1$55551$1$_I\_Z?/Z?9?/C@'X
MUS7M:]CFN8Y$5KFJCFN1?T5KD545%_@J*J+_  X 5[$>C%>U'N:YS6*Y$<K6
M*B/<C?/E6M5[$<J)X:KF^53W)Y Z6BCM(>6@\"%21,AD*2&-")(HW.>R)\R-
M21T;'O>YD:N5K7/<YJ(JKY [U\^%\?JJ+X_P^%\< T6[6NNWK "ZC<-935E1
MH(9!7S9PFGI"@AK5D,4AY,@ASOIOIWND6;S*UZM9)\3O>V-?BJN+](YXJI##
M0FU#$RITY5<++#X6=)5-W>J5)PJN*C!N6]%2;<5:$G))_.5:VUYSE&@IN<:S
MC3W\/*E0E!3<=Z<Y0J62@]Y25VVLHMM)[MU9+3*X$IL@\R3B#R+*))\PSW.B
M8KU@D6*!7Q>_RD;EAB<YOA711+Y8W[2.]NK>MO66]9W6];.SM&ZO>SLKK.RT
M/HH[V['>MO;JWK7M>RO:ZB[7T;2NN"T->.[;+"W5KB,W=V%1-\6J"FMX2)H'
MH& (X6Q):6J^]8&SC1^UBO1$>Z1(FK[W^.6W'EE;Q]F5N?.UPVKVO;*_DOGU
M;4MW)TF!CH75V3#HIZ"25[Y1PD'+$=+(QC'?,Q5D1)%CBB;XD1'>QC%\?H[@
MM^3R-3K8/*9'MZ[JZ[2R4*! B6D3H* S0?@M@:[PP=(60$Q!*3#\LD14<396
MLAEC>0U9O#N5B-M;.PM>6&K5Y=M!*4X0HUJO9IYQ<^SIS4-[-J]KV=M#P5-H
M82E6G1G4;JTU%RC"E5FX*:M'?<(-*]FXW;ND[<B7"[,V_NFT-N1]>88)##DM
M%5T[Z;]ZT+=-[X'&$_%/$M<0-[Y()_I09"(")D<4X5?C]E"IAL3&&+HJ$U.#
M5.MN.,W#>:<;R2G;>B[Q=E=)M9(]%.=*LH5Z2C)3C)*IN6ENIV<;R2E;>6<<
MKM7X&UU8RPC %9:S0$6+8D^LE%8Z,=\WE5=\+'(UWL;Y1J.5K%?[??[&>[VI
MZ3>>[@#@#@#@#@#@#@#@#@#@$'Q>?!R\5K706L-A,9:SV4C$="R89BBAAQPO
MB9*]_P"2,-CGR.1OND>[PQC4:U%^_KJP)QP",;7*5V[QVJQ-O(3%5:[.7>9L
M90Y$B+B!O:TFL*D&D<U[6$1PE/?"YS'M21K5<QS45J@?/J\_9ZS:YXS]KW'>
M:D4(6AI!\V>'<Q8Y]%49VYRQ92YZ'6)#6ZBYJ;0>(^RS\M-6N6K&\4_]EG5P
MN5LE;._/W]]WG>_&YD;#]G5A"= +>#7@K(I++*V5\!-GTA_'C,ON.Y=K!:%V
M%/9U-C)>K-V^0##:E$%S1PT0CI6SH3+&Q;Y$SZ]GJ/1G?V?V?R=EG+6CT]#%
M+EMG)I@*HOKJ@*S=F$\ONI( ]'1_-&-;VM;6=TV$-7=O6.8,_-TAL<'L2<=P
M++X>/Q]]^))>S/0MD>SNT]SV3>:*8A-U2Y>J+J+"OE/AJ8L[!GZ\FLJXG645
M2N8OJZ@:EGGSZDP=;&QLSXI&O,D8H==>SU&OEG^SKUTW>!UZ!I,A#U*92_AM
M9$]7PZ'(K(=N;:=<_FQ\B@D1(Y>U,JJSX]L+1,HRK DC/K<QBSR"9\\O#O;U
MO?*_L7E8MY^S:PUG" P362A-AV%KL+D"*DB"JM787EOW8;8S:.&D/J3#[)E?
MW2: #;.-0V!V=K)'OEAFG'097=[W=^?7<9C._L[\#3: 6WL+Y="-6]J6O9@4
M-W5S6Q)2V;>S2X*2Z=;6I]:>R@NNR9K"@M&5@]D)^!UJRS2EOG*<(\^NNN_,
MKGLK]G"3-UPZKZOV%=#V)#;592Z6Y!KJ0NUJ1*+K3/RU1MU%G=8Z6,6/KD.Y
MJQ+2CN*EUK.R,H..&)A# \#?WH/"VW6'2W5_7-X-G [3#XJARQ0N1D.GSL"4
M@48$$=838A5IIC$&@A^H-(KJ]YA?SE("&V9HT8:W;XMLMW@#@#@#@!?]/^W]
M:IP#Y/\ 6WH\]2/4W7%&'@^U8\SNK#JG0RZ8'/Q 4N.9V_18REJ>KY[L(J/0
ME:QKKXG1';S2QEU$NM^AHF6%=$ ,@,C._"WAG^/'V#)7LO!+3V_-%O,P7K'$
MZ*%HTW:Z':EF$#FP6!4.?VE2$9I;$J$P7?4^A+'LHZ:EDK08*^5![&PCAE),
MOU>KJZ0.N7O*Y*Z9]8NQRE()V1J-47L:S4]57EM98[L^JRF<M*H+KX:BV-;7
MTM30@?2E";"RT=]9K.YH.A$^@BCBE42M@ $SS[^=LKY99/3P\SP'=4_M :?+
MD9;/[.N-K0J+&"YB</55V>M:@\[$ #:B$AX5&(EF'D=]FVEU(ZGUXUAG]P;!
M*TT;._@=N*>6AZ$]8]$0/?3:B^LKJ:QW,VW]G8]:I5W4Z_8=8:9X/7!5A3S1
M]?EOK0-C3E/!2M':X2!@3Q/DJ+$%^/CP'77'K(O+I7KKU<T>UR&C[6[+.OZF
M*P.J=)FGW%"72MQ,V%N):B1XM?F:IY^VK=Q#EAK310RCNL86WA,$4%<>H2!U
MUU^&]_ *8N[72[JZN<GE"1JFCJ$=7Z/0$A#6+RBYF*V>J %-@G$5(HU=&3)+
M%(]55Z,^)BPS2O'RZZYD=]%EQ?MRM_+N*=UM;H^GZ.2/,=OU[8X7P1,SU[)6
MM/8V>9D"O$2<N69Z1>Y7O7X&SJUKW2DN5%<GFJXW!T9J%?%X:E4D[1A5KTJ<
MI.]K*,YIMMNRMG?*W+34Q&'I-*I7HTY:*,ZL(-MM)*TI*]M'D^[,E%#UF56M
MK2H JW0W-[-^\DVLF@^828LQDIQXMD[WFM^B(<1(.)%"K!I8R5*B^.QA4I^]
M2C)*4;2C);T91:<7?---.S36C66=[V,TM[=E&2<6DVUFI*V5FLFFGJ[Y9^&<
M["&!ZGF$[%SHJA",*B!U%*%[F!V@12N1LS(/#V1$C2^)6K!'[E]J>UB.>_Y,
MO#KGUS-G7R,?F^L:;?OM>Q=4QH]KJD#<*VCLOB;7U@<<K!H#OC66O,.]LKF3
MJ6,2\9&)$QS'?(B\G&;%V?C*KKUJ4H5Y1495J4Y4Y2BOS5.-Y4JC5[1E4IR:
M62:61X:VS\+7G*M*#A5DE&52G-Q<HQO93B[TYVN[.<&XZ)JQG-4 ")9=4X:F
MF(.-I[^HLODGF0HP:DI)H"2)SIHV,1C)AQW#L>YD<;Y'10L;YD8G.AAZ,,/0
MI8>G*4H4:<:<7.6]-QBDEO222;M;1)<DD>FE25&G3I1<G&G%13D[R:BK*[5O
M=;A99%[/D9&U7R/8QB)Y5[W(UJ)_2KG*B(G^?_/_ $;C:1*L[ QEWH2<M3:2
MJMKX(20XT"L)^O40:&:&"52B16RACSLE(A;]),0PI4?[TA5C7.:!,. . . .
M >><L45JO))@'8U%<KIYHX6HB?JJND<U$3^M51. 5A?=X=69^11B-C665C[D
M8VISCI=-;/E<OAD* 4,=A/'(]51&I.V)OW\N<B??@EUS^+Y:+O.>4["O]=;1
M-&ZWU5%F'0S2+H=6T6C)D>UJ+ P?.S2ON/;,OGQ*1# Q&JUR>556H\^N?7L"
M=_QR+4X*4SIB+C:["7!UE@14T-2% =JC@G?&88XO[BU,1"?G@C<S^R3MC<QT
MR*K95<.Q\!+NM\OQOZM2._SZZUOP/01TGBOI6,K8;&KLH$]XEL/:V"EPDM1?
MCG\.(6)'->J/7X8X7(J?D>Q?"H%DKOGJ9#KJ_N"9=!D]+/\ 5W^2)%CD/]K6
M+955@TA:TUZ-:UJD?VH1$0K6^7(R">1?>0J<!/5.UURXKG\'K9EG<%' ' '
M' ' ' ' ' ' ' ' ' ' ' -'MI9>J7(]W74N)?;]@]?WEAB *JCU0&8!Q^0
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MF+$8VOKE*]YA,7W:U#OD%4=/<KO9 ^141LS%5UUT@N?J7F\^Z]].'NMO@HX
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M# K,BLMK(K]X>U!>L]?4T(M>9"%9IE;&18S+EMLR1GUM:8RBG&*'^:-Z=_\
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M)+/: $32I#"*R-))B*ZOGE?[?=),"'*]5>+ YD>GFO>@6!R@< < < < < <
H< < < < < < < < < < < < < < < < < < < < < < < < < __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g96389g12u96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g12u96.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1+>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $L*^2 (X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!HE-T@        "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         /\   38          $                          0
M       $V    /\                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   /\     4F=H=&QO;F<   38    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #_
M %)G:'1L;VYG   $V     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      (3     $   "@    (0   >   #W@
M   (,  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ ?0)= P$1  (1 0,1 ?_$ !\
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M62'0()D9"&D!5:.5G<?+LXZ0(YC:3 "J858,<.'EACGV%?-9(ED42QMAU;<
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M:FNX.W.(YRC:R.(J43RFR9S\!),54G4"1JBR8'3;$ FK$A"1)"%S'&FGQJK
MGY/3);J:V0DDDJ7O+@3#REC?IMX1@R&9B[2;P'9KMLC'#7L$%O.P7YH)BMH=
MAQX'0./%S58L.V+HEKK<5K=D*1VQ9+;GFIJR(4/).1,9WO%K"PS>.<08G&<C
M\<V:3DJLTE8>@X1I4!7'I(_KZ^W4L*D6=NK8'YSRMN<R,XWO(;DF1D'44WEW
MWZZ:-\;HVGN0'=E((51&I5-P:,,%6-%.U(EM450QVF.RMI+6W1U)(=4AE<88
M$L^'8EE!%OUC:IT:-2*E&Q6XYH>E#AU+ $IC-[NY;NL=6'#S2.M\7&4*>K9K
M:4CZ!A6=XL'<C0KE L4[70DF8I2+<KL:.))%E25I)%F2)7WER=T%M!:Q2JV=
MR3+';H_4!W=9I)@0\CEJHRQO%)$(XVA:1DV*H!$MU-=O&ZX(>)I)WC,; H8!
M' 08XT4<KO:ST:K_ !Y-XQ>[F)%U5[M,2DGE@%M]-N-*YN93%9K%(=5C,<L7
M*)7M\JJ%(IE:IT3#RBO)!UJ/=14,JQ;SUD"8.#(R-(N\)(9MC*"DEPTXN6N)
M4QL>5IU1RQ'(C2(@P(L0*YC5A&^PE(H5<$=2*"&*2&.WB<Y:. 12R+TP=I+M
M(?E3U*D5; V7W+&.9\0S&YZN%I6<VS^/L[-ANB9-'E:A9*I05+=5W&4@6Y&<
MXWK1H>!14)7ZF:.B22<E/28-.U3<B=>V:,W"%)=S[I)97=MS22M-<&YD$KL2
M9$+L4$; HL6(@O3&VJQ.('5XMB;(DB15X1%CB,*LB@^&0 [^H,-U,29W &HV
MN]I_1FS%;HM5M6XY.X1- B9&HQI+!O(=">:QA*/:C*.L,VXL1>8EM:,/A*T2
MKR+;'\LV7A&BK%TV;))1TS.,I*7?)UA<$!I=T+NS(&ZLMM/)<6L\P8%99K::
M5W@=P=A8@AE+ V>'I&%3LCVR(H1L&-)HA#.D;9RBSQ*L<H4C<%5N'1&7)V=,
M2]'/N(OD9D?(F<*0G8V4'1:Y(I4_=&6D5^W0^+K^KE#&;*\UBLWR.@;DA0;R
M]F9ZL(V&/?H,'4]*\R2Q56X-HXE,,YN47,C3VUR=R[E[Q:,Y@GVG@S*LDD74
M(+=)MG]2,I<[]2$0,PZ8CN85 .UA%=HB3QA@0=C]*-]OS=ZEB#O<-%O(NPSH
MT);$^XO'^+]P>.*!.;B*G[CG]EG=PA,@1]"CQRD?+S=Y0:W*Y.8I5N1@;N\E
M;)67$1(L#L)MTW7>FDV#)*-&+H 106X#""*;369?$9'@TUBD4"R$[D5K1Y;3
M))7IOEU<F022K<$32SG89)(KY , 1B2^C"RR%!C(,J1W!4%1U$!CZ?AVR_H%
M)V 8YS%#9U@,[X^5O=9Q,SPK3TI?<A&2M2H^/$6E/:/H.E4MY<E*Y6D9H*%5
M7$H6,8)(G?1J[]HBT>3,\O*9):0R74HR'O69IFP6+*TPN!$">>DDXZB*,;1A
M%(B"H,<!1';Q;LK;A=@S@%UB,/58 @%S$Q4GR).\@OXJEB&YG;<  'O@\(>
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MS_W_ +@.E*LRXW^K4-NS=6B2"-;OUCMVJG9G3GK5TRE,9,"M45C 82F+R%$
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M%0.=(YTS&3,(F()1\=?+_P#"N=K7X/K*2V9K:0ZY:+U(&,+[3',"I:,JQ!&
M1G! &17H_P 'DTQ;7"TLK;;6T8;G8D$W(!P3R 0O]Y^JLUAAS$/ /^:K&OF#
M_0.J>R-?G4=2U$$_R^]\S_[5/^\KONK+^$8_EK[Y&\0_15C7ZAU3V1JGQEJ/
MX_>_>I_WE.K+]-O?3R-XA^BK&OU#JGLC3XRU'\?O?O4_[RG5E^FWOIY&\0_1
M5C7ZAU3V1I\9:C^/WOWJ?]Y3JR_3;WT\C>(?HJQK]0ZI[(T^,M1_'[W[U/\
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M%D'$&]FB09^:F/G*/MYR<@<5L.SGP<=ASIZVEWIT.HDK&KWKKMN-Z0KNP05
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M-*4TI32E:)-P'^6+N._^@PM_N^2U[C\%?^BM3_XB?^3@KYU^&3_3.E?\-/\
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M.3?W<\DB\!T*Q$;$ J&?M!J<W2#"!%@BO88U2W556+4--ATJ=2 <?T&&-$)
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M38ZM''I-BVY&4N\)+[A)(K2H8LFL:R9QS)(J#*/:-F+- G\1%JT1(W;HE_\
M=313(0OXBAK=^[\@ 'Y , #ZAP*YMF+,S,<LQ))/J2<DU&W+W^4-M0_^=G7_
M '=,=?+'\+7_ /#NQ_X[:?\ IRUZ1\'?GKO^Z6?_ #1J19?,'Y _HU^;[>9^
MT_XUW]?=4I32E-*4TI32E-*4TI32E6S9+A6J>@BZLTTQA&BY9-0CJ04,BV30
MA862L4NZ<N> HLF,;"1$A(O7[PZ#)LBWY55RK+-TELB"VFN2RP1O*ZA"50 D
MF2:*WC55^<S233Q1HB!F+,..:N6.1R B%B71!@$Y=]VU1C^LVTX'K@D9P:X&
MMZJ+VH*7UG88MW3DHY[+'L;=QUT4$;'&7*^>@X3*?F0:BV7!4Q2CP,D</DU<
MUE=)=K9/!(ET\L4*V[#$IEF*K#'C'SY6=0@(&2P].:H59696!#)NW#S*[?G9
M S\W'./L\ZI]A8T;*6/;#$SIV$Y0+3!S41/',[59L7$.8KN.F.=^FJU68E;"
MBZ*=ZFX;+,U$!<)+)'3(H%T+76GW<$T1:"ZMY+>Y@;:"RN.G<V[JK!@VX;)$
M!5@RD94@D"2)I8IE,8^5CD*[=H?QJQ1D9""#X@492"#R".:PM6]JE A[HIDM
ME<,G2]F>NHR3;3SV[J.I$4TH*,KS]B$XU:(24E6;) P591E*_)/G\,#BOQ\W
M$MHV94?2+S<3=HKYK7N+VMC% G6CD@6S6.-]TXG7?#D1K/;W!<Q3QHDZK(UN
M[26VV%)9+IY8Q$4C"[%C4*BC;L,[Q,@P0CH+FY =<,4F?<6\ZHMCP;MIR3<Y
M:TS+UK(V!S?(>RO4U; BI'$N3JDT"IIE:,)1)=@5>T5!7&<<Z;LDS*O5"5U>
M,,SEEC+N)+75]?T^UA@M^HD,=I<6\;)#A^Z][NKUUZL8#E+:[AO;A"3\GBZ#
MYM_"+C/=F'I>,1BWZ/A5E81++=D%F7'B66XNE#-R"S*1E5Q6UMGN%3IS93,K
M(F%B<7E:=%*SR#=.22R$K4W-E9*MD139(-5W=(JS]+L;9LX"1C1D7+ER^D91
MP^CC[4:M&ULR-!_(^X=WW6Z-L;39)I+24D@LSH;J9"&)0Q2F,1A%C".^W!;.
M5))&!MSY1/#@>9.4E;().3M'S551@C*.U/!.1&F.K!3LIQU/.-JAJK6;"G+I
M6UE/V&G2N7UH*,K2:EB81+NZUFR7W(SMFDZ3L44NY:*LI^KSC*)[*GM=,[1:
MOI\MS%<:?)=@6CW,ML8S;O%;36^A)-<3,(995M+C3]%TZ*9U$3+&_5M[B"69
M9*DCNY5BNHWB$BR/-)+X=JJ;J1Q(KE5#B*268*%22,YV*C@$AM@JDS&MI>/K
MZSY DU*L)23CV!Q$'3UA".(UK*O$2 0"F19.)J+17,(EY5'R %*(";EXWHNR
M2S*A,43Q+(X("H9^ITE()+9?HS;?3Y-LD$<X&UM@<ABI<1[R.&<JS@9  W%4
M8X&#P2!@'%7_ .'G_P!O]0_F'YM08/LJG^?\^XU2H::C9]B62B717C(SE^S!
M8J:R)B.XM^ZBI)JJBY31<(N6,DR=L72"R*:J+ENJD<H&((!+-$\+!'&TLD<H
M&5.8YHTFB<%200\4B.""001SG(%64JQ4C!4D'[0?,'R(/FK D,"""0035=15
M2FE*:4II2FE*:4II2FE*_!_,'Y?^ ZO3S/V?]12IT]$9_DARO_W6;X?_ !?9
MIU]P]CO]4^S7_ ]+_P"3AKU6P_H-G_NT'_IK6SK725ETTI32E-*4TI32E-*4
MTI6*<HY?K&*4('OQ&1D)*TRIH6OPT.FS4D9*0(R=2"B:8OWT>T232:LUU#JK
MNDRAR 4O.8>&J$X!)\@"?=50"3@5K)W:Y%MF:3TJ":8PL$-7(&X5R?DW5DF*
M=U"K2)EF[UX88V.EY=RXYFZ9@(@<  YB\HE$#<=8DL@>.4#@[/7V#<<CCS/&
M,^X5-&A5MQ\A[.3S]6#Q[?+ZJM!F:I-B1-L&LW"0NU?<3Z,0X@/<_P!VN8>Q
M0\8V<MGR4C+Q[PKMLX;+JIB5$"E3<'YA,*I@2PK2XBBM64G=@D9 #>9QDXX'
M)\SZCGFIVB=CD#D\X((/V<^1\B,\\\UEO%MHB'3E=W)UR392"\/8&QV,DE&I
M/P4<)@BU-S,WCIB4#$.)$G"+M14IBG%0""/'5PN8<X#@@$ D<C)^O/VCT^K@
M55;>4D#&#Z#'.1YY_NKMOGZE>-'HLH)\]%0005<=GA.HCBBN10ZSL#OFZRH&
M,*A@[$@_6 A0**8@4I393D*-Q((QG.<#!&<#)SY>T8&?0^="I7@^@YP.21R/
M:,^7KR?/(XK+6-V99%JFW<-1*P314<IBD@@DN4I5N9<_W4G.9+D*GQ 1#Q$.
M!"B/C:I60KM\CQZ#G)X^WTY_[U#)&S#</08;<3Z#/&>"/K!]?=+ZHV.$6;LX
M)@=P*S-F/*55N5$HI(G(F82@110H<#*E I1'CR_*8> GS5&T!?9G_'R_)G K
M'J_=74II2FE*UG=+1>K-0-G%UEJM*O(AZZ?-6#E=@=--==F+"5>F;F5,BJ=-
M#M#)LNL"75G5(AU!E4TE%!-R';FZEM.SMY) [QR/LBW(0&P23@$CC./3TR/L
M] ^"[3;35NW&AV=ZD<EL]TIDCD7<KJ"H*D9 S@G&3C.#Z8/@K;REHNUD;A!*
M+3UIG&Y&K=%=(\BHXFG3M5%C'H-VSI:1=OG;DY&I6C5KS*N>SD(J=R!$2^.Z
M-IVXHX#R3,X3>Q8[V?:%W$CQ$Y4>N#GUY/VMVOU2'3K<VJ@6UG:O-M2/9$J1
MJI(>14*(H6,,&=CP2> ,9D1 [2]U=]K18N0VR95))G,=!-\>E2E?9-2IJ' B
MC96?:QB0J T*4JI%4$@,"A4T%UG ','?PZ+J"*?Y'*!C&U8_(XY Y'K\X$'Z
MSZ5XK<=N-"M+@R)K-HT"#(3O:-QM#8R%<'DD$@DYR,^5<>/>C@WOU27GWZ>W
MVZ&3Z@4&2@!$H]I154.F[%%-[(H )3M>*@B18JJ8ARI*GZY1%:%>SVI"4RI9
MR@<C#*H)SSQEN <'./+[#@Y-U\)O9>6"*%M8M !MDD ,LBF1EVJ&Z<8!5,DX
M)'B )!\JZ^0^CTWLJ7BJLG^W#(K=29CA(XE(2%2LT*P.F]>\B<K.UQ])0S)<
M$"HDX/))F4Z:J/\ %2 IB7/V6U.23J/:R>0SM ) )S](^0\CYX ^L5F:5\*?
M9JVAGVZM9LJEV1I'$.=L8.0D@1QNQMQ@Y/ //%_AT<6\%A%O8-CMDNICOHY8
MPV=62KRCU%V4Y3-6I6(2Z8IINNI KA1'G2226,1<4Q3*Y&&?LOJ)C=%TR;E2
M=^5].>$Y)\N<?E^E6=:_"QV>:5+F37[92)X<VI=NF8I"0'#)GD':'7!/.?FY
M(BO0[+?<434.Z0>.X9\J^3-'O&;P$U4U&PIN .D5,2NFZJ8JI'(=4$A%0BG
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M5>FX'()>I<.2E KUT@0H!U:#AT"JJ91$PB4_/Q*!P(6W0XKJ'2K..\;,HB!
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MH&"4GYE:PIQ"$TY/(-T009-XIBH8%W;@3G?HMVZAS2ZEKE['<:)I^FVD/?\
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M*:4JF3+E@SBWSN5,F2-;M7"KXRP%,EV4B)Q7!0I@$#E,GS%$@@/6<>0 $3
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M=R%) W #)7*AAG-52T8*-;)MW-2%L7347Y$V[9*)1ZADS1+R-F;<.VAP213
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M*4.!2E*' I2AY@*4/  #@ !X:XHDDDDDD\DGDDGS)/M/K7?@         8
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M8L(U!,ID29I,XX<S1QR[@,F11)\X9K3_ !GJ*Q"!;VX$*Q=%4$KA5A$4\ B
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M,DV2+<04Y6:7=(-Z)!<QQY8A$0/RF_A"!W@,7;5PD <@.6:R*P%5,F0YDU%
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MO?#1HO9R\%A-HL][*(VG$D-W!9JJS32M;Q[&1I@(4 #D\N ,>TYXV*]"N]W
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&2E-*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g96389g13f64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g13f64.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1S.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '+*^<T8X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!7P           "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         *X   %4          $                          0
M       !5    *X                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   *X     4F=H=&QO;F<   %4    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   "N
M %)G:'1L;VYG   !5     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      2.P    $   "@    4@   >   )G
M   2'P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M1NJQ&N<:;@R]Y&UK2QU;O3:;&N;:^[<UK=GT/?\ I:K*
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M(C$V4W>7UC,W05=UMM<C,CE1EK2W)%AA<7-VD9BRL],G1U)R@8:'H::Q_\0
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M^-4"ZZZT[UU';&0==]7]F5>2_"#[K*^0O<\M_G[P:NZCC\<.R3MEF<5V!&5
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MVL3^LU'U_/\ _3WL'Z__ -7XI71M.[>NZ2LL;FU.T8-74 %V=D9-U]V$D(8
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MV-:UJ(F%=WD=Y)&9Y)&9W=R69W8EF9F.2S,Q)))R2236,  &   .  ,  =P
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M1@25#MVF$)W /C!KFTNQ>,H.H-.RVW.V'6T(&03A_HAN1Y%<'NR.^M6?D/\
MA)\J39A]?=G]'0,\<::JO:F^+[*?!;=B:?1Y95S\<>;CC>RGI;P&\CBF&N8K
MFVL#X'26P$ OPD>O8VB=#:BL0O=.O)_IV66"2)+!H4L+>VN!V[&X8SB6:%X<
MJT30QQJP$4A8-BL-=MHP8I<:_H_JRJ^3+:]0&5I$;9["_0@4%7_A"3=CVU!J
MD/1/8WEKWC!7=8].]CT[>MNL]'+WI<CIV@!H[G,Y!C:X>@PP=Q<Z.N7255$-
M*UESGK4<>;[2*<PT:.5GLDV_6;/IG13/?ZIHEW](:C ND0@V,=O!/=#>;B][
M"+M!;23.H[*6%MFQ?9;!+5CK:Q%V42#JW1/5K=_6'98M?D=8R/S<7:?0Z]H%
M&3(LG)+8(R!4S^&_8'D]Y 469Z_Z3)U==D.H\KH9=DVY%Q&YP_;VM[#)T5N!
M9:3\=9L*10T]C=K=0_B]G[._EAH05#<2DSVIS$=66N@Z'/<7FKV4<MYJMY ;
M7LIY+*]TJUL5@C>.#U.:]6:5(EA_VB>.W5YW+@'G-S864%XB);=3Z6(;>%U<
MM8Z[+%<RR[R&8RZ/$0A9BVQ2_L84XSD;A/'>HWO6.^[*C,ZQW9]D=U[T#66N
M3H;3J6HPN2L\UF=-56+\-1KV%"/2T%_8(98C5T)),H[4:PIL#_:LO4^K7$%]
M%;NL\*HMUJ;I-*+N6[G2>>.9#>3- 3-/&C+&9, -C/.36\2Z99)HVE(=<TT*
M)]1*LMKJZQ9"V"-'$BZ:615*;L.J\O[)(R:MU^/^V_J.["_VAZA_Q,YA.PA_
MED'_ "77]GK&_1UA_.#3?ZMK7]U4_'_;?U'=A?[0]0_XF<=A#_+(/^2Z_L]/
MHZP_G!IO]6UK^ZJC+L3R8)ZP*Q0>IZ-[<2;?:F#'Y[[)DZUNHW7)(\Q426,E
M9V$2RJ"6(>3W6%@HXC'>UCY6N>U%OK/2'ODO)(+NT*V-N;F?M&FC/9!U0[ \
M(,C98>P@9L<XP"1QR66FQF-6Z@TW,K;5Q:ZV><$D'&DG' [S@9P,Y(!DW\?]
MM_4;V%_M#U#_ (F<L>PA_ED'_)=?V>N3Z.L/YP:;_5M:_NJGX_[;^H[L+_:'
MJ'_$SCL(?Y9!_P EU_9Z?1UA_.#3?ZMK7]U4_'_;?U'=A?[0]0_XF<=A#_+(
M/^2Z_L]/HZP_G!IO]6UK^ZJ?C_MOZCNPO]H>H?\ $SCL(?Y9!_R77]GI]'6'
M\X--_JVM?W53\?\ ;?U'=A?[0]0_XF<=A#_+(/\ DNO[/3Z.L/YP:;_5M:_N
MJL0-TVAN^R>J!K?KG4X^".WU,L9]Y:84X>>1,/H6_+11Y?7Z QLSFN61'S"Q
M0(V-R+.CU8Q],D<:+E+B*8E@"J+.I'#<GM88QCX$GW5:W5I;0*K0ZG:7K$E3
M'!#J$;J.\N3=V5M'M! &%<MD_HX!-9YV&G:RPUWW8/QC)DE(^UEV"6:1+#[(
MU&^2^S6O=[T>LGQEE1&^B-]O]*<X1C/)P/GW'G[*L#G' R:B_P"'Y;?K^E/_
M  U'_P /&!YC[?PID^1^S\:?#\MOU_2G_AJ/_AXP/,?;^%,GR/V?C3X?EM^O
MZ4_\-1_\/&!YC[?PID^1^S\:@GO1.TXZ%B]IS=#_ !5:J4ORR:I-6I2._P F
MN?\ E(5LG3-G5KFI&UPS)5:Z9J(GN2<#!Y/=SC]7F ._/CY8YJDY/AR#W\9Q
MDX'!/PY!'?GSJ4/%YO?K:M/O';'^*:C)]C?;ZS,UGHOI\)?9[%E<%\-$]/M5
M(3%]4<CI&*GI'&#YY_S'EY'(S\?*1G@\XQSG]7/=]?=Y_&W_ "*JJO/D6:\#
M/XTMV.?L:^'?T7VN./84=:<#6/C,:80)/H#ZD)/B0+)%.[[4!<R%7/25WHC>
M<T 9IH@CB-]Z[&*NV'!!3"HCL26P  IR:Y(HXY7"2SQ6T9!W33+,T:#!Y98(
MII2#W>S&U?C [TN'&YR+!]&;R7'1UD#<[(#J>H21'UJ>[X#AR)NU))9HE_*]
M'OD>KOK^4O+R[@9KF8W=["+DR-VXDANT<29]K<HM %.>\ #X5D4T[3]J[=>T
MP+@;<6^M8QX8_P#XD\8[JZ&\[![Z>S.#83QXO+ 4S0B";9=-N^L*:4/&SPSL
MM2\ZM7MK=3]!&JQ($"8^K$E1TCI+,=6-1W):6^F#UAKO4MCI [68M[6XE#W:
MD&)9^TCA[. \[W02N. (SGBF33K4[0FO:206 DWPZXI$9SN*;=';+CP!V@^+
M#'/]ZU@L^IL@#B,?T-VRRBK9[$D5MQNNK+PY);,XBQ*^)96G:Q)LK%))E6)D
MDKFP1>R*-K8V-:B^F.HW+W=S?67;2A _96UQ"F(XUC4B.*T5%]E1G:,D@D\G
MF8]*T^)%C77].VKG!:'7';EBQRS:42>2<9/ P!P!6<_>/M/B)"O1G87QE8K_
M (7XR]-?$]B+Z*]&?>BCU8COHKO;Z>OT7T7Z<M?5H<9]>M\9QGL[W&>_&?5,
M9QX57]'6/_\ OZ9_5]:_NFHV[KWVREZ;[;B(Z3[ !'DZQWC)SB+[J62 .%^6
MMFRDS1A=D$ER0C,5TLC!!R27,8YL,$LJL8_GLX(O6[4B]MR1<P84)=@D]HN
M";8*"3P"Q !.20,D970M/LAK>CE=<TYV&J:>51;?6 SL+N(JBE]+1 S$;079
M$!(+,!DC.C-AJ+BI+I[;QYWEE56M?-7V5<==]+% V )H[AS S!9NSWPD#%#R
M/A(@E8Z.:*1\;VN:YR+Q1Q)$Z2Q:E!')&RO'(BWR.CH0RNC+:AE96 *L"""
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M86Y>T\P_''I?J>LO<F'8[7%9GL43H03(]59R,ZSH]-2QJ$1GZK+GOI)CA\U
M+%$0-0PG/B@2+Y.">-KE9JMITUK6JZE-;3M':W;6)UB6XU&<I&\$RI,LLMRH
ME5&N%E#JTQ0')#LIXJ\DO+>&%9!N>,S"V184W'M%8H55."1&48'8&QMX! R+
M>9>DSM%3CCY>BK\[5ENDM&UM=6CU,32+-ZFE3SAC1Q,881/.^8MSF_%>0^1T
MKE>KEYKL\LTTK-<3//( (S(\C2DK& B .Q)**J@)@X"@8XJZ554 *H4=X &T
M<\GC P3X\9SWUD/.&JJ<4IQ2G%*<4J+]C^G_ %%_;VH_N+I.3X'XC[FJ/$?
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M^I+N.2 \21Q*I0;B5 .">3MB[U=U%Y@?9/0G0WD)0X?N7JC=5?>03,Q12W#
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M3H^*1T2?#>]KGM^B\\8WTIGO+N9I3.9+B9^V.?SNZ1B)/:Y&\88 \@'!KM1
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MB&6C0@M%3$R3A6#2U20/15BRK(R81&+$]L**UC9)/53Y]]?WMCJSMB>Z\?\
M-0W?7TO3^.ML=GK:8T'3+V=86:TDV<E,KRQS&9D<61GH1[2!)2&N5R>OK[5Y
M7&YCDCD !,;JX!Y!*,& (\1D<T(!!!SSQQY8^_WU;O%XRMQ.,HL0#).;5455
M'40OL')-.2*QKVK\TY?5)'/:]4>J_1R>J*GUYRW-S)<W,MTX59)I#*0@"JK$
MY]D#N /=5(4*H7O &.?+NY\Z]"DRV=S=,W/4%+6T]$Q"$955HD08+$+>^0E&
M#0-9&U)Y))9)?1$][WN<OU5>4S7$]Q*9YYI)ICM)ED=GD.T +EF)/L@ #G@
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MK8ZH&:,QT*"?.L(A(D+<R>)K&^K?B(]J1GRY/EW?/NI@^?CY#@<]WGX=]=_
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M.3Y19?F$8_VHQ54^_P"S'E\G]58?)3^8TIEP.+LNK1!0R0(ZD\[-3RQVXTU
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MZ$_RARHNONJ#%=;RZ$7H*V'I".F,:^:63K^VSHG>XMN4?IYGQ_C%J*K947S
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D*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g96389g14p53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g14p53.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[29@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )D2^EY8X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!7P           "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         +P   #3          $                          0
M        TP   +P                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   +P     4F=H=&QO;F<   #3    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   "\
M %)G:'1L;VYG    TP    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      ;S@    $   "@    CP   >   0P@
M   ;L@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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MSG5 >CCV&F7EK=X^T;ZW4_I-WOKL_FUF'"ZR VLMS7V>K0?M8R&MVUL:TO\
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M[;+R,APM!8W9_P 3E?2^A=_UO]Q;G3;'BM^)<[=?B'TW./+V1-%W_7*OYP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MRFN,,(-MH8ZV=W,WEDJV4C8_A^%_,^*4/^+=@ TZ]%E[/36BIJ2V\W.:V4S
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MF/DS%#CONX8;(<1['45B:\NC_C%DJ9?YCW0R5,/(Z0$]H0?>!R\X.&X <3C
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MJQE0I67?C1C*U?;*2Y!V 1RM.>I&NG3U]^EU\=04ISG*>SO;['N_JW5G[?\
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M5X0XZIMES3++)5&EEJ:>,N==KS75#Y21S-@BD%,,<S@<\M.2S=H!) UUS_\
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MTZBW92:U(:_*8BK0F*KYEHU_L9[_ .']AUA/UYOUT24&EXU$<0D2;98')<.
M#9&(=:)C4@Z8]#ZZ:^*A#1%AIML]67:]HI6[C=OQ\YU1ASGXIR=J,W%:Q(<V
M25G\FPBZQ$Q[X0+2<_49&GS)F3^7*E?B"F_">/7KUT5_I'F?GY^/=\^[79WA
M<5&.Y[*W3]3;%LKF<)Q$U&<?2K/G'M>6"Z.PKS^OG#SS?C./OG]WWYX;G.*:
MW5LYQ_*I9G#.@YN1P;DX.G,1T6S<%VQUXXMX<MC02:N\4,9 &26-G9)(,?\
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M"9G8$J58)$49@D)!4,&P0:X@6&(98=!:2EE32?9XX16<S0:)C&<_DJI?;_\
M'(?_ */A%4/KO7.G^VK]M3L1I<JJ7&;NZXFA78% <6L: /UADJ!^@_+CX:'X
M8U#J'?JW5-)2=G"7D+6CQGA,'N5O/R#1/[%5+^'(;_HN$5+ZF/TKWMV81::9
M*U&=V]H:!M5")K8,>$'&?0V<MIN<?Q&D1S(UA=CS(I82SP%%-QA+;X[JT+]V
M,$5T/R!1/[%5+/\ CFN0_G/_ !_V/A%4PZH=2MF=L:K'M8KK^]^O%0M\P-4
MHH(:/_ +^'%5R?*DA<1^ 9A^(2?!8>:2ZLB$=G8EYY",20^5D5NQ:73@263
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HQG.,9SC'[LYQC.?USC'Z<BB_>$3A$X1.$3A$X1.$3A$X1.$3A%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g96389g21t54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g21t54.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1JR4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &I:^: 8X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!8            "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         ,8   $\          $                          0
M       !/    ,8                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   ,8     4F=H=&QO;F<   $\    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #&
M %)G:'1L;VYG   !/     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      0(     $   "@    9    >   +N
M   0!  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M#QR"1&[^RL:CI?7G%E6;GEV.<-U%[ZCMM-[G/_6:RVJMK+/2=5ML_P 'Z?\
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M=9?^BHM^I/4O0+!U+TK&AP8:Q9M<7_H[;LACKO=;E8]E
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M&#A9=G>8UPH7&2$W(B,V6):7UAHD)3%4,O_$ !T! 0$  @,! 0$
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MBKN%1XV=D86.J][5VCL>..2<Z20YY1Y4^TE''7:G7.T^. .5'1F-!^Q?0F/
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MYZXZ)&X_RNETL*E*?5#TZXUVU[^Y%W&"# & , 8 P!@# & , 8 P!@# & ,
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M\LD@^DPJD>GW,@L>2OI?)DVWYOT]'V28Y60%"3YFWZ9**M.7G33ASTT1:H(
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MW3^SZ8-G.^E/H#QZM/L]4EBN , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M= /*3C#A;ZK6FPJQ9"'DQS>NN8>U(]HNN4A5,/2+:Q.NV_;&VNQ=!@@P!@#
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M2=,"T(-&YO0(R_\ NHJI]SO_ *@FDJU3!3#:5H4N-):CLNO%RW+!!@# & ,
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M];9W_">9?BD7S8/DT^,=7T=FO:9<W9Y!?CQB?0/*'^)R1M(9O\]F# & , 8
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MQSN'-"S'FPOJOJ7#=SRPX^AX\>?UE4P^%F[]<*TWUX..HM\P08 P!@# & ,
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<$N(X1LILDM8EZ;MWN3!P08 P!@# & , 8!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g96389g22k64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g22k64.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Z24&AO=&]S:&]P(#,N,  X0DE-! 0
M    'G:^=Y@X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!8            "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         *@   (P          $                          0
M       ",    *@                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   *@     4F=H=&QO;F<   (P    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   "H
M %)G:'1L;VYG   ",     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      4      $   "@    ,    >   %H
M   3Y  8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')2
M1T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M       !  #VU@ !     -,M2% @(
M                                $6-P<G0   %0    ,V1E<V,   &$
M    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H
M  (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U
M960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M)'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\
M   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R
M9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M        $G-21T(@245#-C$Y-C8M,BXQ
M                                      !865H@        \U$  0
M  $6S%A96B                      6%E:(        &^B   X]0   Y!8
M65H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P
M       6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT
M=' Z+R]W=W<N:65C+F-H
M                     &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F
M875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V
M,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                      !D97-C         "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                        =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03
M"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                   "CP    )S:6<@     $-25"!C=7)V        !
M   %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M
M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L T #5 -L
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M#$,,7 QU#(X,IPS #-D,\PT-#28-0 U:#70-C@VI#<,-W@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M^YQ752C66.=Z5$!+'0!)Y#D%!8G04$D">++$JK>VQ@J5J7=CLZ51LG0!)/D
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M>20ZXBO[2H$DSVJT8PC1,Y)'FRY)6#1T,;ISK^IN;*-7"2R((:)%)/[F*./
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M5!C4@?N[%%@5>+:S,F?FBB]?MF60UF,"QR;BX'#DL0EA8V5\11>+@9>/0#;
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MZ]\4\37GU_U0<!"N$GGC*CDA:B2WB(XB.(CB) KGKC.7EVEX;]>V65XLMB!
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MR@1&1OR!/X?+GX_'0]8]^];D=QD-AG]K?T=\1$0==T=7HZ\UB1M88YMC;+I
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M^X&L<@L!M00[E=,0 2? D[&]CL15YC0XQ+,BRC*9)\QPT=H4R**R=&V,IL;
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MK5CWC 6-IG95#-K>@3I1I0%&ON@#4V&Z&[5[%N^ULI1W6NM[:IMUO8#@;"2
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MJ:TM-"<%;VK6JO8-JI8MH$NP#,=D@'8&[AT?9L:FDK6'2NM;#4O"CV*BJS]
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MAK&(Y[WK^C6,:Y[W>&L:YRHBYIEFO^M["Q]S?]>Q@W8IU?*T;916=?&39CM
M9/7F@D.^@'(D9&:%&3 BO:Q\)!U<V1GL)\H/KYCZ[_K_ 'GG8V.?T(Z\M;].
MNO74N>JTU%=N2.MLH9B%C=,@<S)@SU@8YK7$( ;&.:HWN<UJ$)!\#G+X;(J_
MCB>IG>(FDT/877XG8.U83U[J+82:4 DP*_R<U$57&FP).UU;3;E:&,N$LM]P
M2;:@(X.5)*V,(LY["F"<U9^T^(ES4C#[38HJFP6X5F$ZEW=$%:=HC$:^MN[<
MFZDV4G0".[!UKICVS1WK5IBYK% IL%F.V*RERW#P)F_9N]7^&Q-U9:O>U1V?
MO%3N:?5YRS"9:=?YBU&,SY]7+HP#GDQUZTA!8[DS@]5FW:,TZTV)"CYT&GH8
MAVD?<D,T#2Z2'Z"RLNS^U<;M%K5I2]+*>$V)<J KQ\7#MD>VHDZWP=X&T0Q'
M"=G<QLRG*-B5K8CU@%ZW53H,-CG6]B D<PO%Q:()71!E[#&U_:5:M8E0ZOHA
M5C@OP;VNACN!36P.@)H00Y6SP!/#>I=6?H@I)QVO@-$S1<Q"OMZNRZ_#X$'T
MUTURW_4:,W?+W^'/W\9:R-1J(B)X1$1J?YD_1//Z_CDQ,!=Y3*Z5PRZ/-Y_0
M.#29!%NZ>NM7"(0L2D(-]>,0L"3K%"LR1>Q)5CB5_N]C/")@_P!UG6/_ '.,
M'_P0SW_N[B)6G877B,^U4G6?3?54IUS]8ECM-/G,VW.XL8?Z9K29* 0:.]TU
MJ:DTRU58(H-;[Q99+:Z"B^"$L=^'XQ,GU5Z?<%U:87HQ H+W?6[5^];FPK:P
M.RF^1B-E"I*VL%$J,I2(G\$5-0AB0NB;&ATI\\?U#GOW[_(1[]^^0Y#E+TXB
M.(E'5$K8+_-92>PJP*;*WUD5G66S;VEO+<6.HO*JLSE=3W=#6A6 E /<(R&[
MJ+ZY4H*B GD"8^QFG%Y^A@N3BX;64UT8>1=9B"X9&/DW5]SD44XM6/D8]26U
MXR9 5<FG)O+ICUEJPUI9*BD\-U&,;*TJQK[6QQ8+J;K4%5]28]=-U-:6)0MN
MA=3=:&2FLE ;"R:I=\]5]AW7;&LO*;(7%K4VZT9 )]?!&5#,T7,TU40U_P ,
MKI()(C*\F-8B&1O5J,F:UT$K)%XG]I.Q>U<CMK.R:,"Z^C(^S/794%<,J8F/
M0X/W@497JLTK#B/)N$JR[Y[M?L_.M[1RKJ\:RRNPU-6Z*'#!<>FMM\))!#HP
MX6"D@ @$,"=5BZ2\.SU?HA@+./+V%JE5+>Q#.B$?+)5%GM$C((B<ULKTCA]_
ML9[VHLD2.CD\_'Q3X^3;BU9:57#"NR.Y.4%*H2:&L"*[ @':A2-:.V7:L!KG
MFKN>JN]$L&.]O=M<$*KLU-8%!8<B?N=!RYKL,"!U"QBSBBC"K>TE),(F*GD6
M45OR3SR/EE?[6"-8WWO>YZ-8UK$\^&,1JHG%BV6/9:]]YLL=G)+KIGL+,>00
M+S))  'HNC/+*69F:QR69G8[719F+$\E\2Q_#6M"=&$6[@LHW1EV3:J"%D\5
MBC U<VUCF\L#^I^E\*WX6M+^-8UE<]B(LWP^85PJN0MZE;+10JBQ;AP'^.#R
MIX^'6N%>\"D<V&MD;$Q 7"_0:SN50/QZ4_Q2Q'=\7#K7".,:''L#3\ X9V'@
M32O?(^ULW/D<Y[W+*-^7O<KWK_L7PBJYR_A$\?G\)^G/9J+DL;[CQ$MOC7J3
MLCDFAS(^ZNAO6AXG)W>_]I9ZGB_'I\^0_I.(".]$L6D(;9C"C$RNJ+!&B(I!
M T-5/,BS**K9G5\A:)[%8C4:4Q9DF<D2Q^*ERJ[P_>7)4K/]GM'=CB=%H+ L
M4/&:38%UR ##B!(!GE!<+"2[JBM_#?2_?*K4YV>$AN[9N@ &F 8,=&?3:M[&
MHUME9HC41$3YAU]J)^$3RHRK_9X7]/"?S7DBH@<KKCKP+!AY ;X-\CK8UR^<
M]&HC_:6#X,OY<.ATZ:F1R]IK\M> Z"OMK2FL0Q#"J*Q8/7JZ84BUU.;G-:PH
M": E)1@IP'/?"Z-LD,SXV,G5\JY<.[/PLI,JN^^FVM'LQ;0M1XJFR,[#:T!Z
MV1RRUO42RMID.M-Q.&,^51<ERVO58BNU+A:P2#=E8YL&T(;:5FHGAUL,=!B3
M+;3OGNE/T[(N?QX\>:O*._3_ '6=7S_;Y\^?U_7E]_RE_: ?_>U__A\$_P#]
ML5O7KO\ "6W[X[5_Z=9_^UB_\#^_ATGIMUC<V6DZWZ_T5O.TBVOL3E;FSG;%
M%"R<ZTHP#BYVPPLCBA26>:21(HF,BB5ZL8QK&M:GUSL?(MR^R>R\J]N._)[.
MPLBY@JJ&MNQJK+&X4"JNW9CPJ HWH #0G==GVV9&!@WVD-;=AXUMC !0UEE*
M.Y"C04%F)T  .@Y2C[KTSW5O<6]O'ZE?4=4,M+(ZQ955&Y!&JJQAI4Q3:ZL%
M=1RN@ #;*@P<*R2.B&BBC5[U;[N6&CYG\/Z3;T/7ZG^LQO\ T*U[_P!]+ZG?
M^'X'_N'DQH>OU/\ 6:Y;?J&SVT][U=UMWGZA^V[=%FI]:1>[RN=U-DG^?80'
MM+M^7+'MK.!?#I,?006=VKV/C/2G:WZIL$'S)^GR\-:'P)C7Q^I\/G[\9O+T
M5U4=TWUS486PVV@WA-<KY%MKV1/ K)(8(DJ*2!SYR*^@#^#S7@$'&R#NEF]A
M#('1#03)EI6]6)=U5E36$;I0+8 RM-B:Y8WR"G#R#3L9(U4=&]8I7(R1JHYC
MO#FJBHBHB>:L5BLH#85(:ENM)#8O8R-$<U9H7L:0UKF.B1JDQR(D;O<B*U$<
MQ6*GF-_EOS_+](_MZ>_T\9Z75P M4 #5@Q+"%6AB@!P^][TB%$AC&'C]TCG/
M?\<,3&JYZJ]WA55SG.=YF)3G?5?#-D@K1[?Z:INP$CE1RM5(;17UDT+_  G\
M4,LY <JL551TXP[O"+&GN1*&ZA;7WN[S[V/0H8(^YE>UOR,9];116(;FR(YK
M7.^AN8&>WQX8XD>)[721>/>D>_Z?/I[YS>GB3-,^^HP*78%6TKD%&)S8%K:3
M.][V+.)+9@RE*U$?(CDK:\"!T<7ECD&8YD23/E=+&];^77Z=>GAT'3QZQ+ ]
M/($*@["X]JH3)=AT2N5R^%#K*<*UA1K?Q['_ %.B+^21OA94;&UR*D,:I/OW
M[_NFQG$1Q$<1'$1Q$<1'$1Q$<1//[61?%K-8WQ^NIT<G_EKHZ;_C]_GB1O\
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M*KO_ )5PZ/\ 2*KG=T9+U-*UL^3C#(TK<O&';6-CFJPY?V;)1 *02U+MA/\
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M:L9ZR:W856U -;CVBU4)"BQ2K56U[.AMJK'-89E3OUJ-A"*9\94.PB?I+6Q
MDJYM'H$MXZLB80@P$8:AHL]"PV>O(, >20VB4]6"%DQ01%PC+,^2*1W(PZ[
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MPNHK:Q,FY6JXSR-BNR*U8^^K,%(VP!H.T[*ER [65JC4I6KLZA#8EUJM6&)
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MYFX>)>+A!UQ#?431[08#"S*^(<;8F4438#OPTN3PJ#MB-Z.@>9'+F!/GH,F
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M&:=L2U+DC^P0W(MU%1*_[@KE-;,*V%]I^!U@ED:VK8]&R\C7/>ST'ZD^/K]
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MCMF!O;'!/(YJ-B>K420CVU45- ,+95Y!!5>RV%@',&FF)JY7L8RS'BCE=),
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M>?YF3O6]>(T0?+8.OPWX20:'TM>HO2 P:G98?K32WH74?]SEDW?5&9LJK/\
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M;>4W38%M4#8?MJ\Z=ZMZ?S'ISTVH,F)2/*R]=:/+;"P=5P1".T]D#UE8Z,I
M.MZ&O+1LZT>>N0\ !O9Y>)/J==>6SL2G6>@/7:IOK&W]C8/FW>[9ZM1.BL<%
M!@:FK+3O3IP#KT"QU>U&I5VAT%A,*^&',WFI&R],2L%Y84A=A49XVI1OF#KI
MKD0-'7IRW\R-]/4\G8WHH[^O)>P(/WK:CN<31>G'JW%0"=R$=/YVJO#\)W=2
M]C;/HNP?TSU'U^\?K[M[$U-IUUJ;^]H-A(/3ZHY4<;!&16%(4@ <N8(V03T
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MZ<>T>[>S&4-QI,W6Z23(5=!::'!LO1NK;NEH-K4GW.6CLB,XZSKYG4^^?O\
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MY]HXT;:8,@6" :<:N0:&8>&*&1CHXVM1$Y8\SFX:4S-Q9ZCBSEBVW984$=4
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>)3[0D<,2 BP+^8N:$4:*29S((VM1,KQ$<1'$3__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g96389g23b98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g23b98.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2MB4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *T:^$0>#A"24T$!       6!P!6@ #&R5'' (   ( !QP"4  (<G(Q-3
M$Q.#$< @4 -TUI8W)O<V]F="!7;W)D("T@26UM871I8W,@+2T@4F5S86QE($
M8M,2 R,#(P($9)3D%,+F1O8W@X0DE-!"4      !"NQJ$8$JV_O)_[-.="U0
M>=.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M  4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<F
MEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0
M!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E
M!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G
M!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V
M]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
M!,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F
M]O;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6
M) ;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M          0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M              4G-L=%5N=$8C4'AL0%?            *=F5C=&]R1&%T86
M)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B
M-2;'0               !4;W @56YT1B-2;'0               !38VP@56
MYT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W
M)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M    UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M     X0DE- ^T      !  7P    $  @!?     0 ".$))300F       .
M           #^    X0DE-! T       0   !X.$))3009       $    'C
MA"24T#\P      "0           0 X0DE-)Q        H  0         ".$
M))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M    !P  #_____________________________ ^@     ______________
M_______________P/H     /____________________________\#Z
M#_____________________________ ^@  #A"24T$"       $     $
M)    "0      X0DE-!!X       0     .$))300:      ,U    !@
M         !!0   9,          0                         !
M        &3   !!0                     !
M   !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M!28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $
M)T;VUL;VYG   !!0    !29VAT;&]N9P   9,    &<VQI8V5S5FQ,<P
M%/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9V
MEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&
M]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   04
M  4F=H=&QO;F<   &3     W5R;%1%6%0    !        ;G5L;%1%6%0
M !        37-G951%6%0    !       &86QT5&%G5$585     $
MYC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
MEH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M  "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'
M0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $
MYO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M      #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M      .$))300H       ,     C_P        .$))3001       ! 0 X0D
ME-!!0       0    $.$))300,     "#0     0   *    !H   !X   PP
M   ""T !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E
M)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M        $  /;6  $     TRU(4" @
M                                 18W!R=    5     S9&5S8P   8
M0   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@
M   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G
M5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P
M D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#
MP   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87
M)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M         2<U)'0B!)14,V,3DV-BTR+C$
M                                       %A96B        #S40 !
M   1;,6%E:(                     !865H@        ;Z(  #CU   #D%
MA96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M       !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'
M1T<#HO+W=W=RYI96,N8V@
M                      9&5S8P         N245#(#8Q.38V+3(N,2!$96
M9A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#
M8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                       &1E<V,         +%)E9F5R96YC92!6:65W:6
MYG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F
M5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                        !V:65W       3I/X %%\N !#/%  #[<P !!
M,+  -<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                    */     G-I9R      0U)4(&-U<G8        $
M    4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &
MT <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP
M#@ .4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6
M<!;@%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"%
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MH,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9
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M4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#
MP,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@
MX.%!0.#@X.%!
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M$X1.$3A$X1.$3A$X1.$3A$X1.$3.,9_7'G_7PB_/'W_1/CS]OM]_]?G^3/\
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MQ/->?88L$R/3BCPJ*CI:7%,S5S'L@87Y8PG JZDI6$7ED:ZAG+)(^(N:[B
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M/->]_A.6''860;PE&<N>6%9]OCVY5=14DLL;Y19L;8YY YU[/-.(C(QMKGB
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M(U=#J?WM#30Q&")-*W'T13_77C"\A4=.^M;%B&8S TTM".%T%(Z.:M,%;4.
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M+^%&?GJ'#*KI-Z0JVOQ!SW9-R?7&FP^E$IEH\4Q*G]A]0T F-S&O:7.+00'
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MV!1NF2V](&@"[NB]XQL!(50.0G 9:/JHM5Q41K>3**(#IC; [TB+%A1S&&Y
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MUF0RTTZ\S[!W&L)\KX4DW).U_1^*@6J_3'I>L9Z&G4[,L]B,@ME6^WQSLG&
MI?$ID[6;16ZWK4=]#RE,P=)8M\RN))3C#SK;@X[S24,IS@H]#70>7?SV^"QU
MO#T_[_,]<-.: @+Y)VJ0IF](EV#V#'Q$;4I>B:7M4Z<QLR+D%CED9F'":+.V
M* R0WEM\[!8_EC"TYS@@T[^SUS[5MWBHN/A(R-AHD1D"*AP!(N,!&1AL<*/
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M3C2DO(7EG/R<(J-]*_4@GNW_ &9[$Z:"K>AJY6M"WW9%"-B M[R4]V$7BB6
M6 C+U(ZIQK./JA&O+<\\^EFP5?:%D<K<@D.'G@F)$W#;+UX>O6BJ(  L;^6G
MA>Y!W&W\?+=?J&=A-5=K:KU3@NAMWV#8MF@7ZQZ@L8&\=&049L&F:Q9@'KC9
MDCSMN#>J^(S%CC?BB;3F)ES\N*_#PR?B=PB+_7W"WY_+OM%M";C2PMKSO;E;
MD5>'??:OKEU;BJW-=BMRT+3H5O/)C*RJ[3PL8_.&QPJ#)9$2'^^EFCPPCK94
MY(#CK!AA7V")0H1A]A:Y4:\@3X FP[3;8=YT72-=T^IK^W(G0S'8353^WIW
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M2OTO>P>C]S=1+5MVP]<PJ5T:UKN_7.O)_20=V9V1OUC<'U 293=(UD@(6(K
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M9*&GL<6.< >XK#XG@F,X))%%C.$XEA,D[7/ACQ*AJ:)\K&D!SHVU,4;GM:2
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MR_<5*LIPB<(G"+%6QMWZHU&3!B;(O,+42;(ZMJ%8E''\+,^)\89U_P #L/\
MTXC1!HK+II?P"-+=3A;Z?"O:2U_FJR>I6ZT_T9WP^RXEQEZ$J#K3J,X4AQMS
M85-6VXVI/V4A:<I5A6,^,^<9Q]N$5R:3_ RH_P!6(#^RA.$4GX18]VMK6M;@
MUS<]96X)HZO76OR4#)LNMX<3AF0&6/AY&,X_*ZRI:76U)\*PI'G&<>>7N&U]
M1A=?28A2O+*BCGCGC<#8\4;@ZU^QP!![BO&>%E1#)!(+LE8YCAW$6\B.U:0&
M_2"[%1%2 U] =Q!%T>)9>!B8*?U['R*8Z-6^\^A@8GX/J4+QEY>5KR_G'NSG
MV^$^,8Z)B>:^C_'9YJK&NCK#JVJJ7"2HF)C#I9; .>\\-SQ :ZZVN=22O3!,
M9S_EGJ?Y/Y[Q["VT[0R%E-754;(F-)+0R,2]79M[ %EM^1LJ_'^A)V+CIA4]
M4>U-4BI!.<*;?C:U8X0S+F,Y5\BGP))I*75JSY6I'M3G/W\8^V.:T^@Z%)Y3
M,>CB:BE<0YSL.Q)U*UKK@W:&&X^OFNKP?I#?I PT3</J>D,XS2-%NIQW#J;%
M ]MK<,GVB)P<T 6%QH.=R2K ZRZ;^KGIY.0*KVYJTY$#MN_1Q]N&?L(/R*]V
M<^P>2?4\TI>?T6X^O"?R_;[<S-'^J2A%X<'S*YK@1]GFQ>66*,GFP.:;'G<$
MZ]RYWF7-^<LV'BQ.#*5/4%P,E?A>7J7#JR0-T:))*=S0Y@'^CP G;O7/L4_Z
M[M&4;AJ%TOL,%C.?I2H2,K*C248SGPM(*7D$86K'_JW%9SC[?IYYZR8AT5?M
M'NP7,D0;JT053JDO[@P $=P)N=E:8=E[$*_J(QFW ::6323[QI9:** Z6#IW
MDL>-=7M%A;Q*PU(]V/6>IZ7/V3=6Q"TM^].7DTOVMK\8_P =.8\QSRG/C.4^
M,8\XQ^GZ<QS\;Z'!Q"6#/-(1VX143-V)]ES20?=KO?DMQINB7.=;8X;G#HMK
MP>$\/\KJ*FD'%8<+F3,:003[0O=IWT*AW_*[>HQ6598LW48$]UO/YU9J]S&P
MKSY_+G #3B<9QG[9RG/\GGSG^2W^]^A2;49@S30WTX:C YVD&^YXHW:6\N8V
M(69_4%TQ</%!%D7$6FUG46=,&D:=K@7J&&_+;GW:\Q'KJ=FXI"DV?I_&A.IS
MCW*PNZ@H3C'CW^_!S&,XSY\^/OC_ $XY(GZ%Y!Q#I'EI@-Q6X>^%WD.I.EP0
M;\]%XGH'Z=^(,@R$S$";V=AF*T%8PV['153KD\AOKKMKR&_\('NK*?8?U@8;
M?Q]E8:L1R4><><9\)=:]^/&<??S^F/O_ "9Y _4Z_5O2U@H'9("QXTO8@Q[]
MO8J#T#_I#MT_4[FF3_M0T['L.MM'"8@WY:E<Y'^$'RN$8P[UB+^7&/S?%9%Y
M1Y_T>1\YQC_1G.?]?\O/04W1.\<3.EO+Q:=1=SKV_P!C?Y\EX.Z$^G]A+7=#
M>< X;C[&W_%V7*%_PA%UM7F3ZQRWQ^?U#LR<*\>?_MAE8\^/]6//)90]%T]F
MT_2SEM[B; .<X GW-]?#RFZ&>GFE'%4]#N<(VV!!%$';]O"\Z>NY28?_  AJ
MAXRC!G678&,>/WS+%IA<>,_;SE/R Y^V/YL^<\N1EG)DENJZ4<IN)U'%*1<?
M_P! L5)T==+< )FZ*LY,X39W^;I"![F&_KQ4H%_PA+1[R6\D:&V<,I2L86G\
M8AWOCQ_E*\H!Q[O;_,G[Y_[_ ![MR/@LFL72%E*0&UC]MB;<G;1\X(OWA8N7
M*_2!#<3='6<(RV_$#@]8[AMO?@@<-.XWTVV79K_P@?K^E:$ITULY2%?X[GUD
M;CV?_=^DSE7^S/G],_R\J_D%AUR#GK*0/^B/O&G]KP_G%AY_N5NW L[N!(R!
MG#A&Y^Y*\6'A]GUUOMV+L&O7^ZX*0K+VJ]FL.8\^UO\ YFY[OYOSH%]J?.?Y
M_P!/USR1T>T[FET><\IO:+W<,5I&VMOH:B^VHM>Z\G87FUCN"3(^;F/.S3@6
M)$GW4I ]]]=E^,^O]UR5E7U.J=G#)Q_B*RH%[W_S?E;'\I\_Z?\ 5R1T>TK_
M .BSKE.0C<#%*5MK\KNJ!<[^Y0_"\W1 &7(N;XP=B<"Q)U]KV#:4GGS Y=JY
M>/7YZT9RG'[6FSO*OOC'P#^?'\^,?3_?'V_T<G]7+/\ K?E2YV'WM1Z_^8Y\
MMUYFBS, 2<EYMLW<_<&*6'_E%RL>OIU<]_[Y0MFML^WPE_Z%M6,N9_QF_9AC
M"L>,^,>[/VSY^WVX_5N^PMFK*I)Y?>]%MVW^T6/A=>?V?,6YR?FP"]K_ '!B
MF_9_[H![R-CV+DM^O?U8>SE+5'V@ZKQY]K<3[U9_7Q]DL9_F\<G]6LQ_#F?*
M[M>6+T6H[1_..WDH=%CS1=^4LU,&NKL!Q,#3?4TO+GV+]3Z\_69.<H)USM8=
MS.<Y;;5$^]:V\Y_*YC"1L92G/G'C&<><?I_)RH]&<U[-S/EAUM_\[48(/9;[
M1V"_9R[;46QRW$<J9HX>1^Y,1(\+_9@+]R]F?7GZO8SC&:#M7&5?;&,PJ\9S
MG^;&,CX\Y_U<?JSJ.>9LL"^U\6H]?#]OOZNH QH@G^2N:+#>V!XB0.R_\VT7
M>0'KI]4IN4C(9RK[0 D):4!C AUUP@A;JSB6A6G4I:82I6,+>3GX\8RI7CQC
M/WQGGG-T:5L;)'MQ_+<K8V/>>#%J.YX03P@=>22[AL+7UMST0.Q;4ORWF.,
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M +M47_A.$3]QEV)_SAO8'_=JB_\ "<(G[C+L3_G#>P/^[5%_X3A$_<9=B?\
M.&]@?]VJ+_PG")^XR[$_YPWL#_NU1?\ A.$6'.Q'5_N50=!;KO.IN\G82\[1
MIVJ-@6C7-+;J=+*<MMY@:K*RE6K:!A@\D$KG)L8*-2.QC+KRB4H:Q[\IX4@
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M[,T?#^$-QW$[#P!JB+=UE")'T>XZ67AP_LU>'E)SG.,IUIK8?[Y_T# LX_\
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M$$YEI76%K.PNF(/>X<S[AW+]_P#@^6IO'M_=,;B]OGSX_":[X\_S^/D\>?\
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H1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g96389g31s12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g31s12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2A 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *"2^$"=CA"24T$!       6!P!6@ #&R5'' (   ( !QP"4  (<G(Q-3
M$Q.#$< @4 -TUI8W)O<V]F="!7;W)D("T@26UM871I8W,@+2T@4F5S86QE($
M8M,2 R,#(P($9)3D%,+F1O8W@X0DE-!"4      !"NQJ$8$JV_O)_[-.="U0
M>=.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M  4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<F
MEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0
M!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E
M!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G
M!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V
M]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
M!,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F
M]O;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6
M) ;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M          0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M              4G-L=%5N=$8C4'AL0%E            *=F5C=&]R1&%T86
M)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B
M-2;'0               !4;W @56YT1B-2;'0               !38VP@56
MYT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W
M)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M    UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M     X0DE- ^T      !  90    $  @!E     0 ".$))300F       .
M           #^    X0DE-! T       0   !X.$))3009       $    'C
MA"24T#\P      "0           0 X0DE-)Q        H  0         ".$
M))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M    !P  #_____________________________ ^@     ______________
M_______________P/H     /____________________________\#Z
M#_____________________________ ^@  #A"24T$"       $     $
M)    "0      X0DE-!!X       0     .$))300:      ,U    !@
M         !1    70          0                         !
M        %T   !1                      !
M   !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M!28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $
M)T;VUL;VYG   !1     !29VAT;&]N9P   70    &<VQI8V5S5FQ,<P
M%/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9V
MEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&
M]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   40
M  4F=H=&QO;F<   %T     W5R;%1%6%0    !        ;G5L;%1%6%0
M !        37-G951%6%0    !       &86QT5&%G5$585     $
MYC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
MEH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M  "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'
M0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $
MYO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M      #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M      .$))300H       ,     C_P        .$))3001       ! 0 X0D
ME-!!0       0    $.$))300,     !VN     0   *    "+   !X  !!*
M   !V2 !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E
M)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M        $  /;6  $     TRU(4" @
M                                 18W!R=    5     S9&5S8P   8
M0   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@
M   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G
M5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P
M D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#
MP   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87
M)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M         2<U)'0B!)14,V,3DV-BTR+C$
M                                       %A96B        #S40 !
M   1;,6%E:(                     !865H@        ;Z(  #CU   #D%
MA96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M       !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'
M1T<#HO+W=W=RYI96,N8V@
M                      9&5S8P         N245#(#8Q.38V+3(N,2!$96
M9A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#
M8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                       &1E<V,         +%)E9F5R96YC92!6:65W:6
MYG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F
M5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                        !V:65W       3I/X %%\N !#/%  #[<P !!
M,+  -<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                    */     G-I9R      0U)4(&-U<G8        $
M    4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &
MT <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP
M#@ .4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6
M<!;@%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"%
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MH,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9
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MRU$[6*M@&V>;;PMVBP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" $T 6(# 1$  A$! Q$!_\0 '@ !  (" P$! 0
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MEMNM;MN+;]/+6]O=@'$F^=AN W'0W-N_N\;7$RUVW29ZHO&Q_!2S"B)6+_\
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M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%J>OW61P5;]K:Z_KZ,-RN;
MA<R(4;*U$7Y>O"C]YE@2J*G@<.":7ZHJM1OE> "=!?N307W=W#7RWJ(TW/;/
M8:>WKS()B<_-]&;'L0>6$\F!W\$FGR<+E)<U[5;*/-:20P31N1?:U?+>7+CX
M?'\+^"ER=!OU._M''=WK*571P$QD5SO-/I=[=-_.7[4L90Z0=RJUSHPZ,!\(
MD8_N3]'%-\PK&_F^]?KY7[ .[RU.>>\:=B6WYGQR\M%+(F:SP"PN#HZD=\'C
MX,L=>*DT:M^YS9OA?%1R??[O?[O/Z^1+"]["_'>LWPJG")PB<(G")PBH@;"X
M:PL1)&N9*#8'!3-<GA4F%*E@D5/*_5OO8JL5$\/8J/15:J*N?[)[AZG&_M'F
ML0,R>_V-^!7E7QX^OE4_=]_[O'^?D:+GN!^&N[5'G+O-E)'4,,CM]%,UKECA
MSETDJ^/*1J092I![U3RB++\";V>?X7PY$3^"O#C>^XW/?:P N-VAUX%1HL3E
MK;/+VBWJ5L>8K-.$3A$X1.$7A+JZRP\?/UP)WM_@_-B#D^WQ]WCXT;_'^;QP
MBU#0=8XC2#/&L*(:%'M5J3UBR5)4:*GCS$17N'DC<GZG-7SRW-[W\\_:I8<.
M0;^U1NO5O8F/_2]:=EGRBQ^%;E^P&OT=.K&I]!1;)OP[:NC<J(KITD*D3\[P
MU47Z3\?7;V6]:OPR&[\/7W+N#[S@SY,--VYG++KBS<]!8[TN-YN$M2&K\-9:
M[2#H^(2(AR+-"/:-&F'@<U"7M>UW+;AGW:^6ON[5-H#7+OO;S( 4[!F"6 T!
MH)0YH9,;9ARA)HR!IXGHCF20SQ.?'+&Y%16O8Y6N3ZHO(JO3PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G_;PB<(G")PB<(G")PBA37:/LVVMY<KU[F9:EB-\
M';W40+'3 M7[UJ*U52>Y*1//L5?8,U_M<]7L]R<HMJ>.F\_ ?T[1#?=R.SMY
M*]..Z8S6=LFZB]G,W&ZD1JS:S3O^=*'D3W.]E*$]7A4@\:N<D,8,3)&-7VK,
MYOAJ">X<^?F@RWGX=U@%,7[?Z_U_^O(JG")PB<(G")PB<(G")PBJAV^/$/O'
MNAB9&AN<IRR/8GA9BT/O W$R>/X4CA! 1W.7Z_#'B1?X/E:+Y\+9^&?N6)-K
M'/U:?U(WC51M_G_9^I%^Y47]:*GGZ>/N_GX&^V=VWUW7U]2Q<X&UMQ!]O.85
M@^CAHF@Z4OV-6>:U&A696HLGP(JX9S(?>OEWPFRR32-8BHQ))9'HGN>Y5',G
M<LP;@%93,=^=2;"POJ^AVE60N<,- L3R%FKZ9Y=9;24-C%7W1\8U99*#=Q2U
M1"@E3HAL;HF*]$]W(JI$74YELI<"Z*B2>O%<:?"MO7I,$&Q$<\LN+YCWC#,1
M45T\S61-1457HB\(OEFLRTBQI'I:"19:U]U$C+FN<LE/$BNDMHT:2OOK8VM<
MYY[?(K$:JNE1$7A%E@S0[ 6$VO+&.#)8D@Y8<\1(L\:JJ))"1"]\4K%5%1',
M>YJJBIY^G"+T\(G")Y_5_7]O")_7^?A%Y300K,68*P$&/")C6,@0R",D:>-R
M>'1S03-?'(QR+X5KVJB_K3A% AO2IV4)FNNE='+B#))7$E9,_P"/:X2UD572
M/8ZJEE62EEGD5J/*J7Q*C6MC;$V+RG*.Z_.[DCLU4MP-NP:>(W\VLM[PFOU=
MVXFKV>'M,K=@?FS%1N;8YNR]J)Y(J[:'PUS7^47X$[(Y6.56)\1&*_BW=K;G
ML5ON]Q]NBDKD1.$3RB>/W_=PB<(G")PB<(G")PB<(G")PB<(JNKZKNNZ2MV]
MSO/F,;48_M+L;K%+&=);(6Q-ZXS;M98FJ\4=K@Y#Z,6T+!KW-FEE2L(CCEDD
M5K5(M4F]=_1(]H^LG;OXHXI-8DUN_"VZ4D G7VFSV1[#M)K+PL;*O#7>OR0V
M@+5OM\Z(%E6VSG&MH:TG#+7U=_/J6 T_KWZQKOLE,S0;?1SF=@19"0%,I9"G
MV]4+IM%C-'H,B-,K%NAJ+4YTNHG4AP$<LGMGA=*+)#.\GJ[^=_O':MN*]<OI
M[#@(LB-!>-S@M6><3K&9BUES\5E7=:6O<!64;/%$\TC4MZYI+;1QUHH$\,S0
M)ZN(MUVC*UQ.?=NRU6BT_P"$'Z='T&CS?8;+7KR[ [)N\13T-\-"+?OJ<_G^
MLC[/17-;,:BPL&O^RJ^D^4HY+PDJ-PMF!"7723%PN>>2AR%SIKSY'@N_2?A
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M5%FL9DG5%JZEU%>EM1RY_KO$AETEG\U4F29FKL"PIK.!37N?)97/.N7;KR.
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M?XE.Q?Z;*?[P<?F:C^T.$>5?_))\XJ_[+8[_ ):'^;3\J.L_Q*=B_P!-E/\
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M+K$]*)(I:5E9@&,4<=764]$R>9M&8F354@CBV]BK+]G:-W%K7$-!(!-@9O\
MX_Z_ZN<XNK51,JB?BOF_WT5,B_Q+7"JO^GG8UOZY5_XF?_5>N-PO^ZL.._Y#
M2?Z$8TT/QN=2J?>J]/\ R@R__HTY")^Y%-?Y3]_W_KY^:=./IT)_],GMY]NJ
M[SHQZ4=3?.\C>S1G8JE^5\+^O\U?'T\_J7QX_B7Z\X$D@&V61Y_!=8_Z).\
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M6$D3'DO,D5 V*]D*$JC57YTW1'&'5,3:R-C:>&5DDDT(D+YQ&X. CC++Q[1
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M/1:"?S#LOP>O;\%R=@*76]=OZS/+.%%W1-W[;JLR]B3-(\,C-?"?(5>" SR
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MW.5[F#01P,<Y?O<YL36HKOWJBK^KBP&@LJ23J2>]:;;Y*TGNB+O/:27/$V8
M];=-2N#LF%0B.G4,\-I7A@EP*PB0=A4S#1)1TAC*KR/EX%CU\]%,Z=U135;J
M5TL;8J@"*.4/:S;ZN2/;%F3LVBT/<)&.:&M?&X-;;Q2TTAF,T$Y@=(QL<PZM
MD@<UI):]@<+,F:"6AS@]A;8.C=L@C9J2F"S]4'45Z2_+!1JU)")'3E$S2/?,
M4:80_P#2$FG%23%FDR*LA)4TTTBJ^1R\]4$$=/"R&,'8C%@7$N>YQ)<^21QS
M?)(\N?(\^D][G.<225Z(8F01LBC!V6"P)-W.))+GO<<W/>XE[W'-SW%QS)65
MY]E]$X1.$3A$X1.$3A$X1.$3A$X1.$3A%HP0PD-SI<L= QX%[%+?@02HU!R1
M;!K ]$#&QWUED'LT^TCU\>UK="(WQ]5XX\W[^2B\^7HZ5Q]N;%6@HM1HRQZ6
M>&")K0AOL*F GA#=&U&QPHL4@LD<?AB.A=&YJ.8J)./:?)+Z=FBD!/XOXOXO
MYU_[/XN5%SPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PBH/W=O>S8NYLF=B@R_L3%W#LQ '*LPPVLT-M3D7-U7-C<UK"XTJ0Q
M@!)7)(R$]ZR#/;(YWC( 6)RW]XM:V_><M!;6^=EB3;/.P-N^X\,A86/?;BKQ
MT=HV[IZRW:,2$ED",9\F9&Z$H59XFR.'(B<B*R6%RK&]%3[V^4^BIS%4&_$=
M^JRO"J<(G")PB<(G")PB<(G")PB<(G")PB<(G"+%VE+6W,<,=B.LWR\J3CRQ
MSDB%"R^Q\;I!3 YARQW21O?#,L,S$FA>^&5'Q.<Q2+T@ !U@D(($#!A8$<D<
M3%<OA7O=)(][WN=)+++*]\LTTKWRS2O?+*]\CW.4B]?")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G"*#>_+$\7)TE=5FE V-[M\E503!$3#$+%-;12EQLEA
M<R3Q(+%*U[4>U'-54=Y:JHM%L[VT.O=SGN4<"18&V8S[CS^!S$XM1&HC4\^&
MHB)Y7ROA$\?55^JK^U5^_D57/")PB<(G")PB<(G")PB@'U$,6OQ]%KXV*K\)
MO<?JE5J?G?"CM8JLMZ^$]RM02TF63Z*OPV+Y3PWE%L^T>L6(]@'9X*&^5MQ]
M68/M4^-<U[6O8Y',>U',<U45KFN1%:YJI]%145%14^BHOGD57UPB<(G")PB<
M(G")PB<(G")PB<(G")PBH;?>L&TQ.06UL,.9M]/>^I7N?H[(9W-CZ+W$B]:6
MG89PQ9WXM9;;V["9<I@#5;)%02!E74PL!A=2%-,>,YYY**/.V/P@8V<Z[M;V
MFQ6BI-)5:B>N-I"(1[[4A5^2O.H2-2*F1&&D+,NK.F[$+HZ^M'<^6"\"6.&>
M>:2%&$&?9[,A<]OJ7;M?PD68Q 2VQ>"ANZQ>IM;V,DN9V)]J@=UE^FK#O9N+
MM[M<(-@@3;+!U[3(YAMO8W0GVG3F$99::PCM&E0+D 9DFP]VOOLNBT]<V[IN
MPK :RZNKF9?!4^C [:J:S=!VSJ*Y"V'4U;5:/(WS<D-+LQ9*;LZN9/3.#SC8
MSE/B<7(^OBE*E]PS-K^'&_\ 53MW?'3V%;7@?77<=FSXJ+)=$:)1^Q>P \GD
M+?1W5WE:,RD^P]YHKJ^(L;OKX92+.FK.O;574>8'U%68394<$>KB0HZ2MJMM
M>SG37DK$9#\(-)M.O,IVB-TEJZ# [,C$6-;L]')KZO/U>%["SEUH*+3W<Q76
M3#83@EK:^LOXJ^NM,!5'Z*F5_9TX+S3!&Z_=KE8G0'M\U"+:^T9C+/N-\E,?
M1'J;+[1U<&(N,M/13$9&344FBM#"XI-C$/<%UEJE&"'F69Q\-')$/!8MCUCK
MH>2>&0J@&%GA+E*D$:JX'"B<(G")PB<(G")PB<(G")PB<(G"(OW+X\?=^O[O
M\_[N$5?^R?\ Q[VMT[DF?GM!LK;=&(W^"R.A#<.*D_W_ )LI)R)$U?*.D8JH
MGYOT<\^%^0BG_P"O^C_/Y_F3^OZDX1<\(G")PB<(G")PB<(G"+3NPLVS7X?5
M9I_A%N:.Q!C>J(JQ3RC2)!,WRB^'Q2^R1B^%\/:B_JX&HOQ&N?J4.AMK;+O6
M!Z9T;M5UED;2?RAT=5%5V<;_ .VQV5,KJLQDR?>DKI15E<B_7](B^$\^.4BQ
MM<'33M /O0&X!\^_>I/Y%4X1.$3A$X1.$3A$X1.$3A$X1.$3A%$5EZ?NA;D[
M26=OTCU%:V6R-$L=?8V76V-..U=@ 2PP$_2%E4LI%Z:$7&PH0JTD*G&)8R>%
M[)&HY"+,Q]0]3PW!&AAZPZ\AORQP!"[V+%9J.X)$JGB258Q%FVL0V8>MD !>
M!#).Z,-X0CAVQN&A5A%J.R]-'0FZI];3WO4N!:NVR5]AK^ZJLG0U&G(S&FK+
M2GN:R#2U]?!<B0F5]W;CO2 QB>VQ-^B_,S_$(MVJ.J^L*"H@S]%UQ@Z6A%%G
M!%I*C(9^MJ!@BK2*[*$@K Z^$*$4FZ@@MYX(X&Q36D,1\C'%1LE:1<T?5G6.
M9LSKO-]<X//7-G</T-E;T>0S]39V%_*(77R7AQX%>.47<2 'G!/LYY9#7B&%
MC.G6$B9CR+!1=#=&P3*1!TQU/"0[4.V[IXNNLA',NT?\=':]964Z/74.0LKW
M7ZN^UE^9G\EK\:3W$6R4O6_7>:O3=1G,%BZ#3604-98Z*ERU'57MA6CRR3CU
MYMN "/8%!03RRS0B3D2012RR2,C1[W*I%NG]5_>OW<(G")PB<(G")PB<(G")
MPB<(G")PB?Z/Z_OX15]PBIK>Y^S-DBN>!E!*_K:H?Y]T,A(SOMB_EB^]&S0&
M3P@S*BHYR1(U4\-7RS\\_60IG<\!EWG+/W*P7"J<(G")PB<(G")PB<(G"(OC
MPOG[OU^?N\?OX11KU]AR\,5L1V'0$4-YI"-!2 QQR,GK'V3&R6L$SW.6.1LQ
MR.GA^$UB,:]6JBN55XX>OM4 USU]2DKA5.$3A$X1.$3^O\_W<(N/*?M3[O/W
M_J_;_%^_A%SPB<(G")PB<(G")PB<(G"*$NOK:S-[3[KKBSB20:@_'QUHLTBO
M@"85123$-'8OTC2:5/B2(WQ[G>%7SX3Q3:PL,R"2>.9'L"@O=V>5Q8<,A\5-
MO(JG")PB<(G")PB<(G")PB<(N//U\>%^[S^[^+^/A%SPB<(G")PB\Y;2'"DM
M$=$PMP\S17S(YT+2%C<D+I6L5KW1-D]JR(UR.5B*C51?"\(M$ZNP[NOL@'0D
MF,L[:0JPMK^V9&L26UY;%R&'GN8Y7/3XCGLC8CW.>D43$<Y53E.N60W<^U0"
MPM>_:I#Y%4X1.$3A$X1.$3A%^)O4OJ9]9'7_ $%Z?]WV,%^-!??61ZBN*^S[
M?.ZMKC:/0&]/?C=O669=!H>H,KFZGL#52 !]?TUM?:#695B7A-G4V\LE5C G
M//XIQX#?V\/'LOO.[.?3O6#W=GP\[IM1C<&/3:/L37Y8#%9@6PTO8I@>=$%B
MI:VM%,W6;FO3M-<2D1$:7(YO4@9D6(:<S-65825>5I46/'0[]XUW:=GK6HA>
MM?U!:(*L"Q>>Z<U)MI9#%3;FLJMX5AZ,>3I3LCM>YZS+K(-$^QL.Q\=:X.IR
ME_:K?4]>HN^H+N3*U=D+-E#"6RX'.UQENM?LUTOI:RPF@];79F]U=KD<G534
MU;6P8/4(34U4M1I:24TBI9=8Z]>_7Z"SMAS(KCYD>WL<)UW#) )YK@="&]UD
MQX6\;^X>Q33??N%K\+9FW:#\5R_UV=KU(%J-6LZ\O&T\?45#937=?\AH^O[[
M=5]I<WUYMDTO;&#H-5DZD,?.T<%W]J=6US]IL0LZZQ(.IRH#B&][=MOZ6\L[
M>*W;KSU2]R=H>H3H_'7\&)Z_KY#7)L^ML_;F:C17P]IZ9(^ROQ\$UM;93Y>]
MZDCW&@?C,T>!5+ ?H<@380ZDQQ#*B BR$?JO]27X^V LV%ZR;@Z_1Y.%\4=7
MO':R?/:3O,+I588CWV;*9ML/#8-W4U@M<\(6O"DI?LTQIB:$"7S[,M>WAX[N
MT9\2B?1>M+N;LT[$5?6,=1F-+08W":;:+7UEWIJJI[1V73OK)*U75^TI$/KI
M)XNO-3T[@+ G/RV=?=0'W$$-I- Z>N5:K;*_?ZK?'G=)F']1'J'M^C>Y-+ E
M7MMI48 ;49?M')Y.ICZKI#%ZX;I5<=A[OM9-78^+*$JOFBRUAHAW6C5D)#JQ
M8I '.?QTOZE,KZY7S/9?/4>Y:?<^O7MFKU<>&R=9UYVA:?DMI+=UT'G+?-4D
M>Z.7I;X9[WB=DZW06&,O1^T+4L9XN/K@JUU H]=KM80RT%K296\._P" .6ZX
MUUX8_1>OWNC/=@]J8B.FZFOF=8V5=B;8@ )E3:!:%Q.%KK3L(FFTW=M/*_KL
M6;1:"UL0K0C+B9L6JJZNP['.DN!K>5SSZD[N==_ENXJT7I@[K[>[.WV\K^T+
M7K>M!@R77NDRF'RP,!EL./?T44UM>"[*LW.GI-1G2K5A \2U<!T%?8L)KX]"
M<T;PI/&_N[%>'^O_ '?U_P!7")PB<(G")PB<(G")PB@'K3_CA[\_E+#_ /P[
M-RG1O=[RH-7=_N"G[D53A$X1.$3A$X1.$3A$X147]5_:VMZJW?4%K5;$B3,$
M6#A+OJ3(7>6J.T]N>=9A 5ECE*G39;0LWM96OG=#H,C6V>2L80)9KP:W*>!\
M@\G//#U^\5.N/7#Z@#<A7]HC]=A%-R%OV3<.P>0O:-QUVVCZ,[(TPG7^_K*?
M<;JQJIZ+24U025=W3,<=9L>R6'#TQ0:0D3V]^7/@G?Q]7Q]O8I+K/5_W?J0#
M*6([I##:%,'M='E-#8P1[$/MX^M)LA*J+KJFP_;^EHZFSSD8<)>OS<V][#);
M,77PH57C&OG%J#/+.]P-+7]9\,SVJ*:WUQ=^Y6E-)O3^K]C9DXP/<5NI?G-1
M2XO;6M=U3D-8+TW@*,/76DH'8V^OKNPSE=8OTM[!#>@2S5^&M??/35Y4C@>\
MVT%^_/SMVJX75_J,[=T_8=M3:O"9V'*V=%ZJ+K%CT(VC@TP#O3/WK3]/C :<
MVRG*K+,SLT2_@T%-%4UE4E/%3$JV3016[&T9"+<]@/OWZ^:KGF_43WOWYL.E
MJ@"YR>>S1'8&,T&X(P-9NAY*\2US%I>'=+:ZT$W0,XVQQ%F-%6Z\ATGV/;DM
M>-9XNI9'&(44]^G;W>1Y"W#N3U[:7K2_WV5#S6*=?8:?LN:Q&T!EZ+'3T&:U
MW4M#B=%I%"26:MJ=75=A6UPPM(?!T-(LM/&1&.:U)?/3Q\#_ $SLG/'D<<UL
M>@]2G<1?2/7?8]!=];UA$WJ7K.L=-KQLA<7."[!ZZBWQN5DU>)#+VPY6="TX
M\0R"F%Z;1C '-+@!MK(9PEG)4\+Y>OUY7[,^Q9[J'U6]D[VO[:-=AJ'<F8SK
M\O;4.?ZVANAK,#5MM-)5C=':N6X.MF3]@Q-I*ZT.LA1J-K*^_%<W*L;!'.:3
MGGG\(BZ^[Y]1W_@=Z_?W6KDK>T\?ZEM9C+S7=M=3$TM5!A ^^64AQ$6,&LLA
M*)FJ7%'R5H-G/:2DU@]7,EI:V-G7&6,A4ZZ ::9[L^.^^\^X92F]:?;FR['/
MZZPE)@KEA6_RF6JMA:YF\JZRBK3K71U>DFNL_6=DZ/06!+/Q>4ZB(NH^M4*$
ML!"8ZJRJI!;@TIW\GGO4.Y[\(_W3I\R[05.:Z@G9<ZVJHZMTA515BXELF'V>
MHDK-]/I^],W S\:M!G!L9D-39DX195'TE^#B=216A9>P*@<3X 9^WAKYYWRF
M+-^K3NBJW-Q0[VTZOG#(]2 O7[<Y49]"=OC\5=X#):2@K(JMG:%65M7E6UZ4
M&_>9ZKNG1,K[&RBQ%C5RM91%.'Q[3V9=V?&^=A^HW")PBZ2'RQ#SR00*3/'#
M*^$9)&1*1*QCG1P)+)^CC65Z)&DC_P QBN]SOS47A%6[KCU'"ZW/=HZS;8XS
MJS.]3:J^Q^BM+W04MU#);YI1&VR#,HW$3.@8\X2,-R,=*?/,V 6)\KFL<3UK
M$;'UG=#94"Q;'L!K+4P9*UU=;C?ESZN\M(ZV@T&E95-CM!!8P;8ZFR][8!A'
M.@GE"KY"VQN@E%>0-]VO:BS=)ZH>NI^OR.QM7,5CJ1FZGZ_$C-'(M#+&^8R%
MXHP(E,.:21*=\1_P(HX7O\0O<_VI]Q+'AV^'%(_5WZ>"5.:!V-7VKP'YN"1E
M57W-DZ<[74/XT9^L 0.OF0^U/S?OO?LX-9BQJB$BP+B@%@FE80W%K[[^8]G/
M8M;/];'0<>HP>=IM@)H1MK"8?-H:R,Q]#GJF#KDOLP0VTL7B(,V<_/QUT[*I
MDOVK!#< %$AQ02^[A%NM_P"J/H_/.M8"=K =84HVA*L:JFKK:XLA(LP,\BV<
M2-7 DO&9&K%&AF(^% 06OR\,CY&O1I%WR^I;J 'J7(]VWFDESW7FUKJZTJ;B
MYJ;851Q;$138WVH_R;YJQD([)7SS&,BA;\-49)(KXD>4OWZD>WU9>Q8PSU:>
MG\%VO2?L 1T>$A4K3D#UET2)7B,.)K2"T*'KY!RA!#@RQ3"19)H19AIHYGL>
MQ4X57C(]7?159:Q4]]N*BI*L;HFJHU9(3:0V0PQ63KY+>>>N#F@IZZ,_;Y@0
MB>UE&B&DMPW32M9(KF$%SNY.F6M]?):5DNR_2H)V[GYL*'"5O>V=#O\ .U^C
MIZ:_*JYKW,.2;<,C)FC?34TA9U<D5J;6P");V CGG3D/B?(A.?-7/X1.$3A$
MX1.$3A$X1.$7CL; .I -L["9HX->+.880Y'.;",-&Z6:5R-1SE;'&USE1J*O
MA/HBKP3;,HJR=;;7+-[:[9(^V@G0ZZXP,&<>R3WI;23Y>8B-HJ,1RN7X2.<_
MRC4C]JH_VJBHE.@[O>5 ?I=]O4 K3_\ 9R*IPB<(G")PB<(G")PB<(G")PBK
MA+ZNO3C 9H 9^V,N/+EK>6BO)2)YX1 K."Z+S1 RF20-&E^!HP2J"66&5\4=
MQ&T!S_CRPMDE]>SX7]Z+S'^L+TYUCM RP[*KA'9ET4=JV>NNXU:3);T-"H02
M.K46SL(;G3YZM) KD**&+N:^">*-Y#6\JMB,N3W<4G]8?IO'-N*R?M&DBLJ-
MXT!]>^*P:8A1.EH,8H0\"B)(4:)KM3GLQ8BCI)-77ML)6&-A*<^-A1>N[]6O
MI[SH%Y97/9517A9R[7-VY! ]DUHMVRMCN":]6_)?$DGKZN5AUDV-COD!W(XI
M8E\)PBUR3U$](=L=IT7IYKW"]@)I\KN]G9F0CSSYBO7J70=9?$ F.EAB#L+%
MMOMJLAL=>20ZK+IIXK!L$RQL4BS)GK ].8 =B<5V56L&KCA0'/97W4[K!YQQ
MU:$32Q0ULDEW7DGUAXD-E5L*!?*,Y4(^')!)*19+5^J/IK%F8B&]TLD%9OL!
MN.SJ31P5EB5GXL9U[45]]I+>RLH!I(Z^(:IL&EL80C)'-@FC<UDOPV2$7&U]
M5G0'79Y=;L.QZJI- *L!; ?Y2U,?7.J:/KS26DIZ@ %(&)7TG:_7MB680L8T
M4.JJVNE^+*L;2?"_@O@/U6^G^P?1Q#]B5;W:.60<-L@=I$@\[+&6G:-=+, Q
M**8BSAD!&AN/DGDD(UD+7_$8KB+T^GROZ%*S$VVZ#K:N+,:=(@V7-:-;PP6
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MJ)< CHB-;Y;,5(B>5\N5?H)ON'AEOY"6/'?OY_II9;MB#^UY#BZ_L2@R PT
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MM0GR9^KO[BE2PT1BK L=E"!/\<2-XH2R? %.+@25%1&NAG1BO?\ =[0]KXW
M%KFECL\[.%CNM?AWWX+ZN:'M+23LO%CO.RX$$ G/,'O"TW$=/ZK+;VOR)FJL
M JT"DF+!MZ,M0G6X*+&*9&^"2)\@EV2]()K P6=&RL8LC86N5')I<(PAV%.G
M8*N2:!^R(87:, UDD!!VICDUTC2UKQFYFUFM=08>^A,C>O<^(AK8F"XR&KY
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M+)%%*Z.2[7QEKBR[FYAI<TAP#L\[Y&QW+*AJ&TU0V1[0YA!8Z[0_9:_(N#7
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MK]=W;=8[0W[9[$EZ!-S?7L=?M(!@48$U[FOGB4&5\"$Y^"QP6O\ 6R?+1+
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<PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g96389g34b67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g34b67.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2JN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *I*^$(F#A"24T$!       6!P!6@ #&R5'' (   ( !QP"4  (<G(Q-3
M$Q.#$< @4 -TUI8W)O<V]F="!7;W)D("T@26UM871I8W,@+2T@4F5S86QE($
M8M,2 R,#(P($9)3D%,+F1O8W@X0DE-!"4      !"NQJ$8$JV_O)_[-.="U0
M>=.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M  4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<F
MEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0
M!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E
M!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G
M!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V
M]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
M!,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F
M]O;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6
M) ;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M          0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M              4G-L=%5N=$8C4'AL0%?            *=F5C=&]R1&%T86
M)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B
M-2;'0               !4;W @56YT1B-2;'0               !38VP@56
MYT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W
M)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M    UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M     X0DE- ^T      !  7P    $  @!?     0 ".$))300F       .
M           #^    X0DE-! T       0   !X.$))3009       $    'C
MA"24T#\P      "0           0 X0DE-)Q        H  0         ".$
M))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M    !P  #_____________________________ ^@     ______________
M_______________P/H     /____________________________\#Z
M#_____________________________ ^@  #A"24T$"       $     $
M)    "0      X0DE-!!X       0     .$))300:      ,U    !@
M          I@   24          0                         !
M        $E    I@                     !
M   !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M!28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $
M)T;VUL;VYG    I@    !29VAT;&]N9P   24    &<VQI8V5S5FQ,<P
M%/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9V
MEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&
M]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   *8
M  4F=H=&QO;F<   $E     W5R;%1%6%0    !        ;G5L;%1%6%0
M !        37-G951%6%0    !       &86QT5&%G5$585     $
MYC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
MEH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M  "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'
M0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $
MYO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M      #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M      .$))300H       ,     C_P        .$))3001       ! 0 X0D
ME-!!0       0    $.$))300,     " <     0   *    !;   !X   JJ
M   "   !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E
M)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M        $  /;6  $     TRU(4" @
M                                 18W!R=    5     S9&5S8P   8
M0   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@
M   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G
M5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P
M D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#
MP   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87
M)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M         2<U)'0B!)14,V,3DV-BTR+C$
M                                       %A96B        #S40 !
M   1;,6%E:(                     !865H@        ;Z(  #CU   #D%
MA96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M       !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'
M1T<#HO+W=W=RYI96,N8V@
M                      9&5S8P         N245#(#8Q.38V+3(N,2!$96
M9A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#
M8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                       &1E<V,         +%)E9F5R96YC92!6:65W:6
MYG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F
M5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                        !V:65W       3I/X %%\N !#/%  #[<P !!
M,+  -<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                    */     G-I9R      0U)4(&-U<G8        $
M    4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &
MT <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP
M#@ .4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6
M<!;@%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"%
M(= B8"+P(X D$"2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O
M4#  ,+ Q8#(0,M S@#0P-/ UH#9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^0
M0&!!,$( 0M!#L$2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3
MH%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0
M:O!L &T0;C!O4'!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$
M8(6@AN"(((E@BJ"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0
MHG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"
MH,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9
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M4 9(     !_]
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ J $H P$1  (1 0,1 ?_$ !X  0 " @,! 0$            '" 8)! 4*
M P(!_\0 2!   04!  (! @0"!0D% PT ! $" P4&!P ($1(3"105(2(Q%C9!
M=;47(S(S.%%5E=,D0F%TMQDE<2=#5UAB<H&4EI?#U=;_Q  6 0$! 0
M             0+_Q  K$0 " 0,"!00# 0$! 0       1$A,4%187&!D:'P
M K'!T1+A\2(R0E+_V@ , P$  A$#$0 _ /3#[9^[,6%]N^2X[)^Y?&^9XOGF
MH7/]UY3H?7WM71M::=9YMM\>6_58GH^;SUEF:C/7686_N!\P3G_7^UM*O6]7
MT10.BI\JKSW\]][&SU3F%W4/-)F:*IL5]HNA],YAZ[=:Z7QG.X[7;_&8'1:R
MAK=W?6F<R*QT=05;G6=H734][:FQUU<(0>)1AC"/T!<0U.^\S\!LM[7B*ZFV
M33OU?\5?V%YC8A:*#'<MO\AG^78XS3X9F=U+=SK-SLO4_K_LHS4Y;0P;9H%-
MAZ0[F0F-*H2<C=GDQ6-K9_TG&G"'!=&X\\X<2I)Y2X\4M^+5XJI5K"\,_$@V
M0/'.C= ]B\*?OEYSU#*8JUV'K=@'C9L"EWN5Q^II[F_H=ET^W-K0Z C9B9:Z
ML@-%;/,L@9S8J<!LJA0T/:?+NRH;>P2X; $,\?ZT@.%',@^XGTR?9)B9-']:
M(YWTO^A[?J1'+\+\I\K_ #\$.5X \ > / '@#P!X \ > / '@#P"/.E:S5X[
M.D6V1YU=](LHQSI/TBCM,Y6S#J,))/#+.NAMZIQ4,TK&P_EZII]BY5^( Y7J
MQKGGE'YD,I'ZO^V?L5UV+5.V?K=;RQ5%ZVO%LLM-5Y(:OB?(K9PK0?I&LKY[
M,VO3Y<1/2/E^?I<QP,4BL:M:AQ3#O9/@J\J,RG,^+A,OK'(O3T&_L<QSW9:>
MNCC;:4>3O+H*$J'\W%&=7U1)D$9$ \T2DL9/$ULD4)#/O(BMCE3ZD?Y#1K.Q
M/O5V#%\JRFW[=A:N\?KQ,WI:/\K2;#G6NL</:4M!)=Z.'"4U+V 06LJ='=,K
M:V\W.GY?26HKXG3D@$?E%M0OY<YTOOOU')V]D1T7EN4;4OM^BYC%UW/=9L=4
M=H[BAZWE>9YJ355T?*9K[+PO?I!"[,C*C[^9\+S)AJ"20<4><.O-1/"\K>E4
M2C%[P:E;/* '\ N\ZVR(YH!K6ZK4G9R[S!W5^RW_ !'(RUN5N<(!=WE69?U
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M5V8Y9@XL&9*6(J2$-*WQS[G5V7X@!MH(G]'>;QU-;;9/)EAZ0S:UUCH:;5=
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MET0*S?D[JL"LAT)'D$G2,N!DJ),-,ULT$B?5\/BD:CXW(K5_EY#9WG@#P!X
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M108D3[?^925/A_E59C%WIIS>#+<SZ;2J/#R_WT<'\Y7W7C_$P*8TWG'5^K]
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M6ZH+>FOZBJGH3Z\L>T@(&&:,X&:![2G2*L:-C1L*N<LJ_P"A\?7\I]/@$?\
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ML]#G(=),3H$.LW6914\I<Q1)I9HDXQ\UKTA<B^_@#P!X \ > / '@#P!X \
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M:!Y(S96#D20L=/ V9&MF;#*YOW(FS(UJ2I&YK9&M:COE$3X Y'@#P!X \ >
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MJDD>Y551#LO '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \
4> / '@#P!X \ > / '@#P!X!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g96389g37z45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g37z45.jpg
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M 0$! 0$! 0$! 0$!_\  $0@ F@#U P$1  (1 0,1 ?_$ !\  0 " P " P$
M           ("08'"@0% @,+ ?_$ $ 0  $$ P$   ('!04"#P    8#! 4'
M  (( 0FW"A$2%!8X>!,5,3ET%Q@AF-=4@24S-$114UAA8W%RE;&RU/_$ !T!
M 0 " P$! 0$            !!P(&" 0#!0G_Q !,$0 "  0# P<)! 0+"0$
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MRZ?F8P,_G,NW],?+OS5[ P."[7\H23F"!@# & , 8 P!@# & , 8 P!@# &
M, Q'\6 ?G\241_\ >8;_ /3GH_@E7_5JC_)F?_)\O*2?^9*_QP?M,MU]U]UU
M]U]\]U]\\]U]U]\]U]U]\^OSW7WS_#WSWSZO?/?/\/?/X9Y]-3ZG]P!@# &
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MVP8C & 1C&?SF7;^F/EWYJ]@8)X+M?RA).8(& , 8 P!@# & , 8 P!@# &
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M>5K.R:RX=N;.F?!@, 8!&,9_.9=OZ8^7?FKV!@G@NU_*$DY@@8 P!@# & ,
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M4_YDW/W]%;_R3L3+CY7/,#&_3POQ>A-2V4Y]H_1J>ZSCO%SC MX8 P!@# &
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MX@2%6%8&447I-Q:K 1;C<PV;-!QLU&6?5FGQ71KVYWZ7GUEMV#$8 P!@# &
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M((1X7.79[-ZR8/?4]47Q$H.XN=&6T%#Q36+K@!&*CW!IM 6D(YW/P;9@75C
MD#N0W2/AXG=KD<N4 FE^RRL\[Y_7"U^B;-S=-U-;%;V=5@(=7,'G+V!1CMY6
M+YLZRTE!E:5\T?,49CP5KH?,(%@2L&SF.5D8&=&R=&(>/9(4G(R8:LI)L&EL
MOKZ]Q'KF0M%ZGL*8,9<<)*H%G08\&%:KJ"G.^+%&# A=3<)*-+*)G-D46*QT
M&20#"*E(2-;CHDK)RS0NF5"LPGM8H;:Q@-W^K6ZE;A]66=YU?WO*9_V6[O\
M*SU#_H[@@AOU78(?<LI7,P.Q!J>#X<Q-V)!2UI4=W0 U^8212L'*CYJ]G*[I
M CV7(*_1&IV.A(LC!2B,<-3J9=,W(]),4'3P2G^_HU3^-^E&<T-T?5U"U.,
MEADUNS1,_(SE4:AFG._8$J@E[+ORZPHFIJ\D;#KB0,BYL"AC%_'PO[T?^/E1
M\6?2#.&%1>-;CX_,,.]%##O0P[T26]$[0PW=KQ/-I*]V[/)-VX$-Y-I-V5[*
MUW9<-%=O2[2N]2JHRZ0D)ZSR0C8\V]J+OIZS%S:"Z/D>8^XV%Y5J,."E*?9
M M6T5#[5V^BA2%T_ T$U3-!D$GH5NVD+ K4L=OBMJ4[%_%Z7_>'9S_OJG_\
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M.!XG(%SN.=B4H1S4FYV;:Q<*[7&2:LT\UGE9:M9/>U5G9V63M;BRUS!B, 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8!SM6EOW99'Q'.JV-&'UHP8!S]:G%T]O*N
MKQ?1--!57KUF%V!>@B[YQ1#2IQ<,M9PRT+(N'UAEX-Y%%DPQD-99FJAZIL,U
MNI9\4^&=\TL^&:^%^+1&FM_BW=;=".:_<^6=0M7AT?TSP"^FSN$K9NG$2%4]
M1[W]%E-;G2+/JFTHV$T%I^LAR)DWLP3 =A(2Y"W'3:O:R*F#B!6$N!)9)WM%
M=-Z.&V>BRLWPX/,RJ@?BM]=>'7*E,J!=?.8TY950K(H63*/'ECW5&6=>ENAE
MA$E9%]B]&PATOY2(P(1D@O$#U27_ ..WB+UB;$%3CKT7D=A&ZFF\\MZUL]+6
MO9:/I;Z\[GIY_P")OWV44?4Y>4V#SC3&]AUS\-GJR1L$7ID^CARKZWO_ *UV
MI.VJ_L+PVOR5:RXO&Q<=&F)*9:S(,LS"'!@%::P\B^A;2'1ENPWRNU>.&U\V
MU"VFK+CHM;OX'53@^0P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# 'U>>?P\^K^/O^_P!]^OWW_?[_ (^_]^ /J\_C]7^/G\/?^CZ_XX P
6!@# & , 8 P!@# & , 8 P!@# /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g96389g41w69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g41w69.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2_@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    +\2^$B*#A"24T$!       6!P!6@ #&R5'' (   ( !QP"4  (<G(Q-3
M$Q.#$< @4 -TUI8W)O<V]F="!7;W)D("T@26UM871I8W,@+2T@4F5S86QE($
M8M,2 R,#(P($9)3D%,+F1O8W@X0DE-!"4      !"NQJ$8$JV_O)_[-.="U0
M>=.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M  4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<F
MEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0
M!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E
M!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G
M!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V
M]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
M!,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F
M]O;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6
M) ;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M          0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M              4G-L=%5N=$8C4'AL0%_            *=F5C=&]R1&%T86
M)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B
M-2;'0               !4;W @56YT1B-2;'0               !38VP@56
MYT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W
M)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M    UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M     X0DE- ^T      !  ?P    $  @!_     0 ".$))300F       .
M           #^    X0DE-! T       0   !X.$))3009       $    'C
MA"24T#\P      "0           0 X0DE-)Q        H  0         ".$
M))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M    !P  #_____________________________ ^@     ______________
M_______________P/H     /____________________________\#Z
M#_____________________________ ^@  #A"24T$"       $     $
M)    "0      X0DE-!!X       0     .$))300:      ,U    !@
M         !D0   ;X          0                         !
M        &^   !D0                     !
M   !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M!28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $
M)T;VUL;VYG   !D0    !29VAT;&]N9P   ;X    &<VQI8V5S5FQ,<P
M%/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9V
MEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&
M]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   9$
M  4F=H=&QO;F<   &^     W5R;%1%6%0    !        ;G5L;%1%6%0
M !        37-G951%6%0    !       &86QT5&%G5$585     $
MYC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
MEH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M  "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'
M0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $
MYO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M      #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M      .$))300H       ,     C_P        .$))3001       ! 0 X0D
ME-!!0       0    $.$))300,     "5.     0   *    "0   !X  !#@
M   "4R !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E
M)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M        $  /;6  $     TRU(4" @
M                                 18W!R=    5     S9&5S8P   8
M0   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@
M   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G
M5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P
M D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#
MP   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87
M)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M         2<U)'0B!)14,V,3DV-BTR+C$
M                                       %A96B        #S40 !
M   1;,6%E:(                     !865H@        ;Z(  #CU   #D%
MA96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M       !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'
M1T<#HO+W=W=RYI96,N8V@
M                      9&5S8P         N245#(#8Q.38V+3(N,2!$96
M9A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#
M8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                       &1E<V,         +%)E9F5R96YC92!6:65W:6
MYG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F
M5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                        !V:65W       3I/X %%\N !#/%  #[<P !!
M,+  -<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                    */     G-I9R      0U)4(&-U<G8        $
M    4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &
MT <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP
M#@ .4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6
M<!;@%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"%
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MH,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9
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M4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#
MP,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@
MX.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,#
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M:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!
M(1 Q$ /P#<S.L=6R,C)R&9%F.W'>&LI9HUHWFK])^:ZS3])ZK7KI<3+RL_ZO
M\ VD6-Q\FVEX%Y'L8X;Z_M&W3V>WUMFY++^K?2,O).3=2?4<9?M<YH<?%[6$
M*YD5EF$^K'8!M9LKK;+1$;=C/3+',]OT-CE/FRXY0 C&B/#_F_UFOAQ983E*
M<N('Q)XC?S5^B\[C=#ZB^O3K7KO'I.QLH6VD[:V?HF64MR/0O997Z.79:_\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M2$RO(IPJY!JY\ )@TX1,9J-FF#^$AB^])-([ ]J>TMSVBAT[5M7EU6SU"&Z
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ME8HX+'@R5S8(' S#N9(,^&-\;D<GKS*:EHNF:MI<VC7UK'+ITT*P&W&8Q&B
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M895E(P5(.05(R"#P<G/6L/@=<^+0-L',_LG3GY.ML(+2MZXL;:W)Q8A A+3
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M5R7,,<\-N[XEN-_=+CKW:EFR?#@'&>"00.>*\[?2[VYL+[4H8MUIIQ@%S(6
M*^<2+$FQ3S)M=T[P+DHKJS#:21A?N." K4Y^(J&.>**@LY(62QM<WWR6(+2'
M-]S?1[T9&,B^ON6%')[?;\KE?L^DLRVMP48J6GC!(.#A8I"N3U R6/ADCG.,
M#1-? :[M X!46UP5SC&3+"&^/ V8SG;GC!;G!-*.-)"00^*)Q$%EGVPSJUJR
MQ-@J<Y],V-ZHJM1K?:K41?1_N57(Y7N5<Y<.^X!2P5H[C*C."&FN=^0#CDDY
M]0Z=.-<A56); ++-9@$CE<6]G@ D9Z<^W.3FM@;?Y%OK^GVI_P!7-#KIU6-H
M>M\OJ+%;2W30J6L$0_\ N;LM?1C?%#[E9_M&DO*\+Y/U;O?-]/\ +)^"2/<C
M6HBE4+\RF#_8V']TKL;_ $JXI3\RF#_8V']TKL;_ $JXI3\RF#_8V']TKL;_
M $JXI3\RF#_8V']TKL;_ $JXI3\RF#_8V']TKL;_ $JXI3\RF#_8V']TKL;_
M $JXI3\RF#_8V']TKL;_ $JXI3\RF#_8V']TKL;_ $JXI3\RF#_8V']TKL;_
M $JXI5+Z_J!\YV)V%GJPFW?4!U.--&%M;VZOG0$GQW/U;X2;P^Q*C2?Z>'WQ
MLF2/^-HK6-7U55/5[1GZR/NK-G%*<4IQ2G%*<4IQ2G%*_%5$15541$15557T
M1$3\5557\$1$_2O%*U$U7VOG4CZWRZT6AZ^UU3FO&VG/UN"/$) L2O(7$ =B
MZGIG\HL$(BCM#:5V]CKC%P#6<[7Q_)5VI+H@K,1TCW]7O[/756T\=.?JZ=?5
MP0<GV^JJWW'YS>6G1G6.4[&WWA11U[--V3@^MTK(/(G-G.&LNUM!D\M@)6SA
MY*;Y/=?Z6>MU;9(H8J1]5(573WH14$_%0 "<9\,YQ[,GQK)]7]IUXE@U&J;V
M5V96X;5]99>\N^U:Z"@[#T&2H;/"W--D^TJ?&[X?#B4/:*=<;2[$S>C(P[K6
M<*=RD%@B0PEJ*H 3T&<\#&#]G3Y<=#7,K[4_P;#Q%CV#/V]<?<--J=CCKL2'
MJ'NDK64=OU_G:;7[&:[PHO7LVTJ*.@RNBH=";I+"A'H$J[BNGBL9'DQQJI@Y
MQQ\X^W./?V50I?M1/&;*&;EW:&V$S=76;R3)=?PYO&]T;'6ZH03I_#=R6$E[
MD >J1[;,Z #+;86T,I(F6\ =2QLIMF-:P7%/4J8]SQXX^;/C]W-99K_M"/$&
MWW>"ZYJ>X0[/1]EA8 S)S5^6W!6;F?VK1$:;K2LN=C%FGY/+WVZH!"+3-9_3
MW-1<V(\;$C!24@6.=3!ZX^SP]G7ZJF=Q44XI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*5!_R L(J[>D1F5%A9C'YVHD8T$&:R:GTQ%BBK+$%&3,+(R3VO'F+C%@
M>]JOA)5\$OQZ/VC]&^3.1O@C"D9/(9N<(&*D'&&;:,GT6X)7LG8.W-QHP:.[
MM[>2&]N5(FF2W;$B19*M,\22*4)#I$TKXX>+:Z[\>=+V)).^Z^&."M)[B6S9
M)8W1T_WDTI@N-MY(VOT/U)H=BZ&-[F1##V914:K.Y@S(6$2LM=+,AUBV61B\
MF[<Q>0R' MW;^$W,CD =%D+#)(7 8UG.U=M%'V?U^6*6U6W2 I!:P(;<Q=YK
M-FI L.[@FM@2 SRR6T43;54REVC1I>]JUT]G<]9#,IDM Y]:X:UE1L2(+7$
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M=<_</?CPYZ,C_/&[6_\ BXO_ !&1P>B_%]YJ%_C?_(_=71G/Y[W9?_1_ _\
M9W_(JL]%^+[S66.*BG%*<4IQ2H)>87@MA_*8>#0CV#,9VA55Z 5NKB":4':A
MPODF%JM*)&Z&8L6&269HIT,GUH#9G>QA4#$$=T7L-Y1-0['.ULT1O]'FE[R:
MR:38\,C *\UH[!E1V 4O&P[N0J,E&)D'*_*)Y+=+[=(MVDJZ;KD$/=0WZQ!X
M[B-262"]C4JTD:EF"2J>]B#<"15$9UG9_P"QU[A)N8H-/V?U]44+9D0FQIQ[
MZ[LG0(Y/<X.L*!I8'RN9ZJUI-D,UJ^GJKOT+UNY\NNAI S6>D:G/<E3LBG>V
MMH0^,KOECDN&"@]2L+^P>-<4M/\ 1S[1/<JE]KFD6]J&&^:V2[NIMN>3'!)'
M:J6QGAYT ..HYK=-X\^.W7OC7A(<1@@WN^:9#;_0GLA==Z2S]OL^MLR(F,16
M0L58@@X_08*%7,A9[Y)I)>!=I^U&I]J]1;4-2D VKW=M:QEA;VD.<]W"I)Y8
M^E)(?3D;!8X"@?2O9#L?H_8O2ETO28R=S=[=W<H4W-[/C;WLS@#A1Z,42_@X
ME)"C+.S9TE>L<4DB1OE6.-[TBB1JR2*QJN2.-'.:U9'JGM8CG-:KE3U<U/Q3
M7*VJHP!>4N=BZ)[=[ZU&*VN7I.E[+MD'6Y;Z 71ZY6=1V5J#<3 U^8*M!R9+
M&.K>8)#&4]!HID^OE';"0^*"<#-2!D@>OW]_JKUWWEYT5DU*9L-#I<=*)C)]
MX^+6=;=DYUY&?#@K2;%U:VVR8JV]I617%=]Y4=2AMP'(0L$P+9X"8H9J/?W^
M;K5.-\TO'BLLRZ>TU6DJ[(*H6WG%M.LNSJ]Z.9)B!B*)BEX^)LNO!L.R<'46
M6-B<_45MWJ:FE.J1[29PC%*\@GFCTK:&;(>E(UMF%BNG&=U66@_(G55V9ESZ
MW.HS\M$R^M:D*N&V(UUD[.J(S)TPUJRQ9,"T9YE?9P!*G'3PR<<_:?''/!Z'
MPS77K_(S=X>OZ!?9]*%6=MW4)3!V<-;N*$ '$:\K'6>RNJ(R6]@KS[,*F I;
M.)EM"".I<L4,:A#R2NCB5%6#I?.4?*]8TO<MWU384/6FUU68SG7NLUG8O7F4
MJ[X/4&6L .BT!5S;P"8BJ>'5?>L"W9*R2A' LF^E,?.+ Y^7X_OQ]U/BYY]O
MZO&LOP^5O5H?4G4W;NKCUV1K>X\X!HLIF"<9IM'LE87EW[$L(G/XRKT1OS5.
M?@+M+$J&.2OBKPR#T+<(WY54KP6'FKXR5A=X*5V@"K,_2LOCK(6CU!](0&X?
M*&2C4UX#2$U.@N@@MQE#+#.T1EC? "W,$Q5=$V Q1E*[.R?+[I_J.TQ('8";
M[.A;K%WFY!NR^L.P75U+549=$!(%JXX<Y)8YF]-/T5;7@T=P")9S61 U:X9A
MYU>.4I7>-Y8]4LD<EZ3?T$$_8U9UD 45C=X^$7178&#)I0=M([)CP];6ED=V
M+FZB&JVDU5.TXQ('R)./905ZE9'Z2[.B[EZMR79D-._/QZH4\EM/(<VR>%]#
M;V%2K'',%":1\C@%G1R"Q>Q)4C]'*SWN4'/L^.LJ<4IQ2G%*<4IQ2G%*<4IQ
M2H9=N[;9T';\!-#<%-'RE)3G09F>R/"S=ZVU;<1V8ET,$KXI92HHX&A6A(-G
M+2$#P&!A2JT@<I5))SQX#/LZXY^3/K^+BK6R/>>O[3[%ZEOX&R9#-%VIE2_*
M@7)=I%<QVF7M323-#,\.K%)>&4(*E.)'7/=7R"RFML95LI01'O\ '3=D@<]2
M#ZN 3U^3X^>GJS/WAFC+:_PY-<57L.L7V.:@"L9#(&RRD_!8PDQSA 63HXX?
MI)HB/F@9$GU [UGC]CF28'5X'DFLVB:/?(7@"2,Z@DCO%8%$DX&U@VY0OI+E
MA@9Q&J6[S26IC9-S,\01RXR3AP041R -K!B1@94Y!X;%EAT]>Y*QSPQUS1O!
MT%WF0G&))91D#6$(%8,5"P=*Z6":%TM4Y09YS0OF<5%%)%"^)5EQLNES6SP(
M\L'=3S6R=YF0%'58U90G=,K!C'A&:2/.X @'K8OI<D,D(>6$I(\"9_"!@R(@
M8!=A4C,?HEG3.X @$>E.%$]$1/V$1/['-PK9Z_>*4XI3BE.*4XI3BE.*4XI6
M*:G^?/M?^@.%_P <;+D^ /M/U8_75(/+#U8^L5VY'^>-VM_\7%_XC(X/1?B^
M\T7^-_\ (_=71G/Y[W9?_1_ _P#9W_(JL]%^+[S66.*BG%*<4IQ2G%*<4IQ2
MNDA(U'G25SV1+#*DCHGR1R-C5CO>Z.2%6S1O1OJK'Q.;(UR(YBHY$7D$@ D]
M ,GXA4$@ D] ,GXA40^JL5XPV6:[BZ?Q!U]J,]OR=;/VQG=;M.S]5]67NH9A
MM=$^PWEU8ETT]]%<R$'"4IH#Y7&-L61->L9"8NQUO2]2FG@LKI9IK4XN$"2H
M8FX]%S(B -@J=N=VU@P&T@U86FJV%]+-%:W"RR6YQ,H1TV-QPV]%7=R#MZD$
M-C!S5$=XL>)9<1_;UIF;^WF?B[0<VZU>\[4N;-,N(#5"7,SJ[1:<HR,HH7)U
M3K$YHC+.RF C*)GG)FDEEN1?VOF;7QD*VR02W#,Z.CB&$,9',3*)/1"GC;D\
M8'(KW%[;FV:[WD0")YB61E81Q[B[=VRB0;=K<;0?9S5GC>"_6&^[#[#[+UFN
M/W&&[@=:ZDW!_#;T/OFU<N%NZ@XRWK]/&Z!V9(PU!894NBH<K>B%BC%V=Q9F
M#RSD^\,T=Q%'-$X:.6..9#TS'*@=&(."-RD'TAFO:.5)HTDC;<DB)(IZ95U#
M(2.HRK9P?7TR*R\7XA=(3IE(*<:ZIH<^#E,\0()L=+8"ZS(8G?L[.KLOJ@;6
MZ.#T4*[-JV!]O;#'7[P#[RE^\XZJ_M1BO3</ CG('(YQUQ\7CBJMP)'().<<
M]<=<>O'B/"L^:/(8[6GY.TT 0MB;B+Z?09B9YDT+:V[=4VF?()2(<B*$IR5=
MO9!2#&,(@8A#GK"DT<;V-R_RAU(ZCJ."/C!X(\*;E]8\1U'4<$?(>#ZJCN3X
M_P#C!UX4(RUI31:IUW-O*NHO]CO[WK_+'Y9QEQ,13YVXOK'%XFJCDORR74=;
M7U--9.)<UU>3\$3([6YOK6T*BYF$09)I-[!NZ1(%5Y6EE ,<0"L".\9=^<)N
M/%6\]Y;VQ43R",,DK[V4]VJPJK2&20 I'A6!&\J6Z+DC%>?6^,_2O:E-UMB(
MBM)28CHC27PX%!1Z79YJ8A;[(&T[J0/7@7M5HV4D%7JU@CAJK>>ME!>N<<Q
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M7ZM76*LCEK@5=*.P25RB#JZ42/\ ]F-(JQ^KQV?[R%RK&W]9J<4K]2MKFB.
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M&YT?6\%CY/;W:8+:;K89^QT>%S5MF:FF2NT555V6@RF;J+$,29;.CKEG*&8
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M*?J3S1JR&/Y3*0Y$B);]$V<@,E2VSPM'^&5?IOR8>4;3YK"U[/:W<K:W]M^
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MVMPER\MN<BXN(%W&9=L:RY78KME&4@*67!RF1MR17K9V=M*DY>#'X:>( [P
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M^&2:+Y9'S2)'6EL1\K_3WRN1L"(Z1_HBO>OZIRIZJJKR@Z;>'&0AP !F>,X
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M1QQNV#SC>N1QD5R&R_T<(EN5;4.TK2V@;)CM+$13LH(]'O)9I$7(R"W=G!Y
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MM2EFBMH3NMXI)I3("BH(P258D<.Q&U5/);C@9(IU77M,T>&WFO;A0MU<0V\
MCQ(\C3L%5U53EHUSN=QD*O/)(!DJ,1"8,.6.[WP%0Q$0/]%3WPS,;)$_T7T5
M/<QS7>BHBIZ^BHB_AS&=*S'6K2M-[GZ;6TN-L)I1[.]"*-$(D;''71K!*V*
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M3$T."C.Q($L5.+E5HB9K, A-&\:\Q\, U>WXY9A%M%C'L!/OB*GBCACC?9R
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MK$7/"^86..T8^:09LSH4C]',598T75M<L+B[N[8V^QBT+)M9U0C:^2V&8%E
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M6!3*DDDD$Y.3FL;'I.G17:7T5I%'=QSBZCGC!C=+A9!*LJ[2%4K( R@ #C&
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MJ,GQR?\ NW__ "N_[N;?O_\ ='_:_P ZTG!]1^8T^.3_ -V__P"5W_=QO_\
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M#QBU&IV#Y9+*FQ8(4;&"R#'&M;+;A"0_#7YL<YSF1(HS)/KN_P"P78*&VMM
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M*HH8N79@>24C*!E0;E&X[Q@D[1@@CD$6=IO(0'X@I\,*VWA%F;-HI;< \&*
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M,%S:QYX/X*%,9)&"S9U/X<GF4+J%K8ZH>,RWL4HNFQD#?>VD]K=R$ XS+._
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M=:T!9SP7['[)M>S *#58IU?A-7<YZ$V0NU898Z'/659<5]<;6RU4#JJ"R$=
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M''Q,M?%66T%>1!#:OLD/-AA'BC.*@8V$4%QS2E"BE-^E4?ZJ5)'FK[MW>0=
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M_A8E!+21#?F1% )+)N4 'GBJS>6B[,W5N.]0R1?AH_PD:@LSQ^EZ:  DLN0
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? -X'_P"<^;SW,GKMOHS?_P"BMN[M_7#_ +D_M:__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g96389g44v90.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g44v90.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1184&AO=&]S:&]P(#,N,  X0DE-! 0
M    %#R^48 X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!7\G\         "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         /4   )<          $                          0
M       "7    /4                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   /4     4F=H=&QO;F<   )<    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #U
M %)G:'1L;VYG   "7     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      )Q@    $   "@    00   >   'G@
M   )J@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
M00"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($
M!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"
M!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,'
M)9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*S
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
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M?95%<S3.P)^/SHG2M'VVO+<F')14L:IWZR>]N9Q3(C&#M_#B@.]_M_/)4@$
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ME;+F(B>5+WX*]]]^2D&B)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+Y(A
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M*/C#JHQ(?N0'@9N5/@S83'$,8;5;6JQ6Q_4L@\.4LJ Q-<BMCWM(+Q/LZ#7
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MUCQMU+2_J39K:JV_9N"J*I-,&A,0D)4%7!=D=JJ+#FIK\?I^_<*;_37YWO\
M"RENJJFB)HBK#<S:'"]U:YN)DM>06$)2<I\AKG%@W]+)45%'ZZR9[7VD5%4'
MHY$<>2T1LOM&TX8EUV8Y7@\SI&EBJ0<0#[.J/=JTC_N8\7'43!$@@@D+9_#/
MB[.O"F)=6RS$ X>M#<9EV):*^7XZGNS$X9\TW$:LJ "I3>&OIN:YK2-#,YVI
MW(VL)YZU@R,XQ%M2)K,,<KR=MX,<>>%R7&X@$]ZB(@]]A0-/L/.%YJ83(&ZO
MFF:^%\?ETU*+78S"C_F4V_YU-MO^+1;=T?[J0,S_ ,-H:2O>,C\4^&O%8:S"
M8BGD.</'OY-F6(#,'7JNU&5YI6(I\#B#PX;,7TZC&@?^^5WN#5!X-E"LXP3J
MR;&G1C/@7XCP/-][:J+@][9?(ZT:*+C9(AMN(H&*&BBFM@[@W!(D'0@P?4$$
M$;%=QB<-B,+4-#%4:E"JT":5:FYCPUPEIAPDL<#+'7:YL.:2T@FU,5W:S;$D
M;:@6CDN"*)_P?8*LJ+VI_5;$R]1CE/ZS)MKX3GE$UW> \09GE\-IUS4I#_DU
MIJ,CDV3+?_25JN:^$\ES8FI6PHI5G?\ B,/%&H3S<6^Z\C0!X<.06P^/=2]/
M(%MK)::57/<"AR:XAEQU)4\EZ#I-N-@B^_Z9U43GA%X\[=A/&N%> ,;AJE%U
M@7T3[1DQKPNX7 3_ .9QCFO/\?\ TUQU.7Y;C*6);<BGB :50 & .-H<USH(
M/Z&">FES4NY6#7X(=?DE;WKPBL2WQ@OBJISV^G+5KO+_ ,4IHOA$5?&MDPV<
MY9BQ-'&42=VO>*3@>45.&8_\LCJM-QOAS.\ [AQ&78D#4/I,-=A'^[BI<< _
M^8-.Q *FC+[$@$<CO-/MK[&RX#H+^P@4A7^.NR:YKA+7!PYM((^(D+IG,>QQ
M:]KF.&K7-+7#S! *Y5YH7 9)UL7G!,VVE,4<<!M01PP;5>XA!7 0R%%05,$)
M44DYJQ79HB\\B7%B!ZDN3'BAY7OD/-LAPGNO<X0IX^OG6#ZC*8E[V,%[O<&B
MVMR0+;K-E*I5/#3IOJ.Y,8YY^#02H3;;H8%2B:S,FK2,.41J(ZLYPB3G@$^$
M%X>[E%3YC%$5%Y5-=;B,[RK# FKC:!($\--WM7'D(I\0D]2.J[K">&<]QI H
M99B8/^JJSV  YGVQ88Y0"3_I!5/9!U+TL9#:QRFE6#J(J#*L22)&0O/"_#M$
MXZZ)<)POJM*B*J\<:UW&>-<-3!;@L.^LZX#ZQ]FR>?"TN<X?^IIZ"+[?E_\
M3;&U8?F.+I8=EB:6'!JU' [![PUK7 :@L<!(O-EKWE>[&;9<CC4ZU<B034D^
MSZ[F)%[%15[74;7U'T05^4GB<)..%76HX_Q!F>82VK7-.D?^31)ITS<F'<)E
M_(%SG&-^?H65>$\ERDM?0PPK8@1&(Q/^;5#A%V<0#:=Y!# P6FY546-C!JXS
MLZSG18,5M4]63,?;890G" 017GB$5-UQ4$ [E-PR$0$B5$7I--_B=3H-=_N>
M96V8?#5\54;0PF'J8BJX.X*5"FY[_=!>Z&,!AK& N<Z.%K6DDAH4VP7:G<C=
M4FGJB#(P?#W53U<PR2O-JUFQ^>"7&,7F@$E7%17$:LLA9BQX[P X-/:Q'A<7
M9<J\+YAF!94K-."PAOQU016>#O2HG2;^_5B" ?9O:05TN>^*?#?A0/IXVO2S
MW.&"&9-EF)#\)1>(@9KFM$FF&V:78?+7UJM1CG-.,PE5G"M]=L]HL+VJKGHN
M-P"<LYZ@[>9)9&LW(+V4(\*_8V+O<\0#^I&AM*W#A,(W%B,-1VFVQ]*R[*\'
ME='V6$I!I,&I5=[U6J[_ '5'GWCT$\+1#6@-  \'\3>+\Z\5XEE7,\0&X;#A
MS,#EN&;['+\!1)GV>&PS3P-)_55K.XJU>H7U:U1]1[W&S]=BM76&NZLK*.T4
M9U(MG!=^+JIW8IK%EB!"B."BB3D22VI19S"$*2(CKK?(DH&)%V4UF-K#]=65
MBRF'3B6,$R[W(-A'04D1C+@>\4Y!Z.]V DJ(['E@*-OAHBRNB)HBB_'VMD;H
M'\\#&18X#^HYD$]GXE5=%?<JNI>ANQU1.Q3N3->78S:ME-^@^O[#Z]%*-%55
MFYFRFUN\:XNNYF%4F8KA=XQDN*%<Q E%0Y!%=8?BW%:IHJQ;"(_$C/QI3?#K
M+S#3@$A BZ)$]^BK>EZ.NG3'&:%BCVVJ:QG&8\ROI&X;DF.,*GGRZBPET0(V
M\*'1/6%#46!5+G="6; 9D^EZJ*2D)G7>_KS6!'H0Z2FZV)2L[(87'I8<25 ;
MIX]<+%6Y#ENRY9QY,%I1CR6F;&PL;:*+P&D6VL)MBQV2I+KA$WF3-KS)MY_S
M\EYXVV'3Y<[A.8]DFV4'$MP*C.VMP\6?EHC/YS6M+A-%MM39IBEW&5MJ9/;V
M[P_'\>GU)+'N:J'2%'<B2*R-&MIC:+_QOR[TV4@=]Z=-%=^TVRNU^Q>/2,4V
MFPRFP?')4J!-?IZ**$."<NMQZEQ:+)5D.!5\:/'J>";O'>Z$-LG%(^XE*JTM
M$6MV^^VG3W>RJ//]Z,4ILCLJ (E5CC,Z(]:6%JZQ?UF45E)74;'>=X^UDM/5
M7<6*L=YJ%-KV;20<:/#=E,D_?]^]U#\*Z/\ ILD4=?93>GS%:*1(IAJ8]'?0
MX5S,I<;:"/'IZ!>[XF)7QJR%"AK"IX+KT*C>1QF ^XB*^X5)O,WUGK_*[ Z"
MND-M^9*;V)P5N79.SW[.6%6"2;1ZQKLMJ)#EB]SWS"&KSO+J^.KZG\-$O[%A
ME !\T4@)&A([_8?!3+$NDOIWP/**/,,/VLQC';W&KC),AH9-5"&(U5WF6O7;
M^0VT.,UVL,SK(\CO!?> $7T[26V*(+JIHHMB]$7FF0X\^*_#E-H['D-DVZ"J
MJ<BOLHDG! 8$B&!BJ$!B)BJ$*+HBP&,VGQ;<ZIE2!=M\?EE6V*%PC[@B N09
M[@(B"*6,$V)@HWR ^LK?*&!"A0?2QVO^^JE&BJQEW9MTM-;W#H*XU4UD^S<;
M%>"<;@1791@B^>%(6E%%X7A5YT31?G%D65WV82!F9!8R)WZ1QYB.KAA#B(ZJ
MD@1(HFC;((':/A%4D1%-57GG$&2>0M.EQM'K;4=>6,<4ZZ\[6,:=8FX(U7UC
MN8W^$O?'T4^4PVVZ$N77"Z3D2P;97O>8?CFJM$;S0FT#JHALJXA@HD"*F201
M>#L(D0;Q)@<H/E;9?I% EA/@PYS?]',C,R X\)VO-BXGNOGW\?7C]^BRU7LT
M1-$46E64JTF.5-(YZ8QS0+2X04-N(J*BE"A<\@_.(5X=<X)J&B\+W2>18)WW
MS[W6/@5L2PM)@M-J=56R4%XW")URVO&217GY;IJIR&Z\D%EL'.!&4+IHA"+2
MB4$R>5H^<_;GYS*G.BJ:(FB)HB:(FB)HB:(M:MT)JS,R2*A+Z=/4QVB;7RGQ
M%@:RD>#^ROH(C1<>^N-YT'/6_P!M/X10!JTDU5G'G0Q;.7!8,XPOBAQV)L\O
MA($PP)51PHYC()L%\*?;W(0\IHVTF+1O^PT]+;;H?Q]?NI9$W%S2K?8E3+D;
MF-\3&:?A2JZNCHXW(D-L&K3T&+'>!T?40FD[R;Y'M(%0N4H=) &AG>]IVV_'
MR+:8"[A N%3N%"X7PJ<HB\*GGRG/"ISX^]=9HOK1$T1-$31$T1-$31$T1-$7
MEFPXUA&=AS&A>COCVF!>.?**BBJ<*)B2(0D*H0DB*BHJ:(L122Y".S:>>Z3L
MVM-";?/]>97OJ119"JJ)WNMHBL2%1"X(6S,U-Y=%!ZVYQ?X?RI#HJFB)HBC%
MN\].GQ:"(X;0O LRW?:)1-JM;) ^&$Q7EMZP<5&$7D#1CUW6RY:X4BD,=AF*
MPS&CMBRQ';!EEH$00;:;%  !1/""(HB(GW:(N[1$T1-$31%PJ(2*)(BHJ<*B
MHBHJ+[HJ+X5%^Y=$!(,@P1<$:@\U3>0[ [59'/F6LC&&*RUL$%)]GC\B30SI
MO8/:TLI^L=C$_P"ERJ@CG<B$JK[JNNHQ>195C7.?7P=/VCHXJE,>RJ.C27LX
M28O'F>:W++_'_BK+J%#",S1^+PF&G^WPN8TZ>84*'$9?[&GBFU13X[<7#$@
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MP)$?"%9<S/11$[CCBZWZ3KH(A$C)=BNJ*-H;:DACF?"V'<"&8][7F>$U*/\
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MM&*2DXRW+DF*,SB% 88"0J(3H"NNLS3,:.6X.OBZD5'4&2*+2.-[GD-8"+D
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MU6S97XU\69-(RSQ!F>%#HD-Q+Z@$" &BM[0- %H: .BK"?TF;/&#IPHV54+
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M%'$3 J2:KL>LBS9DBUMWGW@+T/627,?JL>1PR1&8L(7[<6_T<6?4OBK84[$
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M !XY_P!NHJNY!$?813]B(G]R:(N51%3A414^Y4Y3^"Z(NDHL8^>^.R7/NJM
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M_AVEMB?A'W*2[<-_^8G_ .T+A;3+/_D''?\ \UV:?W8=J6]?+[S]E?>Y"/\
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6RNBJYT1-$31$T1-$31$T1-$31%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g96389g45c23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g45c23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[14F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %0J^4X8X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!7WB3         "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         ,L   ):          $                          0
M       "6@   ,L                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   ,L     4F=H=&QO;F<   ):    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #+
M %)G:'1L;VYG   "6@    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      *E     $   "@    -@   >   &5
M   *>  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #, ET# 1$  A$! Q$!_\0 '@
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MJ^H?2CB_5+H_RGDW'?>;T[]O_#_:#'2;D374[FO2/>XETBY)U!ZFI=4,GGH
M<<9X'@<UYWSMW6W^'/<57Q.!L(/BH5T304_/SR/84/Z_VOSQI:%>?Y2;L5=D
M415@4*^Y!^A]V_2Z;I>C1I>C1I>C1I>C1I>C1I>C1I>C1I>C1I>C1I>C1KRB
M5YU[U<SW=]0^D.AUXX5R_@O3KI!Q/K?_ (=XK[940\XY>GR3F/)\*W3S)>?Z
MW*YB>C"F" 27(G"# 1MJ3.*)K#M>II:'3?-]5=QV[^WVYUL[1_J/=-^,<4ZK
M;?/^C77S@G*NC^_P+C_).E;F5TKYCS_2-U..DKPAKC4]+NK?/.%:P=AM]9,B
M=^9J;.8U) :F6G85^QH OL1Y\\BKX('/@_3ZWQJ-Y[_4AP.G8VJ[OM;]T1=7
MC:7!7.IF$D/VY#T>D]^I>JMD\(0YD;7]QF3COO;9'%&K#X-J\Q%E*,4_6#H-
MU*H,[?O]^^BN_/FA=B_J"0!7WK4_']1;I3?GX^% Z==66,ECJ&QT=4ZBAMTA
MGAC?6!9([-^G85"=7!\\AR[BQ\07+R\)%TTOL#D7^-X1M1^QHK@&QSXY[>_:
MB/L2>#QJ9]G_ +PMKW!]-MKG75CI1L^WVF=S?DG$LI_G')NE0^/<K_1MAO-I
M7 +QCJKS?5KH*57J/6%NI88[N6F<:=%3L>#2?G?UY_W /]-0O+?ZBG33B'->
M;<<:Z1]>]+AO2_J+A=,NIW6K,XYP*>E/!]WDT(1@NNMZ'4G/YKR#">)I*#8T
MN%<)Y/\ HUBUG>!ET(*Q#11_+G^FCW/Z@?3E/EAD[=*^M9^DRG5-?HJ_[DE\
MGI[;HTCU)9?6R:XIEB=21=7"Y8MAM;)8Y>ITJ9X>!\EJWW87 PP$TOYC[<_\
M5_76(<H]^.-RGH;UTZJ<&XSU8Z?\+Z5.;.,GUF=XQT;YYD[VUQ;F@^&\BS^.
M=/%>MRW,0Z"NF-NE4>IF-TYN?.';61EH!$8<- %FO?6C.K7]2#JKQ,?NSRGO
M;IUQX1QGH!R3B^ /KQQ7(]M'4#*X[G;:BS%^3<GZ?<H]U/#N2;(7;$^7-S^,
MY.@\'.+-]!%;1%]&Q^_W^_\ L NN1S]?^OTYYOQ1UV4[[Y.D&4MNBTLOG@>0
M<:]P63[;=7BE\7#IR7_&NJGAZX>2A1_Q/9/_  #3C6Z'ES&]?1HR'CR6J>,L
MCF>5&311_P!_';WOM_SJ%Z)>_KI7USZ@\8X'B<-ZD<57ZC97*-WI!S7ED=-B
M<6ZM8_$+DML/<:3X=U)Y=S;CD7S@FW,I;J;P[@3NQAA)HYRK _"MS2?LZ[F]
M&C2]&C2]&C2]&C2]&C2]&C2]&C2]&C2]&C2]&C2]&C2]&C2]&C2]&C6LNM/4
MW-Z+=(>IO5S84-H9O33@G*>;MYR]X$?1'QO&<U:YP2S0E0E?(M109K#O0-S0
M2]9K68]&@<D#WUQWTWZB^YCA734'ND]SG67H_3I$WT[/U#Y7THX7T2Y&EL\&
M5TDE=/C.3Q/J%'5'==Y;I""T++T ZO"X)R+696KD"P:]URFEKFASX[5?Y6:_
M7C1%OZBW ,++YJ]U0Z(>X;HWH\4Z9 ZR9'&><X/3'4Y!U$Z<'U%LB=W@P>FO
M5?G^:;06;;!]WB?)=3C7+U1DI:^%Y7I2QHH_]^/U-:U/U=_J=N<2Z4]3N3\.
M]KO74'4SIY3I3N"Z;]2 ]'\%W;Z?=5.38^)B]0$V\OK>WE4R#TT;)1C/;N;S
M3+W#) W>*((U?95/W^_WSH )('O?;GC\NWUOMS]];W>]]W',CJ0MTJV>@WN!
MR^59G3W/ZI]43L9W20_&>BG!7%3LL[74/E.=U@?PW"9D D;61TZ<Y]MLW)2^
M3GZ0*F,(T5_Q7D_EK5'+?ZAR.]T[Y?''NF/6SHIR;EO1+J%U2]NO.^J/'NF)
M>-=4\SB. ?8MN\61XWU Z@Z>65?/E;D"^!U4XKPW4?QBB;KCG'>PO1I#Q]:%
MD 'CZ=JOZ7K>?)=_KORCVB\&ZF=/.JO'."]0Q]%>/]2>2[W)>F"?/T.2/3T\
M4Y'HJ1A)\HX,GBVTM+YB691)==2AI&MG5$.E(.VE%6+[7]N/]OZ_GKC+IQ[B
MO>5R;I_[2.)QU8Z2[G67WG8*_.T>9N=#W<?BG0[@F!P0W,N:6#Q)'JF<_4CD
M+MY6RN-5>W>,HJ-7AO37;5BZ\H.>?<:..>?MY)_3C[\_:]3GN/Z_^Y?VY\G]
MN72OJ)[E^D?'"]3N0=4(WNM2'MCY3N_)@\4X>3<XOEEZ9YW4[<E7>;TPG5UM
MG-UZY1%K+%!DY\U-!%]A?/\ ?]*TH%W]A0]S=7?MVX[_ %UK7W3>^OJIT*Y[
MP/AT>Z/HGPO-;]KFMUER^5\Y]O\ R7;KUQY_3EO%\CC7$,;AV1U)PN0<4IR#
M.WK0+.0=U-BC<4B*23N"H?T]OT^WY]CQ[Z;SS0NN_!)%7?;CN/(H 'GSKV$Z
M0\EY?S+I1TSY=U XK;@O.^4\"XER#F7"[WN2W$^4[&"AH;O'+6-,F\L;38:S
MYJ:;'I*_@>9+6\R:-;%]&C2]&C2]&C2]&C2]&C2]&C2]&C2]&C2]&C4'R?$'
MR;C7(>.$8LH/D&'KXA&QTJ6ZU-5!A"[%!6M2I+@@\DJ.UZQ>U8K-JQ,S!H[:
MX/)[&.0\<X?[0<_I+UZ>Z>=0/:1T?T.AF1SU[IQB<T3YEP+D7&>G_'N3R]Q#
M2W<]3(Y&=KIKQC>XYJ5U=7.P]$#"^IB<FS&2I6-*3W\ FZ\"KJO:K/;3/2+^
MGSB=)\C@^6'JGR#DM^%>V7FOMMA_2X[EJ.;*7--V=UGF+E47A*KZ2QIL+]*5
M7&B?RF]3+5_M>C2<W_UY_6A]J_/3FC_3PX/R#B? >%<DYWR!["X5[2>5^T\\
MY^8GE:>IE<H-P]BG.E79;>%D[V,SP]1K/S[*:2%F2ULQ<@02 Y^_W^FEODD<
M7_M=?W/;6,:G]/?E?4/*Y/3KE[C6^H_)6.C8^A73_<Q.E6-P)#A7"K[N9NZF
MII82W*M^>6<UY";&R5MK9C4X_AROG*QD\6R+?9LR:3V^]\\^;[=OW>NY^==+
M\OG_ $;YET8UM!U;&YMTRY#TOT]5*HJ:(,ODG%G.*.Z"8S09>C@E'2,KT+4H
M:GK2MXO2)B31KS-ZE_TL=[JUP_AG&>>=?^(\I<XKT3Y)T"KI<J]M?%>69^=P
MW5,]^D\JX!QOD7.]',X#U:SLYL&-K<^7G9INYZ*GP8.(RLFPJ: 2.YX\@$@'
MGR+_ $]O&MN=0/9SO\.Z1>YR>F.SH\YYOU4]N7%^CV'QDP\WCEB$X/P.O"5F
M%M5O1G/*]MI05K]/U+Y^01F]<Q[0#GL'<$@%?;_LG_UI?^?/^]?[:X1]OGL&
MYQSSAG,^A_,.G&[TMZ2EX]TTY>ASCJ[T>]N*748_7G@>A-<Y>W'NE7+N8<9Z
MB=+,O%@B1LGG(,8\?9,MA.P&1N!7]G_KGC19!X/V^WTOG]WKOQ_V*[S_ $GQ
M.')=1ND_ >?<3ZQ\/ZT\5Y=T@]L?&>FW!$^1\,7>3SU=OI8ASO0-R-=Q32;&
M^T[ST+WR6%9(Z2XH5L?]?TTG'Y??G]:']M=#<Q]NG'=7CO+&>%871KAO5OG.
M8!'F74W0Z$<0Y6#FEKT%&ROS?C=WL72Y3A[EZ7^YD.<R&Q05ZC'JS<<&L:->
M="7L&ZY]).I?MNQN@W5S_!R'!<'KIH<@ZD!Z5\5TNFW'-'J'8!@<)X[T::Y<
MFWQGA@[P2>*XF!R^\X+$7,UJ/"*5<A^_W_WI>+/''L3S]K%#^FMA%_I6</P+
M].-G@/+^!.\QXEP79X+RW6Z^>WWAW7[C_.1<AY8WS?4Y0+C&AR'A9>'\NKR+
M0=)G/8NZ;)!EE'EZ&+JC%!;FB[N_//'O_7]^=;YR/:#SK@?5AWJ1T=Z] Z9Y
M7.>-]-L#K#PM3HYQ#8S>3L=,DW$,G:Z>D+JH9O2YO01TM!'10M@<SQ*IE7KG
MYJ3*8FI-)]/N?U[ZQ[B7]/W"XI_C&!]2]9V.7]+^NW3(T$XVF"4E^N/4E+J*
MYKCFNL3YC<>82KEK*6@8] )):*=6]8#)H'%^Q-G[ZLZ?>QWFW1;DW%MKHI[C
M'N#YI.D/0WI%U:R-+I9QSF!N>I]!<$_'>+\JXGH:NZ /3ODNGEOZJ>U]S,YW
MC&6;7^OD@=1$_<\?[^='O^_U]]=,>XOH8G[A>GR7 7^1-<8 GSOI_P XC23S
MPZ12&X#RS+Y6#/E8S2E:BTBYE4RL0:;K4-8U1&M2!V-&M0=3/:ISQWK?K^X'
MV^=>C=".=\WX5@]/^JF;J]-,7JKPGGN)Q+0VM'AVU/'W][B3N'SCBI.2\C6R
M^1+;CF>PALG3V^/:X@)?7-+?%'L"3[&SQWYX-"^.X%$<@X[3VF]<^-];.0]:
MNG?NG2S-?GW37HQT]ZFK\\Z$<>YJYR\W1QCGC"O)E'N/<VZ<Y7&7^27ZA;5M
M//S.-WS%"C5L@$01_!*>3]>_Y=OTY_8T7=7XNOSK_<7]=4Y7[$,/D>%UC65Z
MB:6+RWJ)[K>%>[S@W-E^.)L:/2?J-P/$Z3XN0ME*WU15W,UU7I>1#>@S65.Q
MQ[E^]QY@55"W,PO[_M_Q_?2<_;BORLG_ '_MKOKT:-<K<W]ZGMOX)U6X?T1T
M>I.-J=4>9\A4XVIQ3CQP;+6&VU>U)9Y8V ]<WC:ZO:"'7TW0ZMQ6BZF<S7O,
M YNO'?\ K_Q^[&D+ $#N3X'/Z^W_ !SV!UT5_BOBW_K+@?\ X8SO_>?1I=+_
M !7Q;_UEP/\ \,9W_O/HT:(5W\%\U54MO(<9)%O!=3238/>*UFUYH()[DMXU
MB;6FM9\:Q-I[1$SZ-&I?T:-+T:-+T:-+T:-+T:-+T:-<8]7?9UF=6.:]<N:%
MZB\CXLUUL]OV%T%:%A(+48XZG@\DW>1BY L^1R)T8?)MWS=3"8776<RZ,JW=
MBKM_B-+?%>+O[ZYHX)_2SQN)X_.DF^IG$TG.=[_0_;<5Z5]!N*](N%Y4]#]?
M-T\T69Q#%Y+KE*WR6F8.N]JZV_INW>.P\&T"L-$9HL\?0$#['OKG;W7>VWK[
MN^]#G_6CAO1CEG.-4JW1RG11\O$/;[U"Z,G;XNL$.XUU);ZE\WXUU'X5&.T1
MIP2G"\AP<&J/;R2O;=I%Z-'%=Z[^.?H.]&_K7WJM=E]*?8$#I=U;8ZEY.QT8
MOB[_ #Q[JKO\?V_;;P[DW4[(YAR$$'Y%C\-Z^M\@1W<OA\:URLXX-+A^OR3-
M7[J@Y)4);T@TG'U_7_GO^NMI='_9QQO@7'^5=/\ J4[P;KOTQ9Z@;W/>G/%>
M?=(>-M/\!:Y'H&U=)9O:T]+?0Y,T%L]XS==;CO&&U58@!Z.$C['HT:Y&S/8O
MU>ZD=3?=!D<PZDZ'3GVX]1.O_&.8DZ6I\$XCH,\[XSQ#.PF,RO$^<*;*VAPC
M&?T<L*NVAJ\>WVC 3H/&_0:VL0A=_P!M+VH^?S]^/-<?8?4'C6Y)_I^:_P"H
MN\,CKWI1[:'NL].NI>BL=.<2>3QRRFTMR6>.1U9G=L6.GI>0*CT#8<<(KR"P
MR,)5Y=1<E($:3V_?[_\ 6L<Y?_39+U&W^O7)^:=8,!3;ZV\%OT\:<Z9]$\7I
MM5G(KS'*Y9G<@ZH 1YEK"ZL<\Q Y ..XO)V:\6$AC,/#IDV.U<L&EO\ 3@^/
MZ<<7[=NUW6LOZN^P5_JE?W18H>M9^/=/O=+C<7KR7C-NGJ6OM<:Y9Q<8E ;^
M)RK_ !5F5/DN(BH-GCCN#8U6JU9%O4%Y*7/W^_V-)^G]>?ZC68;GL1X1R#W;
M,^Z30Y?NRH]PFV&_TF&BG7BK/.Z\<Y1P=;JI^H6-=L7)@<$YIR3C%@C4^)@3
M&>Z1CY\E:DFC4+[4?8FC[5MG-!@[G2#7X3Q/*U<+A,9/MIX5PCK$OCO&-]%'
MFW6C'Y"VSS&,A T9@V4.'<2<U5@A)O,:C,LF8-*3=^Y/)OO^SR?RH"N?03T:
M32]&C2]&C2]&C0+NCGYHZ%TM!) =[^ R.M!4'<GC-O"MCEI6]NT6MXQ,SXQ,
M]OVS/HT:CO\ %?%O_67 _P#PQG?^\^C1I?XKXM_ZRX'_ .&,[_WGT:-:"ZR>
M\/V]] N0].N/]5>?YO&J=3S\B3X]OWM1[C:;G'*X=F5N1:2!&;857(WU92>=
M7KE]@.2Z\E Q28TA-?O]_P!.==$XVWC<CRD=SCVMF;N)J+C;S=?'>5T\O04+
M'D)E)](IU6ER5_-# *0=H_-;3Z-+J3]&C2]&C2]&C2]&C2]&C6*<[X5Q[J1P
MGEW3WER7ZCQ;G'&MOB7(D/.16;Q>0YK.5I &:O>X2W4:+ CT_N +X%',7I68
M-'^W/Z:X/S/8[U4>Z7;/M_ZD>[?E7.^@]N$.\&XMQM?I3P7CG4)!(<J7XGH\
MLZF2QMSRK2X09!$^.3(XIPL>B1:D<B'L#FPY/W^^=+?_ '[?\B_//;@5YCGO
M8!RSGZ'*2]<_<0QU(Y4[TE4Z*\'V\+I7D\ R^&<-!NH;KFB[@!Y9R,O*.9;)
ML\"VIM7V\7(^M'CG<;SK1WDT6?''<^X[5V/[]_&LMZN^PS&ZK?\ $\U^I>MQ
MYWJ'T>Z8=+$VEN.(Z%>..=*N49O+<+E, 8TQ4UX:T\M6C^&6R0[J280M(9+U
M,,T D=O%\_?6;8WM)^[RCJ7S#JCU!GG>UU>Z'Y71;G=<?B0>%YK0$EC*.\BQ
MT_U_DA<H[PC3(<TC;XD2UK>'&8_;Z-)K1^7_ $\>2:>3B\?ZK^XS2ZCXG37I
M#S/HQT/74Z8XW#W.$\>YGQR>'M;O,G5>3;%>H?*T>+46Q%7TUN#Y5UP2R;$L
M^6S4&CW[7[GG]\_G]==R9?2Y?,Z(YW1:NP<RF?TK3Z7UW[)CHR593B0^*1L2
MA!["H>XA_=E.&;#K>?A^>:Q\DFEOF_K>N6MOV-VKTM]LG&^GG6';Z>=6_:=D
M9V5TQZP XEC\@"\L/B\\1Y#E\QX'HOA3V^,\KQB&#IXRO(,IQ<EQL9VVLT 9
M_1I- <L]HGN!Y1O='.I9?=NF3K3TDV.?/+<OUO;]QESAKF1S_C<\9=XUF]/\
MCF_'6<K-S%KE:SG-;F?*=JS;!I<TV00L!<TH/@\B[KM^O?6:ZWL]7Y]S'5YO
MUCYPGU!U.5>VGE'MQYKG)<(!QCC^^CRCE6+R9CE"N9;D>Z3*,M^B 2%C2Z^*
MTDLW.C2U8#)I-=#]&. ZO2KI/T\Z:;/,'^H#_ N)8O$;<SUD19NMR%7 3'F9
MVAJJ@9<%.I?.64'H,U8O+S@S/7@=V+"H:-;-]&C2]&C2]&C2]&C2]&C2]&C2
M]&C2]&C2]&C2]&C2]&C2]&C2]&C7GS[DO<9[I^D763I-T\Z>]'.AG,>,=;>7
MM<)X-R#EW6/F_$]M77R^'O\ *]5CDV'D=(>4)(Y]:Y;BB)<W8U6#S98AUUOD
M)41I0 03?(["KOFN]BO'OKH/C7N1Z8O\5XGM;_+^/)Z/(^IVCT+N/%IR;2QK
M=:\ W($N2<&RGW^-Y+S49NAQ/DBXMA[+S<QJF9<HV(@Z\%-%$?I?Y:TZQ_4E
M]EJNR3!OUFL?3^WMY2(D.G/5?36W^1<<8JMN\.XCHYO!&L[F?/,HMHES@7$V
M]KF0@Q9BV']>ERU-)WH^_;G]U^>LVTO>_P"V+,X)P;J-'45W9X[U*KJ6X0EQ
M'I[U.YOS;>K@^/\ B&0],^'<,W>I"D<:F]*\FG1XHG_APEZCV_H$M6LF@"^/
M[D#^IXU30]\7M9S[]+PQU74UV^M&:#9Z89W%>+<YYEJ\MRC:-,HN@GE<3XQM
M:*BF:^2H=TVHJC3CM?(^[.<O2Y:FC]^W[[?GXUGO63W)=&^@5^/K=3^4:&7I
M<IEZV!@\<X9SKJ'R;15RAT-K:M.+].>-<KY"#"R WH77Y UF Q,L5HN_H+U_
M/HT4>]<>^L0WO>=[;.,\PSN#[/44B^WH3QNA6UN%]0M/B6 QS  F>+(\TY_F
M<4<X)P'3WP' 3+R^;<CX_HMP84#5FQ*1)^_UT4>]?KQ^_O\ \ZYVX3[U>H')
MNK'"> N<7X<#,Y/[JNO_ $&;;6!MU?7XUTEX1D\GP]=>Q=DJ\;FBX^8&J0BY
M$+K4'":*A8L6QH/%?6OZFOW_ $OSMGG7NZP.E7N*Y3TTZFZG%N)=,^/=%<+J
M&+E#8M<W(GN5;O. <31XXBDB5XFQ=ZAHC-Q\?#;W'7NU5Y-6)#Z2^:^E_O\
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M.-) U=[G73'G-^$Y\\SRHSC% DJSQ_&FN]GZV(RW6^==HIHKD \7]/O]O/\
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M"GJ0HPC#@OA.&T%^HVP'O-ICQ+?O'>>_I02.WM7Y:0@'O]]<^_\ P;OLB_\
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M-WUN&:N5Q$)B77"KRX=0W*<TOO1^Q(']1_M9'BO.HSA_L&ZH8?!^HO&]7DW
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M7?O='M_N-'[_ '[?GI?]N7VF_P _\;>+?SV_\/N_S/:8C_YH_F8F.T?S/?\
M'?TNE )[??Q[U_?2GWR^TV/YZV\6C\=__#[O\=^W_P"J/YB9_,?S_P!/1I+_
M ..Q_?Y]M7B]\/M0.88!=;.*W,8E!#I\&W$V(28K2O[LF(CRM,?F9B([]YF(
M_/HTM']?W7W^FA4O?;[2-!,+Z?7#BK";%(N$]%M^*WK/?MWBV/6U;?C\CO6M
MZS^)KZ+ [FM%&KHU[]_WVT_'OE]IMO\ EZV\6F>W?_P^[/\ KV_,?I'?^?\
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MK$S->\V[1W[=O1U+_P"2\]N1SI/AO_X/_P#RG_C0Q.J/3,1!")U$X*,IXO8
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M2%-/=KO/-7L!<E U@X874("Q+$ -8//OVX%M=<]KU,MO8^46RBP17L39!Z5
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MB9CO;\+I-2;:ZZSQA +&A5<5K@FI?J4:O45K+AO?X6KJ"(Q(@&:JLW]>EY)
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MXYG^&\AA#T*E-*0C"F!(NP;*T-2 D9(LUH:(AZ1LJ*YY)=)#X+EH4)KE964
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ML9/'#\?SC8=^0J:$%T<\)[\F;N2[8BSIMDJYV=D_ 9$C^=A&YCCFF9"ZHIC
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MC $D4#9'!Y!-DV;!_I54?I>LD2-M9V8T8*&BY3 RVQ"7F@LW0V:8JS"WZ?\
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M*,0<\19&(I:V("AVAA:)GKM%[KP]=(JRDQ!F[C#/>7,W3X 4"U/>SYKZCO\
MU]M, )(%CDW0X-GVOD#_ )^YU"Z.AAY-XV==D>,1XV8@-QY33<&%J@7T552,
MYN>V! MXTSI488JH-O[%+%^&M9BC?*BKX/;O9Y]Q? %\T .:\.4$]720 ..;
M\7W[B^3Y%GQR=2)[G@A!D^6+P7M8=R^?B2L16T4B9O\ &.)K,_&.*U\XM/;O
M-I]."BNU,;YHBOH37][-'[:'D)-78OFQ?;BJ^G>@:OMI$O4-@-&,N&4$7AS)
M/JS E]#]]V#6-%F%:15.]US>0A%K5KM:]*7BO)+MV)+EP9LD2MDXX=8923:!
MP.OI7M1 (L\CN".^K"'=<W'V[)VV&>1</+:-\B 44D>/_P",MY'3W'<'P3H?
M-G3T6M/[2U&U;Z:\<.L+0SG6P9;>0-=_48*LJS(EKZ"3J6>DJY62I:3AS7'-
MYI/7U*#XL@\ <FN0">]FP.GF_ HZX!9L#DDB[J_%\=JH&S[@B]#-(9[FGQW1
M<QEMZ,QH#XV[MYI,U8J=B3FW2,.[UV= )=%AHZ<K++,)3:I]"8F53(15FN#\
MP/!(!\?3BZ%]R0!V(7D4"39%"CP6!%]N!S5^:// HGBL&P1C$O=:B\E4&.XZ
M@$)=2PP)V4#6E?//.M,75):5[AJ*RQ$QVK%O2'J'RK[V;!NQR.QX'U'/;QI_
M4";L@%;L^]CIKL2.Y(KN.=.3->U[4!44T8^,4V:H]#(+*I%JW:+*+64M9LS:
MDHS]J153H>&K_8^(,W;O^O\ O]--<JHO@FJX^;FJ!LT0.?';M6DJD"I*:$.H
MB8+6V3=RV6-ZSXXUQ<;/@LM!S'19EZ<N?SK?V9SS"=RFAV.%)9ZL1W3$$<<"
M[[D6P'/?@DD_7P.PAX:^[V0+([FCY-6/Y?( )NAJA*'!1:MZW5BQ ,CFU25(
M==<DD&())\(@!F!AHW$P4+"<-)%I81BUD:R+% V:L"JH<\_8<W]M*&"=P?H0
M+HK??^G8T1W^ONU_1J5,KF>X.AE[K3=[I>2M;B^/R_RO/*3$3XU^2!Q%1]YC
MO3QK2?Q6OI4ZC?4 .%[578D\@^YO\P?.HI01T@]K:OJ."+XX-5W^FMW_ -6@
MJM/;IQ43G'XY&-CJOB4JO#HD#)V'QCEYY?&:\S:1 "(M'(")@HDR':JL>%Y%
M;->K=OSMUVZ#;\'+7!DR\V**7)*J[1P"*>218@W'Q9"BH#W"LY';5MLTV;BK
MN69MF4V'N&'AP9&-,L/QU^7<]O7(21#\H5\5IU5F!593%8(L'YMK3(XJ!.7P
MJ%T+OFL-^@(O(%&$YS],8Q3?02?^^!F%+3"]&LA1N]ZF4!4EIMFU0;9C#%QV
M8QVQMJ))846L5SY\ &R!5:Z/4GJ3/]3YQW#<"K9#H(V=%Z+"=@%#$*.;I:J^
M+[:FW]]G1&CYC .Z9;D 48J#BD5FDB'6U*5FPQ2.;5^3SO:][3:]X[=J3TYZ
M2A].Y^\9D6=FY*[M)%(8,J5I(X65I7+)U$_.QEZ210 50%UA-KV=-KFRYDGD
ME&28ST/PH92S,S?^3,6-FQ]!W.H!=.,Y!95=:XDZ5D:=9I<8JABUI@:]IB.X
MJ6F:U\9\:5B!Q$1';UKP0; ()!H^:_?]_MJZL_>R>/O0\5R:H^_MSISM6LS6
MT^-;=HM'[HCOWF+=IB*Q^WQB/**S$_CM,QVM+(I!*O6%=:9EIU*D%25/![]N
M"+!!X-'4N1 <=Q&SQN>A'ZHG$B'K4,!U"A8! 85:M:GMP\J0&:UD<ATI<53R
M"%=M0SFC3.A8%@M/79STRE0N004)\GSUF5QBO_FAT_ESK:,O/*L._/((X)OG
MV)[:9"P62-R0 CJQL,>%(/8=Q[\^-8CA86!Q\H5-; TR/,:&BUF[3C-&,Y>^
MHL5<XK0G!E-!#7%,U))&R#$4@9,M,T,U;RK"VR"'>Y8]XQ-QS^K(>;'GSB9<
M6)');X<:@E6"-1MP2"217;7TSO6_Y.=Z-Q\WTKN7I[96APL?&SL':%_"[GDR
M0?SY.3*Z)(DCE4Z5A8*0 &LG6:)#L.DR/X@4"(0UJ2(Y1#H!M$5Z(H)>1RT7
M&Q2+_7%8:0RT9--!4F+>HQ"***-(45(E4+&B+2A:L!0  ./'O8[Z^;,J;*FR
M99<N5Y<F21FFDE<RN\A8EV9[;J9FLEK)8DFS=ZN)#%((2E9D0Y#54<BH!-7X
MZ4"3Q(L$9R4-$79L0]BD^2WA6U0^(ZKUJ24+CK-D+8ZJJP"..?H?UXL-,,X0
M2F)Q&&KK"D)WLV:['Q]CP=-%9 LZOJG:75*-+->M2\'*"BX&!99_#Z[V6VPS
MJNS9%*;7JG8]H^_-0%@E<3G^AL#<-]&]3NR.KQNJH%5RZJ 0[]RI _E'%_;7
ML6R_QHWO8O1+>CL.%'BD2>)IIVDE2..9RY,,5A4E!8T]GQV(LW:"_P"LLUS2
MMWC3Q6F NY@\=Q4*[PKP4QC*L-NS,D'<4V(+0TUPR/Q&T6/&T56_P1[ENV+M
MVV[VN)DXC)+)APQ!RR$@DLP-*10ORIOZ5IO0V?-Z=]*[GZB]0^D&W/;MR63&
M@W;+R#&#* RA8XW!+K;6E6IZ11(!TUM:62EEZ>VNOE;KN)5?->6JOI2TOK,Z
MUU>Y&ZE DIEB6IY'&(I78<M1D@I6M%)U>\;E-L6S',:!\N2!54HJGJ<@ 7\B
ML1==[H\ UKS#TCZ<QO7/JZ/:H\I-HQ\^>1OBRM'_ /;QV20#))'&>FQ2EJ-W
M7 &GH/\ *LBTFI943>?5EE4MVF7E2'GO1<;@[K*R".TVM!$;$)'C:A*=IF>_
M9-PEW7;,7/FQGQ'R$ZS!(*91?!(/(L<T>1[#5/ZRV#%],>H]SV/$W&'=H<"8
MPC-@YCD91\W20>END\$@D<&CH6EXM<LGM#0",R6!766'42L2&XT8A8((/0-A
M$O5EJ"M$N68*<E:TB.K.Q?QF)D8P=HGEADC25#3Q.ZE5D4\<H2&'8\>-9&>(
MS0RQABA=&4..Z,00K ^*/[/;62<AVE==@9TDV$"57(=ANE4?K/,>/T5D6TB*
MENU10)2.AFY?KQ>LTL*Q+1/K,>C/3>;Z;V^?%SMRFW.:7+FG$LKNQ17-!4+L
MQ!866["S\M:K=CV^?;,::+(R#D22R%P>>E%[!19-$V6/B_MJ!25Q0@;2OF4G
M(?&S9Y +$*0.P6[-9SF=X+'76<S?)=2JZRH*ZRJJ:;C(Z &4=[O.U8>\X,VW
MYBVDRGI(/2Z-1IT:N&4\@^^M]Z3]3;KZ1W?&WW:GZ9\1QU*Z]4,J,?FAD!M6
M60<%3W[]QJZ["J!T\4)'B:!B_53*T&IZY*K2PB6N:BPKF,8@[R42"X["4+3Q
MH1SO,3Y3L\4/I'=UV'&DGRVDD!626@T'Q35D _.IL\BN23YU]->J,G)_BCZ4
MF]9[C!B[3'BP/UP8G65SGPX@U=1!$3DDL%8MPK!>_+XAMG=JH@$[L,F(O8EV
M++""I01K08RYUK&O%YK0=A?&N6EC]S5I6MJQ[0SJD?7(P4*+8M0 KOYH=B>Y
MK7R.D4L\PCB5I&=^E40$LQ/8=/;DD#L._;0LO+A)?C?&F$7W$\UF&,]Y97*R
M +(K#+8*#M\]R6R"0&6A\UQ%Y(PA5(I87Q$@^8P/5VS;CNLVT03%LF.V!Z?\
MM^D$LJ.#RR\$<=C0YUZ1OG\)_5WI_P!,8WJK/Q(X]LR6"GIE#9$*OT!#-'T@
MHKAC5'Z]NQJY32-RP1X*^CH-[+U&LW.XSCMCR<MII-'3)E*Y05M1;) _QA"G
MVEJ RB.$*TRT=Z(OIEAB5G*H SD%V_U,5  MNYH "KX]J//FLF5/*D44DKM'
M K+#&22D09R[!5-JMLQ8D>_T-6??!>K+80<-MF:5G]/=U4F&3:J*:N)^IHV7
M%QVFO&Z?0TS*:;J;"XV39S2[B5&"L *7CQ=IV[#R<K+Q<2"#)S2&RIHT"O,1
MV+L!9[?TXU=[CZJ]0;OMVW;1N>Z9F9MNTH8]MPYYI)(<4-?$2.Q4<,1]C0XU
MD"FH#CA]6@\S+,2[Q0V(I>0^; <?,18.R3[[UC.^=F46R$A P_IB3OGKRC6Y
MLWZM])2^I_\ #XUW7+VZ'$R%FDCQ2!\?H9'2S8*LC(I1A94@'AM8S=-MESIL
M.6/*;'&+,)6C*AXY>F2-@65K!-J#R&7I)X-ZQ18(KF$"*5!7R *L#B+^,1 H
M@E*1:M)O:]8)'E:D6OWF;=[VM&IP,1<#$@Q$DEF6",1B2>0RS2468M)(WS,Q
M+'N>/?6FW7<'W;<,O<)(,7&DRYS.^/AP)CXD9=54B#'B CB0=((50I/4;ZKU
M4-#MT 4()/1U1)R*B^%@E0MJ 9!6Y5",*EM0)QCD@#'#/A;XR6I$6GJ) %D@
M??QX/Z7[_GK@^&[&D!>E\ 7TU?Y\>>?Z:(SQ>?(<K!F;'Y!I@+M(9!2$$R3$
M0V,O&>T^\B+7XZ:&F)1$%:6)H/B84BZ]0'.&ODW/'3-BP W5D2VW2!811$TI
MZ^U#I :P:KCOJ[Q_3NX3;3E;RZ?#Q,4QKU.3UN\DT<*JB42S?$D1>D]-%A8Y
MX^W=.)A5>)B8F !B8G_28%6LQ^/Q^)B?X_'Y[_Z^K+6>[:^1?W;DA[W;>X7"
MS=,BVEA]9I=<,)>GP%IJ/96@O]8\V[-EQF=W-J\FQ$+QH, O\3'Z<6*><^L<
MW)3HCQD9_A9$<AB0@=8:5$^(Q)Y4.I#*.2O8<7KWO^$VS[=-^(R-QDC@&3AY
M,4.5*"1&Z0.[1(.GY))(75D<DBU#&^%',Z.3@\ER+Y.PED95&-Q+8XJJ*TH6
M7UKBUTB-%=(0E:HO 9HDDL:WU?M?5 EGCL$-*4$>+E;YB#'W+"CC2?-J,1S&
M"6#'Z.J21*5NN59(U'0:Z@QIA6KC?]]D]";OMV;Z,E&ZR11)!OV1N#!X@)/C
M]!!4-\0J'C"J&H$JS*'##57$J<K"(S>OH\?T.&2.7<3>&(QLBB:WTVM%71 D
M#RL#Z+0]&UJL/S)URB 8+:=B:]HE98ECR7@7#1@R.Q :-!8+ $DT.P([FN.=
M>?+FO#^*,F!C9LF\S=<30Q!GADF<LR1ED(7C@J&!! Y-BS1*(\JT<*J2Q&$-
M=,4JZ@&P+&^9$#E89;Q7&F&+(1"4I$DEH;.3Y'PUHI42E_/O4WJG:((I<[\0
M76$.K)$PCDD:.0(456%EF<A5(8 'BC9(T+Y>?_#O9LV3?TQ\>1(8LR+;Y".K
M)2>-7@;&82<L(Y4)M2M!^0RUHF<L22+&>T/+-EJ1J,;FHP5RQ$O&R=%F%&%6
M*+IW#<34%H=2Q';F1"I([4M\FWVO,@EVU2<>5\0PP92Y3E5C9)XQ(54 L_Q(
MB*D#*!9Z5!KG$3YN=NL^V;UMF3$<S>)3CIMJ"6/*PXXRJPR9 >,0_#R%<F/X
M,LA"J2_3Y@<^^9HF'AK+:29CA$XE=M1$^II#U5LUPJA'BB*RJX(:@;T76T**
MLR"H&!&*%>\4\WJ#$W&/*VG$#<.%^)$3UN._"@(U*H-K[T>=>D2>E/4/I/'P
M_6F?!'+,.(\6<%HHW,@C24LM*X#-;JK!@K-=E3K#>6(\=W@<3)A'TIY;QCDZ
M^SF%WU@K9N4+'<J_ID9;4TOFO71N-$=KVI4BZJSHK4@;9;QRY21X1V]L"29)
M$8+(DAKX@5J=GH/=B1@!0^8 -V!UI=GR,O>%WM?4./A3P9$#2!L5?B?"F,*-
M#' K,M,K0 EK/0K$ @.:VEMEAO4T&UZ38;$'=J#/GY[')<?V+B4L<@1VJ8_<
M2]V###_<I)#5IY7CTN*:/X$3O(JAU4=3L%#,>*#'INSVJB3VY%Z^=LU?P^1/
M&U0F.9XP&(#"V/R =72&/8J"1W]M0?E8Y!.$$R%@*OU*49^*K(E[$LQ98L+F
M8!6]#$MY2(YJ><S%26K$=YDBC4GX:A YL]%$6!5FN"2?YB>?<^T<N5,ZI\9F
MD^&G0@=RW2@[!0;  K^50%'L.=*Y].C%+@6QG4A67/\ IS]656"%7FM^TZ K
M&#:3WBTCJSG-5!,5I3Q\K7A617'2RV;/)((XYNCQ8\&_KI(YYHW,D1Z+%4#T
M.01VZA3!3S8/_6JNO['9!<#*0YA0PWV3,#W3'_S5CKB5#L 89[C6O0;=+%8J
M&]*P!F1Q4=*+<LN6%D7'4A00'*HI*EB5ZF(H!0!=@=C5=M:[T_MF)F1Y$NX4
MS]):%7FD'Q"H#=*$*Q+L32]0"\'YP.QZ:I7CK %=AIMTQ:#,TD//6+>B_P!C
MXAD'<B]/.M+"5"7X+,$_:&+V_B/*W;#V[!_%9TK10*5ZYR)".IC5J%5CQ?)H
M#Z\"\IOWPML^+-E.F) 6*K&B_%9 30#%.HDG[=OOH5O'*-T<Z"4U;4L4B]BJ
M1=A2"C^)FRLS7RKY!_MDN*:Q8?[9M$?GU8P9V-D019$,R&"<+\.1CTJ_586N
ML @GE0I%\U6JZ.>.6"+(# Q/1BD*]'59J@&HV?:AS5C4<9!EJF7L$<QT\1MA
MPNEF;^,KE;;F90]140I?)1>?L02P&"AT&=9<]KG%V=K:*U'7;MN$> \323JH
MH Q+9=K/3Q7:[KD ,?T'H7I'9,C?(<B+'Q'>=2S1Y#%8X(PJ]14LP^9J!)')
M^O/(].-\/R.59:&?E<C39V4OU.H;:]XJAFL28BIVQW7*\8Y%E#,MCKH#^N"P
M:6)<5K3ZYH\R(Y,2B.0&A*4ZNHJI%CK4GY0P!-'W)'?5ED[3.=NRV.3B$JWP
M.H1"-<@QL$;X!" .4<A206Y/\P'8]$_&M!7+S*:U'1<@?98I8.6!1NQ)+)9?
MU%5DH76HN$]$EJ &5@XX#VF\?-?T_-7"S47&A$<4,\C];PTDHF/D@ @*1P3?
M!\#G7'L\OJ79-Q?/G1<E,## "9S,\8C##HC3J:BJU?2.U$ ]K;U&\$6.D!QG
M>ULZQ5',4"1)5U5U_@*9C0K#ZB_Z4L0DT&+..%MTA27(2J1)L.N>W([/L P\
M/<,R60.Y.,K*S,+!X9[Z"I!\\DT!W%^B>GY/5OKG(W3>]BVS$@,<"1[D8VZ8
MI$!#1M&BCXB."+ZEYZ;!XXU.F.N)T,20@"N*W9HR[D TLY<UZ)-+.,"*-I6N
MN<UA5$*1TM:[))!:WA:PM9AQX&%'C2I&L2Y?2%F:A77R$;MTECR*( (X&O,M
MXGWW>9]QQLC(;)DVR2428R,[J1$Y5WBLL7^'TEK() !8\#5ZC>[1K-"1K0IG
M1;0V'P&%(<[.R)+J&T0NVLWJC2Y"/4YGGMYJF4L"FIG<;;"VR J2E"6C/%(\
ML11/B1@,H+ D@A:9>32 @JQ/G[&L;#,Z2E3*R?#HRA7*@QN69F(4D@AF)4E>
MDFQW[X[MLZ&8G&-N7R>1;[>T;?*CI/ZHHP\M)74PULT$9]T@$;=?&]]8!"W"
MJKG,'*"X7DS&\Q]1>H$PHFQ9OAY&7+*$187#]"DCEF7J"EV8"-?_ #4>:4?2
M?\//1<&^3-O>W!L;:\3#=9<B>(1_B9EC,KQP@L/CI$(F,SUTA'H&U-3,+M49
MQ\YSAB6)Q=;CKNDOHK,"GDJ#LKJ\B9MJ*L/+KZ0E]M;>1NG5$17#[E7A6-1*
MZA>_-QH<C)VY<_&2001QS13VOQ@%@4!'5NY)'2K@]=H;M6K6?VO.W'$VO?)=
M@W>;'.?N&5#E[<T#-B/CR32O<$W342( 9.ENH.C#_5083/TC2[@;4LHGQ4:\
MBY(-$Q\;,Y/7;KE-E"C>L4&SHJL&S,RB+Q0/?JK=F1,'-I5,,KBLN9E0YN*&
MBPU8Q9$$8$;B55)9IGKK8T0X8'@=B"!KCSX<7;]DW#8-WDZMZRHE?"W$RRN$
M@RND1KA$,! JOUAU!%FV((N[/L*\CM;!TL6F)C<E)HE1Y)A&T$M!+3K+"1JZ
M]3RUDNWOJ9^RCL(C$E2[;A7;CK5JM9M&SHIH)MM:$P+E*%M2&)26OB2H ".M
M@@)Z@5()Z@2QUG(-JW+;I]M]00Y:;C+M$T(E3)$AMH+J%B6ZB@,E$JPZ2M@_
M, 0>,%5PCZ(,X[B@^-TS. H).41S*..Z7(\*K'P,ENFI*6'J.<BY7KE;AF^4
MINJ8_P"IO,CPL(/%L6!+AY=39<7PHQDJ$/4'EDDRY6CDD+L1U&,I$%6@'C>D
MK@7?JK>I]XV?JEVM5W+(RHL@R8J,N/BX,.+&J0QH2SDJ7:7+GD<F:1R"U( /
M6C^F .R"W6W*-ETQ 8S_  O%R<Y4<+4K@X[_ %$R\-LP/MZ Z,ZF<F#4) 93
MI G 4)G)M49I.[A?^;I8-PC$FK!;J)%_+==AQQV\:\>R%=>CJ4 CJ2B::DI0
M6%'DBKOF['C7G!UEHW'5OJ:1'1%CECJQR[6;*5.SM-+,QN3,WT<<]Z^3"Z3_
M /D%]%K-I;0 $P KQ)&8$QVL*%@"^*%FQ=<D=^/]SVU5]56.+ZAWJN"Q^U61
M=_7\L4R-=8.I?5#M\BV\72MQ[8S<+6T7&<3 .@FN 0^.Y3"*3&6+:"?3<VP&
MH,T&=6377SPJV!?@F7)9(?@-'"RS1O+\1&97A5C\5%-K3N*"-R 0>*(J";X\
M@C$+*A61"P9"P>,'YT '(9@?E:_E_II8S^AP;)XMA8$UE9-3@_#3&@.GLN,K
M,'2 !5 \+AIQ36R\D^UK;&LVRRGJ964VKJZ"A:J#6\J_B#ON[8PS-LPXVQ<3
M\!)-)NDG5CQQS1@S+&DI/3.<AXUQUC@N822AD62BIU\/I?$W;TAG9,&;*F]G
M)1<?&Q"LTD6(CJ9<B6!4+QK\DG^:2R "F [:RGDP&=01=)M]:,7&#G;''W%^
M5]M)D3D:^?J$UN/2\MFDS,W.978-LC(TKJ5 WN*7-)D$_5;_  B]6Y&Y8(V/
M<H,\;AAM/*T^1CSB!T+(ZJDTRECU%GZ<=RLN.%^"REHF<X3"Q7P%_!&=)Q'9
M#?B%FE ))N4!BX+-U,+ 4@ADX) B,K#[Z6)7;#1+.:U,MM@I,\.?%$'3YZ.@
MU+A?AERN@\WK/UT3V*"E#F%)HHO2EO99FFCCD^!'U/\ "D^%X_S.ERA))[!N
MA30[#L.^K1*^)&D@<(9%+R(02$+ ,0#P6"VP)^U'MJS-T^?;N=E\F2<XOQKD
M&=R#J+FIQFIZ:F<]PO)-C8B>NKEM&:OHL1R-VQRZFXD@TZE2SM5AY]1'+\M?
MQ AWG&AR&WC)5(,IHC'B2YV.,M<AFEFF561$DBCF@1UCB5B>H*OQ&8@#VOTK
MLO\ #Q-UR7SLC<)=K:-#%E2PG\,V5T2%E_SV ,B$H[*&"]0=50(RUL,W A\L
M5>?U]?3U=3+;Y7S!@BAGB:B1MP3F'0/'1Z RTS]H2QKA&P/'\<Y14(RC!))*
M7YW&_;AM>1AQX6/##^,&W;7$XZ3#.L 3))RVQG#38[E0/@G)ZYWE8H9*"KH]
MLS-H7)W@P2X0AB$HQ6R'@=,5U/5CY?67"PO'5*0Q8$@ 5=:[WPIY6E7(Q4V,
M?*SE4U\? 2&J<8 UFOROF8^=9 K1?GDNHU1F2M32]EU"SYCK]^_PZQY(/26U
MG(9I,B=!/E,ZR1]<[D,]12CXJ)9%*;Z5J[J]>)^IMSSMPWG)R,K/BW#(6H1E
MP,ACDCC'3&4:,!32@ ,*! %WWUC#)R1=IDSC$"$O/SV(4E4P*J#FQSP")D(!
MC$*US$H.M9H.27F>TSZV$.TX4>?+ND<9&7-$L+MU'IZ%)91TD]-@GD\FC[\Z
MSS2,0RD#J:BS]V:A0ZCR:JS_ %T6>K*3([&':D A,HB?/+DG7-(_@;GZX;2.
MA;VL2@:C,40!WGS/>DSZL&'2DAC4=7S,JCI4,W3?-\4?>ZYLBM-:1B0QMV5?
M]9)NCP!? '8?3GG0?T!*P)<  430L!;"@.B=H20I1A5TBB9P IC68OW\H5\K
M-=_LL7@TSVBBZGB4E C$!G1C=$GD=5>*[$GZWI>LL%8BF-6A^8+8\'@&SV/B
MK&F7/$5L[2+KZ673C]7CQGK3\V5KM."^J"-M9?/?T7!Q<HA=UJ$NM2+-5'$B
MM?TK*]$CMQP1SQ]3WJB3SY['FV&P3X)[\@]_U_KJJSXGW.3J!4<S&<;=C(N&
M[++J>H"R:YA/Y+QT4:MIUFY%KT%2]!DB*5M/[NR 579N19XNR+L@$@#D&Q7T
MO2]JH@GMP23S="N//Z&N/>1R*&V:V4PBY[3I:N!!!BJ,(G8#X@D;9Z' P&$2
M02]H1>4+=F*!:O8<6%,Q/39!/'/23[$W_M?-^0-(+'B[H<C_ 'X^_P"AT-L(
MZ2Z^@MG9V8PS09+##RQ9BW&]&:E_9G_<Q-BNE4DEK6&#F2@(JQ_:^8GH^(".
MKY;KM9ZOJ: -U9H=^]'OIX 6NKFOFL <=^+L&[ '(/CCMJX.BVZRD*VBF]HZ
M:CQL[-7096:*58ZQMYH8M.U]+5C+?M=%72 N-4&/9."#@Q;FN*00"2 .11X/
MUNC[?7BC8X.E+=5A01Y%U1KN>:Y-4./T[:>LN2XJ4N"T'LS>AR6[#\:_*0+=
MR2T4?S2J>A*%&M634M4PR4FU9\'JP+,!? !%]B#Y'T_?C3*!'')L_?GW)X\'
MMYOCSH08_CO-AV&O;XA#*U"]YD:Z=2U7I,T$4A@JP<E C@9(B37I2MI)$6?H
M!/N .#=&J'Y7]#Y- 7[KY!W(*X#5)^HH!87:#\P#LH/)0X HXN)=P4538^>H
M[B&57O:;T&2MO&+H4 /TV1S7O^7]1?/OI0Y#<<][ />Q9H^/>CQ=W>F4@*@0
M2R<\)T\[,';+S5#D(7ZJRQS5KV.8K!CC-:UCU*<UB7K:+7K6UOPBD-;$%3]?
M)]@+/\OTYYX([:F-.!?%W=FJ[<&CR>PO[^-'77:" #$+_.MH+6NHQ8WQ128)
M0=2$ 2:LTCO-_$3 !VM R3$1-/W2V/<<?T/[(_7ZZB4%2>H'F@#8KD@ ]^W
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M8?B^H,;1W<9G/8FY?MY)CEM:;KB7]1L#@D6 .Y L>X'W^VOG0*Q4L%-#N0+
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MLL"UV./C5/L,L[FKJ1I JXUKY[&*Q2J1U#9[8%P,9E+DNF! -V1TV"U?<+8
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M-;2O>F=8)#DE!FUF#,MT+\=$$3$J@,/87P_%:8A>DCLQH^QXY'8WV_I_2M%
MB^0?K?MQ7L+Y[\FA6GE":(A$#H-ZO*F;E+H9+6B+,S5J@9%!JX1)SDTGD19I
M)L =3T:(Q2EI787BU(JU3T_,4"A@+_U<>P\<'MP?K]6$&@2*[7SY/OR3?O0_
M+1:Y-60)_:7RDW%EV2N+\9U-@7&8-&C>40-9^B9[686?%\9=#2&\"@Z^:51V
M),7B),B*226+I<.E!V9" 0POY6_U'P:\\#F]=DV*T$./.SQ%,@-T".0,XZ#1
M^(J\J3W6QR/N-1V0%G1LE<B Q;&@$5-<&?0YJU96,45@ 88M<YE*4[%4(8E[
M4H;]U_*+^DR<C&PL:7)RI4A@A0N\C]E4<,Q%437;@W^1UQ32PP1F6=T2*)2T
MDK$JH6B19//Z#OHO11SUM;*/LY7&=/=SF8S<Q-I1FVOCSNZX4H5SM&5*PP@X
MM18[X"T.6K]YJOI)KQXVBV_<,3<L6'-P)4R,:8,8Y5%*P!*FQP1S[]_L-&+D
M8^7CIDXQ^)$XX<7R;H=QVXX'!X]ZT('.PLA;X.-K@6R6W=#4'.<]J-YAM!QN
MX=8R(=1DY$Z$T%3A(O3MX$7D=HFPYM-@M ]^HW?V\'G\SWOZ5P-/8_2O8CV\
M"O'U\]^XT[630_0A=.86NJVKE8<J9M%[G^G0[#AVI4)J,O!$%XLULX)2B_Q#
M&""03YG"B/'UK^OY&O/<:0G@?6[)(\CFJ/W/:[X\UJZ8O;]UA ,P,/@F S D
M?D9$M\:RX2&I>PX@<5'/P"*08/*8':M;3Z0^0+NR?E]Z\_G?'TKOJ6A5 <](
MH=C?2!P>.:/<_8BSI]@2X&LU R>R,VN+:;3;A0A,]0>,JNW\>LUXTA*=8%F!
M91XB!-.I_6J.9+$U:S!>YYX';@'DD_NN_?V=09 %OS9OD$$7=][]QP/Z:'8$
M2U@D<69S3 HXN %&C$7>2)90BVQ*9ZS4+,Q!TQ&F+G' W_@()'3*I4'FN1W%
M]ON>W^D=N?)]],H<]1/D^[5P  /"]^11(%#P=*5*W,NRP-HO@$WQ!-^GWS)(
M5+7S+"F81C3N>0;+)8)9_P"F#ZT11>"F*2Z%D+<T;KY2>.XY:['!(_J!=\O"
M])#,/J Q')YH<<@ G[77<@4\<[1B&%#=W2G;:N2!HT5O0U=32J-":A22JT3)
MJ2<ZCLB9ET(!M6<=,8C)$" GJNAV%\ @@T0#V\=JOS=5I&E<_* +)!/D@_?O
M7;S5GZ<#G=S\MK)6U2&S[Z[TX:;[ ;$67Y&X_CYW'\<ZE$'R%<VSZ#@DH.*B
M<&SY&W-J%BEUI0W8&S9H7R._]>?/M[C3X[X#7?8756%\GQP35UR+Y)%^[W]&
MNDCS/<0*[?V2 U>E8+T^N($KV_0^4G)%I"(0"W.=@S!)5I51>Y;) K25BT@B
M(ZG%#@CMV[L !] !_7M5:@E(L"@".#0J_;\NY'WUMO\ J]>7_9QX9XSV_P#E
MAP8G^>_YXES6([=OS^+3$S'^L1,>IM1?LZ^<.:TI,S6H^YV6VC]J?@C3S)7'
M#7K^VMBLLG*8M[Q;O<DS^._;T:4\][Y\\W_M[WYXKG58BXX\>]HI^.\5CM2T
MU[_'-8C\=OQ6.WY[=IC\=_PGZ^??_?\ I?'MHX^I'D_GW_MW^VI7+=*+NE$1
M=9TH)8#3L.[%@7J4:\'B:WJ-DE( QXWB)&8D6BT3/>GW':<3+R<3<9HWDRMK
M^-)A=#NBJ\J!'+QAOA3$ !D^*K=)OITW\#B9>?@39/'X:6PWQ'5 C!0QD /2
M_ +<@TQ-#DW&YU74\3:;W6@ZF]B7.7D(<^ R 1C@SLS*48&E4:_CEDKVBV?,
M!%04!+-UQ%'&1VO?,W"VS>YLV5=PW'"R)9SAPL7,"2?_  Q$+Q7*EN; M:OM
M]!>H?1>S;SZB]%XVRXYV+T_N^#C8@W+*4Q_C<C&ZAG97^8"I+D.L)*JKD)T@
M C4@M;[PN//A9IGZ81T@F:0N>B.6^0KHC^L=<C'F Q39HSH5MX2>EFOAD]+6
M[:O9<C)W/9\3)SHQ%-EP!ID!M1U=1X! /25(H&N.:HZ\P]8;=MVP>J=VVW9<
MI\C#V_/>+$R&Z>L_!:K)0]/4CJQM25)L"^-,<F8G;*'74N4]"K/>*] ,2F2B
MEDP%TLNUA#)(-&#U9"'0L%BTP20IB'2\5\9W+^&.5M>XXPV@SYNWY&1)DY,V
M5*LDN*YR6F,<?RJ1&P8 ,MGCY[)L?3/\-_XV[3!Z/S]M]09;XF\8,<N-M:1J
MWP]PQLC'9/\ [EVZOB/!)PH?II:*DT=/Z4@NWI,BTC"&3].:(!/,P'V@TI?]
M+^E\;(H<J)T7U- YSEAD 0%G.. 5;B+[QCPK''$G!*QJI'@=( Y]R#8[#N3]
M_D'/F&1FY4_F>:21F]^IF;BZ-'ZGZ:#;(0Y_E-$-%"=V4BFO1@R8G+#^95)C
MXZ6$G PA&,=8CQ$.E)[^/>>FA^_W_P"M<I//%@#D43P:'8GGC]?M>FV86(,E
M(7M6!E@)"D:&S1LM15EBPEX4 16@F)NOV*9N&/CA@98K>*06+KS5_EIANS9O
M_GS?//.J#O\ #-KR:00+]PHK69N:U!6+X+#I,V(6E:S%:?MF+=IK/?MW8ZJZ
MLC=5."IZ200#P2#P5-'N*(NP?.D*AP5/9@0>2.""#1'(-=B.;[:1;P>L%+09
M[R030[G_ +MZ&FG>AI@GE-35BW:TSVF)[UGMV]$<8B1(U)Z44*O4230[639)
MKN2;/F_ JA%51V50!9)-5Q9)LD>;/?O>JUM:UH_CM:)[TKWK29[=YF9B/YF>
M\_[]_P#\;S]K_?\ MIW<]O?@<>/'?[_?3RJQ637I!0"H.ACF9/<8@*JBKYD,
M8G;]@@1$VM>\S>?**_NF:QZAR,B'%BDGG<1Q1JSNQ\*!9)_?C75@X63N&5!A
M8D32Y&3*D,**++2.0$4<7RQ%U[C5!R"]%WE7$M%(UX\#+,4N(E13,V^:DV@R
M\7K6TUJU1>]Z]YK$_P"O'M>[X6[XOXS"D^) 9'CZJYZXSTL"!?T^E5SJX]2>
ME]X])[H^T;UC?AL^.*&9H>H&HYEZXR>*-KWY!!!!Y!UD*6V(-5$3&*-@[82Q
M>S>@N(5@-.3F"E5>RF*4MOLUS\JXJ#.JY]<SUSVBY)['1'8J0"#TD\#GR.:-
M_3R">/K0L7JF+#IME6S2UQ:BZ'L:Y(N[L:BTF<]VCS.N]-L]KZ2<(-%TC::]
M(^W<UAOIPP,^];4Q DU[TTF@9BR8K=UY88^3@WC:,3>\";;L^(2XTZ]$B*2I
M(\4?%?D 3VXO7?M.[Y>SYT6?BLGQXNJA+$DT; BBCHX*E6% @C[>=%Z;16/J
M^8=,9DJF44HWE+*#^HBS6MF"-C<<EMUUE^&!QV@< '8M)#>MQVAV'8MM].X$
M6U;9&L6-#9Z.KJ=F-6[DGJ+$* U]P!W' Y\IVR,C)R_@)"V5D/.ZQ1_"B61S
M96-%'2J"ST@$ !>*  , Y#15O A6&#168DC[3#%SDL236LP>20R<9+DMVBI9
MK4<U".*AI2D7=#O5?7M^O_>N4AJYNA[_ .WO^6BZKE<<R6PNZ]&<(&K*6&J_
M&7D;4&OG4E38;NDZNN*TC\+D(&QSKM.5%^^;VBCW*%AD8^7^*DA$'#1J 4G5
MKL,I_P!0X(([4>YK5]A[_B[;M.X8,^VXF5^-Z!'/,K&;%9#R8R&'?N;'DZ=;
M7$,LF#:TJW<,(5'Q?$S"JFF=2;D759+0<N++PTC>3WK]=M<Q@UM:X:SXNXQY
M4KPHX$L14RJ&# (P!]RP)Y[@?3C6;221U1V@>-);,4C(5CE6.A)\-C77T.P5
MZNC]-7V*$D,0H\<#09NLS5H:25;*D=9#D:*J2([?&O>^7LH9>@Q%M%NN8P\Q
M-?N4L6@]7^G\[><&6#;,I<*>4 &5NH\!E)% UTO5,!R5)[5KV7^%7KS9O1V[
M097J';I-UP(&=XX(PMI(0 LP##EXS; DWU4>W< =XQ5LO"T-R3*,57A5U[]2
M*!G7Y+I:2F)QC%:#!1D:$;&TF]<NHN+ZX'<DGZC\C!(NWTCLN];/ T.XYJ3I
M\HC1"S(@44Q(8D@N>P!'3R?>W?Q4]7^D?5>9'E>GMIDPI:+2Y$ZK'D2=95E1
MOA@!Q&H8%WZV8$"^*U0\P:WV;Q-BBAL"I3"%%TTGEN.C>2S[4_?3.:=P0:9J
MEFQ":)7#?L$6@Z[16+%@1T]+4.0;%#GCMSX_7Z^.DGVZ0"0*)/4.]_\ ]1%=
M^#?MIQ;M4Z]!MT5L9U<("7NH.Q3>-V) L)R?B:9NLJT6BPQ&+8(2EH.?@\ZN
MK_?^NE7]!8OM5?6_[>?;7W I]_J*_P"G^7!/_7_T=9F/_P#$>ETW7R%^\)Z<
M_P!SGN#W&<^@1YO4WFZ"\AD8M?7(WLFNEGP1FY:"SG]E/+5^RM(*K0^FT89"
M"*+UYMG[KN@R]VDG$>'MF%/)%#)T-))D?"=ED/2>!2H'X%-8 \D^Z[5Z8].3
M;;Z8Q, S[MZDWK&Q\C-QVD^#!@)-''+$B21NI+F^@B^I:ZW (H\[;FS;3XX)
M^.'H\DRMP+.1I"T0F>T4-? 8HVMD6?R[)%,PHTHN;#=,P*I40#.N('AX4KLG
M*P]Q@QLO$P4RH<S_ "9)"AM6!"LI4<@GJ(('5P2":/%WM>Q[CZ?W'<=LW7>I
M]KR=G'XO&@6>DF#DD.DCV&/S!AVH\BCHX[#;%1S5@E$9&C82IX""F=-4E(85
M(2U*WL2"U(4\-GM_>L6];?%-(C31/+ V%#CX<0@DCD_$R$B(0%$#1J8P+(<N
M$ OY1&2"+%>8Y>-%EP;UE9>ZSR;C%D1?X?CE)9_\0,DLOXB3X_4%C$*JK#^8
ML90H'!("DBMRN77ULR!+,@%-*L!6^G\JJX;A<;8@82P?1"Z6#%)%*D+*5+2,
M0J39)DH5HLJ.H4/3?+9LDJQ[>*)HT>>:U1C:<\1Q,T)=I%OIC'5\P'\G2%ZB
M>]#GG[$ZO:A5/01HYGN!U]ZYZJMEM\JQ 4S,I+[(Y[_$D%JV<JF,0(M1LB<.
M3:;L6M;GDRL*#(QDI?B3J '!4@EG8K1YL ]04\D"@. -6F)LNZ;E@9N>!+\+
M;D820GX@544*&5D "J  #STW7W)MNH0UM.!MN)/WXWIK9Y\9Z5]B(5#]]3/B
M]#48('6V<VZE>TBB9.==4XKU\ALW7%;+P\J2'XD4B*X'2E-(T9!!6@2035'S
M=@&R-2^D]W3#W7#BRHQ+BR9:1RIDVL2(Y^&9 O4H"4U]5@T +'&HU72T6F,(
M_( <F!R/2PJ@U /(A7SU[K#H"L%7% XB[-5Q-V:%-+#:)<!?EF;3;->G,O,?
M+3\5CY.*[0])CD1Z<=1(8L;% CS1/?Q>O3/7VV;/C;-/'M6Y;7N4<.:TRY$4
MD23(S]'5%'$A#$'J-L.H4E \5IXE<^^YQQD+ZK&]QVSGR(#K!!GS&P'L==@_
MXIY),=V+!'-IO]KM:?VQ6NF;(P\C=(8HI0<C'5OB*H!'- J6\@'P#7([F]><
MP;;O&#Z9RLJ?&*[=N$D0B=CS:'J$BJ":!'!)'L?8:<_S7PCO8K3%8_9]MJ\W
ML>U8[S)+5K47E6)B(KVB(IX_B/5\02#P*\^*(YXL^/IYOZ:R2E;!LDF^]L"!
MV ]B/'?V]]-D7 ,;P0,'6J<HGRN7S\DHZ-LBHWH,A(V)J-$GS!BC)=18DKVF
M84F*UI-86DZ2O4XNZ(-T>>Q-=^!^OWU,L'4D@"D*O^8S"OE45U%@+-"ZOGD\
M<<:!U'$4G\_D)Z-L(C3L/5V45H:80188A/YJQ6.SB%B"I8ZHQ0RL#Q968"O_
M )>U6Q"Y9RO@N@4_"=G2K\AQ3<J>P)%@BN^K; RY-RV[(VH.ZF&430)+068+
M=B)N39X(! ZK\:D?JS-$-@UM0(=P0J9XV#MMI6$.A"5E;XJE16J<58,8P8#0
MA+5H29/$U]396XP8\D$<CDC)E6*%D0MU,_930/33&NHU5#D#G4&%LF7G_C98
MHU08,$D^0L\L<?2B5U&,-76]=D7YO '!U4 " 5UW*I@US@G6VEL;&M.?H/C@
M:TPG4CQ-"E6J5':S3\ E:(\;?6K%>TKDR#$@DR?ANRQ*S,D:]3D*#U$+Q9]J
M]M,V_#;<L[%V]9HHY<F5(8I,AS%&HD("B1Z8"B>3R / .@4#XF_F!UL(Q)5:
M=;"VFY44.)["\CC078*'Q$UVOXP)ZE PU6DW^$<5\?7-M>ZP[MB?B<<-T,#&
M5E4JZLIHAD8$!E/<CB^_G5EZI],9WI?<GVS/:'\2JB6*;&D6:.1&%I)'(I((
M:ZYHFJ(JM#Z"F[]A<L"'F?4:L3.@MVK_ "H"K25&XL,H)HQ)"-4OXS85AU''
MYGS]3_X8DKQ3#)D2:, 2,JA!(H(/*H  0  .D5QSSSK@P=[R\#!FP,J&#<%E
M#E7R$!96<$=2E0H^4'A>Q(![Z(JHP<EGV( J QTEYM4!@)G+<E@JC@*X2^9B
MD->!FM6M:5B/E+0=.\6A4$$=P.&!]J-D\]^+/WX]]4)L]5@,K DUX'#=NWT'
MCC3X$=),#R."JKH;S>NS#=KY\&3I6ZJ)4@#5<FBQYMG7R%22A61%,@:Q>[<&
MO>IS))Y(T7#59(S<;410Z6*D '_Q84?'UX&M#Z<DVDR/-N$YB$*DQ'D?YH(
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M%W4E$+0N9TZ9J%LHH<98M4M8M)BC)48I7BW[KS/A+9\:'*A?&R(Q)%(O0\;
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M_EH]5V3SR*'')[GL0=4HRS)+DLQ6U977M5"DG*DAHR%>[9,R[I&'Q*22AJJ
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MC%)RG\RC72I0"_\ E3_5*6M(DT1<AIM<EYER JH4N78* 7( +$  L0* )/)
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MM)%,LT#CX;*"&5B3S=BKY#"S9[5QK'[V=PQ<S'^)'/A9,%R!&4QL!W1E%A@
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MP9!1S+S!-,90$P5XPX?8K+J^0QH:4B !M*K%BHS8W:N?A;U%F8R]1@^=7D8
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M1=!NREF"!R%*^;&)IY7'N+06*W&%Q9!M70=/W*XR2@2UI;O-?D#^(_\ $O\
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MGTLC[+/?L$ VG:VI8T5F]Z4@9"SVFHZQW[^N3+S,;"^$V1,L7Q'$:*YY=CP
M*-$BB#[#QP;ZL3"R\XNN-CR3B)"\GPQQ&H_U-78#\NYHUIFWR5<MGGS=1)N9
MW"6I1:6L\67EO_42?8UHO1>M]2;AN%2*RQ6]&Z36OU;>74K"_E-DDG@]A[?^
M/;MV[\ 5KFZ194FNBP0/!\GDGBZ!Y^OGFW]OF"(BGA8E:7K,7BU1^=8O%+1^
M*VBGEX6O%JQ:*>4>/E$HWQ"&Z  0;YKG^M^]&NYX\4AX!Z3;<T/;S1X\GCGM
MYJKU9:+1XB_;0EXK/C!*][$BM9N(5K>,F\+S;PBD3:PX^3Q[>4Q(&(H-P>FS
MYY_*Z[$^VDZ37 /?M7?@$\G@@'MW_KIV*W#:*WK,7I:T]KQ;O$S,7[S%NT_Q
M:(K_ *17MVGT_P"FGI8 OW[=C7[[>WO?&FQ&"?[-U_&T+:A\JUKCF&!,"3SG
M21,6K-Q5(MIJWCXKVH8)*>7::WK$8  *V0 +_P"B:/85V\_EH=NHD@$=1Z>?
M(%@$=CQV/%>*L&WF\S/T%&LC<J*R&HE;)8HB_;/8,NUKYY7D!:61!#+,&T<A
M*SE;$"3YD*A<*.1VK#66P #\I)L7W %T".>_Y ]_JL9/5\Q H"OOSWHUSS=^
M*JN#HZXAOOAWM*'"LK4/F$M#Y2YS*VMF80>0*4S)/2*@(VBTYG':I\ZNMJ[C
MJMYLI:TM90HL TP/8DT:X]NW)'/-5YU*/G;IZ@*\\_\ CR+OG@W=5?<<5H,3
M5)HN(ULTC0KYHMF!59&N TKKNNRL.8J:T,5;M.?V*2:ULG1J9D1A^H$QW6>6
M82RE)HPHB8DHC D]2"A18-S?';FAS$BJKO)\0N9 J"-R2D9CZB67SU,:/Z>2
M1KW3_HS6G]*]PE/.UYKH=+IM,UK3RO*?.:D+%*_LI\MZ6O-*?MK/[8_$1ZZT
M!!:^D]@"/I?^Q_0U?LDU4E?7GW_EYKQ^G/UUN'^KS,Q[<N&S$]O_ )8,*._;
MO/[N(<VKWC_3\=X_/_28]2?]?T_?&HU\_P#Z3XL\UKYRB]HM-8K<=0E8!%+T
M'Y7JLX=:C0[#F9N!T8QM+>?C:RY!^5:VM:(+_?[_ +:<U60.PL=K_P!57Q7@
M#\N/.F34K.I73H%<1K8.<@8]+6@[3JVCL?.9D'YK>:Y/Z J!BLQ::JV':L2L
M.]JG_!=O_P 1.Z_!K-84TMGJ8=(4*U&B% ^4=A9UI&]6[VVP+Z<;+9]J6198
M\9@*B=9'=F3R/BE@' X(4#WNGQ*0XRR%>PFI162(T07B%E6KNKNPL"TDO8M%
M=/D&K<DVI7P;98H/^W6G:UH>P_ZO]_GK-DDC@^QX-=KXX/< BQ_2M(OS=A6$
M2T?&>A;B[1-C B+4(.*S_P UJP2#TB)B9^*>W:?QZP7KY?44&WX^Y>FY9/Q>
M#*SS8Z@.L^.X'7<9-2%"!2\<%CSKV[^![^@,S?-Q]/?Q"@QEVS>\%8L'<IY&
MA? W&!@T07(7_P""/(5W#N00&2,'@G2@H2Q-U[Q87R%I^R"4\+@,1<X;2>@[
M3(C"M225BPK^/F,A*6K>=5LL^3E;3MV3F(8\N?"QI<F,KT]$[Q(TJ]/BG)!'
M<&[UYEZPP=NVWU1O^W[/,,C:<+=L[&VZ?XBR?%PXLF1()/B U)U(H/6I*F[X
MLZ<M\4A(,@X[W&2L7M R7K6UJ^=:6FOS"^6M!>5A$I%_&M;Q;QIZ[V^(90 $
M^%T'J)ZNOK)%5_IZ0!SYNNPYUFB6L =/37S7_-8_EKP!TGZ7H_YZA%2BZY/.
MR2\6;.LN=-9B[6O4Y14)/S,O@'3)O"K46SOKD^:.[/G-9?W[:=8KMX(_4WYO
MM_S]PU26ECHL3!E9$6AQ$#7ZE3"B8J8%(%%1T4;N,4,A%6*$@5!]XK':6LH;
MN >XY (H][!X//@^>?H71NRN&5B"I!#*:93=\'P2:Y^VACP!MBBN@<3Y]<-U
M1)Z[56&-0:E(J2BU2^,E*,=(^2H8J28&.T5M-8]4^[X.U[CCC;MR"M#,598R
MQ0=:V P*D$$7P+ /F]:KTUNWJ+9-P'J#87FCS,&RV6J+,\8;EF(<..0"&8\@
M<AA>II,=TV4A%A$ZJ=  LI<8Q_HJX03(*7&:!C=N4TTMV=[CK%H@-IM^/73A
M;;CX&''A8B+#!$A2-%'\JT:-\V;YLW[_ $UQ;OO^X[YNN1O.[Y,F;N.5-\7)
MFE-LS@@V1VZ *  %+7&HI5734SV?\0<FG8D^U8F=I:*X4H4AXU!"RAS2*F<"
MHP4<%L*)H$%;7BU(B)]4^VPY.T'*3/W$9)GG8XRO_,JFS7)/;@GBE \W1U/J
M+-V_U6-MEV38#MHV_"1-SFA!=)Y00.LD*%ZV(Z5)MG+5[G1+2NHKJYYIUQ+9
M/A-7\EC-'\I9CR Q8!Z$-6W>U;67-!K_ +)I:_:TS'J67&W2?<<;)Q<Y1A*P
M,R V'0KRH XO@7]^QYUS8FX>FL+8]PV_<MGF.\2(5Q,A@$,4G7Q(Q/S?R_S+
M57]>=,,?$,U[)E;@%8\Y!?P@1+'I>L2>U(FK-U8K$^40.HR$CM%I[SZT?MSS
M^E]_'Y7^7MKS\]^/'V_KW!_W[Z&CRFM)FX1VO)*TM8@Z%-<0I,2@1VM%R6&*
MLDM05;6BL>4U[=_2Z*XO@?6^3^7Z>/;ZZ<K69($8+A/8PJ2U4D,UO19\3$*Q
M2\T$"UBV%,'K4M[A#:/*!VO29-(?Z?H?U!_I_73A13-;2N<; %NUA0&TS1-2
MDQG#7$.]*'^F!E!@=#%K:LL6/XFO6])F,2I\0Q=0^(%#%; /3=6 3=?[?<7/
M^&G&.N28G_#LYC$O20G4.2M]K KS_P!6+FI6\VFM+7\23-;V(-<YK (($O47
MBI6!!O891QY02A!4\)K6/&S_ ,O'['%_OM>H*L@>Y'T\_P!O?3!?&YS7#,P.
MQ+P.DS,]J6GO%?SWMWKW[3,_GM$3WG\^@=K'GG]>=*11(/<$C]-.DL(?C"]S
MS2?""3>(!>WC\=[V%>D6FH;VM<'EVF\R,D_Q:L^EY\_L^=)J^JC1Z3: 6\+=
MI@Q)J&+7M::TK6Y+4K:U[_VA#B9L4DP(<7+,5DTM^*' OM1H]OOV^ODZ':@D
MKL@D\KW=0T%?D6/\+Z]&060,RL:L6L!A>S%+@/2)L$]1VK/>/R:6[NOL11[4
M/IVX]^/UT:#19"Y^H"\:WLU#,KT[P#RL6S-@V''[+CM>MYFDQ:)CO:8G\^D(
M!%$#] >W;N"-*'8'J#$$5_*2/?VXYY)\&SQWT^1JTKUMIZ=U0M)IY%] ^A03
MMB "Z,S96A!(P9[069@CY"A'0U\]:8N.T6M;ASI<=8I%ER# >D_.CE74T2K"
MO(Y(%'ZZN=GQ\^;,BDQ< 9QZ@3',G7%(.H,P8FN]@&C8!T=QYB&M-0<[&D^A
MNFR(4'N1=<20N.ZU\_/O)*WFV=5H?(M&Y?C\X;!GNLGF;A2GU0[!MF9BRS94
MFZ39>-,TGP4F4!B'(;XCL">I@02. !SQ6MIZY]1[3N$.+@8_IS$VC<,,0#+D
MQ)&9 T2,&A2,_P#QAF<M)5VRC_20!]LR4?Y-3O/>?K+]YC^/P.O\=_S$=^\=
MI_T_'K6Z\OU\CONXH:/=3UX "B02:O4SE:Q'[7'1\2ZO+47(!6_Y@^0T(KR>
MK0D3=*KU+@^,QB3-#FX&'EY6///$LD^#-++C.Y/^4\J%'9>>"R<?9?I1Z7P(
MLG\)D21+(^&?B0R$\Q2.H2U^O0:-@\#Z:YO7+:N=H-5SSZ"OZ</6C+T<Z0#T
M;)98N09-*A/\I(\R/#",L5"ZNZ5H-:1<-/)V6JF*9WC2;X2.T:T&;JH@GWLD
M6+[@G@WS=[6\BYD$29#XZY,L<4LBL8PL;,ALFQ:JKW1/RD=K (@!O[;F/DE!
M\2/(-,C;3+:8"C^GG+M&[D9 3O10S%H'0= TK%5 %J:LD/-[5*RY4F/!&BL)
MI!U,1QT*&_U#QP*'')'/?6PDPMNQ<_<,AVC?"QW*1 -9G<Q])"L#\Q#%N>.1
MSJ5UC9?P,+-MZ:^G5EAK(V/T\)4$MBBF==KS!:@Y85=$X'/V #B1W+:C(I(0
M AQ+EQQ&#ID>I'%"1: L A@Q%FB:-=K)]QKAVII_\0?*QL<.([$T<@ (B9T*
MJI<$\HIH\"Z/:M##%G!TRZV<X0[ CVO"ZEI$HK;0)<Q&3JQ:EVP-75D:LLAL
M,(:11:9I>\S/M^"L2F;K+?% #*3:?*M"@>>/<=Q5ZY]YWB3+9,:2"*-L=F"D
M ?%7J<O3F@++$^#Q^5%YJX%0_7R<U50P[,QF?'XCJL;2JS9R0U,2U)+2UYT5
MJB&1R2*577B*6)VZ9U6+&DABD$#2A@C\!0[<L:L"Q3&O!\U6N'#D?(W#'RLJ
M"3.CQF1LB(&V>&/CH+42 UJECL/?MJZ<P^>FW$:&GIKN3Q\@$:LK<?;3<S%+
M+ZNJ1FU2M:RS_D"Y%34M:XHH.2Q?Y+36[1M[8&3EM+E1SMD_#D44.M^D5UD
MGWI378#GR+OU1O<6^86UC'VR?#7;C/CR,&<P*&?JCC0D?+T@!G _F<M5#4>Q
M4WDHS1$;-1,E8GYS'1+%KU $!\IKRLG<@!F>EP382Q>L"$#Q+:21?&;HE^$5
M?_X^HR!1T DD $][\CW]Q9UANHO*J*GR@!C*:Z!9[ ^_:S7T\Z?K>">(C7)*
MT&K,?+?O'A-^][5'_P L7FL3:)\?Q:.\]HCMZ !SV)\U];N_^^>>.+UU,?\
MQYX[#^7@@6 ?>OW9.FQ^3>88^D@P0X%(H7)QG[6-:+N5-6%F9D530*:",P6:
M3::38%:32T]JG>=SDVC%.6,6;*42!&C@0R2A6-%@H/*@V.3]/IJ^]-[)#O\
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M-.+=/('!L=^.?K[>?/U/G3I1PN1BM8K4Q+UTS!7K:T%D@*Y]G*,TK90M_'-
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M@OKINX)\"\5*VQ12@K#@PRSE6(S]2B:SC&4)QM-\DW''QA PT[H(YU!B@+;
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M!(K@@\^XH?8=0\>P[Z4ACY-\=K%6?]0/T(_4=]%ILW(V]F7R]6JW^&D'BG?
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M;L<M[5CY?S\7_P!E4%)[0((JUJ&D105(K%8]1NP1?B,R@(#U,2 .F^;8]O\
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M-B7ZH\E%6M:+Q>PS\[,NZQ#+!*_5C-S#O:A*5I>7J+U4[TO<?>RDL@CJ8<$
M^QJQ[ BZX_\ QKR=9>)Q'*KE.L*ZN4/ <(RL5OO3@,IK_237G6NAG+3YUQ (
M6M:F3LM0%3W:4O6*'&NL6\KZ RJ'-(@^/GHQ6R5)FY!Q"H"P')NOYO) '(]Q
MU$<CCGGGMIG+%FH DD@=R*/86>WCGZ$]]7%6TQUQ/HP@3+AIP&B38>.MIY0$
MU5:9F;B8P0PH1&S!XJQ\MHKF*KP#Y+D,.89-*N.GQ"K-TLB$1J68B5UB6O\
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M7LW?.S*/4^K,Z]1_69JY>!FBW:)[7F)E;KLGI)Y[<\#Z>]> .YKMJ-2>H<J
M/!X4\_7@?T_OJTFG79ND8>%S00-O'=M^OO"7P0\98R:3:V7N94$N95IXHH)Y
MH*F"4=YJN6@IK6  D=JLCQ=>X/F^P%_GVTXDV39 LGPU^_;@<CN3QX'<:) 6
MY*UK6H8N:O>UA1V%:2AJ/R_=6+W%'E:0U)'<43W_ )[QZ0H+ZRME>;[^QX]^
M>#[]O&HVHL"/;IXL<#OWX%\GZ#OI^UU!E'GT?1MJ 6IL72JPH5LV6-\:4&NM
M-9.FF<WS JS:U2384TI%8)%I.HOU<%?;FS^A^X[=KX[7I3?2"#56#WOGM]QV
M_?82U>U8KXU_$]NT1$>,Q,S,>%>T?FT][?C]TS,S^9[S..P^PX_?OIMG^E?E
MJLVD7>9I,5\ZS$S,UKY5F([6BL^7?MW[S'^L=H_/X]1NH=2II@0;YOJ//%#M
M=F_[56EH&P5'2>.; ["KY/CGZV>=2,L[3S(!Y_+:9;\H;)<[-T\L&O@N;2F<
M9K'V&PPO9ZCV U6'T+C..M6ATM6MBUKZKI%.!!#%A8G7&TJQNB$)\))&J246
M:95)+-7(XKB]0<8D4<6+C=:?$"E(R%"(S6TGS=^F[([V-3Q"H[2%,?<"CJ!5
MC+85G47[-,:RFB_J,E<DQ)M3/?T_KE2FL>28U7X^.20M2O'N>W1YB1+(JO+$
MY:*0D@QLR,A92.>I0U'D@@GWO5SB;QNNT1Y2;9E&$9L1Q\E2 5DB+!NDAA_Y
M(K+7(90>.-#$UE-4>;H9E<=UK*7S./Z6L.+6TU&BY&3J<H3,8PI9!K&J3]9:
MQXM9<#[I2M0*A7IGJVW";"BD4S-(7)/PZ"QQ+TGY(U%* ">KQ9)^^JR&*3YG
MER)9YI'4L\E'I-='2.YHA0>3VYOOK'@4A!;DQ>/VS^/.;:C+^CR B(6X7T5,
MS>6!R9\+9!I2ZH3=UW6VXJ"YRMF):;^513WK\S!64 ^+[4?:^. 2>3];XK72
MXZ5!!)'5=GS0KGQ5V":[5^2TBKH2^UIL*9BV?5>VBZQ LW.7--UDKGM2;7&B
MNV^>E%EJWO44L 7I>U:UF>@_>OW^FH0.HE>1V(^_ -^UWX[:(8K8)/B/>?M'
M;:A0=T)$M9>V$\]5"6Q$($[28\G3?^2WPW@!LH?:236A&U?:OY>WD>#SR?)'
MW\'G3G#<WXZAP!5=Q8'V-'[6 16O<K^C'>;9?N&C\37[_2^8MV[6[_6Y]%XM
M'\1%;4[1$?Q,V_W[RY>P^P_L-->^E+]O[!?]JUNS^KFLPW[=>%A6'<A;=8<+
M]E.T?F>(\UBOG>TUI2DDM2)O>T5B9B._>8]0Y&5CXD8ER9HX(RP0/*ZHI9KI
M06(!8T: Y/ZG3\;&R,R9,?%ADGG<-T11(SNW2I8TJ@D\ G7SG@=)E ?UDM10
M:N9>]-%M<TG$E 0T9-\]!#*8HQQV'%PA-225FE9F\TBU%^*].^J$EP3)B;BL
M$JNT3TY61.TB>04)(ZE-^&X)U;^IO0>];3C8P]1[)/#C9B+/!^)@;H/3R#9'
MRL#_ "@D%@;JM!'&6Q;23M>2=B3>?*;6\_&P[5[Q$3!(F)BWX_$Q/:(_C0HJ
MHBHHI54*H/@#@#GV[>^J$*% 512K2J ;  X L]^!W/?3Y8+ Z"F:=O$<47\Q
MVL+R77)YFI0MR01BMZ-CDX@V^%D7Q1<4CO9$5E9RSE@S6H(%(.E5KZ_RWV[L
M>]\.!:J+$VUJ./EI56AS=?+=$ V>+T+$30IB>%9,4U&S$I8M;E9!G?I=#'K:
M_B3P1B 17M\7B%<LT^447]2<_P!O^_\ K2<@GP?^OM]37?W\ZNBO[9[^4]IB
MD1:D_P =K=O^G:+=_P =^_Y_/\>DK^]_TK]_IHKCS]>#VJ[^W_O5+V+X3%*0
M<L4M\(2E@0Y+6/(8[$[6D0[W_;>\1W[?GM,QZ6A[:6SVLG@4+XL5]>?(^OCO
MJ^()8A9^*M)AMP-1B+#47" Y1@9'>8[_ !-"J,\#F.]*W\9_,>C0:#&AQ9 '
M<^0./T_.Z]M6EI:0R+Y65[G'4@RJ$H*U(^0@/'SL,M*VF]9O8,T[R/POWB+3
MZ-)X XY/Y\6.?O>E6?&1VF(M$36;C_,_),3V\;6B/Q-NW:TQV_,_QWB/1[Z3
M1;"6+?->'KNE?#A =U6(63LL Q+5JI?+EOL0!;HG(%5^8F+CM-KU\K3^<KZL
MP=OR-LFR-RLPX<4DA4< FB1R0>17%<@\]M>D_P ,=WWS ]2X6)Z=(7-W2>'#
M5V'(#2+?R@TP[D]P5-'S8JHUQY^*ZL@D@9[/SG"B7DQ?D*M%Q+WM>UNQ!"'$
M4%-XB+#B/*)GMVE])G&EV/!GQ5DC@DB!C61F+%;JSU>"*KZ=M-_BG'G8OK+>
M</<989\N'*99WB5%Z9:!93\.A:GBC9'8B[.F@54J.$5G!L%5J;S6J0Y#@#+/
M<GFPT*+P*[).\4H:]9[1,4B(B8TO>C^8UYV.5//:^*HD=R02/![_ )>^C0#^
M<M1P.2W+>!U7J08IN;\4".#&["%4EIB/D)VK7^9_$QZ-)=]_T Y/  '[^OTT
MP08_*+06#BM-X&0=YD$2,A FK%XK3Y($<10S>L>%K#FU>]9K,FD\>?I[#O??
M_;\])8R0&H=H.QV6JC!2BIKBNX/,&PU4-F&20FH,8_L0,A!T^8MH#,VO:GIC
MWTGY;[_7[<5S?T[:FB(L=1H6!8N^X]S55=4+/GMJ^@WQ[?+MUO7TF:[YV%TL
M?]1N]GCR0$SZ)O&"7L-(OR+5^$2H 0&8FDW-4A+6QVQ;7NL>Z[GN&XY4HAGE
MZ,3"ZU:)(DZNEQT\@FR;)LEK-$5KU'U=ZD]-Y'IGT]L&R;5AG+P<;XVX[RB2
MQYD^1,07AE$M*0E*O4@*@+:GYB=/!FWRBK-3?,9CX[7#\TUI]=0S BLEL7XU
M@$^&B0IK%:$89%0M)K:UHV1%]_?^G'!_/_;G7E9JP*Y%BO<F@#9L5[?EQ6D^
M+ZX]9H@)@.:L_KRJ%D3;%4D<X!6%;N O=-IV6P.DJ5>WQ0,P0WB+AO,\&[;A
M'M6W96?(.I,:)I6'<L!S0\=NW@:O/3&PY'J7?MLV+'98YMQRDQTD<TJ%R Q)
M%\@"P.]BJ-C5S]%Z").6P-BK>1]S$T"$K,%%K9 ',?0*.GE*IUC-RN=(L6*$
MR=I)$P2(F3 SH=PQHLF @QR(& NR.65AQQ\KJRWR#6N3>MHR]CW')VW-0I/C
M2E&!%6I571P"20'C=&%T:(!Y&C='R:EB/[EE0:J[2$?7H61Y*SEM4H#KD&&Z
MUWXU3XK)!D. &4EA%7)#?S_*S,VW%SBAR(^KH:Q1(/\ 3S?/Z'N-=6T^HMRV
M195P9C$)DZ6[,.022%)%'D<CL1]-1HF%X((1! "K2;C*N,%8_;\BM0D&S6WR
MBHNN-L,+4%:I2-4/YUN"M;=<4,<"+'$H11P //W]S0X]M5.5E9&;,\^1(TDK
ML2S,22>.WT/''O9[:2@H8A$%@!EQV]5SB6NU8*IHX_JM$94(6M;67MR-7+RP
M2_\ %:5=2I2>)J1'J0&_W_W[?W!^FH*JJ\]C[]P1S]>#?CQSH<O@N&YS%$%4
M0B,$/$244+#7ANS5#A@D&#\,5+2X8)\@II<<7\ZQ*Z=TU0('<@U=@^+/UL5_
M6M91G@BS5%-+290"\[IJ-:JN@O\ <PIU/M\H5UDZ-+N5HTEK:N)FXXPKP=##
MY)8-:VSQGD<,_6(I#& 9 K?#L6 Q4@77)%_WK4^((VRH1.>F$S0B8@@'X9<!
MZ)!H]!;V(KD]SK[7U/\ PJT1W[0N"/S/>?\ T5?YG_6>W;\_Z]_4VN4U9KM?
M'VU\AGO%HV7W3>X 1@LFIH=3>71435_MKG4H>V61512PIBJ95U9^TO?Y!,'8
M<)/[3V'6L$$,4TS111H996EG=%"%I" .MV ^9R  3R30\\:L<>!4CZHXT5I?
M\QR .J0]"J7;IHD=("&[/8<UKFURI%*,7,R\A=AO-!GK)HT7*N86>"*(BN,1
MS'1T',TC&A%@"L-=UQ4%Z4J*\/)8F(!00S4[%@ @(+=1NFLE>CCGYK(&B4R!
ME 5BM$,>08Q1 -<]2]2A:X[\<#1\%M5?P;84$NFI.RV."TI(TXH4CCM0=K.R
MG_E&BUM KEL(-[^/C$S/&88/QKS(H&4\4<3L)'-I&6*#H+%?D+D=0531//MU
M0[>%#YYC;_-4(\HZNGI0EE"]UM26-\'YC=^(5924=+1TRZ+>B;5'09P.R,R%
M0B93;4@"Q/,=*KL)!(MX"K-.]IFW:TS/,N!&9G;(D^,)"P^$P^4 V#QR+-D<
MCL3K1R;[DKA8\.- N'\)D8Y,9J6U"$?.H#CYUZN_!'Y:D+6^:U[W(&GP .;O
M>+##0*P"&M6:!K':M1@M%:"I/>9I ZS:8CU8T(HRL2#Y4 55"]- U0'N/ [C
MN>-4)<Y$X;)D?_,<_%E=BS$N!9=F)))-W8-CVTV'27\C9[ZP74V*U"Y4=S_"
MR#RH:E:T-2E@$':8E<M8\Z7I-IBL>43C9MWAW?X^WY&&_P"%Z_A2&0CJ#AJ#
M(.6H$7U77WUZ[C>D<OTDF'OV#N\?^)F-<K%&/9C^$P#=,LME2Q *% .03VK1
MPA!&B!86@LL#+I_;&V48+WLT>[%VQBB+3!3L6O%HI>T=JQVB/&9B^P,/#VG&
MBQ,=@L2H&2-VOY69@SV3U4#P/%@T;Y.#WG>=Q]4;KE;AG*)MPF;JG>(=/44
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M<RSL%21PG42_-7Q1%D<=^_U]*]*1YTDFY[6RG-BQ<%0TF/ 9A"A4]+-T\AE
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M7N&B*Q^-#IA,WB?^:96YY_M'C_$1;\=YGS_=^?2+V'Y?T 'Y<^--D[+]V_\
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MJ$ J #VX.J;<LW-W+.R<_<99<C.RI6DRY9;:5YF;_,9R>.IFOOR"*H:1[DO
MAS)KSX3W!\MRTB]IF/,?\SXWK%9BO:)K,3$QZZ_W^_\ K7";H"K-&AWJ_/'<
MT._TLZ;^)BMJU\;CG]MICP^/\TCO,^=IB(M2/W6F;1V_,_CMZ- 7D"R#0-51
M-^W.GJ+F)4Y#D$$( W.9QH]1KB7'WO8I&+6^*M(CO:)BT^7?O7O-H]<V5EX^
M'#)/DRI%%&.IV=@*'TL^>PKO]]=NW[7G;KE186!C2Y.3,P2**-2S,2:'8$ >
MYOC0T%'92SRY*Z@+JW;4KGL+6C1\9B*B799L)4=KVK/>YBTK2(_-N\Q'IN'F
MX^= F3C2"2%_Y6!OZ<_V\\_:]2;KL^?LN;+M^Y8[XV5 1\2*3AEL CQ5>>YX
M]_-"F11LYH/NN?4^XK\MH 9\HZ$N)117.207AFZ]RQ!9!/VHH0A3R6HY[1U4
M/;MR!V%^_P"[KQJO)LM9-4*KS7(%]QY-^WTYU+TK91@@F(BOPMN5)";(VA%J
MW?370*>'!KV8%%/\X,<D57IH)UK1DZH/(H;\"SXOM^?L/W6B^FC7T!NN]_<5
MW_IWH'0XA/EU>57U3K6XEOXPE<;*K4 :YI=!RDZ:-ZI5BP20I&@O8H[$78J6
M;@(;M<E,4FS[IE;INL&Y9'Q]FRH)8XD5N5$U H5*E054&FY/CBM>PR^K?3&W
M>F_369Z?P_P7J[:LV":><Q4I> F3XQ<,K2JYI>C@CGP35UJ4*.E5UZ!&FEQY
M51-0P*LI8Q%$,Q=G1EBPA6()O-Y P2JEBW; I\2L$:K>GK78F+!A8\6-CH(X
MHEZ$450%EO '^IF)X\Z\LW3<\S><_)W'.E,^9EN9996)MB54#N30"J% O@<$
M#MJEJK0RA1LY%=)ZX"+++#.9AD1%W<:[+\@DMZJZ-"(@$N:H0%:P<T@(N49?
MDXLO><##R(\6:8?B) 2(EY?I466*CL !=_[\:M]I]([WO&%D;CBXKC!@94DR
MI 1$9)"56-&KERU#I';CFB-#*[.&ER@W&SZ)2;%.+.<H"+36)?C:!\*FM?\
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M.NP%%;CFJE--9<)WCL+Z;M+ 40$H*7M$UV1G:_MU+$19BQK>,3ZH-YR9,J#
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MHMYQE[&6=SM ,UE=D)+>))^$WQ%B:PA%'JZO<$=OF]Z/<C^@/;OI0&YIN"
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M$Y9 S2FLUJQE'6T'[E44<S6*LPM!/\UF7V/=5]18L\+HNR0P.C8PI(K8-QT
M 4#T\4.6LWXUS;WLC>D\O"GQY9-]FS(91DL26Z8R#U,Q-]) *D>X U#2ZV%'
M.PS:Q'P9XK 9:7EE9+2NMHZ$)Z0LHAKKI,QF/  W=4(:LG$0I;&CXKQO$CCC
M3H5%7@D  T#78]O'!'L/%ZPK22,P8DF@JWR25 X /L/!X[_70=1^=5K?&/[
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M>C7(+-0NK';O>MVC;_3?J;^(N0FX96-MOIY<V7I7J$:28\ <0QJ19 ?H!))
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M)8'-3!.6+U >:22DUCM*,P4$V!T@DV15#N3[ >3QV]M"@LRJHLLW3Q9)ZJ
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MN]*R.PG!_ITJV$V:5]",MPCM3  $L,H11@+-%""^**?"_P *S875>O\ ^T9
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M:^?H;U&27 ZC9H\6; '(-'Z>!VLU[ZJTQ$V%"WR6!_G!3+;![6&FW-"0BN%
MZ"=EE3TBR5M-/49 .Q*?/8I",6G I0*[<F^;^MT+/Z=^?-(;4<"@00+-'P;(
M!YX[7Y[5P-"Q4?Q?MCQ)8G>]J_LCR_$Q':*VK>TS,^<VM2>W:>UYF8A_W^_/
MC335#CGR>:/D#]U7G4><?);ZP&E$^*Z&4?1I74BBZW']?)XZLO\ A@VZSIM7
MY'*9*DF 633D(KQ07E^8]0,T<0+,P"\7U< <<,20 /MV\]]3)$TSE44LY-="
M?,3XI>_?W/L?KJ7M, -)(\8KY?(.P"VFMAW_ 'BN,D5'-HM3QF+>-8_/:(GM
M$R\]+)U*0>/E-DJ>W:O'B_UYYTU@48QE2K D$,"I4W7/4 >H?8>PTW,_8U%M
M-I_D0H6&^,:27(-(>'HWT:5&T;<XXR0N5H&% Z0N84+WIVGS\Y]-46JL0"2O
M/T%D\$"Z!(NP3]^=-L@])\FS9XYJSR /?_>]5I)([UEA@E?,GP04@HN$5ZUH
M-08U50#A4%1Q *$H0U*WM6S!(\>R,JMTGI4E.4)ODD$6.1?L ;N^W@.5W165
M6/2W\R@ W5$<T:'8DBO ]M/'>S@M\?PS+6)K;.+RO12M!!B %C!$L>/LO3,2
MJ1X1;H@5)4=&1$,:Q+V%4-H^A_B];*A:OD8+\P!Y8 VU@GFP .WU!A*#KZR
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MGA .[5QQH)W"3W\\^>[2;)F.&+EL>HPRU49R!"<E@-4^*U!E(3R69L,82,4
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M2(P"FPUWU V--K,Z5M'5HUBW05K0+./MIGKIIZY8U%V=!8C9$T!Y>F^H&M;
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M-_4]A1K7@N[X"[;FSXT,RY4,;LT&1&:$T?=' \7P.GFGNK\R6LUEY*S!8?\
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M3D",B1P(VH@,5)EZ2&4G4ZP9FQTJ)/JY%VI9RDZG ?YVEU\E[0C$0.!.UEZ
MQL=MZ/"U&F*ATH+<A9O<7=NNU94N+'!M4J87PTAA20 !D5&4US=A5 JBI/(X
MYUG_ $]ZCVY<S+G]38TVYKE9$F0T8E8'XLL<ENO21\S2%6)H@!>D_*--:%^0
MBC(IQQ-'4>&R/.:1=DHD:+I51S&&89'<! ,5M&A;/(1A.5=(K@#,#EF#"?\
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M_-&RL">0&5K6U84P9@."#R38J]'"T+*"/48D:79 01F&\/+?>$1EUAJ2@T-
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MQTX8S2L54?:E6I&6H"*2PN.IXN"BP4QC:GR_;2Q3><22U!VO6MXK+81EKD9
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M]%3,+GO-98A4;1KE8N8<P*I9!';O6*YMMB@E:)-PGBRI59I$)4*6+?Z5ZB;
M]N._ &MW_P#5LP3,.R[;+A863BC#F5'>5?PZ'Y_B *J#K4V0>!7<ZB#N-%'R
M02PU0-Y*:]UDIIX"JG#4C9!]?X306OAXW)<D3^RX^]HK$WI48^5E?C,K#Z##
MCP$"*E)'2#\P  Z; [^>]]J.RR=EVC$V;9]PA$+SY,9:>/J$?07!$0('\BU9
MY%$\<'3N6%?1LRAY<;/QV,AK(Y_@"LE%T7V4XD---=,D.+N7O]-Y%:Y.W8/[
MI^&\Q-A^,R)#,BNC8,<#?''Q LH8@BNA:8,?'-B]4 VS BCQIS%/'O,VX1-M
MS_":3'>-)!)\02M<9  KHHWW [@+BF1R-+AV=E\ETH.7#G0KE<AQ\P2D!XR.
M"'1Q9&VNHVX4 *?'-Y6M:D6M6+W%_<FHP]HQ=V@,^:'R1@=0@E+$#X1/5\.0
M*Y5@I %M=5WY.N_U1)#MGJ';,J#"BQL_)5>N$/D"-<B0J&R5C+! 7)+$%*!J
M@.#K"MC>XM-\7EA]KD]<?DNZDC.-^CYIULIS-N.]3W[_ &1G"5LH[D*HO#D1
M>U@Q?XIM'%!M$T[)!MIBP]NEE<2D"0R,Y_FZ?A]*_,/E^8D?0COL<_U+CX2M
ME[\V3O&_X4*28RLT QXH'%"QD+*2$[@1K&Q(JQ?5K*6JF1U&=?0W,%3$4M:#
MIYF=J5L4/SUK0A?@S*W:))+?)>_<Y)\IBLR.9IZUNW;-F860)&RD,<0OX"*J
M*%KBP%4EB.[,;L$^:'E?J+U?M6]83PIMDRY60 OXV:1WD^('MZ9Y& B6S4:@
M!1P"2!HH[$5W:5SLDA-KCNB]CTLU09-%W.^$@C.Y@*T,M80BW^V%2[ VF CA
M@<4FEO&AS/4<4V[R08F.LD^.#'(\T9)0T6M!1LL.037(^VMSM?\ #_+P_2>-
MF[EN30X>Y%<C'CPYP$<6$$<YM6NS3!>.W+$$AMX.P?,#G<CWTOM6T1ZBF@X:
MF:[K(5 Q051*JB\FLP4DJ6Q($.U"3,5,0E;12;<<G/DP9$FR<:&:9P^)&D@$
MBQU19@A%D>!0 ['GG4'I_;=B@WN+(PMLS\W%QXS#NLSX\C0OD!ATQQ_$!4(U
M %RQY%J2"-3HT52)9!&M&KS$(!C3?H%UHGG]T]%R$%]>SI5I6*#XF+Q(Z+=C
M4\Q>9(U>RY49V]$>=9IX(E.0P<%>OM;DFQ9%D'YAS?.O,_6&V94>^3RI@38N
M'FY,IP8_A$%XPR@HBJ&5@O6.58CD$'Y@=1!LW:??RJU&(:NAGO;>(H'CUM=T
M^8D!1HI3(O"$'+UV0MR%:VP7,9%:2B!!(&844<T>YY.Y&3)RH_@ANN#$B*5)
M&.0P'<DL17Y\W6MEA3>G,'T\L6W[5E-E,@3.W+)29!#D2$KT=2V.D-9Z0P)'
M<,>R7%LL;E>1;W#-7)T 9C&;E;1 N_&!<LL]JZ]BB!0Q+R_K0N96M *7;J(W
MVP1\X>S%CDFW/\5D831%81''.U@\G^4\T?Y:JO H^U/N65C87IE]MP=[BREE
MS!D3XB_RH .70LH:[(X+$@$]NVB0_4S1P:MOTU'*RWVROMPNPID(XDB$"]@A
M*T^VR7$J743&%5E<-D;(OF"Q<-"Z'-G_  N+),?B&PJAHT+L&<A Q53?2K-U
M.W95!;L#KSK$5I,S%C..TP.3 @A7EG5I$C()JP"&)+5\HMKH$ZQ*!YN3PA/,
MXRL?=W>H8=0"6IN!S,^&RMKY?'>3Z(G%G#EPM)OCW)^4H9+=F/U+2TC,O,P;
M.9FS&.$\:;5/'A9+R9VZ#("22]<?PYOF5OE+ @(R *P(Y"GCY:]FDP<B7U1A
M9F[[?C8VT>F!@G(BPPLZR0 0R*[%599&=64$,K-1/5U@$&5!9'AR0N/Z6XOG
M9NC85>-E4<J]?/SPEUE3NO;8UCJ1748T*VR:35D2*Z-_F465B@R]&Q0MMT&.
MFYSQY$[%'AZP)/P\@!1E1V)*@*>FPW6P8V11)X/6V;%O^9G2^F\&?!PXXIH\
MLQLT'XZ NL\;SPKT!G)57*])B!1.E054:.1_6QZVR+0U%U<=M/1RL5.)5=;N
M1W/+G96XRR@ 7P53M(-D9*%@QW)FPDZKR.8TDD>2ZY52TKQN( O 7J41H31[
MV5/)-\ <]O.89\/'DV\KC=<L4\393-P9>B;J>/H-J%(!!8#L*(-D"%QC<BQ^
M.;$;60\L;#/]?+/FJ(BV87VU->_(]6XO^ZD9%QG;FNQ.B(A6J'VQ/&9>$)DJ
MV5V7-WJ/;9EW2&99HS) TBI<C=-?YRE6/4""O1SU'DD>->E>L-D])2^I<&7T
MOG8/^%Y:XV2N%)(5A#S7\2.1R%,2QGI^*AH*S1%7?K^7U7_I<9'%E,KJPV!O
M6N;73Z=:,U+GB',YI-#J6/(9-;,8T$OU!]4=G-)>6*OJ-&L'1568B:3;[5M2
MPF:823.,J/'F+,!74S3NRK=L*^)3*W\K6HX&LCZL]59.X38^'+B8N.=KDRX
M("*D#-#%UN0%5F(QA1%\59NR?/CJU4@.K'5*AG2OUKU(Y]_?N$2[,TCD^HQ0
M9%TZV6:L&]KK"+0:Y(7&I2ZYVK-,EU3%@"1TFJ/L/F% CM5$=ZL&_MKSQ5#V
M;8$'BN>QKO[@4* X _\ U:PMA=6,S-:JU8SSI]43:/87Q9ZZ0\Y1/L04=[5T
M9^X[Y,24DR0EQ$A?X!TXL2;,DRLN.:,) C)\"3FW#=986?E( -H5X*U?MI9$
M154J_61W)YKCD<<\'DFR!?RDUR#>\#%>!@(U\8C$/6EF)8BH1C.,2*8$3UT3
M'M6XKULPG\9(% *N6N08; GIY ZCR0!=D\ CD\<^.>/'%Z@%<\=N0">W(OC\
MC=]N._G+\'A;>XJ=L;*R88J4XB'J6]6H59&FPN"]9[A:L5@=QTN.PY&,DVD8
MY@D4^5O4.+/)CF+(>2(J'Z%Z@2R"10#?;I87^0.I8X&<*UCI:_-55V.QL^U=
MN;JM8P.;RX^ P,NJE7V%,U_C/)P<O:?)F--Y'(539$XZ1,G9QG%!*2A\.E1E
MPY@BDUPPPS91R_&@$J*070,BR6*+#J'57![V2/(-4!IKJ5)"HM@T"2U$@ T>
M21S571Y[<D:>R[A9<SF*N+YP&RKF9T%V+5!(0![$J0[N:JYV'X"K<3.8!VE@
M#2D-+S()ARI)H<5WCC:6<*.E1$9+<L.R@V%7FS8X(/-\+'U CJ*FQU$WV []
M/?N>.QX%7SJ4,+CB>0DVQN'$YKKJY9!HYORT6W=(C=$045 OH0O>_P!6F@N1
ME<ZN4PL$KU+@\Y%6XN9N\N0D>1AK'#U%7D5&)'<AJ9F '4 IM@6!_E'&NETA
M0%T8EB 5C8@7VOCMP.?R';G49\UJR]>[! B7"'[EY"P0ASD;J*UJ2L.]'!$A
MI,4U64F@#U<*0E0TGX+/(RH\2*2:<]*PABS*#72+-JJ_.11YHDD@BCVT^*%I
M9%5&0%ELBP>GFC;'P.*H58\: &>AAKLC;1?$:ER*LH!(!(H;%FR_QB(TT7SJ
M/M4][$K6Y8M: CB:UB>*02I'(H95=0XM2"59;!(*BB+JJOGWL:Y77HD*MTLP
M9@.DDKQ7(%WS[=NU:*6(:?(%3R(8:DJO+3+,JA)45_BDQ(&RQ\(C3$FM2A3?
M%6]15F\Q$L,:N2RV&!Y9:!(%=R1VXY% WSSXD#M&&5R&!!Z0UE4ZO*@$ ,.!
MSQ5BKK37PT 7*L!IM#]-I>HR+F9HV6A1Q%5V(UPD?N&YK$(?[,T>L.1Q6M9B
M(KSY6(9Y<>=7*-&;)4T'!(-'D#D>:Y]]3P9"0Q2HP1@0.FQ9!]^0#Q=@"_MY
MTY]5@UN\B8F(\OCI%1@7M'\S,W)XTF8K%R][6'/:MKWFW\>NF64QI\BAG+*
MI95]B2>HWP!P .>./;GACCGD?XTOP45'96",Z6!PGR ])8GN10[GC34B( G>
M;F'([WKW7,@PDQ# (I(RFHLS4D!F8+6JK2S0SS%K7(+N/T"5&8A;)"EG!!Z0
M#?FJ/;@ DV.PK7.C*S%%;D&K![CL.3]_ KVT1FS66 08BX4Z'(TZTP^PM-%5
M0DN2D#!4BS-3Q2T$(U:LHT_NKA88F:0W(<K&9(HVF)*_(O2*#&BQ+$**!+>Y
M'Y#4<I>&R(S+3*"J%>JB0 PZB.!W-&Z!H$7JR;.A"I5ZPV#Z0V)NQB*:3/&
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MZ19TC1&Z#4R^Q+ZAD.XIO?0B-(RXCP](<1L76UY/"Q_#6VHAE'2!TL6]'_B
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MHA1%8F\Q-K]N_J9F 4L1P 6YH<59//WY_/\ /@52[JB\EFZ1P?)H<"S_ $T
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M0!&*Z6:GO6AKS'U[E9D@PH=LB@SO@S,^?C-)$K!/D^"W2YKIZP5D!'53*1=
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M'D/-7\[YZT;V;.X0>J;-#J 3ECD PJL7T+ARJZ2&@13/.S#,ESBQ89+!@HJ
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MKP3R/H:[C]-.#3=8,16?U0H6] 3@E&"KHK)F^.*Q03.7GY>V1 9(LS]/0U]
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M;5**[DJNZ"[7(-EPH%D19)Q^(A?&D/6I*JSJQ96"J$D^44: %V.RTT*7ZY
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M*T2!E:VGCZB[&5IJY[8&6 *@VVRU2*.JAW4<Y\3$PBPGZD;<L*%OAS94,3*
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M?\*<7_\ 5O _GO\ _,^=^/\ ^6_T_P#N^C1JG^$^+=YG_#.!WG^9_1LWO/\
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MB8HO N,<>%!"5,2!XN</S+2L4H6_BM7R)6L16M[=[16(K$]H[>NA410 J(H
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MIA&81+((2>HQ?$;X9;_R*7TD\#FKXU9/ ^#?-1C_  9Q3[%/#P/_ (<Q_FI
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MB#=#.#LUJ09A#<3:<&N4-FK (J)IPPU"+0XR):ZM12LN65@2->M!U;\&+_\
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MT1PFF-_DV=QKAO%>$<.U>5=0N?\ -M2WQYO'>'<;RCR]K[#/^U;!57%_<<9
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C]&C5WHT:7HT:7HT:7HT:7HT:7HT:7HT:7HT:7HT:7HT:_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g96389g58q47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g58q47.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2%F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (4J^A2(X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!8            "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         .@   $U          $                          0
M       !-0   .@                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   .@     4F=H=&QO;F<   $U    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #H
M %)G:'1L;VYG   !-0    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      6TP    $   "@    >    >   .$
M   6MP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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MDDI22222E))))*4DDDDI2B][:V.L>8:P%SCX :E25#K5K:^G
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@ Z $U P$1  (1 0,1 ?_$ !X  0 " P$! 0$!
M   ("08'"@4$ @,!_\0 .A   00# 0 ! @0""@$!"0  !0,$!@<! @@ "1$2
M$Q05%A<A&!DB,353>9BWV"-A)"8G,C1!45)Q_\0 ' $! 0$  @,!
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MMA;"BRI)Q'3)CSB?P"E%XB>(GB)XB>(GB)XB>(GB)XB>(M27G:>M,U=); 3
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M<12N8*U+M(ZR(/QX,E)3I^5REXV((Q&"Q4")>$9)(\"3A#17<6"CT>D<J/@
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MN(RZED3<JP"F,;B#SB''Y3%EGZ&NNNRVX.1%V&==]<(O5-L9^E4(CJ#XB?S
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MI/DHA +0F\M(5<,27 R@P/-#:XD)>4R,NQ;D)F>N\=#M\\'KUVV 6I'+TF!
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MB>(GB)XB>(GB)XB>(GB)XB>(GB+'I9+HK HV:F4WD@&'Q&.,%RLAD\G+,00
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MC!%O-%9\^(&<-[ L"6@CA&-%>XGK@]/$QOOGI(Z2I/\ .UVU;#H[;UU=&7!
M*NM><V0U%7!&;)(":>8TX;AT.C0R+TVS:360[JEFX2+/ADL1FVA<F/LYU.W,
M^B2K2#R.* Q"?T2"8 $]H!S/UZ;>&TROFN'JB&6R>HVH:LG%HQB&7!<#:%6'
M>$<KNTX+%4(CBO[ E(J+5Y?\@AHFOT)5:<[CD0K@<7A$I?RM!A)R*,-? YL_
MB9QD]?2?P4((@[;'<;$XQ,_IUP<Y]$P7\"^I(#4<!GME2N%6;45H368U_9UI
MV#=!*#$*_D-;BXS8H&8VK)9G.H\*DRLP-Q Q%G<E7CDA)-Q!N+"Q#Z-S=R=>
M'A/U'[QY'M"?KGX_01&([G!Z3F\1/$3Q$\1/$3Q$\1/$3Q$\1: Z@N1Y05)R
MFU!RE5:/(\0AC9/:ZK:!T=6^&LAF\<CI98Y9LB:/Q %PS"E2+\$U<M5=I$?:
MBXTWV0<%TG*)/G\!)\8$C,>(7-Y012LI/W+!YG-FW'W4<O)=#(N*VMFV?F<C
M70ECP 87G&ZD=(T9S8QA0B#C9&%9N&B\'A,;"H2%H];L S.3Y=ZY(J9!!V(,
M]9G;>(_+N3'?9P(D@B,<H$D#E(YIYCUF<&3(S"ZPO:6$\1<_%_\ +_9'7G3/
M2[RX>>UX["-^>>J>3N);('6W53J 5+'KLJX_%9+?\]C320KVH=GES$V48CGZ
M&,C;)E74#V18N!YDPH9.MWK^V/QE:D0!TD%P[D%WR ! W$DGM*T0XX9[HF<Z
MJ/JLQSH*ADSYE<_'6 #<XHW'6!$]=8CE!K=[*U)$'EPXQM7$<U=*7,S=U4/F
M,D$OGS>(KYDJ44<K#6JD\?77]4G '?F)\)B!@Q_IR0(R,?=E6*<T<A=51GFH
MH#3O4UQ];5G]1](]-3 /7T8IN[,1</>EH2^:A*D=$+$BDLB+M:.#C0=R9.Q-
MHDCN?;OF0TB0$?1T]"<;?#\O7R0D$[= !\! .PDX!SY1V]7XJ8]*HH"[ECDW
MGY.TI8'^0V\69ZPS &,Q@I+GZ=?TSE0N^C\.&!XN)77QMIKLT!C&+'3\/&4T
M-<[;?6J&.@C^_H*U7Q1/$3Q$\1/$3Q$\1/$3Q%BTGG$*A*+!Q,Y?%HBW*O4Q
MHM>3R 2!1(DE<8V28,%2KMIH\>J8SC9-JWV47WQG&=4\_P O$648SC.,9QG&
M<9QC.,XS]<9QG^>,XSC^6<9Q_=GQ%@E@6G6-3!MI':EC02M(]KG.NQZP)< A
MH;&VN/KG3]4D1 <R^_&/IG.GX_W8QG'UQ_/'U( 3@"3V"J/VZ2OWJZT;:<<[
M2B;#JFKRP'E85B3@UA4758RSC,9@X"7RH[#"%NU!=)>[)H@N5)KL0:;"O*+'
M0IL%<%99))0XDW[+D^O7AD?6%>F,F)\LD9[=.GUWBZ.[XKPK"$K+OMM.^G.W
MHF=NP;3O(+FO'M75?6\LH&UI%4NLUE3 @]/4Y 9S^I"8]))A8%F6O.))"BTM
M1BE$8;9D 8%*O!<W5O9T'W%U6IT*-,?>J5'!C09@-D[N<8:UK9<]Q#6@D@+D
MM)T;5->U*VTC1;"YU+4;UX9;6=I2=6K/^Z7O<0T$,I4:8=5KUZA91H46/K5W
MTZ3'O;SL=9V$/FW3DIZ8L\!:MC6#64(AD4Z.L0P7A3R-U_;MPR2<MH_ %XMK
M--XG2$9@\2 Y@4=K\1)9M@ Z<F4K,F#BSR)7=_T;BFPU_BK2F6NF,HZ9;5;G
MWE5VI5ZUM=7%M0Y'VSC;T;>N:#*U>:WNJSJ=PP4*!J-IU*CZ5'](>R#B+V9>
MQ?C:OK/%]W?<7:M9Z/4M+.GPE8:?JFBZ7JM\^O0U.FS4M0U33F:G6M=-;3M/
MM^GMN--NGZE?T;2M<V]K;7MY8+\<HH^[=V X,5K^OC9?%:>='JP+.@%=P>_N
M:X&0MJ)UU=-[WS'&)F#BZ(@^@,K#CHLY*'SGJ)O  3TF/L(,JD%/<[9LXFMK
M2@ZYJZ9J%PVA39<6KG5K>:M-HINK6^HLHN#Q7Y??>YKZ<WEK5'4_M0IM#A\\
MUZ[]CFL:UJ=/2[/B[A?3*E]=7&CZS198:J&6EU6-W1L]4X6JWM%UN=.]\=/9
M>:9Q348^RMZ=S_"'WCZE)]U=3])QMNM&[G-0"371?)[<Q"8U<,[<12G>(Z<&
M:("TW$:HZV]3-@0L)5IW\TU':3.K6ESVO9:S#5K-GCEA'Q$>B?M#7;6DX,U*
MC<Z14D-YK^FUMHYQ( Y-1HOK:>>8D<C'W+*[AO1:X.:.$J^S76+UCKCA"_TG
MCNU ?4%/ABXJU==ITV@N<;GA2_H6'%#/=,:[W]>CI-S84RQYIWM2D6U7[XF$
MFNSEV4R?LZVY9SY/HC:$-IVH)K&8T:<5 ,K]K'I]-]Z:5@=@3\Y)@]HNS<LO
M:4 )@^DRM3L7[92+R"/" F!9L.8YAKFN:UX<US7AKFN!!:X/CD+2"00Z1RD$
M\TB-POG]2C7HU:EO5H5:5Q0=496HU*;F5J3J7-[UE6F]K7L=3Y'>\:\#W?*[
MF AQ4EZ+HPBRL&T.C+BA%<B[NM<N T9-8VDSE+RM*[A\98QN*PK6Q7T?!EI"
M9<KZG97*G[$>+#-B<DS%A*9@7&6<F/:7C.P$R!F.Q/;Y#X_-21F,,B%AQ@S"
MI[%X_-(?(FF6!Z+RD0P/ ##/\1-;#8D))H.6+Q+1=)%=/5=#?":Z*2Z?VJI)
M[ZE%AE7T74%+:&L5;7D9ACB2JLEI&3$L,9.2+<8DN@*U/R!WLY-F41#=PX;!
MT"9!R@);+K-AR;9%7=/8GQ)\S/XK;'B)XB>(GB)XB>(GB)XB>(GB+%IG!X78
M\=?1"PX?%IY$R>[3<E%YF $RB.D-V#Q @QW?!3C-\-=[LGS5L^:9<-5,MGC=
M!PCG19%-34BX]Z+#48#['IWFV"WKQ$]C53?($5LF-7#5'&_2^>LI=*%K<E9K
M>B))<H.M5N<VT>6>2IY4DCE8R?:Q4= V#%%F,%X$HZ)#DYC'Y]N@ZX"V8Y08
M<):!_-CO)ZY,.Y3N23MOV8^+">(GB)XB>(JW_CN_QOY"_P#4@O?_ (^I;Q%9
M!XB>(GB)XB>(GB)XB>(GB*JR:V)R;4'2G0Y+NJ1T[""\W<1M+GZ6]%N(J-AA
MSG8;44"2E$$K203S72,8)"[G;VR=LB#"'694]UDD..R)D]!%X/HT?#U^WKPL
M$[ F-X!.<]AN=O&,+0D$Y-MJPH"7F)[OKHSE?CY>73QW15'0]G"Z,-0"E59>
M85@BK^US8I"T! (N'RF:@<'E"[-.OZY?12%.8^*4#NA#3Q5JU&WINK7%:E0H
ML!+ZM9[*5-H[N>]S6MCN2!O\/=T_3M0U6[HV&EV%YJ=]7(91L["UKWEW6?(^
M[2MK=E2M5=L(8PF=M\QNDQ/XG^:3:IA>[[MO:U--=D5YQ%K,3KB9DMTOY)KG
M+RI(70I*2MT]MOJLH/E$L([8V4RF->K*X15Z?>\?<.VSG4K:O4U6LV.9FG4G
M5Z;),!SK@\M$MD$_]2^M4@$MIN, _>^'/\,/M2UEE"YUFPL."K"M!97XIOJ-
MC>U6S]YE'1Z;JVI,K#9HU"AI]N7N:VI=4FR]O-ST?VS>YGK$]T7R0^D$)JCB
M&RW%F5E"I'+II8^KF<30+"A-XJ/Y3/$!LWE["9"(B]>31.8[O'S<46.#QBZ#
M(VSSH;Q9;\^@V]W[BTNN(#7=9-H53<MM:3F.9:5:QJ4:)>^YJN8RFT4J3?>.
M<PN<VF\OS4]B&H4V>TC4="=>Z[HGLQ9IU+7WZA8G2+C6KNG<TKG7+33J%I?7
MPMK?2K"G<7=S6J7MU6-K1I7#:5.K=V]*CMRO>OH ?D-GW=O;AJ *6IM8$JMF
MW9  E<L?JGY=-93+7$*H[$4'N"U*FW9:6S5U'F37:-;QQ4S(#^AZ+?O$?K,N
M&JZ'QS=UZ5[<ZMIE&YH!_NG!U.M;VKI?_P!;;V=71ZM-E8TSRNN:M=]=K2YE
M-]*F]U-WT"Q]HW^'+0=+OM!T;@GBZ^T[5G4?XA2=2N++5-68*=.=/U#B"QX^
ML[VXTL7(YVZ11T^GIM6H+>K<T+VZHTZZK(ML1I:,ZK^KZ/KV61",:!)1.(DZ
MLMKN(,&1A;)))<R0%)2F6_MX)EPP>M10I\6UW7?2[8MJP9I%/N?VEJ#]&T_4
M;[7>)V:_1;=VUHYEFVV:VVK<['&WILI#E?<$56W%0P'4J-H]H8'.>!+SA>AQ
MWQ3POPW[./9!7]F=_<:/J^M4JW$+]4=7U;3WV]6BW4KFXO"]]#3:;K9^FT&E
M]6G=WNLT*CWNIT:'/?=\1MAEDZ+,WS9?+M66CB&F875 MI:3Z65\ /':6&/$
M6UH"-YE&RW/A>WQP621Z 2*3JO&=HO2D$2)LV3HU(CY QR>L\1ZKI!;<4;73
MM1LZE&E6HFI<5]/J/ID<KG,OJM&II58U'-=691;<4KEM.K2;]GJ?=>_IWL_]
MD/!?'5.MI]]JW%?"_$%G?W>GWK;;3M+XHMZ5Q2<VJRG7X:L[^TXUL66U.LRR
MN;VII=YH[[NSO*SM4M RK:VW1U6OR;Q6QA[IL;JI@"60W2%F@+ZR H9-FN\T
M_#2$NREP1NH8:LZ>:YRDW':2-51SKG&NJ>=%$\[^O8<>V]]3=[[3Q0<#[NM1
M?>TZ08YTCW3ZNJ4-+M2]VS6"L2Z0($KF>)O\+^J\-7%%]CQ5<7]-[77-C?V_
M#-]>&NR@YKC=T+/@[4N,=:IT:!Y7/N7:8QM$@DN!8Z*/?F(L:+JV74-4"^?+
M*IRK"T*D]I$HRR'-RT'MZ9$'6T1R8:1:F)?/*I60KR/&GZ;J1::Z%S92T=,[
M*_?'\++<#QHZK0TFUJ:-9#0FWUXTW+ZVHZ=8TG&U>R[MS1M[;4:MC4K5;AHK
MF[H!U8"W+7U.2M#OHGL$;:ZCQIK%IQ_K]3VFU.&]"J4](I:?PGQ1Q!J%%NL4
MKG1M49J.JZQPKI_$]K9V6G57:>S1=0<RQ<_4FU[:W]]8L?2N9^+OM\W:?*50
M*W^ F<.?-5GE40Z[)PS4:0Z[OV2]TC 4X].N?L<Q>>FDF[<2?%3-H#TD$^'R
M1K%7)9TDX&#^^Z?KCG6]@=6H"QJ7EK;/9=MJT:^FU[BK2874F7="I4HT7U*A
M+K9E5X;<4:E+W%6K6-2C2_,_$_LVIMU+B;_(VHGB.UT'5M7I76A/LK_3N+-+
MTNSNZS:-Y6T34;>WOM1M+6V:VCJMU84JM32[RWO/XE:VMDVTO[RX'W8U\E3Q
M$\1/$3Q$\1/$3Q$\1/$3Q$\1:XMVQ<U+6TOL?$$L>S<Q(7DG^PJBC&)G9,F_
M]H0;_I\0B^SX9@R4_P#/^/AIE^VQ^7175_$_\?V[$7-_R)*>A8->\ @T$<?,
M16M$2OHHQ,W-2V+\<?/<6HN-#[7M4G/9C'Y'9;@F;G,"K54Q)C"I8L =HN(X
M-=/7H-FQVT22T@$8'K/[_1;P1$,F#G[P.!,X($]!(R<0NH?U6$\1/$3Q$\15
MO_'=_C?R%_ZD%[_\?4MXBL@\1/$3Q$\1/$7\UEDFZ2B[A5-!%+7*BJRV^B22
M6FN/KMONIOG73337&,YVVWVQC'\\YSC'H2 "20  223  &223@ #))V6F,?4
M<UE-KGO>X-8QC2YSG$P&M:T$N<3@  DG 4<+"[%Y4JO13^('0M01QPDIJDH.
M<3L \,86VV^W5+0(->/2ZBVVW]E-)-CLIOO]-==?NSC'N*K:]HM!_NGZG9&L
M)_[/2KLKW.-XMZ!J5SVQ3.<;D!=XL/9C[0M1HMNK?@WB"G8OVU*_TVXTO2O,
MZKJ;;/3F@;DNN0&B28&5II3Y$:B.?7^$E8].WVCM]=4BM2<[V02C.RF<YQIH
MI+Y0(BL7;_=GZ9QLL5QC.GU5TPHEKMOCP_QQM3_PFE:U>'H1I[[%I\14U=^G
M,+>O,UQ!&6S(GWO^C>K:2=>XT]GN@<O\[*G$]+B6NR" 6NM^!;;BRLVJ)(-*
MHQCFN:YM3D+71\"G0O<TQ^Y"N.#M(2V<_3(V2]!W]7D;8?A;8_\ &J0B=88L
MN7,L8Q_:4;K-D7B>,;:9;_=]-O/M.OUH-+2[&S:=W7^I.J5FX_\ A[&TKT71
MU_[>WP)&5/X1[,-/C[=QGQ+KM4 EU'AOA&A:63R#L-5XAURPO*<_Z2>'*N#S
M.#2WD=Q@?)?<%[V1WO=,GM56O-+6YH?Q6-C#,!(24S"J0S'14!/;GH\E/(V,
M-NXLE-4T3;L3( B#.0BQU\F6F[V.RX&/SU77M7U73[W3+:XO&MK.N75:3+&S
MJ6U/5'OI/8-,HFYNK@U74Z K W +J8U/4-'::#!2K.'VKV:\#\$<2\/\7ZOI
M.A5JMBW366E[7XEUVSUB\X/LK2\HUW<7WC-*TG2Z5K1NM1?I[QIM2BRO_E/A
MOCFH-1KNO;2C5^V&=<"S%-1%A8,5@A>>C,/ X05<U_3,7 (5'&RV&$<CL+H*
M##HN5;,6Z&GX:S-._P"&!6;9/1H"&N Z3-^[X&^TWAUEVZEJ;>,^*[ZF6A['
MTKZK2HOJM%0-864[,40&U&ES*%5[J>6M'.WD7T[ASBSVKU]#;7X1J^P#V*<-
M77O#1N:%]P_0O+VC0K5*#JU45;K7&WE1U2G5%.O?V=K1N&\M6I4%"K[\_,B
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M :0KMAC=,,*E&\IBPS[M(VMKIVKA_6:&OZ3::G0 9[]A%:CS<QH7%,\E>B3
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M-M ':7;LM..+-&PPR[A#</%B-\F&$B)+21,?HQ"/!1)J4<[)M%F+I);='?)
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M;<Z;=5;JK8UZ!:ZG3OKRDYCFUFFGIKNOXY^PI%T!-B-?4!8TLJ*3R:*4]2A
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M3%86E,UZ\A$ONXA^&WW@S$O,V!D'EIJ@5+--@18FZ') VVI-4M<I$DC8\O\
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M,C28QH5C$])CXA2A\442NK.UZ(XU95FZN@L?0<VW8 6NX<'BL?<R0PN2-%1
M/)XDR;*(_I4/$&9'&!!R2/%4V+ M*8T+_P#*1.#FK@J 3M'Q('CU(S$F-X![
M*6OBBT-?]^#N?(L-EA.L+NM%F0+;BU1U'5H5LTV'23&O":IL\.%+(;"H^BDR
MW;JEW*F&Z;Q9LWV^F5L;8>O75/B!Y_CY#JOHYLZ#@/5='5WT)5J4C2KVT [D
M]%,RT&O&SZXI J0$IO'89PHLHV0?*CE7@Y;\91)\,79$&^^[=VEMDJ1!(.X)
M'R6\?%%$P#VM1,CZ MWFT>0EZ4_H^M?XK3]^4@LG#0]&)IG"$=?.(W(B@]HE
M-=Q98608$740;&@Z)!@2#IE5C@DL,8O6WJ?)6#]8^*R/E_JFJ^NX+);$J+68
MZ1Z*67.*G+HSJ&G(#(6\MK]^B.D#=S%I,V8R(3HDX<)ZZM3PP280WPJW(BF#
MQ!9NF0@C?L#\")'T*\VY>OZ:HNW**I"<KS#:>]#S%C"8"B"A,A+QQL7),I$_
M&YEDS29I12-8)I120?I0Q\8S(3&@<L\%!'HT.8>CWKUZ_)(W\-_+;\8^:\S^
MFM1&W7[?A]H6//[SWKXG8CQNQ .5X>''!VX0@^CY65?B:,6TR0!R>+R1:-I)
MKO&T>D\<*/-FR!H;^8)RF.;$>8G.TC?.8\!.REKXHHO6+U_3=8=%TCRU)5IA
MO;%^_K682D+A$B?0]FF%C$SEN?W-.\LT8H(>DQ=?RS(@'H4>2)WL)6<[B$!F
M<$/%8,$Q@1.W4Q_>,C'<3K*K?D4Y[M^^=.?XFWLM(\4/W9$X3.#<!(BJQLF5
M\Y%V0*[(]!I4HNHN0>P H^T;$'1,2'$$\H.%(\2,):I;JD((W';MB1(GM(VZ
M_(K:'5'5<+Y(@6;#G$!NV?@T6IXJ70I6JI#9CR,QF*BMS4HETL4%:("8Q& 0
MS3+EV1.%66[GZ[)"VY!9%PFB4]=!^*P()\@_-4GM+ENI(N=F$AD?8-=[6I31
M5A7TL1ACN%J5H:MH:\D,P)C!X,(7,PN/EB#&*[NW,J;[-D\EPHML[:.G$D>O
M*?P5@PX_[=QUWC;P.#V4V_510JZ\[PI_B8>-D-S1.[W4'W;L",OLFOJ?EDXK
MJK09.0L8LP.65,!;?43'VKHT01;H#FJQ21+)Z[N4@F[;9!59LJ 3L/J).^PF
M3MT';J5ZL,[1KZP>B9ISC$*[O<X8KN5.(1-K395476HF-2Q"M =KX!%[13<[
MB&1%S%9/&\-&RZ.BK@J?$#]-?N?H*[DC;Q$CRDC;S!6LQGR4TN5M>RZ/2J[J
M)G:=?5J?M\)"S'/DW"'KEKJ,3%G S4FI0651:$)LU;R,@Q0;(+-0[PJQ<X+"
M6[X8DY=HD@Q/B!N)DB=I[ GX$"3A;7Y8[)K7K=6VV<"B5NPLQ2$T'U]8D?M^
MO7]>G TN(Q]E*-0OZ>_<NMU'K,(3%/23;;9)RP3*CLN4=,/$<[$((B>HD09\
M/Q!"EKXHGB)XB>(GB)XB>(JL^QN4^O9/3MHP/DR^"9<UT%8;/%K8Z*M\U'FL
M H]_^Z7,Z@/-LC@]*SYY6YJ5HF&,.9F34:DZD:B^FQ 4XUD8P8]P\O7?UW6A
M$YQ&1B<@@Y$B08B-O#)*A#9'Q;=02R.SNMX!&.5Z>JSJ#EWG/EF[(G'[/M*3
MH<]1GG"RYF0$FZ2=DJ:!NKAWE-3RG M1A-]*N?"K _$*OC9\?HJ\?S]-NB C
M_5)@N.TR3&\GPSDSMC==$^FFNFNNFN,XUTUUUQ_:SG.<:XQC'W9_OSGZ:ZX^
MN<YSG^>,_P OK]:LK]^(M0W%4J]O!@8="U;>J;8)(VDAV+T[*AT3,F=&C1ZU
MS'SCLB D";R..LO/S3M@DW;+JNVC)7#S35'*>Y%4A>G!?7W1%T_(*ZD[7G*%
MT_V'RRRYEB,D!VW9DEL:)Z5FO;1.KIS(H,\H>-QUSO+"=@"=)Y%AUAK)Q-B/
M(Z@I#,E54,;R#)[$1C<;_K\.RV" &P3().!&_+@&>P_V[]PI7\2\W7_7EM](
M=&=+XJ8+95\1CG.NFT&IB4RN<1"/Q7G*'RL&T/N)7+X379-X;G$AG<E,*ADX
MMHUC09N#%X,FGFKUWB_M^?K=0D0 )Q)R(R8[.(V ]%6/>+*>(GB)XBK,;T5U
MKGY/-^JW$7Y[3Y_SSFOS-KE&XK&7M[,>3GJMJM)[M"5*'0AVIE:2_A1A>)8L
MO9D@$V5D6DH</]-8^JZ@QX?.)^9 5Q&\F=N4".WWI)^$ 'L,%69^**FSY(?C
M0M[KT^8LJGNCU*_F;^,T'7[2#2^*1,M 1\6J_I2(WQ)"PB2.HA*I='#Y4A'!
M$A<L0S9(?.9#7=>1R8NM(JT4W8%II W$X=F!/WF\N_2.^=SC*N(8H.&[%FV>
M/-R+M!HW0=$%46[=1^X21TT7>*-VVB;5#=TIKNMNBW3302RIG1'31/77&"RH
MI]S5+=-^\PV91M$2N,P*86\R&UT>G4E(%V.8A5\K+,Q-LF8SH%"&W3^;[5TO
M)!T,9K_I#'$A?L7KLZ-299WW*C!!/0SM.W0@[@]?#LI#U] XI5L#A59P40W
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M[60IPZV)14[=U'I:!38B#ZA0O'-4WS)DWPK'CKIW%GZBI$0[5V>MC^GUV\4
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(*]WU1/$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g96389g59u30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g59u30.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:84&AO=&]S:&]P(#,N,  X0DE-! 0
M    %GR^5U8X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!7\G\         "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         /<   )<          $                          0
M       "7    /<                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   /<     4F=H=&QO;F<   )<    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #W
M %)G:'1L;VYG   "7     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      ,!0    $   "@    00   >   'G@
M   +Z0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M9\!J
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0,1 ?_$ !X  0 " @,! 0$            &!P4( P0) 0(*_\0 4Q   04
M @$" P0#"0T%!P(' P$"! 4&  <1"!(3%"$)%3%!%B(V(S(U46%T=K2U%R0W
M<7-U=X&1L;.W\"5"H<'1&"8S-%+A\4-R15168F6"E/_$ !P! 0$  @,! 0
M           ! @8$!0<#"/_$ $L1  $# @0#!@0% P(#! <)  $  @,$$042
M(3%!4? &$V%Q@;$BD:'!%#+1X?$'%2-"@C-28A8D-#4E)E-R=K*T0V-D<Y*4
MHK72_]H # ,!  (1 Q$ /P#^_CA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$6.N+:OH:JRN[60D6MJ84FPG2%:\GPHL0+SF>T8VO*5Z,8O
MPPB8\I7JT8F/(YK5^L$$M3/%3P,,DT\C(HF @9GO<&M%W$-:+G5SB&M%W.(
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M6OT-U@-+9P04\:=E<G>Q)^9L*XD2+)JJRTJ!M?,9"625U^QY7^?)!:_/SO\
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M+@W\E,P_:'^K4^"Z=L>K<7UWZGK/1^I[LGJV/KL!1V&/SWJ(Z:Z\ZLNM_*[
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M1Z*YBEC12F&CVHJ*K5>Q/<B*BJGE/*?CPAV*KRBA=AW%+46[]U!CNLZR#8.
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MDGYJ+*I;NUER:R#13)9RP)57'CA5;VIMXXP>V<5[_A &5SFL_=$:CFJ6)/Q
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MMJHD/06\^MAN;!5\;6L8&KD.?=K%IRDMKX_773KR\%(9O8OH$A&@0Y5;U/\
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M)OL1IK.4UIIIW?\ >7XKF_N;%5?*#$C!I^*-\^5YLN'8-088P"GA:9;6?/(
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M;=3/@5^*LI.7B[L:+"+H:VZ.V,COBFK#HJMX19#L7TR>K3?]+===<X3L.O\
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MN^F0*2E+H[L]L"+>15AQX<8$!0N4,F.RR(9TZ.]MD!\AGMD1GJ$8W&".O?\
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MJ)^LJ-YR11U+G!@A?F.H!L#I((C>Y%K2$--[:D7TU7"=7T36N>:AF5FCG"Y
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M$3A%@M3^S.B_S%;_ -GR.%#L?(KJXG]C<I_1RE_LV-P@V'D%)^%4X1.$3A%
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M-:(+H0D(]@:PR*U2,1SW,1%3RJ\^;:O#2^0BLD!DBBC =2N:V\<%3&<SA*2
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MF_T\F%%IH.1S+Z4TID^XH<G86$&XA4M>2)!CE!_>5C&O;,LQ9CB0A%J"!^7
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MH)O^\"373?B,_P#W.CA.'Q_*A53\?/"7 M?2^W07>'?4A?;[+:N5SU1&L=,
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M-8W_ !>4_)4XZZZ^Z;^WR6S_  JG")PB*GE%1?P7Z+PBZ!*JL-[OB5\)ZO\
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MGT!;-*==MIH-3.;)G>W[FK)TP<RO@-<TK75.=AO[+T\X1.$7!)DAB1I$N0]
MQXH#2#E=^]&$ U(4COXFL8USE_D:J\(O.O;=GZ+6R)MI-L)M=3#0QX5-%,2.
M*%!&CR#=(^ YKCSU"B+)*K_"D51L:@QCY.=]OEI\U-S<$6X\?.W+P\S=0)='
MIP4SUG7EN<3WC)%J?O&2D.)(E/%'  :M(A/+RO$R09Q'>Y?<3PB)XXOQO8:6
M.@X[WO;7Y^J6/$Z^%[</&_#GQ/-=\%C>I%#'FW]M,42J]K7V$M! <]?<]D=C
M2-]@4?Y5&JKE5?+E_'PC73CX:"PYGB3_ !P6.7_I'J3^FWOQ6P?2W9=T#20<
MA=SSV=;=?&CU19CU+)@3XT8TQL=AW+[GPSQ(YT:,BJHBB&C%53.X_;SUZW_1
M97UMSVZ^HZON-RJIPB<(G")PB<(G")PB<(G"+6G2]SZMN@NZ_&9ZDGU>:L)%
M5/D74N8"5;6<!RLL8E5\JJ!B)%D-?#^8G-(,AFJ5K?A>$7;J/L_1&DIY<0JJ
MB*>LB;/$R!D;HX(9!>*2?/\ %)G;:0LB+2&$ G,M&K.TF*R5M9%@]#1S4F'3
MR4L\E9+*R6KJ8'!M1#2]W9D0B?FA[R?,USQF RZ&Z,1LJC<YRHT525B#M:Z+
M8.A.,)\N$DAGE!2A,<YPW-<US45S6H]&^YOT7FNXA128=6U-%*6NDII71.<W
M\KLIT<V^MG"Q\-EM6%XA%BN'4>(P-<V*L@9.QC]'M#Q<M=;BTW'U4NYPUSTX
M1.$3A$X1.$3A$X10KL7]BM!_-!_UJ/PBE-=_!\'^9Q?^ SD;L/(>R+N<J+A?
M' 5SGD )[W"='<YXF.<\#E7W!<KD57!<JJKAJOL=Y55:OGA%Q?(PE:UBPHGL
M:YI&M^7"K6D8U1L>UOL\(]@U5C7(GEK%5J*C5\*1?@]96R@K'DUT&0!PE H#
MQ(Y@J!7(Y0J,@W,42N1'*-6^Q7(BJWRGGA%^HU=7PAC##@PX@@C<((XT4 !B
M$Y?<X0V"&UK!N=]7,:B-5?JJ>?KPBXXU35PA_!AUM?$%\<DGX4:'& /YDJJI
M9'L$-C?CD554A?'Q'JJJYR\(N2%7P*T3PUT&' "0I#O%"C!BB><J^XIGC P;
M'%([]8A%17O7ZN55X1=SA$X1.$3A$X1.$3A$X1.$3A%KGZG^QM%UEU_G[C,7
M]#E9U[VGU?B)6ETH(TBGHJC9;"MH;:TE,F%!%;\I"EE*,D@K!#>B.>[PG"+4
MF']H!?5<6ES-CUNW::^R/L*V+ILW:AI<I:$II=C#R=X&MMA.MGT>K+ +'?85
M_P S$@R(LR1Y;!)#<4BQ6X^T;LZ3&5XZCK2/+W5QT7&[0!8PM;3V&/K=.[(S
MM;(RL\BC;-#'2'5S!LN7M?!!(5L22])02,5?KKS3AUUQ4SE?:%4);BFR9NG;
MJXF74;5Q[<-=JLU:5$&92CU"5<4,Z0*+"T--JG9B;&AWU?[ZJ&92CL7#:)KC
MD67Z?];F4V.UZTZNR73%I10=A1 N)TZFM,TS/9&38WVUI5K01(HJ_P#2(D*R
MQL]VCEYX)HU/\]$,=QV&80KKEUUR1>AO_7_7^WA$X15_8?X3<U_1'3_VEGN%
MB?S-_P!WLK X62<(J\ONINMM1:6%UHL70W5K:U24D^=8PFRCFJVF'(;&:XBJ
M@%:<(2M.!!2&O")S3(HV>TBXI'4'6$JMBT\C#Y\E;"M(=W%C+!8B!MH-5#HH
MM@TK50RRQTU="JWE<1SC0(PHI_B!16J1=B)U3UQ GS[2'B\_'GV=E*N)L@<
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MCO6=#)ST.U@Z PC6%Y9VUS*"&(2)!!)T5K/OI<$;3^TI&QIME)!$EF8,\J,
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M5&M@V\<; G(Y$\!"8+!N_%YO*_7Z4>-X[03MI<0IW3-UNZ49),K=W-E_(X;
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MN93UV(89.VOPJ2"/$*8.?2OJ(S+")"US2V9@(+HGM<6.#2"&N):;@+)/A')
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MA&(5+ :JH&:,.%S#&ZY!%]GO!NX[@&W.^/;SM1)B57)AM+*[\)!(?Q#VD_\
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MOK^FBQXDV%SQX\+\K:W.G#35>O'")PB<(G")PB<(G")PB<(G"*O.LOX!N?\
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MVL!#H\V8-6[73W2V:P=!FIDBE<W6PZD094J;;W5Q\H<B*I&0PVEE,BPB,&K
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M"%)#8M1M@&1% 84YJ#8%&S!D&YDEJ"&P2-,CT0;&L\>UJ(A%^7U=80(H[ZV
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MKF]H_P#S'$O'LE6?_P!A2]<?LL_4?X3,/_H7D_FJ?_Q?/_Q?[O*?X^<>H_\
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MKQMLX@EH"VSLAVED[.8FV20R2895@4^(T[23>)Q&6IB8;M-32NM)$;!SV=[
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M0TT:JKI;+:++D/JZZ05APQ7-(8F=U5D9SV@^"[]>55PU>C%;X8QS&(SWN7F
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M8I[7=YAM6&D',V.H+F.:0;_#41!QOP%X1XN-R1ZEA_\ 4W"JIG=8[A4](]P
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M>$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1//GS^/T_D5/]GG\?\
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>PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g96389g61i18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g61i18.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1M&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &RJ^:50X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!7\G\         "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         .T   )<          $                          0
M       "7    .T                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   .T     4F=H=&QO;F<   )<    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #M
M %)G:'1L;VYG   "7     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      0M     $   "@    /P   >   '8@
M   0F  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M_P"JU^]<CZ$#<<0  27XMI(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! ?_  !$( .X"70,!$0 "$0$#$0'_Q  ?   !! (# 0$
M            !08'" 0) 0,* @O_Q !R$  !!0 ! P$#!@(/$P<&!14$ 0(#
M!08'  @1$A,4(0D5%B(Q05%5%R,R4E=A<8&1DI.4T=+3&!DD-CA35'B5EJ&Q
MMK?!U-77\"4S-$)8E^$G-6)E=_$F0T1%1H>BI-8I-TA68W)S@X7C9'6"AK*T
MM?_$ !X! 0 !!0$! 0$            ! @,%!@<$" D*_\0 :!$  @$"! ,#
M!@4-"P<)!@(+ 0(#!!$ !1(A!C%!$R)1!Q0587&1(S*!T? S0E)35'62DY2A
ML=+4"!87)#958K3!T^$U0U9RHK.U)31$8Y6CU>+Q&'-V@K+C)C=%9(,G=,)&
M99:EQ/_:  P# 0 "$0,1 #\ ]_'3$'D?8<>,N\YDY>CNKF-G*G([&,M+%C6,
MW.H8UK&F$(B-8EHB-1J-:C6(B>$:GP1$3K[O@R'(S! ?0V5$F&+<Y=1DDE(R
M;DPW))W)/,^W'YT57$.?BIJ0,\S@6GF _P"4ZT"PEF78">P !( &X)%_6F?D
MR\O_ **W)/\ ?SJ/]J=5^@,B_F7*?^SJ/^YQY_WPY_\ SYG'_:=;_?X/R9>7
M_P!%;DG^_G4?[4Z>@,B_F7*?^SJ/^YP_?#G_ //F<?\ :=;_ '^)\'K.:S*[
M*M%Y_P!VW3:#(1<AV%?8Z[4UN:SF&)F+'$M[+6RZ&19["0B$&*>J#HY4BDMP
MH(CB"HCQQ-=:7AY):WM.&<M\SIJYLKCECH:.:KJLR54:2GBHEI1IC"M(4FDJ
M 2(7=HE5HV?:UAXCD@H1'Q5F0K:S+QFTL,V85D%%1Y8S2)'/-F#UAU3%DC#P
M)3'09XT$KL)%C<2<8=UXHER9?<Q7>=CHJW16%I ?RYH23 Y,Z+I2/<YQ:RP-
MDCFM5Q^EBK)$5\#_ )G*E(D@@D#>5Y?2_!<CP1TV14M49YJ6**2/(Z54D6J:
MD42*\T*:EA%;2-,#9E$\84,ZNJ>P9)QTB5,E7Q!4T8I8JR6=9L_J7EB:D2M?
MLGCAGD*O4-EU8D#?%<P,Q*H\9?+I^*^Z4O2B45MS3HP($U .<MR:SE.[O3ZV
M!^ER^1N;8>KCO0G6,&=O]A1U-B.PT4A; E\,370!6!(E,^;\')2O40</T<K>
M9R5=.)<FIZ:.5UI*RO@A:8TSB)JJFH*B>)VC=>S2[$-)$LE=/D/&[UBTD_$=
M7"HKHJ.HDASNIJI(E-?0Y=4U"0+4QF=*.KS&FAF02(QE9E6XBE>-%R.3[@ME
MC =95<^Z1TMO$0M702<C:,>RCD'Y!H./Y);Q3[P"&OKGFWPY,9-:MZ=--)7@
MQU2J>\D*]7UG"]!7R44W#-&%A9.WJ5RFD:(J^65.9@4_9TLC32B.F92DWFR*
MHED,P$027SY?EW%F99='F$'%-9JF5NPI6S>K692F;4F4EJDRU,20PF6J5E>$
MU4K,T4?8?"M)%B1X;NVFDJXHN2-P^2UM#*D=K^1=B*V \3=T_',HALALPT0A
MS=)>5S2*N=[+>M!F:7;5]>R2!DU;9AP0JSNV4Y:%@ACG>V59>Y>-\MGS821K
M$'9HS24\NB91V,TBE(99;,RT)E?'KM BYOF>JIFDIHP<VS&,+*F:T^3O'(92
MBQRBMJX0\,C+/#$PEJ(X@4U<6>([MZBHDNK'D;;##19<O7R")R9J2+9*H(>N
M/G<RJ&-F/)]F!:A%SGC03TX;7RP6%J(6(6-!,.8<$33"GBRG+W8UB4(;T11+
M )I&EC4&9HUC2\L$D:QNZSR%5:*%U9'-,V6<>P0-439MF4:I0O7]F<XKFG-/
M%'#*Y6!)&E<"*>.1Y40TT>IUEGCDCE1%=N([@['-8_19SGW3VCM!FJG0VPAO
M(UY2LHG7$-]:P@133Z$@FTDKLWF[:]NYT!"C '"*AB:;,T92['G_  Q%5UU+
M5<,T<(I:N>EA>/*J><U'F[4T#2$+2HD2RU=7#3TZB25I7D1CV:%^S]/HSBR:
MAR^KH^*JRH-7105=1')F]33^:FI6KG2%2U4\DS0T=%45=2_91K$L<B*)#I,O
M9'Q;W=R0O(3EJW:U4;,"U_-5HV:W$(<1'7G5<3K=)2!;:8=D%>Y[899I"X'3
M10QM+D%I;..!PVDY) ;:ED/[WX=,#KH[6.9NPTJ\"N'FM<*L;!68F,/"Y)QZ
MT9<9[46L#&#Q',KSQOJ6*2!#4!I(YF0+$=BW:)=5&LI623F+F*-[XW\J\DH^
M-[F/3Z=:=?#F*K7)Y2U5%\*BIY153\'6V#(<B(!&2Y200"#Z-H^1W'^9QI;<
M0<0*Q4YYG%U)!_Y3K>8-C_G_ !Q\?DR\O_HK<D_W\ZC_ &IU/H#(OYERG_LZ
MC_N<1^^'/_Y\SC_M.M_O\"\S<P>%\<K<DHOW+].M1\/T_P#SIT&09%<7R7*2
M.H]&T>_J^HX?OAS_ /GS./\ M.M_O\>M;9G&P]M^PL82RH;"'A71FPGQD2L-
MB,CPYT\9D93'I-&2R=K9F3MD29DJ)(CFO1')\&YYW!F^@:-"UVC3W=.E9=.G
M3;3:PM:UO5C]-?)^BU&><%1U"+.D^;\.I,DP$BS+)6T:R)*KA@ZR!F#AP0P)
M# @G'@@.[@^?&F&(WF_EY&M(G1&_DE;1OA$E=\&I\\HB(GV-\*B>/*_%.OE-
M\VS8,]LTS$;G;SVI'7I\)R'+;H/#'[N0\!\#]C$3P9PH28TN?WNY.;G0M[_Q
M/>^W/$^94KG_ $F S&L?W,<QBZ+D/4VN5XZR &EY$O5NRJ!]8VZ)NK8#2-EH
MHHF63WUPM?2Z.RL%!G:\,-LP,A>6ISF\]+!.<\S&.:KGD@HZ=9ZR7M&AT=HT
MDL<Q,0 <E L<SL$(L+KJT?,XN!,OSW,LK'D[X2DH,ARRFS3B#-9\NR"A6BCK
MEJ6HXZ.EGR\I6L[4X$\LU7E]-3]NEII2DZQ2)/PKW^"S'CS\Q;*$FLL+(8X.
M;G;2#'"UM.^U;<:0@$JY@-@H*N.G,(+)F'86D349$#*0DL$?L.6<5@L&S*H!
M1W5E;-9PP2,OVDQ4R*1"BHQ9B UM@E]A@(^,/(9*D,B<*9.T=3!320RIP102
M0RU%8M,:3+DFBHWB>OJ&JX8XHU=H2S7:=(RCNB3<<][PV;CV!'.FK@S,V<MM
M;%=3\[:<<";-5;Z](;@<@BUA8<+<-M07U/N"DRS.G8,5"&8J#NMM1<3+"*@Y
MM.(3%).)#FTX0Q(5TN&:10PD#J4T:B=@P5CIQ[4S[R-/F+Y3'P7E<F8I7TN5
MM21<$Y;),N85/G&NDD2.E9H):0TTXJ^W$2($:2-IH@9 M9+C3NPV^$S&QSW<
M_L; _9LKI*3-C<K[+WL9IMCJJY[+N0V_#(@F=)E3&50N?K=.9;F2)70CPF>[
M1F5T]%GU32PU$6>U+/4!#% *^IN SS(>T9IE(WA;0(DG>1CH"AK7\>;<1>2[
M)L[S+*:_R;Y33P90:@5N8R\,908I#!3Y94 T20T$T;H%S.(U,U?499#20J9W
M=XNT:)O3\>]]$( 5DG+G(\HAU?7644B<O;>!K8;0+66 T+IB[ 8>0V(;%WJ6
M((TTY5.9!'6VT8=D]X<5EJ3B=51_2-85=4<-Z0JP+.L[JI+$+K"T\I9 6*&R
MN ]U'O3/?(JT\M-^];AU98JBHIW'[U<G<EZ67*X)'TQ022K TF<41IYG1(JN
M)VJ*4S4X65OK;<==]?'M/I+K5<M\C!092@K]%=@C<P[.PMQ C[2>H1)*H&P(
M,BB&-'>PBVFBBSWLWC2CW1#30_;S54?%%''-+/F56H@A2:5!F-4TBK(Y3ZFK
M%@%8&\A AM8K(P87C)L_\BN?5>7T>6<+9!,^:5\^7T4[\)91!1S304R59TU4
MU.D1:2!U,=*A?,-0D62CC,,W9O&\XG[K8*C+7F:[I]1<U-SG*.XNK"WY?TV:
MAHC[+*U&PM1H8I-39V%G39^KOJ5AMXH0$A)5F- -5*KGHST24&?=G#+!GLTD
M<D4<DC2YC/!V3- D\@4-/([Q1)+'KETH29%"H0=L31<3^3"6KS.AS+R:971U
M=%F%=244%)PIEN9/70T^:564TKNZY;304M97U-#6&&A[:<1QTTDCU.G2623N
M'._*LJK6T.YLTPLE/#;S%4LG<'<+>O93B7=A-[K71Z![R%)!S6A*":QZ>VAJ
M27N]G[4-"K;Y=Q3'')(^:SJT2REHCFTO;$1B1CI02G5J6&5EWW$9ZE=7JAXL
M\B$]534T/!^6R+5O2I%5KP'2^9!JR:C@3M*@T "=G-F-!%,2O=:K0#5HF,5.
MOYH3GW]&_E[_ +S-I_MGK7/3&;?SIF/Y;4_WN.L?O#X'_P!#>%/_ /'<H_8\
M>O+Y&#5:C8]F57<Z[1WVJMW;W:0.M=)<6%W9+!#9N;#"XZS)**=%$WZD<?M5
M8Q$\,1K>N[^3Z>>IX?22HGEJ)#4U ,DTCRN0'-@7D9FL.0%[6Y8_*O\ ==97
MEN4>5ZKI,JR^ARVD&29.XI<OI*>BIP[TP+N(::..(,YW9@NICN2=L;:.MXQ\
MO8.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z
M88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z
M88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F(;D?8?T8\0=[_P"?
MKO\ _FUE_P#[Q'7Z"0?\VI__ ',7^ZCQ^:-3_P [J_\ W\O_ -<V$OJYCS8.
MF&)RXIT7.>JO<?QIQWOM;73-,*CSE='K;2IHZ-LT!\]F5Y0IH=8!$.99D%K%
M'X=[X;[&&0D^2.;7\YI>':*GKLXS3+**93&AJI6H8:BHJ"&C2)+%&DFD9HXE
M0,=M$>I@D88;1D=9Q/7567Y+E&:U\+"1_-(5S"6FI:76LCS.3VBQP1JLD[R6
M6Q[28!6>4J[QN\KW)9@3/&KK]'96&OMZ_+B4U'K[:ST"6NDK[=<Y7GA1RM61
M^MIM5H"*:."8QQ0EY:PEM$(.G'E\-/6\)UCU40H:6&*BAEK'J:BA@AI#!2RP
M"JECE9;**&>BIDG9E01O30LA=8U89&IH>,:)*27S^LFGKZB*BCI:6OJ9JLSU
ML4_FD4L*D:_/J>NJFIU4R=I'5SJX1I9$;$CIN[(-;,6%G,4*S:^HM+,>"POT
M4S9WI>9/J+9S(BE]_M#S[?&FMLH4G]1ECE2)B&SEU#WUFHX*D[*1FR(E*&>"
M%VCIB(Z"FCK(IX063X*&.."O0Q-HM'%6*%*I,!;%-Q['V\:IQ$HDS"GGF59J
MN\N8U4E%-3U!"OJFFFFGRV45"ZRTD]"[.'DIV;& Q?=+F,V0^KI^5*C*U"WA
MI# )K6"F$8 ;%9WI#X!B%&6%A^16P,\1OBFERYIGB7YD-D%KEK^#JNK19JC)
M9ZR?S:-.T$#3R&6-H:9 [+JU&*N[*.Y!45L<7=\YC#TQ9=QQ0T;F&GSV"@IS
M522"-JA::,1.)JIBJ,8P@ER\S2:1I9J"60ZO-9&C<,(_=96.I;1=MOJ:ZNM;
M#EZ0:?9W05Q97.\(%MYCAC/>F@S!W-I7!+:6<EHKGVE7"PQ$EK?(_E9^#)_.
M(/,,LJ(*>C:LG9:"GD@B@RU7ITC>,H95>G@EE$,0ALL,I[,D2V;U*O'4+4\_
MI3-*>JJJ\4=,GI&IAJ9JG-'CJ'E24.(C'4SPQ&>;M^]40*)1JAU)C7V.[J:9
ME?4&G<@EM+ITS;!!;FZGA'KCD,K),Y[S,^((T9:X&6,R*K(L*P>E<R(PJ(3V
MD+*J?,.#)S+,L>6(8Y_/#))!3JSRQ]G,*O0MY(V[652C3+%,]1<QQES<TU67
M\<TZQ4TDN:2"2F\RT)/4%4@D[2$T?:.422,P1,KI \T"TIT2,J$KAGTN?[BV
MSU0=#!R/$^KFJWU+:XRSB&KY!!KB.GE#GB):(+# &MW %.V1D+89C88WHTI[
M)/?4U7"UII*ELI83+,)C,D+-()'@:=9%9-;LT@IVD2S$L(F(NBXQM+2\7ZX(
MZ1<W'8- :?L))D6$QI4"G='5U1%5/.1$^I5TF95:SL"E:K2\[9DH,G7Z7D2H
ML;1B6@OSQ>7(]B0QYDU@PMT)!?OD*RFD2'POG9&^5Q*&P>J,ADK[U'2<.5:/
M'0T>5S11'L7$%/ T2D1K&4NB"-M,:B-@I(4*4:Q5@+-;6\443QOF%9FT$LX$
M\?G-1.)G#2-*)"LC]HH:1C*K,!J+B1+JX8P\YSGN<]RJYSE5SG.55<YSE\JJ
MJOQ5555557XJOQZS8  L!8#8 <@/#&NDDDDFY)))/,D[DGVXXZ8C'#OL7]1?
M\74KS'M'Z<,>QC;_ -3'LO\ V&:7_(,[K\]L^Y9S_JU__P!,N/U.\G7^7N!O
MOQPU_7J+'YYIZ^##%3[4)(7]B7]/X?L]?(C[,_M/Z4Q_0-#]2B_]VG_TC%W>
M$N+NZ<KC^FL.(.8X<S@]9<'RV(=5R=<YRJIM)6EXFK;!IJL:*&%EG8G;'#UT
M<H$%I LAH<5P2'!5EN"V7+:'/&I8I,NS%8*6>1BP2LDA2&5&IU F118.[5%,
M@,8D^,HD9%1M/&>,>)?)I'GM73<6<)G,L]RND@6GEJ^&Z/,*JLRZIBSFI+Y9
M4RL[FEIX<HSJ=EG>E<"&9J2.9ZF$3M[.U7?1L["TT64*YWU)U+H#:.POJ.[T
MMD^&_"LF3G"?.,!SG3D-M+$9TWID?[0VT"B>BSV8D9%J%.*:AI):=\TF:.5X
MGDCEE:TJ,"5U!]SK87_I.H.[C5D,PJO(OD]/39?FL?!&5P5E!#6T]!7466TP
M:AFIV2*7S:2!0B>;4\BJ2JE8:68K:.EE:/$EH>\';YZ5;:XY6N*JRK)F 5EC
M9:ZY73!W]_7LLJH1@C+,5'R6_N!]G7W9-7%&K("GM]:PH^##Q'4P_"25TD;Q
MG1&[U$G;I-*H>,!1(MR^EW21D  ##F+WA7>2C):Y/-J3A:CJ*>I0SU--3Y32
M#+9*"AG:GJI#*U-*56D,\%-44<=0S7>(&P;3C5=#W?X)N,ROSCROQW22;*JR
MV30FST];GP-/;'23@MJ!ZI3)I7^\71%BUU ">0Y+"4D2*:4QOMJ(X>(J3S:#
M774<7G,<$&J25(5GD8E @C+%MY2_P2N3K)4$MO74UWDHSOTQF?8\+<05@RBI
MS/->SILLJ:Z?+:2%4E-5)4]FL8[.BCIR*V:!%[!8I71(CID#,9#Y0"ZO<WEJ
M>YYT"'W,*96MN)]#LZ_,%YTRP@#((L2DE22+-HNGC.*]Z"6=X-RLS0IE/]E-
MZH:?BR66&&.3,P*H=@DAEG2%HF<*3(U[B(=J&.M;Z7)"G58X',\U\A='1YCF
ME91\$SODC>E*FDCH,FGS&*OAIWFC2GCTV;,&&7-#%V<V@3T80S)V!9&MKLMW
MBND+I;'1<EZVLOP*?(EG1WFH6FO!BAFWX>:E(TK*>6S&'8Z,Z=JPSUGM'P$-
M)F;*/(^U/3<1L6B:6LJ$D2.!G$DO9R!E[58=4W9EP+ZF(!2]FU'8XR>59GY)
M0L5;39=PWE5103U>:PPFARL5E')%*:&;,5CRXU8II)"&A0EHZG2)(^RCTR(%
M@7B;O>S=)F]@*5R;32 D 0XX('17[KV"4ZKLL](@0M6\B+.)7Y_&2A6+;PJD
M5M%6C(.TH$*;W2XN7\3PQP5"M61E644ZK-(9 7C>*P"7$.F*G*R"5HP(T6UP
MIT^67BGR-9A6YAE4L?#56)HYFS>:?+Z 43I#4TU<G;R5*QM7FHKLX6:G\RCK
M2:VHD,ABGF3M6U-B>]Z2+WHJKYV6(VULZ&0HPW1MBELH!]2-;"$$$E-8UC!7
M[& R<F1HGN[K]DDWLE-3JR:;B<KJ:/-"&D>$NSR?' F5U))V%C.&9CIL9>]N
MV,BF<^1M6[*&IX(UPTM-7K%##EI=:=GRR6EECCCB+$F7T0\,<:F3M/,"J!NQ
MQ44D><0B48B-8IQY7PSQKZ?+)(W*U[%5JN:Y6N\IY8JM5/BU5145==92I*L+
M,"0=[[]02.H/M]I%L=31UE19%;4CJ&4@$74@%38@6N"-B 1U%\>RWY#S^H@J
MO_:%N?\ _JNZ^@?)Q_)N+_\ B:G_ 'K8_([]V3_^<]9]XLD_JBXW#=;[CY2P
M=,,'3#!TPP=,,'3#!TPP=,,'3#!TPP=,,'3#!TPP=,,'3##3U.\P^'%4W:;+
M+9$-&N?[SI=!54<"M;]JMDLRQF.\*J)X:JKY5$1/*HG7MH\NS#,7[.@H:RND
MN!HI*::I8$\KK"CD?*,>"NS3+,L3M<RS&AR^,@D/6U=/2H0.=FGDC!^0XJWJ
M_E">T/)/D@*Y@K+@J/RB#Y:FT>D9(J?='85-014.\KX\*MBU%\HJ*J?'K<*/
MR9<;UH#)D<T"'<O63TM(5']**:=9Q\D1QH]=Y6O)_0%E?B"&H=?K**FK*P-O
M:RS04[4Y\=YA<<L01<_*X=LE=,^&NH>6+]&IY:2!F\Z((_\ 46VUP!C?TU<$
MGZ_6Q0>1/BZ50TM3DM+?FDM55O(/Q%#+&?DEQJ]1Y?>"H6*Q4N?U5N3Q45&D
M9_'YC%(/EBWZ7&&XGRP? JN\+QQRVC//Q=[GCU=X_"C?I8GG]3U)^KUZCY#^
M)+;9KDA/AVE<![_,3^CGCQC]T)PJ3;T1GX%^?99??W>?V_/ARU/RM_;&>]L9
MU#RW1JJ^'2GYC.DCM_3\U6Q/(<B?%?@,BJB?!%7X=>2;R*<71@M'49)46Y+%
M652L?QU#$@.X^OL+\\>V#R^<$RD+)39]3\@6EHJ-UN?#L,QE<B^UPGKMB;<K
M\HCV@ZM[((>6PZ0M_CR/J*'2T#&>?A^66)M0VG:GG[5^<E1$^/GT_'K 5GDO
MXXHP6;))*A!]?1U-)5$VYVBBG,YM_P"ZQLM#Y7?)]7$*N?QTSFPT5M+6TH6]
MK:II*<4XW/V[QZ8M-D>1<!OAO>\/M\EL!O0DBS9C15%XQC%^^1:PPKV:HOP<
MDGI<UWU7(CD5.M.K<KS++7T9CE];0O>VFKI9Z<D^KMD35<"X(N"-Q<8WB@S?
M*<U3M,LS.@S%+7+4593U0 Y=[L9'T[[&]B#L=\/+KPXR.#IA@Z88.F&#IA@Z
M88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88.F&#IA@Z
M88.F&#IA@Z88.F(.X(\0<>:VU^2ZYI,L[$MG*7;^QA1QL[&R[34ME:P@B65K
M)&IA'(CVHY$>U'.^LGYI4:BK]60^6+($BB0Y-Q.2D<:FV7T96ZHH)'_*-[7&
MQL+ \ACX\G\A7$\L\LGIOA4"261P#7U^I0SNRBWHRUP&LUK<KW-]L/\ G67-
MGZ*G;W_?OJ/_ +1.G\,G#W\S\3?D%'_XEBW_  "\4_SUPK^7YA_X7@_G67-G
MZ*G;W_?OJ/\ [1.G\,G#W\S\3?D%'_XEA_ +Q3_/7"OY?F'_ (7B0>,/D].?
M>,=4/JZGF#AX(P6)&1OS?*-[1%RJTP,UL)DYW$^B$,K9)1(U*K9ZUT1+VQ*^
M1&1+&_'9QY4>&LVHVHY\BSQXW:["LR:GJ8PICDCO&D>=4KQRA9"$F28,@) %
MV)QE\D\CG%V35T==3\09!'+$.Z:+.*NED++)'(!(TN0U<<L):)2\+0Z7(7<*
MMC*>N[1^Y+0S8^SKN5>% [[&ZVIV8%O<\A16TAMU0K%\R%VS*O@3-$V\U.R
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MC_[1.G\,G#W\S\3?D%'_ .)8?P"\4_SUPK^7YA_X7@7Y++FSPO\ Y5.WM/\
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MGLM4\Y!/$I"2602PLH9E1@% .IB"K*2Q(OL@LUCZ%IT^)V,I4N@+M#,'*ZI
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M#O!2H8CR4/#N;UU+'F$5%,,L:KBHWS!E_B\,LTBPZI"#K"(S /(%*(;!F#$
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M\R=!8TME9QWNG&*OBACQX@QQK6XA?4-J'$9JN*=9&3!DB J*>=$R-J)5CIL
M.HOJV/06)!MR&_(7Z8EHD4JNH&[69@1=0+#:^P-^1W!)\!ACVG>)R'A M3<-
MS>NY8I\T$<'53LRL-.FRNQJTO6>NDM*6C#!6 BH$ES03)1!Y8=*B43AKK0Q0
M#7,DV5KJ3IM8@#O7!;<CH+6WW!-@"; TA 6&X74#<7Y W'>!).QW.]K>',+G
M*G>%R_F\YR</2\-S5E[61;<;"Z"<G06]=.M.1S]24!1E>/BRG$:*ZL^%ZRQJ
MJ)L4]67%O:(*:R>[W-;RERP#60EAJ V)N5#V(VWW4&UQ8,+$GG4JJ64LPLQ
M(M8B^@D WMMJM?9KJ; @;;)0GND E?)ZO6X<5SD^Q4>J(KO*>$\(B^?AZ4\(
MGA?'1K77;F3?8;^%_?\ IMBA;6DN?#K?F;BWKY=#O;Y:-\F\S<WX?E'D$NJS
M$]UQ5A:S(Q%QDU4#!#R]6-6C#S4UD(];PZX"OK.%;;WAL.5KLY"02:>$3%.3
M!.X/Q;C:P M?UKN 3>_/;GN#OB1I*KW@&-QN=[ WY7L P&W6]@+BV&N%WE\B
MDU]+;F<$'T57I:BH, .MK30(S/%%5O%MA:R;*,;'RR5M:%+R3, +(&PR:<O+
M62DH+!*1)50&O]85N%/>.P-E)OW1:P( V.ZFY ^+(C&]G!WVV[Q-V&P)W)L+
M<N8(WPIV'=WR-3WY=?8\&6#J6$KDLD:Y N#94L,_Q_;;"EA+ #-H:^QLKJT=
MD6WBT-2!8D-H]'22#/+E<KYI&[$%#9=5R0.2W!TBUS>VP Y6W.'9[?'N>[S!
MVU :@2&( %P+[;@\K8?/!W<OH>6]75YRXXULL>/9936WL%D43*4V4O(;T[&2
MPRPM':RO%N0H:_0T4\I!0UJ'831UIYWS6=*P#TTE;:MC;HQ7IMOL18FX)()
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MQD,5RP1Q]-?V,Y&O=E,K6GV];8;VXK8*VN#B@+LZJ"OKI(R+2F&ANP+HTL@
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M?QC\=$A(T4C(I2((Y9/^;CDEC9(_[?S#'.1SOS+OS*+^97\"]5!6()"L0.9
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MDJ,E9SCC?R=Y;Q5%)50!*+.D0]G6*O<J-([L56J_'4\ED [1+[$BZGJGD_\
M*?FG!TR4DYDK\B=P9J)WNU-J(US43L?@WYEHC>.0\[&S#TM<6\JX;F7'5>ZX
M^NQ[R@LXT5)(W(TL I&M6>MLQ/4Z0*P%<[TSCR_^C+$Z6"2*5_RAF^3YCD5=
M-EV9T[T]3">3 E)$N0LL+V DB>UU=?6"%8,H^S<CSW+.(LN@S3*:E*FEG',6
M$D4@ +P3QW)BFCN Z'U,I9&5C(G6,QE\'3#!TPP=,,(NBT=#DJ2STNHN*Z@S
M]*),?;7-L7"#75X<#5?*0440]D4,;&IY5SG?%?#6HKE1.K<LL<$;RS2)%%&I
M9Y'8*BJ-R68D  8MRRQP1O+-(D4: L\CL%50.9+$@#Z#%2(N]?-7ODOCGA'N
M+Y0SSOK!Z[*\<AUN:M85_,%4Y6WT>2/LPY?MA,&KG"S,^O%,]BHJXA<]AD)-
M-09I5Q;Z9X*15B>UMT-3-3LZGHRJ5-C8G&'].Q2#52T&95D=SIFAI@D+@;:H
MVGDA+J3R8+8[V.V.[^:[NO\ LF]U/]Z7'O\ O-ZJ],'^:,Y_)J7]MP],R_S-
MFWXJF_:<'\UW=?\ 9-[J?[TN/?\ >;T],'^:,Y_)J7]MP],R_P S9M^*IOVG
M!_->77_9-[J?[TN/?]YO3TP?YHSG\FI?VW#TS+_,V;?BJ;]IP?S7EU_V3>ZG
M^]+CW_>;T],'^:,Y_)J7]MP],R_S-FWXJF_:<'\UW=?]DWNI_O2X]_WF]/3!
M_FC.?R:E_;</3,O\S9M^*IOVG!_-=W7_ &3>ZG^]+CW_ 'F]/3!_FC.?R:E_
M;</3,O\ ,V;?BJ;]IP?S7=U_V3>ZG^]+CW_>;T],'^:,Y_)J7]MP],R_S-FW
MXJF_:<'\UW=?]DWNI_O2X]_WF]/3!_FC.?R:E_;</3,O\S9M^*IOVG!_-=W7
M_9-[J?[TN/?]YO3TP?YHSG\FI?VW#TS+_,V;?BJ;]IP?S7=U_P!DWNI_O2X]
M_P!YO3TP?YHSG\FI?VW#TS+_ #-FWXJF_:<'\UW=?]DWNI_O2X]_WF]/3!_F
MC.?R:E_;</3,O\S9M^*IOVG!_-=W7_9-[J?[TN/?]YO3TP?YHSG\FI?VW#TS
M+_,V;?BJ;]IP?S7=U_V3>ZG^]+CW_>;T],-TRC.?R>D'R[UV'IF7^9LV_%4W
M[3_Z84L_WF<:D:"JR_(>5Y0X+M;XR*MH)N8L>W.9R[LR%5!ZH'85-IH,G'8S
MHG@<*QN:\@EZ>R'BDE='&Y'GE*9$BJH:O+GE.F(U\(ACD>^R+,DDL(<\PKR*
M3T!.V*X\\I3*L-3#5Y>TA"QM70B**1SL$6='EA#G?2K.I-K 7L#;G[?P>/">
M%\_;_P"'V>%\_'_'F<9G!TPQKWY>[A:SAO&WG(&O'DDHJ$D6.:&GJ?G2YG?8
M64%9&T"N2>&4N2!"E*+;"_VL( YI2M=&.]%W!J"GCCULTFD*MRI!W(ML-B;$
M7/@ ;@"^-82LGD?LT6,N3M?4 ;$M>]B "" M[;D;WL,,NR[O^+J7629,S0 ,
MMA@-(>>8/E[PBBKXL?54%S<Q':4:LDI828*K1T<PPS3WRDJ>$(.CC2PAR(-%
M2J2IDD##6QYD!44$W8+H!L00-0OTWQ(J:IDU"..Q"CG8G42!9=08@E3N!L "
M=L=@O=YQ-.V:079YE&#P&FES+46L$ K@J>YTE@,=/+71PAW(=/FKVQ-IBI(;
MD>*E/]N$R8.5K'F5'8GM'(%_KB -()(^+8, I-C8BQ-MKF/.JL6'8I8[=#O=
M54_'N0;J 0-[BVYMB:X=I8-8UT M:UCVM<U8Q&L:K')ZD\(UR?!R*JHB_!/A
M]GP5;OHR"W.7H1WA\QY^!VVWM?>T<QEONL>UM[[C?PN.7O\ SX^?I<:C$C]Q
MJ_0B^I&(#'Z&N]7J]2-\^AJ^KRY5\>?4Y7?;U!RV&_.6Q Y$;;'U<[\^1_-B
MKTBYZ1^OGOT\?#Q^3H,?;MC8O^#Q*UR>4544)BIZFJYR+]957SZGO<B_<Y[E
M1455\R,M@VN91[+?JGGZK^-AR$>D90-A&=[G<[_*3A5'VUJX.QD6$)'1-$]*
M^Q\I]>5S'>4]2?#PGP^/P\(B_@2T^70]I$"9 #KO9@/BCUK>XMZKWZ<L7$K9
M3%(=,?=5+=T[DMU.KE??;\^*S:SO4P&-Y%L.,-6YU59AA5Y1EK/75Y5*LED*
M.37 M$%M"=.246P@84:6/-RULMB0)4QGNLS PYZ6I*57[-FD!T@@DBUS86-^
M\23>VUB;*#J(&*EJ*ED$BQQE23;8WL.M_BV]18&UVM8$XRYN\?BCVC88M+2G
M".&IIISPZ4Z>M&9HZ^HM,^*Z91FJ:?= W-(0)4545C:1QV=8\P,5IH;IJO,J
M0'ZHY'=ZFP#"ZWNO-@5V%VW!WN,/.JK8]B@/>[I]1*M8 WL&5@2;"XL"=R,&
MN[UN);2PT(3]#5"-S2 RH:=0V48ME!;T^4M&+4O]RD?+8^UV=+3S9]\<.C=;
M3J)\TO\ ,;I(%)2&XUR#3:Y)(!U*I !"WU L!I/>)VL;[#4U((NB;@V Z:&=
M;F[6*]TG5R !-Q:^'$%W9<7E21?-NGI28Y",?6)8 YR^GJXBMZ*!89 (BX&J
MGU8<UR+;U1,,!1D+H&VU6IC1G6023U"AI"=I)>:#FUOA -(OI(N;[>!*["XO
M2:NKZPI:SG<@'N%@U@2"0""#8=#S(('P%W>8*6DQ5Y<7U7F(MWE@=C4#7@4\
M"BTAX<YT1-P= PBJJ(VQBE0^WL+" >4F!P\$LL\D3'A14FE&,CJ'34+L+V\6
MV('M)WL0!?#SFJ!=51'T/8D!K:A;9=[MMO:Q._6V.ZO[O>,;0@,4+9T$DQL7
MMFI-4W(<84;K<^AA6X(, ''H7%W-:=7 1W<M?)8DB3,!;.C550HJ0G:1_5WM
MAO;<D ;E65=6['ERW>=58 /9)8&V_,G2#MWC?NLK'3\47O??#AQ/<EC^13;2
MNQ.FH-";2Q03V4 8AC%&A((*$C?ZR81V2^@P$T(CW=\KA#A"@BDB*&EB94*"
ME8D*\AM>_>&VY Z $W4@^&_*QQ2]94(%[2)!OML?5M8$VMTO?4+6&XO?,B=[
M: @CTIZV5,\WI5/#5<T1[_'V_F57_!Y3X_#K3)>Z);?6A[?)>WZ,;=3*'FIU
M;8/+$K6Y@,Z@VOZCM?&M3EGNOR_$EUA:?9U\*F;NWEK,]*,'6/CA+CN,U0K)
M.ZSN*^=7+8ZJFB9#4PV5@^.0B=H2P"SR1X82.U[!;#<[>HFW7>P)%\=%DR^E
MA,0=YP9+!;,I&K4BVW"WN746%SORL"0!=U_&%O)%#7WN9L9BPIS!FC4=N0X\
M4-\J-:$D8#_G":5HDT]:$(LY=F+ \RK@*%9[9([1[;@?*MN>_7VBY\=C8W&)
M&741/=GE.UR%:Y(%^7=N>5PH!8BY%QC'3NUXS)-H:\.QI[>;5W&?H*Y:K+7U
MH/+9:3/F:>C&.*$KI1A%)H:Z2R<TR6)X8BC3&-%BFB>HR/\ 8I??<@;V(!^4
M';UW^7$#+Z*Z@33MK95&DD[LNM0WP>P91J(/Q18DV(QWM[JJ%?I2\ZE+!R>6
MN+7/6FR+H(YLI/=4AY-=H0(6@V!MVR*B."-BM;.RH@*:!@A!26$@D:D+)D<6
M^)<V(%MP#N+=+VM87ON.N*O1U)WKO4A$)!D++H+*Q5@+"]D.K42JJ+7N<=@_
M==QC.60$#HLF2=!9C4T@P598D%3G$/G&A8-",+)(<-#(.6.4>&TBO!>,5$:2
M,Z"=K(,C\]*V]@V]_+Y>=]ARQ R^A.RU$I;5IV?<FY'1#MS%P+#D3SQF4/<]
MQ[JK8*FH+S*7%Q8DDL$"#K#9BY90!XB)C%:HWY4(P:<:>"TF=&$1 0-(*5*P
MF%SVM]SI7Y5 _3_9_;B5RZB<@+/,6)(L'N;CJ>Z;#;F=C>X/+$K-W]LQJ-8%
M6(U$7PUHTC4;X1?@C4E3PBK^DGQ_5^,=JW@OX/YOIOZ\7O1$'VRH/K,@]^R^
M-A^>W._'Y(5Q_8==^]Y/Y7IVS?:U]P_6P]#P?;JC\,?JX/R0KC^PZ[][R?RO
M3MF^UK[A^MAZ'@^W5'X8_5P)R%<>4_H.N_>\G^F7Q^ST[9OL%]P_6P]#P=)J
MC\,?JXLQQ9:SW.68:1'%'(XPJ-6P-5C/$<BM14:KG*BK]J^%\?I=92E8M$"=
MCJ;EMU^GMYXT;/J=:;,'B4LP$4378W;O+?<V'MY8DGKT8PV*A<P< Z7E/EVI
MT<5G44N:J\?3A+9DUTME?16P.CMK&:"ADCL F4TA A(\9ITD!R%"J\1L42I[
M7K=LCXDI<FR6>F,,]15SUT[]BDJPTS024L$2M5*89#4*KJQCB#1:' <LPVQS
M_B'A2LSW/X*M9Z>EHX,OIXNW:%IJI:B*LGF9:1A-&*8M&ZK)*RRZT)CTCXV&
M!:]C%3:6>:+?I:MH%#@;;*SUKLTZ2&PT%I;"VCM:]5M4:PZ-T$K'(Z.6=[B'
MR>]M\*UV3A\H<\,-6BTDW:U.9P5JRBKL8J:&!X?,1\%<QG4I%BJ@+;0>F)G\
MF,$TU(_GL BILIJ*!X6HM2RUDTZ3C,#\.+2J0X-P7)<D2#D<PSLWMGFU+*WD
M"MK**FM]%:U]=#EIHRP&WL]Q(T$ \6\&6,*"*U2*04F$D=70>V%B%DED5;:<
M=0]G.9LMFEJ*B"EADD:L4QR&G6 &22)Z=@9&,)*NC(X#Z79U4#%V;R=SO)3B
M#-H:>FIZBLGBA2A820^=-4$10RI5(1$BS!3&ZNA*:D6,DW>&?[;Y<IR9QG9T
ML\0^.RN6>NF$$8P(6_V5=(Z.ANG!-=)(TP>&8A9Y'3/;)'(UKU>YOGKPU/%0
MK,IS:&="U=6U@\TD<F1Z:@E%ZFG$G=&AV"Z1IV(N +X]]'P::#.<DFIW5<OH
M: ^?)&!$E7F4)(I*DQ#41(@>0N2UF! ))MAN6_9U&;8;(ROO<U7?26RUQXCH
MLS:#%QLU$P9<4-P;5Z6MFLUIC15F#]@H$4D;_8D0R,5ZO]4/'+)%01RT]7**
M2*AC<&KA=":,2(Q@CFI)5A$\3Z'UB5E(U(PV \=1Y.UEFS&2&KHHA6S9C+':
MAF21?/FCD05$D%; T_FTL>J,+V2L"5=6NQ/U+VH[",H^QK>2J8,\@JBL(?:9
M(^<.:RK@RP; ZQ@3312HIPY;DA"J"*FM'EAB(>'/,LKI XRH"D<4N4SO$B5$
M1M6Q+(L,KI)%'$YI& [-T!:2=9YG4L@D06M+<!Y@LDT\.<TT<[R4LRDY?*T3
M3PQR12S31^?!KRI(0L5.]/ C*KF)VN2EL[,#TENYBMR#;36F=^9QBK(#61$
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M2TEUI;D$LXB_K)*^2DR^<N=">U 7Q1U0,CX'SDN8,[.@ "P  '(#8#Y,9X
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M/$\K66_=/*V+$^QD_._X4_AZ7'B/>,4?_*?</U<'LI/SO^%O\/2X\1[QAO\
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M?F;?W#DC9DV&A BW]!<7%C(I2^^UEY8YFMN JXZOM(%I [Q*"%)XQ'61<6V
MUV  &S'<@@DGO74D @&^U[#E<R77O'1WB2VZC;ND+RV(#%?:06.Y-G%L./.Y
MVOXMY[#SNEVEYIC.0\[6<-Q0Z:>&\%XL WM/H;&24\B_%E6ZFJ;/4YR:WEN
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M09>F^DG8U-5:^BGCO>[6U<N5R=[X/X/]/&HS3-:@97PUEMGS+,7[I?2+BDI
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MI8&-FL98UD<L;)Y'00N^M#$QSG*N6R_A;)\OS&KS6*%Y:ZKGDG,]1(TK0O*
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MC'P=PM5YA'W@,QS"]+1GF"54M&K@6)NE06M:Z7VQT]/)CD.1*LO'/&%#ET@
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M_L'K/?P:\<?Z/U/X^A_:L:C_  L>3[_2.G_)<P_9,'\\$[/_ -&FE_N+J_\
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M#8[EDU9K>03W5O(L=U[4EH&AJ ?G$:W2-'],1<[^OU]21>_N]Y-^0MN+\?\
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MO".]PB!N0N=SC6.,N,LQXNS SU!\WR^"\>6Y=$=-/24RDA%""RM)8#6]KDW
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M70R#K[R[V<;O*;$E5EV800T^:TL%'4YI$62AJ6C:HEB-M-V55(8ZE[A.H.-
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M@<9YS5Q\I&4?&')N.YAO--[VTF^WN9Y$V%8&5Q==2(1[:W PT:\QGW-5*V.
M&A3B.(>6=8IVQOI]/\,2;'>UB>@Y#Y+<K6MUO>^,BAG[S0*5]%S1G^0PJ.]W
MD/+F@.S>H,U:TP/)_%^X4/C8@K/I17S,#Q[S1G:R:WSM1))9!Y_5YP.(PD*
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M^2PY8^Y88IHI)':!SJ78:2;6>-[$'8WTD6WYF_/$&WO:EW+D4^9 J>4)X+*
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MZQUVQ+/+W8S_ (20&UD_K@19&>6I-&C)6*OJ1RJB+UKV?\+Y1Q%&!6P!:B,
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M"KM"@QW_ !^U)8(HI45/S2/1W6UY56>D,KRZN%B*RAI:DVZ--"DC#U$,S+[
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M"^^U0YY>OI;??]-L?7Y(5_\ UFM_N?'U/;M]C'^ ,5>AZ3[.I_*'P?DA7_\
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M7.D70555M)?Q(I87NDS7>^L2/)<A-B80KHI/ILCI&M52?9UEDYZD.UKZE)L
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MBOQ<GP3KR5\RT]#63O\ $BI9Y&]BQ,3SMX8]N60/4YC0T\8N\U73QH/%FE4
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M6"R7ZMGWW]G_ *CEV,+E'U?//OU+_P /R['FH3^J,7_VU+_ERSK]"!_)5?O
MO_#VQ\$U'\M)_P#XHE_XLV-XG/@^M("R:YYNGFS\/(4<W) F*5$UIF)3,ZV&
M&"C8V-\TSF[F7%3VL K?>9:""W;&^/ZST^4I-6F*P)6ZF4*"6*!&&W_SE01O
ML#U)Q]NQA0TVK2&L1&7(TZS(MR=[;+K(O;?2#?%8K:U[N2[D>6GHS7 Y*ZY
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M7#1TAM>GA-HVBWB2XC<W9 ;7TL0&(&Q._/%OTA6[_P :G%Y$E(61EO(@LCD
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M\D?D[5X/;%EFV84T1)&PS]YB&C4^C;[$I:BU,$DEB8^:.=@22 /4+^T7 /R
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ME="*LCI/3,6WT\QX:R^MXRSP<:9U"T.6TA*<.Y=*#;2&-JR12 &:_>!([SJ
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M<USSC.$BE6MG;+LG0H#"^7TC6DE:*PLM5,NM9(RI5C(3JL0>L<>319!E'#W
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M,^.1%GL"5B$-RV(V.[#GTMSY6W'+EB(ZBE&[S2ZBC(2L1L58M<F]AJNQL;7
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MD6M('*#"-I+P^MR]3CJ^:<V*11["O>=?Z&EDC5&RV%,T*=KXS%5N-CT:B'
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M&.DF(**E9###&QB*YSY)'M:U$15\K]G5N66."*2:5@D42/([L0JJB EF)-@
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M5Y7!4B]VMX\[V/2XV!WZ$8=?TCO?QJ3^ZM_D^JO-*;[5'[Q^KBGMZC[8_O\
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M9O!TPQ"O,W<#Q=P&#26')5T;61: H\:LBK:6VOS)&5=<3;VATP=,(:2-65H
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M9GD#74\NA/I>--%ILII)(<IH?>Y+K(VQE)?#T8#J]I>@B%M:XP.,JHA+'*?
MYPTLK%1RL,1)%WV]M\DH/KU5X("9F9]7/>'8K6!YZFKAJKD:YF$T-X14LK**
M[C"XFW_JH[0D:T0C.E"^[>\/ACD7^;Z>_#"CFN[?%6F7YAV]_0;7+9KBWF'"
M</P"VF,U<.VOKSD7+\*6.7C;@9Z:#4B'V^KYII\O75JULLI<<0UM&Y1#FK&Q
M-N76_P#CM[=OSCKC#*[YNW8*M9<EZ/104T>?,O[2WDPVN2MSCP<SKM<3FM.9
M\T>PSVUCH\-HR/H;:O%T3IQ( VUZE&B13,1]/T#\Y( \>F)BXZYOX[Y/0J'.
M6APEL!>6&<-SFGIK7)ZD6VK:>FT1$$^<OQ +:)DF>T-%?"SO%2$JGN*ZQ@>\
M8J*1S#$M],,4N[5?Z=>]3^V_T/\ F1X*ZP62_5L^^_L_]1R[&%RCZOGGWZE_
MX?EV+H]9W&:Q2[>B<2Y"*LO>0;:OIAA[>RFI;+0%UT,0EP%F=);V$]<08,JB
MG0Y.OT\\DP[XY_FF*TB5RP/G8[9AF,^E;B$ "X+*0!8"Y!+@#:]^I!-[C&OB
MAB9C;M>\.\ XWN0 "-'*X MXVVN+8CDCCSM9E93 G9K!(S;'RXZL",S^88EM
M/@:>[+2KE%GIVM4/,TW&EHT1I,;0Z\3+Q#C^S8"-&R#7R[@I!T!'9BW=Y"U[
M64)MT 7U'%?F: !A)4=TW^J[@L;:ME/QC(22-S<D['$B \9<. RTDE969P2:
MI6RESD@$.?'EKG7I"16SZ5\ 3'B?/)4366+@O9_.$\;6$K+*Q&M>?SBQ5801
M<@F.]K\[=ZXO;GZL4FCB8,"TQO;4#)?8#K=!<]!OSY;;X>$>/SLK$DBD-DC7
MSX?&2.]B^%5%\.; K5^**GP5?BB]5>D:CPB_ _QQ3YC3^+_A_P#V\??T+H/_
M %A^[P?ZOT](U'A%^!_CAYE3^+_A_P#V\'T+H/\ UA^[P?ZOT](U'A%^!_CA
MYE3^+_A__;QFP8ZD8,;&GOZLD:.LGDB)5^K)ZV>E4@\>?*KY\^47X_>JKU0V
M85!=&[EQJ^M-MQ;?O;W&_,7-[WWO6M%#V<BJ'[P4GOBX ;_5%OFMB ==H^W"
MDV)N2V%O4Q; :+&>_!6@PA!T8MOIQ(,3(1/-6R(@OTK/BEIY))?8AVZRDP.A
M)CED9)S*8$ANR![I-TW^-MS;EJY= 3T)P&7Q[%>UMWK:7%AL;V[M]UMZB"/#
M"^%P9P,!8'W(]%G?>-##4U[G2?,4@;Q::F*SU775@SQ%%&%&I[6Q C'#C:GN
MUQ80>GV!\L3X\^E%R$@N0 ;1FQ !&PU;;,1M]D?&V!I(R I:86NP^$ZWN6)"
MW)) )OSL-^6,:ZXQ[<I2H3+[.X@LD &WLH; ^IRQBABHV*"XFB-FK)?8.EC,
MBB*:R5LI$<_H<CVR*U:C73&UT@-B0+Q VY7MOU]7/UXCS., V><<K@2L+V-Q
MW0H]=N@-SXX?.1QG'CLQ1S8P9@F6*KA3**&FC"KZQ*TJ)I(SPQ10X88H9(Y6
MRM;'$Q%1RN5/BOD,QG   B"@  !3:W3;5;$&BA+$L9203<EP22-N]=03UYGF
M?&V'%]#*#_UA^[P?ZOU/I&H\(OP/\<1YE3^+_A__ &\'T+H/_6'[O!_J_3TC
M4>$7X'^.'F5/XO\ A_\ V\'T+H/PV'[O!_J_3TC4>$7X'^.'F5/XO^'_ /;Q
M8N>*-U+/!];V;JR:%53XN]"C/9]OCPJ^GSX7[//ZO6KR=X.#U#7MN=[WM_9C
M98"4EA86)22,B_(E6!%[;VN-['&OSE7)]NT)>6JN8;')-*O+ D;'!;1U+[6Q
M.>16 &"T\=BGJ(6<BRIPS1H?5"2\L" F.3VD+5Q"QB]P9+#?:P_/X['IT-NN
M-[;,YB%$B4O]'5<W.P/UIWY7'K /2V>1P%P+9'1V)&=R9=A/=17L1BUV?<21
M> QUL4=DDK8D>0<,RAJ429RODC=35SW>'UPSH@1?&38>-B/E!V',6\"=\2<Q
MG)N8:4'5JO8F[#2-9[NY[JV/+NCEI!Q\D<"<!&25,Y-!D2)*1 UII90L\YU<
MVOE$>"@;_9^88Q2*T"0=C%2.,BO#D8U)1(71M"\R7WZ^^XW-M[G??].).83L
M1\#2G2.Z2""MK$6LMQIL+>%O4,8UWQ?V]5-*90WT>1KZ2Q]F094G-H(!2Y,R
M"#%!.\:1&H\FBKQ*Q@\C42>O@'#]BZ)L<:H$0.]Y">8Z>WGT-SUVW-K8@YG,
M$*F.FTG>S!N:VTW%N0L+> MX;)5EPYVPXRJ.V5I5X7/5 [1(+"]("SP8L/MX
MIPA()B/9-9&\B*U+A;%Y:^=; E7M>\F1SW9;V!D))V!]6^QOO87Y6'+%/I&8
M L8:1;<R%(YW 7=>5F;87N"UP;XSZOA3MTL8A=/45>/EA**@T(=R"-11(XDO
MTRPV4)4+6/:XYT,<SWM<UILL39IDED9ZT=FMR"9+\NG/J#<\CS]6)](SWN(:
M0$'5JLPWYW%E!O?F1[3O8B0Z_!X*F#&J*PN"L!!1@8M<)-7##C(J^8AH!HW,
M9%ZE7S'$UB*[S]5OQZC0GBQ]9M_A[#[QBX,SJUV"TX&VP+ #;PL;#D!\E\*L
M&)S94?MACBB(O4YGM8)AIH_6Q5:]GKC5S?4QR*US?/EJHJ*B*G4=FOBWN'7Y
M<3Z4JSR2 _\ SR]/D]>.[Z T?]D6'[,/\'3LT\6]P^?$^DZS[7!^'+\V#Z T
M7]D6'[:'^#IV:>+>X?/AZ3K!_FX/PY?FQ/\ QS6"U.>:(&^5\+2B'HLWI]?J
M>_RY%]*(GP7X(OW_ &]9.F4+$ #<:FW-O'U?.<:?G,\E17/)($#]G&I"7TV4
M;<P"38[G#]ZOXQ6#IA@Z88.F&#IA@Z88.F&&OM,;G^0,K>XS4U\-G0:*N(K;
M(.9C7))"0Q6^T8KD5&30N],L,B)Y9*QCOCX\+ZZ"NJ<MK*>NHY6AJ:659HI%
M-B&4WL?%6%U8=5)&/#F674F;4-5EU="L])60O#-&P!!5Q:XN#9E-F4VV8 [\
ML>33NN[:]+VT\G6&5L8IR\Q8236&-T"Q/2"TJ'R.]G&^3XL:<$BH.7%ZU<CT
M1_A$>GC[0X,XKI.+,HCK(F5*N)5BKZ:XU0SJ!<@7),<GQT)&X-KD\_@WCS@V
MNX,SF6@G5I*&9GFRVKTD)/3DFRDCN]K$.[(-K$7L ;8K%UMN-'P=,,'3#%O>
M#^Z.3'Y^;B7E_/,Y3X.M7JPG-6,GJN,J^7RU;7&V4J^TKB1U<LK0VR,'>Y/#
M'0^7(_2.(>#Q750SO(ZHY/Q%"+I5Q =A6A=^PKX1M(C?%[2Q:W,-TZ%PSQQZ
M.I&R#B&D&><,3L-='*0:FA)V[?+IR;PR(+G0"%)V!6YNZ.1.T6&\H"N4NV'1
MMY?XU5KBCJ01&IR%BT5JRR!:#/M1I9#16^44L2%?4QJRR0QL5'.\>5\;O!4I
MD_%])Z#S:X2.H?\ R97[Z5>FJ;E%+'ZQVV)"JQ(L/=G'D_2KI9,\X(K!Q#DU
MC)-2Q@>ELMN-1BJZ06=] N.TB2Q4:F518FC\\$XLT@Y,,H\\+U9+#-&Z*6-[
M5\.9)&]&O8Y%^"HY$5.NA*RNH96#*PN&4@J1X@BX(]8QS%T=&971D939E92I
M4CH00"#[<=74XIP=,+'PP=,,'3#!TPP=,,'3#'9%%+/(R*".2:61R,CCB8Z2
M1[G+X]+&,1SG.7SX1J(JJOPZ@D*"S$*H%R20 !XDFP ]>*E5G(5 69K *HN6
M)Y  7)^3%U>-NT282@@Y2[CM#%PSQ6QK2AHK5GC<;%GA96 Y?.._HZ1Q;41(
MRYX6Q^ASI(&$*U6]:%FW&X>J?)^%J9L^SDG2YB-LNH3LIDK*KZF.S^NC5BUQ
MI<I>^.E9+Y/RE(N><8U:\.9$ '1:C_*>8;:EBH:,_",9.2R.@6W>4/:Q2>:.
MZ*&^S'Y#O!V>=Q9PB$Y(Y:P:1/I/N)(OJ+:;.UB7VQ2DIY>E<V5P[4<K)/5$
M]!XKV0<(-35ASWB&J],<0R"ZS,!YGERD7$-!"=D"$V,I ?:XLP+-Y^(^.%JJ
M+][O#%)Z#X9CV:!6_CN9L.<^8S@@R%N8B!T"Y!N"$6G:>5\>4_P_K(OV(OE4
M5?M_7^/6]&PO8WOSV^6W.UK^'KZ6OSO]'T^;'/5.&#_CX],![_IMBQ/;%V[Z
MKN3Y.JL3012C5$,D1^LO_9N<+1444K?>B9G?58I,WE( 1U<CB"GL8GW^-8XN
MXHHN%,IEKZE@]0P:*BIKC74U)4]FBC?N+8O(]K*@)\,;AP3PC7\99U!EE*K)
M3J1+7594E*2E4C7(QV4NP8)&AWD=E4;7MZU>/L'FN,<9GL)D*^.MSV:KH*X
M9B-];FQM\S%$O:B>U+,G=(47,J(LD\LCD1K51J?%F9YE5YO75.8UTIFJJJ5I
M97-[ GXJ(+G3&BV1%OLH N3<G[WRC*J+),MI,JR^(0TE%"L,2 "Y"CO2.0!J
MDD8EY&.[.Q.'EUX<9'!TPQ37.?U>?)?]K;@?\NK_ *PL7^7ZK[VT_P#OY/F.
M,+'_ "@J/O7!_6),7*ZS6,U@Z88B+E7B#C/E)N:,Y"K$(GQ]F1:YZRBM"Z<R
MO), (K3X6%!DCNF&L*\B88D.596/58B(F1F#"D0,,1-DNW/MBMYV<B9BLAM8
MKLPS7UYJ;'0'5(ZV.Q+W!YE/6DW$M?5 &;,JQO"6A#002FESQ/518QAAV'4F
MYN?\?G//&#%VG]K69#3/.IV!":O. \<)7D;2_P#;7(,6=?24T$4ZV_O\EV'E
MJ]E=5VL!#+)E=5A/80^6L#G'88R>0.WWA8?A\;($:6TQN#QVZ'YSNKF+7W,U
MS.;E- NZO[8K33W"W,,9)XTY5B5$8\<2%9!VB>XI[GTQ%@=_7?Y;<_#")>]D
MG;Q<Y&ZSF4 )Q,.WS&9H)C:+077MSJZAJ<[3UEFSVUNPPB^ERV6J:>2^:8EI
M,.)'83$2V47OG2_TL/9]/?SQ(L.7AMUY_3;PZ8?5?VL\ 5BUY ])*YXEC5SS
MSE:V\+6\OZ/E5>::L^_>3:RI<W(/)DAVB'>7[22%]E85K(VU4K 8F%_[?5SZ
M;=,-D#LJ[8:<<"(+,DCOSDM-!7'3;G3E'TH.>H2\W49X8P^\)F"H@LP2ZIBI
MVN8,@PPIZL6W%CLVL.7Z.GM\/5?_  PO&<-]MYZ<I8,]U8:?S+H4.Y!K"-:9
M-<VUWFP ]&+"Y%L5(#=GZPD"RA%1K&15<HD1;2*UH\#&%P/ >[U7]O(7QUA=
MH_;/!0)F(<56%4! 4D,E<3?VQL)M>P7D>N(;.^6TDE)'4;EC?#DR.D=ZOGV1
M9'^T&%= Q!L>?3UD?VX=V=X!X?H,W8Y0$(VSKM/R/C>5[:>\UU]HKB]Y"XS-
MP!^6ORKFVM3+(F>B)XLPZ('&0@#8*&$245!I)X9&)PTK'LO[=;9]DAV'GE"N
M0= %<5#=+IHJ.UFTE;LZ:PMK"GBMF5Y=Y'3\@ZVM!MY8'&!#6(WL9&S4=!+5
ML18?3KUW\?\ $^)Q.%!QQB\Q=:/14U "->:N_9IKJUD9[R=-<,R.7POO(Q!*
MRR@-DR^,SE7,.$Z >=E>DTL;YYIY)'TWQ/\ Z_+XX>_3#%+NU7^G7O4_MO\
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MK_K,!^DC%:Q2-\6-V_U48_H!Q+V([=^<.1GQ)C.+MG=PRJG]'049T=;$U?\
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M1&4U&1=/J CSI&8<]U+&.53H;92H35:2X.BO:K0O7-AYX:NLR3*QBZ-$E8U
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MV2+T_5]$JR(K?"/]7CK-4'!'">6,&I,BH PL=<\9JWU<[AJLSZ2#]B!;I;&
MS+R@\9YLK)6\0YB4:X,=/**)""+6*T:P!A;HU^>^*ZSSD%3RDE$3E$3O=)-.
M3*^>:61WQ<^261SI)'JJ?%SW.<OG[?M7K:5"(BHB*BJ %5%"JH'(!0  / *!
M[+8U%W>1F=W=W9BSL[%F9B2;EF)9B3<DG>Y]>_7TQ1@Z88/*)]J^.F&.%^Q?
MX?'[/P7X?K?'J1S'S7_M&_R[8G?I?EO[/FQ8#M[[;.2^X_709K"U4GN$4L3K
M[3F,EBHZ -7)[4@XM&JUTJ,\^[AQ+(24]$CBC<OQZUKB?BO*>%J%JO,9AVK
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M7YYG%2UMC21T=" ?'3-#7^S<WY;[;RKD_DI^U3-GM-LX.0MQ&U6N;7ZS6#1
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M>[L<J@  $(0P/78'D=^3 D'UDFKM8M O44SD.6*-4)I(-]M1U$V.X#*>0WV
M"#_,_P#>!8ZC2F3[?/XK'R&'6&/RV&VW*$D->2,L*9V"P?<YYS1:B"."..RH
M*%M=F"&-<V+/MC((B? 4[7CD-A:_9WOM8['8'86.YOO?PH[4$G^-TZK>X5:E
M;#U;M\7U"PWW!Y'#.X#[URPJ6*#DFNK+44?0+H+T;?[\A]WHC &15^I I)\&
MRBH:TB=%&FP"A6^>H86NM*2=]J2UP58 ZPN>0^I$$#VAM]MKW4G:X(YFE!
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:8.F&#IA@Z88.F&#IA@Z88.F&#IA@Z88__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g96389g63h82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g63h82.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1G44&AO=&]S:&]P(#,N,  X0DE-! 0
M    &;B^980X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!7\G\         "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         2D   )<          $                          0
M       "7    2D                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   2D     4F=H=&QO;F<   )<    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $I
M %)G:'1L;VYG   "7     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      /00    $   "@    3P   >   )0@
M   /)0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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MW>I;]H>_9_A*ZJ[/
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$!_\  $0@!*@)= P$1  (1 0,1 ?_$ !X   $$ P$! 0            8
M! 4' @,("0$*_\0 3!   @(" 0,# P($!0$& @(3 0(#! 41!@<2(0 3,0@B
M0111"14C,A870F%Q,R0E)U*!D1BA-3=%1V6QP1DF0U5B<O T1%.79W71_\0
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M-^+<:YMSOIYPGH5SRES^KBZ]O@72_+]+>*X5,;3H\MFJ9*'&\VFF6&C-*O\
M-HY:_M20G_,?\_Y[:*MQ^7.#\AP?U_;5B\@_BK8SA7U&X;Z?.:=(\#5OYF',
MXPY#B/77B7/.18'FN"Z;S=0[W'>6\+PG'4?C5!Q5MX6IE+_(!EY)HH,C/Q:K
M2NUBYSHI;3@_LM'%Y7'I[^O.M#^-_P NO<8EY=_\"'42M@DZ$8KZG3=FZU].
M2M?H8^8K\?Y%RJ[%%C)+468Q.7LP18KC%.OD+>=K3P6K-K!EIH*\#9>I[?<P
MU_1;XX*_[7JX^2_Q>*>'ZB\HP=3Z;>;W>CO".J?0SI1S;KD>=<5JQ8#)?45Q
M#B').G>5J]/VI39[,QPV>84\9R.I#=KKC/:2Y4MY,6'JU9_#_P ]<_O5Z.WW
M+8LJYXN\^.&O6LAKF+IQ_&'S71[I9QOC_47C6=^H#J]FN9?5=RS)/9Y)C>$3
M8WI9TIZ\<@X3@\3A!0XAF_\ %'+'IRXO#\6XW%CL9%?CH2OEN2X]@DDYH8^F
M"CS_ #,1\UA><X\#KU$Z[?6]_EKA?IOJ],NC_(NKO5#ZJ8Q=Z7=-LAR''],V
MK8>IP.SU'S^3YGR+,8W.1\=_D'&ZLJV\?!B,MD9<JT=".L%,MB(U7UK-%I[*
M']W7GIPKZ\.O'U<?6Y]$_'^F.(Y[TFZ$YWIWUFYWU9X?4Y=T\7(97G'2?J-2
MZ<\LXMS.3(<*Y%?S'%N&Y.":&&#B.:X[/RVOR6KDH;V,LX@PQQ?'Y_%?\^_M
MS5J ;,V4Y\Q7U,X]^'GQZ#R?7!63ZU\']'\?"^)W/YP<Q6FY?CNLO',KR[#W
M\5TZS'46-LYTEQ6#NY+!XK(4L-/C:EO.\HQ66ELRQ7H<!/BGCN23JO\ S_G_
M #TUQ#UUZJ_6ITT^O&]TYI?5M;7HI3Z ]1/JCGX)7Z']''R"8+IQR#C]6;I?
M6Y5>XW9S9JYNAD+<3<EL69,O3D*2Q=S*-'G]\?M_;_?4A8^M@9];_P"VK$YI
M_&#X=PSIUC>H<W0_E>5AR/T9]'OK$CPN/Y=B5OG$=7N?\;X#2X'#-;Q%>K)E
M\1;Y)#>ES,KUJ5V.LT'Z2F91-' V737X_P"_X^^BF^UYNO:QISJ'XS_%UY2W
M5:ATQZG_ $:<ZZ818WZE.&?2WU'Y3)U;X%RZAPGJ'U0XYC^4]-32H8>E!>Y7
M2RN)R="7D\T'\KK\8>[6CI6^3-^J%2="<)PGYLY*S@YMJ_349_\ CG\52XB>
MIN?^F?F&'Z6<[Z.?4EUE^G/E:]0^.9#(]8,-],^+R^<Y3C<_QNOA4GZ8V^1X
M;"7\EQB:U?Y5'+ D:9!*-B00@T5B[,58V(-4\9YS7C.==AY/J+]0_7[Z-K'5
MOADF6^C/J-EL#)S_ (RF0J].^M>5BX7!03D.$.5I9+&6N*5[7+,') +]!(K=
MOCL\LL$5^U+"MAS4:\K^E_\ %5ZQ_3=])_0GKM]4O*,#]2V2Z[],^-=8\K2@
MY#TAZ*\TZ>\8R&0@PN4QG ^F/%>*SYGJ5'5LW([UC*Y\\5QD9BCQ\'(&N6?T
MBQXOV\<?CSJW;]3'WH3.5H]/^>-=;<\_BW2<)F^H[,R_35F5Z5_3YU<XAT%L
M]8N1]7>&<1X1G.JW4#DO2K!<7H9B7(8NS>X+PVG1ZF'D/->=YNM8Q?%L=AX8
MJ];.V\N(<=-_G_SY^W_GTU%8.<BU7I=^?;[?MJH,A_'-Q&/X-P#D#?33D;/+
M.=<6ZU=3*G$J75NC<H9#I-T7YY#TTEY9P3E57I]/%S[,=2>5IE/\K<#1PV-Q
M/)\%0KYZQRS&5,K05S4]N6GTKWO)C[>,MX+UU?\ 19]:_6GZG/J>^KWIMR;H
M]C.'=&NC4O22[TUY<V=]OF+4>IW2KA743!XCFW&9HFE;+\DPW)K7*/<K-CTX
M='7'$,G6RV21LL34(4-Y3BO=/]O^<'J%Z-1I>C1I>C1I>C1I>C1I>C1I>C1I
M>C1I>C1I>C1I>C1KCWKO]#70CZA^I_&>LW-SU3P/4[B7"+_3?$<QZ4];NKO1
MS,#A&3ST/)KW'+]CI?S/BAR>-LYRO6R,L-\6 \]:LS$_IH!&:DDA6*NZ0<_>
MK_KJM.9_PLOHJZ@YOF7)N7],,IF.3=1;G6&USWD4O4#GT.<YC7ZY8'"\<YUA
M>1Y2OR2*[E>.QXOC/&DXEQ^W-)B>#6>/8:]Q"IA;N/@G4T$D;,<>#Q^-3'!_
MX:_TI\#RF*S^/XWSK.\FQ767A/7\<IYMU;ZG\WY)D.JO3WIYFNEG%.29?,\H
MY7E+V4BQG",_D,+'A;DTN$,/Z,G'=V/I& T"A5^IP<*M?U_W\Z%NJ/\ #+^G
MSDO1'-],>GF"GX9R+&=*?K-X'TGY-?Y#R[/4^$9KZVJ.7EZLYS(XNWR #DE;
M)<ER,&7BH9.6;^4UZ[T,!+BH9 HA+$]1/MH[FQYXPY&BJ?:L:'>B_P#"7^E+
MIATVJ<1SW'N3\YY-?J?3Y+RWE_(.I/4O,7K63^F[,8WEG3;&\6ESG+LI=X;P
M/C_,J,N:QG <%<J<:CALMC+%&QCXXJZ%<^]?T_Y^^C_S_43/A:4NK_8KH+I9
M]#_0KHMU1S_5/IHO4KB]KD7(^6<QN\!I=8>J#='*_+>=W)LER_DF/Z/3<LDZ
M<4,MG,E9MY"Q/6XW&L%VW;LTXZT]F>22=%_;[T7X.:OP>?&AWF?\.[Z6>>];
MI^OG(^(<EFY?D.8\.ZC<@X]2ZC]0,7TPY;U&Z>U:M+@_/N7]*<=R2MT^Y+R[
MC%>E3&*S>7X[;MPS5*UMGDMUX9D/-_\ UH[FJO&?O3XOTYQQE]=6QQWZ5NA_
M%^F'5OHWC.(.>G/7+,]5<]U,X]=S>=OIR#(=:;>6N]1"+UO(S9#&U\U-G,C[
M-;%VJ<.+28+C$J+#%[9HMNSDX]JX_;09].?T/= ?I;M\YR72O%\T.7ZD<>XA
MQ7F.9YQU,Z@]1LME<!P*CE,7Q#%I?YQR/.V,=4P.*R]K%T(,:]2.''I4JA?:
MIUEB-1^W['_,>/3QJJ:?\+7Z/DQ757%9[BO4#GO^<'3^/I1R7*]2^L_5KJ+R
M#$]-*V;_ ,2T.#\)Y!S'F69S'!^/8[D2PYNI3XM<Q?9DJM.T[R25*YCBN><^
M[_P_&I[G'&&S 9]\9_-ZL7&?0-],U+CW5SC.5XCGN:8_KOTPX)T@ZM3\_P"?
M<XYOEN;<+Z;X2_@.)0Y7,\EY!DLH,SCZ.1LR/R2M:@SUK(>SD[.0EOUJ]B.=
M%_\ #']OZ:T='_H!^F_HI?M9[C.%YOG^6WL_@>0WN<=1NJ74;J7S>[-Q7BG(
M.$<6Q5CE7..39W-/QSC?&>49O&X7C8MC"T/ULEJ"DMT"P#_G];T,E >"Z  S
M[ :$;_\ #"^C7)\/PG!;G37*2\<XYTCSO1'"U?\ 'O/$L4. <AYCB>H%ZE#>
MCY$MPY2'F&"Q&;QV?>9LUCK-*)*=Z&N6B)QHMSGE%,59>?ZOMJ[_ *</I0Z.
M_2KCN<T.DU#E44O4OE</..=9CF?/>:=1.0<CY5#Q_#\9_F]_.\XSN?RAGDQ&
M"QL$L4-J.LTD#3"$2RR,QH6_^5_;5-\L_AJ_2;S#'1XZ[Q+F&)>'JOU(ZS0Y
M?BO5/J3Q/D$/-.KZSP]2F@S_ ![E&.RT&#Y=4L24<IQV&W'AC3[8(:4,:J/1
M_P _K;HM_I7 X/\ ZT%\V_AC=#HN@G5SI'T-AFZ5\@ZD?3;QGZ8J/+\Q>Y)U
M$JX;IYP@Y1N*4;6"Y'R)DR4M)<WEH;.7CN4^161<2T<PMZG3L0FCN;MSGN>!
MOSXQ^U>VJ6Z$?PGJN'X=G.,?4;U6Y/SNI2YMQCG'1?%=->H/7GB#] ,[Q[B3
M<3RF9Z:]0.5=8.;]5,5D>;Q3W[W**53F-'C3_K?T-3 Q5ZZNY_S_ )_SC#J6
M6< ?@;S>< Y\51XQ0=KX;Z(.AF#ZC='.KE/_ #-GZD=$.*Y+A'%>7Y7K)U2S
M.:SG%<M9N7[F$ZB7,KRRY)U(H-DLA;RD<'-CFTAR,D=N()-7KM$:B_&,YX/[
MU9]C&J]Y'] _3[GG5_ZI^1=1AB>:]%_JQX1TWQ'/^D^0QUVI+7YIT^KMBHN6
MXWD6/RE:>G+<Q-+ /"]&O3RF.S&+_F5;)B1T6(U'I[?][_O>H>;^%I])EK@^
M*X7D:/6'+V.-\LBYMP_J!F/J$ZWY3JQP;D%?#P\>KS<(ZGW>>3<VXI0CP5>O
MBFPV#S-+$6*L,8M4II$60&INFRC\']2J?S>M]_\ A:_1UD.F_&^F7^#N=8_'
M<9ZD9#J_3Y=A>LG5K"=4KW4[+4IL=D^;9[JMB^9U.H6>S]ZC8EJ37<MR*VXK
M-^GC$<*K&#1:6^N' _;#C'CT\:W7/X7_ -(V2YUANH>3XUU#RN>Q*<3LV8,I
MUIZN9'"<HY)P/"MQ_AG.^<8*[S.?%<TZ@\;Q;>WB^;<FJ9/D<%E8\A_,&OQ1
MV4-%OL?8"O8Q@]N/4T2#^'!]'D?!.F/3ZETDIXC%=(<_!RC@^:P>=Y'A>;X_
M.117X)K]OGN+RU3F.7ER$>3N#*?S3-6QDC+WW!,Z(RFBW+ZX>-%'0KZ'>@?T
M]]1>4]7.&4>>\@ZF<NP]7C5_G'5/JMU)ZM\CH<5HV)+5+BV R74?E');''^/
MUII7:/&8EJD!'8D@=8T"FA5_'@P?L4+[I>@S_P#%Q?33!F^IF4Q475OCF)ZM
MCELO-.!<6Z\=8N-=,[>1YVI3F&8Q_3O"<UH\1P^7SR-*MR_B\35G!L6F@:%[
M,S.:.YP--5R%X\+5IXJZK[&@V]_"=^BAZKP<=X!RSIW8BY-#S'$93I?U6ZG=
M.<QQGDO^&ZO$LGE>*Y/A_+,/<X[/R/ 5(*/*5Q,M6/D97]1ETMVOZWHT6_?%
M4@E>]F?SZ5JW?_@*^EU.EG'.C-?IW+3Z>\5GX3;Q&&I<GY36G%[I_P F',..
MW[N5CS*Y7)WTY$#DLG=R%VS9S,KR+E9;B.RDT6K;S]C3OZD_H>^GOZKLKQG.
M]7,%RJ7.<5PV9XM3S/">HG/.G&4R7#.1O"_(N#\BO<$Y#Q^QR/AN<:",Y/CF
M9DNXNR0_?7_JR]YH%./]M1O17Z2,9TD^HCJSUS@RF+_1<LZ>=->D/3CAF%PS
MXNAT^Z;=.ZLGL8A[$M^ZV4N9')N+TMJ*.C%&JB+V'<M*34.?]]=F>C1I>C1I
M>C1I>C1I>C1I>C1I>C1I>C1I>C1I>C1I>C1I>C1I>C1I>C1I>C1I>C1I>C1I
M>C1JE?J$^GSI=]4/2KD'1CK'ALAGN \FDQL^5Q^*Y#G^*Y$V,1?@R>-LT\]Q
MC)8G-X^Q4O5H+$4U&_7D#QKMB-CT<Z.-<RY_^&/])W-..8CBW4?!]3>K&+X_
M0YS0P,G5KKGUDZG97"_YA4:.-Y!?Q>:YMS?-Y>EEXJ5".# Y6O<3(<:%B^V
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MWK]>5GER;6;,&#L30QV$R"QWU-1B\9/?#_=_WUSK;^L7ZM_IP^J;ZO.=6?\
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MO)J"T\9#^EST&,MVJ$>5B[;R5+$U<3^U*ZDU%_\ ;^M_WT04_IP^G_'?R?\
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M)D8D1NW2CJ2.X_Z=@==/&S^YW\ #\^J_(F)>!:[JL^]"H<\_OG4/4U2PK_\
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MJJPE>!L%Y52.V2/'/E\-&5+NU.%\MUJ$OV!)D[-:663VU*#VNXA7,0 [.[X
MT23O>F)^/'I@)$B)<HDA*&V60_F6C@<?=*JE/%G \Y_H/Y/4S62W'6*4:!:9
M2-2 TJEE]P$DG[NX$Z+#0.]?CY&O2TE=4RIE'A\+=<YM5]&KO5AHLHXNW[X
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M_?G<$66Y*\LA62,$>7)1U\@J0=_[[UY&_CT5VKP-W7 K90)SP>?WU&8$7D>
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M:7(JL_N^*,\5A/.>-$<<<5UC,JJZ0 _W '3[)UK9^ =[.QY/_/I9),14+O\
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M*+$[RY?J) URX;XR\_\ WIW-GH^LETBSZ@Z3;VX[?4S*W.V19*0+<(RH?-%
M^=87<A O'8H<I6ACN71WRU ^O8"@M(%)*DL00J @'7D$>G0>Z6?"9<WBJLPK
M8MWG-WQR=S;CTW4R>B=[Y;)CM[K%N45J*V-1H/+B^=-\1S''/+AXJDHIO4,=
M*K6D<>X\D>R_?&SDE@GGM8D]NB0//IA!83.V/;/-A3ZTOE>%H$TGJ^DZN.YN
M3WCO3_,EN"]K&7Z98_5GD0KDU<,'4#(PYS&O6R*PX?\ 3RI=IM '2Q)HA'6?
M9>$)(-  J&'R3H^N=/HXS94I)S&6 /4DVWXQ?)Z:5%Z?Y&['<V>_=E*)M[O?
M*+ RM!AOW_;.G]WK#:CG*4:=69J4O??QUB3V[ERJRG^MBY=I"\L;:)BF[N]6
MWWC1'HAT$(K\P=M [=UKY9)_U ^1]ZY.&U2V8,8NU/O46<*1@E'K]3C[87.G
M^<L\&ZCX>"&U83&VK:K/7K9&(5IXK*DJI='81,PD5E*K*P=?*]V]^J?+ZKIY
M2[/\Z$4&6V]QXD-M8I.3SRAIG1]3N='O$X,JIC,\L7#$;$?7\Y&ZJT<6RV"N
MMBGJO8HZB+Y:FD35?;8:?<*O[D#(1L_;VZ*Z9M[.R/51[8J29)D<4WGG%^GK
MP>:T;T(=1/YT)QK<DORY2N8F19-X?O6/.70MS:WDJ]8TJE6O-+5E@199"4:2
ML64F1F'R2I)"E3IOM^0/6K;B=DIC=JM_E\%GB[O[XTK8AL._.'4[DX1C%+B"
MDFJ;1Q7[U92:SQ/*[%6JS2X&2"I K/)D_<)CC:/R)JD2J6+.2VV=D"L.T*^]
MC)N0DSS(2(.1454S:%<(713?%=78Z7IH[/?L=6[O5;Z1CTT85&,&\;LK(WB+
M60LO-U9^$Y)Q[E%"RLBI8@J".6420M$T=AB2A'> #(2I(()/Y\#7J)15[6/:
MI<CN$I7[)Q]_!=TX=V'6]!NQEN2(SF/:PGW_ $$@K&#R>#]]-I]V9XIX\U9>
MM2L$+6+]T91^P/!)%]Z]T:KVJRD/&"671^(=B$J92(H'<G-YKTOC%!CQBR7K
MMS9CO1EMQE\^IQE+]4:(W(6A%X&^Y;K-:&H*&1N9RS6KYF">"I*;5*O*&L35
M[LP$_;/8!$T<3!@L<!D6,%5"JP)'JLMKL1@JY5C=,<HX\GE2O".-=./Q3I/\
M/&/5]!<MV%?XCL[5B1(C$NCCDL\V-:"Y[>8S=[(<6P5G)4LQ2AKF_8]F,47@
M-M?UD:2V8W5C8"'W?;+RQH00RG19LI;@PJ*AQ]61P G-*""XOEK6OH.C^&]+
MT<^NZW;V9[/4?.CL;4I/?&=5M[DHPJ7TN3N/6KR:(,9QREQFZM[**KW<E97M
M21Q(A:*,@I #HZC".S=J[&B1O?IDIW&-GU<I8%EVV8<^O_?7G^IZG=ZC;CMP
MBFQT_<648G*QE2=Q@KFK..4AR4*5<1D;/Z:?LL,M:O!'*3.5)'O2P$*O8J1E
M_;8?<2R'Y  7N!NU'+FV5\>0YR)Q_53FOP[=EL]5M[A.,$6I3I@-*=T5S&^?
MN^YH>P$64Y)D<52=LK%A\;/7M6G2>Q4LJL<GO)%. .R['(85BL:)*PR-W$%U
MWEW8PC481(F2+AP)G  %6#S551GUNWNPV-CK-[=ETF]N]5&42.Y&$H14[26V
M_JBEXQ5^:U9\_*L[=RMK'2TS#BRLD48TCPR554*0X(#!W&B$4$%06#@]NV[$
M-IOZ8V\RI[CFI*<OV ?.:OQVYLQV(F]#?CN3E*Y;<@BQGAJ ",<_K0::&\:'
M.6\2II2Q$.*PUJ]<W':[#=DBKU65A)WM:+JR(40*4_J JQC[2CGTJ>XXC*)0
MO;AX++6_NXSPU>NU\&WYSGU$I]9M=+#=V_E2.PGN;I,HC"$RAL%DI1=RIO4=
M2P5'.SVLODJEVE?HU[>,6C(H$!<AGEEJ]H5YDG9U0R,I[O9+*.T]SWVI89&
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M90<J>FKC_P 3XVS5H8_(8&9ZU6:*J^:.ZUF&8J!(\3:_J]Y 92H96&R/]N7
MW8R6$ROJ^GFW.)#Z9BV-O*ZU=1\.VXPWMV>_'YS WH[&V,OUI4+\<J]W''I<
MIE<KR&+*X_(<7RU*[BJT$$<N*ORQ5YGJ1L/?*S'6Y&T1MNWNT%[O6DCMRVY&
MY&1.1?=$.TE15^25U^GWKTUQ7;EMXE&40:O)<JXMS>+=61/P>MG*XRM6:']?
M.BS1U#/%-4!.V 8J69020'[6?M90%\>N:]3/8[MJY,;S)[OYN,.$:NWU6G%N
M=R&[+:^;%A ^G<E"-LC (W:\\X+J\-">>P6?X\]=WHQ2TYX EB*"(6*Z2 'W
M 0X1CO>P"HV-ZWKSOZ;>V-V.4)E>,E1\YX>?3@U2<B$DV)/9&5PDV+R6GBC\
MXYT$9S,18;&Q7J&)E!FMPQ9!(481O$GYBB3[A*@^1VMX\D'P!244FR[EAG*K
M2-Y+^S2U;KI]#LP^)7T^_O&W.!+Y3-KNE/\ E5EY:] OUUOK96O8L5?8A9(+
MD3..XE)%M%0S"1'57! V"2-GQL>?-KC()"T?4Y+JN+Y#-E->%SK)U'2;Y\\D
MW+IYRA.)]01B@,>W%?DXKWUB$OP2RVVQUC%6)9))8YX/ZD$PKLL4$MJ1"C,\
MGR(F4A47P=GTMW;EV_31%"5T-TO/-9Y?3[:ZVWT<-S9)0ZF/4$=LO:D2-V*Q
M)3C&K^F-\\\>NIB2XM?V!*\45RP74R(@1G220DEVV-@]P5%#$D_ (7?IL9"L
MCU1O"N?1JFJ##S^>&QW9=T/\QVX2D&VK+M/J1IL"E.Y\>/7=R"U).V-,D4$J
M>U,OOGM[:\S:C$SDL% *=RJR;.R?R?1(EE:R8[?'<EX_MFQOUT;<)2)=K7;F
M<+3OB(TF;I\8_IK6R6+.)J1RVIOU4+30P/'$'$R*(542AF(#2'N.]E?M&QY/
MJ$N/;M%TX[N7C%XSG'L)QJW3;FP=2.]!=N*W'BDX7Q7M_34]QJ.?CW'DJ&22
MQ<L,IDOV$[Y/ZK>Y,)&5BJK A**HVJG2@^=>E&W:"92W+0IY?#?A]^>=:>KZ
MG_%]1O[VW"&W#;2)LQDA7:1$.:3ZGFK3.=.\;!%B&RF0>6>V+$ZJHD/N+"SQ
MH&]A9!I $3013_<Y.]G?IGRJE44 .Y +0HR^O+?&*]36+?ZJ?4?*&,8_*VS;
M*(BA,),WEE5%MK@Y*TTEY'F),W0QT6/+T9J\D\V0[H^VO)$RB.M)&=-N52Q0
ME0%"-O0 )K.()],>V7'++-=WI3A3SZWQK1M;>R])N]4=1V[^WN$8;-2C+L1&
M9*LD5/-KC.I"_;LRVV$;A$]K3HI3M61$[&+E 2A<!6'YU)X!\GU:$8W&!<JB
MG%N6[5;SZW9^YK)VR6&YO,GN2I-,F!AKP'U2[:,\KJM,GG,GAZ<MN&-"M:2.
MQDE:,&"XMB-QV57<[DEB8#0^WM \MHG=C;=Q[06Z%'N'!33QQ=(\N>'73V-G
MI@W'>WB+-F;)W*Q82J'>'^J+:XK!ZZ#\"&SN0EFLVHYJTGNY&>)XT+PL"-0]
MO:2![CH _D! ?)\^M<H&SMD>QL$/J;$%S'/+RTCC &N=NNZ)*)V!%A9:38]O
M=**_4U?_ /5ZFCX97'XV6+^9SSJU_*5L91@_41&(^X1$(X$<H$C8=S.B!G(4
M_;OQZP[F[\N7=B2G<A;8G;]2GAR-ETASKH]/T._\0@_(A$CTW3;F].1$NHCB
M5G*N%M;KDQ,YKB\E,-=QZ-^I2P;96+O]FO/-[H2V\2[]QQ'(ZDD%6(/QV^#:
M@;DR5A'DCQF%H7F^::S@3#B-SXEOQZ;Y!'M^80VY23ZD"(Q',B);7#V\9U5[
M4<C->D46:Y7) 5I<G9KH):H$C&1XW)4H^U4IWDJ3H,C:\MW(!4H1[&2"7@ ;
M]#^M4#[-NGZ\G&&QU1N[VU![MK9CN+"^WS#-P"V7'%I@1UD\#>HX"NM::/(O
M#:DD6.1PKR$22[5 JJG>%97)V0H\$?)]7C-[#N2,J"CU\G%>P9S^^JQ.EW^O
M8PB[73RCDB,NRS'F^1M;3'I@'N9[+5L:+&<QMZBYDL05P")NVK'(JQSGP1+"
MZL.X [7O+#PF_5C=C$#N)K7U%>:\>S3]\7XUKE\*CN=1/_"=3#>VX1AVLGM6
M<H=WR\HC&C_VRR76CK"YCC=OA68RL%ITH2I7%JQ*)'465FK>U"W<I90?<UVZ
M#*7(;0^5N]$F=W_[%>:Q6,/H<5QY',?#/B<>KCL1V)_XF493C$8_I!O)+!5U
M[<TV$JLM."BET.UBA5K320V7C9EA@E(F4AU76Q*Q]HD[[7)&PN@SYNW*1W=O
M=4<8+X951E;Y.*][<$.CW][<EM.W>Y%E'MDG=W=O<W:W.@B(78^I8SDN0V),
M?,4L7E2I[\'N5X!+*\LX4B=/M;N2(/VO*00'T!O?B4)EN(GCBJ^D,\Y%OGCP
MYT[/1;NQO02&WNRD=[MRD5VU^F5>1E'M%?-N,.CC[6?QE&WBK:T?=7]43%$J
MV)Y("E::S)*5 $AC41$$;8(=#<?E/S=O;DB)C.+?J964X0*1P^'W?MLMLW=S
MJ=B4V.Y':C&4D[(G=N1C"((W.2<Q/JJN+9?HH*E!;+2RKDJSRQH\C!8T4>-.
M4((C![60,"O<NCKQVMW(#,E1VS,(V<RJK_\ MH&W!F-UG,VWNAM,>V<0JT[@
M>UO-]K+!@J['59<.Y'>O=:^J"V+,[FGTYZ/U8UD1@(U7DW6UV2(M_?%[CNRN
M-J2S '8.N-\0C".]'%7"_/\ JEZ8"[0/#?G6S=Z9V8=.!$)]/":C;*2H]U8)
M% F*H-=109*63#\9Q]9@\HP>&4R(1M"V+J=L 8'8*=Q+_@,2#\'4;.V_+)U+
MN=NHA(H$*LK'<U)>:"K!UY;<QN[K9;N2QQCNE^/1<76?-Z<R"WDQ#7B[WGQA
M6/NT2',L@#:.Q_;W'9\['=XV=^@[8$NZZSP&55OUNI!=\<.@^FY75M<^ZA]L
M7Z-^.!W8:J\B[EFIM3*F*2J>V;WE)39;>SWN?/=\  ^=:$2BD&HFYW6?48(A
M^J[Y4L>;O%:F5TQC/N&E6ZIOC+SFL_DT3YGD<V/BJ24YI9>_L$DD\:LZ,J+W
M.)0NQWGNV Q4[\:T-JCTR=W?]1(# 5'-2XJN1#QS]HA-!) B 15MN_5<Y0OR
MXXPZIY]X3^I%ZQ7M*HEEC\2TYXF 8L\3:"^?'=&P;[OG>_2Y[46/RY!/;S)$
MM*<-B9R^+^E/6@AMYE%(3I1%L1/%.6K+P*W2.I#*9GD\]=+N#O8V^L8$DU%5
M1)XXRI(",=EV_NTKD'?^K>P*QV]H6(HU9WA&VUIO%G'C\M:NSL/F=\%*9@@2
MNE2PI+3+7(!1IA@,U/F<I$N1P-BBX:1)+L_M10ET!T  Y,JMY&E W^#\CU&[
MM.V7W#02IY8^4ISCCUP>^E]L1!W8TKD7%XM]"F[;I&W)J>R?'[#7'LT)HT5M
M)(NV (&@54KL:(^[7XT/)#>(ANQ>T6<?I6PJSN?$LVW=^;+-+:%I[@XE9S0\
MG/M[9-05V[VV%H1'1'],@N202JH$[CL_8V^XG;%O/P/3J$$C]-VR*,6AA%\E
MT%+BLU 2[7GM%SXY XQZ/[Y76N*DKVT%Y6TDBL6WM-+O;%1O8 ^?.@"2?V$P
M8$I8%>,\5Z\//!1^[>BF-*42BTU5G/D_YP-9ULRN19?->198"[;5E,?>H.NP
M*=D@J=@#3;WK\:;&,'+([BU7D"Q?&"VZQDT!=EOWJP?^!DJ_MK? +T]0UJE9
MZ\$,ZJT!!'VN@969I/)8/[@;1VNU\=NO2YL8IVR$'+_,Q]5+>5_93(:C _ZK
MNU*O/M@QQ]^/21MB#'8U(KJN"\G=*D+#N5G&P"1X"]H^/@@=HWZ7MDV??'U4
M+>U;I^YR^/&=7:0"-8YK/\O)=G/NF;\Z:<>K4I[TL\1&JX)5FV#VD@;/XTHV
M"#^?/J=V<H124TC>!KE+N.+,I'GCUYU4P4\.<WCQCUQQ1Y]#1W<NPUFBK&3S
M.>U!O9  )/G6M#\[/_S'K.69+SD:/S6''YQGUPR<BNV[X?4QQY], .?6JUE#
MEJ\)2,SQL7;V?])*L03KQY\:'SKT,5<9+>+>$2W_ .[U$9U5XH_V*\WG^W%^
M<;&4:$B *)&=F4%?'QH*?&M'1!'Q\$G?SZBJY?OZ_LUG'!C1WMH X:;]?0&O
M+CEY*U Y+ 5[ZRSR3"-6#!XSVKW'0\J=CSO1).R=;!]-C-@=M"K<5NQJ\9Y+
MR5B_=U4C8,>3UQ?EK/@'[UQ>IG$M8@B2J_;[*]@0+YV%7P=C8UX'S\-_P/2Y
M5)[I5=V<X6CWK^_[FKPNZ!>5P8HMH_K5U_70IR)GM99*M9G$KQ+$X=3V!6V=
M@_CX\Z'SX'SZT;4V-8X).(Y"PSDNJE=!FKO&JR[62R%,X]:&Z <-XO\ =UBG
M?"ZU%$C2Q(%695^&'GS\G8V=? (^?3&40;3'.13T4<N/N_?5,'-TE?G_ ',>
M:_>M1F2RMZG7:4/-+*TC1J[)KMC5?N"@ '0(.B?C]_4QV]N5O+$*X*QRX#%B
MG!Q7C5XG=8K29RX;O'&7G[^<ZA]+(M6S#,[F15>1I%/A@=,/)(?SL> -C0.O
M3-JNV0N26.X][QF\_LV> T70C1@0]//BWT<UIWE*.0L-!9J"62,(!)'$"5#'
M9WH?N &UK2@ZV?DU[HDNV2%W6+BAS?MR%_?TU$6.1YYS7_GS?WUNI<=.0ACD
ML,U<][(Z2@DGQX*$D; \>#\']S\4EOP&/:1D4W=X]D3/FO5XKS;O[5]LF/6D
M_P"[Z^W#'6*;4K<E0L5CC==MV]ON*3L,/.]'SH[_ '/@G7IA/O@L8E^3S;Q7
MN#>=18BUELKU\->].<?O6IPRT/T@]J/W>Z0JSE2'K]P';L 'NV02/D#YW^/5
M W-L^E8^K67-JW[>R^QDU6Y4<\-#X"^/]G#R:DZ$M"M357[+?NMVE>Q00W]H
M#A@=G?YUY&M;\$9V+*>6Q%L.:\/V2AQZ5>IC2HR"@I;]&G-/_,8L8>MNOR1T
M,?;7^UDC9=K'WJ& [O[?#'?;XT /@'U:0RV8U)6+;'*F/?QE3[>E:BBCUM'Q
M9FN7'HOK=Z<7TDGG*/("QF/:B_'8#ON)'R#O6_&_W/YO&-1*L:M"V^>4Q^?'
MGDU#?G\?;VOQIU0$BI("CL(F*%$!^&'RI\['GS^=['X]57;$ODK%6GENS']#
MS]I!IKTSG[\\?L>/?G38L?R^"1T1TD=CV;!TJ#SH^=]Q/YT2/QKY]-AVS:43
M."7GQX'CW,>^K[<&;FZI?Z<^]_\ WC47@<U;N=7/IYCEE8PR=<N%@*%T"RU\
MQY\C?YUOP/G?JF_M;<(=T>; J2_<IXKUSS[Z;LPK<PY+YKT.:/Z7]G.OT*^L
MFMVEZ-&EZ-&EZ-&EZ-&EZ-&EZ-&EZ-&EZ-&N-/X@<7O?2%UIB[_;[^.1KW_^
M7_O"IL_^WIFS_P"KM_\ R-6A+ME&7--_MKQ$MX036J\E=C=E0.]5($;VU8/I
M9&<J#[GSI>T_['UZ:)';&4Y8^I,8#V.<_P!+_??M]7O[S+;C(C+>"#+_ %1Q
M4<X,>6U7-&M63Q]QX,A!:AM))0K0QTUL%37EF?4I91W%N_N+*&8J0#_;L>EP
MWV4@(MMOE3SPY,5XKT?.M$^DZ?:.G=S=*W5=UVQ-S;HI@M@\&03..=!U><44
MEHQT0<A.5EGE<C7MLR[1#HJS=_PQ!(^01\^MDMR4F+)%B 1'D'%77&?WUEGT
M^U&7=#>#;659&0%L>Z+5]V:#C^NG0A6RLO<I^^40V7#!EAB1M%2BG3=OV[[@
M-^1XWZMN.!C*F-KPB>/ZW?.%=8XQG'<<2;?I4D*73V\/'(9XMY';5PGZ6SDI
M(KD4LD31*D4+;9:CQ]X:50X 8@ MHC6QO0(]*V]S<W+N51;;:+3%1S58QGU]
M2]W70VX;&P[4'OW,R[QBV-//U7Q5Y;-:\QB)LK4FFEJR""ND4L<ZHO\ 4]L,
M955T8.W:@V .T*0 "3OU5F,OE"M\UCA#)7+C'IP>M^CW]OI';G%B[T_IDRQV
M7PM\%AQSFZ\O\?5R>=QU"*&:W5BB99U6:-5F"0CLC$HD!?<JZ^XDD [WYUZ1
MV1##?K0^+7_Z]>>-:]SK#IMR>\QVM[=GAD7*-OU$H^"C!'QD\:GZE3$%9L8G
M;%+5J VHS*JNLDCMVNX!=PO>6*MKM/=O0]/@4%.%?&."PQX_#63@=<OJ-W?W
MYQW=V$EDK&XRB/J!@HJ_-<JZ'9:N4PMJ&OC<[?K729_8<SRF-8W4MV$AO;",
MA*J7'@Z* 'U7<VMN?,##<F61HM<W]L?CC6C;ZN9\S<GL0GMD00JX-4-4+D>+
M7%UPD/$NL?(Z62EQ.>A?+8^O*E9DN3Q/9[.X=TL,P!+HJB0A'+,0NAH$'UEW
MNFVR!+9@0G:RF6!SXMYN+FWT#3?_ ,=M?+-W<ZJ$'=@SA'L9+)_D]+$[5.+Q
M?B^),SPC(5H[BB" ,24AD1  _:2=H=KO7^L*0-$$Z._2':ZJ%1E*+&APU?CE
M.6N,M>V-<D^9\P(*R&B5U58*R51SQ>+30!@IN!=1,]8J8:Q8PG)L)>;]15L"
M%3?AKOV2/ @[HY8GC'=]H5T1ED *CQ/41ZCIX191);,DIB- D4MX$N_1?WUL
MV^JGL0WMK>AWNY'M>[#&Z23S=8Y2C\Z?=5YLSA&PF(I<<3,82W8@-ZR/=26"
M:&Q$T+^Y%+$45?#]K$Q2=K1L='S;I=G:ZB&[.>[+;W(1DQB2*KMK'M;SE<:I
MTO7;O1[SN0"I"2O(0E=A>!XK"_MIIG,/4HY7 X^RTER_D,9-+0%>-(Z)M.P>
M!I(CMA[ [%W[A"_>_P!P&O5=B,JE)D,828O=<48H"!355][]"M:9]?LR=R&W
MM=D=Z9)W6Y;L8V*#;0UQGGRWJI,E1Y8T3PWK7Z:9K9B0Q0@(L2';1QJQUW*
M.YS^"=$:!];2,9&)DK#&;>VWFJ>3BGSC5X=1T6S/<W(;4I##M+<_6'<ISG.>
M;OU-698KY6O7Q<'O54KG4IL$JMB;V80J+"%9@ [@O,""5'<&\G7I8@D22(HX
M H+&P\7C'+ENG6';A#Y6_NNTR%[8-%1)X+X>ZW&>33NPEW]"U<B"TQGK^W T
MK@.AD$A*E=DLH4'7A"Q&_M]5W5BQ@%AZ4YD?278IFLWXKPZ?T&W&4YRE*6W
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MLEYNBU'2XWF+RWS?\IPYP'/NEE>1E\?8-F1 C.?<>>$A>WW85#SNY/D%4+*
M02/.CK\/A.X@%E1,V>+\//JM<9?5D4:5<GCPET.,<->,%:<RSNL4+RQ)/70(
MS(^F[)8D4,0P([7T?GRI)WZ!5CA8R0D9&FO8?[G^TT2O+>9-X:;2O-8I,O\
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MK8=6%@I*?<6,M[ABTN^PD G0VP )&Q\^?592^5+MLJ2MMM'MYKQY]J=6(LC
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MR=]3YF]&<0^756,AX> 0]C1WBL5G[.*OQXR98ZF/QY9LB2LMFU.0Q*K74!X
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M7SGCE[-4TJ82VWCRVY\_^-&>-C]OAE$QMV7+-+'@[&R:\-&!UCB/@DROHD
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MDY+8E '%TKC*?U]S47&J!96%T./-'A]/^^=!RXJ5K$\,,?NZ8JA9@NB3ON^
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M.IC!VMGZ9/;_ "EQC6+%S><O&G&'P^43-/+!?2KB+=285TM++)+!=L1]VBQ
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MV8Y*3V!3R$\YD3L[01_TD1B65@?A %)4J/R=#]Z2G./;*"2&C-8;1!NO0_\
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M_0"KEDYKN;7U\KS;2YUKV_B#M0EW;+/=E&>V[I(N4)5AQDC55S@JO!EC>EN
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M2BQ^1\V<MG#BH7VE7B@I#VT&34,CQVY')8JR6ZSLO_:$ =9(V;0[T[3VL%(
M\CSH>? ];HD=W:8C<\]H2[0S5&+7U,/F^=<D8]LA2,DEANK^]\XXK-<:D8<7
M4M3_ ,\Q]B7'>Q(RV*LD2N"#L,NCIE!'=]P/C8UX]4DRB&W*SZ6A.ZQ4.?&'
M]F]#;=1)1$L)5+"U:^;!.+!OUTYQ"96*U:%2P+$+RES$P':0_P#JC)+E=%B/
MQY&O/XGZ"(O=*6:(E4N,K^?4^UZ(]YF,&-''-<M?5XR6\@I=.B&'C]E!<G$]
MB.:XCJ06WV]VSWH2=)KN/GP"" -?'I3*CZ6."32E,FZ6[X].,>+U&%^OZ!;D
M#=G(>XY7%A[<QD^+Y!4K&O1M1]TL@:1RFBNSW.1^%4DC0 /G\^="T.PJ[[:!
M;;L,N7B[O_OJ92[NY[)HU1&05$*RUYO.*\>-8V..9ZW4$39QZLC$ R0Q@?<P
M())!#:^/R/\ @>1ZM\[:@R:91<!0UG.7DK\UZU>JX.=L<.%7\K5#Z]O]-.N.
M8',8DR)D<I_-874"NK1%'1@3W,S%V4@^/  \Z^!ZK+<A)&$2.*3ARM.!OS^^
M=2,166W&-"H2LSBT:_?Q[7>IK(XA<DJ57[XU[EE<(=$@#:G9&U ('@>?'SH:
M]5[^Q[_Y>/7/V]/WOU3!#VMX*9>*XX0SCSY\YK&FL>.DHADFN&RC$!%=4_IC
M0TO?I?)_((/P/C\PR$L43UP.7QQZA7IH>Y B<*(.*O.;;K/GSYU-1XZ@E8-(
M>T/X)31.S\Z 'SX&_!U^^];J3W>X>R 5C)?C(?CVS_08U1$949O OWO^W'[F
MG0JTZ5<3Q=SK\*6&P-_ZB.WSH>//_P O55W)R8R "_-V>;+NUR5]_.ECZUC-
M7^'A]N<'&GE?(U)2L/=IB  6!()_;SL#_GQK7CU+MM/Z6L^EO]>?SHH[K'CA
M%S[8JCA\VI=&GSQQPH\D$2!U4LI4#98 ^/CY)\_N=_G1/JJ#3VW6'CSYX<XX
M]GSH=R<L2E+#Q)7!QYP<YR'J8-"4^1LJWO3O)# C_<Q5M@[W\*!KM'D[\?\
M/I]%)16>??\ Y7&+^VKP&31'"U:+FN,\=WLGMJ7Q6?IY0 5BKA25+@_W%3I]
M ?!/G8\'Q^WGTJ00?J"5J5X/'OC[WEYU,]IVI=LBI%7%*2C'KX>=1V8EKVY)
M8)H2R=VM@?D-\GP?&QX&_P ?[>KQHQ$'-XP?ESEKP:CN8>&ZXJ^>$.,5F_MC
M0/+^HCZJ_3Q"G<E8=<^$GL ([A^GS(4M_MO7Q_P?'IM':MY$\^'_ )Z^I7I.
MU9O%E8E6,??'KG^GKKWA]5UMTO1HTO1HTO1HTO1HTO1HTO1HTO1HTO1HUQ5_
M$2*CZ->N9< I_A0]X*EP5_6U>X% "6&M[&O3=C.]M'K./]]-V.[YVVQLD2$1
MIL]_'WUXE<>Y;=JX6/CF.QU:'#-$TB05HPDPT27E=PNB)'&R&7SL [^/7I8]
M*1W7=%[^.X<!S1>+\//G6CJ]R&^QDRF[B?YQ.3,9=U>6L%6!XU&<,QUGF/*[
ME2<.E:GCY&M1M#W+*HD(]J1Y![8C=-J>P!U_!'GU'6;GR^UC.A*6L9Y^ZW7*
M>IEUNV=KI^EZ#Y_RB>_.;\K>[Z(E79$1)W>6S#8'$'S!%PE;,08"BZ_HY9(I
M84<F.$%&8:[1X55\]R.=$@#R?5MJ49;<?J;S^]N+\8?9.+TW8VY[W4=-N]9$
MV]G<MBU%9(<UYM]<676@K$7>1ST*O(*,:M/'9@CGKSVBR^S!V!YDA?[XU4D@
M;^3Y)(]3&3W&W*J5S2+?NV-^<_CG6CK=KX=W_+95&.QN=LX0[4WQ6)*11*[\
M.?3&C?-9\V( V2>:9'2)%C=R()=R 2$Q*H/N1[^T_<"->!Z<[3&7?!X,6,DO
M%77MCC\&N/TDS=@[(&TQ[YFZ%;F,=MXY3G^FF60C$_M4I#(M)/8: =Y#>WM7
M4AM>8PPTR$_:=Z_;T\B43&/S.ULH<<*A^<\>N-9(=9N;,I0[27<IW+?;FF5E
M9\^MY3C4ER6M:P_&:^566M H=:M>2)A8$@:17A+*H#%V9B"GSH ;(/G)\YM*
M92E)J*44<_8R-X_I6MWP[H=KK^LC"/?/;C"4]W)#M"UR\4UPY,"7J,-[%P<>
MDY%+"TXO3-B[JM5['E?OC03!@"RQ1LQ\J#X)V?CUGEO3^8H6=O$EHS]L>W-7
MQEKM]/\ ">HW^KC\+-^&W\N#U.Q,W"J[93-M&^YK/JOBS4GDN(8+&8C]8UYF
MII$IKQ0*0K2S;D(:3N[84C<!F?6R ?DL3Z?M=4;IVNV;:K:<_2Y_<NCTX*UQ
M]R._'K)SDNYO16,HR%5B5''+CTRGJ98KA^.J+R*WF,JMG)XM\<E6:".=UK5:
MX8,DR!#KW2Q';(X+:V!M2=VW(R8,MJ47<B]T!JI4-C;C-?M?IHW>OE+HX]!+
M8V]G_.ENRWNS_.5:8=QVI&.0%X],:-+.'XR_(K$_'B;\$(C]M(Y#&7>1//OH
M54NT1*A6)(*@^1XW7;GO3C_FQC HH]\<->KP?UTC=EV])M;<=SN9SO.9$8V%
M-OZF[KRNH7ED%2YDL?BLK5WC[54I($G$,"2H>Y=F,AGD!!+*25;[AK0WZ5*,
MMV5=P1A)(B9LYP\U?*ABSG75^&=1N=%TN]U?3LCKMN42/=#O/EN51/IQ1W?<
MYSHNHUC4H83!0*O\M=E@_4SQI,:\5=?<V X*N[:"!G!.B-:('I6[ L.,U=8^
MKVOP\^A19K+L=7NRW.L^(2OYRLI$+A#NW5BU$P 93./2M6!DLEBOUN*N696J
MQ4UDA5#(\B6X71'=&K ,DSE8V"$AFCVS@CY]5.F5CV(L?J*%0HJG*G)?GVYU
M@.JW8['4P^5MSV]X_P S<8G=MJX25K$<77+9SG4-/3Q*9F#/V8UN8EO9DIVZ
MB+#/297(6*=(@&*HPWVR[5U;^XG1]:_KW(=D>YG^EC)H0\CC\WX.-<Q/1"S&
M+>#A%65BW0OIZVIA^H$QSF'QT\*SU<HTL-?(5"&B@>*"24)=B)+0/(B!D)8*
M='L)&]<_=Z(^7NSC*I[8+MJW='Z6LE<8M#[:MW%]OHYN5WG(_F^2@:J]$7*^
M-+RZN\'ZB2K>A :GD*K-%)$=G0[UT&7\D$^1_N3ZS=+OO3.8R8297%!JR_%9
M*P^OVL@[N[->E'D+N*YX\>?)K5P_$<PQ<'Z#.7$R-2%'BAFFCC_4:B!$9#J2
M7C/@;DVXT1OU?J9]'-^9LDH3E;,"19AI&O/*<M.I^MLJ-W;;C.3CD+7)XK.F
MD7..-7[]KAHGDQ^;*35();,(0S6U#J6C[=CQ(!VD$!OMT!L>@Z?=@'4/U;1(
MW)1).(<X&[X1QY#.I(H,D2XL9,3!QYL^]>,^FACC&/ZD<>SV4BO2QY'%-7MO
M#:%DO[3I&\E<O7DV\<F]1CM+!MDDC6O6KJ/\#NPA.#VRE(N -_KSFJXOSX/-
M:JB8\MY\9"LW9F6::QX$-26"YMR;+R7,78H>W=-2T<9>$9[6G$(>,R]O],%C
M]J[ \C9!)V:=1T&Q VYPE4+C*<92MJ7(2?*N>:!6JP,B[I*$ %R/KQQP^XCS
MJ.XCG^=5LGE4Y/"[8F,RI!-<"Q2F?:M#[(^[^FZM[;@^ 4+:\Z]3N;'3RAM.
MR!.03F1>X+<V%%AP\W1ZZ#^:U3UQP!58]6O4PWSJX<)EJN9JS,@2)X)1%(D9
M#:;M![E9 !IO.C^_YT/7-ZG:W-O<MM9!3D6N>Z\8HQ[E\5J3+Q@RWRYJC/D<
M<9K W4R70;C+!0%&F8 ]S#8((/@D:![CH[^//RJYYC: &17'IBK?Q97VU)=4
M"AE\<A9YO"\>6SC6N*.)P5/82"-OI5! .] ?'[[_ '##?Y]0LKPR9%%'X]#!
MFL^<9U6,8WQ'BU+'SC\%6^WMG;###"Q]M8U.CO[1K1.R0=: )\_(/Y_/J;E+
MGN:0'FFG';YY"UJKIU>04XNV@NZ!SB\U2_?#ZZSL3/7@!1 8E5B$14\_ZB2P
M'<3^=[\D@?&CZ VV;4?JDU+NE)O/';=%5X'U^]+,W*_'!$"J&POSQ_;C5=WV
MY);GD-0^SW2I[6_EHB-* ^M#QON!!'QOP=>MT3I2%[D2\#1Y6ZK\X]\Y\S)8
MV&1M)59W%#)4]2J;Y*\FC/ Q7ZRE\E8DF(#*B$*%C4J1LZ&R2^]#SL*I\;T<
MV]+:9!M 6VVUSQ3?.5_?AEK/]=C<D% R>;<<9X+XK(UJ6MV<58G2N\@CL?@:
M"[!) + D'1(TI\_M\C7JL>^(R8RE%X<L0&BG(8S7+^QH[9E-,K:#SW587R6
MWBN+TXQT>+,;24WAGD4-WR1]I;88'6];"[V1X.QX!UZC<L18U[-B'U%T^*/6
MK?!J:DG>R2T+KD'*%F0N[]/'C&_EDHE%]IY>\D.X![4 (!+G6AY#$#QK7D_'
MJ:E.P:I:C=6,<UF[]PKSJD1PU8/ 8.?//I?EMXO'"?*^20Y+ZC>H_P"GFE=:
M?2GH[4<-&4$<J<QZ[2,D9W]Z 2JP;\EC^->IZC98?*[H"RVR:]WF2^OCT_\
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MXY<\@8./.JUW9>[RW9R9JLN!O+9H@S-(+4CD_4A'FJ1(*Z$*>Y@2TCZT//\
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M3]C<)#8H(%MN.:Q?%9Q0NB/>J"DE6VLC[UX0JN?QII6NY;])#61Y&BMR*8U
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MHV>JZ#>W.GWX?3&<9=KW-9'@JJ'Q^*UCQKC'&>'XFWA\9CXX</)W(L=5W"R
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M)QK\[F?Z(<3P5ZS'TPR62X; D<RI@8\?BN2\>J0H#VI5P7(*EBK6\ +W1OW
M#:L" ?7H/\)V=DHV%_3)"97CZ6_R\KQSKJ]/L;6_MNZ[YL;L?I@2JMSCS>+M
MR\G#Z9W<-U*X;P@+ENF'3SG&-FR!<9[BQHX;.)$"K)[V$S%.S'=O%"&]BC<J
M5EE)2,!% ]$([D>HIVMN9VQ!@$40RD96-^0HNO35)2%B[FW&4=N+<=IHN&%D
M XQE?72X_P!3.C$R5<-R;CC\#Y"L3LE3F'$X<-#+: V)[&5AK6\-&A \--DH
ME(8'M7X#9[FW;W'8,J^O;8]N?#29KRF/SK-"8RFE1M6,:6(.2(>'W]L^-6M0
MJ<3FPM2SQFGQ'D.%M&Q%:L8U<-D(D*EI'>.:LDJG3O\ ,<A T-$;].C+8^8"
M0DX[7M*MHY/N>ONFAV=W?C/?W.V+%B&&DR#C&/5Y]JK4;QGB^!R7(8KEWCN-
M1Y?U5.N&QM3L6+M*F<(L'8"R Z9_CT;T(4R.WQ916,7Z%6?MK=\_=V.GGTFV
M;.]M##=W-P+E*DD'=;>;QS7V=/;?$N&8]<F,'0IV;-6Q'#:C;&UP(PQ/W@M#
M_4TP'<8Q_:?/C7JFR=TJ8T5BZX]:JC'CWK&F==ORZG;Z/YL8;)*#(^61*+4$
M/%E@\8,:%/Y=@\9*8TQ>/]^25KUV!:=0R%6U%J)7C 9BP1%53M2Q'R=>GULQ
M4[8Q/#7ZDNTLX+HQFKU.WT_4?$(;C4F&W AM2[0B$57NEEXY_KFM%:U*DTN.
M6FN.K323&0PFE4:3V@4DEB=3'VJ? C(.B&![1L^;3C )5&*U1@QX&E]*_/MK
MG[<9;$)NY#OVHRE R]I-L)9+H[6\>:\ZLV+C&$M8Z]BH<=B4NE)):=MZ57W!
M;D"RD.%0,4^X1@#PI'G7GUE1CG$OJ/'K[559_L<ZB?40W-Z.Y/:[=D[1V]M0
MOU')&35\7[9U7]/%6HTO_P [H1?I:\,\4E9:U8Q6TC52CQE4+]I=0JC8.AOT
M2@;D2Z+5H]3@<57/EX]S72.HV.FEM?X$@3W0?F3+EM=[3%[O%\H'O6=2L,</
M):^/%*E!6LTV4!(HH8I=.I42V$[1M5 U]W@$> 3L^K,-N'\L3E"JY,/KXP\?
MWUEG+>Z;<W/F5/:W)CNL082GRD95QG->>31'E.-PX+C\EZ*E!=LI+*R,*]=9
MK$LJ%'&RO:D*DJ?&R0NSLGQDA"3(2X+)7EH+>&CP4^<UX-=+9Z[I^KW?D;Q&
M&Q\HB,KN';2=G;_-S^=5WB<EF93);O8QIJ]58U_3-7K&&IVHQ-BN'33.[%8P
MWCN9BVP!Z;/;"Y2"2T9H7@^XWS36?/.MDH]+&6WM=#O&SVLI?,;O>&3_ )<J
MPG#58J_.N@TY!0P&-XYE:N+ANQR/'C[=J58Q;K0,.XD%5[I>R1E4(NUUY'A?
M6-A.3VQC3G'GG-(<^<W7FLZY>WLG6'70W^I=F6W.>[#;!-O<D>RXDA;ZE/',
MW9NY7*6[DT%A[F.MUBM6JB]LD3*A4JNO!5B0P!\DD_\ KICM.T(]J)CBR5'J
M\@X;]7TUR-R6QN1VH;>V;>[%3<W,).GFFK[>#Q]7(Z&>!XW"<-S<@IV9(\CE
MKS6<O5823ZFEADCC/N$,L7M-H-[>AW !M@^LV\=QF,D5)8&T3!ZVN,>:UW.L
MW^LZ_H/\Z.SV=+M[>WL2C6VD(RCW&&UF+AOV<Y,N3\GO?SIL'8G@%*PX6*-0
MI9XY$':^_P"XN9B &(!&B/@^M73]/MQC'<(9[?JO+04^U793Z:\HJT923G/"
M&2CUX//@U]EXOD\M22.K:C2;MV(BZDK)$S(\9C4[([SX8[V3L?OZ9'?VX27<
M&J*::C8_S5FKH#T\8JOUWW"Q"ACS)&Y'I7/Y?/.F6 L6<3;N\1RM3OF,4UVC
M88Z*7Z\:R-40Z[NR<*2 OC8D.OOV#=BI#J-J;*"D&)@E!:5O'='U\%^<:M&2
MHU1A(N*1,Y_;.?- 7I[T]S./Y?\ SS(18QZF5Q5U^^(OW5XINPQ2]HUWZ8JK
M20OX[P7']WI750ETYM;<Y]T-V,24V)W4Y,@5F-J!E,<:@+/IQ)SW4K1P9S2!
M=5Z+AL-R73O 9?E+<YR/&JAY%7?] V;,$9OU*8[FCCK6GC>>*D\[M-)'"Z R
M%B=ZV&QW.R@8M !VC*42/AJZOD<F5\ZM<R*,O&0>5,GMG[(_?-C<7X/F\=F+
M&5A>.Q5MQ!(4,I*U$;M!#!]LT950P8$L2=?'GTC?ZK:EM$)7\SRQ.99H/3AS
M)_;516:(!'U2N!.#*X:\V_CY9?DEB3*8_*XVM-9HKWU9E\QVH3*JO Z@CN,E
M;O*[UV.JD;\GU:)M[=3VI5"<9"+=2K#[-_2I9GBC5Y*U^D6E?)><E//[\TYT
M>9 YC'8*G8IUG]Z%8XY*$04,\3ZVAV- (?N/G8UH_._7/V_DSZC<C-[KXF^7
MP7=\>J@E:.[MC?: <>YW4AZ+:C^_J3D]C+?X7M6\76_3YD8N:6C6E91JVT#/
M&D@.XSVR$#6M$[V1^$P(?/8REW0)XD8HL9'+0V*B\6>FB7U,6_TV]O*K?TA^
M*^SJO.'W.6ODB,U#=*R/*DGOH 0I):-F [D#@!7 1BH)=1^/6[JCIS:O;[?=
MBC(]1 X3%>WMJI)9AW6\TV%XKSX+X_;1G?S&.I-6Q%B^E.?(.:^/C5F1IY$V
M>R,K_8$4KW'X'C?R1ZS;<-V4);L8,HQIFT2[?QY9?M6/35I)).<BF:%X0;QV
M_P!_'G37)87*Y*O4&,R2TK='(1269;*M*MB%3]\(8'9[@=$CP3L? ]$-_:A*
M??MDB6W9VXIO*B46<U2>FA; 'AOU/I*JW-X<>_-Z,Z+0LLHBGA9XV:*14D#-
M&R-V/&P!)5B1_:=$?('K+-D=MB"%*+9S9CA\-WEK&IE$PH+')@QW4+Z8IX/1
M?.F&:Q[YE*U4VVKQQ,S2(A[?>1>W[>X:*A?)!WY)_?TS9W/DG=V$I3BQ+*[:
MO.<+44/_ #J&(+VV(B!Z(B&?*B^F:M34S#6@C@0#0E"A0^QW$A"O>01\>%W\
M'XU\^DJJVY4H;K&0'C+[^V<:B3)Q&BU<<A)2TRX6_-WDKEFV-IJ\T[58!-*"
MK6#$GNNOY#R=O<X(\ $GX _'D-S<#M)RQQ&WM+K 8IK%!>&L\309H&T]S#Y?
M7NY,>7G7'O*L;%']0W.Y(Y %L='NC,W:  %(YEUZB[0/P-1 C_8^J[DY3[20
MG8,,E?IE)]_7B\:?L%$LWD;];+OW^^B_C^0DJ\5P\\LK-*N"PXKHI&O:6E5V
MC?.@.T:&M[ /Y]:(=G^712D>XKZFBUY\VT^DN-<R82WI<E[D^ZSSWRO^HE<@
M'MJ+LM>GL13LJE9_ZFQMO<CV#W=I\:4;V0=;'G9'G3VQ,O/IE\V5[G&,HY-2
M84,19!^^<ACWS[MU6C/"BN];(Q%%<+$SQ@-\?:6/@[!;8TNOGSHC\HWP)[19
M&U%<G:@-CY>#W;N^*SC60..3QE+>,JE?8]]#5>S3DMQS.R%D[E6";8;2!B5/
MQOP R^!L-H_) NM4 M1[8^@1&.7')YNBM61: RUD:+;//J93Q17KH\R?(*>1
MQ=:I2"B1(Q[JZVR*& *C\ %0#X_<> 1X3L["3=S=OZ52(\<>?:K!<//&* G:
M)@Y>:7(7ZX^[]DN/RO\ WPJX\1F9JU<I*J?:_P!BHY<;UOM/@$#R?'R1ZOMD
M=HA,3MDUW*V71QXM#U/[D?5&D\WSYKF_2O9OU\&OG&ZL5?'6I;!->&K(?8EG
MT& '>&C0GR&UVD ?._'Y]4W9;GSNT5/U8L&,>?N /BZ'G5IR[L(/:((9M<W1
MG/JUZ<UH>BR,,^0G-*/4Z021QS$]H(=AWLI.O(C[AW,=Z;8&QOUI-M8Q'Z0R
MF;+YD/L+BN&_%AVE%I5VGDO@O]K^]WK?6FK0>XX[+-@MK[@70>?)8D@LW@=N
MO T2='6H8K4;Q*^ZE''<6>;<"<-/I>IJ:@41R??M<49"^[AM>.-/YLG,%"V!
M%(6[2X*#<8((  76F /=Y^[X]1\OM42X<BRMJBK&VW\^<76J]BLO3*5Q[>_D
M_9QYUKFK)8DC->ZB[D,(C<G[2#Y.E&@-G8U\>?R3ZI*;&;'M4NZ(V#BLGY;:
MI/;0+'F-A4LE?GW.??[50296YCZ6'&.$RS78::O'+$O?VL2O>RG9/<3W Z/P
M=G\#U3;-V6[\R4F,/)5*1X0_8T<IBV3FBC-68YX<?[F1WBE/)0_]OD5T>Q_T
M1)L$(0Q,@!\G>] ?[_\ J;[QMR]B(RD?S76>YY:\?\N9MI5*%8K&:_<H/+GQ
M6I?)225[??<L,0S%B')+,$4DJH/@ @D_\Z/I>WVS4B':91Q]3>;Y0"J],^NE
MU)<6K^<^_P"^<X\UJ;CR0MX&U6HP-W,D;1RJYV@!#;?SL #>R/\ D'\"A'_/
MCW?5"0C5=HAFS_Y68.3WT^(=DNY &-G"^+/V?&?3SH:QD!KV'DEC-P/"P=60
M=P[_ /RG8V%()V"2?D:'ITEE% 8A*)#-7$0SYK/N\^>5V20# GJ\8^^<'M;[
M:UU\]#%?@QMM4JTK$FHI"OE?<8#M8GR 3\,=Z\Z_;TMVI]L]R%4B5GRF:\77
M]?MK:Q(\#W!?XK@?-9NO'VS.Q]+^&U^82<S&.BMW[F&;%638(GBD@:7O!6"0
M,JL='N(7QL>3ZXW4[;1-5G^GNQVT-F/#;;1Y\/'K.F_BKXIM?"-GX1T_4NQM
M=/U3U.U+:_R]T91[9#.-*6W<O1OSKAGJ*.+KUR3@BX"IQC,58HLOQB])W?RO
M+T9$,DXD@C[(ZMA+?;"O<=/V%EV=#UPWXB0^(1^'[NUM;2QC/:D@&X4,\K2C
MS7/&<:_1_P##VSUV_P#P.?&WXEUGQ#9ZG8EM==M'^9O]-N[;\MIS>VA6?KMQ
M].-6/T9Z#_3_ !=3LYU,QG3G@C=0KF-;CW)L_C<50E6:2<T[MF/(1&.2M):_
M41I-%8$8F17D'>>X^O31WNGG")"<5)=L@2APAZ9.3U_"_G#^)_A?7_#^I^9O
M=-U'3;75=V]LO4183W-N4J[B+;9_-06OJIKIG/XO'8%FHX?&8ZHUK<B25:%6
M)(P -!1#%'H;(\#6@/6B!&02LK+(NFO%<^QCGQ;;KS$)RV]P7N KME@SY%/4
M07QEX=!?(> 8K^629*Y5-V_GIP]Q['=+"'1 L(ABD!6!4"KV!-?GS\;3M;49
M3NXI$J'<9C_J+\Y^]4WC7I7^+_B3#:Z?IYO3;.QMQVX&PL>ZE&4TH5QEM:Y;
M70C+P[J-QWD/&\MQ0K)PZ]&,?RSC01%D@>4']/G:K.? B"A)XEV>Q@0"?7-Z
MF&]#JXSV]UEM%DX<'"G:^U^V+YJM>T^&?&/X9^+_  +J.F^.0CL?'.F'=Z/K
MZ6741BC+9WFW]7\K2KJF>J757ZBNGG4CBO#L+P^@G3[-W*U.URQ5-VU8FR=L
M+(OL@!:K11-V /W'8# Z&ASNH_QTNJB1@3V)U\R>VOT1[3M$7@?YCDOC&O=?
M ?@_\%?%/A/4_%CK"74]#TT]W:Z6>[&$H[VQ"4XG:5*4)2B6M*8*.>@</T:P
M' .)Y7C7",5+7M\U:[>Y)EI2;&2R&2R']2S)-9<%EUH*@! CC':-:UZZ/3=%
MTVW"=1C$E-FL6F4I@*BMG+Y*3VU\N^(_QO\ $OB7QGI>LZW=[]OX?O0CT^T/
M;M[.WM*1^7$L:BO]&\9J;!\PZJ87E4O#L/0PEYZC11VJ,EF:"WCUWV0V(T&X
MS'+'_4D5O+'^QM'U'8[/4$(2K:D-QKN:.7W;X.?.=?1OB/PW^'OC/\/GQSKG
MJ-G<E&;#>"/;O206,G]7<-%\4C;P=59B>]A\#8SN=1);='&M;OR0HS01+!"S
MR%=?<%C56+?).N[X)];XI$FKB^[.%\F/'HW?W-?#]CHH_$?B,>DZ&1$W=[Y?
M3F[*E5YE)S2\XQXUS]T^Y?ENLT>/Y3Q2]?PN&IY"6O DL<U<9E(9V%EA%* 3
M7^T?IYU #C?C6SZRO_\ $UO;2Q@7=XDI@$RRB^!K/KC7T;K.DZ'^#.EZCX5\
M7Z;8Z_J^LV3<-S;(S.DE(_RV+F7<?S1M\5KJRK'FH;L7N74[5[2J%6WV=@!!
MT1MM@_=\Z)V//C4 Q[)1&?ZB4D6-X[:O![4IFKQ7Q[J)1W-Y^6,8-J)X5?=#
MF@SQG#HMR%E;M0,O<&0=Y4;7ND4>>W9\CQKX\_\ KZIN081I/J(93*/BGT_J
M^,&*[$?\RHIVR>UDC1;RG];_ /.N.NH?U+3=++^7?-].>8/QVBD0_G=.H;<%
MBW)L%>Q.YEA!TONZT-^1X)]8-WJ]^%__ ,-N;L1$8(-+CZ0OM.5/OXU]H^"?
M],?A_P ;Z#I][I_XH^&0ZJ?U[O2[D@G#:NN>XN8^&SQS=TMQ/ZG>HOU*6N0\
M8X;@YN =-HYH*^?ZDP696RN2IF/MN<;XFS(L29&;9@OYJ$M#2C9XZK-,2XU=
M-'>FNYNP^7%S")RGOFSR9KTO./*?Q;_#OP/X)O\ 3]-\.^*3^([QWPZG=E&)
MT\-Z.&&SVYGVY)2:C;A:QT?TUY5T_P 9U)^G/IYQ:E%A#A.NG#ZD>'$+"1^R
MOF'ENRSD,UJQ9<F:Q;G=YIY&:1V))]; 2<L"%$4]PO/G/GQ5??B=7_#G6=)T
MFW\3CV[O2;L";NQ:[&?\LA,HXL>*#&OT?^KZXFEZ-&EZ-&EZ-&EZ-&EZ-&EZ
M-&EZ-&EZ-&N+?XATQK_1SUPG ),7%N_2G1\7JOP?P1^/3M@O>VCUG$?M>?Z:
MO")*<8O"AK\\-#.OELTOMRQL+BV*K0@]MEY"3$K)\!6.RWD:/;X_?UZZ0$2D
MH]:#\)_QO74ETSM;(.W.4X2CN0FE[?;A248F;/6_.=%"<GH#"Y+CT]U[8IS)
M-$RLKR1S0GV&CD&B [LI[F V&'^WJAMLI1F()C@7%T5BSWOV\9@Z??CNF[+8
M80W(S9CB,AC>*3M*;#C^XPFXP+N+$]S'29*M<=X@MF&&U7">%6-8G$B2R!#H
MDH?CR-Z]6B]TIQEVL3]6*BR:S]3X$/3\:S[D]J&W>QW1DXG&2-3\L?8,'[F-
M59F.@73>U=&0PM"]P/)MV16,OQ7*9+!7(Y&<!Y$2C(M:+W&(+Q"N!L;/V^/2
M_P##;=LD;%247M0<T)QQ^WYU4ZO>E&4$BLJ^HB"T 77@SCU-2..XKUFX);OV
M>+]2L1RK'P0%<93Y]A@\\D2$F7_OK#25LE),P4JD]TR)ORRD$[3/;W+CVS&-
MYC,SBZ^N(RIOE2L^NJRCM_)B1=R.[*2;D8XBA5>BJB)G%9ULCZH<^@L+8Y1T
M?RD-6TON2Y?@UVGRRG+)7W[]N>B&QMZC4D4EW1C<E55/:KD:]6EN2VA=W;2F
MKBD_W'.?[UYQJL=NXRA)W>^-44I 46Q>'VXKCBMV#ZL=)N0RQW<=RW"U[ZVS
M&V)S1DQ%SW$E8&"&MG(J%BV8Y4(=*RSA7'VNP79M'=V]ZHJ"%Q%[%:/Y6G'F
MK/MK5'?ZOI&?3;<Y_+DQA2=LGYAG#D$PUXOQJWZ=?'V+L%[#TO<EO.UA(I)(
M_;><J")(2 2L![>[3>#L-L^/1N?Y,63)DM"N?-8?6O\ 8XU<?\80VMZ;L1V(
ML%(+%\Y2K15ODLS>I?A>'S/+\S8LU*LM/^495J/ZD2M)7GVRO.0NAH$C6V)W
MK0T/2G?VNV3WTUGNK@_W<F,>3&=:NMZ-^%;6QM[L]O?CUG3QWR,8G=MWB-RS
M27DQ>+YK5G9SAF0QSK/80)5M69@0R$O[<9\#1^U>X ]H^=>=^?%MG=V]VX;;
M9")W5GF[Q58X?%GOKSDMSZOI*% M;M%'/X\^=!4&,LXS*V;\%2..C8@U(B@
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M;^5"W_4A;XQ]M7QQSD6"YUP_$<DABK7ZEVE6OPO-$K&.;VE99 LB[C>)B!L
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MJ_\ VN#[<>GO2(QVY2G(C<)R[MIM=R**'%"EE^,UZZL7C*<2QN>7(7KJ+2H
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M;G&B691<78-\_G);7CB$''Z0SQ;7!6*J^)</K@N?H5ZGL"&M"M>/W#(8T 0
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MA8E9]+\>]YHQ9C59++MJTONO^OF@O././34%DLTE:>&/02-Y AF[M@:/@'Y
M!!?\ 'R=Z^+NW+MDG=9=CZ<W7K5'CP>4U>(+VBK+!C V9:/0'V**TWR=C(M[
MJT4$\;*63M']I8,=,/C[1^!_OKY'JT.R,+E*F2)=\6W+%TAR^WD=0W&PHH?/
M.%SZ7ZOGFG.AFE^KFM11SQ%7=D5202.\ -^1X8[78('^WJSV_J)+5WD;#V>:
M0^]4:A7Z;HQ2\8OTOWRY],KJP!>G$<4$D3- &*I'*"&0B1E.B"" 1]P(V//G
M]O6:48=PQE+R?;GSG\/K3XR)EDM*U?K=7>$PUP<.IRJ*SLD;/[,3;W8KKL(P
MU]LB[)9=G3ZWH+L _!F3.,))]25[AG)FO%_D;QG550OEM*<A7#'%GEO%GF]$
MU'"1)'+,+D<D#:[&102K:!+%R01_^SK_ .7CUG=R,IOT2; QS6/V,'C%5JJ]
MUXIKQ+G./N^W[7AT4XE:UBL\'O?J6K, 05\@MK[B/_*?Q_O_ .I](GW=S*95
MXKVQ1A/&>;4SJ2@:5JGBO[^SEIQ7I6G][%&SBYZZ%DD/:X95\D[^-#Y_;QY
M^1\^J[<^R49&?;U''WK.3[<ZFKB/*<#DI^_ICEU7T^#FQT4\[=L2!7/N3-IF
M8@J/LT=>0?'QHC\[]:]O=C/<'M>YL%<+2F*Q6'C%56=0$IRB5PN#_E597X=0
MN'@6?(0L9R2'9VG;[5"JI.QO\; UXV"1\^KS>T4MMI3-\-@YH^PO/G$RP=H!
MFGA+*?3&;Y,GH<RT^/D2S*9)V:)&DL=RD 2JH9]%OP6T!KY!\C]_4%1*A_\
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M;A 2ZKV0?;&*L3NN[\/ZL^2RC*%CW1N56=S255#7GATTXYE,C3_F.%C2"/\
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M:H %[SMM'7VML#SY\_!U^23H;(/I8TR++EZYX_2*\JU?-ZBY1E1?:#&ZSQ>
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MW;KPS24)(I1-%(A[>]9$94\$]I*_ V?4=5T722B;A"$MS;%))W*XM+,/</\
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MKU))#[4LZ#R5.CH'?P-8>KZG<VMFH[4I=\XP$^F1&33/%&"WTO'N_<?^GO\
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MB%X+RMGO6$-%N+N6V:6:0E/OV(/[D\MX96.BH_V(UX]9MR$ >$C]312GG_\
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M/\YC 1) K5>JX.<+KV(CIS5[;9"*9#%9A 8J5T2  A# Z[0-C9^/W^/7K^X
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M ]/ZU6;+7+&6Y'>M$8_C''ZQRW([_LPN$@AQE4O86/N8[GL"&%0I)<A3Z/\
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MY=3UG7[W6;TM_J]V>]NR4FS5J[/I/8C0+58QIL^:GLR2E[3:#,$AV%906 4
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MN8YL7CGKK8-&A[;<AJ()$E59%05IG0>Y).58=[LN@^R0!L#,2-MHD7.5 \G
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M $92"G@^N-O,MKJ/\Q9$[[68D?<'B\&+]U>-)W^GEM/RIR@]H3918R,@\F+
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MRBJMEIZM.*1"J6Q&757[@ =,$!CU)HE5!).M^M,H;C"6Y";'LBO;5]V/)S6
M/']*SCT^S*YWNR^O])4>X4C7M=+XK7;G!>D_%.'XD2U:9O2R5Y7>:1A.9(IP
MQ>-&TH="K]H)V>SQL#UYWJ.JWMZ3MSW& ()5N;'FNT7D?2[UEW.IW&49[<8;
M3 4["I$@:<67C#Z^,XWQ49DL?SK*PK3Q6/B48^CL$Q10*PK11QJ>T%%[220?
MN0!?M0DW9AM_*VXC-:E(\--R7G)577"%.5,EG)[E9?\ J,Y4V]UR5*,K?L2/
M0U7?4/J(UBA/#CQ/7>I/ D<99HD)15E6<LI'NJ='0/?&='8(V?3>EZ,-Q[TE
M2G?A[K&@RIVM*9:]*UMA6U#;8]LF<1D]L9I!O!S4L8X_VT"F>GD+L69MY%8*
M^0KTVM%9!YECA$?MQZT1_6C0GN31)&P V_6SNW8P"$2XV=L[NK02C%UP 4\5
M6C;V=K=GN'^;*-H( &;^H^KA/;'*EFB[BZ4+&7JS0UIL;9KQ2V8TDF$ALQPF
M35@HI(5;'G0#DA60#]BJ6\R@QF'>Q[4*P2?<L3D+#BM(ZC8CLR?E2=S;MC+#
M&+-C;&/=VW6<^.<ZT<ILUN0SB6"O ]R(HEH(GN!/='96F"L2JNJCL;6NU^QF
M&F/IVS$A!&348V,A+5, O!87^.:3-W3V^VF7U/:Q%!*:$R>C[I7+H2X3Q5<%
MFIWL7+5&+]39R,K]T4<%F:2M)7CJV9)86:2$M-&\21R1O[D49V0C*T=3MDX1
M838S"Z*M1S+D^\L9YLUU-KXE,V]V#L;&Y&>R;,'<&]EBXW(("2P%4G:JC9IQ
MRK.4,7E)+$8N0W)Z+5ZT9F1J84E7,XC*_P!.;<Q!0ECV1Z"]I\Y]GI\W.@&R
MQN3DS=57.!\!?&M>YO,^BV"#'<@)N;\",XS=SM(,61:Q&J9#>$,Z%#E+\BXR
MW3JM-/1C=_:JH7FL1--W222]_:S&6&,%=$]V^U3K7I^]".W":JI%[9*':]S@
MKF^%NJUDZ/;AU?5;/32G'9V]V2#N2>V,@J M8C>(G],X),E#!FXL?G<?++5C
ML/#-7C>%H(EB<!'C8S+X+,IC<D#0;8(.CZ7T^X[VVQ8=N"(Q6\5QQE3U+_.F
M=7LR^&=5U'3;WRM[<^N-$B29HD(IQ_XJVB'CW*IN-Y6K:@@]T6WJ5;22'2S5
MG10YA5-*IC;;]Y'^@@GM^3J.G-W:8R7Z.Z1?/=BLVMC=^N3&-<J"S48W=QKG
M/%?:QSC')FM=#0WJ%_D>/,6/:1I\8\R9&-08Y(P8F>JS*"-%&C!^&&@H';ZY
MG;N'3R[MVJGQW+1DL2Z6A**3/VJQ[9D6*4=N;&X4TB8HO.;NK,:<<SXK%FL$
M:==XL:YL1VS*$95=HRRM'*8QW]KA@Z_W%F13\ ^HV.J=O=E)N7<$(G;W';]*
MHKBF/I1W+8FJ]OB-\R5%HD9!#*HAGQC+5<]C#]2^-V<GB>.BR,4TPL/?CCCE
MC8V55'GB,J%D94AA/8%8(H[] NWKL?,Z+>J6XC.0$8J%-OA?#?%XL3(-6,R5
M51?=8T5:Y^Q8\Y'+JQ>.6N17BM',REX*U82RV)$(9D$/B5'C"+W-(.U@1\]W
M@:WZR[\-J'=*$8LTC](MR>Y$3-@'@.>,:9&QO';=G L3ZAOW99\*&.=4SE[\
M<_7GFS1RF15Z/]'$#2+HZ'-.O+:'[@=WR?NWO?X]<GJMOY<X64R@23/F4LY7
M/A/%<NF[*).O$J_8_P"">H_8*>)V;\G',<(O>A@BPN-BNHRDAX/T,![T/:!L
M*$[?G2Z[221MY*$8[5R&3M1P''!Z_J!P>N3)CG[E$YV6_,D12V@DGC%M_>RJ
MXMM'FG7(U(VK2*BI+%#*54+[<C?TUE*Z#R$,6/=LL 1_;K34FDV+$P9;XS6>
M&L75+RYIT,;')<J0'T!]TQ5)[AHWL5<<F&$TU,K+*[][UR$D"E@ SJOW-'L:
M(UKM*^020<D&8UW/:23):U=2%&N*<U^4M1W*Q) GBQ\%EN,>EF?+SH,N7$JA
MUQB?IV6)E:0'^_W08F#@#8#J?CXWXU^/6V#W122_3]2I*E_U!^S[(8QJY9AI
M<N,E%8YI]?S[5IKQYGQ"G+6IT%22VK-#.OW":,Z#1(1O:LX /^D@;\CPO>B[
MD7M6P8?2 IE;M\5=\\5CF..')BU<<8<^<%?TJ]2<=H0_JI,HKS19,N^/E/<7
M[V99%DT/M6,(XCD!.SY50#M@=Q+$8MAW.<+F,3FK^GN;?[ZF\J)A;\@9CY\/
M-/YTZEK30+!+%90FQ&@3[%,?:!VHK*RZ1HB-(WAOVV#KU6/8WW$E/%IGZB0)
M(!.VL^6SRA8WAC**J9[G[-^6E#S;RZ$C'$MRVB,?U,:[FFDD4K&2ZJWM]I;R
M[JH .RP.M>=G0K(!R44458=H65:#5UEOF[T%G&2\GK_-[>0XQE$K4C4@BA3N
M8IVHR@M,FY)2-E@J$E?V5=^?R0/.DR'N^IOE\TA1^:7%N; ;74V'+3Q;PXNJ
M^]5>3+?&B"_E<8]6."S'$)5TE:-8]=L0 ]PN5VW<2J]O[%G/D>/5#;W"?= 0
MP9;N/CFZ;9 7S5ZIVI)QARWCF^*7P^?Z:&XE46E>M: $FB(E+CM8:"QZT%/=
MKP0?!.SHCTV5Q+8T@+)JO<>;NOMX\67ODM#+RU5F?MDNZQX\:L+#5C<D#/CS
M(E9N_P#5%VB>#0WLDL P(4_@>>[9UZ5NR_E)5*8_J!>0\%\9MJL>=4DU6<RY
M*N^0NC'G&"GQC6W+W:=JRM>";VX8B 71'&F\*W<5V)%  ^/GSY(\^JD=VAC=
M"]S6*+H1Y/"GA^VJA(S1QYO-/IS>,8]/.L[$4];"32XZTSH)&EC!1D#_  LJ
MJ.[9WK\$C9/CSZ7"493^LN>:8\!0US6!1P4^+RA2VE"9M.6_'I9C+R/)H4IT
MK5^5#%NO.Q7RS!5,G=W;&_*@#Y^1^Q/QZ=N;A"-4]I_,4>>VUQ=WXOSGQJ[*
M)ALK >E%%F.<9\\T^+/Q-],5*M&:S-DK\Q#2@.&6'^W2;;1[ ?(\>3\>/'K)
MNC)9 0"/T8KN'EX?-4WF^-6VFNZ1&HF9 T)? KXYY./;1:SQ55-N0JK*C:!
M)VW@@ _MI=Z^1X_?6>!/=8#(.UDR[@,%UFE>W#>+N[O1"9!DT+(^DM::ML_9
M>7BK\A4O(9;[2J"8X_?T"'(8HBZ((7QH@C8V -ZUY\:8[:628@N?+Q]/V'GP
MU]W5F3!&8SG*DB8A%LP>7BFRE]@UKFR,X@4R;_3$DI\@L'5HY%$F]@[8>#_J
M'[?#>V.V"$;QSE<EM9:.?/">-(E.4Y=TJ:\/'[/^WWU%4)%J6661"D;QDK&I
M'=VR+M&[M:*@']MDD[\GU/S)KVR'MNQK!S_3%WCCV-5M??\ O^_I^:-.,7CI
M;Z6RTNHUETC=Q5B/) 8*3OY WK1T/CY!/<@H=BF,!A,BK1?HKX]<:F^$*H\U
MZ\B\O];]=1MNM>QLB1+MFD=FCU^ "5V-:\G8)UX/SH :]3!C,DD;(_IB^ ,U
M3]5\&<(6ZOE_5=1I/-'DXO->2\9O4R<]+4QZTC-(;$D?V2?F&0MO6^X_N!X\
MZ\'X]+VHCN9C40R)5K@:!_JE/[-N;E%2-GI96 S=9<\WR<:'V[FKV+32JLL\
MWMNFP68@=S/YW\GQ\:WXWOQZV,@D0K+'N$.*\#P-/'']-2-YJZ.2SGT\4V\-
M<>^IGCN':_$#;/LQ GVR!HN2V] ;V/'@$#Y( ._6/>DQE7A..:0Y_=O[8SP!
MM$F_"%%JW;?]EK//YT29&U!3#UW"R:10B'M)&AI>X?[@^-_^P\^E0@J-AS]Z
M.7'I;E]N33$CM_6P/I04Y;+I%&T3U*OR.N4_JMX&.IO0GFW'X\A+B,A4JIF\
M':J2"&6OE</W6ZYCDC .Y.QD /EM_/G?K-UVQ.>WO&TU/<VI$5L^H.Z+PYL,
ME&5<C?T#_IS\4AT/\0=+_B-R>WL=3)V=RB*,=S!&49-)D,G!@T1_1WU*C?Z>
M.!R\CR=4YA<48++SVQ+=N259'K]S)(WN>\YC)9!Y!'@Z\^N7\/ZC<GTFS'J<
M]1#Z)9+4:M#PURH^Q6?1?]2/X4W=K^*.LW/AG2;LN@W=O:Z@G#8D;4)3CW2!
MA'M^Q=GG+6NF:>>_FU:2UCWC>$]W;V:VC_E)E))V01Y/G7G7[=0A&OI.U1MC
MS=<G-X3/J4+KY;U&QN=)U$8=1"0@+&LL;P'')CG&.=<Z]/NE'**'67J/U0S_
M "NQD\;EGH4N.8)YF,&(J01"6T A 6(FP[*JQGM=0'/DZ]<_INB^5U?4;NYN
M_.=R,",4QMQ%QQE7*^%3UU](_B?^,.GZS^%?@G\/]#TATAT^V;O5L=LV_F[O
MZ/F-%S[@+<WQP:Z?E2O.8X&VOZCM0D%21O0)7_?S_P#OY/KJC3R65(]J\<7^
MU'OKY).22JWSP9!<9O!Y+/L5S'Y''X7BF/NW/<;V0&DE>PZE$$89G9F;21HH
MVQ=FT@V20!Z&;.0-<=IA\.?O]WWKVF#)PRE;8*Q.?L >AB_7&-<=8G,Q_4[U
MCZ)XM:<2]",9UUX?C<K'>C)DZL9.N<JYBHLDB-%PW%V:JK+:4G^>V%>N@;'^
MX\MY1E&.'Z%&RZ6O-G_+P^"^S&,)TYW&_L5SFBUOT,>/+^H^M6KTZ\%2I!!5
MJ5(8JU6M7B2&"M7@C6*&""&,+'%#%&JQQ1QJJ1HJHJA0 %ZUZW#\_P#/^_\
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MX+EBN\+7HHJ=J1RRM-,H9$LHS["?<JEAV^0"23\^H9QA&4![GN4LN*>(A1:
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M84ZT1DW=F<9]Q$25-C=Q(EC>+NO-8R:OL;O1=3OD>MWOE[4>^5Q"Y3"7;"N
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MS17=ZVM?I*\<\^VC;@PDN0;"Q+R6<F?WXK.:E9+N/R9#21E+6E6$:/W@@^'
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M+M4QBLWFA*?V]=1W53Q=%9]%/ZN#F[JK'3/%WI(K!6A.B3J=*TAWW-W*B#;
M!2P\:V=D'?X)G<A#M&9W1LQ0EEIF^3/DX?S%%-XY7*/VP^!K_@:LG&8>_DW[
MLC74@,IE&CYWX+*WPKJ3W _/D;V/6+OA [MN4A7B4;&BSR5SVH>*?4TM"SMO
M'*G-8, K7%XJJ^[[*5\GCI4J8Z22O20!?>D'<ID=07\:((4[\'?Q\?/J=KME
M&?<$F2W2#%2QHX]'#?KF]2L;5N_'IA&_M? >G&:U#3Y*:JL5227]83]K21Q!
M=AMC9/:A(4 :(V!O7_%R$"+D' U^JE]:/8HR^_.BB5MAFWEQ2\>;X\&/3G2W
M'%NO(T=I@L?MR2M(2O8'3O, !)'N$C1 UK0_Y,DR/(EJ#'(G"N&KOU?/IF3<
M _3P%4I>&UH<\8*;]]2>&@I"\E>S)W^X@_3@/]O>H&PP\ L=$:/C?@ MKU3=
M5B,8]I1+E[FWMI$R"%F?'AO5;OQ5W?IG.<\(>*\UZ:FFQW=?<V)!%3)2+>MN
M3*X2.)2#HEI'[?DZ.CH:]9Y;TOU #=%%J/CS[N?+I^UL,\1>]!4,5$HE*LY.
M,^/:ZFK&(CC18:LD-:NPU8G9@;:A?+*GX!<#RQ_<Z ]0SG(24L8HSGRUC-5S
M[>U%I5!H%%<73X?JC?EIXR^,:K;E>4LY&<XJ'W(:-9?8CA8,!,Z=I,LA!)<%
ME':=_P"H_D^M>QM0.V692,EYQAO\N.2J;K&HP0+R@I&__3KN&J:]U?;P:%:%
M>2LS&PA["6BCC'@LTP V1K9 'D GP2#ZTLAI8T'GR+9>;H/)YQ[519(_5@Y>
M:IJ_3V6GE]]&&,<47DK3I&D7:#."5.HRO<%&SLL6UO7G9T?V]9]Z,Y2[8'T]
MI2<&;2XG(X2N7VU!*IQW 4/!?O[8SD]*\Z+<+D(X'EJJRI$%]Z0G2A5)7M"_
M.]EOO)/QHCX ](W(R[2R;1)E*DL<E4^!]+K/J:J3+D]N)8[>?[VM8KU\Y=#>
M>Y+;@M7*ZHSO%*\:(@))A(73[ !WH,?VU^/ /K1L;4&'=*+YPT%6%W[AGT3.
M+T$&52;1_>QKC_3P6>:XXU&XC,UZW;-+ 9Y)MCVBP0H2//<VC\?N-:\>?W9N
M1[@C<H(\@4'IR>G[>+:)82D@<!]-#QS@_P!CFGVT[EH8ZG5:_J:(7C(8TD[=
M+*#W;#G1*D; \>?CS\^DLN^3%)2C%/J 51\I<<4Y6O'WK4I(!QAQ=71:UGU]
M*R>="M2O9L^[/"G<D#%Y$[E/NABVBB[WH*NBP!U\G1&_6FCMHIY;Y5QY<>U^
M'UTU*\W;AY/RN!]!O_N0XFY! 7>>FKA"#[4I(8;WME\;T!\DCY'Y'K/NR6/;
M%J[CSB[R,A\G \N#WK_/"FQ:2#Z??/[#6$RZ/L9/B+ZHD,$2M"HD$; MV>X#
M]P!)_)UKUF_S(*2L2O/!?KXL<_?\Z=)B _I_5V_RTETIG-E8>3/HC63EJX^:
M1J1C=F[F>9B#VOO^U#\: .NW7_.AH!NS'O$;>YMD*-ABKPOJ^]>-(^N4J^IB
M&:%,<7R5?%N/&=3_ !R9/96W95@[GN[2=,5WO>B/M!'S\C_@>E;O:-0#!1XX
M7SY7U7^NFQNXU*@;E3=OBSBSBO-^SHUL2T[]*R\.GC$,BLBGO)/:?L 7>RPW
MX(^=C1]8I[;38-G;3D'G)ZW]_P"VNCT?43VM_9W=N=3ANP>Z^*D-O&#QFO<U
MY"]2.E>6XCUO.:Z>4[L\G),?/_.:M9A":IEL(Y+"4R*BV/*CLB&F5BY!*GUX
MKKO@G6[/Q6'5]'-[-Y?G19O87?U$5>WC+7'VU^VOX8_CCX+\9_@Z,OCVULPW
MNA#9CNS[?\QV(UMS%D*]N/I>,^NNR?IKL9"IC>5X/*Q2XS(4<XK,+12)[0L5
M8YC("$C9E0DQJ2OWA>Y=@@CV/1;4MK:23W//=RO&%]GU3T\:_/'_ %?ZOI>O
M^(?".NZ+<C/INHZ"1&45[-LAO2BQ')W-7RUCWTUZB9B3K=RJ7IGQ61(N)\6M
MB#J9U%J!7M06" 9N!\.R*J?:S=F$]G(\I6D]S"U':G"RY&5FJO\ E1?U4SK*
ME\+FN;SKY3L_$>LZ78WMC:ZG=V]G?&,]J$V,-R-X^872' 5G/A'73O%..\;X
MYB<=B..XVEB<9BJ453%4*L8AK5JT,82-(T7M(^"TC'<DCEI'9G+$LI \G!9Y
M//.<_;V;,Y(R-V*2E4N04K[U?#Z'%CGG6Q*$2=2^@,O:$D_SVX42%)*[-?-;
M(V3H'7QO\Z\^H&=4TW5TH>[3]C%?^(VHGS+\@EW9QZ_VQ[7A->Z/JVM>EZ-&
MEZ-&EZ-&EZ-&EZ-&EZ-&EZ-&EZ-&N-?X@<1G^D+K5""%,O&D0$C8!:_4 V/R
M-^F;3V[NW+TD/GU]LZF/)B\\<W^VO"*G3K2B>AW 6JMB4]WL@R2)))VN25)*
MF,@]BZ( *G1/KU;)@LY2BDHDL\1].V\?NY_?6B<H[TMN.UMFVQ@02[CW1RRM
MOMX]S41F)[O#,XV/X[7:1)8X[=R[98^XSN"5AA ('8A)&M'0'<Q! ]4[7>[B
M4NZQ8,6CSS5TF0X;UU^FAM[G30WNJD&W"3MQBQ_53ELO%8+/OC5HW<?5S>(B
MR*Y)_P";5JD4U[^B.]F*@@*)"(OL70[MG8'=H_A6U\S;N&['D^DMRO#CM;[6
M\+GSF]<C<GL'52EM0^7L]X$;2SCW06VO!Z<ZO#B\\:X/$RV9*<=@O%$JQRQ+
M)W'QH]GVO)(H[NU 23X \>N3O3W(_210E]+=T<GO7KFJ;U>/1PW9]01)?Y,)
M;K*FJ<BCXRB^FJ1ZU?I)+\$V-EGDS2S)&C!%D:O$2"9.S:Z_&@WC7D@;]=/8
M-YV"VHQB,HQKG_=^]_C&M?PQV-O='K1=B0L86G?** *-G;=T>GJ:":*VLOV#
MD&<>LD7<2)X5C1)XR#%(RKVF0'MUI"0-A_/SZT[<3;AW0+?PY1XJJ+_'[:S]
M9+:AN[T=J#"+-^_8V@X\X\\EUS>O/P8W*XRY2BBAW^E)I_JGKR5LN8I2)HW@
MD!16F\F*/O*NI*LH)/JT3<C+NDK"E2E6SE<]R>#[Z5T^Y20;(R2+.T[8^3'B
MN<G.=<L4>B%6V9\A1Q&8Z<YFL9+BY+A5Z3CE4![/FQ:QE=+'%K%ATT[R9#"7
M)Y 3]VR?5&&U)N-[<O\ 5M_0KP?3PU?+%?.'CL;W2=!#=)=/OQW=O<*2^[<A
M*,/J"/U6DK*7-#P.K&@X%UEX]>BY!CLQQKJ5#%7.ZO)(9^)<G2BA5C''EL<N
M2P66NSD[1K6/XY64E2710?6>?S8,91W([E+%)"3I0SVJ6W989/76'9^)[VUL
M[GP^6W&?3RFR"0?^IF)(E5DC-EI64K3_ !/U)<>AMRXOF. SO2_)PV(:\DO)
MJ$;<2K%G6)0><49K?$VG96/;7.5%C9T8@Q*A<^I"(;D90_4$I%Q;7^8^E\5F
MVGTU2/PZ?2[D9==MRVMK=@RA-MC.3'Z>VCZKP<XRO(OI9Q"Y@[>!I7L=E,9F
M(9*BV8;6,M5K,+QS1@AU>L\@/=OY&@?W_;E[F^[BE4J$2\+Q>**OCQ7"U6N>
MQ;4*@/;W5QEK/"4>%]GSJ@N;\H=9S/8HZB3*61"'(DVL95(2W:NE$C=["-B?
M[@#H>!U>GVIFW(DB!$X4D>@8$\K6/VUT8QVW=(=)OL8_)@3G*)&3N=M3 N5B
MOC#_ '&XIKUFK=R]C'RT) T"HBPLR%)V[EE0=K!V[$9CV;" @>3H^M,-PQ"X
MWD0Y&[**NLU[XTCK>GAM,3:D3[D9;G<YE'"F!"RN>/9T]H]1\KAY\9#&_9#,
M6A;RI:5I'!0OW'W"55C]WCMU\'Y]4W>FV]R,YSC%D#(L1*(M7?GUKU*LK6/;
MCN20DLHPDM%H#5T^.7-MT9LR35,[_/<^,=?C@.0A$\-&==M(7,8,NM'OCC9
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M+]&O75./U-81SYSR^UKYQ[. L7+5?*S3U^PZF>;VYPT?<\C,2IE++L%6\@Z
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M*,'M8;BQA2@G;S)54>:XP<N9$;L/IQ]+8F")7JT'-6%YQJ@;K0Y#K]U%OT;
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MO!&M Z.][\#U#7S1?THL27=(R@ET\4B.*JK+J7$K\J9:\X:/=6_P\UHRX_\
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M*4E.Z)(M*5].,>^A.QAZLMJ"S5R-T25JTM2_1BB8133,?L82!.^-U!"_ 5=
M'?SZULIL+JX5?=W%X>0Y;]>#.7.E[>Y\FNGWMK;)RG&;ORCW3C 5[>>&ALXK
MQQJU>G?'Z4GZ;'3V+GZJXR^XH:8M"\:]P;W1IHF(7;#?;Y\GSYQ;TAVMR37T
M6'V:;XX3CBP\N-*W^IW-O?)0EMSAMM;;#;BCW9"6'@4"SC/H7GRSJ)7X9CY*
M#2)#<@KPLLTB&5&5CV,Q4:WI1^_:3KR/S@V.D-]-SOCVS9*4V%\WCE*KFJUF
MV=J6_O@P[^Z2D;[2[5JH^!'#X]Z><>H7-:F8@Q=3%XW'R9/*#W;DD?M"S7B:
M0*]E$D5E(/=W@GN"L2& _.[;VY;?=%9$' J6<A1SXN[;'RBZ['0=!NOS>JE*
M&W#IY2[2>2<XN(>!O'AM,4FF5.:U@J$=*KEY1/DPDDD'O-;LR1UQ[)*K$JI&
MI,?]1=*I0'[&).[1C"4\;?=$*92<J_J2O/'I^=4W=_?WG<EOR^6[,3Y9&@A*
M3W"WE_&?8#6[C57F_*>28^KF,?C+G%JRW?<O0 "3V(PAJP*R) #.Y\/69#\%
MM]RDB-R<-D';.SQVR/%9MJO2D.:SSINY_P#C9?#]V9N;V[UE[?;%X&44W'UD
MB#=K]570Z8<TZ-='<-8R7(JF+;@W/;:S6JV8Z=9B[PO+">K$9#8R$'';-/&<
MDM*"))DY-CLU5)[$>O( 1ZSFUM]3,*81;5B,&:H_5VG:Q/"]SX\4\HV-Z6V3
M#N@(*2&$;XBYPOX\/#KF&:MUOQUR;-8WF>*ZJ5XH)+#4^H^/;C?(9F4R*H',
M.*X^?$3=J B"J.#T@_D27UVT@WU/IR,-N9.(A&,H]B8X^9&->G,#R7>6[T]@
MW$+!20C:4'<V+9Y3E,&FIZ]5X,#1CZA\7Y5TN:)+<<6;S5>M<X:/;D,<97F&
M$M9/"XR.Q:1H*<6?L8B];=H8XZGNNL9M#=AW3=V,MONPK3!DX;F':75!)BM%
M&K;NSO=#OD=R,)S@10LG%)1)%5=I&0XNGDY YQ?,I),?^JX;9J9K(VH(6K74
MG@FJ!"$*21SAPC*Z%M,'T[OICX!+=WIX+WP[:Q?U+A*]&[XKU\U9K?T?6[&]
M+9V?B4IQZ*#.4H[0$I*+$[8I52HNCZ3/IJ\N)V8HJ5@9!&LWA V1L_I^WWVO
MQ(SB#WF!C03E"G8OV_=Y*C8])W"48]J6XC@:,5;BJ5KAIJS.N=NL-SJ81N9M
MRD1C.47,.;C12D:7[T>NA^YS"_'1M5)Z]6C+D&6Q&L<A:S==N]WQ94&5V=.U
M3+(ICA?L ! *@T@1AF465#@+!6Z]PX2LI6-=1^'0ZJ3/8WJVX2^7N=T:(502
MYRM9/U-#5&AVU@VY!C8:^3QW;<AGL32R>'@@/ZA6@]\,)%*P!8I8P7<H\AB"
MDLZ^H-F$F6[/$I$8@8>THLYJ\YX<V:Z,/CW4?!]W<Z;X?U3/9N#+<E&Y+VAN
M1BO!**QXI^V-$N5P6 %+"XJ>HDB8VFU^X\D*^^\IBFGG"/..TR67+%0'2.-
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M'7A%&G=IO:@;]=&;,G:LT*0]H*UI&$A]HMVZV"))>XM]N@<>XS=_<83I^KN
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MMN>W$D\3KZ6[NXY0+3QCFQ\-QW+W6LVK,#XJF\$C36'B:))Y.Q#J4R=Z]I9
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M#V<7^&W=R+\A7LCW3M[<QSV4KGS@X]^0K,UX+&<JQ8AKUBDT,U:+"RX]1!)
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M)[.#Q5IJ\$0$CH]"N_ML1KW0RE00Y\;(WL;7G1WIO9MQJ+VQC=^A0^/%.<"
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M=J5^,:E 0*)*EE/'!7*'/'./NZQ\^.N6UAD>>::?^U+4SB%6#COD4@=J ^-
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MJT9)B6,KLD]VY5D0K(BLJL#W$*Q'D=J*LN[]5->SRMC=^:\%<QMT]3O;<?\
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M!FO;72WMK_\ %]7L;G3]7'?.R,X[P2(Q91.Z)?#'A\+PI>LZW#Z>#K5<W<Y
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MF1':W(;&YV$EDR2$6/<]M&*5?U6U@/72@R24:"?RJ>"U8NQ3M7BCF2.8E%=
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MB5ECZYNJ\7_0P--IC7=[T6C;PTA;=53;BAS<;<J6:5::"2Q%-%.HL5XUG1K
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M(+LHU0U[A393*2W:=B'$6;.3@FFLTXX;EJ?'IIOTOO)[LE=>W:RNOMR!XU+
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M&LG$@ ."FCSA2QO/J"I(NU7NU)87)WJ]E+85Y8D;4DT98HL: ]H;[A&Q=/L
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M[4%&K'N2R:XCD,2JDX$L[LJ/K[BS!?D:^TJA4A2/5=K9*C.^Y"0Q?YA!JP
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M0VOC:D-VA0"/42EV1)8;$[<VYS38 ?[U[ZJSDQ;+B-H<^3A\5:O!CG&GM?\
M3FU9AEKPI[?D3HI"QJB_=W'X83 ;VHV2= +X]4G&4H_04G\I(  ML<M\8>:T
M;<;63R)5"1<-VD5*'U XX5U!\F1(XQ;I%C&D:[8 LOE6["G;_:0PTWVDE=!M
MZ)-^GPL6HVC&Q"GWM!/=,WG5YG=W=R1CEL57P693%M'\O&34-A>1VZ;T2\G>
MLS?IYHG"H3$K$%^XJ 2Q)\-_J\?(\LGL&YW]M]\;16J.?)D]5<UREZF+'M(J
M/%"*9QAJPHI,8XN[T6YF268I)$P"*/<TA :,[_M?QX77@CM[O]M$>D0C(B1E
M2GH<'X97]C\'K97Z:/#:#572Y[?M=6_TT[Q5BE2MPV;TW=WHDT50Z)E==$Z;
M?<NOGP"#\=H&_4;D9SC*!0(#W&<V^L:?2[*Y\5:XQ%)6OFTC5YH!,7X+],N9
M6[G\Y:ENK696@OGMJ0*%::N"1HQ$_?Y TRAM'9(T2/5-O9VH L?TWQP/#P71
MGP_DNZC.. [L6RMN_:Z_=.'&F+UKQK30R&)+"GO<QR]\C'7GW$9AVZT0 JGM
M.^X^"2V #WP2@ K!5!:+8WZ-<9=)W>[N&0C304B+?(8;YS3RZ*</1FJX":9Y
MH4253)85G4R!0=]JJFPV_P +M26\^->$;DWYEL64AEV=M% <KXXO$A"\\Z27
M*89Y(G%GL8\?FCU\R>#OT:M>SN4R+,I(1$9&[] :[N]B3\#0 /Y_YINDY1)2
M [9%)4:BMK+ZT3+YS>2Z!NY8FW*7;&A];^Z1 R'C[O-8<<&._P T^@,D4$J3
MOUSX6%!.T0&'-$D$CO\ V[NYCY^!\^E;VY*48F.WDI%:Q]0+7M:?;3>F@RE.
M3(^@QRWCD7)CS@]+SK]!?K/K5I>C1I>C1I>C1I>C1I>C1I>C1I>C1I>C1KC+
M^(/*D/T?];)9(A/''Q@.\+ $2*MZJ64@^""/W\?D^-^F[!>]MG-SB<AY]5#^
MNK0),XD+[E^FK&_9,WZ:\ Y,F@B6+%6,32PMY[ROC*V.KQ&U85E[FL%>]38A
MD?M#]REB 5<=NAZJ.U$W6<A[H1$238-V'8Y +K)EXUW)3ZC?V=J,H;NYO0D'
M=O;\B,8%! ANR 956%6LA9HAXESOD]/%Q\=Q]&(UK4]C'S*4[2B2,8EF6)_:
M8ASLO*5,4; HQ9F5P3Z?9WAW=P.Z(2@EY\6B+5?96N;TCKI1Z7JH2VILE(RE
M8=T)H"'8I1Q;+(9]-2/(N*93B-),@D$%M5CDDLY"%Y6DK/(&,B>R;#=DOW$)
M((M@G2$$#T;>['=.V5]L5^EL)=M4EQI!QR7[NL+74[Y0$YR ^9(A#UNW(+35
M^F'0/%/.8:KT[K]M9Q:9KAEC]AYE5D9H)I4-C1<H?;1B[#R01L,N.YAC*.&(
M8I*1X[@4\J'I?.M<EZ*7:QAO1E*)N?X<%0M",RV$L/+%D6>*U%9'E]W%6WJ7
M,E-*<RM6$8^NC1232N6(,,$05XPW:7^Z5]H?@KY]*);4(@62VWD(U0]OU)=M
M\<'[.NOL?!^J^(]*]5TFQ'9Z>!N;NY.34H;8GZI,I,GA>V-8 -2<-K)8BP<P
MMRO+5I5C)#4L1_J/;D8*6:*1T#O,%V@5A)[<I^U.[3!FY"$T-VRRZJ[\B%/Y
M!KV<.N7M7N;4_A^UM;<NHW=X7?CW=S$O'%4UFZJG-\RO%LU?KV\IR;+8<=LL
M32T)9O<<V3;0=K/ T<80J7*A5=U UW;8D")PAN1(1[2)G,<UY]*?SBWCG2.M
MZ?;Z66WLF_+=F"[@'TPEY(CRA5MX<F*5E6FO9*SE9,ECL?6ELF2;$ICDD2:2
M%%C++;IL%B#2N=1NBJ\F^[;>?4TQF/\ _+C"O#?-%8M><#?FC*[=CTQT^T[4
MMR6[NA&;N!+M&_YU0+K'U-+1Y-]+C#9];>9L5GHV\=5CKPQ&3VH0T3]B"U&Q
M8+($!DU&-$$(TB^%+OGRVXQ@?5%E?UF8QDY8I6;JK+Y\<\W>VB&ZP)QD':]Y
MD;+^JLB8_P!_:N>4<B7 0Q304UNPU#- 18@L79(W5C&LU*G&CM)II6$/8K!D
M;NV-CTR&S#<*F(]Q(8R[6A>:;I<EH8\76M.Q+J/FSV=O=!W8I-[@BQ"[6D4B
M5VV/]#0_A:&)@FQV4R>%FLSP3RRQR67E?V5=D,L@4+*(7*3%56 (_ML%[U._
M4[[(:VV2AF(KDS[GYSX\UK5T\EV]_;EN2C\R)"4",81GV-1>X.UJ[5X> K5P
M87-4#E[--:=QZ=9H["M>%FO')6MPQ2RK"D+I,:D+=HC9@ '4L-,74Y(]TAG*
MNY6*&4D72D7DM9+=>-5Z[:@?X?M1W9P(L(RBA21R@BM7=^>&LB/*N4X?(<AQ
M..M8JSC,5=NH5NTXY3194/='%,\Q=5+F,L K>T&">ZH=4/HAN[FT2=LCNRK'
M=W?2A7TVQ(M<BY5XUMZ?^']W?Z#JNLGO[6P],$W9W=R,9S@W4H1MDU1=15OZ
M;<:G,W1Q-.Y_+X+6\?+)5EHF.M E^&::-4@$;I EDM,NV3MDTW<20OQZ9MQE
MN1CN[Q%DUE1H](TN'G*UX<:Q1ZWJ39CM=)\S9^3%-V>UNS7=C66<9,5/_:Q]
MGQ6BEB1C&:]1JUSE[95#;R%CNRLD$S?U(ZX+(X \S% /<<H!'*OCU:9&@B]M
M*\O:8+DW&5\-MVE525JD^OZGJ]IV>HWY.W")/:VX[8GS8X&HAE%%NN;HT;X#
MCL>(PMC.9JQE$=U(QV.GNR16%F+,6(9X[!'ZAV+N5$DCPCMV7[V")_YLH[4'
M:C%_6PC<9/*]Z8D9SY3#C29=5NT2W E**IW5V@1[:[(TG;R9,^'!J+Y_<R?.
M,/3QD-&O%1M4[,.>59;GZF*,]L<*+:"+,D;[^R-W':Y)B&SXB.UV+MQE] E*
MC@E;97@+X2_S6_X5U6UT$CKY1W)=1MSC/881AN[?<2/IW([B65W8>XE@6N1F
MM3IX?%PX+,Y*:$34XX:F*KS6+3MV/$Y]RJ9OU B"QL@E.F[I%[.[>PQK;5C
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M^/\ N?\ W/IL5N>7GU?5UOEQ#[7^:,_?6ZOT+Z)"S$1T<Z5@AI-$=/>) _\
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$IK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g96389g68a44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g68a44.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2>P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )Y2^$!,CA"24T$!       6!P!6@ #&R5'' (   ( !QP"4  (<G(Q-3
M$Q.#$< @4 -TUI8W)O<V]F="!7;W)D("T@26UM871I8W,@+2T@4F5S86QE($
M8M,2 R,#(P($9)3D%,+F1O8W@X0DE-!"4      !"NQJ$8$JV_O)_[-.="U0
M>=.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M  4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<F
MEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0
M!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E
M!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G
M!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V
M]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
M!,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F
M]O;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6
M) ;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M          0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M              4G-L=%5N=$8C4'AL0%?            *=F5C=&]R1&%T86
M)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B
M-2;'0               !4;W @56YT1B-2;'0               !38VP@56
MYT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W
M)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M    UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M     X0DE- ^T      !  7P    $  @!?     0 ".$))300F       .
M           #^    X0DE-! T       0   !X.$))3009       $    'C
MA"24T#\P      "0           0 X0DE-)Q        H  0         ".$
M))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M    !P  #_____________________________ ^@     ______________
M_______________P/H     /____________________________\#Z
M#_____________________________ ^@  #A"24T$"       $     $
M)    "0      X0DE-!!X       0     .$))300:      ,U    !@
M         "A@   E<          0                         !
M        )7   "A@                     !
M   !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M!28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $
M)T;VUL;VYG   "A@    !29VAT;&]N9P   E<    &<VQI8V5S5FQ,<P
M%/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9V
MEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&
M]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   H8
M  4F=H=&QO;F<   )7     W5R;%1%6%0    !        ;G5L;%1%6%0
M !        37-G951%6%0    !       &86QT5&%G5$585     $
MYC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
MEH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M  "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'
M0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $
MYO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M      #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M      .$))300H       ,     C_P        .$))3001       ! 0 X0D
ME-!!0       0    $.$))300,     !T>     0   )0   "@   !O  !%8
M   !T" !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E
M)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M        $  /;6  $     TRU(4" @
M                                 18W!R=    5     S9&5S8P   8
M0   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@
M   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G
M5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P
M D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#
MP   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87
M)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M         2<U)'0B!)14,V,3DV-BTR+C$
M                                       %A96B        #S40 !
M   1;,6%E:(                     !865H@        ;Z(  #CU   #D%
MA96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M       !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'
M1T<#HO+W=W=RYI96,N8V@
M                      9&5S8P         N245#(#8Q.38V+3(N,2!$96
M9A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#
M8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                       &1E<V,         +%)E9F5R96YC92!6:65W:6
MYG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F
M5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                        !V:65W       3I/X %%\N !#/%  #[<P !!
M,+  -<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                    */     G-I9R      0U)4(&-U<G8        $
M    4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &
MT <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP
M#@ .4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6
M<!;@%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"%
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MH,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9
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MF@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOV@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^% %&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M<8&1H=$BL<$5(S+A\0@6%R0S0E(8)31#8G(F)T138X*B_]H # ,!  (1 Q$
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M[HUII))LR:WVKV*UNAJF:JQR)I.EM[A\J*7N)%A))KQCB3,SI+D(X6=YZ0B
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MZQ7D25#Q[,:V-=D5;&^J7/!3A*J^,8*Q;;J245RR6V[74SMFP%V, 8 P!@#
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MN#M#C?3?&G(C*B6!9&N.;EJF5NFPKJQ+;:5<J[;*JJX5\TXRYHI\V[;;Z?\
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M<0:^\-Y\L7'P]L'$IPL>-&-SNM*BE1AS;V3<I[<TF^KZ(NKEJ:B, 8 P!@#
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MHL5=PV,D3I%1,H#AHBX=(\ >4%&Z"JI-V\B9C  "^()C@# & , 8 P!@# &
M5EVSOXJ&T)_HIM_^ZU\ SI2O[S:G_CK,#O\ _P"U-, D*_\ <%O_ %2G_N&P
M"J>PU_%3T@_S5/\ _&%BR%W?.7[L%L<D# & , 8 P!@# & , 8 P!@# & ,
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M%("4)QM$Y1=R7B:*EWH(P;MA,*J^7^#)&/6KTQ@W-ETE>$X 3/C)Z1?:#WX
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M?QK' B39LV:MTN!!LW10332*!,.F;]D3NP!TS?LB=V .F;]D3NP!TS?LB=V
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M?,4K4V0O" GC'I0%N=Y^@\_4F& , 8 P!@# & , 8!67;/\ XJ&T)_HIM_\
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M /\ NP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M_E-_E^W]G^/R_8!(5UC<E;ZNO_<E/V)^@;^4P"J>PTL8-E32 .2L;_DNP>4
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P"$ZDBW"A6\79"*-@KTJ+A-1-DL11$&:W&4Z4B[8L3E$OVE=O&S<?L572(
M(G ";8 P!@# & , 8 P!@%9=L_\ BH;0G^BFW_[J7P#.E*_O-J7_ &9@?]U-
M, D*_P#<%O\ U2G_ +AL JGL-?Q4](/\U3__ !C8LA?R_P!V"V.2!@%+ME/_
M ,H^V;_K*O\ _@*F8!V>E?\ &ZVJ?\RZ+?\ !PX!L5G^/=JO_JV:5?\ 'M^P
M"XN , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!#=0S'+1[49(4P
M5"!DQ2%06X)\?2*\'$+MNZ; 7BW"(KMETMP?32.7> @3+ & , 8 P!@# & ,
M K+MG_Q4-H3_ $4V_P#W4O@&9*]*QL)I]7)68D&,5&,:I!KO)"1=(LV35$L4
MSXE7#EP=-%%,-X@)E#E#?N\OESA9973"5EMD*JX)RG99*,(12[W*4FDDO:V=
M^+BY.;D58F'CWY>5?-5TX^-5.^^V;[H5U5QE.<G[(Q;VW9(64M%SD2E+0TBQ
MEHM\W459R,:Z0>LG2>Y0@J-W3<ZB*Q0.0Q!$AS !RF*.XQ1 (JMJOKC;39"V
MJ:WA97*,X26^V\91;3ZII[/HTUWDY6)E8.1;B9N-?B95$N2[&R:K*+ZI;*7+
M95;&,X-Q:DE**WBTUT:96/8:_BIZ0?YJG_\ C"Q9S7=\Y?NS'+8Y(& 4NV4_
M_*/MF_ZRK_\ X"IF =GI7_&ZVJ?\RZ+?\'#@&Q6?X]VJ_P#JV:5?\>W[ +BX
M P!@# & , 8 P!@# & 5*VC(;4)Q=]$;%06]IFEJW8G:4K58]JZ)4IB.G9*M
M-G\K:IILLF$4O5H=G+R<(1=)9&2>*G8& @KE-@?/V>?GW>XK)J.IM=EU*LMU
MTMA;JS<J%EU6X3\<>0JJ%-D4:LC7&3"L<[ER-KAC)V!9[&D BQ'*JKE18X'2
M+@>?/<9G79[5$Y!.4;NRK-@KCK10.-O64I^KVY_JTI)G*R.:,6!,L2R(D=!2
M00!?<BR25$O$MO+@-;KSY^Q:/2JJ2U)TWI55EY5Y-3$+ ,FTM)R;Q5\\<R1D
MQ7>\QV<1.X(BY64004/O,+=)+?@=QD#ZQ_(_S\ ?6/Y'^?@#ZQ_(_P _ 'UC
M^1_GX ^L?R/\_ 'UC^1_GX ^L?R/\_ 'UC^1_GX ^L?R/\_ 'UC^1_GX ^L?
MR/\ /P!]8_D?Y^ /K'\C_/P!]8_D?Y^ /K'\C_/P!]8_D?Y^ /K'\C_/P!]8
M_D?Y^ /K'\C_ #\ ?6/Y'^?@#ZQ_(_S\ ?6/Y'^?@#ZQ_(_S\ ?6/Y'^?@#Z
MQ_(_S\ ?6/Y'^?@#ZQ_(_P _ 'UC^1_GX ^L?R/\_ 'UC^1_GX ^L?R/\_ '
MUC^1_GX ^L?R/\_ 'UC^1_GX ^L?R/\ /P!]8_D?Y^ /K'\C_/P!]8_D?Y^
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MW]BII#P\K=\EV#[>/?\ WY6/S>3+DT@M>;JA*8""@!N$>$1XQ#BW#N$0W?8
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MU_TA$G%HVRNJR7]B[787Y/3F&!WGRPVU:O9W$9TQ5Q5Z]$F\RK7@YY"@(F(
M . 7MP!@# *Z[1-ZUGH4-6)+1^CU^Z'=V-HPM!9V:^2 BXIRJ@BFZ:[B'%R<
MZBJA5/(')*0IN$_%NRDUK(UO'ABO1<''S9SO4<E7W]BJJ>GZH]'S-]=]NL=D
MUOOL;YP+IG FI7ZK#CG7]1T&FG E;I<\# ><\K-7/_9M2E'LTMJW'_Y\TENN
M5E@FAG)VK8[Q(B#L[=$SI!(_-31<F3**Z2:NX.81-43$(?<'&4 -N#?ES%R<
M8N:49N*<DGNE+9<R3\4GND_$T>U5QMMC3.5E*LFJIRCR2G6I-0G*/7EE*.S<
M=WLVUX&_OW;]_D /VCNW?^W.1UGW //':7UBTZT1VJMGJY:F65E68$NF&M3%
M)PZ, JO'JSBF&39LFY1YKIR=,BAP01 RG 4Q]VXHY@:EJ6'I.';GY]RHQ:>7
MM+&F]N>2C%)+JVY-)))[OH;!PQPOK?&.M8G#_#V'+/U3-5KHQXRC#FC17*ZV
M4IR:C&,*X2E*3Z)(H)7;9H9J9JE6;Q<I"H3VC$YMO[24PYEK(9J-=-'$V*T$
MQ<+K.C%*S7;.4CI H51)RV=IF(0Q%B9CWY>D9^CRS,JS'MT?(Q^ULLO:C1*B
M7C-R:V6_3O34MMNNQ8Z9H_&>@<9TZ+HV-J6-QGIVHO%QL73HRLU"&?!/]%$:
MXR=CE![]%*$ZWL]XM[RB*8:5R4E;(/2P(-72&P_I+MGZ-9LZD\,G7):"=:&:
M)DD&1E8]P0'K1PZ(N5\1597G+D5!QQ' 0SOTO^G/ QUI78/3N1^K/&DG0X<\
MN;D<6]_U\W,]WO+??KN5_%CXF_[AU1\8+4(\2>L0_JJU6$X9ZN[*I061"<8R
MB^P[)5KE455V:BE%(OKH?3JGIYMF;1U,H,2SK=.;;,NR#-LZY#G52@FDQ+:H
M[:S25D6<>"IVC5W(MX:*;OUFR:9W2<:R*N)^F2X<];;=-FO:GNNG3^"@<7'=
M2BU)-;IIIK=-]4_;T:]QD';8I=^OVS7>J]I?!-;-?$IK3&S5ZOO9!.+:2[BC
MZL4>[.F;B04 Q6J2D?7W8F5 AU/H\*2:BAB$,D]DWTZ)OKW=%X^XB*WE%/?9
MM+IMOU>W3=I;^S=I;^)0C89UWUUVMMI/]:U^T^AZM4-*M+=0:!\I1SHZ:PSU
MYLNG,VSA56+@>>Y!DQJ;TQI1'<BJH8R9R)F*3BTK@OB/-XAIU*S-AC0>)F=A
M5ZOVBWAR[[RYTMTW_C)=7UWC'IO[MZ<_1EH?HUS^&L;1+]3OKU?189^4]1>.
MW#(Y^6==;HG+:4=TK(/>,6X\DY[O;-NS1/Q&KDGM[TVOJ/V;NY:DVL\>[EXF
M18M4V=BHC&G-'BAUD"BH"4G%/CKHH@=8K<B:H%W+)[[K2.(<#6KLZC"[?GT^
MWL;^VHLJBY<TX;UN:2FN:$M]G['W--Z-QEZ-^(N!\'0=0UO^G/'XBQ7E8/J6
MH8V98H*NJR4<B%$Y2IDHW0VY]E)[I=8M+S?V:=)]6YS;34TVEY6L$4T%ML59
M;0X9R<RZ8S2-+I]SI3%E7T%ZZR5 [E6SI.6YI-PU(U;-U4P,Z.<I@T_0,C$G
MQSQ)35//>1'=6QNC3ZJN2<E_;E!NQI-M5J:6R33;:6WM?I$TW6:?0!Z,LO*Q
M^'H:;/LY8EN'9GO5I>L4QL3R86Q6)&4TD\EURFG9MR*"6SVM)-/-:BZKZ!:#
M.-'Z[$.-()?36_6P$=,AC+3$QS=S;(UQ87=ZZ<K=^W=/@<<WE+&,Z(=N<H"!
M>(VVTQUS^N7RMR\"6C.A=CBQA)9L+>GZIO?;E77?>/7=)=SW\:S;. GP#I\,
M31^(:^-EF_\ G=6NMK>A6XV]JG536H<_:./9\BYVXRC9OT:2Q$XVE]H!/:HJ
M%B4M-O&<D)Z&K:\VJA1G2!J@[U%!JO#)E1:EDF\*H@L=$Q3H?+#82D0.Z%(-
MQ=>LR[UQY5BJ^SL7@J3I_IRE%;Q[O7>7G46^K_7RI[)Q[F>CXND:?+_I[RM4
M>!0\Z.O3@LQ\2V0L48W.._\ 0NV[&4TFX*/J_:SB^T[5;;/])%AVA=,:QJY6
MM$)>5?(Z@6UJ#N&CTXIZLR52,4YR M))I&:-U#E3.)"*J (@'V>7-GOU[3<;
M5<;1;;IK/RH<]5:JG*'+UVYK$N6+>W1-]3RO3_1YQ1JG".I\<8>)1/A[2+75
MFY$\NBN^$DXINO%E)76QBY)2E"+2W,WY<FD# -A1R@B=--9=!)18_"B154A#
MJCY-Y4BF,!E#?_5* B'_ +8<HII.23?1)M)M^Q)]_P CG&NR:E*$)SC!<TY1
MC*2A'VR:345[WLCR6_20[.6TAK5=="9C1YY%2E>J]JC7DO"/Z9%3!X95H]!=
MW(+RKVPQBSB,FT#-T'T<=LFV1",34,\ SC<33N*\.W+GI3JX?Q]<[/*YIROO
ME2\-;P?:14?\U+9MJ?Z-XK=]3VGT0ZSAZ3C\71R_2/J/ +RM*5=56#@5YJUJ
M:5O]BQV)NF53:4'3_>EVLN3JCUCC$'C6-CVL@^"3?MF+1!]) V*S"0>(H)IN
M7P-"*+$:@[6*=<&Q%52H<SE%4.!0,.Y'B9S< 8 P!@# & 0K4.A0NI=3D:A/
M+2+5C(':+D?P[A)I*QSQ@[1?,G\<X<-GC=)VV<H)J)BNT<HF#B(HBH0PEP#'
M4+H=$5I.KP$?)SZE)K, \CTHKY=EF4D_FGLHO(N)V2?0:T25VZ7%PH"H&(1$
MIC?P+=(@%# \^?/M.6_T@BU[% R#-]9VL*P1DBR\2-QNIAE%'+?EL5.9\NB*
M8,UOX7R')Q?8(&#R9&WAU^K_ 'WW!KE-(8EU,UEY'O;0RBXQW)*ST:-QNIQF
MF[F)=M&* *#.G,CT4DJW?[RJ)B8$. 3& > 6W7?^7Y\ ?+%I!$R*$62$>VB(
M5:V""?OU1N5U5ZV&8R;=S+Q0 >>4 HRC!)=ES0 ID^=Q%4(.XP2#Y:-((N4C
M4&T ^M$(^3F(%XJ\&XW5;F1C"98O9>/X#3J@!\J1B#N/ _" IBYYA3$,4#EC
M;X_5@^V+2&*D4X<L*]L\2=G8(>0DCC<;JH+^&9O"K2<2 &G3@09!N!D.8 %,
M0#"('(/E!M\?JW_/W!HM6D$9*Q;=K7G]G@Y!.PU*07?#<;JMS8:)M4-*6.)X
M#3J@ ,]7V<I!@IP@9$9'FE.D8@*$;?'ZO\CIX^6NJ-VTZ11$I6IV-@'EG@YQ
M]%/6L3,?/&ZJA&2"S<Y&KT4C3RA5 ;+"57@,F<! NX2F^P6VWM^K?[L>?/GX
MGV>TCAW]8F8R(=V>+GGL#(L(N:&XW50(Z7<1ZS=E*"B:=.50&CTZ3L4Q3,4P
M)\(D, \(ME[_ *O\@WD=)H,D$1BHO9SRX1?2FD_GE=@ 9#IA2!Z"?R]P@'4"
M"P$X-VX.'AW;@"0?(+26$80,:PEW%GDY=M'H(/Y3YY75,'KQ-("JN^6$\0I.
M8IO.!0*4 W[@ /LR-OC]?/S7<P<:IZ0Q436X>-L+ZSSLVT9%1DY@+C=40D'(
M&,)G )DGDBD Q1*&X"%#Z/D*&-EW^?IW TUC2",C6C]*>?VB:<+S4H]9+A<K
MJETL4Z7YC".$"SI .+)+^"%00,)OM$YOMQYZ?GHP;D#I!$QZLZ:7>6B4(^G7
MCZ)+\\KJ3Y,B5B(@VC/HSI /TQB*FXQ$YC<SRG'=N!M\?J_R#1$:/Q;25L;J
M3?VB0CY%XU6A&(7&ZI_)#9)ORUVXG+.D%7G+;EMYCGW;A !#?NR=O.[?[@U,
M-(8I"PS\@\>VAU"R#2$1AXD+C=2?);AB$E\JN.8$Z!U/E(7+'Z)E#@F#+R 3
MB'B T-]'XQ.UR,JJ_M"M=<PL<R900W*Z[VDJW=O57LES?EWC,#MLLU0!,53%
M+TXB4A>(1,VW_P"6OV!I::/1J-MG)9S(6=Q7'L+ ,HF!^>-U+\F2C!S.*3$B
M*P3I3*!*H/HI'EF5.5+Y,XBD(*AA/&RVVZ_5_P#/W'GX^\UET@BPMBDL9]9S
M5TT 1@2"^>-U 23!9 7!Y7F_+O$('9B#7EBJ(!NXN#?O-C;PZ_5[_G[@TKZ/
MQI[A$2Z#^T)5EG6K%&R, -QNIC/YV1E*PZA9GGC.B<@1,?&3S'E H4%/EH#F
M(<4BF).WY[WY^7<#5(:01;BRUZ2:/K.U@X]E/(S,-\\;J899T^^2 B7/-&=,
M*818-) .$IR H+_Z13\!1+'AM_+W^O?]_P!AX_7^//S/L]I!&/W594B'UGBV
M\;822$\A\\;JI\LPH1$NT/$@(SIQ2$TD[C9#F%%,P?)_+X]QS%.VV]OU;_<?
MP:;+H_%R2442"?V>&5:SC!](*#<KJKUT4W!;K(T -.J 077&F/& %$.7Y#AO
MQM\?JP;EGTAB9.(.T@7EHA9(SN.6(_\ GE=5.!LVD&SAZAP#.J /5LTUVN_A
M^CSN(!*(<0-MO;]6_P!V#59=(X:2@WS"#=V>&EG!4 :28W*ZJ],8CI!14>6:
M>4 W-0(JCNX1W"IO#<(;PG;Q_E_MW YLAI37G$0^:,CVAI(KQ[ENU?#=+L8&
M[Q1L=)%V)/E\0-REA*MP\(@/#NW#]F1LM]]NOOZ^?X!PV.D<,A6VD:Z=6AS.
M)0B+)Q,_/*[!SY4C$J"DEROEX  %'8&<\O@  W\/!N\F-M_;]6OV8/M>TDA8
M^ CF$RZM$O,-F94'TJ%RNJ?6.0XN)QRPG2 3?O#Z/ 7=N^S&WCU^KV_'V!P:
M[HZPCJT$9-2=HEI[BFA&9"XW1,.%Y)/W,67DEG$R_P#)K%PR9^5/>?I0.83B
M83&G;SNP<ZOZ1PL?78>.F75IE9II$,6<I+A<[LF$A)(-$T7<@"19Y,$Q<N"J
M+\!2)@7CX0(4  H ;=7TAB(N"9,)]Y:)N60ZKJY0+E=D>I!5ZX6;[B%GD^'D
M-5$6_D*7?RN+RB.\8V\>OU?[;[ ^5[2&(CT)).;>VB66<STT_8JA<KJETD0^
M?++Q<6(%GB<7R<S.FUX]QC'%+C$YA\N-O.[[OY?M^G7Q&B T?C(][:EI=_9Y
M5K*6(TC7VX7&ZI_(D+\BPS((GB"=)S?^5&<G(\P1./\ RCP<8@0"$;?'ZO\
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MZ01<K".65>?6>#E5%V"B$D-QNJH))-W[9P\2$AIU0!ZMFDNUW\ B7G<0"40
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MU771_3.<5OW.?*MHNRQQ<Y3S,HJ1@# & , 8 P!@# & , 8 P!@# & , 8!
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MZ-"$CX#92KS&!DM0'M2/J%K,^HS#4ZOV:LW"K461U9N+VH4Y_&7!T]L)DJO
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M3H]F7[_?@#IT>S+]_OP!TZ/9E^_WX Z='LR_?[\ =.CV9?O]^ .G1[,OW^_
M'3H]F7[_ 'X Z='LR_?[\ =.CV9?O]^ .G1[,OW^_ '3H]F7[_?@#IT>S+]_
MOP!TZ/9E^_WX Z='LR_?[\ =.CV9?O\ ?@#IT>S+]_OP!TZ/9E^_WX Z='LR
M_?[\ =.CV9?O]^ .G1[,OW^_ '3H]F7[_?@#IT>S+]_OP"%ZB-C#1;8#-H+A
MT,%*<A!,'AE%EA:+ FF0K%9%X)CGW 4&RR2P[_X,Y#;A .\FG3H]F7[_ 'X
MZ='LR_?[\ =.CV9?O]^ .G1[,OW^_ '3H]F7[_?@#IT>S+]_OP!TZ/9E^_WX
M Z='LR_?[\ =.CV9?O\ ?@%9=L]NC_8H[08@F4!#2FX;A\N\!^2EO\>[OP#.
M=+;HC4*F84R[QK$%O#]GEBV@[_M__._ )/TZ/9E^_P!^ .G1[,OW^_ '3H]F
M7[_?@#IT>S+]_OP!TZ/9E^_WX Z='LR_?[\ =.CV9?O]^ .G1[,OW^_ '3H]
MF7[_ 'X Z='LR_?[\ =.CV9?O]^ .G1[,OW^_ '3H]F7[_?@#IT>S+]_OP#<
M(0I $"% H".\0#S[@#?W  ?]V >$/Z766U6<:BZ%U>S:";+VJFR:K&VU_:'V
MT+J+'4=)WJ,=HFC&QK:1<'0DX!.)8II.VCF)5.6P*2;ME()D3C6YCB4EU[]U
M[%OT\?'_ %T+U_HTVL@TV1J*D\'1=NT&Q:DJUZ#T!>MI73*I59QJ)9EZY3HB
M;:B))Y]6(D[6&G)U03.9:9:/GSLPNEEA$'WOO^?>7UP0, 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@$)U& !H=L 3 F4:_* )A107X=[-4 $472[9NIP[]XD7<(I&W;CJ$
M*(F ";8 P!@# & , 8 P!@%9=L_^*AM"?Z*;?_NI? ,Z4K^\VI?]F8'_ '6T
MP"38 P!@'"924=)%5/'/V3\B"ID%SLG2#HJ*Y-W&BJ9!10$U2;PXDSB!R[PW
ME#.$+*[$W79"Q1;C)PE&24EWQ;BWLUXI]3OOQLG&<(Y./?CRG!605]5E3G!]
MTX*R,7*#\)+=/P9S<YG0, 8 P!@# & , 8 P!@'Y_/TL5PT]N>HFBLO'SK")
MN^RWJ-J'7)1CJ3LTZA:Y4">=ZDZ6:=SR[1&OPL(^AIA!M!SE??(6 XJH1\T@
MYC&JO6M)-%,<E\-]U[4O/7P^>S/2?]'A81M&RE09HRE-4%S)74@GH.D,IH75
MQZ:YSS?ZCIK,,H^0A5 !( >N%FJ82[P%Y9(3I/2',(?>]_OU^Y=S!!6S7J%N
MTC;=GB8ID'8)I&K:O$F+@,/-IQ;)K3UZA9H9Z:7:*N4"3"(RLI#.468E<"F+
M)9<J7&0IB@5DU-J.U&34N\ZB:.UN4:KW.JPA)9C9YYFF%=6BR03 D?15V\P[
M8]<^8IS#N4,>#_@'::2B*ZZRY4A#V-_3?ROWVZ_/E:H:=[9=IT]=1A;4Q?MY
M/2R#BW\5%D1C+"A=R6=%W(RI5BOF O3HPB8I+-4WC).0*)FX*(JB; >W7V?3
M\%O= (2YUG1G3N!O2"Z5OBX$K6>3=R?RLX!V5TY,059 5%A6.=N9%0Q.<MTW
M$#3G*\@5# 9@XG'9D]K^G '$X[,GM?TX XG'9D]K^G '$X[,GM?TX XG'9D]
MK^G '$X[,GM?TX XG'9D]K^G '$X[,GM?TX XG'9D]K^G '$X[,GM?TX XG'
M9D]K^G '$X[,GM?TX XG'9D]K^G '$X[,GM?TX XG'9D]K^G '$X[,GM?TX
MXG'9D]K^G '$X[,GM?TX XG'9D]K^G '$X[,GM?TX XG'9D]K^G '$X[,GM?
MTX XG'9D]K^G '$X[,GM?TX XG'9D]K^G '$X[,GM?TX XG'9D]K^G '$X[,
MGM?TX XG'9D]K^G '$X[,GM?TX XG'9D]K^G '$X[,GM?TX XG'9D]K^G '$
MX[,GM?TX XG'9D]K^G '$X[,GM?TX XG'9D]K^G '$X[,GM?TX XG'9D]K^G
M '$X[,GM?TX XG'9D]K^G '$X[,GM?TX!"=2#D)0K>9ZFGT85Z5%T)W+-L7D
M T6%3>O(I+L$2\ F 5'B*C<G]LJ0Q $N 3;B<=F3VOZ< <3CLR>U_3@#B<=F
M3VOZ< <3CLR>U_3@#B<=F3VOZ< <3CLR>U_3@#B<=F3VOZ< <3CLR>U_3@#B
M<=F3VOZ< K-MG&7_ +%':$WD( ?JIM_EXO\ ]E+_ ./ ,Z4LR_S-J6XA/[VH
M+_K?L^2FF[]N 27B<=F3VOZ< <3CLR>U_3@&D_..4Q#)EX3E$@AQB'D$! =P
M@(" B CY0$!#R;AWX:W37MZ$IM--=Z::\>J]SZ%!/T?]&B*=5-=30I'YC!M/
M[0%4#Y1E7D@)(C3_ %4M-.KJ)!=*'W*HPL2T(Z<!_"O' '76,)C !:71M T_
M089$,!7J.5<[[>WOG<^=K;]+G_C%+N2Z]7NV;QQOZ0^(_2#?IF1Q#+ E9I.%
M' Q/4<&G"78)\S=JJ_\ 4L<O'I%+_&,=WO?WB<=F3VOZ<NC1AQ..S)[7]. .
M)QV9/:_IP!Q..S)[7]. .)QV9/:_IP!Q..S)[7]. .)QV9/:_IP!Q..S)[7]
M. .)QV9/:_IP!Q..S)[7]. ;B8G$N]0H%-O'R .\-W[!WX!Y/[7>V'M>;,MK
MF9!QIYL;UW1)U-I1.GM_UMVG7.F$M9Q"*:/':3N'=U-RT:/V[HSU/I6S]UO:
M(H.3'+SN$(?-X;?/?^//7W=>22?A)OW)/X%R-D'6V?VA]!JGJM95=)E9B?>V
M5LY/HEJ$75'3KA@[-+0B(0UT(RCRR;@$(],LLB#5/Y.E0>1XB<6PG&5OX]_N
M(?>]M_GWEF\$# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!$+\LX1I5H5:IKJ.204D9!-N
M:1(N=4&BHD(D:(:O9,J@F  *+!FY=@;=R$5%.$HO]]Y#_#^G4E^"1@# & ,
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M*9[%#EN%3UUWK)AOVPMK<0WF#R@.OM\W#_D']F 7,ZMMVZ?M!@#JVW;I^T&
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M<&[=NP#<*4I"E(0I2$(4"D(4 *4I2AN*4I0  *4H        ;@#=@&K & ,
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M>+Y<3\)Y]>NO:&AZ=JSR-?P&XJ>V?@O'@JI5IJ.1&-L^PL_1)OHW8S+TT 8
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MUMQ[+3]VP!R5/6W'LM/W; ')4];<>RT_=L <E3UMQ[+3]VP!R5/6W'LM/W;
M,&:[;0FFNSE!P=AU0FYV/C;%-I0$:>*@59I0[]1!5R/.(R8G!%(B"*B@B<W-
M5X>!LBNI]#*76^(--X?IIR-2LMKKR+E16ZJ++F['%RZJN+Y4DGWO=]T4V;UP
M)Z.>*/2/G9VG<+X^)D9.G8,M0R8Y>=CX45CQLA4N25\X\\Y63C%)+DAOS6SK
MA^HSFU4*L@DNFLJLDX3372.JF"1^6J0IR;T^2@<@B4P")%4P4*(B4P%$!*%R
MFI)26^S2:W33V:W6Z:33]S2:[FMS1YPE7.=<TE.N4H22<9)2BW&24HMQDDT]
MG%N+[TVNIXK?I.]5XZH;1VQBC1-K#9ET&UOI(:TV=O5]I&27<4.QTVSURNPB
M@W&'87RDC%-U7L8J[J4Q*OFBKZ9AGK2ONS=-.-7$A+=/O?5=R]N_CMT^'C\N
ME[MA;72?VB=GN&U&M%ZTHU)L);EJ93I:YZ'P%@K^ELTYH6H%DIQE:>A9+/<G
MS^,3"&(F$VWLDE&32Q%9*,.BR<I-TA#6S\5W/JMGLUNMT7#P0, 8 P!@# &
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MU1F4G2\9'V]XDSD'\4Z.E5)4 1D(MRHT?M#\:11YK5RBHBIN 2\9!X3"&X<
MTQ^N-/E5I9O'L+>Z6@Y(8>633JDKQ,9,&+.2Z-;B2*'-Z&09./H"8G X3^EQ
M<10 ^L];ZA(/9:/9Q]O</8)TW92S<E5E>-B[=1[.5;H+;T@#C5CI!F[+P&,'
M*7)O$#<10 (:X4]U)OX=O'V]63BTFJT@S+5)7FM4GI!4:G4$4@)N7(43$X3&
M'<'E , #KA3PEBP)H^WA+G8?*96 U26YQF KG;=4 \KE\OGIG3W<?'Q%'Z.[
MRX 6UPIS:48PB["W)RLDW=.F#$U4E><Y;,1(#M5/<D).%#FI\?$8H_3#< X!
M\=:X4]G(QD0Z87!&2F2OCQC0U5EN:\+&I)+/A2X4A* -DEDCJ<1B>0Y>'>(B
M&!Y\_4UO-;*C'N(]L]CK>W<2C@S2/34JDKQNW!2"J9%/A2$.(" )AXA*7=^W
M>(;P/DGK=489%!Q)Q]P9HN7K6/045JDKPJ/7JH(M6Y>!(P\:RI@(3> %WC](
MP!Y< 2&MU0BA9!(QUP:C(OF\8Q!2J2HBY?.S\#9LGP)&_A%3CPEXMQ=_VF#
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M$HC@&TA'MFT8C#(1B*46W8)QB+(IP!NFQ20!J1J5/E[@2(W $BE#[" !?(&
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M4JJ1% *H42' JA0,!3E'RE.4!W&+]I1WA@@W< 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 0W4)0R5(M*A!2*8D%)
MF*9=1NBB E9K& 557;5\U33 0^D==HY2*'E414+O*+[@F6 , 8 P!@# & ,
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MOO\ D<LW;*_A_EX&Z]B^_P"1RS=LK^'^7@;KV+[_ )'+-VROX?Y>!NO8OO\
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MSAWA@#>'G#O# &\/.'>& -X><.\, ;P\X=X8 WAYP[PP!O#SAWA@#>'G#O#
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M#@#IV_8(^$3X< =.W[!'PB?#@#IV_8(^$3X< =.W[!'PB?#@#IV_8(^$3X<
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M' '3M^P1\(GPX Z=OV"/A$^' '3M^P1\(GPX Z=OV"/A$^' '3M^P1\(GPX
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M!K?O(:YV==!7:KYPZT;TT<+R44U@GZJU,@%%'D.Q%L+.,<',P,95FU%FT%!
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M9HHBV502=(G75 CHBX$.).$  GO4I><_A+?!@#J4O.?PEO@P!U*7G/X2WP8
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MRX YRGJZG>7 '.4]74[RX YRGJZG>7 '.4]74[RX YRGJZG>7 '.4]74[RX
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MU+L9S.H8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MLWPX WN/02]LWPX WN/02]LWPX WN/02]LWPX WN/02]LWPX WN/02]LWPX
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M?W>>B_G?_B>OVFM3>QP$:TMU==0T@C)GEY8-/5P",4:MN8Q3X N)BF%XM_!
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MV>M4@I/%E[?78LC"?>Q\2<=/5S_*<2@1 S64#BN1.$')E%2\!>,H<KR'$1'
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M#_KX X5>T+X?]? '"KVA?#_KX X5>T+X?]? '"KVA?#_ *^ .%7M"^'_ %\
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M.J*A*OK"]1G+LI_I>^Z;LD!5/V*%W?XD_P"OEZ>?CA5[0OA_U\ <*O:%\/\
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M?M /VA_WB#[@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MU8_B(_'@$1OBB_S,L_ UDS&^1)$ "+<61&2'<V5\C%2DINK<1T/V(GK;9:8
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ML =,W[(G=@#IF_9$[L =,W[(G=@&Z0A$PX2% H;]^X W!O']N :L 8 P!@#
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M.AW*>_ 'UGSH=RGOP!]9\Z'<I[\ W"<S</,X-^_R< & -W^/B$?+@&O & ,
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MUZJFXR@7^QMTK*!O*'$(7V_"/V /[!\W^4<Y>?/T.LZ%W0J(XV_&=N5A&![
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M9+_^5O\ 6)RJ>^#S^O>NW<WZ.;U[L/ZA*W^XX<O;/D5G(U ])\V\\9& , 8
MP!@# & 8TUF_\D>IO_82T_[E>X!%ME[^+/L[?Z"])/\ @"OX!G3 & 4OV)5$
MSU/7;@.0_P#X8.UH?Z)BF^@KKU>E4C>01^BHF<BA#?8<ABG*(E, CQC*,]^6
M49;/9\K3V?L>S>S]QV64VTN*MJLJ<HJ459"4'*+[I14DMXOP:W3]I=#.1UE!
M=%M.H*&VV=JFRM',Z=^:,TY<"DZF73E@)[/ C*R(=&<>5RT7/T(Y,V\K!O\
MP#<"D$=])B:#AX>J9FKU69<LG.W[6%F1.>/'=[_VZ6N6&S[NKY4VELC>]8](
M>N:WPEHG!N7C:-#2]!Y?4[\73*:-2LY8J"]:S8MSN;2WG+EB[9?JL<Y)-36L
MB/\ 9W:K!O\ )_8V:5>3_P#KV_9=FB';K?QW$/\ 5E0_^)DO@%KL 8 P!@#
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M%X//:>&.-A=:HO6Z$D:LDMQK22(.N[12$QH@'9!$QC-2D 38!Z?8 P!@# &
M, 8 P!@# *UZ]Z5VW5"=TH)$06G$K5:M;F]FMZ]KD)&)MR98EW'/X5O3)-A3
MK.9H3Y0:A(3"17L"M*#'QT::138+ORJ-EX_L"K6HVR!KE=KQ/WJ%ME)I$]**
MS$J6PUNU6J/N3P]C0JS5_2%;8UI",C#UB(;5]9"&G6(/9$S=RFW" CB@J<XG
M?NZ+W^]_[\>O^LQ-MFC4A&,5%]K'9[:JOHP.FWS,U"DH"XTY*R+R)ES7%Y*&
MTYB9V<D8UJJ=5@]?-D7;I\BB5X0K(PHIB"SVG5#B--:'4Z#7DDF<35(5G$MB
M,T$6B*AT$P%TZ*V(0R2 O7AW#Q1)("ID47.!  NX, F?*-VZWX7Y6 .4;MUO
MPORL <HW;K?A?E8 Y1NW6_"_*P!RC=NM^%^5@#E&[=;\+\K '*-VZWX7Y6 .
M4;MUOPORL <HW;K?A?E8 Y1NW6_"_*P!RC=NM^%^5@#E&[=;\+\K '*-VZWX
M7Y6 .4;MUOPORL <HW;K?A?E8 Y1NW6_"_*P!RC=NM^%^5@#E&[=;\+\K '*
M-VZWX7Y6 .4;MUOPORL <HW;K?A?E8 Y1NW6_"_*P!RC=NM^%^5@#E&[=;\+
M\K '*-VZWX7Y6 .4;MUOPORL <HW;K?A?E8 Y1NW6_"_*P!RC=NM^%^5@#E&
M[=;\+\K '*-VZWX7Y6 .4;MUOPORL <HW;K?A?E8 Y1NW6_"_*P!RC=NM^%^
M5@#E&[=;\+\K '*-VZWX7Y6 .4;MUOPORL <HW;K?A?E8 Y1NW6_"_*P!RC=
MNM^%^5@#E&[=;\+\K (=J$9VVH]K79JOCND8*3.W(U<R;)R98K10R8(.X""L
M$VW5$P !%HJ$E7J9OI-F#I8I43!Y^'O)CRC=NM^%^5@'F,TOK)S^DH>&0UGH
M*]?<Z$PM<0@DEXH\FLZ^<LF+>E)/2O#%5L:%@=.[,8"I X/$S+"-!FJ8A7)=
M2]<RO^[I8?\ 7M.]4]3C-:#V<?7XV=G&3M[3;=I[]JOU_P#IM+LO_P Q^QRT
M32%Z'*M9_P##SB5:S+69UOT@/(M7#MF,LNZM8L:>;LVXJ*PFE1_^+JLL]<;W
MQ8^G/*-VZWX7Y6;:>.#E&[=;\+\K '*-VZWX7Y6 .4;MUOPORL <HW;K?A?E
M8 Y1NW6_"_*P!RC=NM^%^5@#E&[=;\+\K ,:ZS)&#234S^'6'_F):OMY7_T*
M\_DL#SYV(KLP$$-F?9X,*ZI0#0O241$12 I0^8%?$1WBGY  -_E'[ W[_/CN
M[PDV]DMV^B2[V_89O1%-P0%$'IEDQ$0!1(Z"A!$/(( <B9BFW#Y!W".X=X#Y
M0'(34EO%IKVIIKZHY3A.N3C.$H27?&<7&2W[MTTFOH;O*-VZWX7Y62<2F>Q0
MF8:EKMN65+_X86UN'DY?_P"OZ^#O\J8^4?L\V[[ # .+LIVO6JU7K:4B]4;_
M !UKBM.]55Z+66L;764(9BFA&,YM14JR!.8LU.SF&+5-%X9TZ27:N#F>K$53
MW4.CXNO8]V?+6-2QLZFV[FP:Z,?L98]7-)\DY;+F_2XI)N;3BV[);[+T'C35
MO1]J6!P]5P7PQJF@9^)A]GQ!DZAJ3SJ]2R^2I*VB':34.6<;9.R,,:,XV1BL
M6MPWEV^E8 .UUM4%!R81"%T8 0 4A.(A3Q 0'<3_ *H[]_T?(/D'+U2BVTFF
MUWI-;KXKO1H#A.,5-PDHR_QFXM1EMWJ,FMG[]MS;K29O[.S58.<KO_L;=*Q$
MV]+B'_G[?O((<O< !^SR;Q^W>.2<3SD5H.LRNSU2KPAK(FWTA3U"K+1?2<:I
M%J*K28:PH$,^"Q& 'Y.-;>OQ J $\J(-SE'B"CG@ZP]:AFQU=1TF-/)/2O5:
MVY6[;<_K'_J+=]>_9=W*T;]5KW!,.!;=#LX,G9QC+,=U?%O]6R8QKQG/F5']
M.3]7:C#^WLX;R_S[5/H_=[E&[=;\+\K+PT$<HW;K?A?E8 Y1NW6_"_*P!RC=
MNM^%^5@#E&[=;\+\K '*-VZWX7Y6 ;A"B4-PG,<=^_>?AW_8'D^@4H;O)O\
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M47%Q:W/0_+XM!@# & , 8 P!@# & , 8 P"&:AIKK46V)-6Y'CA2 E"(-5$
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M[[WLDM^Y)&@SDISG*,(UQE*4HUQ<G&";;4(N;E)QBGRIRE*32ZMO=F]DG$8
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MK?\ +K./*VW+F_7UZJ,4MMMS/GZQM/1^R^4S_:B#_?LO2T'ZQ]/?V7NF"/[
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M&I+.R!P1T^O7Z;?Z(]ON_P".O7WGJ+(5^L6,&KR7@(6:$J &:K2L0Q?JI(K
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M+07<*.UD(YDV8HK.U2D(JZ53;))$4<*$33*HL<HJ'*F0IC"!"@ '88 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# /@E*(@80 3!O !$ W@ _: #]H;_V[
MOMP#[@# //3:RJ5>E]:=$YJQQ"<ZS:1=CB4XOYP:@5H%%I:4@$7!Y$])N]8C
G[)#+1Y7;%]5[?#V.%?@Y(J=!,$#)+AY\]5^.OMV/0O & , 8!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g96389g71d99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g71d99.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2,R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (Q:^B8(X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!=0           "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         6\   %O          $                          0
M       !;P   6\                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   6\     4F=H=&QO;F<   %O    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   %O
M %)G:'1L;VYG   !;P    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      8H     $   "@    H    >   2P
M   8A  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M4LM>#I&YQ$0!.B@+FT@%YAA(;'<D^U@:/SGK*?\ :W@^IEW?"K;4/_ F[_\
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M].MW'ILW0R[(_D_S5?Y_^B3YN0\N.+2XL= -]K>6-=]&JL_Z>UO_ &S5[_\
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MCQ5+-=>W'=]G:YUAT&S:2!SNVV_39^8]C/TOO_1JU:9?\-%!)2'&J;BXS6
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M]I#=VUJU<![+,G'LK<',=N+7#N-EBY_'J<W(N9&[8VQFX#\XM<&_Y^T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(ZY3R&@?(*/*E?\ =2.5*_('R/RTI2A.R[GE$!DCS >>'?RXY#8)]>_=7EZ
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ME&L,[VKLDF&67WC."=K:3\5$J&?[M+MS?/6T"76K9;89F,N,.*0I2W4MK'!
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ME5J7GZJ\J;)RZOK"98O1$PY[$ER6N1827BV&0VIU3G(">"KS!UV/6=NW;/\
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M2G'L?>2E@2??G\L^73,_ ^M0.3S\S'PZ>_K5Y%*2A)6L@(2DE1)X 2 23SZ
M>>HJ:C.\N%SW_#:441&CPA/<%U7)_6D \>GP@_='?S5QJW:3IWW= ?>2._7E
M(,$MI(P,B0LSX@..!/-:_P!?UC[VLVENL_=VU$.*!@/+3S)!DMC(3.%*\1P
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ML1]\>" B4P$%J=B=_=G]4D1@28ZCK),CE]S:WE?CDN=[MWJV;P9"MO$X //
M Q(,1;I^Q'@>2X0SCNWH;Q>UB,452A^XL<AL8$S&*K.W]P95"^[%LF;.O787
MLJ0Z+NLD-6\-M26HLAMM  [&K]:5E3HW@Y\("5!6S9.9!QR#@DR1,1U/6"%-
M[&H01 &XJ4"D.!PCS&1@R2 2! S4W>SYM;DFT6"/8IDV7OY8\O(+BUJVU2;>
M= Q>EGNH77XG33L@FV-],JJ=M"DQY-M.?EN*=6I9!))ZGWT/.)6A)1A*5$A,
MJ($%1B!)X$ 0*[F&5LM*0M87E1 !5" 3(2G=)(3QGRYR:](/91X_T:67 _\
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MU26$);#[\^2HDHW+&TJ#:0H)P"$JZ!0YQ[106+ "!"]J#(3WBBDG)E23S!.
M3D?BG@N&VVP6WNTUK.L<(3E-;$E_:7NV-2<SR>SQ"E%S8FUM!0XQ8V<FHJ_>
M[!2Y)+$;F.7'6HACL.+:5P=NENI2E48VDK"$A:MJ2E.Y7)@&.0".03FNQJU0
MTHJ05B=T(WJ*$[C)VC$2<F9,S! ,5,K[+,EER/(;0\RZE2'&G$A2%I4"E25
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MB3V !)/;G7,)D@)"E*5  2.5$C P9.0/?WQQ4H)"E**4I2"2I1   !.XY@
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M?C]I59))"D@^%4*2E1'"8$S)5.X[Q @@28)KI"+Y7"R!N$RL%7*I(&T )C:
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M+%M;LH+CUP^Y^!"$SN6XL\1F<YS5A?\ W+_:I [[$;B=O44K@''_ /9V_/\
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M4:3I#B;K5'OZ8N$*2MIM;19M&U >$EH..%XA4Y<4$P1^C'*K1I2E*0E("4I
M2E*0 E*0.  !V  [ #L!V&J-)*I/)5)GF2>?.?/S/,UMB E,) @)@   !(&
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M95NJF)W'J=SI]ZJ0H5SF%W6+UE8F*&0E*)D>ZH[*4Y(#Y7U*8?;0IE24AL+
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M6J)_W _?3/M;RK')3_;I?R'(UI(\BE%Q,9"AV'8AOD'OR#R"1JA7YF]NB/\
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M<B5)=MUJ1'0F4F""<*Y$DDB*\=CVMTEFZ0YIO:"T:NDSL+%ZVA1/)21N 4G
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M+B$GQYF/!P_'[RKWVH925^]V$-(:+VJM5[(W]CN>M)O+=,J);$/-#D;VSE0
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M$$(#HZF,<B/-$J6W%#MB5%'_ $C'0'6'==ZOVT>>"V=,2;9 E/WA67U & 4
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M ]#F:8WF19[L_.:H]]\;%.PM88A[B4#$F3AMB4JZ ]9-_KY6/.*20XZ9#DF
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M].Z@<;?Z\\#@<3'H<>8K.I:[=+?2Y@5;MC97R8:@ARSM72J#317E(+[SKY0
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MHGH8 R..9K5BU0.--0(1>J;&,T:U=G,61&5/A,M%A?)2[,Y\, J*1^DQ^ \
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M>5O5943(CC@J)AE1/C-<<?J%*\5/[!6/@38K+5TJAJ\.U0PE[D'@#O(Q.,J
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M3K[(BV !Z+", A\^H#Z!PB2V">>'07$\'PW$=2N?=:ZA<6I 2K>U.6EY2?\
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M( 0#\/=1(  )/!Z5*2D%2B$I2"2HD  #DDG %=[:%NK#:$E;BR$I2 5%148
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MVIY]/7Y>F?7Y>UX&4+;9:;<=4^XVVA#CZTH0MY:4A*G5I;2AM*G% K4EM*4
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M-RT1R[!Q^<,1B*!XZV^N@3 EJ:(^'H<D.?"2D]N=>-W5+UR1WZD@_L0@].J
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M;DI=N#,R?,)46;E-A5M6EBZQ5TZ)")<1F2ZQ.(.<QU]QP<]/0=<\4B(@=<Q
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2I1I2C2E&E*-*4:4HTI1I2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g96389g74f39.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g74f39.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:24&AO=&]S:&]P(#,N,  X0DE-! 0
M    %G:^5U X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!7R=M         "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         /T   )8          $                          0
M       "6    /T                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   /T     4F=H=&QO;F<   )8    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #]
M %)G:'1L;VYG   "6     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      ,      $   "@    0P   >   'V@
M   +Y  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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MUKBUQ800'#ENB*ILV7C '#PTP8</ 3+CX^)28D 2= $Z90L[0R3TG*.^W);
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ML"MFS)^F=L4K1HEWHD8=H' QA55.83&]4X+L/2'!,'J:>@PN8U.%T%3(Y]/
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M2B @/ X15N$3")A%TJ.6Z2J#=5PBFNZ%0&R*BJ9%7 I$%14$$S& ZHII@)U
M3*82$ 3&X*'.$7=A$PB81,(H)LG8]4U/4)&]79XM'5B(7C4Y602;*NP8(R4D
MTC"/5D$0,L9JU6>)KNQ0(JN1LFJHB@NH0J1MCA6%5N-5T6'8?&V6LG;,Z&)S
MVQ]:Z&%\QC:YY#0][8RU@<6M+R YS1=PU>,XS08!A\V*8G*Z&AIWP-GF:QTG
M5-GGC@$CFMN\QQND#Y,@<\,#BUCW -,NC9*/F(]C+1+YI)Q<FT;OXZ18.$G;
M)\Q=I$7:NVCI QT7#9PBH15%9(YDU$SE.0PE$!S"EBD@EDAFC?%-$]\4L4C2
MR2.1CBU\;V. <Q[' M<UP!:000"%L(9HJB**>"2.:":-DL,T3VR12Q2-#XY(
MWM):]CVD.8YI+7-(()!7:[=M&#99X^=-V31N05'#IVLFW;()@( )UEUC$22(
M B "8YBE 1#SRVKB[$E4ETDUD%$UD52%4252.51)5,Y0,11-0@B0Y#E$#%.4
M1*8H@("(#A%T2$@PB6#V4E'K2-C(UHYD)&1?N46;%@P9HG<O'KUVX.FW:M&K
M=-1=RY7431013.JJ<I"F,!%PSD8^1!4T>_9/BH'(FL+-T@Z!$ZB1%R$5%!0X
M)G.BHFL0I^!,DH10 $ABB)%]J/6:+ELS6=MDG;PJYVC51=(CET1J"8NCMD#'
M!5<K8%D17,D4P(@JF*@E[R\D53A%TKN6[5(5G*Z+=$IB%,JNJ1%(IE#E33**
MBABD QU#%(0!'DQS%* "80 2+NPB81,(F$3")A$PB81,(OQG]0O\?V\?\\&S
M/ZZ3>>[-F/N:V>_>/"?YA3KYU;8_==M3_G'CGY3JEA_-XN.)A$PB_3_]%Q_>
MB5'_ (RW?^LTAGD;I?\ NXQ#_P!-AW\Q@7MWH1_O?X;_ .KQ/^?SKT1SK!=M
MIA$PB81,(F$3")A$PB81,(F$5F-7*\9FXCC0,,:/=NA?.F)HMB+-R],J5<SQ
MPV%#P%G1EBE6%PH0RPJE*H)^\ $"*O\ 8F7B%6]C:^,4Y%"J^SH^(51-(6Z:
M@'[.X#IH"*)# /<5$13*($'MPBMQ*W74VAF*<!"IL3NPD%&2<4Q*T.^*H"Q7
MIFX-P2,[*J *@Y$GC@H ' _<'.$566*BRN5'Q8Q@5ZL8AU78,VP.E3$3!$AE
M5P3\4YB(E*D03'$2I@"8<%  PB^6L-#L42-V,5&LT$E5G":#5BU;HIKN!$RZ
MQ$T4B$(JN81%90I0.J(B)S&$1PB^W,5%O68QSR-8.X\1*(L7+-NNS$2'\0HB
MU53.@(E4^V4>SR/]H.#>>$501LV2.8Z;=%-0Z9$SG(D0AC))!VIIF.4H"8B9
M?(A!$2D#R* !A%T&C(TZ9T3Q[$R2B"K4Z1FB!DSM5SBHLV.04Q*9!901451$
M!34.(G.43>>$72E!PJ)&2:,/%I)QJ*K>.32CVB9&""Z9DED&12(@5JBLD8R:
MJ: )D43,8ARB41#"+Z91$/$HII1L7&QJ#<JW@I,F;9FB@5<P*. 2(BFF1$JQ
MR@=8" 4JAB@<_(ASA/AN6*MA:1U+M%E6266+<M1KEG=6ZIS-(N-JUM.QEHE(
M:4KLC*Q=EUU/U>:%W+P,U+PTD0L@HE)QTB[:O$ETE3%PBD=-U_K?7E=K57J<
M%"1,+3HI*KUY-509*0CF"W &8*3<NX?S;YW)+*"O(.9"1=R,R]75>2"[QXX5
M74?#7N[4^*E+UA7'+5\QDF,*NR]C;)23)\V8*M1CFQE3LDWS=<AD?8D#%6.U
M(N3P$A!4R0%$#\$6-+SMO55#NU)I%G3F7%TOJ#@M6CJWK&_7Y<8R.?QL&[D)
MF1I%1LC&H5U@\MC%HYF[8]@X)JG*N%%7J;4KY1)^?T\_:4W6]G9]&Y1X)3IZ
MWLM<]&-'4':QU!;=9SUPI\*27B6-7M5/O#'8-" [V*)&QKP\1>=?).9&)C9!
M\R3D("0KEI9B0).+5)>WM'K%E7O-QZ"90D/(NYZN)025NO\ K^#4- /CM6ML
MUHSM_P!?H-@W)#F,S4@6-(MR;M9)%%D[0B7"+%P\*X:D<DW6]'NN.[3Z%WV[
M<.B=>U&M;-MUBK5>JFQI>J56N65W$N"A996].3#5XDI$(Q214&6776<@5XW3
M;M2"Z>OS-44W*Q"+++B/@#$:.'3&(,1N[!ZP6<-F0E0?. $H.FBBI.$G:X*&
M %T3%65[Q#O-W#R18D8[IU!*[5#7+9TDILA56UP0E4@5R+'"EQ\%,6%D:9.U
M!(6K1G98I<B8N? <F<*%1 YT5@*3QP\>-5.7;_6\4:O59XK4&/UB=/E*Q!*$
MBDD99[&)@\?J1+#L!%PY9)J@X<*-TQ52!3Q#& 3".$\>/4I,LTA0;N6[AK%@
MU=HE(\060: @Y;E)X9".4CE\-9$J8@0I52F(!![0 "^6$70,57?:6"AHR%]L
M:,U&T8<63$'+6/,4"*H,3&3!5!F8@%*HDW$J(DX*8HAP&$59&MHMDU(VAV\>
MT8IG5[&\:DW0:D4,H8RW8DU*1$IQ5$YE>"@85!,)_M".$5?A$PB81,(F$3")
MA$PBP%U6UN<N72YU)U"L1;F;LMKT%N*MUZ%9E(=Y+SD[KNQQ<3%M"*&(0[F0
M?NF[1 ISD(954H&,4!$0*00""1< @D<Q?<O,!I2K]3E)BZ:&Z>-D:DHLWJ[3
M.M[G&U**#5$S.[!BG=F<67984BDH+7&00@HQ2N5B0G(QE 6RQF,U0+)!5X,[
MY8I)OIVFW,<AKI8^S?WVZCQ'576HY39VQ(#J0LNV+MTKZL83,?"V&2AX5E<6
M4VVC;LJX95]M,(P5JBXTWO=2/AX_ZQ2J8O@A7!)%P9XWCGV\M#[]^EN&G<J?
MSZVX]NIMN-AZM%?Z=,]=C%IKUPY0VY;+6K4;[6F=9FV4C5XVNO2+V%Q4=FVF
MQNU']8N1P1+!13JF7P4K0IRWD6<@/=*I@/C0GQZQZ4.O,=W@G7?IZPJ*FT/J
M<L,=IVV[7NG4!8B5C>6N96RUZ%KUVJ$U5EW%:697@[E5],R$E=J8K:# X7]V
M)K52$;"):^FG%',4LH;'<+6]IOVZ_"VXW6X>]H!BGUC](]_8:RMD[)U5;:D;
M:=@0E,E9IG7:[;-?/X2$CGE@1051CV+RQ*MSO&;8Y2$.5-^_)V)%6*]/UJ;Z
M'T<=WHX]_!;\84)A%J3US34O7^EO:\O RTE!RK.%1.TE(A\ZC)%JI[:W#O;/
M62J#E W:(@)TE2CP(A\1SFO1Y3P56V&#05,$51#)4.#X9XF31/'5N-GQR-<Q
MPN-SFE<"Z3JFII-A\>J*2HFI:B*F:Z.>GF?!-&>M8+LEC+7L.MKM<TD&UU^7
M@-[;MX#_ -F/:OI_C!MX_M][CS^/(YZ\.SF 7-L#P:W#_JVA'LZD6[K!>(?L
MHVF__46._P#\OB']H5JF-L[6L<>YA[!LS8,[$/"E*[BIFYV.3CG1$U"JE!RQ
M?2:[98I%"$4 %43 50I3@!3%*8+\&"X+22,GI<)PNGJ([EDT&'TL4K'.!!RR
M1PM<"1<$AP-KC47!LU&/X[60NIZO&L6JJ>2PDIZC$JR>&0-<'C/%+,]C@'-#
MAF:0" =XNO9OZ)2\;VDVECI[^/6F-$0:*QXR?F%EDCUFT*'(L,#5ECD5&29O
MR+*O)6(*)&D.H=*13<LW#]1G,=#=-6'[-PR4E=%*V#:2I<T34L#6EM51@.:*
MFL:"WJ9(BT1PS_/G%XBR5D0DI_1O0'B>U,T5;A\L3JG96F#S!55#G--#7.+7
M&DH'6=U\4H<Z:HIM(Z=SFSMDC?,^*I]1>HZH3E]U)+U.N,8&1EY>RZT!NVM=
M</;ZKX#+9U-D9!Q:*JG+0"EBKC*.:.WL[")S<0K)Q3=VT3D&9U073Z 7I1>=
M_P#<X]36CX39=/TO?KHHUH'3V_N>K82EQD!3M42N^=M;EZCK?L&*JM#?+29(
MZ)UW6;%5HG46NI*UN*I6XI"D,9QQ/KQ3>3;OJ\;O'9O3?:]APTOPXGG<'U@K
M#&UJWU=6/1T]49.R]2%\I5VUIU.1,'&T.DR-7OK78DQ1]?Q6IZ7>EMDOI:VS
ME)=2KK;:A9>RN&];52>-8R;462C*H\<N'H[[=W/U>A22!8\B-/=<BQU)&H(-
MP;Z:+.+")ZAJUM"-9V**W= Z;>VZ74<KZ:B8)O9GUF:433[2@&LKABT-(NJE
M[Q2V WD7+X5:^=VW,A:UP8(PY,@;ASTO^<^WC[%"Q% ZGZGJ!(2<EK5/?<C:
MXBQ=93>0/L!^ULK-FRG[S3YO7TYKUU:".H=*9L-.>3R\*XB718N1GVB$?/->
M8X&B,JK0WN1J!;?H?H'I[.2GB-?ZO+<K)QE8N/4[6]3IL]HRM)E+&ZB8K:KN
M6C=4TUQ!QEI>340\GBQ#C;HV@]7:ODFCQY&H$8G7-7UCM'+QXU]P/H5-P+<]
M=^H^KEZ=+&RS;U7UFQWCHUHS2[ZWM6R-NMG.IIIM'1-1<669BK; 6ZI2L_8%
MF$6B9A%RC:+CY18LB"2(HK*.6\:9)1SX1WCE[]4\>+>/2O1^.>IR3%G()(NV
MZ;ULBY30?M5F+Q$BQ"J FZ9N"D7:N" ;M506(11(X"0P (#A%6X1,(F$3")A
M$PB81,(OQG]0O\?V\?\ /!LS^NDWGNS9C[FMGCP^0\)_F%.OG5MB#]EVU.G_
M .8\</H^4ZK58?Y#YYO+'DN.(/EZ^7XXL>2)A%^G_P"BX_O1*C_QENW]99#/
M(W2_]W&(?^FP[^90+V[T(_WO\-_]7B?\_G7HCG6"[;3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A%B3?-3M]ZTWLJFT+ZI?6^S4^;A8 M[CFTM4
M%9!^R5;H(V&/?0]A8N8Q45!(Y3>U^=:=AA%Q#R27>T5(O,[5W0IN2B3%+E;=
M3]"[9@H6:VT=OKRXV8S:NZW_ "AS.L)J&OU))7-"1%4D+?634^U,1BHO7>N4
M72=M=.F-CBE7,JE(%/L!M?2^[O([]^\6TWC[G?H[;+'U.GQ]?U_H"_/S0?4Q
M&7^#O<C,0<$[NN[+]%6.E[N;RK.@6Q_8[WKFJQ;ZF,6<E&PSU*%MLQ'0ERAF
M+0J,B\>/'/FE^))UU/$D[]^G'6_=H5S.=!6W5E-IQB;6B6^&NM8U6+N=M&QF
MZ5\O6V-7OM3&A-FR=@F>G.]J5:&\#6YI*QZBMYM\:ZMTP,.+2,IK5.>+/M/3
MP^* ZBX! [_5OW'6Y&H.H6?]K].6YKI3>GQA (T2"V]0*;1ZY8]XT_9&P-3!
M0GD?(4.0OA*#JRGUA]"WRFV12JN465!N-GKU>08%81<BC(,#ND!*/'/G[5E;
M6>O-PP75%O/9=HKNO&.M]A4W75;K,E![ GIFYJ.];/K<#9[/5-WK.OP\:2RL
MKBX>.BLKG,'A7D6FS(,TE(F?,"+59[]'O9S&;SS&XOQM:^^>JO9,HPE-M;:E
M==HU;>49O-C5$('6\@^=T*$LK!38]:4GW<358Y5(&]@,TEI [D_O* + #?;3
MQX]:F_N U[+>^R^[5T>=0N_J%K#5^V;%3=*5+5FO+/5$%M3VY/;LG;[+-5>/
MJ<3;'26Q]*5%A5'%9CTI=Q#'B49":8.YA=5G.MSD(<)4;C?U<QK^;12?J9Z9
MNI#>'3;K#5Z+K34E?8JDSD!L&3L!8H[0EF>5)&"AK-2K#:],[//'IL) KA])
MI,:=6K%( =F:*MM=49*>V%(.M^V_C<L:6[H%W3/'.X:7*D(.0B[:@N9>2L'$
MT,W :=CC0<DHE B=.&LWY/)Z!LJY2N5&\'/E728R9Q7CP)IK;B=VX:Z\+<=P
M]9/'NC?H^Y=]:*I<+-J+IV9Q#38-ADG>E8::DGE'H]2M%+;U&9D*-97.JX]=
M>ROUT59Y['EIM89N7KCM+,H*IB\4>GW?0E[7M?73EWW'UK7AMTJ;PG(G6;^V
M:TK.YIYWMFXUE& VL,S7*6EIZBUY2K:T=6DQ*O='4 H[C_#<JH*5I\@Z?-4G
M'AE.L18L#COWG?\ #L2_:>&[34>G7OTY]^::?]'AM6!V#69ZWSD#L"#B:Q5&
M;9PWOY*3,U%Q Q%A8NJ9"/ T?;KE(T=R$TA&IDB]DT1!>.CVRTI77ZZ*"24I
M<:'>=0;@'?Q[3^;=OWBZ.-,W?1&KY*BW-I3(Q!&V24A58BGO64V:+K:[..0:
M-;%;F>O-6#<)\JK98KBP2=/2G'C<K89J9G7P*/C%!\?3O*VSPB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$5*]8LI)LJRD6C9\S6 "K-7B"3ENJ " @"B*Q3I
MG ! ! #%'S#G*XY)(GB2)[XWM^:]CBUP[G-((]!5N6**9CHIHV2QN%G1R-#V
M.')S7 M([""%&_J!1?Y&U?\ Y!C/_5<ROE+$/OZK_&)?^-87R1A/X,H/Q2#_
M ):QCN+IUU]M[7TWKYW%1E<9SZL45[*P<-&(2J+)C+,I!VBQ<>SA[,X>-VJC
M,CDP*E;BMXPH+ 04C[? ]J,3P/$Z?$XYI:J2F$QCAJ)Y70.DD@DBC=(S,<[8
MWO#RS3-ERAS;YAI=H=C\'V@PFIPE]/!11U3H!)44M- RH;%%412R-B?D&1\C
M&.C#R'!F?-D=;*<GT:C536M3A:3285G 5FOLDV,9&,2=B:21.3'55.815<NW
M*ICN'CQPHHY>.E57+E5194YS:C$,0K<5K:C$,0J)*JKJI#)--(;N<XZ  "S6
M,8T!D<; UD;&M8QK6M &]PS#*'!Z&FPW#::*DHJ2,1001"S6M!)+B3=SY'N+
MGRRO+I)9'.DD<Y[G$RW,)9R81,(F$3")A$PB81,(F$3")A$PB81,(F$7DMO/
MZ*:F;,NEIO=,V/,4R5MTU(V*4C92*;V.&)*RKA1[(J,B$<Q3]!)X^67='36?
M.BH*+G*@4B!4D4^Z=G>F6OPF@I,.K\*@KX:*GBIH989G4M0886-CB$A+)HW.
MC8UK06QL+@T9B7%SCT+M3T%8=CF)UV*X=C%1AL^(5,U940SP-JZ<5%0]TLSH
MPU\$K6R2O=(X.DDREQ# UN5HU0D_H?-OH*&")V91)%,!^P=ZQF(LX@ ^IB)A
M)=HB' \ <WRY^.<SAZ<<$<!U^$XC$;&XCE@F OP&;J;]]AO[!?@4OZ'S:%A/
M48UA4HOH9(JB$Z;M )K=HN=V\J@:?1!;Q54 'NP-=MDN>!,B,V[. <^8^&=@
MU > \P#O\Q'U^.79.F_9YHO%AN*/<#^RZA@[[];(;GCIZ%:C_0^[3N)$N*X.
MQM],CJF3TD&",:<AZ"LO5#Z'$ <(K7O<YUFO<7QF-6K!&;GM_P ,$Y*4D)%+
MD>/LB,;QY\B'H :*NZ="6/;AN AK_P!C)65;I&$\,T,,<3M/_-X>D\AP_P#0
M[@/:[%=HR]@(SQ4-$(WD"UP)YYIFZZ@7@TY&UCZZZ7T[3M$:^AM;45%XE 0P
MNEDSR#H[QZZ>/W"CM\\<K'X 573I518Q$B)H)]W8BDFF4I0Z3Q['*[:+$ZC%
M<1=&ZIJ,C2(F".-C(F".-C&C@QC6M!<2]UKN<YURN_\ 9W9_#ME\)IL&PMDC
M:2FSEIED,DKY)7F2621YM=SWN+B&AK1>S6M%@LJ9IUO$PB81,(F$3")A$PB8
M1<>O/KQZ?+Y!\P'UYX$./NY\A$B\P:GU7[>A8)Q+S%/LEV1EF=Z,W!I2;5)!
M7MI,YJ'D&VK/$K4(Y64CHI&P3E;<3+[N812M'6CWLNVDT)%# ]?=X*6\=GC7
MNX*KG>I7J@@&\Y:)2J0$?'/]:EFJ-3V^EMMV=Z%S4VV^HS1A99> GC.TFH02
MM?FIX4HIHO%Q<JI8&,?),H5ZA($L==-1S^/CB +J=;NZA]]UZQVFI:PUZR42
MKNGS75:X3E.O<PUD9^3A9HS!.ILX9($) T'/)5]O(UR14"6=M'TLYY;>YD&T
MT3NMO W^/')6W=_4?OBBNZ[2Z?0C6>Q2NKR34E8([76PG4<ZM4C3-AR:1X9R
MS.ZA:RA$SU1@HY2+LDA*2CUW<(YN#9LBR,Z>DU[-_$CV:^-^X+.5EVZ6)TO?
ME:[,SDOM"FZDE)]-K]3YY[/?696+DF5?.: & .:0<.[0U(DC'HL7 .$ ([.W
M-&+%<J$6N*?5_NN'DG",WIR:D(6+E0BIQTRUYLD)>OLVB,ZW2GWQVD<Z8VDE
MJ=1D<[CVM1CO]8T)0J$B5<IFSDY#N[=?J5T+U*]3+]K$S<;J&*:Q,C.3[<\;
M)4_80S;>#KAZT!EUOW^R*W>V$DV]&'.XCR(H^ZUQ40>]JQ48OOTW>WLN@U%]
MV[3CK[_'H^M==2FZ-D[6%@.M+G!4NKR-Y14+(:^L-.&U)-J(O+PC%TO.NYIL
M"[:P-?=[259OF+:07=) >.;F$J RIM[[6XKC7NY>HG:VW-;L'D&I3]>1M@E5
MK<Y;Z_O< 6>35I,W*MJV]<VATBHT/59QDUBW\NBF>)L<DY04CTDVABMEBCVW
M]G<0=;]VBCK+J,ZMD%DXU#64=)(,T[$J[F;'1;F1^^.R>W^39IHIP;F&C$$Q
MB:Y"0C(@-#K.7<LS?*K+J+D0=-;]GMNGCU6O[U<TNJ'J? A9];2#%2ON5TC-
M8!&J7Y.U(-7=PE*DB1V]5=F9&7:-VK2T/%"1"1%(@YD4T$0<HR").[=Z-2+7
ML;VTUTW_ ![6?5SO*>E?;ZUI"1<TMG882+6]YTK8L/8YV/FW>KHE1[$I3+6)
M&*+"OKQ9)!^XDHEV@O&TUXD0C8IW$FU(H.QZL>HZ0DX&?6UU(,*^YK4@P?R0
M:LVA]5(J7EK)HD6\O,51=!*_/G=/96Z[P#A..>LV,JK%R$R)6+"+E2QB_P!'
MMM[U-MUM3WV&F\V.H%OKXVCS3Z1/:*,M:7,SJ%LA$4:NTM[8J:6'LK&\R$Q:
M8?2Q)!.H2+Z1-'3:-2M>W"Q5PB74!&2U;381K-P=Y*RRJ,<4<;7W;_;;QRX+
M;K:&W[,SUUI>Z5*>>*/9G<&KZO<TJ-1)JY1$Y&.+['T_:35$#UR<E(BI138E
MGDVMK3]@$6L2P?M)U9@Y 7Y._EW\/'Q6DCO>W7'7Y)VNV]LOSB(D'2?N1K3'
M4? S\K%0,I*7IBW6=Z.K3]"F1+)&'>4A4]M8RJ-@</*[*W+8#Q1&)90>SX:]
MG9KQ]R#M[?J\<].U2E/=/4O$6MF0+@O;]9C#Z=>L+2W@R-V;UY9]G=,-:K,0
M$DM0(9%W,[+A[;MQ.;5976Y,4#'CI)LTK!4&;+ [=^OOYV]7'VJ=/3Z^>IW;
MSNMP!X[\P7;<>XDMI1[6%F;0VI3[3]MDYU"%H$V#&OWA!Y4#5)ZU>3FD)Z28
MM'#=Q,M'KA23NZIUWZQAI+9"!<O6LJ.7#\_@</BM;V74WUE)1E<0FZI?AD7%
M.UBS>2<3KX .8LRSK"^RML/X%SJ19%92OF=VA&*KZ4[69$5XZ+,KJUT19XEC
MQX[O&JGCH.)UOZB=;>[XK/<_N3J ;].\M-L$[\C=(VRRZ=&NB](8MI79=99R
M\V2O+2M';:QM3F$E9F!:1SU[&O*?0T'4@Z38H3M:(HHLF4>.?U6]/%8KV+U$
M=5%;G[66LL;[8JNB[ICHJ[:@G:R40#F)L+J?K<6X-HV0*UD7DE'1S!)NZA]B
M,&!7;5=6\MS2)4&SQX\!/'CQQ67>G+J VY8-T;!@-R#9X&G22\>QU?&6&C*P
MYBRK]^?P8=63:4R"[I-)@@N98OO:SQSEL0)922A15)%$)IS'*W+X>U13:N[]
MY,KYLUC0;7M)"DP,\SA%'SG1PR$E!3R:+E?P*0/Y,CM[+29!V#6$=3,A]9G2
M2QE9!"79LC$7*3U::[]2">WCW#MYVNK?:W4!.0FYHCZR[*BKS$UW23^C(P^H
MXIJ1K9;=6 );X5K(6?7DA7)J.86%9)W-*KK/UH<B:K--^P2#R'QXL4[N[?V\
M>[T;N:VHZ?)V[R*&R(&\V(;=*4>\H58UD!DTC4W[MK3:JXF$DF+)!NV;IA+N
M7<B1)%,J:)94&R0%103(5Z/K[46Q&$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A%2M6+-BD9!FU0;(G<NWATT$B)$.[?N5GCUR8I"@!EW
M;MPNY<JB'>LNLJJH)CG,(D52)2CZE >/3D ^/K^O@/U81<"4O(B)0_-[1^SR
M(E_W/WAZ_9_L)$$H<\\%'@/D'/X /RXY_#"+K*W;D456(@D55?L\94J9 45\
M,H%3!0X!W' A0 "@81[0#@.,(NP2AY^1?/CGD 'GCTY].>/+CGTPBY[0^0?A
MP''/S_L.$7 % .>  !$>>>T _HXY\OCA%R  'H !YB/D !YCZC^(_'")VE^0
M?J#")P'R#]081   ]  /P  PBX[2\"7M#M'D.W@./,1$?+CXCZ_/U^\2**#0
MJ2,M)3HU.O#-3*L<M+2HQ#$7\BK$.&CN,4>.A1\9P=@Z8,G#4RAS"BLT;*$$
M#H)B4HL+W\</H"DZ+=!NBDW012101*!$D4DRII)D*' %33( %( ? "@ !A2O
MOL*''V2AZ@/!0_PO4/3T,/ C\_CA%0%AHDK%I&$C6)8Z/%B+%B5LB#5F,8=)
M2.%L@!/#1%@H@B=H)"E]G.BF9+M$A1 BN'84>>2E'D.!^R'F'/D _,/7R'RY
M^6$7/:7Y!Z<>@>GR_#[O3"()0$.. X#S#D $ 'X<!]WZ/NPBX[2^?)2CR/(^
M0>8_,?O^\?/"+K4;-U3IJJ(I'51,)T5#)D,=(Y@[1.F8Q1$IA+]D3!P/'ESA
M%V"4OG]DOGZ\E >?Q^>$7/ <\\!S\^ Y_7A%3MF;1IX_LK9!M[4X.[<^"D1,
M5W2A2$4<+=@!XBQR))E,J?DYBD( B(%  (JG")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8111_>Z5%N3LY&V5YD[2.)%6
MSB78IKI'#U(JD9?O2.'ER50"F#XAYYFQX;B$S!)%0U<D9%P]E/*YKAS:X-LX
M=Q*UTN+X7!(8IL1HHI6FSHWU,+7M/)S2^[3V$ J^1TI&R[<'<5(,I)J8>T'#
M!T@[1[@ !$OBMU%"=P (<E[N0Y\PS&EAF@=DFBDA?:^25CHW6.XY7@&QYV69
M#/!4,ZRGFBGCO;/#(R5E]#;,QSFWL0;7XA5^6U=3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3"+\C^\]R;#BMX;HCVT^L9LRVSL9JV*NF1<Z39O<)A)NB
M0YP[O#11(1-,H?FD(4H?FAGMK9S!\.DV>P&1T#<TF"X6]Q:<H+WT,#G.('$D
MDDG4WN=Z\!;5X[B4.U6TT;*EV6/:'&(V!P#BUD>(U#6M!<+V:UK6@7M;0"R]
M>?HF;;8K=K?:SRQ2CF26;7I@W;"N?DC= 8!FH*2"8<%2(*AC'$I0#DPB/X='
M=--)3T>*X,RGB;&'8;(7Y1JYPJ9!F<=[C8#4GZ_0/0)6U5;@V//JIGREF*1!
M@<ZX8UU)$XAH_8@D[N8[+GUGSI9=^)A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$6KW5^JT_(G86JT^WKSYX<$H5T^FIVO1J\P#5V9BVDI6O-G+Y%H*PD7
M$@@1)19!+N.(E*0Q%H'0MB!;K%T419[SLV!W 2"K%LV.YMS^::Q*M);M9F+/
M5'D8# D=*3EVD#-'J('$BR+!B@_>&347*GA/'C?X]*V-W+U);0IFU-R5Z"7C
MVJ6LZ+ 3=#H+JKOG[_<,A.P#^3DGC&?1;+"Q0JKYLFT709F[3\G*Z*)S)AA-
M--=^GT=]UI3=MN=1>T:IKF9MYFB@E+MU:-DZ"Z767>(2&DI9^5C8F,-&L&D>
MZAIKPFD4F<IW:J@@+CM>IB DY^._X=VOHV3ZFK)>*PO4IJ":3<D>/Z49QX=@
MB24.V<SQ):IE2!T5F43&D (=<2E']\]H*\!QWY!W%0=3O-B#J/1;LYZJ)6;J
MUZJZ= 6^WC78>U-I*#W>K4:\WJKZ-/4U]:[-+5(*7EI$J#A:30D8 SF2>MSH
M&(J5LV78IG(=P)FNMO;NYWY]G?PWJ1KQ''V<.]2:I]4?4(UL&C6NP'%45K-Q
MV7*TJ0?41LTM-CLS61EZ!%4N3?L6\6SCXJ(]JL-G0MS^ ,F: 0CHB5.*C,\B
M0DJ>W0#V<>WLXGT$*1[DZL]GTSJLK&J*8R<2U6<.9."M49(5<R:3%<^JKQ>(
M>P1$NDU4?R#<)F!B(QVN+E&'(9RK'=IY%9(,<O';\$MO-]W#CO'CCZ..(VO5
M=U.,(6EP%]EX"OJ;$K?3;=9G;*.O7PP^K(_=>L]YVR<KB\'X*Z4@I&7#4-=I
M,>_D0%TU=;(8J2A4SH-1,Y>+:E1SOP) XWM;7TW/J61*?*N5_HSJ-=;\SM]O
MMT54EYN&A(!W8*Y/W39$S9IRNT6ND%1,LTQ:6BRV&'BDB2*9 CF[Y!V_\--D
M<Y"DVN>(/,<QRW:>_56/6?Y:]4=8/2GHVTAN"UT^J]*.P*;8]@NF0/J#>]DQ
MI=-6.=V#)RA7@&:F]XOI2M1[9XU!S'.1(U: NT?**MHX@=YW:<M_N&O'3<4T
MM<<]PX"YL!<ZV%KGN[E'-F=;>\*U=]]1],=UVV.-;6/J.J3+6K&G2;B6@(?5
MW3?9-P5#94S.)MS%?D?W^,KVNUX=NJ9J]+;8T$"&E&[LI94"YY#MONUL"1RM
MVZ7LIG,;/ZF8':U2IC:6AU[;L*L=/C&=O1::\5KT$C>7G5!-3A8Z#$18E<5A
MI3*PQ;+/5 4<K.&IYD>UX0IHO[#;V7^-N*$9=YU)(WVU%A<7X;].PJ,5WJUZ
MCX:@C8-GN&B;FVZ?U]<8-Y5]>+%"F6JQ[$E:.ZCGB,BFH@X9K,6+"9?.9@@I
M0RKQXJ*0QJ38 E3V]N[Z=WBZK-8=3/5MM6O/IZ-;0$*>C].[#:$E$N*>X5=;
M N"%^V'"R$(R=N46B$821KE':JM$&2)%4WTVBL!"MA1[BA3*U=0>Y-K=$5QZ
M@*#-.=<.IF[5*0UU)1M?]YRK36!=EU6$?RCZ/=(JJ*F?0B\N_D.Y#N;L$7"1
M@!(3' IL+V/<>P\3V\;#CWK'L-U%;GU_8Q;S%C0L59=[UL4#/6..IXFL5IBG
M"4<C7'\16#-3(! '<.#C+N8%5%XR02%T4IT04#"BW#TZZ<_1I:WM-EWQ?7)M
M.NK(HWL6RJ4=,;EB[C.M*DZ<5%A)PNOU;1JV*JTU$L!4ET9>3\&.>"[; _(_
M\6,<B98G=A#;A[5Q5NKWJFMU[;LFU=I->AF])K$BXBK89:'7DC6&B#/+6UHB
M,0O+J(,YPZ;8&#=P5HW;IKIR"::X%*)%O!TC;7LVW]1IV&YJN'%NB;#*5JR.
M!AV\3%+S$<UC73LU95:)(M9JMD/(>%&3B*28O"IJ)KE]I;KX3=S]/+QW]ZV@
MPB81,(F$3")A$PB816,MGK9YI6MDL,&>Q(IE66@"RS TTBB=,JI%58H' ODT
MS)'(H50Z %,F<IP$2F 1(KV(@'J(!\/,>//Y81<X1,(K;*S,1!,%I2<E8V&C
M&X +B1E7S6.8( 8>THK/':J+=(#&$  3J%Y$> \\(JMLY;/$$731P@Z:N$R+
M-W+95-=!=)0.XBJ*R1C)JIG+]HAR&,4P>8"(81=^$3")A$PBQSM#:E/T]6DK
M?>7YHNNFFX2#=2?AF418+STBA&-'3OM^T1FDY<I&=+  ^"AWJB4P$$!VF$8/
M78Y5FAPZ(357D]14,BS!KI&TT3IGL9??(6,=D;^R=9N\K48WCF'[/43<0Q27
MJ*/RFFIGS6NV)U5,R"-\EM1&U[VE[M<K;NMHIZS=M'[1L^8N4'C)X@DY:.VR
MI%V[ELN0%$5T%DS&35253,4Z:A#"4Y1 Q1$!S6O8^-[XY&N9)&YS'L>"US'M
M)#FN:;$.:0001<$6*VD<D<L;)8GMDCD:U\<C'!S'L< YKFN:2'-<""""00;A
M?$A(Q\2R<R4J_9QD<S3%9X_D'2#)DU2 0 57+IR=-!!,!$ $ZJA2@(@ CYAE
M*K7VS>,Y%JW?1[IL^9.TB.&KQFNDY:N4%2@=-9NX0.=%9)0@@8BB9S$.40,4
MP@(#A%P^?,HQD\DI)VVCXZ/:N'S]^\72:M&3)HB==T[=.5C$1;MFR":BRZZI
MR)))$.HH8I2B($76RE(V3\?W=(,7_LJA47/L3M!U[.L=(BY$E_ 44\%0R*J:
MQ4U.TYDE"*  D.41(OM208(NFK%9ZT2?/BN3LF:CE$CIX1F"0NSM6YC@LX*U
M!=$7)D2'! %DA5$OB$Y(JO"*T2]@@:^B@XGYN(@T'+A)FV7EY)G&HN':P@5%
MJ@H]60(JX5,(%203,9501 "%$1PBNP"!@ Q1 Q3  E, @(" AR @(>0@(>8"
M'D(81<X1,(F$3")A$PB81,(OQG]0O\?V\?\ /!LS^NDWGNS9C[FMGOWCPG^8
M4Z^=6V'W7;4_YQXY^4ZI>TWT.G\5NW/OV!'\?Z-L<Z%Z<O\ MC!/WKD_G<R]
M'_H>?^Q,?_?2G_F42]BLZ-7H9,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPBIGC)G((&;/VC5\V,)3&;O&Z3E QBCR4QDEB'3$2CYE$2B(#YAP.$5,>&B%
M7"+M2*C5'3<I"H.3L6IW"!4PX3*BL9(5$BIAY$ AB@4/(H &$7>JQ9*N4WBC
M-HH\23.BBZ5;I'<II*_PB2:YB"J1-0/STRG I_\ " <(NI&(BFR8(MXR/01
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M?T.(B%&]GE:U7XB?9K0Q5).2C8-"0;/45$U&35RNNT!05$W1Q(F@H)RBMWD
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M8_GTB<+\^V2:F\ON_>A>?P_;E!Z-,0X8A3'OBD'],JX.EC#N.%U(_P!9B/\
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M84RX$LCP#IDC)]-W.;<7WCMWJ/.NIBE) /L<;-NA#GR41;M0'UXX$%E_7YB
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MZT^G(^TVRU5ZM("@NY*I.S#"**9LU[/:G!/;7"/B(MO$3%PJ0!(@!RBJ8H&
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M%W2!D4GR9U6IS"3]U334%(Y@*4PF)VJ )1*H!3<AZ<>>4LD9(Y[6.S.C(:\
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M%>)'.7$:*<>X*A[6_.X5*HF8IS()M1,('((%7W7X?3?MYE#?AZCPTW;^?O\
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M52@X2F0[X]);';0$[/QT=+6-J55VN_5.6759$52$[UTY=$1:$;-&ZJZHM&R
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M./A^/G@^+7]M^/=HH4@6M-B7,[,M,/E!>QR$.[[EA$JT6V+VMV)B@';[,D4
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MTD?NP.1NMB:A]#C&)G26O6Y7;@ [?'85BM$2*?XF!.4DI#O('/(%[HL_KR(
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MB>GG_ M^SR_C*0)OZ( N5CIMVGOYU#A+O]%4C^LE6S^A_P!D>&(8V.^>E/\
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MUP%B&7:=8[H^PU\,<#JZN+(Z>:G!M39G-FV@I]H2XGJ;9FU-.V!FEA XW!D
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4PB81,(F$3")A$PB81,(F$3"+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g96389g77s47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g77s47.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1C:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &+Z^8S0X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!7Z%(         "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         2P   );          $                          0
M       "6P   2P                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   2P     4F=H=&QO;F<   );    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $L
M %)G:'1L;VYG   "6P    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      .2     $   "@    4    >   )8
M   .+  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M=R/HHF L")O^MT^BZ222<QJ0,Q^57@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $M ET# 1$  A$! Q$!_\0
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MQO6N?SV=LYY:7Y*F,N >U[\B(^Q!O0[,'V54XT@B/4@@:1/;PG+;YJ9[]=2
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MBFL\I:$&LEM*>WIJ>\5\<DC#AF.F>U*@(%WU&A$F+LVMI&A>5/.O_P!%=O<
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MDK:WI.WQ_4'B-C54Y\PW;&@JQK&?.5=S<0+]XSLV  JTS[5A$C:U1MX1[-E
MP-Q<%YGT^H>VBS>U]"7J*ZVVW8])D^B^TNR_1Z/ZQ>N=S/T'BNZJFKTO973\
M'IK&S]C/1V.K[0H'S5&:[S(;>6N/U6KS[K>6M0X. H48)TD(+] 7ZV'[O?\
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MI,&W=N3I3KRRI(]5GBX91B&T,NOJ['0RU5^(U+$(W*/C'5&$2LE.)'8^$_A
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M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%@='IJ/)5K[?0'L !;+'
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MLJBQ61D,3W,3W,<Z"R<URIY5/K[5<GU\)]?'!_X!FB[YC!F[X=<B/[_%<_\
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MV8(XXEA4UAMO7&#11P3BV%4,\\$F*5C&N:^$H:&1$55:Y6*UZ*QRISS$X?\
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M^.$7F^>!5HST,%5IKO8$Y"(E:6_V.D1HJH_P0[V,<]&PJ]?:USD3PBJA$#L
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M1Q%@]/AHQ\;9&KU?&*FR-8'Z;U5T!L7,'+ L>:,2GYC5\ORT4@FHW! *]_\
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M"X&42MCENM*'?6:VHLC*]MHLE4Z4!I5C[&VG^(1KX()TE6.+V*C.)PS)Y*K
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MLX#Z?Q\^H(<3_0!X[+)(W%P;Z R?!BI#CO\ \Z:C_P!RP_\ N$GGSJT[T_\
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M%IM]AU\RLQR+:<(OIOX_R+Y_@14\*O\ )Y\\HDMO'OQ4)8/[Z^CK8:@-^?J
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MIO"(3$BQAN\V8R/#Z?=99I-P[NP^8M^1T#.5]M]:75FAB%GPL]M;5RW_ $,
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M=V8_KG+B!0V]&R:3-X<K70U;J:.$YY%M/>VUK:#GV$47Q#/N]55*_%^[L21
M9<- ?>T>I+%IF\*DN.66!%6PD@F;OO: UH46T/IE]&4!H.<U>$ZP@M3G]J%C
MU.@M8XK6[_P_%SM[/>; ?:M/O8MU81^"6&H9%&=7@)4H(15@_+:8%W8!W$W=
MWUU<$V05$ANHTV@<IV!$'9P5@8/0-Z-K:KHZF#K6*RAP5YJI:,V#L'L26[SM
MOHP,Y4Z<*"_'V#;D6,JORF: )J''_)PP5 ;&"QN^(^3+ @01!<L3;Q;]X0&J
MX['>X+=1RF&O>ZVDQ'6V&ZY;JV8K.!YYFYV5[V#K/E'$/6ZV6D4=U]?%J1-*
M[YVR^5'^/\)8XO\ %M]D;%]WG5)NPL8!M+WFX B;MU),-WM).FW4%[:OV5%Z
M+T0>ES3XOK7 6?4]7#F.H*4O,]<AT]OI,^;ELW8L$BM,\%<T5S7W4M)9QAB-
M/K2SRA2O@Q22Q+(UKTA$"#9FL7<3N7=K?9!4?F8AK@[N#=XZ=G+@K.E^D+TU
M&UMC3R]0Y2.KM<=UA@3 182PA_NETS?V6IZOIA6"%P($S&Z"WLK:H*"6 QI1
M4CB")T]J)GEZ:^)-BW;4RS7:YZC%KLQ>=2=A !#3977%C\V/J7;6*H'9J9,V
M!DY+GS,I;L[6GV%H#5KYD6-1QS[2P*:JQI*Z0B3W2.;[430(@L8#/T\&EB \
M7\Q9F:')9P)_> )UL&"J!WI8Z"=I:W7)UU6Q7U59!W(AD!]R/']JUVIN]I7G
MDAPV3 C2 =/I+^W#>:/.D!%J2C$2'X3(PY"PD !NYT,??II"?,Q']U^A'AVC
MJ1,K[%]+70@E,?GXNNZO['/J)J&0&0VWFC@IY-!#JXZZO=+8OEK!@M",-;5B
M5\@SJPP8>0!PZPQ^V!I<]FG?W=4A]3KJ=2#=_;J2T_1?5-#C;# 5N1";E;<M
MMA<5Y)=D?+;V"6S+WYVSL3C"+(TK[5BC+^-.6]R.9'$WVP-;$T&!-C$=26WM
MK,;I?</.S,T;3LWT63!ZDZXK+H31 96O&N@KV]TPQ[%)^-#>Z4: 2\LF(Z=T
M?QK$<>"*9%8L:-B:K&,7RJR-M=]-OW0/J7\/7\^C*Q>15<I^/T_A_@_9_?\
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M7'")PBJ_O/66^"Z2[CW6?>.R^Q?5786LI'%PK.*VWSF0N+BM<2.CXUG'::'
MLT221_%C1[?<U7([F@&!.P'_ /</R1V&ZP1=KO%RTT@]+BVVR_$#H_\ 2F=T
M06K,=WV)B0-]UST3::SL"MF\92CV5WI^PNL*KIS94-J9,0X*DV&1[!#D2MBB
M+)GT;2Z<3XID,<+HY<%W;<DCR6R!H^\R0SN&\P#$>DXJOTM?8U[.F[K^F:./
MJZB]-WJ#[9U543J!H=2_5] ]AZ?!7 -!++[/GJHZQS:(-$X5IB V*64[(6BR
MQ<.!H-[:[ZPT,7![E.6&=GJI !$$5AR(F+VT.@G9:^_2.3S=J#=3]<]6P;FZ
ML.T,UUP%9LV=/74OMMNG:#N&YNRK"5SAXH:.HM#JZ45KWSSF@,8UC?C>&A5!
M@@DF7+@/Y'7S4Y3$L&TUECKTAG-UKV[])UI^V]7F,/AJD''GUG?OI^K;/0T-
MV#K<_L.M.U8^R19J\4]1VQH4IN-52"04E'=&V!XADB2/3CFL(BP^_GZIR !]
M)!!Z,23'76+LMH.Z?TA#.IN[]%UG#UC-?9;![3JKKS<Z=-+65]W#INWZ&*_S
M,F;RL\GSMY2UXQE?%>V$:L0624I8&RM"G<VDS($01N9V;T1C# .033!9A_,2
M=/($KV9_UVWY/H\9ZM-7T\1G0-*?DQ.M\C%JJFP)T8^WOZS,YRSN;.-S0<X'
M-8V<9!KCY$D!KXW23(V96QK 2:1L2X?MW[?F$%+$B'DEB=.FT1.XW6O6F_2Q
MWV;;;T3NAQ#=SBH^XRMW7M[*S8^;$"Z4EKI-)-EM&3+&-IYK$"QCDI0A$^:G
M,:X61D:M<YIR(<AM',>J<O,Y&K/U@LS^9T8;7K5OZ2_O>TV1=A98&HH.KJ3O
MG[K@$TMU63::TS[NF=#V56Y_34QTOS([+)M;YENP&I\">..!L+FI(]::B6_:
M'?\ Q'3NG*)(V-QN;!F!$ZSUWL[-?I5-Y;V=:E[Z:#<]F"C.H9[+0P]@9NR(
MK<YW9!*F./CJX)?CF6D!4,B6P#52$8=8W,(DD5\;8Y_RQV(_?Z0LBD.)$/!U
MZ :;_=8/-_I1[['X_(EZ/#$]BA$=7=@=J:F_&OZ0#54M-EM-8T $=GF!G.AB
MBMK.*"LJGQSK*1'%.4K$9%(J457U-G=V&S+Z<CE@P.A(FT%Y T,K'[?]*OV#
M;=3W$..Z-L<OVA<XKMK04MCHM+5468!H,1B8=%!JZ*UOVBQWUA%+9"M@HU'9
M,26+/!&DK7Q+(-3ANKN?'M[\&@H!;:EFAY+Z!N[O=HWW4(]3^[R/4'IOM(<A
M%V'M.T>HKS?7I)-R)GA18<)@J77:4V57L<DI%C'821!"BQ+X)5K7)'#[G-@>
M6U<G1X\ 6T'V66$]&IAA+BW]4&_J%6&^_2!VTD=]3=4Y+.V>JJ\%UMV$U;O0
M,6OKZ_9:"DIK2COODHY5!O*YMQ'+%&Q[XUC17S.C<L;'G9V&FK:[6G8]4 )C
MF!9P>K;DB(^G56OI?6N)EXK4<C%*;>5&N[<QY%2'>!>^<WJG+4FB))&DG5B_
M*7,MO\B)-*V-D7P?C2JUKU\5R (%WL);=K$/T,I52&N26=V#@F&8=M;^$0C=
M^MO09V43(V>4IZC3Z3K\\Y746C;>V6)T]QA[;4Y=EM!\HT!(?@B1/D^)/\::
M1CGC#SBI\17-4?706O\ 91A_,(#OH>]G/6Y'12_M7<]Q,]//178./[&CRV@T
MS>H:[3SSY<&]9;R[IE/!9'(R8T!H<\+RIYXF1-=&Y[D14:U$3D.C6L]@9>0.
MC7E4@!P'+$D=-B!$;=?2/4_:'<UI0][;B7MJ@!9TY?;;#5N$FQP#[&]ER68
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M-'I:BLD#A?GJT#064-%H7"KJJVRLA0;#[='K8U@,@.TW^_O[H0"26:P;:Y
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M]L;+NY((  ?IWE@^Y+M99\GTW]$F#G"$]892<>QKNRZ@Z*0%RM*K>XS6V/:
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M'-5^G:9CV5>?LL_6G@!TU.06L:1L<5.(A#'*;,0=]&(^WW:5!4&+2&8 4F#
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M;?U$V[0W0% X!&CDL^](I;M#"+.X<E1)_HCP,%+UZ#2:S54ESU5A>I,3AM'
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M&;%L ;;,5M;5[(GM<+69^YI])E3*;*X?4YB,*H(&;.8S35^Q$(K6Q-EE*B+
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M[E_IH&NDR7<>(8@^,;GPLHS/ZUL_.X"3-]5=CZRN7-;W8Z(^G=E6ORV:ZZ[
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M EP]CK< ]8/:S0O0R[,ZSK+69->N&)UQI^DM#!G"\^M=2V$W7O3':W2VK,\
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ML@:*#9MN0AB\U2DCAV[&,C9:BQ2A/C'LFQPQ,:="QA*,CC:DJ(QJ)=W8L#8
M/VMK/9U-(!T!O8.[;B6#3/0*0#556#*5.#7@!3G%2&G3"BCP2FF3Q#03F%R0
MQL<07- $'#-/,Y\LD0@L;GJR")K:P)D@.'>+DVO;8&;[J@$6EW+6 >6MII:Y
M@2O9^/[?P_G^OE?[_P ?(Y9M JP=]3JN.15.$1.-^OY!^RA[/^\?>>BOO(A?
M)4(37)XD):XR3RGA5=.J.9Y_A2%(D\_M\>?K^/#DR?8T]%??K[\%C-Z%\Q3L
M*:U/>$0V15\>7?"F1(7HGT_#W+$Y5\_1&)^7TH>PUA%2_(B<(G")PB<(GA?R
MX8[>_8*.-U$>Q\>WL'KW>8.0UU7'M\9J,@ZS:.ACZUFDHSJ9Q[1'3CM*<(AJ
MD-&4B!)EC2-9HO=[TT 9V V,G;N"2(UT6), R))T@VL+R\6W=UII<^B0^UMK
M45O:8T.#T-]D=G>T,F%;/J)-=C>M8^MJN>KUZ:R**NHI1!A;,JKESYIJ2,GK
MH+:( I6Q&-GZV-W;9_=GA:\P6:+.#< ASM]UZ._?3YV OIMZFZGZBD)L;GK/
M5X8E;"HCIZ6T;3YBGO Y;*DK;/88RM^=0LH!$KDW>>5!92I&VA+8755B;Y12
M"7< ST$'K# N&(LY4!^8B[B;07N3=X\0;0ZJ_J[T(7#&934[,Z@S!<N8QX.E
MZUACWMO3T5MB<S+E,\?0+5=S)F(3(JI@1)L-Z%V'\M:1GJ)H; 8V-XSE)9R)
MU$VAMK79[/ <HY<BS?U%C%X+  V?Q4MTWZ/X&ZK^O8ZOLPFFM>MLMUG14) U
M)=U09-AUM-KO@65BN0W64OV#6H6N*&<#5:*M("D$&E2Q*@=,&\P$$AWU,!G=
MR(O:9C=+/XDS M%K7T^JSW_D1N&"2FI][44.<,RW6-+<TM=BK@EK[CK+<@;(
M.UI;&\[#N;,"OM&B25Q=9;%7YK)2?M!+J58U%DO*/]P\ 2!;6S3=]DDD%F&C
ML\^[N-F5G=>>G"\R'3VPZ&T&_!T/7]OCM)@<M-58V7-Z^ASND$M@R9;F^=J;
MH;0W \5O(L)PU10Q.FA:0X1'O5K3$.!+CT82 _@[>+E4%RX%M6ZVD>_K56!]
M"HF5DS!=MM:VXM,S92D-MHJ#9E'W8,61@R%5!;$[GM/?3,*K@X$DBDJ7UH$<
M3E#BK(6-251H(\G-X&C_ +#S4JJIM?\ I;:9VUU\FDK6NH]$O=5#V[?4L,8M
MOUE>YZ;&MV-JVNCK*>GL\!:9*PUE93@]J!V:[$5Q@T(=,?UQ85TPT4_G8#2.
M:0_+7U8DZ0.CSK ;5ALJ*N@B=2\AP0/HY;S)V3)]!5(;D?ND5V :D4UIJ;(F
MR!SC ;"9NEQ@.0^"V>"\^/'\DP&,Q9&D>\B-RA(@S?!'(W]UR(F VKAN[?9'
M#RW27,&-M>D%0N3]'6V2MRTJ]BUZ:O.R6P=A;(#W(T/79^VR=9C9*_2I_P"4
M&W43S#4]9# *P+6!4+!Y)0I<_- D;H]6-^QGMI]0XB8635-@W4O(-G (>':_
M7>;6?H-H37S*'M!ZF":;3R.#"R*/&C&T6$K<-#7L4O2E&2B5(U=\R)&:89,^
M*7Y*0A58XN5!U;I=@(&KG2PA]%HDL0(!\SK=AR]8N'NP5%^HGT8]K3Z_.:/J
MAKM<%))(^[IXX:JF%A4+%AY4*MMHR.T^MBI\]<.$BGM2ZRXLS H6NAAS5BJ-
M?*(F.6VAC[>2@( EY8 P2[]'!CMW-EMGV;Z<M;V7]TKVMV>>Z_T:]3&]4[BJ
MFQ\VXS\V?T8H[KT?*?$TV9(I[((OYD>KN2'637B(.A%>Y6+[A$:%@!ZN"',@
MZ'T#(Y'@TW(\A<0P;Q*M'I3I,#I0;4@5EX5=!Z*SIS1F&#-@(KAJ7,5&8&$F
M(83,EA-)#4,)F+6(7W2S.9\!$;[U"07C5V;<,_4Z="J3+FW4,Y+%YVV[J[/"
M_E^/X?P\C$V!/@JN?"_DO\W(HXLX?9UPGT5%_+A59RBG2.QB8]?$93'B3-14
M5%80UT?GQ^"HGN]WXKX_9X5$7EAC,_*WE]K+# :03<B &#OL]I\>N+(@="1-
M!)Y1T,LD*^4\?K1O5OC]GX^/*<MR]1;JS^$>_-;7GYE$X1.$3A%%=#@<1K"
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M:/8('>>9Z3UF$ZV$TY9'4=/J\71=D&6_8]78]C8BRU6BT>>SC<M$-HL+UV6
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M4<K22X9X$MW8#SEG5F]BP&G:2!)?8A_&=J:ZLKZ>O#JJ@ *JJZX>(,"MKA8
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MKAB'D26[,7>S NQ7.C]!G3FDBD@2ZVE=707.>T6?JV0=<:.IR]U0T\5%]HU
M&ZZ[UHIZW58/!!<CZ=FC!E=$V>O%K9G222(>QMT/C:W3U"MY@]"+[@F3?9B-
M5G#/1?U ;<OO3;'5.LON\_/3N$)R=("T:?&6N&0J*GH<E4U%>4E7;DE1Q5X
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M%Z@S_;4O6L!>-KM6+)UO'>=;W5)IZ[5I;Z6FOJ[J:[+B*S-B)31V%A;=Q9>
M V8 )N*O(;"4EEJ)>Y=P=C'VE[!GW#J4@$'L&+ES,">[WMM_*M4Q^]_TF.<Q
MF2'WFC[A,I]UBO2IM.R>RJ+TR5EKMNEX]]=ZJJ[CH<?B:'#6<%Z?1@U>>(N
M[K,ZJZSBV9=JM>-7R"@CQS$V8CTW[>"WRT@L&(>IGJ/*1:D&8%WM'8*2X/7^
MJ;ICT:>E+/5LG>G6-9?[OU=6/;6[RWIW/V_;M5<S]H]RZSJ.LN.J;3$[ C)5
M/9MX=6369)623Y6$FOJ0[6F^U1K.*V FY/TU[RSQYE0S4?Y8((#P P%R0"&!
M!G7F"U>O/2IZI>_.[*#M3OJI[ @UFV[$_1ZU79F;(Z;PVAR(>>)RY6N[-HU)
MT6 OWLP>!["KH;/1YLD\_*B7Y \FM'LSZRJ)@?,6<.2!8:M(MHWH>Y.+ 6%;
M%ZGV!@N]F:^K.Y_2[U&Z+U>T?J.]-.[NX>Q</AZTGOBCLL+Z:BKWO+);AT>8
MJK'K).QH[;I[*09Z[UQHUI41QV\1%!E71-*KMJ&45,9'2\6$&S$E]3K/4Q)
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M4TK9G'UML0)>6,8M=EA;8TT8'[2DM!F#$LF.P(#'7J=KZ1K^4Y06)?<S\PZ
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M;;RZ>@V%G5 1G90M\F<O+VB>1;UMQ);23P75P% 6.')7Q5YNMS(CU )#P+1
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MT00V>JHQ[".1]5\-A$7V"R)XK T1/2VAN3UV@]]%9VV-Y<%VAO/ZRH93^C7
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-PB?3Z>5(OKA$X1?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g96389g81b24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g81b24.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D04&AO=&]S:&]P(#,N,  X0DE-! 0
M    &/2^8X@X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!7P           "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         ,<   $3          $                          0
M       !$P   ,<                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   ,<     4F=H=&QO;F<   $3    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #'
M %)G:'1L;VYG   !$P    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      .?0    $   "@    =    >   -F
M   .80 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
M= "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($
M!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"
M!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,'
M)9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'
M!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T
M\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]57-]*ZQ
MUMC >J8SB+LW[.US@*7,98&>EMJ</T[66N?6_8[_ (O)S?YU=(LSKOT,'_P[
MC_\ 5)*=-),9@P8/8G75 KKS@]ILNK<P?2:VHM)^#O6?M_S4?JIL)++R\?KC
M\JS[/D-9BN:0P:![262'?S5GT<BMG_6<B_\ T=2E=B]3#ZW57O<QK:FVLW-!
M.WU/5>UQJ^DY_H.?^_7ZB"G2253IM6=3B-KS[1?D-)W6C0$$[F^V&[=OT5;2
M4I))))2DDDDE*22224I))))2DDDDE*22224__]#U59G7?H8/_AW'_P"J5? Z
MGGY'U@S<2UI;BX\L8UK'0"!2]C[;GUL]]S;7N8QEG_GM9M3OK :<8=69#AU.
MK<]Y&HENT8E=+?YEMG^GL_FTE/6&8,:'L4)C<L.!?96YOYP;603\'>JY$L]3
MTW>D0+(.PNDMW1[=T1[5EXC/K6,BLYMV ['G],*:KFO(@_S3K,BQC??^\Q)5
M,LBOKANR_L[VACBTX^^(#?3:US 6^YK_ %_5LWO9_HE';]9 \L:Z@M8T18X?
MSC@7_0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #) 18# 1$
M A$! Q$!_\0 '@ !  $$ P$!              @%!@<) 0,$"@+_Q !+$
M!@("  ,$ PP%"0D!   ! @,$!08 !P@1$A,A"105,2)!=Q87(S(W.%%A<8&T
MME61EM?P&"0E)C9"<Z&Q)S0Y8W9XM<'1\?_$ !H! 0$! 0$! 0
M   ! @,%! ;_Q !)$0 " @ $ P0'!0,(!PD      0(1 P0A,04205%A<? &
M$Q0B@9&A,K'!T>$58O$C)#-"0U)RDA8T5(*3E-(E4U6$HJ.RM,3_V@ , P$
M A$#$0 _ /OXP#%.]-I(Z0TYLO;SFM3MQ;ZXITY;UJQ6DO.FYI.$9*/#LF0"
M10$_&5,3.')DE2LVA%W9T5BHBD<]._P!&7AESDKW*S7%ROTY7*SJU&EWU2AK
MOF.U*_L;7MA=_ HJ?1>5#9+.*J\7/D1;2I8V6;(QJ*L3/1\M$G.X.P.L9N:D
MDG2=_2G;37T^5,G0U=M'K9!XR<MW;1RF59LZ:K)N&SA$X>(BJ"Z1CI*IG 0$
MITS&*8![ 1#!D]& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , PKR+TI$<C-';.T=/3DS6XG9M5?5A[.U]5-&7C$W0IJIN6HJ
ME.BL0BZ*8.F;@AV[]F=RQ<%%%P?!4Z:>]-/Y$%ZG[/77^K-"\DHS<BU,Y!/]
MB!)['?-9S552KE"@9RG:O)3:P]J^O$"RT-#S+*)B$EWM@(LK*R$FZ>.Q70(J
M1NF)]VM+LLDSP(332X8\:D4BE322U)5$DDR !2)I)L@(FF0I?0I"$*4A"EZ
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MH,E?*RPN8-S.S5IW)H(2I6A&Q'BCLS90Q3%:I-54UU7)A!!(BA!44+X@ 0*
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M5JDPF9I('9GI&WT&KHB7C52$H+7:5)OIYJ_NV)(%'Q% P?(0 0_>'>"'. ,
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M1XZ>E_! @_@)<314#($,JHUA5W;0R9O/ R3S\Q?S]W7K[JKY?DCNMO!NEV*
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MW;^6I/!#!G O\S7C;]E%7_A1P"6^ , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , ZSK(IG23453347,)$2'.4IU3E*)S%2*80$YBD*8X@4!$"@)A#H.\
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MN7A;QG!T9,[D-15,'!T2F(B=<&0 L9(AC&,1,RGB$A3&,8I1 !,(@(Y3!+W
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M:I)MVR*3=ND0J:2""1$44B%#HI4TTRE(0I0  *4H 4 #H P#NP!@# & , 8
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M$2!7R".K54R"Z!@#YN!5#>)JY0,/1C" 5\W2OC?GM!D;S/:9?T3PG_MQNO\
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M^JX4^U^P+_J_,[@H?*OPB0VN.%XE-^,7WB\ 4W[2_>P$/Z^\>W\3_P!OS/\
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MM)K=AE8]--1)-L_E8EJ\=$236$5$D!55.=!-0QCD1,0IC&, B.C#W?G[C)>
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M*P\3.LU(V;BHZ9CE3)G48RK)M(,U%$C@HD<[5VDL@8R1P Z9C$$Q#@!BB!@
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MLK!BVC&-B<>^,%_/G64:Q91S265\3]LQ:-FB+@B#=),H6^WSO]^I>@
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M.R\%]QF/];_"_P "Z]]?[<>R)_X,/_,<5D?VE\/NF66\O!??$^H[-&!@# &
2, 8 P!@# & , 8 P!@# /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g96389g84h47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g84h47.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1F,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &7"^91(X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!7P           "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         ,,   $>          $                          0
M       !'@   ,,                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   ,,     4F=H=&QO;F<   $>    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   ##
M %)G:'1L;VYG   !'@    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !CA"24T$#      .^0    $   "@    ;0   >   ,Q@
M   .W0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M'OMLV?S--7K6_HTE,>F?\H=7_P##
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ Q0$A P$1  (1 0,1 ?_$ !X
M 0 !! ,! 0             ) P4'" ($!@$*_\0 4A    8" @$" P(+ P8&
M$P   0(#! 4&  <($1(3(0D4,15!%A@B,C=15WB7M]4CEM07-$)A<8$9)#-2
M=[,E)S9#4U1B<W1U=I.4H;*UMM'3_\0 &@$! 0$! 0$!              $"
M P0%!O_$ $81  (! @,$!P4& @D!"0     ! @,1!"$Q!1)!408387&!D? 4
M(J&QP18C,M'A\15")#,T4F)R@H.2M"5$4V-TA++"P__:  P# 0 "$0,1 #\
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M4_F6;"24;/S-Q7(5TT04( @42!FC!M=@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , X&33,8AS$(8Z?EZ9S%*)B>70&\#
M"'9?(  #>(AWT'??6 <2((I&.=-%),ZH]J'(F0AE!_6<Q0 3C_K,(C@$?WPW
MOT0;=_>RY+_S*DLD=%W+Y D&R@Q!>-X4+7DP$%9%;"F_%JD\ (NIV*:;>BMW
MX#\W%1KML!Q$! R0J H4?J4.^\^Q@=A;0VC1]HPRP[IJ;A][B\-0EO1M?W*M
M2$K9ZVL^!\W%[5P>"J*E7E64W%2M3P]>JK/3WJ=.4;]E[KBBS5_D?K"RS,;
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M5!\E$DCFZZ[.F4P]?J[, CUE4I+237<VOD2RY+R.)6[<H@8J")3 /8&*D0!
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MUU9MK:I1I%5=3+%[*WS7YW\A 2"\9)1\(RM4>ZF7Q';=5%8J+1DDHLY3(?\
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M")IT&QF4'AP4=)2+=BB1T1PH!C@=8JI3 <P&, F[Z$0RF3*6 , 8 P!@# &
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MT7V]R^ ]]#U@'ES6.9+=8N,!ZI\B[V;/0JZ @42FC6FJ%)U!H'MV":<LF5X
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MQT6Y%C$0*D!Q*,22TRX^O@5MZ-O*^3OESUT[38+*08!'S\-[]$&W?WLN2_\
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M.N1S!<OX,$ER'&)LS%(DX^'+MY_3Q-R27-YY-M-M6O=\5DXNSY\+,_0)E,#
M(^?AO?H@V[^]ER7_ )E262.B[E\@2#90, 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# ,9V.P,WTE&Q;%=<'<+>:RSDR>*B1"B^;NG228'_)*NF=(
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M$P>4YC (^?AO?H@V[^]ER7_F5)9(Z+N7R!(-E P!@# & , 8 P!@# & , 8
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M .C@ 1.]\GES7R*TUD_FG\C'_P -[]$&W?WLN2_\RI+$=%W+Y$)!LH& , 8
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M=V3M?@\Y2L[/16U)\)-JH]C9!FD9(BKMB[:IG72%= BCA!1(AED0,05DBF.
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MFLO7()HUD70%#H1=2IR*2+@Q_<RGJNC <P]B'TZ S[@# & , 8 P!@# .(F
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M ("(&Z ?$??V-T(#T/OT(#]^3ZZ% G(!@*)B@80,8"B8 ,)2B &, =]B!1$
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M@@K.\DH]B1U(:=KT@S"&5BC1\#<$W$V4JRZ;@JWI.$TVQSE$G@=,IPZ'OW$
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M*[A*-UK;N6O.O]F\IWOJJ RU1#"L6. Z*TC-21A"-*<J9?529D #*^0^9O<
M^[]>9ZSHI"T7/:]=)U/>C3H4\ZEKNTJG"UUGG?,KCTBG=J&S:-]VR<ZU3\*>
M5U!9.^NOT^ _Y2QKL5CZ\U]-%"27D3G871RQ!<56:;/TBHNVA!(F'IE5*!A'
MHQA$?IWE=+HI5@E_$MHT&J<::C/ PJ-)5'/><H5&V\[-<K:V"J=(*;E?!8*K
M>;G>&*E"]X*-E&<++2[N[YNUC@G*<I7!BN":QH#+TT91$J+^\K++G+)/"NA$
M5&S-1,GH 4$TP$WN4 ZZZ\<2H]%$MW^*;2G>5*3=/ 1C%=73W7E.HF]YO-D5
M7I!=26S\%&RG&T\8Y2]Z6\G>,-U;MDK9Y<M"G^!_)RS)J-Y"=UW06;F*C8QX
M:-1DK-*+)QGS9D?257!FV2,H9XI\P<3&$2]>'8_2^U]%\,U*G0VCM"<:M6K#
MK72PM)2J[B=XQ<Y-15.+BE:SU86'V_734ZV!P<94X4WU<9UZGN.3R<MV*OO-
M/7)LJAKCDO*&=L)?:-&AX]Q)MY%:8KM:?J3RZK=JR:I+H)O5TVC14B;%(PE\
MU2BMY#^:./XET8HJ%2CLG'5ZL*4Z<*.)Q5-8:*G.I-QDZ<7.HFZDU>T;1:RO
M=!X/;M3?A4VAA*-.=2,G4H8>;K/=C"*:4VH1?N)M7=WQ2UK(Z.V]!JHDK>_9
MATT,LY<NOPJ@&DH\;NWIC*/G$:LW<-BI@\7577.@J7P2.<I2&$H#F9;<V-B$
MWB>C]&$XJ,8>R8B=*$HPLJ<:JG&=^KA&,4XYR2=UF/X3M*DTJ&V:LDW*4O:*
M,*DE*><I0:<;;TFW9_AO:+Y44^,4M()I)VS=^RIHJ2#5L1".78P#5)LR5!=J
MW3(V3<' B"X%53,*@F Q>^_;++I12IR<L)L/9=!N4Y-U(U,1*4JB:G)N;BKR
MBW%Y:/NM%L&I-KVC:V/JV48I0E"C%1B]Z*2BI6M+-9LN*7$C60'!1[,;%EC>
MH*IPD;O**IJ*F 0.H9)($2^1P,8#&#HP@8P"(@(AF)=+MJ-6A1V;1RLG2P-)
M-*Z=DY;SMDNZR-KHY@7^.KCJN;?WF+G)7?&R45SSM?-GP_$C6)GJ*@2%W"$3
M$3+50;9(&K[HP^("19L8?5] Y2^*K<JX)JB/D;WPNE^U5"2W,"Z[M;%^QTEB
M(V;=U-)+>3>4G%N/ OV=P&\K3Q:HZO#>TS="78XO.S6JWK/77,OL7Q;TQ%2Y
M9<E84?@CU\G%2TB\DX./, B/FRC':BB"1@[Z#R\R]?0 'WSSU>E.VJM%T7BE
M3WG[]:C3A2KU.R=6"4FNZW:V=*?1_9=*KUJP[G9>[3J3G4HP[8TYMJ[XWOW&
M4V&NZ%&&\X^EU9H?OOU$(*,(<!_U'!MY!_N'/E5-HX^JK5,;BYKE+$56O+?L
M?1A@L'3=X87#P?.-&FGE?BH]K/6HMT&R8)-T4FZ1?S4T4R))A_L(F4I0_P!P
M9Y)2E)WE)R?.3;?F[L]"2BK))):)))>2*N0HP!@# & , 8 P"U3LPTKT),S[
M\3@Q@XJ0F'HIAY'!I&-%GKD2%[#R/Z*!_$.P[-T'> 1D\7?B&RVV+*[:[II=
M3U)4;1IB(Y%:PLR-O/)HK:KFK9,U!N%V%[&QC>"L"+^)(LJ@U7?LS)OD2D=B
M<I@R)IZ9_N_R_<K5EQ[;JRY_+GGQ/$_#VY2\<H#4^U&LUNO7$4X=\H^14HV0
M?6F,;JKQTCL.0<L7J1%%RB=L\0,59!4 \%$S 8HB&%DDNPE^'+ZF^/XX/%K]
MOVJ_[X1'^(R@?C@\6OV_:K_OA$?XC 'XX/%K]OVJ_P"^$1_B, ?C@\6OV_:K
M_OA$?XC *8<QN*HJ&1#D%J<5B$*H9(+G#"H4AA$"G,3YGR AA*8"F$  1*(
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M^QZE/G]Q16(!R;2CQ*/T$63X/N[[Z,@ XZ^G_C\827GEEXD^UNQLO>QF:O\
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MLN'-0V>MJW";-2@9.NZ^U/!S$K:&].8-@CDD'T:VDY-X]7>RY5U3$(@!@+Z
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M9K5,W8K^F^.-H@XBQP6G=/OX6=CFDM%/4M:4\J;M@^1(Y:N" >$*8"+(J%4
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M%G8U:1?-7\7K\C,_'63S=]6UIDEIP2783"8,# & , 8 P!@# & , 8 P!@#
$& ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g96389g85r44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g85r44.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1A04&AO=&]S:&]P(#,N,  X0DE-! 0
M    &#2^898X0DE-! 0      %@< 5H  QLE1QP"   "  << E  "')R,34Q
M,3@Q' (% #=-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3"YD;V-X.$))300E       0KL:A&!*MO[R?^S3G0M4'
MG3A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!9@           "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         2    )?          $                          0
M       "7P   2                       0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   2      4F=H=&QO;F<   )?    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $@
M %)G:'1L;VYG   "7P    -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $    !#A"24T$#      -O0    $   "@    3    >   (Z
M   -H0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
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M;MJK/K6;&,9L_P",_P!$I7=6S&5O(PGAYTJ^FZ=)]S16WZ.YOZ/?_I?W$@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                _^% %&AT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B
M(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X
M;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O
M<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @
M(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N
M;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@(" @(" @(" \>&UP
M.D-R96%T941A=&4^,C R,"TP-RTR-U0P-SHT-#HU."LP-3HS,#PO>&UP.D-R
M96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^4%-C<FEP=#4N
M9&QL(%9E<G-I;VX@-2XR+C(\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @
M/'AM<#I-;V1I9GE$871E/C(P,C M,#<M,C=4,#DZ,S@Z,#$K,#4Z,S \+WAM
M<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(P
M+3 W+3(W5# Y.C,X.C Q*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N
M861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!
M8W)O8F%T($1I<W1I;&QE<B Q,"XQ+C$V("A7:6YD;W=S*3PO<&1F.E!R;V1U
M8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C
M.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @
M/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M
M($EM;6%T:6-S("TM(%)E<V%L92!&+3$@,C R,"!&24Y!3"YD;V-X/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L
M93X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/G)R,34Q,3@Q/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@
M(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @
M(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z1#@S-D-!,S="14-&14$Q
M,3@R,D4Y0T5$1C@S1C)",D0\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @
M(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z1#8S-D-!,S="14-&14$Q,3@R
M,D4Y0T5$1C@S1C)",D0\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX
M;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#I$-C,V0T$S-T)%0T9%
M03$Q.#(R13E#141&.#-&,D(R1#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z1#8S-D-!,S="14-&14$Q,3@R,D4Y0T5$1C@S1C)"
M,D0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C M,#<M,C=4,#DZ,S<Z-34K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I$
M-S,V0T$S-T)%0T9%03$Q.#(R13E#141&.#-&,D(R1#PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,"TP-RTR
M-U0P.3HS.#HP,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F
M<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O
M97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z1#@S-D-!,S="14-&14$Q,3@R,D4Y0T5$1C@S1C)"
M,D0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C M,#<M,C=4,#DZ,S@Z,#$K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @
M(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z1#<S-D-!
M,S="14-&14$Q,3@R,D4Y0T5$1C@S1C)",D0\+W-T4F5F.FEN<W1A;F-E240^
M"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z1#8S-D-!
M,S="14-&14$Q,3@R,D4Y0T5$1C@S1C)",D0\+W-T4F5F.F1O8W5M96YT240^
M"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I
M9#I$-C,V0T$S-T)%0T9%03$Q.#(R13E#141&.#-&,D(R1#PO<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P
M/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @
M(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D
M93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X
M.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_
M>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!#
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $/ CL# 1$  A$! Q$!_\0 '@ !
M  $%  ,!              8$!0<("0$" PK_Q !6$  !!0 " 0("! D%"@L'
M P4$ 0(#!08 !P@1$A,4"14A,188(D%65Y33U1<9(U&3)#AA<7:1E;;4\#(W
M571W@:&QM;?1-3EUM,'%X25"\3,T15*E_\0 '0$!  $% 0$!
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MSD8.#7T$NQAAB8Z6667,LL'7+(XHF.EE<X)$CC3XCU:Q45=8U;(A%DUYQ7)
M$YBD$)).P^E*\.Y.P]KN>P[Y)KJ^DO>;2TU/3WU)06;3UNUFO*H'(EJ@D,X
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M&XW'?)AS#FYCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9'=3K<SB*4S2:^]J\Y1
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M^OV>GV\\IU/^Z2ZT<D:?HNAU4_@LZ6YY/S\K'AGW_P #S'UYZ3'_ '*W3E9
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MN*GM+NGM]37DV<;'E9N@%S5WV .$9+&MD-1159$LA$['OJ/K_?\ VXVV(W^
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ML $*&>+<L">YZ@\YK/4\<8QQC'&,<8QQC'&,<8QQC'&,<8SX%$1"#$%SO2.
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MT>7GEZ+Z\JL1D;/L>PBRXG\F>H_ 2DI:>QES=O8YG0ST,;2[)Q<GQ2Z[_O\
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M #=VMH5%,,DP<TYDTPQ,T;T<EMB6TP5;$C,)"+*@LK;F5%7Q#Q)V9D100=B
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ME+*VS3VISW>>>38%W<[G;LJC95  S\O^K^K]:ZVUJSKFMV/%L3MM%"FZUZD
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M)SQ=G2-*JBYK.PIJXT>JGU$;K,L.9_\ 0,8W)]_O)/UGM]>W;;X?[,P_V/\
M0[XJWR/9TV.[,.M^T=KT1H.J*[1=HXOK*Y'AT5AT===!5NN305F!9L<D_P#
M>W>):#XTX(<LELTL@1%>?<4UHRH8[@_ CWGX[DCOY_[?R]\\=8_1.M_ "B&[
ME[7MJSL7%V6GFZ_U'6;LQ.1FX;;?XSLBFO=+<7?7=&#V%NQ-3E9IK*]M<;6!
MVE?;)6%UQ4M?!92OS_O\?W_FP3W/'L/@?S_7O[_CO]?P[!Y6HL,_G*6EMM);
M;"RJZ\8([4WL-2-<7Q4+$9-9V(]%75%- 44_U?)%6U@(C%7VPCL:B>K+<D'&
M,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'W_?\
MG_,O_=QC.86O\*.P+VYV]A+#U#KH]!VJN^,(V)6K8=V;F)8Y(PNN.S$%ICXO
MP>R*O8_.1#ONA%</"OR +UD>O2PZU!&D*@W(O#J>KJ(?"*UI=P6L5N3J?$EV
M^DW\,]_OF[9Y3=Z$U&Q->D(T:Z+.KG49&O-<\35JA!$>EZL%@D4U:1(-4*9U
M]E=HXCN3:JKP.[2I):,\;L7(6=M1UPD0I-^'=60JG!^,_:O28T1 LL+GFU0N
M@WM6>P<@CXL^<K2H9G(8^."2]]=K.'4UY521B6"%$;8ZG5O$@@[*[1P,I(&R
MR,"/9[BR'T?ZM7\%TU*C+-!$@1[$<\J^(G2NJZ"JNA4%X$LZA%*$=BS58G4D
M.0F8UB^C>[1;1T=83?\ 51LM9;; JK0A+0.#K]NK+Q9L%WA1LOC,M2AW= 7G
M+0VM$#S^?!0FT1Z3MF<:43L_*.KS=ECM+R6$,058S^$LRE)S+-*_"02*&)DD
M.R;;$<0L2/1?JOJ]>%K.D.89;S0\A+&NG&X]&1;&G)4H5*\<]=ZLKQ(E6LG*
M0'F&,CM*[#Z/+L:YL=+]:;K)OAN9K6&^T\1NK9K>WJVZ[JZU[($C[/?&-$R&
M?"9C$7&4QRUUA:+"FG,C'FIJWXHTN)>H*R+%Q@FWC"^'&1"8:C)2LUO[V!)W
M$TLZS3<E3?PE)#OW.U-Z-=3L/:$VH4RMAIA9N*]P7M9BGU[2]4C753Q 4Z?4
MHV*=+PI9BOK<@5H8MT;TV?T=FNU.E[+/;/T_#F+X*I#RF2AHF5=*4+F-+F[C
M*A:D:KQT5@]*RFI3,XMA97FS(@%L'?5$%6$LM<Y%U#%''74BX94+F:;Q.<@,
ML<B2M$7E*CD[B3BJ0@L/;+-LP7?1G<MVM4E+:**EF.%*E-:XA@9:EJK-4CMI
M#060^%7@>KXDMB^RI)]"L4?*,_*U^CNW\B2A4UUUH#1D6G:$V6I_BZ<8/HV?
M<]@T>OH]SU1 )5MA9M\S45DN=&<YM$V*%@;1+>$&6Q$(+U! -F=++2!:OBN1
M$6N^!7>%X+1+D^!(["0[<R3ONF_%A27T::ANZ03Z5'6:756I0?WTJ=/O?U&M
M=KZAHX2+B-0JPPM57<5P%$8681M-&^[WC?T O1M=IOFB*JPO=AK-MI=%<5WS
MKIKA;S;7N@S:'2&M8]\M'26Z5;8XVM'@D^801JQ2*]\+J.H>O-%L&6.&*"*)
M&(]@1P1QR<>/8!W3G\3V)[]L[WIGIT:!%:Y-"]B[<OV[<T1D+6&L7[%FJ9#(
M 2U>O,(=@ BGEP'$[G9M5]/OY&YU..,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC
M&/3U_P"_[U3_ +O^[[N,91GUP%J$36V@(=E7&1/@, L!H3 BH)$])(212620
M3Q/1?1T<K',<GV*U4Y:Z)(C1R(LB."KHZAD93YJRL"&!]X((.9J]BQ4FBLU9
MYJUB%UDAL5Y7AFBD4[J\4L;+)&ZGNK(P8'N#FO[/$#Q5CM$NF>.?2C+)LWS*
M$-ZUR36M(]_Q/CM'2J05LWQ/Z3XJ0H]'_E^[W?;R!^2?2_B^/\G=$\7ESY_<
MNEORWWY;>#MRW[\MM]^^^^>@MZ8/2NU3U%O21UPU7AX?AGJC62?#VXF,R>N>
M*4*^R4+\>/L[<>V;!!A!UPHX( @P(0D,8XH8<$0PHP\3?9% ./"R.&&&-B(V
M.*-C8V(GHUJ(G)Y$2-51%5$0!51%"JJ@;!54 !0!V    [#//)IIK$LD]B62
M>>9VDEFF=I999')9Y))'+.[LQ)9F)9B222<JN79CS#?=?6)/:6?S]6+-1J_/
M[*CUCJK4UC[C+Z".G0ICJ>_KF/120Y%*:9"CF3-C/"$F=$](^<YU-H;Z[3J0
M1M4)J:E4U U[\!LT;8K<_P"][<((YQGF)%[,%FCC8J0N=CT7U-'TMJ&H6I$O
M<=0T:]I(M:79%/4]/:YX1%RA9(/ASJ(C"^Q0M7FF0.I8'-=3_#ZQ/L[TOZ_R
M==]8MM9(+.JS<H5\8MS)F7_4ET8V9_Q\QGTSRQYVM8Z1HL1$;/;#\!SI>/E]
M'D\L]J4V]/A\;QV6>M3:*U(+!I'U6S(&/.E4%0K3A!(C5E4!0G?T.#TO5H*M
M&$Z?JMCU<U5DK6M12>A#ZFNJ#UZE"8U,>IZ@=1#:C98 S/&[$MS 6AL/#O2%
M6V4*CVN>:#F]D?L&JN;%2Z;.9VQH.PY!Q[OY*6X<.16W45(\)MF)7C3#%&(*
M6MI,D.&7T<W9)]/==4J"*CJ4NHC>E'ZR&EZAN:TR):\,V>,D%E:IC\=(4:-Y
M/#D,S;9J_I@TZ*IJT3:-J)L:EHL&CG;4I33,</2>G].I*]+QEIB2*Q2:ZLQK
M2V)$DBB\6(54YV6F\(;2G@&>EKUP8ZNGJG)FY\<0W&:E*\*[$=:;.L4F5;.^
M8ZY5XQBLF]J#HBJU9$6'5K>C":LB%9]&?PGKDTFTYQINH"&.TAFU*#FWC6@;
M/))2K[>& ?,%=^YZ;:MR24&IU'"+,=L?=*/6(SK.E>L34I14T:UX2FMI["F%
ME@#)OXFX!XD/(W^&3QLU<5H5WE3]#9!]9T?X27^1JK6P_!C#Y6LH+*B@*M +
MB:J&MK"M@MX7 M?*.\<5B2-(AA,@W6]&YCI688;-":W/%H=7UR[IU>Q,:6E4
M8*LU59;$-EH([$L"6%\)2R,B;,) LBQB^F3Q-3J69Z6JU]/K3]3WON;I^L6J
ME<ZGKNJVM0JWI(ZD]-;4E."R]1Q.0LBR3-Q:.1X7MH_A#\ D.=E[F(#X&8AZ
MZT7-MBV09&7RUWESUK;9%^/##91V01[6_,,<A%; R?XC8XG-P)Z,.#QN+5!9
MU&EG[HQT@NI124*%FC*8+&W-%F$T4P!?</ @;<*I79E]-OB131FAJ3UI#KB_
M<F74B^CS1ZKJM'5(?6:FWAN]9JT]<GPV!CLR% I9P:^J\+1U&KQ=%/A2:\2V
MRI9>=K,M\/.6K,AU[OL8+>V%<6LL1&KNC=J/9W!\L4B+%0UD"3$RP-G7+7]&
MB<(H[C:4\"6:$DE*"@%HSC3M'U;3([4L$G)7U"U)J:SV92NW"I7CY2% ^8+?
MIGE\2Q+IR:Y%9EJ:K%#J-G52^HU3J_4.@:U+0KV(0CQ:32AT22K3@5@>6H6I
M"D:R&,;C=?9F?%X;)9(HY+(C-YZJI9K!&O:A;ZT.(59VMD5SVM>D2*QKE56M
M]&JOV<]'TFDVFZ7I^GO+X[4J=>J9>X\3P(UCY;,20"%[ D[#89X]K^I)K.N:
MMJT4'JT>I:A;NI!N"85LS/*(R5 4E>6Q( !.YV[Y,.2.1&.,8XQCC&.,8XQC
MC&.,8XQCC&:P>9>C[NR?C;V-?^.M18W?;(*Y!M*'2U(%]H(<^9O,N!V';9FB
MM'LK[O4T/7)6LO,S4%J^*ROJZN#6 A9D'E8_?\OU>[S\LY-=H;[Z0_5WVTPN
M2H>^[S!WN(?1YMFOZER&:%T_6=[U3KFZ[5:V_J&#GYON 3;K655!E!7UYCPU
MK2'5'S!MBZ!E>VWU_'OV_P"!W_I!'EF!JBQ^D?\ 'OK.:HZBZH[PDV5YLPM*
MTI]!7Z:B,AS.#Z*K$S.@ M::\MH(+>-V[4<D:US%7\:FNH9CC;QU,(M!O_.?
MY-^W\V.W?8^_MO\ #X^[ZO/XY*.O-!])5U/+W-E<'D.])L8O</DOI[UVDZRR
MY[\IE=;Y;W=MD-!T(:5++9=AVMKUE=WUXVCNFF($-%7-# C@;5Q$UP=O=\!]
M7N[_ ,_\ONWWS-V<[(^DTDS?8NPU%=W(^FPO4=?9==Y6FZZZ_J-[VC<:?N;?
MY(*VTT9N>T/U1J\CU6/E=UH\I1U2V7HYS!:DBV(#">QV^/?O\=O+<?R^7P^.
MVV:W/$^DT[(_!G0=EP]\(9:8^<7\"(>N:!,9=$8+RK)'J9ME%%6"6&;O;WIA
MM+HHS(?JDNU0:6:.*)7%B<I_M\M^V_\ 1]?P^.V5.WD-O(=^_GL-_+ML#O\
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MNM>>4/"1(_ E8I6'WY\/<J&W'#D1[.YSY7>XZUK#Y)C#*$VU&42M/>)$"?8
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MCC&.,8XQFBOTF']XOY&_Y"O_ /%*[DWTY_EJA_I3_P!ALX/TG?YB=1_ZB?\
M>QYLWTC_ ,3'47_1A@?]5*GD;=_QRW_K,_\ O7SJ=%_R-I/_ %90_P"ZQ9D_
MFMDGCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,906O_LNR_Y@9_\ +R<Q
M3_X";_12?]ALS5_\8@_TT7_;7--/H]/[UO(_Y5=G?^8VGYYKZ'?\P=+_ -=U
MS_QN_GLW]T+_ ,J>L?\ 5?3'_P#&]*S=KGI^>)XXQCC&.,8XQCC&.,8XQCC&
M.,8XQCC&.,8XQCC&.,8XQCC&.,9S#\Z_[Y/Z./\ Z?-5_JU6<X_J/_+'27_6
M5K_NN?2GH1_Y.?[H;_Z%TK_Q*SG3SG89\UXXQCC&.,8XQCC&.,8XQCC&.,8X
MQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&
M:*_28?WB_D;_ )"O_P#%*[DWTY_EJA_I3_V&S@_2=_F)U'_J)_WL>;-](_\
M$QU%_P!&&!_U4J>1MW_'+?\ K,_^]?.IT7_(VD_]64/^ZQ9D_FMDGCC&.,8X
MQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,906O\ [+LO^8&?_+R<Q3_X";_12?\
M8;,U?_&(/]-%_P!M<TT^CT_O6\C_ )5=G?\ F-I^>:^AW_,'2_\ 7=<_\;OY
M[-_="_\ *GK'_5?3'_\ &]*S=KGI^>)XXQCC&.,8XQCC&.,8XQCC&.,8XQCC
M&.,8XQCC&.,8XQCC&.,9^>OZ4[S1SG4OEIXNYY^3M;N?Q_TT?:>FDA)B$;9B
M:RO%$@J:I9F*UY0P RF/FD<V!T\L8JN9Z2R,\LZTZCAT[7=%B:N\ITV4W)B&
M"\EL1^'P3<'VE0%MSL-R!\<^^_[F'T-ZEU9Z*?2=?75*M*/KS33TQI@>-IC6
MFTJQ+*]JT$8%8I;$@A55W<(K2\2"H/?S.W@6FS]%I*U95KM!3UEX L\;H9E"
MM@H#Q%FB>C7Q2K 1&LD;D1S'^K51%1>>H12++''*F_"5$D7<;'BZAEW![@[$
M;CW9\'ZA2FTV_=TZSQ%BA;LTIPC!T\:K,\$O!UW#+SC;BP)##8CL<O'+\U,<
M8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC
M'&,<8QQC'&,<8QQC'&,<8SDA],SY!TG3?B3;88VG.M[OO<DC#4BCO; )515[
M!KFVMSR'L>BM'B8*..&Q/C%3%HYOI".0]G5=(47M:JLX=52DOC."-RY;=%11
MN/,DEB3L />2!GD7IHZAAT;I*6@\+S3Z^ST:Y!XQPB(+/--*WP50JH@]IW<'
M;BKD;2> 7?=+Y&^*O5V\I*DZC;64HF%LJTYS97PV^+ "IC)8)V(UDXI38H2H
M)&HGHV98GHDD;T2,UVB^GZG9@=U?DYG5E[;I,Q==P>X(W((^K?R(SJN@-?@Z
MDZ5TR_!"\ BA6A+&YWVFI1QPN58;<D;8,IV'F1[LW+Y$9V>.,8XQCC&.,8XQ
MCC&.,8XQCC&.,8XQCC&.,8XQF)^\>SJ+I[JO9=A:*,J>LH:F9SA0FHXLL@KT
M$%%@]RM8CYIYF-5[W-CC;[GO7T:O.?ZIUVITWH.I:S=61X*E=B8X@#)(\GT<
M<:;D#=G8#<D #<D[#.JZ(Z8O]8]4Z/T]IS1)9U"VBB68D10QQ;RRRR;;L52-
M&/%068[*!N<TD^B^[>H-OTM;=>@C&"WO7&BMSK5"6L^ 57[S2:/0U1(DL;G(
MJP_W4 3"_P!LC)A4D1%AFB<OF'H*ZCIZKTO/H\*21V]%MV)+"OL5>+5;MRY7
M>-AON%^DB<'8AT) XL#GMW]T_P!(ZAHG6M3J">2&6AU)IU."J8B1)%8T'3M.
MTZW%,K 'VOH9XG7=3'*%)#HP'3/GM^?,^.,8XQCC&.,8XQCC&.,8XQCC&.,8
MXQF,>V^QYNJ<98;5,;J-N%4-6>TK,C"(7<C5[&.?/8L"*)&4J 5K?>0P=[R&
MQ^LC(I$:J<EM%TM=8O1T/7JFGR3^S#+>9T@>4D!8C(B/P9]]E+ *3V)&^^0^
MN:LVB:?+J/W/NZC'![4T-!8Y+"1 $M*(Y'3FB ;N$)8#N%.QSGB[Z73H9KE:
M[#=F(Y%]%10Z!%14545%1;M/145%^Q?1?O14^SGI@]"W49_^/TG;ZI+)[?\
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M$4<,."[)BAA8R***('.LCBBC:C(XXV-ND:QC&M1K6-1&M1$:B>B<F!Z%>H@
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M9.IC*]\CD:A3H&Q*B^OK[4<Y(!NI=%75%T<ZA$-0>0Q+ P8<I4#%H5<IP,H
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M1ZMILL,UA+*>%7*I,QW'AD[<5((#;N2>("G?;MOME9-'U**>"N]602V%+0J
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M'8*!VY[#Q-R=@!WU#3_?U_W_ /Y^]/L].=SG"YYXQF6>D\E3[7L&JH]#MJO
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M@C?--+(R***)CI)9))'(UC(XV(KWO>Y41K&IZN541/OY1F"*68A54$EF(50
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M>Q/?ZN_;?S[#N#GE$7T_X/JB+Z_;ZHO^'T_W_P _&6DC<;,0-MMAL1V\N_\
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MI%%$H5410% &_D/B222?,^_S._)SS36I7L3R/++*2SNY)8LVP.^^_LC8<0"
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M[_CY:=5?CV_]J/U<?(GI/\0:=]C_ &X_%+\;_P!3^._89?W_ !\M.JOQ[?\
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MCC&.,9Q_\Q/_ 'IWT3?_ #CRT_\ (ZSYWN@?YD]=?DT#_P 37.'US_/+HO\
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M,<8QQC'&,X_^8G_O3OHF_P#G'EI_Y'6?.]T#_,GKK\F@?^)KG#ZY_GET7_\
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MD?#G;#/#(YB,D8YS&6X?L+"&9INS$V69+R+YW"LTXMW7$4#B&'NJWP-MH2)
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M=9*11%$RWQMBAPAME-8,/),)8+&]\LO-::?5!#*LSSK%*R)+')[!)"!HQX;
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MJ-8K<]6O'CD.>V!LOK/:?I<%G2M1U"5G,E6:&"&,7*=12TT%J4,1:'.RP:
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*&,<8QQC'&,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g96389g90g91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g90g91.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1B*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &&Z^8E0X0DE-! 0      %,< 5H  QLE1QP"   "0  < E  "')R,3<V
M,S8R' (% #)-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3  X0DE-!"4      ! +=,'SV@4F(];JWT$YQP]M.$))
M300Z      #E    $     $       MP<FEN=$]U='!U=     4     4'-T
M4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I
M>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0%M            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M     #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         ".$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M    \    E$          0                         !
M  )1    \                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    \     !29VAT;&]N9P   E$    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   /      4F=H
M=&QO;F<   )1     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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M<6Q?^[#FN/=GTV^Q*7*:$B6W8?\ H2#R^GS?
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0 "$0,1 #\ N+9,GY+)8I\A,AWDA"34J4A"VV?*4I2OEP*4I0D  I2@
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MBMJ&M!XFM'F  'U 8<6I&BE&B(T1>S=,JRZ*)AY2JJ%3,._+L4X\HFWW#8"
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M"E53D$73A%DIL39!213R"&](8XS>DMAL[)HQPTC()S%)*V%DKII)HRWAQ%#
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MKBXZJ"N-*57Z@, _8(PI]Z3&_P#0Z&U^MLG/_P >N']S77]Q@7Z4N/X%N?\
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MDZQ:GX*N%4"&$,(4K< W#]2N^\/_ +P-.\3(_P#]OV ^6-Y^K/-4[S\F1_\
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M7Z8;J'G^H_7Y>/6OO";ZG^4[8XI*B4(61)V@'_20'PZ)#D%+E#=4P )RJ"<
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M\A_@I-)]: ^D $ ] ;!T#YM%*VT1&B(T1&B(T1&B(T1&B(T1<,A^P77[RO\
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M(T1&B(T1&B($=@$?0&^B*$\GYIA<63F.8&9BY1T?)5@6K\?+)NH>,@8== 6
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M.+R'6G!\8/!'KDQC[<5SWCJ_OER<V]<W^IV+KE;IZY-K7?O</\Z!XA,$!_\
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MZ35^XK#5/,)KU!YKK(9<>MK9@:4HS=S-R6*R2LE.U^ CK@PKU5E9N#BX*K_
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M=R[%+:"D#F2% -C-3&!_\@Z(&^Q^P_WP-O9^CP]URN:&WB^4O[D<#GN9W.T
M1MM49#PW@S0AQ#R6AM?IGL9Z<%XDV'A770X?AKK0Y[H' YV:Z$.:VDS*.#2P
MXA[L[ &OZ-T?\&7O[A'KMOU$1Z[ 4/H -?I\4H*>7IU_6OOR;RHC\*&Q>=,!
M\22)^S!$!6$ ?Q.RA5N7F!,-Q Z0'#F,<IA*(E P4'\:9R]SR<7))%QZ^/4J
MB?=V"H\3)A05]_'C6E:8T(K0X<F#EUL*U&B(T1&B)KG, VMP3G2$2U]@?L@1
M+VX :2DB\XK\G,9(PE I41,8H'*8_)N/-K7%.ZGZOQ>+B'Z67CUG'BU ZL25
M2/QAV(KP+,*"OOY*&M*T..!- 02!B4Y4PV( ?=VZ;>?T?\^NKQJZ?M5RWU*(
MT1:*?X,WW!U!U'R'M@B;<48/'EC#G3,)5HK<A4BIJIB>,3, +*\I3..;813Y
MCG[,GR0 HZHB\;:!R&+DKXIN!IK\O/3B5,?C)]7OF5H,?%MUGC/EK0438DA
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M;YW./UA(;#,;I.7G51P[F\2KJ,/D'J<6<@=FQ23W22"P *0=-C!VJG:;"?8
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M%DPLR<;)1\NRCYI5:/=R2+9"0C&CA)U /X.81,50J$HD14Y1)4<_0[T*%6_
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MHTBI7L\DLA;-D^[NRV.CMMY5(CF;&1% T5%8F'.+9' XOU@8#&M/I 4Y2@
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M(S;JNQM2:7?8A4FI-+-$*D\9/&>563P<4OD;Q0.P;CCRH;CL&X_W 8=X^?\
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M%%Q?])IU5/'B/+3&BIC\9/B31S,#J'N;<!Y=9YST-U#+>+72ADVN2*$X,1I
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M3@/*>@\HQQXU<M]2B-$6B@;D,'[D=0=1QIAKY.=$VXSG&8L91.Y$I58T"%5
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M\OGUK_\ $N_^&+R>-D\_8<ZJ_+'7XH<E/?NXJ5J.CF3B3^L#IMW^;;SCYO\
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MX>7D7#6,;!9*-<*I1I6#08/W+>;?.7$]<H1!@[CXIW%*E<H@X?MEWL:B](I
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M7"27(,(*8 5950_,! .;F$IC"4 *&+<J[_?+)*ZW^&V.%H<++8FT'#$ZFV8
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9J[MAB;=U@ ;@+%90/"<<!!&!B34^?%?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g96389g91j27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g91j27.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %>Z^5A0X0DE-! 0      %,< 5H  QLE1QP"   "0  < E  "')R,3<V
M,S8R' (% #)-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3  X0DE-!"4      ! +=,'SV@4F(];JWT$YQP]M.$))
M300Z      #E    $     $       MP<FEN=$]U='!U=     4     4'-T
M4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I
M>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0&!@           *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M     #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         ".$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M   !*@   ET          0                         !
M  )=   !*@                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   !*@    !29VAT;&]N9P   ET    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   2H     4F=H
M=&QO;F<   )=     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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MJ]7(=LKD-W03SX[0[V_O/5=W6^DM!
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M! ,! 0             ' 04&" ($"0,*_\0 1A    8" 0,"! ,%!@4" PD
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MBY6EKH=1:LU]RFV(X@X==-HD"#4B\6R4(U1*(]J+<AD3 @@40Y*F0H%*(^
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M & , 8 P!@# & , 8 P!@# & , 8 $.0$!]A\#@%"E H  >P?]QYP"N , 8
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M@HRV3$J6"5;7QW/,[_39*R:A?/7M@BHIRG(1;5JI1WC6QLF@ELYF7J*&;WM
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MBS2%:L*C=U"ST4\:JMGY'R3MBV W"P!@# & , 8 P!@# & , 8 P!@# & ,
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MC_A$/("40 0'D!$!]^!X^H?PP2<\ 8 P!@# & , 8 P!@# & , 8 P!@# &
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M'O[<!^_ +-.P\?.QKF,D6B#YFY+PHV7*)T5%"&(HB*@$$#"4BB93" & 1[>
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M":%9SD0K:)90&A&] UOK>,<0CY10\G&2$+7M3TI2)DTWIY!K+Q[B5%RHX?.
M,'AY>.\'0=?AI=.[E;=12R.TVL1U 5=W5=DUMG?G",!(M'==KE7^8,V@QQUV
MDNVBJK#IM'GQ2J:*R:[@&PK.%#"!=B?AT]/:KG5\K,'OMFM&F$8Y'6-TL=L&
M1ME/^5["C=D-%8>3"-03:J?.(PD6N";4J3JLO)&"<IK-W:A\C"WY LTY^&!T
MDV:.?1=@J$]*MW;$C)LNYM#_ ..AE$]UW3?B<E"/$B)N(V2"^[ M!%7*2@_%
M5J1/6W9'$:*B2K'O]=_0G/V^6AG%6Z"="TW?"?4)!IWA.V-+1?KS#UIS=I=U
MKVO7C:;8S;8]M@*HL)THV4N8*+.9MHF[-!+22ZTJE#I21S.AG>_@0;.-2EB[
MQ)(JF[4[/$LI!F<1Y!1]!"=C)MS"/@IO@G<4NW)R)UBE?J  %;*#@%MV+9Y&
MOQT4S@$D%K%:IIK6X,SLHF:-G;M-RNK(.DP$#*H1[-LY=G3+Y6["$\A^40,;
M4UO<4$!D66U;6K9B$%3O?F:+5E=T =PHJ5PK4K%!HL8/1,5LF1=-,3&1.17M
M. +SWOW>B+_5+I)6"DJ3GR;U[%&K2,5*03=R"!3S<2Y.T=((.#@J)6SD"D>-
MA4(HH#==(AR&< )! B@+5; VH,J%#<#+?L0Y9?(OFX>L$>,S'+#* ]&*[!(1
MP4C4&P(]XF6%8%. ,0!'>M/'7P]?4V.B'CMY&-'DC''BGCE$IW$<=8CD6:HA
MR*)UTRID5$/\7>5,@<#P)"B40P28_23'=,Y.</[62>D)9 Q>0*K'E3;Q,.J!
M>! /5AXM@IW (D5'A4AA*<#"!F^ , 8!U7KUK'-7#YZL1NT:(*N7+A4P$200
M1()U55#F$ *0A0$1' -'MC7REWZ53=?)IN)4:%,R;69M\*Z<.F0*',0)&NG,
M@+A@!S'7;'3D EVQ5E/2;%%9=MC>]]"DI)YCKUQG&G7X_(P4K2GQ:Z*C^8>W
M)/DBIHR)B'-9:JD 0$S>5E91T\=)IG 0343C6:RZH=R954$U 6(+-I+/GC3?
MAJ;M:WV% W:*5+%M5(MS#@W;/(544!.R1.0Q6JS8R)NQ:.7*BJ5JN!$1'T5$
MCH(JD%( 33648+U%C_\ "D/_ -4X7^/_  #P0Y_=@2Z/T?T--.?]?&/4P\?+
M^4ON;C=-_/[+3HAQ_P#B$0'G[?+F(CQP'Z^.?KS@UAT?K]D;%8+C & , 8 P
M!@# & , 8 P!@# & , H(<AQ[?PY_P!, PN0.$==(1VL/8A.14C!E/Y!,9)F
M8DNR;G$0$!.LP1EUD>[@H?"+%Y[SD*8#[V>GQ=P;H(22CM)-N=?L%DJFB<Z3
M@@).4%!417(*:Z90 3D(1=/@!163'G ,'G7\)J*JN2Q97#YV\46&!AW#A YU
M70-4T4D06[6XEC6*9$SN5W1UER)<@"JSA9(A^NSL+GB$JE.VE2@XTW)U:[FJ
M,&TU#G=.G5F^:6D8PA.4M<+";7)<\1LN'2MIWL;FI2JUX0E1LU0=U4I)J5:5
M)7->VH)TZ>9.5:M2@FE&4OW)/5O6V\IUE.6,CMFC+&FI. ^(&Q6DT2\:2:X.
M"2ZT0Q192;)Q! T,BNV4(K#MVX,W0*N#-TA^7?'M\9X/Q*XX;Q"RKSN+B[Y:
M523K4Z52/,X3J6TIT6JE",8\^5&$H9Q-QZ+]HN;#V0]J?9WA/&.%\8M[:TLK
M"\J5(V-G:W/Z6W_Q2M+;C<XWM&K9<4E6<J=2%;];.NJ]&I0C/GIRN_0!JZ;N
M4$%FRR;A!9),Z*Z"A%4%DSD Q%4E4S&(HF<H@8AR&,4Q?S%$0\Y]+OQ^I^1=
M3[G-VEY_E[<<\#QR/C@/H(AP(?</? ,-IG>[1G9SN[T9Z>>N6"@\@92+8E2B
M&*Y3  @H@\(P/(,U2F,55F\04#CN[0 S7 & , 8 P!@# & , 8 P!@# & ,
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MFZ#9N@W;I$000131011*":2**10(DFD0@ 5--,A0(0A  I2!V@'& =C & ,
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M89DFPCVI&C9(3& A.3&454.915990QCJ+N%5#"HLX5.HJLH85%%#G$1P"YX
MP!@# -<>I+D:[70^TZH;^(1[D ']!#NP#3X?(_P#Z<?3!A+_ &?J4P02-J3_
M .8]2^WS!T(_;_[K?<?ZX-8=/?X>6]LW==I!$RS=^V J327=%92B90$$Q>*%
M-\O?%)QZ95U5N63E0!(+D'#8#=ZR"(XW^=^)<Q="Q,1V=(1/RB3!3]GHAE\^
M&/)\M^-%S,/ABP>"<70G,W,10%BH P%5(6HNBO"D1,!*28 !? \^1^O/ _4/
MK]>1$!$1Y$?W !SP!@# & , 8 P!@# .)C%(')C 4.!'DP@   >XB(^ #]^
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MUK&*K"UOE):QURPP<M'0J(B4QWM6DXQM9FS\ZO:BA%K1))%=91%)-L8ZR8&
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M"W^L&7Y^X>B"G(?4.0P5DVDVMZDPE#CS[<@' ?H ?O'Q]@^F"QRP!@# & ,
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M6=$JD--1T# 2<3 Q<4]<RCM6><++LFA&@.3QT0X8-N%@1*84/G0G #E 3E4
MZ96]5_S&] 9D=I=DBJ+'ME;3$I1.H*U0>%9$3* F,8"EN23E,I"\B8RKXY"
M B)>.T AM)-O1)9;Z+Y_\\P5&7ML5VJ24*PG6/'>L^K*RJ3TB8!^9<(.154.
MN0I>3F09RKQWV@ -D7BH@02:>,8>4G[GG#]XVC)(F<C9QF#^+<D=-A.HF)B@
M<BB2R0]JB#A!4B:[9=(1 %4%TTUDN?SD+D@N^ , 8 P#B(<\!^@_?]/'CZ#]
M0_C], \LO2] 00]O1 J0_3CTP @_NX[?X8,9?[/?<=!@D=)$QS&.8KLK&33
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M)"J=\.H!!/X #J$*<Y2CP8Q4EC '"9N!:2RGY:_ U?\   (F$"E* F$1'@
M Y$1_0 \C^@#@RC_ ++UW^/,],ZNFHE6J^DJ0Z:B4)%)G(<.TY3$8H%,4Q1\
ME,4P"42CY 0X'!N7W .)C"7@>.0YX'[^P\<?QXYYXX#D< L,S98R#^&3=G56
M>O1.5A&,4%7LF^.3CD&K- IE#$+R'J.5/3:( /<X<(D 38!9B.+S)"8Z+*#K
M2)A'L++BM8'X 'D#.&D4_BX])0PB!!31F'94SE'A=4O8(@?4S>_$#N";J#P
MY_X8:K-1OJ>!X+\9^V$IZ?YO'(,%_N)>.!P"++RO:'=CUD%DKR;"J5ZWKV6Q
M6*/D"R,2F:,K\LUKQ'"7I(2K(JDY(M70JJL%6#<&93.9!NH9(@@3^@LFN1-1
M$Y%454DUD5DS@HFHFH4#%,F8O)3)F+VF3.43%,4>0'C@1 [& , 8 P!@# &
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M7SP14H?XBB./'?Q-ET7IOH0OU*,S.;'"$)X%] ?!E$?\W;(NBF 0$/\ *#L
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MF.8.?/&#3.89?AZ=_P!^_P"1KU5SHR=FB&I2'[&]K@F:Y52$%)P /XMTJ!
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M:(G_ *OW?4TK'CCGD \!X']"AS^GCZCSQ_,.1B;(*H KTVQH"4>4I9POYYY
M M\F<##]@,!@$O'(B4Q1X]L&F&X);>NGQ[B&Z''@G<:(V$O<,I*(R9A  $3B
M>R3R1#"/UX3BB)@)@_P$+["/@3&+3R\=-YT\O?UU3/2$@<!_$?X>>!_U >?U
MP7*C[#YX_7GC_4/; -9MHW.2@E)N5B0 D@4X4JN.S]OI1B@-&DW9)<I3$4*L
M=5=S%Q!&WII"5>*<J&7[>TH"LI87T_.]32XTFZ9.9$\P]1=K.OCYD'!CB@=1
M98_K.V_8LJH)C+NCJ+%.53CM7,D)")I)A@Q;?5OQ[^X[\]8I]P+"8G'J#AI%
M0\9!)LR<$!HQ:%3;LTTG!@*0Y4EEUU#=Z1#F!P<3*'$@BH+.7,DL>'?Z^B+2
M*TL1LC(K2+99@V.\=E9IB<R!$'P)BNFFX,8R0*%%!!4RGH%]11+@RA"G4,)_
M'?F5_)<$9.P.FLHRBII!M#N'[$ZL>1L+E-TYB3+CZZK@CI/M%=)T+< !%0$B
M% X&.H':5O?SWJ3S2>F=.C6F<>37CII@GGIU,E-V*14!O\4P=U=VTE"BF8Z"
M:4@HS4!HNIQV%,MZ1DRIB(',5,X%[A3.!1:'5^G\=^_D;;TAP?Y0XB%CJ+.*
MQ)O*ZHLH(F47;,.Q2*<*''CU%UX9Q'*.C%_+\89<H 7M$H#4S+ & , 8 P!@
M# & =%X_:QZ!W+YTU9-B&*47#I9-N@4QQ I ,LL<B8"8P]I0[@$1$/;Z@?!.
M9C%2E.G(QZA3J))$,F\0.4RBZ(KH)E$JA@%19$IED2!R95(!.0!* FP#FWE6
M#M))=J]9.D5U#((JMG:"R2JY2G,**:B:ABG5 J9S"D03* 4AC& H%-V@<OF;
M(1X!ZS$ ^)Y_XA+_ /)B(._=0./A3!VN1'@$!\*" CP 'R:S,8^10<,I*/=M
MW2*KAJNU=H.47"")@*LL@JBJ8BR2)A*155,QDR&$.XP> $"C6:BWJ+=PSDHY
MVW=F4(T<-7B"Z#DZ/>*Q$%4E#IK&2*FH*A4C&$H$.)@#L,  =Y!PDZ2(N@JF
MLBH0#I*HG Y%"F >#D.43$.40'P8AA >.0'SP $<H.73*;V,Z9,59)\DM G3
M9IG*114@PK8"^F93\IA(3U5!('!U!3],@&44* @15)[,^*>JLVM-AK_8Z?$J
MRS^6]<K-K!LG(E*LF<31<J_:2QS-4P=,&+917L32<JI-$SBW1Y;FG;17ZFXH
MQJ?IU*I&;I1K5*>4N9T\J4DVDE^W&$\:):8U53475J4U+LE*2S#FDL+7E23>
M6O#XI:D8TA:M;3VL*$S5%*B0D&K/NZRVDW#^"MT@5^FB22=$9$0C#)-2AZIT
M7+=JN\<J'7417%50P<=GQFROJSHT)5.T4'449TG%."6CYX.=*.&GG-1R>5HL
M'+;WUO7K=E34X3<.=1E'_:"REK"4Z:QJVLY\>[.;;T@].M8>82.6+B;JR@E"
MQ[* !TW?G;HF3>$:/8^"2, H.$2*()?,4TVYP=<B<O\ =JI^JGE9^NV>AIWF
M?:_K6G+=#Q4[7Z[59!9HT9).O28MU :R2+=,JP.V8I@U%^DL10JSE1N+@71%
M#&4,NF=0)(27<DO=@CRSO[NIN><?:Z:)OVD-38N(EU8AM&N# \7D%'A6LD:2
M=IHKKLT&Y/A46"!WK=!PJB)A*J)2?/\ $ZO&X5__ &-&%2U[)-.G&BZZK+.5
M-5ZT5.EAZ1I14F^LCR[R7$E7_P $(NV5+.84Z<ZG;9U4G5J)<O+JE"&7XO"1
M.,0I)+V"E*RQ!),*TJ:5F4_0(T%-<SVM'3(HV(X=%2]-8SHH%!=4.XINP2<"
M0/9MG5=O1=9YJNG%U/V*G^]K7_&IU%##TPIR]?#TJ3FZ<.T_W<8N>4DU+&6L
M)M+7KAOIH\$GYN7& , H//'CC^/_ -/K@'FUL%("7J\M!_RV62+Y$0#_ (PR
M;L.?;D#"Z#C]3#R/.#&7^S]=]3-=W-_AKL@4P?F5K$ N'CCD"IN6?''N(<LS
M>1'GQP'CC&_#>_ O):Q>>]+&_0VBTPCZ&LJH ?X5VCQZ3V\DD)5^^(8./_<1
MP4WUYYP7W_!)^ , 8 P!@# & , 8!\'2(.&ZR!O\*Z*J(A]!!1(Y! 0^H<&'
M[^>/ ^V >6Z2(C".950H_P!TO"B'//!3&CK&JL7GZB8!3 P#["7Z>^/#YX[_
M *[\3-R:;22TQCKHL?#O^1Z859'X6M5UIQ_]F@8=#]WI1Z"?O]OR<!^O./GO
MW&AWWD3&2#AB[?1[)VZC%3KQKERU07<,%E"@119FLJF=1LJ<A0*8Z)B&,4
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M;X%EZC=7X-KZK0ADVJGPZ7J-DS!VF3;G[.Y$AB@!3%3$I1 .! 0P#L@ ![
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M*0R?K-7:154Q,F< .DH4#"19(X =)4ITS>2#DDF0X P!@# & , 8 P!@# &
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MY#@#U"_?WY'V'Z?N#^O'W#D "A1X\^X\!SX\CX_WX#]X@ ^?& <\ 8 P!@#
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M!33DG%DLJ,4-)BS4ME%MY%V"8;\-[SDW Z#.E_=G35-;B;[:V*GLJOS</I6
MUG,N9!^^L3*N4.CKQ;Z'M O#'(O(04E('@64XBH9>R0<5%34H1*5=.TRQWO3
MWYZ^[RP/#>_^>[T,D(Z-EVIVDFP:2+)4 *JT?M$GC90/;A5NX(=,X?FX_,0>
MW\P^PCD@P.'U+KRO3C:?KE<0K<@@<YN*V\DX&,=BHFHF<)&$BGC2%DP$#\\R
M#!R)#E2.0P=H" $G8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M-,/O"UO;7U+1DF6GL$MC.@L43=FMF/!25K RM%CU[_'S:!R398R3A8UU$)M
M((1K?XF"FJXU!ZKO4KICT]ZCA[A\ON,(WV38UHSJKMZ^U%*.X=3+IM7=V3W3
MF:%3CI.0E7DY'-5&C#]M'UJ;I2Q0.U':Z_$[L:FMV^I;]L_5]1C[3U$O*R7J
M,ERW&U(ZLF8W7-;UW!;Q=,924EIF[Q;B4V3=M8O)![.3+)U U>*MTH47$J(
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M:CDCA-TR5LMZV-,$@/AUDFS!-S:'!07:OC(-&+8Z*!0-S\ 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , IP'V#^7W'D?YCY_?@
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IR?[@/^^ <N ^P8 X#[!@# & , 8 P!@# & , 8 P!@# & , 8 P#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g96389g93b23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g93b23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[13Z4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0%?\F\         *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M     #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         ".$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M    V    ET          0                         !
M  )=    V                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    V     !29VAT;&]N9P   ET    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   -@     4F=H
M=&QO;F<   )=     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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M 0 "$0,A,1($05%A<2(3!3*!D12A
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MEK2VTC,T-E)UP? F5*$G1&)VAJ.RL[71\4-%1D=3_\0 ' $!  (# 0$!
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M55"U[8.MTK:AV0A?+3.?MNB;(QNPUK7FY>T9<,^U=YU?2!S89*R".HS#83-
M9'O=$R1C=AK1(^[G@<2&V);J%R+;ZJ=]*1J=G@#R4(@N\FV(2T>=Y$LFX@"C
MN2:)N>E'-VXF*1<SI-(" <HJB"@ .KFJH@Y[!54KI& .G:!$XQ1 ;+W[)%@!
M+9I( L";9JW7*3;D:RK9O(QM3-NQYBC#2)'%KCYFQ)9I=LM< >!T^0W:EC#F
ML1;?5_)TBXMQG1GXLL0#@13 K=63%R+%)T45"E[,"ICG$Z>Y#"(!JG7<.W!J
M.N4/5K$,E;)$UKWFX;&Z65KFM>Y_F,:,W2%K!8N!536T;83.<0I.K9M9.*AC
M(W2$AK&/EF!#7%Q#6LS#W$,:0'[0YO;C48U&*>/[57F+2=,485P\FXMLWER'
MV(7Q6HLZ*F^ ZH[#V55P!.\3)D*(:M)5X>QD,DU53-;4N IVB2FC=+9A)="U
MC-N9C2-F0L( <-IPMDCJZC8V*66MB J2!3-,U/&9@UCA(8F#.4->,RTMLV[M
M 0LG( "._,2FZ0@!B@ E, @4P (<Q* EZ/WQR"8IE$S 50=]C99<#8;9S=II
ML,VY9Z"^NNIM?0YY@XVN2;DW:+G]7QY^&@Y#Z;!Z@^@-3L,^JWU1[E-SS/B4
MV#U!] :;#/JM]4>Y+GF?$IL'J#Z TV&?5;ZH]R7/,^)7$P!\'D'WP>@/EU=C
M&7/FMT^J.8/+FFK7WS\QQSSS&ASXA74.21=N7S<O7ZM?H7"2?)F&B^1PZC<1
MS<8(R7'F2223J222O"5!/6I\SDZPS.0UL.0OG94W'UC](ZZ2Q7/,^)3<?6/T
MCHESS/B54!'?F)A^0-S"(?Q@ .D01,)>ET>B8! W1'<  =5<2!<<,^-N0O9C
MS:Y'[)_<9:X[32239P-LCM#]H6+V ^;<@;6H!.0)&N=6XG*/9WU>24@;W6HJ
MVV!Y6*G:;)!M6]4L-A9/WL>,(VEHR5EP:O7;N/>MXY.21:'>&3-L43IE*/I*
M[HGB5$VL!K,/GGH(HJBHHZ:H?)6Q4[XX9I)WPS01-?'''+>3=N+F"Q:-D/7D
M\/Z:896U%(.K8E3P8A534E#5U,%J">J;UJ-M.)X9*DQN,D!#'3,;$7;+'.#W
M1A2/9LHU*O0UYDD)J*GY''M<F[%8*Q#3<4O/((0D>L^5;/&8.3N(UPL5N9N'
M:TFY04/TQ.0_1 >32X;B%3/AS'T[J6/$JB&F@J963=7E=/,V(202-C<R5A$C
M' !FW&+@6!<NM5XS04D&(R"HZU-A5'4UE714\T#IQ'3QEVS*TS!\+PX.C))9
M&ZX<7AP8U_0J66H*U/SL54CP2JC"G.XTTK+5\HS;BWP(6)".BH]O*K2YGK%F
MFJFX0?1<>HN1%=VP!\DFLJGEK<*J*%@>V1M2QLF(,EW,<[W1MH*EM-)(2^G8
MW8+G [0>XMNP.:TN*I0X]2U[FQO:ZFD$.'R0[V:FC-2[$(.L1T[FQU;Y!-"P
M6O)2PF9NVX.DV-I90^OM&C$B*R=UJD<FI).85-9W98I! \RQ/U+V*(JL_2!6
M0:+[I+,"B1XDJ8A%2*"8"EU&8?B$KRR*DK)"8HY2&4U0YS8Y6NW4CM@#89(T
M.=O,VW%\G;+AN3XKAE(T.J*^CB<]\\1?+611QMGCSEC9M21ASH0'?HQLN!+;
MW:%:[=DJLU%C.++2T3)3$-'/I$U5;V"O,Y]R6-8EDUTDF\O+,4D3)L%6SQRL
MX4(U1;JE56.1(3&/FH\*K:Q].8XIXJ2>41]<=35E1"-IV[($C&O:7[UKHVL#
M ?UB"",\%=CE!0LJ&OJ:6:JIXWSG#XJVD97EL;(IGM,$E5M!FZ<R3:<39KS8
M#:LKXTN%;<2+*#&?AD[&^9IR1*P>8BQL*;0R0'.88Y!V[47*W,!DW"S?=N&Y
MU"+&3(4Q<#Z2L:Q]0*2I?2QS&)T_5JML3<RQCMMS8@6N<-3M&[V@V< #L18C
M1;R"GZ]3=<FC;**;K5++)L.!VK,VIMIT8!NTAI<0]PR8"/C$7FESLBYA(*XU
MJ:EV1%CO(Z)GXR3D&A6ZR2*ZKEDR<N';=)!==%NL98A^K551(H(BL4@)J&OI
MV-EFH:J*G> P22LGB_2/:Y[6!\H(+B X^:6. V<[658<3PZ>4P4N)4E3.(R7
M1BI9*8SO-ASSN2';$9<T%\@=&+@.#M!%\YQ(8TC6,X[BYA"P+5F_0%!L#!B[
M;MG,=(S<M%Q2K\P/>J%>&8K2A#+2+8QF2BC-XS;KE6;NTT>O!T9Q>22G9+ ^
MG-5A4^(P;5RV6.&&>6P-Q9[A%9HOMDD$Z 'C573'!J:.I?#51574,8H\,K1%
M*UKXYI9HX'R 5&T'TY?4-)>RT-H[!MKA2:-^HX00VDUUJH58'!FGE&:QQ!((
M79%#HJ-AFQ7\6INP,FH!FPK@JDHFHF9 3$$X\KJ&(FIZJ*&J94YR=7,,CY3&
M07M>V  2F(AP&V" +, NUUAVQBF&NIA6^4Z04C9MP:GK$)I=ZT$.B?4-NULS
MK6$;F/)<'EFR8[FWWG)%>H= E\ER2J\E68>)1ECK5X&\B=ZT<N$$FRL:JHY2
M9/$G':4B)+@\*FH)MTU2;&WR8?AM5B&)T^$LV8:J=SH2ZH>^.&-[6O<[;V09
MF/ 82YFZ<YC=DWLX[6#$\9I,*P:IQNHD=)0TT$<EZ5L<KW-FE#&/8]\L;)1(
MXM;$\RAM]MN0! QRK9QI=A);BR?C3'[^BK1:=JBLC(L*TZB$IQFH]A'*SH\J
M\AS-I1NB95HLE+JG$J2_7$3$2@?;K, Q"EDHMV8L0AQ 3.I9<.?)41O=3N$<
MK19K)W%DA:"TQ,8+V.T38:E#TGPVK.(,F,^%3X7+3"NI\5=34TL+*R)\L#GN
M$U13LC?'&]S2V1Y;F9& !BS]O<:DZ227;6JO.&Z\*XL""R$Y&JI+0#(_4O9U
M Y''W:):+_ <2H',Q2VV.J'2 P\WJ=<TALM+4Q2-F92R,=$\$5KMH]6V7C:;
M*YH!$?I9HX+J#$,/DC9)%7T\T3Z5U9%+'5Q/C-$'G^%"6/\ C8FEIVI39H&1
M ;D*.;A4FR!W+FV5UJV2AVMB5<KSD8B@C7GA^J9SJRJKU,B<2\5(=)K(BH+-
MP<_W$Y^J$0EM'622-A;35+Y'5#Z9C&1/WAJH]A[Z9L;!M22,%MN,><&FQ(VU
M)KZ&-NVZMIV,ZNRJ>Z2JA:P4CI&M95;R3:;&R1Q#6OOLN#C9IT'44R!1$(R/
MEU;M5214N18\1)J6*((PDDF[A)JX6CGYW(M9 &RSA!NH+;KR@Z5;IGZ/7E$U
MQA^(/FJ(&T-5O:8VJ6;N3;@D.T_8FCL3"+$V#R"&C,G9!6+RMAFXIJIV)TH@
MJMYU1XJ8GQU+&2%CG12QEC9BQY+"6B^TT -V0%EHFY!L(\]S#SWV$W\7<-PW
M -C"4#& O3^"($$@!JMN=J^5B6V.5MGCVWO:_&V>=UNW/!Q((#@X7 <#?,9D
M<- <K\!8*FX^L?I'5DN>9\2FX^L?I'1+GF?$K**4(^5<%S'XP2#O] @8!#YA
M#D/K#EK0Q/\ D-5_W#_^5=+!\\4H;Y_PEHSSR+'W'<;"_<.2RG.'*5@A#D(Q
M[C<0Y;_=R#S]?,1'^L=?/1H.X+ZK\_/B5F%0_P!A<@?^M64?_KDOJLG\7)_N
M._LE;=!_+J+_ ,73?_,Q:#&[Q^<?TZ\F[4]Y_-?J54U")HB:(FB)HB:(M+LT
M8GR+<>*3 %_K+!1"J5#&O$!6I^VIOXM/R:G;I7H-A4SECU7R4JY66?-U3I]A
M:.4T")E"0%OL !SJNFEFQ"FE8P6#:P CL<W8-^;<@VUMD9Y+U>$XE0TW1G&:
M&I<TS28A@E134;FW%7%351WC=Y;]&TM\UXR#FGB" O/O%/!?F=.DN:9-U7*5
M,R=5<&YKQK"7-2<X=X[$,E(Y C',<BFVDZ%$M,SV]K//>PS2+^Y@_E*K)=:^
M66,\,5%QR*?#*K=F,]:BG%(3O6NPYM"'$?K;QL8FN; AQN0,[Y+V^*],,(ZW
MUJGJ\-J\+JL7PZHDHQ!CTF*4T5$X3N;)#7SRX=3LIX[MW<$;&RMRMJI/6X>K
MID/%O#S0WO!Y"8O;X_S?PTKY40>2V)GR%^IU%C+7%WJ8D6T!)JEL%>ARR @T
M++N'<_9 L[[J(,G5O@5V#13304D1PQD9IZVA#P'M;M"&QFO8V<)+#;O^N;W%
MB5S#CM-0XACU4[I4,6Z]@N.LPAX9B[>H5M8Z,T+8CN;PU%0(XRQC-FG@,;;5
M V66X/N#Z^NCO*F;$T.?&RGA((C,R53%Y3?)4,+>0BL4^F2P7C3LOB9>36[,
MXK81_C9?<S96*%N(D&/)S[_Q3=P,7WNZ+!NNK:;G=EI CVB/,/FC6W YF=*Z
M=K.O^5ZCRD.@7DGK)-1UGRJ*BVZW_5=[UC9L.L%^\MHZUU:%.%?+-/EU[ SP
MJTNV-J9QQ9>RTQP9'R]#;,[3C.X46%K].LM=AI&9;U1L%9F@?RL75I5W%/D"
MG6(BW2%181'#:J)UFT&W *ZLGW)D!88)A^BCW9_1B.,D&-E@UO[-AK<=)</J
MX&PMQ63#L4K.AF$88,;DAKYI:2NIZXRU=/42;@RP.GA.ZGEB>#+'9KW$#*Z4
M'A6SE'R^)9]*E)X_C77%!Q$YA5J<?.5AR&#*5DO&C^MTV/,C$R01CI1O-IIO
MS1]*/)MFB\FL@5,B8&$T18?.XT3R-VPUU;.YK7;#*2"8'=1Q $")C,MB.,-#
M79 *M;TIP>1F,0BNEQ28=&<#P_KDL)$^.U-#B'6:B5TK[O,KV'SY)'N<X.(<
M[BHLA^'W*M(I>+%K'@>/Q*?A<QSQ$365<SISU5=HY50F,>VB+9I5]>E/I&_3
M+:Q.'7C^45GXEF]@2=<#8#/"-VSG%'23QLIGN@$<E!UPU[VM:UU0UK<MES/.
M< ,QM$V)%N2WY<=PNOKL2:S%I,5;TDJ,!CPW#-S62##MBMI99Q)'42NHXVLC
M<Z.)K:C](TELGF$A81PM8ZHF8H.X8=O;! ,@7W@S@(JI6.(+B!U1ZK2ZP[;.
M8B5GG6-YJ3EFMT)<)"(EW4I>6L5,/V4(1L^;(N6Z*"V*BIXJATT#XV-J74(D
MAD#6B".,&]IMD;/6;V\]PVB0>((&[TEK*O"W4.*T<SGX=1],":RBJH\094U$
MD[+1]1;6PQF3#V4]XF1TF[A#_P!47 )WQ\&NSN-UQM;.)/)HI+WW.$Q!L3OD
MS@HBXIV)8%M0*^8@F,<2)OY2+M%B,1!1--T,L@[$#**BH;K8*)I:=U9*")J@
M_HVW_5 !:-@:MN#>P/',6LO$?Z0):6DQ&FP/#W!U%AK99G; :V,38FX3S1;(
M\T ,J*9I%@-F*1I-K VWA7X*EJ^#*\9L4OHV*HYIR??Z%C:2N,*]QK7WDU9Y
MLT'>F,#7B*@I//(]Z#Y%29GI%=B[=*+!%,E5#F&*##'69//*\;$AF9 YSG1Q
MR7)$K&7L),_UMF]KZ#7+TFZ7-F=+28&*3JE;A-!AU=7PX;*_$GQT]*'N@DJ)
M2*E\5]6/@+-LW N;G5\>&CBDC.'C#6(E,/(NB-\+9?J]D<0,=P^6*ZPU]M-Y
MGW]:@K):,H.IAC"8S>0CYO*24ICD%;2$@D9-!5D^*P52T74=>^DI(7P0/+:0
MEH?'$\M<; .:7W .OG WM;/(6](WI#T==T@Q;$QB[H99\7PY\#7'&64M104N
M'A[VMBP^&)CZK;&YW=>)(M@;O-I(,C07"M?HFZ8Q?VOAWA;PSG> RBX6MDJ[
M5QM(FHF:ZC$/CN9*R%F),KN1?F9HQE>:V2 /)+D.@U;D4*S23<%R,H91/3NE
MIF2%V"B E[ XF<'.0W%W2VL-O,ZY\5S9NDE%)2U@I<=?0RT_3.MQ;#XZ=V+P
M"IP64DQ14PAA:&!F98R39:V]P!DL(5X4\E5O#+;'9.$:#N=NR%P@8^Q&%M)+
MXK9I8NRU$V'*;VS35A<24VB^,9!O<ZU9E+!4QE74N^JK1H==\JS;=EPG#ZD4
MXI1AT=YZ"&!DNTQSH9PZ4.G:7"XE&TQY?'Y[M@><2+K?;TFPVHQ:7$7=*I*.
MFH>D]7B[Z;=XM)%C&%34V$QT\#(WPB&,QFDJXA'(!&S?/)LQ[BI]K/"-;FEU
MXJ;'<Z-#W*RRO#MB''6&L@2:E=DI*7N,/A.RTB_K0+E^[._JSR6G"Q4>^E)4
ML(,H"I#(.'##IE-O,H7/EJGR1-<Z6CI:>!SVA[HG=3EWAC)!V3(\ N+""YWG
M&^:X-1TIIA0]':2AQ&>D@BQVLK<:IP) T4CL7AJJ-M1$P$53&P-?N6R,E$ <
M=AH.:CBF\"KEI(X24G<"THS6$X&;%2;T#IE0WI#\0,BTAQ+XT0*_$9*R*'?V
M<Y;<8CYB@9X\,E.( LAU>O%ACW/HP((GE^$R,+71,(?4.<8VR/8]I:]]S^LZ
MY.0) .?1K.F.V,8:S&*QSY^F=)5TT+)ZS:&!1[P!D,K*=KH*4O9YM/&YC06B
MS0;*VUCATSY37G"E,5C%=E;Y,JV.<(T#)LK;)#"]PPZ2H4^P/)2:C)5O,S:U
M]K=SIJ0I/JW,8]2<A(G39 VZMRD\!4RBJ6/HW1P3NGBBI>L/EA@,;(A4,WN[
M=;:C(B! ?':V0!-[#+/CV"U$/2FG=BE.W#<0K\7K\.IH8\3HL3=7STP;"]IB
M@CBJ:&60;BHBJG;MD+G$@L<5[3@ &+OL!!*(?!#<P%W(H8.EO]T*0X%.5,YA
M'I"!.GW:]$+9]QM?GIVDZ\^TE?)"0V1S6NV@; WX7((/'/CPMPL5PU"LFB)H
MB:(FB)HI;J.\?FI JWQ>?^=*?_"AK1J_Y1_Z9_)?G7_2Q_U@HO\ R2B_^Y5K
M*-:J^8)HB:(N)]NB.^W+80$1Z( (" E'?8>8#L(!MS$ #EOOH-1E>SFNMSV2
M''V#7AJH)M;*^;;#7,D6/>#8@Z@BX6O6>J!8[\YQ6U@1DVJ4/DEC+S<M#2$?
M&R,%$I1DHW-*M5Y$!*55-18H)E39.1 QA ";CTB^9Z38958H_!&4CY&MI<89
M7321S[E\40:_:<V5U]@V-@1Q-A8V7G^D&'SU[L%9 Z0-IL59--+%*()8K7O)
M'*;;#[@ N;YV=N16$37#S#MK5AME&5U6TU**MU^LV0G]K>,9IS*S%AKR1FDG
M.(R(HC,.GLTU8=+LS59(3I-^M: BCTR:$_1:DCK\"IX8'5-#!7XA7XC/65$%
M8:FHJV2[+YFR-+IW.GW0N[:O;S_,:0-&7HW"RNP 0P&>AAJ\0J,7?6SP5;IJ
MBIIXY&32,>TF>628,&TXFY)WEP'*.I+#EX/*6.JIX[:JR$WG!GD&%S&G(5Y-
M&"J:$E'R+=!,#N261K(Q<>R/%,XQFP[(B980(!2=88.348%B6^J*$X9"^JDQ
M^'$(L::^%K:6@BECD;"USAM,<V.,Q-IV#<M#P&AJYTN"8H):FF\F0OFEQZ*O
MI\7$C":*BBF8]L+B2)06QL,38(QN8P^[&MV;KIHX<O[>T0K)7%K)V^A>(QID
M5YECQK60<2=16FS.>I3*JH,^8R21^TN(IR5-FFG%F,@W66ZA);$, Q)E; Q^
M$PU%5#TI@Q1^.,J*(25%!OXW"GN(MX-T[9=)'M6+6&X&=L/D3$VUE.'83%/)
M#TIBQ%^-;V%L\]()6.,1>\EXB;^L8CY@,8(VG. 5W@\<Y8;RM,JKG'ZI8"J9
M^E,@KV[RE@3MI& F'4\JU5:Q)7)9#JB)291?"H1)=-0Z0-VYCK.@:YZ;",9;
M4X=3#"CU2BZ3OQ85_E&DV'PS/F>X.IS;S"QSVS MN8R6AS@5GIL+Q5LE!1G#
M;4M)TC=B'E%]=3%CJ>H=,ZW5BVY:X/<U['-;9ISV@]P9\J_B.V'Q?>L:S.((
MM:V>3N0$6V5W#^IN1MTK,3KB7A.I5 _C]%:0,JU$J[]-@2,6C41,<%TDDT(I
M<#K'8/B6%U71ZGEJS35S68X:BED;6.GJ7SP1Q 1BI>_:=$+R%K8C&Q[+;L;-
M:;!)_).(X74X/!/6BFK8VXN]]$XUDLE29Z< [&^+]G98'NV=TV-AVO-\V;!H
M,G<>'1SC[R:3QY.2E35A2PBRD4+9I,MA "NG"D"NLTZF8D6Z;U91L95THE(.
M'*I#NDS;^A\F35O19^%&B9AM0:)E*8&NCC9#,V+9C=(;;#Q+.&"3:#LW;>9
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M'A/^K<,_\MHO_KQ+P=1_*JC_ '_W+CKI+$FB*H=_H]6P]'F(\BAL<0*("80
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M%J\2DEJ:&FEK)ZFL.(F"E9! :N;8E;"ZH9U<9L<VG\UWZNS8%254>)3 S2K
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M!%5W1&C<4$RTP[ G8IB<V&MQ"DI*D/?'3LK&U<#ZD0MF$A$$$%7NI6!MY8I
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MWA9+ID;RKENLF@(G3."70J.CF-4KZ.%]!4;[$HQ+3L;2R/DELU[G,:P';,C
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MH[Q^:D"K?%Y_YTI_\*&M&K_E'_IG\E^=?]+'_6"B_P#)*+_[E6LHUJKY@J"
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M!E"F$7J$@VDU6S]]<W[A 7YR)]HOY4"SAB FWZ]$J(LVJ[$I5-DB"50^Z9#
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MBT3Z&AP["I*+!X(*NDJIJ>FHG=7K',8Z,T]9305-'4G:(=+:&J;&9+"9D@+
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M/012K#&$9EJ9@--%*<CHT44P2YC)BD)DT0BP*EUBO,BZ32,AB::?;?#T:K\
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MO_G\E1%(^-S7L<8I(I-MCAJ"UUVD9VL#;/GV67;#$F.=@VJ,?ML&VPK ']0
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M1]MH1Z6LT-%N!RTR7=\WM-_ +3ZR_P"MU7R;1?=X_5'N6AU:G^R9X)YO:;^
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M[Q^J/<G5J?[)G@GF]IOX!:?67_6Z>3:+[O'ZH]R=6I_LF>">;VF_@%I]9?\
M6Z>3:+[O'ZH]R=6I_LF>">;VF_@%I]9?];IY-HON\?JCW)U:G^R9X)YO:;^
M6GUE_P!;IY-HON\?JCW)U:G^R9X*@X]IO(/$+/F(AS%<?0(__P"P<^6GDZBL
M1U>/SA;)MB,P;@C0@@9J#2TYR,+".T+ZEHM2 >4(S$ #;8.L-MZ Y=,=NX>_
M?U;Z[$=?611LBBJ',CC;LM: /- M8:#0<[\%JNPC#7N+G4<+R;Y/!+1?B!F
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MQQ//DXUO.+,G;A4$&R<S%RL.BZ64$032;O))HV8J*K;?<6P.4W1A*(%1W,(
MXV]]OGVJ 0=.WV:_/AJI73Y](=S#TA 1 P;;#W;!Z #8 $ YFV$!,80,712O
MIHB:(FB)HB:(FB+B?[PW\DWZ!T1:UYQ^-(+^8O/[WHBDK%GQ-8_Z0K__ (ID
M=$4F:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBX*;[;  B(^@-]^\.>P"&P!WB8/A
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M)E)SH*(P<_'M+$V>QR1/GY_PNLN1\(MPB*YG9X')E!Z-\?WEABM!VKCS)2-
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MX&O^#0BN#& K^.@NMA+C_*:&7K/E!S;:>WR$,B\E\=1B]@0&)2LMF7L<B];
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M+YBX BS@^_6?PD53I-95,%=S=GE$':"G0*90'1^@L>;:9'/V\,LCQ(5"\<)
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MS;+Y_-7*CXOA*7)2,XBZD)>PS+=)*9F)(Y#KNG!G"CUZL0I$R]E(^7,U.J@
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MI*46</#-VX+G9"@DS*DW5-UJ1%%D.F D.D5!,R[ARN@)=BIJ&+T\1Z0T_1S
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MK3-UF[1!SLP#B#YUL-8S'ZB1L=2R&5P,SJ<^:_88W9,W8TE^[S)NY_(KOH+
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M_)HLBYZ(FB)HB:(FB+B?[PW\DWZ!T1:UYQ^-(+^8O/[WHBDK%GQ-8_Z0K_\
MXID=$4F:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB#OL.W?MR^?Z!_0/S#HBC*6QT0TQY35*5/4+"H<@22S1D5[$3:!
M3 )DYJ$%=FB^5.F'5@]2<-G:!1,**@* 40(NH3(;F#FT(*^19*Z5XH1*'L:#
ML[RM2Z@B!3$5>K(-SPKLYQ  821%-NF!4GINB!Q?/SE\\@GS\Y_/,J5BG(8
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M0Y6^;*^>A-[<M/0I5X:40[/<W8!OTG<*Q,?O^Z-FCMX=/I>H@291 OH X#S
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M/^U$WW#ML/\ KOIZ1=O7N&W>&IV(1J#ZA]Z":8FP>XGD#(3X+B.2<@ <J8Y
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MGO3R@G1[IJ5[@'XP=]P@(@/^E[A !$![A !'N#1-L<CX?XJOCZ?#;>8E@W$
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M_.#O];HFV.1]GO7>CK9/1[M)UXR>.RD'8[5XZ<+H+IF^^(8IS' IAVW(;<H
M;;?<!'3V]GSQ'#AS4AX/,=MLAW]AXY=RV%K\ZRGF8/&BNX_!!= Y]UFZX],3
M)G)N( 3X(]48-P.!3\QZ.BLKV80$IMA ?@"/?Z! =A^8=AV'T[#HBULSC\:0
M7\Q>?WO1%)6+/B:Q_P!(5_\ \4R.B*11 QC?Q@ #" "("/>)MCD'H_!$OPBB
M!BB0Q! !$2B B1>7'&1P:EG@ELKXFB1\>#TWUPIK!( ">*(&.YG()FF78LT
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MS)>8\?XBITW>KI,IM:_7)&JQDVI'MUY1\P=W6S0M7KQ'$7&]?(IIR$O/QA5
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MX?2Z71* =XF/L()B&X;A\NBL+C3LUX^@ZZC30=ZG*@5AY%D/+/S+I+N4-D6
M'$H%;GZ0E5>"80*9<0WZL $ITBB83;]+8&>8^?GM"NT<;$:6X96Y:Z6N#I:W
M"PC[.0 $I [?]P=>D1_\Y#?F.^X[[[^H0T5U).+/B>QAZ?.%?_\ %,E_]AT1
M6;-6:*;@VGO+;;7?PC]8V@X1NH 2=@E>@(E9,D>D)SE @D.\=*$ZB.:AUQC
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%NY%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g96389g96b02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389g96b02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[11&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %"J^46(X0DE-! 0      %,< 5H  QLE1QP"   "0  < E  "')R,3<V
M,S8R' (% #)-:6-R;W-O9G0@5V]R9" M($EM;6%T:6-S("TM(%)E<V%L92!&
M+3$@,C R,"!&24Y!3  X0DE-!"4      ! +=,'SV@4F(];JWT$YQP]M.$))
M300Z      #E    $     $       MP<FEN=$]U='!U=     4     4'-T
M4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I
M>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I
M;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P
M   *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M    "7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT
M3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L
M  !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS
M8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M    0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M          !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M    0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M        4G-L=%5N=$8C4'AL0%T            *=F5C=&]R1&%T86)O;VP!
M     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M              !4;W @56YT1B-2;'0               !38VP@56YT1B-0
M<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E
M8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC
M<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X
M0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M     #^    X0DE-! T       0   !X.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         ".$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M    ^    E\          0                         !
M  )?    ^                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    ^     !29VAT;&]N9P   E\    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   /@     4F=H
M=&QO;F<   )?     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M      0    %.$))300,      FW     0   *    !!   !X   >>    F;
M !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @(
M"0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,
M# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1
M# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !! * #
M 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<(
M"0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(
M!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/P
MX?%C<S46HK*#)D235&1%PJ-T-A?2
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" #- ?8# 1$  A$! Q$!_\0 '@ !  $% 0$! 0
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MYQI!WVMJ0"2=DE/[]>W%2Z5%CS6'8LEI#S#R"AQM8"D*!T/8@Z4G25((&TJ
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M %M@<KKG@ ;Z D;G!,#K\=J'PT41>V!@EJI; LIH#)'$9I 2#D[R6-E]LSV
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M*^R;XTOCNAW42%B_PGS+Z*]U6AXY>HD]+^L-6<+PM+'6F1.5(N+!42KS:6[
MP+I_;L9QA8G8M%7U C8S^%V61*KF),7]?CJ_LG7ZJ9=2_B[^+7&,NLJO'.BD
MB56Q^N,C 7H1Z!?$3ECF/]+X\7*WJKJ>O,\5BG&,XCYHBEH;"+"Q-H'"CDC-
M)E*56L9]Q,J./[?FM[] _BISKJ/G.-8EG?2/J'@[%QTY>L;"ULNB77'':>NZ
MH5^87E?;8F_D>38A'QR'4MXC%HKRNN)UDW76\BP>C5-O/<8=BL/7?CR4KNT$
M'>C['1^A!_@>$5>$6-FU\2Q:+,IM+C845)4%+;>8=&^UUAYLI=8?;WM"V%MN
M((VE6R-$OPYJ)2<J@XK9UU/D5O%0BT<4Q5S9+K;4A;@TE#-DVG3;9*NUINP*
M68[SSB&5MMO+[E>$E3!%)%#)*QDLU^[8XV<ZPN=. ML38$Z"YT65#0U=1!/4
MP4\DL%, 9I6-NQ@) M?^XZW+6!S@V[B T$B>)<0LD).RG6_!UY]O)&C_ ")^
MGW'/>_TT6+^E^OSY<5]\(G")PBC\K<C(JJ/^\S!AV%FZ![MS'"S75Y5[?E=B
MR;GM3L@&/W:V$GA%FGT][925!()!)(V-#R0?!UO7O[CW!V./4 [[^8(]]_3G
M?9-=+&UB#?T-].7KPX:ZKB+JE\.>2971YK'B*QQAZSL)5O5V,)ZRF9,RRW9Q
M[-$:$Y-KVG(UB6H[C4=Q5Q)91(<])+9C%$=NLSX%//4/D-1''$9,[0WO'/ O
M>U_ UI!UOX[GD  NL8=_$&BPR*@>*?$,0EI*!E-)AU0*>DPN:9M,Z /D$4M0
MV2-KWF6WV*-\I8P.<U[G2#I#IYF>.6>*T["+I/SE56PZZQ9MI#+-LS,@QVHS
MZYR7U-+4^MQI3CKH0$K4HD]JNY(L<;2QC6$YLK0,QO<V%KFY)N=R;[KEU54"
MJJ:BH$;(N_GEF[J(98XN\D<\1QM_M8P'*P:V:!J5J/J+GBLLN*&LQC%KS)*S
M%L\JWK6RB1V45LN?6+=DMUD.4ZH,/*>$8M$D>F\B9$4RMSUD ?:\%N+&.H]3
MD4]VDE5]GCF0M(4]^!W\=#$MYH#9>AN,NO19;:1M2@S(4\U[N(0 .!^O6W7
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M#:$DJ.P//C7CZ:'D>_O[?7W)\\)^WU7RM]IM*EK4$(0E2EK7I*4)2-J4I2B
ME('DDD #D%P:"YQ#0-22; #F3L .))MYJ0"X@-:7$FP U))-A8;F_(7/DM Y
M[UQJJ9#U?C?IVUKI2%2]E=="4=CRI(W*=3H*#+:TM?\ 6[[IY5<6[304I,%$
M&5521E#KVC:XW U )<X.M86#;D:@*\X#V*JJTLJ<2#Z2C#FD0?=GFV(:+@M8
M'@D9B2X7OEN+KCC)<D=ENR+G(;!Z4])<2TMUT*?=>>?<+3$&(PT"I]QUQ7H1
MHD9E2W7%);;;4I0"N?33SU=0)I9)9*B5X:)+DN:^]PQC6DZ,(!!<6CZ+K^'8
M9"R%E%AT$8B8TYF-C#(>[8TE\D[Y+,#0RYEE>\-:T%[GM -^RNBMCGL#%(;G
M4&O-;72W4-8\B:\MR_K*Q0"(*,H!VW&<G*(5!8]5Z17L*CQK1]N8Z8<+JV#"
MO;11C$,IF&C77N\QC[G>"P <!OJ;[G4KA_:^' Z?%Y(<"J#51,!%7+&VU":P
MN_JMP][LLDU-&;L[YT<;)'AQ@#H!'(_H $$;'-LJLJ\(G"+ M'MR*Q._W:6G
M)^F]SKO>]?8@$?S'U/"+&9ME",4Q>WOEL^NJ"RV(T?93\Q/E26H5<P5 CM0]
M.D1D.J('8A2RH%(/!OP&8\A^_7MJG/86!L3M?S(V'G]%K.NZ7.Y/%8M^HMW<
MVUQ-;;E_AK%@[$J:@/)VB+!@(VPTIE);;<>"2MYU ]=QT $1J-2-S8<QZW._
M.W+X7!%LP(M?0@@G8Z D6\R=1[7Y@ZF-0,2E9PS QVYR:!34\Q4NTN9":NWI
M)<.$B<V]73U6,6VN87R!>3$1,BIKCLB)*9:; 7J:S&:>D>^(Q2ROC+0[(Z)H
M .Y#9'M<ZUB=!PTN-1<\)[$U>*Q4$C,2PN!V)Z4D+WU<LQD,I@;'*(*1\+']
M\6M>S[0Z6,._V7.\(Z<Z7U=3>=.,+EXA)77XGD%'!L[&(MV!/GOO2(JU.2H\
MV'+N("+*18J0[8OL2IK?J,%3#[;W<OFRAE;/"R5@<&R,#FAVA <+B]B=1L;$
MZ[%5O%<.GPC$:S"ZET;ZFAJ'T\SXFU#(G.CT)C;504U0&EVK>^@B>6ZY!=?7
M7.(8F,U=Y5R#%RJBMZQ./V*DEV0J5)5\N8[JM)7(9E$)3*C)(+R5+ :*G$GG
MKUUZ+ %KZBXXB]KCB+CGL59='HT8.YA RI;4WJ"+V0SD+DYM*G9T!@N)J'HC
M3_<K\,5'=6ZRT"4-&2M![5J[>?!C8X$.:UU]\S6F_K<6)\[7L;<[RQ[X](WO
M8[2[F.+2XBYS.+2"=+BQ.EA:P 6P,QO<=QG"[DA<%F*B#*@Q*V)Z*?6F2VBV
MS 8CL#PX\Y(1L!*4I#@<=*4?F,M#0+,#0!P;8 >5AMZ;\5]SNG>\R5!E=)*,
MW>39W.> 2T.S/U<+C+>Y%P6W\-AJ3 \JO\7BXSTZS9=9BRGL?_$:FY1)<<6_
M7ME3GX>Z)39CP[P-%U;2)!05-Q)/R[,I3"PW(\[>5CP7G\C:WY\_*VNHOL5T
M%C3UFNK939I)6WVM,/NI<9E2XK;:$MS)C#A4J-)D:+BVEEM?<K:FF5!32916
M#U=\Y+R!N.M+4AA^MG0G];,>U1&(0Z%'92I33;+$@([2_$>=8=*FGEI)%GZF
M<FPBHD!'I.CO:DLG?<Q*966I+!V.X>F\VL#?[PTL>%#1%E.$3A%\!9WH@;V?
M8^#[Z )UM6M;^@WY/V(O@/)42$J02D_F'>"4[\CN3X4.X>1XWX/CA%]I5W$^
M-:_F/._J"1O6B1OZ\(OOA$X14)T"0-D#V'"*$7U].=7^"X^E"[20X(ZIBTE4
M6 5)[G"K8'K/,- O/-("DLI4RV\I+LF,ETE]=K\==O0]?DLQ08_"H8"840N.
M+4Z[(F37U!V7837R%2)LQTDEV0\L#N)_*E"$-(2EIIM"2+/@=N_KLDD^/<_P
M _\ ?]>$7DID*45$[WOP0#[@#WUL>VO!&QH'>M\*+6]?%KQLXW(Z_,K4W4SH
MSB?4=IJ=.2]3Y37,.,T^7U*6F;F"RX0I<&0M22S:T[[B4.R*>S1(@K>;:DM(
M8FL1Y3.KQ'":3$HPV9@;*T$1U#6@RLN02 3NTD EITN =" 1:NSG:[%>S;I(
MH',J\,J'-=5835YG44KVM+&U$;6D.IJV)CG-AK*<LF8TNC<7PODC?Q)E^&9Q
MTT4O^V5;\[CY=<1%SG'HS\ND* 5! R*$E+LW%9*T@),F:AV@=D*0S'MT2I#$
M \[Q+ J_#RX]V9::^D\8S-L-0V1N\9(%P\@,!&6^8M![3A&,X%VE:QV$538,
M2R 2X'B#X8:PN%M</E>^.GQ9K3<ED.2O9=\KZ4PLEG/UC>87%%V6&-W3S+;N
ME[AOB5#EMHV-.,CUH\E!_, 5-K 62ELI<'=S7T==5T+FNI:ET1+@.[,A+':C
M1^89.-AG:!J<M];?.*8115L;X,3HV2RQWS"1KF5,0MX@U^7-&1IIF .FEBTG
MW'Q>9:;."N11J?;J9Y]5R)5Y3"4[$D)#,E&04[M>5J<::[UP'Z[YMMEY7KJ2
MVR5JY?Z;'WMB9]LB:Z2URZ*HI6M>#KX"Y[6>$6S-)8^Y\(/'D]9V38^I>W#Y
MY&PYG-:R2CKG.C<-F26I\[;G0/8V5MO%;+J.V:3K1T_NF&7$73=>XXTVLL6K
M+T H"T Z]9Y(CJT3K27COZ'V)SH.T.%3G+]I$+P<N6=KH[N!L0UQ&5VNQ!L=
MQ=:NI[)8_3:F@?.PBX=2N$UQN#E%I!=NMBP.X6N+*>Q<BI9J4KB6U8^A?[I:
MG1G/'W/:[X'@_3V\^W-HRJIY!X)X7'DV5A/IH[KC9:::@KJ=V6:CJ8CRD@E8
M?AS 5D1+CD;$F-[?_>;_ *["SL'^7/3O(_\ C9_[F_JL<Q3#_P *3_V///DT
MVZU5N[;5[&_7GP6@//<Y*:0G]=E2P/T]_?WY\NFA:"731- %SFD8-/<K[;35
M+R&QT\SW$V ;%(X__BPZ^2BEGU,PFH2LS,BK"M&]LQ7C.?V/.@S#$A9)^G@?
M7FOJ,:PVFS=[5Q'* 2V.\CM?^2XOY'A9;2E[.8Y5EHBPVH =L^9O<1VN1?O)
MN[:;6.W'1:JO?B+I&$.-4-5*L'=*0F1-_P!SB]WG2@T%+D.(UY((9(]CK1(T
M=7VOHV-(IHWRN((!>TM;<W N!J!Q/DK30?P_K9,LE?5101@@N93WGE'$MO81
M@C:X+FZ%P):M"9/U/R_*0MB;9+B0'2=U]?\ [I'6/ #;Y;)=E)1_TNNK02$_
MW>_'*G68]B5=F:^9S(CJV.$B.UB"?%N^PW!)+AH "Y7G#>S&$84 ^*"*6I#1
M>:I!EFL01=C2"R-SKVLUNM[<;C6E8;/)+,T6&U$O++PK2AR-6>FFOK0? ?O[
MQ\HJJ2.T4N.*$J49[Z&UHK:^PEA$)S$HZ&JKY!'21&7.Z[I 'MAC-[%TTC@&
ML(UN!F>[4 .V-FJ6TV&4S,1QFI@PB@ RL?6N#ZBH)L W#J"//65DQ-LC8833
M1^%]554T1,K>J^FWPWPH3\/(NIDN)E-_#D-RX%!&;<_L?12F%!R/);B24)?O
M;*.LE;-C;)+##I$F!70Y"4/CH6%=FZ6C+)ZEK:FI8<S"=8HG6W8T@!Q'![P2
M#JT-.IY7VA_B)+40U&'=FHIL+P^I88:NNF<UV,XA$YI;)%+.PEM'32@VDIJ0
MM+V7BFFDC<]CNDK*L1,82EM99E1G/7@2PG2XDI*%(2XA0[24K0I3,AE)[9$9
MQUE84A93RS<O+EHN8'4D\3<\]3;76^MA;6^YXKTJ[)4QDH>;#,V*X(T^."26
M7P-A:=^51Y#93)BN@$.,.)[NU:7 @I67X1.$3A%C+*R17L*=],OO*6EB-&0H
M)<E2G?RL1T$[2DK5LK<5I#3:5N+_ "H7VD5O4URH8=>DJ#UC,4'YL@=P3ZGN
MB.P%>418Z5+:CMG\Y0%..;<><4HBS*T]XT21YWX__/\ '^OGA%C[&HK;B#,K
M+:##LZV?'>BS:^PB,3(,N*^V6WH\J+(0XP^PZA2D.LNH4VXA10I)!._A[&R-
M<QX#V.!:YC@"UP(L00=QY?X7M3U%11SPU5)/-35-/*R:"H@E?#/#+&0YDD4L
M9:^.1K@"U["US2 6D%<49]\/%]BSSMCTO]7(*%M"G7L&LIX3;5[0/<&\4N)[
M@;FQVD%09H[N6UVE++<6V80AN,ND8KV4L'386&@W+G4KB0VQ&H@.P!X,<;"V
MB[+@G\0J'%[4W:DLP_$"0(\?IJ8BFJ)3H3BU+3@%CI22Z6MHHR<Y,DU,\N?(
MW1];=I,M:(KDVKN:YT"76RV)51?5,E"ME$ROE-L3H4AHZTEQIL+*@XVIP*#B
MJ81-22W/>4]0PD 6,,[+&W]V4AO#.W,UPV%B%>*FA(B'>"GJJ6<%\53%)#6T
M52P@V=3R0F6*5CVAQ!C+S9KFN#9 6+?F+==\FIO28N4(R"(A0!<>*6+$) U_
MYA 2VZ0?J^E2];!63H\L=#VJK:8!E4W[8P$#6S9Q:PT=L[F,VMN*H6)]A,,K
M+RT3G8?,0<P +X"> $6[!>^C"+Z>@W_1=;L$N>UMVP73R2 "Q:M%A'>=;"9:
M"Y%(V?!4XE2@"0G0.K32]I<,J0T.F^SRD7,<S7"VO_$+MXC<@>UR*'7]C<<H
M+N^SBJCOH^G=F<1J03$[+(+@7-FN ) S$FRV9#MZVP0ER#.ARVU *2J-):?"
M@=Z*?34H'^O-W'40R@&.:*0$?V/:X_1UQ[BZK4U/40.+9H)HG#<21N9_^X;?
MVO;BJSK2%6QURYSZ(T9M;+;C[I*4-JD/M1FO4(!]-*GGD)*U]J$@E:U)2"1Z
MW._#TN?H3Z[?"\3QM8D< 1^/7)>Z)2'4)<:*'&U=I2I"@L+2H%06E23V%!2-
MI6%%/Z^" OP.G*^E]K^^NVZGU%N8Y>2]%N]@!("0?.U$@ >^RK7:/'D^3_76
MQ(&_#V'R=/JI )T:+D[ :GXO<^WZJ/V>8XQ3)4JSO:N($I*NUR8QZA(&]):"
MRZ5:!_*$%1]@">8DU?14XO/501>3I6 DVO8"]R?0+.IL+Q*L<&TU%437_N;$
M\-&MKES@&@"X!)=H2M/9%\0N-PPMK'H<NY?T4I??;^2@@I)_-_>GYIU(^P8;
M!_Z]'E>J^UM#%F;31RSOM8.+"V*X.ES<$C6]Q;>V^BMV']@,2J"UU?-%1Q:$
MM8\2SEIX ,#FM-]-23Y67.^5=3LMRT+9G3UQ:Y9__C8(,>*K9VD/=I]22-_E
MT\XK\Q_*THCE.K\<Q#$ 1-*Z&G)UBC);&X< 2/$^_$..X-@1OT'">S6%84&.
MI:83U-BTU$QC?(TD[B-[FF,?\K"7"SN(6NJ6->YC9+H<#IG<FM&ORRY;:_E<
M:I$C94]?Y&MIV'#*0KN;@1A.N9?8L0ZU]#+[C7A1895XD_NZ1GATSS%I;"UA
ML'#O+"Y%SH!FUL-=K#62T>"THKL>K(L-HW ]Q&7";$:US0?^SL-L)YQ<93/(
MV*BB=8S54=V,?V'TOZ 5&)3(>2Y;*9RW-V6UB+.>C]E-C;CK1;?&+U;WJB(^
MXTIR.[<2E/W+L5:XR)C,9U^.YT7", IL. E<&35=K.FL2T7;8A@.G$W<1F(-
MBN0=I^WM7C$<F&X7"[!L%>;2P1R%U=B+00YK<2K6!CIX&N:)&4<>2C;,!*8G
MS1LE;T&_$9>:<9?2E]E]"VWFG$I*'&U-K2M"@1HA:5*20?<']-BP<O+K3DN?
M<2=-;<.7/GUNL36R':Z0:2:XMU0;+U3)<)4J5"0$H5&><[23-AGM"P1W/QEM
M/(+BT2?3*5(P=C?\?Z;\>Q/N.$5>$4<D*4Q?Q'-'TK2JEQ7%D:29=;)9DP64
M>>X*<C3+=X@$%;<92CL(!$'XT.O)#UU<+CGJ?T@ZE9A7]0H$<V#WS,RPG8==
MV.6S)$^N+)9L:TPHM:_7R(:$VC;HB1:V162&X:V(BY+<E#TY59J<,Q"IJY'"
MH?'$R1KV%M0<X;;[I8P,&5U[FYN"!KK<=:PSM5V<PRFPV5U/25$L5)&,0PFG
MPB"*GK9@QS)&35-9'6QR.>TL,DM53U<;9F/FC@,?=PMZ+Z:9?1V6*T\9Z];?
MN:RNBU]NQ:2?E;9$V$RF-)7+C39+LM*E.MK"G7G7U%9(>?6]WZLD;2QC(R2X
ML: 2;DD[7).I)MQUT]%RZMFCJ:RIJ8H&4T=1/)-'3QF,LACD>7LB88HXF9&@
MV;DCCCM]R-@\*TQEE#BO4O-I3$/'I4N@A7M8G-<N<LI+]'-9%<Y'%?6-)E.P
MBDM+9;GRX+)0PI4(RW&NQU!QWT-))*9I(&OD.7Q.N1X=K-)RC?EJMG!VDQNE
MHXJ&FKI:>F@$@C[AL44K6RN+W,-0Q@G<TN)<&ND(:;%MB!:5V-EFO1>J:BQX
ML',</3-C5F/H<E&%?Q3.>*(-2$A*F9X::[BV6T)TRTM:$MH CMY0 :+   #0
M#0 #7VZNM(27$N>YSW$W+G$N)-K:D^0'X[ZK'6V(W&43IN4]3)EGBRW(\$8=
M I+8N0\?MXKK3[#TY*"RF?8R9*(@BQ9KGR;#CEHB*J)*L%OIGK?_  HZLHY?
M5U_)4]4YPU(8S?\ L[9V.%9E3.-5UM,<JFUNOT]LF&%PY[Z6&W)4,/,+/:0V
MI(E/)=>APN"+@7W)W]M];VM^*B]CJ,PN+-!L7Z_<OOXK6-B"0<HN=#KSX8,4
MQ1^[KKE+5_>RKFA=R&?-O9N16U9%RR+(AHMGXILUN4K<V-*G/5BHE8EI-4[
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M)<;025-LONQU/LMJV6VW$MD]R#PI]%-.$3A%%9=C(GKD1(3_ ,M!C%YJTMD
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M:4;$%T>8.:US7!S6D<M9)\.F>4(=>PS((><5X\M5N4?+T>1@;2 R+RMBHH[
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MOI*E=S3V&.N/I@IBVHGHO+R")3=BN6AW\0:B6,=A<AM<%U:I 0WZC+C8<"E
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M^QYE:VU=J@4J[5'M4"DZ((X17/")H'W&_I_(^XX11H=M?>+9/Y(MVE;[:O\
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MC8(WK['['Z'^1X16LF(S*CNQI*$.M/I]-2%IVD@Z\#_I.P%)(\H7I:?('"+
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M1]]#95H.NH;6IMC?W=7VH&OS?F W^8 D7S4PA"K:Z,5%:H\2.AQQ20%O/):
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M&E@>2VM0'OPBNXS[<B.S):4%MR66GVE(((6EYL.I4-GP"E7>!X\ '>_<BQM
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MS^@LDCZ:V"20= G&_70X>I6J)D<HHL1E^QD3<\;<_+K8B3,43%\[_P"4.O\
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LX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g96389img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g96389img002.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( %( _0,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /;]7UO3M"M3<ZC<I!%@D%N^/0=ZN%.4_A YN'XI>&KA]L$E
MU)[K;,0:T]A- :,7C*SGY@LKZ0=CY!&?SI^P?=?>*Y,NOWDO^IT*\/NQ1?ZT
M>R@MY!<#J>N,?W>A@#U>X4?RI<E)?:_ -0^V^)#TTFU'UN?_ *U+EI?S?@&H
MOVCQ*0"+*P7V,S'^E%J7=AJ.$GB0_P#+#3Q_P)S1^Z\PU&^9XF[0Z=_WT]%J
M7F&H"?Q,.MGI[?29A_2G:EW8:@;SQ&O/]EVC#_9N3_A2Y:7\WX!J,76M8BR;
MG0)-H[PS*W^%4J=-[3 B;QI86[;;RVN[7W>$D?F,T>P?1W"YI6.O:;J('V6\
MB<G^'.#^592I5(ZN([HT0:S 6F A) X&: (8)VE=U:,H5/>FU8">D 4 % !0
M 4 % !0 4 % !0 4 % !0 4 5;W3K/4/*^UVL4_E'<GF*#M--2<=@)(K6"$
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MNMBI;^*K,,L6HI)ITY.-LZX4GV;I6DJ3_P"7>H7-U75P"I!!Y!%<[NMT,=3
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MYU&(YQ[>A]JJ=-/WX!>QT8(K$8N10 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!SL@*>.8BI $EJ<CZ&NE:X?YB.A%<PQ: "@ H * "@
M H SM9T>WUFP:UN"R\[D=3AD8="#5TZG([B:,_0-5F=Y-)U,A=3MA\V.DB=G
M'X8JZL$OWD=F"=BU>:I):Z[I]@(2T=T'W.!]T@5G&'NM@W8UZD84 % !0 4
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M6\<@C>9%<]%+ &K4)-72 E%2 M !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M)0!E:AXBTK30PN[Q(V!QMP2Q/H!6D:,Y_"*]CBHO$CZMJHU 6$MS);EEM[<C
M;&G^VQ[M7HO#\D>5/U)W+LNLW.HL$O)+V,#K!8V[?D7/]*R]FJ>L+,-2];ZO
M=V,/DZ=X4NQ'ZD!2WN?>L90C+64RDK$W]N>)6&5\,8'^U<@?TH]E1ZS 4ZQX
MH'_,MH1_U]#_  I>RHV^(G4R=5GO]8:/RO#=[!J,)_UR2",*?][^(5K'EIK6
M6@RTFJ>--.6 7>CP7Z,<$V\F&3W.:AQP\_@E8-39M_$ML5Q?12V,O]R9"/R/
M2LY4)+X7<=RP?$&D*FYM1@51W+UFJ-1O8=QG_"2Z*>FIP'Z-FJ>'G'7E"Y7N
MM?FF7R]'LWNY3P)"I6-?<DTXT8_%)BO<QYM.'AR_TW4IYB[O*PNISP,L/T&:
MVYW4BX(35M3>?Q)I[N8;.47<_P#<A^;'U(X%8*DWHQW.%L-*TF_\57 O;:^N
M)KQRP=E94@//R_X&NQ\].&CT%N>CZ99?V?8I:^<\PCX5I#EL=LFO/E+F=RMB
MY2 3F@ YH .: #F@ YH .: #F@ YH .: #F@ YH .: #F@ YH I:B-1-OMT[
MRA,3C=+G"CUJH\M_>%J9UAX;V7/VW59A?7G9BF%7Z#^M:RK.W+'0+&O;V5M:
MKM@MTB'^R *R<G+1A9$V/:IV&&#0 M !CVH 3'M0 8/I0 UXDD&)(U8>A --
M-K8"H^CZ=(27L(&^J"GSR[BL$6C:; <Q6$"'VC I\\NX61<5 JA57 '85#=]
MQV([FT@O(&@N84EB;JKC(IQDXNZ BLM,LM-C,=E:10*>2(U S3<I2W8;%K'M
M4@*!B@!: "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
3 H * "@ H * "@ H * "@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
